<SEC-DOCUMENT>0001129928-24-000018.txt : 20240312
<SEC-HEADER>0001129928-24-000018.hdr.sgml : 20240312
<ACCEPTANCE-DATETIME>20240312161030
ACCESSION NUMBER:		0001129928-24-000018
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		109
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240312
DATE AS OF CHANGE:		20240312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ONCOLYTICS BIOTECH INC
		CENTRAL INDEX KEY:			0001129928
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38512
		FILM NUMBER:		24742162

	BUSINESS ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
		BUSINESS PHONE:		4036707380

	MAIL ADDRESS:	
		STREET 1:		804, 322 - 11 AVENUE SW
		CITY:			CALGARY
		STATE:			A0
		ZIP:			T2R 0C5
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>oncyf-20231231.htm
<DESCRIPTION>20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:oncyf="http://www.oncolyticsbiotech.com/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>oncyf-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-37">0001129928</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-38">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-39">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-40">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" id="f-41">A0</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-42">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-186" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" id="f-703">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="oncyf-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cadPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>oncyf:plan</xbrli:measure></xbrli:unit><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-08-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-07</xbrli:startDate><xbrli:endDate>2023-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-31</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-07</xbrli:startDate><xbrli:endDate>2023-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-08</xbrli:startDate><xbrli:endDate>2023-08-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="year"><xbrli:measure>oncyf:year</xbrli:measure></xbrli:unit><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-17</xbrli:startDate><xbrli:endDate>2022-06-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>oncyf:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001129928</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">20-F</ix:nonNumeric></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:13.687%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.160%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentRegistrationStatement" format="ixt:fixed-false" id="f-2">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-3">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For fiscal year ended</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-5"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric></span></div></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-6">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>For the transition period from ____ to ____</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OR</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentShellCompanyReport" format="ixt:fixed-false" id="f-7">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;<br/>Date of event requiring this shell company report:</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-8">001-38512</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-9">ONCOLYTICS BIOTECH INC.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Province of Alberta, Canada</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Jurisdiction of incorporation or organization)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">804, 322 11th Avenue SW</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Calgary</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Alberta</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-13">Canada</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">T2R 0C5</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelName" id="f-15">Kirk Look</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-2" name="dei:EntityAddressAddressLine1" id="f-16">804, 322 11th Avenue SW</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCityOrTown" id="f-17">Calgary</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-18">Alberta</ix:nonNumeric>, <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-19">Canada</ix:nonNumeric>  <ix:nonNumeric contextRef="c-2" name="dei:EntityAddressPostalZipCode" id="f-20">T2R 0C5</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tel: (<ix:nonNumeric contextRef="c-2" name="dei:CityAreaCode" id="f-21">403</ix:nonNumeric>) <ix:nonNumeric contextRef="c-2" name="dei:LocalPhoneNumber" id="f-22">670-7377</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E-mail: <ix:nonNumeric contextRef="c-2" name="dei:ContactPersonnelEmailAddress" id="f-23">info@oncolytics.ca</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.578%"><tr><td style="width:1.0%"/><td style="width:29.186%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.735%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.779%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Shares, <ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-24">no</ix:nonNumeric> par value</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-25">ONCY</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-26">Nasdaq</ix:nonNumeric> Stock Market LLC</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:  None</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: &#160;None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of outstanding shares of each of the Registrant&#8217;s classes of capital or common stock as of the close of the period covered by the annual report: <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-27">74,423,960</ix:nonFraction> common shares as at December&#160;31, 2023</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-28">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this report is an annual or transition report, indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-29">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-30">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every&#160;Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-31">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company.&#160;&#160;See definition of &#8220;large accelerated filer,&#8221;  &#8220;accelerated filer,&#8221; and &#8220;emerging growth company in Rule 12b-2 of the Exchange Act.&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.842%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.137%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-32">Accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Non-accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></div></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-33">x</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-34">o</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;U.S. GAAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAccountingStandard" id="f-35">International Financial Reporting Standards</ix:nonNumeric> as issued&#160;&#160;by the International Accounting Standards Board</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Other&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">o</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item 17 </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Item 18&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If this is an annual report, indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-36">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#253;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM 20-F</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.119%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.681%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_16">&#160;Item 1. &#160;&#160;&#160;&#160; Identity of Directors, Senior Management and Advisers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_19">&#160;Item 2.&#160; &#160;&#160;&#160; Offer Statistics and Expected Timetable</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_22">&#160;Item 3. &#160;&#160;&#160; &#160;Key Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_22">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_25">&#160;Item 4.&#160;&#160;&#160;&#160;&#160; Information on the Company</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_25">27</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_28">&#160;Item 4A.    Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_28">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_31">&#160;Item 5.&#160; &#160;&#160;&#160; Operating and Financial Review and Prospects</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_31">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_34">&#160;Item 6.&#160; &#160;&#160; &#160;Directors, Senior Management and Employees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_34">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_37">&#160;Item 7.&#160; &#160;&#160;&#160; Major Shareholders and Related Party Transactions</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_37">51</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_40">&#160;Item 8.&#160;&#160; &#160;&#160;&#160;Financial Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_40">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_43">&#160;Item 9.&#160;&#160;&#160;&#160;&#160; The Offer and Listing</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_43">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_46">&#160;Item 10.&#160;&#160;&#160; Additional Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_46">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_49">&#160;Item 11.&#160;&#160;&#160; Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_49">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_52">&#160;Item 12.&#160;&#160;&#160; Description of Securities Other Than Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_52">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_58">&#160;Item 13.&#160;&#160;&#160; Defaults, Dividend Arrearages and Delinquencies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_58">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_61">&#160;Item 14.&#160;&#160;&#160; Material Modifications to the Rights of Security Holders and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_61">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_64">&#160;Item 15.&#160;&#160;&#160;&#160; Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_64">65</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_67">&#160;Item 16.     [Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_67">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_70">&#160;Item 16A. &#160;Audit Committee Financial Expert</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_70">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_73">&#160;Item 16B.&#160;&#160; Code of Ethics</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_73">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_76">&#160;Item 16C.&#160;&#160;&#160;Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_76">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_79">&#160;Item 16D.&#160; &#160;Exemptions from the Listing Standards for Audit Committees</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_79">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_82">&#160;Item 16E.&#160;&#160; Purchase of Equity Securities by the Issuer and Affiliated Purchases</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_82">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_85">&#160;Item 16F.&#160;&#160; Change in Registrant's Certifying Accountants</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_85">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_88">&#160;Item 16G.&#160; Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_88">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_91">&#160;Item 16H.   Mine Safety Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_91">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_94">&#160;Item 16I.   Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_94">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_2662">Item 16J.   Insider Trading Policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_2662">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_2668">Item 16K.   Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_2668">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_100">&#160;Item 17.&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_100">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_103">&#160;Item 18&#160;&#160;&#160;&#160;&#160;&#160; Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_103">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_106">&#160;Item 19.&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_106">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_109">&#160;Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_109">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_112">&#160;Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ib0923231ce844ed28a280a970e7dcaf5_112">F1 - F27</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this annual report on Form 20-F to the terms &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us,&#8221; &#8220;the Company,&#8221; and &#8220;Oncolytics&#8221; refer to Oncolytics Biotech Inc. Unless otherwise indicated, all references to "$" and "dollars" in this annual report mean Canadian dollars. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements in this annual report on Form 20-F and the documents attached as exhibits to this annual report, constitute &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Oncolytics Biotech Inc., or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include, but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the efficacy of our technologies; the timing and results of clinical studies related to our technologies; future operations, products and services; the impact of regulatory initiatives on our operations; the size of and opportunities related to the markets for our technologies; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Forward-looking statements generally, but not always, are identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects&#8221;, &#8220;potential&#8221;, &#8220;possible&#8221; and similar expressions, or that events or conditions &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could&#8221; or &#8220;should&#8221; occur.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this annual report on Form 20-F are subject to various risks and uncertainties, most of which are difficult to predict and generally beyond our control. Some of the important risks and uncertainties that could affect forward-looking statements are described further under the section heading &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below.&#160;If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, our actual results may vary materially from those expected, estimated or projected.&#160;Forward-looking statements in this document are not a prediction of future events or circumstances, and those future events or circumstances may not occur.&#160;Given these uncertainties, users of the information included herein, including investors and prospective investors are cautioned not to place undue reliance on such forward-looking statements.&#160;Investors should consult our quarterly and annual filings with the securities commissions or similar regulatory authorities in Canada and the SEC for additional information on risks and uncertainties relating to forward-looking statements.&#160;We do not assume responsibility for the accuracy and completeness of these statements.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements are based on our beliefs, opinions and expectations at the time they are made, and we do not assume any obligation to update our forward-looking statements if those beliefs, opinions, or expectations, or other circumstances, should change, except as required by applicable law.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our securities, including our common shares ("Common Shares"), involves a high degree of risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the risks summarized below and other risks that we face, a detailed discussion of which can be found under &#8220;Item 3. Key Information &#8211; D. Risk Factors&#8221; below, together with other information in this annual report on Form 20-F and our other filings with the SEC. This summary list of risks is not exhaustive of the factors that may affect any of the Company&#8217;s forward-looking statements and our business and financial results. If any of these risks actually occur, our business, financial condition, and financial performance would likely be materially adversely affected. In such case, the trading price of our common shares would likely decline and you may lose part or all of your investment. Below is a summary of some of the principal risks we face: </span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our candidate product, pelareorep, is being and will continue to be used in combination with third-party drugs. Those currently being partnered with pelareorep are approved; however, we have limited or no control over the supply of these drugs. If our relationships with current or future collaborators or suppliers are not successful, we may be delayed in completing the development of our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business, including our research and development operations, has been and may continue to be adversely affected by the COVID-19 pandemic and global political conflicts;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical products are subject to intense regulatory approval processes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations and products may be subject to other government manufacturing and testing regulations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on patents and proprietary rights to protect our technology;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management and could materially affect our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developments in patent law could have a negative impact on our business;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we do not obtain protection under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intellectual property rights do not necessarily address all potential threats to our business.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our products may fail or cause harm, subjecting us to product liability claims;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">New products may not be accepted by the medical community or consumers;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our technologies may become obsolete;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-party manufacturers to produce our clinical products and on other third parties to store, monitor and transport bulk drug substance, and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to monitor, support, conduct, and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for those product candidates. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our license, development, supply, and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our employees, independent contractors, principal investigators, contract research organizations, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations could be adversely affected by events outside of our control, such as natural disasters, wars, or health epidemics;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Director and officer liability insurance is costly;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are dependent on our key employees and collaborators;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. shareholders;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potential dilution of present and prospective shareholdings; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_16"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_19"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_22"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. KEY INFORMATION</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1828"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">[RESERVED]</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1780"></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Capitalization and Indebtedness</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1805"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Reasons for the Offer and Use of Proceeds</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1856"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares ("Common Shares") involves a high degree of risk. You should carefully consider, among other matters, the following risk factors in addition to the other information in this annual report on Form 20-F when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the material risks described below or in subsequent reports we file with the SEC actually occur, they may materially harm our business, financial condition, operating results, or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All of our potential products, including pelareorep, are in the research and development stage and will require further development and testing before they can be marketed commercially.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prospects for companies in the biotechnology industry generally may be regarded as uncertain given the nature of the industry and, accordingly, investments in biotechnology companies should be regarded as speculative. We are currently in the research and development stage on one product, pelareorep, for human application, the riskiest stage for a company in the biotechnology industry. It is not possible to predict, based upon studies in animals and early-stage human clinical trials, whether pelareorep will prove to be safe and effective in humans. Pelareorep will require additional research and development, including extensive additional clinical testing, before we will be able to obtain the approvals of the relevant regulatory authorities in applicable countries to market pelareorep commercially. There can be no assurance that the research and development programs we conduct will result in pelareorep or any other products becoming commercially viable products, and in the event that any product or products result from the research and development program, it is unlikely they will be commercially available for a number of years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve profitable operations we, alone or with others, must successfully develop, introduce and market our products. To obtain regulatory approvals for products being developed for human use, and to achieve commercial success, human clinical trials must demonstrate that the product is safe for human use and that the product shows efficacy. Unsatisfactory results obtained from a particular study relating to a program may cause us to abandon our commitment to that program or the product being tested. No assurances can be provided that any current or future animal or human test, if undertaken, will yield favorable results. If we are unable to establish that pelareorep is a safe, effective treatment for cancer, we may be required to abandon further development of the product and develop a new business strategy.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are inherent risks in pharmaceutical research and development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical research and development is highly speculative and involves a high and significant degree of risk. The marketability of any product we develop will be affected by numerous factors beyond our control, including but not limited to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the discovery of unexpected toxicities or lack of sufficient efficacy of products which make them unattractive or unsuitable for human use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preliminary results as seen in animal and/or limited human testing may not be substantiated in larger, controlled clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing costs or other production factors may make manufacturing of products ineffective, impractical, and non-competitive;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proprietary rights of third parties or competing products or technologies may preclude commercialization;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requisite regulatory approvals for the commercial distribution of products may not be obtained; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other factors may become apparent during the course of research, up-scaling, or manufacturing which may result in the discontinuation of research and other critical projects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products under development have never been manufactured on a commercial scale, and there can be no assurance that such products can be manufactured at a cost or in a quantity to render such products commercially viable. Production and utilization of our products may require the development of new manufacturing technologies and expertise. The impact on our business in the event that new manufacturing technologies and expertise are required to be developed is uncertain. There can be no assurance that we will successfully meet any of these technological challenges or others that may arise in the course of development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure or delay in clinical trials for our products, including pelareorep, may cause us to incur additional costs or delay or prevent the commercialization of our products and could severely harm our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our products in humans. Clinical testing, in particular, is expensive, difficult to design and implement, can take many years to complete, and is uncertain as to the outcome.&#160;A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process, which could delay or prevent us from receiving marketing approval or commercializing our product candidates, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may produce negative or inconclusive results, and we may decide, or regulatory authorities may require us, to conduct additional clinical trials, or we may abandon projects that we expect to be promising;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The number of subjects required for our clinical trials may be larger than we anticipate, enrollment in our clinical trials may be slower than we anticipate, or participants may drop out of our clinical trials at a higher rate than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have to suspend or terminate our clinical trials if the participants are being exposed to unacceptable health risks;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators or institutional review boards may require that we hold, suspend, or terminate clinical research for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulators may refuse to accept or consider data from clinical trials for various reasons, including noncompliance with regulatory requirements or our clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to governmental or regulatory delays and changes in regulatory requirements, policy, and guidelines, including guidelines specifically addressing requirements for the development of treatments for our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We might have difficulty adding new clinical trial sites on a timely basis, or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The cost of our clinical trials may be greater than we anticipate;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The supply, storage, distribution, or quality of our products or other materials necessary to conduct our clinical trials may be insufficient or inadequate</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, subject enrollment, which is a significant factor in the timing of clinical trials, is affected by a variety of factors, including the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The size and nature of the subject population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The proximity of subjects to clinical sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The eligibility criteria for the trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The design of the clinical trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competing clinical trials; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinicians&#8217; and subjects&#8217; perceptions as to the potential advantages of the medication being studied in relation to other available therapies, including any new medications that may be approved for the indications we are investigating.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we plan to rely on clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their committed activities, we have limited influence over their actual performance. Any delays, concerns over the quality of the clinical data, or unanticipated problems during clinical testing, such as enrollment in our clinical trials being slower than we anticipate or participants dropping out of our clinical trials at a higher rate than we anticipate, could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenues.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the federal Right to Try Act, among other things, provides a federal framework for patients to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA approval under the FDA expanded access program. While there is no obligation to make product candidates available to eligible patients as a result of the Right to Try Act, new and emerging legislation regarding expanded access to unapproved drugs could negatively impact enrollment in our clinical trials and our business in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our candidate product, pelareorep, is being and will continue to be used in combination with third-party drugs. Those currently being partnered with pelareorep are approved; however, we have limited or no control over the supply of these drugs. If our relationships with current or future collaborators or suppliers are not successful, we may be delayed in completing the development of our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In several of our current and planned studies, pelareorep is being or will be administered in combination with immune checkpoint inhibitors ("ICIs"), a class of drugs intended to stop tumor cells from interfering with the ability of the patient&#8217;s immune system to attack their tumor. We have entered into agreements with Pfizer and Roche to supply their ICIs, avelumab and atezolizumab, respectively, for use in our ongoing Oncolytics-sponsored studies. Specifically, avelumab is being used in our ongoing Phase 2 study in breast cancer (BRACELET study), and atezolizumab was used in our window-of-opportunity study in breast cancer (AWARE study) and is being used in our ongoing Phase 1/2 study in gastrointestinal cancer (GOBLET study). In addition, other ICIs that are being used or have been used in combination with pelareorep in investigator-sponsored studies include retifanlimab (Incyte) in a Phase 2 study in breast cancer (IRENE study) and nivolumab (BMS) in a Phase 1 study in myeloma. Additionally, we may enter into future agreements for the supply of ICIs for use in connection with the development of pelareorep.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop pelareorep for use in combination with ICIs depends on our ability to access ICIs for use in our clinical trials on commercially reasonable terms. We cannot be certain that current or potential future commercial relationships will provide us with a steady supply of such drugs on commercially reasonable terms or at all. Any failure to maintain or enter into new successful commercial relationships or the expense of purchasing checkpoint blockade therapies in the market may delay our development timelines, increase our costs, and jeopardize our ability to develop pelareorep as a commercially viable therapy. If any of these occur, our business, financial condition, results of operations, stock price, and prospects may be materially harmed. </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any current or any future collaborator or supplier cannot continue to supply their products on commercially reasonable terms, we would need to identify alternatives for accessing appropriate ICIs. Additionally, should the supply of products from any current or future collaborator or supplier be interrupted, delayed, or otherwise be unavailable to us, our clinical trials may be delayed. In the event we are unable to source a supply of an alternative appropriate ICI or are unable to do so on commercially reasonable terms, our business, financial condition, results of operations, stock price, and prospects may be materially harmed.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the development of pelareorep for use in combination with ICIs may present challenges that are not faced for single agent product candidates. Developments related to the other product may impact our clinical trials as well as our commercial prospects should we receive marketing approval. Such developments may include changes to the other product's safety or efficacy profile, changes to the availability of the approved product, and changes to the standard of care.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">While we have chosen to test pelareorep in specific clinical indications based in part on our understanding of its mechanisms of action, our understanding may be incorrect or incomplete and, therefore, our pelareorep may not be effective against the diseases tested in our clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rationale for selecting the particular therapeutic indications for pelareorep is based in part on our understanding of its mechanism of action. However, our understanding of pelareorep's mechanism of action may be incomplete or incorrect, or the mechanism may not be clinically relevant to the diseases treated. In such cases, pelareorep may prove to be ineffective in the clinical trials for treating those diseases, and adverse clinical trial results would likely negatively impact our business and results from operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The incidence and prevalence for target patient populations of our product candidate is based on estimates and third-party sources. If the market opportunities for our product candidate is smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population, our business, financial condition, results of operations, and prospects may be materially adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodically, we make estimates regarding the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our product development strategy, including determining indications on which to focus in preclinical or clinical trials.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, the acceptance of such data by the medical community and patient access, product pricing and reimbursement, any limitations on populations and indications in approved product labeling, as well as the approval of new or competing medicines. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which could materially adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, including our research and development operations, has been and may continue to be adversely affected by a variety of external factors outside our control, including the COVID-19 pandemic and global political conflicts.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, general market conditions resulting from high inflation, high interest rates, global supply chain issues, global political conflicts, coronavirus infectious disease 2019 (COVID-19), bank failures, general economic uncertainty and other macroeconomic factors, as well as market conditions affecting companies in the life sciences industry in general, have touched elements of our business operations. We believe the impact on our overall business to date has not been significant. As well, we believe our financial condition, liquidity, and longer-term strategic development remain on track. However, these events have caused and may continue to cause significant fluctuations in stock markets, global economic activity, including inflation and rising interest rates, and healthcare systems. The scale and duration of these developments remain uncertain and could affect our ability to finance and execute our operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face various risks related to public health issues, including epidemics, pandemics, and other outbreaks, such as the lingering effects of the COVID-19 pandemic. The effects and potential effects of the COVID-19 pandemic, including, but not limited to, its impact on general economic conditions, trade and financing markets, changes in customer behavior and continuity in business operations, create significant uncertainty. In addition, the COVID-19 pandemic may cause an increase in costs resulting from our efforts to mitigate the effects. The extent to which the COVID-19 pandemic may continue to affect our business will depend on continued developments, including the duration of the pandemic and the extent of any further resurgences in cases in geographic areas where we operate, the emergence of new variants, some of which have been, and may be in the future, more transmissible or virulent than the initial strain, the timing, availability and acceptance of effective medical treatments and vaccines, the impact on capital and financial markets and the related impact on consumer confidence and spending, all of which are uncertain and cannot be predicted. Even if the COVID-19 pandemic subsides, we may continue to suffer an adverse impact on our business due to the global economic effect of the pandemic, including any economic recession that has occurred or may occur in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, there have been various global political conflicts. The extent and duration of the military action, sanctions, and resulting market disruptions could be significant and could potentially have a substantial negative impact on the global economy and/or our business for an unknown period of time. The ramifications of the hostilities and sanctions may not be limited to these geopolitical areas. They may spill over to and negatively impact other regional and global economic markets (including Europe and the United States), companies in other countries, and various sectors, industries and markets for securities and commodities globally. Any such volatility and disruptions may also magnify the impact of other financial market risks and uncertainties described herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent bank failures could impair our ability to access our existing cash, cash equivalents, and marketable securities and to timely pay key vendors and others. For example, on March 10, 2023, Silicon Valley Bank (SVB) was placed into receivership with the Federal Deposit Insurance Corporation (FDIC), resulting in all funds held at SVB being temporarily inaccessible by SVB&#8217;s customers. Although we did not have any funds in SVB or other institutions that have been closed, we cannot guarantee that the banks or other financial institutions that hold our funds will not experience similar issues. If other banks and financial institutions with whom we have banking relationships enter receivership or become insolvent in the future, we may be unable to access, and we may lose, some or all of our existing cash, cash equivalents, and marketable securities to the extent those funds are not insured or otherwise protected by the FDIC or Canadian Deposit Insurance Corporation (CDIC). In addition, in such circumstances we might not be able to timely pay key vendors and others. We regularly maintain cash balances that are not insured or are in excess of the FDIC/CDIC&#8217;s insurance limit. Any delay in our ability to access our cash, cash equivalents, and marketable securities (or the loss of some or all of such funds) or to timely pay key vendors and others could have a material adverse effect on our operations and cause us to need to seek additional capital sooner than planned.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on terms favorable to us, or at all, and could have material adverse impacts on our liquidity, our business, financial condition or results of operations.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which these events might prolong and/or cause significant disruptions to our business and materially impact our results of operations, including our ongoing and planned clinical studies and manufacturing activities, will depend on future developments. These future developments are highly uncertain, cannot be predicted, and could negatively impact our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Social media is increasingly being used to communicate about our clinical development programs and the diseases our product candidate is being developed to treat. We intend to utilize appropriate social media in connection with communicating about our development programs. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear. This evolution creates uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to report an alleged adverse event during a clinical trial. When such disclosures occur, we may fail to monitor and comply with applicable adverse event reporting obligations, or we may not be able to defend our business or the public&#8217;s legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our investigational products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on any social networking website, or a risk that a post on a social networking website by any of our employees may be construed as inappropriate promotion. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face regulatory actions, or incur other harm to our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any potential marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, pelareorep is generally well-tolerated and has a manageable side effect profile for most patients. However, there can be no assurance that additional undesirable side effects or serious adverse events will not be caused by or associated with pelareorep as it continues through its clinical development, including when co-administered with approved products. As with many pharmaceutical and biological products, treatment with our product candidate may produce undesirable side effects or adverse reactions or events, including potential adverse side effects related to cytokine release, and may exacerbate known adverse events associated with co-administered approved products. If our product candidates or similar products or product candidate under development by third parties demonstrate unacceptable adverse events, or unacceptably exacerbate adverse events associated with co-administered approved products, we may be required to halt or delay further clinical development of our product candidate. The FDA, the EMA, or other foreign regulatory authorities could order us to cease further development of or deny approval of our product candidate for any or all targeted indications.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. In addition, these side effects may not be appropriately or timely recognized or managed by the treating medical staff, particularly outside of the institutions that collaborate with us, as toxicities resulting from our novel technologies may not be normally encountered in the general patient population and by medical personnel. We expect to have to train medical personnel using our product candidate to understand its side effect profiles, both for our planned clinical trials and upon any commercialization. Inadequate training in recognizing or managing the potential side effects of our product candidate could result in adverse effects to patients, including death.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if our product candidate receives marketing approval, and we or others later identify undesirable side effects caused or exacerbated by such product, including during any long-term follow-up observation period recommended or required for patients who receive treatment using our product, a number of potentially significant negative consequences could result, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals of such product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to create a risk evaluation and mitigation strategy plan, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputations may suffer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved. Furthermore, any of these occurrences may harm our business, financial condition, and prospects significantly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial and managerial resources, we focus on research programs and therapeutic platforms that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and therapeutic platforms for specific indications may not yield any commercially viable products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to secure a partnership for pelareorep which could halt future development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are seeking a partner to continue the clinical development and commercialization of pelareorep. We do not have the financial resources to complete the necessary development work internally and should we not be able to secure a partnership, future development of pelareorep may not continue. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Condition Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have no operating revenues and a history of losses. We have no products approved for commercial sale, and we may never achieve or sustain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. To date, we have not generated sufficient revenues to offset our research and development costs and accordingly have not generated positive cash flow or made an operating profit. As of December&#160;31, 2023, we had an accumulated deficit of $446.0 million and we incurred net losses of $27.8 million, $24.8 million, and $26.3 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. We anticipate that we will continue to incur significant losses during 2024 and in the foreseeable future. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We do not expect to reach profitability at least until after the successful and profitable commercialization of one or more of our products. Even if one or more of our products are profitably commercialized, the initial losses incurred by us may never be recovered. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional financing in the future to fund the research and development of our products and to meet our ongoing capital requirements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had cash and cash equivalents of $34.9 million. We anticipate that we will need additional financing in the future to fund research and development and to meet our ongoing capital requirements.&#160;The amount of future capital requirements will depend on many factors, including continued scientific progress in our drug discovery and development programs, progress in our preclinical and clinical evaluation of drug candidates, time and expense associated with filing, prosecuting, and enforcing our patent claims, and costs associated with obtaining regulatory approvals.&#160;In order to meet such capital requirements, we will consider contract fees, collaborative research and development arrangements, and additional public or private financings (including the incurrence of debt and the issuance of additional equity securities) to fund all or a part of particular programs as well as potential partnering or licensing opportunities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics, from time to time, along with all other pharmaceutical research and development entities, may have restricted access to capital, bank debt, and equity, and, from time to time, may face increased borrowing costs. Although our business and asset base have not changed, the lending capacity of all financial institutions fluctuates causing a corresponding change in risk premiums. As future operations will be financed out of funds generated from financing activities, our ability to do so is dependent on, among other factors, the overall state of capital markets and investor appetite for investments in the pharmaceutical industry and our securities in particular.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should we elect to satisfy our cash commitments through the issuance of securities, by way of either private placement or public offering or otherwise, there can be no assurance that our efforts to raise such funding will be successful, or achieved on terms favorable to us or our existing shareholders.&#160;If adequate funds are not available on terms favorable to us, we may have to reduce substantially or eliminate expenditures for research and development, testing, production, and marketing of our proposed product, or obtain funds through arrangements with corporate partners that require us to relinquish rights to certain of our technologies or product. There can be no assurance that we will be able to raise additional capital if our current capital resources are exhausted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur some of our expenses in foreign currencies and therefore, we are exposed to foreign currency exchange rate fluctuations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur some of our research and development and general and administrative expenses in foreign currencies, primarily the U.S. dollar.&#160;We are therefore exposed to foreign currency rate fluctuations.&#160;Also, as we expand to other foreign jurisdictions, there may be an increase in our foreign exchange exposure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party credit risk</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of our business, we have entered into contractual arrangements with third parties which subject us to the risk that such parties may default on their obligations. Oncolytics may be exposed to third-party credit risk through our contractual arrangements with our current contract manufacturer, the institutions which operate our clinical trials, or our contract research organizations and other parties.&#160;In the event such entities fail to meet their contractual obligations to Oncolytics, such failures could have a material adverse effect on Oncolytics and our operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain third-party reimbursement for the cost of our product. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Uncertainty exists regarding the reimbursement status of newly-approved pharmaceutical products and reimbursement may not be available for pelareorep.&#160;Any reimbursements granted may not be maintained or limits on reimbursements available from third-party payors may reduce the demand for, or negatively affect the price of, these products. If pelareorep does not qualify for reimbursement, if reimbursement levels diminish, or if reimbursement is denied, our sales and profitability would be adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical products are subject to intense regulatory approval processes.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory process for pharmaceuticals, which includes preclinical studies and multiple phases of clinical trials of each compound to establish its safety and efficacy, takes many years and requires the expenditure of substantial resources. Moreover, if regulatory approval of a drug is granted, such approval may entail limitations on the indicated uses for which it may be marketed. Failure to comply with applicable regulatory requirements can, among other things, result in suspension of regulatory approvals, product recalls, seizure of products, operating restrictions, and criminal prosecution. Further, government policy may change, and additional government regulations may be established that could prevent or delay regulatory approvals for our products. In addition, a marketed drug and its manufacturer are subject to continual review. Later discovery of previously unknown problems with the product or manufacturer may result in restrictions on such product or manufacturer, including withdrawal of the product from the market.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Food and Drug Administration (&#8220;FDA&#8221;) and similar regulatory authorities in other countries may deny approval of a new drug application if required regulatory criteria are not satisfied, or may require additional testing. Product approvals may be withdrawn if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA and similar regulatory authorities in other countries may require further testing and surveillance </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs to monitor the pharmaceutical product that has been commercialized. Non-compliance with applicable requirements can result in fines and other judicially imposed sanctions, including product withdrawals, product seizures, injunction actions, and criminal prosecutions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our own pharmaceuticals, we may supply active pharmaceutical ingredients and advanced pharmaceutical intermediates for use in our customers&#8217; drug products. The final drug products in which the pharmaceutical ingredients and advanced pharmaceutical intermediates are used, however, are subject to regulation for safety and efficacy by the FDA and possibly other regulatory authorities in other jurisdictions.&#160;Such products must be approved by such agencies before they can be commercially marketed. The process of obtaining regulatory clearance for marketing is uncertain, costly, and time consuming. We cannot predict how long the necessary regulatory approvals will take or whether our customers will ever obtain such approval for their products. To the extent that our customers do not obtain the necessary regulatory approvals for marketing new products, our product sales could be adversely affected.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other governmental regulators have increased requirements for drug purity and have increased environmental burdens upon the pharmaceutical industry. Because pharmaceutical drug manufacturing is a highly regulated industry, requiring significant documentation and validation of manufacturing processes and quality control assurance prior to the approval of the facility to manufacture a specific drug, our manufacturing facilities may never become approved of, or there can be considerable transition time between the initiation of a contract to manufacture a product and the actual initiation of manufacture of that product. Any lag time in the initiation of a contract to manufacture product and the actual initiation of manufacture could cause us to lose profits or incur liabilities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical regulatory regime in Europe and other countries is generally similar to that of the United States. We could face similar risks in these other jurisdictions as the risks described above.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations and products may be subject to other government manufacturing and testing regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securing regulatory approval for the marketing of therapeutics by the FDA in the United States and similar regulatory agencies in other countries is a long and expensive process, which can delay or prevent product development and marketing. Approval to market products may be for limited applications or may not be received at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The products we anticipate manufacturing will have to comply with the FDA&#8217;s current Good Manufacturing Practices (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cGMP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and other FDA and local government guidelines and regulations, including other international regulatory requirements and guidelines. Additionally, certain of our customers may require the manufacturing facilities contracted by us to adhere to additional manufacturing standards, even if not required by the FDA. Compliance with cGMP regulations requires manufacturers to expend time, money, and effort in production, and to maintain precise records and quality control to ensure that the product meets applicable specifications and other requirements. The FDA and other regulatory bodies periodically inspect drug-manufacturing facilities to ensure compliance with applicable cGMP requirements. If the manufacturing facilities contracted by us fail to comply with the cGMP requirements, the facilities may become subject to possible FDA or other regulatory action and manufacturing at the facility could consequently be suspended. We may not be able to contract suitable alternative or back-up manufacturing facilities on terms acceptable to us or at all.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulatory agencies may also require the submission of any lot of a particular product for inspection. If the lot product fails to meet the FDA requirements, then the FDA could take any of the following actions: (i) restrict the release of the product; (ii) suspend manufacturing of the specific lot of the product; (iii) order a recall of the lot of the product; or (iv) order a seizure of the lot of the product.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to regulation by governments in many jurisdictions.&#160;If we do not comply with healthcare, drug, manufacturing, and environmental regulations, among others, in such jurisdiction, our existing and future operations may be curtailed, and we could be subject to liability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the regulatory approval process, we may be subject to regulations under local, provincial, state, federal, and foreign law, including, but not limited to, requirements regarding occupational health, safety, laboratory practices, healthcare fraud and abuse, environmental protection, and hazardous substance control, and may be subject to other present and future local, provincial, state, federal, and foreign regulations.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, and may in the future conduct, clinical trials for pelareorep in sites outside the United States and the FDA may not accept data from trials conducted in such locations. </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted, and may in the future choose to conduct, clinical trials outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deem clinically meaningful. Generally, the patient population for any clinical trials conducted outside of the United States must be representative of the population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside the United States. If the FDA does not accept the data from any clinical trials we may conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of pelareorep.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A Fast Track designation from the FDA, even if granted, may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that our product candidate will receive marketing approval.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received a Fast Track designation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of advanced/metastatic unresectable pancreatic ductal adenocarcinoma (PDAC) using pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel, and we may seek additional Fast Track designations for our other programs. Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need. A clinical program that receives Fast Track designation may benefit from more frequent meetings and communications with the FDA to discuss development plans and ensure the collection of appropriate data needed to support approval. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has broad discretion whether or not to grant this designation. Even if we believe a particular program is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Although we have received Fast Track designation for pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxe for the treatment of advanced/metastatic PDAC, and even if we receive additional Fast Track designations for our product candidate, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may also withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Furthermore, such a designation does not increase the likelihood that pelareorep will receive marketing approval in the United States. Many product candidates that have received Fast Track Designation have ultimately failed to obtain approval.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on patents and proprietary rights to protect our technology.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend, in part, on our ability to obtain patents, maintain trade secret protection and operate without infringing the rights of third parties. We have received Granted Patents in countries throughout the world, including the United States, Canada, Europe, and Japan.&#160;We file our Applications for Patent in the United States and under the PCT, allowing us to subsequently file in other jurisdictions.&#160;Our success will depend, in part, on our ability to obtain, enforce and maintain patent protection for our technology in Canada, the United States and other countries. We cannot be assured that patents will issue from any pending applications or that claims now or in the future, if any, allowed under issued patents will be sufficiently broad to protect our technology. In addition, no assurance can be given that any patents issued to, or licensed by us, will not be challenged, invalidated, infringed, or circumvented, or that the rights granted thereunder will provide continuing competitive advantages to us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of pharmaceutical and biotechnology firms, including us, are generally uncertain and involve complex legal and factual questions. In addition, it is not known whether any of our current research endeavors will result in the issuance of patents in Canada, the United States, or elsewhere, or if any patents already issued will provide significant proprietary protection or will be circumvented or invalidated. Since patent applications in the United States and Canada may be maintained in secrecy until at least 18 months after filing of the original priority application, and since publication of discoveries in the scientific or patent literature tends to lag behind actual discoveries by several months, we cannot be certain that we or any licensor were the first to create inventions claimed by pending patent applications or that we or the licensor were the first to file patent applications for such inventions. Loss of patent protection could lead to generic competition for these products, and others in the future, which would materially and adversely affect our financial prospects for these products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, since patent applications filed before November 29, 2000 in the United States may be maintained in secrecy until the patents issue or foreign counterparts, if any, publish, we cannot be certain that we or any licensor were the first creator of inventions covered by pending patent applications or that we or such licensor were the first to file patent applications for such inventions. There is no assurance that our patents, if issued, would be held valid or enforceable by a court or that a competitor&#8217;s technology or product would be found to infringe such patents.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may not be able to obtain and enforce effective patents to protect our proprietary rights from use by competitors.&#160;If other such parties obtain patents for certain information relied on by us in conducting our business, then we may be required to stop using, or pay to use, certain intellectual property, and as such, our competitive position and profitability could suffer as a result.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may choose to file patent infringement claims against us; defending ourselves from such allegations would be costly, time-consuming, distracting to management, and could materially affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development and commercialization activities, as well as any product candidates or products resulting from these activities, may infringe or be claimed to infringe patents and other intellectual property rights of third parties under which we do not hold sufficient licenses or other rights. Additionally, third parties may be successful in obtaining patent protection for technologies that cover development activities in which we are already engaged. Third parties may own or control these patents and intellectual property rights in the United States and abroad. These third parties may have substantially greater financial resources than us and could bring claims against us that could cause us to incur substantial expenses to defend against these claims and, if successful against us, could cause us to pay substantial damages. Further, if a patent infringement or other similar suit were brought against us, we could be forced to stop or delay development, manufacturing, or sales of the product or product candidate that is the subject of the suit. Intellectual property litigation in the biopharmaceutical industry is common, and we expect this trend to continue.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of patent infringement or other similar claims, or to avoid potential claims, we may choose or be required to seek a license from the third party and be required to pay license fees or royalties, or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, if at all, or if an injunction is granted against us, which could harm our business significantly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our proprietary information and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">know-how, the value of our technology and products could be adversely affected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patented technology, we rely upon unpatented proprietary technology, processes, and know-how. However, these types of trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as confidentiality policies and audits, although these may not be successful in protecting our trade secrets and confidential information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These agreements may be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known, including through a potential cybersecurity breach, or may be independently developed by competitors. If we are unable to protect the confidentiality of our proprietary information and know-how, competitors may be able to use this information to develop products that compete with our products, which could adversely impact our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we rely on third parties to research and develop and to manufacture pelareorep, we must, at times, share trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, consulting agreements or other similar agreements with our advisors, employees, third-party contractors, and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increase the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. Moreover, enforcing a claim that a third party illegally obtained and is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">using any of our trade secrets is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. These lawsuits also may impact our ability to pursue agreements with third parties in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developments in patent law could have a negative impact on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, authorities in the United States, the European Union, and other government authorities may change the standards of patentability, and any such changes could have a negative impact on our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in the United States, the Leahy-Smith America Invents Act, or the America Invents Act, which was signed into law in 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a "first-to-invent" system to a "first-to-file" system, changes to the way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. As a result of these changes, patent law in the United States may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed new and untested regulations and procedures to govern the full implementation of the America Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the first-to-file provisions became effective on March 16, 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Also, case law may have a substantial impact on the way patents are prosecuted, examined and litigated. This also affects the scope of protection that is available in a specific jurisdiction. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developments of patent law in other jurisdictions may impact our business. For example, it is currently not clear what impact the planned introduction of the Unified Patent Court in the European Union will have. Patents that are valid and enforceable under the current system may be considered invalid and/or unenforceable under the new system. Also, patents may be invalidated not just in one single jurisdiction, but across multiple countries of the European Union in one single trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not obtain protection under the Hatch-Waxman amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration, and conditions of FDA marketing approval of pelareorep, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for pelareorep will be shortened. If this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats to our business. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make compounds or formulations that are similar to pelareorep but that are not covered by the claims of any patents, should they issue, that we own or control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or control;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might not have been the first to file patent applications covering certain of our inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our pending patent applications will not lead to issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable as a result of legal challenges;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries where we do not have patent rights and then use the information learned from such activities to develop competitive drugs for sale in our major commercial markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may have an adverse effect on our business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Business Risks</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The biotechnology industry is extremely competitive and if our competitors develop and market products that are more effective, safer, or less expensive than our products, our business could be adversely impacted.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Technological competition in the pharmaceutical industry is intense and we expect competition to increase. Other companies are conducting research on therapeutics involving innate and adaptive immune responses as well as other novel treatments or therapeutics for the treatment of cancer which may compete with our product. Many of these competitors are more established, benefit from greater name recognition, and have substantially greater financial, manufacturing, technical, marketing, drug development, and human resources than us. In addition, many of these competitors have significantly greater experience in undertaking research, preclinical studies, and human clinical trials of new pharmaceutical products, obtaining regulatory approvals, manufacturing, and marketing such products. In addition, there are several other companies and products with which we may compete from time to time, and which may have significantly better and larger resources than we do. Accordingly, our competitors may succeed in manufacturing and/or commercializing products more rapidly or effectively, which could have a material adverse effect on our business, financial condition, or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive, or not economical.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we will face increased competition in the future as new products enter the market and advanced technologies become available. There can be no assurance that existing products or new products developed by our competitors will not be more effective, or be more effectively manufactured, marketed, and sold, than any that may be developed or sold by us. Competitive products may render our products obsolete and uncompetitive prior to recovering research, development, or commercialization expenses incurred with respect to any such products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may fail or cause harm, subjecting us to product liability claims.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Use of our product during current clinical trials may entail risk of product liability. We maintain clinical trial liability insurance; however, it is possible this coverage may not provide full protection against all risks.&#160;Given the scope and complexity of the clinical development process, the uncertainty of product liability litigation, and the shrinking capacity of insurance underwriters, it is not possible at this time to assess the adequacy of current clinical trial coverage, nor the ability to secure continuing coverage at the same level and at reasonable cost in the foreseeable future.&#160;While we carry, and intend to continue carrying amounts believed to be appropriate under the circumstances, it is not possible at this time to determine the adequacy of such coverage.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale and commercial use of our product entails risk of product liability. We currently do not carry any product liability insurance for this purpose. There can be no assurance that we will be able to obtain appropriate levels of product liability insurance prior to any sale of our pharmaceutical products. An inability to obtain insurance on economically feasible terms or to otherwise protect against potential product liability claims could inhibit or prevent the commercialization of products developed by us. The obligation to pay any product liability claim or a recall of a product could have a material adverse effect on our business, financial condition, and future prospects.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future legal proceedings and the impact of any finding of liability or damages could adversely impact the company and its financial condition and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be named as a defendant in various legal actions or other proceedings, including class action lawsuits. Certain of these actions include, and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other results adverse to us. Management does not currently know of any pending, material legal proceedings against the Company, but such legal action could be brought in the future.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of possible future legal proceedings cannot be predicted with certainty. Accordingly, we cannot determine whether our insurance coverage would be sufficient to cover the costs or potential losses, if any. Regardless of merit, litigation may be both time-consuming and disruptive to our operations and cause significant expense and diversion of management attention. If we do not prevail in future legal proceedings, we may be faced with significant monetary damages or injunctive relief against us that may adversely affect our business, financial condition, and results of operations, possibly materially.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New products may not be accepted by the medical community or consumers.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary activity to date has been research and development and we have no experience in marketing or commercializing products. We will likely partner with or rely on third parties to market our products, assuming that they receive regulatory approvals. If we partner with or rely on third parties to market our products, the commercial success of such product will be subject to a number of risks that may be outside of our control, including:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition in relation to alternative treatments, including efficacy advantages and cost advantages;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived ease of use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage or reimbursement by third-party payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">uncertainties regarding marketing and distribution support; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribution or use restrictions imposed by regulatory authorities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, there can be no assurance that physicians, patients, or the medical community will accept our product, even if it proves to be safe and effective and is approved for marketing by the FDA, Health Canada, and other regulatory authorities. A failure to successfully market our product would have a material adverse effect on our revenue.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, pelareorep may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technologies may become obsolete.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is characterized by rapidly changing markets, technology, emerging industry standards, and frequent introduction of new products. The introduction of new products embodying new technologies, including new manufacturing processes, and the emergence of new industry standards may render our products obsolete, less competitive, or less marketable. The process of developing our products is extremely complex and requires significant continuing development efforts, and third-party commitments. Our failure to develop new technologies and products and the obsolescence of existing technologies could adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to anticipate changes in our potential customer requirements that could make our existing technology obsolete. Our success will depend, in part, on our ability to continue to enhance our existing technologies, develop new technology that addresses the increasing sophistication and varied needs of the market, and respond to technological advances and emerging industry standards and practices on a timely and cost-effective basis. The development of our proprietary technology entails significant technical and business risks. We may not be successful in using our new technologies or exploiting our niche markets effectively, or adapting our businesses to evolving customer or medical requirements or preferences or emerging industry standards.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in methods of pelareorep manufacturing or formulation may result in additional costs or delay. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As pelareorep is developed through preclinical to late-stage clinical trials toward approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives or be acceptable to the FDA or similar regulatory authorities in other countries. Any of these changes could cause pelareorep to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay the completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability, or our strategic partners&#8217; ability, to commence product sales and generate revenue.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party manufacturers to produce our clinical products and on other third parties to test, package, store, monitor, and transport bulk drug substance and drug product. We and our third-party partners may encounter difficulties with respect to these activities that could delay or impair our ability to initiate or complete our clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate any manufacturing facilities. We rely on a contract manufacturer to source suitable raw materials and produce sufficient quantities of pelareorep for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards. If we are unable to arrange for such third-party manufacturing sources or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. The process of manufacturing pelareorep is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects, and other supply disruptions. If microbial, viral, or other contaminations are discovered in our product candidates or in the third-party manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any failure by our third-party manufacturers to comply with applicable regulatory and quality standards or any failure to deliver sufficient quantities of product candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our product candidates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have relied upon a contract manufacturer to manufacture small quantities of pelareorep. The manufacturer may encounter difficulties in scaling up production, including production yields, quality control, and quality assurance. Only a limited number of manufacturers can supply therapeutic viruses and failure by the manufacturer to deliver the required quantities of pelareorep on a timely basis at a commercially reasonable price may have a material adverse effect on us. We have completed a program for the development of a commercial process for manufacturing pelareorep and have filed a number of patent applications related to the process. There can be no assurance that we will successfully obtain sufficient patent protection related to our manufacturing process.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to third-party manufacturers, we rely on other third parties to test, package, store, monitor, and transport bulk drug substance and drug product. If we are unable to arrange for such third-party sources, or fail to do so on commercially reasonable terms, we may not be able to successfully supply sufficient product candidate or we may be delayed in doing so. Such failure or substantial delay could materially harm our business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to produce and provide suitable raw materials for pelareorep production, packaging, and testing as well as clinical trial-related testing. We and our third-party partners may encounter difficulties with sourcing these materials that could delay or impair our ability to manufacture pelareorep or complete product or clinical sample testing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on contract manufacture and testing facilities to source required materials for production and evaluation of pelareorep, as well as testing of clinical trial-related samples. As a result, we have less control over the supply timing and cost of these materials than if we sourced these materials directly. In addition, these are often specialized materials and third-party suppliers may also encounter challenges in producing, testing, or distributing materials that can impact delivery quantities and timeframes. If we are unable to arrange for sufficient supply or materials are not available in a timely manner, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of pelareorep or we may be delayed in doing so. If we are unable to arrange for appropriate testing materials or they are not available in a timely manner, we may be unable to execute some clinical trial testing or we may be delayed in doing so.</span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to monitor, support, conduct, and oversee clinical trials of the products that we are developing and, in some cases, to maintain regulatory files for those product candidates. We may not be able to obtain regulatory approval for our products that may result from our development efforts if we are not able to maintain or secure agreements with such third parties on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatory information held by them to us.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on entities outside of our control, which may include clinical and research consultants, academic institutions, and contract research organizations ("CROs"), to perform, monitor, support, conduct, and oversee preclinical studies and clinical trials of pelareorep. As a result, we have less control over the timing and cost of these studies and the ability to recruit trial subjects than if we conducted these trials with our own personnel.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or enter into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll patients on a timely basis or otherwise conduct our trials in the manner we anticipate. In addition, there is no guarantee that these third parties will devote adequate time and resources to our studies or perform as required by our contract or in accordance with regulatory requirements, including maintenance of clinical trial information regarding our products. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to protocols, or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then clinical trials of our product candidates may be extended or delayed with additional costs incurred, or our data may be rejected by the FDA, EMA or other regulatory agencies. Ultimately, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our CROs fail to comply with applicable regulatory regulations, the clinical data generated in our clinical trials may be deemed unreliable, and our submission of marketing applications may be delayed, or we may be required to perform additional clinical trials before approving our marketing applications. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and increase our costs. Moreover, our business may be implicated if any of our CROs violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our clinical trial sites terminate for any reason, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. Further, if our relationship with any of our CROs is terminated, we may be unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our license, development, supply, and distribution agreement with Adlai Nortye Biopharma Co. is subject to certain risks and uncertainties related to our dependence on Adlai and doing business in foreign jurisdictions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2017, we announced that we had entered into a license, development, supply, and distribution agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). Under the terms of the Licensing Agreement, Adlai </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan (the &#8220;Territories&#8221;). Pursuant to the Licensing Agreement, along with payments to be received by us upon meeting certain requirements and milestones, we are also eligible to receive royalty payments in excess of 10% associated with the commercialization of pelareorep for all indications, subject to regulatory approval. Under the terms of the Licensing Agreement, Adlai will be responsible for all clinical, regulatory, and commercialization activities respecting pelareorep in the Territories and therefore the Company will be dependent upon Adlai in successfully undertaking those actions in a timely and economic manner and in compliance with all applicable legal and regulatory requirements within the Territories. If Adlai is unable to fulfill its obligations under the terms of the Licensing Agreement and in compliance with all applicable legal and regulatory requirements, including clinical, regulatory and commercialization of pelareorep, our prospective revenue from royalty payments related to the commercialization of pelareorep in the Territories may be materially diminished, delayed or never realized, which could negatively affect our operating results and financial condition.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, conducting business with Adlai within the Territories, and specifically China, subjects us to certain economic, political, currency, and legal risks, and uncertainties regarding, among other things, the development and commercialization of pelareorep and the release and receipt of payments under the terms of the Licensing Agreement, including the payment of royalties upon commercialization of pelareorep. These risks include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different standards of care in various countries that could complicate the evaluation of our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different U.S. and foreign drug import and export rules;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in certain countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers, and regulatory requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems and different competitive drugs indicated to treat the indications for which our product candidates are being developed;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with the FCPA, and other anti-corruption and anti-bribery laws;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">U.S. and foreign taxes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a reliance on CROs, clinical trial sites, principal investigators, and other third parties that may be less experienced with clinical trials or have different methods of performing such clinical trials than we are used to in the U.S.;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by foreign distributors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism or natural disasters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The governments of the Territories, and specifically the Chinese government, exercise significant control over all aspects of their respective economies.&#160;Accordingly, any adverse change in the economy, the legal system, or governmental, economic or other policies could have a material adverse effect on the business prospects of the Licensing Agreement with Adlai, including our ability to receive money out of China under the terms of the Licensing Agreement. Any disruption in relations, inability to work efficiently, or disadvantageous treatment of Adlai by the governments of the Territories or other authorities could have a material adverse effect on our business prospects under the Licensing Agreement. Additionally, the regulatory environment in the Territories is evolving, and officials in the governments in the Territories exercise broad discretion in deciding how to interpret and apply regulations. There can be no assurance that Adlai will be successful in the development and commercialization of pelareorep in the Territories.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the restrictions and conditions of the Pancreatic Cancer Action Network (PanCAN) Therapeutic Accelerator Award Agreement. Failure to comply with the agreement may adversely affect our financial condition and results of operations. </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a grant from PanCAN to fund a Phase 1/2 pancreatic cancer study investigating pelareorep in combination with modified FOLFIRINOX. If we are found to have used any grant proceeds for purposes other than intended or is in violation of the terms of the grant, then we may be required to repay the grant proceeds received. A failure to maintain compliance with the grant may require us to reimburse all or a portion of the PanCAN grant which may cause a halt of delay in ongoing operations, which may adversely affect our financial condition and operating results.  </span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative developments in the field of immuno-oncology could damage public perception of pelareorep and negatively affect our business.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of pelareorep depends in part on public acceptance of the use of cancer immunotherapies including ICIs. Adverse events in clinical trials of pelareorep or in clinical trials of similar products and the resulting publicity, as well as </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any other negative developments in the field of immuno-oncology that may occur in the future including in connection with competitor therapies, could result in decreased acceptance of and demand for pelareorep. These events could also result in the suspension, discontinuation, or clinical hold of or modification to our clinical trials. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to pelareorep or to competitors&#8217; products, pelareorep may not be accepted by the general public or the medical community, and potential clinical trial participants may be discouraged from enrolling in our trials. As a result, we may not be able to continue or may be delayed in conducting our development programs.</span></div><div><span><br/></span></div><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is an oncolytic virus and, as such, adverse developments related to vaccines for viral diseases or in clinical trials of other virus-based oncolytic immunotherapy products may result in a disproportionately negative effect on the perception of pelareorep compared to other products in the field of immuno-oncology that are not based on viruses. Future negative developments in the field of immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements, and potential regulatory delays in the testing or approval of pelareorep. Any increased scrutiny could delay or increase the costs of obtaining marketing approval for pelareorep.</span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, contract research organizations, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate: (1) FDA regulations, including those laws that require the reporting of true, complete, and accurate information to the FDA, (2) manufacturing standards, (3) federal and state healthcare fraud and abuse laws and regulations, or (4) laws that require the reporting of true and accurate financial information and data. Specifically, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and if we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties. </span></div><div style="margin-top:10pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received confidential and proprietary information from collaborators, prospective licensees, and other third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. We may also be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other intellectual property. We may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our drug candidates. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management and employees.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations could be adversely affected by events outside of our control, such as natural disasters, wars&#160;or health epidemics.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19, geopolitical actions, including war and terrorism or natural disasters including earthquakes, typhoons, floods, and fires. An outbreak of infectious disease, a pandemic or a similar public health threat, such as the COVID-19 pandemic, or a fear of any of the foregoing, could adversely impact us by causing operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result of government regulation and prevention measures). It is unknown whether and how we may be affected if such an epidemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results, and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Director and officer liability insurance is costly. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry liability insurance on behalf of our directors and officers. Given the number of large director and officer liability insurance claims in the U.S. equity markets, director and officer liability insurance has become costly. Because we have limited financial resources, we may forego or delay pursuit of certain opportunities, which could later have a material adverse impact on our business, operating results, and financial condition. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on our key employees and collaborators.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to develop the product will depend, to a great extent, on our ability to attract and retain highly qualified scientific personnel and to develop and maintain relationships with leading research institutions. Intense competition for attracting key skill-sets may limit our ability to retain and motivate key personnel on acceptable terms. We are highly dependent on the principal members of our management staff as well as our advisors and collaborators, the loss of whose services might impede the achievement of development objectives. The persons working with us are affected by a number of influences outside of our control. In the U.S., the SEC recently adopted mandatory clawback rules which requires listed companies to adopt a clawback policy providing for recovery of incentive-based compensation awarded to executive officers if we are required to prepare an accounting restatement resulting from material noncompliance with financial reporting requirements. There is the potential that new compensation rules will make it more difficult for us to attract and retain executive officers. The loss of key employees and/or key collaborators may affect the speed and success of product development.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience difficulties in managing growth-related risks, which could negatively affect our operating results and business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize pelareorep and compete effectively will depend, in part, on our ability to effectively manage any future growth. We may be subject to growth-related risks including pressure on its internal systems and controls. Our ability to manage its growth effectively will require us to continue to implement and improve our operational and financial systems and to expand, train and manage our employee base. Inability to deal with this growth could have a material adverse impact on our business, operations and prospects. We may experience growth in the number of our employees and the scope of its operating and financial systems, resulting in increased responsibilities for its personnel, the hiring of additional personnel and, in general, higher levels of operating expenses. In order to manage our current operations and any future growth effectively, we will also need to continue to implement and improve its operational, financial and management information systems and to hire, train, motivate, manage and retain its employees. There can be no assurance that we will be able to manage such growth effectively, that our management, personnel or systems will be adequate to support our operations or that we will be able to achieve the ability to generate the levels of funding commensurate with the increased levels of operating expenses associated with this growth.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Barbados law differs from the laws in effect in Canada and the United States and may afford less protection to holders of our securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our assets and intellectual property are held by our wholly-owned subsidiary, Oncolytics Biotech (Barbados) Inc., which is organized under the laws of Barbados. It may not be possible to enforce court judgments obtained in Canada or the United States against Oncolytics Biotech (Barbados) Inc. in Barbados based on the civil liabilities provisions of applicable securities laws. In addition, there is some doubt as to whether the courts of Barbados would recognize or enforce judgments of courts in Canada or the United States obtained against us or our directors or officers based on the civil liabilities provisions of Canadian and United States securities laws or hear actions against us or those persons based on such laws.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to complex laws and regulations that address privacy and data security. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security issues. In the U.S., numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws, govern the collection, use, disclosure, and protection of health-related and other personal information. For example, the State of California enacted the California Consumer Privacy </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Act of 2018 (the &#8220;CCPA&#8221;), which came into effect on January 1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Similar laws have been proposed in Virginia, Colorado, Connecticut and Utah and at the federal level, and if passed, such laws may have potentially conflicting requirements that would make compliance challenging.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the course of our business, we may obtain health information from third party that is subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;). Although we are not directly subject to HIPAA (other than potentially with respect to providing certain employee benefits) we could be subject to criminal penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA/HITECH.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be negatively impacted by existing and proposed laws and regulations, as well as government policies and practices related to cybersecurity, data privacy, data localization, and data protection outside of the U.S., such as the General Data Protection Regulation (&#8220;GDPR&#8221;), which took effect in the EU in May 2018. The GDPR extends the geographical scope of EU data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles, and creates new obligations for companies and new rights for individuals. The GDPR may increase our responsibility and potential liability in relation to personal data that we process, expose us to substantial potential fines, and increase our compliance costs.&#160;The GDPR could also cause our development costs to increase in connection with clinical trials we are currently conducting and may conduct in the future in the EU for our products and product candidates. Further, recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the EU to the United States. As well, from January 1, 2021, the GDPR and the United Kingdom (&#8220;UK&#8221;) GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the U.S. and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-US Data Privacy Framework has not been implemented beyond an executive order signed by President Biden in October 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with data protection laws and regulations both within and outside of the U.S. could result in government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company may fail to achieve and maintain adequate internal control over financial reporting pursuant to the requirements of the Sarbanes-Oxley Act and equivalent Canadian legislation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documented and tested during its most recent fiscal year its internal control procedures in order to satisfy the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 (&#8220;SOX&#8221;) and equivalent Canadian legislation. SOX requires an annual assessment by management of the effectiveness of the Company&#8217;s internal control over financial reporting and an attestation report by the Company&#8217;s independent auditors addressing this assessment, if applicable. The Company may fail to achieve and maintain the adequacy of its internal control over financial reporting as such standards are modified, supplemented, or amended from time to time, and the Company may not be able to ensure that it can conclude, on an ongoing basis, that it has effective internal control over financial reporting in accordance with Section&#160;404 of SOX. The Company&#8217;s failure to satisfy the requirements of Section&#160;404 of SOX on an ongoing, timely basis could result in the loss of investor confidence in the reliability of its financial statements, which in turn could harm the Company&#8217;s business and negatively impact the trading price of the common shares or the market value of its other securities. In addition, any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm the Company&#8217;s operating results or cause it to fail to meet its reporting obligations. Future acquisitions of companies, if any, may provide the Company with challenges in implementing the required processes, procedures, and controls in its acquired operations. No evaluation can provide complete assurance that the Company&#8217;s internal control over financial reporting will detect or uncover all failures of persons within the Company to disclose material information otherwise required to be reported. The effectiveness of the Company&#8217;s processes, procedures, and controls could also be limited by simple errors or faulty judgments. In addition, if the Company expands, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">challenges involved in implementing appropriate internal control over financial reporting will increase and will require that the Company continue to improve its internal control over financial reporting.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because the Company is a Canadian Company and some of its directors and officers are residents outside the United States, it may be difficult for investors in the United States to enforce civil liabilities against the Company based solely upon the federal securities laws of the United States.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a Canadian company, with its principal place of business in Canada. Some of the Company&#8217;s directors and officers, including the Company's Chief Executive Officer and Chief Financial Officer, are residents outside the United States and a significant portion of the Company&#8217;s assets are located outside the United States. Consequently, it may be difficult for U.S. investors to effect service of process within the United States upon the Company or these directors or officers who are not residents of the United States, or to realize in the United States upon judgments of courts of the United States predicated upon civil liabilities under the U.S. Securities Act of 1933, as amended. Investors should not assume that Canadian courts (1)&#160;would enforce judgments of U.S. courts obtained in actions against the Company or such directors or officers predicated upon the civil liability provisions of the U.S. federal securities laws or the securities or &#8220;blue sky&#8221; laws of any state within the United States or (2)&#160;would enforce, in original actions, liabilities against the Company or such directors or officers predicated upon the U.S. federal securities laws or any such state securities or &#8220;blue sky&#8221; laws. In addition, the protections afforded by Canadian securities laws may not be available to investors in the United States.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is a &#8220;foreign private issuer&#8221; as defined in Rule&#160;3b-4 under the United States Securities Exchange Act of 1934, as amended (the &#8220;U.S. Exchange Act&#8221;). Equity securities of the Company are accordingly exempt from Sections&#160;14(a), 14(b), 14(c), 14(f), and 16 of the U.S. Exchange Act pursuant to Rule&#160;3a12-3 of the U.S. Exchange Act. Therefore, the Company is not required to file a Schedule&#160;14A proxy statement in relation to its annual meeting of shareholders. The submission of proxy and annual meeting of&#160;shareholder information on Form 6-K may result in shareholders having less complete and timely information in connection with shareholder actions. The exemption from Section&#160;16 rules regarding reports of beneficial ownership and purchases and sales of common shares by insiders and restrictions on insider trading in our securities may result in shareholders having less data and there being fewer restrictions on insiders&#8217; activities in our securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we were to lose our foreign private issuer status under U.S. federal securities law, we would likely incur additional expenses associated with compliance with the U.S. securities law applicable to U.S. domestic issuers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, as discussed above under the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As a foreign private issuer, our shareholders may have less complete and timely data,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; we are exempt from certain provisions of the U.S. federal securities law. The determination of foreign private issuer status is made annually on the last business day of an issuer&#8217;s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our common shares are directly or indirectly held by residents of the United States and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors, and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing rules. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting, and other expenses that we will not incur as a foreign private issuer, and accounting, reporting, and other expenses in order to maintain a listing on a U.S. securities exchange. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors and more expensive to procure director and officer liability insurance. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company is likely a "passive foreign investment company" which may have adverse U.S. federal income tax consequences for U.S. Holders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. holders of Common Shares should be aware that the Company believes it was classified as a passive foreign investment company (&#8220;PFIC&#8221;) during its most recently completed tax year, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future taxable years.&#160;If the Company is a PFIC for any year during a U.S. Holder&#8217;s (as defined below) holding period of the Common Shares, then such U.S. Holder generally will be required to treat any gain realized upon a disposition of Common Shares, or any &#8220;excess distribution&#8221; received on its Common Shares, as ordinary income, and to pay an interest charge on a portion of such gain or distribution, unless the U.S. Holder makes a timely and effective qualified electing fund election (&#8220;QEF Election&#8221;) or a mark-to-market election with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respect to the Common Shares.&#160;A U.S. Holder who makes a QEF Election generally must report on a current basis its share of the Company's net capital gain and ordinary earnings for any year in which the Company is a PFIC, whether or not the Company distributes any amounts to its shareholders.&#160;A U.S. Holder who makes the mark-to-market election generally must include as ordinary income each year the excess of the fair market value of the Common Shares over the taxpayer&#8217;s adjusted tax basis therein.&#160;This paragraph is qualified in its entirety by the discussion below under the heading &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material United States Federal Income Tax Considerations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;&#160;Each U.S. Holder should consult its own tax advisors regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our Common Shares </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Volatility of market price of the Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of the Common Shares may be volatile. The volatility may affect the ability of holders of Common Shares to sell the Common Shares at an advantageous price. Market price fluctuations in the Common Shares may be due to the Company&#8217;s operating results failing to meet the expectations of securities analysts or investors in any quarter, downward revision in securities analysts&#8217; estimates, governmental regulatory action, adverse change in general market conditions or economic trends, acquisitions, dispositions or other material public announcements by the Company or its competitors, along with a variety of additional factors, including, without limitation, those set forth under &#8220;Cautionary Note Regarding Forward-Looking Statements&#8221; in this annual report on Form 20-F. In addition, the market price for securities in the stock markets, including the NASDAQ and the TSX, recently experienced significant price and trading fluctuations. These fluctuations have resulted in volatility in the market prices of securities that often has been unrelated or disproportionate to changes in operating performance. These broad market fluctuations may adversely affect the market price of the Common Shares</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Potential dilution of present and prospective shareholdings.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to finance future operations and development efforts, the Company may raise funds through the issue of common shares or the issue of securities convertible into common shares. The Company cannot predict the size of future issues of common shares or the issue of securities convertible into common shares or the effect, if any, that future issues and sales of the Company&#8217;s common shares will have on the market price of its common shares. Any transaction involving the issue of previously authorized but unissued shares, or securities convertible into shares, would result in dilution, possibly substantial, to present and prospective holders of shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company does not intend to pay cash dividends in the foreseeable future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not declared or paid any dividends since its incorporation. The Company intends to retain earnings, if any, to finance the growth and development of its business and does not intend to pay cash dividends on the Common Shares in the foreseeable future. Any return on an investment in the common shares will come from the appreciation, if any, in the value of the Common Shares. The payment of future cash dividends, if any, will be reviewed periodically by the board of directors and will depend upon, among other things, conditions then existing including earnings, financial condition, and capital requirements, restrictions in financing agreements, business opportunities and conditions, and other factors.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in law could adversely affect our business and corporate structure.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurances that changes will not occur in corporate, tax, property, and other laws in Canada and/or Barbados (or the interpretation thereof by regulatory or tax authorities) which may materially and adversely affect our businesses and corporate structure.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert our management&#8217;s attention.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Regardless of the merits or the ultimate results of such litigation, securities litigation brought against us could result in substantial costs and divert our management&#8217;s attention from other business concerns.</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations may be adversely affected by disruptions to our information technology ("IT") systems, including disruptions from cybersecurity breaches of our IT infrastructure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on information technology networks and systems, including those of third-party service providers, to process, transmit and store electronic information. In particular, we depend on our information technology infrastructure for a variety of functions, including financial reporting, data management, and email communications. Any of these systems may be susceptible to outages due to fire, floods, power loss, telecommunications failures, terrorist attacks, sabotage, and similar events. Global cybersecurity threats and incidents can range from uncoordinated individual attempts to gain unauthorized access to our information technology systems to sophisticated and targeted measures known as advanced persistent threats. The ever-increasing use and evolution of technology, including cloud-based computing, creates opportunities for the unintentional dissemination or intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from industrial espionage attacks, malware or other cyber-attacks, which may compromise our system infrastructure or lead to data leakage, either internally or at our third-party providers. Despite the implementation of network security measures and disaster recovery plans, our systems and those of third parties on which we rely may also be vulnerable to computer viruses, break-ins, and similar disruptions. If we or our vendors are unable (or are perceived as unable) to prevent such outages and breaches, our operations may be disrupted, and our business reputation could be adversely affected. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that risks and exposures related to cybersecurity attacks will remain high for the foreseeable future due to the rapidly evolving nature and sophistication of these threats. In addition, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to meet regulatory or ethical expectations on environmental impact, including climate change. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environmental issues will become more material in the marketplace as the wider healthcare system embraces net -zero climate targets. The environmental targets and performance of our business will come under increased scrutiny by investors, governments, and non-governmental organizations. Environmental considerations are starting to become embedded in the public procurement of goods and services, including medicinal products and devices. Specific intermediates used to manufacture medicines, or those used as excipients or propellants, are coming under increased regulation and some may be subject to time-limited exemptions or potential phase-out. The physical impacts of climate change could impact the resilience of our business operations and supply chain.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_25"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;INFORMATION ON THE COMPANY</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1880"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">History and Development of the Company</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was formed under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Alberta) on April 2, 1998 as 779738 Alberta Ltd.&#160;&#160;On April 8, 1998, we changed our name to Oncolytics Biotech Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, telephone (403) 670-7377. Our agent for service in the U.S. is Registered Agent Solutions, Inc., 838 Walker Road Suite 21-2 Delaware 19904.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of the important events in our development including licensing transactions, our principal capital expenditures and divestitures and a description of acquisitions of material assets can be found in our MD&amp;A and in the notes to our financial statements included elsewhere in this annual report.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains a Website that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC at http://www.sec.gov. The filings are also contained on the Company&#8217;s website at www.oncolyticsbiotech.com. Information on the Company's website is not incorporated by reference herein. </span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1905"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Business Overview </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment (TME). This creates a more favorable TME, which in turn makes the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors, as well as other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and CDK4/6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of PD-1/PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to immunotherapies and other cancer treatments, especially in cancers where immunotherapies have failed or provided limited benefit.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through the issuance of additional capital via public offerings, equity distribution arrangements, and through the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is to develop and seek regulatory approval to market pelareorep in an effective and timely manner, and access additional technologies at a time and in a manner that we believe is best for our development.&#160;We intend to achieve our business strategy by focusing on these key areas:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continue to assess the safety and efficacy of pelareorep in human subjects through our clinical development program;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintain existing and establish new collaborations with experts to assist us with scientific and clinical developments of this new potential pharmaceutical product;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Implement strategic alliances with select biopharmaceutical companies and laboratories, at a time and in a manner whereby such alliances may complement and expand our own research and development efforts. Such alliances may also result in an eventual expansion to include providing additive sales and marketing capabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Use our broadening patent base and collaborator network as a mechanism to meet our strategic objectives; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop relationships with companies that could be instrumental in assisting us to access other innovative therapeutics.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expanding our clinical program, business development, and partnering opportunities to address a broad range of cancers in combination with various other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is based on attaining a number of commercial objectives, which, in turn, are supported by a number of product development goals.&#160;In the context of this annual report, statements of our "belief" are based primarily upon our results derived to date from our research and development program with animals, early-stage human trials, and our most recent data from our mid-stage clinical trials, upon which we believe that we have a reasonable scientific basis to expect the particular results to occur.&#160;It is not possible to predict, based upon studies in animals, or early- to -mid-stage human trials, whether a new therapeutic will ultimately prove to be safe and effective in humans.&#160;There are no assurances that the particular result expected by us will occur.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing a strategy of establishing relationships with larger companies as strategic partners.&#160;It is anticipated that future clinical development into large international or pivotal trials would generally occur in conjunction with a strategic partner or partners, who would contribute expertise and financial assistance.&#160;In exchange for certain product rights and commitments to market our products, the strategic partners would be expected to share in proceeds from the sale of our product or products.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Scientific Background &amp; Summary of Research and Development Highlights </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep&#8217;s anti-tumor activity is based on three complementary modes of action (Figure 1): </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Selective viral replication in permissive cancer cells that leads to tumor cell lysis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Activation of innate immunity in response to the infection, which results in a cascade of chemokines/cytokines, causing natural killer (NK) cells to be activated and attack cancer cells.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Induction of adaptive immune responses capable of attacking tumors by targeting tumor- and virus-specific antigens.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and translational research to date indicates the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has anticancer effects in a variety of animal models demonstrating that it can reduce tumor burden and prolong survival in these models. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The anticancer effects in animal models can be enhanced when pelareorep is given in combination with chemotherapy, immunotherapy, radiotherapy, and other targeted cancer therapies, highlighting the ability of pelareorep to enhance the anticancer effects of a broad range of cancer therapeutics.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">A toxic dose of pelareorep has not been reached/established in animal models and doses as high as 9.0 x 10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">10 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TCID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:1.4pt;vertical-align:baseline">50 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have been well-tolerated in humans;  treatment with pelareorep causes manageable side-effects.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical data to date indicate the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">More than 1,500 patients have received at least one dose of study treatment in clinical studies with pelareorep. Of these, more than 1,100 patients received pelareorep, over 600 patients in Oncolytics-sponsored trials, and over 500 in investigator-sponsored trials received pelareorep.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep has been administered as single or multiple doses (intratumoral or intravenous), either as a monotherapy or in combination with chemotherapy, immunotherapy (e.g., checkpoint inhibitors), and/or radiotherapy.  </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pelareorep is generally well-tolerated and has a manageable side effect profile. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">When combined with chemotherapy or immunotherapy, pelareorep does not appear to enhance either the frequency or severity of the adverse effects of these agents.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Efficacy results from clinical studies show that treatment with pelareorep can improve the outcome of cancer patients with a variety of different tumors: </span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a randomized Phase 2 study with 74 mBC patients, known as IND.213, treatment with pelareorep plus paclitaxel versus paclitaxel alone demonstrated a statistically significant improvement in median overall survival (OS): 17.4 months versus 10.4 months, respectively (HR = 0.65; 80% CI 0.46&#8211;0.91; p=0.1). In a post hoc subgroup analysis of patients with HR+/HER2- diseases, the median OS benefit from the addition of pelareorep to paclitaxel was even greater compared to paclitaxel alone: 21.0 months versus 10.8 months, respectively (HR = 0.60; p=0.1). A second randomized Phase 2 study, BRACELET-1, in metastatic HR+/HER- breast cancer patients who had failed hormonal therapy showed that pelareorep combined with paclitaxel improved both median progression-free survival (PFS) (9.5 months vs. 6.3 months) and confirmed objective response rate (ORR) (37.5% vs. 13.3%) compared to paclitaxel alone.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the AWARE-1 window-of-opportunity study, most HR+/HER2- early breast cancer patients treated with pelareorep showed an increase in CeLTIL score, a measure of tumor cellularity and tumor infiltrating lymphocytes (TILs) that is associated with a better prognosis in breast cancer. Importantly, addition of the immune checkpoint inhibitor atezolizumab to pelareorep increased both the magnitude of the increase in CeLTIL score and the proportion of patients with a positive CelTIL score thereby achieving the study&#8217;s primary endpoint. Biomarker data from AWARE-1 further demonstrated that pelareorep treatment reversed immunosuppressive tumor microenvironments, generated and expanded T cell clones, upregulated PD-L1 expression, and promoted CD8+ T cell tumor infiltration into tumors. Many of these effects were even more prominent when pelareorep was combined with atezolizumab demonstrating synergy between the two agents.</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the GOBLET platform study results, the ORR and disease control rate (DCR) were 62% and 85%, respectively, in the first-line advanced/metastatic PDAC patients treated with the combination of pelareorep, atezolizumab and gemcitabine/nab-paclitaxel. The observed ORR is substantially higher than the average ORR of ~25% reported in historical control trials of gemcitabine and nab-paclitaxel in metastatic pancreatic cancer. Additional data also included:</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Eight of thirteen evaluable patients achieved a partial response (PR)</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Three of thirteen evaluable patients achieved stable disease (SD)</span></div><div style="margin-top:3pt;padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The cohort exceeded the protocol-specified success criterion for Stage 1 of &#8805; 3/12 objective responses</span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a single-arm study of gemcitabine plus pelareorep, known as REO 017, first-line patients with metastatic pancreatic ductal adenocarcinoma, had a median OS of 10.2 months with 1-year and 2-year survival rates of 45% and 24%, respectively. These results were encouraging when compared to 20&#8211;22% and 2&#8211;5% </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">benchmark 1-year and 2-year survivals, respectively, for metastatic PDAC patients treated with gemcitabine alone from two different phase 3 studies.  </span></div><div style="margin-top:3pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a two-arm Phase 2 study (NCI 8601), patients with metastatic PDAC were randomized to receive either carboplatin, paclitaxel and pelareorep (test arm) or carboplatin and paclitaxel alone (control arm). The median OS was similar for both arms, but the probability of survival at Year 2 was 20% in the test arm vs. 9% in the control arm. Evaluation of patient samples collected during this clinical trial identified the immunomodulatory CEA cell adhesion molecule 6 (CEACAM6) as a potential predictive biomarker for response to pelareorep therapy. Specifically, low levels of CEACAM6 mRNA expression were associated with prolonged progression-free survival in pelareorep-treated patients (10.3 months in CEACAM6 low versus 5.7 months in CEACAM6 high patients, p=0.05); importantly, this effect was not seen in the control arm.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Preliminary results from the anal carcinoma cohort of the GOBLET platform study showed ORR of 37.5% in second-line or later patients with squamous cell carcinoma of the anus treated with pelareorep plus atezolizumab, which compares favorably to the 10-14% ORRs reported in recent clinical trials of checkpoint inhibitor therapy is a similar second-line or later anal carcinoma populations. This cohort has exceeded the Stage 1 success criterion of &#8805;2 responses in the first 10 patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Mechanism of Action</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 1. Proposed mechanism of action for pelareorep</span></div><div style="text-align:justify"><img src="oncyf-20231231_g1.jpg" alt="reolysinmoapanel4smalla02.jpg" style="height:341px;margin-bottom:5pt;vertical-align:text-bottom;width:424px"/></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Direct cell lysis - Reovirus Replication in Permissive Cancer Cells</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selective viral replication and lysis in cancer cells and not normal cells is mediated by the host cellular protein dsRNA-activated protein kinase (PKR). PKR is activated in non-cancer cells infected with reovirus, which in turn inhibits viral gene translation. However, in permissive cancer cells, PKR activation is inhibited, allowing viral gene translation and eventual cell lysis. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It was originally established that selective lysis of tumor cells was mediated by the activated rat sarcoma virus oncogene (RAS)-pathway, since active RAS inhibits PKR activation. However, more recent investigations have revealed that reovirus replication is not restricted to cells with an active RAS pathway; rather oncogenic mutations and amplifications in upstream and downstream mediators of the RAS-pathway also allow viral replication and oncolysis. Moreover, active RAS is known to stimulate over 18 downstream effector proteins, many of which have been shown to facilitate viral replication. Cells bearing dysfunctional or deleted tumor suppressor genes and/or undergoing chemo- or radiation-induced cell stress also show increased sensitivity to reovirus replication and lysis.</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Innate Immunity</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical and clinical studies provide compelling evidence that pelareorep functions as a systemically-delivered immunogenic agent that acts locally at the site of the tumor. Indeed, preclinical studies demonstrated that cancer cells infected with pelareorep can produce an innate immune response triggering the release of inflammatory cytokines. This inflammatory environment promotes a chemotactic response in NK cells, dendritic cells, and cytotoxic T cells, altering the tumor microenvironment to support bystander immune-mediated cancer cell death. Intriguingly, preclinical studies have also demonstrated that the beneficial immunogenic functions of pelareorep can occur independently of viral replication. Pelareorep performs this immunogenic function, in part, by activating dendritic cells, key regulators of both adaptive and innate immunity. Dendritic cells activated by reovirus, in turn, stimulate the innate antitumor activity of NK cells and aid in the priming of specific antitumor cytotoxic lymphocyte, demonstrating that dendritic cell recognition of reovirus may trigger a beneficial innate immune response.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial with pelareorep (REO 013) provided an opportunity to study human NK cell activation in a controlled manner. Ten colorectal cancer patients with liver metastases received between one and five doses of pelareorep prior to surgical resection of their tumor. NK cell activation peaked 24-48 hours post-infection, coincident with a peak in pro-inflammatory cytokines. NK cells within a population of reovirus-treated blood mononuclear cells were stimulated to kill tumor targets, but not normal hepatocytes. Moreover, peripheral blood mononuclear cells were able to hand-off virus to tumors for direct oncolytic killing. Similarly, NK cells within a liver mononuclear cell population became selectively cytotoxic toward tumor cells when activated by reovirus. These results showed that reovirus modulates human NK cell activity in vivo and suggest that this may contribute to the therapeutic effect of pelareorep.</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Induction of Adaptive Immunity</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adaptive anti-tumor immunity eliminates existing cancer cells and performs constant surveillance, preventing relapse, and increasing overall survival. An adaptive immune response requires two signals: a signal from an APC, as well as a co-stimulation signal in the form of cytokines. In the absence of either signal, the adaptive immune response fails. Therapy with pelareorep has the potential to activate both signals. Following administration, pelareorep enhances the expression of &#8216;foreign&#8217; antigens/markers on tumor cells. Oncolysis of tumor cells exposes tumor-associated antigens (TAAs) and viral-associated antigens (VAAs) for processing and presentation by APCs, such as dendritic cells. Through this process, pelareorep facilitates the display of existing tumor specific antigens and novel &#8216;foreign&#8217; antigens on the surface of infected tumor cells and APCs resulting in the expansion of these tumor specific T cell subsets. While it is difficult to identify the expansion of novel tumor T cell specific clones, we have identified expansion of pre-existing tumor specific T cell clones in the blood of pela treated subjects. Preliminary data suggests that the expansion of these clones correlates with reductions in tumor volume. Simultaneously, pelareorep induces an increase in inflammatory response including the expression of co-stimulatory molecules and inflammatory cytokines. Together, these pelareorep-mediated immunological events initiate adaptive anti-tumor immunity.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By promoting the expansion of existing tumor specific T cells and the putative expression of novel antigens and the release of inflammatory cytokines, pelareorep, promotes an inflamed tumor phenotype. An inflamed tumor phenotype is characterized by NK and T cell infiltration, increased expression of chemokines/cytokines, and increased expression of checkpoint ligands such as PD-L1. This phenotype correlates with an increase in overall survival and has a positive prognostic value for early-stage cancers. In patients with metastatic cancer, an inflamed tumor phenotype is associated with better clinical outcomes when treated with immunotherapies, including immune checkpoint inhibitors, cancer vaccines, and adaptive T cell therapies. By promoting an inflamed tumor phenotype, pelareorep primes an anti-cancer immune response (Figure 2).  </span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Figure 2. Pelareorep primes an anti-cancer immune response</span></div><div style="margin-bottom:8pt"><img src="oncyf-20231231_g2.jpg" alt="pelareorep-lga02.jpg" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:513px"/></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Breast Cancer Program</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we announced BRACELET-1 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">east c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r with the Oncolytic Reovirus Pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">areor</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">p in Combina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ion with anti-PD-L1 and Paclitaxel) data that showed pelareorep driving robust increases in PFS and confirmed overall response rate at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO). A summary of response and PFS data from all 48 patients enrolled in BRACELET-1 was shown below: </span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"/><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paclitaxel (PTX) Monotherapy (n=15)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PTX + Pelareorep (n=16)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PTX + Pelareorep + Avelumab (n=17)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ORR at Week 16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (20%)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 (31.3%)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (17.6%)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confirmed ORR Over Course of Trial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 (13.3%)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 (37.5%)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (17.6%)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">mPFS (months)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3<br/>(95% CI: 3.9, NR)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5<br/>(95% CI: 6.5, NR)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2<br/>(95% CI: 4.0, NR)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PFS Hazard Ratio vs. PTX Monotherapy</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29<br/>(95% CI: 0.09, 0.98)</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.31<br/>(95% CI: 0.47, 3.65)</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12-month PFS Rate (%)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 <br/>(95% CI: -, -)</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8<br/>(95% CI: 11.7, 92.4)</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0<br/>(95% CI: -, -)</span></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1. Data from an October 2022 cut-off date. Three patients who withdrew consent prior to starting therapy and two patients who discontinued treatment after week 1 were considered non-responders and censored for PFS.<br/>2. Data from a March 3, 2023 cut-off date. Numbers presented may change as they are derived from an unlocked database.<br/>3. Data include all patients enrolled in trial. Response data presented by Clark et al. at ASCO 2023 included the 45 randomized patients and excluded participants in the three-patient safety run-in in cohort 3.  <br/>CI: Confidence interval; NR: Not reached; mPFS: median progression-free survival.</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional key biomarker and safety findings included:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Association between T cell expansion and efficacy measures: A statistically significant increase in T cell fraction, a measure of T cell expansion, was observed in cohort 2 (paclitaxel + pelareorep) but not in cohort 3 (paclitaxel + pelareorep + avelumab) </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generally favorable and manageable safety profile: Pelareorep displayed a manageable safety profile consistent with what has been observed in prior clinical trials that have collectively treated over 1,100 patients  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of this study provided important confirmatory data in a patient population similar to our IND.213 study, in which we observed a statistically significant near-doubling of median OS with pelareorep treatment in HR+/HER2- mBC. These data </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">further de-risk our path to registration, increasing the likelihood of clinical success and potentially allowing for the use of PFS as a primary endpoint. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the data presented at ASCO, we continued monitoring BRACELET-1 patients for survival to allow the assessment of median OS in all treatment groups, which we expect to occur in 2024. We also reviewed our BRACELET-1 data with key opinion leaders to investigate different trial designs as we move toward defining our breast cancer licensure-enabling study. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we also presented data from our AWARE-1 study at the Society for Immunotherapy of Cancer 38</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Meeting (SITC 2023) and 2023 San Antonio Breast Cancer Symposium (SABCS). In the AWARE-1 study, early-stage HR+/HER2- breast cancer patients were enrolled in two cohorts; those in cohort 1 received pelareorep and letrozole, while patients in cohort 2 received pelareorep, letrozole, and atezolizumab.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">SITC 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Samples from cohort 2 were evaluated using a biomarker panel of 37 conjugated antibodies that bind to tumor antigens and immune cells. Novel imaging mass cytometry (IMC) technology was used to visualize cellular interactions down to the single cell level and showed an increase in PD-L1 positivity and cytotoxic T cells. This translational data will be incorporated into the registrational program for HR+/HER2- metastatic breast cancer.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2023 SABCS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Samples from both AWARE-1 cohorts were evaluated, showing pelareorep induced the expansion of existing TIL clones, which are presumed to be anti-tumor T cells and new clones. These data are consistent with results from posters recently presented at the SITC and ESMO meetings and affirm that pelareorep functions as an immunotherapeutic agent.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As previously reported, the majority of patients in both cohorts achieved an increase in CelTIL scores, which is correlated with improved patient outcomes, with 60% of patients in Cohort 2 achieving a 30% increase in CelTIL scores, the primary endpoint of the study</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tumor T cell fractions showed that TILs increased in both study cohorts (1.27 fold in Cohort 1, 2.74 fold in Cohort 2), with a greater increase in Cohort 2, which included pelareorep and the checkpoint inhibitor</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clonal expansion results showed that pelareorep induced an expansion of TILs in tumor and peripheral blood with:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In tumors, new clones were more prominent</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In peripheral blood, existing clones were more prominent</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In cohort 2 containing atezolizumab, there was greater overall expansion </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Gastrointestinal Cancer Program</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our breast cancer program, we continued to explore pelareorep in gastrointestinal cancers through our GOBLET (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">astrointestinal tum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">O</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs exploring the treatment com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">inations with the oncolytic reovirus pe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">orep and an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i-PD-L1) platform study. In 2023, we completed enrollment in the advanced/metastatic PDAC cohort/Stage 1 and third-line metastatic colorectal (CRC) cohort/Stage 1, and continued to monitor patients and patient outcomes. In our advanced anal cancer cohort, we continued enrolling patients and evaluating patient outcomes. We also presented data from our advanced/metastatic PDAC, third-line metastatic CRC, and anal cancer cohorts at various conferences throughout the year. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">GOBLET's PDAC cohort survival data reported at ESMO</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Updated data from GOBLET's PDAC cohort was presented at the European Society for Medical Oncology (ESMO) Congress 2023 showing an objective response rate and interim survival data exceeding historical control trials</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1-4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A summary of the findings was as follows: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tumor Responses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ORR of 62% (54% confirmed by two or more consecutive scans)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A DCR of 85%</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Survival data</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median duration of response was 5.7 months</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median PFS was 7.2 months</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim 12-month survival rate was 46%</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim median OS was 10.6 months</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">T Cell populations analysis of the changes of T cell clones and tumor-infiltrating lymphocytes (TILs) showed</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expansion of pre-existing and new T cell clones, including the expansion of TIL-specific clones</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A correlation between the expansion in the blood of TIL-specific clones and tumor response</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The treatment combination has been well tolerated with no safety concerns</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Most common grade 3 and 4 treatment-related adverse events were related to red and white blood cell counts (anemia, neutropenia and decreased neutrophil counts), but were transient </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Von Hoff D et al. N Engl J Med 2013; 369:1691-1703 DOI: 10.1056/NEJMoa1304369</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">O&#8217;Reilly et al. Eur J Cancer. 2020 June; 132: 112&#8211;121. DOI:10.1016/j.ejca.2020.03.005</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Karasic et al. JAMA Oncol. 2019 Jul 1; 5(7):993-998. DOI: 10.1001/jamaoncol.2019.0684</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Tempero et al. Ann Oncol. 2021 May; 32(5):600-608. DOI: 10.1016/j.annonc.2021.01.070</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">GOBLET's third-line metastatic CRC cohort efficacy data reported at ESMO</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This arm was the second consecutive arm within the GOBLET platform study to meet its respective success criteria and to be eligible to move to full enrollment. The interim results from the third-line metastatic CRC cohort included: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">6 of 15 enrolled patients had SD as their best response, including 4 patients demonstrating SD at week 16</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">These patients demonstrated a 40% DCR, a PFS of 2.8 months, a median OS of 8.0 months, and a 12-month survival rate of 33%</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The data suggested that pelareorep was taken by tumor cells and stimulated T cell expansion even in heavily pre-treated colorectal cancer patients</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">GOBLET's anal cancer cohort efficacy data reported at IMACC</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim data presented at the 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> International Multidisciplinary Anal Cancer Conference (IMACC) 2023 on patients with second-line or later, unresectable squamous cell carcinoma of the anal canal (SCCA) achieved the pre-defined success criteria. A summary of interim data and findings from the SCCA arm included:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tumor Response</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s: Interim ORR of 37.5% based on one patient with a complete response (ongoing at 12 months) and two patients with a PR (one at week 8, one ongoing at week 16)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Safety: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No safety signal was observed, consistent with previously reported cohorts from the GOBLET study</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As well, in 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its US$5 million Therapeutic Accelerator Award. This grant will enable us to continue our research on a clinical trial with pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) chemotherapy with or without Tecentriq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in pancreatic cancer patients.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patents and Trade Secrets</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our patent portfolio to protect the development of pelareorep. Currently, we have 150 issued patents including 15 issued in the U.S. and 7 in Canada. We also have 16 patents pending in the U.S., Canada, and other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus and formulations that we use in our clinical trial program. These patent rights extend to at least the end of 2031.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently aware of competing intellectual property relating to our pelareorep project. While we believe that we have the necessary freedom to operate in these areas, there can be no assurance that others will not challenge our position in the future. Litigation to defend our position could be costly and time-consuming and we cannot be certain we will be successful.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on unpatented trade secrets and improvements, unpatented know-how, and continuing technological innovation to develop and maintain our competitive position. No assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques, or otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our rights to our unpatented trade secrets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require our employees and consultants to execute confidentiality agreements upon the commencement of employment and consulting relationships with us. These agreements provide that all confidential information developed by or made known to an individual during the course of their employment or consulting relationship generally must be kept confidential. In the case of employees, the agreements provide that all inventions conceived by the individual, while employed by us, relating to our business are our exclusive property. While we have implemented reasonable business processes and agreements with which to protect confidential information, these actions may not provide meaningful protection for our trade secrets in the event of unauthorized use or disclosure of such information.</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of new pharmaceuticals is strongly influenced by a country's regulatory environment.&#160;The primary regulatory body in the United States is the FDA and in Europe is the European Medicines Agency (the &#8220;EMA&#8221;). The drug approval process in Canada is regulated by Health Canada.&#160;Similar processes are conducted in specific countries by equivalent regulatory bodies.&#160;Regulations in each jurisdiction require the licensing of manufacturing facilities and mandate strict research and product testing standards.&#160;Companies must establish the safety and efficacy of their products, comply with cGMP and potentially submit marketing materials before being allowed to market pharmaceutical products.&#160;While we plan to pursue or support the pursuit of the approval of our product, success in acquiring regulatory approval for any product is not assured.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market our pharmaceutical product in Canada, the United States, Europe, and other jurisdictions, we must successfully meet the requirements of those jurisdictions. The requirements of the appropriate regulatory authority will generally include the following stages as part of the regulatory process:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pre-Pharmacological Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pre-Pharmacological studies involve extensive testing on laboratory animals to determine if a potential therapeutic product has utility in an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease model and has any adverse toxicology in a disease model.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Investigational New Drug Application</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - An Investigational New Drug (IND) Submission, or the equivalent, must be submitted to the appropriate regulatory authority prior to conducting Pharmacological Studies.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Pharmacological Studies&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or Phase 1 Clinical Trials)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- Pharmacological studies are designed to assess the potential harmful or other side effects that an individual receiving the therapeutic compound may experience.&#160;These studies, usually short in duration, are often conducted with healthy volunteers or actual patients and use up to the maximum expected therapeutic dose.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Therapeutic Studies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(or Phase 2 and 3 Clinical Trials) - Therapeutic studies are designed primarily to determine the appropriate manner for administering a drug to produce a preventive action or a significant beneficial effect against a disease.&#160;&#160;These studies are conducted using actual patients with the condition that the therapeutic is designed to remedy. Prior to initiating these studies, the organization sponsoring the program is required to satisfy a number of requirements via the submission of documentation to support the approval for a clinical trial.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Expedited Development and Review Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- The FDA has several programs intended to facilitate and expedite development and review of new drugs to address unmet medical needs in the treatment of serious or life-threatening diseases or conditions. These programs include Fast Track designation, Breakthrough Therapy designation, Priority Review and Accelerated Approval. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, eligibility for these programs does not change the scientific or medical standards for approval or the quality of evidence necessary to support approval, though they may expedite the development or review process.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">New Drug Submission </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- After all three phases of a clinical trial have been completed, the results are submitted with the original IND Submission to the appropriate regulatory authority for marketing approval.&#160;Once marketing approval is granted, the product is approved for commercial sales.</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacturing and Controls</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Concurrent with pharmacological and therapeutic studies, the manufacturing process is developed, and applicable controls implemented. This information is submitted to the appropriate regulatory authority with more defined requirements for process and product control by later stage studies and prior to New Drug Submission. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketing Approvals</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical and clinical testing, together with manufacturing and controls information, are submitted to regulatory agencies in order to obtain approval to commence commercial sales. In responding to such an application, regulatory agencies may grant marketing approval, request additional information or further research, or deny the application if they determine that the application does not satisfy their regulatory approval criteria. Approval for a pharmaceutical or biologic product may not be granted on a timely basis, if at all. If granted, the approval may not cover all the clinical indications for which approval is sought, or may contain significant limitations in the form of warnings, precautions, or contraindications with respect to conditions of use.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The satisfaction of pre-market approval requirements for new drugs and biologics typically takes several years, with the actual time required varying substantially based upon the type, complexity, and novelty of the product or targeted disease. Government regulation may delay or prevent marketing of potential products for a considerable period of time and impose costly procedures upon our activities. Success in early-stage clinical trials or with prior versions of products does not assure success in later-stage clinical trials. Data obtained from clinical activities are not always conclusive and may be susceptible to varying interpretations that could delay, limit or prevent regulatory approval.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Marketing Regulations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approved, regulatory agencies may withdraw the product approval if compliance with pre- and/or post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, they may require post-marketing studies, referred to as Phase 4 studies, to monitor the effect of an approved product, and may limit further marketing of the product based on the results of these post-market studies. The FDA and other foreign regulatory agencies have broad post-market regulatory and enforcement powers, including the ability to levy fines and penalties, suspend or delay issuance of approvals, seize or recall products, or withdraw approvals.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing Regulations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our toll manufacturers are subject to periodic inspection by the FDA, the United States Drug Enforcement Administration, or DEA, and other domestic and foreign authorities where applicable, and must comply with cGMP regulations. Manufacturers of biologics also must comply with general biological product standards. Failure to comply with the statutory and regulatory requirements subjects the manufacturer to possible legal or regulatory action, such as suspension of manufacturing, seizure of product, or mandatory or voluntary recall of a product.&#160;Adverse experiences with the product must be reported to the FDA and foreign agencies and could result in the imposition of market restrictions through labeling changes or in product removal. Product approvals may be withdrawn if compliance with regulatory requirements is not maintained or if problems concerning safety or efficacy of the product occur following approval.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Advertising and Promotion Regulations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to both pre- and post-market product advertising and promotion, the FDA and similar foreign agencies impose a number of complex regulations on entities that advertise and promote pharmaceuticals and biologics, which include, among other things, standards and regulations relating to direct-to-consumer advertising, on vs. off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet. These agencies have very broad enforcement authority and failure to abide by these regulations can result in penalties including the issuance of a warning letter directing the entity to correct deviations from requisite standards, a requirement that future advertising and promotional materials be pre-cleared by the FDA or relevant foreign agencies. Foreign, state and federal civil and criminal investigations, fines, and prosecutions are also possible if advertising and promotion regulations are breached.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Government Regulations</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various laws and regulations regarding laboratory practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances in connection with our research. In each of these areas, as above, the government has broad regulatory and enforcement powers, including the ability to levy fines and civil penalties, suspend or delay issuance of approvals, seize or recall products, and withdraw approvals, any one or more of which could have a material adverse effect upon us.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market and Competition </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to estimates for 2024 from the American Cancer Society, more than 2.0 million Americans are expected to be diagnosed with cancer in the year, and approximately 611,720 Americans are expected to die of cancer.&#160;Cancer is the second most common cause of death in the U.S., exceeded only by heart disease.&#160;In the United States, the relative lifetime risk of a male or female developing cancer is 1 in 2 and 1 in 3, respectively (Source: American Cancer Society's Cancer Facts &amp; Figures </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023). It was projected that there will be 205,475 new patients with HR+/HER2- mBC in 2023. (Source: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">https://seer.cancer.gov/statfacts/html/breast-subtypes.html (accessed Feb 9, 2023)</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The costs of this disease state are also significant.&#160;In the United States, the American Cancer Society reported in its Cancer Facts &amp; Figures 2023 that The National Cancer Institute estimated that the 2020 cancer-related medical costs were $208.9 billion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology industry emphasizes the importance of proprietary rights and is typically defined by fast-paced advancements in technologies with intense competition. We do business in an extremely competitive oncology market and face significant competition from many sources, including pharmaceutical, biopharmaceutical, and biotechnology companies as well as universities and private and public research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, and drug development resources than we do. Large biopharmaceutical companies in particular have extensive experience in clinical development and in obtaining regulatory approvals for drugs and biologicals. These companies also have significantly greater research capabilities than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly those with collaborative arrangements with large and established companies or universities and research institutions. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors fall primarily into the following groups of treatment: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">traditional cancer therapies, including chemotherapy, surgery, radiation therapy, and targeted therapies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approved immunotherapy antibodies and immunotherapy antibodies in clinical trials; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other approved oncolytic virus-based immunotherapies and those in clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cancer vaccines including personalized vaccines and those targeting tumor neo-antigens; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cell-based therapies, such as CAR-T, T cell receptor-based, and NK cell therapies. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business opportunity will be limited, or possibility eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects, or are less expensive alone or in combination with other therapies than pelareorep especially if these get to market sooner than our product. Our competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep, if and when sold, will compete with a number of drugs that are currently marketed or in development that also target cancer but utilize different mechanisms of action. To compete effectively with these agents, pelareorep will need to show improved clinical efficacy and/or safety compared to competing products. We believe that pelareorep, if and when ultimately marketed, will likely be used in combination with other existing cancer treatments like checkpoint blockade therapies, surgery, chemotherapy, radiation therapy and other biological therapies. Consequently, we believe pelareorep, if and when marketed, would largely complement rather than compete directly with these existing treatment options. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do, however, expect to face direct and increasing competition from a number of companies that are also seeking to develop cancer therapies based on oncolytic viruses and other ways to prime the immune system. We believe that our ability to successfully compete will depend, among other things, on our ability to:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively advance the development of pelareorep;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design, enroll patients in and successfully complete appropriate clinical trials in an efficient manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">gain regulatory approval for pelareorep;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish collaborations and partnerships for the development of pelareorep;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercialize successfully, including demonstrating the safety and efficacy of pelareorep over currently approved therapies to physicians, insurers, and third-party payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">secure sufficient coverage from insurers and other payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">secure, maintain, and protect intellectual property rights based on our innovations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture and sell commercial quantities of pelareorep to the market.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Marketing Strategy</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for the cancer product being developed by us may be large and could require substantial sales and marketing capability.&#160;Before or upon successful completion of the development of a cancer product, we intend to enter into one or more strategic partnerships or other collaborative arrangements with a pharmaceutical company or other company with marketing and distribution expertise to address this need.&#160;If necessary, we will establish arrangements with various partners for different geographical areas or specific applications at various times in the development process.&#160;Our management and consultants have relevant experience with the partnering process.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Seasonality</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations have not been materially impacted by seasonality.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raw Materials</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that sources of raw material pertinent for manufacturing our pelareorep product are generally available. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Social Responsibility and ESG </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a rapidly growing, clinical-stage biotech company, we are not yet in a position to implement a broad-based ESG policy and program. However, our corporate goals are inspired by our potential to impact the care of patients with cancer, especially those with late-stage breast and pancreatic cancers and are informed by our corporate values of acting with integrity, collaboration, innovation, and embracing diversity. In 2023, our corporate goals focused on certain clinical, manufacturing, and business operations and support our desire to obtain an approval for an innovative cancer treatment that extends patient lives. Each year we work hard to achieve our goals and objectives while maintaining a respectful, collaborative, and caring work environment. While we do not formally report on our ESG policies and compliance, we publicly disclose elements of our ESG activities. Our governance policies like our board mandates, code of ethics and conduct, and our public filings are all on our website at https://oncolyticsbiotech.com/investor-overview/corporate-governance/. Our website is not incorporated herein by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1929"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Organizational Structure</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December&#160;31, 2023, we had one material wholly-owned operating subsidiary; Oncolytics Biotech (Barbados) Inc. (&#8220;OBB&#8221;), a Barbados company.&#160;In addition, Oncolytics Biotech (U.S.) Inc., a Delaware corporation, is a material wholly-owned subsidiary of OBB.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1998"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Property, Plant and Equipment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease our head office in Calgary, Alberta, Canada as well as our office spaces in San Diego, California, U.S. and Barbados. We do not own or lease any other office space, manufacturing facilities or equipment and do not have any current plans to construct or acquire any facilities.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4A.&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_31"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2022"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. - D. Operating Results, Liquidity and Capital Resources, Research and Development, Patents and Licenses, Trend Information </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see our 2023 Management Discussion and Analysis in Exhibit 15.1, which is incorporated herein by reference.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.  Critical Accounting Estimates </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2193"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Directors and Senior Management</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the names and places of residence of all our directors and senior management as at March&#160;7, 2024, as well as the positions and offices held by such persons and their principal occupations.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia Andrews</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York, USA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Andrews was the CEO of Sumitomo Pharma Oncology, Inc., a clinical-stage research and development biopharmaceutical company, and Global Head of Oncology and an Executive Officer for Sumitomo Pharma Co., Ltd. from 2017 to 2023. Prior to joining this organization in 2013, she was Executive Vice President and Chief Commercial Officer at Incyte for four years, where she established the commercial organization and launched its first-in-class, first-in-disease oncology product Jakafi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. She was also responsible for business development and completed multiple significant product licensing deals for Incyte. Ms. Andrews held increasing leadership positions at Pfizer from 1991-2008, with her final role being Vice President and General Manager of the U.S. Oncology Business Unit. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University. Ms. Andrews also serves on the board of GlycoMimetics.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 5, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown, MBA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Brown currently leads Canadian Strategic Partnerships at Eversana, a leading provider of global commercial services to the life sciences industry. She held progressively senior roles at EMD Serono from 2000 to 2014, including Executive Vice President of Neuroimmunology for the company's U.S. operations, and President and Managing Director of the company's Canadian operations. In 2012, Ms. Brown was Chair of the National Pharmaceutical Organization (now Innovative Medicines Canada) and served on its Board of Directors from 2007 to 2014. She also currently sits on the Board of the HBSPCA. Ms. Brown holds an MBA from Western University&#8217;s School of Business, an Hons B.Sc. from the University of Guelph, and has completed the Institute of Corporate Directors Designation (ICD.D).</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2, 2017</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matthew Coffey, PhD, MBA<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A co-founder of the Company, Dr. Coffey completed his doctorate degree in oncology at the University of Calgary with a focus on the oncolytic capabilities of the reovirus. The results of his research have been published in various respected scientific journals, including Science, Human Gene Therapy, and The EMBO Journal. Dr. Coffey took over as Chief Executive Officer in late 2016, prior to which he was Chief Operating Officer since December 2008. Since co-founding Oncolytics he has also held the positions of Chief Scientific Officer from December 2004 to December 2008, Vice-President of Product Development from July 1999 to December 2004, and Chief Financial Officer from September 1999 to May 2000.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 11, 2011</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman, P.Eng., PMP, MBT <br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Product Development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Professional Engineer focused on biotechnology, Ms. Hagerman joined Oncolytics in 2010. Prior to being appointed as Vice President of Product Development, Ms. Hagerman was the Director, Manufacturing and Engineering from 2013-2017 and Project Manager from 2010-2013. Ms. Hagerman is a Professional Engineer (P.Eng., APEGA) and Project Management Professional (PMP, PMI). She holds a Master of Biomedical Technology (MBT) degree from the University of Calgary, and B.Sc. degrees in both Chemical Engineering and Biological Sciences.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas C. Heineman, MD, PhD<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to joining Oncolytics, Dr. Heineman most recently served as Senior Vice President and Head of Clinical Development at Denovo Biopharma. Prior to his time at Denovo, Dr. Heineman served as Vice President and Head of Clinical Development at Genocea Biosciences and Halozyme Therapeutics, where he was also the Head of Translational Medicine, and oversaw clinical trials in indications such as breast and pancreatic cancer. Dr. Heineman&#8217;s experience further extends to big pharma and academia where he previously held roles as Senior Director, Global Clinical Research and Development at GlaxoSmithKline and Associate Professor at the Saint Louis University School of Medicine. Dr. Heineman has co-authored over 60 peer-reviewed publications and is board certified in Internal Medicine and Infectious Diseases. He completed his fellowship in Infectious Diseases at the National Institutes of Health and his internship and residency at the University of Maryland. Dr. Heineman earned his MD at the University of Chicago, where he also received a PhD in molecular genetics.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham, MBA, FCPA, FCMA, ICD.D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Holtham held a number of financial positions over a 19-year career with the Canadian subsidiary of Nabisco Inc., rising to become Senior Vice President and Chief Financial Officer. In 2002, she joined Toronto, Ontario-based Hospital for Sick Children as Vice President, Finance and Chief Financial Officer, a position she held for eight years. Through her career she has participated in myriad initiatives ranging from traditional finance functions and operations oversight to intellectual property portfolio management and mergers and acquisitions. In more recent years she has held numerous governance roles on various Boards in both the publicly traded and not-for-profit sectors and held short term contract positions. Ms. Holtham is an FCPA, FCMA, holds an MBA from the University of Toronto - Rotman School of Management and has completed the Institute of Corporate Directors Designation (ICD.D).</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 18, 2014</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy G. Levin, RN, BSN<br/>California, USA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Clinical Operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Levin brings over two decades of clinical research and development operations experience investigating a broad range of oncology drug candidates. Prior to joining Oncolytics in 2020, Ms. Levin was the Senior Director of Clinical Operations at Puma Biotechnology, where she established the clinical operations team and was responsible for multiple global clinical programs leading to the approval of neratinib (Nerlynx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). She also held increasing leadership positions in her role as Director, Clinical Program Leader at Cougar Biotechnology (Janssen, Pharmaceutical Companies of J&amp;J), working on their lead drug candidate abiraterone acetate (ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">). Earlier in her career, Ms. Levin held several different clinical research and sales roles at Merck Vaccines and Amgen. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Levin earned a Bachelor of Science degree in Nursing (BSN) from the University of Texas at Austin.</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CPA, CA, MSJ<br/>Alberta, Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Look joined Oncolytics as the Company's Controller in April 2003, and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst &amp; Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst &amp; Young LLP in Chile.  Mr. Look is a Chartered Professional Accountant, and holds a Master of Science in Jurisprudence (MSJ) from the Seton Hall University School of Law and a Bachelor of Commerce from the University of Calgary.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Place of Residence&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Position with the Company</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Occupations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Director of the Company Since</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons, MAcc, CPA, CA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ontario, Canada</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Parsons served as the Chief Financial Officer (CFO) of Trillium Therapeutics Inc. (TSX: TRIL) (NASDAQ: TRIL) from August 2011 through its acquisition by Pfizer in November 2021 for an aggregate purchase price of approximately U.S.$2.2 billion. Prior to his time at Trillium, Mr. Parsons served as Vice President, Finance, at DiaMedica Therapeutics Inc, CFO of ProMIS Neurosciences (formerly Amorfix Life Sciences Ltd.), and CFO and Vice President, Finance and Administration, at Aptose Biosciences Inc. (formerly Lorus Therapeutics). Mr. Parsons has been a Director and the Chair of the Audit Committees of Sernova Corp. (TSX: SVA) and DiaMedica Therapeutics Inc. (NASDAQ: DMAC) since 2012 and 2015, respectively.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 16, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano, MBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">                                                            Pennsylvania, USA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chair of the Board</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Pisano has served as a Director/Chairman of several publicly traded companies in the US and Canada and has more than 30 years of experience as a pharmaceutical industry executive. He served as the president and CEO of VaxInnate, a privately held biotech company from January 2012 to November 2016. Mr. Pisano is the former president and CEO of Sanofi Pasteur, one of the largest vaccine companies in the world. He joined Sanofi Pasteur in 1997, assuming increasing levels of responsibility. He was promoted to President and CEO in 2007, the position he successfully held until his retirement in 2011. Prior to joining Sanofi Pasteur, he spent 11 years with Novartis (formerly Sandoz). He has a bachelor's degree in biology from St. John Fisher College, New York and an MBA from the University of Dayton, Ohio.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2013</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby, MBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisiana, USA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mr. Rigby is currently an advisor to Guidepoint and until January 2024 was the Group Chief Executive Officer (CEO) of Revolo Biotherapeutics, where he led a team focused on the development of therapies for autoimmune and allergic diseases. Previously, he was the CEO of SteadyMed Ltd., which he led through a NASDAQ listing and sale to United Therapeutics Corporation. Prior to his time at SteadyMed, Mr. Rigby co-founded Zogenix, Inc., a CNS-focused specialty pharmaceutical company that was acquired by UCB in a transaction valued at up to approximately U.S. $1.9 billion. Before co-founding Zogenix, Mr. Rigby held roles of increasing responsibility in commercial and business development functions at large pharmaceutical companies such as Merck, Bristol Myers Squibb, and Profile Therapeutics (now Phillips Medical). In addition to his Oncolytics appointment, Mr. Rigby is also a member of the ImmunoMolecular Therapeutics Board of Directors and the Chairman of BioPlus Acquisition Corp., a Nasdaq-listed biotech acquisition company. He holds a B.S. with Honors in Biological Sciences from Sheffield University, UK, and an M.B.A. from Portsmouth University, UK.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger, MD, PhD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey, USA and Munich, Germany</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Seizinger has been board member/chairman in multiple public and private biotech companies in the US and Europe. From 1998 to 2009, he served as President and Chief Executive Officer of GPC Biotech. He also served as Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances at Bristol-Myers Squibb. Prior to his appointments in the biotechnology and pharmaceuticals sectors, Dr. Seizinger held professorships and senior staff appointments at Harvard Medical School, Princeton University, and Massachusetts General Hospital. He also currently sits on multiple biotech boards, including four additional public boards: Aptose Biosciences, Aprea Therapeutics, Nykode Therapeutics, and BioInvent.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 8, 2015</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Audit Committee.&#160;Ms. Holtham is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Compensation Committee.&#160;Ms. Brown is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Governance Committee.&#160;Mr. Rigby is Chair of this Committee. </span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Member of the Science &amp; Development Committee. Dr. Seizinger is Chair of this Committee.</span></div><div style="padding-left:40.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Mr. Pisano, as Chair of the Board, serves as an ex-officio member of the Compensation, Audit, Governance, and Science &amp; Development Committees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our directors are associated with other companies, which may give rise to conflicts of interest.&#160;In accordance with the Alberta Business Corporations Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ABCA), directors who have a material interest in any person who is a party to a material contract or a proposed material contract with us are required, subject to certain exceptions, to disclose that interest and abstain from voting on any resolution to approve that contract.&#160;In addition, the directors are required to act honestly and in good faith with a view to the best interests of Oncolytics Biotech Inc.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers are related by blood, marriage, or adoption to any other director or officer.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any arrangement or understanding with major shareholders, customers, suppliers or others, pursuant to which any person referred to above was selected as a director or senior management.</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2218"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board of Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Only the Corporation's independent directors receive compensation for their service on our board of directors. The following table sets forth information concerning the total compensation paid in 2023 to each member serving as director as at December&#160;31, 2023.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fees Earned</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">based awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">based awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-equity incentive plan compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All other compensation<br/>($)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,340</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,614</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,954</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,961</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,614</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,575</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,743</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,614</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,357</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,493</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,517</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,010</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,788</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,614</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107,402</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,348</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Nil </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,614</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,962</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">Directors are paid fees in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.3226.</span></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.84pt">The value of share-based and option based awards are based on the grant date assumptions as disclosed in note 11 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2023 audited consolidated financial statements.   </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-4.5pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each independent director receives a base retainer of US$40,000. In addition to the base retainer, directors are eligible to receive the following additional fees depending on committee involvement:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Retainers (USD):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Board chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$40,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit Committee chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$20,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Governance Committee chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation Committee chair</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$12,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Science &amp; Development Committee chair</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$15,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Audit Committee</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$10,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Governance or Science &amp; Development Committee</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-chair member of the Compensation Committee</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6,000</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the combined retainer, the Corporation will grant 30,000 options annually for directors other than the Chair. The Chair will receive 37,500 options annually. All such options vest in their entirety one year following the grant date. New directors will be entitled to receive an initial grant of 45,000 options, which vest immediately. The Company does not provide pension plan benefits to its directors.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also reimburse the directors for any reasonable expenses incurred by them while acting in their directors' capacity.&#160;During the year ended December 31, 2023, total compensation of $768,260 was paid to the independent directors which consisted of fee payments of $495,673 and option based awards of $272,587. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth for each director, other than the Named Executive Officers who are directors, all option-based awards outstanding as at December&#160;31, 2023: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.544%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/7/2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.87</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/18/2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.84</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/30/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.60</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/8/2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.14</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/16/2026</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td></tr></table></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at December 31, 2023, all options granted to our directors had fully vested except for the options granted on August 15, 2023 (expiring August 15, 2028).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors hold share awards as at December&#160;31, 2023. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Named Executive Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables and discussion relate to compensation paid or earned by our Chief Executive Officer (CEO), Chief Financial Officer (CFO), and our three most highly compensated officers (other than CEO and CFO) who were serving as officers as at December&#160;31, 2023 (collectively the "Named Executive Officers").</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information concerning the total compensation paid to our named executive officers in 2023. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-<br/>based awards<br/>($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option-<br/>based </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">awards </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-equity incentive<br/>plan compensation<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All other compensation<br/>  ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>compensation <br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Matthew Coffey</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">735,223</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">401,890</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760,146</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">257,328</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,436</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,246,023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kirk Look<br/>Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">533,404</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,443</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">366,180</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,353</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,786</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,320,166</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-<br/>based awards<br/>($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option-<br/>based </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">awards </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-equity incentive<br/>plan compensation<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension value<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All other compensation<br/>  ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>compensation <br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615,207</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,575</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342,774</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,258</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,999</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,361,813</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410,313</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,529</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,639</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,527</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,631</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">727,639</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amy G. Levin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vice President, Clinical Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">423,232</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,316</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,801</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74,066</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57,132</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683,547</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The value of share- and option-based awards are based on the grant date assumptions as disclosed in note 11 "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share-Based Compensation" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our 2023 audited consolidated financial statements.</span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">The dollar amounts set forth under this column are related to contributions to the senior management's respective retirement savings plan and amounts provided for health care benefits by the Company. </span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">None of the compensation paid to Dr. Coffey related to his role as a director of the Company.</span></div><div style="padding-left:40.5pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">U.S. Employees are paid salaries, bonuses, and other compensation in U.S. Dollars.&#160;These amounts are presented in Canadian dollars and have been converted at a U.S./CDN exchange rate of $1.3226.  </span></div><div style="padding-left:4.5pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment agreements with our Named Executive Officers (each an "Employment Agreement"). The Chief Executive Officer of the Corporation is eligible for a cash bonus of up to 50% of his base salary, the Chief Financial Officer and Chief Medical Officer are eligible for a cash bonus of up to 40% of their respective base salary, the Vice President, Product Development is eligible for a cash bonus of up to 35% of her base salary, and the Vice President, Clinical Operations is eligible for a cash bonus of up to 25% of her base salary. In addition, when available, the officers are eligible for a combination of Option and Share Award grants. The amount of each grant is determined and approved by the Board with the actual bonus provided and the number of Options and Share Awards granted based upon the overall performance of the Corporation as assessed by the Compensation Committee and approved by the Board. The overall performance of the Corporation is determined by the annual goals and objectives approved by the Board and includes specific objectives with respect to the clinical, manufacturing, and intellectual property plans in combination with financial goals. Previous grants are taken into account when considering new grants of Options and Share Awards. As well, the Employment Agreements provide that each member of the Company's senior management is subject to certain confidentiality and non-competition restrictions during and following the course of their respective employment with the Company. Each Employment Agreement shall continue until terminated by either party in accordance with the notice provisions thereof.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not provide pension plan benefits to its Named Executive Officers and employees. The Company does not currently have a stock appreciation rights plan.&#160;</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth for each Named Executive Officers all option-based and share-based awards outstanding as at December&#160;31, 2023:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares or units of shares that have not vested </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market value or payout value of vested share-based awards not paid out or distributed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,263</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,500</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">312,355</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,105</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/16/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">420,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.584%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">options </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option exercise<br/>price<br/>($)</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Option expiration date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of shares or units of shares that have not vested </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(#)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market value or payout value of vested share-based awards not paid out or distributed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,842</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,300</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,637</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,842</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/1/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,578</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/16/2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.84</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/1/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,940</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,900</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,700</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.53</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,466</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,421</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.84</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,263</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.90</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,894</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/28/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.73</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/14/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/13/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.40</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/8/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,800</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy G. Levin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.27</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/1/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,769</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.08</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,700</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/15/2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,700</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.91</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/8/2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-top:10pt;padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at December 31, 2023, all options granted to our Named Executive Officers had fully vested except for the options granted on March 8, 2021 (expiring March 8, 2026), December 9, 2022 (expiring December 9, 2026), August 15, 2023 (expiring August 15, 2028), and December 8, 2023 (expiring December 8, 2028).</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Under the terms of the Company's option plan, options that expire during a "blackout period" (or within five business days thereafter) are deemed to be extended to the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the applicable blackout period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">As at December 31, 2023, RSAs granted to our Name Executive Officers on August 15, 2023, and December 8, 2023, have not vested. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">These amounts are calculated based on the closing price of the Common Shares on the TSX on December 29, 2023 ($1.79). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Termination of Employment or Change of Control </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects amounts payable to each member of the Company's Named Executive Officers based on their respective Employment Agreements assuming that their employment was terminated on December 31, 2023 without cause or due to a change of control of the Company.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.345%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and principal position</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Termination without Cause Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change of Control Severance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">($)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Matthew Coffey<br/>President and Chief Executive Officer</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,654,818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look<br/>Chief Financial Officer</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">608,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,217,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Medical Officer</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman<br/>Vice President, Product Development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy G. Levin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Clinical Operations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363,201&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Named Executive Officers are entitled to exercise all or any part of their vested Options, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated unless otherwise approved by the Board of Directors.</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Upon termination, unless otherwise approved by the Board of Directors, Named Executive Officers are entitled to receive the number of shares equal to the number of RSAs granted multiplied by a fraction (A) the numerator of which is the number of days from the grant date in respect of the applicable share award to the termination date; and (B) the denominator of which is the total number of days comprising the vesting period in respect of such share award. The shares will be issued at the earlier of the 31st day following the completion of the vesting period and the 90th day after the date such member is terminated.  </span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">On a change of control of the Company, Named Executive Officers shall be entitled to exercise all or a part of their Options, whether vested or not, within the period ending on the earlier of the date of expiration of the Option and the 90th day after the date such member is terminated. On a change of control of the Company, Named Executive Officers shall be entitled to all shares equal to the number of RSAs granted, whether vested or not. All applicable shares shall be issued effective immediately prior to the completion of the change of control transaction. </span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">U.S. Employees are paid in U.S. Dollars and are presented in U.S. dollars.</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2242"></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Board Practices</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors are elected by the shareholders at each Annual General Meeting (or Annual Special Meeting) and typically hold office until the next meeting, at which time they may be re-elected or replaced.&#160;Casual vacancies on the board are filled by the remaining directors and the persons filling those vacancies hold office until the next Annual General Meeting (or Annual Special Meeting), at which time they may be re-elected or replaced.&#160;The chief executive officer, chief financial officer, and chief medical officer are appointed by the Board of Directors and hold office indefinitely at the pleasure of the Board of Directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Directors&#8217; Contracts</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive a director&#8217;s consent from each of the independent directors upon their acceptance of their director&#8217;s position.&#160;We also enter into an Indemnity Agreement and Directors Confidentiality and Intellectual Property Assignment Agreement with each director.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any contracts with any of its directors which provide for benefits upon the termination of employment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee</span></div><div style="margin-bottom:12pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation has formed a compensation committee (the &#8220;Compensation Committee&#8221;) in accordance with Rule 5605(d)(1) of the Nasdaq Capital Market which consists of four outside, independent directors, Dr. Seizinger, Ms. Holtham, Ms. Brown, and Mr. Pisano, the Chair of the Board, each of whom is independent in accordance with Rule 5605(a)(2) and Rule 5605(d)(2)(A) of the Nasdaq Capital Market. Ms. Brown is the Chair of the Compensation Committee. No member of the Compensation Committee has been an employee or officer of the Company or any of its affiliates.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation committee's primary purpose is to assist our Board of Directors in carrying out its responsibility for the Corporation's human resources and compensation policies and processes. The Compensation Committee's written mandate is located on the Company&#8217;s website at https://oncolyticsbiotech.com/investor-overview/corporate-governance/. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Audit Committee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation has formed an Audit Committee in accordance with Section 3(a)(58)(A) of the United States Securities Exchange Act of 1934, as amended ("Exchange Act"), consisting of four independent directors pursuant to the Rule 5605(a)(2) and Rule 5605(c)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act: Ms. Brown, Ms. Holtham, Mr. Parsons, and Mr. Pisano, none of whom are nor have been employees or officers of the Company or any of its affiliates.&#160;&#160;Ms. Holtham is presently the Chair of the Audit Committee.&#160;Each Audit Committee member is financially literate.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit committee reviews and approves the scope of the annual audits of our financial statements, reviews our internal control over financial reporting, reviews and approves services performed by the independent auditors, reviews the findings and recommendations of the independent auditors, and periodically reviews major accounting policies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee's written mandate is located on the Company&#8217;s website at https://oncolyticsbiotech.com/investor-overview/corporate-governance/.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2266"></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12.78pt">Employees</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets out the number of our employees at the end of each of the last three fiscal years by activity and geographic location:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Function:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">By Geographic Location:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States of America</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 37pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></td></tr></table></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2290"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Share Ownership</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 6.B. and Item 7.A.</span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two share-based compensation plans: the Stock Option Plan and the Share Award Plan.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Corporation&#8217;s Amended and Restated Stock Option Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Option Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 9, 2023.  </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation, with the approval of its Shareholders, has established the Stock Option Plan. The number of Common Shares reserved for issuance under the Stock Option Plan and all other security based compensation arrangements of the Corporation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(including the Share Award Plan) in aggregate shall not exceed 14% of the total number of issued and outstanding Common Shares from time to time. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Stock Option Plan, the Board of Directors or the Compensation Committee may from time to time designate directors, officers, employees of, or consultants to, the Corporation or any subsidiary of the Corporation (such persons being &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eligible Persons</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to whom Options may be granted and the number of Options to be granted to each. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options may be exercised at a price (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) which shall be fixed by the Board at the time the Option is granted. No Option can be granted with an Exercise Price at a discount to the market, which shall be the closing price of the Common Shares on the stock exchange upon which the Common Shares are listed on the first day preceding the date of grant on which at least one board lot of Common Shares traded on such exchange.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any Option shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Common Shares to which such Option relates shall be available for the purposes of the granting of Options under the Stock Option Plan.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of Shares that may be acquired under an Option granted to a participant under the Stock Option Plan shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one participant under the Stock Option Plan or any other security based compensation arrangement of the Corporation, shall not exceed five percent (5%) of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without obtaining the approval of Shareholders in accordance with the rules of the TSX or the requirements of any other stock exchange on which the Common Shares are then listed, no Options shall be granted pursuant to the Stock Option Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Corporation, could result, at any time, in:</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;a number of Common Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Common Shares at any time;</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the issuance within a one year period to insiders, of a number of Common Shares exceeding ten percent (10%) of the number of outstanding Common Shares; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Common Shares exceeding five percent (5%) of the number of outstanding Common Shares.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of Option grants to each non-employee director shall not exceed $150,000 annually for any individual non-employee director (other than initial Option grants to new directors).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expiration of options is to be no greater than ten years from the date of grant and typically either vest immediately or as to one-third on each of the first, second and third anniversary following the date of grant, as determined by the Board at the time the Option is granted. Options are not transferable or assignable except to the person or persons to whom the participant&#8217;s rights pass by the participant&#8217;s will or applicable law following the death or permanent disability of a participant. The Stock Option Plan provides that if the expiration date of an Option occurs during a "blackout period" or within five (5) business days after a blackout period, such expiration date shall be deemed to be extended to the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the applicable blackout period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a participant providing otherwise, if any participant shall cease to be an Eligible Person for any reason other than the termination for cause or the death or permanent disability of the participant, such participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5:00 p.m. (Calgary time) on the earlier of the date of the expiration of the applicable option period and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day after the date such participant ceases to be an Eligible Person as to the then vested portion of the Option. If a participant ceases to be an Eligible Person as a result of the termination of such participant for cause, effective as of the date notice is given to the participant of such termination, all outstanding Options shall be terminated and all rights to receive Common Shares thereunder shall be forfeited by such participant, and the participant shall not be entitled to receive any Common Shares or other compensation in lieu thereof.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any written agreement between the Corporation and a participant providing otherwise, if in the event of the death or permanent disability of a participant, any Option previously granted to such participant shall be exercisable until the end of the applicable option period or until the expiration of 12 months after the date of death or permanent disability of such participant, whichever is earlier, and then only: (i) by the person or persons to whom the participant&#8217;s rights under the Option shall pass by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the participant&#8217;s will or applicable law; (ii) to the extent that he or she was entitled to exercise the Option as at the date of the participant&#8217;s death or permanent disability.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised, in the case of Options held by non-employee directors, by not more than one year, and in the case of Options held by other persons, by not more than three years, but in no case longer than the normal expiry of the Options.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a change of control of the Corporation (as such term is defined in the Stock Option Plan), all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or the Stock Option Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) day following the change of control.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to any required approval of the TSX and any other stock exchange on which the Common Shares are then listed, the Stock Option Plan and any Options granted thereunder may be amended, modified or terminated by the Board without approval of any participant or Shareholder (provided that no such amendment may be made that will materially prejudice the rights of any participant under any Option previously granted to the participant without consent by such participant). Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Stock Option Plan with respect to all Common Shares in respect of Options which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;changing the provisions relating to the manner of exercise of Options; </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Common Shares from the Stock Option Plan reserve; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of the Stock Option Plan or any Option that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of the Stock Option Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, Shareholder approval is required for any change to the Stock Option Plan or Options granted under it which:</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;increases the number of Common Shares reserved for issuance under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;extends eligibility to participate in the Stock Option Plan to persons other than Eligible Persons;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;permits Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;permits awards other than Options to be made under the Stock Option Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;extends the term of an Option beyond the maximum expiry date set out in the Stock Option Plan (except where an expiry date would have fallen within a blackout period;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;reduces the exercise price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same Option-holder with a lower exercise price will be considered an amendment to reduce the exercise price of an Option);</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;changes the insider participation limitation at any time under the Stock Option Plan; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;amends the amending provision of the Stock Option Plan. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Corporation&#8217;s Amended and Restated Incentive Share Award Plan (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Award Plan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) dated effective as of May 9, 2023.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Corporation, with the approval of its Shareholders, has established the Share Award Plan. Under the Share Award Plan, the Board may, at such times and in such amounts as the Board may deem advisable in its sole and absolute discretion, issue Performance Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to eligible employees, including officers, and Restricted Share Awards (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RSAs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and, together with PSAs, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) to Eligible Persons. The number of Common Shares reserved for issuance under the Share Award Plan and all other security based compensation arrangements of the Corporation (including the Stock Option Plan) in aggregate shall not exceed 14% of the total number of issued and outstanding Common Shares from time to time.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to earlier vesting in accordance with the terms of the Share Award Plan and unless otherwise determined by the Board, Share Awards granted under the Share Award Plan vest on the third anniversary date of the date of grant. Upon vesting, each RSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) and each PSA is deemed to be redeemed for no further consideration for one&#160;Common Share (subject to adjustment for dividend equivalents) multiplied by the percentage (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vesting Percentage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) of outstanding PSAs that will vest based upon the relative achievement of any performance-related measures or criteria as determined by the Board in its sole discretion, which may include the Corporation&#8217;s performance compared to identified operational or financial targets and the Corporation&#8217;s shareholder return.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate number of Common Shares issuable at any time to insiders, under all security based compensation arrangements of the Corporation shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The aggregate number of Common Shares issued pursuant to all security based compensation arrangements of the Corporation, within a one year period, shall not exceed 10% of the issued and outstanding Common Shares (calculated on a non-diluted basis). The Share Award Plan further provides that the aggregate number of Common Shares reserved for issuance to any one participant under all security based compensation arrangements of the Corporation, shall not exceed 5% of the total number of issued and outstanding Common Shares (calculated on a non-diluted basis).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum number of Common Shares that may be reserved for issuance to non-employee directors pursuant to RSAs under the Share Award Plan is 1% of the Common Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Common Shares reserved for issuance to such non-employee director under any other security based compensation arrangement, and the total annual grant of RSAs to any one non-employee director cannot exceed a grant value of $150,000 (less the amount awarded to such non-employee director).</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan provides that if the issue date of any Share Award occurs during a blackout period, then the issue date for such Share Award shall not occur until the date which is the tenth (10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) business day after the last day of the such blackout period.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board in its sole discretion, upon a Change of Control (as such term is defined in the Share Award Plan), all unvested Share Awards shall become automatically vested (in the case of PSAs, with a deemed Vesting Percentage of 100). Common Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with the Share Award Plan.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award agreement pertaining to a particular Share Award or any written employment or other agreement governing a participant&#8217;s role as an Eligible Person if a participant ceases to be an Eligible Person as a result of the termination of such participant for cause or if a participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the participant, all outstanding Share Awards Agreements under which Share Awards have been granted to such participant shall be terminated. Upon the death, permanent disability or retirement of a participant (other than the early retirement of an eligible employees), all outstanding Share Awards shall immediately vest. If a participant ceases to be an Eligible Person other than in the circumstances provided above, all Share Awards awarded to such participant under any outstanding Share Awards shall fully vest effective as of the date of cessation of employment (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cessation Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), unless otherwise determined by the Board, and the participant shall be entitled to receive the number of Common Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the date of grant thereof to the Cessation Date; and (B) the denominator of which is the total number of days during which such Share Award were scheduled to vest upon grant. In such circumstances, the Vesting Percentage in respect of PSAs shall be determined as of the Cessation Date.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Share Award Plan and any Share Awards granted thereunder may be amended, modified or terminated by the Board without approval of Shareholders, subject to any required approval of the TSX. Such changes may include, without limitation: </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;amending, modifying or terminating the Share Award Plan with respect to all Common Shares in respect of Share Awards which have not yet been granted thereunder; </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;making any amendment of a &#8220;housekeeping nature&#8221;; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;making any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the rules of the TSX, or the requirements of any other stock exchange on which the Common Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Share Award Plan or a Share Award may not be amended without shareholder approval to:</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;increase the number of Common Shares issuable pursuant to outstanding Share Awards at any time;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(v)&#160;&#160;&#160;&#160;change the insider participation limit under the Share Award Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vi)&#160;&#160;&#160;&#160;expand the categories of individuals who are &#8220;eligible employees&#8221; who are eligible to participate in the Share Award Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(vii)&#160;&#160;&#160;&#160;extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of the Share Award Plan;</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(viii)&#160;&#160;&#160;&#160;permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes; or</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ix)&#160;&#160;&#160;&#160;change the amendment provisions of the Share Award Plan.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, no amendment to the Share Award Plan or any Share Awards granted pursuant thereto may be made without the consent of an Share Award Plan participant if it adversely alters or impairs the rights of such participant in respect of any Share Award previously granted to such participant under the Share Award Plan.</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2314"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Disclosure of a Registrant's Action to Recover Erroneously Awarded Compensation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clawback Policy</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 2, 2023, the Board adopted a Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation (the "Clawback Policy") providing for the recovery of certain incentive-based compensation from current and former executive officers of the Company in the event the Company is required to restate any of its financial statements filed with the SEC under the Exchange Act in order to correct an error that is material to the previously-issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. Adoption of the Clawback Policy was mandated by new Nasdaq listing standards introduced pursuant to Exchange Act Rule 10D-1. The Clawback Policy is in addition to Section 304 of the Sarbanes-Oxley Act of 2002 which permits the SEC to order the disgorgement of bonuses and incentive-based compensation earned by a registrant issuer's chief executive officer and chief financial officer in the year following the filing of any financial statement that the issuer is required to restate because of misconduct, and the reimbursement of those funds to the issuer. A copy of the Clawback Policy has been filed herewith as Exhibit 97.1.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2320"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Major Shareholders</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security Ownership</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information relating to the beneficial ownership of our shares as at March&#160;7, 2024, for: </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each person who is known by us to beneficially own more than 5% of our common shares;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each of our directors;</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">each named executive officers; and</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">all of our directors and named executive officers as a group.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated in the footnotes to the table, and subject to community property laws where applicable, the following persons have sole voting and investment control with respect to the shares beneficially owned by them. In accordance with SEC rules, if a person has a right to acquire beneficial ownership of any common shares on or within 60 days upon conversion or exercise of outstanding securities or otherwise, the shares are deemed beneficially owned by that person and are deemed to be outstanding solely for the purpose of determining the percentage of our shares that person beneficially owns. These shares are not included in the computations of percentage ownership for any other person. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as otherwise indicated, the address of each person in the table below is 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5.</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.299%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Address of Beneficial Owner</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares Beneficially Owned</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Shares Beneficially Owned</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5% and Greater Shareholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anson Funds Management LP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,814,299</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.06%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors and Named Executive Officers:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patricia Andrews</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah M. Brown</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,211</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Angela Holtham</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,501</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James T. Parsons</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wayne Pisano</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,941</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Rigby</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bernd R. Seizinger</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,126</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,484,630</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.93%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">892,857</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Thomas C. Heineman</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,200</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allison Hagerman</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,717</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amy G. Levin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147,799</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All directors and Name Executive Officers as a group</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,644,982</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.86%</span></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** Less than 1% ownership</span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:54pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Based on information obtained from Form 13F filed by Anson Funds Management LP ("Anson") on February 14, 2024. In addition, according to that report, Anson's business address is 16000 Dallas Parkway, Suite 800, Dallas, Texas 75248. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anson, our directors, and Named Executive Officers do not have different voting rights. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shares Held in the United States</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table indicates, as of March&#160;7, 2024, the total number of common shares issued and outstanding, the approximate total number of holders of record of common shares, the number of holders of record of common shares with U.S.&#160;addresses, the portion of the outstanding common shares held by U.S.&#160;holders of record, and the percentage of common shares held by U.S.&#160;holders of record. This table does not indicate beneficial ownership of common&#160;shares.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.409%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.689%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total number of holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total number of common shares issued and outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of U.S.&#160;holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of common shares held by U.S.&#160;holders of record</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of common shares held by U.S.&#160;holders of record&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,419,768</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,969,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change of Control</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;12, 2024, there were no arrangements known to the Company which may, at a subsequent date, result in a change of control of the Company.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Control by Others</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of the Company&#8217;s knowledge, the Company is not directly or indirectly owned or controlled by another corporation(s), any foreign government, or any other natural or legal person, severally or jointly.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2345"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Related Party Transactions</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into employment contracts with each of our named executive officers (see Item 6).&#160;&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of the fiscal year ended December 31, 2023, up to March&#160;12, 2024, we did not enter into any other related party transactions and we do not have any loans outstanding with any officer, director or major shareholder.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2369"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Interests of Experts and Counsel</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8. FINANCIAL INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2393"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Consolidated Statements and Other Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements filed as part of this annual report are filed under Item 18.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company do not know of any material, active or pending, legal and bankruptcy proceedings against them; nor is the Company involved as a plaintiff in any material proceeding or pending litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The directors and the management of the Company know of no active or pending proceedings against anyone that might materially adversely affect an interest of the Company.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not paid any dividends on its common shares.&#160;The Company may pay dividends on its common shares in the future if it generates profits.&#160;Any decision to pay dividends on common shares in the future will be made by the board of directors on the basis of the earnings, financial requirements and other conditions existing at such time.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2418"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Significant Changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant changes have occurred since the date of our annual financial statements included in this annual report on Form 20-F.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9. THE OFFER AND LISTING</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable except for Item 9.A.4 and Item 9.C.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Common Shares, no par value, are traded/quoted on the Nasdaq and the TSX under the symbols &#8220;ONCY" and &#8220;ONC&#8221;, respectively.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160; ADDITIONAL INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2442"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Share Capital</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2468"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Memorandum and Articles of Association</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Articles of Continuance</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are governed by our amended articles of incorporation (the "Articles") under the Business Corporations Act of Alberta (the &#8220;Act&#8221;) and by our by-laws (the&#160;"By-laws"). Our Alberta corporate access number is 207797382. Our Articles provide that there are no restrictions on the business we may carry on or on the powers we may exercise. Companies incorporated under the Act are not required to include specific objects or purposes in their articles or by-laws.</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to certain exceptions, including in respect of voting on any resolution to approve a contract that relates primarily to the director's remuneration, directors may not vote on resolutions to approve a material contract or material transaction if the director is a party to such contract or transaction. The directors are entitled to remuneration as shall from time to time be determined by the Board of Directors with no requirement for a quorum of independent directors. The directors have the ability under the Act to exercise our borrowing power, without authorization of the shareholders. The Act permits shareholders to restrict this authority through a company's articles or by-laws (or through a unanimous shareholder agreement), but no such restrictions are in place for us. Our Articles and By-laws do not require directors to hold shares for qualification. Neither the Articles or the By-laws contain an age limit requirement for the retirement of directors. The Corporation actively encourages independent board member renewal through its formal term limit policy, adopted on June 30, 2015, whereby the independent director term limit is set at 12 years. Under the policy, the Board of Directors maintains the discretion to extend a directors&#8217; term, if under the circumstances, it is in the best interest of the Corporation and its shareholders. This in practice ensures that new independent directors are appointed regularly, without losing the experience base of long serving directors.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights, Preferences, and Dividends Attaching to Shares</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of common shares have the right to receive dividends if and when declared. Each holder of common shares, as of the record date prior to a meeting, is entitled to attend and to cast one vote for each common share held as of such record date at such annual and/or special meeting, including with respect to the election or re-election of directors. Subject to the provisions of our By-laws, all directors may, if still qualified to serve as directors, stand for re-election. The numbers of our Board of Directors are not replaced at staggered intervals but are elected annually.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a distribution of assets on a winding-up, dissolution, or other return of capital (subject to certain exceptions) the holders of common shares shall have a right to receive their </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pro&#160;rata</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of such distribution. There are no sinking fund or redemption provisions in respect of the common shares. Our shareholders have no liability to further capital calls as all shares issued and outstanding are fully paid and non-assessable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other classes of shares are currently permitted to be issued.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Action Necessary to Change the Rights of Shareholders</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rights attaching to the different classes of shares may be varied by special resolution passed at a meeting of that class's shareholders.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual and Special Meetings of Shareholders</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Act and our By-laws, we are required to mail a Notice of Meeting and Management Information Circular to registered shareholders not less than 21&#160;days and not more than 50 days prior to the date of the meeting. Such materials must be filed concurrently with the applicable securities regulatory authorities in Canada and the U.S..&#160;Subject to certain provisions of the By-laws, a quorum of two or more shareholders in person or represented by proxy holding or representing by proxy not less than five (5%) percent of the total number of issued and outstanding shares enjoying voting rights at such meeting is required to properly constitute a meeting of shareholders.&#160;Shareholders and their duly appointed proxies and corporate representatives are entitled to be admitted to our annual and/or special meetings.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Limitations on the Rights to Own Shares</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Articles do not contain any limitations on the rights to own shares. Except as described below, there are currently no limitations imposed by Canadian federal or provincial laws on the rights of non-resident or foreign owners of Canadian securities to hold or vote the securities held. There are also no such limitations imposed by the Articles and By-laws with respect to our common&#160;shares.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Share Ownership</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, under applicable securities regulation in Canada, a person or company who beneficially owns, directly or indirectly, voting securities of an issuer or who exercises control or direction over voting securities of an issuer or a combination of both, carrying more than 10% of the voting rights attached to all the issuer's outstanding voting securities is an insider and must, within 10&#160;days of becoming an insider, file&#160;a report in the required form effective the date on which the person became an insider. The report must disclose any direct or indirect beneficial ownership of, or control or direction over, securities of the reporting issuer. Additionally, securities regulation in Canada provides for the filing of a report by an insider of a reporting issuer whose holdings change, which report must be filed within 5&#160;days from the day on which the change takes place.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules in the U.S. governing the ownership threshold above which shareholder ownership must be disclosed are more stringent than those discussed above. Section 13 of the Exchange Act imposes reporting requirements on persons who acquire beneficial ownership (as such term is defined in Rule 13d-3 under the Exchange Act) of more than 5% of a class of an equity security registered under Section 12 of the Exchange Act.&#160;In general, such persons must file, within 10&#160;days after such acquisition, a report of beneficial ownership with the SEC containing the information prescribed by the regulations under Section&#160;13 of the Exchange Act. This information is also required to be sent to the issuer of the securities and to each exchange where the securities are&#160;traded.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Provisions of Articles and By-laws</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no provisions in the Articles or By-laws:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delaying or prohibiting a change in control of our company that operate only with respect to a merger, acquisition or corporate restructuring;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discriminating against any existing or prospective holder of shares as a result of such shareholder owning a substantial number of&#160;shares;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring disclosure of share ownership; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governing changes in capital, where such provisions are more stringent than those required by&#160;law.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2492"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Material Contracts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employment contracts with each of our officers as summarized in Item 6B. Other than these employment contracts, we have not entered into any other contract other than in the ordinary course of business over the last two years.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2516"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Exchange Controls </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada presently has no system of exchange controls. There are no Canadian restrictions on the repatriation of capital or earnings of a Canadian public company to non-resident investors. There are no laws in Canada or exchange restrictions affecting the remittance of dividends, profits, interest, royalties, and other payments to non-resident holders of our securities, except as discussed below in Section E, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restrictions on Share Ownership by Non-Canadians</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations under the laws of Canada or in our organizing documents on the right of foreigners to hold or vote securities of our company, except that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Canada Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may require review and approval by the Minister of Industry (Canada) of certain acquisitions of &#8220;control&#8221; of our company by a &#8220;non-Canadian&#8221;. The threshold for acquisitions of control is generally defined as being one-third or more of the voting shares of the company. &#8220;Non-Canadian&#8221; generally means an individual who is not a Canadian citizen, or a corporation, partnership, trust, or joint venture that is ultimately controlled by non-Canadians.</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2540"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Taxation  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL CANADIAN FEDERAL INCOME TAX CONSIDERATIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is, as of the date of this annual report, a summary of the principal Canadian federal income tax considerations under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Canada) and the regulations thereunder  (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Act</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) generally applicable to an investor who acquires Common Shares as beneficial owner and who, for the purposes of the Tax Act and at all relevant times: (i) is not, and is not deemed to be, resident in Canada for the purposes of the Tax Act or any applicable income tax treaty or convention; (ii) does not and will not use or hold, and is not and will not be deemed to hold, the Common Shares in connection with carrying on a business in Canada; (iii) deals at arm&#8217;s length with the Corporation and the Agent; (iv) is not affiliated with the Corporation or the Agent; (v) is not exempt from tax under Part I of the Tax Act; and (vi) acquires and holds the Common Shares as capital property (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holder</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), all within the meaning of the Tax Act. Generally, the Common Shares will be considered to be capital property to a Non-Resident Holder provided that the Non-Resident Holder does not hold, and is not deemed to hold, the Common Shares in the course of carrying on a business of trading or dealing in securities and has not acquired the Common Shares in a transaction or transactions considered to be an adventure or concern in the nature of trade. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules, which are not discussed in this summary, may apply to Non-Resident Holders that are insurers carrying on an insurance business in Canada and elsewhere or an &#8220;authorized foreign bank&#8221; (as defined in the Tax Act). Such Non-Resident Holders should consult their own tax advisors with respect to an investment in Common Shares.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based upon the facts set out in this annual report, the current provisions of the Tax Act in force as of the date of this annual report and counsel&#8217;s understanding of the current administrative policies and assessing practices of the Canada Revenue Agency (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) published in writing by the CRA prior to the date of this annual report. This summary takes into account all specific proposals to amend the Tax Act publicly announced by or on behalf of the Minister of Finance (Canada) prior to the date of this annual report (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tax Proposals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and assumes that the Tax Proposals will be enacted in the form proposed, although no assurance can be given that the Tax Proposals will be enacted in their current form or at all. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the Tax Proposals, this summary does not otherwise take into account or anticipate any changes in law, whether by legislative, governmental, administrative, or judicial decision or action, nor does it take into account or consider any other federal or any provincial, territorial or foreign income tax considerations (other than those described below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), which considerations may differ significantly from the Canadian federal income tax considerations discussed in this summary. This summary also does not take into account any change in the administrative policies or assessing practices of the CRA. No assurances can be given that the subsequent changes in law or administrative policy will not affect or modify the contents of this summary. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">This summary is of a general nature only, is not exhaustive of all possible Canadian federal income tax considerations and is not intended to be, nor should it be construed to be, legal or tax advice to any particular Non-Resident Holder. No representations concerning the tax consequences to any particular Non-Resident Holder are made. Non-Resident Holders should consult their own tax advisors with respect to the tax consequences to them in their particular circumstances, including the application and effect of the income and other tax laws of any country, province, state or local tax authority.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Currency</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for purposes of the Tax Act, all amounts relating to the acquisition, holding, or disposition of the Common Shares (including dividends, adjusted cost base and proceeds of disposition) must, to the extent such amounts are not in Canadian dollars, be converted into Canadian dollars based on an exchange rate determined in accordance with the Tax Act.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid or credited, or deemed to be paid or credited, on the Common Shares to a Non-Resident Holder by the Corporation will be subject to Canadian withholding tax at the rate of 25% of the gross amount of the dividend, subject to any reduction in the rate of withholding to which the Non-Resident Holder is entitled under the terms of an applicable tax treaty. For example, under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada-United States Tax Convention (1980)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as amended (the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treaty</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), the rate of withholding tax on dividends paid or credited, or deemed to be paid or credited, to a Non-Resident Holder who is the beneficial owner of the dividends and who is a resident of the United States for purposes of the Treaty, and who is fully entitled to the benefits of the Treaty, is generally reduced to 15% of the gross amount of the dividend (or 5% in the case of a Non-Resident Holder that is a company that beneficially owns at least 10% of the Common Shares). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders are urged to consult their own tax advisors to determine their entitlement to relief under an applicable income tax treaty.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dispositions of Common Shares</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Non-Resident Holder will generally not be subject to tax under the Tax Act in respect of a capital gain realized on the disposition or deemed disposition of a Common Share, and a capital loss arising on such a disposition or deemed disposition will not be recognized under the Tax Act, unless the Common Share constitutes &#8220;taxable Canadian property&#8221; and is not &#8220;treaty-protected property&#8221; (each as defined in the Tax Act) of the Non-Resident Holder at the time of disposition or deemed disposition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provided the Common Shares are listed on a &#8220;designated stock exchange&#8221; (as defined in the Tax Act and which currently includes the NASDAQ and TSX), at the time of the disposition or deemed disposition, the Common Shares will generally not constitute taxable Canadian property to a Non-Resident Holder at that time, unless at any time during the 60-month period immediately preceding the disposition or deemed disposition, the following two conditions are met concurrently: (i) one or any combination of (a) the Non-Resident Holder, (b) persons with whom the Non-Resident Holder did not deal at arm&#8217;s length (for the purposes of the Tax Act), and (c) partnerships in which the Non-Resident Holder or a person described in (b) held a membership interest directly or indirectly through one or more partnerships, owned 25% or more of the issued shares of any class or series of the capital stock of the Corporation; and (ii) more than 50% of the fair market value of the Common Shares was derived directly or indirectly from one or any combination of (a) real or immovable property situated in Canada, (b) &#8220;Canadian resource properties&#8221; (as defined in the Tax Act), (c) &#8220;timber resource properties&#8221; (as defined in the Tax Act) or (d) options in respect of, or interests in, or for civil law rights in, any of the foregoing property, whether or not such property exists. Notwithstanding the foregoing, a Common Share may otherwise be deemed to be taxable Canadian property to a Non-Resident Holder for purposes of the Tax Act in certain circumstances.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxation of Capital Gains and Capital Losses</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Common Shares are taxable Canadian property of a Non-Resident Holder and are not treaty-protected property of the Non-Resident Holder at the time of their disposition or deemed disposition (other than a disposition to the Corporation that is not a sale in the open market in the manner in which shares are normally purchased by any member of the public in the open market), a Non-Resident Holder generally will realize a capital gain (or a capital loss) equal to the amount by which the proceeds of disposition of such Common Shares are greater (or are less) than the aggregate adjusted cost base of such Common Shares to the Non-Resident Holder immediately before the disposition or deemed disposition and any reasonable costs of disposition.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, one-half of any capital gain (a &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">taxable capital gain</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) realized by a Non-Resident Holder must be included in the Non-Resident Holder&#8217;s income for the taxation year in which the disposition occurs. Subject to and in accordance with the provisions of the Tax Act, one-half of any capital loss realized by a Non-Resident Holder (an &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">allowable capital loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) from dispositions of taxable Canadian property must generally be deducted against taxable capital gains realized by the Non-Resident Holder in that year from dispositions of taxable Canadian property. Certain excess allowable capital losses from the dispositions of taxable Canadian property may be carried back and deducted in any of the three preceding taxation years or carried forward and deducted in any subsequent taxation year against taxable capital gains realized in such years from dispositions of taxable Canadian property, subject to the detailed rules contained in the Tax Act. In addition, the disposition by a Non-Resident holder of Common Shares that are taxable Canadian property (other than &#8220;treaty-exempt property&#8221; as defined in the Tax Act) at the time of their disposition may be subject to certain withholding and reporting requirements under section 116 of the Tax Act. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Resident Holders whose Common Shares may be taxable Canadian property should consult their own tax advisors.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MATERIAL UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS </span></div><div><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a general summary of certain material U.S. federal income tax considerations applicable to a U.S. Holder (as defined below) arising from and relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is for general information purposes only and does not purport to be a complete analysis or listing of all potential U.S. federal income tax considerations that may apply to a U.S. Holder arising from and relating to the acquisition, ownership, and disposition of Common Shares. In addition, this summary does not take into account the individual facts and circumstances of any particular U.S. Holder that may affect the U.S. federal income tax consequences to such U.S. Holder,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, without limitation, specific tax consequences to a U.S. Holder under an applicable income tax treaty. Accordingly, this summary is not intended to be, and should not be construed as, legal or U.S. federal income tax advice with respect to any U.S. Holder. This summary does not address the U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences to U.S. Holders of the acquisition, ownership, and disposition of Common Shares. In addition, except as specifically set forth below, this summary does not discuss applicable tax reporting requirements. Each prospective U.S. Holder should consult its own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership and disposition of Common Shares.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No legal opinion from U.S. legal counsel or ruling from the Internal Revenue Service (the &#8220;IRS&#8221;) has been requested, or will be obtained, regarding the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.  This summary is not binding on the IRS, and the IRS is not precluded from taking a position that is different from, and contrary to, the positions taken in this summary. In addition, because the authorities on which this summary is based are subject to various interpretations, the IRS and the U.S. courts could disagree with one or more of the conclusions described in this summary.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Scope of this Summary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Authorities</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary is based on the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations (whether final, temporary, or proposed), published rulings of the IRS, published administrative positions of the IRS, the Treaty, and U.S. court decisions that are applicable, and, in each case, as in effect and available, as of the date of this document. Any of the authorities on which this summary is based could be changed in a material and adverse manner at any time, and any such change could be applied on a retroactive or prospective basis, which could affect the U.S. federal income tax considerations described in this summary. Except as provided herein, this summary does not discuss the potential effects, whether adverse or beneficial, of any proposed legislation that, if enacted, could be applied on a retroactive or prospective basis.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Holders</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this summary, the term &#8220;U.S. Holder&#8221; means a beneficial owner of Common Shares that is for U.S. federal income tax purposes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an individual who is a citizen or resident of the United States;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) organized under the laws of the United States, any state thereof, or the District of Columbia;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an estate whose income is subject to U.S. federal income taxation regardless of its source; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a trust that (1) is subject to the primary supervision of a court within the U.S. and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">U.S. Holders Subject to Special U.S. Federal Income Tax Rules Not Addressed</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This summary does not address the U.S. federal income tax considerations applicable to U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders that: (a) are tax-exempt organizations, qualified retirement plans, individual retirement accounts, or other tax-deferred accounts; (b) are financial institutions, underwriters, insurance companies, real estate investment trusts, or regulated investment companies; (c) are broker-dealers, dealers, or traders in securities or currencies that elect to apply a mark-to-market accounting method; (d) have a &#8220;functional currency&#8221; other than the U.S. dollar; (e) own Common Shares as part of a straddle, hedging transaction, conversion transaction, constructive sale, or other integrated transaction; (f) acquire Common Shares in connection with the exercise of employee stock options or otherwise as compensation for services; (g) hold Common Shares other than as a capital asset within the meaning of Section 1221 of the Code (generally, property held for investment purposes); (h) are partnerships or other flow-through entities (and partners or other owners thereof); (i) are S corporations (and shareholders thereof); (i) are subject to special tax accounting rules </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to Common Shares; or (j) own, have owned or will own (directly, indirectly, or by attribution) 10% or more of the total combined voting power or value of the outstanding shares of the Company; (k) hold Common Shares in connection with a trade or business, permanent establishment, or fixed base outside the United States; (l) are U.S. expatriates or former long-term residents of the United States subject to Section 877 or 877A of the Code; or (m) are subject to the alternative minimum tax. U.S. Holders that are subject to special provisions under the Code, including, but not limited to, U.S. Holders described immediately above, should consult their own tax advisors regarding the U.S. federal, U.S. federal alternative minimum, U.S. federal net investment income, U.S. federal estate and gift, U.S. state and local, and non-U.S. tax consequences relating to the acquisition, ownership, and disposition of Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an entity or arrangement that is classified as a partnership (or other &#8220;pass-through&#8221; entity) for U.S. federal income tax purposes holds Common Shares, the U.S. federal income tax consequences to such entity or arrangement and the partners (or other owners or participants) of such entity or arrangement generally will depend on the activities of the entity or arrangement and the status of such partners (or owners or participants). This summary does not address the tax consequences to any such partner (or owner or participants). Partners (or other owners or participants) of entities or arrangements that are classified as partnerships or as &#8220;pass-through&#8221; entities for U.S. federal income tax purposes should consult their own tax advisors regarding the U.S. federal income tax consequences arising from and relating to the acquisition, ownership, and disposition of Common Shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Passive Foreign Investment Company Rules</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PFIC Status of the Company</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company were to constitute a &#8220;passive foreign investment company&#8221; under the meaning of Section 1297 of the Code (a &#8220;PFIC&#8221;, as defined below) for any year during a U.S. Holder&#8217;s holding period, then certain potentially adverse rules would affect the U.S. federal income tax consequences to a U.S. Holder as a result of the acquisition, ownership and disposition of Common Shares. The Company believes that it was classified as a PFIC during its most recently completed tax year, and based on current business plans and financial expectations, the Company expects that it will be a PFIC for the current tax year and may be a PFIC in future tax years. No opinion of legal counsel or ruling from the IRS concerning the status of the Company as a PFIC has been obtained or is currently planned to be requested. The determination of whether any corporation was, or will be, a PFIC for a tax year depends, in part, on the application of complex U.S. federal income tax rules, which are subject to differing interpretations. In addition, whether any corporation will be a PFIC for any tax year depends on the assets and income of such corporation over the course of each such tax year and, as a result, cannot be predicted with certainty as of the date of this document. Accordingly, there can be no assurance that the IRS will not challenge any determination made by the Company (or any subsidiary of the Company) concerning its PFIC status. Each U.S. Holder should consult its own tax advisors regarding the PFIC status of the Company and each subsidiary of the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any year in which the Company is classified as a PFIC, a U.S. Holder will be required to file an annual report with the IRS containing such information as Treasury Regulations and/or other IRS guidance may require. In addition to penalties, a failure to satisfy such reporting requirements may result in an extension of the time period during which the IRS can assess a tax. U.S. Holders should consult their own tax advisors regarding the requirements of filing such information returns under these rules, including the requirement to file an IRS Form 8621 annually.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally will be a PFIC if, for a tax year, (a) 75% or more of the gross income of the Company is passive income (the &#8220;PFIC income test&#8221;) or (b) 50% or more of the value of the Company&#8217;s assets either produce passive income or are held for the production of passive income, based on the quarterly average of the fair market value of such assets (the &#8220;PFIC asset test&#8221;). &#8220;Gross income&#8221; generally includes all sales revenues less the cost of goods sold, plus income from investments and from incidental or outside operations or sources, and &#8220;passive income&#8221; generally includes, for example, dividends, interest, certain rents and royalties, certain gains from the sale of stock and securities, and certain gains from commodities transactions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the PFIC income test and PFIC asset test described above, if the Company owns, directly or indirectly, 25% or more of the total value of the outstanding shares of another corporation, the Company will be treated as if it (a) held a proportionate share of the assets of such other corporation and (b) received directly a proportionate share of the income of such other corporation. In addition, for purposes of the PFIC income test and PFIC asset test described above, and assuming certain other requirements are met, &#8220;passive income&#8221; does not include certain interest, dividends, rents, or royalties that are received or accrued by the Company from certain &#8220;related persons&#8221; (as defined in Section 954(d)(3) of the Code) also organized in Canada, to the extent such items are properly allocable to the income of such related person that is not passive income.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain attribution rules, if the Company is a PFIC, U.S. Holders will generally be deemed to own their proportionate share of the Company&#8217;s direct or indirect equity interest in any company that is also a PFIC (a &#8216;&#8216;Subsidiary PFIC&#8217;&#8217;), and will generally be subject to U.S. federal income tax on their proportionate share of (a) any &#8220;excess distributions,&#8221; as described below, on the stock of a Subsidiary PFIC and (b) a disposition or deemed disposition of the stock of a Subsidiary PFIC by the Company or another Subsidiary PFIC, both as if such U.S. Holders directly held the shares of such Subsidiary PFIC. In addition, U.S. Holders may be subject to U.S. federal income tax on any indirect gain realized on the stock of a Subsidiary PFIC on the sale or disposition of Common Shares. Accordingly, U.S. Holders should be aware that they could be subject to tax under the PFIC rules even if no distributions are received and no redemptions or other dispositions of Common Shares are made.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Default PFIC Rules Under Section 1291 of the Code</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is a PFIC for any tax year during which a U.S. Holder owns Common Shares, the U.S. federal income tax consequences to such U.S. Holder of the acquisition, ownership, and disposition of Common Shares will depend on whether and when such U.S. Holder makes an election to treat the Company and each Subsidiary PFIC, if any, as a &#8220;qualified electing fund&#8221; or &#8220;QEF&#8221; under Section 1295 of the Code (a &#8220;QEF Election&#8221;) or makes a mark-to-market election under Section 1296 of the Code (a &#8220;Mark-to-Market Election&#8221;). A U.S. Holder that does not make either a QEF Election or a Mark-to-Market Election will be referred to in this summary as a &#8220;Non-Electing U.S. Holder.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Non-Electing U.S. Holder will be subject to the rules of Section 1291 of the Code (described below) with respect to (a) any gain recognized on the sale or other taxable disposition of Common Shares and (b) any &#8220;excess distribution&#8221; received on the Common Shares. A distribution generally will be an &#8220;excess distribution&#8221; to the extent that such distribution (together with all other distributions received in the current tax year) exceeds 125% of the average distributions received during the three preceding tax years (or during a U.S. Holder&#8217;s holding period for the Common Shares, if shorter).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 1291 of the Code, any gain recognized on the sale or other taxable disposition of Common Shares (including an indirect disposition of the stock of any Subsidiary PFIC), and any &#8220;excess distribution&#8221; received on Common Shares or with respect to the stock of a Subsidiary PFIC, must be ratably allocated to each day in a Non-Electing U.S. Holder&#8217;s holding period for the respective Common Shares. The amount of any such gain or excess distribution allocated to the tax year of disposition or distribution of the excess distribution and to years before the entity became a PFIC, if any, would be taxed as ordinary income (and not eligible for certain preferred rates). The amounts allocated to any other tax year would be subject to U.S. federal income tax at the highest tax rate applicable to ordinary income in each such year, and an interest charge would be imposed on the tax liability for each such year, calculated as if such tax liability had been due in each such year. A Non-Electing U.S. Holder that is not a corporation must treat any such interest paid as &#8220;personal interest,&#8221; which is not deductible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company is a PFIC for any tax year during which a Non-Electing U.S. Holder holds Common Shares, the Company will continue to be treated as a PFIC with respect to such Non-Electing U.S. Holder, regardless of whether the Company ceases to be a PFIC in one or more subsequent tax years. A Non-Electing U.S. Holder may terminate this deemed PFIC status by electing </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above), but not loss, as if such Common Shares were sold on the last day of the last tax year for which the Company was a PFIC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">QEF Election</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a timely and effective QEF Election for the first tax year in which the holding period of its Common Shares begins generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to its Common Shares. A U.S. Holder that makes a timely and effective QEF Election will be subject to U.S. federal income tax on such U.S. Holder&#8217;s pro rata share of (a) the net capital gain of the Company, which will be taxed as long-term capital gain to such U.S. Holder, and (b) the ordinary earnings of the Company, which will be taxed as ordinary income to such U.S. Holder. Generally, &#8220;net capital gain&#8221; is the excess of (a) net long-term capital gain over (b) net short-term capital loss, and &#8220;ordinary earnings&#8221; are the excess of (a) &#8220;earnings and profits&#8221; over (b) net capital gain. A U.S. Holder that makes a QEF Election will be subject to U.S. federal income tax on such amounts for each tax year in which the Company is a PFIC, regardless of whether such amounts are actually distributed to such U.S. Holder by the Company. However, for any tax year in which the Company is a PFIC and has no net income or gain, U.S. Holders that have made a QEF Election would not have any income inclusions as a result of the QEF Election. If a U.S. Holder that made a QEF Election has an income inclusion, such a U.S. Holder may, subject to certain limitations, elect to defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If such U.S. Holder is not a corporation, any such interest paid will be treated as &#8220;personal interest,&#8221; which is not deductible.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a timely and effective QEF Election with respect to the Company generally (a) may receive a tax-free distribution from the Company to the extent that such distribution represents &#8220;earnings and profits&#8221; of the Company that were previously included in income by the U.S. Holder because of such QEF Election and (b) will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in income or allowed as a tax-free distribution because of such QEF Election. In addition, a U.S. Holder that makes a QEF Election generally will recognize capital gain or loss on the sale or other taxable disposition of Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The procedure for making a QEF Election, and the U.S. federal income tax consequences of making a QEF Election, will depend on whether such QEF Election is timely. A QEF Election will be treated as &#8220;timely&#8221; if such QEF Election is made for the first year in the U.S. Holder&#8217;s holding period for the Common Shares in which the Company was a PFIC. A U.S. Holder may make a timely QEF Election by filing the appropriate QEF Election documents at the time such U.S. Holder files a U.S. federal income tax return for such year. If a U.S. Holder does not make a timely and effective QEF Election for the first year in the U.S. Holder&#8217;s holding period for the Common Shares, the U.S. Holder may still be able to make a timely and effective QEF Election in a subsequent year if such U.S. Holder meets certain requirements and makes a &#8220;purging&#8221; election to recognize gain (which will be taxed under the rules of Section 1291 of the Code discussed above) as if such Common Shares were sold for their fair market value on the day the QEF Election is effective. If a U.S. Holder makes a QEF Election but does not make a &#8220;purging&#8221; election to recognize gain as discussed in the preceding sentence, then such U.S. Holder shall be subject to the QEF Election rules and shall continue to be subject to tax under the rules of Section 1291 discussed above with respect to its Common Shares. If a U.S. Holder owns PFIC stock indirectly through another PFIC, separate QEF Elections must be made for the PFIC in which the U.S. Holder is a direct shareholder and the Subsidiary PFIC for the QEF rules to apply to both PFICs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A QEF Election will apply to the tax year for which such QEF Election is timely made and to all subsequent tax years, unless such QEF Election is invalidated or terminated or the IRS consents to revocation of such QEF Election. If a U.S. Holder makes a QEF Election and, in a subsequent tax year, the Company ceases to be a PFIC, the QEF Election will remain in effect (although it will not be applicable) during those tax years in which the Corporation is not a PFIC. Accordingly, if the Company becomes a PFIC in another subsequent tax year, the QEF Election will be effective and the U.S. Holder will be subject to the QEF rules described above during any subsequent tax year in which the Company qualifies as a PFIC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company: (a) will make available to U.S. Holders, upon their written request, information as to its status as a PFIC and the PFIC status of any subsidiary in which the Company owns more than 50% of such subsidiary&#8217;s total aggregate voting power and (b) for each year in which the Company is a PFIC, provide to a U.S. Holder, upon written request, such information and documentation that a U.S. Holder making a QEF Election with respect to the Company and such more than 50% owned subsidiary which constitutes a PFIC is reasonably required to obtain for U.S. federal income tax purposes. The Company may elect to provide such information on its website. With respect to any Subsidiary PFIC in which the Company owns 50% or less of the aggregate voting power, upon the written request of a U.S. Holder acquiring Common Shares, the Company will request that such Subsidiary PFIC provide such U.S. Holder with the information that such U.S. Holder requires to report under the QEF rules; provided, however, the Company can provide no assurances that such Subsidiary PFIC will provide such information.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder makes a QEF Election by attaching a completed IRS Form 8621, including a PFIC Annual Information Statement, to a timely filed United States federal income tax return. However, if the Company does not provide the required information with regard to the Company or any of its Subsidiary PFICs, U.S. Holders will not be able to make a QEF Election for such entity and will continue to be subject to the rules of Section 1291 of the Code discussed above that apply to Non-Electing U.S. Holders with respect to the taxation of gains and excess distributions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Mark-to-Market Election</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder may make a Mark-to-Market Election only if the Common Shares are marketable stock. The Common Shares generally will be &#8220;marketable stock&#8221; if the Common Shares are regularly traded on (a) a national securities exchange that is registered with the Securities and Exchange Commission, (b) the national market system established pursuant to section 11A of the U.S. Exchange Act, or (c) a foreign securities exchange that is regulated or supervised by a governmental authority of the country in which the market is located, provided that (i) such foreign exchange has trading volume, listing, financial disclosure, and surveillance requirements, and meets other requirements, and the laws of the country in which such foreign exchange is located, together with the rules of such foreign exchange, ensure that such requirements are actually enforced and (ii) the rules of such foreign exchange effectively promote active trading of listed stocks. If such stock is traded on such a qualified exchange or other market, such stock generally will be &#8220;regularly traded&#8221; for any calendar year during which such stock is traded, other than in de minimis quantities, on at least 15 days during each calendar quarter. Provided that the Common Shares are &#8220;regularly traded&#8221; as described in the preceding sentence, the Common Shares are expected to be marketable stock. However, each U.S. Holder should consult its own tax advisor in this matter. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election with respect to its Common Shares generally will not be subject to the rules of Section 1291 of the Code discussed above with respect to such Common Shares. However, if a U.S. Holder does not make a Mark-to-Market Election beginning in the first tax year of such U.S. Holder&#8217;s holding period for the Common Shares for which the Company is a PFIC and such U.S. Holder has not made a timely QEF Election, the rules of Section 1291 of the Code discussed above will apply to certain dispositions of, and distributions on, the Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election will include in ordinary income, for each tax year in which the Company is a PFIC, an amount equal to the excess, if any, of (a) the fair market value of the Common Shares, as of the close of such tax year over (b) such U.S. Holder&#8217;s adjusted tax basis in such Common Shares. A U.S. Holder that makes a Mark-to-Market Election will be allowed a deduction in an amount equal to the excess, if any, of (a) such U.S. Holder&#8217;s adjusted tax basis in the Common Shares, over (b) the fair market value of such Common Shares (but only to the extent of the net amount of previously included income as a result of the Mark-to-Market Election for prior tax years).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that makes a Mark-to-Market Election generally also will adjust such U.S. Holder&#8217;s tax basis in the Common Shares to reflect the amount included in gross income or allowed as a deduction because of such Mark-to-Market Election. In addition, upon a sale or other taxable disposition of Common Shares, a U.S. Holder that makes a Mark-to-Market Election will recognize ordinary income or ordinary loss (not to exceed the excess, if any, of (a) the amount included in ordinary income because of such Mark-to-Market Election for prior tax years over (b) the amount allowed as a deduction because of such Mark-to-Market Election for prior tax years). Losses that exceed this limitation are subject to the rules generally applicable to losses provided in the Code and Treasury Regulations. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder makes a Mark-to-Market Election by attaching a completed IRS Form 8621 to a timely filed United States federal income tax return. A Mark-to-Market Election applies to the tax year in which such Mark-to-Market Election is made and to each subsequent tax year, unless the Common Shares cease to be &#8220;marketable stock&#8221; or the IRS consents to revocation of such election. Each U.S. Holder should consult its own tax advisors regarding the availability of, and procedure for making, a Mark-to-Market Election.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a U.S. Holder may be eligible to make a Mark-to-Market Election with respect to the Common Shares, no such election may be made with respect to the stock of any Subsidiary PFIC that a U.S. Holder is treated as owning, because such stock is not marketable. Hence, the Mark-to-Market Election will not be effective to avoid the application of the default rules of Section 1291 of the Code described above with respect to deemed dispositions of Subsidiary PFIC stock or excess distributions from a Subsidiary PFIC to its shareholder.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other PFIC Rules</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 1291(f) of the Code, the IRS has issued proposed Treasury Regulations that, subject to certain exceptions, would cause a U.S. Holder that had not made a timely QEF Election to recognize gain (but not loss) upon certain transfers of Common Shares that would otherwise be tax-deferred (e.g., gifts and exchanges pursuant to corporate reorganizations). However, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific U.S. federal income tax consequences to a U.S. Holder may vary based on the manner in which Common Shares are transferred.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain additional adverse rules may apply with respect to a U.S. Holder if the Company is a PFIC, regardless of whether such U.S. Holder makes a QEF Election. For example, under Section 1298(b)(6) of the Code, a U.S. Holder that uses Common Shares as security for a loan will, except as may be provided in Treasury Regulations, be treated as having made a taxable disposition of such Common Shares.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a U.S. Holder who acquires Common Shares from a decedent will not receive a &#8220;step up&#8221; in tax basis of such Common Shares to fair market value unless such decedent had a timely and effective QEF Election in place.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special rules also apply to the amount of foreign tax credit that a U.S. Holder may claim on a distribution from a PFIC. Subject to such special rules, foreign taxes paid with respect to any distribution in respect of stock in a PFIC are generally eligible for the foreign tax credit. The rules relating to distributions by a PFIC and their eligibility for the foreign tax credit are complicated, and a U.S. Holder should consult with its own tax advisors regarding the availability of the foreign tax credit with respect to distributions by a PFIC.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PFIC rules are complex, and each U.S. Holder should consult its own tax advisors regarding the PFIC rules and how the PFIC rules may affect the U.S. federal income tax consequences of the acquisition, ownership, and disposition of Common Shares.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Rules Applicable to the Ownership and Disposition of Common Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion describes the general rules applicable to the ownership and disposition of the Common Shares but is subject in its entirety to the special rules described above under the heading &#8220;Passive Foreign Investment Company Rules.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Distributions on Common Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A U.S. Holder that receives a distribution, including a constructive distribution, with respect to a Common Share will be required to include the amount of such distribution in gross income as a dividend (without reduction for any Canadian income tax withheld from such distribution) to the extent of the current and accumulated &#8220;earnings and profits&#8221; of the Company, as computed for U.S. federal income tax purposes. A dividend generally will be taxed to a U.S. Holder at ordinary income tax rates if the Company is a PFIC for the tax year of such distribution or the preceding tax year. To the extent that a distribution exceeds the current and accumulated &#8220;earnings and profits&#8221; of the Company, such distribution will be treated first as a tax-free return of capital to the extent of a U.S. Holder&#8217;s tax basis in the Common Shares and thereafter as gain from the sale or exchange of such Common Shares. (See &#8220;Sale or Other Taxable Disposition of Common Shares&#8221; below). However, the Company may not maintain the calculations of its earnings and profits in accordance with U.S. federal income tax principles, and each U.S. Holder may have to assume that any distribution by the Company with respect to the Common Shares will constitute ordinary dividend income. Dividends received on Common Shares by corporate U.S. Holders generally will not be eligible for the &#8220;dividends received deduction.&#8221; Subject to applicable limitations and provided the Corporation is eligible for the benefits of the Treaty or the Common Shares are readily tradable on a United States securities market, dividends paid by the Company to non-corporate U.S. Holders, including individuals, generally will be eligible for the preferential tax rates applicable to long-term capital gains for dividends, provided certain holding period and other conditions are satisfied, including that the Company not be classified as a PFIC in the tax year of distribution or in the preceding tax year. The dividend rules are complex, and each U.S. Holder should consult its own tax advisors regarding the application of such rules.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Sale or Other Taxable Disposition of Common Shares</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the sale or other taxable disposition of Common Shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the U.S. dollar value of cash received plus the fair market value of any property received and such U.S. Holder&#8217;s tax basis in such Common Shares sold or otherwise disposed of. A U.S. Holder&#8217;s tax basis in Common Shares generally will be such U.S. Holder&#8217;s U.S. dollar cost for such Common Shares. Gain or loss recognized on such sale or other disposition generally will be long-term capital gain or loss if, at the time of the sale or other disposition, the Common Shares have been held for more than one year.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferential tax rates currently apply to long-term capital gain of a U.S. Holder that is an individual, estate, or trust. There are currently no preferential tax rates for long-term capital gain of a U.S. Holder that is a corporation. Deductions for capital losses are subject to significant limitations under the Code.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Considerations</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Receipt of Foreign Currency</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of any distribution paid to a U.S. Holder in foreign currency, or on the sale, exchange or other taxable disposition of Common Shares, generally will be equal to the U.S. dollar value of such foreign currency based on the exchange rate applicable on the date of receipt (regardless of whether such foreign currency is converted into U.S. dollars at that time). A U.S. Holder will have a tax basis in the foreign currency equal to its U.S. dollar value on the date of receipt. Any U.S. Holder who converts or otherwise disposes of the foreign currency after the date of receipt may have a foreign currency exchange gain or loss that would be treated as ordinary income or loss, and generally will be U.S. source income or loss for foreign tax credit purposes. Different rules apply to U.S. Holders who use the accrual method of tax accounting. Each U.S. Holder should consult its own U.S. tax advisors regarding the U.S. federal income tax consequences of receiving, owning, and disposing of foreign currency.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign Tax Credit</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid on the Common Shares will be treated as foreign-source income, and generally will be treated as &#8220;passive category income&#8221; or &#8220;general category income&#8221; for U.S. foreign tax credit purposes. Any gain or loss recognized on a sale or other disposition of Common Shares generally will be United States source gain or loss. Certain U.S. Holders that are eligible for the benefits of the Treaty may elect to treat such gain or loss as Canadian source gain or loss for U.S. foreign tax credit purposes. The Code applies various complex limitations on the amount of foreign taxes that may be claimed as a credit by U.S. taxpayers. In addition, Treasury Regulations that apply to foreign taxes paid or accrued (the &#8220;Foreign Tax Credit Regulations&#8221;) impose additional requirements for Canadian withholding taxes to be eligible for a foreign tax credit, and there can be no assurance that those requirements will be satisfied. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Treasury Department has recently released guidance temporarily pausing the application of certain of the Foreign Tax Credit Regulations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the PFIC rules and the Foreign Tax Credit Regulations, each as discussed above, a U.S. Holder that pays (whether directly or through withholding) Canadian income tax with respect to dividends paid on the Common Shares generally will be entitled, at the election of such U.S. Holder, to receive either a deduction or a credit for such Canadian income tax. Generally, a credit will reduce a U.S. Holder&#8217;s U.S. federal income tax liability on a dollar-for-dollar basis, whereas a deduction will reduce a U.S. Holder&#8217;s income that is subject to U.S. federal income tax. This election is made on a year-by-year basis and applies to all foreign taxes paid (whether directly or through withholding) by a U.S. Holder during a year. The foreign tax credit rules are complex and involve the application of rules that depend on a U.S. Holder&#8217;s particular circumstances. Accordingly, each U.S. Holder should consult its own U.S. tax advisors regarding the foreign tax credit rules.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Backup Withholding and Information Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. federal income tax law, certain categories of U.S. Holders must file information returns with respect to their investment in, or involvement in, a foreign corporation. For example, U.S. return disclosure obligations (and related penalties) are imposed on individuals who are U.S. Holders that hold certain specified foreign financial assets in excess of certain threshold amounts. The definition of specified foreign financial assets includes not only financial accounts maintained in foreign financial institutions, but also, unless held in accounts maintained by a financial institution, any stock or security issued by a non-U.S. person, any financial instrument or contract held for investment that has an issuer or counterparty other than a U.S. person and any interest in a foreign entity. U.S. Holders may be subject to these reporting requirements unless their Common Shares are held in an account at certain financial institutions. Penalties for failure to file certain of these information returns are substantial. U.S. Holders should consult with their own tax advisors regarding the requirements of filing information returns, including the requirement to file an IRS Form 8938.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made within the U.S., or by a U.S. payor or U.S. middleman, of dividends on, and proceeds arising from the sale or other taxable disposition of, Common Shares will generally be subject to information reporting and backup withholding tax if a U.S. Holder (a) fails to furnish such U.S. Holder&#8217;s correct U.S. taxpayer identification number (generally on IRS Form W-9), (b) furnishes an incorrect U.S. taxpayer identification number, (c) is notified by the IRS that such U.S. Holder has previously failed to properly report items subject to backup withholding tax, or (d) fails to certify, under penalty of perjury, that such U.S. Holder has furnished its correct U.S. taxpayer identification number and that the IRS has not notified such U.S. Holder that it is subject to backup withholding tax. However, certain exempt persons generally are excluded from these information reporting and backup withholding rules. Backup withholding is not an additional tax. Any amounts withheld under the U.S. backup withholding tax rules will be allowed as a credit against a U.S. Holder&#8217;s U.S. federal income tax liability, if any, or will be refunded, if such U.S. Holder furnishes required information to the IRS in a timely manner. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion of reporting requirements set forth above is not intended to constitute a complete description of all reporting requirements that may apply to a U.S. Holder. A failure to satisfy certain reporting requirements may result in an extension of the time period during which the IRS can assess a tax and, under certain circumstances, such an extension may apply to assessments of amounts unrelated to any unsatisfied reporting requirement. Each U.S. Holder should consult its own tax advisors regarding the information reporting and backup withholding rules.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THE ABOVE SUMMARY IS NOT INTENDED TO CONSTITUTE A COMPLETE ANALYSIS OF ALL TAX CONSIDERATIONS APPLICABLE TO U.S. HOLDERS WITH RESPECT TO THE ACQUISITION, OWNERSHIP, AND DISPOSITION OF COMMON SHARES. U.S. HOLDERS SHOULD CONSULT THEIR OWN TAX ADVISORS AS TO THE TAX CONSIDERATIONS APPLICABLE TO THEM IN LIGHT OF THEIR OWN PARTICULAR CIRCUMSTANCES.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2564"></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">F.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Dividends and Paying Agents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Not Applicable.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2588"></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">G.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Statements by Experts</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2612"></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">H.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Documents on Display</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the informational requirements of the Exchange Act and file reports and other information with the SEC. The SEC maintains a Website that contains reports, proxy and information statements, and other information regarding registrants that file electronically with the SEC at www.sec.gov. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to file reports and other information with the securities commissions in Canada. You are invited to read and copy any reports, statements, or other information, other than confidential filings, that we file with the provincial securities commissions. These filings are also electronically available from the Canadian System for Electronic Document Analysis and Retrieval ("SEDAR+") (www.sedarplus.ca), the Canadian equivalent of the SEC's electronic document gathering and retrieval system.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We "incorporate by reference" information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this Form&#160;20-F and&#160;more recent information automatically updates and supersedes more dated information contained or incorporated by reference in this Form&#160;20-F.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a foreign private issuer, we are exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements to shareholders.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will provide without charge to each person, including any beneficial owner, to whom a copy of this annual report has been delivered, on the written or oral request of such person, a copy of any or all documents referred to above which have been or may be incorporated by reference in this annual report (not&#160;including exhibits to such incorporated information that are not specifically incorporated by reference into such information). Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, Attention:&#160;Kirk Look.&#160;&#160;Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2636"></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">I.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.61pt">Subsidiary Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.&#160;&#160; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Please see Item 4 &#8211; &#8220;Information on the Company&#8221; and Note 17 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in our audited consolidated financial statements beginning on page F-1 of this annual report on Form 20-F.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any long-term debt, nor do we currently utilize interest rate swap contracts to hedge against interest rate&#160;risk.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use financial instruments for trading purposes and are not parties to any leverage derivatives.&#160;We do not currently engage in hedging transactions. </span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.&#160;&#160; DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_55"></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.&#160; &#160;DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.&#160;&#160; MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">A. - D. Material Modification to the Rights of Security Holders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">E. Use of Proceeds</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the conclusion of our Chief Executive Officer and Chief Financial Officer that our Company's disclosure controls and procedures (as defined in Exchange Act rules 13a-15(e) and 15d-15(e)), based on their evaluation of these controls and procedures as of the end of the period covered by this annual report, are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer and effected by the board of directors, management, and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with International Reporting Standards as issued by the International Accounting Standards Board ("IFRS"), and includes those policies and procedures that (i) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Company&#8217;s Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, 2013 Framework, (COSO) in Internal Control-Integrated Framework.&#160;Based on this assessment, management believes that, as of December 31, 2023, the Company&#8217;s internal control over financial reporting was effective based on those criteria.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Attestation Report of the Registered Public Accounting Firms</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Auditor Attestation Report is included in the Ernst &amp; Young LLP Independent Auditor's Report, included in the Company's financial statements, beginning on page F-1 of this annual report on Form 20-F.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Controls over Financial Reporting</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal controls over financial reporting that occurred during the period that is covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.&#160;</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_67"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16 .&#160; [RESERVED]</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16A.&#160; AUDIT COMMITTEE FINANCIAL EXPERT</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board has determined that each of the Audit Committee members, Angela Holtham, Wayne Pisano, Deborah M. Brown, and James T. Parsons is an audit committee financial expert and each is independent pursuant to the Rule 5605(d)(2) of the Nasdaq Capital Market and Rule 10A-3 of the Exchange Act. For a description of the education and experience of each member of the Audit Committee, see "Item 6A. Directors, Senior Management and Employees."</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16B.&#160; CODE OF ETHICS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has adopted a Code of Ethics for the Company that includes our Chief Executive Officer, Chief Financial Officer and Accounting Officer that applies to our Chief Executive Officer, Chief Financial Officer, and Controller.&#160;A copy of this Code of Ethics may be found on the Company&#8217;s website at www.oncolyticsbiotech.com.&#160;&#160;Requests for such copies should be directed to us at the following address: Oncolytics Biotech Inc., 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue SW, Calgary, Alberta, Canada T2R 0C5, Attention:&#160;&#160;Kirk Look Telephone (403) 670 - 7377. Facsimile (403)&#160;283-0858 EMAIL: info@oncolyticsbiotech.com.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no amendments to our Code of Ethics during the fiscal year ended December 31, 2023. We did not grant any waivers to the provisions of our Code of Ethics during the fiscal year ended December 31, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16C.&#160; PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Fees and Services</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the financial years ended December 31, 2023 and 2022, Ernst &amp; Young LLP (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-43">1263</ix:nonNumeric>) received the following fees:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Audit-related fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Audit fees were for professional services rendered for the audit of our annual financial statements and services provided in connection with statutory and regulatory filings or engagements, including review of interim financial statements, accounting consultations, assistance with prospectus filings, and matters relating to the provision of a consent letter for various filings.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Audit-related fees were for assurance and related services reasonably related to the performance of the audit or review of the annual statements and are not reported under the heading Audit Fees above.&#160;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Tax fees were for tax return preparations, scientific research and development return, and other tax consultation fees.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Other fees are for products and services other than those described under the headings Audit Fees, Audit-Related Fees and Tax Fees above.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee pre-approves all audit services to be provided to us by our independent auditors. The Audit Committee&#8217;s policy regarding the pre-approval of non-audit services to be provided to us by our independent auditors is that all such services shall be pre-approved by the Audit Committee or by the Chair of the Audit Committee, who must report all such pre-approvals to the Audit Committee at their next meeting following the granting thereof. Non-audit services that are prohibited to be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided to us by our independent auditors may not be pre-approved. In addition, prior to the granting of any pre-approval, the Audit Committee or the Chair, as the case may be, must be satisfied that the performance of the services in question will not compromise the independence of the independent auditors.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16E. PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16F.&#160; CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16G. CORPORATE GOVERNANCE</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NASDAQ CORPORATE GOVERNANCE</span></div><div style="margin-top:3.4pt;padding-left:4.5pt;padding-right:333pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common shares are quoted for trading on the Nasdaq Capital Market. Section 5615(a)(3) of the Nasdaq Marketplace Rules permits the Nasdaq to grant exemptions to a foreign private issuer for the provisions of the Rule 5600 series, Rule 5250 (d), and Rules 5210(c) and 5255 related to qualitative listing requirements. We are organized under the laws of the Province of Alberta and our common shares are listed for trading on The Toronto Stock Exchange. We comply with the laws of the Province of Alberta and rules and regulations of The Toronto Stock Exchange, including rules related to corporate governance practices. A description of the significant ways in which our governance practices differ from those followed by domestic companies pursuant to the Nasdaq Marketplace Rules is as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Meeting Quorum Requirement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Nasdaq minimum quorum requirement for a shareholder meeting under Section 5620(c) of the Nasdaq Marketplace Rules is one-third of the outstanding shares of common stock. In addition, a company listed on Nasdaq is required to state our quorum requirement in our bylaws. Our quorum requirement is set forth in our corporate bylaws. A quorum for our shareholder meeting is two persons present and being, or representing by proxy, members holding not less than 5% of the issued shares entitled to be voted at such meeting.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing is consistent with the laws, customs and practices in Canada and the rules of The Toronto Stock Exchange.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Board Diversity Matrix (as of March&#160;7, 2024) </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.936%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country of Principal Executive Offices:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Private Issuer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Disclosure Prohibited Under Home Country Law</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Number of Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Female</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Male</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Binary</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Did Not Disclose Gender</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I: Gender Identity</span></td><td colspan="12" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Directors</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II: Demographic Background</span></td><td colspan="12" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underrepresented Individual in Home Country Jurisdiction</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LGBTQ+</span></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Did Not Disclose Demographic Background</span></td><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16H.&#160; MINE SAFETY DISCLOSURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16I.&#160; DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2662"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16J.&#160; INSIDER TRADING POLICIES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 5, 2020, the Company approved its amended Corporate Trading Policy, which sets forth guidelines that apply to directors, officers and employees of the Company and its subsidiaries. There are also specific guidelines that apply to directors and officers, as follows:</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Insider Trading Policy provides for quarterly trading blackouts for all directors, officers and employees beginning five days prior to the meeting of the Audit Committee where the Financial Information will be reviewed and ending one day after public dissemination of the financial results of the fiscal quarter.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Directors and officers should obtain pre-clearance for all trading activities from either the Chief Executive Officer or the Chief Financial Officer. This pre-clearance is intended to provide an additional review of current business initiatives to ensure that trading does not occur while material non-public information exists.</span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Directors and officers must report all trading in securities to the Chief Financial Officer within 24 hours of the transaction taking place. Trading includes purchase and sale of securities, exercise of options, and transfer of securities.  </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The policy prohibits trading while in possession of material non-public information regarding the Company and prohibits short selling, trading in derivative securities, hedging transactions and other similar types of speculative trading in the Company&#8217;s securities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the Insider Trading Policy has been filed herewith as Exhibit 16.1.</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_2668"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16K.&#160; CYBERSECURITY</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Processes for Assessing, Identifying and Managing Cybersecurity Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a cybersecurity program, which uses technology and processes to help mitigate cybersecurity risks, with our management team working to monitor, assess, identify, and respond to potential cybersecurity incidents that threaten the Company. The program also focuses on security awareness and training for employees and contractors with access to Company facilities or systems. Cybersecurity risks for the Company include financial loss, loss of data, and business interruption. The Company maintains technology and non-technology based system controls, cybersecurity insurance, a robust backup program, and disaster recovery testing to mitigate these risks.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity program also follows defense in depth principles, which aim to implement various layered access control, detection, prevention, and response measures. We also engage with independent third parties to assess our vulnerabilities and help us mitigate cybersecurity-related risks. Our security posture is also tested by internal personnel and independent third parties to gauge its effectiveness from time to time. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Role in Assessing and Managing Cybersecurity Risks</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cybersecurity risk management and strategy processes for assessing, identifying, and managing material risks from cybersecurity threats are managed by members of the Company&#8217;s management team, primarily the Chief Executive Officer and the Chief Financial Officer. Per the Company&#8217;s policies, cybersecurity incidents are to be immediately reported to the management team for resolution with outsourced IT support team. Information technology general controls, including controls to mitigate cybersecurity risks, are included with management&#8217;s testing of internal control over financial reporting.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Board of Director&#8217;s Oversight of Risks from Cybersecurity</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity risks are included in an overall risk management assessment, which is reviewed annually by the Company&#8217;s audit committee. The Company engages third-party specialists on a periodic basis to review key information technology systems and provide recommendations for system updates and improvements. Results of these reviews are used to update information technology systems within the Company&#8217;s information system governance policies. The Company's management regularly discusses cyber trends and, should they arise, any material incidents with audit committee. The Company&#8217;s management will also review the Company&#8217;s cybersecurity program with the Board once every year.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">No Previous Material Cybersecurity Threats</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any previous cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company. Despite the security and risk management measures that we have implemented and any additional measures we may implement or adopt in the future, our facilities and systems, and those of our third-party service providers, have been and are vulnerable to security breaches, computer viruses, lost or misplaced data, programming errors, scams, burglary, human errors, acts of vandalism, misdirected wire transfers, or other malicious or criminal activities. A successful attack on our information or operational technology systems could have material consequences to the Company. While we devote resources to our security measures to protect our systems and information, these measures cannot provide absolute security. See &#8220;Item 3D. Risk Factors&#8221; for additional information about the risks to our business associated with a breach or compromise to our information technology systems. </span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_97"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 17. FINANCIAL STATEMENTS.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 18.  &#8211; &#8220;Financial Statements&#8221;.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 18 FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements appear on pages F-1 through F-27.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_106"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 19. EXHIBITS.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this annual report:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">NUMBER</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">DESCRIPTION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Constating Documents</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/articles.htm">Articles of Incorporation</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992822000017/ex12onc-2017byxlaws1636459.htm">By-laws</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description of Securities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21exdescriptionofsecurit.htm">Description of Securities Registered Under Section 12 of the Exchange Act</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Material Contracts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex41august2013hagerman.htm">Employment Agreement, dated August 1, 2013 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex42hagermandec2015.htm">Amending Agreement, dated December 1, 2015 between Oncolytics Biotech Inc. and its Director, Manufacturing and Engineering, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)#</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1129928/000112992818000028/ex444regionallicensingagre.htm">License, development, supply and distribution agreement with Adlai Nortye Biopharma Co., Ltd dated November 14, 2017 </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex47hagermanamendment2019.htm">Amending Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex48kirklook2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992820000012/ex49coffey2019.htm">Executive Employment Agreement, dated January 1, 2019 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992821000013/ex412employmentagreementth.htm">Employment Agreement, dated August 3, 2020 between Oncolytics Biotech (U.S.) Inc. and its Global Head of Clinical Development and Operations, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992823000008/ex419mattcoffeyamendment4-.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech Inc. and its Chief Executive Officer, Matthew Coffey</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992823000008/ex420kirklookamendment4-em.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech Inc. and its Chief Financial Officer, Kirk Look</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.10</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992823000008/ex421allisonhagermanamendm.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech Inc. and its Vice President, Product Development, Allison Hagerman</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1129928/000112992823000008/ex423thomasheinemanamendme.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech (U.S.) Inc. and its Chief Medical Officer, Thomas C. Heineman </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex412employmentagreementam.htm">Employment Agreement, dated September 1, 2020 between Oncolytics Biotech (U.S.) Inc. and its Executive Director, Clinical Operations, Amy Goodowitz Levin</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex413-amylevinamendment1xe.htm">Amending Agreement, dated January 1, 2023 between Oncolytics Biotech (U.S.) Inc. and its Vice President, Clinical Operations, Amy Goodowitz Levin</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subsidiaries</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex80subsidiaries2023.htm">List of subsidiaries</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certifications</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex121ceocertification2023.htm">Certificate of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex122cfocertification2023.htm">Certificate of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex131ceocertification2023.htm">Certificate of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex132cfocertification2023.htm">Certificate of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Exhibits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex151-2023mda.htm">The Registrant's Management's Discussion and Analysis for the Year Ended December 31, 2023</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex152ey2023consent.htm">Consent of Ernst &amp; Young LLP</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex161-corptradingpolicyrev.htm">Insider Trading Policy</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex971oncolyticsclawbackpol.htm">Clawback Policy</a></span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.091%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Schema.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Calculation Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Definition Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Label Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Scheme Presentation Linkbase.</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover page interactive data file (formatted as Inline XBRL and included in Exhibit 101)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">* - Denotes management contract or agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"># - Certain portions of this exhibit have been redacted pursuant to a confidential treatment request filed with the SEC on March 19, 2018</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Previously filed with the SEC on Form 20-F dated March 19, 2018, and incorporated by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Previously filed with the SEC on Form 20-F dated March 6, 2020, and incorporated by reference.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Previously filed with the SEC on Form 20-F dated March 5, 2021, and incorporated by reference.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Previously filed with the SEC on Form 20-F dated March 3, 2022, and incorporated by reference. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e) Previously filed with the SEC on Form 20-F dated March 3, 2023, and incorporated by reference.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: March&#160;12, 2024 </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Oncolytics Biotech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STATEMENT OF MANAGEMENT&#8217;S RESPONSIBILITY</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for the preparation and presentation of the consolidated financial statements, Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;), and all other information in the annual report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In management&#8217;s opinion, the accompanying consolidated financial statements have been properly prepared within reasonable limits of materiality and in accordance with the appropriately selected International Financial Reporting Standards as issued by the International Accounting Standards Board consistently applied and summarized in the consolidated financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include estimates that are necessary when transactions affecting the current accounting period cannot be finalized with certainty until after the balance sheet date.&#160;Based on careful judgments by management, such estimates have been properly reflected in the accompanying consolidated financial statements.&#160;The financial information presented elsewhere in the annual report has been reviewed to ensure consistency with that in the consolidated financial statements. The MD&amp;A also includes information regarding the impact of current transactions and events, sources of liquidity and capital resources, and risks and uncertainty.&#160;Actual results in the future may differ materially from our present assessment of this information because future events and circumstances may not occur as expected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Systems of internal controls, including organizational and procedural controls and internal controls over financial reporting, assessed as reasonable and appropriate in the circumstances, are designed and maintained by management to provide reasonable assurance that assets are safeguarded from loss or unauthorized use and to produce reliable records for preparation of financial statements. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-44">Ernst &amp; Young LLP</ix:nonNumeric>, an independent firm of Chartered Professional Accountants, has been engaged, as approved by a vote of the shareholders' at the Company's most recent Annual General Meeting, to audit and provide their independent audit opinion on the following: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Company's consolidated financial statements as at and for the year ended December&#160;31, 2023; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">the effectiveness of the Company's internal control over financial reporting as at December&#160;31, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young has full and free access to our Board of Directors and its Committees to discuss audit, financial reporting, and related matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is responsible for ensuring that management fulfills its responsibilities for financial reporting and internal control.&#160;The Board exercises this responsibility through the Audit Committee of the Board, which is comprised entirely of independent directors.&#160;This Committee meets with management and the external auditors to satisfy itself that management&#8217;s responsibilities are properly discharged and to review the consolidated financial statements and MD&amp;A before they are presented to the Board of Directors for approval. The consolidated financial statements have been approved by the Board on the recommendation of the Audit Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;/s/Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following report is provided by management in respect of the company&#8217;s internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the U.S. Securities Exchange Act of 1934):</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management is responsible for establishing and maintaining adequate internal control over the company&#8217;s financial reporting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management has used the Committee of Sponsoring Organizations of the Treadway Commission (COSO) framework (2013) in Internal Control - Integrated Framework to evaluate the effectiveness of the company&#8217;s internal control over financial reporting.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Management has assessed the effectiveness of the company&#8217;s internal control over financial reporting as at December&#160;31, 2023, and has concluded that such internal control over financial reporting was effective as of that date. Additionally, based on this assessment, management determined that there were no material weaknesses in internal control over financial reporting as at December&#160;31, 2023. Because of inherent limitations, systems of internal control over financial reporting may not prevent or detect misstatements and even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The effectiveness of the company&#8217;s internal control over financial reporting as at December&#160;31, 2023 has been audited by Ernst &amp; Young, independent auditor, as stated in their report which appears herein.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/&#160;&#160;Matthew Coffey&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;/s/&#160;&#160;Kirk Look&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of Oncolytics Biotech Inc. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated statements of financial position of Oncolytics Biotech Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and its financial performance and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with International Financial Reporting Standards (IFRSs) as issued by the International Accounting Standards Board.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and our report dated March 7, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/Ernst &amp; Young LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chartered Professional Accountants </span></div><div style="margin-bottom:4pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.953%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We have served as the Company's auditor since 1999.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-45">Calgary, Canada</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2024</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:8pt;text-align:justify"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_1649267444383"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and Board of Directors of Oncolytics Biotech Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Oncolytics Biotech Inc.&#8217;s internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), (the COSO criteria). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023 based on the COSO criteria</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated statements of financial position of Oncolytics Biotech Inc. as of December 31, 2023 and 2022, the related consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the three years in the period ended December 31, 2023, and the related notes, and our report dated March 7, 2024 expressed an unqualified opinion thereon.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Inherent Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the consolidated financial statements. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/Ernst &amp; Young LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chartered Professional Accountants </span></div><div style="margin-bottom:4pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.953%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Calgary, Canada</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 7, 2024</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.081%"><tr><td style="width:1.0%"/><td style="width:67.439%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.310%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-46">34,912</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-47">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentFinancialAssetsAvailableforsale" format="ixt:fixed-zero" scale="3" id="f-48">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentFinancialAssetsAvailableforsale" format="ixt:num-dot-decimal" scale="3" id="f-49">20,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables (note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="f-50">15</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:OtherCurrentReceivables" scale="3" id="f-51">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses (note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentPrepayments" format="ixt:num-dot-decimal" scale="3" id="f-52">3,246</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentPrepayments" format="ixt:num-dot-decimal" scale="3" id="f-53">3,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-54">38,173</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-55">35,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment (note 6)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-56">282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-57">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets (note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-58">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-59">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses (note 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentPrepayments" format="ixt:fixed-zero" scale="3" id="f-60">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentPrepayments" scale="3" id="f-61">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-62">38,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Assets" format="ixt:num-dot-decimal" scale="3" id="f-63">37,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities And Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities (note 7)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-64">3,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-65">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities (note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="f-66">332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" format="ixt:fixed-zero" scale="3" id="f-67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-68">133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="f-69">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant derivative (notes 9, 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-70">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-71">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-72">4,237</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-73">3,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liability (note 13)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-74">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-75">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="f-76">290</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="f-77">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-78">11,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-79">10,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (note 14)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="cad" contextRef="c-3" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" id="f-80"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="cad" contextRef="c-4" xsi:nil="true" name="oncyf:CommitmentsAndContingencies1" id="f-81"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share capital (note 10)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Authorized: unlimited</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Issued: December&#160;31, 2023 &#8211; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-82">74,423,960</ix:nonFraction></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;December&#160;31, 2022 &#8211; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-83">61,327,914</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-84">430,906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:IssuedCapital" format="ixt:num-dot-decimal" scale="3" id="f-85">404,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributed surplus (note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="3" id="f-86">42,116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:AdditionalPaidinCapital" format="ixt:num-dot-decimal" scale="3" id="f-87">40,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="f-88">544</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:AccumulatedOtherComprehensiveIncome" scale="3" id="f-89">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-90">446,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-91">418,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-92">27,563</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-93">26,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders' equity </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-94">38,820</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:EquityAndLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-95">37,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">          See accompanying notes</span></div><div style="padding-left:22.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.204%"><tr><td style="width:1.0%"/><td style="width:46.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:51.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;On behalf of the Board:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Angela Holtham</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/Wayne Pisano</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Director&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Director&#160;&#160;&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development (note 20)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-96">17,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-97">15,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-98">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;General and administrative (note 20)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-99">16,082</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-100">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-101">13,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-102">33,791</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-103">26,924</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLossFromOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-104">26,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;Change in fair value of warrant derivative (notes 9, 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-105">5,285</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="f-106">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="f-107">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Foreign exchange (loss) gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="f-108">475</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" scale="3" id="f-110">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-111">1,326</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="f-112">528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:InterestIncomeOnCashAndCashEquivalents" scale="3" id="f-113">99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-114">27,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-115">24,751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-116">26,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense (note 15)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-117">97</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-118">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="f-119">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">27,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">26,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive (loss) income items that may be reclassified to net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-123">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-124">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="f-125">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-126">27,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-127">24,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-128">26,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share (note 12)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-129"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-130">0.41</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-131"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-132">0.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" sign="-" name="ifrs-full:DilutedEarningsLossPerShare" scale="0" id="f-133"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" sign="-" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="f-134">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted) (note 12)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-135"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-136">67,624,036</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-137"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-138">58,029,745</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-139"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-140">53,513,225</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:45pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars) </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.350%"><tr><td style="width:1.0%"/><td style="width:35.174%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.793%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.235%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Share Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contributed Surplus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-9" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-141">356,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-10" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-142">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-11" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-143">31,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-12" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-144">400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-13" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-145">367,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-14" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-146">24,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-15" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-147">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-16" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-148">26,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-149">26,316</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-150">381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-151">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-152">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="f-153">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="f-154">544</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="3" id="f-155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">34,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">34,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-158">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-159">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-160">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity" scale="3" id="f-161">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-18" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-162">3,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-163">3,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-19" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-164">391,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-20" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-165">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-21" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-166">34,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-22" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-167">388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-23" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-168">393,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-169">36,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-25" decimals="-3" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-170">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-26" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-171">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-172">24,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-27" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-173">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-174">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-175">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-27" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="f-176">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" scale="3" id="f-177">98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity" format="ixt:fixed-zero" scale="3" id="f-178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of equity warrant agreement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-29" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:num-dot-decimal" scale="3" id="f-179">3,618</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:num-dot-decimal" scale="3" id="f-180">3,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity" format="ixt:fixed-zero" scale="3" id="f-181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-27" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-182">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-183">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-27" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-184">764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-185">764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-28" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-186">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-187">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-188">404,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-30" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-31" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-190">40,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-32" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-191">662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-33" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-192">418,251</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-193">26,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss and other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-34" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" scale="3" id="f-194">118</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-35" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-195">27,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ComprehensiveIncome" format="ixt:num-dot-decimal" scale="3" id="f-196">27,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan (note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-36" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" format="ixt:num-dot-decimal" scale="3" id="f-197">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-37" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-198">490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="f-199">781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" Agreement (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-38" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-39" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-201">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-40" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-202">17,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-41" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-203">638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-42" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">18,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-36" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-205">2,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-206">2,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (note 11)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-37" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-207">1,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" format="ixt:num-dot-decimal" scale="3" id="f-208">1,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-209">430,906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-43" decimals="-3" name="ifrs-full:Equity" format="ixt:fixed-zero" scale="3" id="f-210">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-44" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-211">42,116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-45" decimals="-3" name="ifrs-full:Equity" scale="3" id="f-212">544</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-46" decimals="-3" sign="-" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-213">446,003</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-214">27,563</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:58.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.988%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss for the year</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">27,752</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">24,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">26,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment (notes 6, 20)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-218">81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-219">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="f-220">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets (notes 8, 20)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="f-221">322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="f-222">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:AdjustmentsForDepreciationRightOfUseAssets" scale="3" id="f-223">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense (notes 11, 20, 21)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-224">1,917</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-225">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForSharebasedPayments" format="ixt:num-dot-decimal" scale="3" id="f-226">3,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation warrant expenses (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="f-227">151</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" format="ixt:fixed-zero" scale="3" id="f-229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense (income), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" scale="3" id="f-230">71</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:InterestRevenueExpense" scale="3" id="f-231">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:InterestRevenueExpense" scale="3" id="f-232">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign exchange loss (gain)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="f-233">282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" format="ixt:num-dot-decimal" scale="3" id="f-234">1,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains" scale="3" id="f-235">426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative (notes 9, 17)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-236">5,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="f-237">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="f-238">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in non-cash working capital (note 18)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-239">1,765</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="f-240">391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="f-241">908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-242">28,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-243">23,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInOperations" format="ixt:num-dot-decimal" scale="3" id="f-244">22,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-245">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-246">20,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-248">20,230</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment (note 6)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-251">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-252">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="f-253">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-254">20,222</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-255">20,403</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" scale="3" id="f-256">286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options (note 11)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="f-257">781</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="f-258">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfOptions" scale="3" id="f-259">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants (note 9)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="f-261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ProceedsFromExerciseOfWarrants" scale="3" id="f-262">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from "At the Market" equity distribution agreement (note 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-39" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-263">10,261</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-47" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-264">12,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-48" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-265">32,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering (note 10)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-49" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:num-dot-decimal" scale="3" id="f-266">21,359</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-50" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="f-267">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-51" decimals="-3" name="ifrs-full:ProceedsFromIssuingShares" format="ixt:fixed-zero" scale="3" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities (note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-269">407</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-270">381</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-271">366</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-272">31,994</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-273">12,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-274">33,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-275">23,768</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-276">31,553</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-277">10,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-278">11,666</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-279">41,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-14" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-280">31,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-281">522</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-282">1,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="f-283">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-284">34,912</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-285">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-286">41,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_136"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 1: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="f-287" continuedAt="f-287-1" escape="true">Nature of Operations</ix:nonNumeric></span></div><ix:continuation id="f-287-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue S.W., Calgary, Alberta, Canada.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2023, we had an accumulated deficit of $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" sign="-" name="ifrs-full:RetainedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-288">446,003</ix:nonFraction>. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares. Failure to raise additional capital would have a material adverse impact on our business, results of operations, and financial condition. As at December&#160;31, 2023, we had cash and cash equivalents of $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="oncyf:CashAndCashEquivalentsAndCurrentInvestments" format="ixt:num-dot-decimal" scale="3" id="f-289">34,912</ix:nonFraction>. We believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months from the balance sheet date.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_142"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 2: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="f-290" continuedAt="f-290-1" escape="true">Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-290-1" continuedAt="f-290-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of compliance</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2023, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;7, 2024. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies, and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. </span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-290-2">Our accounts are prepared on the historical cost basis, except for certain assets and liabilities, which are measured at fair value as explained in the notes to these financial statements.</ix:continuation>  </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_145"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 3: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory" id="f-291" continuedAt="f-291-1" escape="true">Summary of Material Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-291-1" continuedAt="f-291-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the material accounting policies summarized below.</span></div><ix:nonNumeric contextRef="c-1" name="oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" id="f-292" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents and marketable securities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include interest-bearing deposits with our bank totaling $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-293">31,534</ix:nonFraction> as at December&#160;31, 2023 (December&#160;31, 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-294">9,501</ix:nonFraction>). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" id="f-295" escape="true">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ix:nonNumeric>  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" id="f-296" continuedAt="f-296-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-296-1">Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ix:continuation> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" id="f-297" escape="true">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities, other liabilities, and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.</ix:nonNumeric>  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" id="f-298" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" id="f-299" continuedAt="f-299-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-291-2" continuedAt="f-291-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-299-1">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.</ix:continuation> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" id="f-300" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" id="f-301" continuedAt="f-301-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-301-1">Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ix:continuation>  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory" id="f-302" continuedAt="f-302-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-291-3" continuedAt="f-291-4"><ix:continuation id="f-302-1" continuedAt="f-302-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-302-2">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ix:continuation> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per share</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding during the year. D<ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" id="f-303" escape="true">iluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants.</ix:nonNumeric> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" id="f-304" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" id="f-305" continuedAt="f-305-1" escape="true">Depreciation is recorded using the declining balance method at the following annual rates:</ix:nonNumeric></span></div><ix:continuation id="f-305-1" continuedAt="f-305-2"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.192%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.608%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-52" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="f-306">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-53" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="f-307">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-54" decimals="INF" name="oncyf:PropertyPlantandEquipmentAnnualDepreciationRate" scale="-2" id="f-308">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" id="f-309" escape="true">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.</ix:nonNumeric> </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue" id="f-310" continuedAt="f-310-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-291-4" continuedAt="f-291-5"><ix:continuation id="f-310-1"><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" id="f-311" continuedAt="f-311-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have <ix:nonFraction unitRef="plan" contextRef="c-3" decimals="INF" name="oncyf:NumberOfStockOptionPlans" format="ixt-sec:numwordsen" scale="0" id="f-312">one</ix:nonFraction> stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than <ix:nonNumeric contextRef="c-1" name="oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" format="ixt-sec:durwordsen" id="f-313">ten years</ix:nonNumeric> from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share award plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  </span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-311-1">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change.</ix:continuation> </span></div></ix:continuation><div style="margin-bottom:10pt;margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" id="f-314" escape="true"><ix:continuation id="f-291-5"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments became effective on January 1, 2023. Adopting the amendments did not have a</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material impact on our consolidated financial statements.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates, changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on our consolidated financial statements. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification of Liabilities as Current or Non-Current</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 Presentation of Financial Statements, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments are effective for annual periods beginning on or after January 1, 2024, and are to be applied retrospectively. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.</span></div></ix:continuation></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 4:  <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" id="f-315" continuedAt="f-315-1" escape="true">Significant Judgments, Estimates, and Assumptions</ix:nonNumeric></span></div><ix:continuation id="f-315-1" continuedAt="f-315-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of our consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the application of accounting policies and the reported amount and disclosures in our consolidated financial statements and accompanying notes. Management makes estimates based on our best knowledge of current events and actions that the Company may undertake in the future. We consider the potential impact of certain external factors outside of our control, including global political conflicts, supply chain disruptions, pandemics, inflation, rising interest rates, and liquidity, when making certain estimates and judgments relating to the preparation of these consolidated financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from these estimates, and such differences could be material. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div></ix:continuation><div style="margin-top:10pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-315-2" continuedAt="f-315-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of share-based compensation and compensation warrants requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of share-based compensation are disclosed in note 11. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative issued are disclosed in note 9.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-315-3">We assess the relevant factors related to the primary economic environment in which our entities operate to determine the functional currency. Where the assessment of primary indicators are mixed, we assess the secondary indicators, including the relationship between the foreign operations and reporting entity.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_154"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 5: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherLiabilitiesExplanatory" id="f-317" continuedAt="f-317-1" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfOtherAssetsExplanatory" id="f-316" continuedAt="f-316-1" escape="true">Other Assets and Liabilities </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-317-1" continuedAt="f-317-2"><ix:continuation id="f-316-1" continuedAt="f-316-2"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial was jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2023, we recorded <ix:nonFraction unitRef="cad" contextRef="c-55" decimals="-3" name="ifrs-full:OtherReceivables" format="ixt:fixed-zero" scale="3" id="f-318">nil</ix:nonFraction> (December&#160;31, 2022 - US$<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="ifrs-full:OtherReceivables" scale="3" id="f-319">360</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="c-56" decimals="-3" name="ifrs-full:OtherReceivables" scale="3" id="f-320">488</ix:nonFraction>)) in other receivables related to unbilled BRACELET-1 cost from Pfizer. As at December&#160;31, 2023, Pfizer had completed its funding obligations.  </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2023, we recorded $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-321">1,319</ix:nonFraction> (December&#160;31, 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-322">1,327</ix:nonFraction>) in current prepaid expenses and <ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:NoncurrentPrepayments" format="ixt:fixed-zero" scale="0" id="f-323">nil</ix:nonFraction> (December&#160;31, 2022 -  $<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:NoncurrentPrepayments" scale="3" id="f-324">998</ix:nonFraction>) in non-current prepaid expenses.</span></div></ix:continuation></ix:continuation><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="f-317-2" continuedAt="f-317-3"><ix:continuation id="f-316-2" continuedAt="f-316-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"><ix:continuation id="f-317-3"><ix:continuation id="f-316-3">In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$<ix:nonFraction unitRef="cad" contextRef="c-57" decimals="-3" name="ifrs-full:OtherReceivables" format="ixt:num-dot-decimal" scale="6" id="f-325">5</ix:nonFraction>&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at December&#160;31, 2023, we recorded US$<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="f-326">225</ix:nonFraction> ($<ix:nonFraction unitRef="cad" contextRef="c-57" decimals="-3" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="f-327">298</ix:nonFraction>) in other liabilities representing unapplied funding received from PanCAN.</ix:continuation></ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 6: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory" id="f-328" continuedAt="f-328-1" escape="true">Property and Equipment</ix:nonNumeric></span></div><ix:continuation id="f-328-1"><ix:continuation id="f-305-2"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.328%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.042%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.471%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.762%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-58" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-329">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-59" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-330">406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-60" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-331">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-61" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-332">228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-62" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-333">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-63" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-64" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-335">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-65" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-336">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-66" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-337">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-67" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-338">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-68" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-339">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-69" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-340">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-70" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-341">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-71" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-342">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-72" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-343">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-73" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-74" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-345">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-75" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-76" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-77" decimals="-3" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="f-348">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-78" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-349">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-79" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-350">436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-80" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-351">248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-81" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-352">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-82" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-353">977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-83" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-354">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-84" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-355">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-85" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-356">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-86" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-357">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-87" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-358">521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-88" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-359">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-89" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-360">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-90" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-361">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-91" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-362">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-92" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-363">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-93" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-364">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-94" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-365">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-95" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-366">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-96" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-367">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-97" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-368">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-98" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-369">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-99" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-370">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-100" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-371">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-101" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-372">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-102" decimals="-3" name="ifrs-full:DepreciationPropertyPlantAndEquipment" scale="3" id="f-373">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-103" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-374">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-104" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-375">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-105" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-376">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-106" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-377">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-107" decimals="-3" sign="-" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-378">695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-108" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-379">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-109" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-380">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-110" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-381">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-111" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-382">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-383">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-112" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-384">7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-113" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-385">85</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-114" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-386">128</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-115" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-387">62</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="f-388">282</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_160"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 7: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="f-389" continuedAt="f-389-1" escape="true">Accounts payable and accrued liabilities</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" id="f-390" escape="true"><ix:continuation id="f-389-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.250%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-391">1,082</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" format="ixt:num-dot-decimal" scale="3" id="f-392">2,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-393">2,490</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:AccrualsClassifiedAsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-394">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-395">3,572</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-396">3,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_163"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 8: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfLeasesExplanatory" id="f-397" continuedAt="f-397-1" escape="true">Leases</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-397-1"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with lease terms generally between <ix:nonNumeric contextRef="c-116" name="oncyf:OperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-398">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-117" name="oncyf:OperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-399">6</ix:nonNumeric> years. We currently do not have leases with residual value guarantees. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was <ix:nonFraction unitRef="number" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" scale="-2" id="f-400">15</ix:nonFraction>%. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, we extended the office lease for our subsidiaries, for which we recorded an addition of $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-401"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="f-402">392</ix:nonFraction></ix:nonFraction> to the lease liability and right-of-use asset. Under the terms of the lease, we have the option to extend the lease term for one of our subsidiaries for an additional three years. We did not include the extension option in the lease term as we were not reasonably certain to exercise the option. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" id="f-403" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-404">296</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-405">584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" scale="3" id="f-406">392</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdditionsToRightofuseAssets" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-408">322</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-409">299</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:ForeignExchangeImpactRightofUseAssets" scale="3" id="f-410">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:ForeignExchangeImpactRightofUseAssets" scale="3" id="f-411">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-412">365</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:RightofuseAssets" scale="3" id="f-413">296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" id="f-414" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-415">373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-416">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" scale="3" id="f-417">392</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-419">407</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:CashOutflowForLeases" scale="3" id="f-420">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-421">71</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:InterestExpenseOnLeaseLiabilities" scale="3" id="f-422">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="f-423">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="f-424">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-425">423</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:LeaseLiabilities" scale="3" id="f-426">373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" id="f-427" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-118" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-428">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-119" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-429">311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-120" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:GrossLeaseLiabilities" scale="3" id="f-431">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_166"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 9: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory" id="f-432" continuedAt="f-432-1" escape="true">Warrant Derivative</ix:nonNumeric></span></div><ix:continuation id="f-432-1" continuedAt="f-432-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common share purchase warrants ("warrants") with a U.S. dollar exercise price, which differs from our functional currency, are treated as a derivative measured at fair value, and revalued each period end at fair value through profit and loss. The fair value of these warrants is presented as a liability on our consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-432-2" continuedAt="f-432-3"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" id="f-433" continuedAt="f-433-1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the value of our warrant derivative were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:64.098%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.935%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-434">64,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-435">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-121" decimals="-3" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="f-436">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-121" decimals="-3" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="f-437">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-438">64,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-439">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-440">7,667,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-441">7,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" name="oncyf:WarrantLiabilityUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-442">1,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" name="oncyf:WarrantLiabilityAmortizedDiscount" scale="3" id="f-443">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" sign="-" name="ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-444">5,431</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-122" decimals="-3" sign="-" name="oncyf:GainsLossesFromForeignExchangeImpact" scale="3" id="f-445">132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-446">7,731,085</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-447">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding warrant derivative as at December&#160;31, 2023:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.542%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-448">0.90</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 16, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 16, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-449">64,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-450">2.81</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-451">6,667,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-452">2.81</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 7, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-453">1,000,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="oncyf:NumberOfWarrantsOutstanding" format="ixt:num-dot-decimal" id="f-454">7,731,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, pursuant to an underwritten public offering, we issued <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="oncyf:NumberOfWarrantsAndSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-455">6,667,000</ix:nonFraction> units for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-126" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-456">20,185</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-457">15,001</ix:nonFraction>) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-458">2.25</ix:nonFraction> per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:NumberOfWarrantsAndSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-459">1,000,050</ix:nonFraction> units for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-128" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-460">3,077</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-461">2,250</ix:nonFraction>) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-462">2.25</ix:nonFraction> per unit. Each unit consisted of <ix:nonFraction unitRef="shares" contextRef="c-130" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="f-463">one</ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="c-131" decimals="INF" name="oncyf:CommonSharesPerUnit" format="ixt-sec:numwordsen" scale="0" id="f-464">one</ix:nonFraction> warrant, which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase <ix:nonFraction unitRef="shares" contextRef="c-132" decimals="INF" name="oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" format="ixt-sec:numwordsen" scale="0" id="f-465">one</ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-466">2.81</ix:nonFraction> up to <ix:nonNumeric contextRef="c-128" name="oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" format="ixt-sec:durmonth" id="f-467">60</ix:nonNumeric> months from the date of issuance. The expiry of the warrants may be accelerated by the Company at any time prior to the expiry date if the volume weighted average price (if applicable, as converted to U.S. dollars at the Bank of Canada posted rate for the respective trading day) of the issued and outstanding common shares on the Toronto Stock Exchange or such other principal stock exchange on which the common shares are listed and posted for trading is greater than US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" scale="0" id="f-468"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" scale="0" id="f-469">6.50</ix:nonFraction></ix:nonFraction> for any <ix:nonFraction unitRef="d" contextRef="c-126" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" scale="0" id="f-470"><ix:nonFraction unitRef="d" contextRef="c-128" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" scale="0" id="f-471">20</ix:nonFraction></ix:nonFraction> consecutive trading days, at which time the Company may, within <ix:nonFraction unitRef="d" contextRef="c-126" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" scale="0" id="f-472"><ix:nonFraction unitRef="d" contextRef="c-128" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" scale="0" id="f-473">10</ix:nonFraction></ix:nonFraction> business days, accelerate the expiry date by issuing a press release announcing the reduced warrant term whereupon the warrants will expire on or after the <ix:nonFraction unitRef="d" contextRef="c-128" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" scale="0" id="f-474"><ix:nonFraction unitRef="d" contextRef="c-126" decimals="INF" name="oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" scale="0" id="f-475">75</ix:nonFraction></ix:nonFraction>th calendar day after the date of such press release.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $<ix:nonFraction unitRef="cad" contextRef="c-134" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-476">17,724</ix:nonFraction> recorded in share capital and an initial warrant derivative liability of $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-477">7,360</ix:nonFraction>. The difference between the fair value of the warrants and their allocated proceeds was a discount of $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:WarrantLiabilityUnamortizedDiscount" format="ixt:num-dot-decimal" scale="3" id="f-478">1,822</ix:nonFraction>, which is amortized on a straight-line basis over the <ix:nonNumeric contextRef="c-1" name="oncyf:WarrantsTerm" format="ixt-sec:durwordsen" id="f-479">five-year</ix:nonNumeric> expected life of the warrants and recorded under change in fair value of warrant derivative on our consolidated statement of loss and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-433-1"><ix:continuation id="f-432-3"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative with an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="2" name="oncyf:WarrantExercisePrice" scale="0" id="f-480">2.81</ix:nonFraction> was determined using the following assumptions: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.423%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 7,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 8,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="f-481">1.35</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="f-482">2.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted" scale="0" id="f-483">2.26</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-484">3.2</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-485">3.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="3" name="oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-486">3.8</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-135" decimals="1" name="oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" scale="0" id="f-487">4.6</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-136" decimals="1" name="oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" scale="0" id="f-488">5.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-137" decimals="1" name="oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" scale="0" id="f-489">5.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-490">36.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-491">36.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="3" name="oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-492">36.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="INF" name="oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="3" id="f-493">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="INF" name="oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="3" id="f-494">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-137" decimals="INF" name="oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="3" id="f-495">Nil</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-135" decimals="2" name="oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="f-496">0.18</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-136" decimals="2" name="oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="f-497">0.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-137" decimals="2" name="oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="f-498">0.70</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div id="ib0923231ce844ed28a280a970e7dcaf5_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 10: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="f-499" continuedAt="f-499-1" escape="true">Share Capital</ix:nonNumeric></span></div><ix:continuation id="f-499-1" continuedAt="f-499-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="f-500" continuedAt="f-500-1" escape="true"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-501">46,166,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-9" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-502">356,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-503">123,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-138" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-504">381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-505">150,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-139" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-506">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-507">8,401,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-140" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-508">34,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-509">201,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-141" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-510">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-17" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-511">1,256</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-512">55,043,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-19" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-513">391,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-142" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-514">8,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-142" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-515">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-516">40,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-143" decimals="-3" name="ifrs-full:IssueOfEquity" scale="3" id="f-517">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-518">6,235,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-144" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-519">13,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-27" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-520">764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-521">61,327,914</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-6" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-522">404,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-145" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-523">450,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-145" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-524">1,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-525">4,978,605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-38" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-526">10,676</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-146" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-527">7,667,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-146" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-528">17,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-36" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-529">2,805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ifrs-full:NumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-530">74,423,960</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-531">430,906</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="f-532">40,000</ix:nonFraction> over a <ix:nonNumeric contextRef="c-148" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="f-533">25-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. During the year ended December&#160;31, 2021, we sold <ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-534">5,685,097</ix:nonFraction> common shares for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-149" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-535">23,413</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-536">18,503</ix:nonFraction>) at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-150" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-537">4.12</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-150" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-538">3.25</ix:nonFraction>). We received proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-149" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-539">22,711</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-540">17,948</ix:nonFraction>) after commissions of $<ix:nonFraction unitRef="cad" contextRef="c-149" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-541">702</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-542">555</ix:nonFraction>). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="c-149" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-543">707</ix:nonFraction>.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="f-544">80,000</ix:nonFraction> over a <ix:nonNumeric contextRef="c-152" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="f-545">16-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold <ix:nonFraction unitRef="shares" contextRef="c-153" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-546">2,719,770</ix:nonFraction> (2021 - <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-547">2,715,932</ix:nonFraction>) common shares for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-153" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-548">5,744</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-549">4,560</ix:nonFraction>) (2021 - $<ix:nonFraction unitRef="cad" contextRef="c-154" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-550">10,755</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-551">8,655</ix:nonFraction>)) at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-155" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-552">2.11</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-553">1.68</ix:nonFraction>) (2021 - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-156" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-554">3.96</ix:nonFraction> </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-500-1"><ix:continuation id="f-499-2"><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-156" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-555">3.19</ix:nonFraction>)). We received proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-153" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-556">5,572</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-557">4,423</ix:nonFraction>) (2021 - $<ix:nonFraction unitRef="cad" contextRef="c-154" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-558">10,432</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-559">8,395</ix:nonFraction>)) after commissions of $<ix:nonFraction unitRef="cad" contextRef="c-153" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-560">172</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-561">137</ix:nonFraction>) (2021 - $<ix:nonFraction unitRef="cad" contextRef="c-154" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-562">323</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-563">260</ix:nonFraction>)). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="c-153" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-564">209</ix:nonFraction> (2021 - $<ix:nonFraction unitRef="cad" contextRef="c-154" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-565">549</ix:nonFraction>). </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the years ended December&#160;31, 2023 and 2022, <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-566"><ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised" format="ixt:fixed-zero" scale="0" id="f-567">no</ix:nonFraction></ix:nonFraction> warrants were exercised. During the year ended December&#160;31, 2021, <ix:nonFraction unitRef="shares" contextRef="c-157" decimals="INF" name="oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised" format="ixt:num-dot-decimal" scale="0" id="f-568">201,722</ix:nonFraction> warrants with a fair value of $<ix:nonFraction unitRef="cad" contextRef="c-157" decimals="-3" name="oncyf:ClassofWarrantorRightWarrantsExercised" scale="3" id="f-569">456</ix:nonFraction> were exercised for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:ProceedsfromWarrantExercises1" scale="3" id="f-570">231</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="oncyf:ProceedsfromWarrantExercises1" scale="3" id="f-571">182</ix:nonFraction>).</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="INF" name="oncyf:SharePurchaseAgreementAmount" format="ixt:num-dot-decimal" scale="3" id="f-572">65,000</ix:nonFraction> over a <ix:nonNumeric contextRef="c-159" name="oncyf:SharePurchaseAgreementTerm" format="ixt-sec:durwordsen" id="f-573">25-month</ix:nonNumeric> period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2023, we sold <ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-574">4,978,605</ix:nonFraction> (2022 - <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="oncyf:IssueOfEquityShares" format="ixt:num-dot-decimal" scale="0" id="f-575">3,515,462</ix:nonFraction>) common shares for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-160" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-576">10,676</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-577">7,904</ix:nonFraction>) (2022 - $<ix:nonFraction unitRef="cad" contextRef="c-161" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-578">7,594</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-579">5,632</ix:nonFraction>)) at an average price of $<ix:nonFraction unitRef="cadPerShare" contextRef="c-162" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-580">2.14</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-162" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-581">1.59</ix:nonFraction>) (2022 - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-163" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-582">2.16</ix:nonFraction> (US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-163" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-583">1.60</ix:nonFraction>)). We received proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-160" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-584">10,356</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-585">7,667</ix:nonFraction>) (2022 - $<ix:nonFraction unitRef="cad" contextRef="c-161" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-586">7,366</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" format="ixt:num-dot-decimal" scale="3" id="f-587">5,463</ix:nonFraction>)) after commissions of $<ix:nonFraction unitRef="cad" contextRef="c-160" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-588">320</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-589">237</ix:nonFraction>) (2022 - $<ix:nonFraction unitRef="cad" contextRef="c-161" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-590">228</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="oncyf:ShareIssueRelatedCostCommissions" scale="3" id="f-591">169</ix:nonFraction>)). In total, we incurred share issue costs (including commissions) of $<ix:nonFraction unitRef="cad" contextRef="c-160" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-592">415</ix:nonFraction> (2022 - $<ix:nonFraction unitRef="cad" contextRef="c-161" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" scale="3" id="f-593">555</ix:nonFraction>).</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 8, 2023, pursuant to an underwritten public offering, we issued <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="oncyf:NumberOfWarrantsAndSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-594">6,667,000</ix:nonFraction> units for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-126" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-595">20,185</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-596">15,001</ix:nonFraction>) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-597">2.25</ix:nonFraction> per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:NumberOfWarrantsAndSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-598">1,000,050</ix:nonFraction> units for gross proceeds of $<ix:nonFraction unitRef="cad" contextRef="c-128" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-599">3,077</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="oncyf:ProceedsFromIssueOfUnitsGross" format="ixt:num-dot-decimal" scale="3" id="f-600">2,250</ix:nonFraction>) at a price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="oncyf:SharesIssuedPricePerShare1" scale="0" id="f-601">2.25</ix:nonFraction> per unit. Each unit consisted of <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:IssueOfEquitySharesNumberOfCommonShares" format="ixt-sec:numwordsen" scale="0" id="f-602">one</ix:nonFraction> common share and <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="oncyf:IssueOfEquitySharesNumberOfWarrants" format="ixt-sec:numwordsen" scale="0" id="f-603">one</ix:nonFraction> warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $<ix:nonFraction unitRef="cad" contextRef="c-134" decimals="-3" name="ifrs-full:IssueOfEquity" format="ixt:num-dot-decimal" scale="3" id="f-604">17,724</ix:nonFraction> recorded in share capital and an initial warrant derivative liability of $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:WarrantLiability" format="ixt:num-dot-decimal" scale="3" id="f-605">7,360</ix:nonFraction>. In consideration of the services rendered by the underwriter, we issued <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-606">536,693</ix:nonFraction> compensation warrants (see note 11). In total, we incurred transaction costs of $<ix:nonFraction unitRef="cad" contextRef="c-164" decimals="-3" name="oncyf:ShareWarrantsIssuedTransactionCosts" format="ixt:num-dot-decimal" scale="3" id="f-607">3,130</ix:nonFraction> (including a fair value of $<ix:nonFraction unitRef="cad" contextRef="c-37" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" id="f-608">638</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" id="f-609">473</ix:nonFraction>) for the compensation warrants), of which $<ix:nonFraction unitRef="cad" contextRef="c-164" decimals="-3" name="ifrs-full:ShareIssueRelatedCost" format="ixt:num-dot-decimal" scale="3" id="f-610">2,390</ix:nonFraction> were allocated to share issue costs and $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:ShareWarrantsIssuedOperatingExpense" scale="3" id="f-611">740</ix:nonFraction> were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.</span></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_175"></div><div style="margin-bottom:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 11: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="f-612" continuedAt="f-612-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-612-1" continuedAt="f-612-2"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options and share awards</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our amended and restated Stock Option Plan and Share Award Plan (collectively, the "Equity Incentive Plans") were approved by our shareholders at the annual general meeting of shareholders on May 9, 2023. Pursuant to our Equity Incentive Plans, we may grant stock options, restricted share awards, and performance share awards. The number of common shares reserved for issuance under our Equity Incentive Plans in aggregate shall not exceed <ix:nonFraction unitRef="number" contextRef="c-3" decimals="INF" name="oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" scale="-2" id="f-613">14</ix:nonFraction>% of the total number of issued and outstanding common shares from time to time. As at December&#160;31, 2023, we reserved <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" format="ixt:num-dot-decimal" scale="0" id="f-614">10,419,354</ix:nonFraction> common shares for issuance relating to our Equity Incentive Plans. Our share-based compensation expense for the year ended December&#160;31, 2023, was $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-615">1,917</ix:nonFraction> (2022 - $<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-616">2,378</ix:nonFraction>; 2021 - $<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-617">3,826</ix:nonFraction>). </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" id="f-618" continuedAt="f-618-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our stock option activity for the years ended December&#160;31 was as follows:</span></ix:nonNumeric></div><ix:continuation id="f-618-1"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.039%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-619">5,963,185</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-4" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-620">2.91</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-621">5,334,420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-24" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-622">3.53</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-623">3,764,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-14" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-624">4.08</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-625">2,145,400</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="f-626">2.23</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-627">1,005,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="f-628">2.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-629">1,832,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" scale="0" id="f-630">2.99</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-631">280,288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="f-632">2.86</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-633">62,962</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="f-634">3.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-635">110,612</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" scale="0" id="f-636">6.21</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-637">314,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="f-638">4.17</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-639">304,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="f-640">10.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-641">28,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" scale="0" id="f-642">37.63</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-643">450,391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="f-644">1.74</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-645">8,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-7" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="f-646">1.45</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-647">123,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-8" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="f-648">1.94</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-649">7,063,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-650">2.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-651">5,963,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-4" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-652">2.91</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-653">5,334,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-24" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-654">3.53</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-655">5,039,604</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-656">2.85</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-657">4,420,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-4" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-658">3.01</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-659">3,165,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-24" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-660">3.82</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-612-2" continuedAt="f-612-3"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" id="f-662" escape="true"><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" id="f-661" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.208%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.456%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-166" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-663">1.14</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-167" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-664">2.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-665">2,015,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-169" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-666">3.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-168" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-667">1.75</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-668">1,082,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-168" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-669">1.61</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-170" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-670">2.01</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-171" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-671">2.70</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-672">1,260,664</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-173" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-673">2.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-172" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-674">2.25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-675">1,063,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-172" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-676">2.23</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-174" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-677">2.71</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-175" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-678">3.11</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-679">978,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-177" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-680">4.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-176" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-681">2.78</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-682">364,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-176" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-683">2.80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-178" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-684">3.12</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-179" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-685">4.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-686">2,665,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-181" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-687">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-180" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-688">3.32</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-689">2,385,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-180" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-690">3.30</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cadPerShare" contextRef="c-182" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-691">4.01</ix:nonFraction> - $<ix:nonFraction unitRef="cadPerShare" contextRef="c-183" decimals="2" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" scale="0" id="f-692">16.53</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-693">143,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-185" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-694">0.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-184" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-695">9.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-696">143,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-184" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-697">9.20</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:NumberOfOutstandingShareOptions" format="ixt:num-dot-decimal" scale="0" id="f-698">7,063,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" format="ixt-sec:duryear" id="f-699">2.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" scale="0" id="f-700">2.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-701">5,039,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cadPerShare" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" scale="0" id="f-702">2.85</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from <span style="-sec-ix-hidden:f-703">one</span> to <ix:nonNumeric contextRef="c-187" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-704">three years</ix:nonNumeric>.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government of Canada benchmark bond yield rates in effect at the time of grant. The expected life of the options represents the</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated length of time the options are expected to remain outstanding. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" id="f-705" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-706">4.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-707">3.4</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="4" name="ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted" scale="-2" id="f-708">0.7</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-1" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-709">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-7" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-710">3.0</ix:nonFraction> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-8" decimals="1" name="ifrs-full:DescriptionOfOptionLifeShareOptionsGranted" scale="0" id="f-711">3.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-712">72.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-713">96.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="4" name="ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted" scale="-2" id="f-714">110.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="3" id="f-715">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="0" id="f-716">Nil</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted" format="ixt:fixed-zero" scale="3" id="f-717">Nil</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-718">1.12</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="c-4" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-719">1.24</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="cad" contextRef="c-24" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" scale="0" id="f-720">1.99</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" id="f-721" continuedAt="f-721-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our share award activity for the years ended December&#160;31 was as follows:</span></ix:nonNumeric></div><ix:continuation id="f-721-1"><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-722">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-723">40,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-190" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-724">134,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-725">403,200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-726">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="0" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-728">4,760</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-729">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-730">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-191" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-731">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-192" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-732">40,560</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-193" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-733">94,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-194" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-734">398,440</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-188" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:fixed-zero" scale="0" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-189" decimals="INF" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" format="ixt:num-dot-decimal" scale="0" id="f-736">40,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSAs granted was $<ix:nonFraction unitRef="cad" contextRef="c-194" decimals="2" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="0" id="f-737">2.23</ix:nonFraction>in 2023.</span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, we granted restricted share awards to officers of the Company. Restricted share award grants vest over a <ix:nonNumeric contextRef="c-191" name="oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-738">three-year</ix:nonNumeric> period. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation warrants </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, in consideration of the services rendered by the underwriter as part of a public offering (see note 10(e)), we issued <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" format="ixt:num-dot-decimal" scale="0" id="f-739">536,693</ix:nonFraction> compensation warrants. Each compensation warrant is exercisable into <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="oncyf:IssueOfEquitySharesNumberOfCommonShares" format="ixt-sec:numwordsen" scale="0" id="f-740">one</ix:nonFraction> common share at an exercise price of US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" scale="0" id="f-741">2.25</ix:nonFraction> up to <ix:nonNumeric contextRef="c-1" name="oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" format="ixt-sec:durmonth" id="f-742">60</ix:nonNumeric> months from the date of issuance. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate the fair value of the services rendered. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-612-3"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" id="f-743" continuedAt="f-743-1" escape="true">We used the following weighted average assumptions:</ix:nonNumeric></span></div><ix:continuation id="f-743-1"><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:80.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.029%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="INF" name="oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted" id="f-744">2.28</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="3" name="oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted" scale="-2" id="f-745">3.8</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="year" contextRef="c-164" decimals="1" name="oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" scale="0" id="f-746">5.0</ix:nonFraction> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="3" name="oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted" scale="-2" id="f-747">36.5</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="INF" name="oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" format="ixt:fixed-zero" scale="3" id="f-748">Nil</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$<ix:nonFraction unitRef="usdPerShare" contextRef="c-164" decimals="INF" name="oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" id="f-749">0.88</ix:nonFraction></span></td></tr></table></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The resulting fair value of $<ix:nonFraction unitRef="cad" contextRef="c-37" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" id="f-750">638</ix:nonFraction> (US$<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" scale="3" id="f-751">473</ix:nonFraction>) was included as part of the public offering transaction costs, which were allocated    to share issue costs and operating expenses based on the relative fair values of the common share and warrant of each unit issued. No compensation warrants were exercised during the year ended December&#160;31, 2023.</span></div></ix:continuation><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_178"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 12: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="f-752" continuedAt="f-752-1" escape="true">Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-752-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2023, of <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-753"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-754">67,624,036</ix:nonFraction></ix:nonFraction> (2022 - <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-755"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-756">58,029,745</ix:nonFraction></ix:nonFraction>; 2021 - <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:AdjustedWeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-757"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="0" name="ifrs-full:WeightedAverageShares" format="ixt:num-dot-decimal" scale="0" id="f-758">53,513,225</ix:nonFraction></ix:nonFraction>). The effect of any potential exercise of our stock options, share awards, and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_181"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 13: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="f-759" continuedAt="f-759-1" escape="true">Contract Liability</ix:nonNumeric></span></div><ix:continuation id="f-759-1"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="f-760" escape="true"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next <ix:nonNumeric contextRef="c-1" name="oncyf:ContractLiabilityRecognitionPeriod" format="ixt-sec:durwordsen" id="f-761">five years</ix:nonNumeric>, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-762">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-763">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-764">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" format="ixt:fixed-zero" scale="3" id="f-765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-766">6,730</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ifrs-full:ContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-767">6,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_184"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 14: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" id="f-768" continuedAt="f-768-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-768-1" continuedAt="f-768-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments of approximately $<ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="oncyf:PurchaseObligation1" format="ixt:num-dot-decimal" scale="3" id="f-769">12,686</ix:nonFraction> for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next <ix:nonNumeric contextRef="c-1" name="oncyf:PurchaseObligationCommitmentTerm" format="ixt-sec:durwordsen" id="f-770">three years</ix:nonNumeric>. We are able to cancel most of these agreements with notice. We are also committed to office lease payments of approximately $<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:LeaseNotYetCommencedPayments" format="ixt:num-dot-decimal" scale="3" id="f-771">1,098</ix:nonFraction> over <ix:nonNumeric contextRef="c-1" name="oncyf:LeaseNotYetCommencedTerm" format="ixt-sec:duryear" id="f-772">5.3</ix:nonNumeric> years for one of our subsidiaries which have not yet commenced. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification of Officers and Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-768-2"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</span></div></ix:continuation><div><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_187"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 15: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="f-773" continuedAt="f-773-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-773-1" continuedAt="f-773-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="c-1" name="oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" id="f-774" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-775">27,655</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-776">24,751</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AccountingProfit" format="ixt:num-dot-decimal" scale="3" id="f-777">26,255</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-778">23.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-779">23.00</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="INF" name="ifrs-full:ApplicableTaxRate" scale="-2" id="f-780">23.00</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-781">6,361</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-782">5,693</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:TaxExpenseIncomeAtApplicableTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-783">6,039</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="f-784">2,841</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="f-785">3,552</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:TaxEffectOfForeignTaxRates" format="ixt:num-dot-decimal" scale="3" id="f-786">2,716</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="f-787">441</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="f-788">547</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:TaxEffectOfStockBasedCompensation" scale="3" id="f-789">880</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax balances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:TaxEffectOfTaxPools" scale="3" id="f-790">2</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:TaxEffectOfTaxPools" scale="3" id="f-791">338</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:TaxEffectOfTaxPools" scale="3" id="f-792">552</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Barbados rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-793">9,088</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:fixed-zero" scale="3" id="f-794">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:TaxEffectFromChangeInTaxRate" format="ixt:fixed-zero" scale="3" id="f-795">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-796">325</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-797">368</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" scale="3" id="f-798">45</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-799">3,382</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-800">1,614</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:TaxEffectOfExpirationOfTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-801">1,661</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" format="ixt:num-dot-decimal" scale="3" id="f-802">1,215</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="3" id="f-803">5</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative" scale="3" id="f-804">4</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="3" id="f-805">9,770</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" scale="3" id="f-806">765</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" format="ixt:num-dot-decimal" scale="3" id="f-807">1,342</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="f-808">97</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="f-809">84</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:CurrentTaxExpenseIncome" scale="3" id="f-810">49</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we have non-capital losses of $<ix:nonFraction unitRef="cad" contextRef="c-195" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-811">110,450</ix:nonFraction> and $<ix:nonFraction unitRef="cad" contextRef="c-196" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-812">129,884</ix:nonFraction> in Canada and Barbados, respectively (December&#160;31, 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-197" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-813">98,475</ix:nonFraction> and $<ix:nonFraction unitRef="cad" contextRef="c-198" decimals="-3" name="ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-814">145,405</ix:nonFraction>, respectively). These losses are expected to expire between 2024 and 2043, if not utilized. At December&#160;31, 2023, we have Canadian investment tax credits of $<ix:nonFraction unitRef="cad" contextRef="c-199" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-815">4,056</ix:nonFraction> (December&#160;31, 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-200" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-816">4,368</ix:nonFraction>) that are expected to expire between 2024 and 2043, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of $<ix:nonFraction unitRef="cad" contextRef="c-201" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-817">28,376</ix:nonFraction> (December&#160;31, 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-202" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-818">27,663</ix:nonFraction>).&#160;We also have unclaimed U.S. credits for research activities available to reduce future years' taxable income of $<ix:nonFraction unitRef="cad" contextRef="c-203" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-819">1,232</ix:nonFraction> (December&#160;31, 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-204" decimals="-3" name="ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" format="ixt:num-dot-decimal" scale="3" id="f-820">1,285</ix:nonFraction>) expiring between 2031 and 2043. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" id="f-821" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-205" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-822">37,174</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-206" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-823">26,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-207" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-824">25,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-208" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-825">7,742</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-209" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-826">7,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-210" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-827">7,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-211" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-828">3,123</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-212" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-829">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-213" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-830">3,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-214" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-831">382</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-215" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-832">366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-216" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-833">351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-217" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-834">833</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-218" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-835">518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-219" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-836">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-220" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-837">6</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-221" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-838">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-222" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" scale="3" id="f-839">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-840">49,260</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-841">38,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-24" decimals="-3" name="ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" format="ixt:num-dot-decimal" scale="3" id="f-842">37,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-773-2">The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="ib0923231ce844ed28a280a970e7dcaf5_190"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 16: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" id="f-843" continuedAt="f-843-1" escape="true">Capital Disclosures</ix:nonNumeric></span></div><ix:continuation id="f-843-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity, cash and cash equivalents, and marketable securities in the definition of capital.  </span></div><ix:nonNumeric contextRef="c-1" name="oncyf:DisclosureOfCapitalComponentsTableTextBlock" id="f-844" escape="true"><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-845">34,912</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-846">11,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:CurrentFinancialAssetsAvailableforsale" format="ixt:fixed-zero" scale="3" id="f-847">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:CurrentFinancialAssetsAvailableforsale" format="ixt:num-dot-decimal" scale="3" id="f-848">20,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-3" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-849">27,563</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-4" decimals="-3" name="ifrs-full:Equity" format="ixt:num-dot-decimal" scale="3" id="f-850">26,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $<ix:nonFraction unitRef="cad" contextRef="c-223" decimals="INF" name="oncyf:EquityAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-851">150,000</ix:nonFraction> of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received from using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreements and 2023 public offering (see note 10). We use these equity arrangements to assist us in achieving our capital objectives. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2023.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_193"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 17: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="f-852" continuedAt="f-852-1" escape="true">Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="f-852-1" continuedAt="f-852-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, other liabilities, and warrant derivative.&#160;As at December&#160;31, 2023, and December&#160;31, 2022, the carrying amount of our cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-852-2" continuedAt="f-852-3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at December&#160;31, 2023, the fair value of our warrant derivative was $<ix:nonFraction unitRef="cad" contextRef="c-224" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-853">200</ix:nonFraction> (December&#160;31, 2022 - $<ix:nonFraction unitRef="cad" contextRef="c-225" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="f-854">79</ix:nonFraction>) (see note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at December&#160;31, 2023, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the year ended December&#160;31, 2023, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities were denominated in such currency. The impact of a $<ix:nonFraction unitRef="cad" contextRef="c-226" decimals="2" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="f-855">0.01</ix:nonFraction> increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss for the year ended December&#160;31, 2023, by approximately $<ix:nonFraction unitRef="cad" contextRef="c-226" decimals="-3" sign="-" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="f-856">140</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="c-1" name="oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock" id="f-857" continuedAt="f-857-1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies as at December&#160;31, 2023, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:81.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-858">24,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-859">1,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="oncyf:BalanceHeldInForeignCurrencyNet" format="ixt:num-dot-decimal" scale="3" id="f-860">22,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and the Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $<ix:nonFraction unitRef="cad" contextRef="c-228" decimals="2" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="f-861">0.01</ix:nonFraction> increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss for the year ended December&#160;31, 2022, by approximately $<ix:nonFraction unitRef="cad" contextRef="c-228" decimals="-3" sign="-" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="f-862">170</ix:nonFraction>. The impact of a $<ix:nonFraction unitRef="cad" contextRef="c-229" decimals="2" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" scale="0" id="f-863">0.01</ix:nonFraction> increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss for the year ended December&#160;31, 2022, by approximately $<ix:nonFraction unitRef="cad" contextRef="c-229" decimals="-3" name="oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" scale="3" id="f-864">22</ix:nonFraction>.</span></div><ix:continuation id="f-857-1"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies as at December&#160;31, 2022, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.007%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-865">6,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-231" decimals="-3" name="ifrs-full:CashAndCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="ifrs-full:FinancialAssetsAvailableforsale" format="ixt:num-dot-decimal" scale="3" id="f-867">15,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-231" decimals="-3" name="ifrs-full:FinancialAssetsAvailableforsale" format="ixt:fixed-zero" scale="3" id="f-868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-869">1,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-231" decimals="-3" name="ifrs-full:TradeAndOtherCurrentPayables" format="ixt:num-dot-decimal" scale="3" id="f-870">1,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="oncyf:BalanceHeldInForeignCurrencyNet" format="ixt:num-dot-decimal" scale="3" id="f-871">20,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-231" decimals="-3" sign="-" name="oncyf:BalanceHeldInForeignCurrencyNet" format="ixt:num-dot-decimal" scale="3" id="f-872">1,035</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-852-3" continuedAt="f-852-4"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-852-4">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk by managing our capital structure as outlined in note 16. Accounts payable and accrued liabilities are all due within the current operating period. See note 8 for a maturity analysis of our lease liabilities.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_196"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 18: <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfCashFlowStatementExplanatory" id="f-873" continuedAt="f-873-1" escape="true">Additional Cash Flow Disclosures</ix:nonNumeric></span></div><ix:continuation id="f-873-1"><ix:nonNumeric contextRef="c-1" name="oncyf:CashFlowOperatingCapital1TableTextBlock" id="f-874" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="f-875">506</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="f-876">345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="f-877">776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" id="f-878">777</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-879">1,247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" scale="3" id="f-880">349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="f-881">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" format="ixt:num-dot-decimal" scale="3" id="f-882">1,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" scale="3" id="f-883">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" id="f-884">332</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" id="f-885">352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" scale="3" id="f-886">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="f-887">228</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="f-888">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" sign="-" name="oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" scale="3" id="f-889">194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" format="ixt:num-dot-decimal" scale="3" id="f-890">1,765</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" sign="-" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="f-891">391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="f-892">908</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" id="f-893" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="oncyf:ProceedsfromInterestReceived" format="ixt:num-dot-decimal" scale="3" id="f-894">1,554</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="oncyf:ProceedsfromInterestReceived" scale="3" id="f-895">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="oncyf:ProceedsfromInterestReceived" scale="3" id="f-896">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="f-897">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="f-898">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:IncomeTaxesPaidRefund" scale="3" id="f-899">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_199"></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 19: <ix:nonNumeric contextRef="c-1" name="oncyf:DisclosureOfEconomicDependenceTextBlock" id="f-900" continuedAt="f-900-1" escape="true">Economic Dependence</ix:nonNumeric></span></div><ix:continuation id="f-900-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use <ix:nonFraction unitRef="manufacturer" contextRef="c-232" decimals="INF" name="oncyf:ConcentrationRiskNumber" format="ixt-sec:numwordsen" scale="0" id="f-901">one</ix:nonFraction> toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical-grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_202"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 20:  <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="f-902" continuedAt="f-902-1" escape="true">Components of Expenses</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="oncyf:OtherExpensesAndAdjustmentsTableTextBlock" id="f-903" continuedAt="f-903-1" escape="true"><ix:continuation id="f-902-1" continuedAt="f-902-2"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-3" name="oncyf:ClinicalTrialExpense" format="ixt:num-dot-decimal" scale="3" id="f-904">3,675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="oncyf:ClinicalTrialExpense" format="ixt:num-dot-decimal" scale="3" id="f-905">4,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" name="oncyf:ClinicalTrialExpense" format="ixt:num-dot-decimal" scale="3" id="f-906">3,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="f-907">5,789</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="f-908">2,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" name="oncyf:ManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="f-909">1,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="f-910">397</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="f-911">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" name="oncyf:IntellectualPropertyExpense" scale="3" id="f-912">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-3" name="oncyf:TranslationalScienceExpense" format="ixt:fixed-zero" scale="3" id="f-913">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="oncyf:TranslationalScienceExpense" scale="3" id="f-914">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" name="oncyf:TranslationalScienceExpense" scale="3" id="f-915">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-916">6,324</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-917">6,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" name="ifrs-full:OtherEmployeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-918">4,754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-919">1,305</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-920">1,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-921">2,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-922">219</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-923">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="f-924">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-925">17,709</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-926">15,432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-927">12,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ONCOLYTICS BIOTECH INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands of Canadian dollars, except share amounts and where indicated)</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="f-902-2" continuedAt="f-902-3"><ix:continuation id="f-903-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-236" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="f-928">11,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-237" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="f-929">6,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-238" decimals="-3" name="oncyf:PublicCompanyExpense" format="ixt:num-dot-decimal" scale="3" id="f-930">8,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-236" decimals="-3" name="oncyf:OfficeExpenses" format="ixt:num-dot-decimal" scale="3" id="f-931">3,789</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-237" decimals="-3" name="oncyf:OfficeExpenses" format="ixt:num-dot-decimal" scale="3" id="f-932">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-238" decimals="-3" name="oncyf:OfficeExpenses" format="ixt:num-dot-decimal" scale="3" id="f-933">2,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-236" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="f-934">612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-237" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-935">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-238" decimals="-3" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" format="ixt:num-dot-decimal" scale="3" id="f-936">1,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-236" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-937">81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-237" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-938">93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-238" decimals="-3" name="ifrs-full:AmortisationExpense" scale="3" id="f-939">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-236" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-940">322</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-237" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-941">299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-238" decimals="-3" name="ifrs-full:DepreciationRightofuseAssets" scale="3" id="f-942">322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-943">16,082</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-944">11,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-945">13,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, our research and development personnel-related expenses included employee compensation and benefits of $<ix:nonFraction unitRef="cad" contextRef="c-233" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-946">6,324</ix:nonFraction> (2022 - $<ix:nonFraction unitRef="cad" contextRef="c-234" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-947">5,983</ix:nonFraction>; 2021 - $<ix:nonFraction unitRef="cad" contextRef="c-235" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-948">4,645</ix:nonFraction>).</span></div></ix:continuation><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-902-3">For the year ended December&#160;31, 2023, our general and administrative office expenses included employee compensation and benefits of $<ix:nonFraction unitRef="cad" contextRef="c-236" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-949">3,332</ix:nonFraction> (2022 - $<ix:nonFraction unitRef="cad" contextRef="c-237" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-950">2,870</ix:nonFraction>; 2021 - $<ix:nonFraction unitRef="cad" contextRef="c-238" decimals="-3" name="ifrs-full:EmployeeBenefitsExpense" format="ixt:num-dot-decimal" scale="3" id="f-951">2,542</ix:nonFraction>).</ix:continuation> </span></div><div style="text-align:center"><span><br/></span></div><div id="ib0923231ce844ed28a280a970e7dcaf5_205"></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Note 21:  <ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="f-952" continuedAt="f-952-1" escape="true">Related Party Transactions</ix:nonNumeric></span></div><ix:continuation id="f-952-1"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel consists of the Board of Directors, Executive Officers, President, and Vice Presidents. </span></div><ix:nonNumeric contextRef="c-1" name="ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" id="f-953" escape="true"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-954">4,870</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-955">4,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits" format="ixt:num-dot-decimal" scale="3" id="f-956">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" scale="3" id="f-957">319</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="3" id="f-958">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits" format="ixt:fixed-zero" scale="3" id="f-959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-960">1,496</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-961">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment" format="ixt:num-dot-decimal" scale="3" id="f-962">2,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-1" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-963">6,685</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-7" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-964">5,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-8" decimals="-3" name="ifrs-full:KeyManagementPersonnelCompensation" format="ixt:num-dot-decimal" scale="3" id="f-965">6,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>ex21exdescriptionofsecurit.htm
<DESCRIPTION>EX-2.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i8caaec1019e64bcc9d3067e96ff6175c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">EXHIBIT 2.1</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">DESCRIPTION OF RIGHTS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">Our authorized capital consists of an unlimited number of Common Shares. The following is a summary of the provisions attached to our Common Shares&#58;</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%">The holders of our Common Shares are entitled to one vote per share at meetings of shareholders, to receive such dividends as declared by the Board and to receive our remaining property and assets upon dissolution or wind up. Our Common Shares are not subject to any future call or assessment and there are no pre-emptive, conversion or redemption rights attached to such shares. As at March&#160;7, 2024, we have 75,419,768 Common Shares issued and outstanding. After giving effect to the exercise or distribution of all outstanding options to acquire Common Shares, all outstanding share awards granted under the Corporation&#8217;s Incentive Share Award Plan, Common Share purchase warrants, and compensation warrants we would have 91,115,979 Common Shares issued and outstanding. As at March&#160;7, 2024, we have 8,267,778 Common Share purchase warrants issued in 2019 (the &#8220;2019 Warrants&#8221;) and in 2023 (the &#34;2023 Warrants&#34;), and compensation warrants issued in 2023 outstanding. Each 2019 Warrant entitles the holder to purchase one Common Share until August 16, 2024, at an exercise price of US$0.90. Each 2023 Warrant entitles the holder to purchase one Common Share until August 8, 2028, at an exercise price of US$2.81. Each compensation warrant entitles the holder to purchase one Common Share until August 8, 2028, at an exercise price of US$2.25.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:137%">The Corporation has neither declared nor paid dividends on the Common Shares and has no present intention of paying dividends on the Common Shares for the foreseeable future.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.12
<SEQUENCE>3
<FILENAME>ex412employmentagreementam.htm
<DESCRIPTION>EX-4.12
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ic95969062a4f4ad6a289d8b5b14ff45a_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">EMPLOYMENT AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">THIS EMPLOYMENT AGREEMENT (&#8220;Agreement&#8221;), effective September 1, 2020 (&#8220;Effective Date&#8221;), is made between Oncolytics Biotech (U.S.), Inc., (&#8220;Employer&#8221; or the &#8220;Company&#8221;), and Amy Goodowitz Levin (&#8220;Employee&#8221;).  Employee and the Company are sometimes referred to herein as the &#8220;Parties.&#8221;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">RECITALS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">A.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:24.67pt">Employer is in the business (the &#8220;Business&#8221;) of developing pharmaceutical products.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">B.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:24.67pt">Employer desires to obtain the services of Employee as its Executive Director, Clinical Operations, in which capacity Employee has access to Employer&#8217;s Confidential Information (as hereinafter defined), and to obtain assurance that Employee will protect Employer&#8217;s Confidential Information during the term of employment and for a reasonable period of time after termination of employment pursuant to this Agreement, and Employee is willing to agree to these terms.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">C.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:24.01pt">Employee desires to be assured of the salary, bonus opportunity and other benefits in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">AGREEMENT</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">NOW, THEREFORE, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">in consideration of the mutual covenants in this Agreement, and other good and valuable consideration, the parties agree as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. Employer hereby employs Employee, and Employee agrees to be employed as Executive Director, Clinical Operations.  Employee will perform the duties of Executive Director, Clinical Operations for Employer, its parent corporation, Oncolytics Biotech Inc. and other affiliated corporations. Employee will report initially to the President of Employer.  Changes may be made from time to time by Employer in its sole discretion to the duties, reporting relationships and title of Employee.  Employee will devote full time and attention to the duties on Exhibit A to this Agreement.  Employee will comply with all rules, policies and procedures of Employer as modified from time to time, including without limitation, rules and procedures set forth in the Employer&#8217;s Employee Handbook and Company Policy Manual. Employee will perform all of Employee&#8217;s responsibilities in compliance with all applicable laws and will ensure that the operations that Employee manages are in compliance with all applicable laws.  During Employee&#8217;s employment, Employee will not engage in any other business activity which, in the reasonable judgment of the President of Employer, conflicts with the duties of Employee under this Agreement, whether or not such activity is pursued for gain, profit or other pecuniary advantage.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Term of Employment</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  The term of employment (&#8220;Term&#8221;) will not be for a definite period, but rather continue indefinitely until terminated in accordance with the terms and conditions of this Agreement.  The first 6 months following the Effective Date will be a probation period (the &#8220;Probation Period&#8221;). Not less than 2 weeks prior to the end of the Probation Period, Employer will notify Employee in writing either that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Employee&#8217;s employment is being continued or that Employee&#8217;s employment is being terminated at the completion of the Probation Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Compensation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  For the duration of Employee&#8217;s employment under this Agreement, the Employee will be entitled to compensation which will be computed and paid pursuant to the following subparagraphs.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">3.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Base Salary</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Employer will pay to Employee a base salary (&#8220;Base Salary&#8221;) at an annual rate of $275,000, payable in equal installments on the fifteenth and last day of each month, subject to withholdings and deductions as required or permitted by law.  Employee&#8217;s Base Salary will be reviewed annually by the President of Employer and may be adjusted in the sole discretion of Employer based on such review, but will not be reduced by Employer unless a material adverse change in the financial condition or operations of Employer has occurred or unless Employee&#8217;s responsibilities are altered to reflect less responsibility.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">3.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Incentive Bonus.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Employee will participate in Employer&#8217;s annual incentive bonus plan under which Employee may earn an annual incentive bonus.  The terms of the annual incentive bonus plan, including the criteria upon which Employee can earn the maximum bonus, will be determined annually by Employer&#8217;s Board of Directors or its President if so delegated.  For 2020, Employee may earn an annual incentive of up to 25% of Employee&#8217;s then Base Salary, pro-rated based on the portion of the year from the Effective Date to December 31, 2020.  Employee may also participate in other bonus or incentive plans adopted by Employer that are applicable to Employee&#8217;s position, as they may be changed from time to time, but nothing herein shall require the adoption or maintenance of any such plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">3.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Incentive Stock Options.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Upon commencement of employment, Employer will grant to Employee an incentive stock option to purchase 50,000 shares of Employer's Common Stock. The Stock Options will be priced at the time of the grant with 50% vesting on the first anniversary of employment, 25% vesting on the second anniversary of employment and the remaining 25% vesting on the third anniversary of employment.  All Stock Option are pursuant and subject to the Stock Plan and Incentive Share Award Plan (&#34;the Plans&#34;) of Oncolytics Biotech Inc. attached together as Exhibit C to this agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Other Benefits</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">4.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Certain Benefits.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Employee will be eligible to participate in all employee benefit programs as outlined in Exhibit B.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">4.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Vacations, Holidays and Expenses</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  For the duration of Employee&#8217;s employment hereunder, Employee will be provided such holidays and sick leave as Employer makes available to its management level employees generally.  Employee will be entitled to 20 business days paid vacation per year of service and in addition to traditional U.S. holidays. Employer will reimburse Employee in accordance with company policies and procedures for reasonable expenses necessarily incurred in the performance of duties hereunder against appropriate receipts and vouchers indicating the specific business purpose for each such expenditure.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">4.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Right of Set-off</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  By accepting this Agreement, Employee consents to a deduction from any amounts Employer owes Employee from time to time (including amounts owed to Employee as wages or other compensation, a bonus, fringe benefits, or vacation pay, as well as any other amounts owed to Employee by Employer), to the extent of the amounts Employee owes to Employer.  Whether or not Employer elects to make any set-off in whole or in part, if Employer does not recover by means of set-off the full amount Employee owes it, calculated as set forth above, Employee agrees to pay immediately upon Employer&#8217;s demand, the unpaid balance to Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Termination Or Discharge By Employer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">5.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">For Cause.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Employer will have the right to immediately terminate Employee&#8217;s services and this Agreement for Cause.  &#8220;Cause&#8221; means the Employer&#8217;s belief that any of the following has occurred&#58;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:25.36pt">Employee&#8217;s breach of this Agreement by Employee, including, without limitation, breach of Employee&#8217;s covenants in Sections 7, 8, 9 and 10.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.7pt">Employee&#8217;s failure to perform Employee&#8217;s duties for the Company in a competent and effective manner as judged in good faith by either the Chief Executive Officer of the Company or the Company&#8217;s Board of Directors in their sole discretion. Employee shall be given written notice of Employee&#8217;s failure to perform Employee&#8217;s duties and 30 days in which to cure such failure. Employee shall be entitled to only one notice and cure opportunity over the course of Employee&#8217;s employment with the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:20.04pt">Employee&#8217;s material violation of any statutory or common law duty of loyalty to Employer and its Affiliates.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:19.36pt">Employee&#8217;s commission of a felony.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(v)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.02pt">Employer&#8217;s reasonable belief that Employee engaged in a violation of any statute, rule or regulation, any of which in the judgment of Employer is harmful to the Business or to Employer&#8217;s reputation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vi)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:19.36pt">Employer&#8217;s reasonable belief that Employee engaged in unethical practices, dishonesty or disloyalty.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:16.7pt">Employer&#8217;s lack of funding sufficient to support Employee&#8217;s position.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Upon termination of Employee&#8217;s employment hereunder for Cause or upon the death or disability of Employee, Employee will have no rights to any unvested benefits or any other compensation or payments after the termination date or the last day of the month in which Employee&#8217;s death or disability occurred, respectively.  For purposes of this Agreement, &#8220;disability&#8221; means the incapacity or inability of Employee, whether due to accident, sickness or otherwise, as determined by a medical doctor acceptable to the Board of Directors of Employer and confirmed in writing by such doctor, to perform the essential functions of Employee&#8217;s position under this Agreement, with or without reasonable accommodation (provided that no accommodation that imposes undue </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">hardship on Employer will be required) for an aggregate of 90 days during any period of 180 consecutive days, or such longer period as may be required under applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">5.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Without Cause.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Employer may terminate Employee&#8217;s employment under this Agreement without Cause and without advance notice&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Employer will continue to pay, as severance pay, Employee&#8217;s Base Salary at the rate in effect on the termination date through the date that is&#58;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:25.36pt">if the Employee&#8217;s employment is terminated after the Employee has completed the Probation Period but prior to the third anniversary of the Effective Date, 1 month from the termination date&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:22.7pt">if the Employee&#8217;s employment is terminated after the third anniversary of the Effective Date but prior to the fifth anniversary of the Effective Date, 2 months from the termination date&#59;</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:20.04pt">if the Employee&#8217;s employment is terminated after the fifth anniversary of the Effective Date but prior to the fifth anniversary of the Effective Date, 3 months from the termination date&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that Employer will be entitled to offset any severance pay otherwise payable to Employee by the amount of any compensation or consulting fees being paid to Employee by another party while severance pay would otherwise be payable.  Employee shall only be entitled to such severance pay if Employee signs (and then Employee does not rescind, as may be permitted by law) a general release of claims in favor of Employer in a form acceptable to Employer, provided, however, that such release of claims shall only require Employee to release Employer from claims relating directly to Employee&#8217;s employment and the termination thereof, and shall not require Employee to release claims relating to vested employee benefits or relating to other matters, including, but not limited to, claims relating to his status as a shareholder of the Company.  Such payments will be at usual and customary pay intervals of Employer and will be subject to all appropriate deductions and withholdings.  Upon termination, Employee will have no rights to any unvested benefits or any other compensation or payments except as stated in this paragraph.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">5.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:19.33pt">Notwithstanding Section 5.2, if there is a change of control of Oncolytics Biotech Inc., as defined herein, and if this Agreement is terminated by Employer at any time within one (1) year following the change of control other than pursuant to Section 5.1, Employee shall be entitled to severance payment equal to the Employee&#8217;s Base Salary for 6 months.  For the purposes of this Section 5.3, &#8220;change of control&#8221; means any amalgamation, merger or other corporate reorganization which results in any change in the present effective voting control of Oncolytics Biotech Inc., or will result in a change of the person or persons who own or control sufficient voting shares in Oncolytics Biotech Inc. to elect a majority of the directors of Oncolytics Biotech Inc., or will result in a person acquiring sufficient voting shares in Oncolytics Biotech Inc. to elect a majority of the directors of Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Termination By Employee.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Employee may terminate Employee&#8217;s employment under this Agreement for any reason provided that Employee gives Employer at least 30 days&#8217; notice in writing.  Employer may, at its option, accelerate such termination date to any date at least two weeks after Employee&#8217;s notice of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">termination.  Employer may also, at its option, relieve Employee of all duties and authority after notice of termination has been provided.  All compensation, payments and unvested benefits will cease on the termination date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">7.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Delivery of Property</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.&#160;&#160;&#160;&#160;Upon termination of this Agreement or upon request of the Company, Employee shall deliver to the Company all property, documents and materials pertaining to the Company&#8217;s Business including, but not limited to, memoranda, notes, records, drawings, manuals, disks, copies, representations, extracts, summaries and analyses, all inventory, demonstration units, and any other property, documents or media of the Company, and all equipment belonging to the Company, including but not limited to corporate cards, access cards, office keys, office equipment, laptop and desktop computers, cell phones and other wireless devices, thumb drives, zip drives and all other media storage devices.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">8.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Confidential Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Employee recognizes that Employer&#8217;s Business and continued success depend upon the use and protection of confidential and proprietary business information, including, without limitation, the information and technology developed by or available through licenses to Employer, to which Employee has access (all such information being &#8220;Confidential Information&#8221;).  For purposes of this Agreement, the phrase &#8220;Confidential Information&#8221; includes, for Employer and its current or future subsidiaries and affiliates, without limitation, and whether or not specifically designated as confidential or proprietary&#58; all business plans and marketing strategies&#59; information concerning existing and prospective markets and customers&#59; financial information&#59; information concerning the development of new products and services&#59; information concerning any personnel of Employer (including, without limitation, skills and compensation information)&#59; and technical and non-technical data related to software programs, designs, specifications, compilations, inventions, improvements, methods, processes, procedures and techniques&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, that the phrase does not include information that (a)&#160;was lawfully in Employee&#8217;s possession prior to disclosure of such information by Employer&#59; (b)&#160;was, or at any time becomes, available in the public domain other than through a violation of this Agreement&#59; (c)&#160;is documented by Employee as having been developed by Employee outside the scope of Employee&#8217;s employment and independently&#59; or (d)&#160;is furnished to Employee by a third party not under an obligation of confidentiality to Employer.  Employee agrees that during Employee&#8217;s employment and after termination of employment irrespective of cause, Employee will use Confidential Information only for the benefit of Employer and will not directly or indirectly use or divulge, or permit others to use or divulge, any Confidential Information for any reason, except as authorized by Employer.  Employee&#8217;s obligation under this Agreement is in addition to any obligations Employee has under state or federal law.  Employee agrees to deliver to Employer immediately upon termination of Employee&#8217;s employment, or at any time Employer so requests, all tangible items containing any Confidential Information (including, without limitation, all memoranda, photographs, records, reports, manuals, drawings, blueprints, prototypes, notes taken by or provided to Employee, and any other documents or items of a confidential nature belonging to Employer) whether in hard copy, electronic, or other format, together with all copies of such material in Employee&#8217;s possession or control.  Employee agrees that in the course of Employee&#8217;s employment with Employer, Employee will not violate in any way the rights that any entity has with regard to trade secrets or proprietary or confidential information.  Employee&#8217;s obligations under this Section&#160;8 are indefinite in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">term and shall survive the termination of this Agreement.  However, Employee further understands that nothing in this Agreement prohibits Employee from reporting to any governmental authority information concerning possible violations of law or regulation and that Employee may disclose Confidential Information to a government official or to an attorney and use it in certain court proceedings without fear of prosecution or liability, provided Employee files any document containing Confidential Information under seal and does not disclose the Confidential Information, except pursuant to court order.   </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">9.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:26pt">Work Product and Copyrights.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Employee agrees that all right, title and interest in and to the materials resulting from the performance of Employee&#8217;s duties at Employer and all copies thereof, including works in progress, in whatever media, (the &#8220;Work&#8221;), will be and remain in Employer upon their creation.  Employee will mark all Work with Employer&#8217;s copyright or other proprietary notice as directed by Employer.  Employee further agrees&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">9.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:19.33pt">To the extent that any portion of the Work constitutes a work protectable under the copyright laws of the United States (the &#8220;Copyright Law&#8221;), that all such Work will be considered a &#8220;work made for hire&#8221; as such term is used and defined in the Copyright Law, and that Employer will be considered the &#8220;author&#8221; of such portion of the Work and the sole and exclusive owner throughout the world of such copyright&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">9.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:19.33pt">If any portion of the Work does not qualify as a &#8220;work made for hire&#8221; as such term is used and defined in the Copyright Law, that Employee hereby assigns and agrees to assign to Employer, without further consideration, all right, title and interest in and to such Work or in any such portion of such Work and any copyright in such Work and further agrees to execute and deliver to Employer, upon request, appropriate assignments of such Work and copyright in such Work and such other documents and instruments as Employer may request to fully and completely assign such Work and copyright in such Work to Employer, its successors or nominees, and that Employee appoints Employer as attorney-in-fact to execute and deliver any such documents on Employee&#8217;s behalf in the event Employee should fail or refuse to do so within a reasonable period following Employer&#8217;s request&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">9.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:19.33pt">To waive and agree not to assert any moral rights Employee may have or acquire in any Inventions and agree to provide written waivers from time to time as requested by Employer&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">9.4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:19.33pt">Assist Employer (at Employer&#8217;s expense) in obtaining and maintaining copyright registrations with respect to such Works.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">10.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Inventions and Patents.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">For purposes of this Agreement, &#8220;Inventions&#8221; includes, without limitation, information, inventions, contributions, improvements, ideas, or discoveries, whether protectable or not, and whether or not conceived or made during work hours.  Employee agrees that all Inventions conceived or made by Employee during the period of employment with Employer belong to Employer, provided they grow out of Employee&#8217;s work with Employer or are related in some manner to the Business, including, without limitation, research and product development, and projected business of Employer or its affiliated companies.  Accordingly, Employee will&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">10.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:12.66pt">Make adequate written records of such Inventions, which records will be Employer&#8217;s property&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">10.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:12.66pt">Assign to Employer, at its request, and does hereby assign to Employer, any rights Employee may have to such Inventions for the U.S. and all foreign countries&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">10.3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%;padding-left:12.66pt">Assist Employer (at Employer&#8217;s expense) in obtaining and maintaining patents registrations with respect to such Inventions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Employee further agrees that Employee will promptly disclose in writing to Employer during the term of Employee&#8217;s employment and for 1 year thereafter, all Inventions whether developed during the time of such employment or thereafter (whether or not Employer has rights in such Inventions) so that Employee&#8217;s rights and Employer&#8217;s rights in such Inventions can be determined.  Except as set forth on the initialed Exhibit D (List of Inventions) to this Agreement, if any, Employee represents and warrants that Employee has no Inventions, software, writings or other works of authorship useful to Employer in the normal course of the Business, which were conceived, made or written prior to the date of this Agreement and which are excluded from the operation of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;text-decoration:underline">NOTICE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">&#58;  This Section&#160;10 does not apply to Inventions for which no equipment, supplies, facility, or trade secret information of Employer was used and which was developed entirely on Employee&#8217;s own time, unless&#58;  (a) the Invention relates (i) directly to the business of Employer or (ii) to Employer&#8217;s actual or demonstrably anticipated research or development, or (b) the Invention results from any work performed by Employee for Employer.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">In accordance with California Labor Code Section 2870, Employee is notified that&#58;</font></div><div style="margin-bottom:12pt;padding-left:56.7pt;text-align:justify;text-indent:-21.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) &#160;&#160;&#160;&#160;Any provision in an employment agreement which provides that an employee shall assign, or offer to assign, any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on his or her own time without using the employer&#8217;s equipment, supplies, facilities, or trade secret information except for those inventions that either&#58; </font></div><div style="margin-bottom:12pt;padding-left:99.25pt;text-align:justify;text-indent:-27.25pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(1) &#160;&#160;&#160;&#160;Relate at the time of conception or reduction to practice of the invention to the Employer&#8217;s Business, or actual or demonstrably anticipated research or development of the employer&#59; or </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(2) &#160;&#160;&#160;&#160;Result from any work performed by the employee for the employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">11.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Remedies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Notwithstanding other provisions of this Agreement regarding dispute resolution, Employee agrees that Employee&#8217;s violation of any of Sections 7, 8, 9 or 10 of this Agreement would cause Employer irreparable harm which would not be adequately compensated by monetary damages and that an injunction may be granted by any court or courts having jurisdiction, restraining Employee from violation of the terms of this Agreement, upon any breach or threatened breach of Employee of the obligations set forth in any of Sections 7, 8, 9 or 10.  The preceding sentence shall not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">be construed to limit Employer from any other relief or damages to which it may be entitled as a result of Employee&#8217;s breach of any provision of this Agreement, including Sections 7, 8, 9 or 10.  Employee also agrees that a violation of any of Sections 7, 8, 9 or 10 would entitle Employer, in addition to all other remedies available at law or equity, to recover from Employee any and all funds, including, without limitation, wages, salary and profits, which will be held by Employee in constructive trust for Employer, received by Employee in connection with such violation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">12.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Dispute Resolution.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Except for the right of Employer and Employee to seek injunctive relief in court, any controversy, claim or dispute of any type arising out of or relating to Employee&#8217;s employment or the provisions of this Agreement shall be resolved in accordance with this Section&#160;12 regarding resolution of disputes, which will be the sole and exclusive procedure for the resolution of any disputes.  This Agreement shall be enforced in accordance with the Federal Arbitration Act, the enforcement provisions of which are incorporated by this reference.  Matters subject to these provisions include, without limitation, claims or disputes based on statute, contract, common law and tort and will include, for example, matters pertaining to termination, discrimination, harassment, compensation and benefits.  Matters to be resolved under these procedures also include claims and disputes arising out of statutes such as the Fair Labor Standards Act, Title VII of the Civil Rights Act, the Age Discrimination in Employment Act, and any state laws related to employment.  Nothing in this provision is intended to restrict Employee from submitting any matter to an administrative agency with jurisdiction over such matter.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">12.1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:12.66pt">Mediation.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Employer and Employee will make a good faith attempt to resolve any and all claims and disputes by submitting them to mediation in San Diego, California before resorting to arbitration or any other dispute resolution procedure.  The mediation of any claim or dispute must be conducted in accordance with the then-current JAMS procedures for the resolution of employment disputes by mediation, by a mediator who has had both training and experience as a mediator of general employment and commercial matters.  If the parties to this Agreement cannot agree on a mediator, then the mediator will be selected by JAMS in accordance with JAMS&#8217; strike list method.  Within thirty (30) days after the selection of the mediator, Employer and Employee and their respective attorneys will meet with the mediator for one mediation session of at least four hours.  If the claim or dispute cannot be settled during such mediation session or mutually agreed continuation of the session, either Employer or Employee may give the mediator and the other party to the claim or dispute written notice declaring the end of the mediation process.  All discussions connected with this mediation provision will be confidential and treated as compromise and settlement discussions.  Nothing disclosed in such discussions, which is not independently discoverable, may be used for any purpose in any later proceeding.  The mediator&#8217;s fees will be paid in equal portions by Employer and Employee, unless Employer agrees to pay all such fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">12.2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:12.66pt">Arbitration.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">If any claim or dispute has not been resolved in accordance with Section&#160;12.1, then the claim or dispute will be determined by arbitration in accordance with the then-current JAMS employment arbitration rules and procedures, except as modified herein.  The arbitration will be conducted by a sole neutral arbitrator who has had both training and experience as an arbitrator of general employment and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">commercial matters and who is and for at least ten (10) years has been, a partner, a shareholder, or a member in a law firm.  If Employer and Employee cannot agree on an arbitrator, then the arbitrator will be selected by JAMS in accordance with Rule 15 of the JAMS employment arbitration rules and procedures.  No person who has served as a mediator under the mediation provision, however, may be selected as the arbitrator for the same claim or dispute.  Reasonable discovery will be permitted and the arbitrator may decide any issue as to discovery.  The arbitrator may decide any issue as to whether or as to the extent to which any dispute is subject to the dispute resolution provisions in Section&#160;12 and the arbitrator may award any relief permitted by law.  The arbitrator must base the arbitration award on the provisions of Section&#160;12 and applicable law and must render the award in writing, including an explanation of the reasons for the award.  Judgment upon the award may be entered by any court having jurisdiction of the matter, and the decision of the arbitrator will be final and binding.  The statute of limitations applicable to the commencement of a lawsuit will apply to the commencement of an arbitration under Section&#160;12.2.  The arbitrator&#8217;s fees will be paid in equal portions by Employer and Employee, unless Employer agrees to pay all such fees.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">13.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Fees Related to Dispute Resolution</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Unless otherwise agreed, the prevailing party will be entitled to its costs and attorneys&#8217; fees incurred in any litigation or dispute relating to the interpretation or enforcement of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">14.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Disclosure</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Employee agrees fully and completely to reveal the terms of this Agreement to any future employer or potential employer of Employee and authorizes Employer, at its election, to make such disclosure.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">15.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Representation of Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  Employee represents and warrants to Employer that Employee is free to enter into this Agreement and has no contract, commitment, arrangement or understanding to or with any party that restrains or is in conflict with Employee&#8217;s performance of the covenants, services and duties provided for in this Agreement.  Employee agrees to indemnify Employer and to hold it harmless against any and all liabilities or claims arising out of any unauthorized act or acts by Employee that, the foregoing representation and warranty to the contrary notwithstanding, are in violation, or constitute a breach, of any such contract, commitment, arrangement or understanding.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">16.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Conditions of Employment.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Employer&#8217;s obligations to Employee under this Agreement are conditioned upon Employee&#8217;s timely compliance with requirements of the United States immigration laws.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">17.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Assignability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  During Employee&#8217;s employment, this Agreement may not be assigned by either party without the written consent of the other&#59; provided, however, that Employer may assign its rights and obligations under this Agreement without Employee&#8217;s consent to a successor by sale, merger or liquidation, if such successor carries on the Business substantially in the form in which it is being conducted at the time of the sale, merger or liquidation.  This Agreement is binding upon Employee, Employee&#8217;s heirs, personal representatives and permitted assigns and on Employer, its successors and assigns.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">18.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Notices.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Any notices required or permitted to be given hereunder are sufficient if in writing and delivered by hand, by facsimile, by registered or certified mail, or by overnight courier, to Employee at 2563 Angelo Drive, Los Angeles, California, 90077 or to the President of Employer at 4660 La Jolla Village Drive, Suite 850, San Diego, California, 92122 with a copy sent to Oncolytics Biotech Inc., 210, 1167 Kensington Crescent N.W, Calgary, Alberta, Canada T2N 1X7.  Notices shall be deemed to have been given (i) upon delivery, if delivered by hand, (ii) seven days after mailing, if mailed, (iii) one business day after delivery, if delivered by courier, and (iv) one business day following receipt of an appropriate electronic confirmation, if by facsimile.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">19.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Severability</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  If any provision of this Agreement or compliance by any of the parties with any provision of this Agreement constitutes a violation of any law, or is or becomes unenforceable or void, then such provision, to the extent only that it is in violation of law, unenforceable or void, shall be deemed modified to the extent necessary so that it is no longer in violation of law, unenforceable or void, and such provision will be enforced to the fullest extent permitted by law.  The Parties shall engage in good faith negotiations to modify and replace any provision which is declared invalid or unenforceable with a valid and enforceable provision, the economic effect of which comes as close as possible to that of the invalid or unenforceable provision which it replaces.  If such modification is not possible, said provision, to the extent that it is in violation of law, unenforceable or void, shall be deemed severable from the remaining provisions of this Agreement, which provisions will remain binding on the parties.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">20.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Waivers.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  No failure on the part of either party to exercise, and no delay in exercising, any right or remedy hereunder will operate as a waiver thereof&#59; nor will any single or partial waiver of a breach of any provision of this Agreement operate or be construed as a waiver of any subsequent breach&#59; nor will any single or partial exercise of any right or remedy hereunder preclude any other or further exercise thereof or the exercise of any other right or remedy granted hereby or by law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">21.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Governing Law.  </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Except as provided in Section&#160;12 above, the validity, construction and performance of this Agreement shall be governed by the laws of the State of California without regard to the conflicts of law provisions of such laws.  The courts of the state of California shall have exclusive jurisdiction of any lawsuit arising from or relating to Employee&#8217;s employment with, or termination from, Employer, or arising from or relating to this Agreement.  Employee consents to such venue and personal jurisdiction.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">22.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">409A Savings Clause</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">. The parties intend that payments or benefits payable under this Agreement not be subject to the additional tax imposed pursuant to Section 409A of the Code (&#8220;Section 409A&#8221;), and the provisions of this Agreement shall be construed and administered in accordance with such intent. To the extent such potential payments or benefits could become subject to Section 409A, the parties shall cooperate to amend this Agreement with the goal of giving Executive the economic benefits described herein in a manner that does not result in such tax being imposed. If the parties are unable to agree on a mutually acceptable amendment, the Company may, without Executive&#8217;s consent and in such manner as it deems appropriate or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">desirable, amend or modify this Agreement or delay the payment of any amounts hereunder to the minimum extent necessary to meet the requirements of Section 409A. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">23.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Counterparts.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  This agreement may be executed in counterpart in different places, at different times and on different dates, and in that case all executed counterparts taken together collectively constitute a single binding agreement. Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">24.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Costs and Fees Related to Negotiation and Execution of Agreement.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">  Each Party Shall be responsible for the payment of its own costs and expenses, including legal fees and expenses, in connection with the negotiation and execution of this Agreement.  Neither Party will be liable for the payment of any commissions or compensation in the nature of finders' fees or brokers' fees, gratuity or other similar thing or amount in consideration of the other Party entering into this Agreement to any broker, agent or third party acting on behalf of the other Party.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">25.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%;padding-left:19.33pt">Entire Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">.  This instrument contains the entire agreement of the parties with respect to the relationship between Employee and Employer and supersedes all prior agreements and understandings, and there are no other representations or agreements other than as stated in this Agreement related to the terms and conditions of Employee&#8217;s employment.  This Agreement may be changed only by an agreement in writing signed by the party against whom enforcement of any waiver, change, modification, extension or discharge is sought, and any such modification will be signed by the President of Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">, the parties have duly signed and delivered this Agreement as of the day and year first above written.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Oncolytics Biotech (U.S.), Inc.</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;Andrew de Guttadauro</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">President</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;Gilles Gosselin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Director</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">EMPLOYEE</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47;Amy Goodowitz Levin</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Print Name&#58;  Amy Goodowitz Levin</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">EXHIBIT A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">INITIAL DUTIES AND RESPONSIBILITIES</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The Employee will build relationships and interact with Contract Research Organizations, academic groups, key opinion leaders, external physician investigators, and other contracted service providers.  The Employee will act as the clinical operations lead on all clinical trials. The Employee will also participate in cross-functional projects, interacting closely with other Oncolytics team members and departments.  The Employee will be expected to be solution-oriented and plan and participate in the execution of all aspects of clinical projects.</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:18pt"><font><br></font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Duties and responsibilities include&#58;</font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:18pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">In collaboration with internal and external scientific and medical experts, manage the execution of phase 1-3 clinical trials in an out-sourced model from study start-up to final clinical study report&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Author, review and manage a wide variety of activities, including for example, clinical trial synopses, protocols, case report forms, investigator brochures, and the like&#59; manage internal teams to review and approve clinical study reports in accordance with overall project timelines&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Prepare Request for Proposal documents and with cross-functional project team, solicit and evaluate bids&#59; lead contracting process with selected CROs&#47;academic groups, collaborating with relevant departments such as Legal, Finance, and Business Development&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Manage CROs or collaborate with academic groups to execute clinical trials in accordance with contracted scope, costs and timelines&#59; actively engage with academic groups&#47;CROs on defining, monitoring and reporting on all aspects of key trial performance indicators, including for example, country and site initiation activities, patient screening and randomization rates, and data collection activities&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Interact with investigators and sites as needed to support academic groups&#47;CROs and ensure clinical trials are conducted according to plan&#59;</font></div><div style="padding-left:54pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Identify and track trial risks and issues, proactively escalate risks to internal and academic groups&#47;CRO teams, develop and implement risk mitigation strategies and tactics&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Provide oversight and input to additional study-related external vendors, including execution of work and tracking of milestones and deliverables&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Plan and manage budget proposals and approved budgets&#59; </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Assist with Standard Operating Procedure (SOP) development and implementation&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Contribute to wider organizational goals and activities as assigned&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Select and manage data management vendors throughout the clinical trial process, including activities required for database lock and generation of data presentations&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:0.1pt;margin-top:0.1pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:110%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.15pt">Other duties as assigned.<br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">EXHIBIT B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">BENEFITS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Physical Fitness Benefit&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The Employee is entitled to the Physical Fitness Benefit in the amount of Seven Hundred and Fifty ($750.00) United States Dollars per annum to use towards an item or service that promotes physical activity&#59; the details of which are outlined in the Company Policy Manual.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Deferred Compensation&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Employee shall, if qualified to do so, be entitled to allocate a portion of his salary to a 401(K) Plan established for the Employee, up to the prescribed maximum, and in accordance with the requirements thereof. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">The employer will match the employee contribution up to 4% of the employee&#8217;s base salary or the annual compensation limit set by the IRS, whichever is lower. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:110%">Health Care Benefit&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Employee shall, if qualified to do so, be entitled to access the health care menu sponsored by the employer. The menu includes&#58;</font></div><div style="padding-left:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.34pt">Plans for which the employer will contribute towards the premium at 100% for the employee and at 75% for the dependents&#58;</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:110%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:11.89pt">Medical HMO for California based employees</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:110%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:11.89pt">Medical PPO</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:110%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:11.89pt">Medical HSA</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:110%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:11.89pt">Dental PPO</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:110%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:11.89pt">Vision PPO</font></div><div style="padding-left:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.34pt">Insurance contributed at 100% of the premium for&#58;</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:110%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:11.89pt">Life Insurance and AD&#38;D</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:110%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:11.89pt">Short Term Disability</font></div><div style="padding-left:57pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:11pt;font-weight:400;line-height:110%">o</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:11.89pt">Long Term Disability</font></div><div style="padding-left:21pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">-</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%;padding-left:14.34pt">Voluntary life insurance may be added for the employer and&#47;or the dependents at the employee&#8217;s expense</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:110%">Further details are outlined in the Enrollment Guide.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">EXHIBIT C</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">STOCK OPTION PLAN AND INCENTIVE SHARE AWARD PLAN<br><br>AMENDED AND RESTATED STOCK OPTION PLAN</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">1. The Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The Board of Directors of Oncolytics Biotech Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) has adopted this Stock Option Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) governing the issuance of Options (as defined herein) of the Corporation to Eligible Persons (as defined herein).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">2. Purpose</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The purpose of this Plan is to advance the interests of the Corporation by encouraging the Directors, Officers, Employees and Consultants to acquire Shares, thereby (i) increasing the proprietary interests of such persons in the Corporation&#59; (ii) aligning the interests of such persons with the interests of the Corporation&#8217;s shareholders generally&#59; (iii) encouraging such persons to remain associated with the Corporation&#59; and (iv) furnishing such persons with an additional incentive in their efforts on behalf of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">3. Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">associate</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the board of directors of the Corporation as constituted from time to time and shall be deemed to include any committee thereof to which the Board has, fully or partially, delegated the administration and operation of this Plan pursuant to Section 4 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) the acceptance by the holders of Shares, representing in the aggregate of more than 50 percent (50%) of all issued and outstanding Shares, of any offer, whether by way of a takeover bid or otherwise, for all or any of the Shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii) the acquisition, by whatever means (including, without limitation, amalgamation, arrangement, consolidation or merger), by a person (or two or more persons who in such acquisition have acted jointly or in concert or intend to exercise jointly or in concert any voting rights attaching to the Shares acquired), directly or indirectly, of the beneficial ownership of such number of Shares, which together with such person&#8217;s then owned Shares, if any, represent more than 50 percent (50%) of the Corporation&#8217;s then outstanding Shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii) the sale, lease or other disposition of all or substantially all of the assets of the Corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv) the passing of a resolution by the board of directors of the Corporation or shareholders of the Corporation to substantially liquidate assets or windup its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">business or significantly rearrange its affairs in one or more transactions or series of transactions or the commencement of proceedings for such a liquidation, winding-up or re-arrangement (except where such re-arrangement is part of a </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%">bona fide </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">reorganization of the Corporation in circumstances where the business of the Corporation is continued and where the shareholdings remain substantially the same following the re-arrangement as existed prior to the re-arrangement)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(v) individuals who were members of the board of directors of the Corporation immediately prior to a meeting of the shareholders of the Corporation involving a contest for or, an item of business relating to the election of directors shall not constitute a majority of the board of directors of the Corporation following such election&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vi) the completion of any transaction or the first of a series of transactions which would have the same or similar effect as any transaction or series of transactions referred to in subsections (i), (ii), (iii), (iv) or (v) referred to above&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vii) a determination by the board of directors of the Corporation that there has been a change, whether by way of a change in the holding of the Shares, in the ownership of the Corporation&#8217;s assets or by any other means, as a result of which any person or group of persons acting jointly or in concert is in a position to exercise effective control of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means Oncolytics Biotech Inc.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(e) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an individual or Consultant Corporation, other than a Director, Officer or Employee, that&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) is engaged to provide on an ongoing </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%">bona fide </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">basis, consulting, technical, management or other services to the Corporation or a subsidiary of the Corporation, other than services in relation to a distribution&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii) provides the services under a written contract for an initial, renewable or extended period of twelve months or more&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii) spends or will spend a significant amount of time and attention on the affairs of the Corporation or a subsidiary of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(f) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Consultant Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means for an individual consultant, a company or partnership of which the individual is an employee, shareholder or partner.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(g) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means a director of the Corporation or any subsidiary of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(h) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Eligible Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means a Director, Officer, Employee or Consultant of the Corporation or its subsidiaries.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means a person who would be considered an &#8216;employee&#8217; under the Tax Act, or who works full-time or for a specified number of hours per week on a continuing regular basis and is subject to the same control and direction by the Corporation or a subsidiary of the company over the details and methods of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">work as an employee of the company, but for whom tax and other deductions are not made at source.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(j) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Exchange</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Toronto Stock Exchange and such other stock exchange(s) on which the Shares are then listed and posted for trading from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(k) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(l) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">insider participation limit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(m) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Market Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the closing price of the Shares on the TSX (or, if the Shares are not then listed and posted for trading on the TSX or are then listed and posted for trading on more than one Exchange, on such Exchange on which the Shares are then listed and posted for trading as may be selected for such purpose by the Board acting reasonably and in good faith) on the last trading date prior to the date of grant of an Option hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(n) &#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Non-Employee Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#34; means any Director who is not also an Employee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(o) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an officer of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(p) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Option</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means an option to purchase Shares granted pursuant to this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(q) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means each of the Eligible Persons granted an Option pursuant to this Plan and their heirs, executors and administrators.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(r) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means this Stock Option Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(s) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Security Based Compensation Arrangement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(t) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Shares</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means common shares in the capital of the Corporation and shall be deemed to include any other listed securities that may be acquired by a Participant upon the exercise of an Option the terms of which have been modified in accordance with Section 17.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(u) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Tax Act</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:110%">Income Tax Act </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(Canada), as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(v) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">TSX</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the Toronto Stock Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(w) &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">TSX Policies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221; means the policies included in the TSX Company Manual.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">4. Administration</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) The Plan shall be administered by the Board and, for greater certainty, the board of directors of the Corporation shall have the right to delegate the administration and operation of this Plan, in whole or in part, to a committee of the board of directors that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">has been assigned the responsibility of determining the Corporation&#8217;s policies with respect to executive compensation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b) Subject to the terms and conditions set forth herein and the TSX Policies, the Board is authorized to provide for the granting, exercise and method of exercise of Options, all on such terms (which may vary between Options granted from time to time) as it shall determine. In addition, the Board shall have the authority to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) construe and interpret this Plan and all option agreements entered into hereunder,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii) prescribe, amend and rescind rules and regulations relating to this Plan&#59; And</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii) make all other determinations necessary or advisable for the administration of this Plan. All determinations and interpretations made by the Board shall be binding on all Participants and on their legal, personal representatives and beneficiaries.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c) Options shall be evidenced by an agreement, signed on behalf of the Corporation and by the person to whom an Option is granted, which agreement shall be in such form as the Board shall approve or authorize from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">5. Shares Subject to this Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) Subject to Section 17, the securities that may be acquired by Participants under this Plan shall consist of authorized but unissued Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b) The number of Shares reserved for issuance under this Plan and all other Security Based Compensation Arrangements in aggregate shall not exceed ten percent (10%) of the total number of issued and outstanding Shares from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c) If any Option granted under this Plan shall be exercised or shall expire or terminate for any reason without having been exercised in full, any Shares to which such Option relates shall be available for the purposes of the granting of Options under this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">6. Maintenance of Sufficient Capital</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The Corporation shall at all times during the term of this Plan ensure that the number of Shares it is authorized to issue shall be sufficient to satisfy the requirements of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">7. Eligibility and Participation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The Board may from time to time, in its discretion, grant an Option to any Eligible Person, upon such terms, conditions and limitations as the Board may determine, including the terms, conditions and limitations set forth herein, provided that Options granted to any Participant shall be approved by the shareholders of the Corporation if the TSX Policies or the requirements of any other Exchange on which the Shares are listed require such approval.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">8. Exercise Price</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Options may be exercised at a price (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Exercise Price</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) which shall be fixed by the Board at the time that the Option is granted. No Option shall be granted with an Exercise Price at a discount to the Market Price.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">9. Number of Optioned Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The number of Shares that may be acquired under an Option granted to a Participant shall be determined by the Board as at the time the Option is granted, provided that the aggregate number of Shares reserved for issuance to any one Participant under this Plan or any other Security Based Compensation Arrangement, shall not exceed five percent (5%) of the total number of issued and outstanding Shares (calculated on a non-diluted basis).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">10. Term</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The period during which an Option may be exercised (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Option Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) shall be determined by the Board at the time the Option is granted, subject to any vesting limitations which may be imposed by the Board in its sole unfettered discretion at the time such Option is granted, provided that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) no Option shall be exercisable for a period exceeding ten (10) years from the date the Option is granted&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b) the Option Period shall be automatically reduced in accordance with Sections 12 and 13 upon the occurrence of any of the events referred to therein&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c) no Option in respect of which shareholder approval is required under the TSX Policies or the requirements of any other Exchange on which the Shares are then listed shall be exercisable until such time as the Option has been approved by the shareholders of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Notwithstanding the foregoing, if the Option Period of an Option expires during a Blackout Period (as defined below) or within five (5) business days after a Blackout Period, such Option Period shall be deemed to be extended to the date which is the tenth (10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">) business day after the last day of the applicable Black Out Period. For the purposes of this Plan, Blackout Period means, with respect to an Option, any period during which the holder of such Option is not permitted to trade Shares pursuant to the policies of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">11. Method of Exercise of Option</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) Except as set forth in Sections 12 and 13 or as otherwise determined by the Board, no Option may be exercised unless the holder of such Option is, at the time the Option is exercised, an Eligible Person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b) Options may be exercised in whole or in part and may be exercised on a cumulative basis where a vesting limitation has been imposed at the time of grant.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c) Any Participant (or his legal, personal representative) wishing to exercise an Option shall deliver to the Corporation, at its principal office in the City of Calgary, Alberta&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) a written notice expressing the intention of such Participant (or his legal, personal representative) to exercise his Option and specifying the number of Shares in respect of which the Option is exercised&#59; and (ii) a cash payment, cheque or bank draft, representing the full purchase price of the Shares in respect of which the Option is exercised. For greater certainty, the Corporation shall not provide financial assistance in regards to the exercise of an Option.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d) Upon the exercise of an Option as aforesaid, the Corporation shall use its reasonable efforts to forthwith deliver, or cause the registrar and transfer agent of the Shares to deliver, to the relevant Participant (or his legal, personal representative) or to the order thereof, a certificate representing the aggregate number of fully paid and non-assessable Shares as the Participant (or his legal, personal representative) shall have then paid for.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(e) In order to fulfill the Corporation&#8217;s obligations under the Tax Act in respect of withholding and remittance on account of tax payable by Participants on the exercise of Options under this Section 11, the Corporation shall advise each Participant, on receiving such Participant&#8217;s notice of intention to exercise, of the amount of such remittance (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">Remittance Amount</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">&#8221;) required under the Tax Act. Prior to the delivery of the Shares, the Corporation may, in its sole discretion&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) require the Participant to pay to the Corporation, as an additional amount on the exercise of their Options, the Remittance Amount&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii) withhold from any remuneration or consideration payable to the Participant an amount equal to the Remittance Amount&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii) retain and sell on behalf of the Participant such number of Shares to obtain proceeds from the sale of such shares on the principal stock exchange on which the common shares are traded sufficient to satisfy the Remittance Amount&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv) any combination of the above.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Upon receipt or payment of this amount in the manner described above, the Corporation shall in accordance with Section 11(d) issue to the Participant the Shares (or in the case of subsection 11(d)(iii), the remaining Shares) for which the Option was exercised.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(f) Notwithstanding anything else contained herein, each Participant shall be responsible for the payment of all applicable taxes, including, but not limited to, income taxes payable in connection with the exercise of any Options under this Plan and the Corporation, its Directors, Officers, Employees and agents shall bear no liability in connection with the payment of such taxes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">12. Ceasing to be an Eligible Person</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Subject to any written agreement between the Corporation and a Participant providing otherwise, if any Participant shall cease to be an Eligible Person for any reason other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">than the termination for cause or the death or permanent disability of the Participant, such Participant&#8217;s Option will terminate immediately as to the then unvested portion thereof and at 5&#58;00 p.m. (Calgary time) on the earlier of the date of the expiration of the Option Period and the ninetieth (90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">) day after the date such Participant ceases to be an Eligible Person as to the then vested portion of the Option.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">If a Participant ceases to be an Eligible Person as a result of the termination of such Participant for cause, effective as of the date notice is given to the Participant of such termination, all outstanding Option Agreements under which Options have been granted to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by such Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Neither the selection of any person as a Participant nor the granting of an Option to any Participant under this Plan shall (i) confer upon such Participant any right to continue as a Director, Officer, Employee or Consultant of the Corporation or a subsidiary thereof, as the case may be, or (ii) be construed as a guarantee that the Participant will continue as a Director, Officer, Employee or Consultant of the Corporation or a subsidiary thereof, as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Notwithstanding the foregoing, the Board may, at its sole discretion, extend the period during which any Options may be exercised by a Participant that has ceased to be an Eligible Person, in the case of Options held by non-management Directors, by not more than one (1) year, and in the case of Options held by other persons, by not more than three (3) years, but in no case longer than the original expiry date of the Options established at the time of grant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">13. Death or Permanent Disability of a Participant</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Subject to any written agreement between the Corporation and a Participant providing otherwise, if in the event of the death or permanent disability of a Participant, any Option previously granted to such Participant shall be exercisable until the end of the Option Period or until the expiration of 12 months after the date of death or permanent disability of such Participant, whichever is earlier, and then only&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) by the person or persons to whom the Participant&#8217;s rights under the Option shall pass by the Participant&#8217;s will or applicable law&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b) to the extent that he was entitled to exercise the Option as at the date of the Participant&#8217;s death or permanent disability.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">14. Change of Control</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Notwithstanding any other provision hereof, in the event of a Change of Control, all Options which have not otherwise vested in accordance with their terms shall immediately vest and be exercisable, notwithstanding the other terms of the Options or this Plan for a period of time ending on the earlier of the expiry time of the Option and the ninetieth (90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:110%">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">) day following the Change of Control.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">15. Transferability</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">All benefits, rights and Options accruing to any Participant in accordance with the terms and conditions of this Plan shall not be transferable or assignable unless specifically provided herein. The Corporation shall not recognize any attempted exercise of any purported assignee of a Participant. During the lifetime of a Participant any Options granted hereunder may only be exercised by the Participant and in the event of the death or permanent disability of a Participant, by the person or persons to whom the Participant&#8217;s rights under the Option pass by the Participant&#8217;s will or applicable law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">16. Amendment and Termination of Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) The Board may, at any time, suspend or terminate this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b) Subject to Section 16(c) and 16(d), the Board may, at any time and from time to time, amend this Plan or any Option, subject to applicable TSX Policies and the requirements of any other Exchange on which the Shares are then listed, without the consent or approval from any Participant or shareholder of the Corporation (provided that no such amendment may be made that will materially prejudice the rights of any Participant under any Option previously granted to the Participant without consent by such Participant) including without limitation&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) to amend, modify or terminate this Plan with respect to all Shares in respect of Options which have not yet been granted thereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii) to make any amendment of a &#8220;housekeeping nature&#8221;, including to make any amendment typographical, grammatical, clerical or administrative nature or clarification correcting or rectifying any ambiguity, immaterial inconsistency, defective provision, mistake, or error or omission in this Plan or any Option&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii) to change the provisions relating to the manner of exercise of Options, including changing or adding any form of financial assistance provided by the Corporation or adding or amending provisions relating to a cashless exercise of Options&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv) accelerating vesting or extending the expiration date of any Option (provided that such Option is not held by an insider), provided that the period during which an Option is exercisable does not exceed 10 years from the date the Option is granted&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(v) adding a cashless exercise feature, payable in cash or securities, whether or not providing for a full deduction of the number of underlying Shares from this Plan reserve&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vi) to make any addition to, deletion from or alteration of the provisions of this Plan or any Option that are necessary to comply with applicable law, the TSX Policies, or the requirements of any other Exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c) Notwithstanding Section 16(b), the Board may not, without approval of the holders of a majority of Shares present and voting in person or by proxy at a meeting of holders of Shares, amend this Plan or any Option to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) increase the number of Shares reserved for issuance pursuant to this Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii) extend eligibility to participate in this Plan to persons other than Eligible Persons&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii) permit Options to be transferred, other than for normal estate settlement purposes or to an RRSP or similar plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iv) permit awards other than Options to be made under this Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(v) amend or delete Section 10(a) to extend the term of any Option beyond the Option Period of such Option or allow for such Option to be exercisable for a period exceeding ten (10) years from the date the Option is granted, or extend any Option benefitting an insider other than as otherwise provided for under this Plan&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vi) reduce the Exercise Price of an Option, except for the purpose of maintaining Option value in connection with a conversion, change, reclassification, redivision, redesignation, subdivision or consolidation of shares or a reorganization, amalgamation, consolidation, merger, takeover bid or similar transaction involving the Corporation (for this purpose, cancellation or termination of an Option prior to its expiry date for the purpose of reissuing Options to the same option-holder with a lower Exercise Price will be considered an amendment to reduce the Exercise Price of an Option)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(vii) change the insider participation limitation under this Plan&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(viii) amend this Section 16.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(d) Notwithstanding Section 16(b), no amendment or revision to this Plan or any Option pursuant to Section 16(b) shall in any manner materially adversely affect the rights of any Participant under any Options granted under this Plan prior to such amendment or revision without such Participant&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">17. Necessary Approvals</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(a) The obligation of the Corporation to issue and deliver Shares in accordance with this Plan is subject to applicable securities legislation and to the receipt of any approvals that may be required from any regulatory authority or any Exchange on which the Shares are then listed. If Shares cannot be issued to a Participant upon the exercise of an Option for any reason whatsoever, the obligation of the Corporation to issue such Shares shall terminate and any funds paid to the Corporation in connection with the exercise of such Option will be returned to the relevant Participant as soon as practicable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(b) Without obtaining the approval of the shareholders of the Corporation in accordance with the TSX Policies or the requirements of any other Exchange on which the Shares are then listed, no Options shall be granted pursuant to this Plan, if such grant together with grants pursuant to all other share compensation arrangements of the Corporation, could result, at any time, in&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(i) a number of Shares issuable pursuant to Options granted to insiders exceeding ten percent (10%) of the number of outstanding Shares at any time&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(ii) the issuance within a one year period to insiders, of a number of Shares exceeding ten percent (10%) of the number of outstanding Shares&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(iii) the issuance to any one insider and such insider&#8217;s associates, within a one year period, of a number of Shares exceeding five percent (5%) of the number of outstanding Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">(c) The total annual grant of Options to any one Non-Employee Director cannot exceed a grant value of $150,000.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">18. Stock Exchange Rules</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">This Plan and any option agreements entered into hereunder shall comply with the TSX Policies and the requirements of any other Exchange on which the Shares are then listed.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">19. Right to Issue Other Shares</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">The Corporation shall not by virtue of this Plan be in any way restricted from declaring and paying stock dividends, issuing further Shares, varying or amending its share capital or corporate structure or conducting its business in any way whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">20. Notice</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Any notice required to be given by this Plan shall be in writing and shall be given by registered mail, postage prepaid or delivered by courier or by facsimile or email transmission addressed, if to the Corporation, at its principal address in Calgary, Alberta (being currently 210, 1167 Kensington Crescent N.W., Calgary, Alberta T2N 1X7), Attention&#58; Chief Financial Officer&#59; or if to a Participant, to such Participant at his address as it appears on the books of the Corporation or in the event of the address of any such Participant not so appearing then to the last known address of such Participant&#59; or if to any other person, to the last known address of such person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">21. Gender</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">Whenever used herein words importing the masculine gender shall include the feminine and neuter genders and vice versa.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">22. Interpretation</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:110%">This Plan will be governed by and construed in accordance with the laws of the Province of Alberta.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:110%">&#91;DATED&#58; May 4, 2017&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24</font></div><div style="padding-right:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><div id="ic95969062a4f4ad6a289d8b5b14ff45a_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">AMENDED AND RESTATED INCENTIVE SHARE AWARD PLAN</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board of Directors of Oncolytics Biotech Inc. (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has adopted this Incentive Share Award Plan (the &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) governing the issuance of&#58; (i) Restricted Share Awards to Eligible Persons&#59; and (ii) Performance Share Awards to Employees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Purposes</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The principal purposes of the Plan are as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to retain and attract qualified directors, officers, employees and consultants for the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to promote ownership of common shares of the Corporation by such directors, officers, employees and consultants and to encourage such persons to remain in the employ or service of the Corporation and put forth maximum efforts for the success of the affairs of the Corporation&#59; and </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to focus management of the Corporation on operating and financial performance and total long-term shareholder return.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Definitions</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Where used herein, the following terms shall have the following meanings, respectively&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Black-Out Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any period during which the holder of a Share Award is not permitted to trade Shares pursuant to the policies of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the board of directors of the Corporation as constituted from time to time and shall be deemed to include any committee thereof to which the Board has, fully or partially, delegated the administration and operation of this Plan pursuant to Section 3 of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Business Day</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means each day other than a Saturday, Sunday, a statutory holiday in Alberta or any day on which the principal chartered banks located in Calgary, Alberta are not open for business during normal business hours.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Cessation Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means, in respect of a Participant, the last day of active employment or service of the Participant with the Corporation, regardless of the reason for the cessation of employment or service and regardless of whether any or any adequate or proper advance notice of termination or resignation is provided in respect of such cessation of employment or service.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the acceptance by the holders of Shares, representing in the aggregate of more than 50 percent (50%) of all issued and outstanding Shares, of any offer, whether by way of a takeover bid or otherwise, for all or any of the Shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the acquisition, by whatever means (including, without limitation, amalgamation, arrangement, consolidation or merger), by a person (or two or more persons who in such acquisition have acted jointly or in concert or intend to exercise jointly or in concert any voting rights attaching to the Shares acquired), directly or indirectly, of the beneficial ownership of such number of Shares, which </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">together with such person's then owned Shares, if any, represent more than 50 percent (50%) of the Corporation's then outstanding Shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the sale, lease or other disposition of all or substantially all of the assets of the Corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the passing of a resolution by the board of directors of the Corporation or shareholders of the Corporation to substantially liquidate assets or windup its business or significantly rearrange its affairs in one or more transactions or series of transactions or the commencement of proceedings for such a liquidation, winding-up or re-arrangement (except where such re-arrangement is part of a bona fide reorganization of the Corporation in circumstances where the business of the Corporation is continued and where the shareholdings remain substantially the same following the re-arrangement as existed prior to the re-arrangement)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">individuals who were members of the board of directors of the Corporation immediately prior to a meeting of the shareholders of the Corporation involving a contest for or, an item of business relating to the election of directors shall not constitute a majority of the board of directors of the Corporation following such election&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the completion of any transaction or the first of a series of transactions which would have the same or similar effect as any transaction or series of transactions referred to in subsections (i), (ii), (iii), (iv) or (v) referred to above&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a determination by the board of directors of the Corporation that there has been a change, whether by way of a change in the holding of the Shares, in the ownership of the Corporation's assets or by any other means, as a result of which any person or group of persons acting jointly or in concert is in a position to exercise effective control of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consultant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34; means an individual or Consultant Corporation, other than an Employee or a Non- Employee Director, that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">is engaged to provide on an ongoing bona fide basis, consulting, technical, management or other services to the Corporation or a subsidiary of the Corporation, other than services in relation to a distribution&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">provides the services under a written contract for an initial, renewable or extended period of twelve months or more&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">spends or will spend a significant amount of time and attention on the affairs of the Corporation or a subsidiary of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Consultant Corporation</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34; means for an individual consultant, a company or partnership of which the individual is an employee, shareholder or partner.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Eligible Person</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Employee, a Non-Employee Director or a Consultant.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Employee</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34; means a persons who would be considered an 'employee' under the Tax Act, or who works full-time or for a specified number of hours per week on a continuing regular basis and is subject to the same control and direction by the Corporation or a subsidiary of the company over the details and methods of work as an employee of the company, but for whom tax and other deductions are not made at source.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the TSX and such other stock exchange(s) on which the Shares are then listed and posted for trading from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Grant Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the grant date for a Share Award.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">insider</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(j) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">insider participation limit</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(k) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Issue Date</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the date on which Shares are issued to a Participant in respect of a Share Award following completion of the applicable Vesting Period.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(l) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Employee Director</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any director of the Corporation (including, for greater certainty, any subsidiary of the Corporation) who is not also an Employee.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(m) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#34; means an officer of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(n) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Participant</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an Eligible Person to whom a Share Award has been granted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(o) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Criteria</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any performance-related measures or criteria as determined by the Board in its sole discretion at Grant Date to be taken into consideration over the Vesting Period of a Performance Share Award for purposes of determining the applicable Vesting Percentage, which measures or criteria may include, the Corporation&#8217; performance compared to identified operational or financial targets, the Corporation&#8217; shareholder return, and any such other performance-related measures or criteria matters as the Board may determine, in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(p) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Performance Share Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an award to an Employee under the Plan pursuant to which Shares shall be issued on the Issue Dates, as applicable, determined in accordance with Section 5 hereof, based upon achieving the applicable Performance Criteria and subject to adjustment in accordance with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(q) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restricted Share Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means an award to an Eligible Person under the Plan pursuant to which Shares shall be issued on the Issue Dates, as applicable, determined in accordance with Section 5 hereof, subject to adjustment in accordance with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(r) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Security Based Compensation Arrangement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning ascribed thereto in the TSX Policies.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(s) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; mean a common share in the capital of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(t) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share Award</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a Performance Share Award or Restricted Share Award, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(u) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; has the meaning set forth in Section 5 hereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Shareholder</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a holder of Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(w) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TSX</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Toronto Stock Exchange.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(x) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TSX Policies</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the policies included in the TSX Company Manual.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vested</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the applicable Vesting Period having been completed and additionally in the case of Performance Share Awards, the applicable Performance Criteria in relation to a whole or percentage of the number of Shares covered by such Performance Share Award determined by the Board having been met, where &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; (or any applicable derivative term) has a comparable meaning.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(z) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting Percentage</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the percentage of outstanding Performance Share Awards that will vest based upon the relative achievement of the Performance Criteria for such award during the Vesting Period, where such percentage will range from 0 percent to 100 percent reflecting the Board&#8217;s determination, in its sole discretion, of the achievement of the Performance Criteria.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(aa) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting Period</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the period over which Share Awards granted under the Plan shall vest in accordance with Section 5(b)(i), subject to adjustment or modification pursuant to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Administration</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan shall be administered by the Board and, for greater certainty, the board of directors of the Corporation shall have the right to delegate the administration and operation of this Plan, in whole or in part, to a committee of the board of directors that has been assigned the responsibility of determining the Corporation&#8217;s policies with respect to executive compensation. The Board shall have the authority in its sole and absolute discretion to administer the Plan and to exercise all the powers and authorities either specifically granted to it under the Plan or necessary or advisable in the administration of the Plan including, without limitation, the authority to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">grant Restricted Share Awards to Eligible Persons and Performance Share Awards to Employees&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determine the Grant Date for Share Awards&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determine the Eligible Persons who may participate in this Plan and designate any officer or employee of the Corporation as being an Employee under this Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determine Performance Criteria applicable to any Performance Share Award&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">approve the form and determine the terms and provisions of Share Award Agreements (which need not be identical) entered into in connection with Share Awards&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">interpret the Plan and the Share Award Agreements&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">prescribe, amend and rescind rules and regulations relating to the Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(viii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">determine whether and the extent to which adjustments shall be made pursuant to the Plan&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ix) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make all other determinations deemed necessary or advisable for the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For greater certainty and without limiting the discretion conferred on the Board pursuant to this Section 3, the Board&#8217;s decision to approve the grant of a Share Award </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in any period shall not require the Board to approve the grant of a Share Award to any Participant in any other period&#59; nor shall the Board&#8217;s decision with respect to the amount or terms and conditions of a Share Award in any period require it to approve the grant of a Share Award of the same or similar amount or with the same or similar terms and conditions to any Participant in any other period. The Board shall not be precluded from approving the grant of a Share Award to any Participant solely because such Participant may previously have been granted a Share Award under this Plan or any other Security Based Compensation Arrangement. No Participant has any claim or right to be granted a Share Award. There is no obligation for uniformity of treatment of Non-Employee Directors, Employees or Consultants, or any group of Non-Employee Directors, Employees or Consultants.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Any interpretation, rule, regulation, determination or other act of the Board hereunder shall be made in its sole discretion and shall be final and conclusively binding upon the Corporation and all persons affected by the Plan. No member of the Board shall be liable for any action or determination made in good faith pursuant to the Plan or any instrument of grant evidencing any Share Award awarded under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Reservation of Shares&#59; Participation Limits</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The number of Shares reserved for issuance under the Plan and all other Security Based Compensation Arrangements in aggregate shall not exceed 10% of the total number of issued and outstanding Shares from time to time. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The number of Shares issuable to Insiders at any time, under all Security Based Compensation Arrangements of the Corporation, shall not exceed 10% of the issued and outstanding Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The number of Shares issued to Insiders, within any one-year period, under all Security Based Compensation Arrangements of the Corporation, shall not exceed 10% of the issued and outstanding Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The number of Shares reserved for issuance under all Security Based Compensation Arrangements of the Corporation to any one Participant shall not exceed 5% of the total number of issued and outstanding Shares.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any other provision of this Plan, Performance Share Awards may only be granted to Employees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Share Awards that are vested and redeemed, or are cancelled, terminated or expire prior to the settlement of all or a portion thereof, shall result in the Shares that were reserved for issuance thereunder being available for a subsequent grant of Share Awards pursuant to this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The maximum number of Shares that may be reserved for issuance to Non-Employee Directors pursuant to Restricted Share Awards under the Plan is 1% of the Shares outstanding at the time of the grant (on a non-diluted basis), less the aggregate number of Shares reserved for issuance to such Non-Employee Director under any other Security Based Compensation Arrangement, and the total annual grant of Restricted Share Awards to any one Non-Employee Director cannot exceed a grant value of $150,000 (less the amount awarded to such Non-Employee Director in the year pursuant to any other Security Based Compensation Arrangement).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Terms and Conditions of Share Awards</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Each Share Award granted under the Plan shall be subject to the terms and conditions of the Plan and evidenced by a written agreement between the Corporation and the Participant or an award letter from the Corporation to the Participant (a &#8220;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share Award Agreement</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) which agreement shall comply with, and be subject to, the requirements of the Exchange and the following terms and conditions (and with such other terms and conditions as the Board, in its discretion, shall establish)&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Number of Share Awards </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- The Board may determine the number of Share Awards to be awarded to a Participant in its sole discretion.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Vesting of Share Awards </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless otherwise determined by the Board, the Vesting Period in respect of Share Awards granted hereunder shall be three (3) years from the Grant Date of such Share Awards. The Board may, in its sole discretion, accelerate the vesting of all or any Share Awards at any time and from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Upon vesting, each Restricted Share Award and each Performance Share Award (following application of the applicable Vesting Percentage) so vested will entitle the holder to receive one Share (subject to adjustment in accordance with the terms of this Plan) on the applicable Issue Date. For greater certainty, a Participant shall have no right to receive any Shares or other consideration in respect of any Performance Share Awards other than for the Vesting Percentage of such Performance Share Awards.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board shall determine the Performance Criteria for each grant of Performance Share Awards at the time of the grant of the award and, the Board shall, as soon as reasonably practicable following the completion of the Vesting Period applicable to a particular grant of Performance Share Awards determine, in its sole discretion, the applicable &#8220;Vesting Percentage&#8221;.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any other provision of this Plan, no term or condition of a grant of Share Awards hereunder or any Share Award Agreement may have the effect of causing any Shares to be issued pursuant to any Share Award under the Plan to a Participant in satisfaction of such Participant&#8217;s Performance Share Awards under the Plan (or any portion thereof) to occur after December 31 in the third (3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">rd</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) calendar year following the calendar year in respect of which such Share Awards were granted.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Issuance of Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- Shares that are issuable to the Participant on the Issue Date shall be issued from treasury as fully paid and non-assessable Shares. No fractional Shares will be issued and all fractional entitlements shall be rounded down to the nearest whole number.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Delivery of Shares </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- The Issue Date shall occur as soon as practicable and in any event within 31 days following the completion of the Vesting Period applicable to a Share Award. Subject to the remainder of this Section 5(d), on the Issue Date, the Corporation will issue from treasury to the Participant that number of Shares to which the Participant is entitled to receive in respect of such Share Award in accordance with this Section 5, subject to Section 7 hereof, and sent by pre-paid mail or delivered to the Participant. Notwithstanding the foregoing, if on the Issue Date a Black-Out Period has been imposed upon a Participant which is still in effect, then the Issue Date shall not occur until the date which is the tenth (10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">th</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">) business day after the last day of the applicable Black Out Period.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Change of Control </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- Unless otherwise determined by the Board in its sole discretion, upon a Change of Control, all unvested Share Awards shall become automatically vested (in the case of Performance Share Awards, with a deemed Vesting Percentage of 100). Shares issuable in respect of Share Awards shall be, and shall be deemed to be, issued to Participants effective immediately prior to the completion of the transaction which would result in the Change of Control unless issued prior thereto in accordance with this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board Discretion </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- Notwithstanding anything else in this Plan, the Board may, in its sole discretion, but subject to the limits described in Sections 4 and 9 hereof and any other applicable requirements of the Exchange or other regulatory authority&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">make any additional adjustments to the Vesting Percentage (in respect of any Performance Share Awards) or the number of Shares to be issued or delivered to a Participant in connection with any Share Award if, in the sole discretion of the Board, such adjustments are appropriate in the circumstances having regard to the principal purposes of the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">change the Issue Date (including amending the Vesting Period related thereto) for all or any Share Awards at any time and from time to time&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">otherwise amend or modify the terms and conditions regarding any grant of Share Awards or payments in respect of any Share Awards hereunder, provided, however, that no such amendment or modification may, without the consent of the affected Participant, impair or adversely affect a Share Award granted to the Participant under the Plan prior to the date of such amendment or modification.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effect of Certain Changes </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- In the event&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">of any change in the Shares through subdivision, consolidation, reclassification, recapitalization or similar transaction&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that any rights are granted to Shareholders to purchase Shares at prices substantially below fair market value, and such events do not constitute a Change of Control, then, in any such case, the Board may make such adjustments to the Plan, to any Share Awards and to any Share Award Agreements outstanding under the Plan as the Board may, in its sole discretion, consider appropriate in the circumstances to prevent dilution or enlargement of the rights granted to Participants hereunder.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ceasing to be an Eligible Person </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- Unless otherwise determined by the Board or unless otherwise expressly set forth in a Share Award Agreement pertaining to a particular Share Award or any written employment or other agreement governing a Participant&#8217;s role as an Eligible Person, the following provisions shall apply in the event that a Participant ceases to be an Eligible Person&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Termination for Cause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8211; If a Participant ceases to be an Eligible Person as a result of the termination of such Participant for cause, effective as of the date notice is given to the Participant of such termination, all outstanding Share Awards Agreements under which Share Awards have been granted to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by such Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Voluntary Resignation </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- If a Participant voluntarily ceases to be an Eligible Person for any reason other than as a result of the death, permanent disability or retirement of the Participant as set forth in Section 7(h)(iii), effective as of the date notice is given by the Participant of such resignation, unless otherwise determined by the Board, all outstanding Share Award Agreements under which Share Awards have been made to such Participant shall be terminated and all rights to receive Shares thereunder shall be forfeited by the Participant, and the Participant shall not be entitled to receive any Shares or other compensation in lieu thereof.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Termination Upon Death or Permanent Disability or Retirement </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8211; Upon the death, permanent disability or retirement of a Participant (other than the early retirement of an Eligible Employee), all outstanding Share Award Agreements under which Share Awards have been made to such Participant prior to the Cessation Date shall immediately vest as of the Cessation Date, and the Issue Date in respect of all Share Awards held by such Participant shall be the earlier of&#58; (A) the 90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day following the Cessation Date&#59; and (B) the original Issue Date contemplated by Section 5(d) of this Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Termination not for Cause </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- If a Participant ceases to be an Eligible Person other than as set forth in Sections 7(h)(i), (ii) or (iii), effective as of the Cessation Date all Share Awards awarded to such Participant under any outstanding Share Award Agreements shall fully vest effective as of the Cessation Date, unless otherwise determined by the Board. On the applicable Issue Date in respect of such Share Awards, the Participant shall be entitled to receive the number of Shares equal to the number of Share Awards granted multiplied by a fraction (A) the numerator of which is the number of days from the Grant Date in respect of the applicable Share Award to the Cessation Date&#59; and (B) the denominator of which is the total number of days comprising the Vesting Period in respect of such Share Award. In such circumstances, the Vesting Percentage in respect of Performance Share Awards shall be determined as of the Cessation Date. The Issue Date in respect of any such Awards shall be the earlier of&#58; (A) the 90</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">th </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">day following the Cessation Date&#59; and (B) the original Issue Date contemplated by Section 5(d) of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Rights as a Shareholder </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- Until the Shares underlying any Share Award have been issued in accordance with the terms of the Plan, the Participant to whom such Share Award has been made shall not possess any incidents of ownership of such Shares including, for greater certainty and without limitation, the right to exercise voting rights in respect of such Shares. Such Participant shall only be considered a Shareholder in respect of such Shares when such issuance has been entered upon the records of the duly authorized transfer agent of the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Ratification and Approval by Shareholders</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any other provision of this Plan&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">no Shares may be issued pursuant to any Share Award until the Plan has been approved by the Shareholders at a duly called meeting of the Shareholders&#59; and </font><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any grants of Share Awards by the Board prior to the Plan being approved by the Shareholders must be ratified by the Shareholders at the meeting of the Shareholders at which the Shareholders approve the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Withholding Taxes</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">When a Participant or other person becomes entitled to receive Shares under any Share Award, the Corporation shall have the right to require the Participant or such other person to remit to the Corporation an amount sufficient to satisfy any withholding tax requirements relating thereto. Unless otherwise prohibited by the Board or by applicable law, satisfaction of the withholding tax obligation may be accomplished by any of the following methods or by a combination of such methods&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the tendering by the Participant of cash payment to the Corporation in an amount equal to the total withholding tax obligation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the withholding or sale by the Corporation from the Shares otherwise due to the Participant, of such number of Shares having a value determined by the Corporation in its sole discretion, acting reasonably, equal to the amount of the total withholding tax obligation (and in the case of a treasury issuance of Shares to settle Share Awards hereunder, such sale of Shares shall be automatically made on or as soon as practicable after the applicable Issue Date for the purposes of satisfying withholding tax obligations, unless otherwise agreed to by the Corporation and the Participant)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">the withholding by the Corporation from any cash payment otherwise due to the Participant of such amount of cash as is equal to the amount of the total withholding tax obligation&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">any other method determined by the Corporation in its sole discretion, acting reasonably, provided, however, that the sum of any cash so paid or withheld and the value of any Shares so withheld or sold is, sufficient, in the reasonable estimation of the Corporation, to satisfy the total withholding tax obligation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Non-Transferability</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The right to receive Shares pursuant to a Share Award granted to a Participant may only be settled by such Participant personally or through the Participant&#8217;s personal representative or estate and no assignment, sale, transfer, pledge or charge of a Share Award, whether voluntary, involuntary, by operation of law or otherwise (except by will or the laws of descent and distribution), vests any interest or right in such Share Award whatsoever in any assignee or transferee and, immediately upon any assignment, sale, transfer, pledge or charge or attempt to assign, sell, transfer, pledge or charge, such Share Award shall terminate and be of no further force or effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Amendment and Termination of Plan</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board may, at any time, suspend or terminate this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to Section 9(c), the Board may, at any time and from time to time, amend this Plan or any Share Award, subject to applicable TSX Policies and the requirements of any other Exchange on which the Shares are then listed, without the consent or approval from any Participant or shareholder of the Corporation, including without limitation&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to amend, modify or terminate this Plan with respect to all Shares in respect of Share Awards which have not yet been granted thereunder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to make any amendment of a &#34;housekeeping nature&#34;, including to make any amendment typographical, grammatical, clerical or administrative nature or clarification correcting or rectifying any ambiguity, immaterial inconsistency, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defective provision, mistake, or error or omission in this Plan or any Share Award&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">to make any addition to, deletion from or alteration of the provisions of this Plan or any Share Award that are necessary to comply with applicable law, the TSX Policies, or the requirements of any other Exchange on which the Shares are then listed and to avoid unanticipated consequences deemed by the Board to be inconsistent with the purpose of this Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding Section 9(b), the Plan or any Share Award may not be amended without Shareholder approval to&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">increase the number of Shares issuable pursuant to outstanding Share Awards at any time pursuant to Section 4 hereof&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">change the insider participation limitation under this Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">expand the categories of individuals contained in the definition of &#34;Employee&#34; who are eligible to participate in the Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">extend the term of any Share Award beyond the term of such awards provided for under the terms and conditions of this Plan&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">permit the transfer or assignment of Share Awards, except to permit a transfer to a family member, an entity controlled by the holder of the Share Awards or a family member, a charity or for estate planning or estate settlement purposes&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">amend this Section 9.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In addition, no amendment to the Plan or Share Awards granted pursuant to the Plan may be made without the consent of the Participant, if such amendment adversely alters or impairs the rights of any Participant in respect of any Share Award previously granted to such Participant under the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Miscellaneous</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effect of Headings </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- The Section headings contained herein are for convenience only and shall not affect the construction hereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Compliance with Legal Requirements </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- The Corporation shall not be obliged to issue any Shares if such issuance would violate any law or regulation or any rule of any government authority or Exchange. The Corporation, in its sole discretion, may postpone the issuance or delivery of Shares under any Share Award as the Board may consider appropriate, and may require any Participant to make such representations and furnish such information as it may consider appropriate in connection with the issuance or delivery of Shares in compliance with applicable laws, rules and regulations. The Corporation shall not be required to qualify for resale pursuant to a prospectus or similar document any Shares awarded under the Plan, provided that, if required, the Corporation shall notify the Exchange and any other appropriate regulatory bodies in Canada of the existence of the Plan and the granting of Share Awards hereunder in accordance with any such requirements.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">No Right to Continued Employment </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- Nothing in the Plan or in any Share Award Agreement entered into pursuant hereto shall confer upon any Participant the right to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">continue in the employ or service of the Corporation, to be entitled to any remuneration or benefits not set forth in the Plan or a Share Award Agreement or to interfere with or limit in any way the right of the Corporation to terminate Participant&#8217;s employment or service arrangement with the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Expenses </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- All expenses in connection with the Plan shall be borne by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governing Language </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">-This Plan is drawn up in the English language and each notice, instrument, certificate or other communication to be given under or in connection with this Plan shall be in the English language. If this Plan or any notice, instrument, certificate or other communication is translated into any other language, the English language text shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Market Fluctuations </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- No amount will be paid to, or in respect of, a Participant under the Plan to compensate for a downward fluctuation in the price of Shares which impacts the Share Award, nor will any other form of benefit be conferred upon, or in respect of, a Participant for such purpose. The Corporation makes no representations or warranties to a Participant with respect to the Plan or the Share Awards whatsoever. In seeking the benefits of participation in the Plan, a Participant agrees to exclusively accept all risks associated with a decline in the market price of Shares and all other risks associated with the holding of Share Awards.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Currency </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- Any payments and benefits under the Plan to be paid in cash shall be determined in the lawful currency of Canada and paid in the local currency of the Participant&#8217;s country of residence using the currency exchange rate available to the Corporation at the time of payment.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(h) </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Participation is Voluntary&#59; No Additional Rights </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">- Participation in the Plan shall be entirely voluntary and any decision by a Participant not to participate shall not affect any Participant&#8217;s employment or service with the Corporation. In such instance where a Participant provides notice in writing to the Corporation of his or her intent to not participate in a Share Award, such award shall be immediately terminated and the Participant shall not be eligible to receive any form of in lieu compensation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Governing Law</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Plan shall be governed by, interpreted and construed in accordance with the laws in force in the Province of Alberta.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#010000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12. </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Plan shall take effect on May </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#91;4&#93;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, 2017. The issuance of Shares under the Plan is subject to the acceptance of the Plan by the Exchange and any other relevant regulatory authorities and approval of the Shareholders.</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.12</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT D</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:100%">LIST OF INVENTIONS</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> NIL</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011, v.  3</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4825-1831-5011&#92;3</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.13
<SEQUENCE>4
<FILENAME>ex413-amylevinamendment1xe.htm
<DESCRIPTION>EX-4.13
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9b2da79252424b7fb48cde1cb074e9ca_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.13</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">AMENDING AGREEMENT # 1</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">THIS AMENDING AGREEMENT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%"> made effective as of the 1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.82pt;font-weight:400;line-height:100%;position:relative;top:-3.67pt;vertical-align:baseline">st </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">day of January, 2023.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">BETWEEN&#58;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Oncolytics Biotech (U.S.), Inc.,</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(&#34;OBUS&#34;)</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">- and -</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Amy Goodowitz Levin</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(the &#34;Employee&#34;)</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">WHEREAS the Employee is an employee of OBUS whose terms of employment are set forth in the Employment Agreement dated effective September 1, 2020, (the &#8220;Employment Agreement&#8221;)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">AND WHEREAS OBUS and the Employee wish to amend the Employment Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">NOW THEREFORE in consideration of the mutual covenants contained in this Amending Agreement, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, it is agreed as follows&#58;</font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:30.17pt">Interpretation</font></div><div style="padding-left:54pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">This Amending Agreement is supplemental to and shall form one agreement with the Employment Agreement, and the Employment Agreement and this Amending Agreement shall be read together and have effect so far as practicable as though all the provisions thereof and hereof were contained in one instrument.  In this Amending Agreement, including the recitals hereto, unless there is something within the subject matter or context inconsistent therewith, expressions herein, unless otherwise defined herein, have the same meanings as the corresponding expressions defined in the Employment Agreement.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:30.17pt">Amendments to the Employment Agreement</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">The Employment Agreement Section 1 &#8211; Employment is amended as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:42.55pt;padding-right:79pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Employer hereby employs Employee, and Employee agrees to be employed as Vice President, Clinical Operations.  Employee will perform the duties of Vice President, Clinical Operations for Employer, its parent corporation, Oncolytics Biotech Inc. and other affiliated corporations.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Employee will report to the Chief Medical Officer of Employer.  Changes may be made from time to time by Employer in its sole discretion to the duties, reporting relationships and title of Employee.  Employee will devote full time and attention to the duties on Exhibit A to this Agreement.  Employee will comply with all rules, policies and procedures of Employer as modified from time to time, including without limitation, rules and procedures set forth in the Employer&#8217;s Employee Handbook and Company Policy Manual. Employee will perform all of Employee&#8217;s responsibilities in compliance with all applicable laws and will ensure that the operations that Employee manages are in compliance with all applicable laws.  During Employee&#8217;s employment, Employee will not engage in any other business activity which, in the reasonable judgment of the President of Employer, conflicts with the duties of Employee under this Agreement, whether or not such activity is pursued for gain, profit or other pecuniary advantage.</font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.13</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">The Employment Agreement Section 3.1 &#8211; Base Salary is amended as follows&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:35.45pt;padding-right:79pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Commencing January 1, 2023, OBUS shall pay to the Employee a Base Salary at an annual rate of THREE HUNDRED AND TWENTY THOUSAND ($320,000.00) UNITED STATES DOLLARS per annum, exclusive of bonuses, benefits and other compensation, payable in equal installments of THIRTEEN THOUSAND AND THREE HUNDRED AND THIRTY-THREE UNITED STATES DOLLARS and THREE-THREE CENTS ($13,333.33) on the 15th and last day of each month.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(3)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">The Employment Agreement Section 5.2 &#8211; Without Cause is amended as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:42.55pt;padding-right:79pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Employer may terminate Employee&#8217;s employment under this Agreement without Cause and without advance notice&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, that Employer will continue to pay, as severance pay, Employee&#8217;s Base Salary at the rate in effect on the termination date through the date that is 12 months from the termination date&#59; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;text-decoration:underline">further</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">, that Employer will be entitled to offset any severance pay otherwise payable to Employee by the amount of any compensation or consulting fees being paid to Employee by another party while severance pay would otherwise be payable.  Employee shall only be entitled to such severance pay if Employee signs (and then Employee does not rescind, as may be permitted by law) a general release of claims in favor of Employer in a form acceptable to Employer, provided, however, that such release of claims shall only require Employee to release Employer from claims relating directly to Employee&#8217;s employment and the termination thereof, and shall not require Employee to release claims relating to vested employee benefits or relating to other matters, including, but not limited to, claims relating to his status as a shareholder of the Company.  Such payments will be at usual and customary pay intervals of Employer and will be subject to all appropriate deductions and withholdings.  Upon termination, Employee will have no rights to any unvested benefits or any other compensation or payments except as stated in this paragraph.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(4)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">The Employment Agreement Section 5.3 is amended as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:42.55pt;padding-right:79pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Notwithstanding Section 5.2, if there is a change of control of Oncolytics Biotech Inc., as defined herein, and if this Agreement is terminated by Employer at any time within one (1) year following the change of control other than pursuant to Section 5.1, Employee shall be entitled to severance payment equal to the Employee&#8217;s Base Salary for 12 months.  For the purposes of this Section 5.3, &#8220;change of control&#8221; means any amalgamation, merger or other corporate reorganization which results in any change in the present effective voting control of Oncolytics Biotech Inc., or will result in a change of the person or persons who own or control sufficient voting shares in Oncolytics Biotech Inc. to elect a majority of the directors of Oncolytics Biotech Inc., or will result in a person acquiring sufficient voting shares in Oncolytics Biotech Inc. to elect a majority of the directors of Oncolytics Biotech Inc.</font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-right:79pt"><font><br></font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.13</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(5)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">Exhibit A to the Employment Agreement is replaced with the following&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:57.22pt;padding-right:57.22pt;text-align:center"><font><br></font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:57.22pt;padding-right:57.22pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">DUTIES AND RESPONSIBILITIES</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:35.45pt;padding-right:79pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">The Employee will lead the Clinical Operations Team and other related teams (e.g., Quality, Data Management, Project Management). He&#47;she will participate in formulating clinical development strategy and will oversee clinical operations activities on all clinical trials. The Employee will build relationships and interact with Contract Research Organizations, academic groups, key opinion leaders, external physician investigators, and other contracted service providers. The Employee will also participate in cross-functional projects, interacting closely with other Oncolytics team members and departments. The Employee will be expected to be solution-oriented and plan and participate in the execution of all aspects of clinical projects.</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-align:justify"><font><br></font></div><div style="padding-left:35.45pt;padding-right:79pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Duties and responsibilities include&#58;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#160;</font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Membership on the global team, contributing to the development of the clinical programs and decision making in relation to the clinical development strategy&#59;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Participate in defining the Company&#8217;s clinical development strategy and provide operational expertise in its implementation&#59;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">In collaboration with internal and external scientific and medical experts, manage the execution of phase 1-3 clinical trials in an out-sourced model from study start-up to final clinical study report&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Author, review and manage a wide variety of activities, including for example, clinical trial synopses, protocols, case report forms, investigator brochures, and the like&#59; manage internal teams to review and approve clinical study reports in accordance with overall project timelines&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Prepare or oversee the preparation of Request for Proposal documents and with cross-functional project team, solicit and evaluate bids&#59; lead contracting process with selected CROs&#47;academic groups, collaborating with relevant departments such as Legal, Finance, and Business Development&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Manage CROs or collaborate with academic groups to execute clinical trials in accordance with contracted scope, costs and timelines&#59; actively engage with academic groups&#47;CROs on defining, monitoring and reporting on all aspects of key trial performance indicators, including for example, country and site initiation activities, patient screening and randomization rates, and data collection activities&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Interact with investigators and sites as needed to support academic groups&#47;CROs and ensure clinical trials are conducted according to plan&#59;&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:79pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:79pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:79pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;padding-right:79pt"><font><br></font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.13</font></div><div style="text-align:justify"><font><br></font></div></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Identify and track trial risks and issues, proactively escalate risks to internal and academic groups&#47;CRO teams, develop and implement risk mitigation strategies and tactics&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Provide oversight and input to additional study-related external vendors, including execution of work and tracking of milestones and deliverables&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Plan and manage budget proposals and approved budgets&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Assist with Standard Operating Procedure (SOP) development and implementation&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Contribute to wider organizational goals and activities as assigned&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Select and manage data management vendors throughout the clinical trial process, including activities required for database lock and generation of data presentations&#59;&#160;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Coach and mentor their team to maximize its effectiveness and foster the development team members&#59;</font></div><div style="padding-left:35.45pt;padding-right:79pt;text-indent:3pt"><font><br></font></div><div style="padding-left:72pt;padding-right:79pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:14.33pt">Other duties as assigned.</font></div><div style="padding-left:35.45pt;text-align:justify"><font><br></font></div><div style="padding-left:35.45pt"><font><br></font></div><div style="padding-left:54pt;padding-right:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:30.17pt">Confirmation</font></div><div style="padding-left:54pt;padding-right:72pt"><font><br></font></div><div style="padding-right:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;The parties confirm that the increase in Base Salary is a result of an assessment of increases in cost-of-living indices and salary benchmarking.</font></div><div style="padding-right:0.2pt;text-align:justify"><font><br></font></div><div style="padding-right:0.2pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;The parties hereto hereby acknowledge and confirm that, except as specifically amended by the provisions of this Amending Agreement, all of the terms and conditions contained in the Employment Agreement are and shall remain in full force and effect, unamended, in accordance with the provisions thereof.</font></div><div style="padding-right:0.2pt"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%;padding-left:30.17pt">Miscellaneous</font></div><div style="padding-left:54pt;padding-right:0.2pt"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">This Amending Agreement shall be effective from and after January 1, 2023.</font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">This Agreement shall be governed by and construed in accordance with the laws of California.  </font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.77pt">The parties shall with reasonable diligence take all action, do all things, attend or cause their representatives to attend all meetings and execute all further documents, agreements and assurances as may be required from time to time in order to carry out the terms and conditions of this Agreement in accordance with their true intent.</font></div><div style="padding-right:0.2pt;text-align:justify"><font><br></font></div><div style="padding-left:54pt;padding-right:0.2pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%;padding-left:23.19pt">This Agreement may be executed in one or more counterparts, each of which shall be an original and all of which together shall constitute one document.  Delivery of an executed counterpart signature hereof by electronic mail in &#8220;portable document format&#8221; (&#8220;.pdf&#8221;) form, or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing the original signature.</font></div><div style="padding-left:54pt;padding-right:0.2pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 4.13</font></div><div style="text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF the parties hereto have executed this Amending Agreement as of the date and year first above written. </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:50.160%"><tr><td style="width:1.0%"></td><td style="width:14.235%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">ONCOLYTICS BIOTECH (U.S.), INC. </font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Gilles Gosselin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Gilles Gosselin</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Director</font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Per&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Matthew Coffey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Matthew Coffey</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">Director</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">&#47;s&#47;Amy Goodowitz Levin</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:400;line-height:100%">________________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10.5pt;font-weight:700;line-height:100%">Amy Goodowitz Levin</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.0
<SEQUENCE>5
<FILENAME>ex80subsidiaries2023.htm
<DESCRIPTION>EX-8.0
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ibe4827b56f6a430893b16617c81b9ce9_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 8.0</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.222%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (Barbados) Inc.</font></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barbados</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncolytics Biotech (US) Inc.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div style="margin-bottom:5pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>6
<FILENAME>ex121ceocertification2023.htm
<DESCRIPTION>EX-12.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="if52c9016dded49389c888d47e92b367b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Matthew Coffey, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.074%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Matthew Coffey</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Matthew Coffey, PhD, MBA<br>Chief Executive Officer<br>Principal Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>7
<FILENAME>ex122cfocertification2023.htm
<DESCRIPTION>EX-12.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i61397c8d5111491595ec37fd04a2ed21_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 12.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">I, Kirk Look, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 20-F of Oncolytics Biotech Inc.&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:28.5pt">The company's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">Evaluated the effectiveness of the company's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Disclosed in this report any change in the company's internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company's internal control over financial reporting&#59; and</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">5. &#160;&#160;&#160;&#160;The company's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company's auditors and the audit committee of the company's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company's ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company's internal control over financial reporting.</font></div><div style="margin-bottom:2pt;padding-left:36pt;padding-right:36pt;text-align:center;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:5.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.365%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 12, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2.25pt;padding-right:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;Kirk Look</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 3.25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kirk Look, CA<br>Chief Financial Officer<br>Principal Accounting and Financial Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>8
<FILENAME>ex131ceocertification2023.htm
<DESCRIPTION>EX-13.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5919ef7ab93c4b8480764dc0c476098e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Matthew Coffey, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47;Matthew Coffey</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Dr. Matthew Coffey, PhD, MBA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;12, 2024 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>9
<FILENAME>ex132cfocertification2023.htm
<DESCRIPTION>EX-13.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i97f84951157344718136c5a1bf232632_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 13.2</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">18 U.S.C. &#167;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">In connection with the annual report of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) on Form 20-F for the fiscal year ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Kirk Look, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(1)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">(2)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The information contained in this Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">&#47;s&#47;Kirk Look</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">__________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Kirk Look, CA</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Chief Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">Principal Accounting and Financial Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">March&#160;12, 2024 </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%">A signed original of this written statement required by Section 906 has been provided to Oncolytics Biotech Inc. and will be retained by Oncolytics Biotech Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>10
<FILENAME>ex151-2023mda.htm
<DESCRIPTION>EX-15.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i5f09c29289f743c1ac7aabeda8bceade_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div><img alt="oncolyticslogotaglinebluea.jpg" src="oncolyticslogotaglinebluea.jpg" style="height:298px;margin-bottom:5pt;vertical-align:text-bottom;width:682px"></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION &#38; ANALYSIS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">2023 </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i5f09c29289f743c1ac7aabeda8bceade_4"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">March&#160;7, 2024 </font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">BASIS OF PRESENTATION </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management's Discussion and Analysis of Financial Condition and Results of Operations (&#8220;MD&#38;A&#8221;) should be read in conjunction with our audited consolidated financial statements and notes thereto as at and for the year ended December&#160;31, 2023, which have been prepared in accordance with International Financial Reporting Standards (&#34;IFRS&#34;) as issued by the International Accounting Standards Board (&#34;IASB&#34;). Our IFRS accounting policies are set in note 3 of our audited consolidated financial statements for the year ended December&#160;31, 2023. This MD&#38;A, along with our audited consolidated financial statements for the year ended December&#160;31, 2023, were authorized for issue in accordance with a resolution of the Board of Directors (the &#34;Board&#34;) on March&#160;7, 2024. Unless otherwise indicated, all references to &#34;$&#34; and &#34;dollars&#34; in this discussion and analysis mean thousands of Canadian dollars.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All references in this MD&#38;A to &#34;the Company&#34;, &#34;Oncolytics&#34;, &#34;we&#34;, &#34;us&#34;, or &#34;our&#34; and similar expressions refer to Oncolytics Biotech Inc. and the subsidiaries through which it conducts its business, unless otherwise indicated.  </font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_7"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion contains forward-looking statements, within the meaning of Section 21E of the United States </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Exchange Act of 1934, as amended</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as &#34;forward-looking statements&#34;). Forward-looking statements, including&#58; our belief as to the potential and mechanism of action of pelareorep, an intravenously delivered immunotherapeutic agent, as a cancer therapeutic&#59; our expectation that pelareorep&#8217;s ability to enhance innate adaptive immune responses within the TME will play an increasingly important role as our clinical development program advances&#59; our business strategy, goals, focus, and objectives for the development of pelareorep, including our immediate primary focus on advancing our programs in hormone receptor-positive &#47; human epidermal growth factor 2-negative metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies and our exploration of opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study&#59; our belief that our approach will increase opportunities for expanding our clinical program and business development and partnering opportunities, has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval&#59; our expectation that we will incur substantial losses and will not generate significant revenues until and unless pelareorep becomes commercially viable&#59; our belief that our combined cash resources are sufficient to fund our presently planned operations for at least the next 12 months from the balance sheet date&#59; our belief that recent data from our BRACELET-1 study further de-risk our path to registration, increasing the likelihood of clinical success and potentially allowing for the use of PFS as a primary endpoint&#59; our belief that we currently have sufficient drug product to support our clinical development program and our focus on expanding the scale of our production capabilities to ensure we will be registration ready&#59; our belief that continued positive results in the anal cancer cohort could potentially expand pelareorep's opportunity beyond breast and pancreatic cancers&#59; our expected pelareorep development plan for 2024, including our primary 2024 focus on commencing a registration-enabled study in pancreatic cancer and introduce a new GOBLET cohort investigating pelareorep in combination with mFOLFIRINOX, with or without Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#59; our plans to seek guidance on our breast cancer program protocol design from the FDA&#59; our intention to finalize our breast cancer program registration pathway and commencing the relevant clinical study&#59; our ongoing evaluation of all types of financing arrangements&#59; our continued management of our research and development plan&#59; our expectation that we will increase our spending in connection with the research and development of pelareorep over the next several years as we look to advance our breast and gastrointestinal cancer programs into later stages of clinical development&#59; the factors that affect our cash usage&#59; our approach to credit rate, interest rate, foreign exchange, and liquidity risk mitigation&#59; our anticipated use of the remaining proceeds raised as part of our 2023 public offering of common shares and warrants&#59; the effectiveness of our internal control systems&#59; and other statements that are not historical facts or which are related to anticipated developments in our business and technologies. In any forward-looking statement in which we express an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation, or belief will be achieved. Forward-looking statements involve known and unknown risks and uncertainties, which could cause our actual results to differ materially from those in the forward-looking statements. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such risks and uncertainties include, among others, the need for and availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trials, our ability to successfully commercialize pelareorep, uncertainties related to the research, development, and manufacturing of pelareorep, uncertainties related to competition, changes in technology, the regulatory process, and general changes to the economic environment.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the forward-looking statements made within this MD&#38;A, we have made numerous assumptions regarding, among other things&#58; our ability to recruit and retain employees, our continued ability to obtain financing to fund our clinical development plan, our ability to receive regulatory approval to commence enrollment in the clinical studies which are part of our clinical development plan, our ability to maintain our supply of pelareorep, and future expense levels being within our current expectations.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Forward-looking statements are based on assumptions, projections, estimates, and expectations of management at the time such forward-looking statements are made, and such assumptions, projections, estimates and&#47;or expectations could change or prove to be incorrect or inaccurate. Investors are cautioned against placing undue reliance on forward-looking statements. We do not undertake any obligation to update these forward-looking statements except as required by applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_10"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Company Overview</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pelareorep is a proprietary isolate of reovirus, a naturally occurring, non-pathogenic double-stranded RNA (dsRNA) virus commonly found in environmental waters. Pelareorep has shown promising results in changing the tumor microenvironment (TME). This creates a more favorable TME, which in turn makes the tumor more susceptible to various treatment combinations. These treatments include chemotherapies, checkpoint inhibitors, as well as other immuno-oncology approaches such as CAR T therapies, bispecific antibodies, and CDK4&#47;6 inhibitors. Pelareorep induces a new army of tumor-reactive T cells, helps these cells to infiltrate the tumor through an inflammatory process, and promotes the overexpression of PD-1&#47;PD-L1. By priming the immune system with pelareorep, we believe we can increase the proportion of patients who respond to immunotherapies and other cancer treatments, especially in cancers where immunotherapies have failed or provided limited benefit.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our clinical development program advances, we anticipate pelareorep's ability to enhance innate and adaptive immune responses within the TME will play an increasingly important role. This greatly increases opportunities for expanding our clinical program, business development, and partnering opportunities to address a broad range of cancers in combination with various other therapies. We believe this approach has the most promise for generating clinically impactful data and offers the most expeditious path to regulatory approval. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary focus is to advance our programs in hormone receptor-positive &#47; human epidermal growth factor 2-negative (HR+&#47;HER2-) metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. As at December&#160;31, 2023, we had cash and cash equivalents of $34,912. We believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months from the balance sheet date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i5f09c29289f743c1ac7aabeda8bceade_13"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Developments</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Clinical Trial Program</font></div><div style="margin-top:10pt;text-align:justify"><img alt="oncolyticspipelineye2.jpg" src="oncolyticspipelineye2.jpg" style="height:391px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gastrointestinal cancer program  </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with Roche and AIO-Studien-gGmbH&#58; GOBLET platform study</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our GOBLET platform study is a collaboration with Roche and AIO-Studien-gGmbH, a leading academic cooperative medical oncology group based in Germany. The study is investigating the use of pelareorep, in combination with Roche's anti-PD-L1 checkpoint inhibitor atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), in advanced or metastatic gastrointestinal tumors. The study is being conducted at 12 centers in Germany. The study's co-primary endpoints are safety and objective response rate or disease control rate at week 16. Key secondary and exploratory endpoints include additional efficacy assessments and evaluation of potential biomarkers. The study employs a two-stage design with Stage 1 comprising of patients with first-line advanced&#47;metastatic PDAC, first- and third-line metastatic colorectal (CRC), and advanced anal cancers. Any cohort meeting pre-specified efficacy criteria in Stage 1 may be advanced to Stage 2 and enroll additional patients. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we received clearance from the Paul Ehrlich Institute (PEI&#59; Germany's medical regulatory body) for full enrollment of the trial&#8217;s four cohorts. After presenting the interim GOBLET PDAC data in 2022, we obtained FDA Fast Track designation for the treatment of advanced&#47;metastatic PDAC using pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel. Fast Track designation is designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill an unmet medical need. A clinical program that receives Fast Track designation may benefit from more frequent meetings and communications with the FDA to discuss development plans and ensure the collection of appropriate data needed to support approval. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we completed enrollment in the advanced&#47;metastatic PDAC cohort&#47;Stage 1 and third-line metastatic CRC cohort&#47;Stage 1, and continued to monitor patients and patient outcomes. In our advanced anal cancer cohort, we continued enrolling patients and evaluating patient outcomes. We also presented data from our advanced&#47;metastatic PDAC, third-line metastatic CRC, and anal cancer cohorts at various conferences throughout the year.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">GOBLET's PDAC cohort survival data reported at ESMO</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Updated data from GOBLET's PDAC cohort was presented at the European Society for Medical Oncology (ESMO) Congress 2023 showing an objective response rate and interim survival data exceeding historical control trials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1-4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. A summary of the findings was as follows&#58; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tumor Responses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Objective Response Rate of 62% (54% confirmed by two or more consecutive scans)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Disease Control Rate of 85%</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Survival data</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median duration of response was 5.7 months</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median progression-free survival (PFS) was 7.2 months</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim 12-month survival rate was 46%</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Interim median overall survival (OS) was 10.6 months</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">T Cell populations analysis of the changes of T cell clones and tumor-infiltrating lymphocytes (TILs) showed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expansion of pre-existing and new T cell clones, including the expansion of TIL-specific clones</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A correlation between the expansion in the blood of TIL-specific clones and tumor response</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The treatment combination has been well tolerated with no safety concerns</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Most common grade 3 and 4 treatment-related adverse events were related to red and white blood cell counts (anemia, neutropenia and decreased neutrophil counts), but were transient </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Von Hoff D et al. N Engl J Med 2013&#59; 369&#58;1691-1703 DOI&#58; 10.1056&#47;NEJMoa1304369</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">O&#8217;Reilly et al. Eur J Cancer. 2020 June&#59; 132&#58; 112&#8211;121. DOI&#58;10.1016&#47;j.ejca.2020.03.005</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Karasic et al. JAMA Oncol. 2019 Jul 1&#59; 5(7)&#58;993-998. DOI&#58; 10.1001&#47;jamaoncol.2019.0684</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Tempero et al. Ann Oncol. 2021 May&#59; 32(5)&#58;600-608. DOI&#58; 10.1016&#47;j.annonc.2021.01.070</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">GOBLET's third-line metastatic CRC cohort efficacy data reported at ESMO</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This arm was the second consecutive arm within the GOBLET platform study to meet its respective success criteria and to be eligible to move to full enrollment. The interim results from the third-line metastatic CRC cohort included&#58; </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">6 of 15 enrolled patients had stable disease as their best response, including 4 patients demonstrating stable disease at week 16</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">These patients demonstrated a 40% disease control rate, a PFS of 2.8 months, a median OS of 8.0 months, and a 12-month survival rate of 33%</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The data suggested that pelareorep was taken by tumor cells and stimulated T cell expansion even in heavily pre-treated colorectal cancer patients</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">GOBLET's anal cancer cohort efficacy data reported at IMACC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interim data presented at the 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> International Multidisciplinary Anal Cancer Conference (IMACC) 2023 on patients with second-line or later, unresectable squamous cell carcinoma of the anal canal (SCCA) achieved the pre-defined success criteria. A summary of interim data and findings from the SCCA arm included&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tumor Response</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s&#58; Interim Objective Response Rate of 37.5% based on one patient with a complete response (ongoing at 12 months) and two patients with a partial response (one at week 8, one ongoing at week 16)</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Safety&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No safety signal was observed, consistent with previously reported cohorts from the GOBLET study</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recipient of PanCAN Therapeutic Accelerator Award </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its US$5 million Therapeutic Accelerator Award. This grant will enable us to continue our research on a clinical trial with pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX) chemotherapy with or without Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in pancreatic cancer patients.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Breast cancer program</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-development Agreement with Pfizer Inc. and Merck KGaA, Darmstadt, Germany&#58; BRACELET-1 study</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab (Bavencio</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), a human anti-PD-L1 antibody, for the treatment of HR+&#47;HER2- mBC. This phase 2 clinical trial was jointly funded by Oncolytics and Pfizer. The study, known as BRACELET-1, is a randomized open-label study that enrolled 48 patients into three cohorts&#58; paclitaxel alone, paclitaxel in combination with pelareorep, and paclitaxel in combination with both pelareorep and avelumab. PrECOG LLC, a leading cancer research network, managed the BRACELET-1 study. We completed patient enrollment in the second quarter of 2022.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The study is examining potential immune-related biomarkers, including investigating changes in T cell populations in response to treatment through T cell receptor sequencing. It is designed to assess efficacy in terms of overall response rate (ORR) at week 16 per RECIST 1.1. Key secondary and exploratory endpoints include the safety of the combination along with PFS and OS.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we announced data that showed pelareorep driving robust increases in PFS and confirmed ORR. We featured these interim data at an oral presentation at the 2023 American Society of Clinical Oncology Annual Meeting (ASCO) and a subsequent key opinion leader webinar. A summary of response and PFS data from all 48 patients enrolled in BRACELET-1 was shown below&#58;</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Paclitaxel (PTX) Monotherapy (n&#61;15)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PTX + Pelareorep (n&#61;16)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PTX + Pelareorep + Avelumab (n&#61;17)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ORR at Week 16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (20%)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 (31.3%)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (17.6%)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Confirmed ORR Over Course of Trial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 (13.3%)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 (37.5%)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 (17.6%)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">mPFS (months)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3<br>(95% CI&#58; 3.9, NR)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5<br>(95% CI&#58; 6.5, NR)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2<br>(95% CI&#58; 4.0, NR)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PFS Hazard Ratio vs. PTX Monotherapy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.29<br>(95% CI&#58; 0.09, 0.98)</font></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.31<br>(95% CI&#58; 0.47, 3.65)</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12-month PFS Rate (%)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0 <br>(95% CI&#58; -, -)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8<br>(95% CI&#58; 11.7, 92.4)</font></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0<br>(95% CI&#58; -, -)</font></td></tr><tr><td colspan="12" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1. Data from an October 2022 cut-off date. Three patients who withdrew consent prior to starting therapy and two patients who discontinued treatment after week 1 were considered non-responders and censored for PFS.<br>2. Data from a March 3, 2023 cut-off date. Numbers presented may change as they are derived from an unlocked database.<br>3. Data include all patients enrolled in trial. Response data presented by Clark et al. at ASCO 2023 included the 45 randomized patients and excluded participants in the three-patient safety run-in in cohort 3.  <br>CI&#58; Confidence interval&#59; NR&#58; Not reached&#59; mPFS&#58; median progression-free survival.</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional key biomarker and safety findings included&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Association between T cell expansion and efficacy measures&#58; A statistically significant increase in T cell fraction, a measure of T cell expansion, was observed in cohort 2 (paclitaxel + pelareorep) but not in cohort 3 (paclitaxel + pelareorep + avelumab) </font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Generally favorable and manageable safety profile&#58; Pelareorep displayed a manageable safety profile consistent with what has been observed in prior clinical trials that have collectively treated over 1,100 patients  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of this study provided important confirmatory data in a patient population similar to our IND.213 study, in which we observed a statistically significant near-doubling of median OS with pelareorep treatment in HR+&#47;HER2- mBC. These data further de-risk our path to registration, increasing the likelihood of clinical success and potentially allowing for the use of PFS as a primary endpoint. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the data presented at ASCO, we continued monitoring BRACELET-1 patients for survival to allow the assessment of median OS in all treatment groups, which we expect to occur in 2024. We also reviewed our BRACELET-1 data with key opinion leaders to investigate different trial designs as we move toward defining our breast cancer licensure-enabling study. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration with SOLTI&#58; AWARE-1 study</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, we received approval for our AWARE-1 study from the Spanish Agency for Medicine and Health Products. This clinical collaboration with SOLTI, an academic research group dedicated to breast cancer research, was a window of opportunity study in the neoadjuvant setting for breast cancer using pelareorep in combination with F. Hoffmann-La Roche (Roche)'s anti-PD-L1 checkpoint inhibitor, atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). Early-stage HR+&#47;HER2- breast cancer patients were enrolled in two cohorts&#59; those in cohort 1 received pelareorep and letrozole, while patients in cohort 2 received pelareorep, letrozole, and atezolizumab. We completed enrollment in 2022 and presented data at the Society for Immunotherapy of Cancer 38</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual Meeting (SITC 2023) and the 2023 San Antonio Breast Cancer Symposium (SABCS).</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">SITC 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Samples from cohort 2 were evaluated using a biomarker panel of 37 conjugated antibodies that bind to tumor antigens and immune cells. Novel imaging mass cytometry (IMC) technology was used to visualize cellular interactions down to the single cell level and showed an increase in PD-L1 positivity and cytotoxic T cells. This translational data will be incorporated into the registrational program for HR+&#47;HER2- metastatic breast cancer.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">2023 SABCS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Samples from both AWARE-1 cohorts were evaluated, showing pelareorep induced the expansion of existing TIL clones, which are presumed to be anti-tumor T cells and new clones. These data are consistent with results from posters recently presented at the SITC and ESMO meetings and affirm that pelareorep functions as an immunotherapeutic agent.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As previously reported, the majority of patients in both cohorts achieved an increase in CelTIL scores, which is correlated with improved patient outcomes, with 60% of patients in Cohort 2 achieving a 30% increase in CelTIL scores, the primary endpoint of the study</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tumor T cell fractions showed that TILs increased in both study cohorts (1.27 fold in Cohort 1, 2.74 fold in Cohort 2), with a greater increase in Cohort 2, which included pelareorep and the checkpoint inhibitor</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clonal expansion results showed that pelareorep induced an expansion of TILs in tumor and peripheral blood with&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In tumors, new clones were more prominent</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In peripheral blood, existing clones were more prominent</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In cohort 2 containing atezolizumab, there was greater overall expansion </font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_16"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Manufacturing and Process Development </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we currently have sufficient drug product supply to support our clinical development program, we are focused on expanding the scale of our production capabilities to ensure we will be registration-ready. During 2023, we executed a process development production run, scaled-up engineering production run, and related batch testing, where we also implemented new procedures to match evolving industry standards and environmental regulations. We then initiated a 200-liter scaled-up cGMP (Current Good Manufacturing Practice) production run near the end of the year. We also completed release testing of a new master cell bank and initiated potency assay validation using this cell bank. These activities ensure alignment with the clinical development timeline and anticipated registration program. We also incurred storage and distribution costs and completed a product fill to maintain our product supply. Ongoing bulk manufacturing and expanded filling capabilities are both part of the planned process validation. Continued process validation ensures that the manufactured product meets the required specifications and quality standards and will form part of our regulatory submission for product approval. </font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_19"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intellectual Property</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of 2023, we had been issued 150 patents, including 15 US and 7 Canadian patents, as well as issuances in other jurisdictions. We have an extensive patent portfolio covering the oncolytic reovirus and formulations that we use in our clinical trial program. These patent rights extend to at least the end of 2031. During 2023, we also actively filed additional patent applications covering innovations associated with the manufacturing scale-up process. </font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_25"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financing Activity</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public offering</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, pursuant to an underwritten public offering, we issued 7,667,050 units for gross proceeds of $23,262 (US$17,251) at a price of US$2.25 per unit. Each unit consisted of one common share and one common share purchase warrant (&#34;warrant&#34;), which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase one common share at an exercise price of US$2.81 up to 60 months from the date of issuance, subject to certain acceleration provisions (see note 9 of our audited consolidated financial statements). In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants. Each compensation warrant is exercisable into one common share at an exercise price of US$2.25 up to 60 months from the date of issuance. Net proceeds from the offering were $20,770. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. &#34;at-the-market&#34; (ATM) equity distribution agreement</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we sold 4,978,605 common shares for gross proceeds of $10,676 (US$7,904) at an average price of $2.14 (US$1.59). We received proceeds of $10,356 (US$7,667) after commissions of $320 (US$237). In total, we incurred share issue costs (including commissions) of $415.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_31"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash Resources </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ended 2023 with cash and cash equivalents of $34,912 (see </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Liquidity and Capital Resources&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_34"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Subsequent Events</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enrollment Expansion of GOBLET Anal Cancer Cohort</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the positive Stage 1 interim data presented at IMACC (see 2023 GOBLET platform study update above), we announced enrollment expansion for GOBLET's anal cancer cohort evaluating pelareorep in combination with atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in patients with second-line or later unresectable SCCA. As there is currently no established standard therapy for anal carcinoma patients who have failed first-line treatment, continued positive results in the anal cancer cohort could potentially expand pelareorep's opportunity beyond breast and pancreatic cancers.   </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initiation of New Pancreatic Cancer GOBLET Cohort</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As supported by the PanCAN Therapeutic Accelerator Award (see 2023 GOBLET platform study update above), we submitted an amendment to the PEI to initiate a fifth cohort of the GOBLET platform study. This cohort is designed to evaluate newly diagnosed PDAC patients treated with pelareorep in combination with mFOLFIRINOX with or without atezolizumab (Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">). The co-primary endpoints of the cohort are objective response rate and safety. A total of fifteen patients may be randomized to each arm in Stage 1 of the two stage design. Successful completion of Stage 1 will support expansion into Stage 2. The submission will be reviewed by the PEI for approval before patient enrollment can begin.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_37"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Expected Pelareorep Development For 2024</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, our clinical objectives will primarily revolve around our breast and pancreatic programs. We intend to commence a registration-enabled study on pancreatic cancer and introduce a new GOBLET cohort. The new GOBLET cohort will investigate pelareorep in combination with mFOLFIRINOX, with or without Tecentriq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in pancreatic cancer. In relation to our breast cancer program, we have plans to submit a request for a Type C meeting with the FDA to seek guidance on our protocol design. Upon receiving guidance from the FDA, our intention is to finalize our registration pathway and commence the relevant clinical study. Our 2024 manufacturing program includes completing scaled-up cGMP production runs and the related batch testing. We also expect to fill product and perform the associated analytical testing, as well as labeling, packaging, and distribution of pelareorep to our various clinical sites for ongoing and upcoming activities. In addition, we will initiate sourcing of a secondary fill&#47;finish supplier. Finally, our intellectual property program includes filings for additional patents and monitoring activities required to protect our patent portfolio.  </font></div><div><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_40"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Selected Annual Information</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts below are presented in thousands of Canadian dollars, except for share amounts.</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,752)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,835)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,304)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)(3)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.41)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.43)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.49)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38,820</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,334&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,880&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared per share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notes&#58;</font></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)  Included in consolidated net loss and loss per common share for 2023, 2022, and 2021 are non-cash changes in fair value of warrant derivative gain (loss) of $5,285, $(20), and $17, respectively. </font></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)  Included in consolidated net loss and loss per common share for 2023, 2022, and 2021 are share-based compensation expenses of $1,917, $2,378, and $3,826, respectively.</font></div></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)  Included in consolidated net loss and loss per common share for 2023, 2022, and 2021 are foreign exchange (losses) gains of $(475), $1,665, and $(136), respectively.</font></div></td></tr><tr><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)   We issued 13,096,046 common shares for net cash proceeds of $31.8 million in 2023 (2022 - 6,284,125 common shares for net cash proceeds of $12.6 million&#59; 2021 - 8,876,809 common shares for net cash proceeds of $33.4 million).  </font></div></td></tr><tr><td colspan="18" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)  We have not declared or paid any dividends since incorporation.</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_43"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Components of Results of Operations</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses consist primarily of costs incurred to conduct research and development on pelareorep. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial expenses include the preparation and development of our breast and gastrointestinal cancer programs. Clinical trial expenses include regulatory and consulting activities, contract research organization expenses, data management expenses, and other costs associated with our clinical trial program.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing &#38; related process development (&#8220;M&#38;P&#8221;) expenses include product manufacturing and process development activities. Product manufacturing expenses include third-party direct manufacturing costs, quality control testing, filling, labeling, packaging, and storage costs. Process development expenses include costs associated with studies examining components of our manufacturing and analytical processes and costs associated with planned process validation and related conformity testing.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property expenses include legal and filing fees associated with our patent portfolio.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Translational science expenses are intended to expand our intellectual property related to pelareorep and identify potential licensing opportunities arising from our technology base.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Personnel-related, share-based compensation, and other expenses are employee-related expenses. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses consist primarily of public company-related expenses, office expenses, share-based compensation expense, and depreciation. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public company-related expenses include investor, media, and public rela</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tions, marketing communications, </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business development, financial advisory activities, legal and accounting fees, corporate insurance, director fees and transfer agent, and other fees relating to our U.S. and Canadian stock listings.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Office expenses include compensation costs (excluding share-based compensation expense), rent related to short-term leases, and other office-related costs. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants issued with an exercise price denominated in a foreign currency are reported as a liability until exercised or expired. These warrants are adjusted to fair value at each exercise date and reporting period. Any change in fair value is recorded in the consolidated statements of loss and comprehensive loss. Gains and losses resulting from the revaluation of the warrant derivative are non-cash and do not impact our cash flows.</font></div><div><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_46"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Results of Operations</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise indicated, all amounts below are presented in thousands of Canadian dollars, except for share amounts.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the year ended December&#160;31, 2023, was $27,752 compared to $24,835 and $26,304 for the years ended December&#160;31, 2022, and December&#160;31, 2021, respectively. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses increased by $2,277 for the year ended December&#160;31, 2023, compared to 2022, and increased by $2,512 for the year ended December&#160;31, 2022, compared to 2021. The following table summarizes our R&#38;D expenses for the years ended December&#160;31, 2023, 2022, and 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 10pt 0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 to 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 to 2022</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,675</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,295)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,765&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M&#38;P expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,789</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">397</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(74)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(264)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,324</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,305</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,709</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,432&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our R&#38;D expenses for the year ended </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased M&#38;P expenses associated with completing a process development and a scaled-up engineering production run, along with the related batch testing. We also initiated a scaled-up cGMP production run. As part of the production runs, we also implemented new procedures to match evolving industry standards and environmental regulations as we focus on advancing toward registration readiness&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses due to changes in salary levels and the strengthening of the U.S. dollar.</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased clinical trial expenses due to lower BRACELET-1, GOBLET, and AWARE-1 study costs, as well as reduced clinical and safety data management. The BRACELET-1 trial was in the patient follow-up phase throughout 2023, whereas patients were enrolled and treated during the same period in the previous year. Enrollment and treatment for GOBLET's advanced&#47;metastatic PDAC and third-line metastatic CRC cohorts largely occurred in 2022. We incurred AWARE-1 data analysis costs during 2022 for various conference presentations&#59;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased translational science expenses as we focus on biomarker activities related to our ongoing clinical trials. In 2022, we incurred costs related to our bispecific antibodies and CAR T studies.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our R&#38;D expenses for the year ended December&#160;31, 2022, was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased clinical trial expenses as a result of an increase in our clinical study costs due to higher GOBLET set-up, patient enrollment, and sample analysis costs and increased clinical and safety data management consulting costs, partly offset by lower AWARE-1 patient activities as study closure began in 2022&#59;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased personnel-related expenses due to higher salaries and annual incentive awards, the strengthening of the U.S. dollar, and additional headcount to support our R&#38;D program&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased M&#38;P expenses associated with higher production process and analytical activities as we focused on ensuring our active drug substance and finished drug product meet changing regulatory specifications and standards. The increase was partly offset by lower routine testing activities. </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation expense as a result of a lower number of options granted in 2022 and the impact of the vesting of options granted in prior periods&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased translational science expenses as our bispecific antibodies and CAR T studies ongoing throughout 2021 were largely completed by the end of the first quarter of 2022.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses increased by $4,590 for the year ended December&#160;31, 2023, compared to 2022, and decreased by $1,823 for the year ended December&#160;31, 2022, compared to 2021. The following table summarizes our G&#38;A expenses for the years ended December&#160;31, 2023, 2022, and 2021&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 to 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 to 2022</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,278</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,488&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,371)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,789</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(732)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">322</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,082</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,315&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,590&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,823)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our G&#38;A expenses for the year ended December&#160;31, 2023, was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased public company-related expenses due to higher investor relations activities along with media and public relations activities associated with our BRACELET data presented at ASCO. In addition, a portion of the 2023 public offering transaction costs allocated to warrants were treated as public company-related expenses (see note 10 of our audited consolidated financial statements)&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increased office expenses as a result of changes in personnel costs and a change in salary level. </font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above increases were partly offset by decreased share-based compensation expense reflecting the impact of changes in personnel, including a recovery due to the forfeiture of unvested options. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our G&#38;A expenses for the year ended December&#160;31, 2022, was primarily due to the following&#58;</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased public company-related expenses as a result of lower investor relations activities, partly offset by increased travel expenses with the easing of COVID-19-related restrictions and higher board of directors advisory costs&#59; and</font></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreased share-based compensation expense caused by a lower number of options granted in 2022 and the impact of the vesting of options and share awards granted in prior periods.</font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased office expenses partly offset the above decreases as a result of higher salaries and annual incentive awards, and additional headcount to support our administrative activities. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, we recognized a gain of $5,285 on the change in fair value of our warrant derivative compared to a loss and gain of $20 and $17 for the years ended December&#160;31, 2022, and December&#160;31, 2021, respectively. The gain recognized in 2023 primarily related to the 7,667,050 warrants issued as part of our 2023 financing, where the underlying </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market price of these warrants changed from a weighted average price of US$2.28 at issuance to US$1.35 at December&#160;31, 2023. The number of outstanding warrants was 7,731,085, 64,035, and 64,035 as at December&#160;31, 2023, December&#160;31, 2022, and December&#160;31, 2021, respectively.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Exchange </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, our foreign exchange loss was $475 compared to a gain and loss of $1,665 and $136 for the years ended December 31, 2022, and December&#160;31, 2021, respectively. The foreign exchange gains&#47;losses incurred in all three years mainly reflected the fluctuation of the U.S. dollar versus the Canadian dollar throughout the respective periods, primarily on our U.S. dollar-denominated cash and cash equivalents and marketable securities balances. </font></div><div><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_49"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Quarterly Results</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historical patterns of expenditures cannot be taken as an indication of future expenditures. Our current and future expenditures are subject to numerous uncertainties, including the duration, timing, and costs of R&#38;D activities ongoing during each period and the availability of funding from investors and prospective partners. As a result, the amount and timing of expenditures and, therefore, liquidity and capital resources may vary substantially from period to period.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dec.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sept.</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,949)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,925)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,441)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,437)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,554)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,407)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,095)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,779)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted loss per common share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)(2)</font></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.10)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,820</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,089&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,966&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,328&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,334&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,959&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,239&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,446&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and marketable securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,912&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,981&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,351&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,670&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,138&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,362&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,689&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,483&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash dividends declared</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</font></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share are share-based compensation expenses of $759, $599, $242, $317, $749, $500, $490, and $639, respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share are foreign exchange (losses) gains of $(392), </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$310</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, $(394), $1, $(274), $1,526, $888, and $(474), respectively.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Included in consolidated net loss and loss per common share is a gain resulting from a change in fair value of warrant derivative of $4,846.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We issued 13,096,046 common shares for net cash proceeds of 31.8 million in 2023 (2022 - 6,284,125 common shares for net cash proceeds of $12.6 million).  </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We have not declared or paid any dividends since incorporation.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September 30, 2023, we completed an engineering production run, resulting in higher manufacturing and related process development expenses. We also incurred higher public-company related expenses associated with higher investor relations activities and the portion of the 2023 public offering transaction costs allocated to warrants (see note 10 of our audited consolidated financial statements). During the quarters ended December 31, 2023, and 2022, we incurred expenses related to annual short-term incentive awards.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i5f09c29289f743c1ac7aabeda8bceade_52"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth Quarter</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statement of loss for the three months ended December&#160;31, 2023, and 2022, was as follows&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expenses</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Research and development</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,658</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,841&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before the following</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(8,849)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,508)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,846</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Foreign exchange loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(392)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(274)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Interest income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">489</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,906)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,497)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Income tax expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(43)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(57)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,949)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,554)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Other comprehensive loss - translation adjustment</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(111)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total comprehensive loss</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,060)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,615)</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic and diluted loss per common share</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.05)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.14)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average number of shares (basic and diluted)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73,731,359</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,512,765&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_55"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fourth Quarter Review of Operations</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss for the three months ended December&#160;31, 2023, was $3,949 compared to $8,554 for the three months ended December&#160;31, 2022. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses (&#34;R&#38;D&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our R&#38;D expenses decreased by $183 from $4,841 for the three months ended December&#160;31, 2022, to $4,658 for the three months ended December&#160;31, 2023. The following table summarizes our R&#38;D expenses for the three months ended December&#160;31, 2023, and 2022&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">734</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M&#38;P expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">933</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,253</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,431&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">570</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">98</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,658</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,841&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our R&#38;D expenses for the three months ended December&#160;31, 2023, was primarily related to decreased clinical trial expenses due to lower GOBLET and BRACELET-1 study costs, as well as reduced clinical and safety data management. We recorded an adjustment to the GOBLET trial costs in the fourth quarter of 2022 related to non-patient expenses. The BRACELET-1 trial incurred lower patient sample analysis and report writing expenses. The increase was partly offset by increased M&#38;P expenses related to the preparation and start of a cGMP production run. </font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses (&#34;G&#38;A&#34;)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our G&#38;A expenses increased by $524 from $3,667 for the three months ended December&#160;31, 2022, to $4,191 for the three months ended December&#160;31, 2023. The following table summarizes our G&#38;A expenses for the three months ended December&#160;31, 2023, and 2022&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,410</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,003&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">407&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,485</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,276&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">189</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,191</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,667&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our G&#38;A expenses for the three months ended December&#160;31, 2023, was primarily due to increased public company-related expenses associated with higher investor relations and marketing communications activities and higher office expenses as a result of changes in personnel costs. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Warrant Derivative</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended December&#160;31, 2023, we recorded a gain of $4,846 on the change in fair value of our warrant derivative compared to a loss of $29 for the three months ended December&#160;31, 2022. The gain recognized in 2023 primarily related to the 7,667,050 warrants issued as part of our 2023 financing, where the underlying market price of these warrants changed from US$2.20 at September 30, 2023 to US$1.35 at December&#160;31, 2023.</font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_58"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_67"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical-stage biopharmaceutical company, we have not been profitable since our inception. We expect to continue to incur substantial losses as we continue our research and development efforts. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. For the year ended December&#160;31, 2023, we were able to raise funds through our U.S. ATM and 2023 public offering.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no assurances that we will be able to raise additional funds through the sale of our common shares. Consequently, we will continue to evaluate all types of financing arrangements. On June 16, 2022, we renewed our short form base shelf prospectus (the &#34;Base Shelf&#34;) that qualifies for distribution of up to $150.0&#160;million of common shares, subscription receipts, warrants, or units (the &#34;Securities&#34;) in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides us with additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received as a result of using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreements and 2023 public offering (see note 10 of our audited consolidated financial statements). We use these equity arrangements to assist us in achieving our capital objectives. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. We expect to continue to access our equity arrangement to help support our operations.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2023, and 2022, we had cash and cash equivalents and marketable securities as follows&#58; </font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,912</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,666&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,472&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in our cash and cash equivalents between December&#160;31, 2022, and December&#160;31, 2023, reflected the cash used in our operating activities of $28.4 million, cash provided by our investing activities of $20.2 million, and cash provided by our financing activities of $32.0 million for the year ended December&#160;31, 2023. The acquisition of marketable securities was based on a comparative analysis of the anticipated yield from an investment in marketable securities versus the interest earnings from our cash deposits in interest-bearing accounts. We have no debt other than accounts payable and accrued liabilities and lease liabilities. We have commitments and contingent obligations relating to the completion of our research and development of pelareorep.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the periods indicated&#58;</font></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 to 2023</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 to 2022</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash used in operating activities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(28,448)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,355)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,433)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,093)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(922)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by investing activities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">20,222</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,403)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(286)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,625&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,117)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by financing activities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,994</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,205&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,015&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,789&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,810)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of foreign exchange on cash and cash equivalents</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(522)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,957&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(254)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,479)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,211&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) in cash and cash equivalents</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23,246</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29,596)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,042&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,842&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,638)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash used in operating activities</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change between 2023, 2022, and 2021 reflected higher net operating activities and non-cash working capital changes. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2023, consisted of a net loss of $27,752 less non-cash adjustments of $2,461 offset by non-cash working capital changes of $1,765. Non-cash items primarily included change in fair value of warrant derivative and share-based compensation expense. Non-cash working capital changes mainly reflected decreased prepaid expenses, decreased other receivables with cash collected from Pfizer, and increased liabilities with unapplied funding received from PanCAN.   </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2022, included a net loss of $24,835 less non-cash adjustments of $1,089 offset by non-cash working capital changes of $391. Non-cash items primarily included share-based compensation expense and unrealized foreign exchange gains. Non-cash working capital changes were mainly due to additions to accounts payable and accrued liabilities and prepaid expenses.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2021, comprised a net loss of $26,304 less non-cash adjustments of $4,779 and non-working capital changes of $908. Non-cash items mainly consisted of share-based compensation expense and unrealized foreign exchange losses. An increase in other receivables primarily caused the non-cash working capital changes.    </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash used in investing activities </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change between 2023 and 2022 was mainly due to the maturities of marketable securities. The change between 2022 and 2021 was principally related to acquiring marketable securities.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash provided by financing activities</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, pursuant to an underwritten public offering, we issued 7,667,050 units for gross proceeds of $23,262 (US$17,251) at a price of US$2.25 per unit. We also sold 4,978,605 common shares for gross proceeds of $10,676 (US$7,904) at an average price of $2.14 (US$1.59) through our U.S. ATM. During the year ended December&#160;31, 2022, we sold 6,235,232 common shares for gross proceeds of $13,338 (US$10,192) at an average price of $2.14 (US$1.63) through our U.S. ATM. During the year ended December&#160;31, 2021, we sold 8,401,029 common shares for gross proceeds of $34,168 (US$27,158) at an average price of $4.07 (US$3.23) through our U.S. ATM.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We desire to maintain adequate cash reserves to support our planned activities, including our clinical trial program, product manufacturing, administrative costs, and intellectual property protection. To do so, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity. Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to manage our research and development plan to ensure optimal use of our existing resources as we expect to fund our expenditure requirements and commitments with existing working capital. Additional activities continue to be subject to adequate resources, and we believe we will have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months from the balance sheet date. We expect to increase our spending in connection with the research and development of pelareorep over the next several years as we look to advance our breast and gastrointestinal cancer programs into later stages of clinical development. A product candidate in later stages of clinical development generally has higher costs than those in earlier stages, primarily due to the increased size and duration of later-stage clinical trials. Additionally, we expect to continue to incur additional costs associated with operating as a public company. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that will affect our anticipated cash usage for which additional funding might be required include, but are not limited to, expansion of our clinical trial program, the timing of patient enrollment in our clinical trials, the actual costs incurred to support each clinical trial, the number of treatments each patient will receive, the timing of R&#38;D activity with our clinical trial research collaborations, the number, timing and costs of manufacturing runs required to conclude the validation process and supply product to our clinical trial program, the level of collaborative activity undertaken, and other factors described in the &#34;Risk Factors&#34; section of our most recent annual report on Form 20-F. Conducting clinical trials necessary to obtain regulatory approval is costly and time-consuming. We may never succeed in achieving marketing approval. The probability of successful commercialization of our drug candidates may be affected by numerous factors, including clinical data obtained in future trials, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2023.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_70"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as at December&#160;31, 2023&#58;</font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Less than 1 year</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2 -3 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4 - 5 years</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">More than <br>5 years</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,572&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,572&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,085&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,774&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">We are also committed to office lease payments of approximately $1,098 over 5.3 years for one of our subsidiaries which have not yet commenced.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are committed to payments of approximately $12,686 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next three years. We are able to cancel most of these agreements with notice. The ultimate amount and timing of these payments are subject to changes in our research and development plan.  </font></div><div><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_73"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As at December&#160;31, 2023, we had not entered into any off-balance sheet arrangements.</font></div><div><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_76"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Transactions with Related Parties</font></div><div style="margin-bottom:5pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021, we did not enter into any related party transactions other than compensation paid to key management personnel. Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel comprise the Board of Directors, Executive Officers, President, and Vice Presidents.</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,870</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,496</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,685</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i5f09c29289f743c1ac7aabeda8bceade_79"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Critical Accounting Estimates</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing our audited consolidated financial statements, we use IFRS as issued by the IASB. IFRS requires us to make certain estimates, judgements, and assumptions that we believe are reasonable based upon the information available in applying our accounting policies. These estimates and assumptions affect the reported amounts and disclosures in our audited consolidated financial statements and accompanying notes. Actual results could differ from those estimates, and such differences could be material. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Judgment, estimates and assumptions made by management that are significant to the financial statements are described below and in note 4 of our audited consolidated financial statements for the year ended December&#160;31, 2023.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement with Adlai, which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research&#47;manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing our audited consolidated financial statements, we estimate the expense to recognize based on services that the contract research&#47;manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.    </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of share-based compensation and compensation warrants requires determining the most appropriate valuation model which is dependent on the terms and conditions of the grant. We have chosen to use the Black-Scholes valuation model (&#34;Black-Scholes&#34; or the &#34;Model&#34;) to calculate the fair value of our stock options and compensation warrants. Black-Scholes is widely used and accepted by other publicly traded companies. Therefore, we have concluded that Black-Scholes is the appropriate option pricing model to use for our stock options and compensation warrants at this time. This estimate also requires determining the most appropriate inputs to the model, including the expected life, share price volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for stock options and compensation warrants granted are disclosed in note 11 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we recorded non-cash share-based compensation expense for the years ended December&#160;31, 2023, 2022, and 2021, of $1,917, $2,378, and $3,826, respectively. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. We have chosen to use Black-Scholes to calculate the fair value of our warrant derivative. This estimate also requires determining the most appropriate inputs to the model including, the expected life, share price volatility, and dividend yield, and making assumptions about them, as discussed in note 9 of our audited consolidated financial statements. Consequently, in complying with IFRS and selecting what we believe are the most appropriate assumptions under the circumstances, we recorded a non-cash change in fair value of warrant derivative for the years ended December&#160;31, 2023, 2022, and 2021, of $5,285, $(20), and $17, respectively. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the relevant factors related to the primary economic environment in which our entities operate to determine the functional currency. Where the assessment of primary indicators are mixed, we assess the secondary indicators, including the relationship between the foreign operations and reporting entity.</font></div><div style="margin-bottom:8pt;text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_82"></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting Policies </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material accounting policies are described in note 3 of our audited consolidated financial statements for the year ended December&#160;31, 2023. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on our audited consolidated financial statements.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates, changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on our audited consolidated financial statements.   </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</font><font style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on our audited consolidated financial statements. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification of Liabilities as Current or Non-Current</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 Presentation of Financial Statements, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments are effective for annual periods beginning on or after January 1, 2024, and are to be applied retrospectively. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_85"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Instruments and Other Instruments</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, other liabilities, and warrant derivative.&#160;As at December&#160;31, 2023, and December&#160;31, 2022, the carrying </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amount of our cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at December 31, 2023, the fair value of our warrant derivative was $200 (December&#160;31, 2022 - $79). We use the Black-Scholes valuation model to estimate fair value. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at December&#160;31, 2023, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents. </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the year ended December&#160;31, 2023, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities were denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss for the year ended December&#160;31, 2023, by approximately $140.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies as at December&#160;31, 2023, are as follows&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,294&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,476)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,818&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and the Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss for the year ended December&#160;31, 2022, by approximately $170. The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss for the year ended December&#160;31, 2022, by approximately $22.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies as at December&#160;31, 2022, were as follows&#58;</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,115&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,093)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,657&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities. We manage liquidity risk through the management of our capital structure as outlined in the notes to our audited financial statements.  Accounts payable and accrued liabilities are all due within the current operating period. See note 8 to our audited financial statements for a maturity analysis of our lease liabilities. </font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_799"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Proceeds </font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023 Public Offering and Use of Proceeds</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides an update on the anticipated use of proceeds raised as part of our 2023 public offering of common shares and warrants along with amounts actually expended. As at December&#160;31, 2023, the following expenditures have been incurred (in thousands of U.S. dollars)&#58; </font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.452%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount to Spend</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Spent to Date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining to Spend</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pancreatic Cancer Program</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,500&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(229)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,271&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Breast Cancer Program</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and Administrative Expenses</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,540&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,650&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,200&#160;</font></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ATM Facility</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. Our ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65.0 million over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2023, we sold 4,978,605 common shares for gross proceeds of US$7,904. Approximately $68.1 million (US$51.5 million) remains unused under the ATM equity distribution agreement.</font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_88"></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other MD&#38;A Requirements</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have 75,419,768 common shares outstanding at March&#160;7, 2024. If all of our options and restricted share awards (7,428,433) and warrants and compensation warrants (8,267,778) were exercised or were to vest, we would have 91,115,979 common shares outstanding.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most recent annual report on Form 20-F is available on SEDAR+ at www.sedarplus.ca and EDGAR at www.sec.gov&#47;edgar.</font></div><div style="text-align:justify"><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_91"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evaluation of Disclosure Controls and Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our chief executive and financial officers reviewed and evaluated our disclosure controls and procedures. Based on that evaluation, they have concluded that our disclosure controls and procedures are effective in providing timely material information relating to the Company.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management's Annual Report on Internal Control Over Financial Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and has designed such internal control over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation and fair presentation of financial statements for external purposes in accordance with International Financial Reporting Standards.   </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management, including the Chief Executive Officer and Chief Financial Officer, does not expect that our internal controls and procedures over financial reporting will prevent all errors and all fraud. A control system can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving our stated goals under all potential future conditions. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that the controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the design and operation of our internal control over financial reporting as of December&#160;31, 2023, and has concluded that such internal control over financial reporting is effective as of December&#160;31, 2023. There are no material weaknesses that have been identified by management in this regard. This assessment was based on criteria for effective internal control over financial reporting described in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework).  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Internal Controls over Financial Reporting</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during the year ended December&#160;31, 2023, that have materially affected or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div><font><br></font></div><div id="i5f09c29289f743c1ac7aabeda8bceade_94"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Risks and Uncertainties</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company. Prospects for biotechnology companies in the research and development stage should generally be regarded as speculative. It is not possible to predict, based on studies in animals, or early studies in humans, whether a new therapeutic will ultimately prove to be safe and effective in humans, or whether necessary and sufficient data can be developed through the clinical trial process to support a successful product application and approval. If a product is approved for sale, product manufacturing at a commercial scale and significant sales to end users at a commercially reasonable price may not be successful. There can be no assurance that we will generate adequate funds to continue development, or will ever achieve significant revenues or profitable operations. Many factors (e.g., competition, patent protection, appropriate regulatory approvals) can influence the revenue and product profitability potential. In developing a pharmaceutical product, we rely on our employees, contractors, consultants and collaborators, and other third-party relationships, including the ability to obtain appropriate product liability insurance. There can be no assurance that this reliance and these relationships will continue as required. In addition to developmental and operational considerations, market prices for securities of biotechnology companies generally are volatile, and may or may not move in a manner consistent with the progress we have made or are making.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in our common shares involves a high degree of risk. An investor should carefully consider, among other matters, the risk factors in addition to the other information in our annual report on Form 20-F filed with the U.S. Securities and Exchange Commission (the &#34;SEC&#34;), as well as our other public filings with the Canadian securities regulatory authorities and the SEC, when evaluating our business because these risk factors may have a significant impact on our business, financial condition, operating results or cash flow. If any of the described material risks in our annual report or in subsequent reports we file with the regulatory authorities actually occur, they may materially harm our business, financial condition, operating results or cash flow. Additional risks and uncertainties that we have not yet identified or that we presently consider to be immaterial may also materially harm our business, financial condition, operating results, or cash flow. For information on risks and uncertainties, please refer to the &#34;Risk Factors&#34; section of our most recent annual report on Form 20-F and our other public filings available on www.sedarplus.ca and www.sec.gov&#47;edgar.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>11
<FILENAME>ex152ey2023consent.htm
<DESCRIPTION>EX-15.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7d000af1fcb04d87b41962181023433c_1"></div><div style="min-height:42.7pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 15.2</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:118%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Form S-8 nos. 333-171625 and 333-205708</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">Form F-10 no. 333-265510</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of Oncolytics Biotech Inc. (the &#8220;Company&#8221;) of our reports dated March 7, 2024, with respect to the consolidated statements of financial position as at December 31, 2023 and December 31, 2022 and the consolidated statements of loss and comprehensive loss, changes in equity and cash flows for each of the years in the three-year period ended December 31, 2023, and the effectiveness of internal control over financial reporting of the Company as of December 31, 2023, included in this Annual Report on Form 20-F.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.295%"><tr><td style="width:1.0%"></td><td style="width:57.949%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Calgary, Alberta</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47;Ernst &#38; Young LLP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March 12, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Chartered Professional Accountants</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:324pt;text-indent:36pt"><font><br></font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-16.1
<SEQUENCE>12
<FILENAME>ex161-corptradingpolicyrev.htm
<DESCRIPTION>EX-16.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i902bf46ad5e94e88b8e4bb573657b0ce_1"></div><div style="min-height:36.72pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 16.1</font></div></div><div style="margin-bottom:11pt;padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:11pt;padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:11pt;padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:11pt;padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:11pt;padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:11pt;padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:23.8pt;padding-left:1.75pt;padding-right:1.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:9.35pt;padding-right:51.95pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:26pt;font-weight:700;line-height:125%">ONCOLYTICS BIOTECH INC. </font></div><div style="padding-left:90.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:26pt;font-weight:700;line-height:125%;text-decoration:underline">Corporate Trading Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:26pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:3.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="padding-left:2.35pt;padding-right:2.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:125%"> </font></div><div style="padding-left:2.35pt;padding-right:2.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:125%"> </font></div><div style="padding-left:2.35pt;padding-right:2.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:125%"> </font></div><div style="padding-left:2.35pt;padding-right:2.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:125%"> </font></div><div style="padding-left:2.35pt;padding-right:2.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:272.65pt;padding-left:2.35pt;padding-right:2.35pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:125%"> </font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reviewed and approved by the Board March 5, 2020</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36.72pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 16.1</font></div></div><div style="margin-bottom:0.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> &#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160; </font></div><div style="margin-bottom:21.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:11pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ONCOLYTICS BIOTECH INC. </font></div><div style="margin-bottom:11pt;padding-left:0.47pt;padding-right:0.47pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">CORPORATE TRADING POLICY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:17pt;padding-left:0.5pt;padding-right:0.5pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;text-decoration:underline">Table of Contents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="margin-bottom:11.65pt;padding-right:0.05pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.993%"><tr><td style="width:1.0%"></td><td style="width:96.813%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.887%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:9pt">CONFIDENTIAL INFORMATION AND TRADING POLICY ...................................</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;(A) WHO IS SUBJECT TO THIS POLICY&#63; .................................................................................................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;(B) GENERAL INFORMATION ON INSIDER TRADING .........................................................................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">1</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;(C) TIPPING ....................................................................................................................................................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;(D) REPORTING ...........................................................................................................&#8230;............................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">2.   CONFIDENTIALITY OF INSIDER INFORMATION ..................................................</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;(A) MAINTAINING CONFIDENTIALITY .................................................................................................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">3</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">3.   TRADING ............................................................................................................................</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;(A) GENERAL RULE ....................................................................................................................................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;(B) TRADING POLICY ................................................................................................................................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">4</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;(C) CONSULTATIONS REGARDING PURCHASE OR SALE OF SECURITIES OF THE CORPORATION ......</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">5</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">4.   SANCTIONS FOR VIOLATION ......................................................................................</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;(A) LEGAL SANCTIONS .............................................................................................................................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160;&#160;(B) CORPORATE SANCTIONS ...................................................................................................................................</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:125%">6</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">5.   NOTIFICATION .................................................................................................................</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:125%">6</font></td></tr></table></div><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:justify;text-indent:-0.5pt"><font><br></font></div><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:justify;text-indent:-0.5pt"><font><br></font></div><div style="margin-bottom:237.8pt;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:166%"> </font></div><div style="height:66.96pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Reviewed and approved by the Board March 5, 2020</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><div id="i902bf46ad5e94e88b8e4bb573657b0ce_4"></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 16.1</font></div></div><div style="margin-bottom:11pt;padding-left:0.8pt;padding-right:0.8pt;text-align:center;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">ONCOLYTICS BIOTECH INC. </font></div><div style="margin-bottom:11.65pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:27.38pt">Confidential Information and Trading Policy </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">Who is subject to this Policy&#63; </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">This Policy applies to all of the directors, officers, employees and consultants of Oncolytics Biotech Inc. (the &#34;Corporation&#34;).  In this Policy, all of such individuals are referred to as &#34;Restricted Persons&#34;.  </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Restricted Persons are the persons most likely to have knowledge of undisclosed material facts or material changes with respect to the Corporation and, accordingly, this Policy is addressed to such persons. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">From time to time other persons may be designated by the Chief Executive Officer or Chief </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Financial Officer of the Corporation as subject to this Policy and upon such designation, such </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">persons shall be included as Restricted Persons for the period of time designated by the Chief Executive Officer or Chief Financial Officer, as the case may be. </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">General Information on Insider Trading </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">Generally, the philosophy behind Canadian insider trading legislation is&#58; </font></div><div style="margin-bottom:10.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:31.98pt">trading should be free and open in order to build confidence in the markets&#59; </font></div><div style="margin-bottom:10.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:31.98pt">there should be equal access to markets&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:31.98pt">there should be continual and timely disclosure of accurate information. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Securities legislation prohibits any person in a &#34;special relationship&#34; with the Corporation from either&#58; </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:31.98pt">purchasing or selling the Corporation's securities with the knowledge of a material fact or material change concerning the Corporation that has not been generally disclosed&#59; or </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.98pt">informing, other than when necessary in the course of business, another person or corporation of a material fact or material change concerning the Corporation before the material fact or material change has been generally disclosed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%"> </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">This prohibition applies to, among others, the following persons who are deemed to have a &#34;special relationship&#34; with the Corporation&#58; </font></div><div style="margin-bottom:10.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:31.98pt">a person who is a director, officer or employee of the Corporation&#59; </font></div><div style="margin-bottom:42.6pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%;padding-left:31.98pt">any other &#34;insider&#34;, e.g., a 10% shareholder&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:121%"> </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">Reviewed and approved by the Board  March 5, 2020&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">Page 1 of 6</font></div><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 16.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:125%"> &#160;&#160;&#160;&#160; </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">a person or company that has engaged, is engaging or proposes to engage in any business or professional activity with the Corporation, e.g., lawyer, consultant, banker, as well the directors and officers of any such company </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">a person or company proposing a take-over bid or business combination and such company's directors and officers&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">any &#34;tippee&#34;, i.e., a person who has been &#34;tipped&#34;. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The term &#34;insider&#34; is defined in legislation broadly to include&#58; </font></div><div style="margin-bottom:10.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">every director and &#34;senior officer&#34; of the Corporation&#59; </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">every director and senior officer of an issuer that is itself an insider or subsidiary of the Corporation&#59; </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">any person or company that, directly or indirectly, beneficially owns or exercises control over more than 10 percent of the voting rights attaching to voting securities of the Corporation&#59; and </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">the Corporation itself, where it has purchased, redeemed, or otherwise acquired any of its securities, for so long as it holds any such securities. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The term &#34;securities&#34; includes common shares in the Corporation. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Information is &#34;generally disclosed&#34; if there has been a press release distributed to an appropriate wire service, however, even in that circumstance, it may be necessary to wait a reasonable period of time to allow appropriate dissemination of the information.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:121%"> </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">In light of this prohibition, it is important to understand what constitutes a material fact or material change.  The securities legislation defines </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:121%">material change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> as&#58; </font></div><div style="padding-left:73.7pt;padding-right:70.75pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">when used in relation to the affairs of an issuer, a change in the business, operations or capital of the issuer that would reasonably be expected to have a significant effect on the market price or value of the securities of the issuer and includes a decision to implement the change made by the board of directors of the issuer. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Similarly, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:121%">material fact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> is defined as&#58; </font></div><div style="padding-left:73.7pt;padding-right:70.85pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">when used in relation to securities of the issuer, a fact that significantly affects or would reasonably be expected to have a significant effect on the market price or value of the securities. </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">Reviewed and approved by the Board  March 5, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;Page 2 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 16.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">The determination of when a material change has occurred or of what constitutes a material fact may not always be clear.   </font></div><div style="margin-bottom:11.65pt;margin-top:10pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If the Corporation has filed a press release, the Corporation may conclude that such matters described in the press release are not material changes or material facts regarding the Corporation and thus may not file a material change report. </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Tipping </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">Tipping involves the limited dissemination of material information by a person in a &#34;special relationship&#34;.  A &#34;tippee&#34; is someone who learns of a material fact or material change from </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">another person (a &#34;tipper&#34;) in a &#34;special relationship&#34; with the Corporation and knows or ought reasonably to know that the other person is in a special relationship with the Corporation. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">Each tippee becomes a person in a special relationship and is in turn prohibited from tipping and improper trading. </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Reporting </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">All insiders of the Corporation must publicly report via SEDI (System for Electronic Disclosure by Insiders) any purchases or sales of the Corporation securities or any grant or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">exercise of any option or other convertible security within 10 days of such transaction unless exempted by applicable securities legislation. </font></div><div style="margin-bottom:11.65pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:27pt">Confidentiality of Inside Information </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">Restricted Persons who come into possession of material non-public information concerning the Corporation must not intentionally or inadvertently communicate that information to any person unless the person has a need to know the information for legitimate, business-related reasons.  A Restricted Person who improperly reveals material inside information to another person can be held liable under the provision of various securities acts and regulations for the trading activities of his or her &#34;tippee&#34; and any other person with whom the tippee shares the information. </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Maintaining Confidentiality </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Any director, officer or employee privy to confidential information is required to manage such information in accordance with the Corporation&#8217;s Corporate Disclosure Policy as updated from time to time. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Outside parties privy to undisclosed material information concerning the Corporation will be told that they must not divulge such information to anyone else, other than in the necessary course of business and only under the confidentiality obligations to which the party is subject and that they may not trade in the Corporation&#8217;s securities until the information is publicly disclosed and disseminated in accordance with this Policy. Such outside parties should confirm their commitment to non-disclosure in the form of a written confidentiality agreement or as part of their services contract. </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">Reviewed and approved by the Board  March 5, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;Page 3 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 16.1</font></div></div><div style="margin-bottom:11.65pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:27pt">Trading </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">General Rule </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The Corporation has adopted the following rule in respect of trading in securities of the Corporation by Restricted Persons&#58; </font></div><div style="margin-bottom:0.05pt;padding-left:73.2pt;padding-right:70.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:116%">If you have knowledge of a material fact, pending change of material fact, or material change related to the affairs of the Corporation or any company involved in a transaction with the Corporation which is not generally known, or you are aware that the Corporation has decided to issue a press release with respect to the event (whether or not that event is considered material), no purchase or sale may be made until the knowledge has been made public.  In addition, this knowledge must not be conveyed to any other person for the purpose of assisting that person in trading securities. </font></div><div style="margin-bottom:11.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Trading Policy  </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">It is illegal for anyone to purchase or sell securities of any public company with knowledge of material information affecting that company that has not been publicly disclosed. Except in the necessary course of business, it is also illegal for anyone to inform any other person of material non-public information. Therefore, Restricted Persons or counter-parties in negotiations of material potential transactions, are prohibited from trading securities of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">Corporation or any counter-party until the information has been fully disclosed and one full trading day has passed. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">For the purposes of this Policy, the exercise through the purchase of previously granted and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">vested options or warrants, in and of itself, shall not be considered trading in the securities of the Corporation. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">The Corporation has adopted the following Policy to regulate trading in securities of the Corporation by Restricted Persons&#58; </font></div><div style="margin-bottom:11.65pt;padding-left:70.05pt;text-align:justify;text-indent:-33.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:24.29pt">Restricted Persons may engage in transactions involving the securities of the Corporation at all times during the year, except, with respect to the preparation of the quarterly and annual financial information, which shall include the financial statements and notes related thereto and Management&#8217;s Discussion and Analysis developed therefrom, (together defined herein as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">the Financial Information), during a period commencing on the earlier of (i) the date the Restricted Person commences the preparation of the Financial </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Information or the Restricted Person reviews the Financial Information and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">(ii) five business days prior to the meeting of the Audit Committee where the Financial Information is reviewed, until one </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">Reviewed and approved by the Board  March 5, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;Page 4 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 16.1</font></div></div><div style="padding-left:72.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">full trading day after the Financial Information has been publicly disseminated&#59; </font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="padding-left:70.05pt;text-align:justify;text-indent:-33.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:23.61pt">Restricted Persons shall refrain from engaging in transactions involving securities of the Corporation during the period from the date of calling of a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">board meeting called for reasons other than regularly scheduled meetings and, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">if applicable, continuing until the opening of trading on the first day after the completion of a full trading day following the date of public disclosure by the Corporation of matters resolved at the meeting, if any&#59; </font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="padding-left:70.05pt;text-align:justify;text-indent:-33.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:24.29pt">From time to time, the Corporation may circulate notices to Restricted </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">Persons (including those given a temporary designation as Restricted Persons) alerting them to material events and information and specifying &#34;black out&#34; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">periods during which securities of the Corporation should not be bought or sold by insiders&#59; and </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="padding-left:70.05pt;text-align:justify;text-indent:-33.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:23.61pt">The company does not allow insiders to hedge their position in shares, options, DSU's, PSU's, debentures or other debt instruments by use of any financial instrument, which would include but is not limited to options, puts, calls, warrants or short sells, designed to benefit the holder from a change in the market value of the stock of the company. d </font></div><div style="padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:0.45pt;padding-left:70.05pt;text-align:justify;text-indent:-33.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:24.29pt">Trading After Information Becomes Public </font></div><div style="padding-left:37.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Even though material or non-material information has been publicly disclosed, Restricted Persons should continue to refrain from trading in securities of the Corporation until the information has been adequately disseminated to the public and investors have been able to evaluate it. Information is not public merely because it is reflected by rumours or unofficial statements in the marketplace. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">Such information will be considered to have been adequately </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">disseminated and absorbed by the marketplace after one full trading day after its release. For example, if the Corporation issues a press release during the trading hours of the exchange on which its common shares are listed for trading, Restricted Persons are prohibited from trading until at least one full trading day has elapsed.  </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Consultations regarding purchase or sale of securities of the Corporation </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Prior to buying or selling any securities of the Corporation or granting any options or other convertible securities, all persons subject to this Policy should consult with the Chief Executive Officer or the Chief Financial Officer to confirm that no blackout period is in place.  </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">Reviewed and approved by the Board  March 5, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;Page 5 of 6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72.72pt;width:100%"><div style="margin-bottom:11.65pt;padding-left:10.5pt;text-align:right;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 16.1</font></div></div><div style="margin-bottom:11.65pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:27pt">Sanctions for Violation </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Legal Sanctions </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">If a person who is in a special relationship with the Corporation purchases or sells securities   of the Corporation with knowledge of any undisclosed material fact or material change,    under applicable laws, he, she or it could be&#58; </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">liable to the other party involved in the purchase or sale for damages that result from the trade&#59; </font></div><div style="margin-bottom:10.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">accountable to the Corporation for any profit made or loss prevented&#59; </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">subject to sanctions such as restrictions on the ability to trade any securities or act as a director or officer of any company&#59; </font></div><div style="margin-bottom:10.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">subject to administrative penalties of up to $1,000,000&#59; </font></div><div style="margin-bottom:11.65pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">subject to quasi-criminal penalties of up to the greater of $5 million or 3x the profit made and&#47;or 5 years less a day imprisonment&#59; and </font></div><div style="margin-bottom:9.5pt;padding-left:72.45pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%;padding-left:31.8pt">subject to criminal penalties under the Criminal Code. </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">A &#34;tipper&#34; who informs another person of a generally undisclosed material fact or change could be liable to compensate any person for damages who thereafter sells securities of the Corporation to or purchases securities of the Corporation from, the person or issuer that receives the information. </font></div><div style="margin-bottom:11.65pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:121%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:121%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Corporation Sanctions </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Directors, officers and employees of the Corporation are bound by this Policy and by other </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:121%">means to maintain the confidentiality of material, non-public information. Where it becomes apparent that one of these parties is in violation of this Policy, the Disclosure Policy Committee will review the matter and recommend a course of action as to appropriate consequences and remedial measures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:700;line-height:121%"> </font></div><div style="margin-bottom:11.15pt;padding-left:35.25pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%;padding-left:27pt">Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">Restricted Persons will be advised of these policies and their importance.   </font></div><div style="margin-bottom:11.65pt;padding-left:0.5pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">If an individual has any questions regarding any portion of this Policy, please contact either the Chief Executive Officer or Chief Financial Officer. </font></div><div style="margin-bottom:11.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">6.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%">Date of Mandate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%"> </font></div><div style="margin-bottom:11.65pt;padding-left:36.95pt;text-align:justify;text-indent:-0.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:121%">This Policy was most recently reviewed and approved on March 5, 2020. </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:125%"> </font></div><div style="height:77.04pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:125%">Reviewed and approved by the Board  March 5, 2020</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;Page 6 of 6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>13
<FILENAME>ex971oncolyticsclawbackpol.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib2f8f3994fd349e0889cee05a4213c3d_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 97.1</font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Oncolytics Biotech Inc.<br><br>INCENTIVE COMPENSATION RECOVERY POLICY</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Introduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) of Oncolytics Biotech Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company's compensation philosophy. The Board has therefore adopted this policy, which provides for the recovery of erroneously awarded incentive compensation in the event that the Company is required to prepare an accounting restatement due to material noncompliance of the Company with any financial reporting requirements under the federal securities laws (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). This Policy is designed to comply with Section&#160;10D of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), related rules and the listing standards of the The Nasdaq Captial Market, including but not limited to Nasdaq Listing Rule 5608, or any other securities exchange on which the Company&#8217;s shares are listed in the future.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy shall be administered by the Board or, if so designated by the Board, the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), in which case, all references herein to the Board shall be deemed references to the Committee. Any determinations made by the Board shall be final and binding on all affected individuals.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Covered Executives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">1</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Unless and until the Board determines otherwise, for purposes of this Policy, the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Covered Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means a current or former employee who is or was identified by the Company as the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person (including any executive officer of the Company&#8217;s subsidiaries or affiliates) who performs similar policy-making functions for the Company. &#8220;Policy-making function&#8221; excludes policy-making functions that are not significant.   &#8220;Covered Executives&#8221; will include, at minimum, the executive officers identified by the Company in its disclose prepared in response to either (i) Item 401(b) of Regulation S-K of the Exchange Act if the Company files its annual report with the United States Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on Form 10-K, (ii) Item 6.B of Form 20-F if the Company files its annual report with the SEC on Form 20-F, or (iii) Item B.19 of Form 40-F if the Company files its annual report with the SEC on Form 40-F.  For the avoidance of doubt, &#8220;Covered Executives&#8221; will include at least the following Company officers&#58; Chief Executive Officer, Chief Financial Officer, Chief Medical Officer, President, Global Head of Business Development, Vice President, Product Development, Vice President, Clinical Operations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy covers Incentive Compensation received by a person after beginning service as a Covered Executive and who served as a Covered Executive at any time during the performance period for that Incentive Compensation.  </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 97.1</font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Recovery&#58; Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">In the event of an &#8220;Accounting Restatement,&#8221; the Company will  recover reasonably promptly any excess Incentive Compensation received by any Covered Executive during the three completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement, including transition periods resulting from a change in the Company&#8217;s fiscal year as provided in Rule 10D-1 of the Exchange Act.  Incentive Compensation is deemed </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;received&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definition of Accounting Restatement.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For the purposes of this Policy, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Accounting Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means the Company is required to prepare an accounting restatement of its financial statements filed with the Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) due to the Company&#8217;s material noncompliance with any financial reporting requirements under the federal securities laws (including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period).  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The determination of the time when the Company is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;required&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to prepare an Accounting Restatement shall be made in accordance with applicable SEC and national securities exchange rules and regulations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;An Accounting Restatement does not include situations in which financial statement changes did not result from material non-compliance with financial reporting requirements, such as, but not limited to retrospective&#58; (i) application of a change in accounting principles&#59; (ii) revision to reportable segment information due to a change in the structure of the Company&#8217;s internal organization&#59; (iii) reclassification due to a discontinued operation&#59; (iv) application of a change in reporting entity, such as from a reorganization of entities under common control&#59; (v) adjustment to provision amounts in connection with a prior business combination&#59; and (vi) revision for stock splits, stock dividends, reverse stock splits or other changes in capital structure.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Definition of Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Incentive Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure, including, for example, bonuses or awards under the Company&#8217;s short and long-term incentive plans, grants and awards under the Company&#8217;s equity incentive plans, and contributions of such bonuses or awards to  the Company&#8217;s deferred compensation plans or other employee benefit plans that are not tax-qualified plans.  For avoidance of doubt, Incentive Compensation that is deferred (either mandatorily or voluntarily) under the Company&#8217;s non-qualified deferred compensation plans, as well as any matching amounts and earnings thereon, are subject to this Policy.  Incentive Compensation does not include awards which are granted, earned and vested without regard to attainment of Financial Reporting Measures, such as time-vesting awards, discretionary awards and awards based wholly on subjective standards, strategic measures or operational measures.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 97.1</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">&#8220;Financial Reporting Measures&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">are those that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements (including non-GAAP financial measures) and any measures derived wholly or in part from such financial measures. For the avoidance of doubt, Financial Reporting Measures include stock price and total shareholder return.  A measure need not be presented within the financial statements or included in a filing with the SEC to constitute a Financial Reporting Measure for purposes of this Policy.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Excess Incentive Compensation&#58; Amount Subject to Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The amount(s) to be recovered from the Covered Executive will be the amount(s) by which the Covered Executive&#8217;s Incentive Compensation for the relevant period(s) exceeded the amount(s) that the Covered Executive otherwise would have received had such Incentive Compensation been determined based on the restated amounts contained in the Accounting Restatement.  All amounts shall be computed without regard to taxes paid.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For Incentive Compensation based on Financial Reporting Measures such as stock price or total shareholder return, where the amount of excess compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Board will calculate the amount to be reimbursed based on a reasonable estimate of the effect of the Accounting Restatement on such Financial Reporting Measure upon which the Incentive Compensation was received. The Company will maintain documentation of that reasonable estimate and will provide such documentation to the applicable national securities exchange.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Method of Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board will determine, in its sole discretion, the method(s) for recovering reasonably promptly excess Incentive Compensation hereunder. Such methods may include, without limitation&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;requiring reimbursement of Incentive Compensation previously paid&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;forfeiting any Incentive Compensation contribution made under the Company&#8217;s deferred compensation plans&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;offsetting the recovered amount from any compensation or Incentive Compensation that the Covered Executive may earn or be awarded in the future&#59; </font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;taking any other remedial and recovery action permitted by law, as determined by the Board&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)&#160;&#160;&#160;&#160;some combination of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">No Indemnification or Advance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to applicable law, the Company shall not indemnify, including by paying or reimbursing for premiums for any insurance policy covering any potential losses, any Covered Executives </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 97.1</font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">against the loss of any erroneously awarded Incentive Compensation, nor shall the Company advance any costs or expenses to any Covered Executives in connection with any action to recover excess Incentive Compensation.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Interpretation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section&#160;10D of the Exchange Act and any applicable rules or standards adopted by the SEC or any national securities exchange on which the Company's securities are listed.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The effective date of this Policy is November 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; ). This Policy applies to Incentive Compensation received by Covered Executives on or after the Effective Date that results from attainment of a Financial Reporting Measure based on or derived from financial information for any fiscal period ending on or after the Effective Date.  In addition, this Policy is intended to be and will be incorporated as an essential term and condition of any Incentive Compensation agreement, plan or program that the Company establishes or maintains on or after the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Amendment and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board may amend this Policy from time to time in its discretion, and shall amend this Policy as it deems necessary to reflect changes in regulations adopted by the SEC under Section 10D of the Exchange Act and to comply with any rules or standards adopted by The Nasdaq Capital Market or any other securities exchange on which the Company&#8217;s shares are listed in the future. </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:9pt;text-decoration:underline">Other Recovery Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Board intends that this Policy will be applied to the fullest extent of the law. Upon receipt of this Policy, each Covered Executive is required to complete the Receipt and Acknowledgement attached as Schedule A to this Policy. The Board may require that any employment agreement or similar agreement relating to Incentive Compensation received on or after the Effective Date shall, as a condition to the grant of any benefit thereunder, require a Covered Executive to agree to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any (i)&#160;other remedies or rights of compensation recovery that may be available to the Company pursuant to the terms of any similar policy in any employment agreement, or similar agreement relating to Incentive Compensation, unless any such agreement expressly prohibits such right of recovery, and (ii)&#160;any other legal remedies available to the Company.  The provisions of this Policy are in addition to (and not in lieu of) any rights to repayment the Company may have under Section 304 of the Sarbanes-Oxley Act of 2002 and other applicable laws.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt;text-decoration:underline">Impracticability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company shall recover any excess Incentive Compensation in accordance with this Policy, except to the extent that certain conditions are met and the Board has determined that such recovery would be impracticable, all in accordance with Rule 10D-1 of the Exchange Act and Nasdaq Listing Rule 5608 or any other securities exchange on which the Company&#8217;s shares are listed in the future.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 97.1</font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:3pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This Policy shall be binding upon and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 97.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Schedule A</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">INCENTIVE-BASED COMPENSATION CLAWBACK POLICY</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%">RECEIPT AND ACKNOWLEDGEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">I, __________________________________________, hereby acknowledge that I have received and read a copy of the Incentive Compensation Recovery Policy. As a condition of my receipt of any Incentive Compensation as defined in the Policy, I hereby agree to the terms of the Policy. I further agree that if recovery of excess Incentive Compensation is required pursuant to the Policy, the Company shall, to the fullest extent permitted by governing laws, require such recovery from me up to the amount by which the Incentive Compensation received by me, and amounts paid or payable pursuant or with respect thereto, constituted excess Incentive Compensation.  If any such reimbursement, reduction, cancelation, forfeiture, repurchase, recoupment, offset against future grants or awards and&#47;or other method of recovery does not fully satisfy the amount due, I agree to immediately pay the remaining unpaid balance to the Company. </font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.185%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.101%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Signature</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Date</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>oncyf-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0331f315-f217-43c3-a3a4-8d92b75af8cb,g:42af5dc4-a986-45bb-8df7-47c2c2475bfc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:oncyf="http://www.oncolyticsbiotech.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncolyticsbiotech.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="oncyf-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.oncolyticsbiotech.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.oncolyticsbiotech.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION">
        <link:definition>0000003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperations" roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperations">
        <link:definition>0000008 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentation" roleURI="http://www.oncolyticsbiotech.com/role/BasisofPresentation">
        <link:definition>0000009 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantJudgmentsEstimatesandAssumptions" roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions">
        <link:definition>0000011 - Disclosure - Significant Judgments, Estimates and Assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilities" roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities">
        <link:definition>0000012 - Disclosure - Other Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment">
        <link:definition>0000013 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>0000014 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.oncolyticsbiotech.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivative" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative">
        <link:definition>0000016 - Disclosure - Warrant Derivative</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapital" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital">
        <link:definition>0000017 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation">
        <link:definition>0000018 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShare" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare">
        <link:definition>0000019 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiability" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiability">
        <link:definition>0000020 - Disclosure - Contract Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies">
        <link:definition>0000021 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes">
        <link:definition>0000022 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures">
        <link:definition>0000023 - Disclosure - Capital Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments">
        <link:definition>0000024 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosures" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures">
        <link:definition>0000025 - Disclosure - Additional Cash Flow Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndemnificationofOfficersandDirectors" roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors">
        <link:definition>0000026 - Disclosure - Indemnification of Officers and Directors</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependence" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence">
        <link:definition>0000027 - Disclosure - Economic Dependence</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpenses" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses">
        <link:definition>0000028 - Disclosure - Components of Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions">
        <link:definition>0000029 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPoliciesPolicies" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Summary of Material Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPoliciesTables" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Summary of Material Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables">
        <link:definition>9954473 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>9954474 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables">
        <link:definition>9954475 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeTables" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables">
        <link:definition>9954476 - Disclosure - Warrant Derivative (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables">
        <link:definition>9954477 - Disclosure - Share Capital (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables">
        <link:definition>9954478 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityTables" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables">
        <link:definition>9954479 - Disclosure - Contract Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables">
        <link:definition>9954480 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables">
        <link:definition>9954481 - Disclosure - Capital Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables">
        <link:definition>9954482 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresTables" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables">
        <link:definition>9954483 - Disclosure - Additional Cash Flow Disclosures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpensesTables" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables">
        <link:definition>9954484 - Disclosure - Components of Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables">
        <link:definition>9954485 - Disclosure - Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofOperationsDetails" roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails">
        <link:definition>9954486 - Disclosure - Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPoliciesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails">
        <link:definition>9954487 - Disclosure - Summary of Material Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails">
        <link:definition>9954488 - Disclosure - Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails">
        <link:definition>9954489 - Disclosure - Other Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentDetails" roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails">
        <link:definition>9954490 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>9954491 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails">
        <link:definition>9954492 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesRightofuseAssetsandLeaseLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails">
        <link:definition>9954493 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTotalUndiscountedLeaseLiabilityDetails" roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails">
        <link:definition>9954494 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails">
        <link:definition>9954495 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeWarrantDerivativeOutstandingDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails">
        <link:definition>9954496 - Disclosure - Warrant Derivative - Warrant Derivative Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails">
        <link:definition>9954497 - Disclosure - Warrant Derivative - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails">
        <link:definition>9954498 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails">
        <link:definition>9954499 - Disclosure - Share Capital - Schedule of Share Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareCapitalScheduleofShareCapitalFootnotesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails">
        <link:definition>9954500 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>9954501 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails">
        <link:definition>9954502 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails">
        <link:definition>9954503 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails">
        <link:definition>9954504 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails">
        <link:definition>9954505 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails">
        <link:definition>9954506 - Disclosure - Share-Based Compensation - Schedule of Compensation Warrants Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerCommonShareDetails" roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails">
        <link:definition>9954507 - Disclosure - Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails">
        <link:definition>9954508 - Disclosure - Contract Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails">
        <link:definition>9954509 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9954510 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>9954511 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954512 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails">
        <link:definition>9954513 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails">
        <link:definition>9954514 - Disclosure - Capital Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>9954515 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails">
        <link:definition>9954516 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails">
        <link:definition>9954517 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails">
        <link:definition>9954518 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EconomicDependenceDetails" roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails">
        <link:definition>9954519 - Disclosure - Economic Dependence (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComponentsofExpensesDetails" roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails">
        <link:definition>9954520 - Disclosure - Components of Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails">
        <link:definition>9954521 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="oncyf_AdditionalCashFlowDisclosuresAbstract" abstract="true" name="AdditionalCashFlowDisclosuresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_GeneralAndAdministrativeExpenseAbstract" abstract="true" name="GeneralAndAdministrativeExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ClassofWarrantorRightWarrantsExercised" abstract="false" name="ClassofWarrantorRightWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfTaxPools" abstract="false" name="TaxEffectOfTaxPools" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Statement1LineItems" abstract="true" name="Statement1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" abstract="false" name="OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="oncyf_CashFlowOperatingCapital1TableTextBlock" abstract="false" name="CashFlowOperatingCapital1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsOutstanding" abstract="false" name="NumberOfWarrantsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ShareCapitalNumberSharesAbstract" abstract="true" name="ShareCapitalNumberSharesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" abstract="false" name="DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_SaleOfStockDomain" abstract="true" name="SaleOfStockDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_IssueOfEquitySharesNumberOfWarrants" abstract="false" name="IssueOfEquitySharesNumberOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_CompensationWarrantsMember" abstract="true" name="CompensationWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_PurchaseObligation1" abstract="false" name="PurchaseObligation1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_AdjustmentsForDepreciationRightOfUseAssets" abstract="false" name="AdjustmentsForDepreciationRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceAbstract" abstract="true" name="DisclosureOfEconomicDependenceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" abstract="false" name="ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Axis" abstract="true" name="IncomeStatementLocation1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTableTextBlock" abstract="false" name="OtherExpensesAndAdjustmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsTable" abstract="true" name="OtherExpensesAndAdjustmentsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ProceedsfromWarrantExercises1" abstract="false" name="ProceedsfromWarrantExercises1" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ManufacturingExpense" abstract="false" name="ManufacturingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsOutstandingRollForward" abstract="true" name="NumberOfWarrantsOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" abstract="false" name="OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_UnusedCapitalLossCarryForwardNetMember" abstract="true" name="UnusedCapitalLossCarryForwardNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_PurchaseObligationCommitmentTerm" abstract="false" name="PurchaseObligationCommitmentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" abstract="false" name="DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_SharesUnderOverAllotmentOptionMember" abstract="true" name="SharesUnderOverAllotmentOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" abstract="false" name="ExpectedVolatilityOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" abstract="false" name="RiskFreeInterestRateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_WarrantsTerm" abstract="false" name="WarrantsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_StockOptionsOutstandingAbstract" abstract="true" name="StockOptionsOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OtherExpensesAndAdjustmentsLineItems" abstract="true" name="OtherExpensesAndAdjustmentsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" abstract="false" name="NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="oncyf_ContingenciesAbstract" abstract="true" name="ContingenciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_UnusedNetOperatingLossCarryForwardsMember" abstract="true" name="UnusedNetOperatingLossCarryForwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_IssueOfEquityShares" abstract="false" name="IssueOfEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_CashAndCashEquivalentsAndCurrentInvestments" abstract="false" name="CashAndCashEquivalentsAndCurrentInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_IntellectualPropertyExpense" abstract="false" name="IntellectualPropertyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" abstract="true" name="DisclosureofrevenuefromcontractswithcustomersAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_NumberOfWarrantsAndSharesOutstanding" abstract="false" name="NumberOfWarrantsAndSharesOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_IssueOfEquitySharesNumberOfCommonShares" abstract="false" name="IssueOfEquitySharesNumberOfCommonShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ConcentrationRiskNumber" abstract="false" name="ConcentrationRiskNumber" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1LineItems" abstract="true" name="ConcentrationRiskType1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_GeneralAndAdministrativeExpenseMember" abstract="true" name="GeneralAndAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ProceedsfromInterestReceived" abstract="false" name="ProceedsfromInterestReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" abstract="true" name="PropertyPlantEquipmentRelatedTemporaryDifferencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_Currency1LineItems" abstract="true" name="Currency1LineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" abstract="true" name="A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SupplierConcentrationRisk1Member" abstract="true" name="SupplierConcentrationRisk1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_Currency1Table" abstract="true" name="Currency1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OperatingLeaseRemainingLeaseTerm" abstract="false" name="OperatingLeaseRemainingLeaseTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ShareIssueRelatedCostCommissions" abstract="false" name="ShareIssueRelatedCostCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_TaxEffectOfExpirationOfTaxBenefits" abstract="false" name="TaxEffectOfExpirationOfTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Domain" abstract="true" name="ConcentrationRiskType1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ShareCapitalAmountAbstract" abstract="true" name="ShareCapitalAmountAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementAmount" abstract="false" name="SharePurchaseAgreementAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ConcentrationRiskType1Axis" abstract="true" name="ConcentrationRiskType1Axis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" abstract="false" name="ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingMember" abstract="true" name="SharesPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" abstract="false" name="SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WeightedAverageExercisePriceOutstandingAbstract" abstract="true" name="WeightedAverageExercisePriceOutstandingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" abstract="false" name="PropertyPlantandEquipmentAnnualDepreciationRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" abstract="true" name="DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SharePurchaseAgreementTerm" abstract="false" name="SharePurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ClinicalTrialMember" abstract="true" name="ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_ChangeInFairValueWarrantDerivativeRollForward" abstract="true" name="ChangeInFairValueWarrantDerivativeRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DisclosureofsharebasedpaymentarrangementAbstract" abstract="true" name="DisclosureofsharebasedpaymentarrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_PublicCompanyExpense" abstract="false" name="PublicCompanyExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_LeaseNotYetCommencedTerm" abstract="false" name="LeaseNotYetCommencedTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" abstract="false" name="TaxEffectOfChangeinFairValueOfWarrantDerivative" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ShareWarrantsIssuedOperatingExpense" abstract="false" name="ShareWarrantsIssuedOperatingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfEconomicDependenceTextBlock" abstract="false" name="DisclosureOfEconomicDependenceTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_WarrantExercisePrice" abstract="false" name="WarrantExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="oncyf_SharesIssuedPricePerShare1" abstract="false" name="SharesIssuedPricePerShare1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="oncyf_TranslationalScienceExpense" abstract="false" name="TranslationalScienceExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" abstract="false" name="OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" abstract="false" name="OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_DisclosureofincometaxAbstract" abstract="true" name="DisclosureofincometaxAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" abstract="true" name="SignificantJudgmentsEstimatesAndAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ResearchAndDevelopmentExpenseMember" abstract="true" name="ResearchAndDevelopmentExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" abstract="false" name="IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" abstract="false" name="OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" abstract="false" name="IncreaseDecreaseThroughExpirationOfWarrantEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_EquityAuthorized" abstract="false" name="EquityAuthorized" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" abstract="true" name="UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_DisclosureofrelatedpartyAbstract" abstract="true" name="DisclosureofrelatedpartyAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_InvestmentTaxCreditsMember" abstract="true" name="InvestmentTaxCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharesUnderAtthemarketAgreementMember" abstract="true" name="SharesUnderAtthemarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharesUnderPublicOfferingMember" abstract="true" name="SharesUnderPublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharesPublicOfferingWarrantDerivativesMember" abstract="true" name="SharesPublicOfferingWarrantDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_LeaseNotYetCommencedPayments" abstract="false" name="LeaseNotYetCommencedPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ShareIssueCostsMember" abstract="true" name="ShareIssueCostsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_IncomeStatementLocation1Domain" abstract="true" name="IncomeStatementLocation1Domain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_CommonSharesPerUnit" abstract="false" name="CommonSharesPerUnit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ClinicalTrialExpense" abstract="false" name="ClinicalTrialExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ForeignExchangeImpactRightofUseAssets" abstract="false" name="ForeignExchangeImpactRightofUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ResearchAndDevelopmentExpenseAbstract" abstract="true" name="ResearchAndDevelopmentExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" abstract="false" name="ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" abstract="false" name="IncreaseDecreaseThroughIncentiveShareAwardsEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_SharesUnderStockOptionPlanMember" abstract="true" name="SharesUnderStockOptionPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_DisclosureOfCapitalComponentsTableTextBlock" abstract="false" name="DisclosureOfCapitalComponentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_NumberOfStockOptionPlans" abstract="false" name="NumberOfStockOptionPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" abstract="false" name="ScheduleOfForeignCurrencyHeldTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_MedicalEquipmentMember" abstract="true" name="MedicalEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_OfficeExpenses" abstract="false" name="OfficeExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" abstract="false" name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_GainsLossesFromForeignExchangeImpact" abstract="false" name="GainsLossesFromForeignExchangeImpact" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageSharePriceOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="oncyf_TaxEffectOfStockBasedCompensation" abstract="false" name="TaxEffectOfStockBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" abstract="true" name="DisclosureOfShareBasedPaymentArrangementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_RightOfUseAssetsAbstract" abstract="true" name="RightOfUseAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_CommitmentsAndContingencies1" abstract="false" name="CommitmentsAndContingencies1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_WarrantLiabilityUnamortizedDiscount" abstract="false" name="WarrantLiabilityUnamortizedDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" abstract="false" name="ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" abstract="false" name="DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" abstract="true" name="DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_OfficeEquipmentAndFurnitureMember" abstract="true" name="OfficeEquipmentAndFurnitureMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" abstract="false" name="WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="oncyf_WarrantLiabilityAmortizedDiscount" abstract="false" name="WarrantLiabilityAmortizedDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised" abstract="false" name="ClassOfWarrantOrRightNumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="oncyf_ContractLiabilityRecognitionPeriod" abstract="false" name="ContractLiabilityRecognitionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ProceedsFromIssueOfUnitsGross" abstract="false" name="ProceedsFromIssueOfUnitsGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" abstract="true" name="DisclosureOfNotesAndOtherExplanatoryInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ConcentrationRisk1Table" abstract="true" name="ConcentrationRisk1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_SaleOfStockAxis" abstract="true" name="SaleOfStockAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_ShareWarrantsIssuedTransactionCosts" abstract="false" name="ShareWarrantsIssuedTransactionCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="oncyf_Statement1Table" abstract="true" name="Statement1Table" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" abstract="false" name="DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_SharesUnderIncentiveAwardPlanMember" abstract="true" name="SharesUnderIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" abstract="false" name="MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" abstract="false" name="ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="oncyf_BalanceHeldInForeignCurrencyNet" abstract="false" name="BalanceHeldInForeignCurrencyNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>oncyf-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0331f315-f217-43c3-a3a4-8d92b75af8cb,g:42af5dc4-a986-45bb-8df7-47c2c2475bfc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_3fb728f3-a2b8-429f-ab24-6278eb801435" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_64102b0a-81f3-48d0-96b2-92485c0db672" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_3fb728f3-a2b8-429f-ab24-6278eb801435" xlink:to="loc_ifrs-full_CurrentAssets_64102b0a-81f3-48d0-96b2-92485c0db672" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_cac0c4b6-455f-4bd2-a11a-d1d45caba1c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_3fb728f3-a2b8-429f-ab24-6278eb801435" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_cac0c4b6-455f-4bd2-a11a-d1d45caba1c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_cb91404d-5582-4b01-a9fb-468c2261fa9f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_3fb728f3-a2b8-429f-ab24-6278eb801435" xlink:to="loc_ifrs-full_RightofuseAssets_cb91404d-5582-4b01-a9fb-468c2261fa9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments_4215dfd6-658a-4d94-b1f0-392d4f1b9eeb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Assets_3fb728f3-a2b8-429f-ab24-6278eb801435" xlink:to="loc_ifrs-full_NoncurrentPrepayments_4215dfd6-658a-4d94-b1f0-392d4f1b9eeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_112ccf63-9472-4f24-b9aa-09d5a3a30582" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_fdbbeace-4661-4ca5-8ba4-a741a9b85b91" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_112ccf63-9472-4f24-b9aa-09d5a3a30582" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_fdbbeace-4661-4ca5-8ba4-a741a9b85b91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_d767ac2a-8462-4a4e-8807-b505bf068b77" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_112ccf63-9472-4f24-b9aa-09d5a3a30582" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_d767ac2a-8462-4a4e-8807-b505bf068b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_31e59be1-8340-424f-ba6f-dfd07323e331" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_112ccf63-9472-4f24-b9aa-09d5a3a30582" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_31e59be1-8340-424f-ba6f-dfd07323e331" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_35aad82c-6e23-4a28-8958-ff60877c85c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentLiabilities_112ccf63-9472-4f24-b9aa-09d5a3a30582" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_35aad82c-6e23-4a28-8958-ff60877c85c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_bbff6131-549c-4760-8ee4-bf726acc335d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_c988f47a-a911-4268-92b2-fe956ae44bc5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_bbff6131-549c-4760-8ee4-bf726acc335d" xlink:to="loc_ifrs-full_Liabilities_c988f47a-a911-4268-92b2-fe956ae44bc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_6f161b49-5b3f-4749-8356-09d7c2c00b52" xlink:href="oncyf-20231231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_bbff6131-549c-4760-8ee4-bf726acc335d" xlink:to="loc_oncyf_CommitmentsAndContingencies1_6f161b49-5b3f-4749-8356-09d7c2c00b52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_ce9ee820-e019-4f3f-a522-63f5e6e086b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_EquityAndLiabilities_bbff6131-549c-4760-8ee4-bf726acc335d" xlink:to="loc_ifrs-full_Equity_ce9ee820-e019-4f3f-a522-63f5e6e086b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_f7dbc2be-eee3-4d7c-8178-5e2cb8d764c0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_5a418859-0056-4656-8c07-39c2e762d634" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_f7dbc2be-eee3-4d7c-8178-5e2cb8d764c0" xlink:to="loc_ifrs-full_IssuedCapital_5a418859-0056-4656-8c07-39c2e762d634" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_5a1d9f0e-09a4-490f-900a-7b3141f61ace" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_f7dbc2be-eee3-4d7c-8178-5e2cb8d764c0" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_5a1d9f0e-09a4-490f-900a-7b3141f61ace" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_b52d70eb-5904-4063-b842-9342da78497b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_f7dbc2be-eee3-4d7c-8178-5e2cb8d764c0" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_b52d70eb-5904-4063-b842-9342da78497b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_82104f9b-2f83-4026-a1b0-6dd08d6998a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Equity_f7dbc2be-eee3-4d7c-8178-5e2cb8d764c0" xlink:to="loc_ifrs-full_RetainedEarnings_82104f9b-2f83-4026-a1b0-6dd08d6998a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_aca41aad-91c8-47cd-ae0b-95441106099a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_b1dec253-103d-4079-8feb-cb5d9943a76f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_aca41aad-91c8-47cd-ae0b-95441106099a" xlink:to="loc_ifrs-full_CurrentLiabilities_b1dec253-103d-4079-8feb-cb5d9943a76f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_06f2d00d-7f82-48d1-95f2-5ad9b6220aba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_aca41aad-91c8-47cd-ae0b-95441106099a" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_06f2d00d-7f82-48d1-95f2-5ad9b6220aba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_1f090bc9-fab5-4450-a098-4f97aaf9d703" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_Liabilities_aca41aad-91c8-47cd-ae0b-95441106099a" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_1f090bc9-fab5-4450-a098-4f97aaf9d703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_312a972b-9861-41d0-b374-e0581d6e4775" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_82f7e88f-d884-4348-9af1-bf5ceab11df5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_312a972b-9861-41d0-b374-e0581d6e4775" xlink:to="loc_ifrs-full_CashAndCashEquivalents_82f7e88f-d884-4348-9af1-bf5ceab11df5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale_475af382-324b-41b4-b796-32cb4727841f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_312a972b-9861-41d0-b374-e0581d6e4775" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale_475af382-324b-41b4-b796-32cb4727841f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_4a26bca8-f804-4083-b192-9c5a6b69b38f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_312a972b-9861-41d0-b374-e0581d6e4775" xlink:to="loc_ifrs-full_OtherCurrentReceivables_4a26bca8-f804-4083-b192-9c5a6b69b38f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments_0e4c9bdb-c432-46bc-b38b-29543850ca2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentAssets_312a972b-9861-41d0-b374-e0581d6e4775" xlink:to="loc_ifrs-full_CurrentPrepayments_0e4c9bdb-c432-46bc-b38b-29543850ca2f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_e06e8fb9-4195-4e58-9ba5-6ade2838d391" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_03981c94-0842-49b3-83ed-e75d92f78b76" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_e06e8fb9-4195-4e58-9ba5-6ade2838d391" xlink:to="loc_ifrs-full_ProfitLoss_03981c94-0842-49b3-83ed-e75d92f78b76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_79897b69-4a7d-4f79-9ea3-de34c5d9328c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ComprehensiveIncome_e06e8fb9-4195-4e58-9ba5-6ade2838d391" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_79897b69-4a7d-4f79-9ea3-de34c5d9328c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_3c7c0ebd-c94a-470d-93d7-e30a7c09ec8c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_4229d491-45ae-4a5c-b0e5-1f74a08a8350" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_3c7c0ebd-c94a-470d-93d7-e30a7c09ec8c" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_4229d491-45ae-4a5c-b0e5-1f74a08a8350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_5a710463-cf41-412a-b524-84a9ed8f93de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_3c7c0ebd-c94a-470d-93d7-e30a7c09ec8c" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_5a710463-cf41-412a-b524-84a9ed8f93de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_7fb17516-9009-4d5a-818e-8ac4f4640316" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_3c7c0ebd-c94a-470d-93d7-e30a7c09ec8c" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_7fb17516-9009-4d5a-818e-8ac4f4640316" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_21a4367d-55e9-4fac-9a76-a295d351e2c8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossBeforeTax_3c7c0ebd-c94a-470d-93d7-e30a7c09ec8c" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_21a4367d-55e9-4fac-9a76-a295d351e2c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_4880044a-dc2f-4e38-a35b-f3182e0f1505" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_879a1170-f7ad-4c19-ac28-aefb2979a8f0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_4880044a-dc2f-4e38-a35b-f3182e0f1505" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_879a1170-f7ad-4c19-ac28-aefb2979a8f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_a43d2394-907d-46a4-ba32-7eb338e01770" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities_4880044a-dc2f-4e38-a35b-f3182e0f1505" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_a43d2394-907d-46a4-ba32-7eb338e01770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_07d659e0-dbbc-47db-8dd5-37c56966eddf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_1678105c-9f8d-4baa-95dc-d7e84ed39fe9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_07d659e0-dbbc-47db-8dd5-37c56966eddf" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_1678105c-9f8d-4baa-95dc-d7e84ed39fe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_8df0bb2f-8cab-4e50-a00c-fdb294fe9729" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_ProfitLoss_07d659e0-dbbc-47db-8dd5-37c56966eddf" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_8df0bb2f-8cab-4e50-a00c-fdb294fe9729" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_975149b0-4a68-4ddd-bf61-da6ec23f6f04" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_7dd7deaf-95ad-4fbc-b014-fb6b2cd0084a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_975149b0-4a68-4ddd-bf61-da6ec23f6f04" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_7dd7deaf-95ad-4fbc-b014-fb6b2cd0084a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_cc34abe7-8b62-4497-b14c-eac07c2a2131" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_975149b0-4a68-4ddd-bf61-da6ec23f6f04" xlink:to="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_cc34abe7-8b62-4497-b14c-eac07c2a2131" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_20447c93-c330-4189-a36a-6c9ff3ab5b14" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_975149b0-4a68-4ddd-bf61-da6ec23f6f04" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_20447c93-c330-4189-a36a-6c9ff3ab5b14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_bef75316-bfa3-4ad3-a9ff-f8d8a00ea4f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_ifrs-full_ProfitLoss_bef75316-bfa3-4ad3-a9ff-f8d8a00ea4f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_ddb72e58-e3b4-4bc5-ac97-f6e7cb066c38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_ddb72e58-e3b4-4bc5-ac97-f6e7cb066c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_128b80ea-ea48-45a1-bf6d-0e83747153df" xlink:href="oncyf-20231231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_128b80ea-ea48-45a1-bf6d-0e83747153df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_9ab51b9d-3aac-4af4-96f2-9e5a179d5cc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_9ab51b9d-3aac-4af4-96f2-9e5a179d5cc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_c702b444-f343-4061-bfb2-88c6c34e77d3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_c702b444-f343-4061-bfb2-88c6c34e77d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_ef5fe010-f401-4d48-8158-f4b532f11d43" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_ifrs-full_InterestRevenueExpense_ef5fe010-f401-4d48-8158-f4b532f11d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_3327b0c6-2656-499b-bf1f-93dd93d6ca51" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_3327b0c6-2656-499b-bf1f-93dd93d6ca51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_112378b4-e500-4b2c-b83e-f52d2fc96ca6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_112378b4-e500-4b2c-b83e-f52d2fc96ca6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_f147d967-2cbf-425f-ba9c-581ee9287a92" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations_8a6a851f-1b56-4dfe-abfe-5990acd3b60e" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_f147d967-2cbf-425f-ba9c-581ee9287a92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ec25e19b-36f9-429d-b37e-456b7430a3c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_c03632c6-832e-4a9e-b598-b63adf544288" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ec25e19b-36f9-429d-b37e-456b7430a3c3" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_c03632c6-832e-4a9e-b598-b63adf544288" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_92b3009a-6cc8-4e93-bd30-d898d59a369d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ec25e19b-36f9-429d-b37e-456b7430a3c3" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_92b3009a-6cc8-4e93-bd30-d898d59a369d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_000e285e-f8a0-401f-ae56-9a9e0c09ed3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_ec25e19b-36f9-429d-b37e-456b7430a3c3" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_000e285e-f8a0-401f-ae56-9a9e0c09ed3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_70882f7b-07e2-4bc8-90da-7e3763e1832d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_64670757-f2cf-452d-bbab-d06e41298532" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_70882f7b-07e2-4bc8-90da-7e3763e1832d" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_64670757-f2cf-452d-bbab-d06e41298532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_803abc58-620c-4a76-a35e-42c117470bd5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_70882f7b-07e2-4bc8-90da-7e3763e1832d" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_803abc58-620c-4a76-a35e-42c117470bd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_02968b50-0208-48b5-9191-ff7377daf359" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_70882f7b-07e2-4bc8-90da-7e3763e1832d" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_02968b50-0208-48b5-9191-ff7377daf359" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_26ca3b8f-8880-478e-994d-b8edb06c208a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_70882f7b-07e2-4bc8-90da-7e3763e1832d" xlink:to="loc_ifrs-full_CashOutflowForLeases_26ca3b8f-8880-478e-994d-b8edb06c208a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_309535fe-a1e3-4c3a-8a89-9fb9f88480b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_c894171a-9ff1-4535-a5e6-f2a36afcb1e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_309535fe-a1e3-4c3a-8a89-9fb9f88480b4" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_c894171a-9ff1-4535-a5e6-f2a36afcb1e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_4ea6bcad-5aea-4323-9c55-ecfd1a2aaabe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables_309535fe-a1e3-4c3a-8a89-9fb9f88480b4" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_4ea6bcad-5aea-4323-9c55-ecfd1a2aaabe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_03711e26-5411-45a3-9e41-aaf3319be840" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_03711e26-5411-45a3-9e41-aaf3319be840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_0ac1455a-5e75-4abc-9983-dce07645411a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_0ac1455a-5e75-4abc-9983-dce07645411a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_4c84c1ce-ef24-40f6-abf0-9b4326643982" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_4c84c1ce-ef24-40f6-abf0-9b4326643982" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_fadb80ba-3cf0-4ffe-a925-5c25d7030cd6" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_oncyf_TaxEffectOfTaxPools_fadb80ba-3cf0-4ffe-a925-5c25d7030cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_9540899f-f61e-4c66-bb12-604931b61225" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_9540899f-f61e-4c66-bb12-604931b61225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_27908fb6-db08-46da-803a-624df8bc437e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_27908fb6-db08-46da-803a-624df8bc437e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_633894db-e414-4930-a9cf-1810c0186a49" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_633894db-e414-4930-a9cf-1810c0186a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_d098ab41-641a-4a11-85a3-6c96e6ead2d7" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_d098ab41-641a-4a11-85a3-6c96e6ead2d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_dec7b7e5-80a2-49b4-b4ba-6b3ecc7ae856" xlink:href="oncyf-20231231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome_72423460-0761-4352-90cd-a01d1d11acd2" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_dec7b7e5-80a2-49b4-b4ba-6b3ecc7ae856" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_3c08d60a-c21a-4c82-9b29-191bdfcfd356" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_39355186-5e93-4020-a238-af63bd9be5ab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_3c08d60a-c21a-4c82-9b29-191bdfcfd356" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_39355186-5e93-4020-a238-af63bd9be5ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_cc677c25-cea1-4bdd-bac2-e61aca424cbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_3c08d60a-c21a-4c82-9b29-191bdfcfd356" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_cc677c25-cea1-4bdd-bac2-e61aca424cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_0c5b84db-c4d8-45df-8c85-2f45dc0ca88a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_3c08d60a-c21a-4c82-9b29-191bdfcfd356" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_0c5b84db-c4d8-45df-8c85-2f45dc0ca88a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_62e0f465-607e-47b9-9a59-79c7a33806d7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_3c08d60a-c21a-4c82-9b29-191bdfcfd356" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_62e0f465-607e-47b9-9a59-79c7a33806d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_a2342a32-aff8-45e0-846a-5f7eb465ccd8" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_3c08d60a-c21a-4c82-9b29-191bdfcfd356" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_a2342a32-aff8-45e0-846a-5f7eb465ccd8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#RelatedPartyTransactionsDetails"/>
  <link:calculationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_9f2c1779-3367-425a-a167-f4e7657315c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_a4207a6b-ce8a-4767-b5e8-9f41a8a05fa6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_9f2c1779-3367-425a-a167-f4e7657315c3" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_a4207a6b-ce8a-4767-b5e8-9f41a8a05fa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_3879b1ef-b502-443c-87e2-dffc791ab9c5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_9f2c1779-3367-425a-a167-f4e7657315c3" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_3879b1ef-b502-443c-87e2-dffc791ab9c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_d439fa88-ef88-46ca-83a8-2822fc986b05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation_9f2c1779-3367-425a-a167-f4e7657315c3" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_d439fa88-ef88-46ca-83a8-2822fc986b05" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>oncyf-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0331f315-f217-43c3-a3a4-8d92b75af8cb,g:42af5dc4-a986-45bb-8df7-47c2c2475bfc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20231231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_416e6c71-ce06-4189-8150-ac815f36cea4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentInformationTable_416e6c71-ce06-4189-8150-ac815f36cea4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_298501e6-ce2f-4973-a859-8c7f14f7edbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_416e6c71-ce06-4189-8150-ac815f36cea4" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_298501e6-ce2f-4973-a859-8c7f14f7edbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_298501e6-ce2f-4973-a859-8c7f14f7edbf_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_298501e6-ce2f-4973-a859-8c7f14f7edbf" xlink:to="loc_dei_AddressTypeDomain_298501e6-ce2f-4973-a859-8c7f14f7edbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_0a156e72-b091-49d7-8fe8-12c955977b1a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_298501e6-ce2f-4973-a859-8c7f14f7edbf" xlink:to="loc_dei_AddressTypeDomain_0a156e72-b091-49d7-8fe8-12c955977b1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_dcb2c2db-64cc-47cf-9967-9eca21244dbc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_0a156e72-b091-49d7-8fe8-12c955977b1a" xlink:to="loc_dei_BusinessContactMember_dcb2c2db-64cc-47cf-9967-9eca21244dbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ec1bcfa8-b238-4094-9ce1-af50bdfb3c6f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentType_ec1bcfa8-b238-4094-9ce1-af50bdfb3c6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_1fdc3cd1-4fa0-4215-b47a-a700b7ab6bc5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentRegistrationStatement_1fdc3cd1-4fa0-4215-b47a-a700b7ab6bc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7e5bad30-abd8-4151-a5ca-be55a0c057f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentAnnualReport_7e5bad30-abd8-4151-a5ca-be55a0c057f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f3cacfe6-a7a1-4188-a697-3334e0e31982" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentPeriodEndDate_f3cacfe6-a7a1-4188-a697-3334e0e31982" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a090c75c-6081-4472-9eae-086163834f2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_CurrentFiscalYearEndDate_a090c75c-6081-4472-9eae-086163834f2e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_551ee54a-859d-4ecb-a29a-a208f3b898da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentTransitionReport_551ee54a-859d-4ecb-a29a-a208f3b898da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_32b95295-4cd9-4a97-9644-409b2ca772d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentShellCompanyReport_32b95295-4cd9-4a97-9644-409b2ca772d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_913e8104-8512-4044-818e-70f3ecd4f21a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityFileNumber_913e8104-8512-4044-818e-70f3ecd4f21a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_40a34584-f8d9-4eb4-a80e-f8e9e8732137" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityRegistrantName_40a34584-f8d9-4eb4-a80e-f8e9e8732137" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5f83e42b-82db-4325-914a-7bd71026d157" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5f83e42b-82db-4325-914a-7bd71026d157" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_71c1f22d-c88a-40ea-8ab4-e7d37905bc59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressAddressLine1_71c1f22d-c88a-40ea-8ab4-e7d37905bc59" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ae8106b6-b648-482c-8771-aac63aa03402" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressCityOrTown_ae8106b6-b648-482c-8771-aac63aa03402" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ec2a02d3-c87d-498e-9f7d-fe3afe6f5806" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressStateOrProvince_ec2a02d3-c87d-498e-9f7d-fe3afe6f5806" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_d1984547-4623-41c1-96a9-40caf12b10af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressCountry_d1984547-4623-41c1-96a9-40caf12b10af" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_85a499a2-2d2a-49af-9c60-89b0b2a77466" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressPostalZipCode_85a499a2-2d2a-49af-9c60-89b0b2a77466" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_9cc000d8-5f15-4e5d-92a4-87e40ce83673" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_ContactPersonnelName_9cc000d8-5f15-4e5d-92a4-87e40ce83673" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0252b88c-944f-43a5-8c76-375264c8faf0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_CityAreaCode_0252b88c-944f-43a5-8c76-375264c8faf0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f15bc7ab-dac9-417c-b812-9e26548efb07" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_LocalPhoneNumber_f15bc7ab-dac9-417c-b812-9e26548efb07" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_25563c81-b9dc-4936-baf6-eb3565dfac28" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_ContactPersonnelEmailAddress_25563c81-b9dc-4936-baf6-eb3565dfac28" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_be8fb859-15b6-41f5-91f9-3dd3216bc579" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_Security12bTitle_be8fb859-15b6-41f5-91f9-3dd3216bc579" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a7d60597-db9e-4ee5-878d-c69fec3d28f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_TradingSymbol_a7d60597-db9e-4ee5-878d-c69fec3d28f3" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c77ade6a-bb28-47ed-9684-becae56656a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_SecurityExchangeName_c77ade6a-bb28-47ed-9684-becae56656a0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0bba4bd7-4083-4a47-9b60-ea9dc6031ddf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0bba4bd7-4083-4a47-9b60-ea9dc6031ddf" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9026266b-4f21-4e43-ac63-1789c4d4ff84" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9026266b-4f21-4e43-ac63-1789c4d4ff84" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_8f627c09-2a63-4785-b7f2-2d0a30e3f100" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityVoluntaryFilers_8f627c09-2a63-4785-b7f2-2d0a30e3f100" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_667ae1b6-3a53-42d2-b2f9-30b95bdf1935" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityCurrentReportingStatus_667ae1b6-3a53-42d2-b2f9-30b95bdf1935" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7eb13640-d0a3-48ea-b601-f1022d55321a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityInteractiveDataCurrent_7eb13640-d0a3-48ea-b601-f1022d55321a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e0232d65-468f-48c5-9581-8e5ef8b2a99e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityFilerCategory_e0232d65-468f-48c5-9581-8e5ef8b2a99e" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b610911c-71c1-48d0-9f51-b91150d73a0e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityEmergingGrowthCompany_b610911c-71c1-48d0-9f51-b91150d73a0e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_522c6995-375f-4557-9bdb-20362a0d480a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_IcfrAuditorAttestationFlag_522c6995-375f-4557-9bdb-20362a0d480a" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_5f3666e4-9ccb-43e2-9f5e-9ff5ead94b9e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_5f3666e4-9ccb-43e2-9f5e-9ff5ead94b9e" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_4a4000dd-76e5-4763-bf8d-dd6167c6e872" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentAccountingStandard_4a4000dd-76e5-4763-bf8d-dd6167c6e872" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_39bebdd7-f2ec-418e-a62f-f15bbb701656" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityShellCompany_39bebdd7-f2ec-418e-a62f-f15bbb701656" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_185aba6e-644b-433b-98b2-5eb706e6e885" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityCentralIndexKey_185aba6e-644b-433b-98b2-5eb706e6e885" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5340f62d-0b58-4237-bbc0-cb639d9d0d3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentFiscalYearFocus_5340f62d-0b58-4237-bbc0-cb639d9d0d3e" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b276b2a8-7cc2-47ee-bd41-f2c7e8f18de4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b276b2a8-7cc2-47ee-bd41-f2c7e8f18de4" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_24c5cc7a-bace-430a-8d9c-351946904b58" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_AmendmentFlag_24c5cc7a-bace-430a-8d9c-351946904b58" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_d4a2603f-91a7-48d3-919c-4b91681b9f4f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityPublicFloat_d4a2603f-91a7-48d3-919c-4b91681b9f4f" xlink:type="arc" order="37"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b" xlink:to="loc_ifrs-full_EquityMember_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b" xlink:to="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_919b6be5-1a3f-4721-ab8b-f14ec3a26dee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_IssuedCapitalMember_919b6be5-1a3f-4721-ab8b-f14ec3a26dee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_e2f26c12-18f9-44ec-9d3f-d73aecb77ec8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_WarrantsMember_e2f26c12-18f9-44ec-9d3f-d73aecb77ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_57304a68-a1ae-442d-a180-38704b12c24d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_SharePremiumMember_57304a68-a1ae-442d-a180-38704b12c24d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_b5e36516-689c-4823-8711-03ce669de78d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_b5e36516-689c-4823-8711-03ce669de78d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_d3267489-f492-433b-84ae-c032c367f5a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_RetainedEarningsMember_d3267489-f492-433b-84ae-c032c367f5a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_8d58f474-0163-438b-ae5f-8edd2886a126" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:to="loc_oncyf_SaleOfStockAxis_8d58f474-0163-438b-ae5f-8edd2886a126" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_8d58f474-0163-438b-ae5f-8edd2886a126_default" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_8d58f474-0163-438b-ae5f-8edd2886a126" xlink:to="loc_oncyf_SaleOfStockDomain_8d58f474-0163-438b-ae5f-8edd2886a126_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_29316142-7837-47e8-8671-99583ab55002" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_8d58f474-0163-438b-ae5f-8edd2886a126" xlink:to="loc_oncyf_SaleOfStockDomain_29316142-7837-47e8-8671-99583ab55002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_9016afa2-f9e1-4eda-bbe5-614a37c4d094" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_29316142-7837-47e8-8671-99583ab55002" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_9016afa2-f9e1-4eda-bbe5-614a37c4d094" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderPublicOfferingMember_ffde90c8-29cd-4b2e-b9f9-0b88c47284e7" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_29316142-7837-47e8-8671-99583ab55002" xlink:to="loc_oncyf_SharesUnderPublicOfferingMember_ffde90c8-29cd-4b2e-b9f9-0b88c47284e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b98300e2-3d75-4018-acb4-7e9fd0b8aefd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_Equity_b98300e2-3d75-4018-acb4-7e9fd0b8aefd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1d9eaa97-bdf7-4aa2-b5ed-2aabc3bd97f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_ComprehensiveIncome_1d9eaa97-bdf7-4aa2-b5ed-2aabc3bd97f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_06855b99-5016-4bce-b07b-f88e7dd797ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_06855b99-5016-4bce-b07b-f88e7dd797ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_0eefcdff-7896-43ee-85d6-031d19fe16f5" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_0eefcdff-7896-43ee-85d6-031d19fe16f5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_ead8509f-94cf-42b7-b345-0b56faec5da6" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_ead8509f-94cf-42b7-b345-0b56faec5da6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_09f36822-8575-43b3-9611-81f6184f90f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_IssueOfEquity_09f36822-8575-43b3-9611-81f6184f90f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_317289d2-870f-4b50-9ff9-5005ca4f647f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_317289d2-870f-4b50-9ff9-5005ca4f647f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_8214e6fe-8244-44a1-95c2-db85b8614d99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_8214e6fe-8244-44a1-95c2-db85b8614d99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_c07331d2-7a03-4868-ace0-377ef66e2c99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_c07331d2-7a03-4868-ace0-377ef66e2c99" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_03755a12-2224-49d8-8518-eb8e5ba19f64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:href="oncyf-20231231.xsd#oncyf_Statement1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_ae171215-2b5a-41c9-a48d-9f3983341e43" xlink:href="oncyf-20231231.xsd#oncyf_Statement1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_oncyf_Statement1Table_ae171215-2b5a-41c9-a48d-9f3983341e43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_75d87888-6574-4cb6-9551-6d59d8e300d5" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Statement1Table_ae171215-2b5a-41c9-a48d-9f3983341e43" xlink:to="loc_oncyf_SaleOfStockAxis_75d87888-6574-4cb6-9551-6d59d8e300d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_75d87888-6574-4cb6-9551-6d59d8e300d5_default" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_75d87888-6574-4cb6-9551-6d59d8e300d5" xlink:to="loc_oncyf_SaleOfStockDomain_75d87888-6574-4cb6-9551-6d59d8e300d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_9e693717-93ea-4ee2-b204-19e3e55e07d4" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_75d87888-6574-4cb6-9551-6d59d8e300d5" xlink:to="loc_oncyf_SaleOfStockDomain_9e693717-93ea-4ee2-b204-19e3e55e07d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_4ca983d7-23b5-49e4-bd8f-94a89f00fe16" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_9e693717-93ea-4ee2-b204-19e3e55e07d4" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_4ca983d7-23b5-49e4-bd8f-94a89f00fe16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_1d2cdb14-86c8-4ce7-9a0a-cc7941d31309" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_9e693717-93ea-4ee2-b204-19e3e55e07d4" xlink:to="loc_oncyf_SharesPublicOfferingMember_1d2cdb14-86c8-4ce7-9a0a-cc7941d31309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_739c7554-37ea-4ed4-9d69-cd38124689d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_ProfitLoss_739c7554-37ea-4ed4-9d69-cd38124689d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f62944a2-f8c5-49f6-816a-3b8f3ba056f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f62944a2-f8c5-49f6-816a-3b8f3ba056f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_b88d949f-a51d-4a1c-9db0-ec1eadd0098e" xlink:href="oncyf-20231231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_b88d949f-a51d-4a1c-9db0-ec1eadd0098e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_2481bcdd-a371-4a4d-80e3-cf8b53769b08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_2481bcdd-a371-4a4d-80e3-cf8b53769b08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_ae8cbc9c-8e50-4c73-8d1b-5347d5fbbe3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_ae8cbc9c-8e50-4c73-8d1b-5347d5fbbe3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_60b2d543-a4dd-477a-a524-cc8763b983da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_InterestRevenueExpense_60b2d543-a4dd-477a-a524-cc8763b983da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_a16f4925-754b-4218-8780-9b070798720c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_a16f4925-754b-4218-8780-9b070798720c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_5815e786-661b-494e-9f2b-29f52577045c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_5815e786-661b-494e-9f2b-29f52577045c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_131009e2-8509-4bca-8821-a59831f2e4b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_131009e2-8509-4bca-8821-a59831f2e4b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_9ccb2405-88c9-42ce-8fef-3b3db5861d4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_9ccb2405-88c9-42ce-8fef-3b3db5861d4d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_03844f06-2a1f-42e4-9940-cc5a01755d36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_03844f06-2a1f-42e4-9940-cc5a01755d36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_bb46260e-8153-4ed2-98a4-69f04b89707a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:to="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_bb46260e-8153-4ed2-98a4-69f04b89707a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_48351898-c532-42df-a642-c56e592d85e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_48351898-c532-42df-a642-c56e592d85e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d896bbfe-70b0-4724-92b8-a7c500e51eb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d896bbfe-70b0-4724-92b8-a7c500e51eb3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_ee1bee37-0168-4c81-a231-014d3e7d6b35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_ee1bee37-0168-4c81-a231-014d3e7d6b35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_15fa83f7-bec2-4fec-9a57-525910b1aa0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_15fa83f7-bec2-4fec-9a57-525910b1aa0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_81156bb4-3013-4bb3-b605-47c6ae672a38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_81156bb4-3013-4bb3-b605-47c6ae672a38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_0a9cc5a9-134f-4dcc-86ed-50b329e027bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_CashOutflowForLeases_0a9cc5a9-134f-4dcc-86ed-50b329e027bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5c906d23-b02f-4de7-b739-40e14bd59bb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5c906d23-b02f-4de7-b739-40e14bd59bb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_a16a27b5-e8d0-4d84-aa10-344e8055cd2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_a16a27b5-e8d0-4d84-aa10-344e8055cd2a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3703eec5-249b-4adf-8e5b-7dea9243244a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3703eec5-249b-4adf-8e5b-7dea9243244a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_fea52151-3750-4587-8abd-655f3ac7e9be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_fea52151-3750-4587-8abd-655f3ac7e9be" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_5b7b9454-64d2-4184-85c5-6dded6c30f66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5befd1c4-057a-4685-b25a-8f5e4be17821" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_dd46533c-4bf2-4d4d-aaff-1f2566f26fec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5befd1c4-057a-4685-b25a-8f5e4be17821" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_dd46533c-4bf2-4d4d-aaff-1f2566f26fec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_64f163e4-2a91-4ac0-aab9-ad10bf144de0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_dd46533c-4bf2-4d4d-aaff-1f2566f26fec" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_64f163e4-2a91-4ac0-aab9-ad10bf144de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_64f163e4-2a91-4ac0-aab9-ad10bf144de0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_64f163e4-2a91-4ac0-aab9-ad10bf144de0" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_64f163e4-2a91-4ac0-aab9-ad10bf144de0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_64f163e4-2a91-4ac0-aab9-ad10bf144de0" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_f5f0cce0-1ba0-4975-9638-4cc6fbad5573" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:to="loc_ifrs-full_OfficeEquipmentMember_f5f0cce0-1ba0-4975-9638-4cc6fbad5573" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_73701263-8603-46ec-8228-16331dbe807c" xlink:href="oncyf-20231231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:to="loc_oncyf_MedicalEquipmentMember_73701263-8603-46ec-8228-16331dbe807c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_07712b49-932e-4e76-8242-4defea6237a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:to="loc_ifrs-full_ComputerEquipmentMember_07712b49-932e-4e76-8242-4defea6237a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_379c228f-2248-46d4-9ebe-6f698bf2e56e" xlink:href="oncyf-20231231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5befd1c4-057a-4685-b25a-8f5e4be17821" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_379c228f-2248-46d4-9ebe-6f698bf2e56e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#OtherAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:href="oncyf-20231231.xsd#oncyf_Currency1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_0635d583-8020-49f4-b62a-5e7d38a930c5" xlink:href="oncyf-20231231.xsd#oncyf_Currency1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_oncyf_Currency1Table_0635d583-8020-49f4-b62a-5e7d38a930c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_d53e7ee6-2777-45e7-84f1-f567a5949fd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_0635d583-8020-49f4-b62a-5e7d38a930c5" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_d53e7ee6-2777-45e7-84f1-f567a5949fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_d53e7ee6-2777-45e7-84f1-f567a5949fd9_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_d53e7ee6-2777-45e7-84f1-f567a5949fd9" xlink:to="loc_ifrs-full_OtherProvisionsMember_d53e7ee6-2777-45e7-84f1-f567a5949fd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_8ae54e5b-a622-4b04-a317-c7f3a1543d5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_d53e7ee6-2777-45e7-84f1-f567a5949fd9" xlink:to="loc_ifrs-full_OtherProvisionsMember_8ae54e5b-a622-4b04-a317-c7f3a1543d5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember_c5e3206f-95ff-4c87-b36a-6441cf776ce4" xlink:href="oncyf-20231231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_8ae54e5b-a622-4b04-a317-c7f3a1543d5b" xlink:to="loc_oncyf_CollaborationAgreementMember_c5e3206f-95ff-4c87-b36a-6441cf776ce4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialMember_90895aa8-420a-4785-b6d3-34741ed498da" xlink:href="oncyf-20231231.xsd#oncyf_ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_OtherProvisionsMember_8ae54e5b-a622-4b04-a317-c7f3a1543d5b" xlink:to="loc_oncyf_ClinicalTrialMember_90895aa8-420a-4785-b6d3-34741ed498da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_6fd85679-8a38-44c1-9241-8887aabc8d7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_ifrs-full_OtherReceivables_6fd85679-8a38-44c1-9241-8887aabc8d7b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_f758cb62-0828-42c8-bec2-e58f49e03965" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_f758cb62-0828-42c8-bec2-e58f49e03965" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments_2b03347c-84d2-4519-9095-120c38271565" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_ifrs-full_NoncurrentPrepayments_2b03347c-84d2-4519-9095-120c38271565" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_a1fe6450-b093-46ef-9bfc-2b1719fe1d50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_a1fe6450-b093-46ef-9bfc-2b1719fe1d50" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#PropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f630adc2-76c6-4338-a41e-08e7c2808a52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f630adc2-76c6-4338-a41e-08e7c2808a52" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_484f701f-3150-47d1-b14e-670822268bc9" xlink:href="oncyf-20231231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:to="loc_oncyf_MedicalEquipmentMember_484f701f-3150-47d1-b14e-670822268bc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_6a7b9182-3429-4ca5-b9c7-73a038821b6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:to="loc_ifrs-full_ComputerEquipmentMember_6a7b9182-3429-4ca5-b9c7-73a038821b6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember_d133863a-1e3b-407e-855f-055a42ed09a4" xlink:href="oncyf-20231231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:to="loc_oncyf_OfficeEquipmentAndFurnitureMember_d133863a-1e3b-407e-855f-055a42ed09a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_3d49ef7f-6ccd-46a7-b7ec-c1c94406ea00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_3d49ef7f-6ccd-46a7-b7ec-c1c94406ea00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_de111532-e81a-4ca1-8427-f733c47d72bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_de111532-e81a-4ca1-8427-f733c47d72bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_de111532-e81a-4ca1-8427-f733c47d72bd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_de111532-e81a-4ca1-8427-f733c47d72bd" xlink:to="loc_ifrs-full_CarryingAmountMember_de111532-e81a-4ca1-8427-f733c47d72bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_415377dd-ed9c-429b-b44b-a8622cad621e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_de111532-e81a-4ca1-8427-f733c47d72bd" xlink:to="loc_ifrs-full_CarryingAmountMember_415377dd-ed9c-429b-b44b-a8622cad621e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_e55dd779-afbf-4dc3-85aa-fc6ffc860cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_415377dd-ed9c-429b-b44b-a8622cad621e" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_e55dd779-afbf-4dc3-85aa-fc6ffc860cbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_8f1f3752-1f23-4814-82f8-bc99463e5418" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_CarryingAmountMember_415377dd-ed9c-429b-b44b-a8622cad621e" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_8f1f3752-1f23-4814-82f8-bc99463e5418" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f630adc2-76c6-4338-a41e-08e7c2808a52" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_bfc93eee-3ca9-4474-bdac-5eb3cd85c311" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_bfc93eee-3ca9-4474-bdac-5eb3cd85c311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_08f997c4-1750-4bc9-9e84-697ee8ffb4ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_08f997c4-1750-4bc9-9e84-697ee8ffb4ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_5cfde25d-c40b-4f8d-835b-c51db9990247" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_5cfde25d-c40b-4f8d-835b-c51db9990247" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_a2cef860-501f-419a-a69e-87ab6ecec724" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_780f4d4b-3674-424a-a8a0-221421c9e405" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_780f4d4b-3674-424a-a8a0-221421c9e405" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5883e7d-472e-41b2-a5cb-a533e95620b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_780f4d4b-3674-424a-a8a0-221421c9e405" xlink:to="loc_srt_RangeAxis_d5883e7d-472e-41b2-a5cb-a533e95620b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d5883e7d-472e-41b2-a5cb-a533e95620b1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d5883e7d-472e-41b2-a5cb-a533e95620b1" xlink:to="loc_srt_RangeMember_d5883e7d-472e-41b2-a5cb-a533e95620b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8fa588d-c530-4f96-8de5-46ebdea9db9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d5883e7d-472e-41b2-a5cb-a533e95620b1" xlink:to="loc_srt_RangeMember_e8fa588d-c530-4f96-8de5-46ebdea9db9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_994b651d-2ac5-4c3e-9d41-54871c92d3c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8fa588d-c530-4f96-8de5-46ebdea9db9d" xlink:to="loc_srt_MinimumMember_994b651d-2ac5-4c3e-9d41-54871c92d3c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_47c09002-2305-421d-9d44-03b3eb674ea3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e8fa588d-c530-4f96-8de5-46ebdea9db9d" xlink:to="loc_srt_MaximumMember_47c09002-2305-421d-9d44-03b3eb674ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_c92a4a4e-4be9-4d13-8ad0-afb00eb43d90" xlink:href="oncyf-20231231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_c92a4a4e-4be9-4d13-8ad0-afb00eb43d90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_a502b166-8cdd-4db5-a7ff-03256a1baa97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_a502b166-8cdd-4db5-a7ff-03256a1baa97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_64b4ab13-61f3-42ad-853a-95d24877dd36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_64b4ab13-61f3-42ad-853a-95d24877dd36" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_a0aac4c1-ff2f-40cd-a8dc-cd0bbee8c44a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_a0aac4c1-ff2f-40cd-a8dc-cd0bbee8c44a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_44ae4a85-d146-4107-8cdc-97d879050d44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c43e52df-5ca2-417d-8a25-f45e8769cbd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_44ae4a85-d146-4107-8cdc-97d879050d44" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c43e52df-5ca2-417d-8a25-f45e8769cbd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_04030a45-0236-4696-9690-65c258ea7ff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c43e52df-5ca2-417d-8a25-f45e8769cbd3" xlink:to="loc_ifrs-full_MaturityAxis_04030a45-0236-4696-9690-65c258ea7ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_04030a45-0236-4696-9690-65c258ea7ff0_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_MaturityAxis_04030a45-0236-4696-9690-65c258ea7ff0" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_04030a45-0236-4696-9690-65c258ea7ff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_MaturityAxis_04030a45-0236-4696-9690-65c258ea7ff0" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_f8f4d9aa-7dbc-4c66-b1f8-a40c33ab6f84" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_f8f4d9aa-7dbc-4c66-b1f8-a40c33ab6f84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_13c2add3-e8b7-4a7c-af4c-b4aeb525ccf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_13c2add3-e8b7-4a7c-af4c-b4aeb525ccf4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_5113655d-ec47-4838-a985-f5811ea87607" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_5113655d-ec47-4838-a985-f5811ea87607" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_2b3d6075-2f7e-4c9b-8152-0ed1993188ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_44ae4a85-d146-4107-8cdc-97d879050d44" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_2b3d6075-2f7e-4c9b-8152-0ed1993188ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_bdf490af-2863-476a-be1c-9a833f74a7c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_f0894830-0719-4f45-9ab1-203ed8971541" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_bdf490af-2863-476a-be1c-9a833f74a7c6" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_f0894830-0719-4f45-9ab1-203ed8971541" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6ca72aa5-129a-4e97-bba6-c4554adab163" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_f0894830-0719-4f45-9ab1-203ed8971541" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6ca72aa5-129a-4e97-bba6-c4554adab163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_6ca72aa5-129a-4e97-bba6-c4554adab163_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6ca72aa5-129a-4e97-bba6-c4554adab163" xlink:to="loc_ifrs-full_LiabilitiesMember_6ca72aa5-129a-4e97-bba6-c4554adab163_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_7aea1a71-f16c-4db3-9593-1fbb65505f42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6ca72aa5-129a-4e97-bba6-c4554adab163" xlink:to="loc_ifrs-full_LiabilitiesMember_7aea1a71-f16c-4db3-9593-1fbb65505f42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_96a8009f-9b0f-4694-8f5f-eceb615fd48b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_7aea1a71-f16c-4db3-9593-1fbb65505f42" xlink:to="loc_ifrs-full_WarrantsMember_96a8009f-9b0f-4694-8f5f-eceb615fd48b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_bdf490af-2863-476a-be1c-9a833f74a7c6" xlink:to="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_cbb0e047-e622-4c8d-8e08-ff57d5f89354" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:to="loc_oncyf_NumberOfWarrantsOutstanding_cbb0e047-e622-4c8d-8e08-ff57d5f89354" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_a7e251e4-c2ee-4a08-a1bf-80f3e6037b57" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:to="loc_oncyf_IssueOfEquityShares_a7e251e4-c2ee-4a08-a1bf-80f3e6037b57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_350a5151-0fe1-4bb1-a6ce-adb159d22ff1" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:href="oncyf-20231231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_bdf490af-2863-476a-be1c-9a833f74a7c6" xlink:to="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_5c53e622-c32b-48b2-956c-01623a9be9de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_5c53e622-c32b-48b2-956c-01623a9be9de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_b9ce9c80-b83f-433b-a344-8df7a476fd24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_ifrs-full_IssueOfEquity_b9ce9c80-b83f-433b-a344-8df7a476fd24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount_3e66ed1b-4637-4c35-9c09-9c2d0c91c2e6" xlink:href="oncyf-20231231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_oncyf_WarrantLiabilityUnamortizedDiscount_3e66ed1b-4637-4c35-9c09-9c2d0c91c2e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityAmortizedDiscount_ce509e5a-d575-4245-87c0-fff49063705c" xlink:href="oncyf-20231231.xsd#oncyf_WarrantLiabilityAmortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_oncyf_WarrantLiabilityAmortizedDiscount_ce509e5a-d575-4245-87c0-fff49063705c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6e2ad1af-5b4c-4bc4-8a85-9d42176f9df6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6e2ad1af-5b4c-4bc4-8a85-9d42176f9df6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_1748c369-f07f-4af3-b028-8de76fd8bfb1" xlink:href="oncyf-20231231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_1748c369-f07f-4af3-b028-8de76fd8bfb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_0b020855-7358-43f6-879d-c2c171ac462a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_83e55922-7073-45f0-930f-190b60473bc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_83e55922-7073-45f0-930f-190b60473bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_83e55922-7073-45f0-930f-190b60473bc2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_83e55922-7073-45f0-930f-190b60473bc2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_83e55922-7073-45f0-930f-190b60473bc2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_83e55922-7073-45f0-930f-190b60473bc2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_b74ff424-cd0d-4749-b4aa-88290dc8b300" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:to="loc_oncyf_SharesPublicOfferingMember_b74ff424-cd0d-4749-b4aa-88290dc8b300" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderOverAllotmentOptionMember_9aa05197-3b09-4550-b03d-7ba40fc3389d" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderOverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:to="loc_oncyf_SharesUnderOverAllotmentOptionMember_9aa05197-3b09-4550-b03d-7ba40fc3389d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_5aab5dc0-4f83-42a5-8c41-219b6ddb3dfa" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_5aab5dc0-4f83-42a5-8c41-219b6ddb3dfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_5777f42a-37e5-40a7-85a7-d57486f3ea2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_5777f42a-37e5-40a7-85a7-d57486f3ea2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_5777f42a-37e5-40a7-85a7-d57486f3ea2f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_5777f42a-37e5-40a7-85a7-d57486f3ea2f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_5777f42a-37e5-40a7-85a7-d57486f3ea2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_0841c3e2-892e-44ce-8f7d-a463f180ddf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_5777f42a-37e5-40a7-85a7-d57486f3ea2f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_0841c3e2-892e-44ce-8f7d-a463f180ddf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_1aa13a8f-9820-48d5-8b4a-9417d7abcdf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_0841c3e2-892e-44ce-8f7d-a463f180ddf1" xlink:to="loc_ifrs-full_IssuedCapitalMember_1aa13a8f-9820-48d5-8b4a-9417d7abcdf5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_d8564125-c695-4f1e-89ad-ca0a300cac5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_d8564125-c695-4f1e-89ad-ca0a300cac5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_d8564125-c695-4f1e-89ad-ca0a300cac5e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d8564125-c695-4f1e-89ad-ca0a300cac5e" xlink:to="loc_ifrs-full_LiabilitiesMember_d8564125-c695-4f1e-89ad-ca0a300cac5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_a2d0375c-a0a7-4765-95a5-c3254607d5fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d8564125-c695-4f1e-89ad-ca0a300cac5e" xlink:to="loc_ifrs-full_LiabilitiesMember_a2d0375c-a0a7-4765-95a5-c3254607d5fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_1e78b594-d553-4901-91a2-a61c026857e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_a2d0375c-a0a7-4765-95a5-c3254607d5fb" xlink:to="loc_ifrs-full_WarrantsMember_1e78b594-d553-4901-91a2-a61c026857e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c9da4a2d-56be-4629-a264-ef1fc95f095f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c9da4a2d-56be-4629-a264-ef1fc95f095f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c9da4a2d-56be-4629-a264-ef1fc95f095f_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c9da4a2d-56be-4629-a264-ef1fc95f095f" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_c9da4a2d-56be-4629-a264-ef1fc95f095f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_83a4f04e-db1a-4771-a51f-6f36104f5c3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c9da4a2d-56be-4629-a264-ef1fc95f095f" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_83a4f04e-db1a-4771-a51f-6f36104f5c3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_a235d90a-ca23-4f68-9056-d75c533ea0b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_83a4f04e-db1a-4771-a51f-6f36104f5c3e" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_a235d90a-ca23-4f68-9056-d75c533ea0b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc" xlink:to="loc_ifrs-full_EquityMember_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_1c3d57fd-7c80-4f90-a4cc-5a0891d9f2b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc" xlink:to="loc_ifrs-full_EquityMember_1c3d57fd-7c80-4f90-a4cc-5a0891d9f2b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_911c8c1b-4928-478e-94b4-31c4f61d13de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_1c3d57fd-7c80-4f90-a4cc-5a0891d9f2b5" xlink:to="loc_ifrs-full_IssuedCapitalMember_911c8c1b-4928-478e-94b4-31c4f61d13de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_ff768e12-a133-42b9-b4ff-8ce008d029fa" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_oncyf_SaleOfStockAxis_ff768e12-a133-42b9-b4ff-8ce008d029fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_ff768e12-a133-42b9-b4ff-8ce008d029fa_default" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_ff768e12-a133-42b9-b4ff-8ce008d029fa" xlink:to="loc_oncyf_SaleOfStockDomain_ff768e12-a133-42b9-b4ff-8ce008d029fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_57377a48-8995-48cd-9849-0228a4ae1c14" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_ff768e12-a133-42b9-b4ff-8ce008d029fa" xlink:to="loc_oncyf_SaleOfStockDomain_57377a48-8995-48cd-9849-0228a4ae1c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_28828769-52a8-45d0-9495-2d5a7a2b9f0f" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_57377a48-8995-48cd-9849-0228a4ae1c14" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_28828769-52a8-45d0-9495-2d5a7a2b9f0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_eb6378ee-dace-4839-b2da-b491407031ad" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_eb6378ee-dace-4839-b2da-b491407031ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfUnitsGross_82ea5618-a45e-4188-a377-496d0933cbc4" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsFromIssueOfUnitsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_ProceedsFromIssueOfUnitsGross_82ea5618-a45e-4188-a377-496d0933cbc4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_62a51fad-452d-4194-9ed8-19ab2728a6e4" xlink:href="oncyf-20231231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_62a51fad-452d-4194-9ed8-19ab2728a6e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_939a009b-92d8-4d8f-a216-6f9108630cd1" xlink:href="oncyf-20231231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_CommonSharesPerUnit_939a009b-92d8-4d8f-a216-6f9108630cd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_f392470e-9f32-42d0-8b11-dc5bd59c0d20" xlink:href="oncyf-20231231.xsd#oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_f392470e-9f32-42d0-8b11-dc5bd59c0d20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantExercisePrice_87f5534b-5da5-4e7b-a223-36faa9996cc4" xlink:href="oncyf-20231231.xsd#oncyf_WarrantExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_WarrantExercisePrice_87f5534b-5da5-4e7b-a223-36faa9996cc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_9305d1d0-88a7-4d03-b437-137038c9d16b" xlink:href="oncyf-20231231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_9305d1d0-88a7-4d03-b437-137038c9d16b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_ff0a847d-7fb0-4c3c-b887-daaae51dc293" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_ff0a847d-7fb0-4c3c-b887-daaae51dc293" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_13d4ed65-a668-4ebf-841a-35a84cb73964" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_13d4ed65-a668-4ebf-841a-35a84cb73964" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_07832417-80dd-4873-bfbd-2cc5615ef4e7" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_07832417-80dd-4873-bfbd-2cc5615ef4e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_1e1821ab-12a9-45c3-afa8-4baf576eb349" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_1e1821ab-12a9-45c3-afa8-4baf576eb349" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_948f6aeb-aad3-4fdd-a388-ba7dc664d072" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_ifrs-full_IssueOfEquity_948f6aeb-aad3-4fdd-a388-ba7dc664d072" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_25e6c41b-4808-4cda-b08b-f1e68c88c664" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_ifrs-full_WarrantLiability_25e6c41b-4808-4cda-b08b-f1e68c88c664" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount_8106e901-c093-4e5e-8d17-461b74075fc9" xlink:href="oncyf-20231231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_WarrantLiabilityUnamortizedDiscount_8106e901-c093-4e5e-8d17-461b74075fc9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsTerm_8cc8c53a-7d6b-4801-ab01-a818141e3ef4" xlink:href="oncyf-20231231.xsd#oncyf_WarrantsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_WarrantsTerm_8cc8c53a-7d6b-4801-ab01-a818141e3ef4" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_fe9cfefa-3903-4543-9dfc-4e11807c7e2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_fe9cfefa-3903-4543-9dfc-4e11807c7e2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_887098e4-69e2-4062-a657-86088dbaba7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_fe9cfefa-3903-4543-9dfc-4e11807c7e2c" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_887098e4-69e2-4062-a657-86088dbaba7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_887098e4-69e2-4062-a657-86088dbaba7c_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_887098e4-69e2-4062-a657-86088dbaba7c" xlink:to="loc_ifrs-full_LiabilitiesMember_887098e4-69e2-4062-a657-86088dbaba7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_81fa32d6-5472-48ab-8658-e7e095563e50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_887098e4-69e2-4062-a657-86088dbaba7c" xlink:to="loc_ifrs-full_LiabilitiesMember_81fa32d6-5472-48ab-8658-e7e095563e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_1c2d9938-bc19-4f37-ba21-39634c6abe98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_81fa32d6-5472-48ab-8658-e7e095563e50" xlink:to="loc_ifrs-full_WarrantsMember_1c2d9938-bc19-4f37-ba21-39634c6abe98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_a2a84a1d-71c7-439b-884e-40625bee257b" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_a2a84a1d-71c7-439b-884e-40625bee257b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_1d5b5138-6f75-4630-889b-c8ae9da95f24" xlink:href="oncyf-20231231.xsd#oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_1d5b5138-6f75-4630-889b-c8ae9da95f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_235d5970-4780-4079-9145-70752b392e8f" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_235d5970-4780-4079-9145-70752b392e8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_eb6fca33-a61e-4d26-a7ff-48f496cc0312" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_eb6fca33-a61e-4d26-a7ff-48f496cc0312" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_c2e719a0-7d10-41b9-975e-3360f6ad23ea" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_c2e719a0-7d10-41b9-975e-3360f6ad23ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_e75c7a9a-b70c-48b2-91df-5f042c71251d" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_e75c7a9a-b70c-48b2-91df-5f042c71251d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_93b62ac5-2538-4a0b-a1e1-e021f22e0f46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_93b62ac5-2538-4a0b-a1e1-e021f22e0f46" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_996f3110-7ee3-4033-9a39-676ea712b0c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_996f3110-7ee3-4033-9a39-676ea712b0c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_996f3110-7ee3-4033-9a39-676ea712b0c6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_996f3110-7ee3-4033-9a39-676ea712b0c6" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_996f3110-7ee3-4033-9a39-676ea712b0c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a1ab331b-cca3-41c3-9213-6305d04c35ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_996f3110-7ee3-4033-9a39-676ea712b0c6" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a1ab331b-cca3-41c3-9213-6305d04c35ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_c97a4988-e52b-4c6d-84e1-691a77a72916" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a1ab331b-cca3-41c3-9213-6305d04c35ae" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_c97a4988-e52b-4c6d-84e1-691a77a72916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_bfa23e2e-e16c-4721-8a9a-ed1c751ac918" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a1ab331b-cca3-41c3-9213-6305d04c35ae" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_bfa23e2e-e16c-4721-8a9a-ed1c751ac918" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_d8aa1971-a5af-4540-b640-04eb9fada3f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_d8aa1971-a5af-4540-b640-04eb9fada3f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_d8aa1971-a5af-4540-b640-04eb9fada3f6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_d8aa1971-a5af-4540-b640-04eb9fada3f6" xlink:to="loc_ifrs-full_EquityMember_d8aa1971-a5af-4540-b640-04eb9fada3f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_73724594-ed73-4d03-b057-af2ca52bc51d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_d8aa1971-a5af-4540-b640-04eb9fada3f6" xlink:to="loc_ifrs-full_EquityMember_73724594-ed73-4d03-b057-af2ca52bc51d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_65c413e7-2f80-4232-89c9-096007cd5ff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_73724594-ed73-4d03-b057-af2ca52bc51d" xlink:to="loc_ifrs-full_IssuedCapitalMember_65c413e7-2f80-4232-89c9-096007cd5ff4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_8b672706-a7a5-431f-acba-651c4b2d716b" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:to="loc_oncyf_SaleOfStockAxis_8b672706-a7a5-431f-acba-651c4b2d716b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_8b672706-a7a5-431f-acba-651c4b2d716b_default" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_8b672706-a7a5-431f-acba-651c4b2d716b" xlink:to="loc_oncyf_SaleOfStockDomain_8b672706-a7a5-431f-acba-651c4b2d716b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_8b672706-a7a5-431f-acba-651c4b2d716b" xlink:to="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_91140fa5-9f35-44fc-88a4-ecb7f72f4e6e" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_91140fa5-9f35-44fc-88a4-ecb7f72f4e6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_373f8921-5ed8-490e-a3ab-433a4d887364" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_373f8921-5ed8-490e-a3ab-433a4d887364" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_0e58cc25-e13a-40e7-b3c5-7b0421e195b3" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:to="loc_oncyf_SharesPublicOfferingMember_0e58cc25-e13a-40e7-b3c5-7b0421e195b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:href="oncyf-20231231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_93b62ac5-2538-4a0b-a1e1-e021f22e0f46" xlink:to="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_27d71b3f-6155-44f0-b612-747544134082" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:to="loc_ifrs-full_NumberOfSharesIssued_27d71b3f-6155-44f0-b612-747544134082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_9197f374-0f8d-46ad-b0c7-44c322a127bf" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:to="loc_oncyf_IssueOfEquityShares_9197f374-0f8d-46ad-b0c7-44c322a127bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_51d96d43-4cb7-4d37-afe8-6a2aafc80a47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:href="oncyf-20231231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_93b62ac5-2538-4a0b-a1e1-e021f22e0f46" xlink:to="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_a2d9cb9e-c7d9-4dc9-84ab-d0289a856c31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:to="loc_ifrs-full_Equity_a2d9cb9e-c7d9-4dc9-84ab-d0289a856c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_8e4a4e06-b306-4e33-a9b2-dfef46e36c19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:to="loc_ifrs-full_IssueOfEquity_8e4a4e06-b306-4e33-a9b2-dfef46e36c19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_74eb4918-10f3-4343-a343-70425a28ce1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_74eb4918-10f3-4343-a343-70425a28ce1c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_2a95fb6b-185a-4421-ada7-1b1af8fa6f22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_8effb55e-2d24-4329-9983-7c0386ab7f5e" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_oncyf_SaleOfStockAxis_8effb55e-2d24-4329-9983-7c0386ab7f5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_8effb55e-2d24-4329-9983-7c0386ab7f5e_default" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_8effb55e-2d24-4329-9983-7c0386ab7f5e" xlink:to="loc_oncyf_SaleOfStockDomain_8effb55e-2d24-4329-9983-7c0386ab7f5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_8effb55e-2d24-4329-9983-7c0386ab7f5e" xlink:to="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_956992e1-d03c-4f9d-8138-751bf33ee0de" xlink:href="oncyf-20231231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_956992e1-d03c-4f9d-8138-751bf33ee0de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_82a4c2fe-7cc1-4802-921c-bab24685ed84" xlink:href="oncyf-20231231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_82a4c2fe-7cc1-4802-921c-bab24685ed84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_555dadd9-d8ca-42f4-bbcb-13085b0cbf48" xlink:href="oncyf-20231231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:to="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_555dadd9-d8ca-42f4-bbcb-13085b0cbf48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_3a341874-028c-4665-83b8-85d8bd9f75db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_3a341874-028c-4665-83b8-85d8bd9f75db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_3a341874-028c-4665-83b8-85d8bd9f75db_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3a341874-028c-4665-83b8-85d8bd9f75db" xlink:to="loc_ifrs-full_LiabilitiesMember_3a341874-028c-4665-83b8-85d8bd9f75db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_c8ba103a-5d00-4dbc-a1a8-02d842c747eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3a341874-028c-4665-83b8-85d8bd9f75db" xlink:to="loc_ifrs-full_LiabilitiesMember_c8ba103a-5d00-4dbc-a1a8-02d842c747eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_e7c97b48-3d99-46e1-a6d8-b9ac6f6b7892" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_c8ba103a-5d00-4dbc-a1a8-02d842c747eb" xlink:to="loc_ifrs-full_WarrantsMember_e7c97b48-3d99-46e1-a6d8-b9ac6f6b7892" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0e018cf6-9aa7-46de-af21-7f8633d6129b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0e018cf6-9aa7-46de-af21-7f8633d6129b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_0e018cf6-9aa7-46de-af21-7f8633d6129b_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0e018cf6-9aa7-46de-af21-7f8633d6129b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_0e018cf6-9aa7-46de-af21-7f8633d6129b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_dbc583ca-2dd5-4ef1-b9f7-a4844a78b12b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0e018cf6-9aa7-46de-af21-7f8633d6129b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_dbc583ca-2dd5-4ef1-b9f7-a4844a78b12b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_c401b427-a24d-4631-9efd-7065f9d6db2a" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_dbc583ca-2dd5-4ef1-b9f7-a4844a78b12b" xlink:to="loc_oncyf_SharesPublicOfferingMember_c401b427-a24d-4631-9efd-7065f9d6db2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_e1d2667e-0cf9-45de-8c57-95f9f45e33a5" xlink:href="oncyf-20231231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_dbc583ca-2dd5-4ef1-b9f7-a4844a78b12b" xlink:to="loc_oncyf_CompensationWarrantsMember_e1d2667e-0cf9-45de-8c57-95f9f45e33a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_4bcf841f-72ba-4605-9b46-c5de2a10b8a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_4bcf841f-72ba-4605-9b46-c5de2a10b8a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_4bcf841f-72ba-4605-9b46-c5de2a10b8a6_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_4bcf841f-72ba-4605-9b46-c5de2a10b8a6" xlink:to="loc_ifrs-full_EquityMember_4bcf841f-72ba-4605-9b46-c5de2a10b8a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_6f925b22-2048-457f-b293-2f4e6c500fec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_4bcf841f-72ba-4605-9b46-c5de2a10b8a6" xlink:to="loc_ifrs-full_EquityMember_6f925b22-2048-457f-b293-2f4e6c500fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_ef2d4bd7-fa09-419f-aaf4-b8afd7c3dd37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_6f925b22-2048-457f-b293-2f4e6c500fec" xlink:to="loc_ifrs-full_IssuedCapitalMember_ef2d4bd7-fa09-419f-aaf4-b8afd7c3dd37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_501423bc-4329-4670-bd28-23ffd44165a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_6f925b22-2048-457f-b293-2f4e6c500fec" xlink:to="loc_ifrs-full_SharePremiumMember_501423bc-4329-4670-bd28-23ffd44165a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_eb95ea42-1048-4fe4-bc9b-173c960e65c6" xlink:href="oncyf-20231231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_eb95ea42-1048-4fe4-bc9b-173c960e65c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_266128e2-9dac-4eb0-a4ce-c1853b75ffc3" xlink:href="oncyf-20231231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_266128e2-9dac-4eb0-a4ce-c1853b75ffc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_b198f40f-177e-4206-95a3-93309717e9da" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_IssueOfEquityShares_b198f40f-177e-4206-95a3-93309717e9da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfUnitsGross_52e7cb38-6ef1-4052-a78a-1482e01e321a" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsFromIssueOfUnitsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ProceedsFromIssueOfUnitsGross_52e7cb38-6ef1-4052-a78a-1482e01e321a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_cacf6be7-c2b7-4c78-baa5-df3b6b894c31" xlink:href="oncyf-20231231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_cacf6be7-c2b7-4c78-baa5-df3b6b894c31" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_702228fd-485c-4a3c-a6f3-b854c4daf0f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_702228fd-485c-4a3c-a6f3-b854c4daf0f8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_645117fb-271d-48e6-a101-5aa5e63b04e0" xlink:href="oncyf-20231231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_645117fb-271d-48e6-a101-5aa5e63b04e0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_37a88fbc-5146-403a-b92a-ef21c3ac6907" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_37a88fbc-5146-403a-b92a-ef21c3ac6907" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised_e30386fc-3378-4078-97f7-4ccc607501e4" xlink:href="oncyf-20231231.xsd#oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised_e30386fc-3378-4078-97f7-4ccc607501e4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_691ec7ff-ac3c-4bf7-8c2e-7a83bb311617" xlink:href="oncyf-20231231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_691ec7ff-ac3c-4bf7-8c2e-7a83bb311617" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_27bc3b52-e801-4151-b194-70eba14697a8" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_27bc3b52-e801-4151-b194-70eba14697a8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_4a7033aa-c439-43bc-be64-3965368dfa0f" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_4a7033aa-c439-43bc-be64-3965368dfa0f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares_e207a3f8-9642-44be-a960-1d379426aa53" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquitySharesNumberOfCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares_e207a3f8-9642-44be-a960-1d379426aa53" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfWarrants_f0f9ca7c-f0a0-4331-a0f1-e2123887a6b1" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquitySharesNumberOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_IssueOfEquitySharesNumberOfWarrants_f0f9ca7c-f0a0-4331-a0f1-e2123887a6b1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_a4620279-dbe0-4ac5-97ba-2861c0aff468" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_IssueOfEquity_a4620279-dbe0-4ac5-97ba-2861c0aff468" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_86fb476d-4e29-427a-9e61-273b16f070e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_WarrantLiability_86fb476d-4e29-427a-9e61-273b16f070e7" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_227c0fd6-8989-4bb9-bd17-1f6b7b1fae66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_227c0fd6-8989-4bb9-bd17-1f6b7b1fae66" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedTransactionCosts_39f202c0-83b7-45b9-be76-5a9a19a930f5" xlink:href="oncyf-20231231.xsd#oncyf_ShareWarrantsIssuedTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ShareWarrantsIssuedTransactionCosts_39f202c0-83b7-45b9-be76-5a9a19a930f5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_f6711f04-bf7b-4555-a78c-c1996b6dc439" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_f6711f04-bf7b-4555-a78c-c1996b6dc439" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedOperatingExpense_32136f37-556f-4a68-98f7-6d9850319680" xlink:href="oncyf-20231231.xsd#oncyf_ShareWarrantsIssuedOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ShareWarrantsIssuedOperatingExpense_32136f37-556f-4a68-98f7-6d9850319680" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_66990759-a6d5-4665-b54c-21d461aec5fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:to="loc_ifrs-full_RangeAxis_66990759-a6d5-4665-b54c-21d461aec5fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_66990759-a6d5-4665-b54c-21d461aec5fd_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_66990759-a6d5-4665-b54c-21d461aec5fd" xlink:to="loc_ifrs-full_RangesMember_66990759-a6d5-4665-b54c-21d461aec5fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_ca018d8a-521d-45b8-aaeb-231f42a287ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_66990759-a6d5-4665-b54c-21d461aec5fd" xlink:to="loc_ifrs-full_RangesMember_ca018d8a-521d-45b8-aaeb-231f42a287ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_d2252f43-621d-40b5-94a9-40ffca79afd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_ca018d8a-521d-45b8-aaeb-231f42a287ea" xlink:to="loc_ifrs-full_BottomOfRangeMember_d2252f43-621d-40b5-94a9-40ffca79afd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_bf1d9a31-df0e-462f-8573-c2d4d26683ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_ca018d8a-521d-45b8-aaeb-231f42a287ea" xlink:to="loc_ifrs-full_TopOfRangeMember_bf1d9a31-df0e-462f-8573-c2d4d26683ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_814524ee-ce70-4d01-97b2-9b17048d62ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_814524ee-ce70-4d01-97b2-9b17048d62ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_051b329a-23c9-44fd-83d0-a644727c3d19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_051b329a-23c9-44fd-83d0-a644727c3d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_e84aa6c4-8736-4c26-817d-7ff5ce58dec8" xlink:href="oncyf-20231231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:to="loc_oncyf_CompensationWarrantsMember_e84aa6c4-8736-4c26-817d-7ff5ce58dec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_f15a845f-b71c-43be-87f4-e0272dbe5b9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_f15a845f-b71c-43be-87f4-e0272dbe5b9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_f15a845f-b71c-43be-87f4-e0272dbe5b9e_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_f15a845f-b71c-43be-87f4-e0272dbe5b9e" xlink:to="loc_ifrs-full_EquityMember_f15a845f-b71c-43be-87f4-e0272dbe5b9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_5ab27ae3-785c-4626-941a-12094ecd684f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_f15a845f-b71c-43be-87f4-e0272dbe5b9e" xlink:to="loc_ifrs-full_EquityMember_5ab27ae3-785c-4626-941a-12094ecd684f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_9d095aa9-1fe2-4c64-9c11-d86686fea1fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5ab27ae3-785c-4626-941a-12094ecd684f" xlink:to="loc_ifrs-full_IssuedCapitalMember_9d095aa9-1fe2-4c64-9c11-d86686fea1fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_a5f76243-cfc9-4839-9eed-de6392dbd9ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_EquityMember_5ab27ae3-785c-4626-941a-12094ecd684f" xlink:to="loc_ifrs-full_SharePremiumMember_a5f76243-cfc9-4839-9eed-de6392dbd9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_e7528309-5e76-46c9-86e1-40b6a7f316dd" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_e7528309-5e76-46c9-86e1-40b6a7f316dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9c0d1b28-d465-4edb-9c1b-281a1dd77324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9c0d1b28-d465-4edb-9c1b-281a1dd77324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ea0fa56f-be97-40a2-9afb-374935c8e4ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ea0fa56f-be97-40a2-9afb-374935c8e4ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_9d7fc0b7-eb7d-4326-8276-1da7e66ffb5a" xlink:href="oncyf-20231231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_9d7fc0b7-eb7d-4326-8276-1da7e66ffb5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_11395055-06ba-4616-a85f-a0f715ab8abe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_11395055-06ba-4616-a85f-a0f715ab8abe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_951a9d49-8fbe-4fa7-9532-45a03943692f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_951a9d49-8fbe-4fa7-9532-45a03943692f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_db3c1bc1-ab95-4b4f-ace4-a038212355e3" xlink:href="oncyf-20231231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_db3c1bc1-ab95-4b4f-ace4-a038212355e3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_9a00048b-9653-4ba3-8507-907b40290e58" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_9a00048b-9653-4ba3-8507-907b40290e58" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_82871175-4640-4a0e-8722-7e23cda6ebc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_82871175-4640-4a0e-8722-7e23cda6ebc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_82871175-4640-4a0e-8722-7e23cda6ebc3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_82871175-4640-4a0e-8722-7e23cda6ebc3" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_82871175-4640-4a0e-8722-7e23cda6ebc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_82871175-4640-4a0e-8722-7e23cda6ebc3" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_c3870956-2813-42b3-ae23-b1cd97c5986e" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_c3870956-2813-42b3-ae23-b1cd97c5986e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_1df87fd0-ec6c-4c54-b16b-a43556f7a6a9" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_1df87fd0-ec6c-4c54-b16b-a43556f7a6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_1d3ab4de-655d-4ad1-9cce-f507378e4b70" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_1d3ab4de-655d-4ad1-9cce-f507378e4b70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_0976a394-13e0-4b36-abd4-22bbe9bc6b2f" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_0976a394-13e0-4b36-abd4-22bbe9bc6b2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_4078c718-b584-4176-a5df-709f750db035" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_4078c718-b584-4176-a5df-709f750db035" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a33c3b64-408b-4126-bc75-8b5ed76440fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:to="loc_ifrs-full_RangeAxis_a33c3b64-408b-4126-bc75-8b5ed76440fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_a33c3b64-408b-4126-bc75-8b5ed76440fe_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_RangeAxis_a33c3b64-408b-4126-bc75-8b5ed76440fe" xlink:to="loc_ifrs-full_RangesMember_a33c3b64-408b-4126-bc75-8b5ed76440fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_8b2489d9-60a5-4044-9857-4be21540e68b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_RangeAxis_a33c3b64-408b-4126-bc75-8b5ed76440fe" xlink:to="loc_ifrs-full_RangesMember_8b2489d9-60a5-4044-9857-4be21540e68b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_2e92699a-f884-416b-84d9-b105e2fc4840" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_8b2489d9-60a5-4044-9857-4be21540e68b" xlink:to="loc_ifrs-full_BottomOfRangeMember_2e92699a-f884-416b-84d9-b105e2fc4840" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_779cab15-4550-40ea-ad0c-370877ac34e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_RangesMember_8b2489d9-60a5-4044-9857-4be21540e68b" xlink:to="loc_ifrs-full_TopOfRangeMember_779cab15-4550-40ea-ad0c-370877ac34e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_35aea921-6163-4434-8cd9-8d6c8e8e9661" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_35aea921-6163-4434-8cd9-8d6c8e8e9661" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_16178b0d-8ed4-4510-bee4-2ed285d4f923" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_16178b0d-8ed4-4510-bee4-2ed285d4f923" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_c923baae-f361-4286-8bd4-13c98b924668" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_c923baae-f361-4286-8bd4-13c98b924668" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0f1c9919-ec15-4f03-bbee-a1447fe67c9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0f1c9919-ec15-4f03-bbee-a1447fe67c9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_208bd442-7ea9-4cf5-abf0-80dc86f25e93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_208bd442-7ea9-4cf5-abf0-80dc86f25e93" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_90d51d2e-d5f7-4f5c-9cc4-e19cbdb7cc34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_90d51d2e-d5f7-4f5c-9cc4-e19cbdb7cc34" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_d30a5586-5115-4699-bdff-429df81434e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_d30a5586-5115-4699-bdff-429df81434e0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_d30a5586-5115-4699-bdff-429df81434e0" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_6fea6564-5899-4e67-a265-62b0ff26ff0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_6fea6564-5899-4e67-a265-62b0ff26ff0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_41ad9d70-e587-4e7f-8ddc-2bb76fcdc859" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_6fea6564-5899-4e67-a265-62b0ff26ff0c" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_41ad9d70-e587-4e7f-8ddc-2bb76fcdc859" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_fc49b1b8-0fa0-494b-9e80-661eb1cedf97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_fc49b1b8-0fa0-494b-9e80-661eb1cedf97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_414dca79-b6a3-423b-a56f-7c2786d265b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_414dca79-b6a3-423b-a56f-7c2786d265b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_a6fa2131-b16f-43e4-a1b1-9fa2aab79b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_a6fa2131-b16f-43e4-a1b1-9fa2aab79b89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4a422354-5906-44a8-9176-bbd24fbcdea5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4a422354-5906-44a8-9176-bbd24fbcdea5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c3349605-fbdd-4a4f-a56b-e7fb9d1bc83f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_ad129ff7-6375-42e4-8a41-a689f4e4da9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_ad129ff7-6375-42e4-8a41-a689f4e4da9a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3f9d2ada-fe18-43b8-8db4-f69b858d9acb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3f9d2ada-fe18-43b8-8db4-f69b858d9acb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3f9d2ada-fe18-43b8-8db4-f69b858d9acb" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d253d15b-a0fb-4b12-aaff-5ed91a81e222" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d253d15b-a0fb-4b12-aaff-5ed91a81e222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_90ee105a-7f51-4068-b47d-9eb7b86cb12c" xlink:href="oncyf-20231231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d253d15b-a0fb-4b12-aaff-5ed91a81e222" xlink:to="loc_oncyf_CompensationWarrantsMember_90ee105a-7f51-4068-b47d-9eb7b86cb12c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_0bd19b47-7ef5-4742-9a9c-b8179aa9f4e3" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_0bd19b47-7ef5-4742-9a9c-b8179aa9f4e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_f4376d2e-7740-4b30-b9a1-97f9b5c3cdaa" xlink:href="oncyf-20231231.xsd#oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_f4376d2e-7740-4b30-b9a1-97f9b5c3cdaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_544bc00c-45db-471e-89f9-0dc850ad9898" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_544bc00c-45db-471e-89f9-0dc850ad9898" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_181b6627-8738-49e9-97ed-df6f727c5c10" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_181b6627-8738-49e9-97ed-df6f727c5c10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_0ab9037f-2cff-4d7d-a110-86c691b0bdd5" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_0ab9037f-2cff-4d7d-a110-86c691b0bdd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_f4201f8e-f381-4398-90b0-464c4f141f36" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_f4201f8e-f381-4398-90b0-464c4f141f36" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f0a0fe1e-0245-4240-a012-864daaea484a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dddce1b8-23fb-4b98-ac54-d92f2c89410f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f0a0fe1e-0245-4240-a012-864daaea484a" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dddce1b8-23fb-4b98-ac54-d92f2c89410f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_80722089-4a28-49fc-99e1-480e1b6a3625" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dddce1b8-23fb-4b98-ac54-d92f2c89410f" xlink:to="loc_srt_StatementGeographicalAxis_80722089-4a28-49fc-99e1-480e1b6a3625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_80722089-4a28-49fc-99e1-480e1b6a3625_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_80722089-4a28-49fc-99e1-480e1b6a3625" xlink:to="loc_srt_SegmentGeographicalDomain_80722089-4a28-49fc-99e1-480e1b6a3625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_80722089-4a28-49fc-99e1-480e1b6a3625" xlink:to="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_3521b268-e772-4777-af1d-5dcadf34cf1d" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:to="loc_country_CA_3521b268-e772-4777-af1d-5dcadf34cf1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB_71ef2cc3-776a-414c-b928-242c5b5f6ec1" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:to="loc_country_BB_71ef2cc3-776a-414c-b928-242c5b5f6ec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6205ed2a-a1de-4963-9fda-80e9340c8d51" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:to="loc_country_US_6205ed2a-a1de-4963-9fda-80e9340c8d51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dddce1b8-23fb-4b98-ac54-d92f2c89410f" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_1df09952-51c1-490a-b6f3-dad88087db56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_1df09952-51c1-490a-b6f3-dad88087db56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_7554bc35-1533-4596-b8c1-a43a56cab826" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_7554bc35-1533-4596-b8c1-a43a56cab826" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23c16e52-bed5-4842-bfde-98f4b276a7fd" xlink:href="oncyf-20231231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23c16e52-bed5-4842-bfde-98f4b276a7fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_f7e1b971-cd1c-4238-8504-aa61173d35c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f0a0fe1e-0245-4240-a012-864daaea484a" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_f7e1b971-cd1c-4238-8504-aa61173d35c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_1f8ee256-e3ae-484e-a66b-c6e8cdaeea63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f0a0fe1e-0245-4240-a012-864daaea484a" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_1f8ee256-e3ae-484e-a66b-c6e8cdaeea63" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_41dedba8-4237-4cdf-8470-3c411acc8fef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7d004a9f-9687-4f1a-9314-81b3239bb734" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_41dedba8-4237-4cdf-8470-3c411acc8fef" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7d004a9f-9687-4f1a-9314-81b3239bb734" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5c6295fe-6c84-4668-b308-d25b5d45c75d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7d004a9f-9687-4f1a-9314-81b3239bb734" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5c6295fe-6c84-4668-b308-d25b5d45c75d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5c6295fe-6c84-4668-b308-d25b5d45c75d_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5c6295fe-6c84-4668-b308-d25b5d45c75d" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_5c6295fe-6c84-4668-b308-d25b5d45c75d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5c6295fe-6c84-4668-b308-d25b5d45c75d" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_29af1e78-3ee6-4fc6-9e05-aef279ea8f6e" xlink:href="oncyf-20231231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_29af1e78-3ee6-4fc6-9e05-aef279ea8f6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_d43c23b7-6f01-4782-8e8b-08ba783c5cac" xlink:href="oncyf-20231231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_d43c23b7-6f01-4782-8e8b-08ba783c5cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_9bda26ff-8368-46c9-b25c-203146746974" xlink:href="oncyf-20231231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_9bda26ff-8368-46c9-b25c-203146746974" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_9ec03fcf-e48c-4c7c-8551-05c198c6fbda" xlink:href="oncyf-20231231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_9ec03fcf-e48c-4c7c-8551-05c198c6fbda" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_0fd5ff43-95e9-46d1-8d67-049209059899" xlink:href="oncyf-20231231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_ShareIssueCostsMember_0fd5ff43-95e9-46d1-8d67-049209059899" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_780485d5-dee4-4e83-baa4-72267765fe0b" xlink:href="oncyf-20231231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_780485d5-dee4-4e83-baa4-72267765fe0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_53bac258-c2e4-42e7-815c-cf379ff9e9b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_41dedba8-4237-4cdf-8470-3c411acc8fef" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_53bac258-c2e4-42e7-815c-cf379ff9e9b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5a4ce026-4aa5-4d63-849b-9f021076bf27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5a4ce026-4aa5-4d63-849b-9f021076bf27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5a4ce026-4aa5-4d63-849b-9f021076bf27_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5a4ce026-4aa5-4d63-849b-9f021076bf27" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_5a4ce026-4aa5-4d63-849b-9f021076bf27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9306659d-8d68-44dd-bc4d-c24d518ec4a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5a4ce026-4aa5-4d63-849b-9f021076bf27" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9306659d-8d68-44dd-bc4d-c24d518ec4a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_22d3b0a1-9d7f-4dea-aed0-5857947ba3f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9306659d-8d68-44dd-bc4d-c24d518ec4a6" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_22d3b0a1-9d7f-4dea-aed0-5857947ba3f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_9c9dc644-e45f-4150-af06-15932f67c336" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_ifrs-full_TypesOfRisksAxis_9c9dc644-e45f-4150-af06-15932f67c336" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_9c9dc644-e45f-4150-af06-15932f67c336_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_TypesOfRisksAxis_9c9dc644-e45f-4150-af06-15932f67c336" xlink:to="loc_ifrs-full_TypesOfRisksMember_9c9dc644-e45f-4150-af06-15932f67c336_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_a30355d8-c46d-4e53-9735-df26c603e931" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_TypesOfRisksAxis_9c9dc644-e45f-4150-af06-15932f67c336" xlink:to="loc_ifrs-full_TypesOfRisksMember_a30355d8-c46d-4e53-9735-df26c603e931" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_c6bc7f39-2267-4088-9175-afc9bd4435b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_TypesOfRisksMember_a30355d8-c46d-4e53-9735-df26c603e931" xlink:to="loc_ifrs-full_CurrencyRiskMember_c6bc7f39-2267-4088-9175-afc9bd4435b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_c738c055-0121-4846-b530-3023c50370f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_srt_CurrencyAxis_c738c055-0121-4846-b530-3023c50370f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_c738c055-0121-4846-b530-3023c50370f7_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_c738c055-0121-4846-b530-3023c50370f7" xlink:to="loc_currency_AllCurrenciesDomain_c738c055-0121-4846-b530-3023c50370f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_5b4bacbd-a9aa-4ae6-a2dc-6440f58a0072" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_c738c055-0121-4846-b530-3023c50370f7" xlink:to="loc_currency_AllCurrenciesDomain_5b4bacbd-a9aa-4ae6-a2dc-6440f58a0072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_da1879f8-3797-402c-96a8-b8dd34345a0b" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_5b4bacbd-a9aa-4ae6-a2dc-6440f58a0072" xlink:to="loc_currency_USD_da1879f8-3797-402c-96a8-b8dd34345a0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_a2d246d5-d6fd-491e-b598-1ddcde615e38" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_5b4bacbd-a9aa-4ae6-a2dc-6440f58a0072" xlink:to="loc_currency_EUR_a2d246d5-d6fd-491e-b598-1ddcde615e38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_2c836120-0985-438a-97e0-1d8d9fcafee2" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_oncyf_SaleOfStockAxis_2c836120-0985-438a-97e0-1d8d9fcafee2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_2c836120-0985-438a-97e0-1d8d9fcafee2_default" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_SaleOfStockAxis_2c836120-0985-438a-97e0-1d8d9fcafee2" xlink:to="loc_oncyf_SaleOfStockDomain_2c836120-0985-438a-97e0-1d8d9fcafee2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_f5d95cba-7df9-4cd6-826f-6e7c26244bc2" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_SaleOfStockAxis_2c836120-0985-438a-97e0-1d8d9fcafee2" xlink:to="loc_oncyf_SaleOfStockDomain_f5d95cba-7df9-4cd6-826f-6e7c26244bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_d5fb96dd-0188-49cb-9eb7-d94198883394" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_SaleOfStockDomain_f5d95cba-7df9-4cd6-826f-6e7c26244bc2" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_d5fb96dd-0188-49cb-9eb7-d94198883394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b211ecb-4020-47bf-900d-917a6b1428f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b211ecb-4020-47bf-900d-917a6b1428f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_6b211ecb-4020-47bf-900d-917a6b1428f2_default" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b211ecb-4020-47bf-900d-917a6b1428f2" xlink:to="loc_ifrs-full_LiabilitiesMember_6b211ecb-4020-47bf-900d-917a6b1428f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_d2fc37eb-f9c9-460e-bde5-a1421c0d5736" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b211ecb-4020-47bf-900d-917a6b1428f2" xlink:to="loc_ifrs-full_LiabilitiesMember_d2fc37eb-f9c9-460e-bde5-a1421c0d5736" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_bbbd98c5-82fa-453a-84af-1ab644744886" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_LiabilitiesMember_d2fc37eb-f9c9-460e-bde5-a1421c0d5736" xlink:to="loc_ifrs-full_WarrantsMember_bbbd98c5-82fa-453a-84af-1ab644744886" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_250ff844-0745-48e3-9d57-cc3924885154" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_250ff844-0745-48e3-9d57-cc3924885154" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_8fd910c4-09cf-45a4-8cb5-81a606c33b6d" xlink:href="oncyf-20231231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_8fd910c4-09cf-45a4-8cb5-81a606c33b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_4b747e05-ef2e-46e1-80fc-520745b563b4" xlink:href="oncyf-20231231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_4b747e05-ef2e-46e1-80fc-520745b563b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:href="oncyf-20231231.xsd#oncyf_Currency1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_ac2f0b64-b7e5-4e0a-be65-f27923021b7d" xlink:href="oncyf-20231231.xsd#oncyf_Currency1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_oncyf_Currency1Table_ac2f0b64-b7e5-4e0a-be65-f27923021b7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_174da878-62c8-4c51-a3c0-33b1df38deb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_Currency1Table_ac2f0b64-b7e5-4e0a-be65-f27923021b7d" xlink:to="loc_srt_CurrencyAxis_174da878-62c8-4c51-a3c0-33b1df38deb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_174da878-62c8-4c51-a3c0-33b1df38deb2_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_174da878-62c8-4c51-a3c0-33b1df38deb2" xlink:to="loc_currency_AllCurrenciesDomain_174da878-62c8-4c51-a3c0-33b1df38deb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_c7cfb964-2b05-4bfc-852a-ba7fb8db0823" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_174da878-62c8-4c51-a3c0-33b1df38deb2" xlink:to="loc_currency_AllCurrenciesDomain_c7cfb964-2b05-4bfc-852a-ba7fb8db0823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_e2dceb3f-f2a8-4fe1-9edd-8594e5e5b9c1" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_c7cfb964-2b05-4bfc-852a-ba7fb8db0823" xlink:to="loc_currency_USD_e2dceb3f-f2a8-4fe1-9edd-8594e5e5b9c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_9b820614-0622-42cb-b83a-951f031eb7e9" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_c7cfb964-2b05-4bfc-852a-ba7fb8db0823" xlink:to="loc_currency_EUR_9b820614-0622-42cb-b83a-951f031eb7e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a3386b91-09d9-4dd6-8ac2-c2e07eaafa90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a3386b91-09d9-4dd6-8ac2-c2e07eaafa90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsale_deec71e1-ea3a-4e0b-a0ca-500b193d5f2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_ifrs-full_FinancialAssetsAvailableforsale_deec71e1-ea3a-4e0b-a0ca-500b193d5f2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_058a8230-5457-44ba-9d73-9ddca3006266" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_058a8230-5457-44ba-9d73-9ddca3006266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_7b119123-6013-4bba-ba86-2c4273b9be86" xlink:href="oncyf-20231231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_7b119123-6013-4bba-ba86-2c4273b9be86" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#EconomicDependenceDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_06c0ea9c-e1d2-444f-9be6-09000b300888" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_8804f4cb-6553-406a-9be8-87a7cc851b09" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_06c0ea9c-e1d2-444f-9be6-09000b300888" xlink:to="loc_oncyf_ConcentrationRisk1Table_8804f4cb-6553-406a-9be8-87a7cc851b09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_5690e0af-2017-4f7f-916a-50a0c098bf6c" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_ConcentrationRisk1Table_8804f4cb-6553-406a-9be8-87a7cc851b09" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_5690e0af-2017-4f7f-916a-50a0c098bf6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_5690e0af-2017-4f7f-916a-50a0c098bf6c_default" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_5690e0af-2017-4f7f-916a-50a0c098bf6c" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_5690e0af-2017-4f7f-916a-50a0c098bf6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_07c9b24d-ed60-4a8a-9fa2-c6b2b28cea4b" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_5690e0af-2017-4f7f-916a-50a0c098bf6c" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_07c9b24d-ed60-4a8a-9fa2-c6b2b28cea4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_ffe99163-718e-4427-8073-14260f01bcdf" xlink:href="oncyf-20231231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_07c9b24d-ed60-4a8a-9fa2-c6b2b28cea4b" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_ffe99163-718e-4427-8073-14260f01bcdf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_3fa3a337-2d41-452b-a913-585342c37fa8" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_06c0ea9c-e1d2-444f-9be6-09000b300888" xlink:to="loc_oncyf_ConcentrationRiskNumber_3fa3a337-2d41-452b-a913-585342c37fa8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ComponentsofExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:href="oncyf-20231231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_ccafa947-b709-465f-8736-a835339f7de9" xlink:href="oncyf-20231231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_ccafa947-b709-465f-8736-a835339f7de9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_418b23e9-b86e-4682-ab75-b219625eb9ed" xlink:href="oncyf-20231231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_ccafa947-b709-465f-8736-a835339f7de9" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_418b23e9-b86e-4682-ab75-b219625eb9ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_418b23e9-b86e-4682-ab75-b219625eb9ed_default" xlink:href="oncyf-20231231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_418b23e9-b86e-4682-ab75-b219625eb9ed" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_418b23e9-b86e-4682-ab75-b219625eb9ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_3d0c1c43-8318-4679-9597-9040ff69980a" xlink:href="oncyf-20231231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_418b23e9-b86e-4682-ab75-b219625eb9ed" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_3d0c1c43-8318-4679-9597-9040ff69980a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseMember_ba04669f-e6c1-4e10-aaa7-240d490a289a" xlink:href="oncyf-20231231.xsd#oncyf_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_3d0c1c43-8318-4679-9597-9040ff69980a" xlink:to="loc_oncyf_ResearchAndDevelopmentExpenseMember_ba04669f-e6c1-4e10-aaa7-240d490a289a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseMember_2d49c98f-63b1-464a-ae0d-1558cb87eb2b" xlink:href="oncyf-20231231.xsd#oncyf_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_3d0c1c43-8318-4679-9597-9040ff69980a" xlink:to="loc_oncyf_GeneralAndAdministrativeExpenseMember_2d49c98f-63b1-464a-ae0d-1558cb87eb2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:href="oncyf-20231231.xsd#oncyf_ResearchAndDevelopmentExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:to="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialExpense_3249b4e5-1a31-447e-bf83-835db6a5cfbb" xlink:href="oncyf-20231231.xsd#oncyf_ClinicalTrialExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_oncyf_ClinicalTrialExpense_3249b4e5-1a31-447e-bf83-835db6a5cfbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense_df6dfea1-c13f-4b8e-bcaa-b851863d8ad0" xlink:href="oncyf-20231231.xsd#oncyf_ManufacturingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_oncyf_ManufacturingExpense_df6dfea1-c13f-4b8e-bcaa-b851863d8ad0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense_98d8e997-5639-43a4-a769-747f5366df8e" xlink:href="oncyf-20231231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_oncyf_IntellectualPropertyExpense_98d8e997-5639-43a4-a769-747f5366df8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense_585006af-db01-4e0f-9ea4-d63908c73ceb" xlink:href="oncyf-20231231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_oncyf_TranslationalScienceExpense_585006af-db01-4e0f-9ea4-d63908c73ceb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_c7a957b5-9498-4cc1-93ae-6ab88f11aebe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_ifrs-full_OtherEmployeeExpense_c7a957b5-9498-4cc1-93ae-6ab88f11aebe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ca6131bc-f79d-40c0-94aa-85b3223cd1c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ca6131bc-f79d-40c0-94aa-85b3223cd1c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_392ae3f6-3591-4214-93f8-af6b0de201c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_392ae3f6-3591-4214-93f8-af6b0de201c4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_ab04fb0d-96cf-4833-a270-986514bfef8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_ab04fb0d-96cf-4833-a270-986514bfef8f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:href="oncyf-20231231.xsd#oncyf_GeneralAndAdministrativeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:to="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense_04c4e85c-47b6-411c-9688-3ab6a9e7fe9a" xlink:href="oncyf-20231231.xsd#oncyf_PublicCompanyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_oncyf_PublicCompanyExpense_04c4e85c-47b6-411c-9688-3ab6a9e7fe9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses_9c829ef9-6f26-4b39-83a3-ed0c143fd4f8" xlink:href="oncyf-20231231.xsd#oncyf_OfficeExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_oncyf_OfficeExpenses_9c829ef9-6f26-4b39-83a3-ed0c143fd4f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_a6130dbf-b1a1-4645-bebe-8722a0a1974e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_ifrs-full_AmortisationExpense_a6130dbf-b1a1-4645-bebe-8722a0a1974e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_ecb8bda4-19a0-41e0-bf4b-6299eb2e7b6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_ecb8bda4-19a0-41e0-bf4b-6299eb2e7b6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_1f170978-72a9-4a62-b950-51162f316cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_1f170978-72a9-4a62-b950-51162f316cd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_0f93ca2b-c79b-4478-8482-ba22751ecfef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_0f93ca2b-c79b-4478-8482-ba22751ecfef" xlink:type="arc" order="2"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>oncyf-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0331f315-f217-43c3-a3a4-8d92b75af8cb,g:42af5dc4-a986-45bb-8df7-47c2c2475bfc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_f0ab2935-94f4-484a-a839-7e2094a013c1_terseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of increase in value of currency (cad per share)</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:href="oncyf-20231231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_cc150751-92c3-42e7-84f5-ff781a853b85_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract" xlink:to="lab_ifrs-full_CurrentLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LiabilitiesMember_1e18eb30-9bba-4417-80a7-3e7fc2b65d17_terseLabel_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_ifrs-full_LiabilitiesMember_label_en-US" xlink:label="lab_ifrs-full_LiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LiabilitiesMember" xlink:to="lab_ifrs-full_LiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_bb1505f6-f0d0-4f3c-8f02-6997dc3171da_terseLabel_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_ifrs-full_GrossCarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_GrossCarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossCarryingAmountMember" xlink:to="lab_ifrs-full_GrossCarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_3e8bac9d-ae55-467f-8390-ab79f9278a28_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_ifrs-full_ExpenseByNatureAbstract_label_en-US" xlink:label="lab_ifrs-full_ExpenseByNatureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expenses by nature [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract" xlink:to="lab_ifrs-full_ExpenseByNatureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_1d6dbfa9-2b68-4b2d-8a7d-63fffa9f5d05_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_9a835679-b93a-4e40-be37-185612a24648_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Material Accounting Policies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of material accounting policy information [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d2d7199f-0957-43ba-ab9c-5bc4ef9d0a20_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_64e8de4f-5a31-4aa6-aa77-c39d69d85ae3_terseLabel_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum option expiration term</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_label_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_documentation_en-US" xlink:label="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Term Of Options Granted For Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:href="oncyf-20231231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:to="lab_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_6b669b1d-4d73-472b-91e4-688b3a2a6109_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to incentive share award plan (note 11)</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Incentive Share Awards, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:to="lab_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_2b0a7273-12c4-4cbf-a9fd-db0407f32abb_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, other equity instruments granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_7c86acac-d869-4972-9d79-c4f7b2f43b67_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, share-based payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_25b828ac-e165-4949-aea8-f350d9c631de_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Barbados rate change</link:label>
    <link:label id="lab_ifrs-full_TaxEffectFromChangeInTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect from change in tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:to="lab_ifrs-full_TaxEffectFromChangeInTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_0652ca2b-b9c4-4f24-95e6-0b781dc389f4_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_b149c25f-419e-4e60-9089-a78714b551a4_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalMember_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember" xlink:to="lab_ifrs-full_ClassesOfShareCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_44f9f3cf-71b1-4f6a-a5d0-1dc481d5c68a_terseLabel_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (cad and usd per share)</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_label_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:label id="lab_oncyf_SharesIssuedPricePerShare1_documentation_en-US" xlink:label="lab_oncyf_SharesIssuedPricePerShare1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1" xlink:href="oncyf-20231231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesIssuedPricePerShare1" xlink:to="lab_oncyf_SharesIssuedPricePerShare1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_88029e08-4aaa-402c-986e-0e3cf7c75327_terseLabel_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment tax credits</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_label_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:label id="lab_oncyf_InvestmentTaxCreditsMember_documentation_en-US" xlink:label="lab_oncyf_InvestmentTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment Tax Credits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember" xlink:href="oncyf-20231231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_InvestmentTaxCreditsMember" xlink:to="lab_oncyf_InvestmentTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_39dc68f1-b0d9-4597-b06a-b395c9720d84_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - property and equipment (notes 6, 20)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for depreciation and amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="lab_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_35c108f0-118b-401b-a573-0d5a2d6de7a5_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before the following</link:label>
    <link:label id="lab_ifrs-full_ProfitLossFromOperatingActivities_label_en-US" xlink:label="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) from operating activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossFromOperatingActivities" xlink:to="lab_ifrs-full_ProfitLossFromOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_FinancialAssetsAvailableforsale_7c0d6a5f-20ec-489c-9678-3fa268625130_terseLabel_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAvailableforsale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets available-for-sale</link:label>
    <link:label id="lab_ifrs-full_FinancialAssetsAvailableforsale_label_en-US" xlink:label="lab_ifrs-full_FinancialAssetsAvailableforsale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial assets available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_FinancialAssetsAvailableforsale" xlink:to="lab_ifrs-full_FinancialAssetsAvailableforsale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_abb54b61-8a51-402c-a9fa-6469888c26ba_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (note 15)</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxExpenseContinuingOperations_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="lab_ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_048f444f-0a30-4a83-b35b-12ee3fa8e23e_terseLabel_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses</link:label>
    <link:label id="lab_ifrs-full_MiscellaneousOtherOperatingExpense_label_en-US" xlink:label="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miscellaneous other operating expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="lab_ifrs-full_MiscellaneousOtherOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_ecd6c3b4-cb4e-4eb2-b804-dc59e00883ab_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingMember" xlink:to="lab_oncyf_SharesPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepayments_efc9e000-fd58-437d-84bc-8d4f9f6df7bb_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses (note 5)</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepayments_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepayments" xlink:to="lab_ifrs-full_CurrentPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_a43974bc-c451-41bd-9246-e92f3a23d7cb_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option life, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareWarrantsIssuedTransactionCosts_f1a316f2-ac0a-439b-aacc-f528989adc7e_terseLabel_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued, transaction costs</link:label>
    <link:label id="lab_oncyf_ShareWarrantsIssuedTransactionCosts_label_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Warrants Issued, Transaction Costs</link:label>
    <link:label id="lab_oncyf_ShareWarrantsIssuedTransactionCosts_documentation_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Warrants Issued, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:href="oncyf-20231231.xsd#oncyf_ShareWarrantsIssuedTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:to="lab_oncyf_ShareWarrantsIssuedTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a0ce88af-4cda-4a0d-be90-0845caa370b2_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_484a4cdd-eff7-4905-a268-4442cd1c562f_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_c4e5d6c4-ca6b-4027-b0e5-27671afd505f_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade payables</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current trade payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_c49493ba-bdc1-4f7e-b97b-c3cadfb84668_terseLabel_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_label_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Amount [Abstract]</link:label>
    <link:label id="lab_oncyf_ShareCapitalAmountAbstract_documentation_en-US" xlink:label="lab_oncyf_ShareCapitalAmountAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract" xlink:href="oncyf-20231231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareCapitalAmountAbstract" xlink:to="lab_oncyf_ShareCapitalAmountAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_1df1c1ff-8ecc-40c4-a056-8022fc3aa1d1_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sales or maturity of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_77c34c0c-6ad7-44ab-9908-ebcb1e71b348_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangeAxis_2a023e5c-1b6c-4d64-8694-dd561735aaec_terseLabel_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:label id="lab_ifrs-full_RangeAxis_label_en-US" xlink:label="lab_ifrs-full_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangeAxis" xlink:to="lab_ifrs-full_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_44c5ed3c-eddb-43d2-8237-04caef685c89_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:label id="lab_dei_ContactPersonnelEmailAddress_label_en-US" xlink:label="lab_dei_ContactPersonnelEmailAddress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Email Address</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelEmailAddress" xlink:to="lab_dei_ContactPersonnelEmailAddress" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_602e527c-35f8-492b-87d5-a12bbe20d822_terseLabel_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 United States ATM</link:label>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20231231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RestrictedShareUnitsMember_efed55c4-36c9-4ad0-acb6-c912a575f77a_terseLabel_en-US" xlink:label="lab_ifrs-full_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted share units</link:label>
    <link:label id="lab_ifrs-full_RestrictedShareUnitsMember_label_en-US" xlink:label="lab_ifrs-full_RestrictedShareUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted share units [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RestrictedShareUnitsMember" xlink:to="lab_ifrs-full_RestrictedShareUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_3d0665d9-a02c-4739-a4aa-eccc9e80604a_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_label_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Change in Fair Value Of Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:to="lab_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_b8cf837c-19cb-4ff4-ad84-7680a8500a41_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Common Share</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapital_97a94146-c91a-4058-a193-e9f2e268703e_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital (note 10) &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December&#160;31, 2023 &#8211; 74,423,960 December&#160;31, 2022 &#8211; 61,327,914</link:label>
    <link:label id="lab_ifrs-full_IssuedCapital_label_en-US" xlink:label="lab_ifrs-full_IssuedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapital" xlink:to="lab_ifrs-full_IssuedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_d1f6ad0e-11ed-488a-b10d-d376c697011c_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherReceivables_118187f0-46ed-47e9-93a5-f3e9c929fac6_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_OtherReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherReceivables" xlink:to="lab_ifrs-full_OtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OfficeExpenses_3f7824a5-5d59-429a-871e-af58a677b205_terseLabel_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office expenses</link:label>
    <link:label id="lab_oncyf_OfficeExpenses_label_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Expenses</link:label>
    <link:label id="lab_oncyf_OfficeExpenses_documentation_en-US" xlink:label="lab_oncyf_OfficeExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses" xlink:href="oncyf-20231231.xsd#oncyf_OfficeExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OfficeExpenses" xlink:to="lab_oncyf_OfficeExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_740bc779-2fd1-49d9-913d-ca35990e394e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_edc17124-e483-43c6-bf08-06904b5a0f35_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to warrant derivative exercised (note 10)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of warrants, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_7ce6c709-2cb5-4df4-a5e9-feb262daf240_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to stock option plan (note 11)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through exercise of options, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_e0ab604c-553f-4a94-a311-4fe881c2e601_terseLabel_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:label id="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_label_en-US" xlink:label="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis of income and expense [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:to="lab_ifrs-full_AnalysisOfIncomeAndExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_abb1ea51-686a-424c-aca5-2b29bbc79ab3_terseLabel_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 United States ATM</link:label>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2021 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20231231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_331918d4-3692-4e7f-8acc-f2eb0da705c7_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfProvisionsAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of other provisions [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis" xlink:to="lab_ifrs-full_ClassesOfProvisionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_6ec5bbfb-5e56-4490-965f-c2a4c1d2bc86_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_de95395d-8114-4071-8455-2b906fc33e03_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_ae610af3-c2df-4aeb-a3e7-44898d9c48cb_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:to="lab_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_02fc8c3e-bc1c-446f-acf4-d2ec19ede391_terseLabel_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign exchange on cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_095667fe-c9f0-481e-82da-e63e89f83b63_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability (note 13)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentContractLiabilities" xlink:to="lab_ifrs-full_NoncurrentContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_0f01c65d-a6b8-46f3-8f3b-06eec5b1fbe7_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccrualsClassifiedAsCurrent_6de21276-7a1d-4191-b53c-24df0d67406c_terseLabel_en-US" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AccrualsClassifiedAsCurrent_label_en-US" xlink:label="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals classified as current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccrualsClassifiedAsCurrent" xlink:to="lab_ifrs-full_AccrualsClassifiedAsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_a216d45c-452c-44e6-9447-67010955d076_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of share capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised_2920dddf-cbd7-4eba-8d9e-20e55281bd11_terseLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:href="oncyf-20231231.xsd#oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:to="lab_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_19a6e4a2-c522-48bd-ae96-6906798ed14a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash working capital (note 18)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_b065e0eb-507b-4b38-b345-50e37ad4f39b_negatedTotalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Change in non-cash working capital related to operating activities</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInWorkingCapital_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in working capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="lab_ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClinicalTrialExpense_921750a2-e614-4524-bb09-0b2264c305d3_terseLabel_en-US" xlink:label="lab_oncyf_ClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial expenses</link:label>
    <link:label id="lab_oncyf_ClinicalTrialExpense_label_en-US" xlink:label="lab_oncyf_ClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial Expense</link:label>
    <link:label id="lab_oncyf_ClinicalTrialExpense_documentation_en-US" xlink:label="lab_oncyf_ClinicalTrialExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialExpense" xlink:href="oncyf-20231231.xsd#oncyf_ClinicalTrialExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClinicalTrialExpense" xlink:to="lab_oncyf_ClinicalTrialExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_d78d56d2-e7d9-42c3-98bc-4d5d199f6f3a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of trade and other payables [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_a5ebc718-17de-4a15-9669-19833572569c_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent differences</link:label>
    <link:label id="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other tax effects for reconciliation between accounting profit and tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:to="lab_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_e54f8f13-912d-4cca-ab9f-5144b3fff57b_terseLabel_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_BasicEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_BasicEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BasicEarningsLossPerShare" xlink:to="lab_ifrs-full_BasicEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_e54edf70-6d98-453e-93a0-755a0bc2a0f5_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash impact of foreign exchange</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:to="lab_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_b9e866f0-c699-4003-8da7-508797ba92e3_totalLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilities_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilities" xlink:to="lab_ifrs-full_EquityAndLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_e4a2837a-a99f-42b2-877b-1dd84791aa4e_terseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative (notes 9, 17)</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_67059acb-9347-40cb-80b4-d0ceb79dc003_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_0e780cb9-a77b-4a6e-bb2e-b6db14c85952_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market equity distribution agreement</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_label_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderAtthemarketAgreementMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under At-the-market Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderAtthemarketAgreementMember" xlink:to="lab_oncyf_SharesUnderAtthemarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockAxis_74819ee5-6d61-42f8-97cd-383480fe4553_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_label_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:label id="lab_oncyf_SaleOfStockAxis_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockAxis" xlink:to="lab_oncyf_SaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1Table_641f51a8-2688-475d-b50e-6ebdd9448319_terseLabel_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_label_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:label id="lab_oncyf_Currency1Table_documentation_en-US" xlink:label="lab_oncyf_Currency1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table" xlink:href="oncyf-20231231.xsd#oncyf_Currency1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1Table" xlink:to="lab_oncyf_Currency1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8e95deeb-3951-47f0-aea2-d815f9b0b06a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdditionalCashFlowDisclosuresAbstract_label_en-US" xlink:label="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Disclosures [Abstract]</link:label>
    <link:label id="lab_oncyf_AdditionalCashFlowDisclosuresAbstract_documentation_en-US" xlink:label="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:href="oncyf-20231231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:to="lab_oncyf_AdditionalCashFlowDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_90bd8c2f-5759-41e8-b30c-c0ecb2e8c5af_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense (notes 11, 20, 21)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForSharebasedPayments_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for share-based payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="lab_ifrs-full_AdjustmentsForSharebasedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_d9ee88db-35b9-40ef-a177-e2d0c1724be2_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_005633b7-4411-4be6-985f-84e66150ce53_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about financial instruments [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_c5128005-228e-4cc4-b148-6f53366ac3a6_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development costs</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for research and development expense [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_a428ea81-f329-4827-924e-5396a6750a21_terseLabel_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_label_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:label id="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember_documentation_en-US" xlink:label="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unused Net Operating Loss Carry Forwards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:href="oncyf-20231231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:to="lab_oncyf_UnusedNetOperatingLossCarryForwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_1a3ca688-a6c7-40f1-9c45-3f60e95877a3_verboseLabel_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_GrossLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_GrossLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GrossLeaseLiabilities" xlink:to="lab_ifrs-full_GrossLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_ef8f67bd-7487-4233-8d6f-93aea032d79e_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_MaturityAxis_7fc9d809-24da-4358-993e-07fbe0943334_terseLabel_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:label id="lab_ifrs-full_MaturityAxis_label_en-US" xlink:label="lab_ifrs-full_MaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_MaturityAxis" xlink:to="lab_ifrs-full_MaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_f9619ba9-1ad9-4784-b0eb-2625b94b2286_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from warrant exercises</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_label_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:label id="lab_oncyf_ProceedsfromWarrantExercises1_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromWarrantExercises1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromWarrantExercises1" xlink:to="lab_oncyf_ProceedsfromWarrantExercises1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_21d42aa1-7cf3-4882-9fc6-07cbf7bbd26c_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_19fb4783-fac1-4abd-b58a-65f0d7a22c48_terseLabel_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_label_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Options, Outstanding [Abstract]</link:label>
    <link:label id="lab_oncyf_StockOptionsOutstandingAbstract_documentation_en-US" xlink:label="lab_oncyf_StockOptionsOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockOptionsOutstandingAbstract" xlink:href="oncyf-20231231.xsd#oncyf_StockOptionsOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract" xlink:to="lab_oncyf_StockOptionsOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_402a281d-9796-4902-839f-c0864219f6ec_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense (income), net</link:label>
    <link:label id="lab_ifrs-full_InterestRevenueExpense_label_en-US" xlink:label="lab_ifrs-full_InterestRevenueExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income (expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestRevenueExpense" xlink:to="lab_ifrs-full_InterestRevenueExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_32397eec-2019-4fb9-b9a6-488721c80d5e_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:to="lab_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_88155e75-8568-470d-b9dd-2dcccddd7050_verboseLabel_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange (loss) gain</link:label>
    <link:label id="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_label_en-US" xlink:label="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign exchange gain (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:to="lab_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_a03cf2b7-92f4-4853-b470-4034891853aa_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial liabilities</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_7a151b27-9ad1-408d-9fab-45373b20c9b1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derecognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for derecognition of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_257f659b-2a25-4f4b-a8c2-d9831866256d_terseLabel_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets [Abstract]</link:label>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_label_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets [Abstract]</link:label>
    <link:label id="lab_oncyf_RightOfUseAssetsAbstract_documentation_en-US" xlink:label="lab_oncyf_RightOfUseAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RightOfUseAssetsAbstract" xlink:href="oncyf-20231231.xsd#oncyf_RightOfUseAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RightOfUseAssetsAbstract" xlink:to="lab_oncyf_RightOfUseAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_87e6fc92-8d95-4a6c-b981-de0897116f2f_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized foreign exchange loss (gain)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for unrealised foreign exchange losses (gains)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:to="lab_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_6c48a84b-623b-4d22-9aa5-f2ffb6e57abc_terseLabel_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of changes in property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_97a7215f-04dc-44d2-9fe6-704ca2872c2b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLiabilities_61e3da52-e16b-4757-a951-a7df565ddbe2_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_ifrs-full_CurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLiabilities" xlink:to="lab_ifrs-full_CurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_4b6a6197-d05d-4c61-aafa-4965636d12fe_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_283e83c0-30e5-4458-bd25-bf1a7362d679_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average rate</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:to="lab_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_8030074e-2102-4bc6-80d4-a404e51605ea_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_CurrentAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssetsAbstract" xlink:to="lab_ifrs-full_CurrentAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_f5ff65c5-eee5-4069-b663-b6e644db273f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of commitments and contingent liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAccountingStandard_d1e71966-9c05-4780-93ff-a531c18ca116_terseLabel_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:label id="lab_dei_DocumentAccountingStandard_label_en-US" xlink:label="lab_dei_DocumentAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAccountingStandard" xlink:to="lab_dei_DocumentAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_a6bf4f7c-53c7-4165-a12f-3fd3917fa4f6_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Quantitative Information About Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:to="lab_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_012c1097-6dc0-46cc-8dbd-c3e3006a624d_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityLineItems_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="lab_ifrs-full_StatementOfChangesInEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_30f50d96-743b-4f89-83c2-20bbca1e7c23_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_eaf14838-d7f8-4126-8fb4-be3f675efcd2_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other cash flow disclosures</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:to="lab_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_d25c559a-c4df-424f-ae0f-a50746610dda_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income items that may be reclassified to net loss</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments_5afecb5e-2975-4ab1-951c-2e2d493e25b1_terseLabel_en-US" xlink:label="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and current investments</link:label>
    <link:label id="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments_label_en-US" xlink:label="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Current Investments</link:label>
    <link:label id="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments_documentation_en-US" xlink:label="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Cash Equivalents And Current Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:href="oncyf-20231231.xsd#oncyf_CashAndCashEquivalentsAndCurrentInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:to="lab_oncyf_CashAndCashEquivalentsAndCurrentInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_e76d9a28-cdda-44bd-96bb-ba54bca7a281_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value measurement</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for fair value measurement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AssetsAbstract_e8cfe93f-6b1f-4d12-b6fb-87c76e22675f_terseLabel_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_ifrs-full_AssetsAbstract_label_en-US" xlink:label="lab_ifrs-full_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AssetsAbstract" xlink:to="lab_ifrs-full_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_f4c322b6-db28-4bf1-be61-d1c664231b5b_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference in tax rates</link:label>
    <link:label id="lab_ifrs-full_TaxEffectOfForeignTaxRates_label_en-US" xlink:label="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax effect of foreign tax rates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxEffectOfForeignTaxRates" xlink:to="lab_ifrs-full_TaxEffectOfForeignTaxRates" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_e6682b31-8b52-4b8c-aeb5-6107c87d57a5_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract" xlink:to="lab_ifrs-full_LeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CollaborationAgreementMember_aae67fe1-0d6d-4cf3-b30b-88e2761ddd00_terseLabel_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRACELET-1 collaboration agreement</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_label_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_oncyf_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_oncyf_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember" xlink:href="oncyf-20231231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CollaborationAgreementMember" xlink:to="lab_oncyf_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_3762440a-6d5b-4760-90be-eb31cd5e0c3c_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SaleOfStockDomain_ba93ce67-6d46-4cd0-8279-dbaeaa1000f7_terseLabel_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_label_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock [Domain]</link:label>
    <link:label id="lab_oncyf_SaleOfStockDomain_documentation_en-US" xlink:label="lab_oncyf_SaleOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Sale Of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SaleOfStockDomain" xlink:to="lab_oncyf_SaleOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_84663996-0892-402a-9568-1fdc01392ca7_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, threshold consecutive trading days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:to="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_c65b0c9b-b074-4549-abd1-72b4c1853f6b_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLoss_a04019d1-e202-43ea-9163-536f0192f4f4_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_4aeaa2ea-8c06-456f-8b9c-9a051f8ea31b_terseLabel_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss for the year</link:label>
    <link:label id="lab_ifrs-full_ProfitLoss_label_en-US" xlink:label="lab_ifrs-full_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLoss" xlink:to="lab_ifrs-full_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_54408e13-f6be-45a9-b098-da75b191b805_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_c9994677-c3cd-4af4-aa41-43fd385a4bee_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.02 - $3.90</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeThreeMember" xlink:to="lab_oncyf_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_9cc29e4b-6d45-4fe1-b94c-9b12a723bd0f_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash used in operating activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperations_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperations" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_aa73140a-eb03-450b-8810-fa178dadfae3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_351b4559-e3ef-4fbc-9046-06054349d615_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Line Items]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsLineItems_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:href="oncyf-20231231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_c174d476-c78d-4b05-948b-28c70927c7b6_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, end of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_13609f0a-307e-4acf-b917-ed41ad1f758d_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_country_BB_e1d4c011-5ddb-4377-8efa-1e4d606a6e80_terseLabel_en-US" xlink:label="lab_country_BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BARBADOS</link:label>
    <link:label id="lab_country_BB_label_en-US" xlink:label="lab_country_BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BARBADOS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_BB" xlink:to="lab_country_BB" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_ee7a988f-e516-40ac-90d9-ad736788dcb8_terseLabel_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intellectual property expenses</link:label>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_label_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intellectual Property Expense</link:label>
    <link:label id="lab_oncyf_IntellectualPropertyExpense_documentation_en-US" xlink:label="lab_oncyf_IntellectualPropertyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intellectual Property Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense" xlink:href="oncyf-20231231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IntellectualPropertyExpense" xlink:to="lab_oncyf_IntellectualPropertyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_4673054c-faa2-44a1-9d87-f1a2c521a6a1_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of New Accounting Standards and Accounting Standards and Interpretations Issued but Not Yet Effective</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expected impact of initial application of new standards or interpretations [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:to="lab_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_882c6c81-b187-443c-9fb8-0ca52cac69f7_totalLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Compensation of key management personnel</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensation_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensation" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_17c57ce7-f35b-4fe3-b3e2-bba05d8acd76_terseLabel_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits expense</link:label>
    <link:label id="lab_ifrs-full_EmployeeBenefitsExpense_label_en-US" xlink:label="lab_ifrs-full_EmployeeBenefitsExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee benefits expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EmployeeBenefitsExpense" xlink:to="lab_ifrs-full_EmployeeBenefitsExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_d0daf3d1-b86c-4fb5-b2ed-faba994125a9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of cash flow statement [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:to="lab_ifrs-full_DisclosureOfCashFlowStatementExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7afd9f66-c505-4f07-a7f3-e735b41c6e2e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_fb94cdb1-91e3-46a0-bd52-4a250bb01a70_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Expenses</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of expenses by nature [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="lab_ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_9183ef8c-3e3a-4bf9-a5fc-bdcb3cacc136_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options (note 11)</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfOptions_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfOptions" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_d88221b3-42ac-4d8b-9d10-4cdbb412f8f3_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="lab_ifrs-full_StatementOfChangesInEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ContractLiabilities_d6b71499-2ddb-4ec8-96b6-a08b9240467d_periodStartLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning of year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_95d3fac9-3679-4e30-8da9-f2e63b88f4ef_periodEndLabel_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, end of year</link:label>
    <link:label id="lab_ifrs-full_ContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_ContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ContractLiabilities" xlink:to="lab_ifrs-full_ContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_b33f84d4-e00e-4834-a31f-47cd7be7a9fb_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_a30e083e-773b-4839-a3d8-123f756839b7_terseLabel_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="oncyf-20231231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_oncyf_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_809e987a-5433-4a71-8c9e-b6accc241bf8_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Domain]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Domain_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain" xlink:href="oncyf-20231231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Domain" xlink:to="lab_oncyf_IncomeStatementLocation1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_92a78db2-2fc4-41c0-b571-8466c8f9b493_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">More than five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_e0fe6891-4f0a-4cb5-a093-589bbe5da926_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_ContactPersonnelName_e9d57925-fb7c-444c-9404-03272ea817ff_terseLabel_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:label id="lab_dei_ContactPersonnelName_label_en-US" xlink:label="lab_dei_ContactPersonnelName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contact Personnel Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d7d26e1e-0463-4cd9-9bf4-e2ef42cd6d1f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_6910f15d-1731-4243-b79b-86d9370646e9_terseLabel_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net capital losses carried forward</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_label_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:label id="lab_oncyf_UnusedCapitalLossCarryForwardNetMember_documentation_en-US" xlink:label="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unused Capital Loss Carry Forward, Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:href="oncyf-20231231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:to="lab_oncyf_UnusedCapitalLossCarryForwardNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_06036a86-e289-404d-99d9-d858637767ec_terseLabel_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statutory Canadian corporate tax rate</link:label>
    <link:label id="lab_ifrs-full_ApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_ApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ApplicableTaxRate" xlink:to="lab_ifrs-full_ApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_6120ae04-70a0-49c2-9107-c32d3952338b_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of basis of preparation of financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquityShares_632d6639-212d-4c62-a37c-5bff588c7fc1_verboseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to public offering (in shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_9dbac141-101c-43ee-be2e-762f0d426461_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_label_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquityShares_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquityShares" xlink:to="lab_oncyf_IssueOfEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantExercisePrice_a4912a0d-eea2-4f77-940f-0ba3a4e002f0_terseLabel_en-US" xlink:label="lab_oncyf_WarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (usd per share)</link:label>
    <link:label id="lab_oncyf_WarrantExercisePrice_label_en-US" xlink:label="lab_oncyf_WarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Exercise Price</link:label>
    <link:label id="lab_oncyf_WarrantExercisePrice_documentation_en-US" xlink:label="lab_oncyf_WarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantExercisePrice" xlink:href="oncyf-20231231.xsd#oncyf_WarrantExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantExercisePrice" xlink:to="lab_oncyf_WarrantExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentRegistrationStatement_20270a6f-9919-43c8-bab6-1fd704515ba3_terseLabel_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:label id="lab_dei_DocumentRegistrationStatement_label_en-US" xlink:label="lab_dei_DocumentRegistrationStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Registration Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentRegistrationStatement" xlink:to="lab_dei_DocumentRegistrationStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_94beab7e-7b49-4823-b024-3043731443b1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_38c21487-c53a-48eb-852a-0a8627108568_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Domain]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Domain_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Domain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Domain" xlink:to="lab_oncyf_ConcentrationRiskType1Domain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_8c16499e-0f32-494f-9816-21c96a5e7156_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_607c2aef-73df-42f0-a45b-cbe86ffa222a_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_7c46a6f8-4464-4e46-a677-c146be90fc3b_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number Outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOutstandingShareOptions_label_en-US" xlink:label="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOutstandingShareOptions" xlink:to="lab_ifrs-full_NumberOfOutstandingShareOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory_08187530-125c-468a-b3d7-c061e2b74f67_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets and Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_b8310074-58f4-4324-89d3-1f37b61e7262_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of tax balances</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_label_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:label id="lab_oncyf_TaxEffectOfTaxPools_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfTaxPools" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Tax Pools</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfTaxPools" xlink:to="lab_oncyf_TaxEffectOfTaxPools" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccountingProfit_21215154-88d3-4057-9ea6-af34251bb1d8_terseLabel_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_AccountingProfit_label_en-US" xlink:label="lab_ifrs-full_AccountingProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccountingProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccountingProfit" xlink:to="lab_ifrs-full_AccountingProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_2819789d-cbef-46f6-b8f8-b6381d94d21b_terseLabel_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares issuable per warrant (in shares)</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_label_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1</link:label>
    <link:label id="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_documentation_en-US" xlink:label="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:href="oncyf-20231231.xsd#oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:to="lab_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsFromIssueOfUnitsGross_652fcac9-995f-4bc9-b92d-70d811028474_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsFromIssueOfUnitsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross proceeds from units</link:label>
    <link:label id="lab_oncyf_ProceedsFromIssueOfUnitsGross_label_en-US" xlink:label="lab_oncyf_ProceedsFromIssueOfUnitsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issue Of Units, Gross</link:label>
    <link:label id="lab_oncyf_ProceedsFromIssueOfUnitsGross_documentation_en-US" xlink:label="lab_oncyf_ProceedsFromIssueOfUnitsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issue Of Units, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfUnitsGross" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsFromIssueOfUnitsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsFromIssueOfUnitsGross" xlink:to="lab_oncyf_ProceedsFromIssueOfUnitsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_13972997-30ed-4659-ba64-4e126a3c5644_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial assets</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_7776faf4-477f-484c-a30e-5f7ee834382c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of change in fair value of warrant derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_52d709d8-245c-48a2-8076-cee256e9bb82_terseLabel_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements</link:label>
    <link:label id="lab_ifrs-full_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_ifrs-full_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold improvements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseholdImprovementsMember" xlink:to="lab_ifrs-full_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_a8ccbeef-c381-4465-a2e7-1e0c24cc07a5_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_CurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentLeaseLiabilities" xlink:to="lab_ifrs-full_CurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_0ca9f9b3-d24a-4db9-aa6b-8ed145cba93d_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration, number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskNumber_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskNumber" xlink:to="lab_oncyf_ConcentrationRiskNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_9497f35e-9045-433e-a538-127926c1b9ca_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_ad5245dd-2527-4446-b504-f185d930c90e_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense (note 11)</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) through share-based payment transactions, equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="lab_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_a4bf0611-9768-40e6-9ed6-ca4e7042835e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_253c4ff4-2cc1-4378-a4a4-a4a0158f0d9a_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-based Payment Arrangements [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Share-based Payment Arrangements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:to="lab_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_ef211905-bff9-4898-80ab-0406318ec6a2_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksMember_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risks [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksMember" xlink:to="lab_ifrs-full_TypesOfRisksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_d24ed27d-ea24-4815-ac76-1eef7b41d8bd_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indemnification of Officers and Directors</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_c57219a2-e6e8-4314-a69f-0790e1825174_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:label id="lab_ifrs-full_IncomeStatementAbstract_label_en-US" xlink:label="lab_ifrs-full_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit or loss [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeStatementAbstract" xlink:to="lab_ifrs-full_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_c657a338-d4ea-4ddc-9e06-35c09016ba87_terseLabel_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash taxes paid</link:label>
    <link:label id="lab_ifrs-full_IncomeTaxesPaidRefund_label_en-US" xlink:label="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refund)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncomeTaxesPaidRefund" xlink:to="lab_ifrs-full_IncomeTaxesPaidRefund" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TopOfRangeMember_a2e8045e-834f-4d9f-b945-dee9d6eb0e98_terseLabel_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_ifrs-full_TopOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_TopOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TopOfRangeMember" xlink:to="lab_ifrs-full_TopOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2a65d03e-45c7-4d7a-aff5-f8405bf7d6b6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_3e14cd71-8c51-4077-a45f-e57c41a497fc_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for share-based payment transactions [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentInvestments_59840b65-52df-48ae-9ec5-7c01691017a1_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_ifrs-full_CurrentInvestments_label_en-US" xlink:label="lab_ifrs-full_CurrentInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInvestments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentInvestments" xlink:to="lab_ifrs-full_CurrentInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_fecc3e5f-50d3-4654-8af2-4df3517ff7a6_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue related cost, commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_label_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:label id="lab_oncyf_ShareIssueRelatedCostCommissions_documentation_en-US" xlink:label="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issue Related Cost, Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:href="oncyf-20231231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueRelatedCostCommissions" xlink:to="lab_oncyf_ShareIssueRelatedCostCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_a58537e5-5ab7-405b-9db1-5908bfbb99d5_terseLabel_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:label id="lab_ifrs-full_OfficeEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OfficeEquipmentMember" xlink:to="lab_ifrs-full_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_e2eb6cd0-493f-4768-911c-d5a312300002_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Foreign Currency Held [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:to="lab_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_LeaseNotYetCommencedPayments_a2e638fc-9089-463e-9d88-aabd81aaaf94_terseLabel_en-US" xlink:label="lab_oncyf_LeaseNotYetCommencedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease not yet commenced, payments</link:label>
    <link:label id="lab_oncyf_LeaseNotYetCommencedPayments_label_en-US" xlink:label="lab_oncyf_LeaseNotYetCommencedPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Not Yet Commenced, Payments</link:label>
    <link:label id="lab_oncyf_LeaseNotYetCommencedPayments_documentation_en-US" xlink:label="lab_oncyf_LeaseNotYetCommencedPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Not Yet Commenced, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_LeaseNotYetCommencedPayments" xlink:href="oncyf-20231231.xsd#oncyf_LeaseNotYetCommencedPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_LeaseNotYetCommencedPayments" xlink:to="lab_oncyf_LeaseNotYetCommencedPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_4c2dc919-f24a-4cb8-9dda-5982fda8d687_verboseLabel_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:label id="lab_ifrs-full_InterestExpenseOnLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:to="lab_ifrs-full_InterestExpenseOnLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_bd4abd09-4bf5-453c-a075-ae5381f94c37_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) operating activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_72801d5e-ac4a-4aa7-89e4-e64d06e3873d_terseLabel_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than one year</link:label>
    <link:label id="lab_ifrs-full_NotLaterThanOneYearMember_label_en-US" xlink:label="lab_ifrs-full_NotLaterThanOneYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not later than one year [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NotLaterThanOneYearMember" xlink:to="lab_ifrs-full_NotLaterThanOneYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_0dff6c4b-1509-4003-961c-dbd56a71b071_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$0.54 - $1.79</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeOneMember" xlink:to="lab_oncyf_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_3c947a82-dcee-4180-919c-295367183b70_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_9ab9cd81-6314-404e-8a62-0247badfb458_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$7.42 - $52.63</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFiveMember" xlink:to="lab_oncyf_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_aa1621f2-069f-4a73-a3a4-9fdda3086e9b_terseLabel_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and marketable securities</link:label>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_label_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities [Policy Text Block]</link:label>
    <link:label id="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_documentation_en-US" xlink:label="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="lab_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentAssets_1f9ed949-a07b-473b-965e-308bd3d36d69_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_ifrs-full_CurrentAssets_label_en-US" xlink:label="lab_ifrs-full_CurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentAssets" xlink:to="lab_ifrs-full_CurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_2019b32d-d5cd-40e9-b24e-3a08cf49e7c1_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_b456e4ad-7141-49b8-8753-c332aca5d669_totalLabel_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and cash equivalents after effect of exchange rate changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:to="lab_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_494430f6-b6bf-4645-98ee-3d8bdb61de63_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_3c065891-031d-4b20-a8ee-399fbab70dea_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_45853b0e-7e10-4038-ada9-f28c0016af95_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_89d73c4e-6846-465b-928d-87298b136beb_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4fc5c501-7ef7-4475-83be-cf0c4139ed73_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_a20281c5-2d7a-4731-82b2-e1b2eb2c7ea5_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_7f526b98-9937-4c1d-abf7-2659716f880e_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_label_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:label id="lab_oncyf_NumberOfStockOptionPlans_documentation_en-US" xlink:label="lab_oncyf_NumberOfStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfStockOptionPlans" xlink:to="lab_oncyf_NumberOfStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_42cae0a8-be9c-4d36-ac0f-e264f5a6acbc_terseLabel_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of accounts payables and accrued liabilities</link:label>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_label_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detailed Disclosure Of Trade And Other Payables Explanatory [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detailed Disclosure Of Trade And Other Payables Explanatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:to="lab_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_38f0cb22-13e6-4aaf-841c-39a550a92504_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other provisions</link:label>
    <link:label id="lab_ifrs-full_OtherProvisionsMember_label_en-US" xlink:label="lab_ifrs-full_OtherProvisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other provisions [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherProvisionsMember" xlink:to="lab_ifrs-full_OtherProvisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_2cda5619-8d7d-4a77-a669-fed1fef547a9_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options and weighted average exercise prices of share options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_a0012597-0e4a-491f-aa09-5366a69fe993_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_e0dd2c45-10aa-4fc3-92bf-dc773364864c_terseLabel_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022 United States ATM</link:label>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_label_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022 Shares Under At-the-market Agreement, United States [Member]</link:label>
    <link:label id="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_documentation_en-US" xlink:label="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2022 Shares Under At-the-market Agreement, United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:href="oncyf-20231231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:to="lab_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_7a5d0b49-1625-41c3-93a5-24db31fc0ef1_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average fair value at measurement date, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:to="lab_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_5a45a300-92a6-4154-96fe-08cef1a456aa_verboseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk free interest rate, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:to="lab_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e8dad4a8-f189-4edd-871c-8203becb1902_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_85507bda-49d4-4df8-846c-5e94090682d0_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_label_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant, Equipment Related Temporary Differences [Member]</link:label>
    <link:label id="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:href="oncyf-20231231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:to="lab_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantsMember_0b53b6ae-543d-4922-b719-b3b11f8dea54_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantsMember_c04eb2ff-af03-4935-86f3-9283c8086f96_verboseLabel_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_ifrs-full_WarrantsMember_label_en-US" xlink:label="lab_ifrs-full_WarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantsMember" xlink:to="lab_ifrs-full_WarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9fac53f9-d9f6-46ac-84b6-e67c9818916e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_c51b8efe-8a47-4a13-8246-450467054f8d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_46eed29a-5794-4145-bfd0-62cd921096d9_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$1.80 - $3.01</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeTwoMember" xlink:to="lab_oncyf_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_28dbe97a-3843-4d3d-9876-b438541a0595_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for issuance, maximum percentage</link:label>
    <link:label id="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_label_en-US" xlink:label="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum</link:label>
    <link:label id="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_documentation_en-US" xlink:label="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:to="lab_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_f930d616-ba6d-4d58-a964-7b001888dd7b_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of share-based payment arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:to="lab_oncyf_DisclosureofsharebasedpaymentarrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_aec43738-13e7-4dce-9b6d-12a5b1005dd0_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:to="lab_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_75d7a52a-93f0-4cb1-9973-f661b3c485cd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_0c27ace2-e734-4ca4-92c8-1acba2aed6fe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_e614332c-e614-4267-89fa-293fefa39a9e_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_0c6b5270-42cb-487e-b0e7-bca62ea0dff8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_9ff13de6-3508-4bd7-bc5e-73e4006c62dd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_b8045483-03c5-4581-8bee-ea687e69b991_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_label_en-US" xlink:label="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend as percentage, share options granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:to="lab_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Equity_a172edc5-44e5-46d0-99c2-f40da5c505a5_totalLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_Equity_8c09b6c9-2a51-4627-8c4b-eeb1275234b6_periodStartLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Equity balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_Equity_959aa83d-f162-4a0e-a651-10557776f9cf_periodEndLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Equity balance at end of period</link:label>
    <link:label id="lab_ifrs-full_Equity_ebf1495f-6139-4a20-8088-2a9192f92f21_terseLabel_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' equity</link:label>
    <link:label id="lab_ifrs-full_Equity_label_en-US" xlink:label="lab_ifrs-full_Equity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Equity" xlink:to="lab_ifrs-full_Equity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_3796d6c7-b488-4f81-9442-5f1290ab70df_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable federal investment tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsMember" xlink:to="lab_ifrs-full_UnusedTaxCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_a6ee7f3e-e72c-4b49-bf4e-f9ec3f91ec25_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_label_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:label id="lab_oncyf_ConcentrationRisk1Table_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRisk1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRisk1Table" xlink:to="lab_oncyf_ConcentrationRisk1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_0ed51748-3108-4616-a983-acb320937483_terseLabel_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiry of equity warrant agreement</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_label_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Expiration Of Warrant, Equity</link:label>
    <link:label id="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_documentation_en-US" xlink:label="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) Through Expiration Of Warrant, Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:to="lab_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssueOfEquity_394b4778-13d8-49be-9f4c-c719afdf054a_terseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_1074211f-8683-4488-b0e8-8f66ff4db2a6_verboseLabel_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issued pursuant to public offering</link:label>
    <link:label id="lab_ifrs-full_IssueOfEquity_label_en-US" xlink:label="lab_ifrs-full_IssueOfEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue of equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssueOfEquity" xlink:to="lab_ifrs-full_IssueOfEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_ee04d264-4b2a-4f55-8c52-ca8849379f2d_terseLabel_en-US" xlink:label="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Volatility, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_d4923df2-29cf-4969-a3cf-443d21f2cf6d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:label id="lab_ifrs-full_ComponentsOfEquityAxis_label_en-US" xlink:label="lab_ifrs-full_ComponentsOfEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of equity [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis" xlink:to="lab_ifrs-full_ComponentsOfEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentShellCompanyReport_51e6e7a7-59f8-4112-9782-2f123249bbe4_terseLabel_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:label id="lab_dei_DocumentShellCompanyReport_label_en-US" xlink:label="lab_dei_DocumentShellCompanyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Shell Company Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentShellCompanyReport" xlink:to="lab_dei_DocumentShellCompanyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_ed647124-0e96-4b80-80b7-d10aa9347d83_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expenses and adjustments</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_aa338172-93e7-45a6-bbe2-53fc64360b87_terseLabel_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - right-of-use assets (notes 8, 20)</link:label>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_label_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation, Right-of Use Assets</link:label>
    <link:label id="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets_documentation_en-US" xlink:label="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments For Depreciation, Right-of Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:href="oncyf-20231231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:to="lab_oncyf_AdjustmentsForDepreciationRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_c54780f5-54b6-4c69-95c1-79628d95a0d2_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares_695d9b1d-8ade-4d82-aca6-a6e97da8e77d_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of common shares (in shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares_label_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares, Number Of Common Shares</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares, Number Of Common Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquitySharesNumberOfCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:to="lab_oncyf_IssueOfEquitySharesNumberOfCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_12df5c85-70e1-4cf6-8dc6-45064a63622f_terseLabel_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3 of fair value hierarchy</link:label>
    <link:label id="lab_ifrs-full_Level3OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 3 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level3OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_07239635-1a2a-4f89-9205-e6d9f347d842_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_ac8edf51-494e-4891-9fd7-e26ce61cce03_verboseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative (note 20)</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_45286a2c-7d71-4270-be84-c1e4ad218381_terseLabel_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_ifrs-full_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_GeneralAndAdministrativeExpense" xlink:to="lab_ifrs-full_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Liabilities_05392350-2b1f-404e-95ef-245b32ae3871_totalLabel_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_ifrs-full_Liabilities_label_en-US" xlink:label="lab_ifrs-full_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Liabilities" xlink:to="lab_ifrs-full_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_42ee1a39-e01e-4515-893b-b1fca2a44a37_terseLabel_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One to five years</link:label>
    <link:label id="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_label_en-US" xlink:label="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Later than one year and not later than five years [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="lab_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1eb5f551-3f86-40b9-b94a-48a080a8beec_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of share-based payment arrangements [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="lab_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_29a8a84f-583c-48e2-b626-9b6ed229d139_terseLabel_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_label_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:label id="lab_oncyf_ForeignExchangeImpactRightofUseAssets_documentation_en-US" xlink:label="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Exchange Impact, Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:href="oncyf-20231231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:to="lab_oncyf_ForeignExchangeImpactRightofUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_9359f1f0-1a2e-40de-9e45-409e6f68e813_terseLabel_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_ifrs-full_BottomOfRangeMember_label_en-US" xlink:label="lab_ifrs-full_BottomOfRangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bottom of range [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_BottomOfRangeMember" xlink:to="lab_ifrs-full_BottomOfRangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_36feb586-112c-4c46-a8d9-2badaba52290_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. dollars</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1LineItems_4b76e978-f52d-48c5-bc8f-d4f641bde3e5_terseLabel_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_label_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Statement1LineItems_documentation_en-US" xlink:label="lab_oncyf_Statement1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems" xlink:href="oncyf-20231231.xsd#oncyf_Statement1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1LineItems" xlink:to="lab_oncyf_Statement1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_9f2e963a-3920-4ce4-b479-df728bd7b1c2_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortisation [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:to="lab_ifrs-full_AccumulatedDepreciationAndAmortisationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_762e76be-3693-4b33-bb5b-54fe4ecbdb4a_terseLabel_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase through new leases, liabilities arising from financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:to="lab_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_55eb2658-03f8-4799-a4ec-fe9d52c3b89a_terseLabel_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office Equipment and Furniture</link:label>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_label_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office equipment and furniture [Member]</link:label>
    <link:label id="lab_oncyf_OfficeEquipmentAndFurnitureMember_documentation_en-US" xlink:label="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office equipment and furniture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember" xlink:href="oncyf-20231231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OfficeEquipmentAndFurnitureMember" xlink:to="lab_oncyf_OfficeEquipmentAndFurnitureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_7275b050-d911-4c3c-889e-3f42e923b266_verboseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of capital components</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Capital Components [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:to="lab_oncyf_DisclosureOfCapitalComponentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5ec38e3a-b7ed-4d9c-adfb-396b9b8c276b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_e555d8b2-f69a-4a3e-8d20-46c123aa8dab_terseLabel_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_label_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:to="lab_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_aefed1f0-6d53-4da6-b3fd-0ea48882c743_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Line Items]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1LineItems_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Concentration Risk Type1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems" xlink:to="lab_oncyf_ConcentrationRiskType1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ea30a925-2912-49e4-986a-fb06c01e6f20_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_f5c5fb30-c961-4945-b1a4-b727ca4b5f79_terseLabel_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants exercised, fair value</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_label_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:label id="lab_oncyf_ClassofWarrantorRightWarrantsExercised_documentation_en-US" xlink:label="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:href="oncyf-20231231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:to="lab_oncyf_ClassofWarrantorRightWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContingenciesAbstract_64a9044a-b083-4e97-a45f-aa4780ee463c_terseLabel_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_label_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:label id="lab_oncyf_ContingenciesAbstract_documentation_en-US" xlink:label="lab_oncyf_ContingenciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingencies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract" xlink:href="oncyf-20231231.xsd#oncyf_ContingenciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContingenciesAbstract" xlink:to="lab_oncyf_ContingenciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_936fcc72-138e-454a-acb7-3a1e385788b4_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by financing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_a796c1b9-2f50-4ed4-87f8-d9626f4d9d81_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_92b6f047-0dfe-4bed-9b91-e1bea7dc6e48_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarningsMember_label_en-US" xlink:label="lab_ifrs-full_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarningsMember" xlink:to="lab_ifrs-full_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantLiabilityUnamortizedDiscount_bf0f148a-1efa-49c0-9c6a-43ca1f310437_negatedTerseLabel_en-US" xlink:label="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Discount on warrants issued</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityUnamortizedDiscount_label_en-US" xlink:label="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Unamortized Discount</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityUnamortizedDiscount_documentation_en-US" xlink:label="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:href="oncyf-20231231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:to="lab_oncyf_WarrantLiabilityUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_abad80c2-dcd2-415c-a959-679d5f0c469a_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of property, plant and equipment [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="lab_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0ae8ba87-ec40-4605-a5ef-37c304a56b57_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:to="lab_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_dc930811-e61b-4103-af8a-9ae1f834fe8a_verboseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value per warrant (usd per share)</link:label>
    <link:label id="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_7aaa1ca4-6b92-427f-bff7-4592a18851b1_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value of options (usd per share)</link:label>
    <link:label id="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_1bf82f98-79d8-429f-87fb-df6c1428ad8c_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of marketable securities</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of financial instruments, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_7b437dcf-d592-4696-9658-48e3bc6d1788_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementTerm_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm" xlink:href="oncyf-20231231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementTerm" xlink:to="lab_oncyf_SharePurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale_12f66b01-3357-4504-9dbd-6dde4e7b60a2_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale_label_en-US" xlink:label="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current financial assets available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:to="lab_ifrs-full_CurrentFinancialAssetsAvailableforsale" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_a04a7810-84b6-461a-b778-eedaedd8f404_terseLabel_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liability balances</link:label>
    <link:label id="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Explanation of significant changes in contract assets and contract liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="lab_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_1d292924-7d59-413e-9a66-7f1184201adb_terseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unclaimed scientific research and experimental development expenditures</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_4bb6a20d-01fb-4121-ad3c-85c9dc713039_verboseLabel_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Scientific research and experimental development</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_label_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:label id="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_documentation_en-US" xlink:label="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unclaimed Scientific Research And Experimental Development Expenditures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:href="oncyf-20231231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:to="lab_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_e6e6ce8f-a0c7-43a3-893d-3cd629ad5063_negatedLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_3973e045-da9b-4040-954b-d1e733f2dece_verboseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - right-of-use assets</link:label>
    <link:label id="lab_ifrs-full_DepreciationRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_DepreciationRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationRightofuseAssets" xlink:to="lab_ifrs-full_DepreciationRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_94bf3898-5a35-4855-bb57-e7c73921e646_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding [Roll Forward]</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstandingRollForward_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:to="lab_oncyf_NumberOfWarrantsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_71f79e9d-7f14-4edf-8f1a-3c1997f31518_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Disclosures</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of objectives, policies and processes for managing capital [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:to="lab_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_EquityAuthorized_7a248ccc-a517-466e-8c97-8bfdc29e65d5_terseLabel_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Shelf securities authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_label_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Authorized</link:label>
    <link:label id="lab_oncyf_EquityAuthorized_documentation_en-US" xlink:label="lab_oncyf_EquityAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized" xlink:href="oncyf-20231231.xsd#oncyf_EquityAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_EquityAuthorized" xlink:to="lab_oncyf_EquityAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_c182cf32-1f4e-48cf-9c54-b821368cbc47_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_02f1d169-fd38-43a3-9460-3b11deaad4fb_terseLabel_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual depreciation rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_label_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:label id="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_documentation_en-US" xlink:label="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Annual Depreciation Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:href="oncyf-20231231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:to="lab_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_827faa4a-e376-4241-9a47-dff08c4e8c6c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_8dc3c947-3c2d-4cd6-89a7-cb10c3fcfaef_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="lab_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_LeaseNotYetCommencedTerm_af278702-903c-4705-af2f-524e7c94f8b1_terseLabel_en-US" xlink:label="lab_oncyf_LeaseNotYetCommencedTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease not yet commenced, term</link:label>
    <link:label id="lab_oncyf_LeaseNotYetCommencedTerm_label_en-US" xlink:label="lab_oncyf_LeaseNotYetCommencedTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Not Yet Commenced, Term</link:label>
    <link:label id="lab_oncyf_LeaseNotYetCommencedTerm_documentation_en-US" xlink:label="lab_oncyf_LeaseNotYetCommencedTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Not Yet Commenced, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_LeaseNotYetCommencedTerm" xlink:href="oncyf-20231231.xsd#oncyf_LeaseNotYetCommencedTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_LeaseNotYetCommencedTerm" xlink:to="lab_oncyf_LeaseNotYetCommencedTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_588186b3-9364-4d8a-9753-61193f34d074_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants (note 9)</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromExerciseOfWarrants_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="lab_ifrs-full_ProceedsFromExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_36409f2f-746b-4721-ac4b-a5aee72c57be_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_4045a039-71e0-429e-b72d-f53ea0ef6f51_terseLabel_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_label_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:label id="lab_oncyf_ConcentrationRiskType1Axis_documentation_en-US" xlink:label="lab_oncyf_ConcentrationRiskType1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk Type1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ConcentrationRiskType1Axis" xlink:to="lab_oncyf_ConcentrationRiskType1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_08481214-2eb9-48d6-b719-291e5ce01a77_terseLabel_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized deferred tax asset</link:label>
    <link:label id="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_label_en-US" xlink:label="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deductible temporary differences for which no deferred tax asset is recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:to="lab_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_82239041-d805-461e-87e0-eb9e4d4d1773_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation warrant expenses (note 11)</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from equity-settled share-based payment transactions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="lab_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_be1ea4bf-9cb4-4584-9c9f-542581e9e555_terseLabel_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:label id="lab_ifrs-full_EarningsPerShareAbstract_label_en-US" xlink:label="lab_ifrs-full_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings per share [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EarningsPerShareAbstract" xlink:to="lab_ifrs-full_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderPublicOfferingMember_7a670d81-f313-48bb-b144-3217175b7048_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_oncyf_SharesUnderPublicOfferingMember_label_en-US" xlink:label="lab_oncyf_SharesUnderPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Public Offering [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderPublicOfferingMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderPublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderPublicOfferingMember" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderPublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderPublicOfferingMember" xlink:to="lab_oncyf_SharesUnderPublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_ba858bfb-b931-422d-9a5c-67927cb63f0d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_8f8cf33b-4417-404a-a7ee-69060cf9076c_verboseLabel_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer Equipment</link:label>
    <link:label id="lab_ifrs-full_ComputerEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComputerEquipmentMember" xlink:to="lab_ifrs-full_ComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_7fff6908-3c29-40a4-b213-920623a4d1a1_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs (note 10)</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_84d9678f-907f-4502-9f48-5bf4af8e246f_negatedLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_56127016-d061-4ff1-a7b1-de1e737fc16e_terseLabel_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:label id="lab_ifrs-full_ShareIssueRelatedCost_label_en-US" xlink:label="lab_ifrs-full_ShareIssueRelatedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share issue related cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ShareIssueRelatedCost" xlink:to="lab_ifrs-full_ShareIssueRelatedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_a5d4cc06-218b-49ce-ab5d-5ff0c5f83f4b_terseLabel_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:label id="lab_ifrs-full_LevelsOfFairValueHierarchyAxis_label_en-US" xlink:label="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Levels of fair value hierarchy [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="lab_ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_e8c088ae-8333-4756-b316-847f996218b8_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentLeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentLeaseLiabilities" xlink:to="lab_ifrs-full_NoncurrentLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_360cf787-d48a-4d59-af65-bea86bb80c14_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_f1e12cee-1e24-484d-a57a-e383682f5710_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables (note 5)</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentReceivables_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentReceivables" xlink:to="lab_ifrs-full_OtherCurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_aee1cfa3-6cd8-49c6-a88e-2e388f2a194f_terseLabel_en-US" xlink:label="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Dividend As Percentage, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_a12ec6d9-08b9-47d7-96c0-5dfc6c8febf3_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:label id="lab_ifrs-full_StatementOfChangesInEquityTable_label_en-US" xlink:label="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of changes in equity [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable" xlink:to="lab_ifrs-full_StatementOfChangesInEquityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_f914e4ba-dbdd-4900-9aa2-b729c175a9b9_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from share issuance</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssuingShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssuingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issuing shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssuingShares" xlink:to="lab_ifrs-full_ProceedsFromIssuingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Currency1LineItems_b0b139f7-c8e9-4b48-bb9c-a9f3cc91dd19_terseLabel_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_label_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency1 [Line Items]</link:label>
    <link:label id="lab_oncyf_Currency1LineItems_documentation_en-US" xlink:label="lab_oncyf_Currency1LineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Currency1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems" xlink:href="oncyf-20231231.xsd#oncyf_Currency1LineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Currency1LineItems" xlink:to="lab_oncyf_Currency1LineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_91a0eaf7-fad8-435d-90c2-bf7a9c70e7c8_terseLabel_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issue of ordinary shares</link:label>
    <link:label id="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares_label_en-US" xlink:label="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from issue of ordinary shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="lab_ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_766ee48d-c8c8-46e4-8c00-768a374c397b_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of financial position [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="lab_ifrs-full_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PublicCompanyExpense_3b8896db-8f09-4af5-8b35-05b908524a15_terseLabel_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public company-related expenses</link:label>
    <link:label id="lab_oncyf_PublicCompanyExpense_label_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Company Expense</link:label>
    <link:label id="lab_oncyf_PublicCompanyExpense_documentation_en-US" xlink:label="lab_oncyf_PublicCompanyExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Company Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense" xlink:href="oncyf-20231231.xsd#oncyf_PublicCompanyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PublicCompanyExpense" xlink:to="lab_oncyf_PublicCompanyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_da066536-1b09-4ea2-bdf8-bd5cb3151358_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average remaining contractual life of outstanding share options [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5f05d7df-d81e-4bc6-bf0a-93a94959adc1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_e33358d1-3f63-47e4-a0e3-0bd5af8bb40d_terseLabel_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_label_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gains (Losses) From Foreign Exchange Impact</link:label>
    <link:label id="lab_oncyf_GainsLossesFromForeignExchangeImpact_documentation_en-US" xlink:label="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gains (Losses) From Foreign Exchange Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact" xlink:href="oncyf-20231231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GainsLossesFromForeignExchangeImpact" xlink:to="lab_oncyf_GainsLossesFromForeignExchangeImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_b66b921d-3d0f-43c0-b3ee-4e9ff6489767_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfShareCapitalAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of share capital [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis" xlink:to="lab_ifrs-full_ClassesOfShareCapitalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_e5052c0a-b084-482d-86b7-4e0d43e5ab24_periodStartLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_84a1fd35-a85f-4c0f-80eb-7c08772628a4_periodEndLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_fffeda01-f26c-4df1-ae16-acaa4bbe3727_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsOutstanding_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsOutstanding" xlink:to="lab_oncyf_NumberOfWarrantsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_1c845284-58bd-4aa6-9a9d-e7190c3f15c3_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for recognition of revenue [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_accdf6c1-56cb-4d51-8367-d330e20d816a_terseLabel_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number</link:label>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_label_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Capital, Number, Shares [Abstract]</link:label>
    <link:label id="lab_oncyf_ShareCapitalNumberSharesAbstract_documentation_en-US" xlink:label="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Capital, Number, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract" xlink:href="oncyf-20231231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract" xlink:to="lab_oncyf_ShareCapitalNumberSharesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesMember_38364595-3491-4b22-ab4c-075764182ead_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges</link:label>
    <link:label id="lab_ifrs-full_RangesMember_label_en-US" xlink:label="lab_ifrs-full_RangesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesMember" xlink:to="lab_ifrs-full_RangesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_a333b32b-18c5-4786-baff-dafac599b3b8_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_bcdeec83-b8e2-44a4-b6b9-0afbe0e1972c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommonSharesPerUnit_a9f8c60b-ed82-4fc5-83e1-057ff4707d7d_terseLabel_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares per unit (in shares)</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_label_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:label id="lab_oncyf_CommonSharesPerUnit_documentation_en-US" xlink:label="lab_oncyf_CommonSharesPerUnit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Shares Per Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit" xlink:href="oncyf-20231231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommonSharesPerUnit" xlink:to="lab_oncyf_CommonSharesPerUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_ba8fbc45-c555-4cd7-ae95-4ccdab277f8d_terseLabel_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:label id="lab_ifrs-full_TypesOfRisksAxis_label_en-US" xlink:label="lab_ifrs-full_TypesOfRisksAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Types of risks [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TypesOfRisksAxis" xlink:to="lab_ifrs-full_TypesOfRisksAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_ff9b16ae-bb94-425b-8bbe-182f3514660c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of stock options outstanding and exercisable by range of exercise price</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of range of exercise prices of outstanding share options [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c8bee330-db58-4175-a604-42c1ec374514_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_2a41e5cc-b941-4e07-9d5c-39b23f0144cc_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_068c1a56-2014-4900-9c00-05ff5344d1ba_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency risk</link:label>
    <link:label id="lab_ifrs-full_CurrencyRiskMember_label_en-US" xlink:label="lab_ifrs-full_CurrencyRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency risk [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrencyRiskMember" xlink:to="lab_ifrs-full_CurrencyRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_481d757a-c12f-41db-8ed1-24b97195e8d4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_278ce77c-8332-4821-b588-f483367ce2b9_terseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative (notes 9, 17)</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_2c5ecdc2-726c-4843-93ce-695aff90f5e9_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_67ffd394-dd48-4557-b965-2804531aa369_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_1b698f83-8e2c-41cd-a6b5-29935b5044de_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_ifrs-full_CurrentDerivativeFinancialLiabilities_label_en-US" xlink:label="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current derivative financial liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="lab_ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_4d5bef8a-b5c1-405b-8d8b-2919488bfac7_terseLabel_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregated time bands</link:label>
    <link:label id="lab_ifrs-full_AggregatedTimeBandsMember_label_en-US" xlink:label="lab_ifrs-full_AggregatedTimeBandsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregated time bands [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember" xlink:to="lab_ifrs-full_AggregatedTimeBandsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_BusinessContactMember_ee3d6a2a-a402-4d5f-ae7c-cb87699b9afa_terseLabel_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Contact</link:label>
    <link:label id="lab_dei_BusinessContactMember_label_en-US" xlink:label="lab_dei_BusinessContactMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Contact [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_eccce762-8761-4d02-8989-9d831f6fac15_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Derivative</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_f480d657-cb81-48b8-9b6d-27ecdd409df6_terseLabel_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:label id="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_label_en-US" xlink:label="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ranges of exercise prices for outstanding share options [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:to="lab_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAbstract_89da54fb-7b56-4be8-a0fc-4fb47f4d8907_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_ifrs-full_EquityAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAbstract" xlink:to="lab_ifrs-full_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_bf2d421e-db3a-40c2-801a-e6b4c3205bb1_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_b7b3b85c-9eda-4b0f-8180-64984dc54d4a_terseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development (note 20)</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_791382e2-ab00-4c75-9f12-a3dfbfe1a16a_verboseLabel_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_ifrs-full_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ResearchAndDevelopmentExpense" xlink:to="lab_ifrs-full_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_27991d52-2b56-4488-a3fa-5272ed7078cf_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying share price (usd per share)</link:label>
    <link:label id="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Share Price, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Share Price, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_60861550-c58a-4308-a6a0-0510dbd0b49d_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure weighted average assumptions and fair value of options</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_17271c04-ec0b-41ae-af43-8d984891c74c_negatedTerseLabel_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in net loss due to change in currency value</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_label_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:label id="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_documentation_en-US" xlink:label="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:href="oncyf-20231231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:to="lab_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_MedicalEquipmentMember_1d601a05-1dce-436f-8fd1-21e8ea8655fb_terseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medical equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_34854175-886d-46ba-bd24-ad8821c9bd08_verboseLabel_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Medical Equipment</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_label_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:label id="lab_oncyf_MedicalEquipmentMember_documentation_en-US" xlink:label="lab_oncyf_MedicalEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medical Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember" xlink:href="oncyf-20231231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_MedicalEquipmentMember" xlink:to="lab_oncyf_MedicalEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfWarrants_bcb4eaa5-0854-4e99-8b06-8d90a9ed0366_terseLabel_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfWarrants_label_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares, Number Of Warrants</link:label>
    <link:label id="lab_oncyf_IssueOfEquitySharesNumberOfWarrants_documentation_en-US" xlink:label="lab_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Issue Of Equity, Shares, Number Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquitySharesNumberOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:to="lab_oncyf_IssueOfEquitySharesNumberOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantsTerm_55d5abd2-a1d7-47dc-9757-00e5451b31e9_terseLabel_en-US" xlink:label="lab_oncyf_WarrantsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants, term</link:label>
    <link:label id="lab_oncyf_WarrantsTerm_label_en-US" xlink:label="lab_oncyf_WarrantsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Term</link:label>
    <link:label id="lab_oncyf_WarrantsTerm_documentation_en-US" xlink:label="lab_oncyf_WarrantsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrants, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsTerm" xlink:href="oncyf-20231231.xsd#oncyf_WarrantsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantsTerm" xlink:to="lab_oncyf_WarrantsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_d7451875-25da-4a39-a5b4-ffe5730bb011_terseLabel_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_label_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:label id="lab_oncyf_OtherExpensesAndAdjustmentsTable_documentation_en-US" xlink:label="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expenses And Adjustments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:href="oncyf-20231231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable" xlink:to="lab_oncyf_OtherExpensesAndAdjustmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WarrantLiability_d3450501-d38f-4adc-95e5-de2e831d1665_terseLabel_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:label id="lab_ifrs-full_WarrantLiability_label_en-US" xlink:label="lab_ifrs-full_WarrantLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WarrantLiability" xlink:to="lab_ifrs-full_WarrantLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_b43781b2-c16a-43b6-82e8-52d2f7ae3cc7_terseLabel_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements</link:label>
    <link:label id="lab_ifrs-full_SharebasedPaymentArrangementsMember_label_en-US" xlink:label="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based payment arrangements [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="lab_ifrs-full_SharebasedPaymentArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_191d8b8c-8702-415c-9f79-4a7397522e2a_terseLabel_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:label id="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract_label_en-US" xlink:label="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Presentation of leases for lessee [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="lab_ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_59f4aba3-64b4-404f-a76a-4117a9e382a0_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for decrease (increase) in other operating receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="lab_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_a6e03e0f-1f11-4483-93c3-6b8071ece97e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Liability</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of revenue from contracts with customers [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="lab_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_09c378da-cbfb-4df2-863f-81871c6b3829_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translation adjustment</link:label>
    <link:label id="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_label_en-US" xlink:label="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="lab_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_3a53288e-d01a-43aa-8913-0c2aee3a8dcf_terseLabel_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments</link:label>
    <link:label id="lab_ifrs-full_ReserveOfSharebasedPaymentsMember_label_en-US" xlink:label="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve of share-based payments [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="lab_ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_74d66499-7165-49f2-bf92-4504bf8ca614_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_b2b635b0-d2f2-4ab9-8988-eb120ec993db_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RightofuseAssets_6a8e9145-678f-4fcb-9c8e-97c31cc14768_terseLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets (note 8)</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_136e4859-7a58-4528-8437-133c74df3ce1_periodStartLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, beginning balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_8f7d6244-0067-45a1-949b-3e581a3a1357_periodEndLabel_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets, ending balance</link:label>
    <link:label id="lab_ifrs-full_RightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_RightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RightofuseAssets" xlink:to="lab_ifrs-full_RightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_LeaseLiabilities_6a087f69-0171-49e5-ab58-90051a16359e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, beginning balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_4ea7cdc3-84c1-4e9f-9830-ddb71f47b72d_periodEndLabel_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, ending balance</link:label>
    <link:label id="lab_ifrs-full_LeaseLiabilities_label_en-US" xlink:label="lab_ifrs-full_LeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_LeaseLiabilities" xlink:to="lab_ifrs-full_LeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_Statement1Table_347260f6-1047-4144-be3d-f6f7f06ab166_terseLabel_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_label_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:label id="lab_oncyf_Statement1Table_documentation_en-US" xlink:label="lab_oncyf_Statement1Table" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Statement1 [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table" xlink:href="oncyf-20231231.xsd#oncyf_Statement1Table"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_Statement1Table" xlink:to="lab_oncyf_Statement1Table" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_573df399-68c3-4fee-b22f-5804d4cbdc72_terseLabel_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected recognition period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_label_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:label id="lab_oncyf_ContractLiabilityRecognitionPeriod_documentation_en-US" xlink:label="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Liability, Recognition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:href="oncyf-20231231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ContractLiabilityRecognitionPeriod" xlink:to="lab_oncyf_ContractLiabilityRecognitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_534e122c-2343-4337-8ec0-ddd70e0cbfb8_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofrelatedpartyAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of related party [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract" xlink:to="lab_oncyf_DisclosureofrelatedpartyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_aed77c11-b955-4437-8783-476b035cc5f9_terseLabel_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_ifrs-full_AccumulatedOtherComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="lab_ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseMember_cd0fb430-a0a8-482b-9491-0707699ca609_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense [Member]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseMember_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseMember" xlink:href="oncyf-20231231.xsd#oncyf_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseMember" xlink:to="lab_oncyf_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_c6cb9c49-2c27-4d76-8eff-fc6bec1cef5f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_561f3106-58ed-45fc-8d0e-10ce1a972472_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="lab_ifrs-full_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_e5a000c7-438e-402b-ad2f-dc4dac994a15_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="lab_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderOverAllotmentOptionMember_dc888506-045f-4742-8b07-03c150a026f2_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Under Over-Allotment Option</link:label>
    <link:label id="lab_oncyf_SharesUnderOverAllotmentOptionMember_label_en-US" xlink:label="lab_oncyf_SharesUnderOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Over-Allotment Option [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderOverAllotmentOptionMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderOverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Over-Allotment Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderOverAllotmentOptionMember" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderOverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderOverAllotmentOptionMember" xlink:to="lab_oncyf_SharesUnderOverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharePremiumMember_374ed653-2115-4ae8-abc6-32586077c636_terseLabel_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed Surplus</link:label>
    <link:label id="lab_ifrs-full_SharePremiumMember_label_en-US" xlink:label="lab_ifrs-full_SharePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share premium [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharePremiumMember" xlink:to="lab_ifrs-full_SharePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_47c43c8c-cf6c-4063-ab90-2de44a12390c_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CompensationWarrantsMember_006e03a0-771c-4b9f-a974-6844e7b12719_terseLabel_en-US" xlink:label="lab_oncyf_CompensationWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Warrants</link:label>
    <link:label id="lab_oncyf_CompensationWarrantsMember_label_en-US" xlink:label="lab_oncyf_CompensationWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Warrants [Member]</link:label>
    <link:label id="lab_oncyf_CompensationWarrantsMember_documentation_en-US" xlink:label="lab_oncyf_CompensationWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember" xlink:href="oncyf-20231231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CompensationWarrantsMember" xlink:to="lab_oncyf_CompensationWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_d7d0ea08-dae8-4fc9-b167-1362c8b18375_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_d4ec0f01-5c4c-4796-9b4f-9d1d18b2371a_totalLabel_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_ifrs-full_CurrentTaxExpenseIncome_label_en-US" xlink:label="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current tax expense (income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentTaxExpenseIncome" xlink:to="lab_ifrs-full_CurrentTaxExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_d721826d-c2f8-4efc-9e58-58d1e15d7de3_verboseLabel_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting period, if not immediately vested</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:label id="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_documentation_en-US" xlink:label="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:href="oncyf-20231231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_8c0b27e4-4ce4-496e-827c-b0593324e947_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options expired in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_1aae2b93-5e53-4eaf-a0f8-263268a01a94_terseLabel_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_label_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:label id="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_documentation_en-US" xlink:label="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates And Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:href="oncyf-20231231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:to="lab_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_23783ed9-3236-4fdf-a136-eb69b75af63b_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions, net of foreign exchange impact</link:label>
    <link:label id="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions other than through business combinations, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_f928c610-a0aa-4e6f-a8e6-07a858aebc61_terseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiry of tax benefits</link:label>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_label_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Expiration Of Tax Benefits</link:label>
    <link:label id="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Expiration Of Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:to="lab_oncyf_TaxEffectOfExpirationOfTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ClinicalTrialMember_c28f82d3-9c4a-4b7f-88f2-36f9732196e8_terseLabel_en-US" xlink:label="lab_oncyf_ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trial</link:label>
    <link:label id="lab_oncyf_ClinicalTrialMember_label_en-US" xlink:label="lab_oncyf_ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trial [Member]</link:label>
    <link:label id="lab_oncyf_ClinicalTrialMember_documentation_en-US" xlink:label="lab_oncyf_ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialMember" xlink:href="oncyf-20231231.xsd#oncyf_ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ClinicalTrialMember" xlink:to="lab_oncyf_ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_62f2ed2f-c06c-402c-8758-cdf4c883d5e7_terseLabel_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_ifrs-full_Level2OfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Level 2 of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Level2OfFairValueHierarchyMember" xlink:to="lab_ifrs-full_Level2OfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_4d2e7958-5056-4dc9-9405-67e5127a38a0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NoncurrentPrepayments_079e18f7-37cb-4363-a22d-86ef75f3c2b3_terseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses (note 5)</link:label>
    <link:label id="lab_ifrs-full_NoncurrentPrepayments_e8507c99-5b6b-44bc-83aa-3fcc720ca8cd_verboseLabel_en-US" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-current prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_NoncurrentPrepayments_label_en-US" xlink:label="lab_ifrs-full_NoncurrentPrepayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-current prepayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NoncurrentPrepayments" xlink:to="lab_ifrs-full_NoncurrentPrepayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_446bb55b-7fff-4930-8ab9-221c103e6ea1_terseLabel_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with parties other than employees</link:label>
    <link:label id="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_label_en-US" xlink:label="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense from share-based payment transactions with parties other than employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:to="lab_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_b4566dfc-7e5a-425d-88eb-71d3a59d54f2_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributed surplus (note 11)</link:label>
    <link:label id="lab_ifrs-full_AdditionalPaidinCapital_label_en-US" xlink:label="lab_ifrs-full_AdditionalPaidinCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionalPaidinCapital" xlink:to="lab_ifrs-full_AdditionalPaidinCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_18353687-d874-46fb-95a3-d5f07d08315a_terseLabel_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted loss per common share (cad per share)</link:label>
    <link:label id="lab_ifrs-full_DilutedEarningsLossPerShare_label_en-US" xlink:label="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DilutedEarningsLossPerShare" xlink:to="lab_ifrs-full_DilutedEarningsLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_517a16f4-d726-4eda-9a41-14366a7f2dbf_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for impairment of financial assets [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_49b3ec87-c3b3-4e34-8847-0d25127e311b_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant derivative (notes 9, 17)</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for gains (losses) on change in fair value of derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:to="lab_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_bb2625b5-78ff-4a3c-a28b-e7ce710972ad_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of general information about financial statements [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f4082504-f32e-4b7a-9573-3e978c3045cd_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_dca35cc7-8fff-48e5-ba66-92c5d9e34e64_terseLabel_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:label id="lab_oncyf_OperatingLeaseRemainingLeaseTerm_documentation_en-US" xlink:label="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:href="oncyf-20231231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:to="lab_oncyf_OperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_5246bed0-3f27-4024-9741-ab8ed5eebf43_terseLabel_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agreement</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_label_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:label id="lab_oncyf_SharePurchaseAgreementAmount_documentation_en-US" xlink:label="lab_oncyf_SharePurchaseAgreementAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Purchase Agreement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount" xlink:href="oncyf-20231231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharePurchaseAgreementAmount" xlink:to="lab_oncyf_SharePurchaseAgreementAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_81cf6817-25ec-42d3-84c4-d1b53dd7f350_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfLeasesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of leases [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfLeasesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfLeasesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_bc18f2b0-e032-4155-95dc-ef114c19b540_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in other operating payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_0d3d1582-942e-47b0-90af-2b23b0b016ae_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for deferred income tax [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_9ce80a2d-05e7-46c3-92ca-615422b568fe_terseLabel_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Warrant Derivative</link:label>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_label_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Fair Value Warrant Derivative [Roll Forward]</link:label>
    <link:label id="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward_documentation_en-US" xlink:label="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change In Fair Value Warrant Derivative</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:href="oncyf-20231231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:to="lab_oncyf_ChangeInFairValueWarrantDerivativeRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_c35772f4-68fb-4199-93fc-9b46cff5c2c8_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of number of other equity instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subclassifications of assets, liabilities and equities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="lab_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_77ec9b01-505e-4241-a111-82e52b9f22b5_terseLabel_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Information And Statement Of IFRS Compliance [Abstract]</link:label>
    <link:label id="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_label_en-US" xlink:label="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate information and statement of IFRS compliance [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:to="lab_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_e7bcd7b9-3eb1-409a-bcc7-8154c047d5f6_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, expiration days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:to="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_6a5c7ad0-a191-4445-b02f-80ebee36f2df_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_AuditorInformationAbstract_label_en-US" xlink:label="lab_oncyf_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_oncyf_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_oncyf_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AuditorInformationAbstract" xlink:href="oncyf-20231231.xsd#oncyf_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_AuditorInformationAbstract" xlink:to="lab_oncyf_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_a4c50bb1-5d2c-49c5-b612-9dbf568738ee_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_db526f9f-25aa-4819-9a84-ed21f01a3e8e_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price (cad and usd per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_a35adace-15ce-4eed-8ccd-a2ab26e986b3_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options granted in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_67abb20f-195b-464b-8b66-f4a8178bd05d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_ifrs-full_AdditionsToRightofuseAssets_label_en-US" xlink:label="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions to right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdditionsToRightofuseAssets" xlink:to="lab_ifrs-full_AdditionsToRightofuseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_10f5d658-d99d-4a56-a574-defb766d6703_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of property and equipment (note 6)</link:label>
    <link:label id="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment, classified as investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="lab_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_076eaf96-0867-4557-a7e3-b920415431af_terseLabel_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anticipated tax recovery</link:label>
    <link:label id="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_label_en-US" xlink:label="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax expense (income) at applicable tax rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:to="lab_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_45b5be0d-bd38-4cde-924d-1aea65075588_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable, end of the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_10727831-1277-41e0-bb1d-db33ecf30ceb_verboseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number Exercisable (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercisable in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AmortisationExpense_816a5b80-8ed8-4bb0-9c16-3ef40814a51f_terseLabel_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation - property and equipment</link:label>
    <link:label id="lab_ifrs-full_AmortisationExpense_label_en-US" xlink:label="lab_ifrs-full_AmortisationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortisation expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AmortisationExpense" xlink:to="lab_ifrs-full_AmortisationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligation1_46220f71-755f-4e01-be70-b5c6ddd1d1aa_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment for payment</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_label_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:label id="lab_oncyf_PurchaseObligation1_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligation1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1" xlink:href="oncyf-20231231.xsd#oncyf_PurchaseObligation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligation1" xlink:to="lab_oncyf_PurchaseObligation1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_d6999af1-a1ac-4058-8b70-37c036a32186_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for earnings per share [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_21a0dfb9-6203-4449-8fbd-9caa675a5a68_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseAbstract_0bc0d491-1f7e-4b9c-9fd1-eec2a2b93a03_terseLabel_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseAbstract_label_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense [Abstract]</link:label>
    <link:label id="lab_oncyf_ResearchAndDevelopmentExpenseAbstract_documentation_en-US" xlink:label="lab_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:href="oncyf-20231231.xsd#oncyf_ResearchAndDevelopmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:to="lab_oncyf_ResearchAndDevelopmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_236dce70-a46d-4518-b17f-ca0ea5da3b46_negatedTerseLabel_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_label_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:label id="lab_oncyf_TaxEffectOfStockBasedCompensation_documentation_en-US" xlink:label="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Effect Of Stock Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TaxEffectOfStockBasedCompensation" xlink:to="lab_oncyf_TaxEffectOfStockBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_080b801b-ab36-4633-a42c-e1170c29fcfb_terseLabel_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:label id="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_label_en-US" xlink:label="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary difference, unused tax losses and unused tax credits [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="lab_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_65603ece-2803-4158-8005-58703519ad4d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5659fbba-c62c-499b-b093-cd8591bf484a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_4293a43d-9995-405c-bb47-ff07a36fad0f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of related party transactions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of transactions between related parties [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareWarrantsIssuedOperatingExpense_6a174c9c-8b4e-4318-b28e-073617bd0244_terseLabel_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue operating expense</link:label>
    <link:label id="lab_oncyf_ShareWarrantsIssuedOperatingExpense_label_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Warrants Issued, Operating Expense</link:label>
    <link:label id="lab_oncyf_ShareWarrantsIssuedOperatingExpense_documentation_en-US" xlink:label="lab_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Warrants Issued, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:href="oncyf-20231231.xsd#oncyf_ShareWarrantsIssuedOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:to="lab_oncyf_ShareWarrantsIssuedOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_081d0380-5b60-4b58-a2d4-d36d59375f98_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Life (years)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual life of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_22b4f59c-7bcd-491f-8a9e-1b70e88d224f_terseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities (note 7)</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_b3b3874e-0879-4ea5-828c-6da5896daba1_totalLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_1c641a85-7090-41b3-a224-81a834026caf_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_TradeAndOtherCurrentPayables_label_en-US" xlink:label="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and other current payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_TradeAndOtherCurrentPayables" xlink:to="lab_ifrs-full_TradeAndOtherCurrentPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_8c045e40-8cfe-458a-af3c-a29f52d349ae_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_57c51da6-4e62-4103-bf92-cd5c2a879fff_terseLabel_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (note 14)</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_label_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:label id="lab_oncyf_CommitmentsAndContingencies1_documentation_en-US" xlink:label="lab_oncyf_CommitmentsAndContingencies1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1" xlink:href="oncyf-20231231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CommitmentsAndContingencies1" xlink:to="lab_oncyf_CommitmentsAndContingencies1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_a51635ca-7e2c-4a29-8c71-d3de5f6baf96_periodStartLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_b1d56c07-c518-4c52-b170-681b0fa5f659_periodEndLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3fc82746-5e91-4240-8af4-410c0a2457cd_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_957c2bf6-7c30-49a5-8637-5a4ed5a56c9d_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities And Shareholders&#8217; Equity</link:label>
    <link:label id="lab_ifrs-full_EquityAndLiabilitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity and liabilities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="lab_ifrs-full_EquityAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_2179e501-50b2-4fd6-a98f-1d196474b4d9_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_14a63c9d-5e7a-48f7-b1c6-529c1106837e_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Economic Dependence</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_label_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:label id="lab_oncyf_DisclosureOfEconomicDependenceTextBlock_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Economic Dependence [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:to="lab_oncyf_DisclosureOfEconomicDependenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_142e5985-0e34-42e2-ac13-7873bef1179c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of classes of share capital [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="lab_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_6655eaa8-bae5-4265-ac57-64e42e72c6a2_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of depreciation rates</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_67d48ae3-0f3d-4e8d-aa25-14a9c501911d_verboseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of detailed information about property, plant and equipment [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:to="lab_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_643cc101-f954-4545-817c-6f32679e2b95_terseLabel_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_label_en-US" xlink:label="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease through performance obligation being satisfied, contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:to="lab_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_6a94d70b-7258-4100-90f4-ad0ca15bd532_terseLabel_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (cad per share)</link:label>
    <link:label id="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_label_en-US" xlink:label="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price of outstanding share options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="lab_ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_7b169ab2-7970-44e0-af37-a315ab059331_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_142450d9-cdd4-4109-82fc-b3be2070d600_terseLabel_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$3.91 - $7.41</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_oncyf_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_oncyf_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExercisePriceRangeFourMember" xlink:to="lab_oncyf_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_4f36154d-aa1d-47b1-b504-c7d2590fd8b2_terseLabel_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toll manufacturer</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_label_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:label id="lab_oncyf_SupplierConcentrationRisk1Member_documentation_en-US" xlink:label="lab_oncyf_SupplierConcentrationRisk1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplier Concentration Risk1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member" xlink:href="oncyf-20231231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SupplierConcentrationRisk1Member" xlink:to="lab_oncyf_SupplierConcentrationRisk1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashEquivalents_9ffcb48d-3011-4e95-b7f9-4895791991a9_terseLabel_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashEquivalents" xlink:to="lab_ifrs-full_CashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_fe460ee7-dbb9-4099-9abe-88f3a6002239_terseLabel_en-US" xlink:label="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period, granted</link:label>
    <link:label id="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_label_en-US" xlink:label="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement</link:label>
    <link:label id="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_documentation_en-US" xlink:label="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:href="oncyf-20231231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:to="lab_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_6d53b14c-c5ea-47c2-9f63-457a5889a709_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Personnel-related expenses</link:label>
    <link:label id="lab_ifrs-full_OtherEmployeeExpense_label_en-US" xlink:label="lab_ifrs-full_OtherEmployeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other employee expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherEmployeeExpense" xlink:to="lab_ifrs-full_OtherEmployeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_ee20bf44-7fb5-4194-97c2-4fc5194834cd_terseLabel_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:label id="lab_ifrs-full_ClassesOfLiabilitiesAxis_label_en-US" xlink:label="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Classes of liabilities [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="lab_ifrs-full_ClassesOfLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_NumberOfWarrantsAndSharesOutstanding_12c6841f-1386-4446-8c7a-c28c9604a27e_terseLabel_en-US" xlink:label="lab_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of warrants and shares outstanding (in shares)</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsAndSharesOutstanding_label_en-US" xlink:label="lab_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Warrants And Shares Outstanding</link:label>
    <link:label id="lab_oncyf_NumberOfWarrantsAndSharesOutstanding_documentation_en-US" xlink:label="lab_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Warrants And Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:to="lab_oncyf_NumberOfWarrantsAndSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_e350ff12-19ad-406c-b964-5cfad025709f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_3340d979-daa7-4807-a27c-52d2b9fa1b99_terseLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment (note 6)</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_78fd2871-9be8-45ca-804a-c7bd7498b93e_periodStartLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, beginning balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_0952d79e-4720-4aec-837c-422ac4dc415e_periodEndLabel_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, ending balance</link:label>
    <link:label id="lab_ifrs-full_PropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_PropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_PropertyPlantAndEquipment" xlink:to="lab_ifrs-full_PropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_EquityMember_cb48a485-7de5-4cd4-9298-369ba9ba99ab_terseLabel_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_ifrs-full_EquityMember_label_en-US" xlink:label="lab_ifrs-full_EquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_EquityMember" xlink:to="lab_ifrs-full_EquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_f9f85ab8-f796-4efb-80bd-aced3fe12e7a_terseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share capital issued (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_502d8c39-6dc7-42bf-9e90-82db91c2b928_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Share capital issued, beginning (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_701131d0-5bcc-496d-a300-0ac3385b016b_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Share capital issued ending (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfSharesIssued_label_en-US" xlink:label="lab_ifrs-full_NumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfSharesIssued" xlink:to="lab_ifrs-full_NumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ad3fd740-3a80-4431-8b60-0b42ff29a26e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_6e05a359-1c48-42ea-b7e1-6f26affa9899_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureofincometaxAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureofincometaxAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of income tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureofincometaxAbstract" xlink:to="lab_oncyf_DisclosureofincometaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_e9fbb3ff-295d-43b1-a5b5-f11137c4e1bf_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Judgments, Estimates and Assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of accounting judgements and estimates [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_0a9ba697-eb60-419a-9dae-5470d2776446_negatedLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities (note 8)</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_28868720-9272-4366-b77f-a4c3cbcfb17a_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of lease liabilities</link:label>
    <link:label id="lab_ifrs-full_CashOutflowForLeases_label_en-US" xlink:label="lab_ifrs-full_CashOutflowForLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash outflow for leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashOutflowForLeases" xlink:to="lab_ifrs-full_CashOutflowForLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_7433a6da-0b11-4214-a2e0-f34180c847b6_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term employee compensation and benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, short-term employee benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_2218e608-6d06-42a3-a3e7-e5d7d8d5c74a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of financial instruments [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="lab_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_5f27e462-3d4d-4b21-8edb-94e340ea91e4_terseLabel_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_label_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:label id="lab_oncyf_PurchaseObligationCommitmentTerm_documentation_en-US" xlink:label="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Obligation, Commitment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:href="oncyf-20231231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_PurchaseObligationCommitmentTerm" xlink:to="lab_oncyf_PurchaseObligationCommitmentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_d273a978-56dc-469e-b193-e1ac0d0fc375_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incentive share award plan</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Incentive Award Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:to="lab_oncyf_SharesUnderIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_3d0b174b-7fdc-4bfe-8a06-5b62a7a1a806_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_47719fe2-e5ab-4d2e-bc1b-6b4e56ca1149_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused tax credits</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax credits for which no deferred tax asset recognised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:to="lab_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseMember_0a911d06-8c94-4437-a467-bedd6b446db5_terseLabel_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense [Member]</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseMember_documentation_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseMember" xlink:href="oncyf-20231231.xsd#oncyf_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseMember" xlink:to="lab_oncyf_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_0bd9fc43-2389-4ef1-bee3-b03b36e4fb49_terseLabel_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net change in non-cash working capital</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_label_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:label id="lab_oncyf_CashFlowOperatingCapital1TableTextBlock_documentation_en-US" xlink:label="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Capital1 [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:href="oncyf-20231231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:to="lab_oncyf_CashFlowOperatingCapital1TableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_186702b2-b932-4ce8-b0a9-3062c20e533b_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised during the year (cad per share)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average exercise price of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="lab_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_95aae438-c600-490c-986b-19a4d25c204e_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of temporary difference, unused tax losses and unused tax credits [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:to="lab_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_0c91e227-ed3d-43cc-b506-5e4c0917123c_terseLabel_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:label id="lab_ifrs-full_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of cash flows [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract" xlink:to="lab_ifrs-full_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_3a951d81-e4a2-4dc8-805e-c153306dbf3a_verboseLabel_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:label id="lab_ifrs-full_CurrentPrepaidExpenses_label_en-US" xlink:label="lab_ifrs-full_CurrentPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current prepaid expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CurrentPrepaidExpenses" xlink:to="lab_ifrs-full_CurrentPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_e5f8ee56-c60f-4978-90b4-c5333b80e07d_totalLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_2bab6189-4a51-4fd4-ab9a-5f1f50ad3c9d_terseLabel_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss and other comprehensive income (loss)</link:label>
    <link:label id="lab_ifrs-full_ComprehensiveIncome_label_en-US" xlink:label="lab_ifrs-full_ComprehensiveIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ComprehensiveIncome" xlink:to="lab_ifrs-full_ComprehensiveIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_dc53b43e-a9f3-4c45-a1ab-dcc6394867ee_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of maturity analysis of operating lease payments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_f2fa2899-ec7b-4883-bbb4-825da5d99d0f_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of nature and extent of risks arising from financial instruments [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="lab_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_c7a190c1-11fa-4e7c-b90f-6303c7ebb4bc_terseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_2f45ea2c-e2fc-4dc7-8b03-d7bcccb98812_periodStartLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_85db19a5-08bc-43a6-8fa7-2d27b12c2dd3_periodEndLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_04add4b7-6bd3-4a05-8a22-13c309a91ecd_verboseLabel_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_ifrs-full_CashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_CashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashAndCashEquivalents" xlink:to="lab_ifrs-full_CashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_309c2e67-5e53-4126-b624-834960737c53_terseLabel_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash interest received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_label_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:label id="lab_oncyf_ProceedsfromInterestReceived_documentation_en-US" xlink:label="lab_oncyf_ProceedsfromInterestReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Interest Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ProceedsfromInterestReceived" xlink:to="lab_oncyf_ProceedsfromInterestReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_9d7f19e4-d8e0-4a5a-ac7b-8ff3855567a7_periodStartLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_7ea61630-dcef-4847-9bfd-b44b678cf7b8_periodEndLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of the year (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_551d0a58-0f8a-49ed-a6b7-5973d1a8933b_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountMember_831d5808-e74a-4603-9e87-c5db6005c5db_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountMember_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountMember" xlink:to="lab_ifrs-full_CarryingAmountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_5ca2a910-abf0-42dc-b119-e568f109b9f4_terseLabel_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price $</link:label>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_label_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Outstanding [Abstract]</link:label>
    <link:label id="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract_documentation_en-US" xlink:label="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageExercisePriceOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:to="lab_oncyf_WeightedAverageExercisePriceOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_38423012-2f8a-49a8-a4f2-9f11c0dfd5d8_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised during the year (shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of share options exercised in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_e4851f0d-b457-452f-8430-91463fb1192c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of compensation warrants weighted average assumptions</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:to="lab_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_Assets_ce6b1787-2fce-4393-a0ac-70426652a5ad_totalLabel_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_ifrs-full_Assets_label_en-US" xlink:label="lab_ifrs-full_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_Assets" xlink:to="lab_ifrs-full_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_eb77a086-717c-4612-92ed-364ab7cbf114_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_65ed7918-ed06-43a7-a292-b6b6589f2db7_terseLabel_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination benefits</link:label>
    <link:label id="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_label_en-US" xlink:label="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Key management personnel compensation, termination benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:to="lab_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_TranslationalScienceExpense_8555f789-2cf3-47f1-8c40-7a4a6c9584b3_terseLabel_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Translational science expenses</link:label>
    <link:label id="lab_oncyf_TranslationalScienceExpense_label_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Translational Science Expense</link:label>
    <link:label id="lab_oncyf_TranslationalScienceExpense_documentation_en-US" xlink:label="lab_oncyf_TranslationalScienceExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Translational Science Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense" xlink:href="oncyf-20231231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_TranslationalScienceExpense" xlink:to="lab_oncyf_TranslationalScienceExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3977ba39-4826-4f13-814c-c5089660a05a_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_803fcc0b-fc34-41f3-ac87-26a1f48b23de_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, accelerated threshold trading days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:to="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_3566c5c0-d6b1-4e87-a74d-c92cf2d84923_negatedTerseLabel_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_label_en-US" xlink:label="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="lab_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_340930cb-d49c-4c6d-9dd4-a6ba57ec6494_terseLabel_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_label_en-US" xlink:label="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of accounting policy for foreign currency translation [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:to="lab_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_5e398fec-57fc-4d35-888b-6930cd0b5e38_terseLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) financing activities [abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="lab_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_246f77d2-7230-4bd2-a067-55086393f529_terseLabel_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_ifrs-full_DepreciationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, property, plant and equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="lab_ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_8d361be7-15d7-449b-8d79-890f93315dde_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Assets and Liabilities</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of other liabilities [text block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:to="lab_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_ddef4ad1-3716-47e7-8a90-a4d671ca5cb6_terseLabel_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balances in foreign currencies</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_label_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:label id="lab_oncyf_BalanceHeldInForeignCurrencyNet_documentation_en-US" xlink:label="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Balance Held In Foreign Currency, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:href="oncyf-20231231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_BalanceHeldInForeignCurrencyNet" xlink:to="lab_oncyf_BalanceHeldInForeignCurrencyNet" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_ec824650-81a3-43b4-995c-1e91384635c2_terseLabel_en-US" xlink:label="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:href="oncyf-20231231.xsd#oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_20964143-4f6d-4423-be4a-b9279572b0f0_terseLabel_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Capital</link:label>
    <link:label id="lab_ifrs-full_IssuedCapitalMember_label_en-US" xlink:label="lab_ifrs-full_IssuedCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued capital [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_IssuedCapitalMember" xlink:to="lab_ifrs-full_IssuedCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_7f3fb076-06dc-4e4d-97a3-a3233c57ea53_totalLabel_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_ifrs-full_ProfitLossBeforeTax_label_en-US" xlink:label="lab_ifrs-full_ProfitLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit (loss) before tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_ProfitLossBeforeTax" xlink:to="lab_ifrs-full_ProfitLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_4d1a0db8-3c4d-4635-aa55-d8959fc91abb_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_0a599136-ee01-4a7c-a09d-756880543e6c_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of quantitative information about right-of-use assets [table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:to="lab_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_c7ee2aa1-4db0-4335-85d1-eaa64dcea2bc_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of warrant or right, threshold trading price (usd per share)</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:to="lab_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_RetainedEarnings_b989c4f4-5355-4238-9e93-6182c117943a_terseLabel_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_ifrs-full_RetainedEarnings_label_en-US" xlink:label="lab_ifrs-full_RetainedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_RetainedEarnings" xlink:to="lab_ifrs-full_RetainedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ManufacturingExpense_e0a3e47a-0e9a-455f-84f8-62bb13a7589e_terseLabel_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing &amp; related process development expenses</link:label>
    <link:label id="lab_oncyf_ManufacturingExpense_label_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Expense</link:label>
    <link:label id="lab_oncyf_ManufacturingExpense_documentation_en-US" xlink:label="lab_oncyf_ManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense" xlink:href="oncyf-20231231.xsd#oncyf_ManufacturingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ManufacturingExpense" xlink:to="lab_oncyf_ManufacturingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_f45bc559-7a89-4dcd-bce9-85de53050c32_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of fair value measurement of liabilities [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="lab_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_00aa54c7-2796-42d5-97f9-3cd8df763e8b_terseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Under Warrant Derivative Agreement</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_2c0003a4-70d2-4d03-938f-966bf643d5e8_verboseLabel_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivatives</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_label_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Public Offering, Warrant Derivatives [Member]</link:label>
    <link:label id="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember_documentation_en-US" xlink:label="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Public Offering, Warrant Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:to="lab_oncyf_SharesPublicOfferingWarrantDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_a8895fb2-5e99-4d52-94cf-2e9817c1f38e_terseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities (note 5)</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_77b6dfec-1238-4879-b185-2f576b7b8489_verboseLabel_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_ifrs-full_OtherCurrentLiabilities_label_en-US" xlink:label="lab_ifrs-full_OtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_OtherCurrentLiabilities" xlink:to="lab_ifrs-full_OtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_WeightedAverageShares_3b7281f9-ca2b-4c46-9245-4ac8fd987fbd_terseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (basic) (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_09efff87-5567-4fe0-8d27-094b84151b77_verboseLabel_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding (shares)</link:label>
    <link:label id="lab_ifrs-full_WeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_WeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_WeightedAverageShares" xlink:to="lab_ifrs-full_WeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_5f400fe6-2267-4b4e-9d9b-a1adbdae9312_terseLabel_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_label_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Instruments Life, Other Equity Instruments Granted</link:label>
    <link:label id="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_documentation_en-US" xlink:label="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Instruments Life, Other Equity Instruments Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:to="lab_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_650d942f-cc4e-4884-b615-b9e68ea02036_terseLabel_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_label_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:label id="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_documentation_en-US" xlink:label="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure Of Indemnification Of Officers and Directors [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:to="lab_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_af7000b2-b545-44ec-bc9f-e0415b334fad_totalLabel_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash provided by investing activities</link:label>
    <link:label id="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities_label_en-US" xlink:label="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="lab_ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ShareIssueCostsMember_e774b124-10c0-44d6-b2e7-fd78df5ef241_terseLabel_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share issue costs</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_label_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:label id="lab_oncyf_ShareIssueCostsMember_documentation_en-US" xlink:label="lab_oncyf_ShareIssueCostsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Issue Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember" xlink:href="oncyf-20231231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ShareIssueCostsMember" xlink:to="lab_oncyf_ShareIssueCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_701c99c6-738a-4aa5-ac77-fd4c546de7e9_terseLabel_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-capital losses</link:label>
    <link:label id="lab_ifrs-full_UnusedTaxLossesMember_label_en-US" xlink:label="lab_ifrs-full_UnusedTaxLossesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unused tax losses [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_UnusedTaxLossesMember" xlink:to="lab_ifrs-full_UnusedTaxLossesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_WarrantLiabilityAmortizedDiscount_715a0e50-d46c-4f8e-8406-76cdeb15bd7e_terseLabel_en-US" xlink:label="lab_oncyf_WarrantLiabilityAmortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of discount on warrants issued</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityAmortizedDiscount_label_en-US" xlink:label="lab_oncyf_WarrantLiabilityAmortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Liability, Amortized Discount</link:label>
    <link:label id="lab_oncyf_WarrantLiabilityAmortizedDiscount_documentation_en-US" xlink:label="lab_oncyf_WarrantLiabilityAmortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Warrant Liability, Amortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityAmortizedDiscount" xlink:href="oncyf-20231231.xsd#oncyf_WarrantLiabilityAmortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_WarrantLiabilityAmortizedDiscount" xlink:to="lab_oncyf_WarrantLiabilityAmortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_3d439a70-396a-4789-9c4b-4f81a9129350_terseLabel_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents_label_en-US" xlink:label="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income on cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:to="lab_ifrs-full_InterestIncomeOnCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_4a2ccdcc-1c21-46af-a54e-6409d7badef0_terseLabel_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy</link:label>
    <link:label id="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember_label_en-US" xlink:label="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All levels of fair value hierarchy [member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="lab_ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_0de71b7e-f780-4de4-bc7b-ee47804fbb87_terseLabel_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:label id="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_label_en-US" xlink:label="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="lab_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_1199aa2f-9f99-453e-92d1-0d389b601dbe_terseLabel_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:label id="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_label_en-US" xlink:label="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="lab_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_b4941326-f650-43be-8ef3-2a446464fe19_terseLabel_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_label_en-US" xlink:label="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of shares reserved for issue under options and contracts for sale of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:to="lab_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseAbstract_4def640d-6227-491f-a113-1cc6579c584d_terseLabel_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseAbstract_label_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General And Administrative Expense [Abstract]</link:label>
    <link:label id="lab_oncyf_GeneralAndAdministrativeExpenseAbstract_documentation_en-US" xlink:label="lab_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">General And Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:href="oncyf-20231231.xsd#oncyf_GeneralAndAdministrativeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:to="lab_oncyf_GeneralAndAdministrativeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_194a4a54-4310-4eb5-b5c3-798805ef0f6d_terseLabel_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_label_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:label id="lab_oncyf_IncomeStatementLocation1Axis_documentation_en-US" xlink:label="lab_oncyf_IncomeStatementLocation1Axis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statement Location1 [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis" xlink:href="oncyf-20231231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_IncomeStatementLocation1Axis" xlink:to="lab_oncyf_IncomeStatementLocation1Axis" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_6bcd6643-8e61-4ad7-b1da-c4573be8ed3d_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_label_en-US" xlink:label="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for increase (decrease) in trade and other payables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="lab_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_6edc7aa3-10d5-4294-abfa-550c8167af64_negatedTerseLabel_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision to offset deferred tax asset</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_label_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:label id="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_documentation_en-US" xlink:label="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:href="oncyf-20231231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:to="lab_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_b345a85e-0d7d-4139-bb32-4d99df8f9fc3_terseLabel_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares (diluted) (shares)</link:label>
    <link:label id="lab_ifrs-full_AdjustedWeightedAverageShares_label_en-US" xlink:label="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average number of ordinary shares used in calculating diluted earnings per share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ifrs-full_AdjustedWeightedAverageShares" xlink:to="lab_ifrs-full_AdjustedWeightedAverageShares" xlink:type="arc" order="1"/>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_1f00b00a-668f-4783-a3dc-a77ea46fa2f5_terseLabel_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock option plan</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_label_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:label id="lab_oncyf_SharesUnderStockOptionPlanMember_documentation_en-US" xlink:label="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shares Under Stock Option Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_oncyf_SharesUnderStockOptionPlanMember" xlink:to="lab_oncyf_SharesUnderStockOptionPlanMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>oncyf-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:0331f315-f217-43c3-a3a4-8d92b75af8cb,g:42af5dc4-a986-45bb-8df7-47c2c2475bfc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="simple" xlink:href="oncyf-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_8a9697d8-b16e-4f3f-b442-354941185921" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_416e6c71-ce06-4189-8150-ac815f36cea4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_8a9697d8-b16e-4f3f-b442-354941185921" xlink:to="loc_dei_DocumentInformationTable_416e6c71-ce06-4189-8150-ac815f36cea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_298501e6-ce2f-4973-a859-8c7f14f7edbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_416e6c71-ce06-4189-8150-ac815f36cea4" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_298501e6-ce2f-4973-a859-8c7f14f7edbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_0a156e72-b091-49d7-8fe8-12c955977b1a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_298501e6-ce2f-4973-a859-8c7f14f7edbf" xlink:to="loc_dei_AddressTypeDomain_0a156e72-b091-49d7-8fe8-12c955977b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_BusinessContactMember_dcb2c2db-64cc-47cf-9967-9eca21244dbc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_BusinessContactMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_0a156e72-b091-49d7-8fe8-12c955977b1a" xlink:to="loc_dei_BusinessContactMember_dcb2c2db-64cc-47cf-9967-9eca21244dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_416e6c71-ce06-4189-8150-ac815f36cea4" xlink:to="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_ec1bcfa8-b238-4094-9ce1-af50bdfb3c6f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentType_ec1bcfa8-b238-4094-9ce1-af50bdfb3c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentRegistrationStatement_1fdc3cd1-4fa0-4215-b47a-a700b7ab6bc5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentRegistrationStatement_1fdc3cd1-4fa0-4215-b47a-a700b7ab6bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7e5bad30-abd8-4151-a5ca-be55a0c057f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentAnnualReport_7e5bad30-abd8-4151-a5ca-be55a0c057f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f3cacfe6-a7a1-4188-a697-3334e0e31982" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentPeriodEndDate_f3cacfe6-a7a1-4188-a697-3334e0e31982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a090c75c-6081-4472-9eae-086163834f2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_CurrentFiscalYearEndDate_a090c75c-6081-4472-9eae-086163834f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_551ee54a-859d-4ecb-a29a-a208f3b898da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentTransitionReport_551ee54a-859d-4ecb-a29a-a208f3b898da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentShellCompanyReport_32b95295-4cd9-4a97-9644-409b2ca772d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentShellCompanyReport_32b95295-4cd9-4a97-9644-409b2ca772d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_913e8104-8512-4044-818e-70f3ecd4f21a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityFileNumber_913e8104-8512-4044-818e-70f3ecd4f21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_40a34584-f8d9-4eb4-a80e-f8e9e8732137" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityRegistrantName_40a34584-f8d9-4eb4-a80e-f8e9e8732137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_5f83e42b-82db-4325-914a-7bd71026d157" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityIncorporationStateCountryCode_5f83e42b-82db-4325-914a-7bd71026d157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_71c1f22d-c88a-40ea-8ab4-e7d37905bc59" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressAddressLine1_71c1f22d-c88a-40ea-8ab4-e7d37905bc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ae8106b6-b648-482c-8771-aac63aa03402" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressCityOrTown_ae8106b6-b648-482c-8771-aac63aa03402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_ec2a02d3-c87d-498e-9f7d-fe3afe6f5806" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressStateOrProvince_ec2a02d3-c87d-498e-9f7d-fe3afe6f5806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_d1984547-4623-41c1-96a9-40caf12b10af" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressCountry_d1984547-4623-41c1-96a9-40caf12b10af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_85a499a2-2d2a-49af-9c60-89b0b2a77466" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityAddressPostalZipCode_85a499a2-2d2a-49af-9c60-89b0b2a77466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelName_9cc000d8-5f15-4e5d-92a4-87e40ce83673" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelName"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_ContactPersonnelName_9cc000d8-5f15-4e5d-92a4-87e40ce83673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_0252b88c-944f-43a5-8c76-375264c8faf0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_CityAreaCode_0252b88c-944f-43a5-8c76-375264c8faf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f15bc7ab-dac9-417c-b812-9e26548efb07" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_LocalPhoneNumber_f15bc7ab-dac9-417c-b812-9e26548efb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_ContactPersonnelEmailAddress_25563c81-b9dc-4936-baf6-eb3565dfac28" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_ContactPersonnelEmailAddress"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_ContactPersonnelEmailAddress_25563c81-b9dc-4936-baf6-eb3565dfac28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_be8fb859-15b6-41f5-91f9-3dd3216bc579" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_Security12bTitle_be8fb859-15b6-41f5-91f9-3dd3216bc579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a7d60597-db9e-4ee5-878d-c69fec3d28f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_TradingSymbol_a7d60597-db9e-4ee5-878d-c69fec3d28f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c77ade6a-bb28-47ed-9684-becae56656a0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_SecurityExchangeName_c77ade6a-bb28-47ed-9684-becae56656a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0bba4bd7-4083-4a47-9b60-ea9dc6031ddf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0bba4bd7-4083-4a47-9b60-ea9dc6031ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9026266b-4f21-4e43-ac63-1789c4d4ff84" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9026266b-4f21-4e43-ac63-1789c4d4ff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_8f627c09-2a63-4785-b7f2-2d0a30e3f100" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityVoluntaryFilers_8f627c09-2a63-4785-b7f2-2d0a30e3f100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_667ae1b6-3a53-42d2-b2f9-30b95bdf1935" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityCurrentReportingStatus_667ae1b6-3a53-42d2-b2f9-30b95bdf1935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_7eb13640-d0a3-48ea-b601-f1022d55321a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityInteractiveDataCurrent_7eb13640-d0a3-48ea-b601-f1022d55321a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_e0232d65-468f-48c5-9581-8e5ef8b2a99e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityFilerCategory_e0232d65-468f-48c5-9581-8e5ef8b2a99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b610911c-71c1-48d0-9f51-b91150d73a0e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityEmergingGrowthCompany_b610911c-71c1-48d0-9f51-b91150d73a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_522c6995-375f-4557-9bdb-20362a0d480a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_IcfrAuditorAttestationFlag_522c6995-375f-4557-9bdb-20362a0d480a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_5f3666e4-9ccb-43e2-9f5e-9ff5ead94b9e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_5f3666e4-9ccb-43e2-9f5e-9ff5ead94b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAccountingStandard_4a4000dd-76e5-4763-bf8d-dd6167c6e872" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentAccountingStandard_4a4000dd-76e5-4763-bf8d-dd6167c6e872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_39bebdd7-f2ec-418e-a62f-f15bbb701656" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityShellCompany_39bebdd7-f2ec-418e-a62f-f15bbb701656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_185aba6e-644b-433b-98b2-5eb706e6e885" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityCentralIndexKey_185aba6e-644b-433b-98b2-5eb706e6e885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5340f62d-0b58-4237-bbc0-cb639d9d0d3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentFiscalYearFocus_5340f62d-0b58-4237-bbc0-cb639d9d0d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b276b2a8-7cc2-47ee-bd41-f2c7e8f18de4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b276b2a8-7cc2-47ee-bd41-f2c7e8f18de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_24c5cc7a-bace-430a-8d9c-351946904b58" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_AmendmentFlag_24c5cc7a-bace-430a-8d9c-351946904b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_d4a2603f-91a7-48d3-919c-4b91681b9f4f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_a3928532-997a-4787-bf2a-fedc427f4209" xlink:to="loc_dei_EntityPublicFloat_d4a2603f-91a7-48d3-919c-4b91681b9f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AuditInformation" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AuditorInformationAbstract_c849aa42-19b7-4366-a04e-75983e524653" xlink:href="oncyf-20231231.xsd#oncyf_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_82bcb927-714b-4af7-9bf3-078de6a9f146" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_c849aa42-19b7-4366-a04e-75983e524653" xlink:to="loc_dei_AuditorFirmId_82bcb927-714b-4af7-9bf3-078de6a9f146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_d554b3b4-d826-4ab1-8131-d6580e5d21f6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_c849aa42-19b7-4366-a04e-75983e524653" xlink:to="loc_dei_AuditorName_d554b3b4-d826-4ab1-8131-d6580e5d21f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_72a50a8d-b3e1-43f4-b816-eeb291b4e0be" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AuditorInformationAbstract_c849aa42-19b7-4366-a04e-75983e524653" xlink:to="loc_dei_AuditorLocation_72a50a8d-b3e1-43f4-b816-eeb291b4e0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_635bfbe0-f607-41eb-9e26-ed69cd0899c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AssetsAbstract_654c8c8b-7f9f-4065-acc0-816fa4e55183" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_635bfbe0-f607-41eb-9e26-ed69cd0899c7" xlink:to="loc_ifrs-full_AssetsAbstract_654c8c8b-7f9f-4065-acc0-816fa4e55183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssetsAbstract_758d7b42-887f-4f12-9329-175632ed823c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_654c8c8b-7f9f-4065-acc0-816fa4e55183" xlink:to="loc_ifrs-full_CurrentAssetsAbstract_758d7b42-887f-4f12-9329-175632ed823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_6bc9498f-5daa-4bec-a7e1-b09cdf518328" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_758d7b42-887f-4f12-9329-175632ed823c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_6bc9498f-5daa-4bec-a7e1-b09cdf518328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale_ac0cecc4-5ce7-47f2-aaf0-d8e53cdb12aa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentFinancialAssetsAvailableforsale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_758d7b42-887f-4f12-9329-175632ed823c" xlink:to="loc_ifrs-full_CurrentFinancialAssetsAvailableforsale_ac0cecc4-5ce7-47f2-aaf0-d8e53cdb12aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentReceivables_f78513b7-87f8-4e2f-94a1-efabd8c0cccc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_758d7b42-887f-4f12-9329-175632ed823c" xlink:to="loc_ifrs-full_OtherCurrentReceivables_f78513b7-87f8-4e2f-94a1-efabd8c0cccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepayments_ca43d29f-4e6a-4809-9feb-eafe20be1a7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_758d7b42-887f-4f12-9329-175632ed823c" xlink:to="loc_ifrs-full_CurrentPrepayments_ca43d29f-4e6a-4809-9feb-eafe20be1a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentAssets_7e699c6f-7116-4cf8-b9bd-4baf630d98cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentAssetsAbstract_758d7b42-887f-4f12-9329-175632ed823c" xlink:to="loc_ifrs-full_CurrentAssets_7e699c6f-7116-4cf8-b9bd-4baf630d98cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_b5bc36dc-6009-48cf-8f21-1bd55d2552ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_654c8c8b-7f9f-4065-acc0-816fa4e55183" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_b5bc36dc-6009-48cf-8f21-1bd55d2552ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_94753e41-91fa-497b-b49e-2665de472a1a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_654c8c8b-7f9f-4065-acc0-816fa4e55183" xlink:to="loc_ifrs-full_RightofuseAssets_94753e41-91fa-497b-b49e-2665de472a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments_029d3e91-a256-4727-b2f7-d80d69708e0b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_654c8c8b-7f9f-4065-acc0-816fa4e55183" xlink:to="loc_ifrs-full_NoncurrentPrepayments_029d3e91-a256-4727-b2f7-d80d69708e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Assets_e14b950d-1a66-43d3-8432-5d90ec00c980" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AssetsAbstract_654c8c8b-7f9f-4065-acc0-816fa4e55183" xlink:to="loc_ifrs-full_Assets_e14b950d-1a66-43d3-8432-5d90ec00c980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_635bfbe0-f607-41eb-9e26-ed69cd0899c7" xlink:to="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilitiesAbstract_804fa8a3-4643-4e91-976e-6e84ee33e730" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:to="loc_ifrs-full_CurrentLiabilitiesAbstract_804fa8a3-4643-4e91-976e-6e84ee33e730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_97284cd4-77ef-43cf-907c-23289b0b0180" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_804fa8a3-4643-4e91-976e-6e84ee33e730" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_97284cd4-77ef-43cf-907c-23289b0b0180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_469cce5b-de05-4f8a-a1b9-67cf12466ad9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_804fa8a3-4643-4e91-976e-6e84ee33e730" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_469cce5b-de05-4f8a-a1b9-67cf12466ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLeaseLiabilities_64d0d68f-a7d6-45be-97d0-19053839a223" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_804fa8a3-4643-4e91-976e-6e84ee33e730" xlink:to="loc_ifrs-full_CurrentLeaseLiabilities_64d0d68f-a7d6-45be-97d0-19053839a223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e2ea5ced-0492-4513-ae8b-ad6460a78f1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_804fa8a3-4643-4e91-976e-6e84ee33e730" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_e2ea5ced-0492-4513-ae8b-ad6460a78f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentLiabilities_46942793-8392-48fd-8262-645e1d67ced1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CurrentLiabilitiesAbstract_804fa8a3-4643-4e91-976e-6e84ee33e730" xlink:to="loc_ifrs-full_CurrentLiabilities_46942793-8392-48fd-8262-645e1d67ced1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentContractLiabilities_fd2c170e-3e2b-4f32-975c-d4830f9c2b95" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:to="loc_ifrs-full_NoncurrentContractLiabilities_fd2c170e-3e2b-4f32-975c-d4830f9c2b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentLeaseLiabilities_10ca1d6b-06c9-4a37-a10c-9a878a482c2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:to="loc_ifrs-full_NoncurrentLeaseLiabilities_10ca1d6b-06c9-4a37-a10c-9a878a482c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Liabilities_acd5e47e-d3bb-4a0b-ab36-d62713195de4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:to="loc_ifrs-full_Liabilities_acd5e47e-d3bb-4a0b-ab36-d62713195de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommitmentsAndContingencies1_32e3ae89-b06f-4b11-9a80-f66bd34bf0f6" xlink:href="oncyf-20231231.xsd#oncyf_CommitmentsAndContingencies1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:to="loc_oncyf_CommitmentsAndContingencies1_32e3ae89-b06f-4b11-9a80-f66bd34bf0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_741b4d1b-87be-41fc-817e-a80c0b3a47e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:to="loc_ifrs-full_EquityAbstract_741b4d1b-87be-41fc-817e-a80c0b3a47e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapital_91b60248-9a37-4438-892e-3a5a0a68f8c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_741b4d1b-87be-41fc-817e-a80c0b3a47e8" xlink:to="loc_ifrs-full_IssuedCapital_91b60248-9a37-4438-892e-3a5a0a68f8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionalPaidinCapital_a4b71f32-2aa4-4e2d-818b-c5272f6efc94" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionalPaidinCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_741b4d1b-87be-41fc-817e-a80c0b3a47e8" xlink:to="loc_ifrs-full_AdditionalPaidinCapital_a4b71f32-2aa4-4e2d-818b-c5272f6efc94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_7de5d669-77f5-4e72-97d8-aab8a4c2009b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_741b4d1b-87be-41fc-817e-a80c0b3a47e8" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncome_7de5d669-77f5-4e72-97d8-aab8a4c2009b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_262d0b57-139f-48fa-afd7-a8cb36d912c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_741b4d1b-87be-41fc-817e-a80c0b3a47e8" xlink:to="loc_ifrs-full_RetainedEarnings_262d0b57-139f-48fa-afd7-a8cb36d912c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_4a5d6432-28e5-4a67-8ba5-91ea2e36bfc7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_741b4d1b-87be-41fc-817e-a80c0b3a47e8" xlink:to="loc_ifrs-full_Equity_4a5d6432-28e5-4a67-8ba5-91ea2e36bfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAndLiabilities_62db4174-8b9c-486a-8857-266c1d4e4f7f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAndLiabilitiesAbstract_b6e030fb-afce-44a9-91ef-048731de5b4d" xlink:to="loc_ifrs-full_EquityAndLiabilities_62db4174-8b9c-486a-8857-266c1d4e4f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfFinancialPositionAbstract_1ab8acf0-cbc0-4a9b-9229-a8027082ed96" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityAbstract_45d0a4a1-78f4-4be7-bfe1-13f41d7da962" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfFinancialPositionAbstract_1ab8acf0-cbc0-4a9b-9229-a8027082ed96" xlink:to="loc_ifrs-full_EquityAbstract_45d0a4a1-78f4-4be7-bfe1-13f41d7da962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_7668e2f3-eaba-485e-9c33-ad519c22b787" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityAbstract_45d0a4a1-78f4-4be7-bfe1-13f41d7da962" xlink:to="loc_ifrs-full_NumberOfSharesIssued_7668e2f3-eaba-485e-9c33-ad519c22b787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseByNatureAbstract_8e68fbab-000d-4db5-8c7f-ee5c6b7d85f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseByNatureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_ExpenseByNatureAbstract_8e68fbab-000d-4db5-8c7f-ee5c6b7d85f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_d1e55f76-f6b0-4681-b42c-c235f96be2d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_8e68fbab-000d-4db5-8c7f-ee5c6b7d85f8" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_d1e55f76-f6b0-4681-b42c-c235f96be2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_2128b695-6c88-48ee-8404-74f8a1a3edcb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ExpenseByNatureAbstract_8e68fbab-000d-4db5-8c7f-ee5c6b7d85f8" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_2128b695-6c88-48ee-8404-74f8a1a3edcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossFromOperatingActivities_14a4e181-e738-4c39-aae7-93cbacaa601f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_ProfitLossFromOperatingActivities_14a4e181-e738-4c39-aae7-93cbacaa601f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_95a5952d-28f9-415a-abe6-df0c810922b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_95a5952d-28f9-415a-abe6-df0c810922b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_b12b32a7-795e-4776-8cee-36c5db50107f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss_b12b32a7-795e-4776-8cee-36c5db50107f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_43f6c091-292c-4cf3-8ef2-289674124e26" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestIncomeOnCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_InterestIncomeOnCashAndCashEquivalents_43f6c091-292c-4cf3-8ef2-289674124e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLossBeforeTax_51f94ec5-e6fb-472a-b2fa-d5cc02c9543a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_ProfitLossBeforeTax_51f94ec5-e6fb-472a-b2fa-d5cc02c9543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_bc6ec541-05be-43bf-b972-a75d2e3c7e7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_IncomeTaxExpenseContinuingOperations_bc6ec541-05be-43bf-b972-a75d2e3c7e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_d794bb53-b538-40a3-ac53-987c266b8b35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_ProfitLoss_d794bb53-b538-40a3-ac53-987c266b8b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeAbstract_b3142d80-2306-4882-bd2a-27699b481df3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeAbstract_b3142d80-2306-4882-bd2a-27699b481df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d7dbfac6-57e7-46bc-9785-b8bff7a24e29" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherComprehensiveIncomeAbstract_b3142d80-2306-4882-bd2a-27699b481df3" xlink:to="loc_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_d7dbfac6-57e7-46bc-9785-b8bff7a24e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_ca1a84a6-c482-429f-abee-4dbcc0bf9f85" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_ComprehensiveIncome_ca1a84a6-c482-429f-abee-4dbcc0bf9f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BasicEarningsLossPerShare_f5e65efb-a841-4d23-ad18-379f1b9532e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_BasicEarningsLossPerShare_f5e65efb-a841-4d23-ad18-379f1b9532e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DilutedEarningsLossPerShare_550191e2-705c-4534-884d-02c000af1967" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_DilutedEarningsLossPerShare_550191e2-705c-4534-884d-02c000af1967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_3e19325e-b625-4eb2-a26e-562816e676f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_WeightedAverageShares_3e19325e-b625-4eb2-a26e-562816e676f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustedWeightedAverageShares_2987c822-73f6-4d62-af23-c5d0fe6093f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_IncomeStatementAbstract_d4933b22-9762-41a3-be90-14e6819d945f" xlink:to="loc_ifrs-full_AdjustedWeightedAverageShares_2987c822-73f6-4d62-af23-c5d0fe6093f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_7554258d-1aca-4519-ad7e-6dccc3c9954e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_7554258d-1aca-4519-ad7e-6dccc3c9954e" xlink:to="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_1f25b9e8-68cc-4a07-ae2d-0137e7e1360b" xlink:to="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_919b6be5-1a3f-4721-ab8b-f14ec3a26dee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_IssuedCapitalMember_919b6be5-1a3f-4721-ab8b-f14ec3a26dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_e2f26c12-18f9-44ec-9d3f-d73aecb77ec8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_WarrantsMember_e2f26c12-18f9-44ec-9d3f-d73aecb77ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_57304a68-a1ae-442d-a180-38704b12c24d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_SharePremiumMember_57304a68-a1ae-442d-a180-38704b12c24d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_b5e36516-689c-4823-8711-03ce669de78d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_AccumulatedOtherComprehensiveIncomeMember_b5e36516-689c-4823-8711-03ce669de78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarningsMember_d3267489-f492-433b-84ae-c032c367f5a9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_311c2317-2340-4ba6-a975-0238e3992a57" xlink:to="loc_ifrs-full_RetainedEarningsMember_d3267489-f492-433b-84ae-c032c367f5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_8d58f474-0163-438b-ae5f-8edd2886a126" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:to="loc_oncyf_SaleOfStockAxis_8d58f474-0163-438b-ae5f-8edd2886a126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_29316142-7837-47e8-8671-99583ab55002" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_8d58f474-0163-438b-ae5f-8edd2886a126" xlink:to="loc_oncyf_SaleOfStockDomain_29316142-7837-47e8-8671-99583ab55002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_9016afa2-f9e1-4eda-bbe5-614a37c4d094" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_29316142-7837-47e8-8671-99583ab55002" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_9016afa2-f9e1-4eda-bbe5-614a37c4d094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderPublicOfferingMember_ffde90c8-29cd-4b2e-b9f9-0b88c47284e7" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_29316142-7837-47e8-8671-99583ab55002" xlink:to="loc_oncyf_SharesUnderPublicOfferingMember_ffde90c8-29cd-4b2e-b9f9-0b88c47284e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityTable_b928bcb3-6f2d-4c12-8030-dbe028171e8f" xlink:to="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_b98300e2-3d75-4018-acb4-7e9fd0b8aefd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_Equity_b98300e2-3d75-4018-acb4-7e9fd0b8aefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComprehensiveIncome_1d9eaa97-bdf7-4aa2-b5ed-2aabc3bd97f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComprehensiveIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_ComprehensiveIncome_1d9eaa97-bdf7-4aa2-b5ed-2aabc3bd97f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_06855b99-5016-4bce-b07b-f88e7dd797ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_06855b99-5016-4bce-b07b-f88e7dd797ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_0eefcdff-7896-43ee-85d6-031d19fe16f5" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity_0eefcdff-7896-43ee-85d6-031d19fe16f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_ead8509f-94cf-42b7-b345-0b56faec5da6" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity_ead8509f-94cf-42b7-b345-0b56faec5da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_09f36822-8575-43b3-9611-81f6184f90f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_IssueOfEquity_09f36822-8575-43b3-9611-81f6184f90f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_317289d2-870f-4b50-9ff9-5005ca4f647f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_317289d2-870f-4b50-9ff9-5005ca4f647f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_8214e6fe-8244-44a1-95c2-db85b8614d99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity_8214e6fe-8244-44a1-95c2-db85b8614d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_c07331d2-7a03-4868-ace0-377ef66e2c99" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_c07331d2-7a03-4868-ace0-377ef66e2c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_03755a12-2224-49d8-8518-eb8e5ba19f64" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityLineItems_af43c5cc-1a9a-4073-8128-22905c1bf82e" xlink:to="loc_ifrs-full_Equity_03755a12-2224-49d8-8518-eb8e5ba19f64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfCashFlowsAbstract_da5c3afd-af46-49ab-b82b-7c5e42def7e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1Table_ae171215-2b5a-41c9-a48d-9f3983341e43" xlink:href="oncyf-20231231.xsd#oncyf_Statement1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfCashFlowsAbstract_da5c3afd-af46-49ab-b82b-7c5e42def7e9" xlink:to="loc_oncyf_Statement1Table_ae171215-2b5a-41c9-a48d-9f3983341e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_75d87888-6574-4cb6-9551-6d59d8e300d5" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_ae171215-2b5a-41c9-a48d-9f3983341e43" xlink:to="loc_oncyf_SaleOfStockAxis_75d87888-6574-4cb6-9551-6d59d8e300d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_9e693717-93ea-4ee2-b204-19e3e55e07d4" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_75d87888-6574-4cb6-9551-6d59d8e300d5" xlink:to="loc_oncyf_SaleOfStockDomain_9e693717-93ea-4ee2-b204-19e3e55e07d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_4ca983d7-23b5-49e4-bd8f-94a89f00fe16" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_9e693717-93ea-4ee2-b204-19e3e55e07d4" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_4ca983d7-23b5-49e4-bd8f-94a89f00fe16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_1d2cdb14-86c8-4ce7-9a0a-cc7941d31309" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_9e693717-93ea-4ee2-b204-19e3e55e07d4" xlink:to="loc_oncyf_SharesPublicOfferingMember_1d2cdb14-86c8-4ce7-9a0a-cc7941d31309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:href="oncyf-20231231.xsd#oncyf_Statement1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1Table_ae171215-2b5a-41c9-a48d-9f3983341e43" xlink:to="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProfitLoss_739c7554-37ea-4ed4-9d69-cd38124689d1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_ProfitLoss_739c7554-37ea-4ed4-9d69-cd38124689d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f62944a2-f8c5-49f6-816a-3b8f3ba056f7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_f62944a2-f8c5-49f6-816a-3b8f3ba056f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_b88d949f-a51d-4a1c-9db0-ec1eadd0098e" xlink:href="oncyf-20231231.xsd#oncyf_AdjustmentsForDepreciationRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_oncyf_AdjustmentsForDepreciationRightOfUseAssets_b88d949f-a51d-4a1c-9db0-ec1eadd0098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForSharebasedPayments_2481bcdd-a371-4a4d-80e3-cf8b53769b08" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_AdjustmentsForSharebasedPayments_2481bcdd-a371-4a4d-80e3-cf8b53769b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_ae8cbc9c-8e50-4c73-8d1b-5347d5fbbe3c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_ae8cbc9c-8e50-4c73-8d1b-5347d5fbbe3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestRevenueExpense_60b2d543-a4dd-477a-a524-cc8763b983da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRevenueExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_InterestRevenueExpense_60b2d543-a4dd-477a-a524-cc8763b983da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_a16f4925-754b-4218-8780-9b070798720c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains_a16f4925-754b-4218-8780-9b070798720c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_5815e786-661b-494e-9f2b-29f52577045c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_5815e786-661b-494e-9f2b-29f52577045c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_131009e2-8509-4bca-8821-a59831f2e4b7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_131009e2-8509-4bca-8821-a59831f2e4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInOperations_9ccb2405-88c9-42ce-8fef-3b3db5861d4d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_657fc625-1728-4630-81e0-a2553200c845" xlink:to="loc_ifrs-full_CashFlowsFromUsedInOperations_9ccb2405-88c9-42ce-8fef-3b3db5861d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_03844f06-2a1f-42e4-9940-cc5a01755d36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:to="loc_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities_03844f06-2a1f-42e4-9940-cc5a01755d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_bb46260e-8153-4ed2-98a4-69f04b89707a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:to="loc_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_bb46260e-8153-4ed2-98a4-69f04b89707a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_48351898-c532-42df-a642-c56e592d85e9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:to="loc_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_48351898-c532-42df-a642-c56e592d85e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d896bbfe-70b0-4724-92b8-a7c500e51eb3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_4c8d63c0-3f2c-422d-bda9-08bc49e40d42" xlink:to="loc_ifrs-full_CashFlowsFromUsedInInvestingActivities_d896bbfe-70b0-4724-92b8-a7c500e51eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfOptions_ee1bee37-0168-4c81-a231-014d3e7d6b35" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfOptions_ee1bee37-0168-4c81-a231-014d3e7d6b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromExerciseOfWarrants_15fa83f7-bec2-4fec-9a57-525910b1aa0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromExerciseOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_ProceedsFromExerciseOfWarrants_15fa83f7-bec2-4fec-9a57-525910b1aa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssuingShares_81156bb4-3013-4bb3-b605-47c6ae672a38" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_ProceedsFromIssuingShares_81156bb4-3013-4bb3-b605-47c6ae672a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_0a9cc5a9-134f-4dcc-86ed-50b329e027bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_CashOutflowForLeases_0a9cc5a9-134f-4dcc-86ed-50b329e027bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5c906d23-b02f-4de7-b739-40e14bd59bb9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_955d854c-ff34-461b-a4f9-6630da7229a6" xlink:to="loc_ifrs-full_CashFlowsFromUsedInFinancingActivities_5c906d23-b02f-4de7-b739-40e14bd59bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_a16a27b5-e8d0-4d84-aa10-344e8055cd2a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents_a16a27b5-e8d0-4d84-aa10-344e8055cd2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_3703eec5-249b-4adf-8e5b-7dea9243244a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashAndCashEquivalents_3703eec5-249b-4adf-8e5b-7dea9243244a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_fea52151-3750-4587-8abd-655f3ac7e9be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_fea52151-3750-4587-8abd-655f3ac7e9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_5b7b9454-64d2-4184-85c5-6dded6c30f66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Statement1LineItems_c8b8f856-a418-4ae6-9544-8d1197d3f302" xlink:to="loc_ifrs-full_CashAndCashEquivalents_5b7b9454-64d2-4184-85c5-6dded6c30f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperations" xlink:type="simple" xlink:href="oncyf-20231231.xsd#NatureofOperations"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/NatureofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_c7117f8a-dcc2-43f6-a5dc-152f173e76bd" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_e518e8b8-9f9e-4345-a235-29768ce1588f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_c7117f8a-dcc2-43f6-a5dc-152f173e76bd" xlink:to="loc_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_e518e8b8-9f9e-4345-a235-29768ce1588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/BasisofPresentation" xlink:type="simple" xlink:href="oncyf-20231231.xsd#BasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/BasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_18dda0ff-2370-469a-ad31-eee8e3aaa426" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_1660c0f3-1009-4f89-a0ce-650684d1df4a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract_18dda0ff-2370-469a-ad31-eee8e3aaa426" xlink:to="loc_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_1660c0f3-1009-4f89-a0ce-650684d1df4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies" xlink:type="simple" xlink:href="oncyf-20231231.xsd#SummaryofMaterialAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_ca2be3aa-0617-4c97-92f4-ca3fdf349e8c" xlink:href="oncyf-20231231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_4942c7ed-b540-4ec0-8eda-04cbe394415a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_ca2be3aa-0617-4c97-92f4-ca3fdf349e8c" xlink:to="loc_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory_4942c7ed-b540-4ec0-8eda-04cbe394415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="simple" xlink:href="oncyf-20231231.xsd#SignificantJudgmentsEstimatesandAssumptions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_fc0a84d8-5219-4ad2-b5e7-03db8343c181" xlink:href="oncyf-20231231.xsd#oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_0d4f0ba2-6b54-4618-b376-2ccd29caa34f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract_fc0a84d8-5219-4ad2-b5e7-03db8343c181" xlink:to="loc_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_0d4f0ba2-6b54-4618-b376-2ccd29caa34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities" xlink:type="simple" xlink:href="oncyf-20231231.xsd#OtherAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_466b14b5-2650-4612-b4e2-9b1cc1d63172" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_a101882f-eeb0-4914-bda3-b958ce387a25" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_466b14b5-2650-4612-b4e2-9b1cc1d63172" xlink:to="loc_ifrs-full_DisclosureOfOtherAssetsExplanatory_a101882f-eeb0-4914-bda3-b958ce387a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_3b73c95a-bc8c-4ddc-b4f0-22e6ff485647" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherLiabilitiesExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_466b14b5-2650-4612-b4e2-9b1cc1d63172" xlink:to="loc_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory_3b73c95a-bc8c-4ddc-b4f0-22e6ff485647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="oncyf-20231231.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_d522deef-08e8-4257-a503-edff572bb1ec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_b037e392-7c81-4ad0-9076-c22ea64c3ce4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_d522deef-08e8-4257-a503-edff572bb1ec" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory_b037e392-7c81-4ad0-9076-c22ea64c3ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8ee02a9e-f0ca-4bfe-a576-9889339754af" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_bd30d0e6-4e84-4096-a80a-b0f4a2637b98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_8ee02a9e-f0ca-4bfe-a576-9889339754af" xlink:to="loc_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_bd30d0e6-4e84-4096-a80a-b0f4a2637b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="simple" xlink:href="oncyf-20231231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_bbcdb7d7-964a-4f9f-ba77-35a898e731b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfLeasesExplanatory_3f1856cf-7e0f-4b22-a2ed-aceb4b9997e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfLeasesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_bbcdb7d7-964a-4f9f-ba77-35a898e731b9" xlink:to="loc_ifrs-full_DisclosureOfLeasesExplanatory_3f1856cf-7e0f-4b22-a2ed-aceb4b9997e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivative"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivative" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_31af9f2d-5c14-4a98-be3f-e01517373dd5" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_39be409e-508e-4f13-8936-6bb3f845b712" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_31af9f2d-5c14-4a98-be3f-e01517373dd5" xlink:to="loc_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory_39be409e-508e-4f13-8936-6bb3f845b712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareCapital"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapital" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4ec5c4c1-ce66-4c97-b270-f4f909d99873" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_cb852387-d671-47e5-920f-6bde1703f4b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4ec5c4c1-ce66-4c97-b270-f4f909d99873" xlink:to="loc_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_cb852387-d671-47e5-920f-6bde1703f4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_8d7dbf85-57bf-4a58-8656-945c6ec021e7" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_3a78bc0b-dc06-4489-b703-4137a3b4c733" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_8d7dbf85-57bf-4a58-8656-945c6ec021e7" xlink:to="loc_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_3a78bc0b-dc06-4489-b703-4137a3b4c733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="simple" xlink:href="oncyf-20231231.xsd#LossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_5687a48b-d8b4-4ecd-878f-f11134ddd851" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_ef07ad32-4a08-41b8-b008-312eee1b73c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_5687a48b-d8b4-4ecd-878f-f11134ddd851" xlink:to="loc_ifrs-full_DisclosureOfEarningsPerShareExplanatory_ef07ad32-4a08-41b8-b008-312eee1b73c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiability" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ContractLiability"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_4a3ae354-aefb-4ab2-a431-2de0e0f08047" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_58ef5eee-b93b-4875-b714-c2e7582f252e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_4a3ae354-aefb-4ab2-a431-2de0e0f08047" xlink:to="loc_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_58ef5eee-b93b-4875-b714-c2e7582f252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_ebdf1f8a-b8e5-40d1-a439-13f2be43acf7" xlink:href="oncyf-20231231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_d1a9fe9c-0084-4856-bfd3-99cbe5de943b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_ebdf1f8a-b8e5-40d1-a439-13f2be43acf7" xlink:to="loc_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_d1a9fe9c-0084-4856-bfd3-99cbe5de943b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_7fa6c948-4537-4343-bd04-e889d5d61135" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_11f0c558-0087-40e4-81b6-048a2fae1707" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_7fa6c948-4537-4343-bd04-e889d5d61135" xlink:to="loc_ifrs-full_DisclosureOfIncomeTaxExplanatory_11f0c558-0087-40e4-81b6-048a2fae1707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CapitalDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_d27e671d-729b-4007-b084-08bcd1f57276" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_acd68bcb-02f6-479e-931d-bb2ec31088e4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_d27e671d-729b-4007-b084-08bcd1f57276" xlink:to="loc_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory_acd68bcb-02f6-479e-931d-bb2ec31088e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="simple" xlink:href="oncyf-20231231.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_bc575142-1bd6-4084-89b2-cd3397024c2b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_726c001f-f11f-4fe5-b225-fe4485ebdf4b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_bc575142-1bd6-4084-89b2-cd3397024c2b" xlink:to="loc_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_726c001f-f11f-4fe5-b225-fe4485ebdf4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AdditionalCashFlowDisclosures"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_fcce5a3e-946f-44f7-9f59-dbde4538b667" xlink:href="oncyf-20231231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_beefdb59-be1b-42ed-8d98-ee5d1c43886c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfCashFlowStatementExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_fcce5a3e-946f-44f7-9f59-dbde4538b667" xlink:to="loc_ifrs-full_DisclosureOfCashFlowStatementExplanatory_beefdb59-be1b-42ed-8d98-ee5d1c43886c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IndemnificationofOfficersandDirectors"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_69b91e15-cf32-4db3-9969-ce1ca6b9aa08" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_89b8b750-91d1-42e5-821d-98ee865d358f" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract_69b91e15-cf32-4db3-9969-ce1ca6b9aa08" xlink:to="loc_oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock_89b8b750-91d1-42e5-821d-98ee865d358f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="simple" xlink:href="oncyf-20231231.xsd#EconomicDependence"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependence" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_5950148f-a78f-4219-b78c-c0a6694dbd7a" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_9d6d913f-192c-4e92-8cf6-0f1e0aa7e5b1" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfEconomicDependenceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_5950148f-a78f-4219-b78c-c0a6694dbd7a" xlink:to="loc_oncyf_DisclosureOfEconomicDependenceTextBlock_9d6d913f-192c-4e92-8cf6-0f1e0aa7e5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ComponentsofExpenses"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0d26ba23-5457-4545-9456-8d437be8144c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_3134806a-d5d0-4872-ac69-170fc10ab3d5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_0d26ba23-5457-4545-9456-8d437be8144c" xlink:to="loc_ifrs-full_DisclosureOfExpensesByNatureExplanatory_3134806a-d5d0-4872-ac69-170fc10ab3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="oncyf-20231231.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_bf69ba49-3387-4ace-aa54-c625d4422f85" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_e9982694-41ac-4921-a97c-87ca2bbc4aa8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_bf69ba49-3387-4ace-aa54-c625d4422f85" xlink:to="loc_ifrs-full_DisclosureOfRelatedPartyExplanatory_e9982694-41ac-4921-a97c-87ca2bbc4aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies" xlink:type="simple" xlink:href="oncyf-20231231.xsd#SummaryofMaterialAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:href="oncyf-20231231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_418dd0ed-5842-4b2a-b218-197d16e80510" xlink:href="oncyf-20231231.xsd#oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock_418dd0ed-5842-4b2a-b218-197d16e80510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_8a77b044-5532-4d30-95be-c91c793257b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory_8a77b044-5532-4d30-95be-c91c793257b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_35e44cad-0fcb-43c3-8109-f9f6b99f3659" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory_35e44cad-0fcb-43c3-8109-f9f6b99f3659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_254de988-1c88-4a63-a978-db65e41fbf09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory_254de988-1c88-4a63-a978-db65e41fbf09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_98392acf-4ddd-4e91-8f5b-00a2b6b37430" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory_98392acf-4ddd-4e91-8f5b-00a2b6b37430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_72107830-8c9c-4ef0-bb3c-7dd2e648c79b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory_72107830-8c9c-4ef0-bb3c-7dd2e648c79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_a4d20c8d-a585-49b4-a9ad-cb7fb314e844" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory_a4d20c8d-a585-49b4-a9ad-cb7fb314e844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_c5a8147a-6e95-44bb-af86-b6a0dd1f5a50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory_c5a8147a-6e95-44bb-af86-b6a0dd1f5a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_5ee1e8b6-c37e-4707-9466-558f4ab4e704" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory_5ee1e8b6-c37e-4707-9466-558f4ab4e704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_2e7d52d2-9399-42ab-a069-1ee0ec4a8f23" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory_2e7d52d2-9399-42ab-a069-1ee0ec4a8f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_27ecc0bf-84a2-4263-a0c2-0b8a9b4bdebc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory_27ecc0bf-84a2-4263-a0c2-0b8a9b4bdebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_2cb88f2d-92d3-4982-8872-186956ff00cd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_2cb88f2d-92d3-4982-8872-186956ff00cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_e2cb4059-e95c-4425-9780-0b5020cfd90a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue_e2cb4059-e95c-4425-9780-0b5020cfd90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_f733ea0e-b0d4-40a6-b165-2df3f420ef15" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory_f733ea0e-b0d4-40a6-b165-2df3f420ef15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_b1b14e83-5882-43b8-a19b-5c6ad3362d30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_8c905acf-8283-4ff5-8963-315b4f2377f8" xlink:to="loc_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations_b1b14e83-5882-43b8-a19b-5c6ad3362d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#SummaryofMaterialAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_f98ec8f2-b75d-47e8-b6c3-c87a5a58700f" xlink:href="oncyf-20231231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_2cb51e05-67b7-49cd-bc83-bc691582cc8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_f98ec8f2-b75d-47e8-b6c3-c87a5a58700f" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_2cb51e05-67b7-49cd-bc83-bc691582cc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0b1c9e04-71a0-40e0-801b-19a670226808" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_7c44e558-9e40-4194-85b4-9fe300d73fa4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_0b1c9e04-71a0-40e0-801b-19a670226808" xlink:to="loc_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory_7c44e558-9e40-4194-85b4-9fe300d73fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9bc20b14-c493-487b-ad96-4172f18b01b8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_de8617f9-b746-47cf-8fec-cb388c955f96" xlink:href="oncyf-20231231.xsd#oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_9bc20b14-c493-487b-ad96-4172f18b01b8" xlink:to="loc_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock_de8617f9-b746-47cf-8fec-cb388c955f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5e443974-eaca-4d22-a576-a61a2dc84fc9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_b7a9a830-5ea5-49c3-beef-30905b97b4b4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5e443974-eaca-4d22-a576-a61a2dc84fc9" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory_b7a9a830-5ea5-49c3-beef-30905b97b4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_967e9e6c-f1e1-40e7-ac22-ae57217eea11" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5e443974-eaca-4d22-a576-a61a2dc84fc9" xlink:to="loc_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock_967e9e6c-f1e1-40e7-ac22-ae57217eea11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_27481462-fdfc-49f7-a9ad-66a2ebb500fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_5e443974-eaca-4d22-a576-a61a2dc84fc9" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_27481462-fdfc-49f7-a9ad-66a2ebb500fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivativeTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4f8293b3-1411-49ca-aafe-6192370aa982" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_11ba7e61-2c84-4268-8ca6-2efe7f4fb475" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_4f8293b3-1411-49ca-aafe-6192370aa982" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory_11ba7e61-2c84-4268-8ca6-2efe7f4fb475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareCapitalTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_01d24e32-198b-4998-b97b-de2c2c1e3f58" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_f821d1a4-bf62-4953-a7d2-a1d837203cab" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_01d24e32-198b-4998-b97b-de2c2c1e3f58" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_f821d1a4-bf62-4953-a7d2-a1d837203cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_20ac6acc-9328-40a8-876d-d5aab2b92d64" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofsharebasedpaymentarrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_21721c6b-6e6f-4f5c-a00a-4326d252d5f9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_20ac6acc-9328-40a8-876d-d5aab2b92d64" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_21721c6b-6e6f-4f5c-a00a-4326d252d5f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_9008ad4f-0886-4e41-a058-5a4d44c74b5a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_20ac6acc-9328-40a8-876d-d5aab2b92d64" xlink:to="loc_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory_9008ad4f-0886-4e41-a058-5a4d44c74b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_53a3783f-80d9-4818-8830-9338698f012a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_20ac6acc-9328-40a8-876d-d5aab2b92d64" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_53a3783f-80d9-4818-8830-9338698f012a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_a194318f-1d02-4726-a655-3c81f285cb05" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_20ac6acc-9328-40a8-876d-d5aab2b92d64" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_a194318f-1d02-4726-a655-3c81f285cb05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_525b3d75-bc45-411f-8efa-d016b3879461" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_20ac6acc-9328-40a8-876d-d5aab2b92d64" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_525b3d75-bc45-411f-8efa-d016b3879461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_d15aa449-00d7-45c6-93ed-cba061c980ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofsharebasedpaymentarrangementAbstract_20ac6acc-9328-40a8-876d-d5aab2b92d64" xlink:to="loc_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory_d15aa449-00d7-45c6-93ed-cba061c980ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ContractLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_033350d5-761c-4f2f-90d7-97e5b0fd92d1" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_69640dc4-754a-4385-bd5b-fdd4eb8cd610" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_033350d5-761c-4f2f-90d7-97e5b0fd92d1" xlink:to="loc_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_69640dc4-754a-4385-bd5b-fdd4eb8cd610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_0d0adfb7-68ac-40da-aad5-08c57ceda685" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_68cd7013-b4e4-43f4-ba2b-267199c0fc19" xlink:href="oncyf-20231231.xsd#oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_0d0adfb7-68ac-40da-aad5-08c57ceda685" xlink:to="loc_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock_68cd7013-b4e4-43f4-ba2b-267199c0fc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_49b8695e-aab4-466c-b805-1fc0815647a4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_0d0adfb7-68ac-40da-aad5-08c57ceda685" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory_49b8695e-aab4-466c-b805-1fc0815647a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CapitalDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_fb252fdb-e87c-4f84-87e8-fe9cc34bc731" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_0a577044-626e-464b-9055-3b1fc74ecadd" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfCapitalComponentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_fb252fdb-e87c-4f84-87e8-fe9cc34bc731" xlink:to="loc_oncyf_DisclosureOfCapitalComponentsTableTextBlock_0a577044-626e-464b-9055-3b1fc74ecadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_ee245944-65e5-4c3a-8b3b-8593ce5a83bc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_25678b32-3fca-4911-8cc2-30da557bd420" xlink:href="oncyf-20231231.xsd#oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_ee245944-65e5-4c3a-8b3b-8593ce5a83bc" xlink:to="loc_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock_25678b32-3fca-4911-8cc2-30da557bd420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AdditionalCashFlowDisclosuresTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_b6b7f9bb-85a4-40cd-899a-ca372e85a185" xlink:href="oncyf-20231231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_e7e86b4d-f6d7-4c8b-a8f3-c5cf82c82c9b" xlink:href="oncyf-20231231.xsd#oncyf_CashFlowOperatingCapital1TableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_b6b7f9bb-85a4-40cd-899a-ca372e85a185" xlink:to="loc_oncyf_CashFlowOperatingCapital1TableTextBlock_e7e86b4d-f6d7-4c8b-a8f3-c5cf82c82c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_b3ad0c4f-08bb-4f65-8705-7a7e9cc6609d" xlink:href="oncyf-20231231.xsd#oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_b6b7f9bb-85a4-40cd-899a-ca372e85a185" xlink:to="loc_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock_b3ad0c4f-08bb-4f65-8705-7a7e9cc6609d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ComponentsofExpensesTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c38fe1b7-9bb5-441a-a448-5bc71d04b619" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_b98fadf9-b211-4c79-a761-fe55a878105e" xlink:href="oncyf-20231231.xsd#oncyf_OtherExpensesAndAdjustmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_c38fe1b7-9bb5-441a-a448-5bc71d04b619" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTableTextBlock_b98fadf9-b211-4c79-a761-fe55a878105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="oncyf-20231231.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_66dab213-0051-4755-a208-5aea829f8142" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_3b15fb65-3249-4945-a660-eae8f8c56f30" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_66dab213-0051-4755-a208-5aea829f8142" xlink:to="loc_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_3b15fb65-3249-4945-a660-eae8f8c56f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#NatureofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_3773e083-b464-4cc5-8d11-280e67f3e329" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RetainedEarnings_795a50f7-3f7b-43b1-94ab-15c7d08fbef5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_3773e083-b464-4cc5-8d11-280e67f3e329" xlink:to="loc_ifrs-full_RetainedEarnings_795a50f7-3f7b-43b1-94ab-15c7d08fbef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CashAndCashEquivalentsAndCurrentInvestments_20f42984-4549-4543-94dc-0607008585c6" xlink:href="oncyf-20231231.xsd#oncyf_CashAndCashEquivalentsAndCurrentInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract_3773e083-b464-4cc5-8d11-280e67f3e329" xlink:to="loc_oncyf_CashAndCashEquivalentsAndCurrentInvestments_20f42984-4549-4543-94dc-0607008585c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#SummaryofMaterialAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fdeb956a-1b87-48d4-b3b6-818931aa2683" xlink:href="oncyf-20231231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashEquivalents_45a819b1-edb5-4f33-a3da-f85d4a651acb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fdeb956a-1b87-48d4-b3b6-818931aa2683" xlink:to="loc_ifrs-full_CashEquivalents_45a819b1-edb5-4f33-a3da-f85d4a651acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfStockOptionPlans_abc66cf8-fa89-42f5-897d-ba9dcca6cb78" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfStockOptionPlans"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fdeb956a-1b87-48d4-b3b6-818931aa2683" xlink:to="loc_oncyf_NumberOfStockOptionPlans_abc66cf8-fa89-42f5-897d-ba9dcca6cb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_4db82b8d-d1a3-4f45-959b-441a6ae64e85" xlink:href="oncyf-20231231.xsd#oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_fdeb956a-1b87-48d4-b3b6-818931aa2683" xlink:to="loc_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement_4db82b8d-d1a3-4f45-959b-441a6ae64e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_3b4f2837-3176-4bd3-9005-5669bf824071" xlink:href="oncyf-20231231.xsd#oncyf_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_dd46533c-4bf2-4d4d-aaff-1f2566f26fec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SummaryOfSignificantAccountingPoliciesAbstract_3b4f2837-3176-4bd3-9005-5669bf824071" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_dd46533c-4bf2-4d4d-aaff-1f2566f26fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_64f163e4-2a91-4ac0-aab9-ad10bf144de0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_dd46533c-4bf2-4d4d-aaff-1f2566f26fec" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_64f163e4-2a91-4ac0-aab9-ad10bf144de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_64f163e4-2a91-4ac0-aab9-ad10bf144de0" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OfficeEquipmentMember_f5f0cce0-1ba0-4975-9638-4cc6fbad5573" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:to="loc_ifrs-full_OfficeEquipmentMember_f5f0cce0-1ba0-4975-9638-4cc6fbad5573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_73701263-8603-46ec-8228-16331dbe807c" xlink:href="oncyf-20231231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:to="loc_oncyf_MedicalEquipmentMember_73701263-8603-46ec-8228-16331dbe807c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_07712b49-932e-4e76-8242-4defea6237a0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_7284052f-8dc7-47c9-9787-315be9ea989b" xlink:to="loc_ifrs-full_ComputerEquipmentMember_07712b49-932e-4e76-8242-4defea6237a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5befd1c4-057a-4685-b25a-8f5e4be17821" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_dd46533c-4bf2-4d4d-aaff-1f2566f26fec" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5befd1c4-057a-4685-b25a-8f5e4be17821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_379c228f-2248-46d4-9ebe-6f698bf2e56e" xlink:href="oncyf-20231231.xsd#oncyf_PropertyPlantandEquipmentAnnualDepreciationRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_5befd1c4-057a-4685-b25a-8f5e4be17821" xlink:to="loc_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate_379c228f-2248-46d4-9ebe-6f698bf2e56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#OtherAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_aaac3f1a-0d48-4503-9740-76fbf662a7d4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_0635d583-8020-49f4-b62a-5e7d38a930c5" xlink:href="oncyf-20231231.xsd#oncyf_Currency1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_aaac3f1a-0d48-4503-9740-76fbf662a7d4" xlink:to="loc_oncyf_Currency1Table_0635d583-8020-49f4-b62a-5e7d38a930c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfProvisionsAxis_d53e7ee6-2777-45e7-84f1-f567a5949fd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_0635d583-8020-49f4-b62a-5e7d38a930c5" xlink:to="loc_ifrs-full_ClassesOfProvisionsAxis_d53e7ee6-2777-45e7-84f1-f567a5949fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherProvisionsMember_8ae54e5b-a622-4b04-a317-c7f3a1543d5b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfProvisionsAxis_d53e7ee6-2777-45e7-84f1-f567a5949fd9" xlink:to="loc_ifrs-full_OtherProvisionsMember_8ae54e5b-a622-4b04-a317-c7f3a1543d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CollaborationAgreementMember_c5e3206f-95ff-4c87-b36a-6441cf776ce4" xlink:href="oncyf-20231231.xsd#oncyf_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_8ae54e5b-a622-4b04-a317-c7f3a1543d5b" xlink:to="loc_oncyf_CollaborationAgreementMember_c5e3206f-95ff-4c87-b36a-6441cf776ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialMember_90895aa8-420a-4785-b6d3-34741ed498da" xlink:href="oncyf-20231231.xsd#oncyf_ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_OtherProvisionsMember_8ae54e5b-a622-4b04-a317-c7f3a1543d5b" xlink:to="loc_oncyf_ClinicalTrialMember_90895aa8-420a-4785-b6d3-34741ed498da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:href="oncyf-20231231.xsd#oncyf_Currency1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_0635d583-8020-49f4-b62a-5e7d38a930c5" xlink:to="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherReceivables_6fd85679-8a38-44c1-9241-8887aabc8d7b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_ifrs-full_OtherReceivables_6fd85679-8a38-44c1-9241-8887aabc8d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentPrepaidExpenses_f758cb62-0828-42c8-bec2-e58f49e03965" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_ifrs-full_CurrentPrepaidExpenses_f758cb62-0828-42c8-bec2-e58f49e03965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NoncurrentPrepayments_2b03347c-84d2-4519-9095-120c38271565" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentPrepayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_ifrs-full_NoncurrentPrepayments_2b03347c-84d2-4519-9095-120c38271565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherCurrentLiabilities_a1fe6450-b093-46ef-9bfc-2b1719fe1d50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_5de6f644-c524-4b5d-a2cb-ff70c4f32946" xlink:to="loc_ifrs-full_OtherCurrentLiabilities_a1fe6450-b093-46ef-9bfc-2b1719fe1d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#PropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_54a3dd58-5040-47bf-92d5-a6db4ea11c22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract_54a3dd58-5040-47bf-92d5-a6db4ea11c22" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:to="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_61e17675-5d82-4dc2-a3eb-21bc1a8d9a19" xlink:to="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_MedicalEquipmentMember_484f701f-3150-47d1-b14e-670822268bc9" xlink:href="oncyf-20231231.xsd#oncyf_MedicalEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:to="loc_oncyf_MedicalEquipmentMember_484f701f-3150-47d1-b14e-670822268bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComputerEquipmentMember_6a7b9182-3429-4ca5-b9c7-73a038821b6a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComputerEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:to="loc_ifrs-full_ComputerEquipmentMember_6a7b9182-3429-4ca5-b9c7-73a038821b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeEquipmentAndFurnitureMember_d133863a-1e3b-407e-855f-055a42ed09a4" xlink:href="oncyf-20231231.xsd#oncyf_OfficeEquipmentAndFurnitureMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:to="loc_oncyf_OfficeEquipmentAndFurnitureMember_d133863a-1e3b-407e-855f-055a42ed09a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseholdImprovementsMember_3d49ef7f-6ccd-46a7-b7ec-c1c94406ea00" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseholdImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PropertyPlantAndEquipmentMember_5d885a2a-54ab-4500-9971-ea18a133a463" xlink:to="loc_ifrs-full_LeaseholdImprovementsMember_3d49ef7f-6ccd-46a7-b7ec-c1c94406ea00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_de111532-e81a-4ca1-8427-f733c47d72bd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:to="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_de111532-e81a-4ca1-8427-f733c47d72bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CarryingAmountMember_415377dd-ed9c-429b-b44b-a8622cad621e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_de111532-e81a-4ca1-8427-f733c47d72bd" xlink:to="loc_ifrs-full_CarryingAmountMember_415377dd-ed9c-429b-b44b-a8622cad621e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossCarryingAmountMember_e55dd779-afbf-4dc3-85aa-fc6ffc860cbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossCarryingAmountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_415377dd-ed9c-429b-b44b-a8622cad621e" xlink:to="loc_ifrs-full_GrossCarryingAmountMember_e55dd779-afbf-4dc3-85aa-fc6ffc860cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_8f1f3752-1f23-4814-82f8-bc99463e5418" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccumulatedDepreciationAndAmortisationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_CarryingAmountMember_415377dd-ed9c-429b-b44b-a8622cad621e" xlink:to="loc_ifrs-full_AccumulatedDepreciationAndAmortisationMember_8f1f3752-1f23-4814-82f8-bc99463e5418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f630adc2-76c6-4338-a41e-08e7c2808a52" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_f630e548-e63c-48af-a1d7-cc4ebbea8518" xlink:to="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f630adc2-76c6-4338-a41e-08e7c2808a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_f630adc2-76c6-4338-a41e-08e7c2808a52" xlink:to="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_bfc93eee-3ca9-4474-bdac-5eb3cd85c311" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_bfc93eee-3ca9-4474-bdac-5eb3cd85c311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_08f997c4-1750-4bc9-9e84-697ee8ffb4ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:to="loc_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_08f997c4-1750-4bc9-9e84-697ee8ffb4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_5cfde25d-c40b-4f8d-835b-c51db9990247" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:to="loc_ifrs-full_DepreciationPropertyPlantAndEquipment_5cfde25d-c40b-4f8d-835b-c51db9990247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PropertyPlantAndEquipment_a2cef860-501f-419a-a69e-87ab6ecec724" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract_1e788e5a-7eb8-4f0b-b7f8-5a85b8ca80ed" xlink:to="loc_ifrs-full_PropertyPlantAndEquipment_a2cef860-501f-419a-a69e-87ab6ecec724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_52ea72c0-db64-4b01-a8e2-7c9fd22ba390" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_b470f8dd-4580-4622-8553-7eb89e4b91da" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_52ea72c0-db64-4b01-a8e2-7c9fd22ba390" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_b470f8dd-4580-4622-8553-7eb89e4b91da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccrualsClassifiedAsCurrent_07993906-8483-455e-8eed-18ac8070d184" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccrualsClassifiedAsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_52ea72c0-db64-4b01-a8e2-7c9fd22ba390" xlink:to="loc_ifrs-full_AccrualsClassifiedAsCurrent_07993906-8483-455e-8eed-18ac8070d184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_644d623b-954a-4f27-82a5-09861ffbdb12" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_52ea72c0-db64-4b01-a8e2-7c9fd22ba390" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_644d623b-954a-4f27-82a5-09861ffbdb12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_69e58fb3-6213-4026-b30b-7f0d2d9612dc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_780f4d4b-3674-424a-a8a0-221421c9e405" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_69e58fb3-6213-4026-b30b-7f0d2d9612dc" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_780f4d4b-3674-424a-a8a0-221421c9e405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d5883e7d-472e-41b2-a5cb-a533e95620b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_780f4d4b-3674-424a-a8a0-221421c9e405" xlink:to="loc_srt_RangeAxis_d5883e7d-472e-41b2-a5cb-a533e95620b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e8fa588d-c530-4f96-8de5-46ebdea9db9d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d5883e7d-472e-41b2-a5cb-a533e95620b1" xlink:to="loc_srt_RangeMember_e8fa588d-c530-4f96-8de5-46ebdea9db9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_994b651d-2ac5-4c3e-9d41-54871c92d3c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8fa588d-c530-4f96-8de5-46ebdea9db9d" xlink:to="loc_srt_MinimumMember_994b651d-2ac5-4c3e-9d41-54871c92d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_47c09002-2305-421d-9d44-03b3eb674ea3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e8fa588d-c530-4f96-8de5-46ebdea9db9d" xlink:to="loc_srt_MaximumMember_47c09002-2305-421d-9d44-03b3eb674ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable_780f4d4b-3674-424a-a8a0-221421c9e405" xlink:to="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OperatingLeaseRemainingLeaseTerm_c92a4a4e-4be9-4d13-8ad0-afb00eb43d90" xlink:href="oncyf-20231231.xsd#oncyf_OperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_oncyf_OperatingLeaseRemainingLeaseTerm_c92a4a4e-4be9-4d13-8ad0-afb00eb43d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_a502b166-8cdd-4db5-a7ff-03256a1baa97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16_a502b166-8cdd-4db5-a7ff-03256a1baa97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_64b4ab13-61f3-42ad-853a-95d24877dd36" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_64b4ab13-61f3-42ad-853a-95d24877dd36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_a0aac4c1-ff2f-40cd-a8dc-cd0bbee8c44a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems_2ddebb77-1ead-486a-ab60-f23a86b22dd2" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_a0aac4c1-ff2f-40cd-a8dc-cd0bbee8c44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#LeasesRightofuseAssetsandLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8c696dc7-2801-4cd3-9fd4-3cc419b136f5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RightOfUseAssetsAbstract_dae45045-75ae-45b7-8e8e-5a55a78b919c" xlink:href="oncyf-20231231.xsd#oncyf_RightOfUseAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8c696dc7-2801-4cd3-9fd4-3cc419b136f5" xlink:to="loc_oncyf_RightOfUseAssetsAbstract_dae45045-75ae-45b7-8e8e-5a55a78b919c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_6f8f1449-f2a0-4d7d-ba6e-20c4739fe5f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_dae45045-75ae-45b7-8e8e-5a55a78b919c" xlink:to="loc_ifrs-full_RightofuseAssets_6f8f1449-f2a0-4d7d-ba6e-20c4739fe5f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdditionsToRightofuseAssets_7e829d41-1911-4d4b-8683-9a8468a02475" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdditionsToRightofuseAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_dae45045-75ae-45b7-8e8e-5a55a78b919c" xlink:to="loc_ifrs-full_AdditionsToRightofuseAssets_7e829d41-1911-4d4b-8683-9a8468a02475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_a8e549da-f5a5-4911-9c04-249bbc86e8f1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_dae45045-75ae-45b7-8e8e-5a55a78b919c" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_a8e549da-f5a5-4911-9c04-249bbc86e8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ForeignExchangeImpactRightofUseAssets_b60afa2c-651d-4a98-9fc0-32a20df80cc2" xlink:href="oncyf-20231231.xsd#oncyf_ForeignExchangeImpactRightofUseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_dae45045-75ae-45b7-8e8e-5a55a78b919c" xlink:to="loc_oncyf_ForeignExchangeImpactRightofUseAssets_b60afa2c-651d-4a98-9fc0-32a20df80cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RightofuseAssets_38112010-d75d-4db0-a028-14a7d096d0be" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_RightOfUseAssetsAbstract_dae45045-75ae-45b7-8e8e-5a55a78b919c" xlink:to="loc_ifrs-full_RightofuseAssets_38112010-d75d-4db0-a028-14a7d096d0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilitiesAbstract_389c34c2-1eb4-419d-a242-5f45f8e60fbb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_8c696dc7-2801-4cd3-9fd4-3cc419b136f5" xlink:to="loc_ifrs-full_LeaseLiabilitiesAbstract_389c34c2-1eb4-419d-a242-5f45f8e60fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_07a030f9-3c59-4af6-b6cb-1657a9016a2e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_389c34c2-1eb4-419d-a242-5f45f8e60fbb" xlink:to="loc_ifrs-full_LeaseLiabilities_07a030f9-3c59-4af6-b6cb-1657a9016a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_3833a986-bc80-4a64-8d33-b2a7fd6d1431" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_389c34c2-1eb4-419d-a242-5f45f8e60fbb" xlink:to="loc_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities_3833a986-bc80-4a64-8d33-b2a7fd6d1431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashOutflowForLeases_a2b2dfbf-be7d-41eb-87ba-8bdf1897c178" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashOutflowForLeases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_389c34c2-1eb4-419d-a242-5f45f8e60fbb" xlink:to="loc_ifrs-full_CashOutflowForLeases_a2b2dfbf-be7d-41eb-87ba-8bdf1897c178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_bdd1e201-f48d-4c89-be34-1ee7e62b70c3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestExpenseOnLeaseLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_389c34c2-1eb4-419d-a242-5f45f8e60fbb" xlink:to="loc_ifrs-full_InterestExpenseOnLeaseLiabilities_bdd1e201-f48d-4c89-be34-1ee7e62b70c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_ab5d13be-a1f1-435a-93c3-5d99d5bc04ff" xlink:href="oncyf-20231231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_389c34c2-1eb4-419d-a242-5f45f8e60fbb" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_ab5d13be-a1f1-435a-93c3-5d99d5bc04ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LeaseLiabilities_e08147b9-c26a-4b25-a101-05490e312e32" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LeaseLiabilitiesAbstract_389c34c2-1eb4-419d-a242-5f45f8e60fbb" xlink:to="loc_ifrs-full_LeaseLiabilities_e08147b9-c26a-4b25-a101-05490e312e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#LeasesTotalUndiscountedLeaseLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_12ddf0fd-6589-4458-9330-a29f0c579c90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c43e52df-5ca2-417d-8a25-f45e8769cbd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_PresentationOfLeasesForLesseeAbstract_12ddf0fd-6589-4458-9330-a29f0c579c90" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c43e52df-5ca2-417d-8a25-f45e8769cbd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MaturityAxis_04030a45-0236-4696-9690-65c258ea7ff0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c43e52df-5ca2-417d-8a25-f45e8769cbd3" xlink:to="loc_ifrs-full_MaturityAxis_04030a45-0236-4696-9690-65c258ea7ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_MaturityAxis_04030a45-0236-4696-9690-65c258ea7ff0" xlink:to="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NotLaterThanOneYearMember_f8f4d9aa-7dbc-4c66-b1f8-a40c33ab6f84" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NotLaterThanOneYearMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:to="loc_ifrs-full_NotLaterThanOneYearMember_f8f4d9aa-7dbc-4c66-b1f8-a40c33ab6f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_13c2add3-e8b7-4a7c-af4c-b4aeb525ccf4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:to="loc_ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_13c2add3-e8b7-4a7c-af4c-b4aeb525ccf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LaterThanFiveYearsMember_5113655d-ec47-4838-a985-f5811ea87607" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LaterThanFiveYearsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AggregatedTimeBandsMember_87284575-2dad-4b32-9323-a75464d47973" xlink:to="loc_ifrs-full_LaterThanFiveYearsMember_5113655d-ec47-4838-a985-f5811ea87607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_44ae4a85-d146-4107-8cdc-97d879050d44" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable_c43e52df-5ca2-417d-8a25-f45e8769cbd3" xlink:to="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_44ae4a85-d146-4107-8cdc-97d879050d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GrossLeaseLiabilities_2b3d6075-2f7e-4c9b-8152-0ed1993188ca" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems_44ae4a85-d146-4107-8cdc-97d879050d44" xlink:to="loc_ifrs-full_GrossLeaseLiabilities_2b3d6075-2f7e-4c9b-8152-0ed1993188ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_f15c9315-be73-42e9-a48e-795b9277f9fe" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_f0894830-0719-4f45-9ab1-203ed8971541" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_f15c9315-be73-42e9-a48e-795b9277f9fe" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_f0894830-0719-4f45-9ab1-203ed8971541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6ca72aa5-129a-4e97-bba6-c4554adab163" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_f0894830-0719-4f45-9ab1-203ed8971541" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6ca72aa5-129a-4e97-bba6-c4554adab163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_7aea1a71-f16c-4db3-9593-1fbb65505f42" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6ca72aa5-129a-4e97-bba6-c4554adab163" xlink:to="loc_ifrs-full_LiabilitiesMember_7aea1a71-f16c-4db3-9593-1fbb65505f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_96a8009f-9b0f-4694-8f5f-eceb615fd48b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_7aea1a71-f16c-4db3-9593-1fbb65505f42" xlink:to="loc_ifrs-full_WarrantsMember_96a8009f-9b0f-4694-8f5f-eceb615fd48b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_bdf490af-2863-476a-be1c-9a833f74a7c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_f0894830-0719-4f45-9ab1-203ed8971541" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_bdf490af-2863-476a-be1c-9a833f74a7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_bdf490af-2863-476a-be1c-9a833f74a7c6" xlink:to="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_cbb0e047-e622-4c8d-8e08-ff57d5f89354" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:to="loc_oncyf_NumberOfWarrantsOutstanding_cbb0e047-e622-4c8d-8e08-ff57d5f89354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_a7e251e4-c2ee-4a08-a1bf-80f3e6037b57" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:to="loc_oncyf_IssueOfEquityShares_a7e251e4-c2ee-4a08-a1bf-80f3e6037b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_350a5151-0fe1-4bb1-a6ce-adb159d22ff1" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_NumberOfWarrantsOutstandingRollForward_a94f7010-01da-427d-a354-3ee1d987b075" xlink:to="loc_oncyf_NumberOfWarrantsOutstanding_350a5151-0fe1-4bb1-a6ce-adb159d22ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:href="oncyf-20231231.xsd#oncyf_ChangeInFairValueWarrantDerivativeRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_bdf490af-2863-476a-be1c-9a833f74a7c6" xlink:to="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_5c53e622-c32b-48b2-956c-01623a9be9de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_5c53e622-c32b-48b2-956c-01623a9be9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_b9ce9c80-b83f-433b-a344-8df7a476fd24" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_ifrs-full_IssueOfEquity_b9ce9c80-b83f-433b-a344-8df7a476fd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount_3e66ed1b-4637-4c35-9c09-9c2d0c91c2e6" xlink:href="oncyf-20231231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_oncyf_WarrantLiabilityUnamortizedDiscount_3e66ed1b-4637-4c35-9c09-9c2d0c91c2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityAmortizedDiscount_ce509e5a-d575-4245-87c0-fff49063705c" xlink:href="oncyf-20231231.xsd#oncyf_WarrantLiabilityAmortizedDiscount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_oncyf_WarrantLiabilityAmortizedDiscount_ce509e5a-d575-4245-87c0-fff49063705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6e2ad1af-5b4c-4bc4-8a85-9d42176f9df6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_6e2ad1af-5b4c-4bc4-8a85-9d42176f9df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GainsLossesFromForeignExchangeImpact_1748c369-f07f-4af3-b028-8de76fd8bfb1" xlink:href="oncyf-20231231.xsd#oncyf_GainsLossesFromForeignExchangeImpact"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_oncyf_GainsLossesFromForeignExchangeImpact_1748c369-f07f-4af3-b028-8de76fd8bfb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_0b020855-7358-43f6-879d-c2c171ac462a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ChangeInFairValueWarrantDerivativeRollForward_eb6aa46d-fb60-450e-897e-6aa45fa59e2f" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_0b020855-7358-43f6-879d-c2c171ac462a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivativeWarrantDerivativeOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_6be14810-f44c-4e8d-bea3-dd444fbf995e" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantExercisePrice_66b98655-e30e-499b-a338-cd2cbdbe21e1" xlink:href="oncyf-20231231.xsd#oncyf_WarrantExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_6be14810-f44c-4e8d-bea3-dd444fbf995e" xlink:to="loc_oncyf_WarrantExercisePrice_66b98655-e30e-499b-a338-cd2cbdbe21e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsOutstanding_92f3de09-ab89-44e8-8c9c-f8dbec4c75c5" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_6be14810-f44c-4e8d-bea3-dd444fbf995e" xlink:to="loc_oncyf_NumberOfWarrantsOutstanding_92f3de09-ab89-44e8-8c9c-f8dbec4c75c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivativeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_14ffb4fc-5f4b-42dd-a51a-949fdfcd259c" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_14ffb4fc-5f4b-42dd-a51a-949fdfcd259c" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_83e55922-7073-45f0-930f-190b60473bc2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_83e55922-7073-45f0-930f-190b60473bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_83e55922-7073-45f0-930f-190b60473bc2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_b74ff424-cd0d-4749-b4aa-88290dc8b300" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:to="loc_oncyf_SharesPublicOfferingMember_b74ff424-cd0d-4749-b4aa-88290dc8b300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderOverAllotmentOptionMember_9aa05197-3b09-4550-b03d-7ba40fc3389d" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderOverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:to="loc_oncyf_SharesUnderOverAllotmentOptionMember_9aa05197-3b09-4550-b03d-7ba40fc3389d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_5aab5dc0-4f83-42a5-8c41-219b6ddb3dfa" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a0e86a22-be7d-4649-b177-dacb73927c82" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_5aab5dc0-4f83-42a5-8c41-219b6ddb3dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalAxis_5777f42a-37e5-40a7-85a7-d57486f3ea2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_ClassesOfShareCapitalAxis_5777f42a-37e5-40a7-85a7-d57486f3ea2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfShareCapitalMember_0841c3e2-892e-44ce-8f7d-a463f180ddf1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalAxis_5777f42a-37e5-40a7-85a7-d57486f3ea2f" xlink:to="loc_ifrs-full_ClassesOfShareCapitalMember_0841c3e2-892e-44ce-8f7d-a463f180ddf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_1aa13a8f-9820-48d5-8b4a-9417d7abcdf5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfShareCapitalMember_0841c3e2-892e-44ce-8f7d-a463f180ddf1" xlink:to="loc_ifrs-full_IssuedCapitalMember_1aa13a8f-9820-48d5-8b4a-9417d7abcdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_d8564125-c695-4f1e-89ad-ca0a300cac5e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_d8564125-c695-4f1e-89ad-ca0a300cac5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_a2d0375c-a0a7-4765-95a5-c3254607d5fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_d8564125-c695-4f1e-89ad-ca0a300cac5e" xlink:to="loc_ifrs-full_LiabilitiesMember_a2d0375c-a0a7-4765-95a5-c3254607d5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_1e78b594-d553-4901-91a2-a61c026857e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_a2d0375c-a0a7-4765-95a5-c3254607d5fb" xlink:to="loc_ifrs-full_WarrantsMember_1e78b594-d553-4901-91a2-a61c026857e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c9da4a2d-56be-4629-a264-ef1fc95f095f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c9da4a2d-56be-4629-a264-ef1fc95f095f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_83a4f04e-db1a-4771-a51f-6f36104f5c3e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_c9da4a2d-56be-4629-a264-ef1fc95f095f" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_83a4f04e-db1a-4771-a51f-6f36104f5c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level3OfFairValueHierarchyMember_a235d90a-ca23-4f68-9056-d75c533ea0b0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_83a4f04e-db1a-4771-a51f-6f36104f5c3e" xlink:to="loc_ifrs-full_Level3OfFairValueHierarchyMember_a235d90a-ca23-4f68-9056-d75c533ea0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_1c3d57fd-7c80-4f90-a4cc-5a0891d9f2b5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_bb1ac1bf-b7fd-4cfc-aba6-663132dc17fc" xlink:to="loc_ifrs-full_EquityMember_1c3d57fd-7c80-4f90-a4cc-5a0891d9f2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_911c8c1b-4928-478e-94b4-31c4f61d13de" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_1c3d57fd-7c80-4f90-a4cc-5a0891d9f2b5" xlink:to="loc_ifrs-full_IssuedCapitalMember_911c8c1b-4928-478e-94b4-31c4f61d13de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_ff768e12-a133-42b9-b4ff-8ce008d029fa" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_oncyf_SaleOfStockAxis_ff768e12-a133-42b9-b4ff-8ce008d029fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_57377a48-8995-48cd-9849-0228a4ae1c14" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_ff768e12-a133-42b9-b4ff-8ce008d029fa" xlink:to="loc_oncyf_SaleOfStockDomain_57377a48-8995-48cd-9849-0228a4ae1c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_28828769-52a8-45d0-9495-2d5a7a2b9f0f" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_57377a48-8995-48cd-9849-0228a4ae1c14" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_28828769-52a8-45d0-9495-2d5a7a2b9f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_ad7ffc3c-f181-4e70-9b38-b1bafd2f6d09" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_eb6378ee-dace-4839-b2da-b491407031ad" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_eb6378ee-dace-4839-b2da-b491407031ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfUnitsGross_82ea5618-a45e-4188-a377-496d0933cbc4" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsFromIssueOfUnitsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_ProceedsFromIssueOfUnitsGross_82ea5618-a45e-4188-a377-496d0933cbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_62a51fad-452d-4194-9ed8-19ab2728a6e4" xlink:href="oncyf-20231231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_62a51fad-452d-4194-9ed8-19ab2728a6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CommonSharesPerUnit_939a009b-92d8-4d8f-a216-6f9108630cd1" xlink:href="oncyf-20231231.xsd#oncyf_CommonSharesPerUnit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_CommonSharesPerUnit_939a009b-92d8-4d8f-a216-6f9108630cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_f392470e-9f32-42d0-8b11-dc5bd59c0d20" xlink:href="oncyf-20231231.xsd#oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1_f392470e-9f32-42d0-8b11-dc5bd59c0d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantExercisePrice_87f5534b-5da5-4e7b-a223-36faa9996cc4" xlink:href="oncyf-20231231.xsd#oncyf_WarrantExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_WarrantExercisePrice_87f5534b-5da5-4e7b-a223-36faa9996cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_9305d1d0-88a7-4d03-b437-137038c9d16b" xlink:href="oncyf-20231231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_9305d1d0-88a7-4d03-b437-137038c9d16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_ff0a847d-7fb0-4c3c-b887-daaae51dc293" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice_ff0a847d-7fb0-4c3c-b887-daaae51dc293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_13d4ed65-a668-4ebf-841a-35a84cb73964" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays_13d4ed65-a668-4ebf-841a-35a84cb73964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_07832417-80dd-4873-bfbd-2cc5615ef4e7" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays_07832417-80dd-4873-bfbd-2cc5615ef4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_1e1821ab-12a9-45c3-afa8-4baf576eb349" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays_1e1821ab-12a9-45c3-afa8-4baf576eb349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_948f6aeb-aad3-4fdd-a388-ba7dc664d072" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_ifrs-full_IssueOfEquity_948f6aeb-aad3-4fdd-a388-ba7dc664d072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_25e6c41b-4808-4cda-b08b-f1e68c88c664" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_ifrs-full_WarrantLiability_25e6c41b-4808-4cda-b08b-f1e68c88c664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantLiabilityUnamortizedDiscount_8106e901-c093-4e5e-8d17-461b74075fc9" xlink:href="oncyf-20231231.xsd#oncyf_WarrantLiabilityUnamortizedDiscount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_WarrantLiabilityUnamortizedDiscount_8106e901-c093-4e5e-8d17-461b74075fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WarrantsTerm_8cc8c53a-7d6b-4801-ab01-a818141e3ef4" xlink:href="oncyf-20231231.xsd#oncyf_WarrantsTerm"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_0ab76c1e-ef8d-427b-bb7d-78a513e0fc59" xlink:to="loc_oncyf_WarrantsTerm_8cc8c53a-7d6b-4801-ab01-a818141e3ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ab07e83e-06fc-4164-82e4-eb663af8de07" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_fe9cfefa-3903-4543-9dfc-4e11807c7e2c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_ab07e83e-06fc-4164-82e4-eb663af8de07" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_fe9cfefa-3903-4543-9dfc-4e11807c7e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_887098e4-69e2-4062-a657-86088dbaba7c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_fe9cfefa-3903-4543-9dfc-4e11807c7e2c" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_887098e4-69e2-4062-a657-86088dbaba7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_81fa32d6-5472-48ab-8658-e7e095563e50" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_887098e4-69e2-4062-a657-86088dbaba7c" xlink:to="loc_ifrs-full_LiabilitiesMember_81fa32d6-5472-48ab-8658-e7e095563e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_1c2d9938-bc19-4f37-ba21-39634c6abe98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_81fa32d6-5472-48ab-8658-e7e095563e50" xlink:to="loc_ifrs-full_WarrantsMember_1c2d9938-bc19-4f37-ba21-39634c6abe98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_fe9cfefa-3903-4543-9dfc-4e11807c7e2c" xlink:to="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_a2a84a1d-71c7-439b-884e-40625bee257b" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_a2a84a1d-71c7-439b-884e-40625bee257b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_1d5b5138-6f75-4630-889b-c8ae9da95f24" xlink:href="oncyf-20231231.xsd#oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_1d5b5138-6f75-4630-889b-c8ae9da95f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_235d5970-4780-4079-9145-70752b392e8f" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_235d5970-4780-4079-9145-70752b392e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_eb6fca33-a61e-4d26-a7ff-48f496cc0312" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_eb6fca33-a61e-4d26-a7ff-48f496cc0312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_c2e719a0-7d10-41b9-975e-3360f6ad23ea" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_c2e719a0-7d10-41b9-975e-3360f6ad23ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_e75c7a9a-b70c-48b2-91df-5f042c71251d" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_b26d345a-eb72-4843-945b-ff87d6c532cf" xlink:to="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_e75c7a9a-b70c-48b2-91df-5f042c71251d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareCapitalScheduleofShareCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_6f7a9b1e-fcc0-4d4a-9e30-35dc0550188a" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_6f7a9b1e-fcc0-4d4a-9e30-35dc0550188a" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_996f3110-7ee3-4033-9a39-676ea712b0c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_996f3110-7ee3-4033-9a39-676ea712b0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_a1ab331b-cca3-41c3-9213-6305d04c35ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_996f3110-7ee3-4033-9a39-676ea712b0c6" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_a1ab331b-cca3-41c3-9213-6305d04c35ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderStockOptionPlanMember_c97a4988-e52b-4c6d-84e1-691a77a72916" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderStockOptionPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a1ab331b-cca3-41c3-9213-6305d04c35ae" xlink:to="loc_oncyf_SharesUnderStockOptionPlanMember_c97a4988-e52b-4c6d-84e1-691a77a72916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderIncentiveAwardPlanMember_bfa23e2e-e16c-4721-8a9a-ed1c751ac918" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderIncentiveAwardPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_a1ab331b-cca3-41c3-9213-6305d04c35ae" xlink:to="loc_oncyf_SharesUnderIncentiveAwardPlanMember_bfa23e2e-e16c-4721-8a9a-ed1c751ac918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_d8aa1971-a5af-4540-b640-04eb9fada3f6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_d8aa1971-a5af-4540-b640-04eb9fada3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_73724594-ed73-4d03-b057-af2ca52bc51d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_d8aa1971-a5af-4540-b640-04eb9fada3f6" xlink:to="loc_ifrs-full_EquityMember_73724594-ed73-4d03-b057-af2ca52bc51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_65c413e7-2f80-4232-89c9-096007cd5ff4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_73724594-ed73-4d03-b057-af2ca52bc51d" xlink:to="loc_ifrs-full_IssuedCapitalMember_65c413e7-2f80-4232-89c9-096007cd5ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_8b672706-a7a5-431f-acba-651c4b2d716b" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:to="loc_oncyf_SaleOfStockAxis_8b672706-a7a5-431f-acba-651c4b2d716b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_8b672706-a7a5-431f-acba-651c4b2d716b" xlink:to="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesUnderAtthemarketAgreementMember_91140fa5-9f35-44fc-88a4-ecb7f72f4e6e" xlink:href="oncyf-20231231.xsd#oncyf_SharesUnderAtthemarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:to="loc_oncyf_SharesUnderAtthemarketAgreementMember_91140fa5-9f35-44fc-88a4-ecb7f72f4e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_373f8921-5ed8-490e-a3ab-433a4d887364" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_373f8921-5ed8-490e-a3ab-433a4d887364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_0e58cc25-e13a-40e7-b3c5-7b0421e195b3" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_e3347e92-8328-4a10-8af2-28444fea8ed1" xlink:to="loc_oncyf_SharesPublicOfferingMember_0e58cc25-e13a-40e7-b3c5-7b0421e195b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_93b62ac5-2538-4a0b-a1e1-e021f22e0f46" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_227592ca-1b54-4464-b259-d610225e43f2" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_93b62ac5-2538-4a0b-a1e1-e021f22e0f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:href="oncyf-20231231.xsd#oncyf_ShareCapitalNumberSharesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_93b62ac5-2538-4a0b-a1e1-e021f22e0f46" xlink:to="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_27d71b3f-6155-44f0-b612-747544134082" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:to="loc_ifrs-full_NumberOfSharesIssued_27d71b3f-6155-44f0-b612-747544134082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_9197f374-0f8d-46ad-b0c7-44c322a127bf" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:to="loc_oncyf_IssueOfEquityShares_9197f374-0f8d-46ad-b0c7-44c322a127bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfSharesIssued_51d96d43-4cb7-4d37-afe8-6a2aafc80a47" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalNumberSharesAbstract_8dfe7e4a-de05-43a2-8adf-0b2a6f8a8017" xlink:to="loc_ifrs-full_NumberOfSharesIssued_51d96d43-4cb7-4d37-afe8-6a2aafc80a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:href="oncyf-20231231.xsd#oncyf_ShareCapitalAmountAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_93b62ac5-2538-4a0b-a1e1-e021f22e0f46" xlink:to="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_a2d9cb9e-c7d9-4dc9-84ab-d0289a856c31" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:to="loc_ifrs-full_Equity_a2d9cb9e-c7d9-4dc9-84ab-d0289a856c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_8e4a4e06-b306-4e33-a9b2-dfef46e36c19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:to="loc_ifrs-full_IssueOfEquity_8e4a4e06-b306-4e33-a9b2-dfef46e36c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_74eb4918-10f3-4343-a343-70425a28ce1c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_74eb4918-10f3-4343-a343-70425a28ce1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_2a95fb6b-185a-4421-ada7-1b1af8fa6f22" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ShareCapitalAmountAbstract_196b6ff8-bf13-4358-b10e-4d2f0cafabc5" xlink:to="loc_ifrs-full_Equity_2a95fb6b-185a-4421-ada7-1b1af8fa6f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareCapitalScheduleofShareCapitalFootnotesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_048ff1a3-c926-46cb-ae26-8a78ea977763" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract_048ff1a3-c926-46cb-ae26-8a78ea977763" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_8effb55e-2d24-4329-9983-7c0386ab7f5e" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_oncyf_SaleOfStockAxis_8effb55e-2d24-4329-9983-7c0386ab7f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_8effb55e-2d24-4329-9983-7c0386ab7f5e" xlink:to="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_956992e1-d03c-4f9d-8138-751bf33ee0de" xlink:href="oncyf-20231231.xsd#oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:to="loc_oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember_956992e1-d03c-4f9d-8138-751bf33ee0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_82a4c2fe-7cc1-4802-921c-bab24685ed84" xlink:href="oncyf-20231231.xsd#oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:to="loc_oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember_82a4c2fe-7cc1-4802-921c-bab24685ed84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_555dadd9-d8ca-42f4-bbcb-13085b0cbf48" xlink:href="oncyf-20231231.xsd#oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_f4bfd0eb-bbc0-4893-b924-4afd937072be" xlink:to="loc_oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember_555dadd9-d8ca-42f4-bbcb-13085b0cbf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_3a341874-028c-4665-83b8-85d8bd9f75db" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_3a341874-028c-4665-83b8-85d8bd9f75db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_c8ba103a-5d00-4dbc-a1a8-02d842c747eb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_3a341874-028c-4665-83b8-85d8bd9f75db" xlink:to="loc_ifrs-full_LiabilitiesMember_c8ba103a-5d00-4dbc-a1a8-02d842c747eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_e7c97b48-3d99-46e1-a6d8-b9ac6f6b7892" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_c8ba103a-5d00-4dbc-a1a8-02d842c747eb" xlink:to="loc_ifrs-full_WarrantsMember_e7c97b48-3d99-46e1-a6d8-b9ac6f6b7892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0e018cf6-9aa7-46de-af21-7f8633d6129b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0e018cf6-9aa7-46de-af21-7f8633d6129b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_dbc583ca-2dd5-4ef1-b9f7-a4844a78b12b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_0e018cf6-9aa7-46de-af21-7f8633d6129b" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_dbc583ca-2dd5-4ef1-b9f7-a4844a78b12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingMember_c401b427-a24d-4631-9efd-7065f9d6db2a" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_dbc583ca-2dd5-4ef1-b9f7-a4844a78b12b" xlink:to="loc_oncyf_SharesPublicOfferingMember_c401b427-a24d-4631-9efd-7065f9d6db2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_e1d2667e-0cf9-45de-8c57-95f9f45e33a5" xlink:href="oncyf-20231231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_dbc583ca-2dd5-4ef1-b9f7-a4844a78b12b" xlink:to="loc_oncyf_CompensationWarrantsMember_e1d2667e-0cf9-45de-8c57-95f9f45e33a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_4bcf841f-72ba-4605-9b46-c5de2a10b8a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_4bcf841f-72ba-4605-9b46-c5de2a10b8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_6f925b22-2048-457f-b293-2f4e6c500fec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_4bcf841f-72ba-4605-9b46-c5de2a10b8a6" xlink:to="loc_ifrs-full_EquityMember_6f925b22-2048-457f-b293-2f4e6c500fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_ef2d4bd7-fa09-419f-aaf4-b8afd7c3dd37" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_6f925b22-2048-457f-b293-2f4e6c500fec" xlink:to="loc_ifrs-full_IssuedCapitalMember_ef2d4bd7-fa09-419f-aaf4-b8afd7c3dd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_501423bc-4329-4670-bd28-23ffd44165a8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_6f925b22-2048-457f-b293-2f4e6c500fec" xlink:to="loc_ifrs-full_SharePremiumMember_501423bc-4329-4670-bd28-23ffd44165a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalTable_6671df9c-f171-4ac3-ac09-c841c7353169" xlink:to="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementAmount_eb95ea42-1048-4fe4-bc9b-173c960e65c6" xlink:href="oncyf-20231231.xsd#oncyf_SharePurchaseAgreementAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_SharePurchaseAgreementAmount_eb95ea42-1048-4fe4-bc9b-173c960e65c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharePurchaseAgreementTerm_266128e2-9dac-4eb0-a4ce-c1853b75ffc3" xlink:href="oncyf-20231231.xsd#oncyf_SharePurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_SharePurchaseAgreementTerm_266128e2-9dac-4eb0-a4ce-c1853b75ffc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquityShares_b198f40f-177e-4206-95a3-93309717e9da" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquityShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_IssueOfEquityShares_b198f40f-177e-4206-95a3-93309717e9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsFromIssueOfUnitsGross_52e7cb38-6ef1-4052-a78a-1482e01e321a" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsFromIssueOfUnitsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ProceedsFromIssueOfUnitsGross_52e7cb38-6ef1-4052-a78a-1482e01e321a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesIssuedPricePerShare1_cacf6be7-c2b7-4c78-baa5-df3b6b894c31" xlink:href="oncyf-20231231.xsd#oncyf_SharesIssuedPricePerShare1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_SharesIssuedPricePerShare1_cacf6be7-c2b7-4c78-baa5-df3b6b894c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_702228fd-485c-4a3c-a6f3-b854c4daf0f8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_ProceedsFromIssueOfOrdinaryShares_702228fd-485c-4a3c-a6f3-b854c4daf0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueRelatedCostCommissions_645117fb-271d-48e6-a101-5aa5e63b04e0" xlink:href="oncyf-20231231.xsd#oncyf_ShareIssueRelatedCostCommissions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ShareIssueRelatedCostCommissions_645117fb-271d-48e6-a101-5aa5e63b04e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ShareIssueRelatedCost_37a88fbc-5146-403a-b92a-ef21c3ac6907" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ShareIssueRelatedCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_ShareIssueRelatedCost_37a88fbc-5146-403a-b92a-ef21c3ac6907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised_e30386fc-3378-4078-97f7-4ccc607501e4" xlink:href="oncyf-20231231.xsd#oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised_e30386fc-3378-4078-97f7-4ccc607501e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClassofWarrantorRightWarrantsExercised_691ec7ff-ac3c-4bf7-8c2e-7a83bb311617" xlink:href="oncyf-20231231.xsd#oncyf_ClassofWarrantorRightWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ClassofWarrantorRightWarrantsExercised_691ec7ff-ac3c-4bf7-8c2e-7a83bb311617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromWarrantExercises1_27bc3b52-e801-4151-b194-70eba14697a8" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsfromWarrantExercises1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ProceedsfromWarrantExercises1_27bc3b52-e801-4151-b194-70eba14697a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_4a7033aa-c439-43bc-be64-3965368dfa0f" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfWarrantsAndSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_NumberOfWarrantsAndSharesOutstanding_4a7033aa-c439-43bc-be64-3965368dfa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares_e207a3f8-9642-44be-a960-1d379426aa53" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquitySharesNumberOfCommonShares"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_IssueOfEquitySharesNumberOfCommonShares_e207a3f8-9642-44be-a960-1d379426aa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IssueOfEquitySharesNumberOfWarrants_f0f9ca7c-f0a0-4331-a0f1-e2123887a6b1" xlink:href="oncyf-20231231.xsd#oncyf_IssueOfEquitySharesNumberOfWarrants"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_IssueOfEquitySharesNumberOfWarrants_f0f9ca7c-f0a0-4331-a0f1-e2123887a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssueOfEquity_a4620279-dbe0-4ac5-97ba-2861c0aff468" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_IssueOfEquity_a4620279-dbe0-4ac5-97ba-2861c0aff468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantLiability_86fb476d-4e29-427a-9e61-273b16f070e7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_WarrantLiability_86fb476d-4e29-427a-9e61-273b16f070e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_227c0fd6-8989-4bb9-bd17-1f6b7b1fae66" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_227c0fd6-8989-4bb9-bd17-1f6b7b1fae66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedTransactionCosts_39f202c0-83b7-45b9-be76-5a9a19a930f5" xlink:href="oncyf-20231231.xsd#oncyf_ShareWarrantsIssuedTransactionCosts"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ShareWarrantsIssuedTransactionCosts_39f202c0-83b7-45b9-be76-5a9a19a930f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_f6711f04-bf7b-4555-a78c-c1996b6dc439" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_f6711f04-bf7b-4555-a78c-c1996b6dc439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareWarrantsIssuedOperatingExpense_32136f37-556f-4a68-98f7-6d9850319680" xlink:href="oncyf-20231231.xsd#oncyf_ShareWarrantsIssuedOperatingExpense"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_88ef0ed2-c120-4037-aca0-ae7bb8c5be20" xlink:to="loc_oncyf_ShareWarrantsIssuedOperatingExpense_32136f37-556f-4a68-98f7-6d9850319680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_6662d5b9-6957-4eec-8447-3e72b3c12638" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_6662d5b9-6957-4eec-8447-3e72b3c12638" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_66990759-a6d5-4665-b54c-21d461aec5fd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:to="loc_ifrs-full_RangeAxis_66990759-a6d5-4665-b54c-21d461aec5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_ca018d8a-521d-45b8-aaeb-231f42a287ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_66990759-a6d5-4665-b54c-21d461aec5fd" xlink:to="loc_ifrs-full_RangesMember_ca018d8a-521d-45b8-aaeb-231f42a287ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_d2252f43-621d-40b5-94a9-40ffca79afd3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_ca018d8a-521d-45b8-aaeb-231f42a287ea" xlink:to="loc_ifrs-full_BottomOfRangeMember_d2252f43-621d-40b5-94a9-40ffca79afd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_bf1d9a31-df0e-462f-8573-c2d4d26683ea" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_ca018d8a-521d-45b8-aaeb-231f42a287ea" xlink:to="loc_ifrs-full_TopOfRangeMember_bf1d9a31-df0e-462f-8573-c2d4d26683ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_99aeb3ba-d52e-4bae-bc3f-eb6eba41f1e2" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_814524ee-ce70-4d01-97b2-9b17048d62ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_814524ee-ce70-4d01-97b2-9b17048d62ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_051b329a-23c9-44fd-83d0-a644727c3d19" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:to="loc_ifrs-full_ReserveOfSharebasedPaymentsMember_051b329a-23c9-44fd-83d0-a644727c3d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_e84aa6c4-8736-4c26-817d-7ff5ce58dec8" xlink:href="oncyf-20231231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_7a691236-9411-4d71-8218-8612e9f799cb" xlink:to="loc_oncyf_CompensationWarrantsMember_e84aa6c4-8736-4c26-817d-7ff5ce58dec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ComponentsOfEquityAxis_f15a845f-b71c-43be-87f4-e0272dbe5b9e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:to="loc_ifrs-full_ComponentsOfEquityAxis_f15a845f-b71c-43be-87f4-e0272dbe5b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EquityMember_5ab27ae3-785c-4626-941a-12094ecd684f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ComponentsOfEquityAxis_f15a845f-b71c-43be-87f4-e0272dbe5b9e" xlink:to="loc_ifrs-full_EquityMember_5ab27ae3-785c-4626-941a-12094ecd684f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IssuedCapitalMember_9d095aa9-1fe2-4c64-9c11-d86686fea1fb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5ab27ae3-785c-4626-941a-12094ecd684f" xlink:to="loc_ifrs-full_IssuedCapitalMember_9d095aa9-1fe2-4c64-9c11-d86686fea1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharePremiumMember_a5f76243-cfc9-4839-9eed-de6392dbd9ef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EquityMember_5ab27ae3-785c-4626-941a-12094ecd684f" xlink:to="loc_ifrs-full_SharePremiumMember_a5f76243-cfc9-4839-9eed-de6392dbd9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_ce1501af-f9a8-4e94-90ae-a8b611eecb8d" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_e7528309-5e76-46c9-86e1-40b6a7f316dd" xlink:href="oncyf-20231231.xsd#oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum_e7528309-5e76-46c9-86e1-40b6a7f316dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9c0d1b28-d465-4edb-9c1b-281a1dd77324" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares_9c0d1b28-d465-4edb-9c1b-281a1dd77324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ea0fa56f-be97-40a2-9afb-374935c8e4ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ea0fa56f-be97-40a2-9afb-374935c8e4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_9d7fc0b7-eb7d-4326-8276-1da7e66ffb5a" xlink:href="oncyf-20231231.xsd#oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1_9d7fc0b7-eb7d-4326-8276-1da7e66ffb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_11395055-06ba-4616-a85f-a0f715ab8abe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_11395055-06ba-4616-a85f-a0f715ab8abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_951a9d49-8fbe-4fa7-9532-45a03943692f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_951a9d49-8fbe-4fa7-9532-45a03943692f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_db3c1bc1-ab95-4b4f-ace4-a038212355e3" xlink:href="oncyf-20231231.xsd#oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement_db3c1bc1-ab95-4b4f-ace4-a038212355e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_9a00048b-9653-4ba3-8507-907b40290e58" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_c69a5b1c-3e50-4422-8a9e-51c367a4f933" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees_9a00048b-9653-4ba3-8507-907b40290e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_803f80e4-0814-422c-85de-f21b47512524" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_StockOptionsOutstandingAbstract_e7dc750b-d22a-4185-a022-5325099a821b" xlink:href="oncyf-20231231.xsd#oncyf_StockOptionsOutstandingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_803f80e4-0814-422c-85de-f21b47512524" xlink:to="loc_oncyf_StockOptionsOutstandingAbstract_e7dc750b-d22a-4185-a022-5325099a821b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_10413d16-33cf-407f-bfb0-443ba6847caa" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_e7dc750b-d22a-4185-a022-5325099a821b" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_10413d16-33cf-407f-bfb0-443ba6847caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_960aeee7-07b8-40af-8c44-f0081953d566" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_e7dc750b-d22a-4185-a022-5325099a821b" xlink:to="loc_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_960aeee7-07b8-40af-8c44-f0081953d566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_a547d578-c87e-4b91-88c6-f98e89452f3a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_e7dc750b-d22a-4185-a022-5325099a821b" xlink:to="loc_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_a547d578-c87e-4b91-88c6-f98e89452f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_c3f7a380-442e-473c-882f-021e76312a4f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_e7dc750b-d22a-4185-a022-5325099a821b" xlink:to="loc_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement_c3f7a380-442e-473c-882f-021e76312a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_0b877f54-00d0-4ad1-ab9f-def393463ae4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_e7dc750b-d22a-4185-a022-5325099a821b" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_0b877f54-00d0-4ad1-ab9f-def393463ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_feedf667-ba2a-4c46-ae93-7e11c266349d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_StockOptionsOutstandingAbstract_e7dc750b-d22a-4185-a022-5325099a821b" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_feedf667-ba2a-4c46-ae93-7e11c266349d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_f489ce8d-0d3f-4c02-9c02-e534d80eb329" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_803f80e4-0814-422c-85de-f21b47512524" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_f489ce8d-0d3f-4c02-9c02-e534d80eb329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_3e828ca5-df35-4714-93da-8c07ca3a5ce6" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageExercisePriceOutstandingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_803f80e4-0814-422c-85de-f21b47512524" xlink:to="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_3e828ca5-df35-4714-93da-8c07ca3a5ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_c938b5c7-c6eb-4e7a-82ce-43c5af955ac9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_3e828ca5-df35-4714-93da-8c07ca3a5ce6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_c938b5c7-c6eb-4e7a-82ce-43c5af955ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_c141e6d8-e1f0-4dd8-bdee-634ea0031ff2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_3e828ca5-df35-4714-93da-8c07ca3a5ce6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019_c141e6d8-e1f0-4dd8-bdee-634ea0031ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1f6aa01f-36bc-402b-8421-d327342459ee" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_3e828ca5-df35-4714-93da-8c07ca3a5ce6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019_1f6aa01f-36bc-402b-8421-d327342459ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_4dc7a35f-5ed1-45ef-9d42-f3d328714523" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_3e828ca5-df35-4714-93da-8c07ca3a5ce6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019_4dc7a35f-5ed1-45ef-9d42-f3d328714523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_84e4fb0b-9cbc-4cc5-a3cc-2ff7004f4dbe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_3e828ca5-df35-4714-93da-8c07ca3a5ce6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_84e4fb0b-9cbc-4cc5-a3cc-2ff7004f4dbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3358de3b-b3a7-491a-8241-bca1ece52431" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_WeightedAverageExercisePriceOutstandingAbstract_3e828ca5-df35-4714-93da-8c07ca3a5ce6" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_3358de3b-b3a7-491a-8241-bca1ece52431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_993d25c1-d60c-4fff-9d52-c3dee1855437" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_803f80e4-0814-422c-85de-f21b47512524" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_993d25c1-d60c-4fff-9d52-c3dee1855437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a0c51e3e-d33c-4499-9797-50a7c2229b58" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_a0c51e3e-d33c-4499-9797-50a7c2229b58" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_82871175-4640-4a0e-8722-7e23cda6ebc3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_82871175-4640-4a0e-8722-7e23cda6ebc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_82871175-4640-4a0e-8722-7e23cda6ebc3" xlink:to="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeOneMember_c3870956-2813-42b3-ae23-b1cd97c5986e" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeOneMember_c3870956-2813-42b3-ae23-b1cd97c5986e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeTwoMember_1df87fd0-ec6c-4c54-b16b-a43556f7a6a9" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeTwoMember_1df87fd0-ec6c-4c54-b16b-a43556f7a6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeThreeMember_1d3ab4de-655d-4ad1-9cce-f507378e4b70" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeThreeMember_1d3ab4de-655d-4ad1-9cce-f507378e4b70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFourMember_0976a394-13e0-4b36-abd4-22bbe9bc6b2f" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeFourMember_0976a394-13e0-4b36-abd4-22bbe9bc6b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExercisePriceRangeFiveMember_4078c718-b584-4176-a5df-709f750db035" xlink:href="oncyf-20231231.xsd#oncyf_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_e254e414-7c6c-4bf8-acc2-860457b75369" xlink:to="loc_oncyf_ExercisePriceRangeFiveMember_4078c718-b584-4176-a5df-709f750db035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangeAxis_a33c3b64-408b-4126-bc75-8b5ed76440fe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:to="loc_ifrs-full_RangeAxis_a33c3b64-408b-4126-bc75-8b5ed76440fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RangesMember_8b2489d9-60a5-4044-9857-4be21540e68b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangeAxis_a33c3b64-408b-4126-bc75-8b5ed76440fe" xlink:to="loc_ifrs-full_RangesMember_8b2489d9-60a5-4044-9857-4be21540e68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_BottomOfRangeMember_2e92699a-f884-416b-84d9-b105e2fc4840" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_8b2489d9-60a5-4044-9857-4be21540e68b" xlink:to="loc_ifrs-full_BottomOfRangeMember_2e92699a-f884-416b-84d9-b105e2fc4840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TopOfRangeMember_779cab15-4550-40ea-ad0c-370877ac34e8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_RangesMember_8b2489d9-60a5-4044-9857-4be21540e68b" xlink:to="loc_ifrs-full_TopOfRangeMember_779cab15-4550-40ea-ad0c-370877ac34e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable_3d28b8bb-1c2c-4e5f-8fa3-459231fd08d8" xlink:to="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_35aea921-6163-4434-8cd9-8d6c8e8e9661" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_ExercisePriceOfOutstandingShareOptions2019_35aea921-6163-4434-8cd9-8d6c8e8e9661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOutstandingShareOptions_16178b0d-8ed4-4510-bee4-2ed285d4f923" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOutstandingShareOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_NumberOfOutstandingShareOptions_16178b0d-8ed4-4510-bee4-2ed285d4f923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_c923baae-f361-4286-8bd4-13c98b924668" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_c923baae-f361-4286-8bd4-13c98b924668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0f1c9919-ec15-4f03-bbee-a1447fe67c9b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019_0f1c9919-ec15-4f03-bbee-a1447fe67c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_208bd442-7ea9-4cf5-abf0-80dc86f25e93" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_208bd442-7ea9-4cf5-abf0-80dc86f25e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_90d51d2e-d5f7-4f5c-9cc4-e19cbdb7cc34" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems_4b59c1bb-7195-44f3-a56e-743845b74bdd" xlink:to="loc_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019_90d51d2e-d5f7-4f5c-9cc4-e19cbdb7cc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_dae1f6b5-f0c7-49b3-9395-18e0b9b61578" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_93320044-3af5-4980-8445-bf93c48eefac" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_dae1f6b5-f0c7-49b3-9395-18e0b9b61578" xlink:to="loc_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted_93320044-3af5-4980-8445-bf93c48eefac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_7eddd0e8-47c5-4452-8f98-76ebffbb95f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfOptionLifeShareOptionsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_dae1f6b5-f0c7-49b3-9395-18e0b9b61578" xlink:to="loc_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted_7eddd0e8-47c5-4452-8f98-76ebffbb95f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_06ba6b27-e0fb-46f6-8a2c-f5d2b882274e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_dae1f6b5-f0c7-49b3-9395-18e0b9b61578" xlink:to="loc_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted_06ba6b27-e0fb-46f6-8a2c-f5d2b882274e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_e01b0eff-e8fd-474d-b64e-37e69f753da3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_dae1f6b5-f0c7-49b3-9395-18e0b9b61578" xlink:to="loc_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted_e01b0eff-e8fd-474d-b64e-37e69f753da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_d86766c3-e404-4d6c-aced-069935b7c090" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_dae1f6b5-f0c7-49b3-9395-18e0b9b61578" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted_d86766c3-e404-4d6c-aced-069935b7c090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_c2cb55d1-a94f-4e57-9cb8-409ce5d055aa" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_d30a5586-5115-4699-bdff-429df81434e0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract_c2cb55d1-a94f-4e57-9cb8-409ce5d055aa" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_d30a5586-5115-4699-bdff-429df81434e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_d30a5586-5115-4699-bdff-429df81434e0" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_6fea6564-5899-4e67-a265-62b0ff26ff0c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1b35ce0d-005d-4aa5-81f4-b861a2dc5dec" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_6fea6564-5899-4e67-a265-62b0ff26ff0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_RestrictedShareUnitsMember_41ad9d70-e587-4e7f-8ddc-2bb76fcdc859" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedShareUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_6fea6564-5899-4e67-a265-62b0ff26ff0c" xlink:to="loc_ifrs-full_RestrictedShareUnitsMember_41ad9d70-e587-4e7f-8ddc-2bb76fcdc859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_d30a5586-5115-4699-bdff-429df81434e0" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_fc49b1b8-0fa0-494b-9e80-661eb1cedf97" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_fc49b1b8-0fa0-494b-9e80-661eb1cedf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_414dca79-b6a3-423b-a56f-7c2786d265b9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_414dca79-b6a3-423b-a56f-7c2786d265b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_a6fa2131-b16f-43e4-a1b1-9fa2aab79b89" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_a6fa2131-b16f-43e4-a1b1-9fa2aab79b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4a422354-5906-44a8-9176-bbd24fbcdea5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_4a422354-5906-44a8-9176-bbd24fbcdea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c3349605-fbdd-4a4f-a56b-e7fb9d1bc83f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_c3349605-fbdd-4a4f-a56b-e7fb9d1bc83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_ad129ff7-6375-42e4-8a41-a689f4e4da9a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_f5fbc049-98c2-4b80-a7ad-685ef281d5bf" xlink:to="loc_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_ad129ff7-6375-42e4-8a41-a689f4e4da9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3f9d2ada-fe18-43b8-8db4-f69b858d9acb" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3f9d2ada-fe18-43b8-8db4-f69b858d9acb" xlink:to="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_SharebasedPaymentArrangementsMember_d253d15b-a0fb-4b12-aaff-5ed91a81e222" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_dfcbaebf-f7ac-4024-a002-d8d43d7d32ba" xlink:to="loc_ifrs-full_SharebasedPaymentArrangementsMember_d253d15b-a0fb-4b12-aaff-5ed91a81e222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_CompensationWarrantsMember_90ee105a-7f51-4068-b47d-9eb7b86cb12c" xlink:href="oncyf-20231231.xsd#oncyf_CompensationWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_SharebasedPaymentArrangementsMember_d253d15b-a0fb-4b12-aaff-5ed91a81e222" xlink:to="loc_oncyf_CompensationWarrantsMember_90ee105a-7f51-4068-b47d-9eb7b86cb12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_3f9d2ada-fe18-43b8-8db4-f69b858d9acb" xlink:to="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_0bd19b47-7ef5-4742-9a9c-b8179aa9f4e3" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted_0bd19b47-7ef5-4742-9a9c-b8179aa9f4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_f4376d2e-7740-4b30-b9a1-97f9b5c3cdaa" xlink:href="oncyf-20231231.xsd#oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted_f4376d2e-7740-4b30-b9a1-97f9b5c3cdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_544bc00c-45db-471e-89f9-0dc850ad9898" xlink:href="oncyf-20231231.xsd#oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted_544bc00c-45db-471e-89f9-0dc850ad9898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_181b6627-8738-49e9-97ed-df6f727c5c10" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted_181b6627-8738-49e9-97ed-df6f727c5c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_0ab9037f-2cff-4d7d-a110-86c691b0bdd5" xlink:href="oncyf-20231231.xsd#oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted_0ab9037f-2cff-4d7d-a110-86c691b0bdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_f4201f8e-f381-4398-90b0-464c4f141f36" xlink:href="oncyf-20231231.xsd#oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_b393c03e-26d9-4a67-9b68-933c747eddf8" xlink:to="loc_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted_f4201f8e-f381-4398-90b0-464c4f141f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#LossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EarningsPerShareAbstract_cd55cd81-a97c-4db4-b1f0-795b87011c67" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WeightedAverageShares_b34c07d7-9fc3-45fd-9c24-9d5f65a5df41" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_EarningsPerShareAbstract_cd55cd81-a97c-4db4-b1f0-795b87011c67" xlink:to="loc_ifrs-full_WeightedAverageShares_b34c07d7-9fc3-45fd-9c24-9d5f65a5df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ContractLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_b794ec8f-3795-46b4-bcf7-1b7f8e2fafef" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContractLiabilityRecognitionPeriod_8a27cb64-b604-4548-9916-4b0d9bfdada2" xlink:href="oncyf-20231231.xsd#oncyf_ContractLiabilityRecognitionPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_b794ec8f-3795-46b4-bcf7-1b7f8e2fafef" xlink:to="loc_oncyf_ContractLiabilityRecognitionPeriod_8a27cb64-b604-4548-9916-4b0d9bfdada2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_1dffec08-00e8-40f6-89cc-7f8522952068" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_727bb44b-dd3c-4f93-8660-ff732165a3a5" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_1dffec08-00e8-40f6-89cc-7f8522952068" xlink:to="loc_ifrs-full_ContractLiabilities_727bb44b-dd3c-4f93-8660-ff732165a3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_5b19926b-c202-40d8-a0bf-022b26173291" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_1dffec08-00e8-40f6-89cc-7f8522952068" xlink:to="loc_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities_5b19926b-c202-40d8-a0bf-022b26173291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ContractLiabilities_48e6a4a9-3ba0-4867-809a-0550f7455cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract_1dffec08-00e8-40f6-89cc-7f8522952068" xlink:to="loc_ifrs-full_ContractLiabilities_48e6a4a9-3ba0-4867-809a-0550f7455cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ContingenciesAbstract_48cb0382-1e28-49c8-9dc5-10a1f672e4ce" xlink:href="oncyf-20231231.xsd#oncyf_ContingenciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligation1_cbc52a70-0853-4b7c-8672-8c2cd40cb29d" xlink:href="oncyf-20231231.xsd#oncyf_PurchaseObligation1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_48cb0382-1e28-49c8-9dc5-10a1f672e4ce" xlink:to="loc_oncyf_PurchaseObligation1_cbc52a70-0853-4b7c-8672-8c2cd40cb29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PurchaseObligationCommitmentTerm_ec2f3332-00ba-4deb-a848-fdd48d6c24e3" xlink:href="oncyf-20231231.xsd#oncyf_PurchaseObligationCommitmentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_48cb0382-1e28-49c8-9dc5-10a1f672e4ce" xlink:to="loc_oncyf_PurchaseObligationCommitmentTerm_ec2f3332-00ba-4deb-a848-fdd48d6c24e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_LeaseNotYetCommencedPayments_84e28269-461c-4086-b0eb-6d6250d7bfec" xlink:href="oncyf-20231231.xsd#oncyf_LeaseNotYetCommencedPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_48cb0382-1e28-49c8-9dc5-10a1f672e4ce" xlink:to="loc_oncyf_LeaseNotYetCommencedPayments_84e28269-461c-4086-b0eb-6d6250d7bfec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_LeaseNotYetCommencedTerm_4c5a31e2-3fd8-4bb0-bddd-716bf867285e" xlink:href="oncyf-20231231.xsd#oncyf_LeaseNotYetCommencedTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ContingenciesAbstract_48cb0382-1e28-49c8-9dc5-10a1f672e4ce" xlink:to="loc_oncyf_LeaseNotYetCommencedTerm_4c5a31e2-3fd8-4bb0-bddd-716bf867285e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AccountingProfit_b39ef389-a4c2-4405-a2d8-33e0e0b901ae" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AccountingProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_ifrs-full_AccountingProfit_b39ef389-a4c2-4405-a2d8-33e0e0b901ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ApplicableTaxRate_d5e080d5-60b9-4351-963d-d6742aecb6e3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ApplicableTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_ifrs-full_ApplicableTaxRate_d5e080d5-60b9-4351-963d-d6742aecb6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_c60cdc55-40c5-4de1-a029-e39dd60b03bf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxExpenseIncomeAtApplicableTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate_c60cdc55-40c5-4de1-a029-e39dd60b03bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectOfForeignTaxRates_7f77738e-4c4a-4e5a-b976-38fe7b18c477" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectOfForeignTaxRates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_ifrs-full_TaxEffectOfForeignTaxRates_7f77738e-4c4a-4e5a-b976-38fe7b18c477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfStockBasedCompensation_e96a5069-17e1-4868-b939-9650cf5db17e" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfStockBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_oncyf_TaxEffectOfStockBasedCompensation_e96a5069-17e1-4868-b939-9650cf5db17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfTaxPools_51247990-d59a-4c8a-9b72-4d5a3b3a0481" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfTaxPools"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_oncyf_TaxEffectOfTaxPools_51247990-d59a-4c8a-9b72-4d5a3b3a0481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TaxEffectFromChangeInTaxRate_e32fae49-9262-4cf7-adba-4bc97cc07640" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TaxEffectFromChangeInTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_ifrs-full_TaxEffectFromChangeInTaxRate_e32fae49-9262-4cf7-adba-4bc97cc07640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_5ba490fc-a3cf-45d9-8fab-27ae71e0ff84" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome_5ba490fc-a3cf-45d9-8fab-27ae71e0ff84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_e10279e7-7f56-4d7a-8b64-f6a021a8681a" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfExpirationOfTaxBenefits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_oncyf_TaxEffectOfExpirationOfTaxBenefits_e10279e7-7f56-4d7a-8b64-f6a021a8681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_340e7760-30c0-4841-88b7-027e6d6660a9" xlink:href="oncyf-20231231.xsd#oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative_340e7760-30c0-4841-88b7-027e6d6660a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_e4b8a78c-d489-45f6-b3ac-c0ed097e800a" xlink:href="oncyf-20231231.xsd#oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1_e4b8a78c-d489-45f6-b3ac-c0ed097e800a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentTaxExpenseIncome_d527129a-5e07-4808-9eaf-1c77f9c72dcf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentTaxExpenseIncome"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_034783de-a996-4b43-87d4-f7bc903b2b4f" xlink:to="loc_ifrs-full_CurrentTaxExpenseIncome_d527129a-5e07-4808-9eaf-1c77f9c72dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dddce1b8-23fb-4b98-ac54-d92f2c89410f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_80722089-4a28-49fc-99e1-480e1b6a3625" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dddce1b8-23fb-4b98-ac54-d92f2c89410f" xlink:to="loc_srt_StatementGeographicalAxis_80722089-4a28-49fc-99e1-480e1b6a3625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_80722089-4a28-49fc-99e1-480e1b6a3625" xlink:to="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_3521b268-e772-4777-af1d-5dcadf34cf1d" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:to="loc_country_CA_3521b268-e772-4777-af1d-5dcadf34cf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_BB_71ef2cc3-776a-414c-b928-242c5b5f6ec1" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_BB"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:to="loc_country_BB_71ef2cc3-776a-414c-b928-242c5b5f6ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_6205ed2a-a1de-4963-9fda-80e9340c8d51" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_56eae1ec-fdf5-481a-9ca6-d8395428d884" xlink:to="loc_country_US_6205ed2a-a1de-4963-9fda-80e9340c8d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dddce1b8-23fb-4b98-ac54-d92f2c89410f" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5ab78fa8-2f0d-4836-a623-ba9b8eb341f3" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesMember_1df09952-51c1-490a-b6f3-dad88087db56" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:to="loc_ifrs-full_UnusedTaxLossesMember_1df09952-51c1-490a-b6f3-dad88087db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsMember_7554bc35-1533-4596-b8c1-a43a56cab826" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:to="loc_ifrs-full_UnusedTaxCreditsMember_7554bc35-1533-4596-b8c1-a43a56cab826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23c16e52-bed5-4842-bfde-98f4b276a7fd" xlink:href="oncyf-20231231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_26f9be2f-0925-41ed-843f-cb264f985824" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_23c16e52-bed5-4842-bfde-98f4b276a7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f0a0fe1e-0245-4240-a012-864daaea484a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_dddce1b8-23fb-4b98-ac54-d92f2c89410f" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f0a0fe1e-0245-4240-a012-864daaea484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_f7e1b971-cd1c-4238-8504-aa61173d35c6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f0a0fe1e-0245-4240-a012-864daaea484a" xlink:to="loc_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised_f7e1b971-cd1c-4238-8504-aa61173d35c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_1f8ee256-e3ae-484e-a66b-c6e8cdaeea63" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_f0a0fe1e-0245-4240-a012-864daaea484a" xlink:to="loc_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised_1f8ee256-e3ae-484e-a66b-c6e8cdaeea63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofincometaxAbstract_6903343c-b021-460a-a73a-0ef06fc2e442" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofincometaxAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7d004a9f-9687-4f1a-9314-81b3239bb734" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofincometaxAbstract_6903343c-b021-460a-a73a-0ef06fc2e442" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7d004a9f-9687-4f1a-9314-81b3239bb734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5c6295fe-6c84-4668-b308-d25b5d45c75d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7d004a9f-9687-4f1a-9314-81b3239bb734" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5c6295fe-6c84-4668-b308-d25b5d45c75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_5c6295fe-6c84-4668-b308-d25b5d45c75d" xlink:to="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_29af1e78-3ee6-4fc6-9e05-aef279ea8f6e" xlink:href="oncyf-20231231.xsd#oncyf_UnusedNetOperatingLossCarryForwardsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_UnusedNetOperatingLossCarryForwardsMember_29af1e78-3ee6-4fc6-9e05-aef279ea8f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_d43c23b7-6f01-4782-8e8b-08ba783c5cac" xlink:href="oncyf-20231231.xsd#oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember_d43c23b7-6f01-4782-8e8b-08ba783c5cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_InvestmentTaxCreditsMember_9bda26ff-8368-46c9-b25c-203146746974" xlink:href="oncyf-20231231.xsd#oncyf_InvestmentTaxCreditsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_InvestmentTaxCreditsMember_9bda26ff-8368-46c9-b25c-203146746974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_9ec03fcf-e48c-4c7c-8551-05c198c6fbda" xlink:href="oncyf-20231231.xsd#oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember_9ec03fcf-e48c-4c7c-8551-05c198c6fbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ShareIssueCostsMember_0fd5ff43-95e9-46d1-8d67-049209059899" xlink:href="oncyf-20231231.xsd#oncyf_ShareIssueCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_ShareIssueCostsMember_0fd5ff43-95e9-46d1-8d67-049209059899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_780485d5-dee4-4e83-baa4-72267765fe0b" xlink:href="oncyf-20231231.xsd#oncyf_UnusedCapitalLossCarryForwardNetMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_67a45ab5-5f86-4cce-a4d8-4413d4c0fcbf" xlink:to="loc_oncyf_UnusedCapitalLossCarryForwardNetMember_780485d5-dee4-4e83-baa4-72267765fe0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_41dedba8-4237-4cdf-8470-3c411acc8fef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable_7d004a9f-9687-4f1a-9314-81b3239bb734" xlink:to="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_41dedba8-4237-4cdf-8470-3c411acc8fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_53bac258-c2e4-42e7-815c-cf379ff9e9b6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems_41dedba8-4237-4cdf-8470-3c411acc8fef" xlink:to="loc_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised_53bac258-c2e4-42e7-815c-cf379ff9e9b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#CapitalDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_StatementOfChangesInEquityAbstract_e84ad043-43dc-42f5-99c3-07f0da736a9c" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_9e82577f-a2db-43b7-ba9e-ad7d8cce5dde" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_e84ad043-43dc-42f5-99c3-07f0da736a9c" xlink:to="loc_ifrs-full_CashAndCashEquivalents_9e82577f-a2db-43b7-ba9e-ad7d8cce5dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentInvestments_1e22fb6a-9114-4461-8ba8-9d2e7c65fa8a" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_e84ad043-43dc-42f5-99c3-07f0da736a9c" xlink:to="loc_ifrs-full_CurrentInvestments_1e22fb6a-9114-4461-8ba8-9d2e7c65fa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Equity_3a805f08-da0b-43e0-ac54-f7ca81cadfa8" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_e84ad043-43dc-42f5-99c3-07f0da736a9c" xlink:to="loc_ifrs-full_Equity_3a805f08-da0b-43e0-ac54-f7ca81cadfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_EquityAuthorized_003be5ea-926b-4527-9591-8e0017d1f9de" xlink:href="oncyf-20231231.xsd#oncyf_EquityAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_StatementOfChangesInEquityAbstract_e84ad043-43dc-42f5-99c3-07f0da736a9c" xlink:to="loc_oncyf_EquityAuthorized_003be5ea-926b-4527-9591-8e0017d1f9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0e20adf1-c9a3-41c8-a388-9f6c085c2655" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_0e20adf1-c9a3-41c8-a388-9f6c085c2655" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5a4ce026-4aa5-4d63-849b-9f021076bf27" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5a4ce026-4aa5-4d63-849b-9f021076bf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9306659d-8d68-44dd-bc4d-c24d518ec4a6" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LevelsOfFairValueHierarchyAxis_5a4ce026-4aa5-4d63-849b-9f021076bf27" xlink:to="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9306659d-8d68-44dd-bc4d-c24d518ec4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_Level2OfFairValueHierarchyMember_22d3b0a1-9d7f-4dea-aed0-5857947ba3f4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level2OfFairValueHierarchyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AllLevelsOfFairValueHierarchyMember_9306659d-8d68-44dd-bc4d-c24d518ec4a6" xlink:to="loc_ifrs-full_Level2OfFairValueHierarchyMember_22d3b0a1-9d7f-4dea-aed0-5857947ba3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksAxis_9c9dc644-e45f-4150-af06-15932f67c336" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_ifrs-full_TypesOfRisksAxis_9c9dc644-e45f-4150-af06-15932f67c336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TypesOfRisksMember_a30355d8-c46d-4e53-9735-df26c603e931" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksAxis_9c9dc644-e45f-4150-af06-15932f67c336" xlink:to="loc_ifrs-full_TypesOfRisksMember_a30355d8-c46d-4e53-9735-df26c603e931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrencyRiskMember_c6bc7f39-2267-4088-9175-afc9bd4435b1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrencyRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_TypesOfRisksMember_a30355d8-c46d-4e53-9735-df26c603e931" xlink:to="loc_ifrs-full_CurrencyRiskMember_c6bc7f39-2267-4088-9175-afc9bd4435b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_c738c055-0121-4846-b530-3023c50370f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_srt_CurrencyAxis_c738c055-0121-4846-b530-3023c50370f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_5b4bacbd-a9aa-4ae6-a2dc-6440f58a0072" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_c738c055-0121-4846-b530-3023c50370f7" xlink:to="loc_currency_AllCurrenciesDomain_5b4bacbd-a9aa-4ae6-a2dc-6440f58a0072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_da1879f8-3797-402c-96a8-b8dd34345a0b" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_5b4bacbd-a9aa-4ae6-a2dc-6440f58a0072" xlink:to="loc_currency_USD_da1879f8-3797-402c-96a8-b8dd34345a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_a2d246d5-d6fd-491e-b598-1ddcde615e38" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_5b4bacbd-a9aa-4ae6-a2dc-6440f58a0072" xlink:to="loc_currency_EUR_a2d246d5-d6fd-491e-b598-1ddcde615e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockAxis_2c836120-0985-438a-97e0-1d8d9fcafee2" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_oncyf_SaleOfStockAxis_2c836120-0985-438a-97e0-1d8d9fcafee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SaleOfStockDomain_f5d95cba-7df9-4cd6-826f-6e7c26244bc2" xlink:href="oncyf-20231231.xsd#oncyf_SaleOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockAxis_2c836120-0985-438a-97e0-1d8d9fcafee2" xlink:to="loc_oncyf_SaleOfStockDomain_f5d95cba-7df9-4cd6-826f-6e7c26244bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_d5fb96dd-0188-49cb-9eb7-d94198883394" xlink:href="oncyf-20231231.xsd#oncyf_SharesPublicOfferingWarrantDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_SaleOfStockDomain_f5d95cba-7df9-4cd6-826f-6e7c26244bc2" xlink:to="loc_oncyf_SharesPublicOfferingWarrantDerivativesMember_d5fb96dd-0188-49cb-9eb7-d94198883394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b211ecb-4020-47bf-900d-917a6b1428f2" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b211ecb-4020-47bf-900d-917a6b1428f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_LiabilitiesMember_d2fc37eb-f9c9-460e-bde5-a1421c0d5736" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_ClassesOfLiabilitiesAxis_6b211ecb-4020-47bf-900d-917a6b1428f2" xlink:to="loc_ifrs-full_LiabilitiesMember_d2fc37eb-f9c9-460e-bde5-a1421c0d5736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_WarrantsMember_bbbd98c5-82fa-453a-84af-1ab644744886" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_LiabilitiesMember_d2fc37eb-f9c9-460e-bde5-a1421c0d5736" xlink:to="loc_ifrs-full_WarrantsMember_bbbd98c5-82fa-453a-84af-1ab644744886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_a9614fe8-3069-4b44-8275-48560fc784ce" xlink:to="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_250ff844-0745-48e3-9d57-cc3924885154" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:to="loc_ifrs-full_CurrentDerivativeFinancialLiabilities_250ff844-0745-48e3-9d57-cc3924885154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_8fd910c4-09cf-45a4-8cb5-81a606c33b6d" xlink:href="oncyf-20231231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount_8fd910c4-09cf-45a4-8cb5-81a606c33b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_4b747e05-ef2e-46e1-80fc-520745b563b4" xlink:href="oncyf-20231231.xsd#oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_e23286fa-daee-4975-88c3-1750f5f47c98" xlink:to="loc_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings_4b747e05-ef2e-46e1-80fc-520745b563b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_f6ea2b58-d80f-49b3-ae02-76f6113ea040" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1Table_ac2f0b64-b7e5-4e0a-be65-f27923021b7d" xlink:href="oncyf-20231231.xsd#oncyf_Currency1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_DisclosureOfFinancialInstrumentsAbstract_f6ea2b58-d80f-49b3-ae02-76f6113ea040" xlink:to="loc_oncyf_Currency1Table_ac2f0b64-b7e5-4e0a-be65-f27923021b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_174da878-62c8-4c51-a3c0-33b1df38deb2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_ac2f0b64-b7e5-4e0a-be65-f27923021b7d" xlink:to="loc_srt_CurrencyAxis_174da878-62c8-4c51-a3c0-33b1df38deb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_c7cfb964-2b05-4bfc-852a-ba7fb8db0823" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_174da878-62c8-4c51-a3c0-33b1df38deb2" xlink:to="loc_currency_AllCurrenciesDomain_c7cfb964-2b05-4bfc-852a-ba7fb8db0823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_e2dceb3f-f2a8-4fe1-9edd-8594e5e5b9c1" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_c7cfb964-2b05-4bfc-852a-ba7fb8db0823" xlink:to="loc_currency_USD_e2dceb3f-f2a8-4fe1-9edd-8594e5e5b9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_9b820614-0622-42cb-b83a-951f031eb7e9" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_c7cfb964-2b05-4bfc-852a-ba7fb8db0823" xlink:to="loc_currency_EUR_9b820614-0622-42cb-b83a-951f031eb7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:href="oncyf-20231231.xsd#oncyf_Currency1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1Table_ac2f0b64-b7e5-4e0a-be65-f27923021b7d" xlink:to="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_CashAndCashEquivalents_a3386b91-09d9-4dd6-8ac2-c2e07eaafa90" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_ifrs-full_CashAndCashEquivalents_a3386b91-09d9-4dd6-8ac2-c2e07eaafa90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_FinancialAssetsAvailableforsale_deec71e1-ea3a-4e0b-a0ca-500b193d5f2f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsAvailableforsale"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_ifrs-full_FinancialAssetsAvailableforsale_deec71e1-ea3a-4e0b-a0ca-500b193d5f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_TradeAndOtherCurrentPayables_058a8230-5457-44ba-9d73-9ddca3006266" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_ifrs-full_TradeAndOtherCurrentPayables_058a8230-5457-44ba-9d73-9ddca3006266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_BalanceHeldInForeignCurrencyNet_7b119123-6013-4bba-ba86-2c4273b9be86" xlink:href="oncyf-20231231.xsd#oncyf_BalanceHeldInForeignCurrencyNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_Currency1LineItems_3b8b089b-2a0d-40c0-bd99-0e48379b3719" xlink:to="loc_oncyf_BalanceHeldInForeignCurrencyNet_7b119123-6013-4bba-ba86-2c4273b9be86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c71a71c0-4ec4-4c7a-9da3-e450d9b5bc82" xlink:href="oncyf-20231231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_5df30961-fadd-456f-bfa0-7139bd9fc484" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c71a71c0-4ec4-4c7a-9da3-e450d9b5bc82" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_5df30961-fadd-456f-bfa0-7139bd9fc484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_6e332585-f452-4169-a280-953c4a4d6cb0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c71a71c0-4ec4-4c7a-9da3-e450d9b5bc82" xlink:to="loc_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_6e332585-f452-4169-a280-953c4a4d6cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_b797880c-ae53-430a-bafd-d475cdeca104" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c71a71c0-4ec4-4c7a-9da3-e450d9b5bc82" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_b797880c-ae53-430a-bafd-d475cdeca104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_414fab83-8873-4f12-9169-31946622a488" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c71a71c0-4ec4-4c7a-9da3-e450d9b5bc82" xlink:to="loc_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables_414fab83-8873-4f12-9169-31946622a488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_d2cbabb5-faf8-4376-bc06-bed6303bb81b" xlink:href="oncyf-20231231.xsd#oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c71a71c0-4ec4-4c7a-9da3-e450d9b5bc82" xlink:to="loc_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet_d2cbabb5-faf8-4376-bc06-bed6303bb81b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ca0cdb89-1ce1-4eff-a072-10dd8642eb8b" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_c71a71c0-4ec4-4c7a-9da3-e450d9b5bc82" xlink:to="loc_ifrs-full_IncreaseDecreaseInWorkingCapital_ca0cdb89-1ce1-4eff-a072-10dd8642eb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_7180990e-c7c8-431c-bac0-194261a459eb" xlink:href="oncyf-20231231.xsd#oncyf_AdditionalCashFlowDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ProceedsfromInterestReceived_2b8dbbdc-370c-41f7-8614-fe42558dae59" xlink:href="oncyf-20231231.xsd#oncyf_ProceedsfromInterestReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_7180990e-c7c8-431c-bac0-194261a459eb" xlink:to="loc_oncyf_ProceedsfromInterestReceived_2b8dbbdc-370c-41f7-8614-fe42558dae59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_IncomeTaxesPaidRefund_0e8dff2f-bb3c-461c-8f09-12843bd98691" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeTaxesPaidRefund"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_AdditionalCashFlowDisclosuresAbstract_7180990e-c7c8-431c-bac0-194261a459eb" xlink:to="loc_ifrs-full_IncomeTaxesPaidRefund_0e8dff2f-bb3c-461c-8f09-12843bd98691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#EconomicDependenceDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureOfEconomicDependenceAbstract_6be56a47-b39b-4af5-b1ca-be54615e07af" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureOfEconomicDependenceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRisk1Table_8804f4cb-6553-406a-9be8-87a7cc851b09" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRisk1Table"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureOfEconomicDependenceAbstract_6be56a47-b39b-4af5-b1ca-be54615e07af" xlink:to="loc_oncyf_ConcentrationRisk1Table_8804f4cb-6553-406a-9be8-87a7cc851b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Axis_5690e0af-2017-4f7f-916a-50a0c098bf6c" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_8804f4cb-6553-406a-9be8-87a7cc851b09" xlink:to="loc_oncyf_ConcentrationRiskType1Axis_5690e0af-2017-4f7f-916a-50a0c098bf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1Domain_07c9b24d-ed60-4a8a-9fa2-c6b2b28cea4b" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Axis_5690e0af-2017-4f7f-916a-50a0c098bf6c" xlink:to="loc_oncyf_ConcentrationRiskType1Domain_07c9b24d-ed60-4a8a-9fa2-c6b2b28cea4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_SupplierConcentrationRisk1Member_ffe99163-718e-4427-8073-14260f01bcdf" xlink:href="oncyf-20231231.xsd#oncyf_SupplierConcentrationRisk1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1Domain_07c9b24d-ed60-4a8a-9fa2-c6b2b28cea4b" xlink:to="loc_oncyf_SupplierConcentrationRisk1Member_ffe99163-718e-4427-8073-14260f01bcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskType1LineItems_06c0ea9c-e1d2-444f-9be6-09000b300888" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskType1LineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRisk1Table_8804f4cb-6553-406a-9be8-87a7cc851b09" xlink:to="loc_oncyf_ConcentrationRiskType1LineItems_06c0ea9c-e1d2-444f-9be6-09000b300888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ConcentrationRiskNumber_3fa3a337-2d41-452b-a913-585342c37fa8" xlink:href="oncyf-20231231.xsd#oncyf_ConcentrationRiskNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ConcentrationRiskType1LineItems_06c0ea9c-e1d2-444f-9be6-09000b300888" xlink:to="loc_oncyf_ConcentrationRiskNumber_3fa3a337-2d41-452b-a913-585342c37fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#ComponentsofExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_3b656420-987b-4f65-ad2b-05079dfac8e1" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AnalysisOfIncomeAndExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsTable_ccafa947-b709-465f-8736-a835339f7de9" xlink:href="oncyf-20231231.xsd#oncyf_OtherExpensesAndAdjustmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ifrs-full_AnalysisOfIncomeAndExpenseAbstract_3b656420-987b-4f65-ad2b-05079dfac8e1" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsTable_ccafa947-b709-465f-8736-a835339f7de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Axis_418b23e9-b86e-4682-ab75-b219625eb9ed" xlink:href="oncyf-20231231.xsd#oncyf_IncomeStatementLocation1Axis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_ccafa947-b709-465f-8736-a835339f7de9" xlink:to="loc_oncyf_IncomeStatementLocation1Axis_418b23e9-b86e-4682-ab75-b219625eb9ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IncomeStatementLocation1Domain_3d0c1c43-8318-4679-9597-9040ff69980a" xlink:href="oncyf-20231231.xsd#oncyf_IncomeStatementLocation1Domain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Axis_418b23e9-b86e-4682-ab75-b219625eb9ed" xlink:to="loc_oncyf_IncomeStatementLocation1Domain_3d0c1c43-8318-4679-9597-9040ff69980a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseMember_ba04669f-e6c1-4e10-aaa7-240d490a289a" xlink:href="oncyf-20231231.xsd#oncyf_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_3d0c1c43-8318-4679-9597-9040ff69980a" xlink:to="loc_oncyf_ResearchAndDevelopmentExpenseMember_ba04669f-e6c1-4e10-aaa7-240d490a289a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseMember_2d49c98f-63b1-464a-ae0d-1558cb87eb2b" xlink:href="oncyf-20231231.xsd#oncyf_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_IncomeStatementLocation1Domain_3d0c1c43-8318-4679-9597-9040ff69980a" xlink:to="loc_oncyf_GeneralAndAdministrativeExpenseMember_2d49c98f-63b1-464a-ae0d-1558cb87eb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:href="oncyf-20231231.xsd#oncyf_OtherExpensesAndAdjustmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsTable_ccafa947-b709-465f-8736-a835339f7de9" xlink:to="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:href="oncyf-20231231.xsd#oncyf_ResearchAndDevelopmentExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:to="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ClinicalTrialExpense_3249b4e5-1a31-447e-bf83-835db6a5cfbb" xlink:href="oncyf-20231231.xsd#oncyf_ClinicalTrialExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_oncyf_ClinicalTrialExpense_3249b4e5-1a31-447e-bf83-835db6a5cfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_ManufacturingExpense_df6dfea1-c13f-4b8e-bcaa-b851863d8ad0" xlink:href="oncyf-20231231.xsd#oncyf_ManufacturingExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_oncyf_ManufacturingExpense_df6dfea1-c13f-4b8e-bcaa-b851863d8ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_IntellectualPropertyExpense_98d8e997-5639-43a4-a769-747f5366df8e" xlink:href="oncyf-20231231.xsd#oncyf_IntellectualPropertyExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_oncyf_IntellectualPropertyExpense_98d8e997-5639-43a4-a769-747f5366df8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_TranslationalScienceExpense_585006af-db01-4e0f-9ea4-d63908c73ceb" xlink:href="oncyf-20231231.xsd#oncyf_TranslationalScienceExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_oncyf_TranslationalScienceExpense_585006af-db01-4e0f-9ea4-d63908c73ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_OtherEmployeeExpense_c7a957b5-9498-4cc1-93ae-6ab88f11aebe" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherEmployeeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_ifrs-full_OtherEmployeeExpense_c7a957b5-9498-4cc1-93ae-6ab88f11aebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ca6131bc-f79d-40c0-94aa-85b3223cd1c7" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_ca6131bc-f79d-40c0-94aa-85b3223cd1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_MiscellaneousOtherOperatingExpense_392ae3f6-3591-4214-93f8-af6b0de201c4" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_ifrs-full_MiscellaneousOtherOperatingExpense_392ae3f6-3591-4214-93f8-af6b0de201c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_ResearchAndDevelopmentExpense_ab04fb0d-96cf-4833-a270-986514bfef8f" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_ResearchAndDevelopmentExpenseAbstract_e1a2f0d1-3545-4d13-9f66-d8cb1a0dcb97" xlink:to="loc_ifrs-full_ResearchAndDevelopmentExpense_ab04fb0d-96cf-4833-a270-986514bfef8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:href="oncyf-20231231.xsd#oncyf_GeneralAndAdministrativeExpenseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:to="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_PublicCompanyExpense_04c4e85c-47b6-411c-9688-3ab6a9e7fe9a" xlink:href="oncyf-20231231.xsd#oncyf_PublicCompanyExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_oncyf_PublicCompanyExpense_04c4e85c-47b6-411c-9688-3ab6a9e7fe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_OfficeExpenses_9c829ef9-6f26-4b39-83a3-ed0c143fd4f8" xlink:href="oncyf-20231231.xsd#oncyf_OfficeExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_oncyf_OfficeExpenses_9c829ef9-6f26-4b39-83a3-ed0c143fd4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_AmortisationExpense_a6130dbf-b1a1-4645-bebe-8722a0a1974e" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AmortisationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_ifrs-full_AmortisationExpense_a6130dbf-b1a1-4645-bebe-8722a0a1974e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_DepreciationRightofuseAssets_ecb8bda4-19a0-41e0-bf4b-6299eb2e7b6d" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationRightofuseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_ifrs-full_DepreciationRightofuseAssets_ecb8bda4-19a0-41e0-bf4b-6299eb2e7b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_GeneralAndAdministrativeExpense_1f170978-72a9-4a62-b950-51162f316cd9" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_GeneralAndAdministrativeExpenseAbstract_79f20b94-b3d6-41bd-8d7e-f028640379e8" xlink:to="loc_ifrs-full_GeneralAndAdministrativeExpense_1f170978-72a9-4a62-b950-51162f316cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_EmployeeBenefitsExpense_0f93ca2b-c79b-4478-8482-ba22751ecfef" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EmployeeBenefitsExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_OtherExpensesAndAdjustmentsLineItems_4ee39760-72bf-47c8-9bc7-5fb85119bfac" xlink:to="loc_ifrs-full_EmployeeBenefitsExpense_0f93ca2b-c79b-4478-8482-ba22751ecfef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="oncyf-20231231.xsd#RelatedPartyTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_oncyf_DisclosureofrelatedpartyAbstract_38fa2982-abc6-4f50-90b1-848944f4f70a" xlink:href="oncyf-20231231.xsd#oncyf_DisclosureofrelatedpartyAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_dac37dcf-aefa-44be-a5e9-c969d30c35cf" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_38fa2982-abc6-4f50-90b1-848944f4f70a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits_dac37dcf-aefa-44be-a5e9-c969d30c35cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_ede38918-9b53-4858-9ba1-dbe3b322dd02" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_38fa2982-abc6-4f50-90b1-848944f4f70a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits_ede38918-9b53-4858-9ba1-dbe3b322dd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_31790240-964e-4b2c-841a-f03b1ab4c3d0" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_38fa2982-abc6-4f50-90b1-848944f4f70a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment_31790240-964e-4b2c-841a-f03b1ab4c3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ifrs-full_KeyManagementPersonnelCompensation_58ff35b7-ada3-4b19-8154-409eb5cb8339" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_KeyManagementPersonnelCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_oncyf_DisclosureofrelatedpartyAbstract_38fa2982-abc6-4f50-90b1-848944f4f70a" xlink:to="loc_ifrs-full_KeyManagementPersonnelCompensation_58ff35b7-ada3-4b19-8154-409eb5cb8339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>oncolyticslogotaglinebluea.jpg
<TEXT>
begin 644 oncolyticslogotaglinebluea.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP"$  $! 0(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(!
M 0$! @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @(" @(" @(" @(" @(" O_  !$(!H\/  ,!(@ "$0$#$0'_Q  ?  $
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M9(2CU'7BI/_:  P# 0 "$0,1 #\ W^
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                       "&H!$
M$JN0EVP"H"GTGF*:J 7!*KD*( *NV@VT*.HU0 J;9#:4I[:$-M +%7:4;2E+
M;\RD-I>SX 9M^+HJ[2D"GM+V? -I>SX +?BZ*@)-5[$([_,!;\71,"7?YB&_
MS 6_%T3D=5*6TO8-I>SX +?BZ*VTHVE*.TO9\!';[4 M^+HJ[2D=M2CMH-M
M+?BZ+C;&VA1VD&H,%='H3:EN "X!;DZ/\P!5!3Z3S$R/0 F!#4B
M
M
M
M
M
M
M
M
M
M
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MXR*A%'*4MI4XH11X%BNCR9'(40#!< H:J3(\ J@E1R*3
M
M
M
M
M
M
M
M
M
M
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M@JC4IZ*GG(H_M L5D>5$<A0U !< I(]2='H 3
M
M
M
M
M
M
M
M
M
M
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M)HOF([T\Z ^D8JW J(I51Y;H]"<'R+C4%!%)VO[0"H""*1
M
M
M
M
M
M
M
M
M
M
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MB]@,W_%BJC]2<I:HO'B-I?2@/I*ULK%9':%5':ENCM28'R+@%)'E1% (@
M
M
M
M
M
M
M
M
M
M
M   $%4 B2.>2J\D L152!*KD)=Z\=R RHD5=V$NFG$AM=GM)%<#Z;RMYB=7=
M742;2$BKJG8A+M>8'R)W=T)-KL*3G^LI*[M4 JND*:N*2O*3G@%;;0I.>4%?
MY]"DL@!75Y1<\HK)YRDZ3U %9S^_ IJ\MW/\Y163U@%RY_G^$HND+994]!3=
M)YP"Z63TE)TA9+-WU*2R^< OND])267NA8NE[\219/. 7KIN_P"@I+,62R>H
MDZ3S@%XLG=2FLOG+/I4[J2++Y_C +U9"17^HL5F[ZE-9=>L R.VO;\1)TOI,
M<LW?4E6;OJ 9)9"7;,9TQ!9?2 9/I=.)+TOG[^PQBS=]27IO/\(!E>E\_P '
MZ!TOG^#]!BNF7M^$=,O;\(!E>E\_P?H(=*8OIE[?A(]-Y_A ,ITOG^ F29#$
M=-Y_A(I-WU ,QTGF'2>8Q73=]Q'I@#*I)Z2HC_.8A)N_ GZ;OJ 95'KVDW2>
M8Q:2^<G2?OJ 91)?23I(8MLWG^<J)*@!E$F*C9N_ Q:2><J))ZP#+),3I)W0
MQ22>HG27S@&723S^TJ)(8A)>^I6;-WX &4;+W4K)(8MLI623S@&39)WZRJUY
MC&R?K*S) #)(_M*J/4QR2;^)523L^, R37]A51YCDD*J/\X!D&N["HC^TL6O
M]151X!?H[MX$6^;V*6B.[%*C7@%WM(3-=H6Z.]9,WS>P N-R^9?@(ZJG$HHY
M"HCNW>#-RMJ"DB=B^HF1W;N L5T?VE0MR9KM 8*P)4=J3
M
M
M
M
M
M
M
M
M
M                                             IN?U $SG:>DI*I
M@JZ $2FKM=R#37CU$JJG4#EDN_LX$>'G)5<2JY$)->M?8##9-M;]$)51$\ZD
MBN]2%!SM08*KI>_44574E5="@YX!55_847/*3G:E%S^P JN>45D*+I"B]_6
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M1:XK(H
M
M
M
M
M
M
M
M
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MBZ%+AZ"=% :\Y<([4B4$70JM=J#!,
M
M
M
M
M
M
M
M
M
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M$UZW5TE1M*_5&^ZO,D01$ZD3NNOQD0#TSR0 !Z?2/,O1\P  ]'H08
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MJM<BDQ23?O3BA.UVH,M?[%9KRH6Y4:_J!Q*@
M
M
M
M
M
M
M
M
M
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M[S;\[\Q#>E-.8S&U.DQ6(K5IO-=)*Z7<E:*[-V*RXL=_1NTW=F[< #T;GDV
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MW4 5
M
M
M
M
M
M
M
M
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M7:[4 N44J<?26R=O=2HUVH!7:[J4G*6NOI[29KNI0+%=KNTJ%N5&OZ@"H
M
M
M
M
M
M
M
M
M
M                        2N71"*KH454 @JDKG:$570I^=?4G &4/.O'J
M0D<[K"KVE)5]@,,CKUKPZOTE-[_T(0<[0H:@!5[2@Y^X.=["V<X BYY;/?\
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MT7=Y_F*B* 5FN)REQ37K0G:[4&;<RNUQ.6Z*5FNU!@F
M
M
M
M
M
M
M
M
M
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M% :\Y<(NI$HM70K P
M
M
M
M
M
M
M
M
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M=="DU>KK0JHNNY?4#*?H*I.UW446KU$X#5BX!(QVI.#
M
M
M
M
M
M
M
M
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MFE!SD_,F8LR@2Y8PP/)6XSRWB<^IE1(>DQ-A6E<[>R[PP)I=;?3JYJ>[5)'
MZ.!46X4,2Q2U,U@M4MH]#&[M#%)8?$^*I7?1U9=E\HR?N>%^#M8K-KKLKQ&
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M9%+=%U)VJ 5@
M
M
M
M
M
M
M
M
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MW %9NY="H4DW[NOJ)VNU!GM*[%)R@BZ%9%!@B
M
M
M
M
M
M
M
M
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M6KV>;U&<?%UH63X@#"/B3J+&1O:9Q\99R1:]0!A7L+9[._?>99T:IWX%H^,
M^!N7?S?^!\_,,^XV**9M'>[?'.N&<64L#'7:P5$VPKV1N79\;MM4^*%*ZV3/
MZ"I1C7MZ.I;'.WG^<K/D@XXR5Q9481QQ;TIZENW+;+M2N=/9K_;T=LQW*U5;
MVQJ^)^K6STU0R*MHY7[%3"B;+W]/-S._JT^(^2N61R-<&9X8.JL'8SHWNC<J
MU-GO5&D;+SAVZL:YL%SM53(Q[6/8USXZFEE:^EKZ9\E+5Q/@D?I(FI>O=71T
MXT:S<\&W9I^%*E>_A1NUX/7#SI-Y.,=?MGE'2D'B*"5+'17@SBE'I;6M&I9/
M>=O%;5XO)R<3F1]_F7?NUW^9.SJU4?8_+BY$N+LA\;3X1Q1"Z>EJ4EJ\-8A@
MB>RVXDM39$8E52/<BMBK*1SHX;K;GN=46^HDBZ1%IZBDGJ/CC7LW^=.OX5^-
M?2O$LIA,73KTH5:4U4I32E&:X._5^,N#5RI^-P=:A5J4*\'"M3DX3A+)W7/J
M:ZG>S33C=.X !V#J_BP  !#3CY_-U]2KU*J)N15U715W[S:0YC;G8DL<ENR3
MS+NSO<FIG;2Y?8DN=0Z1MLGG<O184N=9.]R1V^65>CL$T\K(Z*66.SH]L"V^
M&'5P(*W73BB]2MU1R+U*U4WHY/X*IO1433@AXNGM!4=(8>5"O%.^<)V\*E)+
M*4.-GU^Z7'D>]JWK'B-%XJ&*P\K.-U4IOQ:L'QA-<US7N7PYG6<C?IU:>GCZ
M%3=IZ.KKXH7L,F_3V&N)S(/.J+F1;*7*C'U>U^/;%0._8]=:B1VWC"R4$:*L
M<LKW.2;$-JIVJM3IY=RH(UKFH^6.K5NQ@Q_?7?NW=7HW*BKJNJZZ:(E3]-Z&
MK8'$5,/63WH2O&3X2@T]V47S3[.'-+@70U>T[0TCA:>*P[6Y47A*^<*J_*4Y
M+.SB^7!IIIM-,S3'E]%(8:*3@7\;CR3VC.1/+QCC#Q2%_&_4 S$4G?OU%\Q_
MZC#,>7\3^ !EHW\-/.7;'F+8_0OF*FX R3%ZBZ:[4QS'=1=,=[0#(,<5M>"^
MTLT4N&._2 7"*5.&_M*#=V[V%5%Z@$5B=CNHHM7J)P&7 )6KJA,
M
M
M
M
M
M
M
M
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M9?A?ZD-$[2&J)Y^_H)T:A,#-UU7^0I:^;X"._L0J "ZZOE*>B]B#1>Q/@*@
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MT(U*34J4XJ4))W3B^:*D8O#5*-6=*K%PJ4Y.$X25I1E')J2^;K68 !]CK@
M']+@[&-UP]=[9?[)73VR]6>NIKE:[C32.CJ*.NI9&RT\\;V^4BM>U-I/L7L5
MS'HK'.1>AOS6G.)VO/\ P&RMJ%AH<=8<Z&W8RLS5:W2H5G][7RW,1=9+3=HV
M](Q=&NHZUM502-V8(9ZGG1GT]R/>5GBG)7'=HQWA63;J*)Z076TR2/918ALL
MSV>/V>M1J.V4J(V[5+4I'(ZBK&0521RMCDIYM+UTU4AI+#6BDL32O*A/FV_&
MA)Y>#+CGDI9Y9F^Z@ZYST1BO";>$K6CB*>;2:RC5BL\X<TLW&Z=[1MU F/\
M;U&1ADU/G[D\9^X;S.P=8L<82K$K+)?J1M33;6RE333-\BKMU;&U7+%<*"='
MTU7#KJR5FJ)LN:J_ND3NOON*L5Z,J<Y0FG&492C*+R:E%V::>:S+C8>O"K3A
M5IR4H3C&49+-.,E=-/FFN#,W$XR$4AA(WZH7T4A\CZF=8[<BEY&\Q$3^'?U%
M\QWL ,Q&\OHWF'B=O+Z-WP &6C?J7;'&,C=V%ZQW6 9)CBNU=Y8,7J+MJ@%Z
MG#T%1%+9B]G$K\%UZE *RKNU3B5$4I,7>3-W+H#EQ\R*S5WE8MRLUVH.),
M
M
M
M
M
M
M
M
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MS#R]FKPOB)Q?Y*BWE!_I5,T^:CWHQ"K\&G'T(GMT1$U[$X(0 + _)W%9>_,
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M1T O^+(EV4(DZ,]1,C$!@I$^PI5 !31A'80G !+L)V#83L)@ 2["=@V$["8
M$NPG8-A.PF !+L)V#83L)@ 2["$FP50 4MA20N  6Y#1%XE=6H2*P HJQ.K<
M-Z=BDX!FY271>&X@K5_455:G82JB]7L ^3O*&SZO02KKU[T*RZ>@*WKZ@8+9
M6HI2<SL+K90D=Y_: 6BIVE)8R_5O9O*"LT ,>YA0<PR3FZENYGJ ,:K.PM71
MF4>SVELY@!BG,[2TDB[_ $&8?'^HM'L]@!A7Q]_I+9[.I3,/C+.2/S &&DC[
M]^HQ\D9GGQ_K+&2/OV &#>SV_&8^2/3AP^!#.21EE)'[>_Z #"R,]G?>6KF=
MIE'LTZBT>WV&4[?=R??^.(/.GG&N0!8,_L#5%BK'06W%5KCJ:O!N)'1*YUKN
MKF*YM/5K&BS2V:X2,B@N<#$>_HM*F!BU,$)SQ,X,H<18"Q+=\(XLMLUIO]DJ
MWTEPHIDU3:;KT513S;FU-'51;,]-4QIL5$+HI$V5VFIU1GL[?@73X>KYCQ1Y
MX;FPJ;._#"8GPM21PYI86I)_<U\36QKBJUHG2R8;KU1$269'LZ:QU3M7T=2^
M:F1'4]=,B2AL]UT>#J1PF)D_4E25HS?]3-Y7]XW;>7+BN#3B':=J#_*%.6-P
ML%ZLI1\."R>(@LVGUU$O%?/@^*:T'@7EPM]11U%125=//25=)/-2U=+4Q/AJ
M*:JIY'0ST\\4B-?%-!*Q\4L;D16O:YO4698Z+NDU9I\&G=-<GYUF56<6G9II
MK)IJS3YJW9P  ,F /3PZ_1U]U147@O'< %_PN-^5NVY[><R=SC;\G,<?L0Q/
M6N3+C'-5#35CI7?6L-XDD=%#;\01JYZ)'0U'[@O,.]%BEIZ^-.DI963[[D$[
M7M:]CFO8]K7L<U4<US7-VFN:J;G(Y$U39U3>B)Q.3.NBHJ*B*BIHJ*FY4TZT
MX+Z]=-^SHJJINW<PASB#L>X3_N38ONBU.,\%T;GV&LK)6.K;_@^.1L=.Q[UT
MDJZ[#>W#;99E1\TUN;;)ZM\U7T]3/"NT[5-23TE0CPW5B81CG:S2JV7%I[BE
MUK/,L!LAUQ<9_P E8F?C)/!U)R\&Z5Y4;O@GX3AU.ZM:QL=1/T_1O3O\QD(W
MF&C>N].OM[_27T$A!/XO^/QF6(_VM^.OYK&:BDX&3B<8*-YDHG@&7C<9"*0Q
M#'<%+N-_?L ,U&XOF.]AB8W%\Q^X R;'%VQW!3',<7;'>P OVNT+I%W:>PL6
M*7+'?  7#7:E7BGG0H*O65F*#*94:NI4:NA23<NG:3@P7 )6KN)@
M
M
M
M
M
M
M
M
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MW[# (LC_ %E]''W[!%&7S&:( 1C9YB[C9^D@QA?1Q $8HR]9'YA&SS%VQOM
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M7109Y>C[2LQ2L6Y7:NX&"(
M
M
M
M
M
M
M
M
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MD)MG7C["9&^TF!EV\_6"9&ZD485$30'$@C="8
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M$JHI48I19UH3HH,%P B@
M
M
M
M
M
M
M
M
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MT((W0G1-09;ZN! JM;H3(FA$'$
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M#%+MJ[@"]3>GH*B*4(W%5J[] "NJ[T7M*A23@OM)V+N!FV5RNQ2<H-7>5P8
M
M
M
M
M
M
M
M
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M^9.'6H!%%1?5U%5K=?02HA/YD]8,I#CN0J(F@1-"9$ ;_'6$34K(F@1-"(,
M
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MT4NV;TT *S2=NY="BU=4*SEX*#**A71=2AJ5&+U P5
M
M
M
M
M
M
M
M
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MQO)=,;["_B9P+>)O?SF3A8@!<1M+V)G?SE&-/T&0B8 5HVE]&THQL[]I?QM
M*C&?H+MC/TDC$ZRZC8 5&)UE=J:DK4WZ<"Z:W=Z.H ::>GXBHU-$")UE5$TW
M_  .&[K)VIH2L3K*B RWR";]Q71-"#6Z$P,
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MHW%TQ=X!=)N70JIU^TH:\%[-Q78N\ J,7<5&KO*2;E5"<&6N'<7 ((NJ$08
M
M
M
M
M
M
M
M
M                                         !*Y=Q,4WJ 4RFOV7?L*
MA21>*@Y1Y]Q(Y>*E+7=Z=2=Z[BD_XD!Q*#EWEK(O'V%=5+21WT@%N]2P>OTE
MV]W$L'NX@%M([C[#&RN+R5?B,;*H!;R.XF,F<7DKC&3+W] !:2.X^TQ<SM5+
MZ9VY?.8QR\1W\ 6=34,8U\DCV11QM<^261R,CC8U%<Z21Z[F1L1KG2/7<UB.
M>NYIS-><'Y24N;.<N/<;]+));:V^U5MPXQRKI#ABR226RR-8Q43HW55)3-NE
M1#O1MPKJE6*[57+O+<[[RD5RQR$QI=::9(KO?*9F$;)HY&R>/XAVZ.22)JJG
M2+2V]:VLE8BH[H:>16Z*W4YSC&[*(B<$1$[>":)\'T\2==D6B+1Q.,E%9M8>
MD^+\'PJC7GW$^PKKMNTY>>$P$&\D\357*\O!I)]>2F^QY\T1 !-9 "C;(  &
M0>K/,S<E5,U,\[!#74?C.'<&1KC3$"R,VZ5S+9401VBBD=]@LM9>9J58XMI7
MNBIJF5K7QTL^SY3&]5X/UR5VX'R=?C.N@V+[F=617B1[F(DD>'+9XS1X>ID=
MO>L;NFKKELO1JLDN,K-%8D;F:9KYII8+1U62;52K>C2MD]Z:L^WP8;TF_>F^
M;-M /2&E*$6DZ.'?JFLVKWC3?@QZGO5-R*7OCWC8GT>A.Q.Q-W47D3>!08GP
M%ZQ.'GZRJ;=^/7?SES.KL5EV+J+F)NOQ&3C:6L+=VID8FF 7,+#)QMX%K"TR
M$: %Q&W]!D8VEM&W]!?QH 5XFE\UO44(4W:EZQ "K&WX"[:FGK*;&^PN6)J
M3QL[^8K:;].I"")HGIW%1J:( 3-0GTU] TZNOK)T30&5^/E(E1C>LE:F\K P
M
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MB>8:-=WH,E"[=H5V+1&8B4R<;OI0PL;OA,I"[AWX@&6B7YC(QNU0P\;C)1.
M,HQ>_M+^->'G,9"[M+]B[@"_C7XR[12Q8I>,7< 7K=Z*A4:O MXW%9O6@!5<
MO7U[_@*Q1ZE\Q5:NX&?]/M*S%W$Y28N\J@P
M
M
M
M
M
M
M
M
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M$T?AJ/!JFI3Y7G+PIO\ :;*/:Y:6]6Z3Q>(O>,JLH0[*='V*"7ZL4^]OAP
M-@-9   /V/D[Y*W',?'F$,!VIKW5F+,0VZRI(U$<E)1U,[%NER>W<YT%JMC*
MRXSHGE]#12+%J](]>H3@_"E!8K5;;):H&TMLL]OH[7;J9FFD-'04[*2F9NW.
M<VGB:CW_ &3WZO?Y;C3;\&[Y.;;WF!BO,FLAVJ7!=JCLMJ>K46/W:Q"U75$J
M:M56S4UJIY6,=&Y-&U4S951LR--TAC>HKMM7TPZN,IX56Z/#4VIVYUJGA?\
M;#<3[;WX%HMBVA%0P-3&27AXR=H/JH4KJ+[I3WVGP:W2XB;P]I>1-U4H1IW\
MQD(&? I%!,Q=QM,E"TM(FF2B: 7D:;B^8W@6T;?@,A"T NHF[B]C9])1C3X"
M_C3X@"LQI>1H4&(7L;4]@!4:FXNHV_2I28F\N--$](!.F]=?456]I(B=1/IU
M=@,I$S6]?P$X*C$ZP)/,G1-"( ,
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M)%+K7=Z "X9Q(L7J*;5X%37?Z087WE5%WE<MRNBZ@R1
M
M
M
M
M
M
M
M
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M1-2LA(Q.LJ P
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M  $47JZS%_QWF+_C\=Q, #)D $BN7L,-@G!+KV_J)C*8
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MKH 1!(JJGSD6KJ84D"8 &0 "&H%R(((I$        $NJZ[N!AL$P(:]A$R
M  "!$           $ "(                  !*J^P F!+KN)D,7  !D
M        E<J]0N"8$NUWWDPN    "57>TCK^@Q<$0 9
M                 !+M(-3%_,$R8$NTA%%,@B"55[]_H)=OCU>I?H[[MQCS
M"Y4!+M=]4^D;7?=])DQ=$P*>VOF^'KX=7H3T^8F:NH,DP)5=H05W9\0!."3:
MW?H(HNH!,"":]9$                             E7J&O?NOT@$P)&JN
MOFZB;4Q<(B"15Z^/?OU!'=_4G?=N,W!."7:[ZI](VN_Z@8NB8$B.[[^^J#5>
MZ*8O^+,S<G!(CEZR"/X_ 9N"H"1'$=KUBX)@
M                          4WKU%)W!2=Z[RD]=P")?X)1=Q0K.X)Z"A_
M"[]@,MW*<B\?86KUW%>0M9%!@M9%XEE(NXNI%^%2RD7X/I +27SF.F4OI%WF
M-F7B 6+^)CY5W%](O'S&-F4 Q\JF-G<7TJF.D7>AE<4"QD7XM=_L].[BFB*J
MKHAH/>$$9S+B?E#W*QQ2*ZBP#AZQ8=8U%18_=*X4C,27.>-4^Q>K+O04,[4T
MV)K<Y/LMI$WVZJICB:^69[8H8F.EED<NRV.*-JR22.=P1&,:YRN7[%$VNHY<
M7*GS.EQIF;F%BZ9VT[$>,\1W9F_5&T]3=*E:2)G9%#2-@BA1-R1,:B*JZJLL
M[(L$IXVOB+94J&[&Z]O5DE?O48SC\I"^VW2'1X##X?-/$5U*<;\848.3OEPW
MYP9^#  L-W=_G*O@   ]X?!W\E78DSWJ,2SP-DMV7^$KG=E>Y%<UMZO<D5BL
MT6SLJS;=2SWNMC<Y6JDEM9IJNSL^#QNM>#:9+-L^5.*<;2PM;5XUQ4ZE@J$1
M$>ZTX8@6C@@<FNJM9<JBZ3QN<B-<VJ\E5T133-H&D/4^BL0[V=7=H+K;JNS2
M_44S?]F.B_56F<*G'>C1<\3-<K48WA)]U1P5N=V;&K4X><OHTXEK&A>LZD]!
M5*Y<DO(6&3B3OZ"RB;IJ9*%.'J_2 7\3?H,A&A:0H7\3> !>PM,C&TLXF]_2
M9"--W?T@%U&A>1M+:-/A+Z-/H +AB=9<QH46IHA=-^( GTW^@KL[>PHL*NF[
MT@RE<G:G63D$X%5@,-DZ$0
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M5->W?UG):JXT?%(U>#F.;V<6JG'J.HQR0\V?V=96Y?8O67II;_A&Q5U7*O\
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MZ(TA4I3G3J0H2E"=.3A.+33O&2S75D:PG[=ORK_PVXD_HC!W^[1+^W;<J_\
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M'A:]:G*E6JN,TJ-.+LJ<Y9-)-9Q1OP_#P]>[C["J2IW]JDQ *998  R
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MO>/9)Y$:[3M8\7HS!T:^$G&%2>(5.3E",UNNG)VM*ZXQZC98^JQLN/P28_\
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MX),?_P!)X9_/31T ]:[0_P"9J?OZGWCUW--_GZ7_ $]+^$WB_JL;+C\$F/\
M^D\,_GH^JQLN/P28_P#Z3PS^>FCH!ZUVA_S-3]_4^\>NYIO\_2_Z>E_";Q?U
M6-EQ^"3'_P#2>&?ST?58V7'X),?_ -)X9_/31T ]:[0_YFI^_J?>/7<TW^?I
M?]/2_A-XOZK&RX_!)C_^D\,_GH^JQLN/P28__I/#/YZ:.@'K7:'_ #-3]_4^
M\>NYIO\ /TO^GI?PF\7]5C9<?@DQ_P#TGAG\]'U6-EQ^"3'_ /2>&?STT= /
M6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28__ *3PS^>CZK&RX_!)C_\
MI/#/YZ:.@'K7:'_,U/W]3[QZ[FF_S]+_ *>E_";Q?U6-EQ^"3'_])X9_/1]5
MC9<?@DQ__2>&?STT= /6NT/^9J?OZGWCUW--_GZ7_3TOX3>+^JQLN/P28_\
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M._$Q\2?$92%O#OP +^-"^B3>6K$X>8OXD^D OHT^$OF-UTT]9;1MWIYC(1H
M7$:%[&G M&)N+YB %=J;RX37VE&-/H+GKT[ "HU."%3BOH)&]O83,3K!E,J%
M9J;BFWB5@8
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M/B^YOM/[2$474I,<BKU\._L[>!50A-/EZ?N+ )D0 9,@
M    &J?X6%]RS*K\9-3^2=[-%\WH/"PON695?C)J?R3O9HOEF]EWDFG\+6^F
MRI.V#RU5^ P_T&  2*1:#9J\%B^[GC'\6]7\O6@UE39J\%B^[GC'\6]7\O6@
MU+7OR1CO@E].!NNSGRWH[X:7U50WY$[^U28E3O[5)BI:^_YRZ8 !D
M            E5VA,2N (ZH05R%)7:>GON3OZ#X6Y=?.)Y9\GS#K;WCN\,9<
M*UD_['\+4#HY\18BGIVMZ1MNM^TCVTL#Y(FUESJ>BH*%)8O&)T?+!%+]\)A:
MM>I&C1A*K5D[1A"+<I/J[,LV^2XV5SJXW&TL-2G6KU(4J--7E4F[02[^>>22
MS;R69]L7W$%#:Z.JN%RK*:@H**"2IK*VLGCIJ2EIXF[4DU143.9%#&QJ:N>]
MS6HG%35LYP?PF#"6$9J["N2%L@QW?H$DIZG&EQ<Z#!EMG^N,5MK@CV:[$U7
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M*#\9?\2VZGPWF1KKEM)PFC-ZA3W<3C+/V&,TH0R_K9K*+7%T_&:ZD;%_+_\
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M!TM#V&?1UXI;^'J-*:X7<>52-VEO0O;@[/(_? 2)P[Z_#\_L)S5S<0
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M"V&R?6OU=@_4E:7\YP:4&F_"G0RC2GQN]VVY)VY1OQ/VG4B2H3$;(E@
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MZ_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P  @LL0
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MM-^[KX\/5\7J*Q%-^/83.F  9,@
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M#A^BT3A%;QX3J/M<ZLFGYU<IEM*QO3:9QDKW49TZ2[%3I137FD_3<  W$T0
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MX%JQ.LO "O'U=^LK,[21C=WHX%5J: %3J])41-"14X(5 9ZB=B=95)&<"<&
M
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M!KOO5,,>^O'OY57$]["G^M?E+'?&:OTF7CU,\E:/^*TOH@ &OFS
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MYVE\$\3A<1AU)1=:C4I;S5TNDA*-VN=KWM=''FU0:H=6M.;%Y-G_ $>\D/\
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MA_8JO[RG]P]8RO\ V^E^YE_&<I3:3M0(O?CU[^"*NY/-Z51-YU;$YL7DV?\
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M?\.I'>7:X>.EV-$:Z2T)B\')QQ6'J8=_\:$XQ?O:ENCEW)F. !WUZ>Z_VGF
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MTTO8J/ZL7O37NVT[V1#9)@#022P
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M G3[(J$C.LJ-XH#+XLK(1 !@
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M  -?-F                           !*Y-RZ:=_9\9,04-@\(.?GYN?\
MNV95SXCP]0NJ<P\N:>OO5B93QH^KO=G9&L][PW&C6]+45%5! E5:8&O3;N5/
M# B.=4'.+AE:]C'M5'->U'-<U45'([>BHJ<45%UU3<NNO'4[)ZMW::)V>;37
M?JG7JB\/B.=GX05S=ZY/YH-QQAZAZ' 69]777"G2GCTI;+BYKO&KW9W(U5;
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M/\7B#Y'J#I?)P0KEM;\HTOBL/K*I:;8IY,K_ !RI]"F1 !%A,0
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M5^/BQ648*_*$;)=?>2_H'0U+1^$HX2DK1HP2;]U-YSF^-W.6;SR[BH #S3V
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M35"LA(C?-U$Z$2+S][_'^Y-=_F5^_L["( ,F0
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M?67+ "LG%._G*[>OT%%$W^@K)P7OQ )V<"JSB4V<"JP&7Q95  ,
M
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M3;S;;>;=RV5"A3I0C3I0C"G!*,(12C&,5DDDK))  ' ^H
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MI3$1]DJK=PB:\2B_&JQ[:CRB^4(]4B"*NXJ$$0B0XE;TW)V0 !D
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M\X_DT_ZRJGXTGQIJW@Y2:WK;LC45J+W[^O\ 054(;),0PO23TE;(  R9
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M4*5MMW;=VVVV^-V[E^8P44HI622274EDD  #D
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MX)W[0"=G K1]92;P0JQ]8#94
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M?T3HRE@\-1PU".[2HP4(\+NW&4NN4I7E)OC)M@ '2/1
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M&-.$:<(J,(14(05DHQBK122X)))+L0 !P/J
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M^HIU^^3]^\/ _O0PW\BT1">V3Q-'^^Q7S4"P&PGQM)]V%_QC]@ !!98@
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M)/<
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M-Z_2I57[%._:4F\5*J_8IW[0"HG!"K'UE)."%6/K *@
M
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M]18'8AH6[Q6D)K-6H4F[9-VE4MS\7<2[')9IA$T7ON*@!!J5BPX !D
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MMMN]R\E&E&G"-."480BHQBE9*,59))<DLDN  !P/H
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M\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_P"*TOH@ &OFS
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M\U14U$TBMCB@@BC?)+*]S6,8QSG*B(IR\N=>Y?-;RA,V[SBB&:H;@ZS/FL.
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MNHJ,>1<K9[JI'16 A"27JFONU<3+FI6\&E?JI)[MN#EO2MFR8 &GF^
M                            U:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^
M,-OR#<C:M1O*^"^%_N3-+VB>1=(? KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P
M#)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6
M'UE4M-L4\EU_CE3Z$"( (L)B                           !^>9N_O4Q
M/[W[S\G5)^AGYYF[^]3$_O?O/R=4GTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QL
MO]HXI%6H^V2_QLO]HXI%V:?BH_/^?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@
M?WH8;^1:(Y E?]HF_BI/ZBG7[Y/W[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&
MTGW87_&/V  $%EB             04B "DJ\$Z_H[H<POGKN40[,CE)YCU\4
MZ5%MPU<FX(M+FN58VP881U#<-&HJL1Z7M+DQ[F:](V-JN550Z2O*!S6I\"X$
MQEC2K1'083PKB#$DD;E^W)9;757!($1%:KGSN@;"QB.:Y[Y&L:NTJ'(:JKE5
MULTU;7SOJJZMFEK*ZJD762JK*J1T]54R*B)J^>>225ZZ)JYR[B9-C^CE*MB\
M4_ZN$:4'U.JVY-9<HP5N]D#[<=)[M'!X-->R5)UIKKC2M%)KME-^A6S*  )\
M_'R6*W_C\=W  $%7OWZOI0S;AVY+OX*_G,7^1-OT96/<CP?+DB+FARA+->;A
M2^,87RNIEQI=^D:CH)KPG2T>$;=(NTBHZ2[JZ](QS7PS18>GIIFZ3IKT@]=R
M=]QKC>#,<F]N%LAZC&M3 UERS(Q!77*.56(DBV6RR/L]N8DOV?1/J*:MFZ-$
M:QKWN>FUMJY=CM$^!"JFT32_JO2=9)WIX9^IX+EX%W.2[74OFN*27(N'LNT'
MZCT30;5JF+OBJE^-JBBJ<?U::CE[J[RX$Z*1 -))&
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MM545-%1="LU=33S>T[DP !D
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M67,?S@%RG%?45-=W?SE).*E5."^H J-7<A6CZRBS@5F*#+*@ !@
M
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M^Y9E5^,FI_).]FB^;T'A87W+,JOQDU/Y)WLT7RS>R[R33^%K?394G;!Y:J_
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MZ[OQ?22;B^+]HHV[+$0 :6;^
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MG$-?D,.DGU3K3W?3N4WZ>&=SZ= !7LLZ
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ME19<LJ6KB:J22KK%>\7-C57*U&(CK/99'M:JHMTJVM<Q;=.FN9S>G(FO6?\
MFGA_+VUNFI+?4RMN&*KS$Q'>X>%Z.6);K6LVVK$ZMEB<E':X9%5LU?4P[;?%
MHJAS.I[EQEW9L)V"SX8P]0PVRQV&W4EJM5# FD5+144+(((VJOE/=L,19)'J
MLDLBODD<Y[W.6(]J.M'04?4%*2Z7$1O6:;O3HJUH]2=65[_H)]:9-6R#5'U3
M7_E&O'V'"S]@3652NT[RSXJC'ARWVE[1I_VB,T[[N&GM\Y.A$%>RSP
M                              -6KPK#[CV7GXPV_(-R-I4U:O"L/N/9
M>?C#;\@W(VK4;RO@OA?[DS2]HGD72'P*^L@:(J_1\1 BOT?$0+:K@BE2^_YP
M #)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q
M6'UE4M-L4\EU_CE3Z$"( (L)B                           !^>9N_O4
MQ/[W[S\G5)^AGYYF[^]3$_O?O/R=4GTH^/'WT?G1\<1^3G[R7T6<?>H^V2_Q
MLO\ :.*15J/MDO\ &R_VCBD79I^*C\_Y^-+WS  .9Q+2O^T3?Q4G]13K]\G[
M]X>!_>AAOY%HCD"5_P!HF_BI/ZBG7[Y/W[P\#^]##?R+1$)[9/$T?[[%?-0+
M ;"?&TGW87_&/V  $%EB             05-2( /&;G]LS788Y+.8RLE=#-B
M%EHPM"]BJCT6\W6F9*QNBZ_7:>*:%R<%CD=PXIS2-W5PZM^N[JW[M?8GH3@;
MYOA4N.I*')C!%DCD1&XAS!IVS1];H[59[G<6/5.D8FS'/'$FKD<FT]K=6*Y'
MMT,U[^CJZDZNO1$7BB(FXLELGPRAHR52V=7$5'?KC!0@O0U+TE4MLV+W]+1I
MW;5'#4UW2J2G-V[TXW76B  ).(D!3F638=T4;Y9-%2**)JOEEE5%2**-C45S
MY)'JUC&M155RHB(JZ(5#ZNY".7?[+,Z\IL.JQ)8[EF%A7QF)>$U%17:FN5?"
M[>FC9J*CJ(W:+M(CE5N]$5/CB:ZI4JM1YJ%.<VO@TY_):YVL#0Z:M1HV_*58
M07Z\MRWRG4/Y'&2<66^5&7& XD8CL)X+P[9*I\:(C:BX45KIH[G5KL[E?6W%
M*JKE<FY\D[G=9])$D2(B:-X)HB:<--$TT\W9YBH4IK5G4G.I+-SE*;?;)N3^
M5E]\-15*G3IQ5HTX1A%=D(J*^1  'S/N
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MHU'WQBU;G<DO1&U30^*<8NO+"S=ENXI*$;]E5.5+LSDG?E;,VA]2&UOX>L_
M\C.4_E]F;;DNF <8X?Q91;#9)'6:XT]544S7*K4\;HT<E92*KD5J)500[2M<
MB<#]Y:NO7KJF[=NX<4WKN7J\W6:/4I3@]V<7&2XJ2<6N]/-><D*C7A4CO4YQ
MG%\)1:DFNQK)KM*B*1((FA$X'V
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M2C7CH7C.!8QKP])>Q]8!D(^LN(^LM(UX%TSB 7"<?5\Q7;U^@MT3AWZRY9Q
M)F<"LSB4&=95:N] 9?%E<  P
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MU7IJ&C<!%</4>&?IHP8 !XY[P
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MSLDB[FAM%4<#AJ.%H1M3HP48O*\G;PIRLEG)W;=EFRH #I'J
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MI71T%SQ=%_LS3_NG1^9P[]_,3$D?#OV)\Y.4_+Q@
M                              $-$[#SKYPOFTLN>49AQ+7BV@2BQ!;H
M9F8:QG;H8FWZPRRJCW11S.;_ 'Y;)I6L=66JJ5]),[ZXQL50C9V>BI+H=C"X
MRKAZD:U&<J52#O&<&TT_-U\'Q37%'4QV HXFE.A7IPJTIK=G":NFN7<T\TUF
MGP.5WR]>;&S5Y/%XGI<:6A:S#4M6Z"R8YL[))\-WB%TJ)3+)*J++9KE(Q6)4
M6FY,BEBJ%=#15%QIEAKJGSU.PYCK+^RXGM-=8L1VFWWRRW*!]+<+5=:2"NH:
MN"1JM?'/35#7Q/:Y%7[)%T_@JBFJ1R\_!@[+=):W$>0M[;ARKF66HDP'B2HF
MJL/K,Y5?T=AO.Q+<;1 YRKI17#W4IHE54IIZ2G9'2I/&K.U2C54*6D5T%3)*
MO!6HRRXSBKRC)N]^,.=HE<M;=C^(HN=;1C=>EG+H)N]:GG_5O)3BEDD_#Y/>
M-)H'[QRB>3!F#E+>G8?S'PE>,)W)72)3+<Z9Z6^Y,BT5\]HNT:RVRZPHBM=(
MZAJYG0[;65,<$NL:?@_P>G<2U0KPJP4Z<XU(2SC.#3C)<+IIM,A6OAJE*;IU
M:<Z=2+M*$XN,D^V+M:_'AW  'V1\0  %V<@     #^APEB^[X?N-->,/W:ZV
M"[T<B2TEVL=RK;-=*25--F6EN-NJ*6KIY&JB:/BG8Y--SD-@SD>>$GYU8#?2
M6W,.*DS5L$6Q%)/7)!:,70Q)HB*R[T<#:.OD:UFPU;A0+-(JOFJ*V:1=372!
MY&E= X/&P<,3AZ56ZLI23WX=L9QM)>E]Q[.B-8L=@)*>$Q%2C9W<(RO"7OJ<
MO!?G.GYR(^>+R0SV;%18;Q)[@XL5JK-@K%J0V:_>1N?);W.FEMMZIE1-KI+3
M6U4T+',6OI:*:1L!ZHHNY$7C\)QMH)GQ2131/?%-!*R:&:)[HY89XW(^*:*5
MBI)%+$]J.9+$Z.5BZ+&]KVM<FPYS>GA$.:.5U10X>S*=/F;@%J-@6:L?IC>Q
M1(C&QR6V\OF;%=Z.)J/Z6VWF*2I?M1K1W>BCIW4M5#6LFR>I3WJNCJCJ*S?0
M5'[)UVA.RC/J2DHOMDV3KJOMGA4<*.DZ?12=EZII)*D^5ZE.[E!OFXN4;WRB
MCH7D3YBY*?*\R_SGPO!B[+S$-)?;5)LQU44:K%<K35JW:=07BVR?WU;:V-$7
MZS41LZ5OUZ!TL2I([Z;VDUXD/UJ$Z<W3J1E"<7:49)Q::XII\'?D3GAL33JP
MC4IRC.$U>,HR4HR76G%M/S,F!#:0(NI\S[D0
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M"\8N\LF%X@!=IP]"E5O%"BU=RE1J\% *J+O4J%->*+VE0&65T4B2M7<3 P
M
M                       ""J 454I/ZBH2+Q0'*/$E>N\H=:^@JN7>4>KT
M@XE"3B6DB\?07+EWEI([B 6DG463UT]I>/+!_;J 64B\3&RK\9?2*8^5?B +
M*1>)BYE^(R,KC%RKQ]@!CY>LQLCM_P !?RK\.IC'KQ +21?A4\N^>7QBEEY,
M^:\R/5DEQLE!8HD17-61+[?;5;*F/5J+HCJ"IJW*U^C9&-=&NYV_U"?U&O\
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ML?L,JKH-(0Y]-1DEV.$U?_M+\ $,$\@
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MVC454\[3$]S"8J;Y8:N_-&G*_GR9ZFA*6_C<)#W6)PR7>ZU-(ZK " I@7T
M          !!>KOU*1(+U=^I0"'5ZOF.7)SS/WT^=_OPC^0+*=1OJ]7S'+DY
MYG[Z?._WX1_(%E)8V/\ ].Q'Q7_$@0QMN\FX;XW'ZJH>9@ +$%7@  ^"[_N,
M/E^.3.C)X-=]ZIACWUX]_*JXGO8>"?@UWWJF&/?7CW\JKB>]A3_6ORECOC-7
MZ3+QZF>2M'_%:7T0 #7S9@
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MM%^J,7&.Y?C2H+.-N:=7*4OT=Q=8;P)@"+R80
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M$K_M$W\5)_44Z_?)^_>'@?WH8;^1:(A/;)XFC_?8KYJ!8#83XVD^["_XQ^P
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M--W?3LW>;L)R1B]G:OZOU>CJ)RGI>4
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MJL(SA)<U+DUQ33NFGFGD^HF !USN
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M"HBE)%XH3L7<#/V?>7#%)RBSB5@8
M                                                    !*Y=Q,4G
MJ 2%)%XKZ"HJ[BEU>D&5S_'-%-R[BDY=WHWE1W5YRC(O'V P6ZEH]2Z>NXLI
M% +:1>)82+HB^WVEV]2RD=J 6,QCI%XE].O?U&-D4 M)C$2J9.9QB95X@%C,
MICI';O3J7\_?V&.E4 LW\34=\)PS&VJS*C"+'HY&P8AQ+4,:J?6I-JDM=*YZ
M:[2++')4HS7=I$[0VX'KQ-!3G^LT$Q#RD+_;(Y6R08+P]AC#"-8[:C;4S6_]
MDM6Y%U5JRHN((:6=S-=)*-()')+ ]I(NR_!]+I6G)KP:-.K-]^[NQ[K.5_,1
MAM=Q_0Z&J0OG7K4:5KYN&]OR2[]Q+SGBT "S?^OS_<5'?R\^_@  # /9/F$,
M#>[7*8PK,YG20X>L&+<0S)IJC5@M2VFDD5=?)Z.XWBB5':.U71FSY6TWQL]7
MGT]&_P"8V<_!CLMO&<=YHXP?%HEGPE:,+TLJHU4<[$5Y]UJ^-COLE5C<+6]T
MG4B3,3?J:QKGB>AT7C)WLW1E%=\I*'VFX[/\)T^F,!&UXJNIR[J:<W\R-RJ'
MCZ^Z^;5$3=YN)?P-TT7OQ+&--V[TF0@ZN_45&^]^CEZ$77Y+\?C,R$*&5AXI
MZOF,=$FXR<*< "_89&#J]1CX_G,I$@!>Q(7T? LXVKHO:9"-.'?J +IB;R\9
MP+6/K+MO! "YC3@56<"1OS%1G  J]2&L)X5']QG _P","+Y'KS9Z[._6:POA
M4?W&<#_C B^1Z\VO4CRK@?C%/[33MHC_ /)-(_%JGV&AN "VO5W+YD4HY+S_
M #L   VBO!5?NP9B>\"E^6HS?%Z_9\YH=>"J_=@S$]X%+\M1F^+U^SYRKVTW
MRO6^#I?01;G9%Y%H?#8CZ;(@ T D\      IO;KW]7SGCASP_-7VKE&8*\8M
M4=%09GX6I9Y,'WJ5&0^/,7Z_)AJZU:,5_N97R;2TSY-IENKY&UD:QMDJE?[)
M*@T3L.YH_2%;"UZ>(H3<*M*5XM<+/*46N#4DVFN:9Y^E-%T<90J8;$04Z56.
M[)/Y&GRE%YI\FCCJXQP9=\.7:YX?O]MJ[-?+-6SVZZVJOA?!6V^NIW*R:EJ(
M':;+VN36-[7.AE8^.2%TL,L<I_-&_3S]/,^IFI9ZG-K+>V1MS*P_2JZ_VJF8
MUCL<6"EB>YS(D31BXDM;&[5OE>G]_4R24$SVO2EE9H,R1.8YS'L>Q['O8]DC
M7L>R1BJCF2-<C58]BZM=&K6*U[7,<Q',4M;JKK-2TGAE6@]VI'P*U)VO3G;A
M9<8S]I+@U>^::5-=<=4ZVB<4Z$U>C).="KRJ175P\.-TIQRL\U>+3)  ;.:C
MZ5W#Y^/G]*<%]?SKK[+\SISJUUY.F-&4%ZDJ*_*K%%;#%BRUM<^26RSR[$$>
M*K/%P\:HU6);I2(BMN5OCECCV:]E,\\:".O?OZ5]IY^D]%T<90J8;$04Z56+
MC*_%-\)1?M91>:?6>EHK2U? XBGB\/-PJTI*5U>TK<8R7MHR63CS.Q/A#%]M
MO]LMUZL];37*TW6DIZ^VW"CD26FK*.JB;-3U$,C55'1R1N1S5UZ]%1%U1/Z@
MT(.8/YX+^YA=*;)[,N\[&75ZK&LPG>;C,UL&"+S5RJDE%454BHM/AF[3/8[Z
MZY*2T7!TD['04E35K%OK0O1R(NUM-<U'-<BZHK5T5%U151=475%3<O\ !U33
M2J&LVKM;1F(G1JJ\,W2J<JE._C+M7MURXK)IES-4M::&E<+&O2=JB25>E=.5
M*HTG9_HR]H^:[;ER""*1->3-J-4_PL+[EF57XR:G\D[V:+YO0>%A?<LRJ_&3
M4_DG>S1?+-[+O)-/X6M]-E2=L'EJK\!A_H,  D4BT&S5X+%]W/&/XMZOY>M!
MK*FS5X+%]W/&/XMZOY>M!J6O?DC'?!+Z<#==G/EO1WPTOJJAOR)W]JDQ*G?V
MJ3%2U]_SETP #(            )7\#DT<OS 3\,9YYQ6-[=E*3,O&<T#=--F
MCN=^K;M0-TU7["AKZ9FUKY>STFRS:V&]9=QS9?"%<K'8:Y4F-*I&*V'%ELP[
MBACT1R,?+-;8[3.UJJFFVQ;3&LJ-W;4B.7RGJ2SL@Q2CCL12;MTF&NO?4ZD7
MP[(2F^XA7;?@W/1V'K)9TL2DWU1J0DN/;)07?8\2P 6'*PWN O?7X?1NX>?<
M 9CQ1A\&;SG@J&9S:S+3,?"<DB=+8L94]T@AW;24MZM<2OF7K1'U=),S?KN;
MQUU0VLFKN.?YX+[GG%A[/B^8*JIV0P9B8-JHZ-CWZ.J;WA*5]YIJ:)G6]UEG
MQ#5/5-^Q0KU<.@(WS%5]HV"='2U=M65:-.M'M4H[LG^W&2+B[+-(K$:&PUGG
M0<\/)9-Q<)-Q3_4E#+_<B #1B1
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MV)Z05/2&(P[?](H7@NN5'P[_ +$Y&PZ "O):
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M[XS5^DR\>IGDK1_Q6E]$  U\V8
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MJ(9<E30F*LW;S>;?'O+BI)*R5DLDEDDN278N0  ,@
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M4N-.<X2[XMK["_&!Q*K4:56.<:E.G43ZU.*E]I.""$3X':
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M]15*Z*4"JQ0<2<
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MM)/M3R9>>A6C4A"I"2E"I%3A*+NI1DKQ:?4UFNPF !P/J
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M][#P3\&N^]4PQ[Z\>_E5<3WL*?ZU^4L=\9J_29>/4SR5H_XK2^B  :^;,
M                                       04_@\T/WM8BX_\17?T?\
M%]0?WI_"YH?O9Q%_,5W^3Z@^V'_*4_?P^DCK8Q>Q5?@Y_19QV+1^Y*7^3P?V
M33(F/LW[DI?Y-#_9-,@76I>+%=27T44$K>//WTOG8 !]#YEI7K]8G_B9/ZCC
MKY<G1O\ YOL"+_\ @;A?Y#H4.0;7_:)OXJ3^HIU]N3G]SW GO-PO\B4)"FV1
M7IX%?IUOHP)\V%KV72/P>'^E4?V'[&U-._?L)B1.*^CZ"<@E?/F6,  ,@
M                                    &K5X5A]Q[+S\8;?D&Y&TJ:M7
MA6'W'LO/QAM^0;D;5J-Y7P7PO]R9I>T3R+I#X%?60-$5?H^(@17Z/B(%M5P1
M2I??\X !DR>R/,#_ 'U.7/\ %X@^1Z@Z7R<$.:#S _WU.7/\7B#Y'J#I?)P0
MKEM;\HTOBL/K*I:;8IY+K_'*GT($0 183$
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MP<G0DGQW$DZ4NNVYX-^N$N1<@ CXE
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M@)VKHI11=%])5!E_<7 )6KN)@8
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MPR:W9UE*O-9IJ563:7["@^K/@4VVFZ46*TQBG%[T*#CAH-<&J44I/]XZB\R
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MR'XN_P Y>QI\):QIUE[&G  NXT^ N&%%A=1)\(!5TWHG9O*["DG%?456[D4
MF8G7VFL%X5']QG _XP(OD>O-GYO!#6!\*C^XS@?\8$7R/7FUZD>5<#\8I_::
M=M#\BZ2^+5#0W !;7J[E\R*4]7XYL  &#:*\%5^[!F)[P*7Y:C-\7K]GSFAU
MX*K]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
M     04B0=P,,'YWFGEA8,9X>N^%<46NEO-@OU%-;;I;:R-LE/54D[5:YCFK
M]B]NY\4K%;+%*ULD3FR-:Y.9[SK?-F7[DVX]EMVE5<LO\03U55@;$<K%<LM(
MSZX^Q7:9K&Q-OMJ8Y(I516)<J5C;E!%&CIZ>GZ@:IJN_X%X'S!RPN27A'.O
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M-2U[\D8[X)?3@;KLY\MZ.^&E]54-^1._M4F)4[^U28J6OO\ G+I@ &0
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M*-G\G%,N_H#35'2&%I8JB_!J1SC?.$UE*$NIQE=?Z  'EGL@
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M.[(-;EB,/_)M>2Z?#QOA[V\/#>Y3YRI/)KW#C;Q6>A()$>G=%3X.HG(F)K
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MOZWT8$^["ORND?>8?Z50_8D^R7OV$Y(GV2]^PG((7!%BP #(
M                           !JU>%8?<>R\_&&WY!N1M*FK5X5A]Q[+S\
M8;?D&Y&U:C>5\%\+_<F:7M$\BZ0^!7UD#1%7Z/B($5^CXB!;5<$4J7W_ #@
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MSC*+X-/_ %L3  'T
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MCBY5>"@%9$U0G:NXIM7>3)N4 K-712L6Y68NX F
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M:'7@JOW8,Q/>!2_+49OB]?L^<J]M-\KUO@Z7T$6YV1>1:'PV(^FR( - )/
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MUDUFLBW6 Q]'$TH5J%2-2E-7A*+337V-<&GFGDR8$-4"*=8[A$
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M[5[N$O;0EU.+NL^J_!E'M.Z&JX#%UL)634Z4GG9VG!YQJ1ZXR6=UDG=<4T
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M^'TO05G&&+A%=/0OG=9.=.]MZFWFFK[M]V6?']F!#:3M0B:@;R
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MG@??UOHP)]V%?E=(^\P_TJA^Q)]DO?L)R1/LE[]A.00N"+%@ &0
M                              #5J\*P^X]EY^,-OR#<C:5-6KPK#[CV
M7GXPV_(-R-JU&\KX+X7^Y,TO:)Y%TA\"OK(&B*OT?$0(K]'Q$"VJX(I4OO\
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MJ.8]CE:Y%1454T,BBD$O)M/EQOR+&QDFDUFFKIKJ9$$-I"(,@
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M]' M]KK]6A61= +E5JZH3HNA1X+KU+W^ J@S+B7 *;'=14!@
M
M $CU )'.U)%70B4UWKIV RB"+IOZU*3E]O45'+J4.._LX ,.7J3UEJY=2H]W
M46[E!@HR.^@M'KU%5[O46KW %M*I92.XE>5Y8RN +65WT%@]Q<2.XEA*[< 6
MLK^_QF-E?W\Q<2O+"5W'V %E,[5="PD<7+UZ]?,6,CC#=D^Y_-]G$=Q;O7X>
MZ^KM7J-%?PA/E,+C#.F/!-#4)+9\LK3!;)6,7ZW+B:]14]UO4BJW=(E%2RVJ
MV)M:/IZREN<2:QR.:[=#Y0N=%MR[P1BK'%W>UEOPO9*^[RZ[UEDI('.IX&MV
MFJ]\\ZQP,C:JOD?(UD35>[0Y@V86.[ABB_WO$MVD=+=,07:X7FX2/<KW+67*
MJEJI]7NWOV7RJQ'*FKD:BJ3!LCT1OXBKC9*ZP\.BAU.K52WI+MC"Z??:_(A'
M;7ISH\)0P,))3Q-3IJJ5\J-/.$6_TIV:7/=O:R/X_0 %@?\ 3/KRM\EBLW^O
MSW^T  & ?87-_9$NS+SIRWP9T;GTUSQ)355QV&Z[%ILD<M]NSW)HJ;*4%NJ$
M\KR5<Y$UU5$7X]-I'P:+DW.J\0XYS8K8$6&T6^/!>'Y'M5=:RYOI[I?JB-'-
MT1T-'26VCCF8KEV:JX0JB(YR/U[6S2BP>C\56X2C2<(=LZW@QMVQ<E+]6YM&
MINB7C=)X.A[656$ZGZ-.C+?E?LG&-OUDN9N"4T#(VLCC8V..-K6,C8FC&,C3
M2-C$ZFM3R43J:B)U&3A;K[?U%I&GP]1DH&Z%092;;;S;+PJR5EE;@7D:&2A:
M64:</:92!G#OW[#!@O(TX%_"G?T%HQ.LR,+0"[C3@9")I:1MU+^- "YC+V-/
MB+6-OTEXQ.L N(TW_ 7")N3VE&/YRNBZJ 56\?03-XJI*W@I48FX&>7G7VDQ
MK!^%2?<8P/\ C A^1ZXV?FIO-8'PJ3[C&!_Q@0_(]<;3J3Y6P'QB'VFF;0O(
MND?BT_L-#, %M^KN7S(I4^7XYL  &#:*\%5^[!F)[P*7Y:C-\7K]GSFAUX*K
M]V#,3W@4ORU&;XO7[/G*O;3?*];X.E]!%N=D7D6A\-B/ILB #0"3P
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M[BYVIVJU/1.#AAXN,JLFJF(JI6Z2I;.WZ,?%BK\,^;(M4B :Z;8
M      ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/WT
M^=_OPC^0+*2QL?\ Z=B/BO\ B0(8VW>3<-\;C]54/,P %B"KP  ?#N:^5HP^
MOJX^A_C(Z,G@UWWJF&/?7CW\JKB>]AX)>#7K_P"BIACWUX^_*JXGO9M(4_UK
M\I8[XS5^DR\>IGDK1_Q6E]$B"&T@VD-?-F(@AM(-I "((;2#:0 B"&T@VD (
M@AM(-I "((;2#:0 B"&T@VD (@AM(05WK%P3 EVMY,
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M"%<MK?E&E\5A]95+3;%/)=?XY4^A B "+"8@
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MZZN#NFDU8F'5O3M/2."HXNG9=)%;\4[]'55ND@^=T_2FFFT3  \@]T
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M\9I?#MQ;I89O$U';+P%[&G[ZHX6YV3MP9L1MZNO=W\WL*I+IP7S$Q5<N(E8
M R9                                       !*Y/@)@ 6Y3ZU3M*A3
M<F]%!RB_ER*2IJ4G;T3V%PY-"CIQ3U@XEHJ:%I(G'S%](GPEK(GQ %@_B6,B
M<4])D'IN+)Z<0#&RM^ QDC3+R)O,?*S=N ,5*WZ#&S,,N]#'3-[^@ P\B<3&
M/;O7OPX?&9B5/C^,QD[=.'I]7?X@#\@SHRKMN-\)XDP==V,?;L2V:OLU4DC5
M>UC*ZFDA;,K$^S\7D<RH:CMVU$B-3>NO+DS&P'<,*8AQ!A>[Q/@NN&;Y=\/W
M*%Z:.CKK+<*BW5:+P14Z6F>K7-39>U6O8JL<U5ZM<C>OT?2GLU4T8_"'>2ZN
M$<WJ7']!!L6C,JWLJ*QS6Z1QXGLL4-#7ZKN:U]=;V4%4C43RYHJJ>55695)?
MV3:9Z/$UL+)V6(2G!<M^G?)=\&_.B$=M.@NEP=#&QC=X:7156EGT=6UI.RS4
M:B7FE<U_P 6!N5E   !L:^#D\J5<.9BX@RON=4D=HQ_0-NMDBE=LQPXML4:H
M^.%O7)>K(^6.77:>^:T6V&%K4?+MZY1_<Y89CW7!V([#BNQR=%=\.76BO%O=
MM*QKJFAG9,V&1S=Z0U#6NIYM-_0RO1NBZ'C:Q:*CC<%B,.TFZE-[G94CX5-]
MEI<^T]_5;3,M'X_#8I-J-.HM]+G3D[55;G>+=EUG56:Y?0O7YNM$7U*FG%%3
M?KU)>QN/P/DW9YVG,O F%,>V23;MN*;-272%OD[=--(CHZ^AG1-S*FWW&*KH
M:F+?T4]-)'KHF[]VC7X"GM>A*G.=.:M*$I1DGRE%[LDUV/)]I>.A7A5ITZD&
MI0J1C.+6::DMY9\'=-/+*S,I XR<;S#,=P7L[H9")VX^1]C.0N,@Q>!A8G=_
M,9.-^X RL3C)1N,*QWP&2B> 95C]Y>L7X?C,7$OP%Y$_4 R<;BZ13',=\!>L
M=[ "]8[K*J+IN]A:-7>7*;T\Z< "NB]1.U>KL***5>K7K *B*5FNU*"+J3(N
M@!7!!%(@
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MRZFN*+B-N]/09*)-VA:1LU7X/5V>PR,:=9!Q80O(6]_092)-Q8Q-[^@R<:<
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M5M"JM2>!(G122V<U.UWH:3@J<FJ6+BO"HWRG[J=%OBN?1\8*_%+>*D:\;/\
M$:)J2J0C*M@Y/V.LEG36=J=9+*,EE[(_!J96\*Z/CL#3OW54^%?2#>_]O1\I
M'@   [_']*[_ +).I4(.:BHJ*B*B\==^OF=KKM)O7<[7BI$#\9.WX?6_D,9]
MG;=7OV6X>?,^QN3MSA&=N4[V+E]F7BBP4S71N6UNJHKQ8Y$CUV626*^P7.TN
M;LJYFTVC;(QCW]%)&Y4>GNYD'X5+F7:FT]+F-@##&+8F*UDMVPY4U.&;FZ)J
M(G2.MU0ZZ6^IJI5T5[H)[93(Y?)@C;Y)JN@U_2>JVC\7^7PE&4GQJ1CT=1_K
MPM)V[9-=AL^B=<=)8*RP^,K1@N%.<ND@NQ0FI12[HI]IT$<J/">^3[>F1MQ'
M08UP;4/<UJMK+,V[TL:+]DY]7::B?1&KNT; ]=W!--#[UP7SU?)9ONQXMG7@
MZA5Z(JMQ#45N&.C56.>K9),14EK@;LHU6J_I5CVMEK7*KV([E\CX-."IN5/0
MJ</4:9BMDFCIN].KB:2]S&<))=V]!RMWMOM-[P>VG2=-)5:6%K?I2A.,N_P9
MJ-^Z-NPZSF%^7OD9?-CW&SGRHNVVKT9[F9BX/KMM8M.E1OBUXEVEBU3I$356
M:IM:'Z9;.4/@*N29U#CC!]8V!J.G=2XFLM0D+5X.F6&M>D353545^RBZ;E.0
MD^%CM[F-<OG:B\.'%"@ZWTZZ:P0KIPUB8NGM:>4]CE+ECJENIT(OY>D5_0CV
MH;=*WMM'4^]8B7FRZ+[?0=="OY7>5%)"ZHJ\S\O*:FC:CGSU&-<-0PL1=$:K
MI9;FUC45531RN1%541%WGX=B?G4N33:$D6LSYRF5\+G,EI[?CS#=WJV/8J(]
MCJ*TW"MK$>U=RLZ#:3BJ:(NG*C;1PIO2*-%[48U/7N3CY^)<HFG!$3T(B'.E
ML<PZ?AXVM)=4*4(/TN4_F.%;;IB&O P%&+ZY5IS5^Y0IO_N.DUF-X0GR5[ U
MRP8^K,2R-U18L-X:OU8JNU<FRR:MHK?32:[.J/CG?&J.14>N_3S8SE\*XP?2
M1RQX!RPO]]G35(JK$ESH['0/5?L$<RC9=*YKD^R5CH$5R*B,55VE;I&=]V[X
M?B[.H?1IZNSOZ#VL'LIT73LY^J*W6JE5*+\U.--_+W6->Q^V/2]5-4WA\.N7
M1T=Z2\]6I47R=]SW3Y0_A%/*7QPDU+9\06?+>UR+(Q:?!=II_=-\,B*B1SXA
MOGNM6LE9KY%59662;7393:35?%_'^8^(L5W"2[8IOUYQ)=)7.<^XWZYUEVK7
M.>J*YWC-?-/*BN5$5=ER(J^L_C._?Z ;OH_0F$PBMA\/2I=L81C+]NSFWWLC
M[26GL;C'?%8JM6Y[LYRE!=JA=07F2'J[^CAN^+=PT0 'IV[_ #N[7<>3G_LK
M#S]GJ^+U\-^]4X;C<:\&,YP9L/NCR>\3W%.C66MQ%ENZJE:U(TE5:G$.&:7:
MT396IZ>_T5-]M=+/>GPH^%NQ3:<I_:Y;9CWO!^(;)BS#5?-:\0X;NE'>;-<(
M7:24M?0RMFA<J<)(9-E8:JG?K%54LDU+,U\,KV+X&LV@X:1P53#22WY*]*;]
MI56<'?ESB^N+:YFQZI:?J:+QU+%P<G&+W*T%PG1G93BU?-Y)PZI)/E8[#2$3
MXVY!?+ LV>F5^%\Q;-T<#KO1)'>K6R1)76:_TND%VM;W;2NV:>K21:=STVY:
M5T$KME7JT^R2HN(P\Z,YTJD=V=.4H3C[F479KS-%W<)BJ=>E3K4I*=.I",X2
M7.,E=/T  'Q.P            2/[^8I*W7OZ/AW;E]FXKJU!H8MY^?=W!^CJ
M?-?A'@3ST/,W6S/VSS8TP9#2VS-RQ6]644SE2"BQA;Z9'21V*\/3R8ZIBND2
MT7-S5=2RR+3SJ^BFD:SGGXWP/>L,WBXX?Q':KA8K]:*J6BNMGNM+)17"WU4.
MRCX*FFF1LC')JCV/1%CFB?'-$]\,D<C^Q%HB;OU\>_I/%7G7N9MPARC;;[N6
MV2EPGFE;*58;5BI*57TMX@B3:CLN*((%CDK*+^!17!O25UI<]\E.D].LM'/*
MVHNT)X+=P>,DY863]CF_"E0[.MT[YV6<>,4U=$-;1-FJQV]C,!",<9&[J4[J
M$<0K-[R]JJO+DI\&T\SFO _<.43R;\;948JN&#,?V&JP_?[>]VU!.FW2UM.C
MW,CN%JK6)XO<;;4(B/@JZ=SFJB[,G1RH^)GX>6'P]:-6$9TY*<)14HRBTTT^
M#35TT^M-HK#7H3I3E3J0E"I"6[.$DXRB^&:=FO.  <[GR []_1Q3SIOW;@#-
MO]T[/TF&O]FK^?L?:?T6$\7W:P7""[V&ZW&R76F5KJ>Y6BNJ;;7PJUR.;T=9
M1R0U#4:YK7:=)IJUNNNA[=<F+PBCE'9?MIJ*^WFV9H62!6,2DQG2,CO;8(VK
M]9I\56IE)<)9'N\I]7?8,0U'\%KV)L(WPC'?Y_CW^D\O2.A<)BX[N)P]*LN3
MG",IKNJ-;Z_5::Y,]C1>GL9@I;V%Q-6B^+4)RC"7OH)[LO.K/FC>SR.\*@RK
MND<46/L$8LPC5:-Z:>U)38DMVVO%8EC?0U_1,_A224C=$WHU5U1/4G+?GM>2
MSB9D7BV<N$[1+*QKG0XJGJ<)] Y4UZ.>JQ#3V^@1S>"NCK)(]==EZH<P/]??
MX_3O(JNO'OZ.ST(:)C=D^C:CO2GB*'.T)J<?14C)V_6X(D?1^V?2E)*-6&'Q
M"5LYTY0GVYTYQC_V=N9URL%<K+*[$D;9L.YDX OT+F[39;-C##MSC5J(Q5<C
MZ&Y3M5J))&Y51=-'LW^4W7]L2_T7_+*3_M,/7_[_ &:?&<;^2BA?]G#$_P#R
MHV.[>U%[5+7W$HO^1TO_ &>+_P !X538W#VN/DO?8=-^E5HKY#8J6W6=O#T=
M%OKAB'%>ATG\YV/+EC2ST<?35=UMM+"CFM66IKZ2"-'.71K>DEF8S:<NYJ:Z
MKU(I\R8^YP3(G"RJF(LYLK+-+Y6S3U^/<+05DJQZ;;8*)US\;G>W7RHX(9)$
MW>3V<F!EGI&[VTM,U>U((D7VHPO8XF,^P:UG5Y+4;\2)WU[3-+8W3NM_'S:_
M1P\8OTRJSMZ#A6VZ5+>QZ.@GUSQ$I)>:-*-_VN!THLU_"$.2UAEDJ4^/I\5U
M$:JWQ;"=BNUR1S]G5J1UM12T-NF8[<G24]7,Q-=ZZHJ)Y%\H'PK:)(YJ;*[*
M^26;21D=VQM<VPP,<GVJ>.T6?I)ZIFGV=/-<*%Z?_34T--4&QX#9;HNBTZD:
MN):SM5GNPR_1IJ%_UFT[6M8U726U_2]=.-*5#"IW5Z-)N>?Z56<[9<-U1Z[\
M+>D/*?YW+E"YN^-4V*\QKI262J<[_P E\*,BPOA^.)ZHOBZQ6ML=SN<#535B
MWRZ7>5NJHD^SY*>;R<55.+G*YRKO5SEU57.UUVG*JJJJN]RJNNNX WW!8"AA
MH='0HTZ4/<PA&*\^[%;S[7F1SC])8C%3W\17JU9<I3G*3[;;SENKCDLAW[_.
MJ[UXKJH .V=(  PV  G=?T'KES8'-!8]Y2%SAN#%FPIEI1UCHKUC:II5E6J\
M6>K:NV87I95CCN=SVVNI)*I9%MUKFZ62J\9J*1]LJ>CI/25#"49UL15C2IQ]
ML\^[=7MI/E#B^H]+1>B<1C:T,/AZ4JM6>2@N76Y/@HJ_A-Y),_%>;BYN?&?*
M/QNS#>'HIK?AVV+#4XQQ?-3/?;</6Z1^C(6O79BJKW<$:]EJM;9.FFZ.>L>U
M*&CJI8^E=R3>2=@G);!-JP%@.UMMMGMC'/GF>[IKE=[E/Y==>;Q6.3I:VY5T
MJ+)+([2&*-(J.BAIJ"GI:6'(<F3DP8*R@PE;,$8"LT%FL5M;KL,^N5==4N8Q
MDUQNE6YJS5]QJ5:U9ZJ=VVY-EK=F...-/HC93L*R:Y:YUM)U=V*Z+"P=Z=&_
MC2X=+5MQG)<%FH<N=[9ZB:A4=$T5*>[5QE2*56K;*$>*HT_T(OC+)SYY62@U
MJ)V]GS_.3D$0B:0B0P #(               !!>KOU*1(+U=^I0"'5ZOF.7)
MSS/WT^=_OPC^0+*=1OJ]7S'+DYYG[Z?._P!^$?R!926-C_\ 3L1\5_Q($,;;
MO)N&^-Q^JJ'F8 "Q!5X$4]"[]R:=O'3SKLH[1$3J]2P!BU_2OD:'^OI:MZ#=
M%YD;G9\A,H.3_8L$9@8V]P\2T6(,6UU3;TLE^K^CIKI?JRNHI?&;?;:FE<DU
M-,R1$9,KF:[+T:Y%0];OJ@/DH?A,7_-?%?\ L4YIGK7VJ/6OM4CC2.S# XFO
M5Q$ZV)C.M4E4DH.GNIR=[*\&[><E;1FUW2.%P]'#0HX64*%.-.,IQJ.345:[
MM42OW)'2S^J!.2A^$Q?\U\5_[%(?5 ?)/_"8O^:^*]__ -93FF^M?:H]:^U3
MI>M%H_\ /XKTTOX#O>O;I/\ ,8/]BK_FG2R^J ^2?^$Q?\U\5[O_ *RCZH#Y
M)_X3%_S7Q7_L4YIOK7VJ/6OM4>M%H_\ /XKTTOX!Z]ND_P Q@_V*O^:=++ZH
M#Y)_X3%_S7Q7_L7U? /J@/DG_A,7_-?%?^Q3FF^M?:H]:^U1ZT6C_P _BO32
M_@'KVZ3_ #&#_8J_YITLOJ@/DG_A,7_-?%?^Q2/U0)R4/PF+_FOBO_8IS3/6
MOM4>M?:H]:+1_P"?Q7II?P#U[=)_F,'^Q5_S3I9_5 G)0_"8O^:^*_\ 8H^J
M ^2A^$Q?\U\5_P"Q3FF>M?:H]:^U1ZT6C_S^*]-+^ >O;I/\Q@_V*O\ FG2R
M^J ^2?\ A,7_ #7Q7O\ _K*/J@/DG_A,7_-?%>[_ .LIS3?6OM4>M?:H]:+1
M_P"?Q7II?P#U[=)_F,'^Q5_S3I9?5 ?)/_"8O^:^*_\ 8H^J ^2?^$Q?\U\5
M_P"Q?4<TWUK[5'K7VJ/6BT?^?Q7II?P#U[=)_F,'^Q5_S3I9?5 ?)/\ PF+_
M )KXK_V*07P@3DH)_P#1-77L_8QBOA_0QS3O6OM4>WVJ'LBT=^?Q3X>VI+O_
M *M_8/7LTG_9\'^Q5X\OZWO.OODEG3AS,3"UCQIA&N6Z8<Q%11W"TUZTU12+
M4TDBN:R;Q>LB@J8D<K%T26)JZ(BZ:*BGZR>7G,M;^2WDLO7^PRA_KS)\1ZAD
M Z2PT:.(KT8W<:5:I33?%J$W%7M;JZBRNBL5*OAL/6DDI5:-.I)1X;TXJ3MY
MV  =([X               /X7-#][.(OYBN_R?4']T?PN:'[V<1?S%=_D^H/
MMA_RE/W\?I(Z^+_)5?@Y_19QV;-^Y*7^30_V33(&/LW[DI?Y-#_9-,@76I>*
MNY?,B@=7QY>^E\[  /H?,M*_[1-_%2?U%.OMR<_N>X$]YN%_D2A.037_ &B;
M^*D_J*=?;DY_<]P)[S<+_(E"0KMC_)X'W];Z,"?=A7Y72/O,/]*H?L2?9+W[
M"<D3[)>_83D$+@BQ8 !D
MU:O"L/N/9>?C#;\@W(VE35J\*P^X]EY^,-OR#<C:M1O*^"^%_N3-+VB>1=(?
M KZR!HBK]'Q$"*_1\1 MJN"*5+[_ )P #)D]D>8'^^IRY_B\0?(]0=+Y."'-
M!Y@?[ZG+G^+Q!\CU!TODX(5RVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
M                       !^>9N_O4Q/[W[S\G5)^AGYYF[^]3$_O?O/R=4
MGTH^/'WT?G1\<1^3G[R7T6<?>H^V2_QLO]HXI%6H^V2_QLO]HXI%V:?BH_/^
M?C2]\P #F<2TK_M$W\5)_44Z_?)^_>'@?WH8;^1:(Y E?]HF_BI/ZBG7[Y/W
M[P\#^]##?R+1$)[9/$T?[[%?-0+ ;"?&TGW87_&/V  $%EB
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MJ&,>ZKW:IXB*2@^SI%:#[=SJ-[8%!J]JK^DJM77>5O[&OQYLD6JO]W-<.\F
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M#LWU2_DK!>RJV+Q.[5K\]S+P*2?5!-WMEO-D0 :,2(
M                           47IO*;N!7?P*0"915=40I.XHI61.*%-R
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M47V$Z+IZ.H'*W^Q68N\K%N3-=H#B5@
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M?R]:#4M>_)&.^"7TX&Z[.?+>COAI?55#?D3O[5)B5._M4F*EK[_G+I@ &0
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MV$":1T9B,)4=+$T:E"I')QJ1S[U;*2[8MJW,F [[]WP*#N'0
M     'XR  (/<C4555$1$55<JIHB)O55771-.WJ,-K@G?KR>7??GW,S9^Y:\
MZ:?=8B%73?Y]$XKO541$W;U555$1$WJJHB;U0]+>1+S2^=>>\M+4X6PQ-:,+
M3[$BXUQ/'46K#SJ9ZM5)[<^2)U7>VJQ5=&ZTP3T\FPYOC+9&JB;GG-[<P)E+
MDNM%B#$J?W3L?PJDR7N^T4,5AM$^BM1F',-JZIAI]AJHUU?=*FZ7&27I98)J
M"FG;0PZ7K#KY@-'QE%U%7KK)8>EG)2Y;\K.--)\;O?ZHF]ZL[.M(Z3<91INA
MAV\\36\%)<'T<,I596>5EN=<T['P-X,KR;L]<%1XJON)[5+AW*3%]N@J[7:;
M^LU+>Z_$U++31TN(+/9E8CZ"UU-J=54=PJZ]M))<UIK5)1TTL%/XPNW 46MW
MIKQ_7YN&_AU=7FK%:].Z9EC\55Q4Z4*4JC7@4U:-HI)9^V=DDY<6UR+8:MZ"
MAHW!T<)3J5*L::?AU7>3<G>5O<QWKN,<]V]KNP !Y![@              !2
MXZ\>/L[_  !6[N'LU^(J@,'Q?RT^0;EOGYA=V&LP;%'6+!M36:^TNS3XAP]6
M.31:FT71&NFA1^YM51R=)0UK&HRJIY=B-T>@ASD7,J9IY U=9=Z>BJ\<9:H]
M7TN,K/2++/;(U5=FFQ5:X5DJ;5/&U$9[IQ,EL]2B,7QNEJ)&T4?2_+2NI(JB
M*2">*.>":-\4T,T;98I8I&JR2*2-Z*R2-[55KV.:YKFJJ.313;M6==,7HR5H
M-U<.WX6'FWNJ_%TW[1\W9-/G%NS-%UMU P6EH[TUT.)2M'$TXK?:7"-19=)%
M<KYKE)(XW+51=--%1>&SHJ+NU\G3=IIO31$\G?IQ(G0%YP/P</+;,N2LQ+EA
M5Q97XPF=)45%!3TK:G!%[ED\N3QJTQ=%462LEET=[HVF1:?5TKZJSULCVR0Z
M:?+ YN_-[(RMF@S"PC74%K;.V&EQ30L=<<*URR.1L/0WFG:L%-+,]>CBI+@E
M'5O>CFQPO1$<MA= :ZX#2$8JG55.NUX5"J]R=^:C?*:YIP;R\91>167674'2
M.BY-UJ?2T+^#B:*<Z5N6];PJ<NM3LO<RES^)@/9U]>[=QW\ ;;R[?1\CS7GX
M\LC2_N_'X^<                   $NTGDIQ5SFL:WK>][D:QC4357/>Y4:
MQK45SE5$:U55$#M_KP2\_P"$<HQ;X*_8GG]OW]A'4RUBL5==*VFMMKHJVY7*
MNE93T5NMM--6U]9/(Y&LAI*2F;)/43/<J(QD;'+M*B[M-3VUY#7,"YW9OK17
M:^T2Y8X/J%CE=>,4T<R7RKI7;+NDM>&'.@K7/DC5>C=<GVR)%:BN5S'-VMU3
MD'\T_E!R?:.-<(V1USQ.^-&5^-\1+#<,2UKU8C)$AF;#%36FD>B+LT%HIZ.E
M:CG*]DLLDTLD?:Q[1L%@5*%*2Q.(5TJ=)WA%_IS2W5;FHN4ES2XDD:K;+](:
M0<:E6+PF&=GTE56G)=5.G???OFHQZFV:Y_-@^#<W"Y/MV-N4/3NMUN^MUE#E
ME35&S<:I-(Y8/V75M+)I0P/U7IK#1RK5(W9BKJFGD6:DAW.L&8.M.'[5;[)8
MK90V:SVJDAH;;:K920T-OH**GC2*"DI*2G9'#!!#&UK(XXV,:UJ(B(A_0HS3
M]"?!Z$^+SE9J[BONGM9<5I*KTF(G>*ON4HW5*G[V/NG[:3NWS99G5O5/!:+I
M='A:5I.W25YVE6JOCX4[7W5[6*M&/)7S)--/@[\"H >$;*
M       ""]7?J4B07J[]2@$.KU?,<N3GF?OI\[_?A'\@64ZC?5ZOF.7)SS/W
MT^=_OPC^0+*2QL?_ *=B/BO^) AC;=Y-PWQN/U50\S  6(*O
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M"0KMC_)X'W];Z,"?=A7Y72/O,/\ 2J'[$GV2]^PG)$^R7OV$Y!"X(L6  9
M                                      -6KPK#[CV7GXPV_(-R-I4U
M:O"L/N/9>?C#;\@W(VK4;RO@OA?[DS2]HGD72'P*^L@:(J_1\1 BOT?$0+:K
M@BE2^_YP #)D]D>8'^^IRY_B\0?(]0=+Y."'-!Y@?[ZG+G^+Q!\CU!TODX(5
MRVM^4:7Q6'UE4M-L4\EU_CE3Z$"( (L)B
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MLM3]&:B]9."NLG>3EDKW=EDLW?)<K<$N2+2PCNI1NWNI)-N[LDEF^;=KM\V
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MLZ>'OV/*=5<IK*.:C?BX-1=.SOW[->S30J-UZR8$7DP
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MJ
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M)63]XENI<%=OF4KUZUE>E,?5KQ;Z&F^CH)\%265[<+U))RD^-E%/@  ;4::
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M3CNSLI)Q23X.2^4G3470%71FCX82O*$ZD*E6=Z>]NVG-N/C)/)9$P -9-Q
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MDB"1Z:+KP^C3OZ5)]GAYB8&JV-R(:;@B$09
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MFVW6?,S ]S8FUT<=707JW3.T:]6[2HRJA9M.2-BKMJC5<KOL6GSW>_!D>4G
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MS!:.AT>$H0I)^-*UZD[>[J.\I>=V)=-Y%$(@\BQ[@ !D
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M$VNGG0')YY\.PK-=H544H:A%!Q+@$J.)@
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M"(                               (;*#0B  2JU%)@ 05"(
M                           (:$0 0V4&RA$ $-!HA$ $$1.'4-"( (:$
M-E.SOP]7I)@8L"&R@V4(@R"&R@T(@ AHA$
M         $$30B ""H1  (:(-"( (:!$(@ AH@1J=U]1$&+ @J$%:BDP,@AH
MA$  AH@1J$0                                  0T"(1
M                        !#0B                             ""(
M1                                              !!4"(1
M!#0B $@                                   $@     +
M                        $--^I$  @J:D08L"&R@V4[._'XR(,@EV$&PG
M'3>3 "Y#0:$08LNH$NPG8-E"8&1<ALIV)["&PA,#%@01"(!D$$30B
M                   "&A$ $- J:\2( (:#93L(@ AH$:B=^PB "&A#93AH
MFG9Z>/MZ^TF L"&B!$(@PU?B@0V4(@&0
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M7]I11VG$G 2+C4%!%*K7:@P3
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MIGQ%)B=97TW(G: 3M[>TJ\$])*B=1.G'T RB9J:(5&)O)2JQ-P,$X
M
M
M
M
M
M
M
M
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M279ZN^A51.H F;N15]1.U/A)535=$X(5 9N10KE-B=94!@
M
M
M
M
M
M
M
M
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MJ"EMJ2ZJ 5R&J%  %57D-LID%5 ";:4@2*_L&_T Y;K)]217DN[MU\PV^Q-
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MY8WV%)B%QYD]8!%O:56KHBD&IU$Z[UTZD!E*Y,U"=$(%1C>L&"H
M
M
M
M
M
M
M
M
M                                                   47(5B5R:@
M%!4U0IIO30JDCDZP<HJY1<FI35-=_7UE=W:4G;EU[>(.):.0MWM+U[?T%NJ
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M
M
M
M
M
M
M
M
M
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M:>PCJWL+1%([2@%WJG4NGJ(;7G^#]!;;2DVWY@"Y_P#>3X"&_M0M^D\PZ3S
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MI,U.L&5UDR)H3M3524K-3<#!,          0U (@               AJ1
M               !#4 B   "&I$7                      !#4B  -0
M!J  "&H!$                :@ #4
M                                               #4  $-2(  &H
M!#4B              !J     "&H!$             :@     AJ 1
M                               &H  U               (:@$00U(@
M              AJ 1    &H                    (:@$00U0B  "&H!$
M$-2(
M
M
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MX^U]_P",[<D51UWVB8G2TG3@Y4,'%^!1CDZG+?KN]I99QAXL6^;28 !O9'0
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M.NX CL]7M*B)U$&IH5.&[K4&5;F1TUW=2%0@U-"9$U ;^0F8G652")HA$&
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M+&$E9O)9R=^LE+9=KICM*U<9#%RIR5"%&4.CI*GG4<U)/-MVW4?48 (L)C
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M)::**-8-1<?H^]2=-5:"O[-1O**7Z<7:</UENWX29,VK.T;1VD[0A4="N_\
MT]9*,NZ$U>%3S2WN'@H]2]")3237J]I,CO4:;<WVY,""*1,@      $FG;WW
M:$Y!4U,,PSSSYP_G&L'\FVP8>Q)C*VWNYT>([X^P4<=CA@GGCJV6VJN:OF;/
M-"U(5AHI4VFN5W2*UNFBZGD]]5.Y&_XIY@_T?;OSX_.O"PDTRKRI3_\ 274?
MDC?S1B)KU&U%P&/T?#$8B-5U)5*L7N5'!)1EEDEQZV0%M"VB:2T;I*>%PLJ*
MI1I4I+?I*;WI1N\VUEV<C?B^JG<C?\4\P?Z/MWY\/JIW(W_%/,'^C[=^?&@Z
M#</6LT3[BO\ OY?<:/Z\6F_=X;]POO-^+ZJ=R-_Q3S!_H^W?GP^JG<C?\4\P
M?Z/MWY\:#H'K6:)]Q7_?R^X>O%IOW>&_<+[S?B^JG<C?\4\P?Z/MWY\/JIW(
MW_%/,'^C[=^?&@Z!ZUFB?<5_W\ON'KQ:;]WAOW"^\WXOJIW(W_%/,'^C[=^?
M#ZJ=R-_Q3S!_H^W?GQH.@>M9HGW%?]_+[AZ\6F_=X;]POO-^+ZJ=R-_Q3S!_
MH^W?GP^JG<C?\4\P?Z/MWY\:#H'K6:)]Q7_?R^X>O%IOW>&_<+[S?B^JG<C?
M\4\P?Z/MWY\/JIW(W_%/,'^C[=^?&@Z!ZUFB?<5_W\ON'KQ:;]WAOW"^\WXO
MJIW(W_%/,'^C[=^?#ZJ<R-7_ .=/,'^C[=^?F@Z!ZUFB?<5_W[^X>O%IOW>&
M_<)_WE\Z.FAS?_/,Y=<HO%5UPCA"RXGMM?:;*Z^U$UZIJ2&F=2MJX*/HHW05
M,SEE62H:Y/)1J-:[5==$7U^;\YH0^"OZ?W;L;;O_ *'4WRY;?TF^\G7WZD(2
MUWT-1P&D*F&PZDJ<84I+>EO.\X*3N[+FRP&S[3N(TEHREBL2X.K.I6B]R*@K
M0J.*\%-VR763  U(W8      QEVN3:2EJ:MZ.<RE@FJ'M;IM.;#&Z1S6ZZ)M
M*UJHFN[4UGJ;PJ'(R2-DK<*9@[,C&O:BT%NUT>U')N\?XZ*;)F-O^)KO_-=?
M_JLQQQK/^Y*7^30?V;23MG6JF$TGZK>*4WT'0*&Y-P_*=-O7LG?\G'J[R(]J
M.N.-T3ZC]22IQZ?IM_I*:J?D^CM:\E;QWU]QOY_53N1O^*>8/]'V[\^'U4[D
M;_BGF#_1]N_/C0=!)GK6:)]Q7_?R^XB7UXM-^[PW[A?>;\7U4[D;_BGF#_1]
MN_/A]5.Y&_XIY@_T?;OSXT'0/6LT3[BO^_E]P]>+3?N\-^X7WF_%]5.Y&_XI
MY@_T?;OSX?53N1O^*>8/]'V[\^-!T#UK-$^XK_OY?</7BTW[O#?N%]YOQ?53
MN1O^*>8/]'V[\^'U4[D;_BGF#_1]N_/C0= ]:S1/N*_[^7W#UXM-^[PW[A?>
M;\7U4[D;_BGF#_1]N_/A]5.Y&_XIY@_T?;OSXT'0/6LT3[BO^_E]P]>+3?N\
M-^X7WF_%]5.Y&_XIY@_T?;OSX^C>21S_ -E1G+F)AS+;#N'L8T5YQ+)<(Z.I
MNE'1Q4,2V^UUEVE6>2*LDD:CH*&1K-ECE61S&KHU55.<@>O',-??991_RO%'
MY%XA/,TULUT71P>)K0C64Z5"K4@Y57);T(.2NK9YH];0.U72^)QN$P]65#HZ
MV(HTI[M%1ENSJ1B[.^63.FFUJ>TJDBKN]&A%O KNOQ\I: F !D
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MK#4+]%2FHPWI.3LX1EQ?'-LL=J9I:KCM&83%UW%U:T)2GNQW8W52<5:/+)(
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M
M
M
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M:SY#Q7O\/]?3-54 %I2GY2G^UR?Y#_ZJG6RY$/W',K?>#A3Y$HSDFS_:Y/\
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M;?-2#P33]YN<WOKPQ\AU9MOE3-?/*^-^$A]53+G;-/(>C_@I?6U  #43>@
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M;$? 5?JY')QI_M<?^0W^JA6*-/\ :X_\AO\ 50K%TEP104&XCX);^[<\OXG
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MYYO/F\_LX=R+I15E;JY=0 !R,@
M
M
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MV7(A^XYE;[P<*?(E&0YME_(8#X2M]"F3SL*_+Z2]Y0^G5/J, $!%CP
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M4)=GSK[1L^=?:3 6[?F^X$NSYU]I#9\Z^W]!.!;M^;[@2[/G7V_H)53Y^)4
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M?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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MYB=)XE8?#1O:W25'XE&+\:4W]%*[D^'-KR=YO;F0\X,^DI;ZZC_8'E],J/\
MV88BI9$END2.<V1,,V/I(:ZZ;V*Q+C+XI9V.^U55;+%+3&X'R6_!_P#DXY<P
MP37/",69-Z8UJ2W/,"."]T;Y$T57PX=DC;8(VN5$722@J7,77HWM1SD/:R@H
MHJ>*.G@CC@@@C9%!!"QL<444;49''%&Q$9'&QB(UC&(C6M31$1-"^*YZ?U_Q
M^.E)*IZFHWRI4'N9<M^:M*3MQS4>J/,M)JWLST;H^,7*E'%8A+PJV(2J6?53
M@[PA%<LG+KER/YO#>%+99Z2GH+1;:"UT%)$D-+16VCIJ*DIH6Z[,5/34T<4,
M,;=5T9&QK4U71$U/Z+OH3 TB3;;<G>_&^?SW?RDA1@HJT4HKDDK)>;@2IZ-"
MA/ V1-E[&O;V/:UR>Q=2Y!A*W#+N,M)JSS7:><7*-YIOD]9HMJY,49789BNM
M6C^DQ'AZWPX;Q$LK]5Z>2ZV6.CFKI6ZKL^Z/CL;5551BNT-8KER># XKL$%;
M?\CK\N,:*)))UP3B&:DM^(DC;M/6.S7I[Z:UW.1K=EL=)<EMDDB(]4KI971T
M[MY(D<FO=/G1?1U=9M.A]<=(X%KHL3.=.ZO1K2=6DUU;LLXKWCB^TU'3FHNC
M,>GTN&A"I;*O02I54^3<HJTNU34EV7L<Q[FM.;@O^;&?U!@#%N'KI:+/@N1V
M(,S*"\T%1;ZFAM5MJ6PPV6KIJN.-Z55^NG0VZ*E>U'RT27.L9%)3V^I1O34H
M*&&D@AIJ:&."GIH8Z>"&)J,CA@B:D<44;6IHUD;&HUK4T1&HB)P,?2X;H(:V
MJN4-%217"LBIX*RNCIXF5=7#1]+XK%4U+6MFGCIEGF\79(YR1))(C%3I':Y]
MO!#.M>M=72M6G4G&-.%*&["G%N45)YU)-Y7E-]BLDER/GJ5J;1T-1J4X2=6I
M5J;]2JXJ,I12M3A:[M&"X9YMN7,E3C\/K12< U8W,
M
M
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MJ<7G"2>3BT5;TQH;%8"LZ&*HRHU%=V?BRC?*4)\))]:_T40 >B>8[<@  8
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MVJKY>O!S!SI\<R']ZEDM[VJKY>O!$6V#^AX7XS_A5":]AO\ 3\;\47UU(]6
M 5\+. @JD2FY41?5\^[]1ANW$$ZKZSSLYU_-6EP;R=LV[U4U"4Z_L.N5MI-=
MG:GK[O'[FT=+&CTV%EJ)JEL3$<J:J[>K=RGW;BG%ELL=NK;O>;A0VFTVZGDJ
MKA<[G5P4%OH:6%NU+45=74OCIZ>"-J:OEED8QJ;]414UT&>?IYW6VYUU]#EE
MEO6/J<N,.7!;G>+VQLD;<88@IT=#1I2M<C7+8;*U\LL'2QZW"XSQ5B,CCM])
M)-M>IV@:N/QE%0B^BISC5JU/:QA3DI-;W#>E9)+CG>UC2M>=9J&CL#6<YQZ>
MK3E3H4FUO2G.+CO./%0BFY.?#*R>9K<QMV6M;V-1/8FA. 6V?%VZ_P#7Y+E*
MHO)?;Q7^_%=C0_3\":KYN&_>="/P9')6HPSR=)L1UD2QS9A8XOV(J/;9T<GN
M/;H;?A:A1=6HYT4U38KC7TSUU;+35T<L>K'HJZ*?)AY/5]S8S PIEUAN)\EV
MQ5=H:")[$U2CI&,DJKI<Y>+4@M=LIZNNF<Y-E(X5UXHB]7_(O*"T8 P=A?!-
MAA2"SX5L=ML5OC1$;I36RECIF.=IN5TO1K(]>*N>Y57554AW:YI:,,/2P<7>
MI6DJLTGXM.FWNIKKE/A[PG+8IH253%5L=)>QT(.E3;7&I52<K/\ 1@DG[_L9
M^LH1 (!+,         $KNKTH:+?A7GW4LJ/>%>/RB-Z1W5Z4-%OPKS[J65'O
M"O'Y1&][-O+&&][7^HJ$;[6?(>*]_A_KZ9JJ@ M*4_*4_P!KD_R'_P!53K9<
MB'[CF5OO!PI\B49R39_M<G^0_P#JJ=;+D0_<<RM]X.%/D2C(<VR_D,!\)6^A
M3)YV%?E])>\H?3JGU& " BQX      (*1 !\K\MGE&TF4N5..LPJMS4_8SA^
MOK:-CMC6>YNC6"UTS$>J->^HKY:>-L:K]<5VQ_".3=?[_676OK[K<973W"Z5
MU7<;A4/57/GKJVHDJ:R9SG:N5TE3+*JZN557>JN^S7>E\*CSW?9,I<"Y?TTZ
MQSX^QC+<:^).%18<%4C*VHB73[%4O]VPS.U>"M@D9LKJJMT0^_F+%;)-%JE@
M:F*:M+$U+)_\.D]U)?\ ,Z2_7NIE6]M.F.ETA2PB?@X6FFTGDJE5*;;_ .7T
M=N]]X !*R_'V_(0W^._J7I/U#)/)G$.8N+L.X&PG2-K<1XINE/:+5!(]\4#9
MIU59*NLF8R1\%!00,EK:^=D<LD5)3S2113/:V-W5&Y$?(^PSD;EU8,O<,1-=
M!:Z9C[I='1-BJ[_?)F,==+U6HS5K9JZI1\C(4<Z.F@Z*FB^MPM5=4WP6#DE4
M]TO>.\Y[G3-E9AV2/ V%Y)&JJ,N]=1TUVQ%4QJKD^NTMKJK-3QJYKTV+E)L.
M1S'*[=J1O7W^GX2NVU/6&5?%+ PDU1PZ3J17"5::4L^OHX-1[).19_8[JO&A
MA'I&I%.MBKQI-\8482<;KJ=2<7*_.*BB*(1 (H)I      ! B #^=Q3A6WWN
MVUUGNU'37"U72DJ:"XT%9$R>EK:*LA?3U-+4P2-<R6&:&1\<C'HK7-7145-4
M.8+SM/((J>3UF_=<*T\<SL(WR%<2X%KWH]T<]AJYY(9K8^==6OKK!61R6^LA
M5RSMI5ME=*Q(KE3.?U&U/ ?PBCDC09BY!W#%-)3=)B+*ZH_93;Y8T597VB38
MI,146C6.<Z*2A<RL5BN9$V:ABJ'_ &A#?=GFL+P6/ITY2?08EJC4C?)2EE3G
MV6G9-]4F1MM.U86/T?.K"*]48-.O3DEX3C%>R0[4XK>2?.*L<Z@$$5%1%1=4
M7>B^;<J*G7HNN[S$2T=_QYBG\>'"ULO0._?S)IJB=:[]?)1%Z&O@V?*B?C?D
M_P .$;A5255XRMN]1AA'2JKI$PY5*ZZ8:9MJN^*WT=1-9J:)C=B"BME'$FFB
M[//*-E?P7O/.2PYX8@P3+,C:''6#ZJ:)CWKLNN^&*F*LIV0L5=E)9K?67)TK
MT3564;6.X(J:#M)T9ZIT56:5YX=K$0?-;MHS\W1N5_>KA:Y)&RS3#PFF*$7)
MJGBHRPTE?+>GX5-M<WOI;O5OOKSW^0 5=+@@              'D#S]OWI.<
M7\W89_+C#!S+EXJ=-'G[?O2<XOYNPS^7&&#F7+Q4L1L@\GXCXY+ZF@5>VX>4
M\+\1A_\ (Q!  $KOE^.3(7?W?.;Q?@G?W.\V_?\ 6[\F;<;8IJ=>"=_<[S;]
M_P!;OR9MQMBE3M>_*V-^$C]7 N?LU\B8#X.?ULP #43>@              #
M^7QM_P 37?\ FNO_ -5F..-9_P!R4O\ )X/[)IV.<;?\37?^:Z__ %68XXUG
M_<E+_)X/[)I.6QKAI'OPGS8DKSMW_P#IG?B?\$R( )O17WT+OX&P]X,)]\W6
M?BFQE\OX(.ABASSO!A/OFZS\4^,OE_!'JW]2<5T<J(J-4Z%Z>GXBL^U7RJ_B
M]+E^E4+9[')?^31OE_.:W/L@3@D]?Q#U_$1L2I=$X)/7\0]?Q=^ %UUHG!)Z
M_B&OG^("ZZR;4(I(UR>GX2=%,)F2( ,@      $%X$2#ET35> #=NPT._"BN
M5&Z_YFX5RKH:C;MN [/[MW2)CFN8N(,2-1(6R(W16ST=HIXU5DB+LLN#71*B
M2RHNKH?4G+?SQES*SCS.QV^;IXL28VOU5;I431/<*FK9+9AV+CIM0V"AMD*N
M1$1ZQ/D1$VU1ORV7"U7T6L)@,+063A3CO]3J32G4:_6E;\6*-ZW:7>-TEB\1
M=N,ZTE#LIP;A3\V[ #X$[JO#>JZ;]$370']5@3!=PQ+?;'ANT0OJ+MB2]6C#
MMJ@C35\]SO=QI[9;X6IHNKI:RJA8Q%14<Y=G9>ODGMSFHIR;LHIMOJ25S7J4
M'.<815Y2DHI=;>27GX&U_P"#0\W!#>:ZKY0.+Z%DM%9ZJILN6]%4Q(]LEUB^
MMWK%>RYJII0*J6FSN:Y)&U:7:I>QO14$KMV+H]_F]>O#3NA^)\F[(FT99X$P
MI@.Q1LCMF%K)06B%6,1GC$E+ QE36/;OTEK*E):F3>NCYG)P1J)^XE0=:-.S
MTCC:^(DVX.4HTHOA&FGX*MW6;ZY-EW-3M7*>B\!1PT4E4W5.O-6O.M)+?=[+
M)>+%<DK7;S)$1=2< \ VD                     $J]7?K0F)5ZN_6@!JM
M^%@?<DRM_&B[\C<3&BJ;U7A8'W),K?QHN_(W$QHJEG=EOD>C\+7^F5'VP>6Z
MOP&'^@"*=??K0@->_P _HUT37J54)#(O7%=YTBO!ROO1\N_YXS'_ .\G%A[C
M'AQX.6NG)'R[_GC,?_O)Q9[#W%VD*<ZRO_S''?&\1];,O-JF_P#RS ?%:/T$
M3 EVD&TAXE_Q9FPW1,"7:0;2"_XLQ<F!+M(-I!?\68N3'DSSX_WJ^;WO>B^4
MJ(]9-I#R9Y\9?_18S>ZO_)Z)/3_PC1=T/7U?_IV#M_::/UB/$UE?_E^-^+5O
MJY',7 []U!<J]\RB?^@-U_P3#]Z^=?OEPC\CW0TH#=?\$P_>OG7[Y<(_(]T(
M^VG^2*OPM#Z9).R3RWAO@:_T)&WB "L!;\
M $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ=/KGM/O6<Y/>M)_K5*<P5>*
MEA]D']!Q/QG_  XE8MN'E#"?%?\ %F0 !+2^_P"8A1\/VOHF[CX)I^\W.;WU
MX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?54RYVS3R'H_X*7UM0
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M15;$2MX6]*\H0[%3C+=MU[SYDFG G -.2-^
M
M
M
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M.U4Z*K](Z.E8UF(XH6(J*^VPLKY&L1S;=*][T;/VK&TK"XS<I8FV%Q#LK/\
M)5)=2D_"@Y/D\NJ16G6W91B\!OUL+O8O#+-V256E'KE""3J*/.4$_P!*"XFO
M>"M4TTD$LL$\<L,\$CX9X)XWPSP31KLOBFAD:R6*5B[GQO:CF.VFOT>BHE$D
MQ.^:MGGD[K/M_P!^]D425FTTTT[9JSNNP  &      +@AHG#JX:<4T\^O'1-
MR:]6[@1 ,W/U;)S/7&F7ER==\"XIOF$[@_9Z>>R5\U)'6(S16,N-(BNH;E"U
MS6/2&XT]3"CF,<C-MD:M]S^3UX1SFEAYE/1X]PY8\>T<?1M?6TSW8;O\D3=$
M<Y\U/!56N6I?Y3G2.H&-79:G1,UWZ[0/%TIJ[@\:K8C#TZKZ]W=G'M4X6E?S
MGNZ'UIQ^CY)X7%5:2YPWMZG+ADX2O#EU+O-^/D_<_?R?\:]#37:[W;+RZ2(U
M'4>-;>RGMZR:[+DI\06NHN5H6+738=<)[74R(NK:-/*1GKQ@?,6P8FI(J_#U
M[M5]HIF-ECJ;1<*6OB=$[>U^U3/EV4=O1%>C4T:BKY3MA.5(?VF!<R,187JF
MUV&K]></U;'I*VHLMSK+;)TB<'N6DFB1[DT317HY2.M*[(\+/PL)7J4I9^QR
M3K0_:\&HK=MV2IHC;=BZ:4<;A:=>.2=2DU1J=O@^%3E?O@NQ'5:21.W0J;:G
M/IR9Y]'E(X/6..HQC18UH&(UJ4.-['1721$1?+5+S;6VC$$LCTW=)67:J:U4
M:[HET5'>L>3OA-5ND2&''^65;0NT:V6OPG>(KA!M:Z.J%H;K#0SQ1\?K$4]6
M]JHC>D>JJXT'2.S#2M"[A&GB%_PI9_L32MYFR2-%;7=#8C*I4J86757CE^W3
MWUZ;&ULU_:3]+Y_@/(/*OGQ^3=B=K4EQTN&)U1OUC%EIN-J:LBZ[3$JXH:JB
M1K=$UDEJ(F;*ZM7733T7RUS_ ,"8SB2;"&-<(XIBZ-LBNP[B2S7ES&.X+*RW
M5D[X7I]C(R5C71O16.:QS7-33L7H7%X?*MAJM-KBYTZD%W9WBWVI^8WG!:>P
M6)2>'Q6'J75U&G6IU&UUV3WEGEG8_:6RKZ29)?48Y'ZIJB+IV]14U4\UI\\C
MU?Q=%]TGG^,GZ1.Z_3J8]'*3)( 7W2+U+\1-MJO\+X"PZ3M'2( 7_2KV_ [Z
M!TJ]OP.^@L-M!MH 7_2KV_ [Z"/2+V_&8_;0;: %_M?]9->_K^ @K_.OP%CM
MH.D +WI$Z_C0DVT[ZEHLJ]U)5>H!>=(G80652R5_G(;77HJIVZ&4C#=BYZ7S
MDKI#\VQYFUA7"U-XYBC$^',,T>_2LQ#?;39*;=Q1)[I54D*JB;][UTZ]QYY9
MI<]+R;L+-EV\R+?B">/5'4V$J6LQ YVG_P!)JZ6%MMD1VFC71US]==I%5-E3
MT,)HC%5_R.'KU;Y7ITY22?>HJ*\[MUGF8S36#PUWB,50HV5[5*D(NRXVC*2;
M\R9ZI*]2FLB+Q7OUJG4B)Q55ZNK4U>LX/"9,*4C98L"9<7N^3-5R1U>)+G3V
M*@>U=S9.BHXKE7M5NJN6-T4;7)LM;*Q/KC?)W.OG]N43BSI(+1>K'@"@>YS5
M@PG8J62XR1.141DMZQ#[M5<4B;G)46IMGE<K6Z-:BJC]QT=LSTI7M*=..'B_
MSSL_/&FIR^8TC2>UK0^'NH5IXF2Y4:>3[%.HXQ]%S?*Q%BFVVBF?67:OH;71
MQM<Y]5<*N&CIVM8BN<O2U+H6:-1%55155$1=&N5NR[RCY0?/A<GK 39X&8JJ
M,;W:';;[DX$HTO;EE:NRL<MWGGH</TKFO\E[)[HRH:FTK:>56J:'.9N=N,L:
M5,E7B_%>(L35$KD=))?+O7W!'.331RQ5,SXD<FB?8QMTT1&Z(B(GY@;WHW9#
M0C9XO$NJ\FXT/ @^S?DG-=648]Y'.E]M^(G>."PM.BL[3KRZ6I;D^B@U%/GX
MTER:-EOE"^$GXYNO3TN6V#+3A*E>CF0W/$-1^R"\(US=E9$IH6T5LIY-ZOC1
M/&^A>C4=)-L.VO"#/SE49C9I5:5>8.,K[BE8YNGIZ.X5CTL]'*B*U)*&RP=#
M::.5K'+'T\%&RH>S[;-([RC\#!(VBM6L#@OZ/AJ4)+V]M^?#G.3D[]=FD17I
MC6W2./OZJQ56<7_5I[E/]W!1CSRNG;AR";DT3<G8GP>S1-.K<B<-Q'4@#W6:
MX  8L+@ &0    "#G(B*JKHG:NY$UW:JO4B<571=$35=$151U\K<WP2,6Y\+
M=O']%1YW(G]%A+"5TO\ <Z*RV.VUUWN]RF2GH+9;::2LKJR9R*NQ!3PM<]^P
MU'/D71&1L19)9(XV.4]2^0=S.6:6=<E-=ZBBFP/@.1S'.Q1?J26&HN<.VJ2)
MANSRK#6W)$9Y3+C*V&SR;3$IZJJ<V:./<\Y%O-QY79%6U(,'67I[Y/$UMUQ=
M=U96XCNDB-5'IXTK&LMU'M;70VRVLIJ2%'*Y[*BH5\\FA:S;0,'@$Z<)>J<3
M;*$+1IP=KKI:F:[=V-W;DN))FJ>S#':1<:E6+PN&NFZE1/I:D>?14TUW;TFH
M\[/@>"W-Z^#SRN6EQ5GVK&-VHI[?EW;*Q7.6/R)-K%ETAV&LVWZQ.LMLDE:Q
MC=JKN#G2/HH-KG"6$;98[;16:RV^CM5IMM.RDM]NM]/%245%31HB,AIJ>%K(
MXF)O54:U-IRN>_5[E<?TK(N_5^DK1QZ\/@*^:=UEQ>D:CGB)^"OR<$Y0HPZ]
MV+XOM>;YEF=7=5,'HNDJ>%I*-_RE6<E*O4?+>DDK+]%62X6)&1^;]?F^'S[]
M.!>1PE1D7:7+6<.PU]LV0E:SL+J*,J1Q%['$ 21Q%XQFGS%1C.SVE=C/U@$K
M&%XR+AN)F1<"\8SJ (,9YMY<LC_63QL+IC.T D9'UETUOFW!C?87+6@!C/,7
M#6]9,UI5:WK #6EQIHFO7U$6IHFI%$UWK[  U.LJM;V\ U.M>"$>/F0&0U-?
M0503-34!L-;J5@ 8                  !J]^%2?<8P/^,"'Y'KC:$-7OPJ
M3[C&!_Q@0_(]<;3J3Y6P'QB'VFF[0O(ND?BT_L-#, %M^KN7S(I4^7XYL'N;
MR7O" ,Y<IL 89RYPY9L&5%DPI0R6^WSW*AK9:Z2&2KJ:Q75+XJN.-STDJGM1
M6,:FPUN[755\,@>;I/1&&Q<(PQ-&-:,9;T5-72E9JZ76DVO.>GHK36+P,Y5,
M)7GAYSCNRE%VWHWONO+A=)]Z-DCZJ)Y0'_,&7W]&W'\^'U43R@/^8,OOZ-N/
MY\:VX/&_\#Z)_L.'_P"_[SV_7"TU_P"Y8C_L^XV2/JHCE ?\P8 _HRX>W]W<
M$]1_#XR\)CY2ERB=#;W8'L2/8K5EI<.25E0W=NDAEJZY\;':Z:*L,FG#8ZS7
MO&O?OZ$]ARCJ7HE.ZP.&R_1<ODED8EK_ *9DK/26):ZE*,?EBDSZAY2'+7S8
MS>E;)F1C[$.*H(Y6ST]LK:IM/8Z:5FO12T]CH(Z2TLGA:JLCJG4;JS95=N=S
MG.5?E_S:)INW:(O#AQ[."+Q1-R:(JD ;%A\-3I05.E3A3@N$(148KN44D:SB
M<75K3=2K4G5G+-SJ2E.3[W)MCO\ 3^CL/[S++*_$6-+[;\,81LMPQ%B"ZS)!
M;[3:Z=]15U+_ "=7;+=T4,:.1T]1(K*:!JHLTT>\PN$%M"72@7$"7-;(E5&M
MT;9?%/=9U$BZRLMWCSF4:5;TT;$ZH7HVJNTK7*B-=OI\RWRC>15;*.'#>4;8
M<&X\O710U\.8<C6XZQ)5-C16TM-B"MD?0W&)J[3J>S6&>DHHY5J9J2SL?+4R
MOU[6G6&IH^@ZE+"UL3.SLX0;HTUPWJTE=QBLVK1Y9RC=,V?4_5FEI/$*E5QE
M#"0NE:<U&M4<O:T8R6Y*5\LW?/*,N!]$\RYS0M%R=L/38EQ3XE<\V<3T#:>]
M5M*J3TF&K3+)#4_L6M%2J(LS.F@IIKS71HV.X5]/&V%7T=)2O?[HHW0IQ=?I
M[]^&FBIN*I572>DJV,K3Q&(GOU)O-\DEXL8KE&*R2^=YEQM#Z(H8'#T\-AH*
M%*FLESE)^-.3YRD\V^?+*R  .B>F         2NZO2AHM^%>?=2RH]X5X_*(
MWI'=7I0T6_"O/NI94>\*\?E$;WLV\L8;WM?ZBH1OM9\AXKW^'^OIFJJ "TI3
M\I3_ &N3_(?_ %5.MER(?N.96^\'"GR)1G)-G^UR?Y#_ .JIULN1#]QS*WW@
MX4^1*,AS;+^0P'PE;Z%,GG85^7TE[RA].J?48 ("+'@      @I$@H#-#'PJ
M;'ZU^<> ,/H]5BP]@&6I6/55:VKOMYGDF>W^"BOI;=0(NFJNV-ZJC$TU?CWS
M\)3KI)>5'=XGZ='38*P='$B=DE)53.UWKO5SETT1-&IYUVO PMMJ/24-$X&*
MX.C&:[-^\W\LRE.T&K*>F])2:_\ 4."?Z-*$*2^2("JB(JKU>S3K!:URZ03+
MV12?U%-JSY&G+_3TY'3JYCC).+ W)ARNHDB1E9?K5/C*YN<S8F?78JJY;NK:
MCR6[4E'2U%+;FJK=T%'"S5=A'+ZX'X7R9[%3VS+K 5OI6(RFI<'X;AB8C4:B
M-2T4:IHC41J;U7<B?.?NA2[2F*=?%8BM)W=6O5J7]]-O[2^NAL&L/A,-0CPI
M4*5/]F"7V  '0/2         !_'8^P/;\2V*]X=NL2S6N_VBY62XQ(NBRT%T
MHYJ&KC151417T\\C4547153<I_8DCN'?T&8MIIK)K@^K/(X5(IQ::NFFFGS3
M5OF..;B;"5;A^YW.P7-NS<[!<KA8[DU$5$2X6>LGMU<U$=O:C:JFE:U':N1J
M;+EVFJKL(?:_.3X=BM7*%SLHH=$C3,[&%8B(BHB/NMXJ;K,FBJJ[IJR3@J-[
M&Z::?%!=3 8CIJ%&KPZ6E3J?MP4OM*#:1P_0XBO1X]#6J4F\N-.;CRLN0/1C
MFBLQEPMRG<CKJC]A)\?6S#CEU1&O;C.&JP<C'(KF;6TZ_L:W<[ZXD>SJYK&K
MYSGT-R1;NMNS<RFN#4<K[?FCEW7M1K^C<KJ+&5EJFHCTT5B_6D5KD5';M==3
MY:7H])A<13Y5*%:'9G3FG=><[&A*_18W"5%[3$4:K_Y=6GZ.I'7)12(!2\OH
M               >0//V_>DYQ?S=AG\N,,',N7BITT>?M^])SB_F[#/Y<88.
M9<O%2Q&R#R?B/CDOJ:!5[;AY3POQ&'_R,00 !*[Y?CDR%W]WSF\7X)W]SO-O
MW_6[\F;<;8IJ=>"=_<[S;]_UN_)FW&V*5.U[\K8WX2/U<"Y^S7R)@/@Y_6S
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M:-;2VCZ<E=/$TW;D]SP\^SP?/P-_EJ=_0I,2\-WI)BH1=\  R
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M+T*P  ,@
M
M
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M5'35E9+)5UDSDW(Z6IG5\\BHFY%?(_<FNC2D >NDEDE9=AX<IR><G=L  R8
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M!PI\B49#FV7\A@/A*WT*9/.PK\OI+WE#Z=4^HP 0$6/      !!2)!>'=?@
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ML;\)'ZN!<_9KY$P'P<_K9@ &HF]               '\OC;_ (FN_P#-=?\
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M47>+G=6DD^:+!;-M!XG1VC5AL7!0K=/5G92C);LMW=SBVN7R$P -*-^
M !YY<Z[9Y:[DWYS4T.STC\"7IZ*[:TTAB9.]-&M>_79C>J>3IKO543>GH7IO
M[]A^*\H[ 4F*,O<=8;BCZ6:_80Q)9X(^*NJ+C9ZRE@1$71%<DTD:LWIY6G!#
MM8"IN5Z,_<5J<O,I)G1TE3Z3#8B'NZ-6/I@URS.0PQ?);Z$^)"<IPIHQJ+Q:
MB-5.&CDW+JB[T5%1VY414UWHBIH5"ZN\GPS3X=J*"V:\'W-D^Q]0-DCP76_0
MT_*!Q!02(G2W#+JZRP[]/)H+K:>FW<5_=<7#XS6W/5SF0LZHL#<J#*NLJ9V4
MU#B*[5&!ZV1[ME'+BRDEMUIA1RJC=JHQ)[AP(U>.VJ(FVK#7=;L,ZVC,;3CQ
M>'J-)<7N+?LN_=-GU+Q2HZ6T?4?!8FG']N\/[QT\T0B2M7OZU)BH*+P@ &0
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M&Z_X)A^]?.OWRX1^1[H1[M/\D5?A:'TR2MDGEO#? U_H2-O$ %8"WX
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M14U3RHY&KN54[%,X4O::;3XIM6ZK9%]8M-)KFD[]C28  .0
M
M
M
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M3G!KS22?GX+F1 !V%^.5^ZYU5^,U?OM>]@
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MU+PYVY[J@FG[Y+F27LHT.\5IBE-Q;IX2,L5)YVWX^QTT^5]Z2DD^.Z^H]YD
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M23K02IXB'MHUH*TG;CNS:WHOFGV%8$J.)C5S<        0U (@E1Q,
M    "5>KOUH3$J]7?K0 U6_"P/N296_C1=^1N)C15-ZKPL#[DF5OXT7?D;B8
MT52SNRWR/1^%K_3*C[8/+=7X##_0!%.OOUH0(IU]^M"0R+UQ7>=(GP<K[T?+
MO^>,Q_\ O)Q8>XQX<^#E?>CY=_SQF/\ ]Y.+#W&*=:R^4<=\;Q'ULR\^J7DS
M ?%:/T$  >(;"      #R9Y\C[U?-WWO1?*5">LQY,\^1]ZOF[[WHOE*A/7T
M!_3L'\9H?61/$UE\GXWXM6^KD<Q4 %RGQ91%<$#=?\$P_>OG7[Y<(_(]T-*
MW7_!,/WKYU^^7"/R/="/=I_DBK\+0^F25LD\MX;X&O\ 0D;>( *P%OP
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MF[M2@E>7NU+L/Z($B.4G-%)&       !  B"5%\Q,@
M
M
M
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MR:=CG&W_ !-=_P":Z_\ U68XXUG_ ')2_P G@_LFDY;&N&D>_"?-B2O.W?\
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M$=JJZZ:(F_4;KZGZ']PZ2/NH^E&0!1:N_=W^,JIYSBG_ *=QR3[NVV=GU$0
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MR<6'N,>'/@Y7WH^7?\\9C_\ >3BP]QBG6LOE''?&\1];,O/JEY,P'Q6C]!
M'B&P@      \F>?(^]7S=][T7RE0GK,>3//D?>KYN^]Z+Y2H3U] ?T[!_&:'
MUD3Q-9?)^-^+5OJY',5 !<I\6417! W7_!,/WKYU^^7"/R/=#2@-U_P3#]Z^
M=?OEPC\CW0CW:?Y(J_"T/IDE;)/+>&^!K_0D;>( *P%OP
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M!?U\4&B[2/)&)[Z7UD20=EWEO!_\WZJ9N=IQ3OU(5"FG%._4A4*L+[_G+C@
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M$G&<)*SC)9--$NX/%TZ].%:E)3IU(J<)Q=U)/A;\73R:31, #XG9
M
M
M
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M[@@ :G9Q[>I"9&^TBB:$^B=OJ (:$WHX=9%$U]'85 9_'XR)6MT)B*(54;H
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MT;Y5*BS3J+C&+\3B_"MNS(S<-%T[]^!.A$AU>GO)U_#((1 ,@
M    \@>?M^])SB_F[#/Y<88.9<O%3IH\_;]Z3G%_-V&?RXPP<RY>*EB-D'D_
M$?')?4T"KVW#RGA?B,/_ )&((  E=\OQR9"[^[YS>+\$[^YWFW[_ *W?DS;C
M;%-3KP3O[G>;?O\ K=^3-N-L4J=KWY6QOPD?JX%S]FOD3 ?!S^MF  :B;T
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M+>_SX_.0/4M+\W#]B/W#U;6_/5?WL_XC]&_NQXQ_QPQ9_G+>_P ^']V/&/\
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M2@-U_P $P_>OG7[Y<(_(]T(]VG^2*OPM#Z9)6R3RWAO@:_T)&WB "L!;\
M                        $%^CXR)!?H^, \J^>T^]9SD]ZTG^M4IS!5XJ
M=/KGM/O6<Y/>M)_K5*<P5>*EA]D']!Q/QG_#B5BVX>4,)\5_Q9D  2TOO^8A
M1\/VOHF[CX)I^\W.;WUX8^0ZLVWS4@\$T_>;G-[Z\,?(=6;;Y4S7SROC?A(?
M54RYVS3R'H_X*7UM0  U$WH         \1?"+/O0\S?YRRV_[TL%G-J7J[]:
MG25\(L^]#S-_G++;_O2P6<VI>KOUJ6*V1>3Z_P ;E]52*M;:_*='XK#Z<R
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MGQLLRT.Q+%59Z/Q%.;;ITL0NBO[53IJ4HK]:[:7-LF !%),X
M
M
M
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MXN5]U2G%Q3=L\F^1R#".[NGZ3I<LY@KDK]66<*?_ %8O"?\ V:I/^T$\E?\
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M>?.3;RO8LMJMJY1T5@Z>$I/>M>=2H^-2I*V]-]5\E&/",4DB( /#-C
M
M
M
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M2= G:9/HR78[[_H ,=T/?>.A[[S)=&.B3N@!C>A[[QT/?>9+HD[H.C[ #&]
MG:3=%WT+_8[[_H(I& 6/1+W0BD/?@7R1DW1^90"Q2'O^HF2)"^Z+S?"12+S
M%DD9/T?F+U(NZ(3I%Y@"R2/U$_1=]"];%YOG*J0^;X@"P;%YB=(B_2)"HV).
MI "Q;#VE5L)=I%YBJV/]0!:I%H56Q^;UERD:%5L0!:HPK)%H7+8RJUG8@!:I
M'YO@^<JI&7",[2HC>Q "@C.K3VE5(^Z%=K.TK-9Z@"W1JE5L>G:5T:B$Z-4
MIHPJ:$[6?J*VSIQW %%L?ZBMLHG'=YB9J=F[SDR-]8!+HJ\-R=A.UNA-LJ3)
MYMZ@RD$;V[B.O8GK&SKQ*@&7G)$83@J-9V@-DK6ZE5$T(@&
M                                         "&A$  AH1
M
M                (:$0
M                                  0T(@    AH1
M
M
M                 (:$0
M
M
M
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M
M
M
M
M
M
M
M
M
M
M                    05-2( *:L["F7!!4 *!)L=FXKJSL*>@,IE)=>O>1
MV47@5"16:@Q<IJFA)LIZ"MHH73KW* 6ZHO7O[^8EW>@N%;Y]2&@!;K'KYRFL
M?J+A6$-%\R@%LK%*:M0O=W6BD-CSH 6*L3J).C]!>NC\Q(C/. 63H^Z$BL+W
M0@ 6*Q^@D6/S>PR"IJ2='YP"PV$)5C,AT9*L?F +#H^^JDO1^;XB^Z+TD.B[
MZ %AL?\ 54AL(7_1^<AL %@K._="7H_1W]1D=A1L* 6'1IWT)=A.Q?8A?]'Y
MAT?F^( L-A.Q?8A%(T[/B+[H_-\0Z/S?$ 6'1>@BC.^OZ#(;"C84 L>C]'M_
M01V/,I>[!'H_. 621^;3V?.3]'WX?%N+OHN^A%(_-\8!9]'Z"?8+SH_,3; !
M9MC\VI.D?J+KH_.3-;H 6J,)D8GI+HCH 44C]!,C"OL$S8_6 4$30G1JEPC/
M0A,B)YU +=&%1L?FT*FB^A"*, )51$[H11%ZDT*B(3(WMW %-&]N\F0G33TD
M=%7NB+W]8,VZ\O,01O;N&O8A%&$^@#L2HWM7U$R)H1)T8 V2$Z,*B)H1!@E1
MJ(3
M
M
M
M
M
M
M
M
M
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M(!D2;UX)IY]Q'8[5)P!?L((FA$F1BE1&Z P4D34F1G:50 01$0B
M
M
M
M
M
M
M
M
M
M
M                                      "56HI, "FK.PDV5["N "W(
M:%PK44E5B %#93L&SZ4*NPI!6J#-RBNO4-I>SX"H +]GSE+5.Q0B)YRJ05$
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MC.TCLH#!21J]A,C.TJ@ E1J(3
M
M
M
M
M
M
M
M
M
M
M                                 $-!HG81 !3Z/SCHRH "BK%(:+V*
M5P 4-%[!H5P 6X*RM0AL( 4@5=A!L( 4B&B=A6V$&P@!1T3L(E780;" %(%7
M80;" %(%780BC4 *)'1>PK@ H:+V*1V%*P *6P1Z/SE0 $J-0CHG81
M
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M.CL?5='"8N%>JH.;A&-2+4$TG+PJ<4[-I//*Z/N9%(D$(GA(V8  R
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M.K!/H5&$J<7&,\E-WG>\4XY/,]GT74F)6IYNLF-9CP^<VX  R
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MM'XO'>H,+5=>HH3G*<%>DE#=36^_&=Y>UNNT][D!+KV$QK!N(
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MGN6HK?IT\FVYU/%Y-6BY._&QM\*OGX?$3E!K>&O??H5D\YJR_'G-R_U(@ R
M                               2[2 $':=?7[2"N1/U\#Q\Y<W/>9&9
M(R5MGJ[ZF,\;4CWT\F#<(20U]91U4;T8^"^71'>Y5AEC=JCZ6MJ?=-J>6VWN
MB5TC? /D^<^AG!GIRE\I<,PS4^!<O+AC#H*K"MC5LM7>:5MLN,T3,0WV>+QR
MI9TD,4BT5O2WT2JWHZEE8S9>W:-'ZEX_$4:F(Z)TJ%.G4J])63@I*$-]='&V
M].ZX2LH/W1I>D]?-&X:O3PO3JMB:M:%'HZ#C4<'.<8>R23W:=G+Q6]_+Q3>#
M !JYN@   *;5T[_H*AJB\[;X0A7Y7XONV5V3EOLMTQ'AZ5M%BG%EZAFK[3:;
MHC&NJ;':[=3U-&EPN% U[8;A52U3:6AK^FH5AJ*JCK*=GKZ%T'B=(5E0PT-^
M5MZ3;W8PC=+?E+@DF[<V[V2/#T_K#A=&4/5&+J.%.^[&,5O2J3LVHQCQ;LF^
MI<S:VVO7Z^_?0AKWUZ^LT,.2=X3QFK9;_1P9O6RQXNPE//''<:ZQVA+-B6UP
MOD^NUU,RGJ5MMT92QKM>Y[J6CEE:UR,JW2*U%WH, 8ZM.*+'9\2V"NAN=BQ!
M:K?>K-<J956FK[7=*6*MH*N!7(UW15%+/%*S::QZ-<B/:UR*B=G6'57&:,E"
M.)A%QJ74*L&W"37%)[L;27.+2=L\U>W2U9UPP6E8S>&G)RI).I2G%1G%2\5V
MO*ZOS3M?+B?V328E:3&OFT@                             $JKZ>.FX
ME5R;OIT[[M^[L"NT15XZ:K^A/.:JU9X5AEE!// N5V.7+!--"YS;A8]ESH97
M1*K=J9%T56JJ;D\E4W<43U=$Z"QF.=182A.MT6[O[NZMW?WMV^]*/'=E;N9X
M>F-8\#H_H_5F(CA^EWNCWE)WW+;WBQEPWHWOUKK-JO7SH-?.AJF?57F67X+,
M=?TA8?\ [<%\*[RR_!9CG^D+#_\ ;CV/_ &E_P"PU>KC1_C/#6T;0>?_ )A2
MRX^#6R[_ &,VL]?.@135,^JN\LOP68Y_I"P__;A]5>99?@MQTGHN%B_^W#_P
M#I=?^AJ^FE_&/7'T'_[C1Z\U5_RS:SUZN_TE/37L]O=37DY'7A$> LY,S<(9
M86G &+K1<<85EQHZ6YW&MM$M%2/M]CNM^>ZHCIY%F<V2"U30,Z-JKTLC%=Y*
M*I]C\YGSK6&>3$W!K\1X7ON)?V9OOC*-++4T,"TBV-EL?.M3XZ]J.2;W3CZ+
MH]=GHW[6FJ:^;6U:Q]/$0PDL-..(JQ<J=)[KE**O=JTK62BWFUDCU:6MFCJF
M&GC(8JG+"TI*%2M:>[&3LDG>-^+2R3S:1ZKZJGG^ -=J:Z7)0\(ZRRS5S$PM
MEXW!N*,+U&*Z]]KH;Q=ZNTRVZ&XOI9Y:"EG;2R.F1UQJ8F4%.[392HJ(NDT8
MJJFQ2S>GH73XM?/U^M.!U=*:'Q."G&GBJ,J,Y+>BI6S7"]TVN*MDW;@T=S1&
MG<)CZ<ZN#KQQ$(2W92C=*+M>UG&,N#35UFGEEF5D"J&\ IYQZY+KWUX$$]GK
MU)7*FBKZ%]!X2<OKG[<N<@\PZG+>OPS?\6WFW6NW7"[RV*JMD5/:*BZ1OJ:6
MUU:5DC)$KEMKJ2Y.8Q%:VCKZ-VJND5K>_HW1>(QE3H<+2E5JV<MR*7BJUVVV
MDDKK-M*[2YGEZ6TSA<#2Z?%UXT*>_N*4N&]FTK).3;L\DF\GR3/=O9*J'C7S
M:W/+83Y3&)<1X:P[@_$6'*C#=DI[Y4U-YJK?-#405%>R@;#"VBD<]LK7O1[G
M/T;L)HFJJ>R;>!PQ^CZ^%JNAB*;IU8I.4':Z35U>S:S3NL^!]=&:3P^,HQKX
M6I&K1DVHSBFDW%V=KI/)IIY<28 '3.^
M
M
M
M
M
M
M
M    #5[\*D^XQ@?\8$/R/7&T(:O?A4GW&,#_ (P(?D>N-IU)\K8#XQ#[33=H
M7D72/Q:?V&AF=$+P9G[V&E]_F,O[>B.=Z=$+P9G[V&E]_F,O[>B)GVM>2Z7Q
MNC]36(&V+>6)_$:_UV'-@U."$2"<$(E;RU8                      ((H
M!$$NN_S$5\P!$             @J^8 B"&I$       &K3X5?&BY0Y>JO5F"
MNFY%5-;%7HJHJ\-W5HJ.151=#:6-6KPJ_P"Y#E]^,!?D2N-JU(2>EL GP]41
M^9FF;0VUH32-FT_4T[-<N!HB'1,\&C^]<M7OVQM\J1G.S.B9X-']ZY:O?MC;
MY4C)FVN7_DRG?^V4[6ZNCKV((V+6_E:LU_8*J:XYJI0OZ38$ !6\M4
M "&\ B""*1       !KH>%!(B\FNBU373,W":IZ?<_$7L[-?CX+L7FNEX4!]
M[71_C-PG\GXA-BU12>E-'W5UZKH9=?LD35]=G_Y1I+XEB.'P<CGN]^_I75?7
MVZZ[\W@M'W"\4_C N'^H4!H,&_/X+/\ <+Q3^,"X?ZA0$Z[5%;1+7+U31\WC
ME==CC7\M*RM_-<1QS;_)YW-F5O'V?$I4*;>/L^)2H5G7/\<D6Q7!  &3(
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M=9;S9?IOU9HF@I.]3"_S>I?C:FET<NW>A97[.?$J)P0B$!I!(B  !D
M @NHW@$3YKY97W(\SO>#BWBFO_L*NZCZ40^;.63]R/,[W@XM^0JX[6!_+T?A
M:?TT=+27]'K_  -7A[R1R.:-$Z&)$X)''IV(B,:B(B:*N[?_  M-Z^2BFR/X
M+.G_ *2V(U__ $(XP^''65WT&MS2?:HOXMG]5#9%\%H^^6Q'^)'&'Y=96EI]
M>$OY(QMLET$<N2\4ISL]\M:/XWZ9MW=V\JAT#^OO_A%0I]??_"*A4XNF
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M."$;[3?+&(^#H?5(EC9+Y#PWPF(^NF1 !H))0
M
M
M
M
M
M
M
M          -7OPJ3[C&!_P 8$/R/7&T(:O?A4GW&,#_C A^1ZXVG4GRM@/C$
M/M--VA>1=(_%I_8:&9T0O!F?O8:7W^8R_MZ(YWIT0O!F?O8:7W^8R_MZ(F?:
MUY+I?&Z/U-8@;8MY8G\1K_78<V#4X(1()P0B5O+5@%)5]/#JZC3RYZ?GBL\<
MD\\ZS N KO8:3#T.%,-79D%QP_'<:A*NYMK_ !IWC+ZB)58Y::/8C5%5FKMZ
MZMV?9T#H*OI&OZGH.FJFY*?LDMV-HVNKV:;SR7,\'6+6&AHS#^JL0JCI[\8>
MQQWI)S4FFTVK++-O)<>1N) YQL?A'G*E<YC?V082\I[6K_Y(P)N<Y$X^.KIO
M7354TU5.!ME<OOGF,$<GW"&&_==DF+,RL38?M]SMF#[4^.%6-J*&*66\X@JU
M5T5ELWC+^B@8C9[G<)55ELH)Z>FN%90^UI34/2&%J4*4H0JU,1O]'&C)S:Z/
M=WG+P4HQ2DFVW9+-Y'@:)VD:,Q='$5U.=*EA=SI9UHQBKU-[<4;2DY2ENNT8
MIN^1[3*O?O\ JT)4<OG]AS*>4_SY'*/S-JZQ?V>7# UEG>_Q>PX!FEP^E+"N
MJ1M??*5S<032M8NPZ9ESIF/55D\71R-1/..X9_X_K)GU%7CW'%742KM2U%5B
M_$=142N_PI9IKD^5[N.][U7CO-KPFQ[%SBG6Q5"E.R>Y&]2U^N2E%7ZTK]YI
MV,VWX*,FJ&$KUH)V4Y2A1WEUJ,E)I=]GV'7S:J_H[Z^;L^8G.3YE1SBV?>")
MX:C#6<.8=&E.K5BHZW$]QOMI8C$1J-]Q\0U%TM:,5B(QS6T3$5B)LNU8Q4V+
M>0?X4!<J>KI+#R@+/#46N5[(?V>86H965=N;HUOC%\PY"LSJVE9HKZBHLVU7
M(JN?%:YT5D9YNEMEFD,-!SHRIXM)-N%.\:N7'=IROO)991;D^29Z>A-L6C,3
M-4Z\:F#<FHJ=7=E1N^4JL,H/WR2ZVC=6!_+8-QG:L0VFWWRQW&BN]FNM+#76
MRZ6ZIBJZ&OHZAB205--4PN=%+#*Q4<U['*F]4UW']-M<",W=.S333::>337%
M-/GES)9A-22<6FFKIK--=::R:)P"#N!BYR(@\]^=-Y0>)LJ\A\?X]PA44M-B
M+#]NI:BVS5M*VMIF2RW&DIWK+3.<ULJ+%*]J(KFZ*J*BZHAI)KX1_P J7@F(
M<)>G]B-.J(O_ &W?U:ZZ+KQ1#;]7]2\7I*E.MAW14(5'3EOS:E=14KV47EFE
MWFD:RZ_8+15:%#$QK.=2"J1Z."DK.3CQWEPLWW'1T!JU\R)SNV/,U(\Z+QG?
MB;#5%AO+NQ8/N\5TCMT-BI+=%=*G%3+I/6S]/-TR.CM5$VGB1-O;:]D;'R3-
M0^!.7MX3CBJ]5E?8,A;<W#5ACDEIF8VQ!10U.(;FUCW1K6VFS3NEHK/33*C9
M:);HRJKW0Z.K*"CGD6DA^U/4'2,\74P<:<'.CN=+5W_8(=)!3C>HTKO=:=HI
MOLYGQK;2-&4\%2QLZDU"OTG0T=R^(J='-PENTDWDI+QFU&V=S>+VO9Z%^/OP
MW\4(-5=R;_/JFGLW>CCIYCDJ9E<MW.;&-1)58GS8S%N[Y7](L,V,+W3V]DBJ
MU56GM%#74EJI-58QRI24,+%5C%TU1-/XK#W*6S+M$Z55HS(S"M52FG]\6S'&
M*+?/HFJM3IJ6[0OTU5=RNTT<[<J*J+MZV.5[9XVDI6X=%4W>[>WEZ=VUC1I;
M<\-O98&JXWX]/23]&[Q[+W3RY'7D12)S7N3#S_O*.RYJ:=MRQ4F8UDB5K9;/
MC:)M75.@;Q;!B"FC@O$<ZKI]=K);DNG5H]53=-YM[G:<MN4C;)8K')-A[&]M
MIUGO>!;M- ZYTT+',C=<;541*D5ZL[GR1HE93MCFIWR,AN%+1S*UKM.U@U$Q
MVCHNI4BJU!.SKT7OQC?ATD<I0ZKM6ZFS>M6-HNCM*35&G.5#$/A0KI1E+X.2
M;A/N4MZV>[8]5 0;P[_I^,B::;X "1W4 3@_*<X\[,)Y?V*LQ-C3$-JPQ8+>
MQ'U5TO%9%1TK-7(QL;5D<CI97O<UD4$*23RR.8R.-[G(BZM_*Y\*;PU;9JJU
M9+8.J\3R1JZ)N+,6]-9;-*NBIT]ML;?^&JJ'>CHY;E[D/5S%8ZA5CDE3V]#Z
MNXS'NV%H3J).SJ>+3C[ZI*T5W7;[#7=.:UX#1ROB\1"G)^+2SE6DNN-.*<FN
MVRCRO=HVYB1'+UIW^#Z=-%.8]G9SY?*?QO)/T^9E=ABBFU1;=@NBH\/01M5V
MB;%=%'4WMCFM78UBN::JJ.<UGV1\"XDY4&9]YDZ:\9F9C7>5';22W3'6*K@]
M%5$;JCJN[3.8NRC6;ME$8C6-1&HB$A8;8]BY*]7%4*;MPBI5%Z;P5^ZZ[R,L
M9MQP,)-4L)B*D5[>4H4K_J^&UY_0==IRZ]2^Q29%W;SD,6+E)9D6J9*FUYC9
M@VNI39TJ;;C;$]!.BL<CF:34EUBEU:]$<W155KDU313T<Y.?/L\I7+R>GUQ[
M4XVM,.PU]HQU%'?$EC33;1MXV8L0-FD:U&]+45]8K=5>D.VJJ_&+V08R$&Z6
M(HU9+A&2E3;[$VYJ_4G8S@=M^"J22K82O1C?.:E"I999N-H.WRY<&=,Q%(GB
M#S8G/?9>\H62/"]? N!LRXZ=9787KZEDU!?61,:ZHJ,*W5-AE?T7EOFM<[(;
MM3L8^9D%511/K%]NTZN_P$8Z1T;7PE65'$4Y4JD7G%]7)IK*2?6FU?+BB7-%
M:7P^-HQKX6K&K2EPE'BGU2B\XOG9I96? G ,-B&J?!0UD\:[,D-)4RQKIJB/
MCA>]JJG6B.:BJB[E3=Z.DE?(]&4DDV^",R:M?A5_W(<O?Q@+\B5QX(VSPD7E
M324T$CL081VI(8I':80@1-I[&N73:K$735=WFZU/DSEE<ZIG%GU8K9AW,:YV
M2MM=GN?NO1,MEDCM<S:U:>2E1TDS:B;I(^ADD1(_(U>J*BJNXFG5O9OI#"8[
M#8FI+#NG1JJ<E"KO2<;-72W;<>5[D"ZV[4M&XS1V-PE*.)Z6K2=*.]2M%2;7
M%[WBY>-:QYR'1,\&C^]<M7OVQM\J1G.S7OWW_.>HG),YXC/#)/!\&!< W:P4
M>'J>X7&YQPW'#\=QJ4J[I,V>K<M2^HC5T:R-^M,5/(:KD57*J:2)K[J]7TG@
MH4,,X*<:T*EZLNCBXQA4BTI6:3O-<;9)D7;.=9,/HG'U,1BM]PEAJE+V)*<E
M*<Z4EE>-TE!IVYV.H8#G%KX1]RI?\8,)?YHT_P">GVKS<W/I<H7,C/++3 V*
M;UAN?#V)<1QVZ[0T>&8:.IDI5I:F96PU3:J187;<+$VD8J[*JB;]Z0OBMF&D
M:-*I6E/#.%&G.I/=JMM1A%R=EN9NRRL[=I/6"VNZ+KUJ5&$<3OUJD*=.]));
MTY1@MY[[W5>2O<WGP2,7<A.1R2D 4M>^O#V'Y?G/G7A3+W#MPQ9C2_6_#F'K
M5$LM;<[E+T4$:(BN;'&UJ/FJ*B395(:6FBFJ9W)L0Q/?Y*\H0<FHQ3E*345&
M*;;;RLDLV^P^=6K&$92G)0C%.4I2:BE%<VVTDNUL_5215[Z=_-OW[]=QI-<M
M+PH^^UU376?(O"\-IMC7RT\&,<94Z5%SK6L<YBUENP[3U"T]#3U#$Z6B6XU,
M]:C%BEJJ&FG62@9K[9K<Y;R@L:U#Y\19R9A3;:NUI;3B6NPS;E:Y?)8ZVX8F
MM-!*QJ(B,Z>G>[=JKE>YSEDG1FRS2%>*G6=/")YJ-5MU//"/B]TFFN:1%&E]
ML6C,/-TZ$:F,DG9NE:%/MW9S7A+AG&+B^3=CJV[7F7V?HZNKX2*:]_I]'F]9
MR X<\\<QO;)'CC&D<C'(]KX\5X@9(QZ<'-<VXHYKD7@Y%U1>"GUYDKSL?*/P
M%-%)8\W\9U=/&]'K;L576?&%#(Q-E.@='B);G44\"[*;+*.IH]$W->Q%=KZU
M;8[B5%NGC*,Y<HRA."?ZUY67;NGCX?;CA7)*K@L1"-\Y*I3E;N34-Y]B=SJA
M@U(^0-X3K9+_ %M!AK/:RTV$JNJ?%3P8ZL22RX:Z=Z(C77^VRR2UME@E?JU*
M^EDN%% KF^.>*T[9:MFV%8KW1W.CIKA;JNGKJ"M@CJ:.LHYXZBEJ::9NW#/3
MU$3GQS12,5',?&YS7-5%:JIHJQMIK0&+T?45/%4G3O=QE=2A-+G"2NI?.NHE
M706LN"TE3=3"5E4W;;\&G&I3;Y3A))KL?BM\&9H$K28\<]X&NEX4!][71_C,
MPG\GXB-BTUTO"@/O:Z/\9F$_D_$1L>J'E71_QNA]9$U?7;R1I+XEB/JY'/<-
M^?P6?[A>*?Q@7#_4* T&#?G\%G^X7BG\8%P_U"@)TVJ^2G\8H_WRNFQORTOB
MN(^>F;,K>/L^)2H4V\?9\2D%3]&\K.G^/,6R7+N_"*H-)'G2>=]Y4.1>>&,<
MOZ*^X;3#\+Z*]X2FJL*T\TU3AB]4_C%"Z2=:J+QB6BJX[A9ZF=(V))5VR=6M
M1NCE^+,NO"3^432XAL=3B:[X8K<-PW:WR7^DI<+105,]E;51>ZC*::.J>Z.H
M\3Z9:=4:JK*C&]>I(6%V:Z0KT*>(I2PTZ=2$9P2JO>:E#?22W/&LK-7REX/$
MC3&;5M&8?$3PU:.)IU*=5TI7I+=3C/<<FU.Z@GGO-6<?"61T008#"V(Z.\6V
M@NUOG94T%THZ6X451&YKXYJ6L@CJ*>5CV*YCFR12,<US7*U475%74SY'[33:
M:LUDUU-$E1DFDTTTU=-<&GP8 )7*8.1,"DJKN[^SCO3JW*:C7/=<]EF5E%FW
M1Y<Y3W"R4D5CPU1UV+*FY6J*[22WV]3RU-+;XMNJB2G9;K/#0U$BZHZ:6[2,
M<UJTS%?[.@=!5](UUA\.H[^Y*;<W:,8QXMM)\[+AQ9X6L6L6&T9AWB<2Y='O
MQII02E*4I<$DVN2;;ZLS;J!SB7>$?\J1$72_X4<O\%K<'P.>]5X-1/'=5<O4
MW375=G34WS^1=78\K,K,#5^9U52U>.[G8*2ZXE?14C*"DIZZZ(M>EO@IHGRL
M1EK@J(;=TNTCJE:9:IZ,?*Z-OHZQ:H8K1D*<\3*E[*VH1IS<I/=2;=MU9*Z7
M>>1JQKS@]+3JPPL*WL,%*<JD%&"WK[L;J3SDDVNQ'U."DS7K]7GW%4U4W0
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MLJ&AITAMU^RSLL52Z-$=!)BG#K&4>)W-F:QC)99JJLIZMRM1=(:BGU75=_\
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M=D;/ZJ&R-X+/]\MB/\2.,/RZRM)KUX\D8WMH)^AQ1 .S[RW@.RLUW^#-_:=
M[K[_ .$5"GU]_P#"*A4TNF 0=P4_+LW,Z,)X!L57B7&F(K1ABQ4+=JINEYKH
M*&E8O!&-?.YO33/7<R&)'RR.71C'*<H0<I1C%.4I.T8K.3?))+-ON.%2K&$7
M*;48Q5Y2DTHQ2XMMY)'ZD#4>Y7?A36%[7/6VG);!]9BF2%SH(\78KZ6RV.9V
MG[IMEF:JWNJI]^U')=665[GL<CJ-8%9,_7\SLY\OE/XWEFZ?,NNPS12JO_!V
M"J*BP_ Q-5V5;7,BGO37,:J(NS=(HWN57*CW;.S(&BMF>D\2E*<88:#2?L\F
MIV^#BG*_9+=[;$9:8VMZ)PKE&G.IBYQ;3Z"/L=U?^MGNP:NK7C=<U=9G3@5R
MZZ)W[^KM&J[N/?U'(GQ+RH\T+U)TMYS,S&NTFTKT?=<=XJN#VN5$35KJN[SJ
MWR4:Q%1478:UNY$1$LK#RDLR+5/XU:LQLP;75::)4VS&^*+?4Z:HNB5%)=H)
M=-41?LT35$7J138_6<KVOZMI+OI2LNO^LOQ[/,:N]NN'WK?R?6MV5H-VZ[*%
MK^>QUZ0<S+D[<^SRELO:JG<['U5C>U1*WI+-CF*.]-FCW;;6W=60WR.1[-T<
MTMQJ4C<FUT#M7:[B/-@<]W@#E$2?L8K:1^!\R8(>F_8U754=30WZ&.-'5%;A
MBY(D2U;8=[JBV5<5/<:9CFR1MK:=LE2S4M/[/\?H^+JRC'$4$KNK0>^HKKG&
MRE%=;S2ZS==6MIFC=)2C2C*>&KR=E1Q"W7)]4)J\9/C99-\D>W@***OP[M_'
M]"<"JW@:.2&1 ,9=9GQTM1(Q='QP32-<J:HCF1N>U53K1%1-4UT7@.Q?+DO2
M8;LF^K,R8.<M<?".>5''45$;,083V(JB>)FN$J95V8IG,;KI6[UV43RD715/
MN[FMN?,SVS*S^RZP-C_$.%DP9?9,8/Q"Z&P4]J?'26/+S%^)*>;W16L<VD9#
M<;-133RN:YJT[)8W[+7J]LAXO9GI&C1J5Y/#RC2ISK24*CE)TX1WFXK<S?9>
M]R,<%M9T77KTL/%5XU*M14H[\(QBIMM9O?=HJV<N"-WLD<J]2=^_F-1CG"/"
M;K98ZVOPKD':Z/$M33=)33Y@WQDBX=\9:YS'KAZUQOCJ;S3Q.:B-N57)1T=2
MJN=1PU-*D5;-J^YR\YER@<?54M3B3-['KXY5>BV^S8@KL,6A(G*KDB]RL.36
MFCGCC1=ABU<-3-LHFW+(_:>[Z:%V8X_%0Z2JX86FTFE54I56GPM1CX2_6<7V
M'PT]M>T9@Y]'2W\9)/=E*BXJBFN*Z:7@R:_0WEVG5F1>Q%[--._T$Z:]^_T'
M(+MV?^/Z.5M11X]QS23QZK'44F,,1TT\>J;UCF@N+96+PWL5%W<>L]!.3SSV
MG*5RZJJ9]-F5=\66V#5)+-CN1,54]2UR(B[=SKWK?FRHU%2)WNQT;'NVY&2:
M(B>MBMC^*BFZ.+HU9K^KDI4V^R[<\^JYXF#VXX.4E&M@\13C?\I"5.JK=>ZM
MUNW.UW8Z>8-?KFSN?VR_SPJZ'!N+J9F7N9%4U64=#4U'38:Q-*UNTK,/W:16
MOAK]E'/2SW-D%3*QJNH9Z[9F;![_ +5T1.U>.O%._K3L54(STGHK$8.JZ.)I
M2I5%[62XKKB^$D^N+?5QR)=T1IK"XZBJ^%JQJTWE>/&+YQG%VE"2YJ276LLR
ML"BO7KJ'<%T[-./Q'G?C[CU'U<^157J[]2DOZ?ZR&L3S^W.>YMY 8GRUMF6U
MRLU#1XFL.)*Z[,NEFCNKY*FVW"TT](Z!\D\*P,2*LG21NCD>Y6*BILJKO 3Z
MH^Y4NJ?^4&$=/>C3]NG_ "Y%^9.LWO1&SO'XW#4\72=!4JF];>G)2M&<J;;2
M@^<7S(YT[M.T;H_$U<'75?IJ=D]RFG"\H1FEO.2Y27G/+#EC_=CS?_&OF5^6
MU\/ICF>?OH,D_?BGR-=CX#QSC*NQ'?+YB.Z/9)=,17F[8@N<D4:0Q27*]W"H
MNE?)'"BN;#&^JJI71Q-<YL;%1J.70_K,C<Y[_EUB_#^.<+S4]-B'#%?[I6F>
MKIDK*:.JZ":F5TU*JM2>-8:B1NPLC?*<CDT5"Q^*P<Y8&IAU9U)X65!6=UO2
MH]&I7LO!OGPO8JQA](TXZ1I8N5U3CC57?!O=5;I+9-J]LN-CK]@YQ?U1_P J
M7_&#"7^:-/\ GI'ZH_Y4O^,&$?\ -&G_ #T@/UIM*=>&_>R_RRR7KT:'ZL5^
MZ7\9T<P>4',O<J_&6=.1%EQ[CRJHJS$5=B#%5OJ)K?0MMU*M-:;U4T5&UE*R
M25K7-@C8DCD>[;?M.UTT0]7D4CO'82>'KUL//=<Z-2=*;B[QWH2<79V3:;3M
MEP)/T=CH8FA1Q%--0KTX58;RL]V<5)76=G9D0#2OYW+GJ<^LH,_\;9?8)O&'
MJ7#=CI\+R4$%?AZ"OJHW73#%INE6DE4^JC=(CJNLF<Q',:K6.1C=4:AZ.@-7
MZ^DJTJ&'<%.-.53PVTK*4(Y6C+.\UYCR=9M9\-HJA#$8I5.CE55*].*DU)PG
M--IM96@^!NGZ(1.;W=O"1N5/%2U,S,081VXJ>:1BKA"!4VF1N<W5$KF[M437
M>AT;K94/EIX)'KY3X8GNZDVGQM<JHF[=JO4NB</1VM8]4\5HKHEB73?3;SAT
M<M_Q-VZ:LFO&B=35C7/":657U*JJZ'=WNEBH>/>UG=]3R,L"CJJ[CX&YS?'N
M9&$\DL<XNRGK*.FQEA.@AQ'315]N;<Z>NM-JJ8I\0T?BBZ/EJ76-*^HM[(5;
M)+<*>E@UV)GH>#A*#K5:=*+495)Q@I3>[!.;25Y<E=I._#B;)C<4J%&K6<9S
MC2A*I)4X[TG&";>ZN;LGDLV??X.<3]4@\J141R8APCIIKNPC3*B]>Y4K4^/0
M]^>86YWS'.>N*,<X#S1KK34X@M]FH\486EMEL;:DJ;52UC+5B&GEC;+*U\M%
M4UUDJ(EVD?(RMJ=&)'2J]=TTOL[TA@L/4Q-7H94Z23GT<W*5FTKI;BNE>[?)
M9FA:%VH:,Q^)I86CTZJUFU#I*:A%R2<K-N>3:B[99O)9FSZ"33S^?CQ(LX&A
MWSMS^PD:_P"/,3 $FUQ,@G!XE\^7SB.(.3[EA:*_!53008WQ3B2EM=G?<*1M
M?3T]NH6.KKW5.I'2Q)([H(X*.)55&M=5OEVMJ)K7:H'U1]RI/\8,):>]&G^'
M^_47V&ZZ!U#QVD:"Q%#H8TY3<(]+-Q<G'BXI0E>-\K]:?4:%K%M&T?HS$O"X
MCII55"-27104U%2X)O>5G;.W4T^9T<P>+W,@<I7-_.#*NNS$S7N%MJEO%_JJ
M3"D-MM#+0QMGM;&TM35SL:^59WU=Q2HZ*5).BZ&!FRQKE>KO:!J[C5](X&6&
MKU</-QE.C-TYN#WH[T<I).RO9W3RXIFW:+TA#%X>CB:<9QIUX*I!5([L]V6<
M6XW=KJSM?@R(*6NGPA7]TZ^KT>O<GG0Z7<=\JD%/(7G&^>7RLY.S$M5RDJL7
M8]J8DEH\$X?DA6JIH7M<L==B&XS?WG8J%SFHQC)/&+I5*[;HK7401U513:>W
M*9\(7Y1V/JFHCL>(:3+:R3=(R.W81I('W!*>1%:K)[[=(*JNZ1&Z/2>@903Q
MN149(U=43=- Z@Z0TA%5*=/HJ+X5JMXQ?O$DY2[U'=_2-!UCVDZ,T;)TYU76
MKQXT*%ISB^J4K[D7V.6];/=L=(%5W]??U$NJKNT^ Y%F*>53FG?9NGO>9V8U
MXF5RO1]SQSBBN5JJB-^MI4761L2(U$:C8D8UK$1C41J(A'"7*KS2P_.E58LS
M\Q;-.CFO5]MQSBFBZ16*CD;.VGN:1SQKL)MQ5#)(9&:,?&XW)[&ZZ2OC*=VL
MO8*EK]2>]?\ [317MTPZDE_)]>W'\M2O;M6[;Y3KK(1.<IR7?"*>4/@*H@AQ
M-=Z',VQM>Q)J/%%-!37=(&HC.CI+Y:J:FF1R,U?TE?25TCI%:LLSDU0W)^;N
MYV?*WE&V]8\-5D]BQE1TZ2WG E]?#'>J/8:U)JNW2Q.6EOMH217)%<*%>D:Q
M&^Z%%;IU=3-TG6#4?'Z.BZE6FJE!6O6I7E&-^&_&RE"_6U:^5\T;]JWM#T=I
M.2I4IRI5WPHUDHRE[R2;C/N3N^K)V]1 2M7<3&GF]   %->KT+\1S.^?N^^H
MS*]-B^1Z4Z8B]7H7XCF=\_=]]1F5Z;%\CTI*6R+RE/XK/Z=(A_;5Y+I?&X?5
M53TG\%"^Z9FO[R[!\LUQO0FB]X*%]TS-?WEV#Y9KC>A/,VF^6,1[RA]3 ]?9
M-Y#PWOZ_UL@:;?A:GVK(C^/S"_U?"9N2&FWX6I]JR(_C\PO]7PF=79WY8PG_
M #_J*A]]J?D/&=^'_P#D4C343]?H/TO)C-^^9?8NPUCK#,[:>_X2O5!?;5(_
M;Z&2HH)VS+2U36.:^6AKX6RT-?"CF=/1U$\6TNUHGT1S<V5EIQQGCEI@V^T[
M*JSXGQ"EFN,#TVFNIZR@K8]K1%1=J.3HY6*U45KF(Y%:Y$5/PG/_ "5N^7&-
M\58#OL;H[KA.]U]EJMK369*29S::K;LJK-BLI%@JV*Q59LSILN<GE+9VIB:5
M2M5P<DI3="-7<E:TZ52<Z4EW7C:7+=DBI5/"5J=&GCH-QC'%.E&I&Z=.K3A3
MJQSZVI;T+>VBSK'Y YV6?,;!6%L=8?DZ2S8KLE#>Z%7*CGQQUL#97TLJIHWI
MZ.7I:6=$33IH9$1=$37]'Q%B"CM5OKKI<:F&CM]NHZJOKJRH>R*FI**CA?45
M53/*]6LC@@AC?++(]4:QC'.5R-34U-/!<.6DVZX?Q3D9>*I5N.&>EQCA%DCM
M5J<.5]5#37VCB7>Y76:]55'4*QSD3Q:]0,A8K*6=6_8/A(?+,;E[DH_ -MJE
MBQ%FR^HL"MBDV9H<*0-CDQ-.[22-Z4];#+#99=&R,DCN,D$D>Q*JMJWBM5:L
M=+?R;%/PJR4)6O[!+PU4[=VEG+M3+?837.C/0G\JR:6[0;G&Z_I$?8W37;*K
M9+*]FLC2:Y?G*TK<[\V\99CU+I$HKQ<G4^'::5'L=187MVU2V*F6*362&5]$
MQM950O5W15E751L=L1M1/CHRU@P_77:OH+3:Z26NN=SK*6VVVAAT6:LKZZ:.
MEHZ6+543;GGEBB:KE1J;2*Y4:BJGVGSC?)H@R=S1J,MHECDJ,,80R^BN]3$C
MT96XAN.#;/=L1US4D\ML=5>ZZNDIXG*JP4JP0:Z1M1+0X>5'#/#X*-HM4WT<
M%;*E1Z.&\^S>FDNMMO/,J'BU7Q*Q./GO24JJ52I*^=6MTD]U=O@R;7))+A8]
MO/!0_NK9I_B^MOY1P&]4G!#15\%#^ZMFG^+ZV_E' ;U2<$*W;3?+&(^#H?5(
MM7LE\AX;X3$?73(@ T$DH
M
M
M
M
M
M
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MJJ="'9(Z=>Y/1V$/8W:MCJ]&K0G0PNY5ISINT:EXJ<7%N-ZC5TG=732?(G#
M;&]'X:O1Q$,3B]ZC5A5BM^FHR<)QFE*U--IN*3SX97YD6KN0F((1(O)>/SO-
M3-"Q8*PW?,6XFN-/:</X=MM7=[M<*E^S%345#$Z:9^G&21R-Z.&"-'2U$SXX
M(8Y)9&,=S-.=)YSC%7*0QM/7U,]9;, 6:HEBP9A+I5;2TE,U71^[5RB;LMJ;
M]<H]9*B>7;=10O914BQQQJLFP-X4ARU):*@POD19ZE6.O44.,<:-AE<W6V4M
M6^+#MKJ6M1$DAK+E2U5P=$Y[F+[EPNDBUZ%YI<HNF_AIJO'M1-=Z\-R:*O\
M@[U3J)^V6ZJ4Z=%:1K0O5J[RP]U^3I\'-+W4WSX[CRXLK/M>UPJ5<0]&4)N-
M&CNO$[KMTE3BH2:XPA=)1X;ZSX(+KU\55$TTW[3D31NS]EM+JC4;IOT1$U74
M]?>2]S%O*-S3H:>\T>#H\(6&J9#-373'54ZP2UE-*FJ5%%:%@J+TZ-K%;+&^
MKH[?'4,>U]//*S>FP1S /,\6.S8;L&>^9-J@NF)L14D-XP#8[E DU'AFQU;6
MRV^_S4<\:1R7Z[4RLK*"61LC;9;IZ=U.C*R>=[=L1K%]'?\ 5YE[.M?CK7M1
M=&M/#Z/C";IO<J5ZD;Q4UQC3A=7<7E*4FU=-)6S?8U+V1+$4*>)TG.I"-6*E
M3PL'%2W'FI59M.V^K-0BHR2SD[Y+0QKO!6\YV4CIH,=X!J*M(VN;1JR\0M=(
MK45T:U3H9&-1KM6[:1>5IKHFNAX[<L?FSLZ,B'MDS"P?4P625Z,I\665[[UA
M225[FMC@?=J:)C;?4R.T;%!=Z:W3U*II2MJ$:YQU7#^:Q7A"VWRVUMHO-!1W
M:U7&"2DK[=<*>*KHJREF39D@J*:=CXI8W)Q:]CD]"HBIJVC]JVD*=1/$1I8B
MFWX<5!4IM?HSA;-+@I*2?"W,W#2NQG1E2DUA75PU5)[DG4E5I[W+>A4WLGSW
M7%\SCJ_.GM3M3M]2Z:[E73<;)?,.<[Q<<KL36K*/']VDGRRQ+6PV^PUUPJ=8
M\"WRLE2.D:R>=W][X9N=0]E/5Q.D936JIDBK8V14[ZU[/GGGQN:_IN3YCNAN
MV$H9&9;8Z?52V&G<^25</W>D;')<</++(KI'TR12-K;4Z21[TI5FIMM4H]&^
M'+V;37-553::Y%TUZT73MXKIOTW:IHO$FFI2PFF]'KA*E7C>,K)3I3BG:2X[
MDH2O%I<>=TR!*5;&Z TD\W3K4)6G&+>Y5IMIN#SM.,XV:;R5U9*2.R<WX]Y,
MJGD_S+?*ZGSBY/\ @^^W*H\9Q'88Y<(8ED?(CYY;G84931U=1IJK9;A;UHZ[
MZXKI)$GZ5ZJZ13U<:NNY>PJCC\'/#UJM"HK3HU)4Y=\9..78[778T7-T9I"&
M*P]'$4W>%:E"K'WLTLN]-V:Y-,JFNEX4!][71_C,PG\GXB-BTUTO"@/O:Z/\
M9F$_D_$1[.J'E71_QNA]9$\77;R1I+XEB/JY'/<-^?P6?[A>*?Q@7#_4* T&
M#?G\%G^X7BG\8%P_U"@)TVJ^2G\8H_WRNFQORTOBN(^>F;,K>/L^)1I\':&\
M?9\2E0K/U]_W%LEP7<:F7A3/)-2[8.P9G%;J76OPC7+A7$$L;$VY</7R5T]M
M?-LM<^1MMO2.2%5V8H&76O>Y465-='M41=>"Z[NU/5U*GP*G#?HK>N5RM.3_
M $&:F6F-\N[BK(Z?%V'+E9XZA[5>VBKIZ=SK9<-A-[UM]Q92UK6[]IU.C514
M547DIXIPK<K#=+G8;S2NHKQ8[C7V:[43U17T=SM57-0W"E<YJJURP5<$T:N8
MNPY6[;$1KD5;%[)],.M@IX2<KRPDO!3S?156Y1]%3>5[9)I<+%7-LV@?4^/A
MC*<7&.+I/?:;2Z:DE&7#A>FXNW-J_$Z*O@[O*F=F)R=+%9:^K2IO^6=74X)K
M]I^LRVBD<ZKPI*]%U5&LL$]+:D>]5?/):IJA=GI$1/=U.'T<#GM>#3\JE,%9
MYS8#KZGHK1FC:9K;3->Y>B9B>R1372U[MS&+6T$=SI.E<J*^=M%2LVI)V-7H
M0,7<BZ^C7CU\>^A%&O\ HAX/2=>*CNTJSZ>GU;M1MM+WLU-=B2)HV;Z;6-T3
MAVY;U2A%8:IGG>DDDW[Z#A+SE8 @[@:8;X?Q.8N.+?ABPWK$EWJ(J.U6"U7"
M\W*KGD;%#34-LHY:RJFED=Y+(V0PO5[U^Q1-==VJ<E3E)YYW#,W,#&.8%T=(
MM7BW$%QO.Q(C4?!2U,[O$*1R,^MM6DH6TU,Y(_(VXG.:B(NB;WWA*G*C_85D
M')@FAJ70WG-.[4F'G=&_9E9ANW307;$3M475(Z^*GI;)*U[=B:ENE6W7::B+
MST_;KZU7CIUZKYU\ZD^;(]$='AZV-G'PJ\NAI7Y4Z=G/S2J-+]1V96C;9ISI
M,3A\!"5XT(.M6BN#J54U375>---_KYJYZ1<T?R6US?Y0>7N%)J=\]GH[B_%F
M)5:B[$5@POL7&=9G(CMAE9<4MEHC>K58M1<H8I-6R:)U)HHFM8UC&HQK6HUK
M6HB-:UJ(C6HB:(C431$1$T1$T3<AJ:^"R<E%+5A#&N<-P@1*W%M:S"F'Y7M3
M;9A^QR>,7*2%SFM?&VXWJ1K)D17QS16FA?JCV*C=M)#1]IFEUB=)2I0:=/"0
M5!6X.=W*HUYVH_JDB;(]!>I-%1K2CNU<9+IWPOT:2A23R3SC%RL[YRNK$J)P
M\Q, 1V2F      "54^@F(.70 UR_"7N5)^PO(ZGP/15217?-&[LL[HFO8DJX
M>M/17*^3*QRH_P 7>Y*"@DDC7:CDKH&[D>NO/DX=7#J7=]"I\&A[K^$2<J!V
M8?*-N]GHZETMCRRM-'@NWQ->KH%NRODNV)JYK-7,943U]93VJ=S-6RTUAH'J
MB/:YIXDX1PE7W^[6JPVF+I[I>[C0VBVP^4J25UQJ8Z2E:[9:YR,Z:5JR.1J[
M,:.?HJ(6HU T6L%HJBYI1E6A+$U6\EX:3I[W5NT]WN=^LISM)TQZOTQ75.\X
MT9+"44L\Z>4]WC=SJ[W>K+B;R7@L_)E;9,K\59JUE/LUV/;_ #6:SS/8J.?A
MW"<LE#/)$]43:BJ,0K=('(J+LRVQ=A4:[939DS)P';L58>O>&KM$RHME^M==
M:*Z*1C9&OI;A324TJ*Q_DJK62*YNJ:(Y&\%X?F?)3R(MV6&7&",O[6W9I,)8
M;M=E1RHW;GGI:9B5E7,K$1KZBLK%GJZF5$^O3S22+O=J?0#V=FY>KOW^<KCK
M!I9XK'XG%IOPZKE3?-0@[4DNJT4NXM'JUH6.#T;AL&XI[E",:JY2G-7JWMQO
M*4K_ ''(/S\R@K\OL<XOP+<XW15V$,1W?#T[7[U=[F5LM/#*CN$C)Z=L51%*
MU59+'*R6-58YKE]'.8WY47]RWE&8+J:FI2FLV,GR8$O:O>K85AOTD"6M\J:I
MJL=[@MW1)KLK(]JN;HB*OVWX3GR6OV*9TVK,FAI]BV9GV2G2Y/9&]&,Q3A>G
MIK3,^1^B1M?7V)EGZ*)JJ]S[;6U#]5D536S@J9H)(YJ>:2FJ()&34U1"Y8YJ
M:>)[98*B&1JHK)H96,EB>U45CVHY/*1%2SF!K0TMHB&]PQ6%W*CY1J..Y*U\
M_ JJZOU)N_$J3I"C4T+IJ2C?>P>+<Z:X;U)2Z2.:MX])I-I+BUEP.R0CD(ZG
MQ/S=W*<CS@R4RYS!VF>.WS#5 V^Q,V=FEQ+;F^YF(J=K4>YS8&W>DK'4G2;,
MDM&^FF=&Q948GVQH5/Q-"5*I4I35I4JDZ<E^E!V=NPNA@\5"M2I5H-.%6G"I
M"WN9Q37GY$0 ?$[(**KQU7S[^I/9N3K_ %H5CQ$Y_;EC3939!WNDM52ZFQ+F
M+*_!%GEBDZ.>FIKC32NOM;"YOEMDI[.VJBBD;LN9+/&]DD<C8W)W=&X">*Q%
M'#T_'K5(P3ZKO.3[(J\GV)GFZ7TE3P>&K8JKXE"G*H^VRRBNMR=HI=;-7#GS
M^=EK,Z\6567V"KL],IL*5SX>DH952GQO?:1ZQRWJHEC<K:ZS4<C7Q6-G[DFT
MDN;6R=+22-U^25D:-1&MW(W1$1$3@B(B)NX(B(B(B=6]5T:C5]E^9BYKV;E&
M8_DGORSTN6F"Y:2MQ=/#M1SWN>5ROH<*T-0W3Q=UQ2-\MSJV*LU/;&21TR1U
M59!54EL84\'H7 <J-"A#-VO.<G;>S5KU*DFDFEQ:RW58IA*KCM.Z0B_RV*Q4
M]V/A;L(0C=VLVU"E3@KWXY.]V[OX@Y+/(2S<SIJ9H<M,"WK$E-2R-AKKTR..
M@P[;Y51KNCJK]<)*6V)5,C<V9:""HGN#H521M(]CV*[UDMO@R'*6FI4FEER[
MI9WLVTI'XGKI7HNRUS8I966-T3'ZJK']&V1C'MVD=*U=#?\ LOLO+'A6ST&'
ML-VJ@L=DM5,RDMUJMM-'2T5)3Q[FLB@A1C4U^R>]=9)'JZ21SGN<YW]MLH0K
MI#:SCIU&\/3HT*:>2E'I:C2R\.;DD[\<HJU[7=KD\Z+V*Z/A2CZJJUZU5I.6
MY)4J<9/CN147)+ME)WMO65['+JY3_,Z\HC*.BJ+MB;+ZLN5AHV[=5B'!]0S%
M%JI&(CE?+61T+&WBBIH6IMSUU7:J>@B:J=)5L^Q3S$:YKDU:J.3<J*BHO6FB
M[M>"]?4J;]%0[)BMX^Q-QJ0\_+S+5EK\/WS._*:SP6S$%D9+=L=85MD#8*+$
M-I:Y7W+$-LI8T;#37RU,5]=<((F1,NMNCK9&:W&"""OVC57:EZHK0PV.A"FZ
MCW85J2:BYMV49Q;DX;S]NI;K;LXI9FI:Y;(/4M"IB='5*E6%*\IX>HU*I&"S
ME.G-;JGNJ[<)1WMW-2;5C23[_I-C[P6?[Y;$?XD<8?EUE<:X"+KHJ<%1%1=V
M]%UX>SCPZM=38^\%H7_TEL1_B1QA^765IO&O,E_)&-^!LOVHF@;/%_YUH_X=
MMW[82[CH']??_"*A3Z^_^$5"I9=0E=P7T&I-X5?R?KC<<&Y;YE44M;+;\,7R
MLPUB"@2:9]!#%B2)DUDO3Z7:\7AEIKC03V=U5T?32NOU+!M)&Q4-MIW!?0?)
MO+?Y+E)G-E5C3+6LJ(*+]E%HDI**XST[JN.UW2&2.JM5T6G;)$Z5U!70P5+6
MMD8JNB16JU3W=6=*K!8_"XF6<*=5=)E=]'*\9M+KC%MKML:YK=H=Z0T;BL)'
MQJM*3AX6ZG4A:=--\E*22?9D<F'7>U.MRHUK4WN<Y=S6M:GE.<Y539:U%5VT
MW91=INOJ5R:N9@Y2&:4,-?8\NJ^PV>=J.@O6.7KA*BF8Y-IDE/27"%;Y402L
M5'0U<%H?13M5.BJG:J;QO-_<R]D_D+2T-=26N+%^.X49+4XXQ'2T]37Q5B+M
MJZQT2M=2V*FA>NS2)2(M;'$UO3UU3.Z6>3US:W?QXKW]&[=PW^TE'3>UUW=/
M 4(RBLE7KK)I<XTH[MEU.<G?FD0]J[L432J:1Q$HMYO#X=K)OVLZSWDVNJ$4
ME[KF:)&&/!3\W*NF;)<\R,!VBH5C5=31T-ZN;6.77::D\?BK7HW=Y21MVNQ#
M\PS?\& S[L--+4X:O6"L;+"QSUI*6LK+!6U"-9JC*9MRCDIGSN5K6-9/64T.
MJZND:B*XZ!;>!%>!J<-J&EE+>=6C./N)4*>Y_P!JC+_N-VGLBT*X;L:-:G+\
MY'$5-_\ [I2C_P!MCC[YKY/XKP)?JW#&-,.WC"^(;>[9K+3>J*6BJHVJYS65
M$>VG15='+L.6EKZ1\U%51_7:>HE9Y1_*X7Q5=+%<J"]6.X5EIO%JJH:ZV72W
MSOIJZWUT#NDIZJEFC<Q[)8WM16Z+HYJJU[7QN<UW24Y[_D"VG.C)C$5?2V^%
M<?8$MU7B;"%SCA:M;,MNC=57/#LDB(CY**^444U/'$YW1TUR6CKM/K#VR<TN
M.1'M:YJ[37)M-['-<B*BKUIM)V:;.Y$30F_5#6F&E\+*<X*%2G)4J]*RE'PD
MLXWSW*D7)).[5FKNUW7S775*IH7%PIQJ2G3J+I,/63M+)M.+:MX=-J+;5D[I
MI*^74JYJ+EQLS]R:P]C.K= F)J5'V'&-/3M9&R+$=M9&RKJ&0LT;!#<HG0W.
M")&L:R.K1D34C:P]*$-(#P4/.F>FQKFMES),Y]+=L,6O'%%3J[1D%5A^Z4V'
M[O4,CTT<ZMAQ#88Y7*OUIMO@8W:Z153=^;P*Z:X:(C@=(XBA!6I[V_37)0J)
M3279%MQ78BT6HFFY:0T7A<34=ZF[*E4?74HR<)2_6LI><F,/?&_WC6?R2HZO
M_N+S,&*OO[AK/Y+4?V+S6X>,N_[3:ZWB2]Z_F..I=_W96_RVK_UF4MZ:JEA<
MKX99(7+'/"Y\4CHGK!4P24U7#ML5%6*II)IZ>IC^QEI99X9$?%))&^XN_P"[
M*W^6UG^LRG][DMD[B#,'%N'<#X4H5N.(\4W2GM%II$56L?4S;3WS3O1%Z&CH
MJ:.>NKZE6JVEHJ:HJ7ZMB5%NPZD8TU*I)1IQ@W*4G>,8J-YMWX)1\W64"W9S
MJN$(RE.<MV,8I[UY2M%1W?"DY/P;+.Q_)84PC=K]<:2S6"TW2^WBNDZ&AM%D
MMU9=KI6S:*[HJ.W6^"HJZF3917='! Y=EJNV4:BZ>T>4G@[W*AQ31Q5]1A:Q
M80AE1CFP8MQ%34MRZ*1B/;(Z@M5/>'1:HJ;5/4STE3&[5M1%%*U\:;J?-J<U
MY@7DYX3IZ"T4M-=L:U]-$[%>-:BG9[I7.K5-J6DH9'M62WV2GD5S*2AA5B2-
M:V>K2:H57)Z:KZNI->_P:$%Z<VN5G-PP%*$:<6TJM6\I2M[91O%0B^*OO-I\
MN!875[8M1Z*,](UJDJDTFZ%&T8PNO%<VI.4EP;CNY\Y+,YS&9G@WW*=P_125
MU#9L*XJ2*-'>(X?Q-&ET>Y'2*K88+O1VNDD1K4:J:5T;G*[HVQ.5%5_B5CS
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MB #022@
M
M
M
M
M
M
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M &BDC@
M
M
M
M
M
M
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M,86IH/3DMRZ6&Q,*]*%K;U"<G-1NN3IWA+-VNUF=D!R_-Z34K\*AY5WN7A+
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MU$1$1$1$1$3@B(FY$3J1.!. +$-!H1 !!41>*!$(@
M
M
M
M
M
M
M
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M6.U0F-7-S!KI>% ?>UT?XS,)_)^(C8M-=+PH#[VNC_&9A/Y/Q$;'JAY5T?\
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ME:Z3M>QNLIQ)BE&NO!=?TIJB_"5343>$P  9
M
M
M
M
M
M
M
M                                 !J]^%2?<8P/^,"'Y'KC:$/@CE\\
MWG@KE&X8M6%,<W+%%LMUGN[;U32X5K[705KZMM--2HR>6Z6:]1/@1DSG;$<$
M3U>UJK)L:L7V]6](4\)CL+B:N]T=&K&I/=5Y67)*ZNS7M;-&5<;H[%X6CN]+
M7HRIPWWNQN_=2L[+S,Y4QT0O!F?O8:7W^8R_MZ(_+E\%>Y/.O[[LY/\ ./!R
M)Q]X'?JTXGLIR%^1)A3D_8%CR]P97XAN-DBN]SO3:C$]7;ZZZ>-79\;ZB-9[
M9:K/2K3L6)J0M\3Z5J;2/EDW*DC:_:[X'2."IT,,ZSJ*O3J/I*6XMV%.I%Y[
MTLVYJV7619LXV?Z0T7I"6)Q?0*F\+5HKHZKG+?E4I263A'*T'G?J\WV4G!")
M(WK]).0\3H#G4>$M_?1W+WA8+^*['131?@XGB[RW^8RRCS^Q[/F)C+$&8UNO
M=1:+79G4N&KQARBM:4EI\9\6>R&Y83O%6E0_QF3IW+7.8[99L11Z.VMPU%TW
M0T?CEB,1O]%T4Z=Z<=^5Y[MLKK++/,T3:)J_B-)Z.>&PO1])T]*=ZD]R&['>
MOG:5WX622.:Q%]G'_&1_VC3L$9/_ +TL+>]VR?)E*:\S/!8>3RU47]EF<>YS
M7)KB3!W%JHJ<, (N]4TW+KV*B[S9 PO8XK7;J&V4[I'P6ZCI:"!TSF.E=#20
M1T\;I',9&QTCF1M616L8U7JY6L:FC4]S:)K;@])^IEA74]A=5SZ2"@_#Z.UE
MO2O;<=V:]LPU+QNB'B_5?0^S*BH=#4=3\GOWWO C:^\K&> !&9+@--WPM;[3
MD3_*<PO[#"!N0.7=V=^_F[=QYG\X;S6>7O*89A1F/;OC&UI@Z2\26O\ 8G<K
M/;W3.O;;>RK\?6[6"^)*D:6NG\72!*785TW2+-JSH]CU2TK2P6D,/B:V]T=-
MSWMQ;TO"IS@K*ZOG)<S4]=]#UL?HS$X6AN=+45/=Z26['P:D9N[2;64>HY<:
M=_8ITP.8'^]*RC_DV*/RUQ(?%J^"O\GG?_Y79R>G]DF#NW3_ ! TUZNT]Q^2
M'R6\/9+9>8=RTPK5WFNL.&F7!E!4W^HHZNZR-N-UKKM-XW46^@M=)(K:FNF9
M#T5#!LP-B:_;D1\K]XU_UTP.DL)2I8;IM^.(A-])34%:-.K%V:E*[O-<K6OF
M1WLTV?Z0T5C:F(Q70='/#3I+HJKF]^4Z,EDX1RM3>?6T?3(((NX*1&R<#R,Y
M]C[U7-O^:*#Y8MQS(SK@\K#DRV'./ &(<N<3U5WHK%B:FBI*^IL5324MUBBA
MJ8:IJTD]=07.EC>LD#$<Z6BF385R(U':.3PN^I7N3SK^^[.3S?\ E)@Y?_X
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M+@3#J-LJ6CZT,9BZW2XBF[TJ=)RC2@[6WIR=I5&N"64.;3Y0CX)W^GA[.PG
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MSY+)<BR%"C&G"%."M&$5"*NW:,59*[S>2Y@ 'S/J
M
M
M
M
M
M
M
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M1T[]T(@IZEDB[Q)KYE[^A""MWK]!4!RL"GO[./Q$S4)@82M_NW\YBP !DR
M 0(*3  IJWNI'3A[-Q. P4U[=^[J)F<"8  I-3J*H!AHIJW<15.Z(A.##5S)
M*U-/C)@#(2!!5(@ $JH3 Q;F"DJ*A43@1!DPE^.0  ,@   E=PW;B8 %-.W?
M\_ FZ^!,##0*:-[[R;90F L/QED0T(@"P  ,@
M
M
M
M
M
M
M
M
M
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M2'ZL;+S$NZ$T7'!83#X6%K4*4(-KVTU'PY?K2;?G)@ = ]4
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M@
M
M
M
M
M
M
M
M
M
M                                     @J#93L(@   6
M                                                        (:$0
M 0T0:$0+
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
D                                             __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>oncolyticspipelineye2.jpg
<TEXT>
begin 644 oncolyticspipelineye2.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" >J#6@# 2(  A$! Q$!_\0
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M\)]:T:VT&=4BO(99)?M +G*L ,<CUKQ;_AJCQY_S]6O_ 'Y/_P 57>?MR?\
M(S>&O^O:;_T-:^9* /7_ /AJCQY_S]6O_?D__%4?\-4>//\ GZM?^_)_^*KR
M"B@#U_\ X:H\>?\ /U:_]^3_ /%4?\-4>//^?JU_[\G_ .*KR"B@#U__ (:H
M\>?\_5K_ -^3_P#%4?\ #5'CS_GZM?\ OR?_ (JO(** /7_^&J/'G_/U:_\
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M]^3_ /%4?\-4>//^?JU_[\G_ .*KR"B@#U__ (:H\>?\_5K_ -^3_P#%4?\
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M #]6O_?D_P#Q5'_#5'CS_GZM?^_)_P#BJ\@HH ]?_P"&J/'G_/U:_P#?D_\
MQ5'_  U1X\_Y^K7_ +\G_P"*KR"B@#U__AJCQY_S]6O_ 'Y/_P 51_PU1X\_
MY^K7_OR?_BJ\@HH ]?\ ^&J/'G_/U:_]^3_\51_PU1X\_P"?JU_[\G_XJO(*
M* /7_P#AJCQY_P _5K_WY/\ \51_PU1X\_Y^K7_OR?\ XJO(** /7_\ AJCQ
MY_S]6O\ WY/_ ,51_P -4>//^?JU_P"_)_\ BJ\@HH ]?_X:H\>?\_5K_P!^
M3_\ %4?\-4>//^?JU_[\G_XJO(** /7_ /AJCQY_S]6O_?D__%4?\-4>//\
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M_P"*KR"B@#U__AJCQY_S]6O_ 'Y/_P 51_PU1X\_Y^K7_OR?_BJ\@HH ]?\
M^&J/'G_/U:_]^3_\51_PU1X\_P"?JU_[\G_XJO(** /7_P#AJCQY_P _5K_W
MY/\ \51_PU1X\_Y^K7_OR?\ XJO(** /7_\ AJCQY_S]6O\ WY/_ ,51_P -
M4>//^?JU_P"_)_\ BJ\@HH ]?_X:H\>?\_5K_P!^3_\ %4?\-4>//^?JU_[\
MG_XJO(** /7_ /AJCQY_S]6O_?D__%4?\-4>//\ GZM?^_)_^*KR"B@#U_\
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M6O\ WY/_ ,57D%% 'K__  U1X\_Y^K7_ +\G_P"*H_X:H\>?\_5K_P!^3_\
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M\>?\_5K_ -^3_P#%4?\ #5'CS_GZM?\ OR?_ (JO(** /7_^&J/'G_/U:_\
M?D__ !5'_#5'CS_GZM?^_)_^*KR"B@#U_P#X:H\>?\_5K_WY/_Q5'_#5'CS_
M )^K7_OR?_BJ\@HH ]?_ .&J/'G_ #]6O_?D_P#Q5'_#5'CS_GZM?^_)_P#B
MJ\@HH ]?_P"&J/'G_/U:_P#?D_\ Q5'_  U1X\_Y^K7_ +\G_P"*KR"B@#U_
M_AJCQY_S]6O_ 'Y/_P 51_PU1X\_Y^K7_OR?_BJ\@HH ]?\ ^&J/'G_/U:_]
M^3_\51_PU1X\_P"?JU_[\G_XJO(** /7_P#AJCQY_P _5K_WY/\ \51_PU1X
M\_Y^K7_OR?\ XJO(** /7_\ AJCQY_S]6O\ WY/_ ,51_P -4>//^?JU_P"_
M)_\ BJ\@HH ^P?A9\4]?\8?"7QQXCU&X1M2T:&5[4Q@J@*PEQN&>>17CO_#5
M'CS_ )^K7_OR?_BJ[3X!_P#)O/Q4_P"O>?\ ])C7S90!Z_\ \-4>//\ GZM?
M^_)_^*H_X:H\>?\ /U:_]^3_ /%5Y!10!Z__ ,-4>//^?JU_[\G_ .*H_P"&
MJ/'G_/U:_P#?D_\ Q5>044 >O_\ #5'CS_GZM?\ OR?_ (JC_AJCQY_S]6O_
M 'Y/_P 57D%% 'K_ /PU1X\_Y^K7_OR?_BJ/^&J/'G_/U:_]^3_\57D%% 'K
M_P#PU1X\_P"?JU_[\G_XJC_AJCQY_P _5K_WY/\ \57D%% 'K_\ PU1X\_Y^
MK7_OR?\ XJC_ (:H\>?\_5K_ -^3_P#%5Y!10!Z__P -4>//^?JU_P"_)_\
MBJ/^&J/'G_/U:_\ ?D__ !5>044 >O\ _#5'CS_GZM?^_)_^*H_X:H\>?\_5
MK_WY/_Q5>044 >O_ /#5'CS_ )^K7_OR?_BJ/^&J/'G_ #]6O_?D_P#Q5>04
M4 >O_P##5'CS_GZM?^_)_P#BJ/\ AJCQY_S]6O\ WY/_ ,57D%% 'K__  U1
MX\_Y^K7_ +\G_P"*H_X:H\>?\_5K_P!^3_\ %5Y!10!Z_P#\-4>//^?JU_[\
MG_XJC_AJCQY_S]6O_?D__%5Y!10!Z_\ \-4>//\ GZM?^_)_^*H_X:H\>?\
M/U:_]^3_ /%5Y!10!Z__ ,-4>//^?JU_[\G_ .*H_P"&J/'G_/U:_P#?D_\
MQ5>044 >O_\ #5'CS_GZM?\ OR?_ (JC_AJCQY_S]6O_ 'Y/_P 57D%% 'K_
M /PU1X\_Y^K7_OR?_BJ/^&J/'G_/U:_]^3_\57D%% 'K_P#PU1X\_P"?JU_[
M\G_XJC_AJCQY_P _5K_WY/\ \57D%% 'K_\ PU1X\_Y^K7_OR?\ XJC_ (:H
M\>?\_5K_ -^3_P#%5Y!10!Z__P -4>//^?JU_P"_)_\ BJ/^&J/'G_/U:_\
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M5Y!10!Z__P -4>//^?JU_P"_)_\ BJ/^&J/'G_/U:_\ ?D__ !5>044 >O\
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MJCQY_P _5K_WY/\ \51_PU1X\_Y^K7_OR?\ XJO(** /7_\ AJCQY_S]6O\
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M /7_ /AJCQY_S]6O_?D__%4?\-4>//\ GZM?^_)_^*KR"B@#U_\ X:H\>?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% !1110 4444 %%%% !1110!]#_L2_\ )1=;_P"P4W_HZ*BC]B7_ )*+K?\
MV"F_]'144 :G[<G_ ",WAK_KVF_]#6OF2OIO]N3_ )&;PU_U[3?^AK7S)0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110![=^Q[_P EBC_Z\)__ &6O-OB9_P E(\5_
M]A:[_P#1SUZ3^Q[_ ,EBC_Z\)_\ V6O-OB9_R4CQ7_V%KO\ ]'/0!S5%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %?2?A3_DR[Q5_U_?\ M:WKYLKZ3\*?\F7>*O\
MK^_]K6] 'S91110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'TGK'_ "9/
MH?\ U_-_Z535\V5])ZQ_R9/H?_7\W_I5-7S90 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 ?2?P#_P"3>?BI_P!>\_\ Z3&OFROI/X!_\F\_%3_KWG_])C7S90 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7TG^UU_P BQ\,/^O&;_P! MJ^;*^D_VNO^18^&'_7C-_Z!;4 ?-E%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!^C__  3Y_P"2%W'_ &%[
MC_T".O4OB'^T)X!^$^M1:3XJU[^RM0E@%S'#]BN)MT99E#9CC8=5;C.>*\M_
MX)\_\D,N/^PO<?\ H$=>3_MV_#CQ;XP^+6EW>A>%]:UNU32(XFN-.T^:XC5Q
M+*2I9%(!P0<>XJJMU))?UH10BG%M]+_F?0L?[:'P;GD6-/&2AFX!;3;Q1^),
M.!^->EW$'ASXF^%2CK8>)- U"/(Y6>"9?4$9'![CD$>M?E+:_ +XEWEPL4?@
M'Q*K,< S:5/&OXLR@#\Z_1?]D_X::[\*_@_9:-XA_=:G)<2W36H<.+97(Q'D
M$C/&XXXRQI<L7%W!R:DK'Y^?M(?"5/@S\5-0T*V=I-+E5;RP9R2P@<G"D]RI
M5ESWV@]Z\NKZ:_X*!:Y::I\;;6SMI%DETW2X8+C:<[9&>23:??:ZG\:D_9/_
M &38?BY!_P )3XJ::'PQ'*8[>UA8H]\ZG#$MU6,'*Y').0",5G2O*/I?\S6J
MU%^MOR/F&BOU=N_AG\$/! LM+U+P_P""=-FF 2WAU6&U\^;MP9<NY]\DUYW\
M;_V(?"/C32+K4/!EI%X:\0HADBAMR19W)P,(R=$SC 9, 9Y!IRERJ_04=='N
M?G-14]_8W&EWUQ97<+V]W;R-#-#(,,CJ2&4CU!!%?<?[,/[%^C3>';#Q7X^L
MVU&[O8UN+71Y"5BAC."K2@8+,1@[3P <$$]+C'F7-T(D^5\O4^%:*_5GQ'\,
M_@<MROAO5="\%:=?WB[8[,1VUI>.#P-FW;)GW4YKB/"G["?P\T?6->;5M/?7
MM+N)(Y=-6:\GBEM%PV^)C&ZAQG:0QYP<'IDI?@4S\W:^YOV3?VE/AQ\-/@W8
MZ'XE\1?V;JL=U<2/;_8;F7"L^5.Z.-EY'O7BO[9GPQ\,_"GXF:;I/A73/[*T
M^;2X[EX?/EFS(995+9D9CT5>,XXKVK]DW]FOX<?$SX.V.N>)/#O]I:K+<W$;
MS_;KF+*J^%&V.15X'M3IRYHMHF<>644_ZN?/?[6'C[0?B9\9;_7?#=__ &EI
M4MM;QI<>3)%EE0!AM=5;@^U>.U[%^UAX!T'X9_&6_P!"\-V']FZ5%;6\B6_G
M22X9D!8[G9FY/O7TE^S+^Q?X<_X1'3?%'CJR.L:E?QK=6^F2,RP6T; %-Z@C
M>Y&"0WRC.,'&:SHI<K?2[_,TJ2?,EULOR1\%T5^K$GAOX!VNJ#2)=-^'46I[
MO*^Q20V N-W]W:1NS^M<5\:_V*?!GC;0;NZ\)Z=#X:\21H9+?[(2MK.P'$;Q
MYVJ#TW* 03DYZ4Y2LK]!):V/SCL+7[=?6]ONV>=(L>[&<9(&<5^F_A']E_P-
M\'?!NJW-AIW]J:VMA-G5M2 DF!\MO]6,;8^I'RC..I-?-7[%/P4\,?$36_&,
M'C'0Y+R[T5[80QR7$T#02;I0X(C=<G*#AL]*_0:^L8=0LI[29?,@EC:.1,D9
M4C!&1ST-75C>ERQW:>OD]B8_Q-=D?BA17V/^VE^S_P" OA+\.]&U/PKH7]E7
MUQJJVTDOVRXFW1F&5MN))& Y5>0,\5TW[*O[-/PW^)7P8TC7?$?AS^T=6GEN
M$DN/MUS%D+*RJ-J2*HP .@J8[.W3_@#EI:_4^$J*_3GX=?L<> ?!_B+7-6O=
M!L]52ZN&%AI]\IN;>RMP  -LA;>[$%BS9QD 8Y)\,_;H^'?@SPS<>$K#PMX9
MM--\2ZM.Z^7I<7E*\2X55\I,+N9W&#C/RD4G+X;;OH-*]_+]#XYHK])/@G^Q
M9X,\#:#:7GBS38/$GB-D$EP;W]Y:P$C)C2,_*P'3<P))!(P#BNYTCP?\"_%%
M])INE:-\/]3OHP0]K8VUC+,N.#E4!88K1Z.RU(3TN?E%7IO[.?PKL/C)\5-/
M\-ZG>7%E8RQ2SRR6H7S"$4G:I8$#/K@_2OI?]J[]D+PUHO@W4_&?@RU;2+C3
M5\^[TV-BT$L6?G= Q^0J#G .W"G !KL_V*?A#X2MOAGX7\=QZ5M\5S)=1R:@
M+F8Y7SY(\>7OV?=4#[O;UIT[>])]/UV%4C*RY7O_ $S _:V^$_A3X3_LYO8^
M%]&M],C;4K82RJ"\TWWSEY&RS=3U.!VQ7P/7[)>/_AOX=^*&@G1?$UA_:6F&
M19O(\^2+YUS@[HV5NY[U^;O[8'PX\.?"WXM1:-X7T[^S-,.FPW!@\^2;YV9P
M3ND9C_".,XXKFNXSN^K_ $-M)1MV1]C^'?VR/A!8>'=-MI_%^VXAMHXW7^S+
MPX8* 1D0^HK\V/$5U%?>(-3N8&WPS74LB-@C*ER0<'V-?I/X=_8W^$%_X=TV
MYG\(;KB:VCD=O[3O!EBH).!-ZFOS8\16L5CX@U.V@79##=2QHN2<*'( R?85
M<OXJOOKZ="*?\'3;3\F9]%?:O[-G[$.GZYH=GXG^(4<TR7B":UT2-VB C(RK
MS,,-DC!"J1CC).2!]$W7P_\ @?X:U"VT2^T+P+8ZE* (;.^M[,7,F>!@.-[9
M_&M9*SMU)C+F5^A^4-%?HY\9OV&_!_C+3;B\\(V\?ACQ JEXTAS]CG;LKQ\[
M!Q@%,8SDAJ_/+7M"O_#.M7NDZI;/9ZC92M!/!)U1U."/?ZC@UDI:\KW+:TNM
MBA17Z ?LY_LM?##QY\%_#.O:[X9^W:M>0R-/<?VA=1[R)74?*DH4< =!6CX/
M_9!^&OPQOM7\3>.)-.:S>_E:PM-3N]EC96Y<^4K&1OWKE<9WDCM@D;CJURR:
M?0B,N:*<>I^=U%?K-<? ?X1^.M 7[/X0\-7.FW29CO-)MHHBR_WDFAP?Q!K\
M]/VE_@A_PHWXA?V;:S27.BWL/VJPFF^_LR0T;$<%E(ZCJ"I[UFY<LDGU-%'F
M3:Z'DE%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!]#_L2_
M\E%UO_L%-_Z.BHH_8E_Y*+K?_8*;_P!'144 :G[<G_(S>&O^O:;_ -#6OF2O
MIO\ ;D_Y&;PU_P!>TW_H:U\R4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >W?L>_
M\EBC_P"O"?\ ]EKS;XF?\E(\5_\ 86N__1SUZ3^Q[_R6*/\ Z\)__9:\V^)G
M_)2/%?\ V%KO_P!'/0!S5%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !15W2-%U'Q!?)9:7876I7C\K;V<+2R-]%4$UT\GP3^(D,1E
MD\!>)TC R7;1K@ #Z[* .+HI\T,EO*\4J-'(A*LCC!4CJ".QIE !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7TGX4_Y,N\5?]?W_ +6MZ^;*^D_"G_)EWBK_ *_O_:UO
M0!\V4444 %%%% !1110 4444 %%%% !14EO;RWEQ'!!$\\TC!4CC4LS$]  .
MIKL(_@G\19(Q(G@'Q.\9&0RZ-<D?GLH XNBK>J:3?:'?266I65QI]Y'P]O=1
M-%(OU5@"*J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!])ZQ_R9/H?_7\W_I5-7S97TGK'_)D^A_]?S?^E4U?-E !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!])_ /\ Y-Y^*G_7O/\ ^DQKYLKZ3^ ?
M_)O/Q4_Z]Y__ $F-?-E !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNKJ*-R@C<NF05PQ#$G+ D]S7H'[;G_)R'B;_ *Y6G_I-'7+_ +-OP^LOB?\
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M^6KX(_81_P"3AM,_Z\KK_P!%FBC_ !9>G^8J_P#!BO[R_-'U%^WY_P D'/\
MV$[?^3U^;-?I1^WU&S? =R!D+J5L6]AEA_,BOS7K"G\4O7_(VG\*/V@\(_\
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M*** "BBB@ HHHH UO"/_ "-FB_\ 7[!_Z,6OV@9A'&68A5 R23@"OQ?\(_\
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MES]$V+^%:17*G/M^9G)MM177\CM=(T'P3\#_  BRVL.F>%-#MPOFSR,L2LW
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MF#4<RYK%<KM<_9'PDV/".D?]>47_ * M?CKXL_Y&K6?^OV;_ -&-7[%^$?\
MD4]'S_SYP_\ H"U\Y> _V$?",$MYJ?C9YO$&I7DTDWV2&=X+: ,Q8*"A5V8=
MSN ]N]*<7[:_3_AB:4DJ-NNGZGYV45^D7CS]@KX<^(-)>/P[!=>%]2528IH;
MF2YB+8X$B2LQ(_W2IKX ^(7@+6?AEXNU#P[KMN(-0LWVL5.4D4\JZ'NK#!!_
M/!R*.97Y2^72YSE%>E? SX#:_P#'?Q(^G:24L["UVO?:E,I,=NI)QP/O.<'"
M\9QR0.:^Y/"O["/PLT/3UAU33[[Q'<]6N;R]EAYQSM6%D 'L<GW-:--+4SYD
MW9'YHT5^DGC?]@GX;:_IKIH4=[X6OPI\N:"YDN8RW;>DK,2/964^]?"/Q;^$
M?B#X,^*Y=#U^%0^/,M[J')AN8\X#H?T(/(-1S*]F7RNUT<317T+^R/\ L\^'
M/CU<>)D\07NJ68TL6[0_V;+&F[S#)NW;XWS]P8QCO7N$?_!/GPW#\0K()J.K
M3>$H+7SKE;J>,SW$Y<@1*R1KM3:,L<9Y !YR*<7%I/J3>Z;['P517WG^TQ^R
MU\*O 'PCUCQ%I>EW6AZA8HI@:WOI91-*S!%1UE9_ERV3MP>.M>9?LP_L;+\5
MM#B\5>+;NZL-!F8BSL[,A9KH*<%V8@[4R"!@9/)RO!*C[S:[#EHD^Y\LT5^H
M\?[%/P:6,*?"+2''WVU2\R?REQ7FOQ@_8%\,:AHMS>^ Y;C1]5A0O'87$S3V
M]Q@$[ S9=&/9MQ'MSD3*5E=E15W8^#]$TJ77M:L--@9$FO+B.W1I,[0SL%!.
M.V37WG'^Q;X.^%?PL\5:MJ;-XH\0PZ/>21W-TNRW@<0N0T<63R./F8L<@$;:
M\?\ V-/V?="^+%]K&JZY=:I97_AV^M7@BM)(T4MEF(D#QL3R@'!'>OT#\3^'
MX/%GAW4]%NY)([;4+62TE>$@.J2(48J2" <$XR#6DTU#E6[7Z&=-_O+O9?H?
MBY17TY^UE^S'X7^!'AO0]0T&_P!8O)[Z\>"5=2FB=0H3=E=D2<Y]2:\W^ G[
M/>O?'K7IK>PE73M'LROVW5)D++'GHJKD;W//&0/4CC.<'SWBNA<O=L^YY717
MZ9>'/V$_A1HNGK!J&EWWB"XZM<WM_+&V?9860 ?@3[UE^//V!?AYX@T]QX<%
MYX5OU4^7)'.]U"6_VTE8L1_NLOXU4OO$C\X:*ZWXH?##7OA'XLN?#WB&V$-W
M$-\<L9+13QDG;)&V.5.#[@@@@$8KV3]DC]FWPS\>M/\ $<_B"^U:S?398$A&
MFS1(&#AR=V^-\_='3%.*YTY1Z?\ #"E[C2EU/FZBOOC3_P#@GWX:M?B0'EO=
M4N?!UO:1R-#=7"&>ZN2[;DW(B[8PH7.!N);@^F9^U5^S)\+_ (;_  GOO$6B
MZ;=:'J=O)'%;)#>R2I<2.X&UQ*S\!=S?*0?EJ)248\S_ *Z%1BY2LCX:HHHJ
MA!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?2?A3_DR[Q5_P!?
MW_M:WKYLKZ3\*?\ )EWBK_K^_P#:UO0!\V4444 %%%% !1110 4444 %=G\(
M/A7JWQD\<V/AO2<1/-F2XNG4E+:%<;Y&'?&0 .Y('&:XROO_ /X)W^"8=/\
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MG;;-I%V)3Z+Y+Y-? O[ G_)?(_\ L%W/_LE*E_$E'I:_X"K:TXOS2_%'TO\
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MG9?M<VKB6)>^U(9 Q'MEU'XBLJJ5.TEUL:4I<S<7TO\ E<_/BBBBK)"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ3_ &NO^18^
M&'_7C-_Z!;5\V5])_M=?\BQ\,/\ KQF_] MJ /FRBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH ^^OV'?B5X0\(_!N>RUSQ5HFBWAU2>06^H:C#!(
M5*1X;:[ X.#S[5XI^W9XJT3Q=\6-*O-!UC3];M$TB.)KC3KI+B-7$LI*ED)
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M9TR?]DHV/]\UYM_P3U\/W6H?&+4M62-OL>GZ7(LLO8/(ZA%^I"N?^ FO;_\
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M;;_Y.0\3?]<[3_TFCKPJHI_":U?B^2_(****U,0HHHH **** "BBB@ HHHH
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MW8]?.?K^&*_,>OO/_@G7\0+>Z\+^(/!T\P%Y9W']H6\;$9>%PJO@?[+*"?\
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M*FE!6\_T)C;VNI^5NN?$SQ5XB\6?\)-?Z]?S:ZLGFQWOGLKPG.<1X/R =E7
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M +Q;T/RZ\2>-O$7C*2"37]>U/77MP5A;4KR2X,8.,A2['&<#IZ5^J/[,O_)
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M2_\ !._Q[JDWB+7O"-Q>RW&EK9?;[:VD8LL+K(JML_N@^8,CU /K7 ?M\?\
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M%IL;[(<LY<E@N-YW$D%LX[8KFZ*UZ6,S[<_X)K_\U _[</\ VXJK_P %)O\
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MOFE\C16@K1^844459(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'T/^Q+_P E%UO_ +!3
M?^CHJ*/V)?\ DHNM_P#8*;_T=%10!J?MR?\ (S>&O^O:;_T-:^9*^F_VY/\
MD9O#7_7M-_Z&M?,E !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW0U>UF?I9\>/VR?"7PYT6ZL_#>H6WB7Q/(FV".S<2VUNQR-\LB_*<?W%))(
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M)&.@;*LCCT)4G'0UH^ ?A7X"_9O\+WTVG^5I-H0'O=6U*<>9)MZ;Y#@ >BJ
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M.,99SC)XZDY->3_L'RVLG[/NG+;E#*E[=+<;>OF>82,^^PI^&*\._;A^$'Q
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M9?%7Q+\(?$2ZSX;O_LER1LFA==\-PF<[)$[C\B.Q%?3^C?\ !234K>RC35?
MMK>W8'SRV>I-;HQ]0C1R$?\ ?1KXRHJN9V%RJ]S[)U[_ (*1:Q=V+IHO@FST
MZ[_AFOK][I!_P!4CS_WU7RSX^^(6O_$[Q)/KOB349-1U&4!=S !8T'1$4<*H
MR>!ZD]237.45'*KW*N[6"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ]N_8]_Y+%'_P!>$_\ [+7FWQ,_Y*1XK_["UW_Z.>O2?V/?^2Q1_P#7A/\
M^RUYM\3/^2D>*_\ L+7?_HYZ .:HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KZ3\*
M?\F7>*O^O[_VM;U\V5])^%/^3+O%7_7]_P"UK>@#YLHHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#Z3UC_DR?0_^OYO_2J:OFROI/6/^3)]#_Z_F_\
M2J:OFR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P!$^\*_^"6V_P#B*_*7XJ6<&G_$_P 7VMK!';6L&L7D44$*!$C19W"JJC@
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M_P#Z+:N0_P""CW_(Y>#_ /KQG_\ 1BUU_P#P3=_Y%3QI_P!?MO\ ^BVKD/\
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MX3^-GVS3[?RK?Q! MYY<8X^T;BDF .Y(5C[N:^AO^'B7PWR#_8GBK_P$MO\
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M'(\F+Y01[,VY_P#@=>65G3U7-WU_R-9Z:=M/\PHHHK4S"BBB@ HHHH ****
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M ->$_P#[+7FWQ,_Y*1XK_P"PM=_^CGH YJBBB@ HHHH **** "BBB@ HHHH
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MY8<2*& ;=&RGHS<9QS7G?_#%?P9_Z$W_ ,JE[_\ 'J_.O_A>?Q(_Z*#XJ_\
M!U<__%T?\+S^)'_10?%7_@ZN?_BZRL5KU/T3_P"&*_@UMS_PAO\ Y5+W_P"/
M5\:?MG?"WPQ\)_B)I&E^%M+_ +*LKC3%N9(?M$LVZ0RR*6S(S$<*. <<5YO_
M ,+S^)'_ $4'Q5_X.KG_ .+KGO$7BS7/&%Y'=Z]K.H:W=1IY23ZE=27#JF2=
MH9R2!DDX]S1K=6'%JS36Y^I/[*?_ ";OX(_Z\C_Z,>OSU_:F_P"3@O&__7]_
M[(M<MI/Q<\<Z#IT&GZ9XT\0Z=80+MBM;359XHHQG.%57  Y[5SVJ:M?:[J$]
M_J5[<:C?3MOFNKJ5I99&]69B23]:*B]I6]HO/\69TUR4U!]+?@?:/_!-?_FH
M'UL/_;BJO_!2;_D)^ ?^N5]_Z%!7R3X9\<^)/!GVC^P/$&JZ']HV^=_9E[+;
M^;MSMW;&&<9.,],FD\2>-_$?C1K=O$&OZIKK6X80G4KR2X,0;&[;O8XS@9QU
MP*NL_:2C)=+?@BHZ7\S])OV-?'VG>,_@=HMC;S1C4-%C^P7ELI^9-I.QL>C+
M@YZ9W#L:Y7XK?L)Z'\2O']WXEMO$5UH:W\WGWUFMJLP=SC<T;%EV;N2<AN2?
MI7P'X1\;:]X!UA-5\.ZM=:/?J-OG6LA7<N<[6'1ER!\I!'%>C:M^U[\7M:T^
M6RN/&MRD$B[6:UM;>WDQ[21QJX^H-*=G+F2U)IIQ7+T/T6^$/AKP?\-])G\"
M^%;I)Y=%"27T;2B2<22Y(>4@ ;FVDXXP . ,5\4?\%"-#GL?C-I^HM&1;7^E
M1[).S.CNK#Z@%/S%?/F@^/O$WA>ZN[G1?$>K:1<WAS<S6%]+ \YR3ERK MR2
M>?4TGB3QUXE\:?9_[?\ $.JZ[]GW>3_:5[+<>5NQNV[V.,X&<>@J))R<9/=%
MQM%-+9_\.?J=^S(/^+!^!O\ L%Q?UKS[XL?L\^"/VIL^(=)UMM,UNU=]/N+V
MUC64;XVVM'/$2#N7! (8'!'4;:^!--^+WCS1=/@L-.\;>(K"QMU"0VUKJL\<
M4:CHJJK@ >PJ/P?\5/%W@'7)]9T#Q#?:?J-PQ>XF64O]H8DDF56RLAR2?F!Y
M.:N5IR;9G#FA%)>A^EW[/_[-F@? .QO&L[F75M:O %N=3N$"$H.0B("=BYY/
M))/4\ #Y5_;N^.%AXX\06'@_0[I+S3M'D::\N(FW))=$;0@/?8NX$CNY':O)
M?%7[4GQ3\::3)INJ^,+I[*4;9([6&&U+J>"K-$BD@]P3@UY76<E*;5]D:QM%
M.V[/O+_@FW_R*OC3_K]M_P#T6U<A_P %'O\ D</!W_7C/_Z,%?+7AOX@>)_!
ML,T7A_Q)J^A13,&E33;Z6W60@8!8(PR1[U%XD\9>(/&4T,WB#7=2UR6%2D4F
MI7DEPT:DY(4N3@9]*JLO:3C)=+?E8RHKV<7%];_B?<?["/QUT_5O"</P]U:Z
M2#6=/9SIPE;'VJ DL44GJZ$MQ_=QCH<=9\</V*- ^+_B>7Q%8ZQ-X:U:Z*F\
M\NV%Q#.0,;]FY2KD8R0V#CIG)/YM0SR6LT<T,C131L'22-BK*P.001T(->N:
M+^UQ\7?#]A'9VOC6[DAC&%-Y;P74GXO+&S'\35RM-J3W'&\4UT/T.^&/PC\+
M? ?X<RZ/'*CZ?$7O+_4-2V 2-@;G?/RJH50 .P'<Y)_.#]HSX@:%\1?BGJ6I
M>&],M=-T.("VMOLMLL!N I.9G"@9+,203SMV@UF>/OCIX]^*$ M_$WB>]U*U
M&#]E!6& D'()CC"J2/4C-<)6;O*7-(M6C&R/T^_9'^.5A\5OAW9:9<7*KXGT
M>!+:\MW8;Y44!4G7U!&,^C9]1GE/BI^P7X=\?^,+G7=*UZX\-F]F,]Y:+:BX
MC9V.6:/YU*9.2<[AD\ #BOSZT77-1\-ZI;ZCI-]<:;?V[;HKJUE:.1#TX8'(
MXKU6X_; ^+]UI[V3^-+A86386CM+9)<8QQ(L8<'W!S5SM)\UM2(IQ7+T/T*^
M%'AWP7\)U3X<>&9P]_9V_P!OND9@\[;BJ^;,P &YN,#CA>  !7S+_P %)O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110![=^Q[_ ,EBC_Z\)_\ V6O-OB9_R4CQ
M7_V%KO\ ]'/7I/['O_)8H_\ KPG_ /9:\V^)G_)2/%?_ &%KO_T<] '-4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5])^%/\ DR[Q5_U_?^UK>OFROI/PI_R9=XJ_
MZ_O_ &M;T ?-E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?2>L?\F3
MZ'_U_-_Z535\V5])ZQ_R9/H?_7\W_I5-7S90 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?2?P#_ .3>?BI_U[S_ /I,:^;*^D_@'_R;S\5/^O>?_P!)C7S90 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7TG^UU_R+'PP_Z\9O\ T"VKYLKZ3_:Z_P"18^&'_7C-_P"@6U 'S911
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\ (O\
M\11_PQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_W5_*@#\T_P#AB/Q3_P!![2/_
M "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\ X8C\4_\
M0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(
M_%/_ $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_W5_*@#\T
M_P#AB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?
MRH _-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'
MEK_=7\J /S3_ .&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\ XBOTL\M?
M[J_E1Y:_W5_*@#\T_P#AB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K
M]+/+7^ZOY4>6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%
M_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#
MVD?^1?\ XBOTL\M?[J_E1Y:_W5_*@#\T_P#AB/Q3_P!![2/_ "+_ /$4?\,1
M^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q
M%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\
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M_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\
MX8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J
M/S3_ .&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_
MW5_*@#\T_P#AB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZO
MY4>6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2S
MRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\
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M (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^1?\
MXBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^
M1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#
MVD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'X
MI_Z#VD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\
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M (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^1?\
MXBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^
M1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#
MVD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'X
MI_Z#VD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\
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M (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^1?\
MXBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^
M1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#
MVD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'X
MI_Z#VD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\
MPQ'XI_Z#VD?^1?\ XBO5M%^ 6KZ;\!-9\!OJ-B^H7MSYR7*[_*4>9$V#\N<X
MC/;N*^UO+7^ZOY4GDIG.Q<_2@#\U/^&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#
MVD?^1?\ XBOTL\M?[J_E1Y:_W5_*@#\T_P#AB/Q3_P!![2/_ "+_ /$4?\,1
M^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q
M%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\
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M_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\
MX8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J
M/S3_ .&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_
MW5_*@#\T_P#AB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZO
MY4>6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2S
MRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\
MXBOTL\M?[J_E1Y:_W5_*@#\T_P#AB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'
M_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG
M_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\ (O\ \11_
MPQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_W5_*@#\T_P#AB/Q3_P!![2/_ "+_
M /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\ X8C\4_\ 0>TC
M_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_
M $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_W5_*@#\T_P#A
MB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _
M-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=
M7\J /BF^^ 6KW7[/^G^ 5U&R&HVUP9FNCO\ )(,TDF!\N>C@=.U>4_\ #$?B
MG_H/:1_Y%_\ B*_2OR4SG8N?I2^6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q
M%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\
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M_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\
MX8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J
M/S3_ .&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_
MW5_*@#\T_P#AB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZO
MY4>6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2S
MRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\
MXBOTL\M?[J_E1Y:_W5_*@#\T_P#AB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'
M_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG
M_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_ $'M(_\ (O\ \11_
MPQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_W5_*@#\T_P#AB/Q3_P!![2/_ "+_
M /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _-/\ X8C\4_\ 0>TC
M_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=7\J /S3_ .&(_%/_
M $'M(_\ (O\ \11_PQ'XI_Z#VD?^1?\ XBOTL\M?[J_E1Y:_W5_*@#\T_P#A
MB/Q3_P!![2/_ "+_ /$4?\,1^*?^@]I'_D7_ .(K]+/+7^ZOY4>6O]U?RH _
M-/\ X8C\4_\ 0>TC_P B_P#Q%'_#$?BG_H/:1_Y%_P#B*_2SRU_NK^5'EK_=
M7\J /BGX:_ +5_!/PP\9>&;K4;*>ZUN*2.&:'?LC+1%!NRN>I[5Y3_PQ'XI_
MZ#VD?^1?_B*_2SR4_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 11_PQ'XI_
MZ#VD?^1?_B*_2SRU_NK^5'EK_=7\J /S3_X8C\4_]![2/_(O_P 17JWQN^ 6
MK_%#2?"-I8:C96CZ-;R0S-<;\.66( KA3_SS/7U%?:WEK_=7\J3R4'1%'X4
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M (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^1?\
MXBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^
M1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#
MVD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'X
MI_Z#VD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\
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M (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^1?\
MXBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#VD?^
M1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'XI_Z#
MVD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\ PQ'X
MI_Z#VD?^1?\ XBC_ (8C\4_]![2/_(O_ ,17Z6>6O]U?RH\M?[J_E0!^:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >,6<-]J5UJ;-K6I1".\E
MB58[E@, \?SJU_8]Y_T'M6_\"FI-!_UVL?\ 80F_F*UJ ,K^Q[S_ *#VK?\
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M/^@]JW_@4U']CWG_ $'M6_\  IJU:* ,K^Q[S_H/:M_X%-1_8]Y_T'M6_P#
MIJU:* ,K^Q[S_H/:M_X%-1_8]Y_T'M6_\"FK5HH RO['O/\ H/:M_P"!34?V
M/>?]![5O_ IJU:* ,K^Q[S_H/:M_X%-1_8]Y_P!![5O_  *:M6B@#*_L>\_Z
M#VK?^!34?V/>?]![5O\ P*:M6B@#*_L>\_Z#VK?^!34?V/>?]![5O_ IJU:*
M ,K^Q[S_ *#VK?\ @4U']CWG_0>U;_P*:M6B@#*_L>\_Z#VK?^!34?V/>?\
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M8]Y_T'M6_P# IJU:* ,K^Q[S_H/:M_X%-1_8]Y_T'M6_\"FK5HH RO['O/\
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M:M_X%-1_8]Y_T'M6_P# IJU:* ,K^Q[S_H/:M_X%-1_8]Y_T'M6_\"FK5HH
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M_P"@]JW_ (%-1_8]Y_T'M6_\"FK5HH RO['O/^@]JW_@4U']CWG_ $'M6_\
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M[S_H/:M_X%-1_8]Y_P!![5O_  *:M6B@#*_L>\_Z#VK?^!34?V/>?]![5O\
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MM_X%-1_8]Y_T'M6_\"FK5HH RO['O/\ H/:M_P"!34?V/>?]![5O_ IJU:*
M,K^Q[S_H/:M_X%-1_8]Y_P!![5O_  *:M6B@#*_L>\_Z#VK?^!34?V/>?]![
M5O\ P*:M6B@#*_L>\_Z#VK?^!34?V/>?]![5O_ IJU:* ,K^Q[S_ *#VK?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH#Y<;?[669CZ9 ZBOCS]DO\ :8/P.\3I8:M9VUQX9U"0)<W"VZ"YM23CS%D
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MXQ&" 6#H67&6 Y()STKAC1JR@ZD8W2/0GB*4*BIR=I/8^=_^"G7_ !\?#_\
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MVE6VBG2[?P_H,4HN&M(9C-)-( 0"\A"Y R< *.>3GC'U1_P[9^&7_0=\6?\
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M3_>7/RHWNB@UZ[6&*QU.5+V&'C:)OA<OJ*K]8Q,N:7]?D?"'_!3K_CX^'_\
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M9&F < D'///&3GUL;BJ.*I1DM)K^FCR,#@Z^$K2CO!_TF>AT445X1] %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&3H/^NUC_L(3?S%:U9.@_P"NUC_L(3?S%:U !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!DZ#_KM8_["$W\Q6M6#HMMK
MEQ<:L^G:4MY#]OFW.9T3:V1E<$^F.?>M/^S_ !9_T+Z_^!<?^- %NBJG]G^+
M/^A?7_P+C_QH_L_Q9_T+Z_\ @7'_ (T 6Z*J?V?XL_Z%]?\ P+C_ ,:/[/\
M%G_0OK_X%Q_XT 6Z*J?V?XL_Z%]?_ N/_&C^S_%G_0OK_P"!<?\ C0!;HJI_
M9_BS_H7U_P# N/\ QH_L_P 6?]"^O_@7'_C0!;HJI_9_BS_H7U_\"X_\:/[/
M\6?]"^O_ (%Q_P"- %NBJG]G^+/^A?7_ ,"X_P#&C^S_ !9_T+Z_^!<?^- %
MNBJG]G^+/^A?7_P+C_QH_L_Q9_T+Z_\ @7'_ (T 6Z*J?V?XL_Z%]?\ P+C_
M ,:/[/\ %G_0OK_X%Q_XT 6Z*J?V?XL_Z%]?_ N/_&C^S_%G_0OK_P"!<?\
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M_ N/_&@"W153^S_%G_0OK_X%Q_XT?V?XL_Z%]?\ P+C_ ,: +=%5/[/\6?\
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MXT?V?XL_Z%]?_ N/_&@"W153^S_%G_0OK_X%Q_XT?V?XL_Z%]?\ P+C_ ,:
M+=%5/[/\6?\ 0OK_ .!<?^-']G^+/^A?7_P+C_QH MT54_L_Q9_T+Z_^!<?^
M-']G^+/^A?7_ ,"X_P#&@"W153^S_%G_ $+Z_P#@7'_C1_9_BS_H7U_\"X_\
M: +=%5/[/\6?]"^O_@7'_C1_9_BS_H7U_P# N/\ QH MT54_L_Q9_P!"^O\
MX%Q_XT?V?XL_Z%]?_ N/_&@"W153^S_%G_0OK_X%Q_XT?V?XL_Z%]?\ P+C_
M ,: +=%5/[/\6?\ 0OK_ .!<?^-']G^+/^A?7_P+C_QH MT54_L_Q9_T+Z_^
M!<?^-']G^+/^A?7_ ,"X_P#&@"W153^S_%G_ $+Z_P#@7'_C1_9_BS_H7U_\
M"X_\: +=%5/[/\6?]"^O_@7'_C1_9_BS_H7U_P# N/\ QH MT54_L_Q9_P!"
M^O\ X%Q_XT?V?XL_Z%]?_ N/_&@"W153^S_%G_0OK_X%Q_XT?V?XL_Z%]?\
MP+C_ ,: +=%5/[/\6?\ 0OK_ .!<?^-']G^+/^A?7_P+C_QH MT54_L_Q9_T
M+Z_^!<?^-']G^+/^A?7_ ,"X_P#&@"W153^S_%G_ $+Z_P#@7'_C1_9_BS_H
M7U_\"X_\: +=%5/[/\6?]"^O_@7'_C6YX;TUY_,BUJ%;&^)S':K<(S,F/O<'
MUR/PH SJ*[#_ (1>R])/^^J/^$7LO23_ +ZH X^BNP_X1>R])/\ OJC_ (1>
MR])/^^J ./HKL/\ A%[+TD_[ZH_X1>R])/\ OJ@#CZ*[#_A%[+TD_P"^J/\
MA%[+TD_[ZH X^BNP_P"$7LO23_OJC_A%[+TD_P"^J ./HKL/^$7LO23_ +ZH
M_P"$7LO23_OJ@#CZ*[#_ (1>R])/^^J/^$7LO23_ +ZH X^BNP_X1>R])/\
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M X^BNP_X1>R])/\ OJC_ (1>R])/^^J ./HKL/\ A%[+TD_[ZH_X1>R])/\
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M G"[C"9AN ]<=<5)_P (_I?_ #T_\B"@#DZ*ZS_A']+_ .>G_D04?\(_I?\
MST_\B"@#DZ*ZS_A']+_YZ?\ D04?\(_I?_/3_P B"@#DZ*ZS_A']+_YZ?^1!
M1_PC^E_\]/\ R(* .3HKK/\ A']+_P">G_D04?\ "/Z7_P ]/_(@H Y.BNL_
MX1_2_P#GI_Y$%'_"/Z7_ ,]/_(@H Y.BNL_X1_2_^>G_ )$%'_"/Z7_ST_\
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MG^-%F!K45D^9XC_Z :_^!*?XT>9XC_Z :_\ @2G^-%F!K45D^9XC_P"@&O\
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M_@2G^-%F!K45D^9XC_Z :_\ @2G^-'F>(_\ H!K_ .!*?XT68&M163YGB/\
MZ :_^!*?XT>9XC_Z :_^!*?XT68&M163YGB/_H!K_P"!*?XT>9XC_P"@&O\
MX$I_C19@:U%1:']LDOU36K2/3+,@@3&Y3ENR]>_/Y44@-OX9_P#'KKO_ &%I
M_P"2UV5<;\,_^/77?^PM/_):[*@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D_BE
M_P B)J?_ &R_]&I72V?_ !Z0?]<U_E7-?%+_ )$34_\ ME_Z-2NEL_\ CT@_
MZYK_ "H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCM0_Y*EI7_ %X2?S:NQKCM
M0_Y*EI7_ %X2?S:@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^
MOO\ DIUU_P!@Y?\ T,5LUC7W_)3KK_L'+_Z&*V:TCL2PHHHIB"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .9\1?\ (T>&O]^;_P!!6NFKF?$7_(T>&O\ ?F_]!6NFH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KF?!_\ Q_>(?^O]ZZ:N9\'_ /']XA_Z_P!Z .FHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MYOQY_P @>#_KZB_G11X\_P"0/!_U]1?SHJ);C-KX9_\ 'KKO_86G_DM=E7&_
M#/\ X]==_P"PM/\ R6NRJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D_BE_R(FI
M_P#;+_T:E=+9_P#'I!_US7^5<U\4O^1$U/\ [9?^C4KI;/\ X](/^N:_RH G
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KCM0_P"2I:5_UX2?S:NQKCM0_P"2I:5_
MUX2?S:@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^OO^2G77_8
M.7_T,5LUC7W_ "4ZZ_[!R_\ H8K9K2.Q+"BBBF(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH YGQ%_R-'AK_?F_P#05KIJYGQ%_P C1X:_WYO_ $%:Z:@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9\'_
M /']XA_Z_P!ZZ:N9\'_\?WB'_K_>@#IJ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .;\>?\@>#_KZ
MB_G11X\_Y \'_7U%_.BHEN,VOAG_ ,>NN_\ 86G_ )+795QOPS_X]==_["T_
M\EKLJDH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **2EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHI* %HHHH **** "BBB@ HI*6@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/XI?\ (B:G_P!LO_1J5TMG
M_P >D'_7-?Y5S7Q2_P"1$U/_ +9?^C4KI;/_ (](/^N:_P J )Z*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *X[4/^2I:5_P!>$G\VKL:X[4/^2I:5_P!>$G\VH [&
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** //K[_ )*==?\ 8.7_ -#%
M;-8U]_R4ZZ_[!R_^ABMFM([$L****8@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#F?$7_
M "-'AK_?F_\ 05KIJYGQ%_R-'AK_ 'YO_05KIJ "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGP?_ ,?WB'_K
M_>NFKF?!_P#Q_>(?^O\ >@#IJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"V.IQ7FG[/GQGL/CU\+M(\6V,8MYIE,-Y:!L_9KA.)(\]QG!![JRGO7YO_\
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M/4?G1N'<BOQ'^('[(/Q<^%OA*\\2^)_"1TO1+,H)[K^T;.79N8*ORQS,QRS
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MR=DOQ/)K9A"G6C1BKMM)Z['ZD44E+7FGK!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% ')_%+_D1-3_ .V7_HU*Z6S_ ./2#_KFO\JYKXI?
M\B)J?_;+_P!&I72V?_'I!_US7^5 $]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=
MJ'_)4M*_Z\)/YM78UQVH?\E2TK_KPD_FU '8T444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Y]??\E.NO^P<O_H8K9K&OO\ DIUU_P!@Y?\ T,5LUI'8
MEA1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 <SXB_Y&CPU_OS?^@K735S/B+_ )&C
MPU_OS?\ H*UTU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<SX/\ ^/[Q#_U_O735S/@__C^\0_\ 7^] '344
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 <WX\_Y \'_7U%_.BCQY_R!X/^OJ+^=%1+<9M?#/\ X]==
M_P"PM/\ R6NRKC?AG_QZZ[_V%I_Y+795)04444 %%%% !1110 4444 %%%%
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M >$?#7B/Q=_9VM6%O*MQ;#3+R7RV,\C ;DA93PP/!/6O63_P4#^ ?&/'A_\
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M>!K+4-0O[S5T6ZM[*7RD:#RI,^<Q8*$W;?OG&<=\5X:?^"MQ_P"B5#_PHO\
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M2?S:@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^OO^2G77_8.7
M_P!#%;-8U]_R4ZZ_[!R_^ABMFM([$L****8@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
MF?$7_(T>&O\ ?F_]!6NFKF?$7_(T>&O]^;_T%:Z:@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=U$&;4O%.M".W5AG8)) D:GV5=H^BU]D?\.D3@'_ (6KU_ZE[_[JKT3]G_\
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MJ-QI<L=Y8L]AJVCW.8VEB)&^,G'!!565N1D \@\_M#X1TF^T#PKI&FZEJ/\
M:]_9VL=O/?\ E>5]I=$"F39N;:6(SC)ZUYG\>/V3OA]^T'&)_$6G26FM1H(X
MM:TUQ%=*HZ*Q(*NOLX.,G&*X\'BHX9SIRUA+?_,[<9@Y8J$*D?=J1V.'TG_@
MHU\$=0T2.^NO$%]IEV4W-ID^EW#3JW]W=&C1D_\  \5\!_M@?M13_M,>-+-[
M"TGT[POI2M%IUG.1YLC,1OED ) 9L*  3@#J<FOI6\_X)*VLEXS6GQ-F@L\_
M+%-HBR2 >A<7"@GWVU[3\#_^"?\ \./@WJUMKDZW7BO7[<AX;G5=ODP2#^..
M%1@'N"Y<@@$8-=E.>7X>7M8-MK9=OP1PU(9AB(^QFDD]WW_$E_8)^!MW\%_@
MO%+K-JUIXAU^;^T+R&1</!'MQ%$WH0OS$'H9&':OBS_@IG_R<P__ &!K3^<E
M?K5MQ@#BOD?]IK]@D_M%?$T^+AXY_P"$?S9PVGV/^R?M/W-WS;_/3KNZ8[5R
M8?%+ZW]8K.RU.S$8-K!/#TE=Z?/4Y?\ 97_;*^#_ ,-?V?\ PCX;\1^+_P"S
MM;L8)5N;7^S+R7RV,\C ;DA93PP/!/6O6/\ AX%\ ^WCS_RCW_\ \8KYY_X=
M(D_\U5_\MW_[JH_X=(GM\5?_ "W?_NJNJI'+ZLY3E4=VV_O^1QT99C1IQIQI
MJR26_;YGU5\//VNOA-\6/%-MX;\*^*O[5UJY1WBM?[.NX=RHI9CNDB51@ GD
MU\_?\%7O^26^"?7^V7_]$-70?LZ_\$^6^ ?Q6TWQE_PGO]NBRCFC^PC1_LV_
MS(V3._[0^,;L_=YQ7J/[5W[,I_:>\*Z)H_\ PD?_  C?]FWC7?G?8?M?F90I
MMV^8F.N<Y-<3^KT<1"5*3<59N_KZ([X_6JV'J1K12D[I6ZJWJ?$W_!//]H3P
M!\"[7QNGC?7O[%;4GLS:C[%<7'F;!-O_ -5&^,;UZXZU]B#_ (*!? /J?'AS
M_P!@>_\ _C%?/7_#I$_]%5_\MW_[JH_X=(_]55_\MW_[JKTL1+ 8JHZLZCN[
M;+LK=CS,+',,-35*%-6UW?\ P3ZO^&_[6OPI^+GBB+P[X2\4?VMK,L;RI;?V
M==PY5!ECNDB5>![U\0_\%6/^2M>$/^P*?_1[U[]^S;^P%_PSW\4+7QA_PG?]
MOB"VF@^Q_P!D?9MWF+MSO\]^GIMK>_:L_8I/[3GBS1]<_P"$Q_X1O^S[,V?D
M?V7]J\SYV?=N\Y,?>QC!Z=:X(RPV'Q=.=*3<%NWWLUV]#NG'%8C"5(58I3>R
M75:'CW[$_P"UI\*/A#\!],\.^+?%/]E:S%=W,DEM_9UW-A7D)4[HXF7D>]>]
M?\/!/@'_ -#V?_!/?_\ QBOGG_ATB?\ HJO_ );O_P!U4?\ #I$_]%5_\MW_
M .ZJZZO]GUINHZCN_P"NQR47F-&FJ<:2LO/_ ()]0>"_VT/@Y\0_%.G^'/#_
M (P^WZSJ$GEVUM_9EY%YC8)QN>$*. >I%>W9XX&:^)O@O_P3;/PA^*7A[QC_
M ,+$_M?^R9S-]B_L3R?-^1EQO^T-M^]UVGI7VRH[5Y6)CAXR7U>3:ZW_ .&1
M[&%GB)1?UB*3Z6_X<^<O^"@W_)JOB_\ WK3_ -*8J^-O^"6O_)PNL?\ 8NW'
M_I1;5^A_[0WP@/QU^%.L>#!JW]B'4#"1>_9_/\O9*K_<WIG.W'WAUKQC]EK]
MAD_LU_$2\\4?\)K_ ,)$+C3I-/\ LO\ 97V7;NDC??O\]\X\O&,=^O%=F$Q%
M*EAJM.3UEM]R.+'8>K5Q-*I!74;7^\^L/\*\G^*O[,7PU^-VN6VK^-?#9UC4
MK6W%I%-]ONH-L09F"[8I5!Y9CDC/->L9HKR8RE%IQ=FCV91C.+C)73/G7_AW
MY\ _^A$_\K%__P#'Z]_T^QATRQM[6W3R[>!%CC3).U5  &3R>!WJT!S2FKG5
MJ5-)R;]69TZ-.D[PBEZ*Q\R?\%%O^35?$W_7S9?^E4=?*G_!*O\ Y++XI_[
M9_\ 1\=?>O[1GP9_X7]\*]3\%C5_["-[)!)]N^S?:-GERJ^-F],YVX^]QFO*
MOV5?V)6_9E\9:KKW_"9?\)']NL?L0M_[+^R[/WB/NW><^?N8Q@=>M>CA<13I
MX6K2D]9/3[D>3C,-5JXNE5@KQCO]Y]3T445Y1[@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!R?Q2_Y$34_P#ME_Z-2NEL_P#CT@_ZYK_*
MN:^*7_(B:G_VR_\ 1J5TMG_QZ0?]<U_E0!/1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 444F: %HIN]?[P_.C>O]X?G0*Z'44FX'
MH<TM PHI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *X[4/\ DJ6E?]>$G\VKL:X[4/\ DJ6E?]>$
MG\VH [&BBB@ HHHH **** "BBB@ HI** %HHI* $R!1QS7D_[57C;6OAS^SI
M\0O$_AV]_L[7-+TB:ZL[KRDE\J11E6V.K*WT8$5XK_P3'^/'CK]H;X&Z[XA^
M(&N?\)!K%MXAFLHKG[)!;;85M[=PFV&-%/S2.<D9YZ\"B*YN9+I8)>ZD^[L?
M8E%%% !1110 4444 %%)FB@!:*** &_=HKF?B1JMUH/P_P#$NHV,OD7EGIMS
M<02[0VR1(F96P00<$#@C%?CS\%?VK?VXOVB)M7A^'GB=O$<NDK&UXJ:;HEOY
M0D+!#^^A3.=C=,].:SC+FDX+=),;5H\SV/VMH-?E)]M_X*:_W9O^_/AO_"LZ
MT_X*-?M(_LR>,M.T7X^>!X]1T^X.YY9;)+*[DCR-S6\T)^SR;=PRH4\X!9<Y
MK2VJ5]R7?HKGZUT?A7D7C3Q]K7Q,_9JU3Q9\&;O[=K^K:*;OPY.JPY:9ER@*
MS_NPP.05DX!!!Z5\!_;?^"FG]V;_ +\^&_\ "EJI.+6J&M4I(_5GUI<U^)7C
M#]KS]MSP!\5--^&^O>*SI_C349;>&UTLZ7HCF1YV"PCS$A,8W$@<L,=\5ZU]
MM_X*:=EF/_;'PW_A19VYN@/1VZGZM9H[X-?-?[+MG\?=;^ >O67QDU:XT#XD
M3W=S'8ZG%;Z=(]K"8H_)D"0(T#X?><,I)Z'M7R;\!?V[/BS\)?VJ-0^%/[1N
MMQZA:33C3XM1:QMK5+28G,$X:&.,-!*&7E@<;E/RX8&DKS]FGK8F_N.=MG9_
MYGZCT8% .17R)_P4(_;2@_9:^'@TWP_<PR?$?78V73(2JR?88N0UW(C @@$$
M(K##-V(5JB4N4TBN;8^NZ*^<_P!B%?C)J?PEM_$GQI\43:QKVMA+JTTF33K2
MT_LVV(R@?R(D)D<$,0WW1M& 0U?1E7*/*[=3.,E)70M%%%(H**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //;[_DIUU_V#E_]#%;5
M>3_M'_\ (H_%/_L2=0_])WK\9*]C!8'ZW%RYK6\CQL=F'U.2CRWOYV/WSHK\
M#**]'^R/[_X'F?VY_<_'_@'[YT5^!E%']D?W_P  _MS^Y_7W'[YT5^!E%']D
M?W_P#^W/[G]?<?OG17X&44?V1_?_  #^W/[G]?<?OG17X&44?V1_?_ /[<_N
M?U]Q^^=%?@911_9']_\  /[<_N?U]Q^^=%?@911_9']_\ _MS^Y_7W'[YT5^
M!E%']D?W_P  _MS^Y_7W'[YT5^!E%']D?W_P#^W/[G]?<?OG17X&44?V1_?_
M  #^W/[G]?<?OG17X&44?V1_?_ /[<_N?U]Q^^=%?@911_9']_\  /[<_N?U
M]Q^^=%?@911_9']_\ _MS^Y_7W'[YT5^!E%']D?W_P  _MS^Y_7W'[YT5^!E
M%']D?W_P#^W/[G]?<?OG17X&44?V1_?_  #^W/[G]?<?OG17X&44?V1_?_ /
M[<_N?U]Q^^=%?@911_9']_\  /[<_N?U]Q^^=%?@911_9']_\ _MS^Y_7W'[
MYT5^!E%']D?W_P  _MS^Y_7W'[YT5^!E%']D?W_P#^W/[G]?<?OG17X&44?V
M1_?_  #^W/[G]?<?OG17X&44?V1_?_ /[<_N?U]Q^^=%?@911_9']_\  /[<
M_N?U]Q^^=%?@911_9']_\ _MS^Y_7W'[YT5^!E%']D?W_P  _MS^Y_7W'[YT
M5^!E%']D?W_P#^W/[G]?<?OG17X&44?V1_?_  #^W/[G]?<?N;XB_P"1H\-?
M[\W_ *"M=-7X&44?V/\ W_P_X(?VY_<_K[C]\Z*_ RBC^R/[_P" ?VY_<_K[
MC]\Z*_ RBC^R/[_X!_;G]S^ON/WSHK\#**/[(_O_ (!_;G]S^ON/WSHK\#**
M/[(_O_@']N?W/Z^X_?.BOP,HH_LC^_\ @']N?W/Z^X_?.BOP,HH_LC^_^ ?V
MY_<_K[C]\Z*_ RBC^R/[_P" ?VY_<_K[C]\Z*_ RBC^R/[_X!_;G]S^ON/WS
MHK\#**/[(_O_ (!_;G]S^ON/WSHK\#**/[(_O_@']N?W/Z^X_?.BOP,HH_LC
M^_\ @']N?W/Z^X_?.BOP,HH_LC^_^ ?VY_<_K[C]\Z*_ RBC^R/[_P" ?VY_
M<_K[C]\Z*_ RBC^R/[_X!_;G]S^ON/WSHK\#**/[(_O_ (!_;G]S^ON/WSHK
M\#**/[(_O_@']N?W/Z^X_?.BOP,HH_LC^_\ @']N?W/Z^X_?.BOP,HH_LC^_
M^ ?VY_<_K[C]\Z*_ RBC^R/[_P" ?VY_<_K[C]\Z*_ RBC^R/[_X!_;G]S^O
MN/WSHK\#**/[(_O_ (!_;G]S^ON/WSHK\#**/[(_O_@']N?W/Z^X_?.BOP,H
MH_LC^_\ @']N?W/Z^X_?.BOP,IRT?V1_?_ /[<_N?U]Q^^-%?@I'4BTO['_O
M_A_P1_VY_<_$_>>BOP<7M4J]J/['_O\ X?\ !*_MK^Y^)^[U%?A*M2+VH_LG
M^_\ A_P0_MK^Y^)^ZU%?A:M2+TH_LC^_^'_!#^VO[GXG[G45^&D?>GKUJ?[)
M_O?A_P $?]M?W/Q_X!^Y%%?AVM2+VI?V5_>_#_@A_;'_ $[_ !/W HK\0UIZ
MT?V5_>_#_@C_ +8_N?C_ , _;FBOQ)7M3Z/[*_O?A_P0_M?^Y^)^V=%?B:M2
M4O[+_O?A_P $/[7_ +GXG[745^*:TM']E_WOP_X(_P"V/[GX_P# /VKHK\5Z
M%ZT?V7_>_#_@A_;']S\?^ ?M17,^#_\ C^\0_P#7^]?F!\#?&7_"&_$"RDED
MV65Z?LEQSP Q^5C]&Q^M?8>@_P#'QJ7_ %\-7%6P3HR2YOP.^ACE6BWRV^9]
M145\[KVJ6.L/8>9T_6/(^@Z*\#6IE[5/L?,?M_(]VHKP]:D6E['S'[7R/;**
M\97M4P^[2]EYA[7R/8**\C6IEI^R\RO:^1ZM17EJU-_C2]GYC]IY'IE%>;KV
MJ0?>-+V?F'M/(]$HK@/\:<M+D#VGD=[17#C[M2?XTN0?M/([2BN/7M3J.0?.
M==17++4BT<H<YTM%<Y3AWHY1\QT-%8*]*?2Y1\QMT5CTZE8.8UJ*S%[4^BP<
MQH450':GK1RCN7**I]OQIX[46"Y9HJ!:6BP7)J*C':D7K4C):*92CO3L ZBB
MBD 44+WI?XJ $HH;^M% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 <WX\_Y \'_7U%_.BCQY_R!X/^
MOJ+^=%1+<9M?#/\ X]==_P"PM/\ R6NRKC?AG_QZZ[_V%I_Y+795)04444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% ')_%+_ )$34_\ ME_Z-2NEL_\ CT@_ZYK_ "KF
MOBE_R(FI_P#;+_T:E=+9_P#'I!_US7^5 $]%%% !1110 4444 %%%% !1110
M 4444 %%%% #>:0'WH(XKC?B!\5_"_PSL6N-?U:*V;;E+=3OFD_W4'/X]/4U
M=.G.K)0IQ;;Z(PK5Z6'@ZE:2C%=6['9Y-4M2U:RTFW>>]NHK6%%+,\KA0 .I
MYKXM^(7[=FLZE)/;>$]*CTJW8%5N[PB2?KPP4?*IQV.\>]?/?BKXD>)O&MT\
M^L:S=7SL6XDD.T9.2 .@' X'I7V6#X5Q5>TJ[4%][/SK,..<%AVX86+J/OLO
M\S]"O&'[3G@'P?'+YFKI?SQA6\FR^<G<<=>GO7DGB+]O;3K>XN(='\/2W487
M]S<7,VS+8[J >,^]?%C-ELL2Y]^3706OP[\5W]K%<VWAG6+BWE4/'+%I\K(Z
MGH00N"*^HI\-Y;AE>O)R]78^(K\99QC+K#)17DKO[W<]FUW]M_Q_JECY%DNG
M:/+O#?:;:#>^!_#B0LN#],UR&K?M4?%#6;&6TG\4SQ1R<%[6"*"0?1T0,/P-
M><:QX?U;PW-'%JNEWFF2R+O1+RW>(LN<9 8#(S6=]:]RCE>7))TZ47\D_P 3
MYG$9SFTV_:UY=K7:_!'6?\+>\>?]#MXB_P#!K/\ _%T?\+>\>?\ 0[>(O_!K
M/_\ %UR5%=OU+"_\^E]R/._M#&?\_9?>STKP[^T=\2?"ZRK:>+=0G\S!/V]Q
M=D8]/-#;?PQ7:^'?VV/B)H_G?;I[+6M^-AN[94\OZ>5LZ^^>E> _C17-4RK!
M5;\U&.ODK_?N=E+.\QH6Y*\E;S=ON9]K>$_V\M,NRD>OZ#+:$19:>SDWAI,C
M@*P&!U[GI7M_@7X[>#/B!##_ &;K$*W,B@_9;@^7("1TP?Z5^7-2V]S):R+)
M#(T3J<AE.#7@XGA7!5DW2O!_>OQ/J<%QQF6':5>TX^:L_O1^P88'N*45^=OP
MN_:X\7> I[>VU*7^WM(# /%=$F5%W9;8_7//\61QT%?</PW^*.@?%31%U30;
MHSQ [989%VR0MC.UESQ^&0?6OSS,LFQ.6N]17CW6W_ /UO)^(\'G"M3?+/\
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MC\8#_P 6H\9?]@:\_P#1#U^9G_!$#_D/?%O_ *X:9_Z%=5^F7Q@_Y)1XR_[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#P44^%NF'POI4^G^+--MT$%MJ\UYIMPT:C@%9+EDF?K_RU5CQ^%=#^S_\
M\$V_&_B;XP1?%G]H[Q-#XEUV.=+R+189OM'F3+@I]H?:$5$(&(8@4. ,A05+
MBKS3O9=>XK\L7?5GTA^U-INF:+^PGX[L-%M)+#1[7PBT-E:RER\,"PJ(T;<2
MV0H .XD\<FO#_P#@BYG_ (9E\4?]C7<?^DEI7U/^U5X)UOXC_LY?$+POX=LO
M[1US5=(FM;.U\U(O-D885=[LJK]6(%>*_P#!,?X#^._V>?@;KOA[Q_H9T#5[
MKQ#-?16WVR"YW0M;VZ!]T,CJ/FC<8)SQTY%5!ZU6^J7YB:M"$>S?Y'QU\0/%
M/Q'_ ."C7[7_ (B^$UAXOG\(_#_1I;N-K2,L8?L]M((VFDA5E\^5WVX#G"AN
M,8.?I'PC_P $:_@IH,UO/K6L>*_$LJ#][;S7L5O;R'_=BB$@'_;2N'^/W_!/
MKXM^ ?CY?_&/]G77;:WU.]N9+Z72IIT@GBFE.9E3S0898G)9BLA7&<8; (V(
MK'_@H1\5;-=#U-O#'PPM&7R[C6(Y;5IW0C#%3"]PRMC)!0(<]"*RA_#BDO>Z
MW[FE36;=].A\O?&3P+\/OA?_ ,%+/AMX1^'&FP:3HNCZ[H-M/;0S23 7)N4=
M]SR,S,V'0').",=J_;?M7Y(>//\ @F7\2?@[\8?AIXN^'-M?_%*33[JWU?7]
M0O-0M+262^BNA*Y59Y5.UUQCYG.0Q9N17ZUPDO$I964D<JV,CVXXK5/]S&-[
MM-_H1+^(VEI9$]%%%0,^!_\ @LY_R:WH1_ZFFV'_ )+75?2G[&_/[*?PD/\
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M2&M?$;1?A/JI^%/AH^)_&]R/LUE$;JWMTM2P.;AS/(BL$'1022Q7C&2/D/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+B)U#$ G&?6OTP\/R/-H>GR2,7D:!&9F.225&237Y0_\%MO^2@?"O_KPO?\
MT9%7ZN^&?^1?TS_KWC_]!%%'7#W?\S_,53^*O3_(U!7Y8_\ !13XP>//!/[;
M7PYT+P[XW\1Z!HEW9::]QINEZM<6UM,S7LRL7C1PK%E !R.0 *_4WUK\A/\
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M1/EY8[O3[S6G;FN]EJ0_\$T]6\=^*?V9_$_COQMXKUWQ#?Z]?W4MA)JNHS7
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MK]C;:5<I:SKK'C'5(79V3>"HC#@C'J17ZU?M:\_LO_%C_L5]2_\ 29Z^-O\
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M2:DU>Z6P^BBBI+"BBB@ HHHH **** "BBB@ HHHH **** .3^*7_ "(FI_\
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MM_>[A2T45)H%%%% !1110 4444 %%%% !1110 4444 %%%% !24M% !1110
M4444 )2T44 %%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'S_P#M(?\ (H_%/_L2=0_])WK\9*_9O]I#
M_D4?BG_V).H?^D[U^,E?59-_#EZGQ^>?''T"BBBOHSYH**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[M0KVJ9?Z5+#J2+4RU"M3+391(M3?XU"M3?XTBR1>U2#[QJ->U2#[QJ )?\
M&G+3?\:<M)#1*/NU)_C48^[4G^-242+VIU-7M3J"M25:D6HUJ1:-0'4]?ZTR
MGK_6C4L<O2GTQ>E/J0'TZFTZI8#U[4^F+VI](!1VIZTP=J>M!8+TIP[4U>E.
M':@!ZTM(M+0 X=J1>M*.U(O6@:'4H[TE*M ]15Z4M(O2EH#4%[T[FFKWIW-0
M UOZT4-_6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .;\>?\@>#_ *^HOYT4>//^0/!_U]1?SHJ)
M;C-KX9_\>NN_]A:?^2UV5<;\,_\ CUUW_L+3_P EKLJDH**** "BBB@ HHHH
M **** "BBB@ HHHH **** /R,_X+< GQ]\+AZZ?>C_R)%6A8?\$1;G4K"WNQ
M\8XD$T:R!/\ A&B<9 .,_:_>J'_!;7_DH'PL_P"O"]_]&15^KWAG_D7=-_Z]
MH_\ T$4J*_V>_7F?YCJ2?M$NEO\ (_+?_AQO=?\ 19H?_"9/_P EU\P?&?\
M99D_9%_:G^'O@Z3Q*OBEKJ73]2^V+8FT"[[MDV;/,?./+SG/?IQ7[\?Q5^0O
M_!3SG]OCX6_]>&E_^G":KIR:K4TNK!I2I5&^B_5'Z\/S'_P&OP$_9G^$'Q6^
M,WQV\<:1\(_&W_"":];Q7%Q<WW]JW>G^;;BY53'OMD9F^9D.TC'RYZ@5^_;'
M]V?I7Y"_\$D_^3O/B=_V";K_ -+8JBFN:O\ ]NL<I..';7>)J>*_V)_VY/#.
M@W6HVOQOU/Q%- A<:;I/CC5?M$N.R><L:$^Q89[5X%^SI\,5_;"^*0\'_&CX
MU>*-)\2V-VT%OHNOK-=W%T5)$L,4]Q*5AF!!!1D)XX#<@?O-7Y<_\%8_V2Y;
M&2'X\>"K>2TO[66)-?6SRKJ00(;X%>0RD*C$?[#=F-)3Y))R6GY!RN::B[,_
M0?X*_!/PE^S[X!LO"'@O3?[.TBW)D9G;?-<2MC=+*_5W; YZ      #P;]N3
MX!?'7XUZEX0E^#GQ#?P-;Z?%=+J:+KU[IOVEG,1B.+=&W[0K_>Z;N.IK2_X)
M]?M71_M/_!F!]4ND;QOH 2SUF+@-,<'R[H =I #G' =7'3%?4O\ $:TJQ?/>
M3V_$RIOW=%8_$#]K3]E[]I?X3?"&?7OBI\69/&'A5;V"%M+;Q/J-^#*Q.Q_*
MGC"'!!YSD=JZSX%_L>_M:^.OA%X6U_P1\:)/#_A2_LUFT[3%\7:I:BWA).$\
MJ*,HG(/"G%?:_P#P5&\$>(OB%^RO>:3X7T#5/$FJMJMG(MCI%E)=SE59MS".
M-2V!W..*]/\ V*]!U/PO^RO\-=)UK3KS2-5M-)2*XL;^!X)X6#-\KHX#*?8B
MLZ7O1G?HTEZ6+D]8I=OU.;_8D^#GQ=^#/@?7]-^+_C5O&^M76HBXL[MM7NM1
M\J#RE79ON%5E^8,=HXYS7SA^TL!^T)_P4T^$OPYCS<Z/X+A75]14<A),?:F#
M>S+':K_P.OT:NKJ.UMY9Y7$<4:EW=N H R2?PK\ZO^":=M/\9OV@OCM\=KU"
M\.HZB=+TR9QR(F?S&3_@,26J_C51?-73?V5?Y[(4ERTI6ZNWW[_@?H1XH_Y%
MK4_^O:3_ - -?@5^Q/\ L8R?MC:QXJT^+Q<OA(Z'!;S&1M.-YYWFLXQCS8]N
M-GOG-?OIXI_Y%O5/^O:3_P! -?E+_P $0_\ D=OBI_UXV'_HR:HI)2JSOV_S
M'4DXTE;O_D:O_#C>Z_Z++#_X3)_^2ZYOXF?\$;Y_AK\.?%7BU_BS'J"Z'I=S
MJ9M%\/&,S>3$TFS=]J.W.W&<'&>AK]?J\O\ VHO^3;/BI_V*VJ?^DDM34DXP
M;6Z-:2YJD4]KGP[_ ,$1?^1'^*'_ %_V/_HN6KG_  6V_P"28?#C_L+W'_HD
M54_X(C?\B3\4?^O^Q_\ 1<M6_P#@MK_R3'X;_P#87N/_ $2*VQF\?^W?T,\+
MN_\ M[]3R+X4?\$=;GXH?#'PEXQ7XKQ::NOZ5:ZH+-O#YE,'G1+)LW_:1NQN
MQG SCH*ZG_AQO=?]%EA_\)D__)=?H%^R;_R:]\)/^Q4TO_TDCKUBKJ+EG)+;
M4SIR<H)O<^+/V)_^"=LW['_Q&UCQ0_CU/%8U'3&T[[*ND&S\O,L<F_=Y\F?]
M7C&!UZUZ)_P43_Y,S^)O_7C%_P"E$5?1QKYS_P""B7_)F7Q._P"O&+_TIBKE
MQ#<J>O0Z,/&U5/NT?F+^QQ^S!^T;\8OA3=:W\)OBU_PA'AN/4Y;:73?^$DU+
M3]UP$C+R>7;Q,ARK(-V<G;["NG^/G[/O[:7P!\&7/BC5/BSXH\3Z':H7OKCP
MWXPU*X-I'W>2.3RVV>K*&"@$M@<U]7_\$;/^35M5_P"QFNO_ $1;U]TW5K%>
M6LL$T2S0RJ4>.10RNI&""#U!%=-9-.T=]/R.>E*]VUU?YGX\_L-_LA?#7]KO
M4'\9^./BIJ_C?7[39+JWA6ZC>"[5L\&:Y>5WFA.,;H]I[%E/%?L!I.E6>@Z7
M::=I]K#8Z?9Q+!;VUN@2.*-0%5%4<     >E?BS^U!\+_$?_  3E_:NT?X@_
M#]9(/"FHSM>:='D^3M)_TG3I#W7!XSSM92/F0D?K_P#![XK:%\;?AOH/C7PY
M<?:-*U>V6=!N!>)NCQ/CHZ,&4CU4T*7M*:E';JNS"2<)VEK?9G9GUKXU_;I_
MX*#:%^S7I=WX4\+2V^O?$ZZCVQVBGS(M,W#Y9;C'\>""L74\$X4C/-_\%#_V
M[K[X+M!\+_AMNO?B7J\:)+<6Z^:^FI+@1JB '=<29^5?X00V#E:I_L-_\$Y+
M?X:W-K\3/BX@\1_$FZD^W16=Y)]HCTR5CN\R1B3YUSDY+G(5ONY(WUC&/M;M
MZ17XFLG[.VEV]E^IA?\ !/']B/Q#I_BJ7X\?&,7%SXWU)WN],T^_R9[=I0=]
MU< ])6#$*G\ )) ; 3[3^-7[07@+]G?P_9:Y\0==_P"$>TN\NA96]Q]CN+G?
M,49]NV&-V'RHQR0!QUKT3H0.GM7G?QJ_9_\  7[1'AZQT3X@Z%_PD&F6=T+R
M"W^V7%MLF",F[=#(C'Y788)(YZ5<Y-V459+9=D1%:N4G=L\<_P"'HO[,?_13
M/_*!JG_R-7O/PI^*WA7XV>"K+Q=X,U3^V?#UXTB07GV>6#>8W*/\DJ*XPRD<
MCM7@W_#KG]F/_HF?_E?U3_Y)KWGX4_"CPK\$_!5EX1\&:7_8WAZS:1X+/[1+
M/L,CEW^>5V<Y9B>3WIJUGW$^ECL6K\\/^"UG_)OO@K_L9T_]);BOT/:OSP_X
M+6?\F^^"O^QG3_TEN*SET]5^9M3^+Y/\CZ#_ & ?AKI/PS_9-^'L.FVD<$^L
M:9#K-[,H&^>>X02EF(ZX5E49Z*H':OC/_@MYHEFMW\)]76W1;^9-2MI)P!N:
M-#;,BD]P"[D>FX^M??\ ^R;_ ,FN_"3_ +%32_\ TECKX0_X+@?\@_X0_P"_
MJO\ *TJ\7_'OVD+":QUZI_D?>G[,/P^TCX7_  #\#>'M%MH[:T@TFWDD:- I
MFF>-7EE;'5G=F8GWK\W_ /@KG9P:!^TS\*]=L81;ZG)8HSSI\K.8;K,9)'.1
MN//7IZ5^H_PF_P"27^$O^P3:?^B4K\OO^"Q__)=_A-_V#W_]*15R_P!\I?XO
MT9STG?#2OUB?HA^UBV_]EOXK-W_X1;43_P"2SU^.W[%O_!/V;]L7PKXBUF/Q
MROA0:/>QVAA;2C>>;N3?NSYT>W'3&#7[$?M6_P#)J_Q5_P"Q5U'_ -)GKX[_
M .")?_)*/B+_ -AF#_T3402YZC[)?F;N35"GYM_DC@[C_@AW?)"QA^,5O)*/
MNK)X;95/U(NCC\J\QT.Q^*G_  27^*]A>Z[H7A_Q9X6U_="VI6ELK23Q*5,D
M<5RR+-!(!M;RVS&W7#8W#]JSZ5^:?_!:+XE>'5^&_@[P(+J"X\42:L-6:V5@
MTEO;I#+'N< _+O:0 9Z[&QTJ>=PDFN]K!&*G>,NWY'WG9>+-/^+7P=7Q#X<G
M-QIVOZ,;JRD<%6*RQ$J&'8C.".Q!K\O_ /@BG>0V?Q5^)&G2A1>RZ5;RID_,
M$28JX_.1/TK[Z_8+\+ZAX0_9#^&>FZLKI>_V9]I,<F0R)-*\T:D'H0DB\=J_
M.'7[J\_X)Q_\%$+G7;RRE_X0+7III5>%20^FW3AG"8ZM!(!\O4^4/[P-:\JI
MXJ4>C32]5_PYCK4PWFFG\C]GZ2N?\%>.- ^(_ANQ\0>&-8M-<T6\0/!>V,HD
MC<>F1T(Z%3R#P0#4'Q"^(GAWX5>$]0\3^*]7M=%T2QC,D]W=.%7V51U9B> H
MR22  36<O=O?2QI'WK6.FI5^E?C]^S#XX\>?MC?\%!M6\=:'JVO^'O UK=)?
MW]O9WTMO&;.!=EI;3"-@K-*47<AR"#+U -?L O84^5J"E)6;U%=<[BM;#Z**
M*!A1110 4444 %%%% !1110 4444 %%%% ')_%+_ )$34_\ ME_Z-2NEL_\
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M7XTVY.[/Z-A%0BH15DAU%%%26%%%% !24M% #,8ZUY3^U1_R;_XS_P"O0?\
MH:UZO7*_$WP9'\1O >N>&Y)C;_VC;-")@,[&ZJV.^& KIPM2-.O3J2V33?R9
MPXZG*MA:E.&\HM+U:/R9\$V,6J>,-"LKE?,MKB^ABD7U4N 1^5?L/:6L5K:0
MPQ1+'#&@1(U&%50,  =@!7YX^&_V-?B9X>\?:1/)I5M/8VE_#(]W%>1["BR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[4]:"P7I3AVIJ]*<.U #UI:1:6@!P[4B]:4=J1>M T.HHHH'J.7I2TB]*6@
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MWVTUYH#,#;:E'$3&0V<(Y'"OP>#Z9'%>6?3K7[AA\32Q5-5:,KQ9_,V*PE?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?/_[2'_(H_%/_ +$G4/\ TG>OQDK]F_VD/^11^*?_ &).H?\
MI.]?C)7U63?!+U/C\\^./H%%%%?1GS04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOFWP7X:F\8>*--TB '==3!6;^ZG5F_  U]P^$;*'38;JTMT\N""3RHU'90,
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M:BO)"T445SG<%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2CZ[7_G8?4,/_(CY%_X8%\"?]!?Q)_X$V_\ \8I/^&!? O\ T%_$G_@3;_\
MQBOKS^S1Z4G]FC^[1]=K_P [#ZAA_P"1'R)_PP+X%_Z"_B/_ ,";?_XQ3?\
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MC_\  FW_ /C-?7?]FC^[^E']F_[-'UVO_.P^H8?^1'R+_P ,!^!?^@OXC_\
M FW_ /C%'_# ?@7_ *"_B3_P)M__ (Q7UU_9O^S2_P!FCTH^NU_YV'U##_R(
M^1?^& O O_07\2?^!-O_ /&*3_A@/P+_ -!?Q)_X$V__ ,8KZ[_LT>E']FC^
M[1]=K_SL/J&'_D1\B_\ # 7@7_H+^)/_  )M_P#XQ2?\,!^!/^@OXD_\";?_
M .,5]=?V</[M']FK_=H^NU_YV'U##_R(^1O^& ? G_07\2?^!-O_ /&*7_A@
M'P)_T%_$G_@3;_\ QBOKG^SU]*/[/']VCZ[7_G8?4,/_ "(^2%_X)_\ @/\
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M!EK_ /(U?6RK3PM'UVO_ #L?U##_ ,J/DM?^"9_PP_Z#WBW_ ,#+7_Y&I_\
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MO&08=.@_X#7JM<SX/_X_O$/_ %_O6,JU2;O*1O&A2@K1C8I#X4Z2O_+Q>_\
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MR5+2O^O"3^;5V-<=J'_)4M*_Z\)/YM0!V-%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ&'6_P#P+_\ K4 =C17'?\*W7_H8=;_\"_\ ZU'_  K=?^AAUO\ \"__ *U
M'8T5QW_"MU_Z&'6__ O_ .M1_P *W7_H8=;_ / O_P"M0!V-%<=_PK=?^AAU
MO_P+_P#K4?\ "MU_Z&'6_P#P+_\ K4 =C17'?\*W7_H8=;_\"_\ ZU'_  K=
M?^AAUO\ \"__ *U '8T5QW_"MU_Z&'6__ O_ .M1_P *W7_H8=;_ / O_P"M
M0!V-%<=_PK=?^AAUO_P+_P#K4?\ "MU_Z&'6_P#P+_\ K4 =C17'?\*W7_H8
M=;_\"_\ ZU'_  K=?^AAUO\ \"__ *U '8T5QW_"MU_Z&'6__ O_ .M1_P *
MW7_H8=;_ / O_P"M0!V-%<=_PK=?^AAUO_P+_P#K4?\ "MU_Z&'6_P#P+_\
MK4 =C17'?\*W7_H8=;_\"_\ ZU'_  K=?^AAUO\ \"__ *U '8T5QW_"MU_Z
M&'6__ O_ .M1_P *W7_H8=;_ / O_P"M0!V-%<=_PK=?^AAUO_P+_P#K4?\
M"MU_Z&'6_P#P+_\ K4 =C17'?\*W7_H8=;_\"_\ ZU'_  K=?^AAUO\ \"__
M *U '8T5QW_"MU_Z&'6__ O_ .M1_P *W7_H8=;_ / O_P"M0!V-%<=_PK=?
M^AAUO_P+_P#K4?\ "MU_Z&'6_P#P+_\ K4 =C17'?\*W7_H8=;_\"_\ ZU'_
M  K=?^AAUO\ \"__ *U '8T5QW_"MU_Z&'6__ O_ .M1_P *W7_H8=;_ / O
M_P"M0!V-%<=_PK=?^AAUO_P+_P#K4?\ "MU_Z&'6_P#P+_\ K4 =C17'?\*W
M7_H8=;_\"_\ ZU'_  K=?^AAUO\ \"__ *U '8T5QW_"MU_Z&'6__ O_ .M1
M_P *W7_H8=;_ / O_P"M0!V-%<=_PK=?^AAUO_P+_P#K4?\ "MU_Z&'6_P#P
M+_\ K4 =C17'?\*W7_H8=;_\"_\ ZU'_  K=?^AAUO\ \"__ *U '8T5QW_"
MMU_Z&'6__ O_ .M1_P *W7_H8=;_ / O_P"M0!V-%<=_PK=?^AAUO_P+_P#K
M4?\ "MU_Z&'6_P#P+_\ K4 =C17'?\*W7_H8=;_\"_\ ZU'_  K=?^AAUO\
M\"__ *U $OQ2_P"1$U/_ +9?^C4KI;/_ (](/^N:_P J\[\8>!$T_P -7URV
MLZM=") WDW%QN1OF'48K87X;(H 'B#6P!P +K_ZU '9T5QW_  K=?^AAUO\
M\"__ *U'_"MU_P"AAUO_ ,"__K4 =C17'?\ "MU_Z&'6_P#P+_\ K4?\*W7_
M *&'6_\ P+_^M0!V-%<=_P *W7_H8=;_ / O_P"M1_PK=?\ H8=;_P# O_ZU
M '8T5QW_  K=?^AAUO\ \"__ *U'_"MU_P"AAUO_ ,"__K4 =C17'?\ "MU_
MZ&'6_P#P+_\ K4?\*W7_ *&'6_\ P+_^M0!V-%<=_P *W7_H8=;_ / O_P"M
M1_PK=?\ H8=;_P# O_ZU '8T5QW_  K=?^AAUO\ \"__ *U'_"MU_P"AAUO_
M ,"__K4 =C17'?\ "MU_Z&'6_P#P+_\ K4?\*W7_ *&'6_\ P+_^M0!V-%<=
M_P *W7_H8=;_ / O_P"M1_PK=?\ H8=;_P# O_ZU '8T5QW_  K=?^AAUO\
M\"__ *U'_"MU_P"AAUO_ ,"__K4 =C17'?\ "MU_Z&'6_P#P+_\ K4?\*W7_
M *&'6_\ P+_^M0!V-%<=_P *W7_H8=;_ / O_P"M1_PK=?\ H8=;_P# O_ZU
M '8T5QW_  K=?^AAUO\ \"__ *U'_"MU_P"AAUO_ ,"__K4 =C17'?\ "MU_
MZ&'6_P#P+_\ K4?\*W7_ *&'6_\ P+_^M0!V-%<=_P *W7_H8=;_ / O_P"M
M1_PK=?\ H8=;_P# O_ZU '8T5QW_  K=?^AAUO\ \"__ *U'_"MU_P"AAUO_
M ,"__K4 =C17'?\ "MU_Z&'6_P#P+_\ K4?\*W7_ *&'6_\ P+_^M0!V-%<=
M_P *W7_H8=;_ / O_P"M1_PK=?\ H8=;_P# O_ZU '8T5QW_  K=?^AAUO\
M\"__ *U'_"MU_P"AAUO_ ,"__K4 =C17'?\ "MU_Z&'6_P#P+_\ K4?\*W7_
M *&'6_\ P+_^M0!V-%<=_P *W7_H8=;_ / O_P"M1_PK=?\ H8=;_P# O_ZU
M '8T5QW_  K=?^AAUO\ \"__ *U'_"MU_P"AAUO_ ,"__K4 =C17'?\ "MU_
MZ&'6_P#P+_\ K4?\*W7_ *&'6_\ P+_^M0!V-%<=_P *W7_H8=;_ / O_P"M
M1_PK=?\ H8=;_P# O_ZU '8T5QW_  K=?^AAUO\ \"__ *U'_"MU_P"AAUO_
M ,"__K4 =C17'?\ "MU_Z&'6_P#P+_\ K4?\*W7_ *&'6_\ P+_^M0!V-%<=
M_P *W7_H8=;_ / O_P"M1_PK=?\ H8=;_P# O_ZU '8T5QW_  K=?^AAUO\
M\"__ *U'_"MU_P"AAUO_ ,"__K4 =C17'?\ "MU_Z&'6_P#P+_\ K4?\*W7_
M *&'6_\ P+_^M0!V-%<=_P *W7_H8=;_ / O_P"M1_PK=?\ H8=;_P# O_ZU
M '8T5QW_  K=?^AAUO\ \"__ *U'_"MU_P"AAUO_ ,"__K4 =C17'?\ "MU_
MZ&'6_P#P+_\ K4?\*W7_ *&'6_\ P+_^M0!V-%<=_P *W7_H8=;_ / O_P"M
M1_PK=?\ H8=;_P# O_ZU '8T5QW_  K=?^AAUO\ \"__ *U'_"MU_P"AAUO_
M ,"__K4 =C17'?\ "MU_Z&'6_P#P+_\ K4?\*W7_ *&'6_\ P+_^M0!V-%<=
M_P *W7_H8=;_ / O_P"M1_PK=?\ H8=;_P# O_ZU '8T5QW_  K=?^AAUO\
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M?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\
MZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&
M'6__  +_ /K4?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W
M7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\ ZU '
M8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__
M  +_ /K4?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8
M=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\ ZU '8T5Q
MW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_
M /K4?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\
M"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\ ZU '8T5QW_"M
MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4
M?\*W7_H8=;_\"_\ ZU '8T5QW_"MU_Z&'6__  +_ /K4?\*W7_H8=;_\"_\
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M^M1_PA*_]!G5?_ C_P"M0!TU%<S_ ,(2O_09U7_P(_\ K4?\(2O_ $&=5_\
M C_ZU '345S/_"$K_P!!G5?_  (_^M1_PA*_]!G5?_ C_P"M0!TU%<S_ ,(2
MO_09U7_P(_\ K4?\(2O_ $&=5_\  C_ZU '345S/_"$K_P!!G5?_  (_^M1_
MPA*_]!G5?_ C_P"M0!TU%<S_ ,(2O_09U7_P(_\ K4?\(2O_ $&=5_\  C_Z
MU '345S/_"$K_P!!G5?_  (_^M1_PA*_]!G5?_ C_P"M0!TU%<S_ ,(2O_09
MU7_P(_\ K4?\(2O_ $&=5_\  C_ZU '345S/_"$K_P!!G5?_  (_^M1_PA*_
M]!G5?_ C_P"M0!TU%<S_ ,(2O_09U7_P(_\ K4?\(2O_ $&=5_\  C_ZU '3
M45S/_"$K_P!!G5?_  (_^M1_PA*_]!G5?_ C_P"M0!TU%<S_ ,(2O_09U7_P
M(_\ K4?\(2O_ $&=5_\  C_ZU '345S/_"$K_P!!G5?_  (_^M1_PA*_]!G5
M?_ C_P"M0!TU%<S_ ,(2O_09U7_P(_\ K4?\(2O_ $&=5_\  C_ZU '345S/
M_"$K_P!!G5?_  (_^M1_PA*_]!G5?_ C_P"M0!TU%<S_ ,(2O_09U7_P(_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <Y\0O^1-
MU7_KD/\ T(5T=<Y\0O\ D3=5_P"N0_\ 0A71T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %<Y<_\E"TS_L%W?_HZWKHZYRY_Y*%IG_8+N_\ T=;T ='1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% '%:I_R4";_ +!D7_HV6KM4M4_Y*!-_
MV#(O_1LM7:T6Q+"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PM:_Y&+P]_UUF_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5SES_R4+3/^P7=_P#HZWKH
MZYRY_P"2A:9_V"[O_P!'6] '1T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110!Q6J?\E F_[!D7_HV6KM4M4_Y*!-_P!@R+_T;+5VM%L2PHHHIB"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,+6O\ D8O#W_76;_T4U;M86M?\C%X>_P"NLW_HIJW:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *PO#/_'UKW_81;_T7'6[6%X9_P"/K7O^PBW_ *+CH W:*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%SDC<Q8ENN%.,$Y'T?\ M@?L(> /!_PBU7Q?X"L9M O]#C%Q/:&\EN(;F'<
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M7:)3$#)LQN^YSG;GC-*C@XU:U7F;:@WZO4*^-E1H4N1).27HMC]#-#_X*?\
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M?!/]FOP'\-=2?P;J^GZ7XWM60VVGV&LRW[SG> R2QM))L&TL03MY Y[5E?\
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M_KB3RO\ CZ_[:?<_'M7F?_!2;18?#?[+?AO2K=Y)(++6;.VC:3&XJEO,H+$
M#.!V KBO^"3)_P!#^)./[^GY_*>O.I45+"5:D9.R>U]'MNCT:U9PQ=&G*";:
MU=M5OLS[R\1>)-+\(Z+<ZOK6H6VE:7:IYD]Y>2B..-?4L>*^8?$W_!33X.^'
M]0>VLQX@\1(IQ]JTRP01'Z>=)&Q_*OE7_@HY\=;_ ,=?%JX\#VES)'X>\-E4
M>!&(6>[*@O(P[[0P09Z8;UKW[]G7_@G5X#7X<Z9JGQ"T^X\0>(-3MTN9+7[9
M+;PV0=0PC41,I9@"-Q8D9Z#CETL+1IT%B,0W:6R0ZN*JU*[PV&2NMV^A[;\'
M_P!L[X6_&S48=,T77'L-;F_U>EZM#]GGD]D.2CM_LJQ/'2O<]W2OR!_;6_9;
M@_9I\7:/JOABYNO^$;U9G>T,TF9K*XC()CWC!(P05/7@Y)(R?O;]A[XY7GQP
M^"-K=ZO,;CQ!I$S:;?3N?FG*JK)*?=D9<GNRL:C$86G[%8G#M\O5/=%8?%U%
M7>&Q"7-T:V9M>,OVSO@[\/?%6H>'/$'B_P"P:UI\@BN;;^S+R38Q .-R0E3P
M1T)IGQK_ &Q/AI\![I;#7=5FO]:*"3^R=(C$]PBD @OEE5,@@@.P)'(%?F!^
MVAQ^U'\0B/\ G_3_ -%1U]J?L]_L'>"/%WPYT[Q=\2XKWQ;XH\26ZZG/)-?S
M0B S#>H'ELI9]K#<6)&<X&*WE@\/2P].O4;U6JTWM?0P6-Q%7$5,/3BKQ;LW
M?;NSTSX2_M\?"CXN:Y!HMO?7_A[5+EQ';6^NP)")V/15D1W0$] &8$G@9-?1
M_O7X=_M._"2W^!/QNU[PKIMS-+I]L\=Q92RMF012(KJ"1U*YVY[[<U^PWP#\
M27?C#X)^!M:OY&FOK[1K2>XE?J\AB7>Q^IR?QK/%X6E"C#$46^67<VP>*JRK
M3P]=+FCU1Z#24;AZC\Z3<.>17D'LW1^'?[5__)R7Q'_[#5Q_Z%7Z2^$_V"_@
M3JGAC2;RY\#>9//:12R/_:]\,LR DX$^!R>U?FU^U=_R<C\1O^PU<?\ H5=/
M8_MY_'73;."TM?'7EV\$:Q1I_9-@=JJ  ,F#)X'>OKO8UJV$H^QERZ+JUT\C
MXOVU&CC*SK1YE=]$^I^BG_#OWX!?]"(?_!Q?_P#Q^O1?A'\!? GP-AU*+P1H
M9T6/471[E?M<]QYC(&"G]Z[XQN;ICK7Y6G_@H!\>S_S/O_E(T_\ ^,5^C'[$
MOQ.\2_%SX#Z=XB\6:E_:VL37=S$]SY$4.520A1MC55X'M7E8K#8JC3YJL[KM
M=GKX7$X2M54:=.SZ.R.E^*?[4GPR^"OB"+0_&7B4Z/JDUNMTD']GW4^8F9E#
M;HHF7JK<9SQ5'QQ^UO\ "_X?^"=(\4ZGXB$ECK-O]ITRWMX7:ZNXST982 RC
MC&YPHSQFO@__ (*D_P#)P6D?]@"#_P!'35W7[%O['?AWXV?#^W\=_$E[WQ!!
M,&L-+TTW<L,45O 3'DLA5OO*P"JP P2<D\*&#H_58XF<GOK_ )+S*J8RM'%R
MPU.*>BM]RW/<?!?_  4H^#WB[6HM/N9=:\->8P1+K6;-%@R3@9:*23:/=@ .
MY%?4EK=0WMM%<6\J3P2J'26-@5=2,A@1P01WK\@?V[/V== _9^^(VE1^%Q-!
MH6M6C7,5G/(93;.C;70.Q+%>5(W$GD\FONW_ ()Y>*+SQ-^S'H"7LSSR:=/<
M:>CR')\M)"47/HJL%'LH%&(PM'ZNL30;MV9.'Q=98EX:NE?NCT[XQ?M#^ O@
M19P2^,==CL+BX!-O8PHTUS,!W6-02%[;FPN>,UX#_P /3?A/]H\O^Q/%VS./
M-^Q6VWZ_\?&?TKE_CS_P3W\9?&3XMW_BZ;QYI]S:ZC>+YEO<VTL3VEH" (XL
M%PQ5.F=H)Y.,FM#XH?LM_LJ?#WP;>V6L:I9Z#K<=JRQWCZ]+)?\ F!3A_L^]
M@QSC($6/85G2AA53BYMN3Z+H;UIXMU)*FE&*ZOJ?27P<_:.\ _'>UG?PAKB7
MES;*&N+":-H;F$'N8V )7) W+E<\9KS3_@HN1_PRKXF'?[39?^E4=?G7^QCX
MDN/"_P"T[X$FMIV1;F^^PR[<@21S*T94CN,L#SW /:OT3_X*+8_X95\2^OVB
MQ_\ 2F.M,1A(X7$TE%Z-K\S##8R6+PU7G6L4]O0^._\ @F[XRT3X?_$+QKKW
MB+4[?2-(M-"W3W5T^U5_TB( #N23P%&23P!7U+<?\%/O@]#K1LDMO$L]MOV_
MVE'I\8@Q_>P91)C_ (!GVKX(_9'^ *_M%?%>/P]=W<UEHEK;-?:C-;X$AB5E
M4(A((#,SJ,D' R><8K[A^.'_  3G^'%Y\-M3G\#:;<>'_$MA UQ;R&]GN([I
MD7)CD61FQN (!3&"0>1Q7?CUA573KMZKIT7F>;ESQ3H-8=+?KU?9'U+\._B;
MX9^*WAN'7O"FKP:SI<AV^="2&1L9*.A 9&&1\K 'D5\S_P#!48_\8\Z7_P!C
M!;_^B9Z^/?V ?BWJ'PX^/VCZ0+B0:+XE?^SKNUW'89"#Y,F/[P? SZ.WK7V#
M_P %1F!_9WTK_L8+<_\ D&>O/K87ZKBJ:B[Q;5OO/4H8SZWA:KDK22=_N/.?
M^"3/-I\2?^NFG_RGK[F\=?$#P[\,O#=SK_BG5[?1=)M_OW%RV,GLJJ,EV/95
M!)["OAO_ (),\6?Q)_ZZ:?\ RGKP7]O#XQ:I\6OCYJ6@17#OHGAVX.F6-HK?
M(9@0LLA'=F?(SZ**ZL7AY8K,94UV3?I9''@L1'"9<JK[M?.[/L'4/^"H'PBL
M]2>U@L?%%_ K8%Y;V$(B8>H#S*^/JH->]_"/]H#P)\<].ENO!VO0ZB\ !N+-
ME:*Y@S_?B8!L9XW#*D]":\)\#_\ !-WX4Z?X"MK#Q'87FK^(Y+<?:=734)HF
M28K\WE1JPCVJ<XWJQXYS7P9J9UK]CC]IR[ATJ_DGF\.Z@ )/N_;+1@K;' XP
M\; $=CR.@J(87"XF3I46U)+=[,UGBL7AHJM62<6]4MU<_:[:*^??C%^W+\*_
M@SJ\^CZAJ=UK>M6[;+BPT.%;AH&[J[LRQAAW7=N'<"IOVM/C5)\.?V:-6\5:
M#<&.^U2"&VTVX4X*-/C$@]PA9A[@5^<?[&O[-\/[2GQ+O+?6KJXA\/Z7$+O4
M)(&Q-.S-A(@Q!P6.XENN%/<@CDPF#C54ZE5VC'?U.O&8R5+DIT5>4]O3N?H-
M\//VW/A?\;[>]T;2M1N]%UN:WD%OI^MPK!).=IXC96=&;_9W;CV%?FK^R)_R
M<M\._P#L*Q_R-?<?[0'_  3Q^'T?PWU35OA]8W7AOQ+I-N]Y $O9IX[HQKN*
M,)78JQ ."I&#C@BOAS]D7_DY;X=_]A6/^1KUL"J'+5E1;VU3^9XV8O$?NHUT
MM]&OD?M\OW12TB_=%+7RQ]>M@HHHH&%%%% !1110!SGQ"_Y$W5?^N0_]"%='
M7.?$+_D3=5_ZY#_T(5T= !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.7/\ R4+3
M/^P7=_\ HZWKHZYRY_Y*%IG_ &"[O_T=;T ='1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_HN.@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^2.^+/\ L.G_ -)XJ^9O^"E7_)T6H?\ 8,L__0#7TS_P2G_Y([XL_P"PZ?\
MTGBKYF_X*5?\G1:A_P!@RS_] -:O_D:_=^1'_,I_KN?HM^S/#;7'[,/P_AO%
MC>TD\/VL<JS8V,AB (;/&"#BODKXF?\ !.WP5XV\2ZDOPI^(>E6NI(#/)X:O
M+A;E8 6 R'C8R1H"0/F1NO6OHCX>_"[3?C/^Q+X3\'ZJS1VVI>&[54N$4%H)
M516CD [E6 ..^".]?GK/X ^-7[%/Q*?6K+2[JV>V#1+JUM;-<Z=>P,>59@,8
M; .UMK @'@@&N6DF\76Y*G+*[MV>K.JLTL)2YZ?-&ROW6B*'Q0_8L^+?P=T^
M\UG5- 6ZT:P'FRZII-VDT<:C^,J")% _O% !7T1_P3M_:B\8:]\0$^'/BC5;
MG7]-N[626PN+Z0RSVTD:[RGF'YF0H&X8G!48P,BO)_'7[=7QD^._AN\\&6VE
M:;#'J<9M[B+P[IL[W,\9^]'\TDA (Z[0#C-?0/\ P3[_ &0_$?PYUR7XA^-;
M%](OVMVMM,TJ< 3QJX&^:4?P';E0IY^9L@<5WUI2^KR6,M>VG>_0\RE"/UB#
MP7-NKWVMU-G_ (*M?\D;\(_]A\?^D\U8_P#P2=S_ ,(/X]_["-O_ .BFKU'_
M (*%_"/7?BO\#8AX<LIM5U/1=034/L-NI>66+8Z/L4<LP#@X') ..:_/3X ?
MM&_$/]G&[U[1O"NDVES>:L\:3V>I64LLT<L>X*4565@WSD88$=.*XL''VV"J
M4H/WK_Y/]#T,=+V..I5I+W4O\_\ ,^Q_^"KW_)+O!/\ V&7_ /1#5G_\$G84
M7P?X^D _>-?VREO81N1_,_G5;_@I/JEUK7[/_P +[^^ADM;VZO$N)X9$*/'(
MUH692IZ$$D8[5<_X)._\B/X]_P"PA;_^BC127+EU6+Z/]4*LU/,:,UU7Z,^O
M_C)\1(OA+\+O$WBZ:'[2NDV3W"PEL"23HBD]@6*C\:_)/09?BQ^W)\4O[#N/
M$<EY<3+)>O'>7#QZ?80J0"RQ*"% +*HPI)+#)ZFOUG^-GP[7XM?"?Q1X0,ZV
MKZM9/!%.P)$<G#(Q]@P7/M7X^:8?BA^QO\5(]2DTNXT'6[,O #>6Y>TO(CPR
MAONR1MQRIXXP01QGE7(W4VY[:7-LV=1*GORWUM\CWSXO?\$\=*^"/P3\4>,M
M8\:W&KZIIT$;6]M:V2V\'F/*B;6+,[./F[;:H_\ !+%1_P +V\0G:,CP_)@_
M]O$%5?%7BK]HG]MSPS<I<:/%I/@W3;>34)?LMK)9V5P\:,R@-(SO,YQ@*K$
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MM/\ %6G3!K8$DD1$-&VW/(!)7TJK+&X6G3IOWHZ6$V\#BYU*B;C+6ZZ'T?\
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M.92<]FDOP1QT\/.OE:C#XDV_Q9GV_P#P296YACEB^*ZO%(H96'A[(((R"/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7.7/_)0M,_[!=W_ .CK>NCKG+G_ )*%IG_8+N__ $=;
MT ='1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%:I_R4";_L&1?^C9
M:NU2U3_DH$W_ &#(O_1LM7:T6Q+"BBBF(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PM:
M_P"1B\/?]=9O_135NUA:U_R,7A[_ *ZS?^BFK=H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K"\,_\?6O?]A%
MO_1<=;M87AG_ (^M>_["+?\ HN.@#=HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB#T+$'G-?2?!Y(HV@#VI:\JM5E6J2J2ZGKT*,:%)4UT"BEHK$Z!-H]!2T44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N<N?\ DH6F?]@N[_\
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MFM_J>(_D9A]?PW\Z/KNBOD3_ (>=?"[_ * /B_\ \ [7_P"2:/\ AYU\+O\
MH ^+_P#P#M?_ ))H^IXC^1A]?PW\Z/KNBOD3_AYU\+O^@#XO_P# .U_^2:/^
M'G7PN_Z /B__ , [7_Y)H^IXC^1A]?PW\Z/KNBOD3_AYU\+O^@#XO_\  .U_
M^2:/^'G7PN_Z /B__P  [7_Y)H^IXC^1A]?PW\Z/KNBOD3_AYU\+O^@#XO\
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MH_X>=?"[_H ^+_\ P#M?_DFCZGB/Y&'U_#?SH^NZ*^1/^'G7PN_Z /B__P
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M2:/^'G7PN_Z /B__ , [7_Y)H^IXC^1A]?PW\Z/KNBOD3_AYU\+O^@#XO_\
M .U_^2:/^'G7PN_Z /B__P  [7_Y)H^IXC^1A]?PW\Z/I[6O^1B\/?\ 76;_
M -%-6[7QEJ'_  4H^&5UJVE72:%XL$=J\C.&M+7)W(5&/](]36E_P\Z^%W_0
M!\7_ /@':_\ R33^HXC^1A]?PW\Z/KNBOD3_ (>=?"[_ * /B_\ \ [7_P"2
M:/\ AYU\+O\ H ^+_P#P#M?_ ))I?4\1_(P^OX;^='UW17R)_P /.OA=_P!
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M_P#)-'_#SKX7?] 'Q?\ ^ =K_P#)-'U/$?R,/K^&_G1]=T5\B?\ #SKX7?\
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M-'U/$?R,/K^&_G1]=T5\B?\ #SKX7?\ 0!\7_P#@':__ "31_P /.OA=_P!
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M(P^OX;^='UW17R)_P\Z^%W_0!\7_ /@':_\ R31_P\Z^%W_0!\7_ /@':_\
MR31]3Q'\C#Z_AOYT?7=%?(G_  \Z^%W_ $ ?%_\ X!VO_P DT?\ #SKX7?\
M0!\7_P#@':__ "31]3Q'\C#Z_AOYT?7=%?(G_#SKX7?] 'Q?_P" =K_\DT?\
M/.OA=_T ?%__ (!VO_R31]3Q'\C#Z_AOYT?7=%?(G_#SKX7?] 'Q?_X!VO\
M\DT?\/.OA=_T ?%__@':_P#R31]3Q'\C#Z_AOYT?7=%?(G_#SKX7?] 'Q?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.?$+_D3=5_ZY#_ -"%
M='7.?$+_ )$W5?\ KD/_ $(5T= !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 44E+0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Y<
M_P#)0M,_[!=W_P"CK>NCKG+G_DH6F?\ 8+N__1UO0!T=%%% !1110 4444 %
M%%% !1110 4444 %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !124M !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'AG[2W_(B_%#_L1KW_T5<U^*]?M1^TM_R(OQ
M0_[$:]_]%7-?BO7UF3?!+U/C\\_B1] HHHKZ$^:"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ J:/M4-31]J3 LQU9C[56CJS
M'VJ>I:+$?:K$?>J\?:K$?>I*)X^U6$ZU7C[583K4&NI.E21]ZC2I(^]# [#X
M6^+#X+\:Z=J+-MM]_DW'_7-N&_+@_A7W!;L)%#*0RL,@@Y!%?GHM?8_P#\8?
M\)9X#MDEDWWNGG[+-D\D ?(WXKC\C7EXR&BFCUL#4U<&>I0U=AJE#5V&O)/:
M1=AJW'VJG#5R/M6;-46XONU:CZ55B^[5J/I69:+4=68^U5HZLQ]JEEEE>U6$
MJNO:K"5F6B=>U64JLO:K*4%$BU,O:H5J9>U2]RR5:FJ%:FJ 'KUJ1:C7K4BT
M%DB]J4?>-(O:E'WC0 ]>E+2+TI:"M16I*5J2H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** ,;Q5_R#[7_L(67_I5%11XJ_Y!]K_V$++_ -*HJ*B6XS?\&?ZG6/\ L*7/
M_H==%7.^#/\ 4ZQ_V%+G_P!#KHJDH**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \^^+WQM\(?
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M%% !1110 4444 <Y\0O^1-U7_KD/_0A71USGQ"_Y$W5?^N0_]"%='0 4444
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MLO5>AIT444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M):]O,^_OV*?BI\6?C=\+8_&OQ0TG0-!BU8K-HMCHUG<02M;8/[^;SII.'X*
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M9/B\:C'_ &=M$1/F?94[2_)]W=][BOU?]:_-2\_Y2<)_V&(__2):(J]:.O\
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MB*U\7?L.?$'7+([K34O"KWD)_P!B2)77]&%>$_\ !%O_ )-D\4#_ *FNX_\
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M6B?%7X6)X*\.PZI%=PZ@OA[4; M<+'*JQ^9<2LARKN=H&3MSV->D_"']M_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>*O^0?:_]A"R_P#2J*BHEN,W_!G^IUC_ +"ES_Z'715SO@S_ %.L?]A2Y_\
M0ZZ*I*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M11@* ,  >F*FS7@5ZKKU)5'U9]!AJ*H4HTUT0^BBBL3I"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y
MSXA?\B;JO_7(?^A"NCKG/B%_R)NJ_P#7(?\ H0KHZ "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ I*6B@#XA_P""E7P_\4>.K?P OAOPWK'B%K9[XSC2;"6Z\K<(-N_R
MU.W.TXSUP?2OK#X4V-QI_P ,?"-K=026MS!I-I%+#,A1XW6% RLIY!!!!!]*
MZS .* ,=*4/=BX]W<)>])/LK >M?F+\</"OQ1\)_MA:[X\\(^ -<UK['?1SV
M5PNBW5S:3'[,B$[HU&X<GHW45^G9I,&E:TE-;H=_=<>Y^?'_  UA^U7_ -$B
MG_\ "3U'_P"+K \7:Q^U=^TEI[^&[KPI>^'=%NL)=0_8#I<,BY_Y:/.=Y7U5
M3SZ'@5^E%-(JM/M*XM5L>&_LH?LVV_[.G@>XLIKF/4?$6I.LVHWL((3*@A(D
MSSL7+<G!)8G X \ _P""DGPY\6^.=>\#2>&O#&L^(8[>"[$[:3I\UT(B7BP&
M,:G:3@XSZ&OO(T4IWG)2?0(>XFD?G7HO[37[4>@Z18:;;_".Z:WLX([>,R>%
M-1+%44*,G?UP*9J7QE_:]^)B'2M.\&:AX9,PV--;Z(]B<$8/[ZZ)"=>H8'T-
M?HO^-!^M-ZN["/NJR/CC]D_]B.[^&GB(>.OB#=QZGXMRTEM9QR&9+61L[I9)
M#_K)>3TR!DG+$@C[&Z4HQ1VH;O9=$2HZM]Q:***"@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KG+G_DH6F?]@N[_ /1UO71USES_ ,E"TS_L%W?_ *.MZ .CHHHH **** $[
MBO#/VXO^31?BO_V +G_T&O<^XKPS]N+_ )-%^*__ & +G_T&L:OP2-:?QQ]3
M\L?V(_!_[0?P[^'EU\8_@BEKXIM'OYM)UOPC<)O\](D21)?+WJ9,>80/+82*
M> &5F%>T?$#XH_MG_MB:/<> -/\ A1/\--!U +#J=[>65QIQDA/#J\]R03$?
MXEA0N0"/F!(/L_\ P1L_Y-5U7M_Q4UU_Z(MZ^\*ZJMN9*6JLCFIR=G):.[_,
M\$_8W_95TG]DWX4Q^'+:X74]<O9?MFKZH$V_:)]H 5 >1&@^50?<]6->)?M_
M_L":I\?M6T_XC_#B_CTGXD:6B*T,DQ@6^6,[HF24?ZN=#PK' (V@E=H-?="T
M?3K64KSDI-ZHN'N)K>^Y^7VC_M@?ML?#?2_^$;\1_ 6\\6ZS:H(8]9CT*[F$
MC#^.5[5C#)VY0H./QK.^&7[%7QJ_:X^.%G\4?VCX5T+0K9XY(M ?:)9XD.Y+
M6.!6;R(<D[O,/F'G@EBX_5+THV].:J,N62FU=_EYBZ.*T3/&?VP?#^H>(/V6
M?B7I&B:9<ZIJ-SH<\%KI]A;M--*Q7"I'&@)8^@ KP7_@DG\/?%/PX_9Y\1:=
MXM\-:QX6U&7Q-/<1V>M6$MG,\9M;90X215)4E6&<8RI]*^X#SUI1QFE%\KD^
M]BGJHQ[.Y^4'Q:_9;^/'[)/[4&M?&+X)Z&?&>BZI<7%R]E!%]HD19WWRVLUN
MK+(Z;^5:+) 5<E2.?2;?]KS]L+XK6JZ-X0_9SE\(:M(OERZQXCM[B"&+(P9$
M%R(5!'7!,G3&UJ_17]*/7-3%>ZH/5(<GS2<^K/Q9^)/['7QF^!O[1OPT\?:U
M::_\6=3NM2M?$&OZIX<TBYOEMKB*[5Y(BR(20$"E250'D!0%K]HH9/,C5@"%
M(S\P(/X@\BI-U'#5:E[BAV;_ !)>LN;K8?1112&<WXS^'_A?XCZ4FF>+/#>D
M^*--BE$Z66M6$5Y") " X216 8!F&<9PQ]:T]&T73_#FDVFEZ386VEZ;9Q+!
M;6=G"L,,$:C"HB* JJ!P !@5HTA- "T444 <E\5+.>_^&?BRUM89+FXGTJZC
MBAA0N[NT+!551R220 !7YZ_\$>?A+XY^&6L_%!_&'@SQ!X32\AT\6S:YI<]D
M)RK7&X(947=C<N<=,CUK]-F -)4P]R<IK[22^X)>]%1[.XZBBBJ **** /RN
M_:P^#WCWQ%_P4R\!>)])\#^)-3\,VNIZ#)/K5GI-Q-91+'.AD9IE0HH4 EB3
MQCFOU.7[N*7BBB+Y::I]K_B$O>ES>27W'EG[1WQ2UKX/_"?5M=\->$M8\:^)
M2OV?3=(T;3YKQY+A@=KR+$K%8EP69C@<;0<L*^"O^">O['/C#QE\6M8^.7QP
MTC4[?7(;YY].T[Q!:/!<SWA.YKMXI%!5(\@1C &[D8"+G]2,48[TH>Y)RZ_D
M$_>BH=+Z^8O:OBS_ (*4?L;_ /#1_P .5\4>%[)9?B'X;A9K9(T_>:C:C+/:
M\<EP<M'_ +6Y>-Y(^T^M&T5,HW]2HRY6?%'_  35^)GQ-O\ X>GX>_%/P1XN
MT#4O#T*C2]8UW1KJUBO+,':L+2R(%\R/@ 9RR8Z[6-?:PH]J/QK24N9W9E&/
M+HAU%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /#/VEO^1%^*'_8C7O_ **N:_%>OVH_:6_Y$7XH?]B->_\ HJYK\5Z^LR?^
M'+U/C\\_B1] HHHKZ$^:"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5(O:G4#0Y>E+2+TI:!ZBM24K4E0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8WBK_D'
MVO\ V$++_P!*HJ*/%7_(/M?^PA9?^E45%1+<9O\ @S_4ZQ_V%+G_ -#KHJYW
MP9_J=8_["ES_ .AUT524%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 444
M4 %%%% !1110 4444 ?*OQ$_X)T_#3XD^.M7\4ZAJGB6SOM4N6N[F"QNX%A\
MQCEL!H&8 G_:[UZS\%_V<O GP#L9X/".C?9+FX 6YU"XD,US/CH&=N@[[5 7
M/.,UZ=GFC/Y5NZ]5P5/F?*NAS?5Z*J.IRKF?4?1116!TA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '.?$+_D3=5_ZY#_T(5T=<Y\0O^1-U7_KD/\ T(5T= !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7.7/_ "4+3/\ L%W?_HZWKHZYRY_Y*%IG_8+N_P#T=;T
M='1110 4444 )6=KN@Z;XFT>ZTG6=.M=8TJ\C,-S8WT"S0SH>JNC JP/H1BM
M*BEOHP.<\&^ /#'PYTEM+\*>'-)\,:8TIG:ST:QBM(3(0 7*1JJ[B !G&>!7
M14M%/5[@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!X9^TM_P B+\4/^Q&O?_15S7XKU^U'[2W_
M "(OQ0_[$:]_]%7-?BO7UF3?PY>I\?GG\2/H%%%%?0GS04444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %2QU%4L=# LQU:C[55
MCJU'VJ2T6(^U6(^]5X^U6(^]043Q]JL)UJO'VJPG6H-=2=*D3K4:5(G6A@2K
M7T=^RSX/\N"_\23Q_-(?LML2.PY=A^.!^!KYYTS3Y]5O[>SMD,EQ<2+%&H[L
M3@5]W>#_  _#X5\.Z?I-O_J[6)4+?WF_B;\3D_C7GXJIRPY5U/1P5/FGSOH=
M'#5V&J4-78:\4]]%R&KD?:J<-7(^U9LU1;BJU'TJK%5J/I4ZEHM1_=JS'VJM
M#]VK,?:LV665[582JZ]JL)692)U[58C_ *577M5B/^E!9*M3+VJ%:E6I>Y9,
MM35"M35 #UZU(M1KUJ1:"R1>U.IJ]J=0-"K3J:M.H'J*U)2M25 !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!C>*O^0?:_\ 80LO_2J*BCQ5_P @^U_["%E_Z5145$MQ
MF_X,_P!3K'_84N?_ $.NBKG?!G^IUC_L*7/_ *'715)04444 %%%% !1110
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M>>1)-Y2E@H.R-6<\L!P#UI2]U7>@+5V6YU%%?*G_  ]%_9C_ .BF?^4#5/\
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M;5ZN#QLL+%QBKW/)QF CBY*4I6L?B9_PS_\ %'_HFWB[_P $5U_\;I/^&?\
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M[+&$TTPT_P"UY_R(/[%I_P S/QJ_X43\2O\ HGOBK_P27/\ \11_PHOXD?\
M1/?%7_@EN?\ XBOV3,--\BC^UY_R(7]BT_YF?C=_PHOXD?\ 1/?%7_@EN?\
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M_$3_ *$+Q/\ ^":Y_P#B*_7_ .RBF_9O:C^UY_R(7]BP_F9^0/\ PI/XB?\
M0A>)_P#P3W'_ ,11_P *3^(G_0A>)_\ P3W'_P 17Z^_913?L=']KS_E0?V-
M#^9GY"?\*3^(G_0A>)__  3W'_Q%'_"D_B'_ -"%XF_\$]Q_\17Z]?8:3[![
M4_[6G_*@_L:'\[/R'_X4K\0_^A#\3?\ @GN/_B*/^%*_$/\ Z$/Q-_X)[C_X
MBOUW^PTAL:/[6G_*@_L>G_,S\A_^%*_$+_H0_$W_ ()[C_XBC_A2WQ"_Z$3Q
M-_X)[C_XBOUW^PTGV&I_M>?\J#^QH?SL_(G_ (4O\0O^A$\3?^">X_\ B*/^
M%+_$+_H1/$W_ ()[C_XBOUU^P^U(;$^E/^UY_P B#^QZ?\S/R+_X4O\ $+_H
M1/$W_@GN/_B*/^%+_$+_ *$3Q-_X)[C_ .(K]<_L)]*3^SSZ4?VO/^1!_8]/
M^9GY&_\ "E_B#_T(GB;_ ,$]Q_\ $4?\*7^(/_0B>)O_  3W'_Q%?KC_ &>?
M[M']GG^[1_:\_P"1!_8]/^9GY'?\*7^(/_0B^)?_  47'_Q%'_"E_B#_ -"+
MXE_\%%Q_\17ZW_V>?2C^S6]*/[7G_(A?V/#^=GY'_P#"F?B#_P!"+XE_\%%Q
M_P#$4?\ "F?B#_T(OB7_ ,%%Q_\ $5^N']F'TI/[-/I1_:\_Y$']CP_G9^1K
M_!_QY'(B-X)\1J\F0BMI-P"V!DX&SGBG_P#"F?B!_P!"+XE_\%%Q_P#$5^JV
MK:<?[>T,8_Y:3?\ HHUK_P!FGTH_M>?\B'_8T/YV?DE_PIGX@?\ 0B^)?_!1
M<?\ Q%'_  IGX@?]"-XD_P#!1<?_ !%?K;_9I]*3^S/:C^UY_P B%_8\/YV?
MDG_PIGX@?]"+XE_\%%Q_\11_PIGQ_P#]"-XD_P#!1<?_ !%?K9_9A]*3^S#Z
M4?VO/^1!_8\/YV?DI_PIKX@?]"-XD_\ !1<?_$4G_"F_'_\ T(WB3_P47'_Q
M%?K9_9A]*3^R_P#9H_M>?\B#^QX?SL_)3_A3?C__ *$;Q)_X*+C_ .(H_P"%
M-^/_ /H1O$G_ (*+C_XBOUK_ ++_ -FC^R_]FC^UY_R(/['A_.S\E/\ A3?C
M[_H1_$G_ (*+C_XBC_A3?C[_ *$?Q)_X*+C_ .(K]:O[+]J/[+]J/[7G_(@_
ML>'\[/R5_P"%-^/O^A'\2?\ @HN/_B*/^%-^/O\ H1_$G_@HN/\ XBOUJ_LH
M^E)_97^S^E']KS_D0?V/#^=GY+?\*;\??]"/XD_\%%Q_\11_PIOQ]_T(_B3_
M ,%%Q_\ $5^M/]EG^[2-I7^S1_:\_P"1!_8\/YV?DM_PIWQ]_P!"/XD_\%-Q
M_P#$4?\ "G?'W_0C^)/_  4W'_Q%?K1_91]*/[*/I1_:\_Y$']CP_G9^2_\
MPIWQ]_T(_B3_ ,%-Q_\ $4O_  ISQ]_T(_B3_P %-Q_\17ZS_P!D_P"R:/[)
M/I1_:\_Y$']CP_G9^2__  IWQ]_T(_B3_P %-Q_\11_PIWQ]_P!"/XD_\%-Q
M_P#$5^M']DGTI/[)/I1_:\_Y$']CP_G9^3'_  IWQ]_T(_B3_P %-Q_\11_P
MIWQ]_P!"1XC_ /!3<?\ Q%?K/_9)]*/[(/I1_:\_Y$']CP_G9^3'_"G?'O\
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M4[X]_P"A(\1_^"FX_P#B*/\ A3OCW_H2/$?_ (*;C_XBOUF_L?\ V:7^Q_\
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M]_T(_B3_ ,%-Q_\ $4?\*=\??]"/XD_\%-Q_\17ZU?V6/[M']D_[)H_M>?\
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M (4S\0/^A%\2_P#@HN/_ (BC_A3/Q _Z$7Q+_P""BX_^(K];_P"S?:E_L_\
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M[_@B)_R.WQ3_ .O*P_\ 0YJ_41/#=EX.^&JZ%IT0AL-,TL6=O&.BQQQ;%'Y
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MM?V4?C-_P4/T&/XC?$KXDS> O"NL8N=!\(65N]W##:')BD>/S8T#,I!WG<[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK=^R^]'V7WIA8PO[/]J3^SSZ5O?9?>C[+[T!8P?[//I1_9Y]*WOLOO1]E]Z
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MC_L*7/\ Z'715SO@S_4ZQ_V%+G_T.NBJ2@HHHH **** "BBB@ HHHH ****
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MUU?YGY-_\$S_ -I+PY\-?B(?A!X^\#Z%X2\:B5M+L_$<.FQ6M[-,K$&SO)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0'[VX4M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH YSXA?\B;JO\
MUR'_ *$*Z.N<^(7_ ")NJ_\ 7(?^A"NCH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *YRY_Y*%IG_8+N_P#T=;UT=<Y<_P#)0M,_[!=W_P"CK>@#HZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH XK5/^2@3?\ 8,B_]&RU=JEJG_)0)O\
ML&1?^C9:NUHMB6%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A:U_R,7A[_KK-_Z*
M:MVL+6O^1B\/?]=9O_135NT %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5A>&?^/K7O^PBW_HN.MVL+PS_ ,?6
MO?\ 81;_ -%QT ;M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\!!_\50!V-%<=_PLF+_H ZY_X"#_ .*H_P"%DQ?] '7/_ 0?_%4 =C17'?\
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M3%_T =<_\!!_\50!V-%<=_PLF+_H ZY_X"#_ .*H_P"%DQ?] '7/_ 0?_%4
M=C17'?\ "R8O^@#KG_@(/_BJ/^%DQ?\ 0!US_P !!_\ %4 =C17'?\+)B_Z
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M_P! '7/_  $'_P 51_PLF+_H ZY_X"#_ .*H [&BN._X63%_T =<_P# 0?\
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MX63%_P! '7/_  $'_P 51_PLF+_H ZY_X"#_ .*H [&BN._X63%_T =<_P#
M0?\ Q5'_  LF+_H ZY_X"#_XJ@#L:*X[_A9,7_0!US_P$'_Q5'_"R8O^@#KG
M_@(/_BJ .QHKCO\ A9,7_0!US_P$'_Q5'_"R8O\ H ZY_P" @_\ BJ .QHKC
MO^%DQ?\ 0!US_P !!_\ %4?\+)B_Z .N?^ @_P#BJ .QHKCO^%DQ?] '7/\
MP$'_ ,51_P +)B_Z .N?^ @_^*H [&BN._X63%_T =<_\!!_\51_PLF+_H Z
MY_X"#_XJ@#L:*X[_ (63%_T =<_\!!_\51_PLF+_ * .N?\ @(/_ (J@#L:*
MX[_A9,7_ $ =<_\  0?_ !5'_"R8O^@#KG_@(/\ XJ@#L:*X[_A9,7_0!US_
M ,!!_P#%4?\ "R8O^@#KG_@(/_BJ .QHKCO^%DQ?] '7/_ 0?_%4?\+)B_Z
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MR1,"!GIB,Y^HH ](HKCO^%DQ?] '7/\ P$'_ ,51_P +)B_Z .N?^ @_^*H
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M^*H [&BN._X63%_T =<_\!!_\51_PLF+_H ZY_X"#_XJ@#L:*X[_ (63%_T
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M_0!US_P$'_Q5'_"R8O\ H ZY_P" @_\ BJ .QHKCO^%DQ?\ 0!US_P !!_\
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MYW_A,#_T ]8_\!?_ *]'_"8'_H!ZQ_X"_P#UZ+H#HJ*YW_A,#_T ]8_\!?\
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M/_0#UC_P%_\ KT?\)@?^@'K'_@+_ /7HN@.BHKG?^$P/_0#UC_P%_P#KT?\
M"8'_ * >L?\ @+_]>BZ Z*BN=_X3 _\ 0#UC_P !?_KT?\)@?^@'K'_@+_\
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M_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^%
M';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4
M?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M1
M7$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\
M)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\
MPD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\
MS\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/
M_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_
MXXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/
MQ_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A
M0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^
M%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';
M45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'
M_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_
M ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_
M ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:
MC_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\
M?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\
MS\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_
MX4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+
M_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!
MVU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A
M1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$
M_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H
M_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD
M6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\
M_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_
M ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XX
MO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_C
MB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4
M =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_
MX4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45
MQ/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%
MJ/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\
M)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/
M_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H
M_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^
M.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_
MXXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^
M% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XX
MO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU
M%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"
M1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/
M_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:
MC_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%
MJ/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'
M_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\
M?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+
M_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^
M.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =
MM17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_
MPD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<
M3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD
M6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"
M1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/
MQ_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\
M_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_C
MB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'
M_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^%
M';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4
M?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M1
M7$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\
M)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\
MPD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\
MS\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/
M_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_
MXXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/
MQ_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A
M0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^
M%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';
M45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'
M_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_
M ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_
M ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:
MC_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\
M?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\
MS\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_
MX4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+
M_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!
MVU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A
M1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$
M_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H
M_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD
M6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\
M_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_
M ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XX
MO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_C
MB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4
M =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_
MX4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45
MQ/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%
MJ/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\
M)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/
M_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H
M_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^
M.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_
MXXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^
M% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XX
MO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU
M%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"
M1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/
M_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:
MC_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%
MJ/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'
M_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\
M?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+
M_A0!VU%<3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^
M.+_A1_PD6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =
MM17$_P#"1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_
MPD6H_P#/Q_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<
M3_PD6H_\_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD
M6H_\_'_CB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"
M1:C_ ,_'_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/
MQ_XXO^% ';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\
M_'_CB_X4?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_C
MB_X4 =M17$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'
M_CB_X4?\)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^%
M';45Q/\ PD6H_P#/Q_XXO^%'_"1:C_S\?^.+_A0!VU%<3_PD6H_\_'_CB_X4
M?\)%J/\ S\?^.+_A0!VU%<3_ ,)%J/\ S\?^.+_A1_PD6H_\_'_CB_X4 =M1
M7$_\)%J/_/Q_XXO^%'_"1:C_ ,_'_CB_X4 =M17$_P#"1:C_ ,_'_CB_X4?\
M)%J/_/Q_XXO^% ';45Q/_"1:C_S\?^.+_A1_PD6H_P#/Q_XXO^% ';45Q/\
MPD6H_P#/Q_XXO^%% &#9?\A#6_\ L)7'_H57*IV7_(0UO_L)7'_H57* "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G9
M?\A#6_\ L)7'_H57*IV7_(0UO_L)7'_H57* "BBB@ HHHH **CN+B.U@DFF=
M8H8U+N[' 50,DFOE#XK_ +36J:U>3Z?X5G;3-+0E#>H,3S^X)^XOICGW'2O1
MP6 K8Z?+36V[Z(\?,LUP^54_:5WOLEN_0^LZ*_/*WT?Q1XT9[F"QU?7GS\\T
M<4MP<^Y -.M-7\3^ =0V0W.IZ#=KAC"2\)/^\AQD?48KZ+_5U?"JRYNW],^-
M_P!<FO?EAI*'?^D?H717B7P%^/3^/I/[#UWRX]<1-T,Z *MTH'S?+T#@<X'!
M&< 8KVVOE\5A:N#JNE46O];'W6 Q]#,:"KT'=/[T^S"BBOCGXY?%[6[SXBZC
M;Z+KFH:?I]B?LJI97;Q([+G>Q"D9.[(^@%=&7X&>8572@[65[G+FV:T\IH>V
MJJ]W9)'V-17S7^RW\4-1U?6M2T'6]4NM1EGC%Q:27D[2L"O#H"Q)Y!!Q_LFO
MI2L\=@YX&JZ4W?S[FF5YE2S3#K$4E;=-=F@HIDTR6\+RRL$CC4LS-T  R37Q
MO\5OVAM<\6ZI<6FB7LVDZ'&Q2/[,QCEG _B=AR ?[H.,=<UI@,OJX^;A3T2W
M?8RS;-J&4T54K:M[);L^RZ*_/.'P;XIUJ 7\.AZQ?0N-WVI+2616]]P!S6CX
M3^*7BOX?WR?8=3N8XX6P]C=,SPG!Y4H>GID8/O7ORX=NG[*JG)=+?\$^1CQD
MHR3KX>48/K>_X-'WW17*_#7Q]:?$CPG;:S:IY+L3'<6^<F*4?>7/<<@@^A%?
M-?[0OCCQ'HOQ4U.TT[Q!JEA:I'"5@M;V2-%S&I.%5@!S7AX7+ZF(Q$L,WRR5
M[W\CZK'9S1PF#CC8+GC*UK>9]?45^?/_  L[QC_T-FN?^#*;_P"*H_X6=XQ_
MZ&S7/_!E-_\ %5[G^K=7_GXOQ/D_]=:*T=&1^@U%?GS_ ,+.\8_]#9KG_@RF
M_P#BJ^C/&GB35[7]F72-4AU2]AU.2*U+WL=PZS,2PSEP=QS]:X<1DL\.X+G3
MYFE]YZ^!XFIXV-62I-<D7+UMT/>J*_/G_A9WC'_H;-<_\&4W_P 51_PL[QC_
M -#9KG_@RF_^*KN_U;JK_EXCR5QK1>U&1^@U%? ^F_&7QQI,PEA\4:E(P[7,
MYG7\I-PKZ=^ _P :S\3;2XT_4TC@UVT0.WE#"3QYQO [$$@$>X(ZX'GXS)*^
M$INJFI16]CV<MXHPN85EAVG"3VOL_*_<];HJ.>>.UADFF=8HHU+N[G 50,DD
M^E?)WQ8_:8U;6K^?3O"UPVF:7&2GVR/B:?\ V@W\"^F.??M7G8' 5L=4Y::V
MW?1'LYEFN'RJG[2N]]DMWZ'UK17YY6^C^)_&LDES!8ZMKS@X>:.*6Y(/N0#4
MUAX@\5_#W4!';W>IZ%<IAC;N7BS_ +T;<$?48KZ)\.KX8UDY=OZ9\:N,?MSP
MTE#O_2/T'HKQ'X'?M!#QU<)H>O"*VUO;^XGC&V.ZP.1C^%\<X'!YQCI7LU^Q
M2QN64E6$;$$=1P:^8Q.%JX2I[*JK/\_0^YP&/H9C1]MAY77XI]F6**_/ZV^)
MGC!KB('Q7KA!< @ZC-Z_[U?>FM2-%H]\Z,4=8)"K*<$$*>17=C\KG@.3FDGS
M?\#_ #/*RC/(9LZBA%KD[_/_ "+M%?GVGQ0\91NK#Q7K9*G(W:A,1^1;FOM#
MX1_$*'XD>#;74@56^C_<WD*_P2@<G'H>&'UQVK3'915P--56^9>70PRKB/#Y
MI7>'2<9+:_7N=I15+6I&BT>^=&*.L$A5E.""%/(KXF^'OQ$\5WOCSP[;W'B?
M6)X)=1MTDBEOY65U,B@@@M@@CM6&!RZ>-C.496Y#LS7.:>5RI1G%R]HVM.EK
M?YGW-17E'[2VM:AH/PV^U:9?7.G7/VR)?.M)FB?!#9&5(.*^4/\ A9WC'_H;
M-<_\&4W_ ,573@<GGCJ;J*:6MCAS7B*GE=9494W)M7T/T&HK\^?^%G>,?^AL
MUS_P93?_ !5'_"SO&/\ T-FN?^#*;_XJO2_U;JK_ )>(\-<:T7HJ,C]!J*^:
M_P!E7Q9KGB+Q#KD>JZSJ&IQQVJ,B7ET\H4[^H#$X->6_$#XB>*[/QUX@M[?Q
M/K,$$5],D<4=_*JHH<@  -@"N*&23GB98935XI._J>O5XFI4\##&RINTFU:^
MNA]S45^?/_"SO&/_ $-FN?\ @RF_^*H_X6=XQ_Z&S7/_  93?_%5V?ZMU/\
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MQE'=/].Y<HKX*\1?$CQ=#X@U../Q3K4<:74JJBZA, H#G  W=*SO^%G>,?\
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MZ5,LL/BC4W9>@N9S.O\ WS)D&O0?#=6VE1'BQXUP]_?HRL??-%>/_ 7XW/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX!_"O7OA;;ZS;ZO=V-S!=M%)"MG([;64,&)W(N,@KTSTKUJN-^%_Q.T[XHZ
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MU*;DVV]+=D?27[5VDZ*/ \5_-#;QZS]I1+>4 "5P<[USU(QS[<5X]^S"9_\
MA;VG>5N\OR)_-Q_=\L]?^!;:Y'1?#_BOXI:HT=FE[KUY&HW23S[MB]LNYP!^
M-?57P*^"8^&-K/?ZC+'<Z[=H(W,7*01YSL4]R2 2?8 =,GEK.GE> GAJD^:<
MKV7JNQW4%6S_ #:GC:-)PIP:N^]G?[V4/VJ/%TV@> 8=-MG,<NK3>2[ \^4H
MRX_$E1]":\#^ _PYA^(WC=+>]4MI=G']INE!(W@$!4R.F2?R!KT3]L:1_P"U
M/#$?/EB&=AZ$[D_S^-6?V-XTW>*Y/^6F+9>G;][WK/"2>$R:5:GI)W_.QTYE
M%8_B2GA:NL(VT^7,SZ0L[.WTZUBM;6".VMHE"1PQ*%1%'0 #H*PO'G@/2_B%
MH$^F:G K[E)AGQ\\#XX93V^G?H:Z2BOAHUJD)*:=FNI^I2H4ZE-TI13B]+=+
M'YT7<%]X-\32PAVM]1TRZ*B1>"LD;<$?B*^]]!\0+XJ\"V>KH HO;$3%1_"Q
M3YA^!R/PKXO^.:+'\6O$P08'VK/'J54G]:^H/@/(\GP,T@N#Q!<*,^@EDQ7W
M&=)5L'0Q$OB=OQU/R_AC_9<UQ.#@_=5_P=E^!\4VO_'U#_OK_.OT8UW_ ) >
MH?\ 7O)_Z":_.>U_X^H?]]?YU^C&N_\ (#U#_KWD_P#032XBWH?/] X)^+%?
M+_VX_.2.-I9%1%9W8X"J,DFO1O@3\3&^'/C*)KF0KH]_B"\7LHS\LG_ 2?R+
M5S?PU4-\0O# (R#J=L"#_P!=5KK?V@/AD?A_XP>>TCVZ-J1::WVCB-L_-'^!
M.1[$>E?28BI2JR6#JKXU^7ZGQ.#HUZ,99CAWK3EK\^OH?9>N,'T&_92&5K:0
M@CD'Y#7P/\-/^2B>&/\ L)VW_HU:^BOV?_B=_P )/X!U+P[?R[M3TNT?R68\
MRV^T@?BIPOT*^]?.OPT_Y*)X8_["=M_Z-6OG\KPT\)]9I2Z?BK/4^NX@QU/,
M(8+$4]FW\G[MT?H/1117P5VGH?K?*G%71^?'Q*_Y*%XD_P"PA/\ ^AFON#X8
M_P#)-_"__8,MO_1:U\/_ !*_Y*%XD_["$_\ Z&:^X/AC_P DW\+_ /8,MO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB!QV"CUKW2O SNM3K8R3INZ5E\SZKA;#5L+EL8UE9MMI=DSRS]IK_DC^K?\
M76W_ /1JU\[_ +-/_)9-$_W+C_T0]?1'[37_ "1_5O\ KK;_ /HU:^=_V:?^
M2R:)_N7'_HAZ]O*?^157^?Y(^8XB3_M[!_\ ;G_I3/MNO)OVH/\ DD=]_P!?
M$'_H8KUFO)OVH/\ DD=]_P!?$'_H8KY7+_\ >Z7JOS/T#-?^1?B/\,OR/ _V
M8_\ DKVF_P#7"?\ ]%FOIKXK?"G3/B5X?N(7@BAU9%+6MZ$ =7[*Q[J>A'XU
M\R_LQ_\ )7M-_P"N$_\ Z+-?:M?09]6G1QT*E-V:2_,^-X1P]/$994IUHW3D
M[I^B/SNL;[6?A_XF\VWDFTS5]/F*-C@JP."I'<'N#P17W#\*_B';?$KPC;:K
M$%BNE_=7=NI_U4H'(^AZCV/UKQ_]J3X5>=%_PF.F0_O$ 34(T'5>BR_AT/M@
M]J\N^ OQ+/PZ\91_:9-NCZAM@NP3PG/RR?\  2?R+5Z6)IPSG!*O37[R/]-'
MC8.I6X9S1X6K_"GU\GL_5;,]@_:^\/O=^&]&UB--PL[AH96'99 ,'Z97'XUY
MW^RWXTM_#?CJ;3KN010:M$(4=C@><IR@/URP^I%?6/B3P_9>+O#]YI5\@FL[
MR(HV#Z]&!]0<$?2OAOXD_"W6OAGJ[07T+263-_HU_&I\N4=N>S>JGG\.:YLI
MK4L5A9X"J[/6WSU_!G=Q%AJ^#QU/-\/'F2M?Y=_5'WQ535-4MM%TVYO[V98+
M2WC:661C@*H&37QMX9_::\;>&[%+1I[35XXP%1M1B9W4#MN5E+?5LFN?\>_&
M3Q1\1HQ;ZI>+'8A@PL[5/+BR.YY);\2:XZ?#N(]I:<ER]ST:G&6#]CS0C)S[
M6Z^?D8/C#7V\5>*]5U=E(-[<O,J]PI/RC\L5]P?#_P /OX7^%>DZ9*NR:'3\
MRK_==E+,/^^F-?/O[/\ \";S7=4M/$>O6S6VD6[":WMYEPUTXY4X/\ .#D]>
M.V:^J]2_Y!]U_P!<F_D:USS%TG[/"47=0W_)+Y&/"F7UU.KF.(5G/;SOJWZ'
MYQ6O_'U#_OK_ #K]&-=_Y >H?]>\G_H)K\Y[7_CZA_WU_G7Z,:[_ ,@/4/\
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M[[_@+!<(XB6'C/ZRX.23:2>E_F?FI7WI\&?&0\=?#O2M0=]]W&GV:ZR<GS4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHGB*2)]5T>PU-X@1&UY:I,4!Z@;@<5/H^@Z;X?MVM]+TZUTV!FWM%9P+$I;
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MO!OA_7[H7.IZ%INHW(4()KNSCE?:,X&6!..3Q[U2_P"%8^#O^A4T/_P6P_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\:7^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
MC0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]
M7_&C^UK'_G]M_P#OZO\ C0!;HJI_:UC_ ,_MO_W]7_&C^UK'_G]M_P#OZO\
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M]M_^_J_XT?VM8_\ /[;_ /?U?\: +=%5/[6L?^?VW_[^K_C1_:UC_P _MO\
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MM:Q_Y_;?_OZO^-']K6/_ #^V_P#W]7_&@"W153^UK'_G]M_^_J_XT?VM8_\
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M^-']K6/_ #^V_P#W]7_&@"W153^UK'_G]M_^_J_XT?VM8_\ /[;_ /?U?\:
M+=%5/[6L?^?VW_[^K_C1_:UC_P _MO\ ]_5_QH MT54_M:Q_Y_;?_OZO^-']
MK6/_ #^V_P#W]7_&@"W153^UK'_G]M_^_J_XT?VM8_\ /[;_ /?U?\: +=%5
M/[6L?^?VW_[^K_C1_:UC_P _MO\ ]_5_QH MT54_M:Q_Y_;?_OZO^-']K6/_
M #^V_P#W]7_&@"W153^UK'_G]M_^_J_XT?VM8_\ /[;_ /?U?\: +=%5/[6L
M?^?VW_[^K_C1_:UC_P _MO\ ]_5_QH MT54_M:Q_Y_;?_OZO^-']K6/_ #^V
M_P#W]7_&@"W153^UK'_G]M_^_J_XT?VM8_\ /[;_ /?U?\: +=%5/[6L?^?V
MW_[^K_C1_:UC_P _MO\ ]_5_QH MT54_M:Q_Y_;?_OZO^-']K6/_ #^V_P#W
M]7_&@"W153^UK'_G]M_^_J_XT?VM8_\ /[;_ /?U?\: +=%5/[6L?^?VW_[^
MK_C1_:UC_P _MO\ ]_5_QH MT53;6;!5R;VWQ_UU7_&B@#I/"NBZ?>#69;BP
MM9Y#JER"\D*L?O\ J16]_P (WI'_ $"K+_P'3_"L_P &?ZG6/^PI<_\ H==%
M0!F_\(WI'_0*LO\ P'3_  H_X1O2/^@59?\ @.G^%:5% &;_ ,(WI'_0*LO_
M  '3_"C_ (1O2/\ H%67_@.G^%:5% &;_P (WI'_ $"K+_P'3_"C_A&](_Z!
M5E_X#I_A6E10!F_\(WI'_0*LO_ =/\*/^$;TC_H%67_@.G^%:5% &;_PC>D?
M] JR_P# =/\ "C_A&](_Z!5E_P" Z?X5I44 9O\ PC>D?] JR_\  =/\*/\
MA&](_P"@59?^ Z?X5I44 9O_  C>D?\ 0*LO_ =/\*/^$;TC_H%67_@.G^%:
M5% &;_PC>D?] JR_\!T_PH_X1O2/^@59?^ Z?X5I44 9O_"-Z1_T"K+_ ,!T
M_P */^$;TC_H%67_ (#I_A6E10!F_P#"-Z1_T"K+_P !T_PH_P"$;TC_ *!5
ME_X#I_A6E10!F_\ "-Z1_P! JR_\!T_PH_X1O2/^@59?^ Z?X5I44 9O_"-Z
M1_T"K+_P'3_"C_A&](_Z!5E_X#I_A6E10!F_\(WI'_0*LO\ P'3_  H_X1O2
M/^@59?\ @.G^%:5% &;_ ,(WI'_0*LO_  '3_"C_ (1O2/\ H%67_@.G^%:5
M% &;_P (WI'_ $"K+_P'3_"C_A&](_Z!5E_X#I_A6E10!F_\(WI'_0*LO_ =
M/\*/^$;TC_H%67_@.G^%:5% &;_PC>D?] JR_P# =/\ "C_A&](_Z!5E_P"
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MX5I44 9O_"-Z1_T"K+_P'3_"C_A&](_Z!5E_X#I_A6E10!F_\(WI'_0*LO\
MP'3_  H_X1O2/^@59?\ @.G^%:5% &;_ ,(WI'_0*LO_  '3_"C_ (1O2/\
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M (#I_A6E10!F_P#"-Z1_T"K+_P !T_PH_P"$;TC_ *!5E_X#I_A6E10!F_\
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MP-+_ .@;9_\ ?A?\*/[ TO\ Z!MG_P!^%_PJ_118+LH?V!I?_0-L_P#OPO\
MA1_8&E_] VS_ ._"_P"%7Z*+!=E#^P-+_P"@;9_]^%_PH_L#2_\ H&V?_?A?
M\*OT46"[*']@:7_T#;/_ +\+_A1_8&E_] VS_P"_"_X5?HHL%V4/[ TO_H&V
M?_?A?\*/[ TO_H&V?_?A?\*OT46"[*']@:7_ - VS_[\+_A1_8&E_P#0-L_^
M_"_X5?HHL%V4/[ TO_H&V?\ WX7_  H_L#2_^@;9_P#?A?\ "K]%%@NRA_8&
ME_\ 0-L_^_"_X4?V!I?_ $#;/_OPO^%7Z*+!=E#^P-+_ .@;9_\ ?A?\*/[
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MH?V!I?\ T#;/_OPO^%']@:7_ - VS_[\+_A5^BBP790_L#2_^@;9_P#?A?\
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MN-<#V%JP74&5=T*G \N/@<=*ZFL+PO\ \?.O?]A%_P#T7'2L--V9>_L#2_\
MH&V?_?A?\*/[ TO_ *!MG_WX7_"K]%.PKLH?V!I?_0-L_P#OPO\ A1_8&E_]
M VS_ ._"_P"%7Z*+!=E#^P-+_P"@;9_]^%_PH_L#2_\ H&V?_?A?\*OT46"[
M*']@:7_T#;/_ +\+_A1_8&E_] VS_P"_"_X5?HHL%V4/[ TO_H&V?_?A?\*/
M[ TO_H&V?_?A?\*OT46"[*']@:7_ - VS_[\+_A1_8&E_P#0-L_^_"_X5?HH
ML%V4/[ TO_H&V?\ WX7_  H_L#2_^@;9_P#?A?\ "K]%%@NRA_8&E_\ 0-L_
M^_"_X4?V!I?_ $#;/_OPO^%7Z*+!=E#^P-+_ .@;9_\ ?A?\*/[ TO\ Z!MG
M_P!^%_PJ_118+LH?V!I?_0-L_P#OPO\ A1_8&E_] VS_ ._"_P"%7Z*+!=E#
M^P-+_P"@;9_]^%_PH_L#2_\ H&V?_?A?\*OT46"[*']@:7_T#;/_ +\+_A1_
M8&E_] VS_P"_"_X5?HHL%V4/[ TO_H&V?_?A?\*/[ TO_H&V?_?A?\*OT46"
M[*']@:7_ - VS_[\+_A1_8&E_P#0-L_^_"_X5?HHL%V4/[ TO_H&V?\ WX7_
M  H_L#2_^@;9_P#?A?\ "K]%%@NRA_8&E_\ 0-L_^_"_X4?V!I?_ $#;/_OP
MO^%7Z*+!=E#^P-+_ .@;9_\ ?A?\*/[ TO\ Z!MG_P!^%_PJ_118+LH?V!I?
M_0-L_P#OPO\ A1_8&E_] VS_ ._"_P"%7Z*+!=E#^P-+_P"@;9_]^%_PH_L#
M2_\ H&V?_?A?\*OT46"[*']@:7_T#;/_ +\+_A1_8&E_] VS_P"_"_X5?HHL
M%V4/[ TO_H&V?_?A?\*/[ TO_H&V?_?A?\*OT46"[*']@:7_ - VS_[\+_A1
M_8&E_P#0-L_^_"_X5?HHL%V4/[ TO_H&V?\ WX7_  H_L#2_^@;9_P#?A?\
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M5SU-SKI_";O@S_4ZQ_V%+G_T.NBKG?!G^IUC_L*7/_H==%6!V!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% '.?$+_D3=5_ZY#_ -"%='7.?$+_ )$W5?\ KD/_ $(5
MT= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7.7/_)0M,_[!=W_Z.MZZ.N<N?^2A
M:9_V"[O_ -'6] '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q>I?
M\E G_P"P7%_Z-EJ]5'4O^2@3_P#8+B_]&RU>KLI_">;6^)A1116AB%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 86M?\C)X=_ZZS_^B6K=K"UK_D9/#O\ UUG_ /1+5NT%
M]$%%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %87A?\ X^=>_P"PB_\ Z+CK=K"\+_\ 'SKW_81?_P!%QT%K9F[1
M1100%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 8WBK_D&VW_80LO\ TJBHH\5?\@VV_P"PA9?^E45%<]3X
MCKI?";O@S_4ZQ_V%+G_T.NBKG?!G^IUC_L*7/_H==%7.=H4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!SGQ"_Y$W5?^N0_]"%='7.?$+_D3=5_ZY#_ -"%='0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5SES_P E"TS_ +!=W_Z.MZZ.N<N?^2A:9_V"
M[O\ ]'6] '1T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q>I?\E G_
M .P7%_Z-EJ]5'4O^2@3_ /8+B_\ 1LM7J[*?PGFUOB84445H8A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% &%K7_(R>'?^NL__ *):MVL+6O\ D9/#O_76?_T2U;M!71!1
M1102%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6%X7_X^=>_["+_ /HN.MVL+PO_ ,?.O?\ 81?_ -%QT%K9F[11100%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1110 4444 %%)N&<9&?2EH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.<^(7_(FZK_UR'_H0KHZYSXA?\B;JO\ UR'_ *$*Z.@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &U
MRWQ$\?Z=\./#5UK&HR*$B4F.-VV^8P&0N<''Y5K^(->LO#.DW.I:A,MO:0+N
M=V. *_.OXT_%_6_VC/'\/A[0D<:;YHBCC SWQO..U>[E.5RQ]6\]*<=9,^;S
MG-HY=2Y:>M26B7ZGI]Q_P4A$4S(GP_$BJ<!O[8(S[_\ 'O4?_#R=_P#HG?\
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MG$/_ $$+[E_D?/\ _P /*'_Z)W_Y63_\CT?\/*'_ .B=_P#E9/\ \CU] ?\
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MA?ZV8/\ DE]R_P S] Z*_/S_ (:L^)7_ $,C?^ %K_\ &Z/^&KOB5_T,C?\
M@OM?_C=']A8G^:/WO_(?^M>#_DE]R_S/T#HK\^_^&KOB3_T,<G_@!:__ !ND
M_P"&L/B3_P!#')_X+[7_ .-T?V%B?YH_>_\ (/\ 6O!_R2^Y?YGZ"T5^?7_#
M67Q)_P"ADD_\ +7_ .-T?\-8?$G_ *&1_P#P7VO_ ,;H_L+$?S1^]_Y!_K7@
M_P"27W+_ #/T%HK\^?\ AK/XD?\ 0QR?^ %K_P#&Z/\ AK/XD?\ 0QR?^ %K
M_P#&Z7]AXC^:/WO_ "#_ %KP?\DON7^9^@U%?GS_ ,-9_$C_ *&.3_P7VO\
M\;H_X:T^(_\ T,<G_@!:_P#QNC^P\1_-'[W_ )!_K7@_Y)?<O\S]!J*_/G_A
MK3XC_P#0QR?^ %K_ /&Z3_AK;XD?]#')_P""^U_^-T?V'B/YH_>_\A_ZU83^
M27W+_,_0>BOSW_X:V^(__0QR?^"^U_\ C='_  UM\2/^ABD_\ +3_P"-T?V'
MB/YH_>_\@_UJPG\DON7^9^A%%?GO_P -;_$?_H8I/_!?:_\ QNF_\-<?$?\
MZ&.3_P %]K_\;H_L3$?S1^]_Y!_K5A/Y)?<O\S]"J*_/;_AKCXC_ /0Q2?\
M@OM?_C=)_P -<?$;_H8Y?_!?:?\ QNC^Q,1_-'[W_D'^M6$_DE]R_P S]"J*
M_/7_ (:Z^(W_ $,<G_@OM?\ XW2?\-=?$;_H8I/_   M/_C=']B8C^:/WO\
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M&MOB/_T,4G_@!:?_ !NE_P"&MOB1_P!#')_X+[7_ .-T?V'B/YH_>_\ (/\
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M ,@_ULP7\LON7^9]_P!%? '_  U1\2_^AD;_ , +7_XW2_\ #4WQ+_Z&4_\
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MKRK1E05(]<@C'UKYA?\ :$^*/QDURZL_AKHHL-/@/-R\<;.H[&227]VI/4*
M3UZXKCP^"JXCF:LDMV]$O4]'%YI0P:A>\I2V45=OT1]><TG4XQQ7R#JWQ2^.
M_P '&CU+Q=96^M:.SJCR-'#L&>V^$ H3T!8$9[&OHSX6_$[2OBMX5@UO2BR9
M/EW%K(1O@D &4;\P0>X(/M58C U,/!5+J4>\7=$8/-:.*JN@XN$[7Y9*SMY=
MSYD^,N5_;$\-]_\ 2-._]"%?9JY*CZ5\/_M&:[!X6_:DTS6+E7>WL/L5S(L8
M^9E0AB![\5U;?$#]H'XE1#6/"NC+H6C2?-;Q[;<-(G4',_+9'\0 ![5[.(P<
M\10P\DU%<N[=D?-83,88/&8N+C*<G+1)7=K;^A]; =Z/6OE+X3_M-^*[7Q_;
M>"_B'9"*\FF%J+GR1#-'*W""11\I5B0 5 Z@\BOIW7M<LO#.CW>JZC,MM8VD
M3333-T50.37A8C!U<+-0GK?9K5/T/J\%F5#'0E.G=<KLTU9KU1?[>E'0\G]*
M^1;C]HCXF_&'7KK3_AEH@L["WZW4D<;R =C(\A\M,X.%P3P>346M?$KX]_!]
M8]4\5VD&LZ/N >1HH2BY[%H0I0^A88SZUW+*:VBE**D_LMZ_<>8\_P /K*$)
M2@MY)7CYZ^1]?X'7&:.W%<3\*/BGI/Q:\*Q:QIA:*0'RKBUD(+P2#JI]1W![
M@]CD#POXV?M!>)/AA\<XK%+^1_#4,$<TVG1V\),I*$D>85W#)QSGBN2C@:]:
MLZ"5I*^C\COQ&:8;#X:.+;O"36J\SZJ/RY[5\]_M:_&'Q%\-=+T>R\/S1V<N
MI^;YMYLW21JNWA,\ G=UP3Z8KEK7Q!^TAKS6^OV=G;6>F7+J\6F/';@+&Q&"
MP;]YC!Y^8-[5Y;^TY8?$2SU336\=:E:7]N\MP=-6U2--B;ESD*H/3;]XL>.M
M>QE^6Q6*@JLXR6MU>[T78^?S3.IO U)T*<XO2S:LM7Z[,^\-!D>;1;&65FD=
MX$9F8Y))49)-7\\C S^->+_ ?2_BG9W4LOC?5K6^T9K1!9Q0+$&1LK@G9&I^
M[GJ37M.T?C7@XFG[&JXW3]-CZG UGB*$9N+CY/<4_E7!_%+XP>'OA/H[76L7
M:M=LI-OI\; SSGMA>RYZL>!^E=U[5\\Z3^R18:IXWU3Q+XRU2377N;R2XBL$
M9A&$+DHLCD[GPNT;1M QCD5>%A0<F\1)J*Z+=^7D1CJF*C34<)!.3=KMV2\_
M,\8^#OQ$U/XG_M2Z+K^JD":;[0L4*?<AC%O)M1?8?J23WK[N7'&*^*/!MG!8
M_ML2VUM%';V\-W<1QPQ*%1%%JX"@#@ #M7VQT^E>IG7L^>BZ<;1<%9?-GS_#
M7M5'$JM+FDJC3?>R0ZBBBOGS[(**** "BBB@ HHHH **** "BBB@ HHHH YS
MXA?\B;JO_7(?^A"NCKG/B%_R)NJ_]<A_Z$*Z.@ HHHH **** "BBB@ HHHH
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MJ=8_["ES_P"AUT5<[X,_U.L?]A2Y_P#0ZZ*N<[0HHHH **** "BBB@ HHHH
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M ;Q5IG@KXL:#K6LW/V/3;5I3+-Y;R;=T+J/E4$GE@.!WK[3'[6?PK_Z&=O\
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M%% !1110!SGQ"_Y$W5?^N0_]"%='7.?$+_D3=5_ZY#_T(5T= !1110 4444
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MNPTS1-,O8[F>>9E/EEU0GRX\\EVP, @9. >C$[:ZW2_+8YZ*=[;.[_,^(O\
M@E#(_@_]KSXO>#M/9FT5+*Z YX/V:]2.(_7;*_YFO&_&7Q.\9:;_ ,%*O&OC
M'PWX)N/B)XDT77;Z.UT.WMIKIG2!&MD?9$I;Y%56R!P0*^K/^"/_ ,$=:L=(
M\7_%_P 1P213^)6%IIK3)B2>$.7GGY_A>3: >_EMVQ7DG[4UOK?[#_\ P4(T
MWXQIIUQ>^$=>N3?%H1@2+)%Y5[;[CQY@RTB@X'S)[X7PU:2D[6BU\R[J<:KB
MKIO3S1ZM_P /"/VJ.!_PRGKW_@CU7_XU7SA^V!XK_:#_ &P%\,-K/[./BKP]
M=:$9_*N+#P[J+O(LNS*MNBZ Q@CZFOU>\#_M7?!_X@^%H]?TCXC^&VT_RA+*
M+O4XK::W!&<31R,K1'@\,!T]*^(?VC_^"B'C7QO^T)X5^'7[-.K6^K,TQM;N
M\6RBNK?4;AV'",ZDB&)58M*A (+')50:GEO4C&VM]/+S&G[KELK'TM\?KC5;
MK_@G;XEGUR">VUJ3P.CWT%U&R2QSFV3S%=6&58-G(/(->2?\$6_^39/%'_8U
MW'_I):5] _MF0W,/[&/Q,CO95N;U/#<PGFC78LD@0;F"]@3DXKY]_P""+?\
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MGF#8^GE?UKTWX;_L4Z-X=OH-0\4:C_;\L;!EL8XO+MMP_OY):0>WRCU!%?3
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M1J1?M;:/I_PY^1TX9E_9$I4Y+V5]5U_X8]U_8A^#\O@GP>VNZ@FR^O<^6/\
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M\"VU]X#G/8UY&:X%9?BI48NZW_X#/9R?'RS+"1KRC9[/_-$E%%%>2>X%%%%
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MTN9YS,\\T6Q/*GC&,1K@8)R3SVJ6]4NK*2;3?8_0.CBORL_X;Z_;>_Z-S_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M><_&SX1:=\7/"=QIURJK=*-T$V.0P!P/SKX8^&GCK7_V4?B9/I&M1R+I4DNR
MYCYV[>Q%?I7Z5XG^TK\![3XM^%Y)8(576;5"87 QO]CCK7U&49C"FG@\5K2E
M^#[GQ^=97.HUCL'I5A^*['JOA?Q1I_C#1;;4]-G6>VG4,&4],CH:U_PK\\/V
M:?C7J'P-\92^$/%'F0Z9)+Y8$W'DL6^]D]J_0;3[^WU2SAN[259[>9=\<B'(
M8'N*X,TRV>7U;+6#UB^Z/2RC-(9E1YGI-:279EG[N:^??VUO^21R?]=?Z5]!
M>U>$?MB:%J.O?"MX-,LY+VX\W/EQC)QBLLJ:CC:3;MJC7-XRE@*JBKNQ\W_\
M$^_^1UO/HW_H-?1?[9V@+JWP?U"Y/6T1G%>%?L)^#=?\/^,+R75-(N+"(AL/
M,,#I7U!^TQIMUJWP4\3VUE;/=W3V^(XH_O,<]J^GS.LHYW3G%]8GRN5T92R*
MI3FM;,^6O^">9!\1:H._V=OYBO%OVA=-N-+^/FNM<)Y?FZBK(?49%>N_L.^'
M?$_A;XG3C4-&NK*SDM2#)*N!GTKO?VQOV;]2\6WL?BGPW;/<W2 F>WC&6=L]
M17N?7*6&SJ?-)<LXI7/G_J5;$Y)#E@^:G)NW6Q]/^$;R"/P/IUPTR&%+5"9
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M:CTHXYKX:I4G5FZDW=L_0:-*%&"ITU9(=11169L%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<Y<_\E"TS_L%W?\
MZ.MZZ.N<N?\ DH6F?]@N[_\ 1UO0!T=%%% !1110 4444 %%%% !1110 444
M4 ,89H5<9KB_C-\1#\(_A/XO\:_V?_:O_"/Z9<:E]A\_R?/\I"^SS-K;<XQG
M:<>AKS']BW]JP_M>_#75/%W_  B__")FQU:32_L?]H?;=^V&*3S-_E1XSYN-
MN#]W.>>!+FO;H#TLWU/H6BBB@ HHHH 2CI7RC^W!^W,?V-9/""_\(5_PE_\
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M*75(#TP4M,5MRAAT(S3J8"T444 %%%% !1110 44E+0 4444 %%%% !1110
M4444 <7J7_)0)_\ L%Q?^C9:_.OXL?\ )4O%_P#V&+O_ -'-7Z*:E_R4"?\
M[!<7_HV6OSK^+'_)4O%__88N_P#T<U?;<-_Q)>GZGY;QM_#I^IRE%%%??GY(
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6G4VG5(T.6GIUIBT].M#*0]NE.6FMTIRU)0Y:2E6DH+):<M-IRU!0M/IE/H
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M"2^.3VBOQ>B_4WI[P7\S2^74[O\ X(J\?L\^,?\ L9W_ /26WKZL_:*_:A\
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M7U?Z')=JE4DNE[>J>Y^HVJZK9Z#I=WJ6H7<-C86D33W%S<2!(X8U!+.S'@
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MG,,$<1_V% J::%+B,I(H=3U5AD4_% XKAYGN>CRJUBI;Z9:VK;X;:*-O[RJ
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M444 %%%% !1110 5SES_ ,E"TS_L%W?_ *.MZZ.N<N?^2A:9_P!@N[_]'6]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN*\>_P""GW['_B;]I+PQX2UKP#HRZQXPT>YDMI+7[3#;&:TE&XG?*ZJ2CHI
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MU?\ &@?&CP>W_,;M?^_J_P"-'U3$?R/[@^NX;_GXOO.WQ[T8]ZXG_A<_@_\
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MW#^V=8S^)O!>KZ1\/O!-RSPVTWE0VUNQ5BK>6[1S7+D'@N/ER"!@@@2?%/\
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M8C/_ $.G_E*_^W5]4-WJ-J]/^U\;_P _/P7^1XG^K>5_\^OQ?^9\LG]B5O\
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M']G_ .S1_:V,_G_!!_J]EW_/K\6?+?\ PRK?_P#0X?\ E+7_ ..4?\,IW_\
MT.'_ )3%_P#CE?4O]F_[-)_9G^S1_:V,_G_!!_J_EW_/I?>SY;_X94U#_H</
M_*8O_P <H_X95U#_ *&__P I@_\ CE?4G]F?[-']F?[-']K8S^?\$'^K^6_\
M^E][_P SY;_X94U#_H</_*8O_P <H_X93U#_ *&__P I:_\ QROJ3^S/]FC^
MS/\ 9H_M;&?S_@@_U?RW_GTOO?\ F?+?_#*>H?\ 0W_^4M?_ (Y1_P ,IZA_
MT-__ )2U_P#CE?4G]F?[-']FC^[1_:V,_G_!#_U?RW_GTOO9\M_\,IZA_P!#
M?_Y2U_\ CE'_  RGJ'_0W_\ E+7_ ..5]3?V:/[M)_98_N_K1_:V,_G_  0?
MZOY;_P ^OQ9\L_\ #*>H?]#A_P"4Q?\ XY1_PRK?_P#0X?\ E,7_ ..5]2_V
M:/[M']F?[-']K8S^?\$+_5_+O^?2^]GR==?LRZA:WUC;?\)9N^U,Z[O[-4;=
MJENGF<]*N?\ #*>H?]#A_P"4Q?\ XY7T;J^G?\3_ $$;?^6DW_HIJV?[-_V:
M7]JXS^?\$/\ U?R[3]TOO?\ F?+7_#*>H?\ 0W_^4M?_ (Y1_P ,IZA_T.!_
M\%:__'*^I?[-_P!FC^S3_=I_VMC/Y_P0O]7\M_Y]+[W_ )GRW_PRGJ'_ $.'
M_E,7_P".4?\ #*=__P!#A_Y3%_\ CE?4G]F_[-']F_[-']K8S^?\$'^K^6_\
M^E][_P SY;_X92O_ /H</_*8/_CE+_PRE?\ _0X_^4M?_CE?4?\ 9OM1_9OM
M1_:V,_G_  0_]7\M_P"?2^]GRY_PRC?_ /0X_P#E,7_XY1_PRC?_ /0X_P#E
M,7_XY7U'_9H]*/[-'I1_:V,_G_!"_P!7LN_Y]?B?+G_#*-__ -#C_P"4Q?\
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MOJ/;3\8I?VOC?^?GX+_(/]6\K_Y]?B_\SY;7]AW_ *G7_P I7_VZE_X8=/\
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MYC_A7NG?\]KK_OM?_B:!\/\ 3U_Y;77_ 'TO_P 373T4>VGW']7I_P IS?\
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M;=%+VDNX>QI]C&'A6T''F3?]]#_"E_X16T_YZS?]]#_"MBBCVDNX_90[&/\
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MY]?^32_S/B/_ (=M/_T49O\ P3G_ .2*/^';3_\ 11F_\$Y_^2*^W.:.:/\
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MR:G\NEVF@"$0TODU-LHV4 1>6*7RQ4OET;* &>6*7:*?MHVT -VTM+MI=HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KG+G_ )*%IG_8+N__ $=;UT=<Y<_\E"TS_L%W?_HZWH Z.BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** .+U+_DH$_P#V"XO_ $;+5ZJ.I?\ )0)_
M^P7%_P"C9:O5V4_A/-K?$PVBC:***T,0VBC:*** #:*-HHHH -HHVBBB@ VB
MC:*** #:*-HHHH -HHVBBB@ VBC:*** #:*-HHHH -HHVBBB@ VBC:*** #:
M*-HHHH -HHVBBB@ VBC:*** #:*-HHHH -HHVBBB@ VBC:*** #:*-HHHH -
MHHVBBB@ VBC:*** #:*-HHHH -HHVBBB@ VBC:*** #:*-HHHH -HHVBBB@
MVBC:*** #:*-HHHH -HHVBBB@#"UI1_PDGAW_KK/_P"B6K=VBL+6O^1D\._]
M=9__ $2U;M!?1!M%&T444$!M%&T444 &T4;1110 ;11M%%% !M%&T444 &T4
M;1110 ;11M%%% !M%&T444 &T4;1110 ;11M%%% !M%&T444 &T4;1110 ;1
M1M%%% !M%&T444 &T4;1110 ;11M%%% !M%&T444 &T4;1110 ;11M%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5A>%_P#CYU[_ +"+_P#HN.MVL+PO_P ?.O?]
MA%__ $7'06MF;M%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!C>*O^0;;?]A"R_P#2J*BCQ5_R#;;_
M +"%E_Z5145SU/B.NE\)N^#/]3K'_84N?_0ZZ*N=\&?ZG6/^PI<_^AUT5<YV
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% '.?$+_D3=5_ZY#_T(5T=<Y\0O^1-U7_K
MD/\ T(5T= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7.7/_ "4+3/\ L%W?_HZW
MKHZYRY_Y*%IG_8+N_P#T=;T ='1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '%ZE_R4"?\ [!<7_HV6KU4=2_Y*!/\ ]@N+_P!&RU>KLI_">;6^)A11
M16AB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 86M?\C)X=_ZZS_\ HEJW:PM:_P"1D\._
M]=9__1+5NT%]$%%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %87A?_CYU[_L(O\ ^BXZW:PO"_\ Q\Z]_P!A%_\
MT7'06MF;M%%%! 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M [&BN._XKK_J"?\ D6C_ (KK_J"?^1: .QHKCO\ BNO^H)_Y%H_XKK_J"?\
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M_J"?^1:/^*Z_Z@G_ )%H [&BN._XKK_J"?\ D6C_ (KK_J"?^1: .QHKCO\
MBNO^H)_Y%H_XKK_J"?\ D6@#L:*X[_BNO^H)_P"1:/\ BNO^H)_Y%H [&BN.
M_P"*Z_Z@G_D6C_BNO^H)_P"1: .QHKCO^*Z_Z@G_ )%H_P"*Z_Z@G_D6@#L:
M*X[_ (KK_J"?^1:/^*Z_Z@G_ )%H [&BN._XKK_J"?\ D6C_ (KK_J"?^1:
M.QHKCO\ BNO^H)_Y%H_XKK_J"?\ D6@#L:*X[_BNO^H)_P"1:/\ BNO^H)_Y
M%H [&BN._P"*Z_Z@G_D6C_BNO^H)_P"1: .QHKCO^*Z_Z@G_ )%H_P"*Z_Z@
MG_D6@#L:*X[_ (KK_J"?^1:/^*Z_Z@G_ )%H [&BN._XKK_J"?\ D6C_ (KK
M_J"?^1: .QHKCO\ BNO^H)_Y%H_XKK_J"?\ D6@#L:*X[_BNO^H)_P"1:/\
MBNO^H)_Y%H [&BN._P"*Z_Z@G_D6C_BNO^H)_P"1: .QHKCO^*Z_Z@G_ )%H
M_P"*Z_Z@G_D6@#L:*X[_ (KK_J"?^1:/^*Z_Z@G_ )%H [&BN._XKK_J"?\
MD6C_ (KK_J"?^1: .QHKCO\ BNO^H)_Y%H_XKK_J"?\ D6@#L:*X[_BNO^H)
M_P"1:/\ BNO^H)_Y%H [&BN._P"*Z_Z@G_D6C_BNO^H)_P"1: .QHKCO^*Z_
MZ@G_ )%H_P"*Z_Z@G_D6@!FI?\E G_[!<7_HV6KU<7>7'B=O&4T<BZ;_ &BM
MD@8KO\ORPY([YSEC5[/B[TTK_P ?KJIOW3@J1O-NYTU%<SGQ=Z:5_P"/T9\7
M>FE?^/UIS>1ER>9TU%<SGQ=Z:5_X_1GQ=Z:5_P"/T<WD')YG345S.?%WII7_
M (_1GQ=Z:5_X_1S>0<GF=-17,Y\7>FE?^/T9\7>FE?\ C]'-Y!R>9TU%<SGQ
M=Z:5_P"/T9\7>FE?^/T<WD')YG345S.?%WII7_C]&?%WII7_ (_1S>0<GF=-
M17,Y\7>FE?\ C]&?%WII7_C]'-Y!R>9TU%<SGQ=Z:5_X_1GQ=Z:5_P"/T<WD
M')YG345S.?%WII7_ (_1GQ=Z:5_X_1S>0<GF=-17,Y\7>FE?^/T9\7>FE?\
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M>FE?^/T<WD')YG345S.?%WII7_C]&?%WII7_ (_1S>0<GF=-17,Y\7>FE?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 <G\4O^1$U/_ME_P"C4KI;/_CT@_ZYK_*N:^*7_(B:G_VR_P#1
MJ5TMG_QZ0?\ 7-?Y4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5QVH?\E2TK_KP
MD_FU=C7':A_R5+2O^O"3^;4 =C1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5QVH?\E2TK_KPD_FU=C7':A_R5+2O^O"3^;4 =C1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'G]Y_R4Z[_ .P<O_H8K:K%O/\
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MR!8/^OJ+^=%'C[_D"P?]?47\Z*YJFYW4OA-?X9_\>NN_]A:?^2UV5<;\,_\
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M')7"CY1@>N:];^!/Q,N_C5\)-1M[IXSK]O%)87#M\JR,T9\N4@#@,#S@=5;
M[5\5?%#X8ZK\)?$BZ)K$]I<7;6Z7(:R=WCVL6 &653GY3VK7*,#"&-E3Q#7-
M#96O?S,^(<UJ5,KA6PB?+/>2=K>3_%'WA^S/(O\ PH_PHNX9^SOQG_IHU<I\
M;OV7?^%P>,DU[_A)QI&VU2V^SM8>=]TL=V[S5Z[NF.U>/_LZ?L[^);C6/"?C
MQ+S3!HPE^T^3YLOG[064C;Y>W.1_>K)_;8_Y+%#_ -@J#_T.2KIX=_VFXX6M
M9N[;MMKM9[F,\:GD:GCL/>,5%)7^)65G=+0^R/AGX+'PY\"Z1X>-Z+_[!&4-
MSY?E^9EB<[=QQU]3TKJ=RL>"#7SSX/\  J?$?]D/3M%V;KF2QDEM3CD3)([)
MCZD8^A-?.G[+_C5_ GQ@TZ*X9H;74B=-N%;C#.1L)'8B0*/8$UY\<MEBGB)J
M=YP;NK;[Z[Z7]#U99U# QPD/96IU$K._PZ+3;6Q^B1QUQ2>8HR"P!^M8OC+Q
M+!X/\*:KKET?W%C;-.1_>('"_B<#\:_/7X1^&+KXR?&:R2^!N$NKIM0U%FR0
M8PV]P?\ >.%_X$*YL#E_UN%2I*7+&"NW:_ZH]'-,W_L^I2HPASRJ.R5[?H?I
M(<\'M6!KGQ \,>&YUAU?Q%I>ES,,B.\O(XF_)F!KQ[]J[XU7GPU\/V6AZ'*;
M?6M41B;E>&MX!P2OHQ/ /;![XKP+X/?LQZW\9-'F\17NLKI%C-*XBGFA:XFN
M&!PS8W+QG(W$Y)!XK;"Y;"=#ZUB:G)#9:7;.7'9U4I8E8+!TN>I:[ULEZL^[
MM'U_3?$5J+K2M0M=1MR<":TF61<^F5)%:'-?G)XF\/\ C#]E_P"(4'V74MDS
M()H+JW)$-W%GE70]1D8*G..H/0U]Y?#/QK;_ !%\#Z3XAMT\M;V'<T><^7("
M5=?P8,/PK+&Y?]5A&M3GS4Y;,URO.7CJL\+7I\E6&ZO?3NCJS7FW[1G_ "1+
MQ=_UYG_T(5Z2:\V_:,_Y(EXN_P"O,_\ H0KS\-_'AZK\SW,7_N]3T?Y'P-\)
M_AZ?BAX\T_PV+_\ LTW8D/VGR?.V[$9_N[ESG;CKWKZ&_P"&!F[^.A_X*/\
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M/2#_ *YK_*@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.U#_DJ6E?]>$G\VKL:
MX[4/^2I:5_UX2?S:@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M_O/^2G7?_8.7_P!#%;58MY_R4Z[_ .P<O_H8K:KKI_">;6^,****U,0HHHH
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M9Q9')5@5"J.IQR?<XK[.^(/@7_A.OASJGANYN/,GNK78MS(HSYRX*N0  /F
M)P/6O.QU>M0G0CB5%*+3M%.Z7XJQ[.487#8J&+J8-S<I)QO)Z.^S6E[GRA^P
MTD1^(^M.V/-732$]0#*F<?I7VY(BR1LK@,",$=C7YJ> _%VN?L__ !,-U/8,
MMY9L]M>6$Q*>;&<;ESCCH&#<C@'D5[WXW_;/@\1^'I-(\(:%J2ZW?C[,DERJ
M?NF?Y?W:HS%VYP.G/Y56;9?7Q6*5:BN:,DM>B,N'LVPV7X*6%Q3Y9Q;TL[OT
M/G;P/''%\9- 2$ 1+KUN$"]-OVA<8_"ON?\ :?\ ^2#>*/\ KE#_ .CHZ^#_
M (:PR6_Q2\*Q2J5E36K564]01.H(K[P_:@_Y(-XG_P"N4/\ Z/CK;.%RXK"J
M]]OS1S\.2YL+CI6M=;=M&?-G[#W_ "5;4?\ L%2?^CHJ]@_:8_9PO/BC>P>(
MO#TL*ZU#"()K6X;:MP@)*E6Z!ADCG@C'(Q7C_P"P_C_A:VI9X_XE4G_HZ*NJ
M_:N\0?$WP/XG-S8^(-1M_"MYM^S/9XB$#XPT3.@!SD9&3R#[&EC%5>;KV$E&
M5EOL_(>5N@N'YO$TW.',[J.Z\_D>%7WA/XB_"2YEE>RUWPZPX>ZM6DCC;V\V
M,[6_.NY\ _M@>./"]S#'J\\?B33@0'CNE"3!?]F10#G_ 'PU>C> ?VVM+T_P
MO9V?BC2M2N=4MXEB:ZL_+E%QM&-[;W4JQ[]><GVKP3XI>+(_C'\2GOO#^@&Q
M-YY=O#90*&EF?IN8*,;CGMZ#D]:]2G&>*G*GCJ"LOM=/EU_$\.I*E@:<:^5X
MN5W;W.NO?T]#]&/"_B*S\8>'-/UFQ8M9WT"S1EA@@,,X([$=#[BOS;TW_DM%
MK_V'U_\ 2@5^A7PC\(S^!?AOH.A73!KJTME6;:<@.?F8 ]P"Q&?:OSO\2?:?
M!OQ6U"2Y@9;G3M7:8Q'@G;-N'Y@#\Z\;(E%8BO"F[KIZ7/I>*)5)8+"U:RL[
MKF\G:[/T_P#^6?/I7Y=:?9IJ'Q.MK64 Q3ZPL3 C((,P!_G7WG\(?C]HWQDO
M-4MM*LKRS:PB1V^VJBE]Q8' 5FX! YSWZ5\)Z!_R5S3O^PY'_P"CQ5Y%2GAZ
MM>-16DDOU(XHQ%'&8?#5*4N:+EN?I^H_=H/:O!/VBOVE#\);J'1-&M(;W7YH
MA,[W&3%;H<A<@$%F.#QD =>>E>]H?D7UQ7P9^V=X9O\ 2_BW)JTT+_V?J=M$
M;>;'RED0(R9]1@''^T*\'*</2Q.+5.MM9NW=]CZO/\77P672JX;26BOV3ZD^
ME^(/C[\:+4SZ7=:H=.<G;-:M'80D9P0KC9O .0<$GBO(OB-X.UCP'XNN](UZ
M:.?58U22:2.0R@ET##+$<G!&:^A_AG^V-H_@[X=Z=HU_H-[-J>GP+;Q?9/+$
M$JJ,*S,2"I(ZX5N>>^*^>_B5XFU7QQXLO/$NJVC6<NK'[1$FPA/+'R+L)^\!
MLQGN0:^XP7MX8B<'2C""O:RU;Z?AY'Y;F4L+5P4*JQ$JE5V;3;:2ZZ=-?,_1
MGX2((_A;X34=!I-M_P"BEK\\;K_DLDO_ &'C_P"E%?H5\&;J*^^%'A.6)E93
MI=NOR^HC4$?@<BOSR\=0W7A/XL:W]HB*7-GJ\DVP\9Q*74_B,'\:\7(],77B
M]]?S/IN)?^1;A)K96_(_3]<[!Z8K\P?%/_)8-7_[#LW_ *4&ON;X0_M":+\8
MM3OK#2[&]LWLX$F=KP("V3@[0K-P#CDXZ]*^&?%/_)8-7_[#LW_I0:60TIT,
M15IU%9\I?%.)I8O!4*E%WBY;GUA^W!+<)\+=(2//D/J<?G8Z<12%?UKE/V"H
MHMWC*3:OFC[* W?!\TG]17O?QK^'8^*'PUU'0XW5+QE6>T=C@"9#E0?8\K^-
M?#OPP^(FN_L[^/KHW>FR!L?9M0TR<F-F4'((..&!Y!Y!!/8YK/+_ /:LMJX2
MF_?O>W?9_I8US>^ SG#YA57[JUF^SU7ZW/T=EC62-U8 J000>E?F+X346_Q@
MTA=/.%3781!MZX%P-N/PQ7T'\1_VV++5?"UW8>%M*O[74;J,Q&ZOA&BP C!*
M!6;<<=,XQU]JY']DOX+WWB?Q;:>+M1MVAT337\VW:52/M,XSMV^JH?F)]0!Z
MXURVC4RW#UJ^)7*FK)=S#.L52SK$X?#8)\S3NVMDM#V[]M+_ )(NO_81@_D]
M>6_L'PHWB;Q5,1^\6UA0'V+L3_Z"*]3_ &U?^2,C_L)0?R>O,/V#?^0_XL_Z
M][?_ -">L<)_R)JWK_D=.8?\E)AO\/\ F>U?M8_\D,\0?6#_ -')7SK^P_\
M\E6U+_L%2?\ HZ*OHK]K+_DAGB#ZP?\ HY*^=?V'O^2K:E_V"I/_ $=%4Y?_
M ,BC$>OZ(6=?\C_!^B_-GI_[6WQ>\7?#/7/#UOX;U;^S8;J"6255MX9-S!@
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MQ\-_^A^\,_\ @WM__BZ^/O\ AWWKW_00'_?:T?\ #OO7O^@@/^^UH_LW*?\
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M?5V/J2EHI*0"T444 %%%% !124M !1110 4444 %%%% !1110 4444 %%%%
M!1124 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'G]W_R4V[_ .P<O_H8K:K%N_\ DIMW_P!@Y?\ T,5#JOQ"\+Z%
M?266I>(])T^\CQOM[J^BBD7(!&59@1D$'Z&NRBI25HJYY6*J0IRO-V7F=!17
M*_\ "VO!/_0X:#_X,X/_ (NC_A;7@G_H<-!_\&<'_P 773[*IV?W'%]:H?\
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MG!_\71_PMKP3_P!#AH/_ (,X/_BZ/95.S^X/K5#_ )^+[T=517*_\+:\$_\
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MNC_A;7@G_H<-!_\ !G!_\71[*IV?W!]:H?\ /Q?>CJJ*Y7_A;7@G_H<-!_\
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M'#0?_!G!_P#%T?\ "VO!/_0X:#_X,X/_ (NCV53L_N#ZU0_Y^+[T=517*_\
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MXNS.B,E)7B[H****104444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK,NV2&= Z./0J>"*M$&E[5XTZLZDN><FWW;/I:6'HT8>SIP48]DDE]QY1?\
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M45\N?8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<=J'_)4M*_Z\)/YM78UQVH?\E2TK_KPD_FU '8
MT444 %%%% #"*Y+XJ_$C3OA'\-_$/C36+>[N=,T.S>]N(;%%>=T09(0,RJ3]
M6 ]ZZZO#?VXO^31?BP.W]@7/_H-95)<L6T7"*E)1?5G%6_\ P4@^#?\ PI6Q
M^)>IW^HZ%I>H7-Q:V.DW]NC:E=R0D!]D,4CC;DCYRP49&2,BN,\$_P#!7CX"
M^+]<33KQ_$GA2-VV+?ZYIT?V?).!DP2RLH]V4 =R*^:?^"4?[(GAKXIZ3?\
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M_C@_PI/[1O?^>W_CH_PJ7R3Z4>2?2BS[A=>1&-2O?^>W_CH_PH_M*\_YZ_\
MCH_PJ3R3_D4>2:+/N%UV(_[2O/\ GK_XZ/\ "E_M*\_YZ_\ CH_PJ3R?:CR:
M+/N',AG]H7G_ #U_\='^%']H7G_/7_QT?X4_R31Y)]*+/N',NPS^T+S_ )ZY
M_P" C_"E&H7G_/7_ ,='^%.\FCR33LQ70W[?>?\ /7_QT?X4OVZ]_P">O_CH
M_P *=Y-'DT6870W[=>_\]?\ QT?X4?;[O_GK_P".C_"G>31Y-%F%T-^WW?\
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M/'FN_P#/]_Y!C_\ B:E_X3C6_P#G]_\ (2?_ !-<VM3UXKI0_E7W'U'MJO\
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M/EE-5,0W9NVBN?:&:-U?"G_#<7C[_H'>'_\ P&G_ /CU'_#<7C[_ *!V@?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"4?6BN<\=>--/\ ^&[S6-2E6."W7<<GJ>PJH0E4DH15VS.I4C2BYS=DC$^,G
MQ5T[X3^$;G5+J1/M&TBWB)^\^.,^U?G_ .%O#OBG]JSXI&YNVEDLO-+O(Q/E
MQ)G)12>U+XK\3>*?VJ/BDEA:&62S,@4(GW8H\XW'\*_0'X/_  KTSX3^$;72
M;"%5FV*;B8#F1\=:^^]SAW#='7FO_ 4?G/[SB;%WU6'@_O9N>"?!NF^!/#MK
MI&F0K!;0+@!1C)[FL#XS?%"/X3^$9-9>$3A6VA3GTS7?8Q7S]^VJ?^+12?\
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M"N1;:7;[5)MI=M,+D>VC::DHH$,VT;?:GT4 -HVFG4J]: $"D4C+FGGZ4V@
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M:+6]O/?\3Y#_ &>_^2U>$O\ K\7_ -!-?I<OW1]*_-']GO\ Y+5X2_Z_%_\
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MYIV&6&0#MKV+-'%':OB<1B*F*JRK57=L^\PN%IX2E&C15D@KY^_;8_Y)&_\
MUV_I7T!7S_\ ML?\DC?_ *[?TKNRG_?:7JC@SG_D7UO1GS+^POXHTGPSXPNW
MU6_@L$8-M:9MH/%>B_MK_&SP[K7ANW\/Z/?1:E<,Q\R2W<,JY%?-/P/^#>H_
M&36GL;"X%L8P2S[MO09I?C%\"_$7P:U)(M7C$MO,<17"'<&^IK]2JX/!U,U5
M:=3]XE\)^24\=C:>42I0I_NV]9'TK_P3Y\$ZA:VU_P"()D,5HX:!0PP2?6MO
M]LC]HS4O!,T'ACP[*L5U<*1/+C)4@]!Z5VW[&WQ&L_&GPU2UCM8+&XL6\HPP
MC&\ 8W'W-?$_[0^J7&K?'O7%N3N$.HJB#/;(KP</A_KV<U9XB/P=/R/H<3B/
M[/R.C##3^-[_ )DEO\+_ (I:UX?E\4J^K&U ,A(D?GZ<U[7^R5^TMK$/B=/"
M/B>X\RU8;8I)/OJ_0 DU]D>#+&V/@C3;;[/&L#6J!HP/E.5&:_,'4M07PW^T
M5<S6\2JB:UM6/' &^NC#XF&>0KT*M-+E5U8YL1A:F0U,/B:55OFT:?7N?I+\
M:_B=;_"GP'?ZW(5::-?W46>6)XX%?G1'JWQ)_:*\37;V-S>321DR%;5F544G
MC(!KZ2_;P\0Q2> =$A<[9;Z/>%'3M6O_ ,$_]"M(/AM-JB1@7EQ(T<CXY*@\
M"O/R_P!GE>62QW(G-NRN>EF/M,WS6.!4W&"5W;[SYE\/^/\ XB?LW^,K>'5)
M;I4=@7AO"S;TSR1FOO;4O&EM\0?@E<:Y:*5AN[4MM/4>M>8_M7?LSZW\:M<T
M[4]&EA22W@\EEE<*.N<UT?@_X;ZC\*_V?[[0]3N/M%Q% 1\K;@/I6&.Q6$QU
M.AB(V56ZND;X#"XS+ZE?#2NZ-G9OT/SS\*ZMK^E^,+Z'PV7_ +1O)W@ C!W'
M+=JZKQIX'^)_P[5-<U>358%<AS,TCA58]CS79_L;Z=;:A\<M0-Q"LIAD9X]P
MSM;?U%?7'[95NDWP-U(,N<31D?K7TV-S18?'TL-[--2M=O?4^6P64O$9?6Q;
MJ-.-VDMM#C/V,?C_ '_Q&TVZT'7)5DOK%5$<N.7S5K]L3]H2\^%^E1:+H<BQ
MZM= %V89Q&1VKPG]@, _$+4B1RH']:Y+]LG5Y]6^-ER+ALK#$%4>P->7'*\/
M/.Y1Y?=2YK=+GK2S;$4\BC+F]YOEOUL9.G?#'XJ^.-+E\20MJLD+CS@R2/AA
MUR.>E>Q?LF_M,:OIOB:W\&>*9FFAG?R8))?O1MWW$UV?PW_;/^'GA3X=Z-HE
MX;L75K:B&54ARN[ZU\NZKXLTGQ!\?K?7-#06VFRW*M&F-N/7BO2Y*N81KT,5
M0Y8I/E=NVQYG/2RZ5#$83$<TG;F5^^Y^L*,)%##D'D$4[UK,\-R^=H.GOUW6
M\9_\=%:E?D4ERMH_9X2YHIGS;^UE^SO#\2/#LFMZ1;!-=LU,A\L?-, .!QU-
M>'?LI?M"7_P_U\^#O$TCK9-)Y868_/%)TQD]!7Z _7D5\9?MF?L_VT=O_P )
MKH(AL+N-AY\:G8&/4M]:^RRG&T\53_LW&:QE\+[,^%SK 5,'5_M7!:2C\2[H
M^R(;B.YA26)UDC895E.014M?'7[&?[1-YXBFL_!FL":YG;<EK<D%L!(V<[CV
MX0U]B\<5\YF&"J9?B'0J?+S7<^HRS'T\RPT<13Z[KL^HZBBBO//5"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.U
M#_DJ6E?]>$G\VKL:X[4/^2I:5_UX2?S:@#L:*** "BBDH 2O#/VX_P#DT7XL
M'_J 7/\ Z#7N59^NZ#IOB?1[K2=9TZUU?2KR,PW%C?0+-#,AZJZ,"K ^A&*S
MG'FBTBHRY9)]CX?_ ."-?_)JVJG_ *F:Z_\ 1%O7WCC\ZYWP;X \,?#G2VTS
MPIX<TGPQIK2F9K/1K&*TA,A !<I&JKN( &<9X%=$*WG+F=T8PCR*WFW][N+2
MT45!H%%%% !1124 %+110 4444 %%%% !1110 4E+10!Y=^TEX0\5>.?@;XP
MT;P1J]YH?BZXL]^EWMC=-;2K<1LLB()5(*ARFPG.,.<\9K\_/V:_^"GVH_!.
MQO\ P!^T7I7BB7Q-IMVRKJS6RO<HC<^7<Q.R-\O577=N##CC)_5%C7,^,?AC
MX/\ B+;Q0^+/"FA^*(HO]7'K.FPW:K]!(K8J8WBWV8W9I)]-3\Z?VEO^"JGA
MWXF> ]4^'_P:\.^(=:\3^(X6TU+ZXM!&(TE4J_D1(S222D$J!M4 G=EL8/T1
M_P $W?V9-8_9K^!DD/B>%;;Q7X@N_P"T;ZU#!C:H%"PP,1P6"@L<="Y';-?1
M'@OX3>!_AQYO_")^#O#_ (7,O#G1=+@L]_U\M%S76*,5:]Q/EW=K^B)=Y671
M#Z***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[!Y,+,.A=T15;'JQ/K7T#^S+^SK/\+Q+KOB 1MX@N8_+2&-@ZVL9P2-PX+G
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M_P"2U>$O^OQ?_0#7Z7 ]*_/CX*?#+Q9H?QD\.SW?AC6K6RM[[Y[FXT^5(U4
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M0DF%">N!_*I:H2=U<6BBBD,**** "BBB@ HHHH **** "BBB@ HHHH ****
M//[S_DIUW_V#E_\ 0Q7Q#^U%_P EQ\1?2V_])HJ^WKS_ )*==_\ 8.7_ -#%
M?$/[47_)<?$7TMO_ $FBK[#AS_>7_A?YH_-^-/\ =(_XE^3/*J***_13\:"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8I&\B)\\C.X(6-2I."=PX#>/?\$3I&_X5+\0XRQ*+K4)"]@3 ,G]!^5>T?M
M?!K]G[X=_&[2?CY\3O%,WA_Q#9S)/;07E\'M[IX8@B;+7RVD<I\KXBZ-@FG6
MBE42O9.WY7)I:Q>EVKV_X)X')/\ \%'O&%D^O6LFD^&(IAYL6AK#I2R;2 0
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MI*]:->2_M;?\FO\ Q8_[%?4O_2:2N>M_#D=%#^+#U1\;_P#!$O\ Y)3\1?\
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M]\:_#-AXR\(W,XB:_CBMHP>/N)/: +$Y[":,[L' [C[Y_97^'NG?"_\ 9Y\
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MJU)0ZI:BJ6DRD*O>G4U>].I#%:G1_=IK4Z/[M)FB'4^F4^I&.6E7K2+2KUH
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M:D^&/@OXN:3\,=:\2?8_'&J^3]BTK^S[I_-\TD1_O5B,2Y*G[SC&.<5\S_\
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M<L@YH]R?;1MJ#[9;_P#/9/\ OH4?;+?_ )[)_P!]"CED'-'N3XHVU!]LM_\
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M!JEGKJWD]O\ ;+>VV0BWF3=NFD13\SJ, D\]*^S**EJY2;6QPGP0\.ZAX/\
M@WX&T+5X/LFJ:;H=C9W=OO5_+FC@1'7<I*G# C()![&N\Q3:,\54I.4G)]3.
M$5"*BMD*:^-_^"KGCGQ#X)_9)U-= DF@75]1M],U"X@)5H[5P[.,CH'*)&?4
M2$=Z^R.XKF/B)\/?#_Q6\&:KX3\4:9%K&@ZG%Y-U:39 89!!!&"K @,&!!!
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M&62UG4([_0.D.?09/:O-A_P10U'/_)>KH_\ <M-_\G5^A/PO^&4'@#X/>&_
M6H7,?B.WTO2(=)N)[FV"I>*D8C8M$6< , <J2W7&32G%2C=/5/0<)N$O+^D>
M/_L!_M*>'/CY\!?#5K;:I"_BO0=/@T_5]+=P+B-XD$8FV]2D@4,&&1DE<Y!%
M;W[9_P"TEX=_9R^"VO:EJ.H0IX@OK26VT;3!(//N;AE*J0F<[$)#,W0 >I /
MS[\6/^"/?@#Q/XC;7?A]XNU7X:WLDWG?9X81>VL!_P"F*EXY(^>?]80.@ &
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MZ%?=_P#PJGP?_P!"GH?_ (+H?_B:;_PJGPA_T*>A_P#@NA_^)H_U@I_R,/\
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M#_\ $T?ZPP_D8_\ 5"I_S\7W'Q']LM_^>\?_ 'V*/MEO_P ]X_\ OL5]M_\
M"I?"7_0K:+_X+X?_ (FD_P"%2^$_^A6T7_P7P_\ Q-+_ %@A_(P_U0J?\_%]
MQ\2_;+?_ )[Q_P#?8H^V6_\ SWC_ .^Q7VS_ ,*G\)_]"MHO_@OA_P#B:/\
MA4OA+_H5=&_\%\/_ ,31_K!#^1A_JA4_Y^+[CXF^V6__ #WC_P"^Q1]LM_\
MGO'_ -]BOMG_ (5+X2_Z%;1?_!?#_P#$TG_"I?"?_0K:+_X+X?\ XFC_ %@A
M_(P_U0J?\_%]Q\4?;;?_ )[Q?]]BF_;;?_GO'_WV*^V/^%2^$_\ H5M&_P#!
M?#_\31_PJ;PG_P!"MHW_ (+XO_B:/]8(?R,/]4*G_/Q?<?%'VZW_ .>\7_?8
MI/MUM_S\1?\ ?8K[7_X5+X3_ .A6T;_P7P__ !-)_P *D\)_]"MHW_@OA_\
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MBO[=;_\ />+_ +[%)]NMO^?B+_OL5]<ZU\+?#$.O:)&GAO24CD:0.JV,0#8
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M_P#H5M&_\%\7_P 31_K!#^1A_JA4_P"?B^X^*OMEO_SWC_[[%'VRW_Y[Q_\
M?8K[8_X5+X3_ .A6T7_P7P__ !-+_P *E\)?]"MHO_@OA_\ B:/]8(?R,/\
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M@_Y[1_\ ?0H^U0?\]H_^^A7W!_PJCPE_T*FB_P#@OA_^)I?^%3^$NWA71?\
MP70__$T?ZPP_D8?ZH5?^?B^YGP]]J@_Y[1_]]"C[5!_SVC_[Z%?</_"I_"7_
M $*FB_\ @NA_^)H_X5/X0_Z%71?_  7P_P#Q-'^L,/Y&'^J%7_GXON9\/?:H
M/^>T?_?0H^U0_P#/:/\ [Z%?<:_"GPC_ -"KHG_@NA_^)IP^%/A'_H5=$_\
M!=#_ /$T?ZPP_D8O]4*G_/Q?<SX:^U0_\]8_^^A1]JA_YZQ_]]"ON=?A3X0_
MZ%71?_!=#_\ $TH^%/A#_H5=$_\ !=#_ /$T?ZPP_D8_]4*O_/Q?<SX8^U0_
M\]4_[Z%'VF+_ )ZI_P!]"ONG_A5/A#_H5-$_\%T/_P 33O\ A5/A#_H5-$_\
M%T/_ ,31_K##^1A_JA5_Y^+[F?"OVB+_ )ZI_P!]"D^TQ?\ /5/^^A7W9_PJ
MGPA_T*>B?^"Z'_XFG?\ "J?"'_0IZ'_X+H?_ (FE_K#3_D8O]4*W_/Q?<SX2
M^T1?\]4_[Z%'VB+_ )ZI_P!]"ON[_A5/@_\ Z%/0_P#P70__ !-.'PI\'_\
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MKT]T]TPYEBB9ES_W^>XK>_X*Q?$J7P7^RS<Z!92,NI>+=1M])C2/[YC!\Z7
M[@B,(?\ KICO7T9^SO\ #:+X/_ _P1X-1%C?2-*A@GV]&GVAIF_&0N?QK.F_
MCJ/R7ZO]"I)14(+U^2T7ZGYK_M7'_C;=\.?^PAH7_H:UO^&@?V2_^"LE_IG%
MIX8^(@8Q9.$_TL^8F!TR+N-D'H&]ZY_]J[_E+=\.?^O_ $/_ -#6O5O^"POP
MYO+?PCX!^+>B%X-7\+:FMM+<PCYHXY"'AD)_V)8P![RU-*7LX4Y/;FDG\]/S
M*J+VE2<.O+%KU5S]"=<UBT\/Z/?:I?S+;6-E ]S/,_ 2-%+,Q]@ 37Y/_LZZ
M1=?%WX9?M@?M!ZM$QGU[2=5TS33+]Z*(P-+(H/HJ?9D'^X17T%^V]^U%:W?_
M  3[L/$NDRB*]^(EE:V%O&ART?G+ONDX_NHDL9]R*ZK3/A#_ ,*-_P""9OB#
MPI+!Y&HP^"-0N=07O]JFMY)9@3WPSE?HHJ91<55F]X^ZOGJRZ,N:5*/\S3^2
M_P"">;_\$5SC]GGQB?\ J9I/_26WKA_VV/C%X]_:<_:;LOV9/AIJDFC:0K"'
M7+R%V47#&+S9O-9>3#%'P4S\[Y!S\N.X_P""+'_)O'C,?]3/)_Z2V]?'GA7P
M+\4OB5_P4"^*VF_"[Q?:>#/&BZOK$RZCJ%Q+ &A6Z(>,,D4AR00<;<84\UTU
MDI8B,6KJU_N2,Z=XTIR3L[V^]L^U=+_X(U_!:W\,BPOM9\5WFL,@#ZK'>0Q$
M/@9*1>45"Y_A;<<'[QZUX]\ ?&7CC_@GU^UUIOP)\6>()/$/PW\1O&NE3SY"
MP>>S+!/$I)\K,H,<B [<DMV!/8?\,F?MY?\ 1P.@_P#@WO/_ )!KC]>_X)L_
MM0_$+X@>'/%/CGXF>$O$M_HTL1AN+G4[QY8XTE$FU/\ 0P.N3SW-13;]HKO1
M[DR2]FUU2T]3U;_@JW^S;X-UWX1^)OC#=17I\9:3:6-A:R+<D6_E&[5<&/')
MQ,_.?3TK(_X)C?L>?#NZ^%?PY^-DD&H_\)RLE\XD^V'[/E9[BV'[K'_/,>O7
MFO;O^"H2X_8E\>?[]@/_ ">@IW_!+W_DR/X>GWU#_P!.%S10TA5:Z-6^:957
M54[];_@>#?MH?#?XX_M6?M/:-\++2PU[PQ\&H?+$^MQ6[FPN"(Q+-/*RG:[
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M_@JA^S7X,\5?!WQ1\7KV*^_X3'0K"RL;*2.X*P",WJ*0T>.3B>3G/IZ5QO\
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M4_$#) /_ "$+'_Y#K>\)_P#!'GX!^&]0^TWY\4^*81_RZZMJJ)&?_ :*%O\
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M_P#1J5TMG_QZ0?\ 7-?Y4 3T444 %%%% !1110 4444 %%%% !1110 4444
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MX"_\P_U8H_\ /^I_X$O\C\\_^%5_M2?\^UY_X,K/_P"/4J_"O]J1?^7:]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV/VH^Q^U:_V44OV<4 9'V,>E+]E'I6M]G'I1]G'I0%C*^RT?9:UOLX]*/)%
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M5H^&_P#@L1\&O%'B#3-'M/#/CJ.ZU"YBM(GFL+((K2.$4L1=DXR1G -?3/\
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M='"L/=17YC_\$C_BE??"_P"-/C;X)>(R;2>^DEEM[>0_ZJ_M2R3QCW:-2?\
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M8_9?^+/_ &*VI?\ I,]=1X9^#_@7P;XCO/$&@>"O#VA:]>B076J:;I4%O=7
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M/!5A!\1M*UO1O%5M ([R33[1+BTN9%&"\9WAU+8R59<+G&X]:\ ^-WQ U/\
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MAOQ5>V\?DPW&MZ1;WDD<>2=BM*C$+DDX'&36>JG":WB[_@:)KEE%]4?&D?\
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M  2A^+VL:KI&D3>,OA'J\BB29@PMIXPQ\H2R*#]FN4W%0Q&ULG 8<+](:?\
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MB@HHHH **** .3^*7_(B:G_VR_\ 1J5TMG_QZ0?]<U_E7-?%+_D1-3_[9?\
MHU*Z6S_X](/^N:_RH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*6BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.U#_DJ6E?\
M7A)_-J[&N.U#_DJ6E?\ 7A)_-J .QHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#S^\_P"2G7?_ &#E_P#0Q6Q6/>?\E.N_^P<O_H8K:KKI_">;6^,;
M13J*U,1M%.HH 9MHVT^B@!FVC;3Z* &;:38*DHH C\NCRZDHH C\NCRZDHH
MC\NCRZDHH C\OVH\OVJ2B@"/R_:CRZDHH B\NCRZEHH B\NCRZEHH B\NCRZ
MEHH B\NCRZEHH B\NCRZEHH B\NCRZEHH B\JCRJEHH B\JCRJEHH B\JCRJ
MEHH B\JCRZEHH B\NCRZEHH B\NCRZEHH B\NCRZEHH B\NCRZEHH B\NE\N
MI** (_+]J/+]JDHH C\OVH\OVJ2B@"/R_:CR_:I** .5\21_\53X:X_CF_\
M05KIO+]JYWQ)_P C3X:_WYO_ $%:Z:H6[-);1_KJ1^7[4>7[5)15F9'Y?M1Y
M?M4E% $?E^U'E^U244 1^72>74M% $7ET>74M% $7ET>74M% $7ET>74M% $
M7ET>74M% $7ET>74M% $7ET>74M% $7ET>74M% $7ET>74M% $7ET>54M% $
M7E4>54M% $7E4>54M% $7ET>74M% $7ET>74M% $7ET>74M% $7ET>74M% $
M7ET>74M% $7E4>74M% $7ET>74M% $?ET>74E% $?ET>74E% $?ET>74E% $
M?ET>74E% $?ET>74E% $?ET>74E% #/+H\NGT4 -\NCRZ=10 W91L%.HH 3:
M*-M+10 ;:-HHHH -HHHHH **** "N9\'?\?WB#_K_>NFKF?!W_']X@_Z_P!Z
MCJBX?"SIJ***L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH YSQ]_R!8/^OJ+^=%'C[_D"P?\ 7U%_.BN:
MIN=U+X37^&?_ !ZZ[_V%I_Y+795QOPS_ ./77?\ L+3_ ,EKLJP.H**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Y/XI?\ (B:G_P!LO_1J5TMG_P >D'_7-?Y5S7Q2
M_P"1$U/_ +9?^C4KI;/_ (](/^N:_P J )Z*** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *X[4/^2I:5_P!>$G\VKL:X[4/^2I:5_P!>$G\VH [&BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** //[S_ )*==_\ 8.7_ -#%;58MY_R4Z[_[!R_^
MABMJNNG\)YM;XPHHHK4Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\2?\C3X:_WYO\
MT%:Z:N9\2?\ (T^&O]^;_P!!6NFJ%NS26T?ZZA1115F84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<SX._X_O$'_7^]
M=-7,^#O^/[Q!_P!?[U'5%P^%G344459 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SGC[_D"P?]?47\Z*
M/'W_ "!8/^OJ+^=%<U3<[J7PD_@+7]-TV+6X[O4+:V=M4F=5EE525(7GD].#
M74_\)AH7_08L?_ A?\:Y7P)X?TS5(=:DO+"VN)%U29%:6(,0H"G'/;DUU/\
MPANA?] >R_[\+_A6!U"_\)AH7_08L?\ P(7_ !H_X3#0O^@Q8_\ @0O^-)_P
MANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X4 +_ ,)AH7_08L?_  (7_&C_ (3#
M0O\ H,6/_@0O^-)_PANA?] >R_[\+_A1_P (;H7_ $![+_OPO^% "_\ "8:%
M_P!!BQ_\"%_QH_X3#0O^@Q8_^!"_XTG_  ANA?\ 0'LO^_"_X4?\(;H7_0'L
MO^_"_P"% "_\)AH7_08L?_ A?\:/^$PT+_H,6/\ X$+_ (TG_"&Z%_T![+_O
MPO\ A1_PANA?] >R_P"_"_X4 +_PF&A?]!BQ_P# A?\ &C_A,-"_Z#%C_P"!
M"_XTG_"&Z%_T![+_ +\+_A1_PANA?] >R_[\+_A0 O\ PF&A?]!BQ_\  A?\
M:/\ A,-"_P"@Q8_^!"_XTG_"&Z%_T![+_OPO^%'_  ANA?\ 0'LO^_"_X4 +
M_P )AH7_ $&+'_P(7_&C_A,-"_Z#%C_X$+_C2?\ "&Z%_P! >R_[\+_A1_PA
MNA?] >R_[\+_ (4 +_PF&A?]!BQ_\"%_QH_X3#0O^@Q8_P#@0O\ C2?\(;H7
M_0'LO^_"_P"%'_"&Z%_T![+_ +\+_A0 O_"8:%_T&+'_ ,"%_P :/^$PT+_H
M,6/_ ($+_C2?\(;H7_0'LO\ OPO^%'_"&Z%_T![+_OPO^% "_P#"8:%_T&+'
M_P "%_QH_P"$PT+_ *#%C_X$+_C2?\(;H7_0'LO^_"_X4?\ "&Z%_P! >R_[
M\+_A0 O_  F&A?\ 08L?_ A?\:/^$PT+_H,6/_@0O^-)_P (;H7_ $![+_OP
MO^%'_"&Z%_T![+_OPO\ A0 O_"8:%_T&+'_P(7_&C_A,-"_Z#%C_ .!"_P"-
M)_PANA?] >R_[\+_ (4?\(;H7_0'LO\ OPO^% "_\)AH7_08L?\ P(7_ !H_
MX3#0O^@Q8_\ @0O^-)_PANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X4 +_ ,)A
MH7_08L?_  (7_&C_ (3#0O\ H,6/_@0O^-)_PANA?] >R_[\+_A1_P (;H7_
M $![+_OPO^% "_\ "8:%_P!!BQ_\"%_QH_X3#0O^@Q8_^!"_XTG_  ANA?\
M0'LO^_"_X4?\(;H7_0'LO^_"_P"% "_\)AH7_08L?_ A?\:/^$PT+_H,6/\
MX$+_ (TG_"&Z%_T![+_OPO\ A1_PANA?] >R_P"_"_X4 +_PF&A?]!BQ_P#
MA?\ &C_A,-"_Z#%C_P"!"_XTG_"&Z%_T![+_ +\+_A1_PANA?] >R_[\+_A0
M O\ PF&A?]!BQ_\  A?\:/\ A,-"_P"@Q8_^!"_XTG_"&Z%_T![+_OPO^%'_
M  ANA?\ 0'LO^_"_X4 +_P )AH7_ $&+'_P(7_&C_A,-"_Z#%C_X$+_C2?\
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M_ A?\:/^$PT+_H,6/_@0O^-)_P (;H7_ $![+_OPO^%'_"&Z%_T![+_OPO\
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M?]^%_P */^$-T+_H#V7_ 'X7_"@!?^$PT+_H,6/_ ($+_C1_PF&A?]!BQ_\
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M8L?_  (7_&D_X0W0O^@/9?\ ?A?\*/\ A#="_P"@/9?]^%_PH 7_ (3#0O\
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M]^%_PH_X0W0O^@/9?]^%_P * %_X3#0O^@Q8_P#@0O\ C1_PF&A?]!BQ_P#
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MO^@Q8_\ @0O^-'_"8:%_T&+'_P "%_QI/^$-T+_H#V7_ 'X7_"C_ (0W0O\
MH#V7_?A?\* %_P"$PT+_ *#%C_X$+_C1_P )AH7_ $&+'_P(7_&D_P"$-T+_
M * ]E_WX7_"C_A#="_Z ]E_WX7_"@!?^$PT+_H,6/_@0O^-'_"8:%_T&+'_P
M(7_&D_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%_P * %_X3#0O^@Q8_P#@0O\
MC1_PF&A?]!BQ_P# A?\ &D_X0W0O^@/9?]^%_P */^$-T+_H#V7_ 'X7_"@!
M?^$PT+_H,6/_ ($+_C1_PF&A?]!BQ_\  A?\:3_A#="_Z ]E_P!^%_PH_P"$
M-T+_ * ]E_WX7_"@!?\ A,-"_P"@Q8_^!"_XT?\ "8:%_P!!BQ_\"%_QI/\
MA#="_P"@/9?]^%_PH_X0W0O^@/9?]^%_PH 7_A,-"_Z#%C_X$+_C1_PF&A?]
M!BQ_\"%_QI/^$-T+_H#V7_?A?\*/^$-T+_H#V7_?A?\ "@!?^$PT+_H,6/\
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M7_&C_A,-"_Z#%C_X$+_C2?\ "&Z%_P! >R_[\+_A1_PANA?] >R_[\+_ (4
M+_PF&A?]!BQ_\"%_QH_X3#0O^@Q8_P#@0O\ C2?\(;H7_0'LO^_"_P"%'_"&
MZ%_T![+_ +\+_A0 O_"8:%_T&+'_ ,"%_P :/^$PT+_H,6/_ ($+_C2?\(;H
M7_0'LO\ OPO^%'_"&Z%_T![+_OPO^% "_P#"8:%_T&+'_P "%_QH_P"$PT+_
M *#%C_X$+_C2?\(;H7_0'LO^_"_X4?\ "&Z%_P! >R_[\+_A0 O_  F&A?\
M08L?_ A?\:/^$PT+_H,6/_@0O^-)_P (;H7_ $![+_OPO^%'_"&Z%_T![+_O
MPO\ A0 O_"8:%_T&+'_P(7_&C_A,-"_Z#%C_ .!"_P"-)_PANA?] >R_[\+_
M (4?\(;H7_0'LO\ OPO^% "_\)AH7_08L?\ P(7_ !H_X3#0O^@Q8_\ @0O^
M-)_PANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X4 +_ ,)AH7_08L?_  (7_&C_
M (3#0O\ H,6/_@0O^-)_PANA?] >R_[\+_A1_P (;H7_ $![+_OPO^% "_\
M"8:%_P!!BQ_\"%_QH_X3#0O^@Q8_^!"_XTG_  ANA?\ 0'LO^_"_X4?\(;H7
M_0'LO^_"_P"% "_\)AH7_08L?_ A?\:/^$PT+_H,6/\ X$+_ (TG_"&Z%_T!
M[+_OPO\ A1_PANA?] >R_P"_"_X4 +_PF&A?]!BQ_P# A?\ &C_A,-"_Z#%C
M_P"!"_XTG_"&Z%_T![+_ +\+_A1_PANA?] >R_[\+_A0 O\ PF&A?]!BQ_\
M A?\:/\ A,-"_P"@Q8_^!"_XTG_"&Z%_T![+_OPO^%'_  ANA?\ 0'LO^_"_
MX4 +_P )AH7_ $&+'_P(7_&C_A,-"_Z#%C_X$+_C2?\ "&Z%_P! >R_[\+_A
M1_PANA?] >R_[\+_ (4 +_PF&A?]!BQ_\"%_QH_X3#0O^@Q8_P#@0O\ C2?\
M(;H7_0'LO^_"_P"%'_"&Z%_T![+_ +\+_A0 O_"8:%_T&+'_ ,"%_P :/^$P
MT+_H,6/_ ($+_C2?\(;H7_0'LO\ OPO^%'_"&Z%_T![+_OPO^% "_P#"8:%_
MT&+'_P "%_QH_P"$PT+_ *#%C_X$+_C2?\(;H7_0'LO^_"_X4?\ "&Z%_P!
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M  H_X1?2/^@9:_\ ?I?\*/>#W?,/^$FTC_H)VO\ W^7_ !H_X2;2/^@G:_\
M?Y?\:/\ A%](_P"@9:_]^E_PH_X1?2/^@9:_]^E_PH]X/=\P_P"$FTC_ *"=
MK_W^7_&C_A)M(_Z"=K_W^7_&C_A%](_Z!EK_ -^E_P */^$7TC_H&6O_ 'Z7
M_"CW@]WS#_A)M(_Z"=K_ -_E_P :/^$FTC_H)VO_ '^7_&C_ (1?2/\ H&6O
M_?I?\*/^$7TC_H&6O_?I?\*/>#W?,/\ A)M(_P"@G:_]_E_QH_X2;2/^@G:_
M]_E_QH_X1?2/^@9:_P#?I?\ "C_A%](_Z!EK_P!^E_PH]X/=\P_X2;2/^@G:
M_P#?Y?\ &C_A)M(_Z"=K_P!_E_QH_P"$7TC_ *!EK_WZ7_"C_A%](_Z!EK_W
MZ7_"CW@]WS#_ (2;2/\ H)VO_?Y?\:/^$FTC_H)VO_?Y?\:/^$7TC_H&6O\
MWZ7_  H_X1?2/^@9:_\ ?I?\*/>#W?,/^$FTC_H)VO\ W^7_ !H_X2;2/^@G
M:_\ ?Y?\:/\ A%](_P"@9:_]^E_PH_X1?2/^@9:_]^E_PH]X/=\P_P"$FTC_
M *"=K_W^7_&C_A)M(_Z"=K_W^7_&C_A%](_Z!EK_ -^E_P */^$7TC_H&6O_
M 'Z7_"CW@]WS#_A)M(_Z"=K_ -_E_P :/^$FTC_H)VO_ '^7_&C_ (1?2/\
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M)VO_ '^7_&C_ (2;2/\ H)VO_?Y?\:/^$7TC_H&6O_?I?\*/^$7TC_H&6O\
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M-<6:R@E6*]=$#1@[5]![5#YKHI<MF=#_ ,)-I'_03M?^_P O^-'_  DVD?\
M03M?^_R_XT?\(OI'_0,M?^_2_P"%'_"+Z1_T#+7_ +]+_A5^\3[OF'_"3:1_
MT$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU
M_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] R
MU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_
M $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'
M_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+
M7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#
M+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T
M$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_
MT$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU
M_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] R
MU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_
M $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'
M_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+
M7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#
M+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T
M$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_
MT$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU
M_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] R
MU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_
M $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'
M_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+
M7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#
M+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T
M$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_
MT$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU
M_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] R
MU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_
M $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'
M_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+
M7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#
M+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T
M$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_
MT$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU
M_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] R
MU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_
M $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'
M_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+
M7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#
M+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T
M$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_
MT$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU
M_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] R
MU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_
M $$[7_O\O^-'_"+Z1_T#+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'
M_03M?^_R_P"-'_"3:1_T$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+
M7_OTO^%'O![OF'_"3:1_T$[7_O\ +_C1_P )-I'_ $$[7_O\O^-'_"+Z1_T#
M+7_OTO\ A1_PB^D?] RU_P"_2_X4>\'N^8?\)-I'_03M?^_R_P"-'_"3:1_T
M$[7_ +_+_C1_PB^D?] RU_[]+_A1_P (OI'_ $#+7_OTO^%'O![OF8'C77-.
MO-)A2"^MYG%S&Q5) 3@'DT4GC70M.L])A>"QMX7-S&I9(P#@GD45SSO<ZZ=N
M70Z?X9_\>NN_]A:?^2UV5<;\,_\ CUUW_L+3_P EKLJP.D**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH Y/XI?\B)J?_;+_ -&I72V?_'I!_P!<U_E7-?%+_D1-3_[9
M?^C4KI;/_CT@_P"N:_RH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCM0_Y*EI7
M_7A)_-J[&N.U#_DJ6E?]>$G\VH [&BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** //[S_DIUW_V#E_\ 0Q6U6+>?\E.N_P#L'+_Z&*VJZZ?PGFUOC"BB
MBM3$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH YGQ)_P C3X:_WYO_ $%:Z:N9\2?\C3X:
M_P!^;_T%:Z:H6[-);1_KJ%%%%69A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5S/@[_C^\0?]?[UTU<SX._X_O$'_7^]
M1U1</A9TU%%%60%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 <YX^_Y L'_ %]1?SHH\??\@6#_ *^HOYT5
MS5-SNI?":_PS_P"/77?^PM/_ "6NRKC?AG_QZZ[_ -A:?^2UV58'4%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <G\4O\ D1-3_P"V7_HU*Z6S_P"/2#_KFO\ *N:^
M*7_(B:G_ -LO_1J5TMG_ ,>D'_7-?Y4 3T444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5QVH?\ )4M*_P"O"3^;5V-<=J'_ "5+2O\ KPD_FU '8T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Y_>?\E.N_\ L'+_ .ABMJL6\_Y*==_]@Y?_
M $,5M5UT_A/-K?&%%%%:F(4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/B3_D:?#7^_-_
MZ"M=-7,^)/\ D:?#7^_-_P"@K735"W9I+:/]=0HHHJS,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9\'?\?WB#_K_>
MNFKF?!W_ !_>(/\ K_>HZHN'PLZ:BBBK("BBB@ HHHH **** "BBB@ HHHH
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M^/T?\-Z?%?\ Z%S0_P#P N?_ (_1_JWF'9?^!(/]:LO_ +WW'Z%8HQ7Y[?\
M#>7Q8_Z%O0__   N?_C]'_#>7Q8_Z%O0_P#P N?_ (_2_P!6\?V7_@2#_6K+
M_P"]]Q^A.*,5^>W_  WE\6/^A;T/_P  +G_X_1_PWG\6/^A;T/\ \ +G_P"/
MT?ZMX_LO_ D'^M67_P![[C]!V^M'('-?G[8?M^_$*#4H$U;1-"MK9F&\K:3J
M^W/)&9Z^V_A]X]TSXC>&;76-,E#PS+EE[J>^17GXW*<5E\5.O'1]5J>G@,ZP
MF8R=.A+WET:LSJJ***\@]T**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[4/^2I:5_P!>$G\V
MKL:X[4/^2I:5_P!>$G\VH [&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH_L7&?RK[P_UHR_N_N/M2BOBS_AM3QI_T#O#_P#WXF_^/4?\-J>-/^@=X?\
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MO_CU'_#;GB__ )]/#O\ WZF_^/4?V-B^R^\/]9L!W?W'VQ17Q/\ \-N>+O\
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M%]E]X?ZS8#N_N/MFBOB;_AM[Q=_SZ^'/^_4W_P >H_X;>\7?\^OAS_OU-_\
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M>'^L^7]W]Q]K45\4_P##;7C#_GS\._\ ?F;_ ./4?\-M>,/^?/P[_P!^9O\
MX]1_8V+[+[P_UGR_N_N/M:BOBG_AMKQA_P ^?AW_ +\S?_'J3_AMCQC_ ,^/
MAW_OS-_\>H_L;%]E]X?ZSY?W?W'UCXD_Y&GPU_OS?^@K735\-WW[8/BN^U"Q
MO)+/0?,LRQC"Q2X.X '/[[VJ_P#\-L>,?^?'P]_WYF_^/4EDN,N]%]Y3XHR]
MI*[^X^U:*^*O^&V/&/\ SX^'O^_,W_QZC_AMCQC_ ,^/A[_OS-_\>I_V-B^R
M^\G_ %GR_N_N/M6BOBK_ (;8\9?\^'A[_OS-_P#'J7_AM;QG_P ^/A[_ +\3
M?_'J/[%Q?\J^\/\ 6?+^[^X^U**^*_\ AM;QG_SX>'O^_$W_ ,>H_P"&UO&G
M_0/\/_\ ?B;_ ./4?V+B_P"5?>'^L^7]W]Q]J45\6_\ #:GC/_H'^'_^_$W_
M ,>I/^&U/&G_ $#O#_\ WXF_^/4?V+C/Y5]X?ZT9?W?W'VG17Q9_PVIXU_Z!
M^@?]^)__ (]2_P##:7C7_H':!_X#S_\ QZC^Q<9_*OO#_6C+^[^X^TJ*^+?^
M&TO&O_0.T#_P'G_^/4?\-I>-?^@=H'_@//\ _'J/[%QG\J^\7^M&7]W]Q]I4
M5\6_\-H>-_\ H&:!_P" \_\ \>I?^&T/&W_0-T#_ ,!Y_P#X]3_L7&?R_B'^
MM&7=W]Q]HT5\7?\ #:'C?_H&Z#_X#S__ !ZC_AM#QO\ ] W0?_ >?_X]1_8N
M,_E_$/\ 6G+N[^X^T:*^+O\ AM#QO_T#=!_\!Y__ (]1_P -H>-_^@;H/_@/
M/_\ 'J/[%QG\OXA_K3EW=_<?:-%?%W_#:'C?_H&Z#_X#S_\ QZC_ (;0\;_]
M W0?_ >?_P"/4?V+C/Y?Q#_6C+N[^X^T:*^5/A[^UEXC\3>(%T[4['2(!,A\
MEK>*53O'.#F0]1FO5U^*FK-_R[V7_?#_ /Q5<=7+Z]&7+-'IX?.,+BH<U-NW
MH>J45Y;_ ,+2U7_GWL_^^'_^*IX^*&JG_EWL_P#OA_\ XJL?JM0Z?[0H>9Z?
M17F?_"S=4_YX6?\ WP__ ,53_P#A96J?\\;3_OAO_BJGZM4']>HGI-%>=#XC
M:D?^6%K_ -\-_P#%4Y?B)J1/^HM?^^&_^*I?5ZA7UZD>AT5Y^OQ!U$D_N;7_
M +X;_P"*IZ^/M0_YXVW_ 'RW_P 52^KS']<I'>T5P@\>:A_SRMO^^6_^*IP\
M=7__ #QM_P#OEO\ XJCZO,KZW2.YHKB5\;7S?\L[?_OEO_BJ</&E]_SRM_\
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M4J]:<%!I7"S&45*(Q[TODC'>BZ'RLAHJ80KZFF2*$; HN#BT,HHHIDA1110
M5S/@[_C^\0?]?[UTU<SX._X_O$'_ %_O4=47#X6=-1115D!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2C&9OMRS*8?+'5]^=NWCKG%?$W_##OC[_H)>'_\ P)G_ /C-?3VC?#?4]/\
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MI72V?_'I!_US7^5 $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:.O>OC*F,Q%23G*;N_,^YIX'#4H*$::LO)')?\*E\(_] .U_[YH_X5+X1_Z
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M)>)=(\4Z=#,;>2\T6_BO(5D #%"\;, P#*<9SAAZUYA^W%S^R+\6/^P!<_\
MH-?.7_!%OC]F3Q/_ -C9<'_R4M*<%S.5^B7XL):1B^[L?H#1112 **** "BB
MB@!A[4"O'_VF?VFO#'[*G@&T\7>+-/U;4--N;^/3EBT:&*682.DC@D221C;B
M)N<YR1Q7<?#3Q]I_Q2^'WAWQCI4%U;Z;KEA#J-M%>*JS)'(@90X5F4-@\X8C
MWI1]Y-KII\P>EK]3JZ***8!1124 +1110 44E!Z&D!YSX@_:-^%'A+6;O2-=
M^)_@W1-7M&V7%AJ.OVEO/"V </&\@93@@X([U0'[6'P0'_-9/A__ .%18_\
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M3[4>2?3]*.0?M#.^SCTH^SCTK1\GVH\D^GZ4<@>T,W[-1]FK2\@^E'D'THY
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MO#Z5,M0S?>'TIQW"6Q'1116AB%%%% !7,^#O^/[Q!_U_O735S/@[_C^\0?\
M7^]1U1</A9TU%%%60%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFT%@H^59"3R1T%=9^QM_R6RU_P"O*?\ D*[)93;"SG1Q/-&*;:6UTO4\VGQ
MZF-I4L1@^2<FDF]TK]+Q.O\ V[==DD\4^&]'$G[BWLWNB@/&YW*Y/X)^M=W^
MP[X9AL/ .J:TT8^U7]X8O,[^7&HVC_OIG_2O-OVZ-/>'XAZ'>8/EW&F[ ?\
M:21LC\F'YUZU^Q/JD5Y\)Y[16'F6=_*CKGGY@K _0Y_0UK4]W(X\G5Z_>_U,
M:-I\43]KNEI_X"OT/H6O ?VSO#4&K?")M29,W6EW<<L;]PKG8P^G(/\ P$5[
M]7B/[8.J1:?\$=2A=E$EY<001J3R3O#''X*:^9R]R6+I.._,C[C-8QE@*ZGM
MRO\ (\$_8AUR2Q^)^H:9O86]_I[,4[&2-UVG\%+_ )UK_MX?\CAX8_Z\9/\
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M)_NBM.(/X6']'^2,N$O][QOJO_;AQKC?C)_R2GQ?_P!@NX_]%FNR-<;\9/\
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M )+AXN_Z^A_Z M>QPW_O4O\ "_T/!XT_Y%\/\:_)GWW\)?\ DE_A+_L%VO\
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MGAIJ*BZFCMIL]S;"8JKEZQM*4W)4;.-]7JKI-]CS_3/&/QA_:5U*]?PY??\
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M:XK*\92I5:KJ4ZC:U2NGTVZ'VI1117@GV(4444 %%%% !1110 4444 %%%%
M!1110!R?Q2_Y$34_^V7_ *-2NEL_^/2#_KFO\JYKXI?\B)J?_;+_ -&I72V?
M_'I!_P!<U_E0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1132=O)X% $5Q<1VL+S2NL<2#+.QP /6OA#]K#]I.7
MQGJ1\&>%F>2V$HBGDCSEY,XP".HKM?VNOVEH=*L9_"'AZ?S+R8;+F6,YX(/R
MUD?LC_LQ-*T/C7Q5#O9_GM;60<$'D-^=?<9;@Z.6T/[1QJU^S'N^Y^?9ICJV
M:8C^S,"]/M2[+L=S^R?^S3!X!TN'Q'KL7G:[<J'5)!GR?3%?3%Q<16L>^:58
M4_O,0!^M/4!5"J, =*\,_;$U:\T?X4RS64[6\OF8W+UZ5\]*K5S?&KVDM9.W
MH?21I4LEP+]E'2*OZGL?_"2:5_T$[3_O\O\ C5JWO;>\7,$\4X]8W#?RK\E/
M ]G\0?B3=?9?#\US?W"]55\5U-UX\^+WP)U2&#4;RZT_YA^Y?!#^V:^EJ<+6
ME[*%9.?9GR]/B[F7M*E"2AW1^I1[<4NZO(?V<_C=#\:/!:7SH(+Z$^5-'G)8
M@<M7KF[J*^*Q%"IAJLJ-16DC[S#XBGBJ4:U)WB]A]%%%8'2%%%% #:;)(L49
M9R%4=23@4YCUKD_BE,\/@75WC8HXA.&':KIP]I-0[LQJU/9PE/LKF];ZQ87L
MACM[VWGD'5(Y%8_D#5ZOSL_8U\0:IJ'QLU:*YOI)H@6^5B<?>K]$Z]3,\O\
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M^.'P?\*>.;*'[/#K=BEP]ONW>3+RLL>>^UU9<]\5\Y_\%:$#?L:^(&(Y74;
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** //[S_DIUW_V#E_\
M0Q7YZ_%K_DJ7B_\ ["]W_P"CFK]"KS_DIUW_ -@Y?_0Q7YZ_%H'_ (6EXO\
M^PO=_P#HYJ^TX;_B2]/U/S#C7^%3]?T.3I-M.VFC::^_/R,9M-&TT_::-IH
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MHOPE_P"28>$_^P5:_P#HI*Z[M65X>T2'PUH&GZ5;N\D%C;QVT;28+E44*"2
M!G YP!6IGK7CU)*<W);-L^APU-TJ,(2W22_ /K7SE^VG\/[KQ)X(T_7;&%IY
MM%E9IU0$MY#@;F^BE5)]B3VKZ-[TQXA)&4=0RL,%2."/2M<+B)8:K&K#=,SQ
MN%AC<//#SVDK?Y/Y,\0^ ?Q_\->*/ ^F6.I:Q:Z9KEC EO/!?3+&92J[1(A8
M@,& R0.0<Y[$\O\ M/?M V-GX=B\/>#]=-QKUU.GF7.DW!)@13G;O0_>8X&T
M'.,YKJ_%W[(/P^\57SW<5M>:'-(2SKI<RHC$]]CJRK]% %:OP[_9D\#_  XU
M"/4;2SGU+4H3NBN]1D$C1GU50%4'WVY'8UZRJY?&K]87,W>_+96OZ]CYSV.<
M>P^IOEM:W/=WMM>UM[>>YP?Q&^%OB?Q5^S'IMOJTUQJ?BRPQJ;K/EYCG<6B]
MV5'Q]5J#]ESX_:!_PA=IX6\0:E#I.I:=F."2\D$<4\6X[0&8X#+G;M.,@#&>
M<?3F*\C\??LO>!/B!?2WUQ82Z3J$QW27.F.(C(?4J04SZG;D]ZSIXVE5I3H8
ME6BWS)KH_3L;5\LQ%"M3Q6"DG.,>5J3?O+U[W%^+7[1'A7P%X9NY;75[/5=9
M>,I:6=I.LK;R.&?:3M4=<GKCBO+_ -B7P#?6\&M>,;^-HA?8MK-F&#(@;=*_
MT+!0#ZJU=SX7_8[^'OAN\2ZF@OM=9"&2/4IU9 1ZJBJ&^C9'M7MEK:Q64$<$
M,:PPQJ%2- %"J!@  = !2GB</0P\J&&NW*UV]-%T2'3P>,QF+ABL;:*A?EBG
M?5]6SXY^,W_)XOAO_KYT[_T(5]FJ/E'TKR[Q/\ -!\4_$VP\<75YJ2:K9R0R
M)#%)&("8B"N04+8..?F_*O4MO:N?%XB%:G2C'[,;,[,OP=3#8C$5)[3E=>EC
MXO\ VRO^2R^$L?\ /E#_ .E#U[G^TUX N_B%\);VVT^(SZA8NE]!$HRTFP$,
MH]RK-CW JU\3/V?M ^*WBC3=<U2^U*VNK&)8DCLY(U0A7+C<&1CG)/0BO40-
MHP/2MIXU*EAU3^*G?\TT<U++92Q&,E67N54DN^B:?_ /EW]E?X]Z!;^#;;PG
MXBU&'2-0TXLMO->2".*>,L2!O8X#*25VG&0!C/./3/BE^T)X4\ ^&;JX@U>R
MU35FC*VMC9W"RNSD<%MI.U1U)/IQDTSXA?LQ^!?B'>RW]S82Z9J4IW2W6FR>
M4TA]64@H3[[<GUK$\,?L;_#WP]>+=7$5_KA0AECU*=3&"/58U3=]&R/:MJE3
M+Z]3V\^9-ZN*2U?6S[,Y:-#-\)16$I\LDE92;:LNEU;5HX/]B?P+?&XUOQKJ
M$31K>K]FM7<8\W+[Y7'MN"C/J&]*Y[XW_P#)X'AS_KYTW_T8M?95K:0V-O%;
MVT4<$$2A$CC4*J*!@  <  =J\U\5?L]Z!XM^)-CXVN[W4H]4LW@DC@ADC$!,
M1!7(,9;G'/S?E3IYE">+GB*BLFFDNVFA%;)9T\MCA*3YI*2DV]+N]VSU%!\J
M_2ODC]O2-_\ BCY-IV'[2N[W_=G%?7"_+@5R/Q&^&>A?%/0_[+UZU:>%6\R&
M6-MDL+XQN1NW'8Y![BO/P.(CA<3"M)72?_ /<S3"3QV"GAX.S:TOY-,@^'/Q
M!\-^+M'L+?1];L=0NTM(Y'MH+A&FC7: 2Z [EP2!R.IKM.F#FO)/A9^S7X>^
M$?B276M'U+59YY+=K9H[R6-DVLRMT6-3G*CO7KFWWQ66)]E[5NBVXON:X#ZS
M[!1Q,4I+31W5CSSX[:#KOB'X8ZQ#X<O;RRUB%5N(/L,S122;#EHP5(/S+D8[
MG%>,?LM_M"6$>AS>&?%^L_9=2MYG:VO-4F($J,<E&D<\.K;N&/(( Z5]5FO)
M/B%^S)X&^(M_+J%W8S:;J,IW2W6FR")I#ZLI#*3[[<GUKJPN(HJC+#XA:-W3
M6Z?^1PX_"8IUX8O!R7-%6<7>S7Z/S&_%C]HCPM\/_#=W+::K9ZKK+QE;:QM)
MEE;>1PS[2=JCKSUQQ7E_[%/P[OH%U?QMJ*/&=07[/:%Q@R)OW2/]"P4 ^S5W
M'A?]CGX?>';Y;J:*_P!=*$,L6ISJT8(]515#?1LCVKVVWMX[.&."&-8H8P%1
M$ 554#   Z "MI8G#X?#RH8:[<[7;TT71(YJ>"Q>,Q4,5CK1C"_+%.^KZMEJ
MBBBO%/J0HHHH **** "BBB@ HHHH **** "BBB@#D_BE_P B)J?_ &R_]&I7
M2V?_ !Z0?]<U_E7-?%+_ )$34_\ ME_Z-2NEL_\ CT@_ZYK_ "H GHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!G<<
M5\\_M3_M%V?PRT&;2-,G677;E2@\LY\CW85V'Q^^-FG?"/PG<3/*KZE,I2&%
M3ELD$9Q7Q-\'/A+X@_:5^($NM:P\G]E+*'N;F0G+#L%SUKZS)\NIN+QV,TIQ
M_%GQ>=9I44EE^!UJS_!'3?LP_L\:A\5?$0\9>)E<:;'-YJ+)G,K@YY]17Z!V
M=G#86L=O!&L4,:[551P!5/P_X?LO#.CVNFV$*PVUN@1548Z#&?K6G7F9IF53
M,*W,](K9=D>OE.5T\LHJ"UD_B?=A7S]^VQ_R2-_^NW]*^@*^?_VV/^21O_UV
M_I6>4_[[2]2\Y_Y%];T9\\?\$^_^1TO/HW_H->U?MV:;9S?#:&XEBC-S&S;)
M-HW=!WKXY^ GQKO?@KK3ZA9Z>FHF0'=&P/<8[5H_'+]I+7?C9-#%=PKI]C"?
MEMXB<'/KFOTC$99B:N<1Q4=(*VMS\MP^;8:EDTL(]9N^EOU/7_\ @GC-)_PD
M&I1[V\OR&.S/&<CFOLGXA?$K0_AKHTFHZS=I JC*1LP#/]*\=_8R^$]OX%^'
MZZG))%<7U\?,\R-@VU" =IKYE_;2\?3>,OBHNB+,QM=/E^S^7GC)(KYZMA89
MSG$XIVBMWZ'T]'&5,DR6G-J\Y;+U/:;O_@HEX:AU!H8]#O7B#8#@CGWKWWX5
M_&OP[\6],6XTFY47&,O:LP\Q?7BO /#/[#N@WWPUC:>XD_MFX@\Q),# )&0,
MU\Z? _6=1^$?QY_LV";;LNC92@MA6&[!/UK66699CJ558%M3I]^IC3S;-,!6
MI/'I.%3M;0_42ZNH;.W>>=UBBC&YG8X %?-GQ#_;J\(^#=4>QL[6;5WC8J\E
MNP*\5I_MH>/KWPG\++BVL&\N6]7'G*<,HSVKYH_9+_9OL_B[]OUC77D%@H_=
M%!G>^><YKSLLRW"_598['-\B=DD>GFN:8MXR. R]+F:NVSZ9^%'[9GA'XE:D
MNGS))HURYPANF #>@KU;XJ.&^'^KLIR/))!K\[_VI_@_9? WQSI@T*:X:.6+
M[2)"N-C ]!BOK?X9^.)_'?[,IN[MI)+M+4K(\HY;GBM<;EN'I*CC<&WR2:T?
M0QP.:XFLZV!QJ7/%/5=3Y!_9K^(6E?#/XH:WK&KD_9QO"J#@DANE?1\?_!0[
MPQ)JY@_L6]%KOVB;(QCUKY*^$?PP;XM?%"31BYCMENF:=AU";N<5] ?M*?LE
M^'/AU\.'U[1[B<S6K)&T;@ -GN<5]/F-#+*V+A3Q5W4FDE;9=CY3+L1FM'!S
MJX2RIP;;O:[[GV-X#^(.C?$;08=5T:Z2>&09*JP+)[&IO&GC?2/ 6BR:EK-W
M':0*#C>V-Y]![U\1_P#!/WQ-?V_BC5]*5RUE(%_=D\+UZ55_;U^(5QJWC6V\
M,03EK."-9&4'C?T-?*?V$O[3^I*7N[W\C['_ %@<<J6-<??VMTN>F:M_P4.\
M,V6I200:+>3PJ^T2*5P1ZU[Q\)?C9X>^+^EBZTBX"SJ,R6KL"Z?6OGCX6_L8
M^%_$7POL-4O;B8W]];>>-H&$)!P*\!^'%UJ_P%_:$M=(2X(5;D)/&K?+(G8&
MO0GE>68R%6G@FU4I]^MCS:6;9I@YTJF-2=.IVMI<_4BLS7M#L_$FESZ??0K-
M;3*596&:LV%T+ZRMY\8\U%?'U&:M5\!=PE=;H_1VHU(6>J9^:_QF^$NN_LS^
M/H/$&ALYTEYO,@D&3L/4@^U?9G[/_P ==+^,'AB&1)1%JT*A9[=V&YB!RP'I
M79?$7P!I?Q*\+W>BZG&&BG0JLF,M&3W%?GAJ&C^)OV2_BQ')^\%@SYCD4DB2
M(MT/OBOO*4Z?$&%]E5=J\%H^Z/SJM3J<-XKVU%7P\WJNS/TXH]>*XOX7_$S2
MOBEX8MM6TV93O4&2+/S(?0BNTKX6I3G2FZ<U9H_0J-:%>"J4W>+V8ZBBBLS8
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *X[4/^2I:5_UX2?S:NQKCM0_Y*EI7_7A)_-J .QHHHH **** $[BO#/V
MXO\ DT7XK_\ 8 N?_0:]S[BO#/VXO^31?BO_ -@"Y_\ 0:QJ_!(UI_''U/@/
M_@E#^V1X/^&OA_5OA?XZUFV\-Q7%ZVHZ3JNHRB*U+.BK+ \APL9R@92Q .YA
MD':#]N_M*?MR?#'X#_#W4]2C\6:/K_B5K=AIFB:9>QW,\\S*?++JA/EQYY+M
M@8! R< _(W_!/']E[X<_M-?L<WNG^.]"6_FM/$MY]CU*VD,-Y:%H+?/ERKS@
M]2C;E) )4D"O>?AU_P $E_@)X!UR/4[NTUWQB8G$D5KXCODDMT8'(S'#%$''
M^R^Y3W!KIK1YWRO31;'-2DE>25]7I\SRK_@C_P#!#6['2/%_Q@\1P217'B9A
M::8\R;7GA#EYY^?X7DV@'OY;=L5Y)^U-;ZW^P_\ \%"=-^,::=<7OA'7KHWQ
M:$8$JR1>5>V^X\>8,M(H.!\R>^/UVL;*WTRS@M+2WBM;6!%BB@A0*D: 8"JH
MX  & !6#\1/AKX6^+7A>Z\-^,-#L_$&BW0_>6E['N7/9E/5'&>&4AAV(J)-\
M\9P5N56MY&D=8R4]>;5^IQG@C]JWX/\ Q!\+1Z_H_P 1_#C:?Y0EE%WJ<5M-
M;@C.)HY&5HCP>& Z>E?$?[2'_!1#QKXX_:#\*_#G]FG5K?56:8VMU>+9175O
MJ-P[#A&=21#$JL6E0@$%CDJH->FZ]_P1Q^!&L:M)=VEYXPT.V9LBPL-4A:%!
MZ S0228^KDU] ? #]C[X6_LSQS2>"/#B6^JSQ^5<:Q>R-<WLJ\97S&^XIP"5
M0*I(!(IQ2YE)[+IW%K&+2U;ZF9^V9#<P?L8_$R.]E6YO$\-S">:-=BR2!!N8
M+V!.3BOGW_@B[S^S)XI_[&NX_P#22TK[2^*OPWTWXN?#CQ#X+UBXN[;2]<LW
MLKF:Q=4G5'&"4+*R@_52/:N)_9C_ &7_  M^RCX%O_"GA#4-8U#3[W4'U*27
M6IHI9A(T<<9 ,<48VXB7C&<D\^A'1U+]4K?>-ZQC'L[_ ('Y6?"B?P3-_P %
M)O&LG[01L_LO]K:D(O\ A(=OV$7(EQ;B??\ )Y0B^YO^7_5]L5^MVO?&3X6_
M"?PJFH:GXN\,>'="CCW0[;R".-U R!$BG+G'14!)["N$_:'_ &%_A+^TUJ U
M3Q7HDUKX@$8B_MS2)_LUV4'0/P4DP  "Z,0. 0*\H\$?\$A_@)X1U1+R_B\2
M>+44AA:ZYJ2"'(]1;Q0DCV)(/<5,;^SC!Z65O^".=G-S6MSX'^('[0=A^T5_
MP4<\">,]+@FM_#B^)]'L=-DN$*/+;Q74:^:1VW,7;'4 @'D&OW27/'I7S-\:
M/^"?OPQ^,WB#P=K#S:QX,NO"ELEII:>$WMK2**-)?-C&QX) -CY(VX^\<YKZ
M5A4K&JEF8XP6;&3[G'%7&RI1@NC9,KRGS>2)Z***D9\P?M_?LS^*/VJO@WIG
MA'PG?:3IVI6^LPZB\NLS2QP^6D,R$ QQR'=F5>,8P#S7KGP#\!ZA\+?@GX'\
M(ZM+;W&IZ'H]KI]S+9LS0O)'&JL4+*K%<CC*@^U>@=:7IS1'W4TNKN_5*P2?
M,U?H.I*6B@#R/]K7_DU_XL?]BOJ7_I-)7R?_ ,$5^?V>?&7_ &,\G_I+;U]R
M?$7P18?$OP'XA\)ZI+<6^G:Y83Z=<RVC*LRQRH48H65@& 8XR",]C7GW[,'[
M+7A3]D[P?JGAKPCJ&L:C8:A?G499-:FAEE60QI'A3'%&-N(QU!.2>:=-\KJ7
MZI)?)W'-WA&*Z-O[U8YG_@HD?^,,_B=_UXP_^E$5>4?\$>S_ ,8ER#_J/WG_
M *#%7U9\:?A/I'QS^&6N^!==N+VUTG68EAGFTYT2=5#JX*,Z.H.5'53QFN>_
M9M_9Q\-?LO\ P]/@WPK?:KJ&F?:Y+WSM8EBEGWR!0PS''&NWY!CY<]>:BG[L
MIWZVL35]Z,$NC;?W6/$/^"M'_)F?B#_L(6'_ *4+6Y_P2^/_ !A'\/?^XA_Z
M<+FO7OVA?@)X?_:6^&5YX&\3WNIV&E74T,\DVD2QQS[HW#J TD;KC(Y^7\JM
M? 7X*Z%^SS\+-%\!>'+K4+W1M*\[R)]4>.2X;S9GE;<R(BGYI"!A1P!UZU5/
MW:=2#^TT_P +!/WG"W0_,+0_^4TDW_89G_\ 36U?L O*U\W6O[!_@&S_ &GF
M^.J:OXC/BYKE[HV1N;?[!O: P$;/(\S&TY_UG7VXKZ2&*(NU&G3>\59A+6K*
M2V8ZFL-W!Y%.HH&?CE^T%\-_'/\ P3?_ &J!\7_ NEM??#K5KEV,2@BV6.9M
MTUA,5'[OYOFB8C'"8W%&%?>/P=_X*)? KXMZ##?-XYTSPAJ&P&YTSQ1<I820
MMW >0B.0>Z,??!XKZ*UK1=/\2:3=Z9JUA;:GIMW&T5Q9WD*RPS(>"KHP(8$=
MB*^0OB-_P29^ 'CW47O;/3-:\'22N7DC\.Z@$B))R<1SI*J#_90*!V%3%N,5
M!ZVV[CE:4N=:-[^9U_QD_P""BWP*^$?A^:\C\;Z;XQU/8QMM+\+W*7[S,.BF
M2,F.,>[L.,X!Z5\)?LT_"WQO_P %#OVIW^,WCW3I+7P%I=VDRHRG[-((6S!8
M0DXWJIYD8#'WLX+BOL'X;_\ !)WX _#_ %".]N])U?QE-$X>-?$=^)(E(]8X
M4B1Q[.K ^E?7>BZ+8>'=*M=-TJQMM,TVUC$5O9V<2Q10H. J(H 4#T JX<L)
M<^[Z>1,KRBX+1/?NSS3]K7C]E_XL?]BMJ7_I-)7P%_P2)^-?P_\ A?\ #7QY
M:>,?&_A_PI=7.JPR00ZQJ<-J\J"'!91(P)&>,BOTR^(G@>P^)?@/Q#X3U2:X
MM].URPGTZYEM&59DCE0HQ0LK , QQD$9[&OB;_ARO\$?^AI^('_@QL?_ )#J
M8WC*3Z-)?=J7*TJ<8]4V_P $?47_  U]\##_ ,UA\"_^%#:?_'*W?!/QZ^&W
MQ*UB32O"/C_PWXGU-(FG:STC58+J81@@%RB,3M!91GIR*^0/^'*OP0'_ #-/
MQ _\&-C_ /(=>L_LT_\ !._X<_LK_$&?QAX3UKQ1J&I36$FG-%K-W;2P^6[H
MQ($=O&V[,:_Q8Y/%4N7J0[VT/J>BBBD,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#S^\_Y*==_]@Y?_0Q7Y[_%G_DJ?B__ +#%W_Z.:OT(O/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G]Y_R4Z[_P"P<O\
MZ&*_/?XL_P#)4_%__88N_P#T<U?H1>?\E.N_^P<O_H8K\]_BS_R5/Q?_ -AB
M[_\ 1S5]KPW_ !)>GZGY;QM_"I^OZ'*4445^@'Y(%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?)A_X+EE?^:*?^77_P#<536__!<B!IT%S\&9(H<_,\7B<.P^BFS7/YBO5_\
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MFNUQH^AW$,%\J$X$DH6>[?T.RW11[$,*SUG.,$]6_P #16C&4Y;)'V'^Q/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .<\??\ (%@_Z^HOYT4>/O\
MD"P?]?47\Z*YJFYW4OA-?X9_\>NN_P#86G_DM=E7&_#/_CUUW_L+3_R6NRK
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M^"5/QV\46/BKQC^S]XUNGO+SPMYS:9)*Y=H%@F$-Q;!CU16*,@[#<.F &_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSG(P!]&_\%>+"ZO/V0;N:WSY5KK5E+<8)'[LET&?7YW2N]_X)LZI8ZI^Q?\
M#@V;+B&"Y@E51C;(MU,&!]\\_C2I>^ZE26K327W7O]XI^Y&$(Z)[_P"1P_Q\
M_P""67P=^(G@N_B\&:!'X&\61PEK&^L9Y?(:0 E4FB9F4HQX+* PZY.,'R[_
M ()._M%>)]2O?$_P.\:S3W.H>&(WGTQ[IR\T$44HBFM68]5C9D*^@+#H% _2
M23E3SBOR-_8/E3Q#_P %.OBGJ>EG.FK-KMR6C.Y&C:\55Y]"64BKHW]HX/9I
MOYH=1+V7-U37XGZZTM%%2 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'G]Y_P E-N_^P<O_ *&*^/?B
M)^SO\0M<\>^(]1LO#WGV=YJ5Q<02_;;==Z-(S*<&0$9!'!&:^PKS_DIUW_V#
ME_\ 0Q6LU>SE^-J8)N=-)W[GRV<991S/EA6;2CKI;]4? G_#,WQ+_P"A8_\
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M_)^W_P#BZ^X#;#TIIM?:E_;V)[+[@_U2P/\ -+[T?$!^ _Q$'_,L?^3]O_\
M%TT_ GXB#_F6/_)^W_\ BZ^WFM/:F-9^U']O8KLON8?ZIX'^:7WH^(_^%%_$
M,?\ ,L?^3]O_ /%TW_A1WQ#_ .A8_P#)^W_^+K[;:S'I339^U']NXKLON?\
MF'^J>!_FE]Z/B7_A1_Q#_P"A8_\ )^W_ /BZ3_A2/Q#_ .A8_P#)^W_^+K[9
M-C[4W["-W2C^W<5V7W/_ ##_ %3P/\TOO1\3_P#"D_B%_P!"Q_Y/V_\ \72?
M\*4^(7_0L?\ D_;_ /Q=?;']GCTI&T\>E']NXKLON?\ F'^J>!_FE]Z/B?\
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M.KYC7Q$N>5CV,)DF%P=/DIW?J]?PL>6_\*MU7_GXL_\ OM__ (FGCX7ZJ/\
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M<U3<[J7PFO\ #/\ X]==_P"PM/\ R6NRKC?AG_QZZ[_V%I_Y+795@=04444
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M_P""K$GP3\!Z-\//B=\,=>M_$/AVTBTR)K-1#+,L:A(Q+;S!&C?:%!P6R<G
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M/BC\&OV@A^T+\![.;5+F2<WNHZ/8P^=/%.R[9F$(YFAF!.Y5RP+,>G*R0?\
M!9RZLK,:5JGP6U)?&J$0-I\>I&.-Y1PWRM 9$.<_)M8C&-QZU^G.<CUHQ2C[
ML>3HMBFU)\UM?S/RE^"/[,/Q?_;,_:,L_C3\<=&F\,>&+":*:TT:]@:"2X2)
MBT-M% YWI"&^9G?&_<<9W$K]@_M]_LLW'[4GP/?1]%:&/Q5I%P-1TDSMM260
M*5>!F_A#JQP3P&5,\9KZ9;UHHG[T5!:);>HHMJ;F]7^A^2WP>_X*+?$7]D7P
MCI?PX^,OPHUB8Z+']BL-1D9K.<P1_*B$2(4F"@;1(C %0OWNIR?C=\=OB_\
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M?S]?L2_ML2?L;WWBVXB\'KXL_MY+:,JVI&S\CR3(<_ZJ3=GS/;&.^:^J9/\
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M@ HHHH **** "BBB@ HHHH \_O/^2G7?_8.7_P!#%:[5D7G_ "4Z[_[!R_\
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M=%'C[_D"P?\ 7U%_.BN:IN=U+X37^&?_ !ZZ[_V%I_Y+795QOPS_ ./77?\
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M5TMG_P >D'_7-?Y4 3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 E+110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7':A_R5+2O^O"
M3^;5V-<=J'_)4M*_Z\)/YM0!V-%%% !1110 4444 %%%% !1110 4444 %%%
M% "4M%% !1110 4444 %%%% !1110 4444 %%%% "4M%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'G]Y_R4Z[_ .P<O_H8K9VUC7G_ "4Z[_[!R_\ H8K:KKI_">;6^,3;
M1MI:*U,1-M&VEHH 3;1MI:* $VT;:6B@!-M&VEHH 3;1MI:* $VT;:6B@!-M
M&VEHH 3;1MI:* $VT;:6B@!-M&VEHH 3;1MI:* $VT;:6B@!-M&VEHH 3;1M
MI:* $VT;:6B@!-M&VEHH 3;1MI:* $VT;:6B@!-M&VEHH 3;1MI:* $VT;:6
MB@!-M&VEHH 3;1MI:* $VT;:6B@!-M&VEHH 3;1MI:* $VT;:6B@#E_$B_\
M%4^&O]^;_P!!6NGVUS7B3_D:?#7^_-_Z"M=-4+=FDMH_UU$VT;:6BK,Q-M&V
MEHH 3;2[1110 ;11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %<SX._X_O$'_7^]=-7,^#O^/[Q!_P!?[U'5%P^%G344459 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!SGC[_D"P?]?47\Z*/'W_ "!8/^OJ+^=%<U3<[J7PFO\ #/\ X]==_P"P
MM/\ R6NRKC?AG_QZZ[_V%I_Y+795@=04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R
M?Q2_Y$34_P#ME_Z-2NEL_P#CT@_ZYK_*N:^*7_(B:G_VR_\ 1J5TMG_QZ0?]
M<U_E0!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !7':A_R5+2O^O"3^;5V-<=J'_)
M4M*_Z\)/YM0!V-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >?WG_)3
MKO\ [!R_^ABMJL6\_P"2G7?_ &#E_P#0Q6U773^$\VM\84445J8A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% ',^)/^1I\-?[\W_H*UTU<SXD_Y&GPU_OS?^@K735"W9I+
M:/\ 74****LS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KF?!W_ !_>(/\ K_>NFKF?!W_']X@_Z_WJ.J+A\+.FHHHJ
MR HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#G/'W_(%@_Z^HOYT4>/O^0+!_U]1?SHKFJ;G=2^$U_AG_QZ
MZ[_V%I_Y+795QOPS_P"/77?^PM/_ "6NRK Z@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#D_BE_R(FI_]LO\ T:E=+9_\>D'_ %S7^5<U\4O^1$U/_ME_Z-2NEL_^
M/2#_ *YK_*@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N.U#_DJ6E?]>$G\VKL:
MX[4/^2I:5_UX2?S:@#L:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M_O/^2G7?_8.7_P!#%;58MY_R4Z[_ .P<O_H8K:KKI_">;6^,****U,0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@#F?$G_ "-/AK_?F_\ 05KIJYGQ)_R-/AK_ 'YO_05K
MIJA;LTEM'^NH44459F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !7,^#O^/[Q!_U_O735S/@[_C^\0?]?[U'5%P^%G34
M4459 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!SGC[_D"P?\ 7U%_.BCQ]_R!8/\ KZB_G17-4W.ZE\)6
M\(_\)+MUC^R!IIM_[2FW_:M^[?\ +G&.V,?K70_\5U_U!/\ R+2?#/\ X]==
M_P"PM/\ R6NRK ZCCO\ BNO^H)_Y%H_XKK_J"?\ D6NQHH X[_BNO^H)_P"1
M:/\ BNO^H)_Y%KL:* .._P"*Z_Z@G_D6C_BNO^H)_P"1:[&B@#CO^*Z_Z@G_
M )%H_P"*Z_Z@G_D6NQHH X[_ (KK_J"?^1:/^*Z_Z@G_ )%KL:* .._XKK_J
M"?\ D6C_ (KK_J"?^1:[&B@#CO\ BNO^H)_Y%H_XKK_J"?\ D6NQHH X[_BN
MO^H)_P"1:/\ BNO^H)_Y%KL:* .._P"*Z_Z@G_D6C_BNO^H)_P"1:[&B@#CO
M^*Z_Z@G_ )%H_P"*Z_Z@G_D6NQHH X[_ (KK_J"?^1:/^*Z_Z@G_ )%KL:*
M.._XKK_J"?\ D6C_ (KK_J"?^1:[&B@#CO\ BNO^H)_Y%H_XKK_J"?\ D6NQ
MHH X[_BNO^H)_P"1:/\ BNO^H)_Y%KL:* .._P"*Z_Z@G_D6C_BNO^H)_P"1
M:[&B@#CO^*Z_Z@G_ )%H_P"*Z_Z@G_D6NQHH X[_ (KK_J"?^1:/^*Z_Z@G_
M )%KL:* .._XKK_J"?\ D6C_ (KK_J"?^1:[&B@#CO\ BNO^H)_Y%H_XKK_J
M"?\ D6NQHH X[_BNO^H)_P"1:/\ BNO^H)_Y%KL:* .._P"*Z_Z@G_D6C_BN
MO^H)_P"1:[&B@#CO^*Z_Z@G_ )%H_P"*Z_Z@G_D6NQHH X[_ (KK_J"?^1:/
M^*Z_Z@G_ )%KL:* .._XKK_J"?\ D6C_ (KK_J"?^1:[&B@#CO\ BNO^H)_Y
M%H_XKK_J"?\ D6NQHH X[_BNO^H)_P"1:/\ BNO^H)_Y%KL:* .._P"*Z_Z@
MG_D6C_BNO^H)_P"1:[&B@#CO^*Z_Z@G_ )%H_P"*Z_Z@G_D6NQHH X[_ (KK
M_J"?^1:/^*Z_Z@G_ )%KL:* .._XKK_J"?\ D6C_ (KK_J"?^1:[&B@#CO\
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MI?\ (B:G_P!LO_1J5TMG_P >D'_7-?Y4 3T444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5QVH?\E2TK_KPD_FU=C7':A_R5+2O^O"3^;4 =C1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'G]Y_P E.N_^P<O_ *&*VJQ;S_DIUW_V#E_]#%;5
M==/X3S:WQA1116IB%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 <SXD_P"1I\-?[\W_ *"M
M=-7,^)/^1I\-?[\W_H*UTU0MV:2VC_74****LS"BBB@ HHHH **** "BBB@
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M=?\ QVOM\;1RG+YJG5I-MJ^C?^:/RO+,3G^:TY5*%>*2=M4OTBSR/_AOI_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *X[4/^2I:5_UX2?S:NQKCM0_Y*EI7_7A)_-J .QHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#S^\_Y*==_]@Y?_ $,5M5BWG_)3KO\
M[!R_^ABMJNNG\)YM;XPHHHK4Q"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9\2?\ (T^&
MO]^;_P!!6NFKF?$G_(T^&O\ ?F_]!6NFJ%NS26T?ZZA1115F84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<SX._X_O$
M'_7^]=-7,^#O^/[Q!_U_O4=47#X6=-1115D!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.>/O^0+!_P!?
M47\Z*/'W_(%@_P"OJ+^=%<U3<[J7PFO\,_\ CUUW_L+3_P EKLJXWX9_\>NN
M_P#86G_DM=E6!U!1110 4444 %%%% !1110 4444 %%%% #?XJ^3/V]+Z1;'
MPC9C(B:2XE//!8! /YG\Z^LF^6OG#]M[PO-JWP[TS684W#2[S][@=(Y!MS]-
MP3\Z]7*91CCJ;EM?\T>!GU.53+*\8;V_(Q/V#[2)=!\5W07]])=0QD_[*HQ
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M;^:BNH_;P_Y'#PO_ ->,G_HRJ/[#OAR6\\?:QK13-M8V7DAO^FDCC'_CJ/\
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MJ>Q.57/;)KW8<9Q7Q_\ MY6\WVSP?/@FWV7*;NV[,9Q^5=V5TH5L93A/9O\
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MA_8NMPQEX/+D=HYB!]QE8G&?48.>N:[[]G6\@O/@KX2>W(*+9B,X_OJ2K?\
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M_P#T+FA_^ %S_P#'Z^VV^$?A%NNAVO\ WQ2?\*A\(_\ 0#M?^^:?]I93_P!
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M (U1_P -0?#+_H9?_)"Z_P#C5'U/$_\ /N7W/_(/[3P/_/Z/WK_,]4HKRO\
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M_P"2%U_\:H^IXG_GW+[G_D']IX'_ )_1^]?YGJE%>5_\-0?#+_H9?_)"Z_\
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M?O7^9ZI17E?_  U!\,O^AE_\D+K_ .-4?\-0?#+_ *&7_P D+K_XU1]3Q/\
MS[E]S_R#^T\%_P _H_>O\SU2BO*_^&H/AE_T,O\ Y(77_P :H_X:@^&7_0R_
M^2%U_P#&J/J>)_Y]R^Y_Y!_:>!_Y_1^]?YGJE%>5_P##4'PR_P"AE_\ )"Z_
M^-4?\-0?#+_H9?\ R0NO_C5'U/$_\^Y?<_\ (/[3P/\ S^C]Z_S/5**\K_X:
M@^&7_0R_^2%U_P#&J/\ AJ#X9?\ 0R_^2%U_\:H^IXG_ )]R^Y_Y!_:>"_Y_
M1^]?YGJE%>5_\-0?#+_H9?\ R0NO_C5'_#4'PR_Z&7_R0NO_ (U1]3Q/_/N7
MW/\ R#^T\%_S^C]Z_P SU2BO*_\ AJ#X9?\ 0R_^2%U_\:H_X:@^&7_0R_\
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MZ/WK_,]4HKRO_AJ#X9?]#+_Y(77_ ,:H_P"&H/AE_P!#+_Y(77_QJCZGB?\
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MN?\ D']IX'_G]'[U_F>J45Y7_P -0?#+_H9?_)"Z_P#C5'_#4'PR_P"AE_\
M)"Z_^-4?4\3_ ,^Y?<_\@_M/ _\ /Z/WK_,]4HKRO_AJ#X9?]#+_ .2%U_\
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MO6_]V3\A_C2_VY!_<D_(?XT<LNP_:1[FC16>NMP-_!)^0_QI?[:@_NR?D/\
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MB:?)2H*#O>Z_+9'O99E&*P-;VM;%2J*UK.]O7=@?:OS8_:0_Y+AXM_Z^A_Z
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M%3S+C_GO+_WV:/,N?^>\G_?9JWY'M1]G_P XHY6',BKYEQ_SWD_[[-'F3?\
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MR5+2O^O"3^;5V-<=J'_)4M*_Z\)/YM0!V-%%% !1110 4444 %%%% !1110
M4444 %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!XI\9O]5X[_ .Q6NO\ T6U?GI7Z%_&;_5^._P#L5KK_ -%M
M7YZ5^@\-?PIGX[QM_O5/T_45NM)117V1^;"+0U+2YXQ0 RBG44 ,VTFVI**
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MM%@&T4[;1M%.PKC:*?118+B+2T44Q!1110 4444 %%%% !1110 4444 >^?
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MA\.;;51(D\MO<7<4<G58)KF62+\"CJP]FJJ;=2E-O=.R\[HF24)1MUZ'R?\
MLB_&#Q[XD_X*4>/O#&K>-O$>J>&K6]UQ+?1KW5KB:SA6.=A&%A9RBA1P,#CM
M7ZFFOR$_8K_Y2K?$?_L(>(/_ $H:OU[]*(_PJ;\D74_C5%YCJ***"1#VK\K?
M^"F_QA\>> OVLOA]H_ACQOXC\.:3=:3:2W%CI.K3VL$SM>SJ6>.-PK$J "2.
M0 *_5+=7X_?\%8N?VS/AK_V!;+_TNN**?\>DO[WZ#E_!J/R/V!7[H^E+2+]T
M?2EH)6Q^5W[6'QB\>^'?^"F7@+POI7CCQ)IGAFZU/08Y]&L]6N(;*59)T$BM
M"KA&# D,".<\U^IW4"OR$_;*_P"4KGPX_P"PIX=_]'QU^H_QD\97OP]^$?C3
MQ1IT4,M_HNBWFHV\=TK-$\D,#R*'"D$J2HR 0<=Q4Q:CAE-]Y&DX\U?E751.
MT[4M?F3\-O\ @KQJ%]\'S>^(/"5EXF^*>H:W)IVD>%O"T<T*/;B*$K-+O>9P
M2\DBJ%!+E< #!:L'7?\ @IE^TW\,)(M:^('P%@T?PDT@4M=:1J6G/S]U/M,K
MN@;ZQ\^E5RN+LR#]5*/K7C_[,?[2WAK]J;X8P>,/#D<UGME:UO\ 3;H@S6=P
MH!*,1PP(965AU!' .0/G;]KC]OOQ!^S/^U%X-\$RV>AKX#O[.UOM8U"\M+B6
M]@B>XE24Q&.4+PD8(!1N?7I0URR4'NPC[T7)=%?]#[I/YT<CM7YHS?\ !1']
MI+QC<OXL\!?L^37_ ,,&E_T6:ZTV\FO+F$''F"6-P@!')*QNJ\C<V,U]I_&+
M]HKP]^SS\(X?&_Q&==&E:&-3I-G)]IEEO&3<;: D+YA!##<0HPI8[1FA^['F
MD):RY4>MT=J_,2P_X*/?M)_&9Y=3^#_P"BO/#*%U6\U"SO+]9"IP0)HW@CW>
MJ#<1[UWGP'_X*B2:I\0K?X>?'#P-/\+_ !3.T<,5Y,DL5MYK_=6:&8"2!6RN
M'+.ISR5'--)MI=0;LF^B/T ].*#5'4M4M=)T^YO[RXCM;*VB:>:>5@J1HH)9
MF)Z  $YK\Y_%'_!43XA_%#QAJ>@_LZ?"*X\:VFGRA'UG4+6XN4D4D@.T,)3R
M48@[3))DCJ%.0(OKRK<JVG,?I,M)^%?F3'_P4_\ C/\ !77K*V^/?P0?1-,O
M) B7NE6]Q9''5C&)WDCG8 CY1(ON17Z*^ _'&B_$CP=H_BCP]?+J6B:K;)=6
MET@(#HPR,@\@CD$'D$$'D5?+I=;$7ULSHJ3\:^1_VP?^"B'A/]EW5(/"VGZ9
M+XT\?3JC_P!BVLWE1VJO]PSR;6(9LY6-5+$8)VAE)^?F_;P_;%TVS'B&_P#V
M=8QX65C(\:Z)J,=TL0Y)8F5BHP#\YBQWJ(OF5^G?H6TU9/=]#].NE)T%?-/[
M'_[<W@S]KK2[J#3[:;P[XOT^,37N@7<PD81D@>;#( /-CR0"=JE21E1E2?;?
MB1\1O#_PF\%:KXL\5:E'I.A:9"9KFYER<#. J@<LS$A0HR22 .M5/W%[Q,?>
M=EN=12]*_,JZ_P""H7Q?^,WB&[L_@!\$Y=>TZTDV/?:K;7%X2",@R+ \:0$X
M. TC9]>U:WP[_P""IWBGP9\0++P;^T3\-9/A]=W3 #5;2">WCA#-M61[>8LS
M19#9D21L;>%/.!)MVV8/1-[V/O?XF>-$^'/P[\3>*Y;=KR+0],N=2:V1@C2K
M#$TA0$@X)VXS[U\]_L!_M4>)/VM/"?C?Q/KVGV6D0V>LBST_3K$%A!!Y2. \
MC<R/ECEL >BCI6+_ ,%#/B#\8M#^%]Q:_#'PCI7BCP7JV@:E_P ))JET"SV-
ML80!)"1/&/\ 5M*WW7^Z..Q^&O\ @G5\3/VB/!OA+5=/^$GP]T?Q9X5NM:C?
M5=0U!&:6WD,:*RKBYBX"8;[K<G\***YY23[)+R=];CJ6C",EW_"Q^UGI17E?
M[1'[1'A#]F3X=S^+O&%S*MJKB"VLK50]S>3D$B*)20"< DDD  $DU\/6/_!1
M#]IOXQ0_VO\ ";]GV*;PTV1'>:E:W=\DN"0=LR/;HQR.0N[%2GS7MTW';1/N
M?IKUJ.7B)C[&OS.\!_\ !6;Q?X'\>6GA7X_?"Z3P9).R^;?6-M<6DEJC' E:
MUN-S/'D$EE?. <!CQ7Z51WD5]8I<02+-!+&'CD0Y5E(R"#W!%35B_9N2VL*+
M]Y1>Y^:?_!)3XM>.?B-\0/BE;>+?&?B#Q5;V=O:-:PZUJL]VL!:28$H)'8+D
M  X]!7Z;9_"OPM_83_:OT#]D_4/BIK.IZ==Z]K6JQ6EKH^C6F5:[F$DQ(:3!
M"*-RY."?F&%-?2FL_P#!0K]JWP3;CQ7XH_9YAL? HS-+OTR_@GAA]99R["+_
M 'GA /I6GV(^A=2+5:HEWT1^GW2OS@_X+#?%+QK\,['X6OX.\7Z]X3:\DU,7
M+:'J<]D9]HM=F_RF7=C<V,]-Q]:^I_V3?VO?"'[6W@V?5= CETO6K#8FJ:'=
MN&FM&8':P88$D;8;:X S@Y"GBOC#_@M__P >'PA_W]5_E:5E53C**\T70M)O
MT?Y'Z/?#.\GOOASX8N;F:2XN)M,MGEFF8L[L8E)9B>223DDUU':N3^$[ ?"_
MPD?^H3:_^B4KXY_:,_X*A6?@GXA3?#KX1>#[CXG>,XY7MI9+?S'MH[A<[HHX
MXE,EPRX.[;M QPQP<;U7:HTMSCH7=*+?8^]/2BOS!O\ _@HA^U)\)88]>^)_
M[/T$/A,*&EN+.PO;'R@2 -\[R3I&><8=02:^YOV<_P!I+P;^T]X#C\4^#[J3
MRT?R;W3[H!;FRFP#Y<B@D=.0P)!'0]<*SLV:W2WZGK-%%%(8QN]?D3^WY^T-
M\3_'O[3FO>#/A/XN\0:#IO@G1)KC45T#5;BS69X8FN+F1_*8;BB[8QGHRD=Z
M_4'XU?$JQ^#OPI\4^--1VFVT6PEO/+) \UE7Y(QGNSE5'NPK\[O^"1_PIN/B
M%J'Q3^+_ (MC&H3:]+-HZM,O$[3,)KQL>A+1+_WT*S2YYNWV5?YO8NZA!-]7
M;_,^HO\ @G/^T%/^T!^S9H]WJU[)?>)]!=M(U6:XD,DTSQ@&.9V8Y8O&R$L>
MK!Z^I >E?D5^PWK=Q^R#^WAXT^"VKSM'HFN7#V-JTQP&D3,UE+GU>)RONTBC
MM7Z[#%=$FII5([25S!)PDZ;Z?ET#]:..*^)/VR/VXO%/[-?[0WPX\'6-KX=7
MPGKRV\NKZAK$,QFM8FNC%*Z.DR*H6,%LLK8(SR.*\T\8_P#!33XK_$?6+\?L
M\_!34/&'AVPG:W.OZAI5Y>I<$8Z1VY019SD!I"Q!!*KT&,7S1YEWM]SL;.+B
M[,_2;\*.U?G/^SQ_P56U'Q%\3[+X=?&?P.O@?7[JY6R%_;+-!'!<N0$CGMI\
MR1 D@;MYP2,@#+#]%BX5=Q.!U-4URI2Z,B_O<O4=^%+7Y[_%O_@J9=77Q"OO
M ?P(^'=Y\4-;M6>-M1199;=G0X9HH(5+RQ@\&0L@XR,@ACP/B3_@H1^UI\(X
M5UGXB? ;3;/PS&0;BXATR^MT0$X :X,\J1DD@#<OX5*=U?N4TU==4?J+Z5^7
MO_!3[XN>.O /[2WPRTOPQXT\1>&],O+")[FSTC5;BUAG8W3*2Z1N QV\<CIQ
M7VA^R;^UCX9_:U^'DOB+0;>?2M0L91;:GH]TP>2TE*[AAQ@.C#.U\#.#D @B
MO@+_ (*UG_C*SX4?]@^'_P!+'JXQMB*47_-^C);YJ-1KHO\ (_7!?NCZ4M(O
MW1]*6D"V"BBB@84444 %%%% ')_%+_D1-3_[9?\ HU*Z6S_X](/^N:_RKFOB
ME_R(FI_]LO\ T:E=+9_\>D'_ %S7^5 $]%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4E+2'H: /)OC]\;--^$?A.>>259-2
ME4I#"IRV2",XKXF^#GPE\0?M*_$"76M8>3^REE#W-S(3EAV"YZU=_; \#^*M
M%^(5UJVLS2:CH]Q<RR6S8PL4+2L5C_!2!7UK^R;XH\-:Y\+=.M="$<4UK'BX
MA7[RDGO7Z'"V496L1AO>G/>7\I^8S;SK-GAL7[L(:J/\WF>M>'?#]GX8TFUT
MVPA6&WMT"*JC'08S]:U:.?6BOSV4G)MO<_2XQ4(J,59(*^?OVV/^21O_ -=O
MZ5] 5\__ +;'_)(W_P"NW]*]3*?]]I>J/(SG_D7UO1GPW\!?C7>_!76GO[/3
MUU R [HV![C':M+XY?M(Z]\;9(8KJ%=/L83\MO$3@Y]<UV/[$/@S1O&'B^ZC
MU>S6\1 VU7Z=*ZW]LW]GW0?!5A:^(O#\"V*2,1-;KD@X%?J=3$8&.:JE4I_O
M&M)'Y%3PN/EE$JL*G[M/6)[1^QG\)X/ W@!=2DDCN+^^/F>9&P;:A .TU\R_
MMI^/I_&7Q471%F8VNGR_9_+SQDD5ZY_P3]\>7%]HVH>'9RTB1EIU=CG Z8KY
MB^.B_P#%_?$0_P"HFO\ ,5Y67X>2SBO*L[RBKKYGL9CB8_V)AX45:,G9KT/J
M?PU^P[H5]\-XVGGD.LW$'F+)Q@$C(&:^=?@?K.H_"+X]?V;!/MV71LI06PK#
M=@GZU^EO@OY?".E_]>R?^@BORN\9.T?[0%Z5.&_MSJ/^NE8Y/BZ^8/$T,1+F
MC;J;9U@Z&6K"U\-'EE?_ "/NC]M#Q]>>$_A9<6VGMY<EZN#,IPRC/:OFC]DO
M]G"R^+OV_6-<>06 '[HH,[WSSG-=_P#MW:O<0^$?!]HN3%<0$N?7&*]"_8%X
M^#RC_IO)_.N:C.>7Y(ZE%VE*6_7L==2$,SSY4JZO&,=NFUSY>_:G^#]E\#?'
M6F#0IK@QRQ?:1(5QL8'H,5];?#/QQ/X[_9D:[NVDDO$M2LC2CEN>*]8\;?"K
MPQ\16B;7],COFC&%+DC K+\7>%=+\'?"S5-.TBU2SLXX3MC7I7EULVCCJ%"C
M43=2+7O'K4<FGE]>O7I-*G*+M'7L?FO\(_A@WQ:^*$FC%S';+=,T[#J$W<XK
MW_\ :3_9,\.?#OX</KNCW$YFM62)HV  ;/<XKB?V*_\ DN6K?5O_ $,U]9_M
MB?\ )$-4S_STC_K7T>8YAB:.:4*%.5HZ:=[GR^79;AJV55\14C>6MGVL?.?_
M  3]\37UOXHU;2@Y:RD"_NR>%Z]*J_M[?$*XU;QM;>&+><M901K(R@\;^AJI
M^P'_ ,E"U/\ W1_6N#_:VS_PNV_QR=G'YFNJ%"$L^E-K:-_F<M3$5(</PBGH
MY6^78^A/A9^QAX7\1?"^PU.]N)OM]_;>>-H&$)!P*\!^&]UJ_P !?V@[72$N
M"%6Y"3QJWRR)V!J7P_\ &+XTZ3H5G8Z7=7":;#'L@58P1LKG--T3QMX@^(UA
MK>J:=<7%[),#),5QG%=%*CB(NNL95C.$D[*^QSU:V&DJ#P=&49Q:N^_],_5W
M3[K[;8V\^,>:BOCZC-6367X95U\/Z:)%VN+:,,/0[16I7XY)6DTC]NIMN";.
M5^(OP_TSXE>%[O1M3C#13H5#XRT9/<5^>&H:1XF_9*^+$<G[S[ SYCD4DB2(
MMT/OBOTX^IKYB_;@U[PK:^!5L-4BCN=8D8-;QYPX'.#^=?4Y!C*D*WU24>>$
M]&OU/D.(L#3E1^NQERU(:I_H>U?"[XG:5\4O#-MJVFS*2Z@R19^9#Z$5V7IQ
M7PA^PGX6\5IX@754GDM_#R,WVF%E^6;,3A,?1BI_"OO *>YKS,WPE/ XN5*E
M*Z_+R/5R7&U<PP<:U:/++\_/YCJ***\<]X**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[4/^2I:5_P!>$G\VKL:X
M[4/^2I:5_P!>$G\VH [&BBB@ HHHH ;BBC->:_M'?$34_A#\"?&_C/1H;6YU
M70]+FOK:&^1G@=T&0'"LK$?1@?>HDU%.3&DVTD>E=J.U?F;X1_X*S^(O$7PN
M\/V>F>!K;QM\:-:NKB./0?#L%PEI:PHV(W=2TLCLP!.Q6'R@L2@QENO?\%$_
MVE/@/=V>H_&?X$65EX7N75!=:6D]ML+=%,[2SQ[\ D(VTG';K6EG<G=:'Z:[
MJ/PKS[X(?&SPK^T%\.],\:>#[UKO2;P%6CF79-;RK]^&5<G:ZD\C)!R""003
MP_[6'[87@K]DOPI!J/B(RZEK5]N&F:#9L!/=%<98D\1QKD9<^N &/%3+W'9C
MC[VQ[S1FOS LO^"@7[6_CZS;Q'X(_9ZMW\)R()K=KC2;^[DFC(R#'*LL0FR.
MZ1FO;OV4/^"DFA?';QDWP^\:^'+CX=_$)7:&/3[IV:&ZD4?-&I=5>*48;]VX
M[<,3Q5)-Z=12?*K].Y[5^V-KFI>&?V7/B;JNCZA=Z5J=IHEQ-;7UC.T,\+A>
M&1U(92/4'->"?\$DOB%XI^)'[/7B/4?%OB76/%.HQ>)I[>.\UF_EO)DC%M;,
M$#R,Q"@LQQG&6/K7M_[<1_XQ%^+'_8OW/_H-?./_  1;_P"39/%'_8V7'_I)
M:44M74OV7YCJ?##U?Y'Z 9&*6OEK]L3]O;PC^R4MEI,NG3^*O&FH1>?;:':3
M"()&6VB2:4AMBDA@H"L6*G@#FOF^Y_;@_;1U&S?6M)_9TMX-#/SI#<:'J,UT
M4SV G1FX/41^^*B+YKM;=QV:LGNS]-J3BOA;]D'_ (*:6?QX^($7PY\<>%6\
M$^.)3)%;^7(S6US-&"9(61P'@D 5L*VX':1N!P#]T"J::2?1DIJ[78=1124#
M.<\:?$#PQ\.-*34_%GB/2?"^FS2B!+S6;Z*SA,A!(0/(R@L0K'&<X4^E:6BZ
MWI_B32;35-)O[;5--O(EGMKRSF6:&>-AE71U)5E(Y!!P:^&?^"SG_)K>A#M_
MPE-M_P"DUU7TG^QQ_P FI?"4?]2QI_\ Z(6B'O1G+LTOO5QS]UQ\TV>RT4E+
M0(3\*1JKW5U%8V\MQ/*L,$2EY))&"JJ@9))/0 5^>/C[_@JEKWC'QS?>$/V?
M/A;??$:\M<C^UIHII8G ;:9%MX1N\K.,2/(G7E1WF^O*M6.VEV?HMGI1ZU^6
M_B3_ (*-?M2_!AHM4^*'P'T^S\.!E62XAT^]LDR3@+]I:6:-6)Z KGVK[J_9
MD_:5\,_M3?#.#QAX:2>T59FM+[3KK'G6=PH!:-B.&!#*RL.H8< Y OENG)="
M6^6U^IXQ_P %$/VT]<_9+\.^'++POHMI?Z]XD^T+!?W[DPV:Q>6&;RA@R,?-
MXRP (R0W2OK71+B2\T>QN)3NED@1G;IDE02:_$C_ (*9>.?C1XN\9:!;_%+P
M;IOA?2-/O-23PW<6*,'OK?S(P7DS/)SM6$]$^\>/3](/V.?B5^T-XXO=2M?C
M)\/M(\'Z';6$#:5=::C*]P^<$-FYE_AP>B_TI4O>I-];CK>Y**7;[W<^J*,\
M5\<?M=_\%'/"_P"SAXBC\%>']%F\>?$"0HKZ5:S&*&T9\;%E<*Q:1L@B)5)(
M(R5R,^%R?MZ_M@>&K$>(_$'[.\*^%$S+,L>C:C!<1Q#)+.YE<Q@ '+-%CO4Q
M?,K].X[/;KV/T[-%?._[(_[:G@S]KKP[<S:/'+HGB73T5M2T"[D#R0AN!)&X
M $L6>-V 0<;E7(SS7[8'QD_:(^&?B;P_:?!?X;Z?XXTRZM'DO[B]L9YS!,'P
MJ QW$0 *\X(/UIRO!I-;BC:5[=#ZNI.*_-3_ (:T_;R_Z-^T'_P3WG_R=7FG
MBS_@J1^TYX%\;P>#M;^'/@FT\53-$B:.MA=RW.^0@1H42]8J[9&$.&PRG&",
MM*[45NPZ-GZZYHS7,KXJ7P[X#3Q#XOGMM#6TT];S5)97"0VI$8:7)).%4[NY
MZ=37Y^>+?^"JWC/XD>,KSPU^SQ\)[KQJ;9N-3U"VN)_,3.WS#;0[3%&3C#22
M#@\JIXI/?EZA'WH\VR/TJ6CKVK\QX?\ @J!\9?@MKUI;_'OX(2:'I5U($2^T
MJVN+(XQEC&)WDCG8#^$2+[D5^AGPS^)7ASXP>!])\7^$]3CU;0M2B\VWN8\C
MOAE93RKJ05*GD$$&JMI=;"O9V9UM%%%(84444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!XK\9O\ 5>._^Q6N?_1;5^>U?H3\9O\ 5>._^Q6N
M?_1;5^>U?H7#/\*H?C?&W^\T_3]0HHHK[,_-@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OIGX3^)O^$D\(VQD;==6G^CR
M\\G'W3^(Q^M?,U>R?L]V5T)=5N]Q%D0L6WLTF<Y_ ?SKR\PA&5%R>Z/<R>K*
M&)45M+<]K6I*C6I*^3/T)#H^]/ID?>GU+*1(M/6F+3UJ"T/3[U/'WJ8GWJ>/
MO4F:(D6I%Z5&M2+TJ66*M.IJTZI+'UG:'_K]2_Z^&K1K.T/_ %^I?]?#5#Z%
MQV9KK3J:M.H*0ZGKVIE/7M062+2TBTM9LI$U.7I3:<O2D4A5IU-6G5+*0^GI
MTIE/3I2*0]:=35IU2RQU.6FTY:11)'3J9'WI]2RQ]+_#24O\- T+']X4^F1_
M>%/J66A].6FTY:0QRTM(M+28T/IRTVG+4,H<M+2+2TBQ].6FTY:EC0J]:=35
MZTZD6A]%%% Q5IU-6G4%CJ<M-IRU #EIU-6G4%#J***D:%6G4U:=045G^\WU
MIM.?[S?6FUJ<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 <YX^_Y L'_ %]1?SHH\??\@6#_ *^HOYT5S5-S
MNI?":_PS_P"/77?^PM/_ "6NRKC?AG_QZZ[_ -A:?^2UV58'4%%%% !1110
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M5-<C=^AE3?-%'Y(_MEC_ (VO?#<_]17P[_Z/2OTL_:@^;]FOXIG_ *E;4_\
MTDEK\LO!.LK^V'_P52M_$WA^*2\\-Z;JL>H)<[<JMI8QHL<QST$DD:8SSF5>
M]?J;^U%_R;7\4_\ L5M4_P#226LJFF#2>_O/[SHB[XM)=.5?,^!_^"*?PQTF
M;3?'OC^YM8Y]8ANH=(L[B106MX_+\R78>H+[XP?9 /6OT;^+7A6P\<?#/Q3H
M&J0K<:?J.FW%M/&Z[OE:-AG'J.H]P*^%O^"*)_XL?X['_4Q#_P!)HJ_0+Q1_
MR+>J?]>TG_H)K3&? ^W+^AC0^._6Y^8__!$"^G:W^+MFTC&VC?2Y5C[!F%V"
M?J0J_E7"_P#!53PXGC#]N+X=Z#(_EQZGI6FV3-Z"6^G0G_QZNT_X(>_ZSXP_
M32?_ &\K#_X*1<_\%$_@]_UPT;_TY2UU5;?6*-_+\A4]*=:VFGZH_6'1]*L]
M!TNSTZP@2UL;2)(+>", )'&BA54#L  !7X^_\%5_B)9>*/VOO"'A'Q-=W4?@
MCP[!:?;X;4$NJSR"2YD0=W,/E@?[M?L>.5&*_'W_ (*7:%;_  K_ &Y/ OQ$
M\0:)%K7A#4EL;FZM[JW6>"Z6VD"7,#(X*L?*\LX(Q^\%<F]:FV^O4N"2IS26
MRT_ ^G/#O_!5;]FKPGH>GZ+H_P#;>FZ580);6MG;Z*4CAC4 *J@-P !7RI_P
M47_:X^!?[47PWT<^%!J;^.=)OE:WNKO3/)W6K*PEB:3/3.Q@/5?<U^E'A7]G
MC]GWQIX=T[7M#^%7PZU+2-0A6XM;RW\-6+1RQL,JP/E5X#^V9XH_9R_8_P!!
MT.>\^!'@#Q-KFK7!2#1HM$L+:3R%!WSEC;OA0=JCCDMUX-%2U_>WNO45/:\=
MK'5_ ZZUS]IK_@FW:V*7);Q%K?A6]T2.XN&(\R>,2VJ,[?[1C7)]R:^$_P!B
MO]N2/]AFW\2?#3XC> =46/\ M1[NXELE2/4+:8QHC1R0RE0ZX12#O7&3]X$8
M_2C2/C%HGPQ_9!MOB;HOPWD\/Z!:Z5_;$7@_2(8+=H()'WE@J!8U&US*V!T+
M'!-<?\#?B!\)?^"C7PONM<\2?#W1KJ[T^ZET^;3=56.[NK)>&1DFV*Z!U(.4
MQR&&3BMI.7MJCBO5?,SCR^Q@GM?1G+^*OVE_V7/V[/AW/\/M<\=KHBW[P7 M
M]3QIEW;S)(K*(IIT,)<\H0C,2&8#KFOH[X5_"[PS^S;\((/#7AHWC^'=&AGN
M8?MEP9Y-K,TK_-CH26. ,<U\.?MC?\$P/@WX,^#OB[QUX1N-0\$WFA:=)>1V
M<E\;FQG9.1&WG%I SG"*1)U8?*>E=E_P27\3Z[\2/V5/$.@Z]=W%[INFZE-I
M6GS3EF,<#01L8E8]50R' [!L= *PE>5.I[/1I7_0OX7!RU3=CX?_ &/?VD/A
MUX7_ &F/%?Q>^-#7U]J]RTEWIGD69NA'=32$M)C/RE$^5/0-QT%?H+_P]X_9
M[Z?;O$7_ (*&_P#BJ^+?^"=7AWP#X+_:8\;?";XP^$_#NJZI=-]AT\^)--@N
MECO;>1P8HS,AVF56)!&-VQ1R2M?JI_PR?\$/^B.?#_\ \)>Q_P#C5:NWLX6V
ML*5_:SOO<_(_4OCWX%D_X*->#_B+\'5NK'0]8U2R34;>6V^S!I;A_(NP(P>C
MJV\^KL37TC_P6L^(-YI_@WX=>"[>5DM-5N[K4;I58CS# L:1J?49G8X]0#VK
MHY/CQ^S_ *;^V!IWP>\'?L]>#]?U&/48;1?$FD:58)]ENE.^5E46^<0 ,6</
MD&-@!QFN9_X+7?#V^U#PG\.O&EM$SV.EW-UIUVRC(C,XC>)CZ F%QGU('>LI
M6Y*2?PWW\NGXFL+^UEWM^A]S_LV_"?2O@K\$_"7A31[6.VBL["$W,D:@&XN6
M0--*Y'5F<DY^@Z 5QO[8W['^A?M?>"])T;4M2_X1_4M,O1=6NL0V:W$R1E2L
ML(!9?E<;2>>J*<'%=I^SC\5M)^-/P5\)>+-'NHKF*\L(A<)&P)@N%4+-"V.C
M*X(Q]#T(KSG]NW]K!_V3?A'#KNEQZ;?>*M1O8[73=-U+>R2J"&F<JCJVU4!Y
M!P&=,]<'3$?&^;N88>[BE'^NYI_$3X>_\*G_ &'_ !AX.&K76N1Z)X)U"QCO
M[T*))8TLY0FX+QPN%^@%?-7_  11/_%C_'?_ &,*_P#I-%7O%]\2/$'Q>_X)
M^^)_&?B?1K?0=7UOP9JEXUA:NS(D36\QB8%N?FCV/@]-V*\&_P""*++_ ,*1
M\>+GYAX@4D=_^/>/_ TU=5:W-O9?F6[>QI\NUW^1[E^VI^Q/I_[6O_"-W>J^
M.;KPI9>'5F<Q+:I- X<H9';+IM.V,#=G &>*Z.Z_:^_9T^$/A^STE/B=X4M=
M-TN!+6"STB]6\,,<:[50);[SP!C&*^(?^"K'Q*\3>.OV@O!'P/MM:;0/"MY'
M9RW+,Y6&:>XN&C66;!&Y(@H(!X!W'KC'TMX#_P""4/[/GA/3;:/5?#^H>,+Z
M, O?:MJ<\9=NY\N!HTQGL0>.I/6LX7]G=:)MCG922>KM^#/B_P#X*??M;?"/
M]I31?"&G^ ;NYUO5]'NYI9-5?3Y+>(0.F#$#*%D)+*AQLQQUK]1/V7[J6^_9
MC^%EQ.V^:7PKICNWJ3:1U^;W_!6;0?A3\*?#?@7X?^ _#>@>'M<^U2:G?0Z1
M:113+ (_+B,[*-S%BS;=Q)^0U^CO[*?_ ":S\*/^Q3TS_P!)(Z/=^K5.7:_Z
M,4K^TIW[?J?FC_P2&^$.D>,OCEXW\9ZK;1WLWA6&%;".90RQ7%P\H\X _P 2
MI"X![;R>H%?L#<6T5Y!)#-&LL,BE'20!E92,$$'J"*_(;_@C[\5-)\)_&SQ[
MX-U&ZCM;OQ-!!+8>:0OG36S2DQ _WBDS,!WV&OUWO+R"QM9KFXF2"WB0R232
M.%1% R68G@ #G)K2I;V<.UE_P?Q*G?ZQ4[W/R/\ @CIJ_LQ_\%9-5\$>'4-M
MX<UBXGM/L:<(EO/:B[C0#TC<(![+[UV7_!;[FP^$/^_JO\K.N0^ M]_PU!_P
M5<UGQ]H&^Y\,:-//>?;%R4:"&U^QPL#Z2/M8#T)]#77_ /!;[BP^$/\ OZK_
M "LZPES>QH<VYK"WUBI;L[^MM3ZQ^.GQ'O/A/^P?JWB;3IFMM1M?"UM#:SQ_
M>BFF2*!''NK2 _A7YW?\$X?VH/@A^R]X=\2:OXW74CXZU6Z\A+JUT\W'E6*J
MI"*^>"TA<L!UVIGH*_0WX^?#N]^*G[!>L^'-.MVNM0G\+6T]M;QY+2R0)%.B
M#U),0 ]S7R'_ ,$FM/\ @Y\5/ /B#P3XQ\#^#]>\;Z9>O>P/K6BVMS=7%DZH
M/E>1"S"-PP(S\H=?6NA7]M5[V_"YQQM]6I7[_HK7_K<]UU+_ (*S?LY:OI]U
M8WLNNW=E<QM#-;S:*725&!#*REL$$$@@]<U\E_\ !-?XB:/H/[=WB;1? \MR
MO@'Q2+^.QM;A2C"&,M/;%E).&159!SG#GUK]-=2_9A^!&CZ?=7][\)?AW:65
MM$TT]Q/X:L$CB102S,QBP  "23Z5\T?L<_M"?!WXS?M!ZSH/P\^ GA[PM)H:
M74UMXPTK3K2(O;J_E*_R0(\1E##"ACP6!)P:FE95&UJ[,NI?V=GM='WS1136
M;:"3P*11^;?_  6:^-PT'X=^&?AE8W6R\UVX_M+4(T;G[+"<1JP]'E.X?]<#
M71_LL_MN?LP? #X"^#O Y^)*K>:=9*U\T>A:FP:ZD)DG(/V;D>8[ >P%?,]G
MI-G_ ,%"/^"D^K1ZG&=5\!:69EDB29U5].M1Y:!70AE$LS!LJ0<2G!K[O_X=
M=_LR#K\,_P#ROZI_\DTJ2<:5W]O7_(=2SJ<O\J^5W^I^=W_!13X\?"WXF?&3
MP/\ %#X.^,5U/Q'8HL=]MTZ[M6BDMY!);3_OH4#'EE."3A%XK]?/@3\5;#XX
M?"'PKXWTXH(-9L4N'C0Y\F7[LL1]TD#K_P !KY:^.'_!+?X)7/PA\5CP'X'?
M1O&26$DNE72ZO?38N$&]$*2SNA#E=ARI^]D<X->4?\$9?CD;K1/%?PEU.7;<
MZ?)_;&F)(<$Q.0EP@'^R_EMC_IHWI54^5QE26ZU7SW(J7]VJ]MG^AP/_  5^
MT-O$W[3GPOTA'V-?Z7%:AO3?=NN?UK]6? O@W2/AWX1TKPUH5E%IVCZ7;I;6
MUM"H5511CMU)ZD]222>M?F!_P5,_Y/*^"G_7"U_]+C7ZOKRHJ*.F'7G*7YE5
M=:WI%'Y+?\%J/#EGI?CSX6^);2)8-6O+6\MI[B,;7=87A:(EAW4ROCZU^G/B
M#P]-\0?A;J.A_P!IW&DSZSI3V9U*U \ZW,L6TR)GC<-V1[U^;G_!;K_C^^$/
M^[JG\[6OL[]K/XLZQ\$?V0_$WB_P^=FM6>FP06DQ /D2321PB7!!!*>9N /&
M5&:2M]5:EJKO0TE%NO3Y=VCSC]G'X/?![_@G98>(M-\1_%/P^-<URX6X^U:W
M-;Z?=BU10(X1&969P&+MN  )<<<"K/Q8_P""E'[-5KX7UK29_%__  EGVFUD
MMY=-TS3+B9;A70J4WNBQ$$''+U\E_P#!/K]A/P1^U)X)U3XI?$_5]4\57UUJ
ML]N=/2_9,LH5GDN91^]:1B^1AEXP3G=Q]G:[^R[^S5^RW\._$'C&3X>^'[&S
MTFV:Z-YK"M?RK(!\BQ-<M(1(S;54+@EB .:=?X'[1].GIL12:<O<[GR!_P $
M1KEU\8?%F!"1;M::?)M]P\X'Z$U!_P %;/\ DZSX3_\ 8/A_]+'I_P#P1)??
MXZ^*[=-UE8G'I^\FIG_!6S_DZSX3_P#8.A_]+'K5?Q\.WW_1F;^"O;M_D?K@
MOW1]*6D7[H^E+4%+8****!A1110 4444 <G\4O\ D1-3_P"V7_HU*Z6S_P"/
M2#_KFO\ *N:^*7_(B:G_ -LO_1J5TMG_ ,>D'_7-?Y4 3T444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 <A\2OASIGQ-
M\+W6CZE&K+(I\MNZMC@_3-?G]:S^*?V0?BJWFI))I;2?.5!\N9/;UQFOTNYK
MS/X[?!NP^+WA.6SFC4:C$I-M,0,J?2OI,HS-8=O#8A7I3W7;S/E,ZRIXE+%8
M9\M:&J??R9T?P[^(6E_$CPS:ZQI<ZS12*-ZJ02C8Y!KJJ_-OX/\ Q)US]E_X
MD2Z%K\<B:1+)Y<D;9VH"WWUK]$?#_B"Q\4:/;ZEITZW%I<('1U/8_P JPS7+
M'@:BE#6G+5,Z,FS59A2Y:BY:D=&OU-.OGW]M;_DD3_\ 7;^E?0=>*_M6>"M7
M\=?#5['1H!<78EW;"<<8KERN2AC*4I.R3.S-H2J8&K&"NVCYA_X)]_\ (ZWF
M/1O_ $&OI+]L30TU3X,ZM<,,M:QEUKQ[]BWX/^+?A_XJN;G7+!;6!@V"&SVK
MZ-_:&\/W_BGX0>(M,TR(3WUQ 5C0\9-?29GB(?VS"K"2:NM3Y?*\-461U*-2
M+O9Z?D?*/_!/*1/^$EU1"1N^SMQ^(KQS]I#1Y]#^/6M/<D!9[]9%/MD5[?\
ML<_"+QO\/OB3+<ZMIXM;![8J6#9YKTW]K#]F&?XJ>5KGA]%76(%.Z+(42^Y-
M>T\PH8;.92E-<LXI7['@K+L1BLEC%0?-3DW;JSVGP?XHTL?#NQU(7T+V4-HI
M>56&!A1D5^9TEJOC3]H2<6;;HIM8\Q6!XV[^M=);_#CXU:7IK^'8#=16#94V
MZR'8:]^_95_9-OO".K#Q/XNC47X&(K7(9?4-GUK.C##9+3KU_:J3GLD:5I8K
M/*E"A[%P4-V]B?\ ;MT-(?AOI+&,NUFFP2 <#H*?_P $_P#QEI\G@B?P^952
M^@=I2K'J">U?0_Q8^&MC\5/!M[H5]^[2=?EE4992.F*_/C5OV?\ XJ?!WQ%<
M2:()88P?DN+:3EUSQG%<&7U*&8Y=+ 5*BC).ZN>EF-+$99F<<?2IN<6K.Q]!
M_M:?M.:]\*_$=CI7AFXM)&> R3;AO*-GH:['X=_$#7/B5^SM>ZSKZ*MU- 2&
M1=H//:OEGP5^S#\0_BGXI@OO$:LELT@DFN)G^8C.2.:^[=6\#1Z!\*KCP[HT
M0VQ6_EQ)TR:QQ\<#@Z='#4K.HFKR1ME\L?C:M?%5DXP::C%^A\-_L5_\ERU;
MZM_Z&:^M/VQO^2'ZI_UUC_K7@/[*OP3\9>#?BYJ6I:MIRVUFY.UPV<_-FOI#
M]J#PIJOC3X2ZAIFCPB>\DD0K&3C@9S6F9UZ4\WHSC).*Y=>A.6X>M#)J].47
MS.^ECY*_8#/_ !<+4OH/ZUS/[9VA3:!\:Y99B"LT2R*?8G->L_L:_!SQ=X#\
M;WUWKFGK:V[D88-FO6_VJ?V=1\8M%6_TP*FMVP^5N!YB@<+FO2J9E1P^=>T<
MDX2BE<\JGE=?$9'[-1:G&5['6?!.;0;KX.^'[LQV,_D6*F9MB$J0,D'WKP"Z
M_:_GNOB[#X=T31+&737G\I'%NI?/?%>(V?P_^-'A&&70;,W5K!+PT,,AV$>E
M>X?LL_LFZOH'B*'Q7XM013PMYMO"&#9;OFN>I@\#@E6Q->JI\U^57[F]+&8_
M&NCAJ%)PY;<SMV/LO3YVN+"VE=-CO&K%<8P2.E6J3T X%<[XZ\<Z5\/?#MSK
M&KSK!:PKGW8]@!7YY&,JDU&"NWT/TR4XT8.4W9+=F!\9_B_I7P?\*3ZG?2*U
MQM/D09&7;Z5\+^"?"'BC]K+XH2:IJ9>/34<NSR [%CSG8/?%,\0:MXF_:\^*
M:16D;QZ3'*!&BGY(EY&[GN:^]OA-\,=,^%?A.VTFPC4.%!FD Y=\<FONG[/A
M_"V6N(FO_ 4?GB53B7%W=UAX/_P)FSX-\'Z?X&T&UTG3(A%;6Z!1ZGW)K?H^
ME%?!RE*<G*3NV?HE.G&G%0@K)"T444C0**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[4/^2I:5_UX2?S:NQKCM0_
MY*EI7_7A)_-J .QHHHH **** $[BO#/VXO\ DT7XK_\ 8 N?_0:]S[BO#/VX
MO^31?BO_ -@"Y_\ 0:QJ_!(UI?''U/EK_@C7\'M'T?X0:[\19+6.7Q#K.H2:
M?%=$ M%:1!/D4_P[I"Q;'7:GH*^]/B%X'T?XF>"]:\+:_91ZAHVJVSVUS;R+
MD%6'4>C X((Y! (Y%?"7_!&OXL:1K?P4UKP"UW$FOZ+J4MXMFS8>2TE"$2J.
MX$F]3CIE<_>%?<WQ,^(6B?"GP'K7B[Q#>QV&CZ5;/<SS2,!G X1?5F.%4#DD
M@#K71B;6][:WZ'/0YKZ;W?YGYF?\$@_$FH>!_C9\5_A3=7+36L$3WBQG[BS6
MLXMY& [%A(F?]Q?2O&OC]\8/!_BK_@I-JFM?%8W-]X!\+ZHVG-8QP&?Y+1&5
M(O+R,HUP"S#H0[=C7M?_  1_\(ZGXT^+7Q5^+5W;-#:7*M81R'[LDUQ,+B55
M/?8$CS_UT6O-/'6C^%_@-_P5'U1_BAH.EZEX&U_4I;Q_[>LX[JT\J]1BEP5D
M#+B.=B"V/EV-Z4ES>UH\V_*]^_\ PQ<N7EK<NU^G;J?9*?\ !77]GF*-46\\
M0A5& !H[ #V^]7P?_P %!OVF?A5\</'W@KQ]\*9-0L?&&G%EU"\FL?LK/Y;(
M]K)NS\SH0XSUQM&< 5^M\'[*_P #;F%)8O@_\/GC=0RNOABQ*D'D$'RN17R7
M^UG\7_V</V7_ (A>'_!L/[//@?QKKFH1^;>VNG:+I\4MBK,HA4K]G;>\F6(7
M*G 4_P 0J?\ EY'O?0<?A=MK'N?[2/BIO'/_  3]\7>))$\N35O!8ORG]TRP
M(Y'YM7C?_!%O_DV7Q1_V-EQ_Z26E>[_M<6\-G^Q%\0X;;2TT2WC\+2)'ID*J
MB6BB( 0J% 4!!\N ,<<5X1_P1<_Y-C\4?]C7<?\ I):5I#XZSMT7YF>JI4U>
M^OZ';>./V,? ^B?M4+^T7X[^(MO;:=:W"W)TOQ D,%G#*D/E08N'D4*(RJN
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MV8<_[PI4;^TG;:VH5OX4>]U;]3]4:***8!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'BOQF_U7CO_ +%:Y_\ 1;5^>U?H3\9O]5X[_P"Q
M6N?_ $6U?GM7Z%PS_"J'XWQM_O-/T_4****^S/S8**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF+3UJ"T/3[U._BIJ?>IW\5)FB)5J1>E1K4B]*EEBK3J:M.J2Q]9VA_Z_4O\
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M=C\K?%/_  1[\;^!_$DNK_!GXNMI3DD0C5'GL;J!/[IN;4-OY[B-/IQ6<_\
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MNWMTK]/J3':IBN56Z=BW)NS>_<^5/V./^"?OA#]DL3:N+Z3Q7XWNHC!-K=Q
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M_D4Y.3<GNSQ3]E_]E/P;^RCX)?0?"L4ES>W9674]9O,&YOI " 6QPJ+D[4'
MR>I+,?&_^"C'[&?C;]KJU\"1>#M4T'33H37S77]N7$\0?SA $V>5#)G'E-G.
M.HZ]OM#%':E+WVG+H$'[/X?/\3 \$Z+/X;\&Z'I-R8WN+&Q@M96B)*%D15)4
MD XR#C(%?$/[1'_!*_3O&WCR;X@?"/Q;-\,O%K3M=M!$'6U-P>?-ADB826Q)
M))V[ASPJ]_OO=WI<T2]Z7/U)A[L>5;'Y?:M_P3Q_:L^*EE%X=^(WQ_M+CPHP
M"30P:E?7ID4$$&2%HH5E((!^=SSSFOM7]EW]E'P9^RAX)ET+PM%)=7MXRRZE
MK-Y@W-[(!@9P,*BY.U!P,GJ26/MOI252DTFEU$U=KR%KAOC5H/BGQ/\ "GQ3
MI'@JZLK'Q3J%A+:6%WJ$KQP022+L\QF1'8%02PPIY ^M=S0:SE%33B]F7%\K
M31\8?\$\?V'=<_9'T_Q=?>+M0T?5?$FM20PQ2Z-+++%%:Q@G;NDBC;<SL20!
MC")SZ?9V.33J*T<N:WD2E:[[C&7(-?G=X=_X)W_$?X6_ML/\7/ FL^%H/!LF
MLR7KZ7>7=S%=?9;@$74(1+=DX\R38-^/E3..WZ)-0*B/NR4EN-^]%Q>S/B+]
ML_\ 8E\=?M%?'SX=^./#6J^'['2O#L<"7<.K7,\=PY2Y,I\L1PNI^4X&6'/Y
MU]NJNU0**6G'W8\BVNW]^X/67,][6/BC_@HM^Q9XW_:XN/ LG@[5- TX:$+P
M77]N7$\6_P TP[=GE0R9QY;9SCJ.M?4WBKX;Z3\0OAK?^"_$MJM]I&I6'V&\
MB5B-RE "5;J"",@]00#77T4DO<=/HW<;DW)2ZK8_,33?^"9OQY^ OBF]NO@/
M\:[72=(O'+/;ZM+/:,5!.P2QQQ313,H.-Y5>^ N<5WGA[_@F[XZ^*FO6&J_M
M(?&'4OB#:6DGG)X9TN:6*Q\SUWG9M!&0?+B1CG[XK] .*6JOM?6PN_2_8^%_
MV+?V&_'/[*?QZ\;ZY)J7AR\\ :Y%-!:6UG=7!OH4$^^V+(\ 3A"RL!(>3D$X
MI/VXOV&_'O[2WQJ\$^,/"^J^';#3=#M4M[B+5[F>.9V6X:0E!' X(VGNPY_.
MONCCK1@<T*Z<)?R[":7O+^;<4=!2TE+0,**** "BBB@ HHHH Y/XI?\ (B:G
M_P!LO_1J5TMG_P >D'_7-?Y5S7Q2_P"1$U/_ +9?^C4KI;/_ (](/^N:_P J
M )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /!/VHO@#!\5O#,M[90J-:M5+J5'S2@#A:^</V7?CM>_"+Q5-X
M.\5N]OI[2F/,Y_U+] M?H17RK^UU^SC!XMTU_$^AVVS5;89DCA&"_.2W'?WK
MZ_*<?3K4GEV,^"6S[,^(SC+JM"JLSP/QQ^)=T?4EK=17UNDT$BRQ2#<K*<@B
MI<!L CBOBC]CO]HF6QF7P/XIN&21#Y=K-<-@Y[AB:^UU8.H93E2,@CI7AYA@
M*F7UW2G\GW1]!EN8TLSH*K3^:[,545>B@?04%0W!&13J2O,/7&K&J\A0#["G
MT44 1^3'U\M<_P"Z*?TZ4M%,05&T:2?>56^HS4E%(8Q8UC^ZH7Z#%/HHH 8J
M*O(4 ^PI2H;@CBG44 -5%7HH'T%+2T4 1&WB;DQH3Z[13PNT8 I34-Q<1VD#
MS2R+'$@W,S'  ]2:>LM"=(ZE76]:L_#NEW&H7TRV]K A=W8XP *_.SXY?%;6
M?VDOB%#X=\-1RW&F12&.*.$\2KG[WTKI_P!JWX]W?Q,\0Q^"O"LDDEFL@21H
M2<ROG!&1VKWC]E;]GVV^&/AR+4]2MU;6KI0_[Q?FA'I[5]SA*%/)<.L;B%>K
M+X8]O-GY[C<15S[%/ 89VI1^*7?R1U7[/OP3L_@_X3BA"*^J3KFXF YYYQ^%
M>L^U%%?&8BO4Q-65:H[MGW6&P]/"4HT:2M%"TM%%8'4%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7':A_R5
M+2O^O"3^;5V-<=J'_)4M*_Z\)/YM0!V-%%% !1110 WO7AO[<7_)H?Q7_P"P
M!<_^@U[ET->,_MC:'J7B;]EOXFZ5H^GW>JZI>:)<0VUC8P--/,Y7A41068GT
M S6-7X)&E/XUZGYB_L6_L/7'Q^^  ^('@?QMJ'P]^)NCZ[=VMOJEM+(L4T(A
MA*HQC8/$07;YTSPQ!5N,>S2_\$T?CY\:M4LX/CC\=!JOARTE65;+3;JYOBV.
M"529(HXW*DCS-KD9Z'I7LO\ P2A\ ^)OAU^S;J6E^*_#NK>&-3;Q#<SK9:S8
MRVDQC,, #A)%5MI((SC'!K[4]JZZEE)6\OR.:FY-.^]W^9Q?PC^$?ACX&^ ]
M+\'^$-.73M%T]"J+G=)(YY:21NK.QY)/Z  5YM^UA^QKX)_:V\-6]GXA\[2M
M>L%;^SM>LD!FM]W5&4\21D@$H<>Q4G->_P!#9K&2YG>1K'W/A/R^TS_@GQ^U
MI\.;%_#G@/\ :!M8/":KY4$4^J7]HT4?I'"L4HAZGA''UKU?]EO_ ()A:3\(
M_'D7Q%^)'B>3XC^.HYOM<!F1OLT%R>3.S2,SSR@\J[[0#SMW ,/NJC':JC)I
MWZ]Q25U;H>:?M'?#S4_BY\"?&_@S1IK6VU37-+FLK::^=D@1W& 7*JS ?12?
M:O)O^"??[,/BK]E'X/ZUX5\6W^D:CJ-YK<NIQR:+-++"(V@@C )DBC.[,3<8
MQ@CGT^H^F:3;UHC[M_,;U279W/@/]IS_ ()BW?CWXJ7/Q1^$/C5O /C*YF-Y
M-!(98HC='[T\4\/[R%FY+ *V2Q/'(.+!^Q-^UI\1K-=$^)7[1L5EX:QLFC\.
M23RS7$>,,CGRK?<"./G9ASD@U^C&WC%'"U$5RKE6PY-R=^O<_-'XB?\ !)^^
M\*_$+X<^(?@EJ&CV,7ALP7-^/%=_<":]NH9Q*DV8H)%^8?*0 @&T8')K]*(2
MWEKO 5\<JIR ?8X&:EV]>*7K5W?+R]/\R;>]S?(6BBBD,2EHHH **** .(^+
M_P )_#WQP^'.M^"O%-L]UHVK0^5,(FV21L"&21&P<.K!6!P1D#((XK\]_#O_
M  3?_:.^ .M7L?P4^.&G6&@7+F1H-3DN+4,QX!>W6*>)G  &_@G'0=*_3Z@U
M"5FVNHV[JS/@3PK_ ,$T_$/Q$\16?B#]HWXK:K\3Y;7+P:!:S2Q6$3D8/SD@
M[>GRQI%D@9)&16W^P!^Q?\0?V0_&'CLZ[JOAS5?#&O)#]F;3+FX:Z1X7D\HN
MCP*H!25\X<X('4<U]OXHVU:ERNZTTL3)<RL]=4?+_P"W5^QC'^V!X(T:SM-:
M30?$FA2RRV%U<1&2"19%4212 <@$HA##)&WH<UPO[#O[+/Q__9[\<7K?$?XC
MVGBWP6=)-C9:3!KE_>"TE62,QM'#/"L<:A%=?E.>0,8K[:H[TH^Y>W4<_?23
MZ'QE^UY_P36\*?M(>(CXRT#6)/ GCLE6GO[>#SK>]90-K2QAE*R#  D5LX'*
ML<8\-N/V"OVQ=<TP>'-7_:&MY/"[YBEQKFHRSO$>"K PJ7&"?D:3':OT_I>E
M)+E5EMV&VWKU[GS!^QW^P?X._9%LKF]M+N3Q+XPOHO)N]>NH1$5CR#Y4$8)\
MM"0"?F9F(&3@ #P7]N[_ ()Y_%C]J3XX?\);X=\2^&;;0(;""TM;/6[ZZ22%
MER9-J);R( S'/!Y[U^C%&:)WE)-]-A1]R]NI^77_  P[^V\%2.+]H'3K:&-%
MCC@M?$^J011JH 551+0*H  X %'_  PW^W)_T<1:_P#A7:O_ /(U?J,!15 >
M:_#;X<ZFGP)T/P5\2KB#Q?J?]D+I^N3SRO=17[E-LI+R*&<-D\L :^'_ !=_
MP2I\9_#;QE=^)/V>/BQ=>"FNF_Y!NHW5Q;^6F=WEFY@#&6,'&$DC/ Y9CS7Z
M58HQ2>LG+8(^['EW1^95M_P3!^,?QJUNTN?C[\<)M<TNUE\Q=/TFXN+S(Q@^
M69UCC@8C^(1-[BOT'^%_PO\ #7P:\#:7X1\(Z9%I.A:?'LAMX\DDDY9W8\L[
M$DECR2:ZZ@_6JOI;9"MK=BT444AA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% 'BOQF_P!5X[_[%:Y_]%M7Y[5^A/QF_P!5X[_[%:Y_]%M7
MY[5^A<,_PJA^-\;?[S3]/U"BBBOLS\V"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHK=\#^'F\4>)[*PQF)GWRGTC7EO\/QJ924
M(N3V1=*$JDU".[/<_@[X;_L'PC%-(FVYOCY[Y'(7^$?ES^-=W3(D6- B *J@
M *.@%/KX:M4=6;F^I^H8>DJ%.-..R)%IZTQ:>M9'6A\?>GTR/O3ZEE(D6GK3
M%IZU!:'I]ZG?Q4U/O4[^*DS1$JU(O2HUJ1>E2RQ5IU-6G5)8^L[0_P#7ZE_U
M\-6C6=H?^OU+_KX:H?0N.S-=:=35IU!2'4]>U,IZ]J"R1:6D6EK-E(FIR]*;
M3EZ4BD*M.IJTZI92'T].E,IZ=*12'K3J:M.J66.IRTVG+2*'Q]Z?3(^]/J64
MA]+_  TE+_#04A8_O"GTR/[PI]2RT/IRTVG+2&.6EI%I:3&A].6FTY:AE#EI
M:1:6D6/IRTVG+4L:%7K3J:O6G4BT/HHHH&*M.IJTZ@L=3EIM.6H <M.IJTZ@
MH=1114C0JTZFK3J"BL_WF^M-IS_>;ZTVM3G"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G/'W_(%@_Z^HOYT
M4>/O^0+!_P!?47\Z*YJFYW4OA-?X9_\ 'KKO_86G_DM=E7&_#/\ X]==_P"P
MM/\ R6NRK Z@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "DHKF/'OQ(\+?"WP[/KWB[7[#PYI$)PUWJ
M-PL2%NRKD_,QQPHR3V%2VEJQI7.GI:^&_%G_  6&^ 7AS4#;6"^*O%,0_P"7
MO2=*1(C^%S+"W_CM=W\&_P#@I9\"?C1J=KI5GXEF\,:S=.%@T_Q+;_9#(Q.
MHE#-#N)( 7S,DG@&J2;V);MN?5-%)2T#"BBDH 6BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P# %_J;_P!/_P /^"?FCYJ?WU_.D\Y/[Z_G7Z5M#3&@H_UA_P"G?X_\ ?\
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MX_\ OL5]]_V6/[M']EC^[1_K"_\ GW^(_P#4Y?\ /[\/^"? ?VVW_P">\?\
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M?:H/^>T?_?0K]!?L/M3A8^U'^L3_ .??XA_J<O\ G]^'_!/SX^U0_P#/:/\
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M !1110 4444 %%%% !1110 5QVH?\E2TK_KPD_FU=C7':A_R5+2O^O"3^;4
M=C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1_9X]*W/LH]*/LH]* ,3^SQ1]@'I6W]E%'V84 8GV$?W:/L(_NUM_9A1]E%
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MV=AK \J\D7][J-Y 2 481_);P\X=BS @\LJ[@22EM!:A&V\G9'VO^R;_ ,%
M/#?[6/C+6/#.D>%-:TF]TR&2ZDO)6BELFA$HC0^9E7#ON!"[.S<\<X7[:G_!
M0S3?V8]>L_!/AO0&\9?$*]C2061D9+>S5\B+S-H+2.QQB)<$@Y+#*ANF_8)_
M8_A_9-^%DL&I/#>>-===+G6+J$Y2/:#Y=O&>ZIN;GNS,>F /AK]MG1_$7[+_
M /P4"TOXW:IX>EU_PA>7UI?VTVW,3-';K#)!O((29=A= ?\ 9(Z'%24?:0A?
M1]?,F+;C.:5^R/5K?XI?\%#?BQ:6T^D>!='\"6MQTN7M+6V>('NT5[-)(/IY
M9/M7R3^W]\-?C9X%UOP7??&WQY:^,];U6.Z-I;V,K-#81HT6X!?*C12Y<9V)
MCY!R>,?H5<?\%?/@%#X;344F\23WS)N_L=-*Q<@^A8N(ORD-?GE^WA\0OB=\
M?=6\/_%;Q5X*O?!O@*\WZ;X8MKTX=XUQ(TC X8F3<&W[0I  4MM)+7NU8NVB
M>Y<?A=]VC]FOBT?^,:?&'_8K7G_I(]?%7_!$NW1?AC\2)@H$K:M;HS=R!"2!
M_P"/'\Z^R/B!JUMKW[*OB/4K.19;2\\(7%Q#(ARK(]FS*0>XP17QW_P1+_Y)
M5\1O^PS!_P"B:<;^VK>B_P#2C'>A2?G^A^BVL_\ (+N_^N3_ /H)K\L/^")?
M_(S_ !@_ZY:;_P"AW-?J?K/_ ""[O_KD_P#Z":_+#_@B7_R-'Q@_ZY:;_P"A
MW-31_BS_ ,/ZFM3^"O5&/\;L-_P6,\-C4^;4:GI0MO-''_'G$4Q_VUS^-?KB
MG0?2OSH_X*??LM^,M<\3^&/CC\-+2XOO$?AM8OM]M9IYEP%AD\V"YCCQ\Y1B
MP8 $XVG& :M_#'_@LI\,]0\'P'QYH6O:%XG@A NX--M4N;:>0#!,+&0,N2,[
M7 VYQN;&:FFTJ*AU3>@ZBYJOM%LTE]Q]V>)O'WACP7<6,7B'Q'I.@RWS,EJF
MIWT5NUPRXW",.PWD9&<9QD5^3'_!8B.]U7]I#X=P1W4=O97&A1+;7,K?N4D:
MZE#.2 3@#RR2 >!QFG>)M2\5?\%8OVD/#_\ 8_A^_P!"^$?AABD]Y>#F.)F5
MYB[*2HGE"HJQJ6V@ Y(!-?5O_!2K]CO4?V@OA3HNI^"[)9_%GA /]ET]2%-W
M:,JB2%,\;UV(R@]<,.K"I:<?9U9]'>WEM<J,DW*G%[K?S['ED?[)O[>!4;/V
M@M!VXXQK%YC'_@#6-XS_ &&?VU/B'X9OO#OB3XW>&]8T2^0)<V5UJUZ8Y5#!
M@&'V+U /X59_9P_X*R:5X%\*6O@GXW:!KVF^*-#46,FIVMJ',PC&T?:8799(
MY0  <!LG).WI7!_M:?MVZO\ ML6UE\'/@=X4UZZMM3N4DO9YHE2YO!&X9%5$
M9A%"&"NTCL.@R% .=)Q;=HJ]_P"KF=/17EI8^XOV"?V<?%7[+OP3NO!OB[4=
M+U/4&U:>]CDT>:66!8G2,!<R1QD'<C$C;CGK7Q-_P2RC1OVVOBXY4;UL+\!N
MX!U"+/\ (?E7Z'?LH?!>\^ ?P)\->#M4U276-9MHC-J%W)*TH:XD.YU0MSL3
M(1>G"@X&:_//_@E?_P GK_%[_KQOO_2^*K3_ -IWO[LOR1BU_LS\Y1?XGZX4
M445!L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!R?Q2_P"1$U/_ +9?^C4KI;/_ (](/^N:_P JYKXI
M?\B)J?\ VR_]&I72V?\ QZ0?]<U_E0!/1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7':A_P E2TK_ *\)/YM78UQVH?\ )4M*_P"O"3^;4 =C1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'G]Y_R4Z[_P"P<O\ Z&*V-IK'O/\ DIUW_P!@
MY?\ T,5M5UT_A/-K?&-VFC::=16IB-VFDV4^B@!FRC93Z* &;*/+I]% #/+]
MJ/+]J?10 SR_:CR_:GT4 ,\ND\NI** (_+H\NI** (_+H\NI** (_+H\NI**
M (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI**
M (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI**
M (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI** (_+H\NI**
M .5\21_\53X:_P!^;_T%:Z;RZYWQ)_R-/AK_ 'YO_05KIJA;LTEM'^NI'Y='
MEU)15F9'Y='EU)10!'Y='EU)10!'Y='EU)10!'Y='EU)10!'Y='EU)10!'Y=
M'EU)10!'Y='EU)10!'Y='EU)10!'Y='EU)10!'Y='EU)10!'Y=+Y=/HH 9Y=
M'ET^B@!GE^U'E^U/HH 9Y?M1Y?M3Z* &>7[4>7[4^B@!GETNRG44 -V4NT4M
M% ";12[1110 ;11110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5S/@[_C^\0?\ 7^]=-7,^
M#O\ C^\0?]?[U'5%P^%G344459 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!SGC[_ ) L'_7U%_.BCQ]_
MR!8/^OJ+^=%<U3<[J7PFO\,_^/77?^PM/_):[*N-^&?_ !ZZ[_V%I_Y+795@
M=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMI$L44:^BJH  ^E7J :*?J!R'C3X0^!/B/)%)XL\%>'O%,D0Q&VM:5!>%!Z
MR(V*N^#_ (>>%OA[9/9^%?#.C^&;1SEK?1["*TC8^I6-0#71T4+38-Q,5QOA
M3X/^!/ NM7FL^&O!7AWP]J]X&6ZU#2=)M[6XG5F#,'DC0,P+ ,<GDC-=G11U
MN'D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 <G\4O^1$U/_ME_P"C4KI;/_CT@_ZYK_*N:^*7
M_(B:G_VR_P#1J5TMG_QZ0?\ 7-?Y4 3T444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MQVH?\E2TK_KPD_FU=C7':A_R5+2O^O"3^;4 =C1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'G]Y_R4Z[_[!R_^ABMJL6\_Y*==_P#8.7_T,5M5UT_A
M/-K?&%%%%:F(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P )AH7_ $&+'_P(7_&@#9HK&_X3#0O^@Q8_^!"_XT?\)AH7_08L?_ A?\:
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M_P )AH7_ $&+'_P(7_&@#9HK&_X3#0O^@Q8_^!"_XT?\)AH7_08L?_ A?\:
M-FN.U#_DJ6E?]>$G\VK8_P"$PT+_ *#%C_X$+_C7*WOB+2G^(NFW2ZC:FV2R
M=&F$R[ Q)X)SUH ]#HK&_P"$PT+_ *#%C_X$+_C1_P )AH7_ $&+'_P(7_&@
M#9HK&_X3#0O^@Q8_^!"_XT?\)AH7_08L?_ A?\: -FBL;_A,-"_Z#%C_ .!"
M_P"-'_"8:%_T&+'_ ,"%_P : -FBL;_A,-"_Z#%C_P"!"_XT?\)AH7_08L?_
M  (7_&@#9HK&_P"$PT+_ *#%C_X$+_C1_P )AH7_ $&+'_P(7_&@#9HK&_X3
M#0O^@Q8_^!"_XT?\)AH7_08L?_ A?\: -FBL;_A,-"_Z#%C_ .!"_P"-'_"8
M:%_T&+'_ ,"%_P : -FBL;_A,-"_Z#%C_P"!"_XT?\)AH7_08L?_  (7_&@#
M9HK&_P"$PT+_ *#%C_X$+_C1_P )AH7_ $&+'_P(7_&@#9HK&_X3#0O^@Q8_
M^!"_XT?\)AH7_08L?_ A?\: -FBL;_A,-"_Z#%C_ .!"_P"-'_"8:%_T&+'_
M ,"%_P : -FBL;_A,-"_Z#%C_P"!"_XT?\)AH7_08L?_  (7_&@#9HK&_P"$
MPT+_ *#%C_X$+_C1_P )AH7_ $&+'_P(7_&@#9HK&_X3#0O^@Q8_^!"_XT?\
M)AH7_08L?_ A?\: -FBL;_A,-"_Z#%C_ .!"_P"-'_"8:%_T&+'_ ,"%_P :
M -FBL;_A,-"_Z#%C_P"!"_XT?\)AH7_08L?_  (7_&@#9HK&_P"$PT+_ *#%
MC_X$+_C1_P )AH7_ $&+'_P(7_&@#9HK&_X3#0O^@Q8_^!"_XT?\)AH7_08L
M?_ A?\: -FBL;_A,-"_Z#%C_ .!"_P"-'_"8:%_T&+'_ ,"%_P : -FBL;_A
M,-"_Z#%C_P"!"_XT?\)AH7_08L?_  (7_&@#9HK&_P"$PT+_ *#%C_X$+_C1
M_P )AH7_ $&+'_P(7_&@#9HK&_X3#0O^@Q8_^!"_XT?\)AH7_08L?_ A?\:
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M_P :/^$FTC_H)VO_ '^7_&BZ#E?8TZ*S/^$FTC_H)VO_ '^7_&C_ (2;2/\
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M7_&C_A)M(_Z"=K_W^7_&BZ#E?8TZ*S/^$FTC_H)VO_?Y?\:/^$FTC_H)VO\
MW^7_ !HN@Y7V-.BLS_A)M(_Z"=K_ -_E_P :/^$FTC_H)VO_ '^7_&BZ#E?8
MTZ*S/^$FTC_H)VO_ '^7_&C_ (2;2/\ H)VO_?Y?\:+H.5]C3HK,_P"$FTC_
M *"=K_W^7_&C_A)M(_Z"=K_W^7_&BZ#E?8TZ*S/^$FTC_H)VO_?Y?\:/^$FT
MC_H)VO\ W^7_ !HN@Y7V-.BLS_A)M(_Z"=K_ -_E_P :/^$FTC_H)VO_ '^7
M_&BZ#E?8TZ*S/^$FTC_H)VO_ '^7_&C_ (2;2/\ H)VO_?Y?\:+H.5]C3HK,
M_P"$FTC_ *"=K_W^7_&C_A)M(_Z"=K_W^7_&BZ#E?8TZ*S/^$FTC_H)VO_?Y
M?\:/^$FTC_H)VO\ W^7_ !HN@Y7V-.BLS_A)M(_Z"=K_ -_E_P :/^$FTC_H
M)VO_ '^7_&BZ#E?8TZ*S/^$FTC_H)VO_ '^7_&C_ (2;2/\ H)VO_?Y?\:+H
M.5]C,\2?\C3X:_WYO_05KIJXO7M<T^?Q)X?ECOK=XH7E,CK("$RJXR>U=#_P
MDVD?]!.U_P"_R_XU*:NRY1=EH:=%9G_"3:1_T$[7_O\ +_C1_P )-I'_ $$[
M7_O\O^-5=$<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O^-%T'*^Q
MIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G169_P )-I'_
M $$[7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O\O\ C1_P
MDVD?]!.U_P"_R_XT70<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O
M^-%T'*^QIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G169
M_P )-I'_ $$[7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O
M\O\ C1_PDVD?]!.U_P"_R_XT70<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_0
M3M?^_P O^-%T'*^QIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70
M<K[&G169_P )-I'_ $$[7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:
M1_T$[7_O\O\ C1_PDVD?]!.U_P"_R_XT70<K[&G169_PDVD?]!.U_P"_R_XT
M?\)-I'_03M?^_P O^-%T'*^QIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?
M^_R_XT70<K[&G169_P )-I'_ $$[7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:
M=%9G_"3:1_T$[7_O\O\ C1_PDVD?]!.U_P"_R_XT70<K[&G169_PDVD?]!.U
M_P"_R_XT?\)-I'_03M?^_P O^-%T'*^QIT5F?\)-I'_03M?^_P O^-'_  DV
MD?\ 03M?^_R_XT70<K[&G169_P )-I'_ $$[7_O\O^-'_"3:1_T$[7_O\O\
MC1=!ROL:=%9G_"3:1_T$[7_O\O\ C1_PDVD?]!.U_P"_R_XT70<K[&G169_P
MDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O^-%T'*^QIT5F?\)-I'_03M?^_P O
M^-'_  DVD?\ 03M?^_R_XT70<K[&G169_P )-I'_ $$[7_O\O^-'_"3:1_T$
M[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O\O\ C1_PDVD?]!.U_P"_R_XT70<K
M[&G169_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O^-%T'*^QIT5F?\)-I'_0
M3M?^_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G169_P )-I'_ $$[7_O\O^-'
M_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O\O\ C1_PDVD?]!.U_P"_
MR_XT70<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O^-%T'*^QIT5F
M?\)-I'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G169_P )-I'_ $$[
M7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O\O\ C1_PDVD?
M]!.U_P"_R_XT70<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O^-%T
M'*^QIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G7,^#O\
MC^\0?]?[UI_\)-I'_03M?^_R_P"-<]X5US3[6\UQIKZWB66]=T+R ;E]1ZBI
M;5T6HOE>AVE%9G_"3:1_T$[7_O\ +_C1_P )-I'_ $$[7_O\O^-5=$<K[&G1
M69_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O^-%T'*^QIT5F?\)-I'_03M?^
M_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G169_P )-I'_ $$[7_O\O^-'_"3:
M1_T$[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O\O\ C1_PDVD?]!.U_P"_R_XT
M70<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O^-%T'*^QIT5F?\)-
MI'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G169_P )-I'_ $$[7_O\
MO^-'_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O\O\ C1_PDVD?]!.U
M_P"_R_XT70<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O^-%T'*^Q
MIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G169_P )-I'_
M $$[7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O\O\ C1_P
MDVD?]!.U_P"_R_XT70<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_03M?^_P O
M^-%T'*^QIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70<K[&G169
M_P )-I'_ $$[7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:1_T$[7_O
M\O\ C1_PDVD?]!.U_P"_R_XT70<K[&G169_PDVD?]!.U_P"_R_XT?\)-I'_0
M3M?^_P O^-%T'*^QIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?^_R_XT70
M<K[&G169_P )-I'_ $$[7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:=%9G_"3:
M1_T$[7_O\O\ C1_PDVD?]!.U_P"_R_XT70<K[&G169_PDVD?]!.U_P"_R_XT
M?\)-I'_03M?^_P O^-%T'*^QIT5F?\)-I'_03M?^_P O^-'_  DVD?\ 03M?
M^_R_XT70<K[&G169_P )-I'_ $$[7_O\O^-'_"3:1_T$[7_O\O\ C1=!ROL:
M=%9G_"3:1_T$[7_O\O\ C1_PDVD?]!.U_P"_R_XT70<K[&G169_PDVD?]!.U
M_P"_R_XT?\)-I'_03M?^_P O^-%T'*^QIT5F?\)-I'_03M?^_P O^-'_  DV
MD?\ 03M?^_R_XT70<K[&G169_P )-I'_ $$[7_O\O^-'_"3:1_T$[7_O\O\
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M_P#"&Z%_T![+_OPO^%'_  ANA?\ 0'LO^_"_X5M44 8O_"&Z%_T![+_OPO\
MA1_PANA?] >R_P"_"_X5M44 8O\ PANA?] >R_[\+_A1_P (;H7_ $![+_OP
MO^%;5% &+_PANA?] >R_[\+_ (4?\(;H7_0'LO\ OPO^%;5% &+_ ,(;H7_0
M'LO^_"_X4?\ "&Z%_P! >R_[\+_A6U10!B_\(;H7_0'LO^_"_P"%'_"&Z%_T
M![+_ +\+_A6U10!B_P#"&Z%_T![+_OPO^%'_  ANA?\ 0'LO^_"_X5M44 8O
M_"&Z%_T![+_OPO\ A1_PANA?] >R_P"_"_X5M44 8O\ PANA?] >R_[\+_A1
M_P (;H7_ $![+_OPO^%;5% &+_PANA?] >R_[\+_ (4?\(;H7_0'LO\ OPO^
M%;5% &+_ ,(;H7_0'LO^_"_X4?\ "&Z%_P! >R_[\+_A6U10!B_\(;H7_0'L
MO^_"_P"%'_"&Z%_T![+_ +\+_A6U10!B_P#"&Z%_T![+_OPO^%'_  ANA?\
M0'LO^_"_X5M44 8O_"&Z%_T![+_OPO\ A1_PANA?] >R_P"_"_X5M44 8O\
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M_P"%;5% &+_PANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X5M44 8O_  ANA?\
M0'LO^_"_X4?\(;H7_0'LO^_"_P"%;5% &+_PANA?] >R_P"_"_X4?\(;H7_0
M'LO^_"_X5M44 8O_  ANA?\ 0'LO^_"_X4?\(;H7_0'LO^_"_P"%;5% &+_P
MANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X5M44 8O_  ANA?\ 0'LO^_"_X4?\
M(;H7_0'LO^_"_P"%;5% &+_PANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X5M44
M 8O_  ANA?\ 0'LO^_"_X4?\(;H7_0'LO^_"_P"%;5% &+_PANA?] >R_P"_
M"_X4?\(;H7_0'LO^_"_X5M44 8O_  ANA?\ 0'LO^_"_X4?\(;H7_0'LO^_"
M_P"%;5% &+_PANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X5M44 8O_  ANA?\
M0'LO^_"_X4?\(;H7_0'LO^_"_P"%;5% &+_PANA?] >R_P"_"_X4?\(;H7_0
M'LO^_"_X5M44 8O_  ANA?\ 0'LO^_"_X4?\(;H7_0'LO^_"_P"%;5% &+_P
MANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X5M44 8O_  ANA?\ 0'LO^_"_X4?\
M(;H7_0'LO^_"_P"%;5% &+_PANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X5M44
M 8O_  ANA?\ 0'LO^_"_X4?\(;H7_0'LO^_"_P"%;5% &+_PANA?] >R_P"_
M"_X4?\(;H7_0'LO^_"_X5M44 8O_  ANA?\ 0'LO^_"_X4?\(;H7_0'LO^_"
M_P"%;5% &+_PANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X5M44 8O_  ANA?\
M0'LO^_"_X4?\(;H7_0'LO^_"_P"%;5% &+_PANA?] >R_P"_"_X4?\(;H7_0
M'LO^_"_X5M44 8O_  ANA?\ 0'LO^_"_X4?\(;H7_0'LO^_"_P"%;5% &+_P
MANA?] >R_P"_"_X4?\(;H7_0'LO^_"_X5M44 8O_  ANA?\ 0'LO^_"_X4?\
M(;H7_0'LO^_"_P"%;5% &)_PA>@YS_8]E_WX7_"E_P"$-T+_ * ]E_WX7_"M
MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A#="_Z ]E_P!^
M%_PH_P"$-T+_ * ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%
M_P *VJ* ,7_A#="_Z ]E_P!^%_PH_P"$-T+_ * ]E_WX7_"MJB@#%_X0W0O^
M@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A#="_Z ]E_P!^%_PH_P"$-T+_
M * ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A
M#="_Z ]E_P!^%_PH_P"$-T+_ * ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_PH_X
M0W0O^@/9?]^%_P *VJ* ,7_A#="_Z ]E_P!^%_PH_P"$-T+_ * ]E_WX7_"M
MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A#="_Z ]E_P!^
M%_PH_P"$-T+_ * ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%
M_P *VJ* ,7_A#="_Z ]E_P!^%_PH_P"$-T+_ * ]E_WX7_"MJB@#%_X0W0O^
M@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A#="_Z ]E_P!^%_PH_P"$-T+_
M * ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A
M#="_Z ]E_P!^%_PH_P"$-T+_ * ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_PH_X
M0W0O^@/9?]^%_P *VJ* ,7_A#="_Z ]E_P!^%_PH_P"$-T+_ * ]E_WX7_"M
MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A#="_Z ]E_P!^
M%_PH_P"$-T+_ * ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%
M_P *VJ* ,7_A#="_Z ]E_P!^%_PH_P"$-T+_ * ]E_WX7_"MJB@#%_X0W0O^
M@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A#="_Z ]E_P!^%_PH_P"$-T+_
M * ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_PH_X0W0O^@/9?]^%_P *VJ* ,7_A
M#="_Z ]E_P!^%_PH_P"$-T+_ * ]E_WX7_"MJB@#$_X0O0L@_P!CV7'_ $Q7
M_"E_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A
M?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\
MH#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/
M9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#
M="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^
M$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ*
M ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_
M  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A
M?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\
MH#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/
M9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#
M="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^
M$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ*
M ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_
M  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A
M?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\
MH#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/
M9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#
M="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^
M$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ*
M ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A?\*VJ* ,7_A#="_Z ]E_WX7_
M  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\ H#V7_?A?\*/^$-T+_H#V7_?A
M?\*VJ* ,7_A#="_Z ]E_WX7_  H_X0W0O^@/9?\ ?A?\*VJ* ,7_ (0W0O\
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M?]^%_P */^$-T+_H#V7_ 'X7_"MJB@#%_P"$-T+_ * ]E_WX7_"C_A#="_Z
M]E_WX7_"MJB@#%_X0W0O^@/9?]^%_P */^$-T+_H#V7_ 'X7_"MJB@#%_P"$
M-T+_ * ]E_WX7_"C_A#="_Z ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_P */^$-
MT+_H#V7_ 'X7_"MJB@#%_P"$-T+_ * ]E_WX7_"C_A#="_Z ]E_WX7_"MJB@
M#%_X0W0O^@/9?]^%_P */^$-T+_H#V7_ 'X7_"MJB@#%_P"$-T+_ * ]E_WX
M7_"C_A#="_Z ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_P */^$-T+_H#V7_ 'X7
M_"MJB@#%_P"$-T+_ * ]E_WX7_"C_A#="_Z ]E_WX7_"MJB@#%_X0W0O^@/9
M?]^%_P */^$-T+_H#V7_ 'X7_"MJB@#%_P"$-T+_ * ]E_WX7_"C_A#="_Z
M]E_WX7_"MJB@#%_X0W0O^@/9?]^%_P */^$-T+_H#V7_ 'X7_"MJB@#%_P"$
M-T+_ * ]E_WX7_"C_A#="_Z ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_P */^$-
MT+_H#V7_ 'X7_"MJB@#%_P"$-T+_ * ]E_WX7_"C_A#="_Z ]E_WX7_"MJB@
M#%_X0W0O^@/9?]^%_P */^$-T+_H#V7_ 'X7_"MJB@#%_P"$-T+_ * ]E_WX
M7_"C_A#="_Z ]E_WX7_"MJB@#%_X0W0O^@/9?]^%_P */^$-T+_H#V7_ 'X7
M_"MJB@#%_P"$-T+_ * ]E_WX7_"C_A#="_Z ]E_WX7_"MJB@#%_X0W0O^@/9
M?]^%_P */^$-T+_H#V7_ 'X7_"MJB@#%_P"$-T+_ * ]E_WX7_"C_A#="_Z
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M/ 5023P 33/AI\1-'^+/@?2/%OAYYIM$U:'[19R31F-WCW$!BIY&<9P><$9
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M+^VM%L-0,?E&ZMTG\O=NV[E#8S@9QGKBIB^9-KH[ _=:3ZZHTZ***H HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBD)X)H 0=J6OE/]E']N,_
MM/?%#QUX/_X0O_A&O^$7)_TS^U?M7VK$S1_<\B/9]W/WFZX]Z^JPU):I2[BV
M;B]UH.HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@!*3CBAFP*^6_V3?VVC^U!\0OB!X8/@S_ (1G_A%)%C^U?VK]K^UYEDCS
ML\F/9_J\]6ZX[5-^:7*MQ/2/,]M%]Y]344E+5#"BBB@ HHHH **** "BBDH
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M!_9WVW[)O\V0)N\SRY,8SG&WGVJ%)./-TO;YWL.WO<O7<]HHYKS?]GGXO?\
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MY^%FL>/?$MKJ%[H^EF$30:7'')<-YDJQ+M5W13\SC.6'&?I7C/C+_@I+\&/
M?P[\,>*M6U+44G\0V U&R\.V]LDNI^220&D19#'%D@XWR '!P3@XC_X*B?\
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M6G_IG2OUD6OQ:_:Z3Q_)_P %1-27X7.L?CXR67]DLWD8$G]EQ;O]>#']S?\
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MK^WD,=POA>U2>*)AU'G221QO_P  9N>.M9?_  52^,FH_"_]EB2ST>X:UO\
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M2XVK_$^\!C_$4R>22?J?_@K%<O>?L8R32)Y;RZII[LGH2Q)%?.7PW^ 7QO\
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M  3U\<_#O]K3PQ\2/V>;32M!TGS/ME[:7EY]FL[24-B6$(H9_)F1B-B(0OS
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M"DGP9\2?"&\^)%_J&I>%=$@U.32(K/6;>/[==W"11R$0PP22EUQ*GS9 '.[
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M2#<E[/26O<4?WFVG8_1OX@<^ ?$9_P"H=<?^BFK\_O\ @B7S\*?B+_V&8/\
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M?[2@@]02*]G_ &>_VS/A7^TUYMMX*\0;M:AB\Z;1-2A-M>QIW8(>) .,F-F
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MCC_@KQ\!?"&LO86+^)/%J*Q5KW0]-3R 0<'!N)8BP]U!![&O;_V>?VP?A?\
MM/0SIX(U[S=6M8Q-<Z-J$)M[R),XW;#PZ@D LA902 2"14OP,_9/^&WP$\#6
M?A_0?"VF33+;K'?:M=6D<MW?OCYGED8$D$DD+G:N<  5\_\ C+_@G=>:)^UE
MX3^+/P@U+1? .EV4D<^JZ3''(BRL&(E6&*-=BI+$2K+E0#R!S5))3Y6[KO\
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MC!8HY/,FCP[YR%&3C!. 1G\^? OQG\9?\$K/B?\ $3X<:]87'B7PWJ-K)?\
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MMM(\11^+;6>:W>\FM[<6!:*(RL0XG,F"H./W?7TZU0_X)K_\F4_#7_KWNO\
MTKFKO-'_ &4?A7H'QDN/BO8^%O)\?W$LLTNK?VA=-N>1#&Y\DRF(94D<)QVY
MKLK?[S)R^'7UOT.6G_"LMSV*DI:CED6.-F8[5 R2>U<S:2NS8\D^/W[4OPW_
M &:-%MKWQYX@73I[P,;/3;>-I[NYV]=D2C(7MO;:H) + D5X5\-_^"M7P'\?
M>)8=&N9]>\'F9A'%?>(K**.U9B< %X99-@_VG"J.Y%?+W[*O@;3?V^OVT?B/
M\1_B!#_;_A?P_(C6&DW.3 ZM(Z6<3J>#&L<3NR=&8Y((+ _HM\6?V6_AC\8_
M =QX5USP?I,=GY!AM+FRLXH;BP./E>W=5S&00.!P<8(()%"O&"G+5M7L5*W.
MZ:=K.S?F8OPK_:_\&_%WXY>,/A7HMCK":[X7222[O;F*$64RI(D9,+I,S-DN
M",HO&:]'^)WQ8\(_!KPG=>)?&NO6GAW1;?AKJ[8_,V"0B( 6D<@'"*"QP<"O
MR[_X)2^#;KX<_MD?%7PK>2B>YT/3+O39)0" [0WT4>X ] =N:S_VKO'7AW]H
MK_@H99>!OB/XHA\-_"OPBYM9FN[K[/$S)")9QN/W7EDVQ;NNU1@YI[^SC%ZR
M5V_);LGX95.;:+_1'TQ=?\%D/@3;ZT;&/3_&-S;"39_:4.EP"W(S]_#3B3'_
M  #/M7U;\'?CIX&^/GA8>(/ ?B"WU_3=WER^4&26"3^Y+$P#QMWPP&1R,CFO
M$]-^+?['NC^$?^$7M-?^%L/AYD\M],_T0PR#OO4CYB>Y;))Y)KX<\#^-O _[
M-/\ P4;\/Q_!OQ19ZM\-/&3VUC=V>F78N+: W+F/R2V3_JY@DBYY56VYP3FX
MKFDJ=M]F3*Z@Y]M6?HW^T-^UUX/_ &:_$?@G1/$^FZY>W?BZY:UL6TF"&1(V
M5XD)E,DJ$#,R_=#=#^/G'QJ_X*A? _X*^*;GP]/?ZMXMU6SE,-Y'X9M8YX[:
M0=5:622-&(/!",V""#@@BOF;_@ML\J:A\'VB=DD4:F593@ALVF"#VK[@_9Y_
M91^'WP/^%VE^'[+PMI-Q?O9)'JNI7-I'-<7\I7,AD=@2REBV%SM . *SA>5-
MS?1M>II*T917=7&? W]M+X3_ +0'AC5M;\.^)H[!-&@-UJMGK0%I/8P@9,L@
M8[=@[NK,HZ$YKQ3Q'_P6 ^ N@^(FTNV7Q1KULK;#JNFZ;&+7W(\V6.0@>R?3
M-?%WC_\ 9O\ #5U_P4ZO/A+I*RZ+X+UG4()+W3K!FBC:V:TCOIK8!2,1ETP!
MT7Y2,;17ZQ:I^S7\+]2^'5QX)?P'H$/AF2%HA8P:=%&J9&/,4A<K(.H<'=GG
M.>:;:]FJR6ZV#EY9NF_)W\F;?PG^+_A'XY>"[7Q5X(UJ'6]$N&*+/$&5HY%^
M]'(C ,CC(RK '!!Z$&O)/VH/V[/ 7[)OB30]%\6Z1XCU&ZUBV:Z@?1;:WE15
M5]A#F6>,@Y] :^3O^",=Y>:3K?QG\+FY:;3;*YLI(XST$FZX1G'NRHF?]T5]
MO_&K]DKX4?M$:OINJ?$+PK_PD%_IL+6]I+_:-W;>6A;<1B&5 >><D$U<DE*$
ME\+U?>S1"O%RA+=-H]>AF$T:N.A (_&I>U1QQB-0JC  P*D[<4O04;V5]SE/
MB-\3/#'PC\)7OB?QAK-MH&A62YFO+ICC)Z*J@%G8G@*H+$\ &OD+_A\1\!E\
M1?V;Y'BQK+S-G]L#2X_LN/[^WSO.V_\ ;//M7B7[<EU??M3_ +>W@#X"'4)K
M?PQIC1-?10,03(\)N;B3T+BW554D?*2WJ:_0G0?V<_AAX=\$)X0L/ 'AY?#@
MC$;6$NFQ2I+@8W2;U)D8XY9B6)Y)J(7E#VCZWLOU+E:,N3K9-_,\UUC]OWX6
M6?CSX<>&-+FU/Q.?'PB;2=6T>*&2S3S)C"!,7E22-E<'<NPLN,$9XKZ&U+4[
M71[&XOK^YALK*UB::>YN)!''%&HRSLQ.%4 $DG@8K\9_B-^SOI?[-?\ P4N^
M&6@^'?,C\-:GK>F:OIUI(Y<VJ27.QXLGDA7C?!/.W:"2037O?_!8[XRZEI>@
M^"?A=IM[_9UKXAD>^U68N45X8W58D<_W-Y9S_P!<UHO>G%QWDVE?^N@<MJTH
MRV23_,]5^('_  5P^ O@?6I=,LY_$/C#R6*/>>']/C:W# D$!YY8MXX^\H*G
MJ"17L'[._P"VI\*/VFW>T\':^ZZY%'YTNAZI";:\5.[!22L@'<QLP&1G&17D
M'P#U_P#8]_9_\$66B:'XV^'T]^D"QWVL7=U;R7=Z^/G:21N<$Y(0?*N< 5\A
M_M]:A\%_!WBCP9\6?V?O%OANP\:6>J 7ECX6N(PC$*9$N?)3Y5Y4H^!AQ(-W
M?-Z1DHO76U^Q*O)-K3U/U-^/7QJT+]GKX5ZQX\\26NH7ND:6T(F@TN-)+AO,
ME2)=JNZ*?F<9RPXS]*\;\8_\%)O@OX#^'7ACQ7J^HZBMQXBL%U&Q\.6]LDNI
M^220&E19#'%D@XWR '!P3@XX[]NWQM'\3/\ @FQJ?BV%!"FN:;H^I",'.SS;
MFV?;^!;'X5QO_!*7]F?P<GP+L/B=K>AV.O>*];N9_LM]J4"SM96\$C0*D.\'
M828W)88)! S@"E&,FYIZ<K0<RY83MO<]E^ /_!23X-?M#>*H/#>DWNJ>'=?N
MFV6=AXBMD@:Z;^[&\<DD9;T4L&/8&J/QR_X*;?!+X%^*KGPY>7^J>*=:LY#%
M>VOAJU2X6UD'5'DDDCC+#H0K,5((.",5\A?\%B/AAH'P[\;?#;QIX5L(?#VO
M:I]K6ZN-+06QDDMV@>*;*8_> RM\_P![A>>!7WW^SC^RK\._@O\ "K1]&L/"
M^DWM]/81C5=4NK*.6XU&5E!D:1W!8J6+80G:H. *4??ASK2SM\RI+D:3ZJZ]
M.I/^SG^V#\-/VIK.Z;P5JTW]IV:"6ZT;4H?(O($)P'*9*LN<#<C, 2 2"17K
MNO:]IOA71[S5]9U"VTK2K.)I[F]O95BAAC R6=V("@>IK\KO#/@O3?@7_P %
M@K/0?!UK%HF@ZD'9M-M5V0I'-IK2R1JHX">:NX*.!@ # Q78?\%<O'FL>*_%
MGPO^"&C79MU\07$=W>1J3B1WG$%L&QU4-YK8]0I[4F^:-/V:UF[?YCY>64E)
MZ)7^3/5O&7_!7WX#>%=9:PL6\3>*XE.TWVBZ8@@R#C@W$L3'ZA2#VKW;]GK]
MKCX8_M.6EP_@CQ!]HU"U0276DWD1M[R!20-QC;[RY(&Y"R@D#.:L?!?]E/X:
M? WP3:^'- \*:6VVW6&\U&ZM(Y;J_;'S/-(P);)R=OW1G  '%?/>N?\ !/.^
M\)_M=^&OBS\(]3T7P)H%LT<NJZ+''(HE;<5GCAB1=BQRQ'!&0%;D"K22GRO5
M/J9-MQYEHUT[G:_M%?'SX(_#S]H[P'X2\>?#G_A)O'NKK9G1M<_L.QN_L7F7
M3QP_OYI%ECVRAG^0'&<CFO/O^"I7[3WA;X?_  HUWX3:CI^L2^(O%6EI<6-U
M;0Q-9QJMRN1*S2AP?W;?=1NHKQ;_ (*(_P#*1CX"9]-'_P#3I+7V!_P45TNS
MN/V._B5=36D$MU'80B.9XU+I_I,71L9'4UA/_=U/I>2?R.N*M74>MH_>?,/_
M  2__;2\$Z7X)\ _ B32]?;Q=<7%]MO5MX/L W/-<#+^=YGW!C_5]?;FONWX
MU?M$_#W]GG08]6\>^);70H9R5MH&#2W%RPQD11("[XR,D# R,D5X)_P2OT>P
M;]C;P3>M8VYO1<:ABY\I?,_X^YA][&>G%8WQ-_8)UKXW_MEVOQ-^(6M:3KOP
MVL846V\-L91*HCC_ '<3J5V-&92TC_-SG:01755UFH_>SDIVM)_AYW,F3_@L
MU\#(]0-L-%\;RPAMOVQ--M?*(_O8-R'Q_P !S[5]4? W]HKX?_M&>'9=9\ ^
M((=:M[=A'=6Y1H;BU<@X66)P&7.#@XVG!P3BN7\?:U^SGX3\.OX<\7W?PUTK
M2(XMHT?4FL(T"@=%@/L> HSZ5^?G_!.._P##FB_\%!/B'IGP[U W7@"\T^_-
MAM\P(]NL\+Q8#@,=F2H+#.,^M1"TI<GDW]Q4KJ//Z'7?\%''1?V]OV>6=@BK
M-IQ+,< #^TNM>]_$S_@K!\"/AKXHGT.*YUSQ?);R&*>\\-V<4UK&X."!)++&
M''^U'N4]B:^8/^"LW@^X^(G[6'PC\+6DBPW6M6,&G12L,A&FO6C#'V!;-?H?
M\)?V6?AA\'? -OX4T/PAI,ECY BO+B\LXYY[]L89YW927).>#P,X   %9TK_
M %=>4I?/4NI;VMNMD.^ ?[4GPW_:8TF>^\!^((]1GM0IN]-G1H+NUR.-\3#.
M.V]<J2" QQ7"?MM?&KX0?!7PSX:O?B]X#_X3S3KZ\DAL;?\ L>SU'[/*J L^
MVY=0N5XRN37Q!^TEX)L/V"?VZOAWXX\ Q_V'X6\12>9>:5 2L"(95CO(47H(
MRCHZKT5L8 "J!Z=_P6R.[X7?#4COJ]S_ .B11-ITXU(]7;YIZCC%^T<&^E_P
M/NGQ%\3M"\ _!2[\?/8W4?AS2M%_M;[#911B9;=(A((T3<$#!< +N [9Q7C"
M?\%(O@M!\%](^)&JZGJ&AV&K2W$-AHUY;(^IW+0N4<K#$[@+D??9@O(!()Q6
MK\<_^4?_ (O_ .Q"E_\ 2.OD#_@D?^S'X-\<>"=9^)?BW1;7Q+J5MJ+:5I,&
MJ1"X@LDC5)7D2-LKO9Y>&(RNTD8+'.W+>I.-]%_F80E^YIS>[_RN>]?#W_@K
MA\!?'7B"+2KR;Q!X/\YPD=]X@L(TMBQ. "\$LNP<_><*H')(K[.M[B*\A2:*
M19HI%#)(C!E92,@@CJ"*^'O^"IGP#\$ZQ^S'XB\:Q>'M.L?$_A^2TDMM3M+9
M(IF1[B.%HG90"Z;920IX! (KH_V*?B_-X?\ ^"=&B>-=6=K]_#6BZB[*<Y:.
MSEG6*//^Y&BUGS1]G.?\OXFO++F@EJI:?,]3_:#_ &ROA5^S*([;QIXAVZU+
M%YT.AZ;$;F]D7LQ0<1@\X:1E!P<$X->,>!?^"NWP%\8ZW'I]X_B3PFLC!4OM
M<T^,6^2< %H)92H]V  [D5\??L'7GP;^(7CSQK\7/VA?&'AV^\57&HD66E^*
M+F/RF9E#O<&*3AP,K'&"-J;3@9"X^SOC9XJ_8Z^.W@>[\/>(/&7P^1FMVBL]
M2M+JVBN[!\?*\,BX*X(!V_=;&&!'%#3@DWJ[7L@TE)Q6BVN?7NDZM9:]IMMJ
M.FWD%_I]U&L]O=6L@DBFC895T920RD$$$<&O _B#^W)X$^&_[1.B_!K4M(\1
M3^*-6EM88+NUMK<V2FX.(]SM.K@#OA#[9KY=_P"".OQ>U*[T_P >?"N^U%=3
ML/#\RWVDRH^Y1$\CK,J'_GF7"./>1CWK[/\ %G[*'PK\;_%O3OB;K?A;[;XY
MTZ2"6UU3^T;J/RVA.8CY22B,[3ZH<]\U<HJ,XO[+_(S3=I1?Q+3RN>P"BBEJ
M2SSOXR?'KP'^S_X9&O>/?$=KX>L)&\N%90TDUP_&5BB0%Y",C.T' Y.!S7R9
M=_\ !9CX&6NH26R:/XWO(0VU;R'3;81,/4!KE7Q]5S6U\=OV#]?_ &AOVN-
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ME'TS1/$ET@MY6D+]8WX>.%%1%0Y7GD<"ONOXG>/OV.?BYX/F\-^(O%/PYN+
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MDG@ FOCK5O\ @L=\"-+UF2RM[+Q?JULK[5U*RTN%8&']X"6=),?5 ?:OG?\
MX*!_$#3?C;^W%X4^$WB[Q0OACX;^'7A&I7$TXAA662'SYI2QX#F,I$I.=I)Q
M]XY^P_"OQ4_8Z\%^$QX7TCQ!\,;30O*$,MD9+619UVXS*6!,I(ZLY)/<FN6%
MY1]I??9'3.T9<EM;7;]>A[)\#_VBOA]^T9X?EU?P%XB@UJ"W8)=6^UHKBV8Y
MP)(G 9<X.#C!P<$XKL?%GBS1O _A^_UWQ!J=MHVBV,?FW5]>RB.*)<]2Q]R
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M2EI%^Z/I2TAK8****!A1110 4444 %%%% 'R?_P5%_Y,F\??[]A_Z705I?\
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M\TH-=%;\3\Q_'7'_  6E\,G_ *8Q_P#IIDKN/^"U?/[/G@H_]3.G_I+/7?\
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MD1RO"J0NC$Q*F-S+E@<X'-?H9I.EVFAZ7::;8PK;V=I"EO!"@PJ1HH55'L
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MD9#*1=8((.<BO _CC\'OV'_V?_B9X?\  FN_#+6-1\1:TBO#;Z+JNH7'E;Y
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M7X'>!==\,V=G"BZLNJRSNUPT4<DB1H9+B9=P!).TC[ZY[5\C?L[_  G\1_\
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M))^6OVM/^"='CKXC?'I_BW\(?'MMX0\378C-TMY<W%FT4J1"(RPW$"NPW1@
MH5'\7)#8'1*:]NJB6EFOFTM3GC#FIRCMK=?Y'Z"4M>5_LT>#?'GP_P#@QH'A
M_P")>OP^)_&%B)EN]6M[N:Z6X4S.T9,DJ([$(RJ<C^&O4ZAI)VO<J+;U:/R9
M_P""@6@ZI^R[^VWX'^/NFV4D^BZC/!+=M'T,\*"&>$GHIDM\;<GD[_2OTX^%
M_P 3O#7QB\%Z9XJ\):K!K.C7T8DCGA8$H2,F-QU1UZ,IY!X-1?%CX2^%_C9X
M'U'PGXPTN/5M$OE DA<D,K#E9$8<HZGD,.:_/+5_^"3_ ,3?A7KUY?\ P*^-
MEUX?ANFYM[ZZN=.F$8^ZLD]KN$V#ZQJ.>E1!\L?9R6U[/]#2=I2YT];6/TC\
M8^,=$\ ^&M0\0>(=3M='T;3XC/<WMY($CC4>I/?L!U)( YK\Z/V.?VD/BQ^U
M)^VIXNU?1?$6IV?P>LWDNKC29T22 0B/R;6)=ZDQ/(RB5@A'W9*R8O\ @EK\
M<_BUJ5NGQJ^.C:MH]K(LD<%O?WNK/Z,$%R(DB8C(W -UZ&OT!^ _P$\&_LX^
M ;;PEX*T[['81GS)[B8A[F[F( ::9\#<YP.P & H  %7!<LG-OHTE^IG)WCR
M);[OT/SY_;8^)GCS]H?]LS2?V:]#\4W'@OPH6AMKZ2W8K]K>2W^T2/(%*F11
M&P58B0I89/4$>R^#?^"._P "O#KQ3:O<^*/%3 #S(;_44@A8]\"".-P/;>?K
M6U^V?_P3QB_:0\86/Q \'^)V\$_$&S2-3=,CF&Z,1S"Y="'BD3@"1=W"J,<
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MMJ$5U"^B3S2HJK%L(8RQ1D'/H#7UR.*<DEHF).YY+^UM_P FO_%G_L5M2_\
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M_07Q2_X)^_LV?LV?!'QAXOU/1+C5+S2],G>TOO$&J2N6N3&RPH(T,<;LTA4
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M ,DD9K8N/^":OCOXE>&_$NM_&+XG-\1OB'+I-U::!:W,TRZ1I=U+&56;.W)
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MG2)@/^!&C]KS_@G#/\:OB4/BC\-O&#>!/B"/+>5V\Q(9YHU"QS+-$?,@D"@
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M#XE:9X:_9IC\)272'6O$NI6ZV]H&&\Q0.)9),==H98USZN*\H_:N^">N:/\
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MG;^+?^"F?[7'C/P?XE\;7_AKX>^&WGE@T.R(_P!3#.(4VQGY3*Q.YI7#%<X
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MO_!/?]IGX$RW&E_!GX\V5MX8D+,EIK#SVZQ;B2<0B*XC#>KKM)ZX%=E\#?\
M@F+>V?Q.M/B/\<O'<WQ-\4VTB3Q6;&22V$J'*&264[Y54X*Q[448Y!'%.RE)
M-.RZ]QZQ33U?2QH?\%'M*TCP_P#\$]8].T'3Y]*T.T&D06%A<ES+;VZO&(XW
MWLS;E4 '<2<CDFO7/^">OQ(TKXC_ +)/P_DTV>.272+!-'O(58%H9K<;"K#M
ME0CCV<5PW_!6=?\ C#3Q"/\ J(V'_I0E?.?P%_88^(7_  I?P%\3?@'\49_
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MTVZOKZXCM+*VB::>>9PJ11J"69B>   22?2OB3]I[]B[P/\ M7>/9?&WPO\
MB1IOAKXJ:/(([RZTB\2<-+"=J^<(7\R":,A5\P<@* 5) (XRV_8._:4^+$=M
MX>^-/Q^6Z\!PE?M&GZ#<333WJ*0=DI>&$'(&=TGFX.#M-5S.<(IZ-*VOE_P
M=E4E+N[V['GW_!-7Q?9_$']O/XW>)M..;#5[?4;ZV)!&8I-0C9#SZJ0:\_\
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M,DL;J&5E(Z@@@U\U_M$?MS:9\"_C=X'^&5KX7F\6ZYXD,8D6SOEBDLVEE$4
M*%&W;SN/WEP%SSD5\[:/^P+^U-\%[>;P]\)_C[8P^#VW"*WU66XMV@#$DB.(
M0SK&>2249<GGBO8/V4?^"=MK\%?'DOQ+^(7BJX^)'Q*E+.FH76\Q6LC)M9PT
MC,\LF,J)'Q@'A0>:U5I3YOLKIW\C!W4.7KTM^9\Y_P#!1#YO^"C/P%^FC_\
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MQC& >:TQ/OM<NOP_A:X8=\K=]/B_&YW/[,O_ ":7\,#_ -2=IP_\E(Z^"/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %)2T4 %%%% "4M%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6EKXB4.B5S*#_P!FY]W>*^\V_P#AN+]N3_HW:U_\)'5__DFI/"__  5J\?\
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M-+N/%Z>$?C3X(O/AKK =8)+\"0P0R'_GO!(HE@7IS\_7G &:_1  8QBOG?\
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MQ#+);C_EO*99Y/E<_<4 <#=DAA7T;5>WMHK*WC@@C6*&)0J1QJ%55 P  .@
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MX%^,+CP9H&B7_P 1?&=M*+>>QTR00V\4V0/):;:Y,G/W41\'()!!%>2>+_\
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MXB\067A?0=1UG49UMM/T^WDNKB9S@1Q1J6=C] #7SK^Q=^V/?_M@:?XIU9?
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M\,SZIX,OY$O;,A;_ $;4$6*]M"<[2Z!B"IQPZDJ>1D$$ Y6U= W8]II:\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 )2T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%[]U;1A6BHPG..TE]S_ ."?K#_P54CNY/V*_%_V;F,7%@9\?W/M<7]=M/\
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M=HQN?#KQ9>?ML?\ !-'6=-MW:_\ %T>C2Z1<Q9R\U]:A7BS[RA86^LGM7/\
M_!'_ .-NBZK\';SX77EXEGXK\/W]Q/%IL[;99K65MY=%/)V2&16 ^[E2?O54
M8\E6I'K9?<1*7-1IOSU^[K\SW/\ X*#_  1T'XP_LS>,YM3LH6UCP[IMQK&E
MZAL'G020H9656ZA75"K#H<@]0,>3?\$;1_QBOJH_ZF6Z_P#1%O7K_P"W]\9M
M!^$/[,?C==5O(8]2UW3+C2--LF<>;<S31F(E5SDA Y9CV ]Q7D/_  1K_P"3
M5]5/_4S77_HBWJ*5OWO:R^^^I5;X:7>[^ZS/(/@M"?V._P#@J!XC\#2?Z'X2
M\>JQL%Z1CSB9K?'^[*LL _WJ]Q_X*T?&9OAU^S;_ ,(O8W'EZQXSNUT]5C;#
MBU0B2=@.X.(XS[2UQO\ P5T^&U[:>%? WQG\/*8==\&ZE%'-<1CE87D5H9#Z
MA)U4#_KL:\GF\:0?\%"_V^?AI'8_Z3X)\)Z-::Q>0\&-7"1W$ZD<\F>2"!A_
MTS/I4PC[:$*;^R[/_"M4_,N4O9SE6[JZ]=C[J_9-^ \OP7_94\-^"(96TC79
MM->>^O(T#20WMPI=WP<9,;,%&>T8%>3?L[_!/X+_ /!/*Z\1R^*_BIX?F\4Z
MY()4OM>F@LKU+0#B)(S*S,"^YF=0-QVY'RBOH+]J#Q[JWPN_9Z^('BK05!UC
M2M'GN+5BNX1R!<"0CN$SNQ_LU^<G_!.?]D/X8_M5>$?$_C[XHW=[XY\3MJKP
M7&GW&J31F(%5<33-&ZRN\A9\,6VX4C&0:TO*=6<HZ::_?LC.RA3BI/=_CN>W
M?MA?M[?LW>/_ (&^-O!<?B'_ (334[^PF@LK6RTN9UBN]I\B82RHD8V2;6W*
MQ( . >E3_P#!&6\FN/V7_$$,DC/';^*+E(E/1%-M:L0/^!,3^-:G[6?PS_9W
M_9/_ &<?%TFG^"?"VB^(]4TJZTS1-UK'/J4EQ-$8MT4DNZ7"A]S,#P!ZD9Q/
M^"+LBM^S1XJC# LOBJX)'<9M+7'\C3I6M5MV7YE5/AAZ_H?//[)/PFT/XJ?\
M%-OBF_B#3H=4L?#VIZQJ\5M<1AX6N%OA'$64\':92PSW0'M7ZX^*/#6F>+_#
M>HZ'K-E#J&E7]N]M<VEPH:.6-E(92#VP:_,S_@G[Q_P4<_:$_P!_5O\ TYI7
MZD2?</TK.2_V:"?\I4F_K-1]4_\ (_+3_@C3(^B^./C5X>CFD>SMVLFC5ON[
MDDN4W8]2,?E[5B:/H-C^UY_P59\36?BZ,:MX;\'F=(M+N1NA=+(K$L14]4-P
MYD*]&R0<@UK_ /!(''_"ZOCC_P!N_P#Z47%8WA_7K/\ 9(_X*N>*;GQ=*ND^
M'?%YN6BU2Z(2%8[PK,DA8\!!.AC)Z#!)X%73;E4I.7\K^_I\PJ*WMDM+26W;
MJ?J_+IMK-IKV,EO$]F\9@:W9 8S&1@H5Z;<<8Z8KY?\ V>?V'='_ &6?BMXX
M\>:%XINVT?7(YL>&DM%BMK2(R"1%#;B7,>&53A?E8C%?4-QJ%M:V$E[-/'%:
M1QF5YW<!%0#)8L> ,<YKXS_9[_;:\0?M.?M,>/? .C:)I-[\,-'BG\OQ%:B5
M9WC&(T)8N4;S9"[+@+\BDX.,UG[UY<GQ69.G(N;X;K_@'P?^RS^T/\)YOVI?
M&_QB^.=Y-)J$TYN]#@ELI;V.*9W;#856P88U1$SP,@CE01][:]_P5 _9?\3:
M+?:3JVO7&IZ;>1-!<6=UH%S)%-&PPRLK1X(([&OC7]A'0/AQ\)_VG/B!\'OC
M3X4\-ZC?W%RMGI5UXHTR"YC2XA=]L:-,IV">.164\!MJ#DLN?TVUK]FGX!^'
M=)N]3U/X4_#FPT^TB::XNKKPW81Q11J,LS,8L  =S5RM[*/\MAR_C3[W_JQ^
M=7_!,WXCZ)X:_;3\>>#O E_<7'PX\1QW4VEPS*Z8$+^9 Q5_F!6(RID\GC-:
M7PO\/V7[67_!5+QU=^,+==7T;PBUTUMI]V!) 5LY$M84*G(V^8YEV]"V<YR:
M]Z_8U^/'PD^-'QU\3Z5\-_@-X>\*0>'HYC%XTTNPM(#+"7,:<);H\9F&2$W'
MY0V>E>"_#_Q#9_L>_P#!4GQK%XSG_L?P]XR-R;;4[EMENJ7DJ7$4C,>-@E1H
MBQX4Y)P :NG_ !*2?\KM?J^GS[$R^"KWYEIY=3]5-<T#3?$FBWFCZM8V^I:7
M>0M;W%E=1+)#+&PP492,$$=C7Y0_L<_"VR^"O_!4KQ?X-TTM_9FF6]]]C5CN
M*0211RQ(3W*I(JY[XK]8-4UW3]$T6XU?4;ZWL=+MH3<37EQ*J0QQ@9+LY. H
M'.<U^4O[(?Q0T_XS?\%4O&/C#2OFTO4+>^%G)@CS(8HHX8Y,'IN6,-C_ &JS
MI?Q_^W97_0*G\'RNC]1O&WPX\)_$JQM[#Q=X7T;Q58P2^=%:ZWI\-Y%')@KO
M5958!L$C(YP36MHNBZ?X<TFTTS2;"VTO3;.)8+:SLX5AA@C485$10%50.  ,
M"LKQM\1_"?PUL;>_\7>*-&\*V,\ODQ76M:A#9Q/)@ML5I64%L G YP#6KHNM
M:?XCTFTU/2;^VU33;R)9[:\LYEFAGC895T=2592.00<&A;.P^US1HHHI@>2?
MM:_\FO\ Q8_[%;4O_2:2OF?_ ((V?\FKZK_V,UU_Z(MZ^F/VMO\ DU_XL?\
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M@I\.M*T7Q5H1,<.MZEF5I;.52[W161'V$1Q!005_UF5)SQ7S/X:\16?[&_\
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M)8PCQS$#JY5G5F[[4K].?@Q\7O#OQR^'.C^,/#-_%?:=?PJ[K&X+V\NT%X9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3>I <#U4X8>X%=9[4G>KJ?O/BUOI^@H^Z[Q[GR;^Q)^P+IW['5_XGU)O%/\
MPF.KZU'#;I=MI@LOLL*%F9%'FR9WL5).1]Q>*^L\=:=10WS;B2LVSX[\!_\
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M G<1FO=J6BK;ON0E8****104444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 E+110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %)2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
7 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>oncyf-20231231_g1.jpg
<TEXT>
begin 644 oncyf-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" (; I\# 2(  A$! Q$!_\0
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M%ZS.0*N^<95(]:I2V+>9\O/-!!>TFY9E^:K5U<;!4>E6+ #=UJQJ%IN@/;%
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MI7_@CQ!Y/_!0OP![_P!H_P#IMNZ^:K>;SACK7T]_P2(BV?\ !0GX?'_L(_\
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M%^R1^V3\+=+N_%GB6]^*FJ>';C6I[06,9T<Q2V\J-$L@(D1UPY!.X,(SG:6
MKRCX _L0>!OVF?$NO7&L:E\2+C6M6\7:EIS?V#HH_LW0@+F39+=7,R['#<<1
MDD9 (ZD<;X,_X*X^/O#1\)WDGAKP!JWB/PC8C2X=?O=,9M2NK,*5\AY XV@G
M#,4VEB.V6SD>%/\ @ISXT\%_#O3-!B\,^!=0E\/ZU<:]HVH7UA)-/I5S/-),
M[(OF!&8&60*S LH;N0""S.?V.*5Y7U=E>Z\_+;5?UH:_AS_@GIX.T;PM\=M6
M\=>,/$-C9_!/Q#%ILT^D644QU"V.PDK$_29PZJOSA58Y.0*]D_9S_80^%'P]
M_;$^%LDM]K7C+P;\3/#LNN^%[/5K&!PTR0[Y([U< %5C='0J!\XP<@9/'_#K
M_@HMH>H_ ']H+7M?T_P%8^./'%_I]S:^%IK&2XT_7MBQ1SEXW)W;U#[B7!!Y
M&"!7C>M_\%)?B#XF_:+\'_$2&S\-Z--X#M#IVAZ+96C+IEG;,A22+9NW'>IP
M2&! 5<8VTM0Y,34YHMVZ?^2K;3OU/H7P9X6\-V?A']JYOACXJ\8:;X?TK1Y9
M-9T^\TZR07ER);X2V\9V,4@5%V(RE6PY]!7-6W_!,_P;??&C26B\4>(?^%47
M_P /G\=3:R?(^UP(A :+.SR\C<AQMSC(]Z\RUW_@H=KVHQ?$:'3O!?@/P[;?
M$[2UTS5H=,M)857F=FN%_>?-,YG?+,"#A>..<RT_;Z\:V/[)4GP>CM=#.AR6
MKV U,PO_ &G':/.)FMP^[;Y9/RXV_=./>JU-/J^(6L=+V[;62OZH]R_9[_X)
M3>&?'_P8\&^)/$FL>-;:Y^(43WEB^EQV7V+P_;-S"]XTS*\A92I/E#@DC  S
M7SCX(^'NH?"W]M[0?!ZZPL>HZ'XUMM+35+)4D4,MVB+/&KAE/&& 8$=CFNN^
M%O\ P4'\1^!/A?H/A75/!_P_\<6OA'S!X>NO$6EFZN-&#YRJ$, RC/ 8= !D
M@#'C^B_$"_\ "GQ7T[QE#;V+:IINKQZU'"(!#:F9)A,%\N/:%CW#&U<8' Q1
MJ;4Z==.?.]'M_7H?8WQX_8Y\-_%7XP?M)>-OB1X[\5?\6OO=,,U_9Z?:O-?0
M/:1.R^2JHGF!0(TVE1G!;/-7+'_@E]\')?C!X+\,Q^/_ ![N^*F@MK'AB+^S
MK??:JD/FNUU+C!!4C:BJ#D,"W0U\\^,_^"@OC+Q]I?Q?LKK1_#<,7QH:V;6&
MBCFW6?D1+$GV?+G&54$[]W.>E7H/^"C_ (RL/BG\,O%RZ-X:;4/A7HKZ%I<)
MCF\FZA:(1%IAYF2^T9^4J,]J5F<ZH8E1LG;3R_E5NG<[7X=_L+_#K3OV>X/'
M7Q!\7>+-/$/CJX\&W$&C6D4XNF2X>WC:,.,QY9=[,Q;"@@*217;^+?\ @EG\
M.[#QU\3/ 6G^/O%EQXY\&Z WB>T$NG1)IZ6I7,<,SCYI)20-S)L #*0"017S
MCK7[:GB;Q%\%O^$%GTW0TTO_ (3"3QIYZ)+]H^UO,\QBR7V^4&<C&-V,<UU&
MK?\ !3CQM)\>/&7Q"_L/PO\ VQXX\.CPU>V_ES_9X+<  /&/,W>9Q_$2/:C4
MJ5/$W;4N_;NK=/4U](_8%\,WY_9?9M<UY?\ A>L;R:L,P_\ $OQ%&X^S_)ZN
M1\^[I772_L _#'P'\-?B/XL\6^+O&ECHOP_\>3>%BMA:07-Q>VR>4J$*0H$S
M-+RV=H53\I.!7G?P=_X*>^-OA?\ #CP'X;C\,^ ]8F^'+;-"U?4]-:?4+. \
M-$K;P%W(-A=0&V^_-9GQ%_;?\3_$OX3>-O"%YIF@PZ?X\\3MXKOI84E$T%RS
M1L8X\N0(_P!VO# GD\T:E1IXERLWI?RVO_D>XO\ \$D=,NOVN==\(P>*-9F\
M%Z'X8@\4M/%!$VJ3QS/(B6J!ML>\M$YWL ,8! )R/(OV\_V)=)_9?T7PAXA\
M.ZGK4ND^*S-#)I6N?9_[5TB>, [9?L[-&RLI)!!XQU.15S4/^"FWQ O?CHOC
MM=-\+K/-X?3PQJ&DO:R3:;JMBK,VR9&<MDESR&''&,$@^:?M _M!2?'JYT=5
M\(>"?!FFZ# T%G8>'=,%K& Q!8R.27D.1P"<#)P,DDGJ51IXKG3J/2VOW?YG
MFR+A?K52X'[WVJ_(O%59(]SU3.X? Q\O%9]Z&,G(K:L;;*_-1<Z:K?-2'8S=
M)1D;FOJG_@D3)_QL&^'X]?[1_P#3;=5\QQVPC-?2W_!(D_\ &P_X>_\ <2_]
M-EW0SFQ7\"?H_P CYC@N_FJT1NCK#+,&_&M2PG9H\-0=!#>/M>BSG8O@U+>6
MWF?,*;;6Q5LT 743<,]J;)\E.#86HY/FH*Z%6>8FJMU:?;(]K*&'H1FKQM]Q
MJ2.+8.!02<^FA1QR_P"IC&>#A>U;FC0_9T"J-J^E3- KFM_X7Z9!J/Q)\-VU
MQ''/;W&KV<,T3C*R(TZ*RD=P02#]: VU,2YCB*;=D>.N,=ZK^6K,S;5+-P3C
MK7Z-?%OX7?";Q#_P4BT7X$Q_#CPOX<\/R:C;ZM?:I;LT5YJ4@L9)5L4Q@10.
M?+!1""Q4GJU5OVL/@M\+9/ARTTWPZN--U?1?&MGI%H/"O@_4M(_M&T:YCCEL
M7DG'ES3O$SE)5(#,$VD9.5<X?[0BW%<KU2?W['YX J"ORK\GW>/NU-%Y97[B
M?E7Z(?MH_L^>%=1_9V\6:YX'^&_@72]#\)W%G$SW.B:AH7B+1<S1K+O,W[N\
MSDKP0N&SESC/JFN_LF^ ;G]K[5OATWP+T&R\ ZWX3.JW'BN*UEC:QN5^0+!+
M_JX<8R57#EB6)(XHN3_:4;7L^O;I;_,_)62.-GRR+GL2*<RQ'DHN[KG'?UK]
M$O@1\ ?"7@[X-? 5=*^$NB_%2'XKZC+:^*M?O;22[?2HO,VYC9?EM]@W')P/
MW3?Q'(QO$/P>^&'[-?[.WQZ\26_@7PWX\F^'?Q$73M%_M<O(L<3+:#[/)(A#
MO'$TT@V$X9E&[/-.Y?\ :$>;E2>]NG>WRU[GP%,J2\$!E[Y&14D4",VY57.,
M9QSCTK])O%_[.OPA\$_MXM)>?#6XNM!U#P!;^($L-.TB?4M*T>^>=XS<3VL'
MSF(J%&U01D,=HSN72\/_ +$7A/Q5^UOX;E\5>#?A]::5>^#KW7=-L_#T-W:V
MGB.YBEA"F:PEQ)%Y<<RGRUW%R3DG;M"YB/[2@M6GM<_,9K./;CRTV@Y QP*1
MX%^8[%^?[W'6OL3_ (*+>!/ =A\&?!/B31?"Z^&/%FH7\]K=MIWA6_T'2M2M
MU#\I%= 8DC94!YR=S'D8Q\?-R*:9V4:RJ1YUH026Z%1\JY7A>.GTJJ-.C8G]
MVAS_ +-7F&!4#3;7ILT(+NW6-&^5?F'S<=:KVT"F51M7:I^48X'TJ].OG"DM
MK3#_ $I 7846*/"J%7T K'U\Y%;"G"XJAJ=KYZYH&SG+:)GGK>T_3_EW&J\%
MCY;?=JX+AHA@4$EL#:O%)&?FJ.&YWCYN*DCE5FJADQ&16?=QX>M G%0R1B0U
M)3*,2E7S5E;K%)+'A>!5?;B@DNK)N.>U).-RU';YJ4 L*8$, R]75&!4*+M/
M2I@<TBEN1.<M3XZ;(O.: V*HD62+<*I-PU7E?BH)HMQI#'VHW)3I(\K1;KM6
MI'% &7+;X?\ &K%J-BU*T:E\T\#:*+"%CY-/,65ID1S3WDPE(I;%*==KU&SE
M:?)^\D-$\/[CWH BBNL/5\2[EK)B3:]:,2DQB@D1Y1NJ1.M AW<XIPCVTP$$
M*L:JW\0B;@<5<1JI:O.%7WI 0VLV9!6HJY%85NW[W\:V+:3,=" >_P M0M/A
ML?G4S_,*KS18&[%4!Z-^RG^R_K'[7GQ>C\&Z'?Z?INH2V,]\DUX',1$07*_*
M"<G<,=J]$T#_ ()H:[XG\;:MIEGX^\ W.E^%M)74_$^N6]V\^G^'Y&>1/L;L
M@)DG!B<X48QWY&>7_8'_ &IM/_8^_:'M_&FJ:3?ZU:0Z=<V)MK.1(Y2TH3#9
M<@8&T_G73?L1_MVK^RI>>.+"_P!.UJ[\.^/4 N9-&OA9:IILJ-(8YH)#QN"R
M,""1R%.>H,G'6]O>7L^RM]^OW(OVG_!*7XA:A\;M#\):;JWA?4M-\0Z*_B&R
M\1Q32#3Y+%"BN^TKYF\-+&-@4_?!SC.*VD?\$[KSQ=\<_"O@?P[\2/A_XBF\
M6Q7DD%Y93RM]A-JA>1;B KYL>[&%)&&.?2NDU[_@H-X;\0?M#:!XDFT_XL7'
MA_P[H\^G6LLWC23^VH[B;;OO%<?NU)50#%G8Q )Z!:]W_9Y_;?T']JK]OCX/
M0:?H=_I\?A.PU6.;7=>GMWU75=]FX"S/$JIM7;D=<D]!SE:G/.KBHQYFNC?3
M>S_X!\M_$O\ X)Q>)O!GP?N_%VE^)/"/C)=&U>/0]:T_0KIKBXTB\>18EB<D
M!6;S'13M/!;N 2-[Q;_P2C\7>$-#\01P>+O ^L^,_">E+K.M>$K&[=M2LK8K
MNW9*A68+S@8!XP3E<]'\6/VZ?"OPR^'?C7P3\,_!FJ>'M:\0>,3K6MZA?ZDM
MY;>=:W@D46P #>6SPJ0&QM5F&6."-+Q7_P %1/!<FM>-O'?AWX=ZWIOQ8^(&
M@C0=0N[K54ETFS78J&:*,#>S81#@@9*+D]<O4:J8IK1?EY;Z[;[',^!_^"4_
MB/QI9^!I&^('@#2IOB-HZZKH-I>3RK=7K&(2M"L87)*(06<<#(QFN=^&W_!.
M/Q-XL\"Z]XF\2>*O"?@+0]!UR;P[)=:K)+*LMY"YCD4>4IVQA@1O8C.,XQS7
M3:?_ ,%$]!L_B)^SSK7_  C.M-#\%M&?2[V+SX=^I,ULD(>(YPH!7/S8.#6I
M\ _^"C_A'X0^,O%6MW6B_$RVN-=\4WGB(1Z/K\0L[Z*:3<EK=6LH,7RC@O'\
MS9/(X%+4<I8NW_#=W^ENYP/PQ_X)]ZYXUM_%VJ7WC3P-H7A/PCJW]B2^(I+M
M[K3]1NSM^2V,2DNHWKEC@ G')!QY[^TK\ /$/[,'Q7O/!_B;[&]]:Q1W,5Q:
M2&2WO() 2DL9(!VG!&" 05(KZ!^'O_!6?3-+D^(&D:IX5\3>%_#/B[7_ /A(
M-./@G5DT_4-'D*1H\18@(ZR>4&8C'S._!R"/GK]J3]H!?VD?C3?>)K>'7+/3
MVABM;*WU?57U.ZAB0'[TS\\LS-M'"[L GK0;4)XAU/WBTMY>7_!.#;Y337CW
M4!LU*@W"J.U$*Q;#45S;^8?I5FXD$0JLU^N2HYI"'646Q\U::;BJL,NXXJSL
MR*"HBJ_S5(6W#M4&,'BE'- )C9FVU5:97D'M4FH-Y<6:SEN<R4"-^R?(I]W-
ML6JUG+A!]*29BY]:!D37&YJ^EO\ @D."?^"AWP]/_82_]-EW7S7!9Y/3)]:^
MFO\ @D;&(_\ @H5\/>>?^)CQ_P!PR[H.;&?P)^C_ "/E^73\G(J2WMO+%6G^
M49Z&JLUX(C0=.@^9MBU$ET-W2H9;U9A42YWT$FB7RM-S4<&2O-2;=U,!R&G'
MBD5,&GA>.:12&]ZFL[V;2[N&YMY)(+BWD6:*5#M:-U(*L#V((!!]JC4Y-22Q
MYA]Z +7C/XH>(O'?C)O$6M:]JVJ>(&:-_P"TKFZ=[O='@1GS,[@5 &"#QBM;
MQ[^T-\0?BW;V$7B?QQXKUZ+2Y!-9I>ZG+*MM(.DBY/#CLWWAZUQ<JJDV,K[Y
M/2IPRQ1K[]/>@SY(]CL_''[3/Q$^)>C6>E^)_'/BSQ#I%G-',MC?ZG+-"2A!
M4E2<,1C@MG%>M_M>?\%"O$G[1OQ+U;4O#.H>+/!OAG7--M[&^T,:J?*NC&&5
MF<1D*0RD ^H&#D<5\VB=6DQ5N( 4$^PIN2=MOZ_0ZKPA^T3X_P#A-X=NM+\*
M^-/%'AW2[PEI[33M1EMX7)&"=JG )'4C!-<Q:?$OQ+;>"K_PQ%KVL)X;U:Y%
M[?:6+I_LMY."I\V1,X9\JIW'GY14-P%E&VJXL\&@IPC>]CO;7]I3XB0^+K7Q
M$OCOQ8FO65HMC!J"ZG*+B.W&2(0P/,8))VG(YK.\2?'?QSXG^(%KXJU#QCXF
MO/$UB +759=2E-W; 9P(Y,Y0<GA< Y/%<L7*"I8(A+VS0'LX]D;?Q(^-GC#X
MR:E;WGC#Q1KWB:XM4*02:E>/<>0IZA QPN>^ ,]ZPX7W&DN[78M9[WYA?K^M
M!2BHZ(UY$RAJC+$=WM20:TKKS2B[$K^U [CE_=QY-1K?[6IFHW/[KY:RDO/W
MGXT".@CD\P4XC-,TU=\.:GE7%,97>)0*IS+\_2KK9S3/+!/S<FD(K ,HI0Y!
MJPZ97CBH8X@S<F@"5+C/6E-T*;)#C[M1^4=U ]"S'^]&:5K5<TVT!2IG;"&F
M!5EG$;845)!.'%9EY.1,?K5G2V\VD(N@;C4L:4B1XI_W%IE)",N*B=MM/>3)
MJM>R;%HZ"8])=S4\+NJG:R9DK4CCP@HN"&)'@4QS5@C"U!(O-"'Y#,9H89%%
M."[A3)&@XI&&ZG>7MH7EJ-P&1P 4EX0D56Q#\N:IWL>ZD44T&7J_&>*J0P$M
M4\TPB&.]!)94\4USQ4=K/YM22+F@9&<MG%9E^"S5JKP*KSV?F-F@11T^S:66
MM9(=BTVVA$(HFNMHP*!Z!+)L--D.^,U5>9I6S5B#YQ[4A%/HWO5RWA+1"OJ+
M]E?PC\,OB1^S;KVEZYHL%UKMF[RWEU;KC5K,%OW-S"W>(9",N"H8$,!O4UY/
MXZ_9TUCPG/<-IN[7K&%3(6MX2MS"GK)#R1[E2R^XKP,/Q)A)8VI@*UZ=2+LE
M+1271Q>S3[;^1U_4JOLU5CK'NNGDUOI]QYTL6PTK)QS2N<.1W4X(/4&D5M[5
M]"<A'<2[!4,#[W_VJ-238-U4K:X;[0&[9I ;<<6%H=,K@U-9#S8NE=1X3^%<
MWB_P)XM\0/<?8]/\+V8F+%-WVF=F 2$'MUR3[KZUE4J1@N:?=+YMV7XLM1OH
M<)-8;VXI8[7RF]J?#,2U63#FM";$*MB@7&U:D>/ J%H<DT"*.I7S-)M["HK,
M^?-Q^-+>0%)#4NCQ>5)\PH TK2VVCI5E6X*]*(Y<1U&[G=063+;9/%!C\H?2
MFVTGS&GW*L4H QM;N]L++65:SAG'UJ]K<+!&K'B8QR ^]!#W.JM3B!?I3O-5
M6Y(K.MM2_<CZ4TS[WZT ;D<RK%Q7T5_P2,EW?\%%?AX/^PEG_P %EW7S/9%G
M6OIK_@D3#_QL.^'K>G]I?^FR[H9CC-<//T?Y'SCCS!6;J4+*":T+=^*;=*LB
MD4'0<^)MIJ_:74; ;AS4%S8E&.!5<Y5O2@DW(I%D-6((MQK'L)6\S;6U9M@4
M%(D:W"#-0VUK-J6H0VMK#-<7%PXCBAB0O)*QZ*H'))]!6OH6BW'B?4H[&T56
MFD#-EVVJBJ"69CV  SG^N*]O_8D\/Z6OB^\U16ACTS20T=[JLRCSIY1]ZUMA
MGY5[2/U !7.20"YQ8S'0P\==7T1@_#?]A;Q;XELK;5/$6WPCH<V6\VZ7S+MP
M"0=L .1TZN5'(ZYKWSX<_L _#&;0X;KQ%=:]Y,*[FN!J CEOCCG9$J8C4]@6
M)]S6?\??C#_;.GWFJKJ>U;<C[';1JTD84' W[1W]L 5XC<?%;7/%TLDUO=76
MK7%NHE%Q,AAAC]4=&+9"C.-H!]\TDFV?.U<TQ%5Z.WH?8/B;Q%\*? WPYL/"
M>AZ=IMO#'$(X[+4+>-_M W#+R%E.YB1DL<D_E7 :7X8^%]Y?7&BP_#O2]0DU
MB7-U<16)9,>J.W^KQV\K9S[U\NZ-XSUZ[^)]D_B-;(6<*E8RKMY0)^Z_))8
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MVM:M::;>V.GMI5GYXDN]P2ZN';9;V:8'^NG?*IGCY23P*XS23OB&ZO8/A_\
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M3TMMIYH-K!;VBQ**^D_^"2+@?\%"_A\O_81_]-MW7S=)/Y5?1/\ P2*DW_\
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MM@L6%<3\.?V4?^%@^'O!<[>,=$TK6/B))<V^@:7<6MP[3S0S-"5FE12D",P
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M-TO28E2)HN6VJN /K[^I-?F7'/%=+&91'#X;2<VN:Z?NVZ;:MO:W1:V/;R_
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M7P/^V-=?#H:;'IG@_0%M=!U:?5M+MGOK_P FU:?;YBR(LP%P?EPCS!FCW''
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MK;\;EO%.A72,TGEVL[S0D _.VT\'U')Y[5\Z-:"&:XFU76ETIKI\1G.UH6.
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MH^#^B1PR^/(;R\3QU\3]/O-,MUDTU]-UJXCT\6SB5(?[1S#+Y4@AAE:+<55
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MKN%^8G)SJ^)?VIM4U_Q%KE]J?A[PAJMKXJC@;6M-N+.4V>IW$))2\(64/'<
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M/6G@Y4DITW[OXO\ R\NI]R?"OPQ\._%-];S7G@'PO+JEQ)Y(E@.XN!@Y /
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M?LCW5C9W#:U,NB:I!;&^US49E#1^&[$9+1 GC[0R@[AV.%Z*^?F;XL^(]/\
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M[CPE+;Z=! VM7(L[9XWA=<>?(,,$))(.57GBOF,1M/(L:*TDDC!551EF)X
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M>I\X_"">\N_A_INE^'9O MI8ZA+=0^.'U@6YO6A,B&!0L[*K6;1@API)#*>
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M!LM/'9'V_*V/^>:80=RU9_B/X^R>/=$NM)\26[76CRNDD=K"Y@6 IG:$V\*
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MDS0L L4(^9BX[#MGKD@5[5JNL>#[SQ3<:+?W^GRR>&XT/]D6TJ.--! *RSQ
M@[B"""1@ CN:^OR_B+-I1]FJG*EILE;YZVZ;6>I\KC)4*=1Q4.;3?=V\E^K-
M3X2^&/ WPG\(;O"FDR0/*"S74T+RR7)[GS'!.">_?KBM2/4]:\7W%U<-L;1K
MR%HI[.9]R3*PVD*V 4.,]017#ZU\:?#_ ("N\1W&H2"$#R1;V\C,_'3# #]:
M^>OC5_P5PTC0;R\DT&"P\1:H$\JQM82WV*U/>6ZF! F;_IG$"!W>L<REF>*J
MQ5"?/-VT^S;^9O6UNE]]M3RXX%/WHQ^;W].GW]/(E^(/[/#_ +*USJ%P^K--
MX6U;SI;(S ;[.Y8J0I !*9"KN9>#L# @BOGWQ-X!\2>'/&6B2Z+XHO=<B\:7
MUK=W<VH67VF;^SG@NK9[6SOTB$5M(@G>3;&0SAY#F,YS[OH?QMU+]L[X)6=[
M?Z;';QMJ;V4MO*52221(T8'3V) D,9RQC89?<RY#*IKR_P",7P^\2?"_PC=:
M7_R$_#M\XG7S;1[K2[H]&AN(%*G:V 2G#J0#@D$'TLJS+$8)QP./T2=XWOIT
M?>ZT7?2^ZT.G%9;%477HOFFTXRY6M=;I:VL[7:O;WK.\=SYR_:MO+WP5K/@W
M5M%OO#.N6NO1QZ1KOV LFA:CJD$5O]MC1U(_=^;(K%D.%D!*,,#'S/\ MA_!
MN\_:$U%I-:UJ33[719UN;31+&2410W@PDEW/<R.TUU=,$6-99F;9&H10!7I?
MQD^#/[1'Q_\ VC/!?B1=/\+7WA#X?(^DZ%X8\,6PL;+1+!R')C4R%FFW(@)D
M4 C/0UW'Q,_96^(VH74UUX>\#Z[J5PKDF*^>U38SDLV8HY"SE<G Y_0"OUC!
M\0TI8+ZE6Q47!M-Q]HE%O3WN7FM?;>[T78_",VR[,*&,E/ 4*D82;=N26E^C
M;7ENK+7L7?V"++P5HWPXAM=0^'VB>(-4M[DL]]J%HMT\I!^4C=V![8QQWK[-
MLO'2_%#15T>\T6*33]/"K%!;I]G^Q* <",I]WM@8P/TKX,^!UEK/[/OB]M/\
M0K<Z)/M$LMM-;D,L9)'W&^8 'HW/%>OZ#^UK)X3M9KR9K>Y5GPT:JWES*/\
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M[ U\=I936S-'*C1RH2KHPP4(Z@UUG@;]HF3X52M%?:6TUY<I:V%C>6]P85A
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MJ1_,*DNAF(LOI3KCPYJNF^'+/6)M-OHM'U">2VM;YX66WN98\&1$?&&9=RY
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MIF>2,.[/R>%$6 !C.:\M^)]Q#?Q^'+W3+A6OK56T\J[*[,5!SYB8P 5QM4C
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MTKFIU2*?Y8UX.1QTHW+J4.:5V_Z_R_4CTR&2:[FFD6-7N)&D8)&(T!)).%4
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MHW>24=4X^JL^UC<\1ZQ9ZYXFNKJQMUM;60KL01+%DA5#/L7Y4WL"^U>%W8'
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M<JG*HSE?FIV=WR:V7-LW:]O)N_#^/+3PWXIT^WLM4TS3_#]NO""&R2T:!B,
MJ^T,>><-N!K@M=_9IU;3;_?HHDU"QF+&W$I5)W4?^.,?H1]*]W_9Z\5:?\:+
M%KC6-)DU^6-4FB+J%MXQ_=53@9SGZ$&O3M>\=>'=!233K[3K>&*&,^7:>4-R
ME5)PCKGYAQ@[N*[OJ[:O \["X[$4_P"%+F79Z_K?\CYW^+GPEC\(:%K4>H:%
MH.CZ;;Q6_P#PC-Q!(QU+4G+_ +QIR6^;]WDN"H"-M"GJ*\:_U<OE]*]9UWQU
MJ4OBR/2)+J/6]%O97G1;U=[*#_%O^\F.G!X(]*U-&^!.AZW!_:DOVB&WMI!&
MT(EW><V,X)P"/PZ^U?/N*P%)NK*4E=N[UM?I_ET]#[/!YU#-:RBH0I22BK1T
M3LDF];ZNUY:ZN[1YAH7@#4?$?%C:W%TQ./W:9 ^I[5UNE?LF>+M13S6.G6K=
M0DUP-Q_+BO2O^$WT3PK:@1RS;8QM\I L:H.V!_6H;OXYZ>L?[FX55V_*9#E<
M^A/:O$K9WB9?P8:>>I]'3RVC>TI<S\OZ_P CR'QU\&?$/@RU:34+-EMQQ]HB
M.^+\QT_&K'[.IE3Q!K5G;:A>:/<7UE]ECUJT4-+I+[PV1R#AU4J2K!L=#UK)
M^)'[5^N7=G=0>=]CT^-_*BG$JF2Y;OY?52@Z%FX'3!/3Y_\ %GQ.U8VDTL.H
M-##O.VVM9/+5<G/(&,GWK+$9Y.K1EAZD5=Z73T_X?YGTN3\)U/:0Q7/R*+35
MXINZ>ETU9KU5O4^UOVE/L/P+_:@^&_Q:MKZ:_P##OBFV3PSXHNGP7N62)89)
MY,<;WBVR_P"] :[[QQ^QU#X0\5ZA=6,FFZT_V:673K+4F,5K<W''EAV4@%,$
MG&0"=H)P37R7^S;'XL^/G[.OB[POK6A:U+I]Q$-6T"\NH)/L]Q=VY+B-9",?
MO$$D>1UW]Z]NNOVB;GQ1\&]4\;:'XCUKQ)8:WJD&GVVC7D'EQ^%!%ES%L P
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MJ:UN$\GQ=25/!8A-QWM9V?9V>C\MSZM^%G[./_":Z:)M2O%M8MH(AA(,G/\
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M59$FG6\JPJ?:M?Q=\1)-;\.^%=+G@CMT\*VLUK!+&QWS"6YDN"S>A#2$#'8
M]:L6=GYM[9V,,9FFNYXX$C#A#(SL%"ACPN2<9/ ZU[1\6?V9?#NJZ=HGVC3;
M3PLT/Q!LO"FIW&EC4#!:VLRN)%EGO%$<TT;1@>=$%CR_(QMIZD5JD*;2D>8>
M"OVDO$&C^+M,UN\U>_U^;26D\N#5[R:[A>.2-HYHR&;(5XV93M(.#G.0*Z+1
MOBZ_AO48_$7@_P #0Z;HND0S:?JI%U<W'VJ.]4QF*:[!5HLJI\K9M92I.6.:
M;\/+.'2?CIX/GNO@_%X3M=-\=V^CF2YGO?LTZF90L,RS/F2XCQYGF(RH>C(0
M0*Z:XL=)BC^(.N:YX/\ [,M="\2Z6DNEP27EM%>6SW=Z)R5DD)+.L> W12OR
MXYR75C'VD9:<O;KW=K:/S//K/XSPV_CIM0_X1F2;29]%N]!N;&\UV[N[B[AN
M1^\=KJ0EE<?+MV(J@( 5)R:H>/?&4/C#P]X9MY-)AL;SP]IR:2;J.Y=Q=V\9
M8P@QL,(RAB"P)W<' KV:Y_9XTSP?XWT7PY_9MOXBU+Q#JMWJFG^?>R6L4F@P
M0.\,K-&"VV;YI#L4N5M]J8+YK8\/^"=(\%_'WX3ZI8^&]-NH?&.CZJ9;<6FH
M06+7$2W2(]O%<,LP9E51AR0=Q90,J1/47MJ47S13VNOE?S\GN?,\^EWEOX<7
M5FL[K^RS<&T6[\IO(:8*',0?&-X4AMN<X.:P'U*2]D.SY56O?/A3\*=)^*>A
M^%5U;19O#JZQXY;3;C3K:>X@C6$:9%,D$:SNQ225\*)&RW[T<X %:W@'X*Z'
M\1-1\"WFL>!AX-;4O&T7A^YTR"2ZB35;-HP\A G=I%DA;",ZD ^:N0"*+HVE
MBDF[_P!?CY'S0))3+DEJ^E/^"5"&3]O/P')Z?VA_Z;KJN0^(?ACP_P")O@M_
MPD6E>&[7PY=:;XD.BE;2YGF2[MVMFF0R>:[?O5*$%UVA@WW1@5Z!_P $K8%3
M]N+P/A<%?M__ *;[FCFZ$XJ7-AJC\G^1\O7*JHP.#3;92XV]ZT)M.5NII;2!
M86;O1HMCJY6,M](<?,?NUG:];JB;6'XUU*%4M<U@>(8U\K<P_*G&5WJ#6AS\
M*K ^*E^SBX4LO\-8T^L@WNU0<9K;TV3,!./O"GH9E4%A+STSTK9M-,$EH?EQ
MGG-9T<)>567G=R,=ZZ[2;=I;/:R[>/2IZ%1C<XN_MDM[@ MT-*[LR;1R>U7O
M$NFJTWR]:N>']"^V*I*].YH=@Y=;&;IVGR3+NDK(U;2ECN6V]Z[*_P!':U+8
M.*YO686C8JWR^E-.Y,HV17TN VB_+5B]U"9T55W8I_AVS,YVMSSBNKA\(0RP
MK2V8*-T<A:39D7?^-='I4ENR_,OX5#JOAG[*?E_E3M)TYE'/:FM=2N5EN_<>
M7A!C%<YJDKRP2EU^[P#71W-JTGS9Q69JUBP@/3I0FK%21R.EVTD]\NT'[W->
MBZ-8+%&@9OFQ61X.T.2_OE6VMIKB1FY\N,L2?PKT.S^$GB*_^6WT/5I'QP!;
M-S^E14J1C\3L%.#,B6-1%\I^E9MVS1C('->]? /]B;5_';MJ'B19M*LXY"B6
M;N(IYB/7/W1^M>R:W\-_#/PTTEK:/PQI8;;L:X:#SCM]V.?SKQ<7GN'HRY(7
MF_+;[STL-EM6LN;1+SW^X^';*22X<J<L?05T7@?X-:Y\5]3:UT>R,VW EE=M
MD4(/]YOZ=:^P--O? GP\\,WFLZI9:/96^G6QO+F:6U#>3$,#>V%)4'( &"3D
M<5SM]\8]!\&^(F^PV=BL&%D,<;!8)%=0R.-H'56!S[]JXI<2*;<:,/>MU_R.
MR.1RC%5:K?LV[7L[-JS:N]+I--K>S7<XV+]F&;5[M/\ A)M:T6U22X%U??V7
MIZ137EP$V++(X $DFT$;F]2<9)->J?"+]FWP#X:\9V&HV]M/=7&GW$<UJ;R\
MSOG'^K4H!M.6&>>!BN$U'QS;^+M537IO$6O:99VME<:;)H@B0:=J#2ON^T_W
MFFC! 5N@V)@CY@='P+\5-&U&\AT_32UJT=TWVGS,EI$C@DE+.QSG:8\@\8SG
MVKERVMB*E=4Y/EBGLK)/KT[O?_@F?$484L)*I&?/-P5V^9N.O+RW>[44K-:)
M-);-+T+Q5IGAS]J/QS=:Q)XNO)_"7A5X[/5+.&WF@2[O6>0JZ/(-LBDHRE@,
M@I@  @UWFN>(FUKPY)#ILW]FV%K.(TDDYC3N 0/7!X':N'\=>([/2(K**^U#
M3;"QU]Q>6LT#11'4IRA'FYB&V5P" 2YW+D8Y8UY+\1_C^W@N]DT^QD+7D,PD
M=8XRTC(&#,3$3@C"\AL'!]!S]WEF%K.@GB&G*[NUM;H?G.81P%7$RGE\90I:
M64VG+97NTDM9)M:*R:1ZA^T[I>L>(/[$L[[28;;<$"7C!MLWRAF4+ZX/0X-<
M'\5OV;!+\.!K=SIM];Z3;Q[R[6^U+F0DCY/]G(X/MQ77?#2/R?B%::QI^O>%
M[7P'XM(UCQ3:7U\MY>1W3)*&6-W(E4!FC$;1J2,L&.U<5V7C^RTCPUI=YXS$
M*KK6O:9%H)COM2$MI+;((P7@AZ_\LD[[0V6 RQHP,L36IN'LN649J,KNR2UU
MB_M=.B\CWLRR'+,(U"CC%.,X*<>6-WS-V]G47-[CNI-N\M$G;73P?]G>XNO
M_A?&GZAJUPUU(98XIU7Y3RO'/!XZGUKMM)N+NYN;6^6XNHX)[D_:K>5%/F]
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M5IQ_9]Q$A93;1*(D)49*DA-V" ><TGBK7]"?P;))</Y&L!&:21Y"TDDA*[5
MR<KC<<@#@>HYXGPQK+:VBVLEPODR/\JNP!&?3=W]J^<Q<<3@Z,5)QDIVE:-]
M-+?+^O1?6Y=3PV8U:F*IJ5.='FIWE%*ZNI-KHUHM;K[FFZ/P%\0O\1/&-KX?
MTG[5;7EYF&?RV,1=.K;SQP/?H*]6\4>*-/\ $FKN\WF?\*W^'@QR<)JUT?\
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MT5;[1-#T^5U $(!W*?<@\5Q_ZQ8>^D7^'^9U+)L1'W9V3_KL?"^K>']0U.W
ML;&[O)&X AA9\G\!6Y\-/V4_B)XP9;AM'?2[64_(]^WDEA[*?F_2OO6VN=+\
M/> [>STF&PL[5?E M@J>8?KW_$UP-K<:EXR\3M$LW]EPK*(A/.K*SMQ@(O\
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MFI[@;R\GD_?L2,8)Q@+C[J+P/U/'VWB#P;:?#SP_JFC^9HEK>VJ1P70^_$5
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M#[_PW\(-=\O1+6'2]-,C"6Z<AYF/7!D;D*., '%9?C;]HR_2_P#,BN)&M6)
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M+O?M^GZC;[5+RIG*G+@@JN,@D$ \'V3X2_%^+5]?ACDL+.X\/JF(?(TW;]F
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M$?M?_'WQ%\3I(]8^#$GA[QQI5[:M(IT9H]3U**=2"8Y[(LLD< 3HP4G=P=@
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MOX<+-X=UQ6DP[07MQ"^1Z88Y!X[\USE_\-/%VF7;+J7AS4-,CP&#R0G:I(Z
MC(KZ<U+XV70LY9)),B3YM[R\#Z5R%Q^T1#IFHMYUY)</C(MU/#'T;/;Z5\S4
MS+&XJ*EB6Y6T6KLO+6Y^CRA1MRN3]6_^ <1X]_9<TOQ38^#[WQ)KVI6LUOIK
M,^E6N(9)0\K,KO,<E5VXPH&>>HKJ?AW\)OASX/&_3?!_AVSF7_EYGM_M%S)S
MDDR2EB3D=?6M/7O$-C\9S]KA6.UUQ8DV.6VI=!5^XP[>@(Z8 Z5YKKOQ0M[K
M5'TN\F739H,Q2J\0#*P_AY]?U]:TPM&OB:JP].5KZ;V7G?U_X!<:T8.^E^_]
M=MCT^3X6_#?QUJ31_P#"%^';K4)VW/+%%]GD#=-VZ,K^73BLCXW?#K0?BQH7
MAOP%%JT_AKPGX9U%M0O38+NFOW*; @<G"XRR!B,?.3SBN#N?$S16K0V6K"&1
MLKY8V@/_ "/O7+IKE]I2W N+F9IC@^7CC@YQGOGG\J[L1D>.P5JTFFMKIWMZ
MWV^[YA.M3<7&7^7Y'T!X2\3:#X-T^XT?PU;P^&[2Q_=BUMX_+DR!U9L;G8]2
MS$YJCJ/Q)N6A6UFN+B1V?AI9/+ _$UX[XZ\87&M_#\>(+&:>WU#0]OVCRSS-
M #C/U0GKZ9'85P]K^U#->S_9]0@M[N-R >0C9_ENZUGEN6X>O>6)FXOTO]_]
M(4LR2LF].G0^H!\6K?2=1M1'(UY;Z7_I!D?E?M!^0.F>ZJQ /<UCZ[\68/ -
MVS:DMQ>6^J1-+:7:-A"0>0WH1W'XUX?9_$>U^PR+O96VD)&7W *>?\*V-:FU
M+XX_!V32M#CDN-?TV[BN((8FVM(I.QQGZ$'\*QE@U&I[._-&_P"'?RN9RQT:
MEVEKOIY=/N/3;?4T\3&*ZCNH9/,8DQK)\H &>O?-7]8^*,RZ)>0V^V*&Q5(X
MTDXDW,26<CT.  1VSWKSWX>_LI7.BHLFN>*&M+V-@##8 %D;N"QX)'J!7H%Y
M^SCI^K6<UO#XHUQFDC"AI8TF"_CP375F$\JG2M1A*,U\UY[O\C:-:LX^]9?F
M9=E\2Y+C2#JB3-<+:X^UQAOF"] RGV. 1TP<U:TO]HNQCO)AI]U87C(^WRKA
MC'(P[_[N/<=ZA^$/[+FI:#XHNH;K6K:_TBXMYH7EA!C8 H1RO8\^M:S?!GP'
M\-]24Z?H%MKE]:X62^U;_2)IF'4@MP!GH *Y\-6P=.+^L4E43T6Z:_R.VG5F
MVNCM=OIO9?,P_'GQ^E\2:79QV6^Q+R.7!<-DK@ 9].O\ZL^)?'=Q>?"K^WK4
MKOTMHUOU7DX8X5Q^/6NNAU6QOY&AETGP_!;M@^0EI'D?7 K8T[2/"^CZ%-+=
M:7ILEK>2I=&U&8UN!"^X,1G&W=QZ'%>6ZM!5TN1J-[VWT[-_J=$JE2;ERZNW
MIJ>8>$T^('CW2;6Z\.Z+?7D(RZRS0(ELW?AGQQZ8KTKQ3X2\;:MJEE>7MSH6
MFK;01P^5]MR,@?,%QGO5;Q-\?;O4YI%DNH;&)A_HP=]JNO\ L_3]*Y*\^(<$
ML;7%U+/<&-OF*2#Y/P/6O4Q$JV9U5#"8>,+;**UMYNZ7X=3EE4DW[.<G)?UL
M3?'7P=XNLM-TG5_#UK<:E=W$_P!DO+.SD^\2/EE4]!W!/N*=X3^$&I:8L=]K
MWB-M)N'3!M;)OM$L!]&8G;GU'-1I^U$ES<W5AI?F0VNF:<T@,IVR33,R@\ G
MY0IP"/>J>A>*8?B/X>O-0L?._M:SC:5K16&VXQRQ /\ $!DXZ''K13QV-PM!
MX/EC%W=VXIR]'>^WY'1*I#FYDV^VNFF_F=EJVF>%;\MYEUKTLV%)G$R(00,$
M[=N.?TJ8^'O"OAF2#7/[-GU;6_)V">XDW#9U4^6.&?W->0R_%ZW&E2(FH+#=
M*666-75E3TSQ^/6N%\0_'&?6+V$M=21M%A0(R2,CC\C6E;)<9@Z4,2IZ371Z
MZJ_9;^1SU,9"+YWO_7Y'T'%\>(/$+/;)J4,:PN4%H_R2;NAXQU'\Z]C_ ."?
MGBVZF_:O\*VUQ?3-'>_:S' \+?,!9SM][IQC]*^(_B3?VO\ PA"^/%DNK*?3
M9(X+N:TB60S._P L;,I^\<\9&#R.>*^A_P#@D5X+\=:_^UKX,\5>([V&QTQ1
M>M;6,R_Z7=*UC<*K%>D8^;=SR<=*Z<NP67NE[7$3:J77*K:-]-;.^N^WJ<.9
M8Y_5:L?B<H2?HFGOV_JPOPW9;%;?4M:VQR7"EH[)ARR>KC^Z?3O7:ZUX^TT^
M![NQM6M],6*,7-O!"JV]N%4X8= ,G.0._->7'X;>(+6Z:\U35-)CF9LM&KO)
MM4>X%</\1M"^*#7_ -NT6#1]6LTR%MH+I=[+T&5;!)[\5\YAZ-&M6C&K4Y8-
MZOM\NYZ7M)T*:LF_ZU]#LM1^--SI992[!LX"A2H(^M=-\.]9_P"$]BDEUGRY
MM%"XD\]=V_/\*9YR/4=*\M^$D6O>/=>FC\1V'V*"Q'G74>.8@@SM^89'I79:
MG\2X=6O=MO'N6-0D<,*_)$@X  7L*[,RPN'PM=++ZCEUO:UG_76R.6C6>M5R
MT[=_4]8\,>!_#WP_TC4+S1[.&;[4@)ENYO-E:+DA?11D8Q],UY]XJ^*]E=R2
M1:AHNCSV\QV[6MPBD?5<5YAXX_:DDT>_FL+B'5+2&W&SY8&CRN<G+XQ@^@YJ
M71?$VC_$ZV1H;J<I(-L$<0)ST//ISQZUZ]/AW$5:+S#$UXIVO=R;??==?)79
MU3QU/V?+"U_E^NIV.G?#OP7\6[B&TM'O-"N0=D)MYVD4'_<?/7V-=IX9_9UU
M#X>?#S7[2?4-.M9VNDDBN8P6\Z(+@$J.1U/'K6'I=M:_"W3EM-/\EO$$W_'S
M./F^S+_SS3/?^\W7C XZY/B7X\Z]X<D2S6]C\UXF$N1G>A.=I].GU]*\J.99
MCBE]1C4E4B^CU_%ZZ>>B&O9PM4G[LEKH5?%GP=CUC09K7_A-61F;<I-D1M/;
M^+L>:X^^^"_Q.T@A+/6-$\2:4F6>2VW+<LOJ8V[X_NFJ^J>.+25))I]4M(W<
MY6+>5+'/W<_3)S[5ZE\ O#7V>WA\2:M.T6G[]EG LV[[6XZLV/X!^9-=L:F9
M9.^5R2;UMH_^&9BY4Y.[^]/_ #.-U30?&0\':;I?A?PQJ,ZW1::YEBA\L,X.
M%!+' 4#/&>I-7;GX2?%:;P2IBTFS74&(*1OJ4*-%G )(SU]J^@_&OQ^TBS\.
M36-XT[S3)O@\HA0#G'(R/R%>"S>.[R75&:-KB-=QX+E?,^F>E>=&IBZM1X[V
M?,KW;:;5[WUM9?(<I1EJGY?\'^NIY?KGAOQUX"O4;Q!I4VCHL@6WD 6:&5N^
M'3^(^_ITKK_&GBJ^\/V&BZ2RR-=74*WC(BER[MT(4<\#C'UKZ"^#'C)M0T*9
M=;LXKC2[H^7'',0S7!Z%E]-O][L:Z_Q'J>@Z'H$WE_V7I]Y:CRHC'$#*Z=AY
MAYS[9KIS3/L1CVEB-ULEHO76[N_F1&$X[/1Z7[/^O3<^1/$VI>)O[!M[>S\*
M^(+R?4)50F.QE4"+'/S!3@$X^M,\/F[UJ-+6_P!+6RU"!\2PSQE9%QP JX&!
M[\YS7H5[\1M4\-^(I9'NI/L\DF=N3E?\*]T^$GB"R^*$,::E:1:F((R=\R#]
MPO<[SR,>N:TP?$&-P-"5"A:,9=;*^O9V_KH7/#S2O=NW=6/!O&NJQ>$?#N@V
M,I\O;;F8QG^*5V.2??@"O%OCC\8;SPKK$+6=O')I448 <%<"4_>W \YQTXQ@
M]>M?8'Q ^&W@[QKKKK);W&H_V?N5)9I#'$@SG&%Y_$D5R.L^ ?AM<:<VDWW@
MK2;B)N"QMBS-_P #))S[@UQ8',E@\0JU-<TE_6FVQ4J%24;WY7M;_@+O]YX!
M\$-7U/XR^(H_MB'R]HPT3;3",YR<<''/!KVOXK_%&'PIHQG\P^39VXMX S8V
MHJX'^/U->D?"3X5>$O!7@>\7PWI<%C"H9[EY3NDMH\')#=2!^E?/OQO_ &6O
MB-\;-9M8]'6RL_#;#>+V_G\B%\GA@/O/QZ"M,7B*F.K/%5GI=7;TZ:?AH9>T
M]G%P=W/HN_>WX.W8X/PA\5Y+ZWOI)KQ6PQ6./?D  9/&<#)XSWSBNX_9S\*:
M?XQUV]U[5GN%L]/(N)(F^7>Q.%0'W[_C4GPN_P""=.E_#_6/MGB#QE'K"M@R
MV]C"T:Y&,#).2!]/2O;O%_@?38?AM):^$[**SCLV620]9+D@'J#SW.,C%>AF
M.=0Q>%I8'"*W(M?-I=%;U?S^^:-"K3G&IBE:*W^>FO8L^./',>GRW]^D.O0^
M=8Z?:'[1-C1GB EE4V:9QYJY*S-@8)4>M<A??M$0V<-Y=6,.EV=SKCP'4;R.
M,F341#$8H2QSM^5!M&,<=1GFO!_''Q=GMI+BQU(^5(RON4C^'TKSS6]<O+CP
MZ)6DOIS*-T,"-AE';(')[=JY>'L/EU*<JF91<VM8JVEWO?N_73N:9CF<ZE64
M(72Y8P:3>JBHZ/RO%22V32MLCW/XI?$[4H?!JZY+J$,EO(H>-$B/EA3*8MID
MS@2[@6\O&=GS9[5Q_@+XEQ:QH5SXJURY\O2K&<VUG9PR?O-2G507/^S&NY06
M]2< D5\QR?#OQUXDU1KJUTF\M;56W&\N#]G7TZN1N_ &O<O$WP#U[P7^RAX1
M\0WL9^PF_O+&YGC8&*XFD/GQ[,<@A"X;<!]P$<,*\[.J=&?.L,TE)WLMXQ[;
MO^F>[PI@JT\93JU:,J<-DW>SE9NZ;2W2;2UV,;5/%LWQ$\7M<7DUK;QR.=BJ
M-D,"D]%'7\3DGO5^ZT>U\0:A]GTN&YU%H]REK>%GX7&YR!R%&1R17+>#/"4V
MN:Y;PM_JY74!B=JG) X/<\]*^C1\.;/]FK2]4FCO[>:&X8V-Y>1Q.T4,ZE60
ME\*X4,#D+G.<X(%+(<AIX_$KVD^2E'>6B2Z_UMWN?4<?>(SX=PRCA(^UQ$E[
ME.*NY:I=-O+1WVMJ<K\+?VA/&O[->D36OAV_M[_2YW>0Z;J$#26ROP#)&%9'
MC<X .T@$#D$XJ'7_ /@I-\4/%TT-O8ZE'X2N]-NQ?1?V+ 8VDD"[<LTA<L#R
M2IX)/.<"NDUWQ%HGQCAO==L7N)XY)22LI5IG8\%B0%^7(.T8R%P.3FO+_&OA
MRUL-2AU/3K-II(/EGR"HQW_PKV<YH^RI5,'@92;@]&G:]M;;[/HUN/A_!X/,
M*-/.\RPD56FDY*45)IM:W;BKR76Z[J_4^@/A%_P45^*$?B72;?Q-8^'[J.\N
MXW_M1M&2.XVAAOY4A<D<AMN0:Z#]ICX47S>"+C3;2ZFC"W$LE[(,R/*H).22
M.^<[CUKY]\9_$A?"-K;-'-:31SHIA)'^I!'4?3IFO7/C[^T?K.I? ?PEXVLY
MXY+F]LI]&U!6(99+FV1&61EXY>$@\]2K<U^*9A7Q^:TX59N[INZNVU;9[]5I
M^)]?@\@I4ZU"OE6'IT^>33Y4HJ32<HW2792L^]M-3XY\511^"]<:UTRW^4$[
MI9E5F8>H'I[FMKPC^TIJ'A2R_LN"XNI!>QF&X<%?W"Y5MT?&Y6!7DA@"#BN<
M\9>)9/'>K?VH[22S3@ J/E11Z #T]*X[5K.2WF\M89"S#CC:&'U[BOL,CQM>
M@^>E4<)-6=F?8<2</8'-L+&EF=*-11:E:6MI=SWW]G;0T^*$NJ:A-$LDPF:.
M"W0[D&<DN?\ :)Y-;GB;X,3:#<+>>9'"/-",%8+G)]/\\UYI^R-X^U'X2^)9
MX_LLA@U%N QV[&]\_ED5[/!%?>/=1DDN)+<0QS"1XU;<Y;/?_9[U])[3#>SE
M3C)6Y5IUOZ>O7YGQ].IBJ,W%K1=;?ETM8VOAU\+=<M=9TEM)NK*WL?M:OJ"2
MQ>:;F,?PI_=;WXQ[]#J_!_X]ZQXM^*UQ\-X=>?X?^*M-^VZZ-4U"Q35H- 6(
MAI(YW(C\F*.%9P-RR*YE4!Q\I/KG[/OA.1+ZS6U#>:PVG]V6W9ZURO\ P4?_
M &L?#?A?]F+4-$\+FSM_%7C&^&C:Y']F47$<$',JRRKP^2L:J0S#:2.*Y<'A
MZJBY.-U'=]O7U/@N),\@JT<-)KFJ.T5YZ;)WO;>Q\<_MK?'35/VBOVG]>UG4
MKFVN+#3)6L]*2"99K5+5&(C:,@E2'_UF1U+&N4TW]ISQMX3^#5YX1\+ZU>6N
MF^*A)'?VX*9A#Y0QPDC=YTRH00AY4!0"S<<5+J,<QO-K@2//"J^N!N8_J17K
MGA>_T;X8P:+XJL[6-]6M[A;V2".,R-)'&?WX3@XD,+NR!1D%..M;8)4:^-HP
MQ7NPE)7;Z*^K^XWS3GPN15982GSU*<&XQ7VI*-TM>[W>_3K8U-"^%5I:VBV^
MLV=WHVJB$M-;3IY160+EMZE=R,2"=I&<_E7GWCWP7K%K#(VF73B#'R2&/>4.
M?O+G@GZ\ \XKV4_''0?VAM#TF2P74+:.UM4:07T@DN+@O\QESR1&QR0"S'+-
MEN@#=<TQ8[55CCWC!V@#&!USBOTC$X+*Y8ETX)2IZ6=OQ3W/FN&\_P VJ9?3
MEF471KR7O13^'RNOOT];GS;;?$/Q-JGB)=%OM0UG5]-T;3(K>+^T'5O)<%.C
M  L2B(N3D@(HS@ 5I3V5EK<2M-&UK)G@$84GV->@?$GX>16NCR:U:QJ@M)4\
MQL<ON(!!/?J/I5GQ/I/@>?\ 9XM[R"^D3Q8\FUH-S_,WFX92FS8(Q%AA(&)+
MG&.P^!XCPL,!B8TJ&L))6[KO>WGU_4^LRY2G1:EO%OTMT2_*VOW;>5Q^%;.]
M\46>DWUXNGZ/?,3=W:1&=K%5!9I$0<N^!A4&-Q(!(&2/O+_@FG\(?@+I7BVS
M\2_"VRUCQMXR6R2*\&OW8M]=T,SW*022QVR@6PM5A=V>97D;HN5W<_ L=O)H
M\,-V&5A;SK)M)W*VTCC/K_C6[\&?VC?B!^SW\3]2M_A7:V=OXR\6*GA[3;PV
MZW,EHDTZ'$"N"@9R(QO93M4' R<CAP]2]HK[SS<PC.I3D[ZQZ/;YVL].A^PW
MB;X,Z-K'BVQ\436,D.OWT2R3:9J*VS3'=\GV=]I:-2 =I=2W.PECMKP7XF?&
M,_$"SU32/#^C2:+:Z'<3226T=FL!OV$A\^[;8%QE@'<D%B"K8YJUK7[$-U_P
MM*Q\=^,/%=YXX\3:3I-G%9Q,K6<,NJ0VZ127$T\(+&-V5V6-55-S$D$G(\S^
M,W@3QAIMMK4FD;O#N@PWD]U!=ZE;9N-0.#S&A7SF9@,$C&0!NX&!]1E^<8*K
M/V&<N510C:GVB_DU]UMM-K'Y_/A/'X?%T\=PJZ=*52IS5KVO)):V3C.[U:3?
M6[U?,S#\7^!K?QYH=P+B%I#L+.68 [?4>F!7S[\2_@I8Z9/*ZZ@M]'(J&)Y8
M>".1@GKP,=:P;O\ ;&\;>$M::/4XX[JWS\PDC"E@?7.#BIM1_:(N?%]FDUII
MUF1<2+$8PP5F)//?H,_>-=$,1A</\,XI=-?S1^GXC'5ZDO>B[[/3^OZL<=XD
M^&$WA2]6UCTZ:2XN,NT[/F)1_=QT''-?0O[-_P"W%XL^&/PY_LE]-TWQ7X>M
M(#!!97SR)/;Q#ILG0[@H(X#!@.V!7D%]JFN:_I]XS+:^= C6RQCYE91R2..2
M5&,]Q72Z1XB\1?%3P'JDVDZ)H</]B0BWNVL(5MFDX9ERN[YG(#$[?X<'&*^5
MQF95*F/E+)[WO]G\=.QGC*.48G +#Y[&,X7O:=K+HK/=/5K1IZV/O[X+?$+P
MA^W3^SD/%_A":'0[[PVDEIXDTN_E$]QX?NEYBN8KA$64EVVE2Q"D '&5.*NB
M?'K4O#NGVNN>,=)MO%%DUTVC-?Q6ZK<PR(@,9DP=LOF<XW <@X.!FOA7_@E5
M\/;\?MC6NK32:I8^$9X9])\4BVD*Q36LT4@4RK_$(9 DW()79N'O^E7ANR^&
M_P +[JY\/>/-/EU705U(WNFZG83+<6<O[H"-V91^^8+D CY2&/H:_3N'<ZE7
MHMO64=&ODC^2/$CA.7#^<<F%:A2J*\;WLM7:+WT5M'O9[]2'P7\*M/\ BCI,
MGB*V75;..Z_X]K"YC59(N^589(4C[O0XP>F*L:/K>F:7I[>&8-4LVM;"[^U3
M6=FC22/M4H%*,0NW<1N.220#@=1YS\=/B5'JEC)XH^VV7@GP+I$K06>J:IJ<
M>GK=,1DEI790\C;>(X\XQBKWP6T_6_'&MV5OI"Z7J5WH=M;^(O#NHV+PM_;-
MD\GS S*VV1-C'YQN(+8;IFOJ)9BY1M4Z:VOMZGR4<VEH_9-IO22NDW;5+372
M]DV_Q/4M1^-^H?"'PO-<QZ38-)=,L;6T2'[1;A\D%!C+&3#,-P&W')Z$ZWP1
M^,.K:C\-=8U+4K.ZMM)OKQ8)9+C#W-Z(LL0%W;56-" 6 '+8_A%>$_&_XW>!
M_P!DW3==\1^*+RYUC4-4O7%A'8;9#>S$EA9QRLOW$4J78 ("PSG !\=^'W_!
M9:'PS\)VBO?AXTGC1(F@A>&\VZ5-DAHWFC8&3Y65257/F;<%E!-?/YEFV'IO
MDK.S>NS_ *]#Z3)^&\_SJ'UO"T_W:?+NEJ[]7:Z76VBV\CIOVG_^"B+^"_VI
M;K01#<7NEZ1>QSW@8F.'46^3S(4;D!44>3D<[@Y[UV'COXV_#7]K_P 527W@
MFZM/AWXAN56./0-<>.WT_46' ,%VA\N.5N!Y<H521D-DFOSOUW7[WQVA?5)&
MF-X[2.V[8SR%BQ=3V;))]^G(XKUWX$_L8>-O&^^2:ZTNWTV-@HO+MS')*N >
M(P#D\X/09S7Y_4Q-*O*4Z]DWK]VBL_)'[GF/"=3*J%%823E!+EOUON[K;5W=
M_5:=?8_%1U#X6>);C1O%NCZMHNK)AE@NHBI"G^->S*>"'0E3[UQ'BJ:S25KR
M%I&FY^=@,$<8QWKZ)^$WP?\ &GAO08_#>O>*/#OCSP/&<+H6O6,LJ6GJ;2=6
M$UJ_H8F"^JFN@UO_ ()N>'/&B_:/!OB:[:XDY&A:M=1BXB/]R&?"K,/0,$?Z
MFO2IYLGA/J<;./IKO?T;O\_(\:M*NHVJK3O_ %M\]/,^2/"7C^:VU&']XRGS
M ,CK[UJ_MD?"_5+3PSX6\3V-C=7FJ^))I+2,6UN99;A(U!!*#DXSC.*]\T?_
M ()L^)++Q99PS>'O$WEM*!,QTU]D: \G<!C\NM>P^+O _CJ]FN+'1_!OB:SL
M+!5L;(G2IAF% .AV\;FY/J17FN+@_:I;?C?^KFE&4)+V4FM>M]DNOKT1^8WA
M_P"%/Q6N[-9H_!'B!X=OF;_L_E;Q]&(.?;K74V'A?QY<6L9NO"/B"R5CB62X
MM6P/?/-?=]O\-?BE"CM)X/\ $4@'R;?[-FY_\=K!UWX=?$YI-L?@OQ@HQG$6
MD7&W/_?-%3'8B2Y91NOF7'"X=.WM/Q1Y1^S]^S=>>,?AYX@DU3$,.L6K:99B
M1?F>>3@D+_LKEOPKKHOV9OA3\&[*/2]/\,1Z]>1@12:A?Q_:)KEQC<<G@<]@
M.!6Q:>'/BMIZO')X)\:K:KN8G^QKE/)X.YP=F!P,$UH_L\+>?&WXA-X4NO$%
MKH,+:9<:K#JDUN)4C2$+NW9("@;OF.> /0USOVDK4X)KJ_-]/D:N5*A>M=22
M5O3NWOJSS/Q'HO@>"\:&7PKIJMT 6W6(+]<8K0^&-CX;\)W-\OA^&#2[Z\M6
MBC+,SK$<\'GOGN,U)\2_V=O$"_#R_P!5U!;IO&5OXQ/@\Z-!#NDEN#"95=&!
M^8MQM4+\P8'-<-XJ_9\^)W@'Q7X9TS5/"]S'=>(M1_L?3IH;^WN(I;T\?96D
MCD98I@>J.5(Y]":]/%9%BL-1C6E-7[)MM?A9_(TEFE%);:Z=/^ 7U\2CP5<3
M6VMS*MU'N?:WS;_0@YY!/>DTSXP2W-H\EJ_G!&V- &$3%3R"&YY//&*Z+QY^
MQM\2OB=X/N+.[\.-:^)-!M5OG22_MDDMH6D:(^>3)B,$HQ.\C:%W' YKRR]_
M9*^+WP,T+Q!KFL>%;JWTWPS#]JU+?>V[-';#'^E1JLA>2 !O]<@*#GG@X>48
M:CSOZW&\7IUT\]#EEFM*,UJK/SN=3H'[1.J0:Q>0Q1PZ?:_9W40AB7=^#\S'
MKQG& !UK)\1_&*2Z\*76K0M-]HL4+W"0D%I8A]YAGNHY]QFN>^+WP@\?^"_A
M-'X^U#PA=6^APVUO=W4OVJWDN+*WN#BWEN+=9#-#'(3\K.BAMU='\:? &B?L
M^_MCZM\.=-N+ZZTRW@LU$]X5:5UNK**60/M"J0/-8#CH!GUK+,,KI4:C]B^:
M.C7SZ?\ !.BCFCK55333W_3\KGG'A_\ :&L?%6HW:*]Q#\PEMC(P67I@_,N.
M_3ZBKT_Q;U3^U=0NKN^DNOM]L(-SG)0*<HHX  QGH.OZU_A=_P $B_C!=>$[
MSQ1XRMYO#?A&W(EMC'Y4M_<P,Q$4S0;BT,;<89ADDC@5[4O_  2);1-/T]/$
M4GC*TTN[O[:WFD6_MFFLO.<!1*B@F)F!X\Q1_2O4Q>/PT\,L+5A>4$K-+ITO
M^NZ?KL4<96G#G;BKM_:6O?3Y_B>;^!O&A^)'A>\T5&CDOEB>XL)'PS12J"1U
M['&#[&N'^$_CGQ_\:$GM='\*:EJFGJYSJ7^IMX7(P0)7PK8QT7-?:7AG_@FQ
MX"_9YN_B%JVDZUXEU.7PAK46C6\-_/&4=)$?<9"J EO<8'M7'ZM\0_\ A';F
MVT^.SMM(T"PC6VLDC(2*-5'10.YZXZUY.%S"IETW/"VYGI9]NNGJC3#J52*F
MI.T5TZWLTON=V[>1X1+^S#\5--U;^T;&WT:YE"^7Y1U) SJ>#UP/UKH_@/\
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M%23YBOL.X]ZU/A39W&N:M&MHUPUQNQY.TACCGI7+?\,X>-O"PGELM8;6-/\
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MJX^7(Z"O(?V+OA[X9\#_  _;P[JW@K3UD^(9<:AIVI6SQIJ2VK?N;6=)%)5
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MO+/'?A^+0EDN;F[?IMWMS@]B .^>,?SZUSUW^T>N@Z]Y<"-,PS%<1(<,!D9
M]"" ?J.:WO#:ZQ\8(5^SZ=J%U;Q_.Y,&%7D84 <$GV_K7V^383*J655*N)LZ
MNNCW\N5>?=>?8_/5CHRI^9K?!7QK?:A'-8W3-)#*!$L;_,&4\'KU!KYN^,6J
MWO@OXSZS9V-O,(M/OWMX)5C*[U5L=".17UWX/^%5VNIK/<0"Q6Q82LKKM;"G
M)X[<4[0[:P\;^+M0;481=0^<TCN\2E@Q/3/K7S.#Q2I2=2]FMK$SP;K45)/E
MU/"? ?P_UKXZ:8CV]K<W$5J )YI!F.+T&X\#Z5[K\#_V=['198[O59&6QL74
M2,!N64]D3NS$^E>J:39:#I/AS^SM-LVAA4[R.%4D]R!@$UQ/Q;\1ZYHFD27V
MGPM?V>D6SRK! G[X2!>&"?Q>O%5/%QQ%9SJS;OO>]W]YI1R^K2CS+67RT\]S
MI_"7AWP[9_$/Q-J.GPQ7&JW4P3=-B86F%&0@/3 P.*O3WDMY>M$TC22*?O%C
MMS7Q3\&_VE;VPT2XNI+F:.ZO+^:1I?XU)(%>Q>!?CM!XANA#?:E]F#C"NYY:
M3MD_3/XXJ%EL\9B53C9.6BULD=4<1&-J:EIW>[?5_,]<U[6K?2W;S',DR#@A
M<A/SS7F?QGLM:\3:KI/BQ=2:\L]'CECOK;&& ? 68 =<<@CMD'UJ3Q1XNN(#
M)]GF2_MY,,6&-Q]_0]>E<=IWQI@T?7%AW":"Z/E7$1'WE((.1^8K7%9/B\![
ME5:/9IW3_KS,ZF,7M%"IMT?5>GZ^1>U?]INZ\/6(@@U"0;1C"M[<54M/'<VM
M6.Z:^DO+BX4D)$X*Y*DXST/;K^E>:?&/P./ /FZG(DEUI=PQEMIXP6 ']UL=
M#VKS7P?XLNM5OOM5GI]^T.XCY(W"R'\.#7J9/4PV%;J5J7/=:/>WR?<\V>)5
M"HZ;5_,]6\7_ !4CT;_0Y@_VK(.5^[^%7[Z[O?BS\.KW29(Q-=&$W5KZB1!D
M?B1Q[YKSG7O#&L>*9(YET>^C"#'^H;@?3K7T-^SG\.7T/P/J^K7T_P!C\BR:
M*&X9 3;EE.6 /&0N2,]\5YF(IPG6<J,>6[;2[:W_  #!R<Y2E/:VI\4W/QD(
M_P")7-;37,RL""BE6B8?K^(J]<?$:9+=8HVN&DQM\MXSN /7H*^^O!?[.F@S
M>&M/N/#ND:5YRVB&6^GB62XN&(R27(XZXXXK \4?!*^T1VU!+..%G.':%%^;
MZX__ %4GFT4G2C=1?2^_R-,1E3@K.=WUMLO+Y'S1^S[K$C^+M-CE#+F=0Y[C
M)]*^L/A#\)M(\*:?#<1Z7IEWJMS=S[;FZA7[00LA P2/E_#%<GI=KI=AJUE/
M?:= ;BSF242[ KMM.<$^AKG=6^+&L>'O%4[:TS(S7,LT)5_E>$N65E(]?S%<
MM6I*HK4M#KP-J-&2=F^GEL?245A?>(XMTJ1V20L5++D'CVIR>((?"<R[;TS3
MP@LDIX=#CMZ5XGHG[35OK.HVL=]=>59W#>4V&VA6(."<>GOCMDU>\5>+MEKY
MUK(TUJWS!G(9E4X[YY'//H:]'#\.8C$81XJBT[-^[ULNOKUMIY7>AK];;@[6
M-SXG?$37K;3;J[T.4ZA&KK)<0X_>1HJ@9"_Q+U)QR,^E96B_M*75WX=A:2*U
MMPS@2-;IM*9_B[X'KZ9]*\_M_BPVD>,T6SNFD56&\>G3D?3I7*?M-^(E^%>O
M0ZC:[;:QUZ)IHHU4G]ZI_>!>W<''^U[5R82;IUXSE%2=[ZZWMT9SUL0ITE*"
M5H[+R_K<]]O_ !U=V^EKJ5MJ*WT+?-M!^Z#R,$8/3/J*\Y^('Q0D<+?--(79
MAC)!P/0CTKY\\"?M"M)--"M])''DD)C@9ZX&.*KZU\1[K6/$"Q0[[B//S,IR
M!D_I7N9U4P&)<*N&I>SG]KHON6E_DO,\^IC.9IP3_KL>K?'CQ.TWPJO/%D+,
MK:(D?VEH6_UD;,$&?H2,>Q-=)_P0U^.-]XV_X*1_#G3LWAM9AJC,,DQC&EWC
M GL,D#\:VOA9\,;;Q'^SKJ$.I8AMO$=_;6+1,.)XPX9P#VYVC(K[$_X)W?L^
M>&?@M^TGX9C\,^$-'T&WS=;KB$&2>7_1)A\TC$L2?KBO-PN,]C*,(W3D[=M+
MV^96,PLIX6IB)RLN5_-V;_*US\V=4^/4VK>)[BUD-TLRR'S01\Y/<8ZUW_A/
MQ3;^9#<2R7FGWD9_=RI\A3G/((P1WYK[5T+]G7P)X&>35;71[6/4+QB9;UX5
M>XN.V-_4?1<"LO7/AGH-XTDEG$D8D!WI-$&#?G7BT\TA1J7H736S6A[4\'[2
M3DZNO:U_QN<;\*-'U+Q_I\+0ZA/J"0(%CB0;G;'<@?EGTXZ5T\GQ">SNET&.
M7<VX+<2#HS?W1_LJ./KFNR^#-U;_  \,RZ7%;1I> QW"QH$()[C'2OBOXW?&
MRZ^$OQ/UK2%:3S//8I<L#E48G[H/?W-;5JM;'2]O4DY/;7==OD34@\-=U^R:
M??OZ-:?>>_\ Q1^/<?A75&M+"3:MK&$=OX3(3@#\R*SE\0P:Z9Y=0D^U@0J\
MA).U,CD@9QMS]#SVKP32/B1!XG\-*VZ2.<,LPE90V&!SSZUVWPCU";QMJ?V%
M8UDM6<,(PA'F'C SUX.*^JX?QN795AZE:K%2K=-+O;1)]+O?7;N8T<5S3<Y1
MUZ:'>^#/ #^++.W9K4*;AR$&[$<:]2[^@ Y_"O:_"FL^'/ .F_8=!BDGFQF:
M\(&Z4C@[1_"OICFN$^/4'BGX&> M L?#.C:5KNJ:]=)'J,,F9/LMD0P)10P+
M$2"/=C=A3G &6'#>(_VFO#/PI\'ZMJRWMIHWB33;B'2IM&UFRNH9--NI251R
MAC<O"^ T3@2(V\9/RD5Y^!X6S',J-/$8?E?M)-63UCUYI*WNQZW7EW5_GLSX
MXRW*Z]6CC>9.G!2NU[L[_9@[^]*^EM-F^CM[M+X/UCQ,(;F\N%ACN27CCN%D
M:1U[$(F6.<\%L D\&OG7XD_M+^ ?AK^U3X/\0+I\VI^5HNI:;J%\5AM+JWNX
M;BVBM'\N1BP:WCEU##,.8Y&"@G81Y?X,^--K^T2OB'4OB7-X=O/"MU]KNK;6
M[LSV6DV)R%$UN!=#[1>8<*JM&G*C+MM$9\9\.64WB"PCT77H1'H+(\4,JWLR
M[YW#-")P\&Q89'C.T([(NXJ)"1@_LG#?ASEN#F_;RE*HX\MTW%-25I+39-::
MMOJMC^>N+O%S-<>HNC&$:<9<UG%2:<7>+][JGK9)*VCW/T=^#_[4'@_XTZ-+
M'<:MJWA^>)DB6"_A,BK(RE@(IXAMF 49.T' ]:POC%\-=<U+Q''+X<AM[^&;
M+?;K>16M[E<;@?-4XW<]#SSTKY5^%GAO1_A_J&BP:;K>I^&I[AIYKG3EB6VA
M-_"&D6V:-WD 1D!4 (?F:UPJE@1],> /C9J'P>\3:/:^(K6^;1?$5I;7;-)+
M&\,ELTCQR2F4'+R!RD8B^\GE;N02 9IX>X>E"3R=N,K>[!NZ>ETDW:73N_06
M2>*5>O5A'/DIPVE-*TEJDW9-QW:TLO4S;'P3XZ42)/IL0\L=1.K*_P!"#7H/
M@3X;ZMIS+-J4]JD"#,@BD#$?C6=^T#\9+/X?7.H:=X?M'\:>+Q8C4-*\.V1D
MDGN(6Y6ZNE7FVM@NX[I2I=EV(&8XKG?!OQ+UJ]\%>'-2UBWM](\17\327ME'
M ;<*NX%&,3?-&2"1M<!CMW%5SBOSW#U,?# O&8F"BD^7E;M)^:B]U=6OZ]F?
MJM?#Y15QT<%@I2DW'FYDN:*VT<D[)M.Z7:W5I/C?^"C_ (LTGQQJOAGP/XA%
MZ=#TS3'UV2>TC:>\5Y7,8&W< ($6-)'&1G:3G@5\C^$/C[>3>&]:T=?%$WBW
M0-/N((],EMM(&F7<A<(LB(6CR\;-RT( 1ER<YX/UI_P4+\.:YHUEX/\ BCX=
MN(;6ZC\K1[E)@%D5E9Y4G0%3O3RV>)L A6:,GAJ^?_'.D:7H^B2ZI'I]Q;VV
MI:='=G3=.O"+568.ZIYC(4B=/+9I2/NAV0#<<']OX7G0KY31JT=K:[_%K?\
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MC?X[0Z3JGAW1&M[C1]4UMIY#/-IR1I#!; $1AW3#-.#RP90"3G KT3]E^_\
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MNZT3Q,9!IZ(BM,DL(59]Q[ 2' '?K7*^'OV*O!-M-]ML--#3<95Y0R(?H?\
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MHN1MD"GJ" PP#V(_2+2/^+K^'K.ZMY%\5>'=:3SM-O+><&50>-B,V3D'AHI
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MC'!#O@@<< FO#SS/*N*K1JQU?2RT7Z?B>R\CQF'A[.A23EUYGT]%K;[CY&\
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M,U[BO\D>;3PJY^6K)KU;_P _R*O[.EC\.=0NM3UU_AC-HS>'D:57;Q7=S*7
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MA/9RM:W#8^Q/?2Q*;3R\Y\@."4X+BOC?PI^QQKEG$LWVRTE7@22$-N"_3O\
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M]$UI:U^BO\KZ9;0ZSX;\(MJUWIVM:MX\N?*U:););B2UBCN$*Q,1(H:0,%9
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MI6-Y*$@EB#*;*1%1'C)R&R=V3U5F[5T&K^#)/#NIW%O<Q/#.&)96'6M7X?\
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M57AECC2>#@2H1E&!X(^A&>/>LZD*N%G['$Q^_P#X!RU(4ZDO9MV?1GSK>_M
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MXLM[Y>HMY[00D>P;D'\<5Z%:FOBN_DO^">!!Q<O=:^;_ $2?XG7_  F_9_\
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M"M9N_$?DP6-Q-'(0,%2=O_ZA7U6*XPC+%U*\E4JQ:CRJ5E9I:[:*[VT;L<7
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MGAB;:N'$; @[AN!(Q]WK6'??"'PYX@\&R7FK:;-X3UBX+7=C>Z?92/I^HQA
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MO,&[#IW/O7UF<\1SS' 0P:A^\33<NEDFO76_^6YS8C'*5-*70\B^%GP=BO\
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MG=7=O\V[]&K)>:;-[Q'+IOAO]G'7(M#N/#>DZI,/L^BW5[,BP+>W'EI',,Q
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MB\5CJLY5Y.\E:W1*][)=OZW/CW1? 7]I6ICDC#$]B.M>\_LX^#HOV,O#-O\
M%_4(4/B+4/,M_ FBR']W<RCY)=5N$[VT&2L:G_6S?[*$UU'[-_P"TJ\TR_\
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MN[--07[1:J/,GB896;:1@$<YQG=@\$@"O8_V(OB=:>/OVUO![*L?VD&]&YF
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MT_7(98V$N=J72!@3$Y_A##C=V[\4Z=.G=*LVH]U_P>A,7@Y*])-2[/\ *_\
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MJM(0P-=52:9/L</-<ZIM?._X:?F>M?$:^O-;\+7*7VFW:76/W<3H?]']2S=
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M0?&:PMO[8\/W&GWT2!M\J;89F]48\\]:^BM3\90:/8*6BMH_+^9U27S&(Z]
M*_.7X;>-=6LYO,COKA79L$AJ[K4O&NK7^F_O=0N6W'GYL9_*O1J5KR=H_C_P
M#GCE>'DTW)WZZ?\ VUOP/I7XG_MF:I>Z/?:/I_AE?[(FADMYM36?YXCL.,Q
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'[/\ %'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>oncyf-20231231_g2.jpg
<TEXT>
begin 644 oncyf-20231231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !     %$2  0    !
M  !!9&]B92!);6%G95)E861Y  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" 00!@0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HKXZ_P""R?[17C+]G;X,^ IO
M"=QJ&EP>(_&5II.JZE93+#):PM',ZIO;A1)(B*3D9&5S\U;O_!*_]HKQ/^TM
M\*?$.N:]J,VL6*ZJ\.G7DD:J2H+!XP5 !"E5^A)'6O8ADM666O,E)<JERM=>
MGEYGB3SRE',UE;B^9QYD]+=?GT['U11117CGMA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD;\>?A]X7^&_AOX;:WI_BS0)=5NY/$NGWMS-'*EPT0$9M[N !=H!P03GOVH
M_6VBOY^/VL/^#S?Q1X+^'_P]TWX6>!_ >N^-KKPSI6I^,=6U1;N31;;4[BSB
MFNK*SMHITEQ#*[(7DG8JRLF&*[S^A_[=?_!<GP[_ ,$Q_P!@WX7^.OBEI=OK
MWQ<^(GARSO;3PCH;M9PWE\;6&2[8/(96MK2.27;O?S7^90 YW$ 'WQ17\U5_
M_P 'H_[2%UXC?7;'X._"B+P%;ZA!;S12VFJ37*!E+FW-\MRL*S2+',4)@X"D
M['"'/Z\?\$7_ /@N#X"_X+#?#W6?[+TFZ\&_$+PBD+Z]X;NIQ<!8Y,A+JUF
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M'X>F[GM['4/&,%[=W>LI&4RZ_9YX(X6 ;+)F8KYB9/K^JG_!$_\ X++>&?\
M@L5\!];URRT&3P?XR\&745EXBT)[M;I(/.5F@N89 %+0R[)0-ZJRO#(N" '8
M ^TJ**^0_P#@L+_P6%\!_P#!('X$V'B3Q)I]QXF\5^)I9;;PUX:M;A;>75)(
ME4R222D-Y5O'OC#R!'(,B *2U 'UY17\T^I_\'H?[2ESK;Z]8?!_X2P>!8]0
MBMF2:RU2:=<C>;<WJW21><R+(5/D< 9V,%.?U@_X(C_\%Y/!O_!8?PYKNE_\
M(_+X$^)GA.!;O4] >\%Y!<VC/Y8N[6;:C.@<JKJR QM(@RX8,0#[XHK\0_\
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M/IOQ<M;S0_@CX%TOX=WB_:+2QUI[Z35]1MO,D02I=I)'"H8ICBWD561QN;L
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS]D#XB^%?$FK6D-OJ$7A7X6Z[9VM_)$"!<2K,LSM.RE59]_(C3C@D^W>#?\
M@G[_ ,%&_P#@@O\ 'GQ!J'P=\*^*O$6DZM<P6<^H^$-%3Q1IGBBVC9Y(C-9J
MDL\( \U2SQQ/&9&"R 2*S^V_L1_LW?\ !5']O[]L;0?B)X\\=_%OX+Z'A;;5
M=9U4)X?BALHW=6@BT,(BRRL"Y0RVNS=MD9\[6(!SO_!W7XS\8:C\/?V/-+\4
M+J5E=-X&FU'4[.Y9E9=3>.Q6X$B, ?-0KM)8 C<PP.17ZD?\&O/PO\,>%?\
M@B5\*[C2;.QDE\6G5;_6YQ$NZ_N?[2NH&$O'S;(XDBP?X8P*TO\ @OQ_P1I/
M_!6[]E[1['P_J=EIGQ0^'\TMYX<OM0 6WOEE15N+2=T0E%E\N-@RC"O&O&TF
MOQ/^!4__  54_P""4OP]U7X0^!?AW\8=-\/W0DN(;?2O!$7BNUTR:293)-:W
M<$%S&CMY3J4$A7$S2! [)( #Y]T6QB_9Y_X.%!IO@&/^Q['PI^T ^F:);V!,
M20VL?B%H(X$"_P#+,Q 1E>A4E3D$BON3_@]S_P"3P?@O_P!B=<_^EKUW/_!
MG_@VW^+7A[]KK2OCY^TKI4OAR/P?J;:SHVA:C>0WVJ:YJ@;?'>W)5I!'''*3
M*-["5Y8U; 3#/H?\'@O[&OQ@_:9_:I^$FH_#?X4_$GX@Z?IOA2>VN[GPUX9O
M=6AM93>.PCD>WC<*Q4@[20<<T ?>?_!L9^S!X0^"7_!(#X9ZSI.D6 UWXAVM
MSK>OZB;91<:C))<RHB.W)*1PI'&JYQ\A. 6.?QK_ .#QC7;Z\_X*Q:9I<WF1
MZ9HO@/2X-.@#?NHXVFNG8HHX7+LP_P" CL!7[X?\$,?ASXA^$G_!)7X&^&_%
M>@ZSX8\1:3H!AOM+U:RDLKVR?[1,=DL,BJZ-@@X8 X(KY8_X.3_^"#FN_P#!
M4'P_H/Q*^%?]GGXM>"[!]-?2[N:.UC\36&]I4@69\+'/'(\A0R,L9$KAF7@@
M _/;X2_\%.OV^M$_8>T3X-Z#^PQI6M?":3PM%H=M$?A!XHNX-5L'@"^>[K<^
M7,\JGS#*!AV<OWJ'_@UK_8M_:$_9C_X*P:3K7C#X,_%KP/X5U+PUJNFZGJ>O
M>$]0TNR"-&DL<;2S0JF6FABPI()(XZ8KE_A?\</^"M_[*7PKM?@3X;\$_&RS
MT728;;1]+GA^'\>IC2+8H56"#5!;21K%ME0;S,Q@\E0KQ;&%?J-_P;D_L-_M
M>_LV>&-:\1?M+?$OQA+I.H6[6^A> M8UM=;EL69D9KN:9FE,/RQ@1P12X'F2
MEU5CB@#\%?\ @M)I6GZ]_P %P/C=8ZM>?V;I=Y\0)(+R[R/]%A:2-7DYX^52
M3SZ5_35_P67^ ?@4?\$4_C7X5?0]&L_#/A'P#>76AVBVR"#3I[*V,EF85QA&
M62.,*5P>?<U_,[_P6/\ ""?$'_@NG\9= DF:VCUSXBG3VF5=S1"66.,L!W(W
M9Q[5]>?\%'OAI_P5-T'X?R?LR^(K'XC?%3X7I+_9EEK?A3PNE['XEL(FA%M]
MKN[:)IHD 524N'1B3)YC2A0P ,/_ (,Q/$6HZ=_P51\4:?;37']GZE\/-0-Y
M"LA$;>7>V!C=EZ%E8E0>H\QL<$Y_J*K\F?\ @V _X(E>,/\ @FQX,\6?$KXL
M6EOI7Q&\?VD.G6NC1S1SR:'IRN)66:1,KYTL@C9D5B%$*9.XD+^LU 'X;_\
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MO^"9_A/X?_\ !*[4/V6?#-U-8^';GP1?>$8]2>)!,TUW!*LM\ZJ ID>>9YF
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M:UI/B">70]6NS\*T0W]NX6 V[7\=H+?[/N4O]I1@3O9C.R8P ?J9_P &Z?\
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MYR<'TH ^+O\ @K_X5M_'7_!>+XO:'>%Q::Q\2/L,Y0X8)+-$C8/KAC7[U?\
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M&;XE_#/X@_#M=:A\/#3CXF\.WFDB_,3:GYGE?:(T\S9YD>[;G;O7.,BOD?\
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M/#.I?#WPOHGB&'QQ>R:R(K75M?OUF^V)$EDGSP;I]C2>:D052RJ"P*K]3?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8(K["H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6UA<:UXDNVTK1O$D.GKIMW!J0RJV=[;H%CS(ZE%9$0K(55E(;*>O_P#!H?\
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MQQ3P3QQJL9=3+&RNBKD;PP) )_8^348(6VO/"C=PS@$5_+-_P9O_ /*7*_\
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MJG_!8*X*J%+^#-)+$#[QS.,_D /PK]C_ /@H?_RJ]ZQ_V1W1/_2:RH _GO\
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M^#-/3;>U_P""4&N3QPQI-=?$+4FF=5PTA%I8J"3WP  /:OQ9_P""7MG#<_\
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MI2QYEGFMLK MPK[5$C!8,.-REL!OT#_;ITRWTS_@U9O+:WABAMX?@QH(2-%
M5<6UB> ..O/UYK\Z/^#(^TC;]L+XSS-&AFC\&VZ*Y'S*K7J%@#V!*J<=\#TH
M \U^"_\ P<C?MF?L"_MGR>&OVA=3OO$UCH^J1VGBSPMKFCVEK>6<3%2[VTMO
M&A601L'C.6B<%3@JP-?LO_P73_X+9Z9_P2>_9G\.ZQX>TVQ\4?$+XC&1/"UC
M=.RVD4*(C2WLX4AVC021 ("I=I%&0 Q'X-?\'6R*G_!;;XEE57YM,T0G ZG^
MS+8<_E7T%_P>">"]8M_$'[+OB"2.8^'[OX?G3K>3!\L743122C/0,4FA..I
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MC]S[.BB0?ZOYGRW3GFO[%*_G*_X/>U/_  TA\"6YP?#6H@''<74?^- '-_\
M!%OXP_\ !2'2],_9^T7P=IOBR3]F?^W-/@,T7AW2I+3^QFU$?;#]H>+S]H#3
MY;=N'.T\"M'_ (*7_P#!>W]J[]G_ /X+!^/?A;X1^*7]E>!]%\8VVE6>F_\
M"/:7-Y-L_D;D\R2W:4YWMR7)YX(XK]2O^#=+XU>#Y/\ @C;\!=/_ .$K\.K?
M164^EO:MJ,2SK=F_N0+<H6#>8<C"8R<@@$$$_P ]?_!;34X?"_\ P7M^+E]?
MLUO:V/CFTNIG8?=B5+9RV/\ =Y^E ']$7_!QG^V3\1_V$/\ @FEJGQ ^%?B'
M_A&?%MOX@TVRCOOL5O>;89782+Y<\;IR .2N1V(KQ/\ X-8O^"DGQF_X*-_!
M[XO:M\9/&'_"77WAC6+"UTR3^S+.Q^S1R0RLXQ;11ALE5.6!(QU KE?^#MO]
MKCX;>(?^"4NF^&])\:>'=;UKQQXBTV]T>UT[4(KJ2[M8A)*]R C']R!M&\\$
MN@!)->;_ /!D#_R;[\?/^Q@TO_TFGH ^0/V9_P#@Z'_:R\)?M87^G^(M<N?B
MW9S/?Z1H7A*#P_80'4=2EW0V"L]M D[*LS(2J/N<#:#DY%7]JO\ X+6_\%+_
M -@W]H#2[OXNZM>^#+O6HO[2L?#VH^'=-;2+RVW8*+Y:,Q"GY6Q,)5R,L"03
MX5_P0TL8=0_X+X_"..XB295\9WT@5QD!D@NV4X]0R@@]B :_03_@^/11K?[-
MK87=Y'B(9QSC=IM &+^T!_P7<_;N_P""AGP+NO'W[-'PSU[P#\,_!&E1OXLU
MW3=.M]1GFOXH5EO1#)<!LP1$Y"0H90F&D(W;1ZM_P;1?\'!?Q7_;1_:/F^!O
MQMU"T\6:CJ6EW&H^'O$2645I>>9;@/+;7"PJD<BF+>ZN%# QD,7W K]*?\&Z
M]A#!_P &Z?A?9#&OVG3/$[RX4?O&^WWZDMZG  Y[ 5^*_P#P:B?\IM_AK_V#
M-;_]-ES0!^B/_!>K_@YI\??LV?M,ZI\"/V=;;38/$'AR5+'7?$MS8C4)_MSJ
M#]CLX&!C+(656=T<E\JJC:6;Y2^+/_!4/_@JE_P36M=!\=?&";Q%:^%]=N5A
M@B\3Z!IEQI]S(5,@@E-NBR6[LH8["\3D*V/NG'S+\;KR+]F?_@XMUK5OB4?)
MTWPW\=AK>L37(^7["=9%T)R.Z&W99!ZJ17[5?\':7[2WPYU3_@DA-H-MXJ\-
M:QK7B_Q!I<NA6]E?PW4MPL4GG23QA&)\L1 @N./WJC/S#(!]0?\ !,O_ (*P
MZ3_P5!_X)WZQ\5-!LQX;\6>';2[L->TH.)ETO4H;;S0T98?/"ZLDB%AT)4Y*
MDG\*OV0O^#J[]JGPMXJ\3?\ "9^)&^*6H:IH$NF^$M$_X1VQAC.MS3VZP3/]
MD@CFD5(_.(B5OG8JO!.1]8_\&?/A#5K#]@7]J779X9ET/5)XK*S=@=DD\&G7
M+SA?<+<09^H]*^ ?^#6?PQI_BC_@ME\*EU"SM[Y;"VU>]MUE4,(IX]-N3'(!
MTW*>0>Q /4 T ?L5_P &\OQL_;>^,O[0?Q/N/VJX?'FF^'X]#M+O1+'7_"\6
MCVYN)IVRT!6",Y2.-@T>3MWJ6 )!K]9*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** /YT/^#X'_ ). ^ ?_ &+VJ?\ I3!7V;^P5\:_
M$W[.'_!ICIOCSP;J7]C^*O"?@'6]2TJ]\B.?[-<1W]X4?RY%9&P>S*0?0U\9
M?\'P/_)P'P#_ .Q>U3_TI@KZD_9Z_P"5,_4?^R9:_P#^EUY0!\+?L$_\'(W[
M;OQO7Q=\/?#L-Q\:OBYXO2UB\(H- L(8/#T<?G/>W3I;Q0K(2AA"F9O*0@LV
M?NMR>G?\'$/[>'_!/#]K^;0OCIJEYKEQH]W$WB#P=XBT:QM?-@<"3]Q-;Q*8
MRT;YCDC9D.5)#J,5W7_!E%80S_\ !0OXG7#Q1M/!\/95CD*Y:,-J-EN /;.!
M^5>;?\'@D:I_P6"N"JA2_@S22Q ^\<SC/Y #\* /L#_@ZS^.'[1?Q+^#^CWW
M@&WUN;]DOQ=X&T76_$5TNEVC6@O9M0:6W\R=E-Q&QS8_*C!<E>N37YN?\$=/
MC-^V]X%T;QYIO[(-OX@O+.2:RN?$\>F:)I^H^6Y69;8N;J)RN0LP 4@':<C@
M5^V'_!9W_E53M?\ L2?!/_H_3*^6?^#&[_D,_M)?]<?#O_H6I4 >"_\ !TYJ
MWC[7?AU^QK>?%2.ZA^)5U\.)9?$Z7$$4$RZB6MC<!HXP(T;S-V0@"@\  5^P
MO_!"CXF:?\%O^#?SX3^,-62\ETOPKX2U/5[N.T@,]Q)%!=WDK+&B\NY"D*HY
M)('>OS._X/@!_P 7_P#@'_V+^J?^E,%?H/\ \$3?VM_ _P"SE_P;U?#[QMK6
MLV=U8_#OPAJVK:K9V<Z2WBI;7EV[QB+.?,/RJ <#++D@'- 'Y@3_ /!<O_@H
M=_P5A^/WB32?V;=)OO#6DZ'FZ_L/P]I=E))IUL6*QF[O;Q3^]8@\!D#$-M3
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M#P7JNK7&J_8X(?,N86NQ$_E1HL0V^6G 0 XY!R<_EO\ \&[O_!<7]I_]N?\
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M1NFAEA!*QW")F0&/".BO\J%1O^3_ /@IC_P<(?M&?L:_\%I?&'@>W^(D]O\
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M_P &7'PS\:> _"%I\*?B1K/@K7=!L?L>L7FM6 U6/Q'(79S<LJ21>1(-Q4!
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MQ!^)7C>Z^+.N>&[A+[3-+&EKIVD6]RA#1RRH9)'N"C ,JED3(&Y6 Q7Z_44
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MPYTW_A8W_"O?^$!N;^X\S^PO[4^V_:5@7&//AV;?)SG)SNZ#'/WE10!\S_\
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M4-GI.O\ ]@A-/\,;;F&:26*T\_=-,Z1M%O:50JROA<G-?9W_  1"_P"",/\
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MCU_PO/\ MC^P?%<GB;^Q/^$1\CS]\DC^3Y_VQL8WXW>6<XZ#/'TI_P %P_\
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M_P OY_YGV@__  6X\9#IX#\-_P#@?/\ _$T1_P#!;GQDQY\!^&@/^O\ G_\
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M4N4/[/P_\OYGVF?^"VWBX?\ ,B^'/_ Z?_XFF_\ #[SQ9NQ_P@OAW_P.G_\
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M/&)/_(B>&_\ P.G_ /B:^+XTW4]XPE%D"R^@_L_G_F?:(_X+7^+O^A%\._\
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M%+,0: ^*?*@^HX?^7\S[7_X?8>+O^A%\._\ @=/_ /$TI_X+7^+O^A%\._\
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M[\*_AJ5Q_P#$U?@_X+[>,Y?^:>^%Q_W$;C_XFOS8TO4\@'=6[8:EC%'*=?\
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M(OAO_P #Y_\ XFD?_@MKXO7_ )D7PW_X'S__ !-?&14-]*0Q\9HY4']GX?\
ME_,^R#_P6^\8*?\ D0O#?_@?/_\ $TG_  ^_\8?]"'X;_P# ^?\ ^)KXSE@#
M=JB^RY[4<J#^S\/_ "_G_F?:/_#\#QA_T(?AO_P/G_\ B:>G_!;KQ>R_\B+X
M;_\  ^?_ .)KXGDAP>G%.@7;1RH/J&'_ )?S/MK_ (?;>+?^A%\._P#@=/\
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MI_\ XFFG_@MEXO"_\B+X=_\  Z;_ .)KXSV?+[U#(<*U&@?V?A_Y?S/M,?\
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M#O\ X'3_ /Q-*/\ @M=XN/\ S(OAW_P.G_\ B:^)U;FIHJ.5 LOP_P#+^?\
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M /B:^+P=RXQ2[03CY=U%D-9?A_Y?S/LF3_@MQXQ3_F0_#?\ X'S_ /Q--/\
MP6^\8#_F0_#?_@?/_P#$U\:O'D=*B:WYHY4+^S\/_+^?^9]G?\/O_&'_ $(?
MAO\ \#Y__B:<G_!;WQ>Q_P"1$\-C_M_G_P#B:^0O WPZU?XH>,;#P_H%E)J.
ML:G(8[:V1E4RL 6/+$  !2220,"J.FZ1$/$]O9:A<?8(/M:V]U/M\S[,N\*[
MX'WMHR<#KCBCE%]1PW\OYGV@G_!;3Q>P_P"1%\.?^!T__P 336_X+;^+E_YD
M7PY_X'3_ /Q-?+?QM\'^&? OQ,O]+\(^)?\ A+M MUC-OJ?E>7Y[,@+KC@?*
MQ(R!@XKCYX\T<J%' X=KFY?S/M$_\%OO%H;'_""^'/\ P/G_ /B:<O\ P6[\
M6,?^1%\.?^!T_P#\37P_+&P>K&E:5=:WJ4%G8VUQ>WERXBA@@C,DLK$\*JJ"
M23Z 4<J*_L_#_P OYGVZ/^"VGBTC_D1?#O\ X'3_ /Q-,E_X+:^+D7CP+X<)
M_P"O^?\ ^)KXLU:QO/#VJ7-AJ%K<65]92M#<6]Q&8Y8)%.&1E8 JP(P01D&M
MOX6?#/7OC7XUL_#OAK3Y-3U:^R4B4A5C4<L[L<!44<DD@#ZD G*B?J.&2NXJ
MWJ_\SZN;_@N+XP5O^1#\-_\ @?/_ /$T^'_@M_XQE/\ R(7AO_P/G_\ B:\B
MA_8&NM>U5]'T3XE?"_7O%48.-$M-6;SY7 R8XW9!&[CT! X//%>,ZIX;O/"^
MLW6FZA:S65_83-;W%O,A22"120R,.N01BBR)AA<+/2,5^)]FK_P6Q\7D?\B+
MX<_\#I__ (F@_P#!;#Q>#_R(WAS_ ,#I_P#XFOC&)<$_+7H'@[X*6OBG]G;Q
MQXWDO[B&Z\)7MA:0VJ(IBN!<.58L>HV@9&.O>EH5+ X:*NX_GU/HP?\ !;7Q
M=G_D1?#G_@?/_P#$TH_X+8^+\?\ (B^'/_ Z?_XFOFOP7\&+7Q7^SIXZ\<27
M]S#=>$;ZPM(;544Q7 N7*DL>HVXSQU[UP40R1_M4[((X'#2=E';U\O,^T1_P
M6R\8$_\ (B^&_P#P/G_^)IX_X+7^+C_S(OAW_P #I_\ XFOB^1 @J&2=8QUH
MLC3^S\.OL_G_ )GVHW_!;'Q:O7P/X; [G[=/P/7[M>X?$']O+Q)HGP^&HZ)X
M?T'4=8A=7DL)[QT^U0,@97@8#YB<A@"/F4\$D8/Y:_; []:]B^!/Q2T'6Y=+
M\-^/+BZM]*LPT&G:M"QW:<&.0DRX)>%2201R@) RN /G.(J>9QIPQ.62UIMN
M4&DU.-MN]UTLU\]$=.$P.7W<<1#1[-7NFOS3ZGO+_P#!:WQC'(RMX#\.JR$J
MRM>S@@]P1MX/M2'_ (+8>+P?^1%\-_\ @=/_ /$UY9^T+\#[7P,9VUB::[\Q
M5N=.U>VP_P!MMC@;U8?)<* 0>"' !!XP*\6U3P-?6VB/JEJ$U/2HS\]U:DN(
M?^NB_>C^I&/>EDO$V$S"G%_PYO3EEH[]DW:_Y^157(:48NK3CS0[J_XJ^GY>
M9]='_@MIXN'_ #(OAO\ \#I__B:!_P %M?%Q_P"9%\._^!T__P 37Q1$XE-2
MF*OI.5'#_9]#^7\S[4_X?9^+?^A%\._^!T__ ,336_X+:^+QT\"^'#_V_3__
M !-?%GE[:7R]U'*A_P!GX?\ E_/_ #/M%?\ @MMXP[^!/#?_ ('S_P#Q-.'_
M  6U\7G_ )D7PW_X'S?_ !-?&%M8R7UU'##&\LTSB.-$&6=B<  =<DG JUXA
M\.7?A36KC3[Z-8;NU($B!@VPD!L9'!X(J>:-^7K_ %_F@_L^AOR_G_F?8P_X
M+9>+C_S(OAO_ ,#IO_B:/^'U_BW_ *$7PW_X'S?X5\5E,C--DJN4/[/PZ^S^
M9]K_ /#[#Q=_T(OAW_P.G_\ B:/^'V'B[_H1?#O_ ('3_P#Q-?$P.*FCYI60
M?V?A_P"7\_\ ,^U/^'UGB_\ Z$7P[_X'3_\ Q-(__!:[Q>O_ #(OAS_P.G_^
M)KXQ$FT=*BFD -%BGE^'_E_/_,^SI?\ @MWXN3_F1?#?_@?-_P#$TU/^"WOB
MY_\ F1?#?_@?/_\ $U\173;Y*;",M3LB?[/P_P#+^?\ F?<$O_!;GQA&./ O
MAL_]OT__ ,34#?\ !</QD/\ F0O#7_@?/_\ $U\8J-R4P0Y:BP?V?A_Y?S_S
M/M>W_P""W/C&8<^ _#:_]O\ /_\ $U8'_!:_Q<?^9%\.?^!\_P#\37Q.@VX]
M*<#FCE0+ X?^7\_\S[4;_@MCXN4?\B+X<_\  Z?_ .)JN_\ P6^\7(W_ "(G
MAO\ \#Y__B:^+KJ?9&:RY+CS'/-'*@_L_#_R_G_F?=5O_P %M_%TP_Y$7PV/
M^WZ?_P")JU'_ ,%J/%CKG_A!_#O_ ('S?_$U\+:9+EZUE.U/PHY4']GX?^7\
M_P#,^SI/^"UOBU6Q_P (/X=_\#IO_B:*^*99AOYHHY0^H8;^7\_\R2)0ZT%=
MIJG8SD "KA;UIG=$=%)Y1I9)PPQBJS-@T*V6H)OJ$S?-]*$?;1(.:C#?-0!,
M<.*:J[::K8J13NH%U IOJ"ZM,QFK2X[4.N0:"K:7,0C!JYIWRGZU'=6^'^M2
M6 VR?2@18NX\BLV1=IK5E'F+5*>WP>* '6DY55':KD<N:HPIS5J%.* +"OS4
MR)G^&H(DR:L*,"@IZC&@S5>X'E YJ]LK-UA\*: D4WN?WM7;63S ,5C%\&M+
M269A027W@RM59[7)Z5?7E:C?K0!G26S!<U4DEVG%:SC,35D7,#+(: 'VL^']
MZTHSG\:R[:(F05K1QX44 2=#3C*%'O46XT<M0-NXD\O5JHR3X-7)8\C%9=P=
MLQ% C0M+O<<=ZL2R?)659G]Z.<5IE-R4 9MY<,3UJ."4A@:FO;4JU-M;1G<>
ME &G9'<!3[E]B&I;*+9%[TV\@+*: ,6>ZR_6I["YWOBJEU$5F-3Z?&RR"@#6
MACW#.*<;?;3H3^[%2,0!0!#Y?'2FE5'6GRR;:C+*1[T (101D4[S*:?GYH'L
M1,F332N#4C_>IDAH(%23%*\IJ.DD_P!6:"B*:XW5 H\XTR5LM5JPBR: "&W.
M?:K07:HJ>&VROI43C"_2@4D)'\S<5?M5Z5GQ,%:KUDW/K0+J;%@-M:L+<"LK
M3SDUK0X*?2@SDC3TR78175Z%+N&:Y'3#N?Z5U6@''%!S2-]3OBKQ[_@KMHO]
MI^ ?A?XJ49.R?396]RJ.H/XJ]>R0QYC'O7(?\% ?#G_"7?\ !/NXNL;I?"VL
M07.>Z(7,;?AB45,11TG%^9^?FEWC!16Q8ZE@CFN5TVZRHK6LI<,.>M4>@=UH
M>H^8,;N:ZG36#*.:\\T6=E<?-79:+>%E7GF@#IK63I6I:7.U16):R96KUM+Q
MUH*;-4S>9VJ-6RU1V[<4_!!Z4NI#V)4?%#C(J,/S4B/CZ4PZ6'*,"D,.^G(0
M13U.10-(S]0M]@!JHGWJU[E-T1K,:':YH"2Z%VP&8\>E1WL=2V)VQTMQ%YE
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M[,'Q*^&W[5OQ=L?AC=?"'PKX9T'Q$D]OI&JZ;),=9TV58GDBDEG9\3$A,,"
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MO;^MA_B3P7X;^.G[27@[PWX9\,ZI\.[SQ!);V6N:7=*PBT^Z9CYKVZO\XCV
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M<DDU]!_LLWTG@S]C#X\>)M-9X=;:/3-$6YC)62VM;B8B;!Z@.#@GV'I7AGQ
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M[MG(6:)QT*NA((/?!Z@&O-SK(*&,IR<5:??OY-=;]_\ AAT\3.GL]#U;XH?
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MB=FU7Q1)-'@LJ6ECL<@''5F(!^@-<9X_T#P_\,K0?8_#5UJ,JXW3:E=.1R<
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MMH-@JPHP*6)0BDU!)+M(]ZH)#IDW#'K55[5E]ZL*^ZI%7=B@-BHELS8[5.L
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M./+(];_:J_95D^!=U8^(O#MZOB3X;^),2Z/K,3>8$#9(@F(& X&0&(&[!X#
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M .?6E<R=2*;3Z*[_ !_R.4^S[A5.]@P#Q6[XNTQ?#'B[6-,C=IDTV^GM%=@
MTBQR,@)'0$A<G%9$[^8#3-MUH8\L&U^M21/S]*F=02>*8D>!TH))X-Q^E.>7
M&:CB<K4R1EP=R]:"D);?,>M78-JU5BA\L^N:L1?)0/J6DZ5'<'-$3;CUJ1U^
M4FIMJ,IH3NQ5ZWCRE5XEPU6X?OTKB2L/2W]J;(F :L L=O%5[R;RNM/9#&J.
M.E.1#BJC7WS*!5F"X#BA(">&'-5M1A^4^U7(KI57'>J]XVXTM0,>.+9)CM7N
M_P"R?^U2GPD@O/"7BRR;Q%\-?$&8]2TV0;S:%L SPC.0PX)4$9P""& ->'_9
MV:2KMO&5--&=2G&I'ED>R?M3_LMR?!&>R\0>'[S_ (2+X>^(L2Z1J\1WA V2
M(92!@.!D!B!NP> P('C,TVTFO;OV6?VHU^$<%YX3\66?_"0?#?Q#F/4M-D&\
MVA; ,\(SD,."0",X!!# &J/[5W[*DGP3FL_$'A^\_P"$B^'GB'$ND:O$=X0-
MR(92!@.!D!B!NP> P(!Y,RIU)1E[*KOT??\ X/YGCD4VXYJ4/E*K)E<U*CY%
M2=*) H)YILT/R' Z4Z#EN:M"VWIZ570;U9CD;&/%!RR?2K$]O\U206N5QC.:
M.8CE,EHL,S?WJ(7P,=*O75IY8/'%9\R[&HB,N6TV!4WVG -9]LY!-27$F(_<
MU0#I+[<QI@42U2>0B2K6GG=^= HL=]FQ[U#LW-BM&6W^3BJ<EN5)-!0MO !4
MWD8%,B;Y:>\WEK4I&8;O*--GN-JBH9+C>.*8=TN*HKE)#*72JUZF^K5K#P<C
MFGW-MO7/<4D29MLK!OEK?TQF55K)MX-C8[5KZ9*1)CM0E81NV$V<5T6DRY K
MG=.A#<UN6&(R/:E$RD=-I[945I1+E161IDFY.*U[4X6J.=HZ'X=7W]E^-=+F
MZ 7"J?HQVG^=? G_  4J\&?\(+^V[XUC5-D6IRQ:G'Q@$31*S$?\"#?C7W78
M,8)$D7AHR&'X&OF;_@M3X86U^-7@OQ-&O[O7]!\IV ZO#(2,GUVR+4Q"CI47
MH?*>DR;L5UV@RXQ7 Z=?;378>'K[<%.:H]!,]$T.0E5K<4[XC[5S6@7(9%KH
MHI@83_M4MD45U?\ ?&MG07(EK'*?O.GO6UX>3+Y/:GTL9G26APO-5-6N/*@Z
MU;A'[O\ "L77)2QVT 5/.WG.:NZ<=Z5CE]K >IK;TI?W(]Z!(+ML?C4%O=8?
MGI5Z\@PIXK+F38=U S7A?<M#-NK*@O&C]<5I0/YD8)H'<CE+,:EM_O"E:W8C
MBI+6VVGGH*5Q&C;Q;DIES!M'M2QS>6*5I]U,HR;JWQG-1)\AQ5VYQOJ'9EZ!
M20Z$EB*F9C&!WJ '::GB#2'D4#B-5BTHJY"0,5"8,N&[BID4\&D$BTASBG.<
MBH0PS4P7*BEJ45)%*O5BU3YLTV1,/FI8]W%# L+!N[4YXL"G19*T7#;$ZYHV
M KA<-2JNX_PU6EO<$XZTZVN\_6B(7+D46YZOV'AB\U[*VL#.J\,[$+&GU8D
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MI2+J<_V+?/\ X!G^!OV<_$'C7XZ:%X"OK"^\/ZMK5U'"Z7]LT4MK$P+-*48
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MB.F06^UJD(P_I210YI@HH,F[%9NHWWES<&M+P7IEQXRUZUTRT7=<7;[5ST0
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MV^D_V='$F94A*!9$B7IEV=F8GDE0.P ^/R/(UF^9*C.HU!)R=MW:RM\[]?\
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MW(:I3V.Z7TP<UJ!&#<CBAK<$]*-B[%6PAV=JOKTJ!1L(JU"FZF,@E4AJB,@
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M_=*#'"C'3/..<=3VVD?'36H]5T^#2[S5+72K:'?$AD$4T[L5+.[1\;F/08(
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MS)N6)., @' "CJ?K4,^;S2NY5>1;(]A\9_&K6O[2FO6MKFZM0,&:(C,6<Y+
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MDKJCH@X"M'Y9 ' ' Z5U/Q@\4PV7BM=!O]1ALAI%XP6X#GRTCX#!MIR",+@
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M2"W?S4U.%W!C=" 0'C PP)! Y!.37,>&M+32ET;4-3V2V]Y@B$Y& I*D$<9
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M\?1D[\BZGD/BK2=<\!ZE-8VY1Y-*NS P+X\L/AE=1W#*,8QUQCO7*Z]K]_\
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MQ"V"'@%G0$DG/T(QGTKL/"7Q2\-W-_\ 9[J&V.GV<(BAEDMXWFGWJRJZ'Y2
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M,=J?I\JRS 'L:J0M"U8Z=MCZ5>M5:,[3TJY:K&(_E&:)$52#C%+F(DC6T1\
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MS_9IE9"RNC!E8'!4@\$'J"#7T[\*/VN])^(&L6^G^*F;0I)(]D=[&H-L\IP
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M+9P,<Y/ )XKP_P")'AEOBY\4-2\)Z'JWA[5(O#,1\_1H]0#ZA;C(#3318"#
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MU2SBN[4NHP'$<@(W ="!G%>S0?"S3=9D^V:BJ:A?2JH:>X48VJ!M"H,!5&
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M7W3:MJ<Y9^'=)L?!]UX@\1>(+;P[H5I=Q:?]IDMY+F26XE!*HL<8R1@$DG@
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M.^-\ICC49?! SR<9QUJJFEZ]H7B2)KC1;^,/;3O:-<6LL<5X[ (%5L '@D@
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M955:T')VC?1;:>FM[KS:6IW=YX8T_P )WR;=7U6&XN<QP*=5(DR 6(4E3D@
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MK,FX&53R&7N!G/;@UU1JTJT_91EK\]#:MEN)AA(XVK3]QR<5+HY*S:];._\
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M@SW,2X@LA!$H3  !=N69B.I/YUXO\3/$$U_IS7EK-=/J$TPW77EGRHMWMR,
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M-?:M<"8J/+7Y0D2] %7& !TKYW%X_$X=\E2SZIH^TP-3!XJG[6+:MHXO=/\
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MM;Q;R19KB7;.67?A<9Z8/)^GY5Z?\ _#?AS6]"_LJ\L;;5'UA60R&("X1N>
MR@$>@(P0>]>;7@E[JU.*5K66K74\A^"FIW6EZ)YC2-)!O/\ HTBB2.1,<YXX
M)_GWKV+P?\*]'\>^)],AN;*ZM=/OIA++<B0A4C# ,".<$?W<@C.1Q7J%U^SK
MX8\/^!I+2U1M$DO8A!!NQ))DGDA<EB#R,GL<@UY?J-SJGPW\;S>&S);.M],\
M<<,4Q8(L:J4D!QU8%@0<$ ?0GQ<=AY3@ZE-VDEWW\F>KD^92H5%0EK"3^YO2
MZ_7HRQ\*=0\5:EXI\96/BKPAHO@[PWH]F?LCVNGR6\]M<"X98XQ<,BK<"2(
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M. Q<Z"E&7*WMJM]M.O<^MX;SQYME=+'6<542?+)./1.Z3;T?1]5]Q]U_L^_
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M:7*K6?5WM'Q._CN-%TXS6DTGS_,L>XDGG!&.E7/!_P 9]?\ A_JT:R-,UNS
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M_A%(]'7QC)9+_8DNNP'^STD\U#)N8@*&,>\(6(7=CD"NBI3C1ESX5.W1;O\
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MW81H2RE04/ 9>Y!((SGIFN\\2:I#!X&DAMFLX#?1 I/>LS7+J7.0J[F0$@'
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M8,"",]P02*ZOX0_LO:+<>.M+U+XJ>/-'FMKU)+F4WM^\\LL87$3.B[I KG!
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M\(R+/<+IOB:!"^FWD0"DD=(I1W1B,,#T'(YZ^$Q^)K6W>W^SB219?G$C2B/
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M ?,@SG(YX))'8YY%>8^)=)O;S3+NWGF2SF6[DN5O)&8B=F0!E<LQ5%&T;0
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M)=W%U*=B@@ X4\#)XXZD#O7S9X3\"?\ "J]3U5M0=1%'JLEO9JH)S#@.A(Z
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MPD0(C07!FCCSQD#)  ]/SJA,MS9W.A^'X;C^S;+5KN*.YN-O5F8*">0/ES@
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M2NT#!(SG SR.O%?/XRI&NG&?O7Z6T^1PQQ]:G65>C-QFG=-:6?=/OYG@>O\
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MT^%E56(CV!4()7D?,<\8KR[Q1+<^#]5AUSPQJ5S%,ETZ+<VLA2:W#,0H# #
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MZ)N^SZ7I=FK  B*T1<@=,G';)Z^M0W?Q%TW6K-(;ZUTV_MAD^7<6J-LR,<'
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M,2"1>0#A6Z'KU[U\W_"'XR-/J4LECX6L]2;S8$9;F 3#R(E**)%)P=JC).<
MCT %>C>&[GQWJ7B)]8A\/K*VH2>8D5K,@ 4#"A8MV0   !SP!UKV.+*F45L%
M3A@/CV;Y7LNEW;JT[JY\5PG1SYXZO5S)^YNES*UY=4E?9)JSLET[GTTF@R>*
M[K3X;7>;N2/RMB@-\W0 CKG->:^)/V,O$VD?M/Z'=W%C;Z/:^+!(;Q[F4)$)
MH0-V#_>=65@HY)#^E>]?\$K=)U+Q3\1M0\0>(=.DM=)\/6S&*6[C*B2X<@ +
MD<[ ')/..,\U5_:VD^*W[2GQ9TGQ5H=AI.A^!_#L\TV@KK#FVBU21)8U$Q8Y
M+&1MN !RN,9P<_G^6Y;6LZT9_#?2U]$M6^R_R/TC#YE&%3ZK72Y6EJW97?PI
M=W>QTWB.*/X2>!)M+T];6T6U(2ZE\])'C=A\IEVDE=W100..>IKP_5_CG8V5
MYMN);B1R2-X8$ \YXYXZ8Q7E7Q'O/^&<O$_Q(UZS\&>-H=2^)5UC5M3N[V*_
MTRW8R^:XA>(MU;A0Q!49& >*\@O_ (JI?W :*7=SDJ>"/4$=<UZ>5T_;P<ZB
M5[][NW3T/2XAE3P=:-+#3<J;C%W<>5.32<DM7>SNKIZGU%=^+7\5Z>US#>1L
MD7"H 0P(X ;G(! ST.!S6':>+;S[:L;/;P$. C-DAR?T&/?%>"Z)\3Y[&5)(
MW968\@]/RKM]#^(8NH-]Q"PW9!. 01WR<]3T-?9X?+\OK4.6;Y)+K?\ '71_
MUL>%#&4YGO?ASQQ=>%;B"\MY-TRD;F;E.HX ]ZV-:U;3/BGICMJ2!+Q"3%<@
M /&QYPQ_B4GJ#^&*\5T#QC):I$E](T4$@/DKRS.N< 8[8X&376>&9I+JZ=84
M9H9V *+RV2<#COGVKY.IAU3D^5[=>X_K#D[;>1R,7CW4- \42VOD/%+8RD2I
MO.)#R00>F",'/<=ZZNY^-MG-$D&HV=Q$9"0?W1='W9 .Y<].I&>A_"M?XP?L
M<_$+Q#XJTF;0-%6ZBE@*Z@WVF-%L&!#)YQW90LK< C/%:&C?L&>(M/E^T:KX
MJTFS++_J8(GE9#GH2< CW_2O=R_B)8.DHMKEWMU_ <_:\_+35^^W5?Y'G\7B
MQ; W46DW4,EO,@9H\X:+KSCU'3CJ/?-9:^*KNWU5;P2+GA2,Y'3!%>EZ_P#L
M5W2Z@L]MXHMS/GY]]NRJ1C!Y!)S7--^S!KVA%_,EM=23<0/(EP<9X^4@'/YU
MQ8[,*6+K/$1BHWMHOZW)JTZW*KK\;G%_M&Z_')X=T+76G^S"9Y+)U7@R,H#
M@Y'0&LWX?>'?B%XLC#:'X;FNM/D4;Y]0 LT<C. &?!8$@C(YZ<CBOH34]#T?
MX>>$/#^FZAI=C?ZY#YE[%)-$)&L/, 7*YR Q5>N,C/!%0V?B6:ZDROF-$#W)
MXQVS_C583-*V#=\-I*W7L];?D'*IOFF[>GEIOZW.;\+?!;QII-I+<;?#\.I"
M$B*!;W=M8C)&[9R?X1S@#J><UGR?!CXD1K"U]I:W$* DO;3QSX!.>0ISG)/
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M)I?NT[ZI)-ZM[O7?J:NBZ;I?Q5NH/%*Z>NCZ=J5VTS*#O1"K!5!W''!R,@$
M,23WKZ"_8N\/1:T\&K6<%Y,-/O;NW:W8@I<^:Q82D\D@ #D<= .F#P7@[X'R
M:9X>BUCQM?75G"%:&UTNV !OVC#NX5>5.], J1SR0.,CU3X>>.-=\ :1''8Z
M1-X8T^[D_>/=.EQ,F 2HV* $4#H "1W//'H9ABYN+A'5=/ZZOT^1Y=2I)1Y8
M;6MV_I^2-C]K_P#:!\?? /X9Z;>>#_#]EK%U?7<\,L]S#)/;Z2J1[XD:./+L
M96RJC(Z8!!(KHM?\97VH^&M*O-7TI;:ZDL89-4L+=R?LEQ+'\\08@$;22%)
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ME0R#-PDH9$&>2>X&/6NN\5>*='A\5ZB=(TZUM2\@2:[BB"S7C(H169NI "#
MS@>E>?3K1@_:+^G_ , TI\UE"6G7:^B_S9X_X%^$_P 3M>2#[5H>EV%BK81K
MZZ2"6-,9SY:@D'/!!'X#K7H%U\%?'$&@06NE3Z).[R"2<K=>6=PY&-R@;1@
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M"9('!&"986.5R><CCGH*O_#TV_C#6]2US2]<TFU\,-(+5K,VKI<229&)1D<
MG<,#@C QDYK]$IYA1G'D;2ZZZ_\  /SRGB&URNR]==?3S-;Q!XPU*/P>MQ>"
M'5;JW5?+>Y81"1R^%4'H I.2!CCWQ6C^S7XHU+QQXNU.U\36%K--JWF16\DD
M0C0/$.JHWS8SD'L>G/2K^G? !KNV_M+4M3AU.UM3((CO0Q11L00#'@*P&.21
M@'DCC-<IX[^*EUX9^--OI\.B+HFFZ$%O_M*.9I-42)5"Q;L_* 2 5X SD@\5
MAB\5!KEI:)]M_3[^FB-:U:&T7:^[6YZ=X<_:-^%?Q4^(6H>%?#OCG3]6\2Z#
M'/#<6%I,V"\#;9_)=E"3-$P*N(V)0@AL$$#'\5RV/Q/UJ:"\-X+"UB<^<LPC
MF3*$!E.,!@<#&#^->4?LQ_L-^#OA]X_;QMX5\VXMH;>=--TLVBPW=I+,\K/+
M-.92'*K,Z#RT3<H7=D@D^T^"/"=IINK6]C(&EGE8_:&+AA ""6)))&57DG.!
MZ\U\S@<1BJL9/%047?36^G]?\,>EQ1A<HP]:E#)L1*M'DBY2E'E]_6Z2[+3J
M[=V?)G[1O_!0SX-?\$]=4CT6&\USQW\0Y6S-H]EJ 2+3HV (:Z=@41F!!5 K
M.1@D $5XU\:_^"QMY^T-\,I/".A^%'\*Z+K *ZMF_P#M-S?*2"8@ZJ@6-@ &
M !+#C(7(/YX?M1^,X/CA^VG\3?%MO"D6G^(O$=W<V;1L72>!9#%%*C'[P=8P
MP(XR2!@ "ND\ L^B>6T3L^T [&.TGT ->)G&:<J=)2<?33\=T?NG _AUE].C
M3QF,I<]31ZMZ/TORZ>C=]3ZB\'^$6^)^O:;INCZ?I^GS7Q(5I8P$MT52SR,V
M"=JJK$GKQ5Z7X56^C:)<>(?"OB^U\2:1I\D,&I1S:<;80"928945MRR1MTR"
M&4\$ UX[X#^/^N^ ?&6GZOI:J+_3Y?,"/B2$@@JR,N>0RD@CH0:]:\9?'[4O
M'OA'^Q(=&TGPCIVH7$,]S;07$US)/(JA80S2L?+A0* J(   .P K\^QT>57]
MI=^;N_U?]:G[%A?K5"JH4X-1TMHN7?WN:ZYOA^'EM[VKT.1OO@'9_$1Y$AN!
MI.M1HJA&D)LI^< Y(W1DCJ.1WXR<^?:IX O_ (>W5^M] \%PC-:8D4$$D@,%
MX(.1T(^H/>O0]=;6M*LSJBS.KP_)*T.<@CCD=#C&/\XKVCX6Q:3^UC\&-5TW
M7+?_ (J3085DM;R./!>(< MP0"I(!SU!]N*PF,Q3M*,KM=5HSNS&M".'<JL%
M*#T?6UW:[3W5WKV]$>6^#-)\/W5SIFL:YJ6M67_"/V%OI$6EVUP(9K9=Y>2Y
M5L@DD; 0,$ $$X->Z? OXR6_P]T_4]0UFYA72]_FB22#:;>(D#!*EBS$GL,D
MD  U\_Z=\,]4T'6H;>X3SV<G]XH.T8.!D_3FO=/A1^SSH,5CXIU#Q#<7DVBZ
MA:1SZLL[R30PQQ80"&-/F5BS+]T@DX)(QD?=9YQ%6SJA"EBXJ,87>G7:SVT>
MFMK)WV2T/YZRCPZR_AO$5G1E*I.MRJS;NGK[J2?O)MKE3O)66K>IZ1\*_&NC
M^);6^\8/=6LFCW$Y5I8R)YG9Y/+A"(I+$,P,?3KP<8-=)XB\2:5IRM-?2-:L
MF2\2X>6-03@8!ZXP2.W /(->#?&WQ!H/[$B^'=2U6ZA7X9:]-8W/A+2-($D%
MW/N!FG\X-M=8]KK(V\MND< @$YKZ[\0^"?AW^SCX&E\4^)I['1=(BE51>WV^
MYF+N,*B<,[,<$@ $]23@&OM*V89/2P-&6&O*IRJZZ1LEI>R^32LU;:SO\#E6
M8<14<TQ5/,HQC03M3:^)Z[N-Y-.R5XMIQDW=--->%_"KP]XN^/%_KBZSX;3P
M[X;M-2:+3YBO[_4[4 %7ZG 8Y^; [X!KT?P_^R9-+X2\49L[A+B[E:>PMEN5
ME\OR /(V.X.PML'!)5,\ 8)KX,_:U_:QO?#W[>#?$GX+Z_J]O9FPM;>Z2\1A
M9ZH8DVLKV['!B88 ! ((+#!(->D^*O\ @M_\4/&GPLUC0[?P+X7TFZU:SDLO
M[6M3<M]E5T*,R(S%=V"<$D@'G!Q7S<.*L33G)4JS@M-$W;37O9^K_P SU<SX
M;IYPZ=2MAHU&KV<DDU?3=KF6G1/[VD>I_LC_ +1_AWX'_"/7(/C9\5?"MOKU
M[KKW.CZ8NJG6+NQMF4"1)YH59 6E#2+&"0@)&1T%/_@HI_P4"^$.E_!6[\&V
M^CM\7(?$UE'--;Z?=>381('5XS+. 65LH"%0$@#DC(K\V]!^'\FL7\EO<2V]
MM#"HE,UU((X8%4C)<DC [8ZG.!S7<OXV\'R:]>6<6J2+NVJ\C6KFT+8Q\K@%
ME4= 2 !7@RG*K'FII+^M?+\-.Q]1B,OGAZBYI.3WLKV6R6NK[O5W;NV^I[%\
M&/CC\,?^"L7[3'A;1_B3HWC+P7XIG>#3VLO#TR7>BZY:VOF3I [2*9+;:H8L
M1E7 '1@"/T)^,=_J&G^"(5\5V7AFVADU"6TDATF[ECM_LC2;+4!Y5XF,?WER
M!NVA3DXK\BX/ASXB^%WBG2_&W@EH;C7=$OH=4TV= DBB2)MP!9>'4C((/!!(
M(P37VM^R-_P6)T_]I'XP>'/A[\7O -GINLZ[=II]I>V:,UK)-(0 D]M(2%WD
M !E8@$] ,FO0RVI3I8BG6Q4.:,7=Q_F\O^#^>QX>?87&8K 5:.72L^5I2W<-
M'=I/=:ZK=V5FMQW[3/@#POXGB_MK1K2Q,.H7%JV@727T]Q>:C;+&R7+W5O(H
M6W*SKM4)PW)Y&#73_#7QA=? ,06_B2XCTG1H8M1TV;4=*O!=WNB:E):HJNT"
M,0LRJV2&(8=5&2<>G_&W]E#7!X>6XD\00ZIKUK=W#I=C3EMHA:MM$5L40# 3
M:Q!P0-Y R #7S3\9_AS\1/B!--!JE]I,<!F:ZD6"W6%;B9E"M+*413)(P4 L
M^3@#FO>P7$.'PZG1HKV=*?.I1FVY*+O;EY$HIJ_9Z&=;AQ9G0P_UZJJE3#RA
M*,Z2:C*4%%-M5>>;4K-R3M=N_+HCC?VJ/B+X?\5>"?#VA:;K-WXIO=+NKR^N
M-6G2551;AP1;Q>=^\V(!G)P,Y(')%>(_"SX,Z7XVM_$6OZUJL<6G6"QPBWC
M%SM;B691)A6$*LI(!R<@C&.>B^('P5US1KL0S7+;3@[57:KDG(&>I)/05D^'
M(_$GAJZ%K9!8HY \3K(A?&\@E@&)"D;0,J!D9!R*\G+<PRNC6A0K-RH15^[O
MT[:7=WZ:*^_VW$%/.\?@:CR>:CB)RW;25F[R>B=F]4DDEKKIJO'/C_I]Y\._
M&ME91W;WT<UJLD#2L&66!F(C^3HH(R0,GDYX/%=?\,/A+KGCGX2ZI+,KV=K?
MJT=D90[/<8(&]54$^6&!&\X!P0,X-?2_P_\ V'9/C%XP/CGXB?9[?PIIMU'-
M<B8B"74U5,+!"% ;!  R % ).20 =/XC_&[^P-2OWTY[#1]-9@#M1(+>*,#"
MH"3C:H "C/  ]*^2SW,H2F_J$+J_NI]$K6[O6RWU9^A<)8/$X*FXX^:J5%%>
MUDFN7F>Z;2LFG)MI*T5;57T^3?B9X1F\%>$TAT/3KG4A"JQW#)$?-'&" N V
MTGN!TZXKQ_0OCSK6B:E<Z?*%AMH,(8+IO*:-NH .<@$>WXU])?%7QWJ'BNS^
MU1W,?F$GR9XV'[\8SD>O'?%>(>*YH?%$,T&L:?9WR%=C&:(;QZ8?&X8[8(Q2
MR/'8B%1JO#EGU3_R:_R/8X@PG]I8=5L+6C'EV2U6G:4=O/1B_L\?%%OB?^U=
M\-= DUJ;PXVN^*;*S34;.15GL'>=0)8RV%W9P!D8R1P>A_8/]I^^ELOA@\<.
MR.>TO)K&\1L,PR=Y!&  ?F!&  .,#L/QH_8:_8N3XO?MGZ+=37-S/X-\%2Q>
M)]5 DV73I#<1B"T5N@,UPT<>\<A-YP2!G]4/VLOBXVLZ_=Z3"D:/<7;WE\T8
M(5YFZ@<D[5 "C)S@#-?L62N=6*DTK>2L?P?XQ9A/ZXL/B)>_&+36]KO1I^=O
MP\SHOA;\8[+2?AWIWA6^U;38=-O8_/CN7A9WLR"Q> [6!4,S$@D$9Z8!S3=/
MU%IO$4UUX@O-;BT9$,.F7%J1OM6#_(6(.$R.<IR1C)Y)'E?PS\)1^+--FWM*
MWV5L2JB;B%;E3C.<$Y QW(%>D:!9V=AJES;ZU/?_ -GVB!2(H#/,5/* +D*2
M#G)Y(P>I&*^PIP@H\T==+M?Y?,^ P.*YJ,%TM=KR32WZ6>O_  "K/X7UO2]=
MEU:\TY#I^O,5CO"#_JV!Q*1C;N<#=UX)R02"3!JFJV/AWQ5>FQN&1BD6UHE+
MI P((+.H(/!SCG' XYK5^+/PDN-.TRPEM+METZ:W^U*MQ+*EF[;0&,0 !,@)
M&00" 2,#!QG^%?&4/AC15L-3L-/L[+4%+/>3VIFF1L 81EP3@_=!.,9SFO4P
MM1SH<T+2>S7=>G=6V/7P^(YL/R4VG+:SZ]=.[,G4?&JGQ'%?17<DES:@3V\\
M.%D1@WRCD=2!TQSZ5)\0?C#K'Q66WT75M0MIXK+-W;VJ*$BBG V@J.@.W("C
M"@8X'4]EJ/PMT'QE<AK,WT-O=0+,?M]N%EVL0%<HI(4L22HW$D8P!TK@]8^!
MW_"'7>K7EC+=6PT3=YWG6$LI-R,@P9"E5;: QW$ #N2*YO[0I.UH>\MKG/+-
MK1<513T[[^J_$XBPU74-(\;V[PQPVVH6N9=HPT1 Y.,C _7I4EGHIAGFAC*R
M274PNYIG.22QY 'X\9_J36GX:\+SW5U/>:AJ%FQED$7GGY$C4X8LPQD#;C(Z
M XQFO8/AK\)-%\5WUK%I,OVJ1;:22^F:,^3Y9DY*E@"0BA<, .N.:O'5U&*T
M]>R.S$5^:C%<OO6^ZYQ-OKMWX/G:\ACC3_A&]#DED7DEW8D)M'4LTC9 [X]*
MXSQ9JM[H.I:1+&K(-4LH]2W,A3<2[JPSP2I*'IZFO4O"'PHU/QGKTTUQ>V<!
MM9VO)8KESNU,1-Y<2# ((CR25  YR2,9K7_:*_98U[XT^.;72?#>L^'7US00
M/M6E3ZDBW.EZ;@+%(\0RP7*@@ 9^?)&3FOSOB3'4J;IRO:7-=/M;7_(]+P[H
MXFMC<1B87]FHWDEZI)OLEM?S\]?+X_C=>6UM''<Z>UT&(8&W(8/P 05X//)Z
M<8YJ#3/'5C:>,;.XC:2%&E5KNUEB*^;&'!8#@ Y4' ['H>37INF?\$_(=#,<
M^N>,I%F5<-#9VP"KQQAF)/7KD<^U1^)/V-/#]P$:/Q#J2S(1MD9$(X]1@9_.
MO%J\6>UHRPKM+F5F[/\ X:Y^M4Z>(WE9>KU.)\9>.+L:+X@CU#QW;>-)+_6E
MO=#C@TL68\/V:AOW!.T$DAE4J,C*$Y&<5Q?QOUQ=8^#UOJER9!)I]_';)L'^
MN,H("]"2<KT'6O0KG]E!M*NY7L];MK]=WRI,IC8#ZY(-=E'8K\%?AQ9VLEM#
M/J>I7)N S1AQ9[1M4J<$!\.Q!!R,BOGL'3IT(J$&VE=ZO4ZLPQU?%8B5>LHI
MR27NQ48Z)*_+%);*[TU>KU9\U^ /A)\1_%<4$FE68T*R;AY=8E\I74X/RIC?
MSP?N\X(ZYKU3PG^SGXBL%22^\3:&M^$.U;2VE>&-SD9SD9(' X&"21710:[-
MJ$A:,-LZOSD>OYFK5S\05LX50I(KG( 4#!Q[]>:]5YYCW1>'C/W&K6\NUWK;
M_AMC&*ITWS*[?G_DM#SV']E?XD(TC1^+?#J>:Y=LR3\D_P#;.BO08_'=U<KN
M=84[ .^&Q17E^VGY?<B%S=+_ 'L[/XLZ]8SD:AIY,$,P+^4Y^>/USZCT(XKC
M-.UFWN7W+<JTA/\ >Y'_ .JO,(/CI9)NC5%NI#\O[PER0!SU[G)(X&>!TQ79
M?"+3F\9ZA;21R^4K/F6%U&(XP<D XY^7CDY'O7J9IDE/!THR51.3W5K?->7K
M8ZXUE*6C=_Q9]-_"HB_\%V\FJQQM:3!OLZ2GYYUP07 ZA3T]36KK/CO3O!OA
MP?9Y;:" C;%"@^7C@\@<$>I_.O*?&'CMEU!KEI6BAB01Q(IPL: 8  Z"O%U^
M*]YJGBPVL,LA5V=ACYB1G  'H<=1CZUY>"P4\;7C0@[)_P!7_P" 36EJISLW
M_6AZMKGQ=M;_ %A]T<CMDG@]/QZ4RS\03>)+Y#"KJG^T<5Y#XQUYM398('5)
MV<-DL,!>O)]3].HS7J_P!\ -I=LNM:Q+(T/6&!O^6K#N>>@KMSC+Z.!K>RA*
MZLGKO=DT??JN,3UBR\+V=YX7@DUN1LL,10+RTJ>A]!Z&J>D>"_">EW#7&F^%
MM-:7<6:2:(2R;O\ 9+9&?I67K_CB,/))))F1R HST7T [5/IWQFL=$T>5%@\
MZ4C(4 ;NW3/ KR(QK5VJ%%-WV2W_  _I&F(E&E.Z5Y.U_P"OUW-76/$WD1LS
MV$Q13\P!V@'WKG]:UR'6_"6M6,&M:UX1GU2*-(]5TD(]]9JL@9PF[@%P-N1R
M,YKC?&OQP6UMI)/LZKYB[B P?&0"<\<8S@^XKS>[^,T<UV!YK!&Z[3P"?7VK
M3$9/B*'[K$P<;K[UY-?HQX;,JE&M&K%6E%IJ]FKIW6C33]&FGL]#ZDUNZTWQ
MOX-O-2A:90L<<%R)F#2NJJ%65C@ LV,L0 "3FOCCX@Q>)OB1\3YO"O@VV_M"
MZ5#)-*SA(+2,9R\LA(5% [D\G@ GBNX\/_$W6_B!K4/A'P?_ *3>ZDI2YDP6
MCMX3@.[CT / [G ')%=1KUAI?P9T4^&='NEE8D&\D!!>[F(PTDK#.]O10=JC
M@>_'C<RIT81HTU[Z_!>?F=V!PKE5E4F[PDD^7S77T_/\3S+X9_L6>$M%U87O
MC2>X^(.MMRFFP2O#I$3=<L<JTP'J0 ?0CFO=-0TY-.\+6^E6$5AH.E0$%=/T
MVV6WMTQ[+@'ZGDUROA&&2-"QG7>>[#(R?4^]0>)O$<RDPP;)I$(#,&*J#Z#U
M_"OFZDJ^*J6E)R/;C&A3=TDCKS>KIVGM' 'D+ [G/RC\Z\O\7W,<*_:I(YB)
MF*I)L(PP)R ?48Y&<BJ/B_XGZY82QPM:V[1( 0$<C/?!//6NA3XFV7C?P;-<
M75P]Y%9I>V=LDL(M9]/N6<,(G@4!9%(&WS1CD;N20#]SP[P-]:P-?'8NJJ:I
MJ]NKTD[:Z*]EJKOLF]#X'BSCBKE>887 T,/*HZSY;]%K!7TU;2D]'RKNTM33
M^'?Q TOQO\9OAUXPO(FLO'G@J[6W74@P6/7=/D4Q2P3_ /394;*.?O!=I[8]
MV_;5^"EG<VNI^+M+@475Q;6=A.\><M )9G4'L5)<?3 ]J^,O"UY;2>,K=+AG
MMT%PK@I(0R@'KG Y!]J^S]#T?5/B5X$FL;I[AWL]-DM[5C(0LI#++$2.C$JK
M*,C(('/-?%8BM)-4M[:+_@>6VGDCZJMA8W6,I^[_ #+R=ON:^[MH?+]EX@A\
M*W%I-<V*:Q/++,B:?(&CCG"0&2,AS@*Q8Y4D\F)@!P<U?$=C>>$]1@MIGFNK
MX644ER8I$D@\QT$A*L@ _CP20.4R !@GOO$_A32?#GB&TUJUU*XMM1@CE#F-
MVD$I9=JB1,[9$0%L!AG)'.,BO-[V:'2;$6MFDD5A",(TK%W(' )YQSZ<U^E9
MEQ/D5?A^E@,%0M5LN9M*_,KW?,M[_DU=))(_)<AX:SZGQ)5S/,*]Z/O**3=N
M5VLN5[6M]]VFW)LQ[31_^$AU W&HS-;V,,\44WDL/-P[$94'J0JL0.^T@>W1
M:/IUM'Y%Q;S".RO6D:T$ZF.:2 .RI*%(  ;8V>O3CCFN#O=:GTZYCN/+CNXX
M;B*=K>X4E) CAL J0RMQP0<#]#E_$#XL:QK-Q!_I<D:/*\-C;RN76VA9BWE
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M%]>J]&S]+-%^)WPU\-_!AM<LU:S^'NA2O"L=I;,HO9%?84PV&8%V_P"!'/.
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MC. <#GVQ751RO,:,/KBIR4>_^:O>WJK'F8B4*T.2K35OR\UV.\M/#%SX8O\
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M#X3FT&37+BXM4O)9Y9GMX(YQ%(Q:.U5855?+A7*H6R2#DXR /A_5O#NDZO\
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MU;F18T^=O[V<_P"<U6-]A.TJ4>5]>QQ2Q5]$=]=3KXO\+2*H_P!,M%+PL.I
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MG QJ5YJ%2F[OFT=_+I)6T_%I,\V^ GPFL_BQX_T[1[K;I-O*QDDNKV%V@>
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M?H[GH?CNYD^'"K-$[RZ7<G$4H/*9Z(Q]>P/?ZUS.F>*]/U==[S2-=*,D,^<
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MW_71GU+S/ZS5EB'&*=EI!**TBDK)62O:_F[MN]S5N?&^K2:=%;QR_9X5)9Y
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M6/$7CV"\O+_4+1+BVB%I.D$8B,WF2-.AB3Y8Q*-KEP5)/!&:](_:5_X)X/\
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MQ)9FTCDC.PJ<Y5NX8,IR<Y!(&#QT7A+XSMX3^'5H+6WCNF2=7E+,2X0%64J
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M23(&YL'/%:WPR^&5EJ_AG6]:\5);Q>$M-MA/JLLF2MP.%6)!U,SL0%P1@G/
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MKK/BBPLI 64SKN&>P.<@^V*^2?VSO'<OB7]L7Q8H?SK;3Y8M.7'(Q%& 0/\
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M&K76E_&2;7TM6M$NI(TN?XHI;H1 NP'/$BD.![D=J^2J8-XCE=[2CI>U]/\
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MUY3A9"^ N"PR, $$9!\C\<?#;X?V5[YVG0MJ2Z;;0:?ID=XI^R1+&@1,Y"C
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M@#D#!/4 _'WP]_8"^*7CKPQ'K']E6UG;WJF>4W,QBD2$_<+A5+#(Q@$@XZ@
MUV8'#VP_/7T;_I%9MFDZV,]CAM5!6NNKZZ]4>J_!GX[V7@>[-O)+=2:.^GI#
M=Q-/''AD8>24\O:S#=M# DDAF)X'/M3_ +1VA_$_Q7?ZA;Z5#8 (J3P0W;7:
M/<*H5Y5;/"$CY54[0<G R:\#/_!.[XA:S9Q0V]]X;EMPBLTB2/ B]M@^4D@#
MOQFO(;F'7O@=XLN+:QG_ +073[AH/M5F'DMWD7[P5L . >"1^7>OO,)Q-5E@
M?[-KOW=D_P!'WZ;W_*WP>#X-P6'S:6<Q3]I+IT72Z3VOKM;RZW^OCXF1?&%I
M?6<;2,D<MM/:,DDBZG ZG,10Y4$'!4X^\ 2#TK+^(7[3FH>/?&D0U2'3X+G3
M+:.W+6MD+47H0 ;YE(!:0+M4$] H XQ7 >!/VZ=4NM+T_3?LNBZ3>VX"^:UJ
MD6< Y+,S  D9Y./05Z?KOPKB_:*TK3;R^UZQ?Q8BK) C-$MK<VXA$LQDE0A@
M$)*<X((8 $ $^K7CC<XRF678=KDCKTV72]MNMM[ZZL>,APQD6;QSW%QY:]72
M]V[OORWWTY4[62=FTK6]ZL/@OX:O?%@\ Z>WC9?$S6ADEUD(!HT%U]FBG$2K
MMRT9$J LC$@D$C!KP'XX>$M1@\-:;=:\LVEWUU;+<6-]@,MW"V0I+*>F0<$\
M\$8(H^&W[;7Q,\$Q6>BQZOIM['I:KIPOY+6%+\6P.T1K>%3(BKV.<@ 9R.*U
MOBA\<--^)GAG5([%;RZU#6+ZWNIUOKCHB0A'BE4*H<F0;E=",#J!DBOSCAW(
M<#+ XC%8_$*%:F_<7=I:]KK5:+6-FVFF?;<4<59E#-<#EN5X+VF&J)*M)RO9
MW=WK\%TK6:Y7HHN,KL\Q\)?%:30[F"QU2)[>X*Y2<?.DX[$'WZ_RS7L7PV^-
M&O>$KPW6AZK-:-*@5VMW \Q><!E.00.V0<=JQ? /P:CN/!FG6^K6Z#7=?N%.
MBVLI+/;PJ3YTT@P,(WR@#UYXQ7U3\._V2/!O@G2K:XOM*75-0" R22$B'=CG
M:F0,9Z9R:*.8TZM+]['7;U/-S[(?J6,Y:$KQ>N^J\OZ_X)X)JWQ-N==U"2ZU
M"^N+V[GYEEF8N\G'<\GCL.F.*T-#\1KJ*^7%'<2MGY54$C/4D#\*^H[3PUX5
M:X(;1-'&WL;5/\*V[+2?"]C,C_V)IRG& 8H C<]>5 SFM:>.4=(77HSQ98-]
MSY'U'PY?7OS-;7$8[9C(X]N*F\->$;VYU&&..*1F+ *-IY&>E?6MWX7T'49@
M+>.:V8]B<K46E?#R'3->BOI)(9[:WR\:(O)8= ?45:Q%.6E[&?U9PU9G^*?A
M?I>H?"BV\*ZM-)"UPL=U?O#CS %&5C!.0"3C)]!7+^%_@7\/=*SMT:.8D!?]
M(D:1N.Y.< GO@"KFM^-O/\6WK7QD62X<*%<$* #V_&K27>G1W*<K@C)VMUP1
MTJI5->2&R_%]RE;EO4^)_AY&P_PB\&7$41_L330$&!B,+Q[D$9_&I!X$\+VQ
M"V^FI;E>,Q,1^F:I-K%I FZ,,58X"GK[X%5I->^7YE=1)RN>/ISTK:GAZ\H>
MTC?E[]#%\KU?Y'H7@_5]-\/Z++96_P DLQ&9<C)4=1GU-<3_ ,%"O%<UU^P;
MXAM+$^1<:_>V^G1JS;0(_-#-S]$/YUG#6F=BVW(QD'H>#R!^%<=_P4<\3?8_
M@_\ #O0_-$;W4TFH2ANI54 &1W&7-'-+E]":,:<J\/77T6I\,^&O@K?ZF%$V
MJ6=N%P%58S)G(YZX&14VG_LEZS:ZZLUGJ%K>6[,,C9Y;H.YQR#^!KI!?R!QY
M;M&,]5^8?@.M==X&U.XDN$VS.[*1[5QJM4W3^1]%.G0D_P#@G;^#/A;'X#\*
M%5E6:X9!N&,$>OO7&_%/QS):*FG6<4TUU*/X%)*9..F.IZ"O<] T.Z\2>'M]
MG#&^H2XB?S3A2IZL?<5YKXSU:WUCPRUKIL?D02,]R6C=A->(K;277( +,I 4
MD@#!YS7H9;EOUN5V[);GS?$G$D<JP]N7FD_AZ;6OKKIJK&+I>OCX4?#N*UEU
M:&ZU#4G\Z2TMDR$Z "1\9."N !GJW/.*]D_9Q^).H^!M'N+QKF:76]3:6:=8
MR-I#@<3%@58   QX('0XZ4W]G?\ 9[\'ZGHT>OWD;^)9]0C$RR7179;;259(
MT7E<-D'//RC& >>AM_A%-J&L7.M&]T'PYX7DG-K#)J%^EC#*48+M4L,MEV )
M.%!(&2:^U_V2A1]G4:C%=7MZ:GX[@<'F&8X]5Z:<ZLW=*";?JDOPZ(E?Q_K_
M (TLGAU+5;;SO+:+3;-(([:UBC8DL(TC55!(ZG&2><UPT=Y_PC%T6Q;1,7*@
M3/A <X.3^E=1XX\.ZCX;^(,-F\<FGZEI,11X6QLCR00PP2&!&",'!XQQ6)+:
MQ2:M=7,]L]\L>Z:XFC@R(U'+$XSMX].>PKV<'1A&CHERVNDNWR.ATZTU.IC&
MV^O,VWYMWZW[LI^$?C!?^ )M8\RSL&M+B01$HQ=$;!)+*>2"<D#(X'(-1KK'
MA?XI7#?:-&FFO8P&,MM,D*.CC@E 23QD\G@>HK8\3^'?#_\ 8O\ :5I<-:S3
MPDC<Z'S6()VLIR<\$8P#7GO@_P 'Z9KFN26\EQ<6#WP!D\I 6R!@G Z#)ZCI
M4^SO%SCL<<<'?#RJT:GNKH[67E?4Q[[PCI?P(\:7&K:+'<WVES2YGL6.9-HY
MD"@G R!@#.,\<#-='\1_V]=,T'Q#J]UIOB_7O%%OXBU2UO;"RNK 6D/A"V16
M#0J^X[@Q(4!0!A?7D]+XA^$S7'A&.\MG:XU#2B8[HNI(O8B0$<#D$@9S@DGG
MGI7FES^QU-XR\06FN6-E"M@8"DT6_:/,#':V""""."2,?C7FXK+:->I2KU&[
MTW=:V7;7N&'S7%9?E^(H8/EY<5%1J)PBVE&2:Y)-7B[K5QM=:/S[K5/V9_ O
M_!0V^M/$KWT/A;Q,&9+S6M)MHDDOOE 1KJ%B%EP1_K%(?!P<C!'SG\7?V:_'
M'[/?QZ/@O5+ZSU-K%(+B'4+5@8[FUFSME6-R#G"N"AR0RD D8-?2UO\  'QE
M\'?#%^MH+..UUBZ6W,MNP#00 ^:RA1@!B5"DC@J#CKQV?[2'B*./0? 5]>6>
MGBZNK"[CN;O[(DE[=V\*!5,3,0"$$K?*2<_0$UY6*X>P^*Q$*D-'>]UOHOZU
ML?4<)^)>;9;A9X*J^>*C:*GJE=V]6K/9NWY'DOAGX5^%-9TVTTW2]"FO;Q]#
M6_L_LSFUU"XE4GS&E60A2%7D#).5(QU-<+XL^%GVII2NZ=6 &\KA2<<@>P/I
M_P#6KD_BW\<I_!OB*?3]-U+SM/EN)%CD9"9X(P0&0$C*!]H)52!CMQ7JFC^.
MX?&_A:SQ(T4L>"2C%0_89!ZDCD]O?@UEQ!FN%JTJ<<LIJ/*W&3Z[]'%V:^2>
MNRV7[AX2Y-GU"53%9W7=2-2THQ;;44UNU)<R>R5GRV5];IGA7BKX-2>&M>AO
M(@L<$RX;+%=ZGAE/3MZGFO1/!_@W1=/T!?.@AN!<J=K;,@ ]\^O?-:NJ>%V\
M::<T=U<QM&&4;0P+1@\#/([GGKBKUC\/]0\*>%IM%O+K2H;K[!+JVFP!B[:C
M&L@C=8V4$,X8Y\L9(&"< BOS/B+AO-LUM+ IU)Q^**5M%;;N]5IO8_5,\XIR
MC(I068UHTXU))7;2LVG9OJH^Z]=KH]8_89U#PWI?CB]\'M<;U\1636]K(A(6
M.Z#K+$""0#N9-O/]^J?QQ^)_AT6.J:=K2_8;JWO'MMW+2;@3@>H./:OE_P &
M_$&\^'WQ7M8;B.YLIQ<+)&73#QL"#G@D<'D$'T^E=S_P4*\2VGBWQ;>^+M+B
M>#3/$K07494_+'>!5^U(#T^\20.NUAFOSK%9#*K-*NW[2F[>>[O]S_,^^P.2
MX;&XN&.I5&X5(*2DGM*-FO\ P.#VM]AGG.J?#F^^(FM7UUH=JHL++=A[MS'"
M^U0Q(D.%WD'(0D9XQDD"O,/$^FS6.HRPS+<Q21X#(Z;&' )!&3CV/<<UZI\+
M/&M]XN\+OIKQ3744D@90A=L%2IRR9"L"%P#G<!G!P.8?CO\ ##7+R]O=6GM(
M]/6=C<P6JEII1"V, ,220N. <XY%?;N&4X? 4I0JWKZ*2?W[7TZ+2Z=NFQP9
M=G6=//L1@,QI16%BGR2O=M^ZM[>]LWJHN-]>;1GC\M]?^9$UG'\EC^_E51D1
MQCAG8]2!QG^5?<_P/^(FB:E\*H[N22'[3]G#$-(">,#([ <]O7UKYB_9R\,>
M&?\ A/[236X[75+F-@\>FZG(8+"Y 9<B27(P2"0%/&>O%?0&M>%/,^%UIK6M
M:3;Z/JVI:U?6ACCNXXI"J-N5!;QHN8U#863&#MY)R*^^R_AUU<@EFDIQ4(O9
M2BF]M&VTHO7X6[OR;/R#BSQ*P^&XQI\+PHU'*HDW+DG9+79).4T[?%%<JU?O
M)-E;QW\1VU2TBL[66.6<W )C,8*A1]YCQT(X_&NY\-:A+XVUR"ZO/[6N)YK,
M:<K)=EY8Y//#J5.T!HC'^[*GD 8!/6O.?#/A]FE-HNFXO97 'E@M)*3R 1R1
M[=J_4?X0_LL:'\"_@?IUNMG;W&O^0MW=:KY0\P3NH)53@X5<A0.AQD\FC(N(
M,5%5:>!2C":LVU=JZ:NK;/73IIJF>%XKY/D]:IAL3F47*K3E>*C*R=G%VD]G
M'372^NC5F<S\%/AKI/PHMQJ>H0QG6X]-EMHIV"E[<3;=T0;@$L4!( VC8 "3
MTXK4O&?@O5?B?8_#.[\4--XYGOI;:.%+7?:6]T</]DD<-N1B' #%=A;Y0<\5
MUO\ 9=Q=ZQ+/?+<7,GF$HK,9/F3@''0G'3 P*MQ>&/"$?Q+C^($VBW,?B^V\
MV2)DNF73Q/*$$ER\.!F4B-#G)&5! !R:5; XJE3A#!62OK?LWK_7R/C,MQF6
M8NMB,3Q"JDFZ<E3Y&M)V]SFO=\J>^M^K;>^YX]^'VE^"-!W7%FOD6<)654.T
MHPQR!G.?S/K7E?AWQK9^%M8::YT^UN@23 6)9L Y 89.3CT'TKHO&&I:YXX$
M[O)9BU>4B&*=B'D4DG>"/<8 [CJ:L>%+/3/"%C(]Y]FGE8;-DEL'$I.!M7J0
M3[_6O=E3A&-FU?\ KL?*RITX1LWK_78@M/VE8==O(H;VPMA82Y^X"< <$$$
M\=^,5=\:_LV>#_COX+OM-L6NK5-34,Z)=-Y;D$,%())4$JOW<8ZX[4WQG\&K
M>?24NM)5K'7+*(221QC?'+C)VA>2' XR.O0YX(XSPQ\54\)6=Y>+=I'>10NS
MQ)@I*P!*A!V)(P1P1],UCRW5T13<HM3IMIJSWZ]&NQ\6?M,?LM:;\/\ 1]0G
MCCFLK;37CLY1>QC=>73$D^0P  "@#([G<1V%?)?B_P"$$?AOQ#<:Y';QM<;%
M0JR E$'4@]03GMTZ&OT4_:\\6WGQ8^#\U[!*T$,FHP7=U;AL?, R ,.A(=N,
M^H(YKY6U*+3V\-ZI)>30[Q"PC7(^=F' )R .2,Y_.O<Q6.H8S"^QK027+:5O
M7==GUTZ_<?I/ L,5]3E6Q5=U'&;<'*UXI16C:W2V3>MM[[GFWPR^!U]\5[RX
M728;>7[+;FYFDFG2WAMX\@!FDD*JH)( R<DG KE?&*ZM\._$M[H]U#);75E(
M8+B&?!:)AU&>1[@@D$8(R#7U%^Q?\#=<L_ 6I:Y-KWA'3+36)QH+Z7K$#W,E
MVR,'$L(C=0VW!P0ZY!< XX/@G[3,%_9?%"]O=?D;4-2U>7[3,ZVS6N<\ A6
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MU4$R*6?YMI&-I(SSGZV_9G^"EOX<@6]CO6UBXA9HVO5^2%&4D.$!^9B#D$G
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MP)2($J22KR%!QDG.!SQ7BP4^3VC6G?IW_(^C]FI5O8P?O/TOV_,^)?\ @O\
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M3WL[O5K3?6I6PTL<\,W&$M9:_9BE>4VNLFEU^%67Q;<O^U?^T]X6_9S\'?\
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M \$@>^>?I^/2O+5UY8KL*S(I<Y;)_+COQ70^$_$46KWLD4D4<LB$($+''?D
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MI)&X)Y+;"R[B1G)P>V,5K>%OVS;?X??$9=4T^+4+J.YD6YN$D=(8)I@"IDV
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M"BG['5A^P5^U+J7@C2?$5]XDT-K&WU6PN+RW$5S'#,6 BD( 5W0HP+* "-O
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MI5_J"A+NYU)A CP)<AC*ETH#;UC4@QC'W2#U)#O!/QSTJZ\1EKJ^U;3+*>W
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M^Z_AO^SY\-/V>K"QUZX$>D-:JSA+VZDGN+"<K@J48 LQP "JC)  '0U]0_\
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M[*UJ1;BT>-DD(W3+MGB(^Z3M. P&,X/TKTCX7>([;2KME01^5-\K X)4YSD
M],GKTSWJLMXLGEM&M3J4%.4DTF]&G\K-I]5=6:4EJM>KB#PREQ)4PN)HXN5&
M-.2DXQU4D]>MXJ26SY7S)N,KIW3O"?P_A^"?Q0MO$6E3:U:W5E(TEG>Z;=O;
M2Q,2075P0V<$\9 (/-=-\9?COJW@LP^)H_''BKQKXHO%:UL8-<O'NX+:W8 2
MAHI,@+M)7J"2Q()QFMSQ#I+2V4-Y;(DB/A1$0(R/4@]QZ8ZUSM_X1L_$JII\
M\%O-#.X.V096-^F0>Q[5\[@>(\507M;M2COT?;0^[S+P\RS,<+RJ,9-JSNDU
MWU]?+3Y'E7BCXX:A\:M:MM5U>[NKR[BM8]//FS%\)&3Y8V\   XP!U&3R36G
MX1TN3Q+J%O:PQKF298P)#A4)( )/0 =2?2MB7]DNXB\>PVNGW'ES7SE98 I8
M 'T)Y!!Y'6ONS]F7_@EEI-IX?MM3\2F2Z,@#A&SM)]QW_&EBLR6)F\3-\SEJ
M?,T<'0R*$<-5BHJ%DDNUE:WR/GWP;\++RY\':HW@FVANO$6KK'IG[IR4LK<D
MBYG67 0,ZC8H!)"LQZ]/I?P/J_B[]GWP?;6I\./%;0Q!-\6V5$P  3M/ ^HZ
M5[^WP,\+_">;2_#UMKWAK1=9UEUAL--NI?+GN9&4,D>[!578$%58@G(QU%<I
MKGB3_A']2GL-0BDAFB8QLK#[C#@@CZUST<1&3?*D^K[GC\08BIB^2I)2C%Q]
MVZ:35WJKK76Z;6FENA0TW]HFX\0?$O4O$-Q\0DOO!M]H*:?:>"!IAC-G>",*
M\K.5V_ZP%]P)."!BG7OC'7K7X7WFK>!_!MOX]\4)J5M:_P!DS7GD)!:R E[D
M!2&<@@# /&<X.#7.:Q\+M'\:3/<6.VSO3R)(P ';T8="/UKE-*US4OA'XPMI
MIHD6]TJ=;B,/G9,%.00>I!Z>WUJ?JJE3DJ,FF]?->GD>1_;$HXFC7Q%*$XTE
M&/+R\L9*/2?+RMM]97YGW/;/$^N:;/'J6H:#?:+J5GIUS':7T%GJ*73:7=,N
M7@<]<A@P!Q@@=<Y%<?%\1V?4;:2075OIPN(TN;A$)C12P#$-C;D#/?\ "O.]
M)\5^$O#OA;6M-\'>%[/PRGB#4#J.ILEP\\EQ."Q7:SX"J-[G&,98GVKH-=\>
MO'J]YXFM?&VH)X3F\,C1K?P,E@4CMKIH]IG9_N$,V90Y._MC%?3RR?$4LLIU
M)4G*HWJXNZ4>[OIMVZG37PN5U\16>$KN%*,.:+J)WE)13<$H\UFY746W:R3;
M6IUW_">^,M1\1>-8?%GA+P_I?A>P#WGAGQ%HUV'M;R$RA(K9R23+,Z[F;@%#
MD8(YKQGXQ,=-N8M0MABVF.)=O2-CT/T-<A_PG=QJ(CM59S# <XW'8A[D#. 2
M.IQ7=:%;_P#"76GV)PT@FC,95N><9!'XUY.#PSPZY92<M;Z]/(\W,,TI8ZM&
MI2HQI+EBFH7LW%6<K-NSEN[65^AP7_"8<>OU-%<;JVM>7?R(K+ 8V*,D@Y#
MD'MTHKV?JYX#Q6I^D.D>#],\,V ;3[.."V,;*9E^Z,C'7L:\(^+%Z]QK$EM\
MT<</&/4^M?0'P^UB/6-.N-)U2)'@NEV-@?*3V..W->/_ !RT".T\0S:>HV7D
M2%H2W_+PHZX/<KW'I@UY-.E[:/M.J>Q[];$<D_9OX6E9^?F>>W>D27FF1_NU
M= 00W.X'U![4[3-5U![673YI%E21AABN)$4<8ST(_"H9/$&H^'+9+>XLVA@<
M;E=T)!!]#@C-;?PZ\%77CK5HI+/SE6-\R7!0B)%'7J!FNNCBL31@Z=.32?\
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M?4=LCD>XKTWQ)XBD\8>(+O7KTPK>7D@18D4(MLL>4$*@YQ@!>"1D<$=:\_\
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M8'\ZW/"?A>U\+P'4+A8Q& /)MT/#GL2>_-.\4?%'RM>TNQDE66XF??(!@!%
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M%SI?PT7Q/K*QFTM9YWE.CW#LI+&56()>/Y0$8A3P02>3]AD,O90=)='IZ/\
MR9^-^(&%]I6CC%IS))[Z./R>ZV]&>(? OP;%XW6]T^X:VVV]N9)>2T\>X8&!
MT*XYR 2._'7T[P3J%UIGPZTQ8SJJ16JO;QNTQ5, G:<8QLSG&2>O  XKS/\
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M\PWL2!P!@\_J?[*7AOXE?&#4]#\,65]_9=I>%+AIOGMX%Y#[FR05C((WDY.
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MP1@$XR"#DUL_M%_!C0?VD["W\(F/5;>72+E;.TG60R&PO!"98I-V/F4 E6!
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MQAR078# !)XQ7*^+O'4WC_0(-WG+&$&0\A<Q\DDJS9(//(Z9Y&*V7TWPW8^
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MMW0G#  @$[F!(X' Q]>:L>!?A-=ZEK6I:]XHO?#-A\2M<\0QZGI5_!91:F-
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M_B;:=LWP7T*\LLB>N,X/4=0:Z#P9\,=0\:7,2Z=:75U*2"6C0_NQ[GH!]:]
ML?#T^E^('\*Z/;)J?B?4K>2-D>0".T4C:997.555SU.23@ $D _$UHTW"\]N
MO8ZL'>'O?@>O?LA_%GX,_M):8WB+09=%T7Q.]LHG6Z"F9$7_ )YNV-R*3C'!
M4X! X%>N:KIGA&WL5O+[4GUN&S)5':0RQ*W?_9SGCU[5\:_!'_@F7\,_@"\T
MFL:]X@\2ZO?$R7D<=X+'3O,).[8,&0CD@G*Y'4#I7T%\-['1=!C72=%L_!]G
MIJC;LNKO[=+(/?S)#^@!KYW%5\'']U2M)+K:3_"ZB_R.F.!K2O7YIQCOJTOD
MGK+\!_BOQ+'XBU;3YO"MUI>F:;:WB2ZI&;8^=<1(P9XW+#A2H/ '/K7Q]\6-
M?\0:_P",=3OKRUNM*CU&>6Y@@N('\UHF<L&;@8R#D^G>OT2^'O@$6VMV<UC8
M>&9+)'#2K;VT<;KCH003^5>F>)/"UOJL?F-;V<K*I ,D"N0#Z&NK*<CJUZ,J
MO1/1.-ONL[?U8X,5Q!0PU14E&]UOS7:];J_](_$_7]-O=?NUM_D8J<KGD'\,
MYK0M_B-JG@'2+NQT73+/5=0>1+"&[6V=[W2+R4D>A4J4VE<Y&.200:_3+QU^
MQ'X-\<WDET=#MH+L982V'[AL]\JORG/T%>(>._\ @GDME!?3:/=:I9W<FUXD
MO( 5=E8;<L"5('. 2""?<U]=PIFF$RO$N684N9-65XIV=U=W?339>?FG\OQE
MA<3G>$C0RZO[-IWE[S5TD]$E=7;=[O:R\FOE+XF6MYI/AC4K2*\U*\U:&53,
M;HMYCNHV2J 68!>XVG!/?)IW[.&E23Q?VC>2V^GZ3;2$W]U=RA7M8TB+F14^
M\X!VK\H^\Z@X&<>]7W[%7C+5K^,0PM>P2R$L975'#$Y+-R<\\DU8US]@3Q(F
ML0Z:D%B/M5C*9[YO-$5K%)B-@CJ"/.S@A"#P"< \U[7#N;9?7S2I+'WA2J<T
MNDDKIZ/9I+2UKV:2VVX>(L)F66Y)"EE$XSKPY5ORMV:U2=U*3U;4K)W;W/)=
M1^*%TUC#=6ME-<0>([>.ZTN.-$'E0 #YB%R=S[@Q#'Y00!R":<GAC6/$PGFC
ML+J2ZO<?N8266/ P![D#J?7I7T%\ ?V+K'PMHUFOB#1H4\5Z###:3WMQ:^3!
MJ'!=)E96)?&\[N!A]P(. :]HTKX<Z-X?9I;J:6^DC3>(H(MD>?08YY__ %UY
M?%TL)+&3H8!_NDU;ST5K.[O&VS>KW=VSU.$:^.JY92J9HOWKU:5WK=WOHK/R
M6BV5DCY6_9V_9#UI]<7Q)KU@$LM%D$PCF4!IY,C;D=2JDAB3UP!TS7L?CW5T
MM;)(?LTUPZ$L^TY=LG)('<]]O4GBNZ^.WQ)UWX+?"#4=2\(>%8?&7BJ> -IG
MA>.X$*7@=E1@6Y8D!B2< 84@8ZUQ?C;P%KOA/3+1?$%G;V&KW5G%-<0VLIF@
MMI64%T1R 6".2 2.<9[U\/BL Y-5'JEI;_ANY]?1Q4YIP3Y;WM9J^F^GE?>U
MM>MCXMN?B+>?$#XFZSHECX4\1#29K6'4;B6V@,CVC.2)%4JW*L/G8C!3DXYK
M8U'Q;YFEQ+'-(RAL$@$9P<$8^M>E>,?AS-!''<:?)-93V\QN)I8AM^V%E*R!
ME! &\$YQ@ \X->6^*;!M-N@2'.2<KM/;G@>U?0\1XW+L6J2P-)P<59_\'371
M+WFTVMT>/P?E>:8%5O[3K*IS-<OEZ?RZM^ZE9?99-\-O%T-A\5IUO;A8;>[B
M5XM[  G !..O!]/SKN/&OQGT+PZDD8O(99$<IB$[BX!!SC .1DCWKQ7Q5<6L
MUG^_56';(P03Z'J,^U<#_8=HFI&:)I;=XG5AOF9L$'@@=3C\:C+<=1BHQQ$7
M[METM;YV_P F?1RG.-YTK=;7OO\ *Y]-6GQ)U3Q%H<"C1KJVM[R+[5#=R8!D
MM2_EF54^\REL*"."W%;G[0M\]O\ !Z[O8+C7)M0F%O!#8V-UME=5< RPQ$%3
M,F\,< D@ 8)P#QWPCO=3\6S:>E_JFJ/;V=L;;3&L9/(MK9@QE+R1;"&\P\.&
M?!P-N"37T3X:UZ/2M/BA?R6GMT4;P H=@!DX[9(SC-?>9AB\ORW&X;&8&?M%
M&TG%-J^JMK9I7:U6K35ET9^74:V:Y[@,9@LTI>Q<FXQ;L[)JSTNFVD_=>BDK
M-]4?._[+FA>,;_XVW?BWQ,L/B>;P_):Z+9YE)/V<I(6F/RB,$9 ^?+ G)*'-
M?1W[17B74OBY\++KP+X3F\*V7Q3\3:0VI^'[#Q-!'<Q6Z1RQQSS%<.IDC60[
M2 0&Y.0#7E7P/^&N@_!OQ5XJ7P_>:K.GBK6)-8OHKN^-PGVF0DL8@0-H.<$9
M/ '/%?0;ZSX<^'$^G>+M0TO2[OQ9:6<EIH]S+$K3V4+D&0ANH0D#C.#C)XZ_
M/\9<9QS;%0J*"A9)*UW9;M=%NW;1=-3T^!^"5P]@Y4H595>:3E[R23>B3:NW
MJDN;WGI?J9?[8UA\2OAUX(^$^@_#^:.::/Q%H<7B9+:**"#3].AWO>RM]TLD
MS",, "0%7 Y->5_\%3/"VL?'C]E35;7PEI5SK?B;2+V*]TR&UDVW !W0S;!D
M;\PR.#'G##L2!5GQK\:]4\3:E?#^U4N[VXNHD18CNDC5PQ=G&,878<8R3GH
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MQ['#G"A0<DCVS@"JOPRGC,37$ENCQE@(PV2,=SCTKG?&'Q G^)^JP1L/*M
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M:YDDF.Q"-C1H1&> "%3DG-9WC_X\^'_A?'J6@^ UTNSGU*8W6K:K#&J&[NF
M#/E1\[  9<Y)P3P #7DOC;QU=VNG1:BNH)>16UM%]KFC#>4\KNZX4L W 7))
M !S@9QD_,X+#XO&T*E6A"\8:R?RZ=_E^6I]56Q& P>/I4L;-0=7W81:U=VM9
M/[+UTYK:>:LN?_:S^&FK^-_VYOA;XZL=#O\ 4/#.DRPZAK]S97(4I-8^<\+.
MFX?,%90I4$OC82.*ZS]A3]L[Q'^TEJ7Q'UC6K^QDTR/4[0Z196[E_P"RHWMM
MSP%MJEB"%+$Y^<N!@<5'X!\9V_CGPOJ-O:W%M_PD"RP30&:\6!$4,593N!!W
M @ ##9Z'BO/M,^)^G_#N[NK73[73=/%Q*99'LTV1W;8P9=Q =L[<!G&XXR?4
M^GFG#V+PF6T\RFTXSLEW5]=?76W71WM8SROB_+\RS>MD%.#56BMW:S2>K7II
M=[:QLVG<^PYOBPL*[3,H([9Z5Y[K&M:G:>)IY='UFZTVPO95DN;6PN!'=2LN
M< 8#,5+-O 4 Y!!X.*\6TGQ;KGQ'@%UI=MJ7]EJ0+K4EC)3[VTB,8R0IR&;H
M#QU-=_X<U72].T^>P#7%NUU:R6KW-DYBNXPY&)$?)PV!@C/S!F&1G-=>1T\Q
MPD7B+6YEI%KXEOUT6MK/7NM"LSRC*\Z7U5S_ (<E>47K![=-=KWC=76^MF9/
MP0\,>&=0_:^LX?&JZMK/QG\(:%+<)XBB$AL?LDSRI",R$"2YACFP&D0#)91G
M&!2_:MU6X\-^'M/L6UB\\1WVG12I<:K>$+/>%I78#Y2<! P09).%YXP!I>,_
M%=[X<UB&^TN^FCM;2WM[27[3.TKSI&BQ>;*^#EB!N9AG!SUKSGX]?$/3_%B>
M+%TW3M0M-)TZ[(L;V:UD6.\R &C5V."3(6*O@!^0!QFJJ<)X[%49X]V?*KM+
MN]6K)6OU71ZVZGGX_C+!Y3CZ.42O:=E&Z5M+J+YI.ZCJTU>R=KK9GA[_ !:F
M%WL2XOH6SAV2<J=H/ SD8(KZ-^&5MIOQN_9]E\*WFKWWAN:.\DN1=/;2W$%T
MLR1Q,98HF5FD4+A<Y4[VR,\U\0SZ)->>)8Y%FE$<K_+NX/7H?>OI_P"!WB^/
MP7X#DFEN-L_VJWMXQ+S&4>4(Q8YZ E0.N,YQ7YWF4+*,(=7J?H^6YM6IXRE*
ME+DG&2:>CMYV::>E^C-?XUW=]:_M87]YI^IZAHO@S^P[2W^T8\[4]0BME5&=
M86)1YB ?]8<[0I!)KP7XO^#I=,\9Q:S:W$>IQ:B9"5>0BXW!B!%*GW1)Y;QR
M%1@;6&,XR?K_ .)_@,3V.H6MM<6]I"&9(EO(7DCB+@!WCDC8.@*%@0 >,D#@
M$>/?M>^%M'\,Q:'X@U;Q9JEX;>W@T^P:VC%];.R@*EI"L9WAG. "XYZLW&1^
MC83,LNQ>10RVG1;Q;:2MMH]-D]TWIY:O9/\ ,,YPO$&5<52S+$XE++HP;L[7
M=XZW=TKII:MVO+2.KDO,[[X?>#_&7ABRN'3Q!9ZE:697:UM'-#J+'"M&3&08
MQCG<<D$9YYSI:?X1U+7=!T_3[%KFVLK!2D=H)7>,9/+@,2 Q[X'(X.:O_ G3
MY/BG82WEA8W]FD,I6\M[R#RO*<$KG.2I.1SM)'8U]$_#WX26\<$9;;-.YR2@
M(&>F,8X'>O+QV,S;#4UE^.O%K5QE9M*5FE;5KNET;32V9ZV5Y9D&/J/.,O49
M<SLIQNDW&Z;35E+^5RUNDU=ZHYWX)>$=1M?,TF;S'CU")857&/+D RC >S=1
MW!8=Z]3TWX4-J.CS20VS2-- 8;RQ-L'CC51EW!.<9*Y QD>O%=Y\/OAY-J-Q
M:V\ENCM&P,<^W$@ [%NX'OS7:Z;I3Z'J,[!'9'WJ0#@N#D')YS[UY]%*'O(]
MK$5KP='==MT?$/B[]G'Q!XI\3M]H2YT72[K5K:WF:)6QJ-B)"PWHSA5D4OY9
MR-I 4@$Y%>G:MXLM_#E_?:/XBM;.U2R5X].9K<0FYA#D1G"@H2%QG;C![#D5
M]'>/_ACI_C32##<6Z75O*RGRR1G>C!E)'& "H(/3CFO._B=X,TOQEJVJ>$9-
M4T&77=%L;74+RPN6,0MX;AQ' XG?$9=V( "MDD@#DXKZ_/./,1B\-1P>)IQY
M(/SOHM&FWO:]U;M\ORKAOPQP^79G7S'!2G*4U>75).2YKI1TCS.*3;>KMO:_
MQ1\6=<C?Q.UO8RH\4<N\[E^1USW'4#UQC/L*YS4/$6VRNK5T0PZBK1LL3,OD
M<##%%.UT!3H3D G!%>Z>-_V*SIVIRQ6,NH2WBS&)XT/FDMG!50>2 >#6'HGP
M>:Z\6-X1C\*74VK6@:YU&7[0G]JG+?9BC(SJAMXY"CY4!B,GG&#[?#4:V90J
MRR^2BZ<7?FM;5/I?76RUT5]6NN_'V=Y;EM&AALTIRJ1K227)>Z::UNE=:7>G
MO.UDFF[>$MX7D^*GC)+JUM/L\<<RM'%RV%  VAF).,\XS@$\>M>V?M/>.K;X
M7?!:_:VAMM/O-46/2X+H(/.*H@=@C'.,S2#)'92*]*^"_P"S4]E:M<-$T<R2
M8''W"#R3].E>S?'SX'?#/0?AYK-Q\0O#/]LVBVABLUEE,:V:*@+2PX(Q*TCD
MAB, !>#TK\ECBI8K'SJ8EZ1=WU^76ZT^X_8L)5IX3 K+,O3NTE%+1]/35+4^
M"OAY^T5XJ\?^';32YM?5]0@5&N(VBBC_ +59!@/(ZJ&D(ZX8G!YKT#QY'I7Q
M/TGX<7EQ\1O$'PYN?AWJ$M]>Z3;+,R:O(\BNLRB,X:157RP'P #Z$Y\8T']F
MFS\?7[W?@?59K JVZ&TO9=L@.>"LB@J3ZC QZUV=G\+?BYHF%N_#_P#;!A0!
M)\Q,3SC(8-_,9KUJ];+L32]BWR+LE8\6/#W$62XV.88>*J-?"W::VMM*][+:
MZ9Z#X>^)LGQ;^/GDL/L6B>*];59A/PT$,LP!)QQN"GZ ]#Z^K> /&OBCXM?M
M*Q?#O4OA[X5\/^#I&O[8V6^ ZG;Q03O"MV"H$T4B!4D(D)$B,6& 17SLGCWQ
MQX):/[5X7T^WF8X437D22$CN!N!)]*];\$?MP^+_ !MH+V.J>)H=).W[+<+]
MG"W<BKP$>0@2,H' !.,5TX_$U\53IX>C7?)!6LGTT^_MKIJ99+[;+:%>&88%
M5/:Q<82G=<C::O'2S>J?>Z5FKW.FM?A7=6>K-;WA541MH"D,S@'&1Z$BF?$7
MR?#QM=-CB5_LQ(0DY8LQR0/8< T6/QCTGP?9+]CN9-4U6XY,LOW8L^@]:P-$
MGD\7>)9+^ZW2.&^7/0$GM2Y7'6Y\WS+#7CU_K^O/L>E^!;U=(LH1):PR3;06
M)7=@_7H,5UH\3'4[?;B-$'  .W(/7%8>FZ;;VUO;(P:2XO"%5 X7 )QD_CT'
M>JNH:S#H-\;>6W>-T) =3N0@=\CIQSCK6U/"8NI3]M3C)Q\O\M_P+IR3A>23
M?HC8UC39-:\KRYVMFBP%#<QD#L*\1U^_UC1_B_NU*WFMW3?Y1/*R+@@%3T(/
MZ5Z\_BZW>U'SJ5R>^,?2GBRL?&>FK;WR+,B,'1LX9".A4]01W]>]%&O)>[,\
MZM4BVTM#C-%\;R/)N8-N7C/."*[;PKX[LV3R[K<3*<J>V0 "IX/O_P#7KCO$
MF@?\(A,X^66!AE'QUY[^X]/RK(L=9C69XW"G:<C'Y@@]C7L8*O[*?M4KGF5J
MDJ4SH/\ @H5XWA\%_L410V\C*_B?6(($ X#@$N>/3"+G\Z^(_"YCN+0AEWLZ
MA9'D0'.#D$#'0'(]\&O=/^"N7B7[%X&^&GAE9'+6\,NI2@\D$A$!/J02WZU\
MX_#RZ:ZTV/<ZSA%V!2X'7I@=SBOI,OK4G.=9)7[]E9,]C*YITN;O=GK'@'1K
M>\MU&]#MZX(QUXQST]*];^'VD274ZR0;1!"P4NW0?4UXUX!\&7US>P6]N[;&
MP!MXXXXSZ"O?O!6DQ>'].2S8Y*'<Y!)#M_\ 6K\]Q4U*<I^;_$]+"_%<Z#Q/
MX;T'7=9AN]25;M+=8RL14;?,7.''?-;VGZOI3695M+MC;X.8B,;QC!R<@GBN
M<M;*'Q!;R2-)L2/H3_GK60EQ)#<!5/[H<#YN#@]>O:N6.)K\O,Y-%5*6%:<'
M%2[W5SP#Q5\ O%'[//QGD\<>"]2MY?"EK:W%Y>6TUP(([2(/DQ%6;# AOX1D
MG) !.#]!^#_B#X)_:0\,6QN(V2Z:-9(K>:-A+;3, -T)P-Q4D9QRIY(&*M23
M0WUHRR);R1'G8Z!U#=FVD$$J>1GO3M!_9XM=6TJU\0^(!9ZAX:TZS>\\0ZZ]
M\]I<Z>EI!O,T,48"1J C$H.7WMD@@$?H.0\3TW1<<7*SCK?NM[^J_K=GY#G/
M"^*P^*2RJGSTJC2Y5KRR;22[V;>G;KLKW)8/%WA+6+6&71--\;W'F[=-U>[A
M!GLIEQL69\ANNT G<N 01SFNY^&Z^+O$\5Q'XE\3V_@6^UN17D"7*Q6KS,22
MLCH PD /*_<P0!@C%>8> =+L?BKX3UOQ=\+OBGXSU9-'N(Y+J*^L8EBOO-)6
M&:U7)C>,,IC*$@C !!)!/7>"_P!FX_&W4K34?'/BVQL[];9VBAO[<P?9XU(#
M!4W +D9+ C<N<]"#7T.'QV%QM#V^&FI1[V[>1Y.<9'F>38V67XNFZ=:-FXS?
M+HTFM5KJGUZ,]BB.FV/@2XL=)TZX\1P17HDWPIM_MN924"JH!*0J68DDDN=Q
MX P7_LB> =0-ZESK5C8)% 3)9V]O;QK;P$.XPK %F* #DL><G)/3*L]=9- O
M;?3M:MY--MI9C;S!I%-MID61\B8#L&#&-6)(  8 G&>?MOB'XG^(]E?:5IUY
MH.@^&M/2.6ZU:SF>PATJW)VQ12!CYBDM@!2@W]N<BLZKA2HRYFDNK;#"PI^T
MA3IQ<JCTC%:N4GLDEJUVW^^YW/Q4^*&O>*[F6+318Z%H\MRR-<W3DMA3AB J
MD!CC !)]QUKS-8++P!X2\8>.M4U[5;;0-"MI9[N\LXW4W%JA5A'N4@ 2$9*]
M6RF,#)&BU[XY\(?!>?5/^$DT/QIX-U%K>PTO6;6=+CRHWWI*(F(#>80-C[QO
M7&0<\U\Y?\%9/C5:^ OV4O"/PJLFN8=8^(5PNO:U%Y*,8]-A8+"%D'023Q @
M8/R(P.,\^;4QD(T/:0:<>C74,#DV,S/-XY;7A*-1-\RDG%QMH[KRMM_P3COB
M5^VO>_M-:Q!;^$[NW^'WATPF*2XU2[%UJ5V[,2\@?+)""" H0E@/XLGCC_VB
M_@_-\,/A39WECJ%YK5[XGF6R:]DNA<*(8\/E6RQ&2>,D8 ) [UXQ\-K>*WB7
M-K))!"5,C2R@D \#L" >W6OLG]E#]I#PYI,3>']2^&MKXBL2IGFE@GE>:V4
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MG:>AS7E_BKQIKGB.U;4M>6.*\OG)2$$DQA1R"['D#@#@9)QUXK*_:'\9ZOX
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MX<^ ^@V))OI-5O"Y!;=,=KG/<<"N@U;PMI]KHU_K&N:TN@Z5IJ*]W?7%W)%
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MLK,&*/6-0MC))<+D$F* D*B\<%\D]2!TKB_A/_P6Q^)'@6Y6/Q%H/A'Q59G
M<&W-E<'U(=25S[%<5\DZAXICD3;O5 >K-D@?AC)_ 5TOQ/\ V?[WX=^&K&^O
M-6TV>YEM5O+FVMI/-D@1@"01D?-$617'&"X/(S7I8?!5Z\9U*$;J"NWV7G^?
MHGV9Z&(JY=A?987&M1=1\L4]V_+K?IIU:74^XO@Q^WO\/_C#^T8/$VN>-O'/
M@*&[B6-/#FK>1?>'TN<$"=90A:%EW<'"G."6P,5]>V.EZ'-JEG<6&L>'M=CO
M<O#*+J*2)R>0>&(8D=,G%?A#I>K-'CM6]:6AN+)9<-#&QRLB_<!Z<D=#]:X8
MJ#]ZVIV8C+)-J,965K6W_'?\3][OB3X(T?Q;8Z/=:OIUIYVD-YEI%)(LMM&Y
MQ^\$62NX8X)!Q7*ZA\/K6*[M9;4/YEQ.SLK2%AEVSA1D[5R> , =  *_&#P+
M\6O'GPAU5K[POXIUS39$3G[/=,R.H&0"C94CTR#[5]._LQ_M]ZM^W_\ #[6_
M@3XVDO-/U?6+68Q^)=#DCLKU[>-2\L,HVE0'4,#(H!QD$#)-;8C$U:M-49R?
M*ME?;KHMNK/!CPM'#R=:G:[?O2M9V>EWU=DEI?9:'Z8?&#XC>%O@3HGAG1=9
MU"ZM8M:>2WM5M+.2Y-S-L+LSLBE88\ _.Y )*C-?(NDZU)XZ^(GB[Q%X=L]/
M: H+3,S!YY0O .<\$= !^))Y'F-I_9.A^#--\,^'_%5G/X>\/+'HL<\=\;U+
M-8BJ%6*DDLNX%A[] *ATGQ)H_P"S;XTGT^#4I)!::A*KV]W<B(ZPX3?"T.W*
ME)!YQ,;,#^Z49.2:[LNX+KYM">-ITGR13MO9J-MN]MM%H]]6?*8[C#!</8J.
M7U:RYYM=E9MNW,OL76MVW\D0>)OC1J5CXU:WF@N='OF81Q30SDH23@ @YY)/
MH<?3FLCXD?M$>+]/A-O=W%]<1GY&VD1L,=_E /'UKNO&GP,\9>+_  98^.M6
M\)MHFE3RF:$O*KRO$X#I*8ESL1@< L03GICFNZ\/_!3PGX5^%MW\1OC)=)HG
MAZ&-7M[)P(WNU_A8JN&)<\*B@%AUX-?+YEE^$I8CDH*]MT];/LKGU^%S2K7]
M]U&T]K=?2Q\X>'++7/BMHUUI=Y,VL:5=Q-++!??OEM54%FG5NL)0 DR*0<#!
M)'!\.^%,4FE^(+VR_M&34+2SD*1SN"ID&<\CL<8)';..U>U?&']N#6OCI9W'
MA3X6^!;?P3X)D=5GNY1_I^J1J>%DVC:D9(!*#.< 9QD'D?"WAG6/AW)-)J/A
M^&^L;YQ)<;%.=QZE2I)5OP^M>OE>&E2NZGNWV7ZF>.K0J4?9*3O?K=[=-+K5
M^IW7@#65ANHUD[< ^U>J-K$B:-Y-O+Y4CX9'ZX(Y&1Z'H:\-URP.B:%)K7AF
M2;5-'3YI[9A_I6G,>H8?Q+[@5<^'GQ^M]8L1'<?>3Y0<D9]#ZCZ&O3E1E&2J
M0Z:GAQJ.G*T]#W#0_'L5U&+'4E6.YCR$4\"12>,'N">O? K/\1VN[_28W5@H
M)+H#@X.".P^G^-<+>^/;?4HO+=%E3JA)Y'T]#18^-;R6U\G<YC0%5R<G!&"#
M[GN>IKZBEG5.K0=/$1UM;39FM7&IQLSL-&UB."1&AD59!U![GO7H.A,VIZ==
M*5W.+=WQUS@9Q^G%>1>%M(+2>=(V#UY^M>T?!J&WO]3DCOHW>P\AQ<XR,IM(
M8>Q(XXKYEJSN<F'NW=GF5_X%E\0WPGTR5896Y,4HVYSU%>J_LZ_!Z\T77+W6
M-2NHXX]/LI)2J@D)@9)!..P-;WA[PKX<\8ZA*VGV=S96-J?*16F)>4XSDDY(
M ^N:O_&NWL/@M^R?\1-=C5H9$TQK:*0N6.Z3$:XYZY>NJ.(BY*/4RQ6#@M>K
MZ/\ X!\$>)[BW5KBXC;=-J5T]Q(Y/)+,6)_6L:;Q L\T4,+_ +L'D]B17%7?
MBUIX$CC9C$@Y8DG=FH=$UX/?JC-A=P)_&N.M3?-8]^E44*:UW/7O#;2WS3^9
M^]C";1G)PN>2/<8[=.I/2IK)+J+6/LX8LF<H['KW()[D=CWKF]%UU- O/.CE
M>2*0 LH!;8<$'(S@ C\N?:O2(DL?$WAMKA985N$ 9"&.0QQ\J^H(&/?\,U]A
M2P.&QF6I72Y5OU32U_X/?[B^:-2%NJ+VCZ;<OY4K1L%1LXSU(-?2FGZKI?B?
MX)OK&H1-)/X?A#2 )YC2(#C&WN1GZXKP'X417'B'4TL]C>8WRX [5]6^#?"M
MG\/? 5U]J9H3<1A,+@L6[X'3-?#4Y<LTNG7T)JX?FH6>]URVWN>/:O\ #3PY
MX^D6[LS=:;/(H<M"HP0>A*MC'XBG:1^SE;HQ\[5M6FC.0>2F1V'3D?RKO8X%
MU6<-;1QHH&UF &XJ#T)[\UF>-X?!/PWBT?\ X2SQA9^&;OQ)*(=-MKFXN)))
MR7*"1@F[RX]PP9& 0'J0*F6.PL$[IV]36GDF,J5%1I24F]DH2E+\+MV\C1\)
M?"_POX2EAN)+&YNIK8[U%S/E>#D'YC@ GU%>-?MM>+OAA\;?'>AWFJ^(ETSQ
M=X2TY]-A2"&74],EM7F)V20QD%+@.Y"N 2/0$ CNO%&D/I&MW&EZA)<">QD,
M+;W)>-@>S=QW&>*^8_VD="'PQ\=0>(OLMG##J,A2XNHXP<2 AHK@KD#<CHK$
M=" 20<<\V/6'Q&%E"FG?M?\ JYZ7#%?'99F=/%8>JE--VDE=:JUK/36]M5Z:
MV/3OVL?BWIOP^TVS@M/M%U>W6FV\=Y/<EOM'DVR&.(,<EO,D.6))+!%!)W'-
M?*UQX\OO&.+F73[DZ:)3S"@5<#J0O?'J2>>IK5^*5UJGBGPND4T\,E_' +BX
M:24&1R[%EVCN2B@Y]\5T/P@\5:$_A^TL[R>.%T"X\UU0$D' Z<DG.0,'DYKS
M>&\KIRNZZNX_>_Z_X!^B8C-J]"A]7H2M=-M]V_Z1ZOX>\*^&];\#6D.@Z??R
MPV>A&ZU76&6..-)MY;S(FD<$LB\20[,*,%2217H=U^T7#\.]5UK7]+^(>GWG
M@V30+>TT#P9;Z:8;G1[M!&)+B:7;M4+B5R^\F0/@C KR3Q)\,-'\6VD\?VJ:
M-I#YIB^[')(1C. 2"-O'TQZ4SX+_ +,MOJWB.U^WZS,FDW9.FW>D.L3V\JDD
M;@S ,&()4@G&.3@ U]1QM3R[$4Z%; 4_9\FCM=-Z/1VWLMGO;>^Y^>\"Y?F^
M6U,2\XQ?UA56[<T8RLFXN\>9-PDVK-QL_P"5J[1^@/[#O[;?AWXWZ-#93307
M=Y"K(7M[U)T*G'RR(&( Y^4D8SD<5W?CC]J_P#\.XKY'\0Z7X5?33+]L@U>=
M;$*1P""YZD] !D]L=_@?Q%X-M?V!OV,_$GB7X>^!Y/ 6MZG<"S\N>075QIX>
M<1+>M*5!/R@[%/ )4C(QGX(^,OA^31K6VU.^ENM2U'509I+N[E:5Y&)RS%F)
M+$D\DFO%P^(<L.H5%S=FU[WWG3F7"V$JX^I.G[J3U2:E&Z;O:S::[6=NJT/V
MD\'_ /!1'X<^++UK63XO^!K@@$J+FZ55S_O,%''XFNUN/VK_ (:Z;9BXOOBE
M\/;1&3F6U\10D$=SY9)_(5^"_P (O@#XC^.%E-<:3<:3;Q+>IID!O[P0?;+Q
MT9TMXA@EI"JD\@ =R,UPC:O)9 JR+O4E3E>00<$?@:*&.IQ;@G=K?6_WE8CA
M)-*:]U2VM%)/H[;)Z[[G[-_'3_@L7\$?@AX@OK[PQ"WQ$\5/9K8-J6GV*6J2
MPHQ989+V1=S1JQ) 56 )XYYKXD^-G_!;/XJ?%"_E_L/^Q_"%G(3_ ,>%M]HF
MQGC,LQ(X']U /:OC/4+Z[>'=(CI&Q #%< YR0!^51Z9]GFG9;RXDMD\MBKK%
MYGS $J",C )P"<\#G!Z42J1G)))+YV7WO]6=N%R.CAU[6;<FEOJW9=$DON21
MZYXA_:R^(7CO4/M6I>/O%D]Q@@>7J+PJ 1@@+&54 C@\5WW["7[8.N_L0_'2
MQ\6:<LU]I5P?L^MZ8TAQ?V[$;B,])5ZJQ'7@\$UA^&?V*[[QMK?@[2]+'BS7
MHIM$_M?4$M#:PP037$H0012X(<G8QPQ)&20<G X#Q' /#7C/5]+6XDO(].OI
M;-9Y$*-(8VVD$=01T..,@XXKZS/>%<7E%&G7JM/FMM:\797O\W9-73ZV;2/A
MN%>/<LXFKXC 8>#7)=/FVFKM)Q]8IMQ=I+I=)M?OI\7?!NA?M0_"W1?B5X1F
M_M.SU6SCNE,8YG@9>N.H9/NL.HP1U%?/GC#X/[D:&:)%,*[E!!P01D?IBO"_
M^"-/_!0.W^"FH-\+_&E_]E\'Z]<^9I-_+)A-&O&(RC$\"&4]SPK]<!B1]\?&
M/PVOA+Q)?22PK?:?=&.ZM(W4JK$@ K'(.F,<@Y!&...?D\RP<:\?K-/1]?7O
M\SVLNQ6*P-5Y;-WBM8/O'32^UU>WIY6/@#QUI6I6FMQ:':Z?I]BFN2)8&2XC
M+*8V#.2'"D0LK(091@ %<\G!^5OV@M+N-/\ '5V]BODP%R<1W(GC!(!*(^ &
M53N <<,,$ 5^G7Q7^",?CC3[B?2[4S27"?- 5 N8B,_(!QN7)."N<]P*^(_V
M@_V>/%UEJ*VJ^&]:;:V(TCT^0LX/ & IXKNS#B>GBLOH9=&A&#I;R2U;V=NV
MBC=MMMK=+1\W"O"]7"9SBLSJXJ<_;;0D_AUNK]]7*UDDD]I/5?-W@O1;KQ%X
MHM2\LAY8A40SL2H+$ *0>HP?3KVKZ2\&:E>68$5SI]\\D"9>&971DP0"2I&[
M ) YK#\*_L=>+-'\4:3=ZQI]SIDBPF3<MZ8[G3H-K$ P1DN2SB+<2,*F0#DD
M5]N_LYZ:_P .?"T[:IX/>X\0ZG+)/>ZE#>I);7; *N]9& 958*K>6%VJ=XP,
M<^EG&59=@^'X9FL5'VLF_<]WFZ:?%?W=VDKZK35'CT>-,WK\45<EG@I*C%)*
MI[W*]W=7@E:6UV[>Z]79GS7>_P#"1>+['=I>BWQL;-1)=SI&4MPIX W-@9ZY
MP2?:O0K5=6\ ^$+."WT_=-K\0=E +);0R$K&S'N7*N1D9(7('(KL_B9XSO?B
M5K@T>3Q!;V]O-*L?]EZ5$9,!C@"67&,'Z\]EKJ?B3<CPOINGZII^K6U_KMY9
MMI$-G;)M@\FWCD(W,P*-*BK(%X) 7.0<"OS&-3VD>9IV_KHW^'^1^V8.G4P=
M%4W3]Z?KLE?>SMUUVTLKGR+K_B6WU7Q%=6-JSW<-D7CN+I\@7<@)#,JD JN.
M%!&2.2!G XOQ-\8+K3+6333/(UH_RON(,KJ&W*C/C+*IY"D\'ITKT^P^'WAC
MXC^)M?CT;7(X-9,HNX4EN4AM=1B<9*J2!MD0@@CD,.>,&N&^)/[+NM>$+B[O
MKJVCU*.VMH;BY$-PDJP+*Q5"NT_.6*L !DY!XQS7L9/3S*I*>'P7-RS5Y)=4
MM-5_V]\M^AQYI4R*E6AC,ZY8NF[0E/2TM]'T;Y?G:WD5?#WQ!F\*Z7#):2NJ
MZHK)<*KD"2, X![C!.01R" 0:XGXG?$C5O$OC<7,TT<LVI$11.Q+LBJ@0#))
M)PJC&3UR>I-<;K_CJ2SU[[#;(X@4%58<J,]B?7VJIX8N1JGQ$M_,90;=@$!8
M#)(!."> 2>AQCCFOKLJK8K$TJ>7UZC=&#<N7II^E_P VSYW%9+EV'S"KFN'I
M)5ZBY7.S3:_._P#DET/J_P $^-;C1?A/HUKJNPZ7HRSFUL8[I[=;GS2&,3LI
M+F,,HD"JXPYR<CBL6+XP"];;;R,C !V"978JDYV\]<XQZUTDOCGPWX=\%:2E
MWJ?A6+1(-.NX?$.FW=F9M7O;UD80&W=02%'R %2 "&SDD5\WZ/XGATNX,TCL
MTTJ!F(S\@'49Y)QU/YXQ7W&'SG$YC!PQ$7&-)V5U9/S26GS/$R?A/*\GG4QN
M"LYXGWY--R:UE9-R5UWLFXM-/T^H)_B%:7'@J[&I+(P%NQD4*5R<8#=<$8[]
M^W-?._B34!K$.KKJ;ZA=6>GVHNXK9K\VD#HN%,I)5MVQ22, YZ9&1GHOAEXB
MD_:"UJQ\)0ZE;:3I<MRMO)>2*7$K,?EC0+]Y^,8'![D8JC\0OAKJ7@SPG=>)
M/!=UXGO])>^N='U*/4?#Y\V#R4+!P!N_<,<C)  .">G'AT^(L!2S2GA,9)^S
M=U)?9=]KWTT:3>WKI8\[B3A_,<=EE?&95%*K3Y7&=M8MM[-*]Y+F2W3?WG+:
MGHUKING^'_$%E9ZM!HFLR-'8MJ(W.ZHH()  *DG/!Q@8. "*]+U+2Y_'_P *
MM0M-'LVBU26U\VW!81!W5PQVGH"<<9QU["N=^ O@35_VP_B%;Z8;JPL+HVXE
M:6+>+:%4 4D)DG<1@8! ^@S7UK\.?V:8_AYH%TEQ?0RPVL[6$<@Y:\8 AV"\
MX SC_@)YK\[XTQF$J9E[;+U:-TUNM=+W3\[Z+O\ )?0\)97C</@*-+.9WK*Z
M>J>EW9IK?W;;ZZ?-^*:7^TC/K/AC2;/QUI]UI=SIK+!<W+19GDVJ4!VX!4<$
M9!(R",$')W]5^ GAWXNZ#;GPYJEKK=YYKW-O9ZE"6M(V,3IEP&5@"'. #@G
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M^BMHD[:I:I^3_%:GAZP7W[0/QNT/PIYKZ?=:K?+:_:@04B4Y+E1P"0H) [G
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M8*&$6) >A)*'! ST_P"S;\</#?A#X=Z+#_PE,?AJYLM7EO/$%L^E&[?Q#:G
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MC!JFJ:[XS.K7L]Y<F9%C"RRM*+= #M1,\JBYX'0<]\U<\$:LUQ"_*@0J&.6
M)!. 0.IY]/?TKM-:BA\6^+M/L]/U"UTZ1 ;B_>:Z-NC6P(5D+;2 7#E2"" ,
MG!'7ZW^)W@CP;XS\%7FCZ%X<T32?#+^';?4H;R[5(K7PXT Q,D=P@#&1U).&
M#?.1W8@S_JO5SBO6Q\)*#2;=[).6KWZ=6W;I9:[>+Q)QUE_##PV30I.46XQB
MHMMQBK*R3W=K**YNMWMKP'_!/?\ X*$:Q^Q+\1%%P;C4_ FM2!=8TL$MY?\
MT\PC.!(HZC@..#S@C]AO#?BCPK\7O =CXJ\)W%KK6@ZM$)K>XMOFC<=P1U#
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M 2H',@(&TD$<X R":POBE\,19Z4FH_V7)HTFI*MQ)!)$QCGD()!A<LQV\,&
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M@# Y.!DU[0^H"QTJUN$5A:RA$CF?&!D<@OT!R.<D?3O7#^,=4TOQAKMAIO\
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M<9.,U][_ +&%]HVI?!_0-)\$PZ'!HBZW;7'B3[>PCU*./>48WLRA5DMP69B
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MYT]!<0O;S)("TB8VCD$D-@G)(P?4<5Y-8_#M?$LL^O>?#<6LLQ5 P#>4F2%
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MBP#*.Q&!DYKT+2OAM!\2/A?\%KS7+RZ2\LO%]KH9NTF=)[FSF;)MVD4ABK$
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M  !_9CT'X77/A?2-/UGP_P"#[OQQI\^NZMHE\HN/$&L&5%D)CED82+#!EQ@
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M R\Y^AKN_A3%9?"[2_)+Y3.21DLY]AS6]<SO\4-1A$VS3-)A):2:4@2.HY(
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M.=LJQN5=5/7!/5\ X.1DXQEV7Q[F^%.JZ!-I-C;_ /"1:Q=VL%C>W:B5[(J
MA.QE(8  ,"",'ICG/1^,O@]#IOA6XU6:"%IM166X=TCP&=R79CUY+$FOT7,,
M\RZC&$L-'FEKK]V]T[_YWW/RKAO*LZQ&*JK,Y>Y%1T_\"LE9JW?57M;OI]4_
ML_\ BW3/BK\%++2?#NF2?V/I\&_7-.M]'>YGN%6"1K5YUW9N TV\*8B"05R#
MC(^)_ '@/5/C=\<[[PYX?L6B>UT&;6]0_M*X2W33-KA0ID<@*JDXPQ).<'D$
MU]$?L,:/9+\"='A\1:C?:6VI^+C+X>^RW#I)J=Q%%&OE2%5;RXE8  GIEL
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MYYM]SJN]?,8(1C>6!(()4C@5E:=8?V5XBDEF^SQF%LA9&VYY['&*]K\'>--
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MO"9  0#SDYP>,GFOH'X:ZWI_AZ^T;18;G5-5N-0(1G>':\9V@CGJ03E5..N
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M!]C73P_6IX3&PJU/AU3^:W.NIB)0K:G9>(O#']HZ4[2?NY3.%0%B3Q@Y'3C
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MI)IL @LN % &/4GDG-=5\??VB;K0=372M.O([^.ZM8KFVN;7_CWE@E4-&Z#
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M& "2,8_/->::7XIU#P>PTG6TV/L*K*#NBN%/0@X_2KNHZX\%H_EW6^.50N6
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M-<0ZG,K#S':7@0LZ/$R0G!() R017TGXJ\,Z1XA^"5CXLT^_VRZM%C:D?W'
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MO$.LB>1?5(U9OKC<Z?C7Q)X6TV2Z*LQPV/Y>W6OI[_@K#\08?^$Q\$>&K/;
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M5K$4&0CL&P>QV@XS]37ROXU^+/@.?Q]?ZZL=[J>N7Y/F7-S,7!!&-H' "@=
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M>H_%2X36O$^DW'B+1;=I;?4B+.*]O8RJ';N.!,JDD8DR>._!%>=>,OA1X/\
M"/BB/5H+2ZUS08+=W-K,9(Y[978;!(>,E"&^900"R[B<C-G2/BA>?"+XEW&D
M^+(=4\)ZOI,C6]PUDVV:.0'(.[.UE[C!&00<BK$/Q>L[[5Y7AU5+BS1S)',8
MBL^[DDD*202>,@X.>>,U>49QC<LKK$8=6>SZZ.VU[K6W^0\\P. XBPOU+&7<
M;WM=JS2T>EGI?:YY)^T7\:(_B'XDL+6U6_ETGPYIL>DZ1]LO1-+;*C%V,K8
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MN)%BW$;B2Q ! ]>>E?*,'QST&^U.*3[))IZ ;8KB(%_+ & '7J1[CGV->M>
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M+2:VE6.4&*0LLT3*[OYA(8L&# './,]&_:\G\0^$Y/%?AO45MKRVM+4W,"Q
MKJ$3&12=C @A2%.#@C>PR,5[/XK_ ."@.K?'']I+X:_#.Q\(Z?J+ZKHMOJWC
M6^U&%S;V<,ML)I!:.NU0$R2SD#+$#'6O!-?_ &?=2^(7Q7N)/!\VGZ;:V"R2
MW4]\XM[*"R5\9E*@X'*@  G)  Y-<?MH5Z<N65^3K:R?7\CZ:I]8RJ=*.(I6
MCB4Y0CSJ<E%R<5S62][F3ULKK=7O;EO$_P 1=#^/?B:TD\2^&M#NYYIX[:2X
MMY9-/= Q RQRR9 .<G''4XK$^-?[--G\/=.N-5TO5+?Q'X8U M;0,+@2RZ>
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M!1[Y)["OCO6-&\5?%F"WCOK^YN/#VBA+6!O,"V VX BC7),S@<$G'O@5[G\
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M[J?<?K5[0OA5;V%Y"LZQRK&0W(!Y'2L>?XA+XA\;:A>:AJ#6\$LA$;VK[&8
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M;CPW=()PN^2U#9$RGH\9[@^W2O-=<O?$&GHUO);S(R'T.,CV]:;X,^,FB>
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MPCI;L9#&K'!);IGM@9ZUC4BYR<GL>]2E*$(Q6^AZ/8>)%U)VCM9%%AI[>3&
M>)9NK/\ 11@#\372^'I8P[;I=P/WN>HZX]J\K\ ;O^$6TY9"R.Z!W [,W)&?
M7FO0_#GD,SV\:YN"GFX+!?E&!G/N3BN/V-7$U/9TE=O9(]114(<BZ[]V.\>>
M!K3QE:E)#M,>6BD'WD]L]P>XKS;0H+[PAXB%K,-JH^5?G$BCNI[_ ,Q7?>)M
M<ET1?)NE^S^9DQL3D''&"1T)ZC...:V/!FD6/C*S2&]5&P-R/D9!Z@@]O\BM
M:V'KX9\E:+7K^AYN(IVES+<[KX:Z%;^)-(:2$\D@^4_# D9RIZ$$YXZU)X@T
M2\T.XWPAFVKNV =_ZU-X:LAX7B\F-T\E#QSV_F,]?8UV?AOQ59ZW ;>9%D=P
M0-X'SXZ\]B/U'([UPRBI/4,12J.'M(ZI_AZGCFH^,O\ A)KI(+J98?)8/O)&
M8V&<9'7GH1Z&NB\"^,;>_O#$J1[UVKB0X#A03P%SD' YZYXXXIGB7X7VHUF6
MXDB81W#_ ".IZ>@)]:[KX4_"'3[)U\Y'*GHW3&>Q->]E.?U\!%PIQYD^C[]_
M\T<\,3*&B+/@KX9W&I6)F$6YI"6/EIZDD\=JZ+0_!D-E?_,GD)'RY?(.1VQ7
MJ?@K2]/\-VY6U#+D <G-+J]EI_BGQ1:6K2(?(8R7!XQ@<@$_XUX%2C4<W6K;
MR?XM[DX6LI3>]K7N>4_M;>)+'PW\%[>SN$\R?5&4K;#K*H.$0CN"><=Z^=KW
M]G/Q=>VD5W'KD<<LJ*?LJH42#(R5&.!CITKT7XO>+K7XO_M-+9;LZ;X?#, O
MW-ZX"Y]NGXUT$6O_ &2X\M6SY3<G/4=JWQ%:5/\ =4GHM_/S-L+237M'HW]Z
M73\/Q/F77_V>/&4=Z?.M)+R1OXEG5A^.2,&L*\_9^U[89+C1KX.I^]Y?\CWK
MZAU+X@3W6K&'3;=&E0X9I.F<XX'?G@GM^M-OI]4NK0,LMM,VWE9,)EL<J.01
M[<&N["Y7F6(I^UA%6[-V;_KS*>'DW='QGXD\,:AH4OE7-M<1D= ZE?P.>/Q!
MKT[]G[XTZKI%S;:7<W'V^S9MAAG(,D8/H6!! ]#GZBO1=7TW^VK[R;A-F!E@
MPRK\9^4]#^'6N??X5Z3%J_VF&':[$%@O'S#N!VS7/6]K2E[*O'EDBHXAP?+4
M]Y=F?6WP:\:?9;1/*L[-HB!G9&(V ]U''Y<5V/Q+\.I\9M$T6SB\2^)/#46G
M:O;:I,^C7OV.6_6%BPMI)!EA"[;2X4@L% )P2#XW\!M09UCTVX'F12+L!/WL
M8(P3]#7GO@7Q#/X8^)WBF%KVYN;30W9(H7D)7<6PI(]JTPG)4NY.UMSEQ%&+
MFJM)>G];'U7K.J>'_ ]_>Z9X=T_2=-O?$%TU[JL]E:QPO=S,/GEE*@;G(&-Q
MR3W-,U35[73=*+-,BHBY)9@  !U)KP/P1XSNIO$LUU.))))8R58Y.22"?TKJ
M+GQ1;>(-.FCN;NWC$1#LLK;1)M.=G0\GMGC.,T2E[:K&FWRQNM>R[G)3BH[O
MU?\ 7X'/_$?XD6>O7%VEC.BQ644EQ<7,C"*"TBC4L\KRMA550"2<\5XU\1_$
M-_?ZE$+BUMS:W&-2CFL(8?L]Z;E%<W(>( 2-*H0F0Y)P,GBNYUCXIVLVIW#6
MT<=J1N@=+A0T9#@@Q[>5D4@L#D$$$YJQX=\*ZO\ %K5"\,*7,<(2)611'$FT
M87 4!5 4 !1C    KZA<-X*E)5IU$X6WNKW[WVM;UU/:C*DJ#BI--O77W;=-
M.]^M_D'PGTMM/GL]9N=$6WNKC3ET:/5F28--:+.9Q",MY9Q(2<A0Q P3@5YS
M\$?V;?A[\:/B'J/Q=\5>$+SPG\1[+5[^6Q\-WVHEH+@1O&@UI;9U#F1OE4NN
M8MZY ) :OIJS_9SOHKO4=45'&I:U!907W^G32V^VU0I$8H6.R(D,2Y4?,>>.
M<U/&/@?3_#FGPZI/I]A)KJ12V$=\;=?M45N2&:(28W"-F 8J#@D XS7R$.6+
ME9*UW\_/IJ]SI6,YI*-*K*?NQC=NS22U@ES/W4[Q6UTKI1;L>>MX!L?%3W-U
M=1)<&-MJ*XR,D9)(Z$_6N2^-O[//@+XI?\(CJ7C!M2L;KP*LMM9BU@6XM[NW
MDE$S1F%F51(2& <AAM8@@D CM/!FM/! 0V[RWG8$'Z  U7\4O'_PEP:^$BVT
M"H5902 IR"Q' ()ZC.>!SCBM<+E/]HXE8>3]W?[B<HS+%9=B8XK!SY)J]FK=
M59[W6Q\>_M66#?%;XIZW?3:.\=O>.HLPPSLA1%1%)ZE@JC)]>>E?..J?"K4=
M(U1QIM]=6;+R(RY*\_CTK]!OC%H]CJ5BD=N\(NHOWB!?N."#G+'&2 .0  #7
MS;KWP^O-;OWO%3;@D!6.#MSQV[U]-F>5X?!TE%/79+R/+Q4G3GSQD[O4\O\
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MU3"3ISC"I'5]#Y#GJTYJ%_Q/ECPE'H?@GP^NE:"8[3RYFBM[2*W3,"@#)"J
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M>/)X[?6FN;/S'@Y1(W;< N<[2,>O.?6O>Y?BA%XDTYH]4TRWN(V_B@;:2/4
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M";X.MH]K,;>Z^T8?S8P5P0>X!SR#7*^.O%]G<: ]C?63QSP9V2<A@XR 0<8
M /3D5#X._:*DGA\FSN[:5<_+#<K^\0>F,C(^AK<UWQAI?BBW7^UM*RV/]9;O
MR/P;!Q[9-.G)TY*<&XR1R5J-=/WM5W1\[W=[+I-[+&D;7"2$M\Y+$D]2#ZGO
M6EH7PCU+QYF2QTN9\'+;%R >N2>E>P:=X>\*B96M6C=F;[EPA7'XX(_6O8O
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M"2<D\]ZJZOX7QX@>V:-E123NQQ@>]<.48)8&DZ47=MMM^9YF:M5;58*R>O\
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M8O\ 9M/F@BMI81YCQ>7$JLH';)W9]ZY7X8>)=/\ AD1#&VJ2S*</]IN7./\
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M2B\7-25&FJ4=$K15VEHE?5O5W=NIY;\??&6I1:?_ &4MLEW=BWD@\Z3 D.<
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MGE:C05*2NDTEY)M+]3\W-)^ E_KA&I:U--<3-SAY68*/3))))ZDGDGDU[_\
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MJJ=WLU:UO4XZ$:%*K>I[R2OH]]B;X@_$J_\ %NJ/!#,MS<L/*\T\+$H_A4=
M!7*P? RVNI?M.I3+NZDYY-=3X;^&5Z^RXMXV8!2S8YQZY]#6GJFDJ#+#=+<K
M+%@?+D<G&WGMG)['IVK;*\#+%5_8TW;2]_(SQ682Q<N6UDMD<!JWP]\,6%BY
M61LJ#R,]?K7GE[X/N?/D;2;N:,Y. &(/X5Z=?P6NIW*"29AN^[O!(*C/08 !
M!Z=NO.:CM/#LERPGMDVQG:1M(PR^QQUSWQ^7%>]C,CIX6@ZLZGWVU?8YN1Q^
M%V]#RRSU/QAX5NUW7ER%!X#9(KWKX!^)8_B39WFCZS @-W$4+X&0V, YZXS7
M/?$>UMY-(C<[5EC'(/7BJWPBOOLNN%H1B1DRK#N0037S,VN7F2U-L-BJZJ*G
M*;:?=E;P-X1N=(UC4=%B#+<VMRT0 '7DX_2N^\&65]X(U&6.\A=&.1DXQQQ]
M*O?8_P"R?B;8ZS-$%CO@4GR./, X./<>G/7%:GBSXBQ7\TT*Q0ID@;QP#M
M(&2/\XYKGY7+5&&(@Z=5QZ&SKWQ#;2=$@M[=_(GOF\L2*/F08R<?[1[>O0<X
MKC-8M)K$B:VN<3,S;V,A!)SSG=USCKC]:PO&GBR\BMK)K9TWPR@G R,8(_0$
MD5%JGBFXU(06UJ'9F12 1OER<#(.>@P,8YZD]*^\X5HT7A'=*]VGY_\  -(R
M3BT0WGQ5D>;YX%5U&&&TCGZ45<B^%&I3KYLL2PM,=X69AN(/?\:*^/QU.,,1
M.-#X4W;TN>5*G.^C/K#5(9/"NE6TVJ+%]@NIC!%<H1AV[JR=<_3(KHO!&CZ;
M87236=K:W&X[@8E!8>O':OG[]LC]H(Z4(?".ERK(+&3?+-CD.>"![^]<=\*/
MCQK7@^T#+=[GXP6&['M7"XRY5S:L]_%4Z<I2M*W;S7Z'WYIWQ#^P'$ENT(3
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M2KRJ8:'+%]//KZ>AG[-1]]:(YWX1-<V;*GS%<C+<_J*ZSQSX*.ML)[&94NE
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ME;L<7XUTK_A((MT;K'*X.[:WRGWQD$'L3W&0<YKSW4O!$D-WYDK/@-G!/R<
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MS_+%=<*BO?J<M;+:\7IJNZU.HT'PQ9>']/>Y\L23MC;N Y;USUP/3IQ7BO\
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M!,06 #8/" 9!W9YY%</JGPZN/'FMS76G1.T:$-)YXV_OBHWJO^RI! / .,@
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M4X\"^*HGSDYMXV'ORKFG:]\*/'TL6VQ^'WBAGQSFW1 3]=_%?H)11_9\>[_
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M5"'_ )-_F?G?-^SO\1VMEAO_  #JUT@_BMGC/Z,PY_&M33_@]XRTV$*OP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%1W%S';+F21(U]6.*YW6_C)X1\+JYU/Q5X<T\1
M??\ M.I0Q;?KN88I2DEN7"G.;M!-^ATU%>*^+O\ @HS\!O JG^U/B]\/[7'4
M#6H9"/KM8UYGXK_X+F?LK^$BZR?%O1+YD_AL8)[G=]"J$'\ZPEC*$?BFE\T>
MKA^'LUK_ ,'#5)>D)/\ 0^MJ*^ ?%'_!R;^S/H:M]CU#QGK3+VM-!D /XR%:
M\X\3_P#!TW\)].:1=(^'/Q"U9>=C2BWM=WUW.<?K7++-\''>HOS_ "/:H>'W
M$=7X<'/YKE_]*L?J+17XY>*O^#K.=E(T/X*R ]FU#7EP?P2/C\Z\V\6_\'3'
MQBOV8:/\-_ .EJ1A?/N;FY8>^<J,_A7/+B#!+[5_DSUZ/A+Q-4WH*/K./Z-G
M[K45_.WXJ_X.0_VH=>1EM-0\$Z*K'@VVAB1A]#(S?RKSOQ-_P6\_:I\7%FE^
M+6I6&[J-/T^VM@/IA#BN>7$V%6R;^2_5GK4?!7/)?Q)TX_\ ;TG^43^FBH;B
M^ALEW331QKUR[!:_E/\ %O\ P42^/OC0.NJ?&/XC74;YR@UB2)>?9< 5YWKG
MQ:\8^,I2VK^+_%NI$]3=:Q<R_P#H3FL9<44_LP?WGITO!'$_\OL5%>D6_P W
M$_K,U_X\^!_"<+OJGC'PKIZQ_>-SJL$6/^^FKSGQ9_P4R_9]\#;EU3XQ?#^W
M9>H76(I<?]\$U_*O?67VZ0M(SS/_ 'I7+G\V.:;!91V2_P"JC'N%%<\N)JC^
M&"^\]&GX+X2/\7$R?I%+\VS^E[Q7_P %X_V5/":ON^*NFZ@\?\%C9W%P6^A6
M/!_.O-?%?_!S'^S1X?4_8I_'.M'_ *==!=1^!D9:_GUCG1T_A%5[NY+C:HS6
M7^L&)>R2^3_S.^GX39)#XY5)>LDORB?N-XF_X.M?A7:F1=%^&?C[5&'W&GDM
MK53]?F8C\C7G/BO_ (.P[^0'^PO@K&GH=0UX'/\ W[CK\>8?,@_AZU,)"_5:
MR>=8N7VK?)'=3\.\@I_\N.;UE+]&C],/%W_!U5\:=2D>/2? 'P\TD-G:TKW-
MRR?^/*#^5>:>,/\ @Y+_ &I-;0_9=;\&Z,K=/L>@H[#\9&;/Y5\)3Z=YS[JD
M&G*1\W-92S'$RWF_Z]#LI\*9-2^#"P^<;_\ I5SZAUS_ (+<?M4>-C(9OB]K
M=BLF<K86EO;#W VID?@:\R\:_M_?'CQO)LU3XQ?$>[1OX3K<T:\^@4C%>7A4
MM5]*"$EYZUE*O5EO)_>SLIY=A*7\*C"/I"*_)&EK_P 0/%7BUV?5/%OBC4F;
MEC=:M<2D_7<YS7.WUE&T<C.&FD*\M(2YZ=R2:OEE7O45ZI:W?;Z'^59^IU1E
M):)G]/G_  1;&W_@FK\,,<?\2X\ ?[9HI?\ @BZ,?\$UOAC_ -@\_P#H;45^
M@8/^!#T7Y'\J\0_\C3$?XY?^E,ROB4FL-^U3XP.BFS:Z6"W+0W3,(9E* $.5
M!/N,=P:Q=1^'%]KD[>9HOAM_L9+72B[N88[?(W$(D> PQD_,#D\8 K4^+&E0
M:Q^T[XRAN+C4K3-M#)&]G>26SNRQ [24P2,<X) X[FM"'X):/>:?9S74NH2R
M0()/,:]<G)&<LV<MSW;/'M7/S)-^OZGVV$DEAZ=_Y8_DC#O[+4-'L+4^=X;D
ML9@&MHY+=SYA(P?.?YLI@XP%!'K5>]\&_8;ZV75?!>EZL\:%H(-&5,VF#PZ>
M:R$ D\C/!P0#S6H/AW /#HU*VEN[E;@LK1R7+RQ;2Q&(5/"@GD@ 9ZXINO>#
M?#_A,R0ZCXDURQCCA%R_FZM<^=""P4%6SD*3QM!Y..,"CF6R.KVBZ;AH?BZW
MTB^>Z71?$4BI'Y(@CMA=W%HV26#&-BN#V^8XZ<<BD.O7>IZ+)80:3JOVB_G,
MZ7"VWDV\8)!4;F)^;(P0,G.<\4RV\/>']:FCMK'7+IXYH1)9M;ZH8&O7.249
M@P,A/4@\\G([U9T_P1I&O:!=:@NJZY&(E:*:&?491%9R(,%=F0J%2!@J 1U!
MYH]W<.:*U]"76=2\336"MJ6CZ+I]O%(LGF_VB]RI?. '00KA23R03CL*AN9?
M%WAR]@N)O^$?U"Z:-E%M!)+90&( $DEBXRIY!QR,]*HNEYX6M;6WN'FU*UMW
M%[";G54+R;EXC)E(<+G)#.2,G&>!4>I^*+S4-2>[DOM+T2:[41M$98KZ>*W7
MABI5@H4DDLYR .!DBA1?E_7X@ETT-2STGQ=>:<UQ;WVDPQ:@#-<;XR\AR/\
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M;*X162>VTU9'W'G!0E#@^QS_ +..:JS_  \"Z,NH3:E?Z9MROV5[MXK>X Y
M$>=I)QZ9..N*;<:E=>((5@U!M*M++3X&,+66K!KBX8* !NPHC8]@<D'G/'+U
MZ/\ ,YY83#3WA%_)'3:-^TS\4[;Y=0T7PHLWEF86\D[K<&,=3M4D ^PS]36I
MI7[8GBN_L1=6_@S3]>M]_EM)I6K(WEGN&#8(([@X(]*\]\'>&M0N5A>SFO\
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M@YJ2J,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_B7_ (.8_A%8JW]D^!_B-JV.[VD%J#^+2&N6IG&"A\56/WGN8;P[XFK_ ,/
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M/#>O:?J/V.*#P>]XL>TK;PO;Q6L9))*Q[F D);.20".>:D3Q+XTL$DMX]/\
M#]Q;VK"(ETG1D7L"JEAG'?.#Z#I2MI9?F3SNUK_B41JNBV.@:?#:VNFR3PN3
M>1Z?"FZ(+R49%RP9LCCC)YX%9^LVVF:O:P'_ (076K.VA8N;5@ENTZD<F(QR
MX# \D$@$=:O&2^TQDGDMO#Y\TE88'C$%W=J/OJ&;<6"[@5(  Z'.<BWH&M6>
M@);QZ7HNMRZA!-))/:/:/;2N6&#AI"(V/ )VL1@9IVMJOS*YK:K\S!GM8HUC
M$R:WINF6@$L.GWUG]I^R, 07)CWDD@Y )).<@ YJ[%KMAK'AY[0>'=5ODD#*
MNHRZ2$M]Q)*AD8B0KG@_)C'ICC8U#4O$%ZMY?2:?8:;#@6UW#->&7RU/(8%%
MP9!GID@#N:AM_$'B;5O#WVRWUOPK?Z4S&!FMK*<RXZ$;C)PX'<C&><8HUL#J
M/3_/^OS,/4]2\-RQCSV:6SE"JMA96LKRR, -Z(H"E%4]R1CUJ.S6QMX-^DZ)
MXSTF#=RD-TC3R9(&5WR. F.&&03Z9KHM)?Q1>7F^&+3=1FCC"O#=*;:.>(<*
M6;#'S!TR!@CL*OR7_BBYO8I(=#T_3;ZVA9%BGU 26Y0GYG!1=V!T *@D^@HV
MT_4)5+.WZG#RV&E7=U]HU(7NZS!C5]8F1H;+'*F$X*A21C& X. 3TJ[!'I,<
MCS)X9U1;Z9-C:O%"%M[@@Y^;#;B0O&63V!YK>72_$&OZ/PFE36PRZW5LP:[6
M0DE@492A )X!R>F0:--U?Q)K]E%HZV%NZ1)BXOY?]'\W!RICC7*@< $DC)SA
M:/ZW&ZE_^'*-IXQ\)Z=,LPBNGMXXS$%?39O-N)B<D!"@+8'0@ #UJM?ZHES>
M^=I\/B#2H+D>4\4VD&1W7DX;)W1*2!M;)!.:Z/5(O$YN[5M0L-$N9&+1PP6D
MS?O 1R6,J@97@@ X/2JN@V.NZ9%-:Z+X=MX]Q*7%SJ5[MAEQD%42/+_B0,=.
M:G3?]40JFG-^J.=C?P(;B226XU#5/$)RL+ZK;W+7&X]"BN@"J#W4!1ZU,=1T
M&SO(Y)_"JBQBQ]I?^S3YTLN/]<J8W$*1C< 2<D@<5L6_]O:7ITEK%IZW]DT_
MRSC4'+QNI'[C;M+&,D8'/ /0BEO/%^O:W(D<VAPZ//&ZL;AKAKE'8$A!@*K%
M<GG.#Z>M5;^KE<S]?F8DOBI;*66_T/4K\Q9,<2WNAW=QY .,HD8".<GD$D@'
M@GFL_6M&CUJZLY;BVCFO;<^9+?ZGI7F37#DYVQ#(6-0/XL9!XSD<]S)8>,HM
M4A\R_P##:ZD\;"%Q9SB ID%E*^9DMGG((XZ@\54FT?6D62.2STVZ\JX+*ZW+
M%$F;&Z(HPSL8X(.[(.>*(O\ K^D$:J_IG.I&MM;2-8QZ]HCHQ:XO/(-S9SJP
MP_EJI8J3QD *<\C.":T=.\/Z-9>$Y;Z0+JVEVX\E]+CLHV<R$XVD-ABQ)!^8
MX[\<FIM3\2^)KZY>WNO[+TBWB(!MK0-/*C#D9F)48!P<!!Z9I-3\%7W]K0WU
M]IUC-J=X/+6;2[HVPG"C(D9'.6*CD $D'D$'-'J/VCZO^OZ\S(N'DTV)6M+/
MX@:'IH50]M8R0,\"] 65BQ Z;2C$X&, 5!=#2[V]02:1XDNKI.8+JZN%>T@;
M.0_E>8I#'N=F0>><5T?AO3-<L9)%L[/^V;CRS;M)J=R4\I"0<.^TO)C& #DG
MN<#-1*FH23"&31+>YC$AM8KJVO$11(3G]Y&0&X'0@G..0 :?];ASZ_\ !(;$
MZ#=VL=S:Z7#I#6]RL>IF:V2-'!&=[8.&! )#9..<X(Q67KEUH&HS"XN/#.L7
MR.Q:SN]+E%OY40/&"98W).,XP1GIS6M=:'>KXBCCGT?1[:=T"V\$U[+,THSC
M,H51&JL>P)(/3C-2:]H&O::VQ?[6:X91M73$MII(XL\H#,54*"< C#=/K2LO
MZ8N==_Q,F"\\*6US%<7VC:]?W*'-G(]M-<W$2$8)=F8@,.Y)W8/<5'I^E6=O
M/';V5KXT,A8R&!9I%TTDDG@%L$D<;1P#R0,9KH&M]2TO3%O5T*&Z@8B5&O;K
M;-(2" C!590.Y89&>,$<U:;QW?:_I]K;P^&]8M9K9T=WC:/[-&RGA$=L"0,.
M!\H [X-'I^8>T?3\SD;G3;'5+V/S_">K:O9X8&UEOG;4(F[[AYFR0$]07X'3
M(X&IIEUHOAFW@74O"%Y8VX!$=[%8I)!8(QX4$$NH ^\0I .3DU<_X2B;1-1A
MD@\,WS26C,MU<33B&/DG<%"AVD8 XQ@ D8!/%2:+XGTW1]4N[C13K&OZ?J"X
M6PMXFD1)LY;B3:(QC[V2 3ZGJ.[02FW_ ,/_ ,$P5CTQ=5;[-8>(+B^G)/FV
M-Z8[9U!^0.H=0TF,[2%)!P21P:C^Q66G,[VGAWQQH]W]Y[JYU %I<'.06FD!
MD_NEEP.<D5U$-_J?ARVAU!/#K-'&3N99XE:X5SPJ@D;"IXR< C@=:;K=W-XF
MOX[R7PUXFLG6,1*TSVYBD4G.U0LK#<QZ' !XR0*.O_!#VGO>7J<S;V+"_;4-
M-L/%&DZG*GDR2K8V\U]/&2.^YE"]RY/!YQR*L1VWAR&."+6?!^O:S=6['R[^
M>P%Z96)RS!PQ88/7(!ST&*T'M%TW2)K*.U\6Z4TTPFO&2+?+Y)'^I5U9@C$\
M[4(SG@T:-XFU+PU>;[>UM=/T>=PTL%Q!/)>;,!0^5; ; R5"'T)SS3:N4Y-K
M0S+N'P]?V$=G<:/'9:DI)$KZ,5M[L'L)=I!8#J21SG%9=KX>\+V%^LEY#H^H
MV[DBUMM(MVGNKO ^8YC8 JI.-QP,]22*[.7Q?/+H$.DV]A?C:<SW<\;Q0(N<
MC8W1SG (X &<^E7+=_$GA74X[J[TVWU-IE:-H-*5(O,4<JX61\!E'!PP!!S@
M8J.5=4+VDDG\^IP,W@W2;?4S<0KXX\/2.H>"S^U2B)SW1S'O$9(&02<'(ZG(
MK8_X32WM@L.B>*/B+YNW:LL9FDM8W]&:10,9ZD C^5=(_BF^-W?32:/K44NH
MQ""&!K<9MNP,C(651G)!R<]*@UG2=>GA2XU2UMTV((Q]F)DPB]"Q;E6/4XX]
MZ%"/],B7+/2:7SM^I0MOBWXJT8>9)XT\56EK#A)Y=0T82J&QPRG:2R9ZD=!R
M>.:ZCP=\5?B-K6FFXM_%'AB^$;'<KV/(7DJ6VD$9'/('%89UOQ%J>I06GEV.
MGP0E!:)-"[W 8#"O(0V #U*J#Q_%UJGX@\#W^HWTDVK:3"UYL"W$NDZBUK#<
MQDX#RH2/E!X,9+9['K3Y>E[?,YYX/#RTE"/W+_@&]_PV3XHT.4Q:@W@F:4L1
M&B2W"&5<X#*0K*0?K6MI7[9?BB4.LGP[O+HQD!C:70 8=<KO R/<'&>*P9/$
M7B#P%:"QD\.VHLW3R[*2TNR1&<#F4,!@=\IDCI@CFFS6'BCPW!#?+'9S0V"X
M$2NP,L).65QSA@>0PR.@QWIJ4NC_ !1SRRO!R_Y=KRU?Z,[*+]MV.TE9=2\!
M^,[$QC)Q;";/TVGGZ#FM#_ANCP7:Q;K^'Q%I8[FZTN15'U;D?X5P=S\0K?Q)
MJMK=:-:W^M"P!:2&W4HP=N N)-BAAUR3P,_2FQ3>+KZVGFM?^$=TZT9WFG2_
MWW<D+=T8*RJ ,=><^F.:/:5%N<TLEP;6L6O^WO\ -,]8TW]L#X=ZH!M\16\6
MX CSHI(^/J5Q6]IOQ\\%:N!]G\4:*^>@-TBG\B:\!_LWQ$NB)J-K_8MU"@,L
M<4MJ_P"\#'+[AN& ?X>,J.2#5'5;6X\7R6ZGPGHNEV\SXB^V[/M%S(.<!5 V
MQYZDY)&.!FJ]I4\C"7#N'?PR?WK_ "1]567BW2=2Q]GU33[C/3R[E&_D:T(Y
M%E7Y65E]0<U\9ZA\"!J&H-,WA7P^VI  R16VJSV=M$#D X4$MG&2,#V-.L/A
MQ=0O-;VMA>;XSB6XTS7Y$2R<#IL<EF QV.<\$57MI=E]YA+AV'V:OWI?_)'V
M917R'H'A_P 77>K2-IOB_P 6:;#'&I2UO+U))(\C[[8+95CTP!QUYK2AO_BK
MX;E@MY?B%:R7%VY6 S:>'3CL0222?4$#UH]OT:,)<.U%I&I'\?\ )GU517S7
MIWQ(^+D=XT,.K>$=4^RL$G:2T>(;L9P-I/([C/%7-)_:*^)0F$=YH/A-RP9H
MR+]XS(JG!..<'KP?0^E5[>)SRR'$K;E?S_SL?1%%?.NB?MS7>H:G]C7PS9ZA
M<9P5T_55DSSC(RH!&?0FNDTS]KM;J.1IO!OB=$B<QLT"1W"AAUY5AG'M3]M%
M;F,\EQD=X?BO\SV:BO)8_P!LCPD-RW5OXBT\QD"3S],D C/N1FM*U_:R^']T
M<-XBM[9O2XBDB/ZJ*:JP?4YY9=BH[TY?<STBBN3TWXX>#=7V_9_$VBR;N@^U
MHI_(FMRS\3Z;J/\ Q[ZA8W'_ %SG1OY&J4D]CGE1G'XDU\C0HIJ,)%RI!![B
MG51F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%9NJ>+-+T*+S+W4]/LX^[3W"1C\R11
M>PXQ;=D:5%>>>)?VLOA?X-)&J?$3P38E1DB;6[=3^6^O._$O_!5[]G7PJ&^U
M?%OPD[)U2WN&N&_)%-83Q5*'QR2]6CT</DV85_X%"<O2,G^2/H>BOCOQ!_P7
M7_9QT5RMOXJUC6"/^@?H=S*#^:"O/_%/_!QA\'=*W+IOA;XD:LX^[_Q*TMU;
M\7DX_*N26;X*.]6/WH]W#^'_ !)6_AX&K\X-?G8_02BOS&U__@Y"TYESHOP<
M\13C'!OM8M[?/X*&(KA=>_X.*_B5>I)_9'PG\)V2_P #7NLRS,/J$4 _F*Y*
MG$N6Q_Y>?<G_ )'OX;P=XNK;81KUE!?^W7/USHK\0_$__!?_ /:)U:7%CI_P
MZT4=/W=A/<G_ ,?<"N#\2_\ !9;]ISQ(LF_XBZ?I:R?PV&@V\>WZ%@Q'YUSS
MXLP*VN_1?YGM8?P&XGJ?Q/9P]9_Y)G[\4C-M&3Q7\Y6M?\%#/V@/%LNW4?C1
MXZ,;?PVMREJ/P\M0?UK UWXF>-/',+/J?Q"\?ZBTGW_/U^X(?Z@, :X:W&F&
MAM3D_N_X)]#@_HYYM5_BXJG'T4G^:B?T?ZMXVT7P_'NOM6TNR7UN+I(Q^I%<
M3XH_;*^$O@G?_:WQ+\#6+1C+++KEON'X;\U_.+>^!(M1E+7EQ?7N>2;F[EES
M]=S&LO4_!>EVK?NK*S&W_ID#_2N-\;INU.G][_X![]#Z-L8J^(QS^4%^LG^1
M_0-XF_X*^?LU>$PWVGXO>$Y67JMK*]RWY(IKS_Q!_P %^OV:]#D=;?Q-KVL,
MO3[!H5S(&^FY5_6OPOAB2R/[J*- O94 _I5IY);SGY@!WK&IQ?BOLPBOO_S/
M8POT>\CC_&KU9/R<5_[:S]AO%'_!R7\'M,4C2_!WQ(U=ATSI\5LI_%Y/Z5Y_
MXE_X.;]/1F71?@QKTPQ\K7^M00\^I"JW'XU^7]J88TQ(<FG#1HKMMR-Q7%4X
MMQKZI?+_ #N?08?P)X6A:].4_6;_ $L?H)KO_!R;\3-1B;^R?A9X-T[^Z]YJ
ML\Y ]PBJ/UKA=?\ ^#@7]HC7I3]B7X=Z(K=!%I<MR1_WV_-?',FAJ8MN:IRZ
M+]F0ONZ5PRXDQT_^7K7I9?H?08?PCX5H?#@HOU<I?FV?3'BC_@L'^T]XFA96
M^)]OIT;<XT_1+:$CZ,03^M>9>*_^"AO[0'BEV&H?&CX@29R"+>]%JOX"-1Q7
MDEQJ4@9ESP*GT]!,I9Q7//,\:U>I5D_FSW,/P9P_2:6'P5*/_;D?\C3UKXS^
M./%LC?VQXZ\<ZFK\N+C7KEE/U&\#]*Y'6;*+4YMUP]S=D]3<7$DN?KN8UO7
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MK7':W_P7S^#MLQ72]!^(^M<<&'0C$I_&1U_E7)4S?!0^*K'[T>[A^!.(Z_\
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M;&%FEB8]%157YE[8 !'4Y'-,U6]U#65N[F+28;>WDV"4:CM$L '1@@# N<Y
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MA8[AMZF<GC,Q4$@YX&,CZ5M?\(U)JVI0V]WJEQ>+YS&0+;HL<DB@8<X)QC(
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M5 "@'IUZ>QIUYX)U#3IHXX==U*4R(Q=[LI(95'5"=O YSD8(/>C38GVD=O\
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MN);HQ"WVSPF)3(#]YN!P!TQ@'IG-"01E\S,,/AJ73/*#Z:-65?+V,$6XXX*
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MV$L.E0LL<$*-C *H!C]*XY<=5;VC32]6W_D>M1\%<#%?O<1.7I9?HSZ:OO\
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MTQX)DN%L[4< B=G+L3U&!T7T)ZD5)%<R)<"XN9MI#;G9<A5'< <G&*M>7<+
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MC5 =AA2+:<#WR3CWJ6;2'CMPZW5TS-C8&8?NR?3CBD+KJ0RPZA<3_O+?3&F
MW*I)*=>I.,DCM2"*^ D;R[/'(E&XG:<<[>,\CUJ::2[D.YE6S90$:1F#$#U
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M?_$4_P"SL5_(_N#_ %TR/_H*A_X$C!HK=_X9,_:&_P"B>^%?_"H3_P"(I/\
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M5D^8.DJ5"E)+Y?YG'A^..'E4<ZV+IM^IYVQW'ZU);V<EP_R(S9]*[^+]@_\
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M4B?_ !-7+/\ 8%_:"@_UO@3PK)Z >)4 _P#0*I<-YDW_  G^ ?\ $1>&TO\
M?(?>>8:19M+,JMW//TKM;:^MK2%8]Z]*WKO]A#]H:1<0^!?"<([_ /%2IG_T
M"J3?\$_OVC&/_(E^$O\ PI%_^)KLP^2YGAV^2BVWU.>MQYPW6MS8V"^9QOB>
MQ6\F\R.16SP1FN=FTI8/F ;(KU4?\$_OVBQ_S)GA/_PI$_\ B:=_PP#^T0WW
M_!/A-A_V,B?_ !-<U7A_,YS<E1:N=%/Q"X;A%1>-@_F>0+>SK)MV\9J2\LFO
M$!)QZUZW_P .^OV@MV?^$'\+_P#A2Q__ !%7;7]@[X^VJX_X5_X5;W/B6/\
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M[-^5?O5SC>-V,F/.7->N:Q_P3D_:*U:1V_X0_P )KNX_Y&)/_B:P_P#AU?\
MM%?:-_\ PBOA+KG_ )&!/_B:FMDF:U)M^SDET_JY='Q$X5C%7QE._77_ (!Y
MSJ=_->QE]VYL<5RVH6%UJ+G<OXU]!P?\$U?VB(HPI\(^$3C_ *F%/_B:D/\
MP37_ &@MO'@WPON]?^$B3_XFN6/#N:IW]B[_ ".M^)G"MK?78?>_\CYOM=%N
M+6<-C:/6KVL79GM5C63YN_->\7__  3*_:*NHBJ^$_"2?]S A_\ 9:R8O^"4
M?[1*3[W\,^$V[X_X2!/_ (FJ_P!7<SEK*D_P#_B)G"R5EC8?>_\ (\1TK09O
M,#L[ ?6MJ9&$!53\V*]J3_@F1^T1%"%7PCX3X_ZF%/\ XFJ[?\$P/VD"^?\
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M_'_(^<O$.KR6(_=C-<O?7UQJ<BJV[FOIR_\ ^"17[1U[(6_X1_PF!Z?VZO\
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MCH/YO_(^>GTV&5MVU2:N6*Q6RGG# <5[Y!_P1C_:3@7 TCPB?^XVO^%3V_\
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M*'##=UCH?>_\CX3V[C392!VK[M7_ (-V?VBB?^/?PC_X-5I6_P"#=;]HD_\
M+OX3_P#!JM/^P\=?^&R?^(F\+V_WZG][_P CX-(R*:5R*^\?^(=3]HC_ )X^
M$O\ P:+_ (TP_P#!NE^T5_SQ\(_^#1:<LDQSVIL4?$SA9;XVG][_ ,CX-?K4
M;BOO0_\ !N?^T4?^6/A'_P &JTX?\&Y/[1)ZP^$O_!HG^-3_ &'C_P#GTQ_\
M1,X6M_OT/O?^1\#GI4>>:^^&_P"#<C]HH](_"/XZHM)_Q#B_M$?\\_"7_@T2
MJ_L7'_\ /ID_\1,X6M_OM/[W_D?!!;%0.-Y]J^_&_P"#<7]HIO\ EGX1_P#!
MHO\ C3/^(;_]HK/^K\(_^#1:/[%Q_P#S[8+Q,X6_Z#8?>_\ (^"538*KS.V[
MBOT '_!N!^T8!_J_"/\ X-%H_P"(;[]HS_GGX1_\&B_XU7]BX[_GVR/^(E\+
MW_WV'WO_ "/S_$K+]X4>8)*^_C_P;>_M%'^'PC_X,U_QJ/\ XALOVB@<X\)_
M^#-/\:E9+CO^?3*_XB7PM_T&P^]_Y'P'SOI#C'S5]_'_ (-MOVC#_!X1_P#!
MHO\ C3&_X-L_VBG_ (?"/_@S6G_8N._Y],7_ !$KA?\ Z#H?>_\ (_/N6X*-
M\M/$VY/F%??Z_P#!MA^T0A^[X1/UU-:5_P#@VR_:*D7&WPB/IJ:T_P"Q<=_S
MZ8GXE<+_ /0;#[W_ )'Y^#8YXJ0#%??B_P#!M3^T5$<@^$OQU)/\:<W_  ;9
M?M%$?\RC_P"#)?\ &C^Q<=_SZ8O^(E<+O_F-A][_ ,C\_+B+>M01PK!RU?H0
M?^#:S]HH_P 7A/\ \&:_XTT_\&TO[11Z_P#"(M_W$U_QH_L7'?\ /IB_XB3P
MO_T&P^]_Y'Y\2WRHP%/=5N(_K7Z /_P;/?M$2]_"(_[B2?XU)%_P;3_M%1+C
M=X2/UU)?\:/[%QW_ #Z8O^(E<+_]!L/O?^1^?*VZ1"HYKM(UZ\BOT,?_ (-J
M/VBY.H\(_P#@S3_&J[_\&RW[1#GKX2_\&2_XU7]CX[_GTR?^(D<,?]!L/O/S
MTCU RL0!FI"S%?NU^A,7_!LU^T1"?E_X1'_P9)_C4O\ Q#3_ +17IX1_\&:_
MXT?V-C?^?3)?B1PQ_P!!L/O_ . ?G6[3+]*2"620_-Q7Z*'_ (-I?VC&_P"A
M1_\ !FO^--'_  ;0_M%#_H4?_!DO^-']CX[_ )]L7_$1N&/^@V'WGYZN5QSS
MBHU=7. *_0P_\&S_ .T4QZ^$?_!DM _X-H/VBE_Z%'_P9+_C3_L?'?\ /MD?
M\1%X9_Z#8??_ , _/4H!S6?J,<S!]AXP?Y5^C4G_  ;._M%N/O\ A(?]Q%/\
M:B_XAF/VB@K?O/";9&,?VBO^--9/C?\ GTQ?\1$X9_Z#8??_ , _7+_@BY_R
MC6^&/_8/.?\ OLT5U?\ P38^ OB?]F7]C7P?X)\81Z?'KV@PO!,+*?SHMN\E
M3NQC)&,XR/>BOTS"Q<:,(O>R_(_B;B"K"KF>(J4GS1E.336S3D[-'O5%%%=!
MY(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%?'.C*P1[S0]4AOXHG(SL<QLVUL?PM@^U5[C]J?X9VGQBG^'<OQ"\$Q>/K:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !17Y:_\'2O_!13XQ?\$YOV=/AAKWP=\7?\(CJGB+Q'
M<6&H3?V;:7WVB%;8NJ;;B*15PPSE0#[XK[>^#_[4.B>$?V'/AK\2?BMXR\.^
M&H=:\+:->ZKK>MWMOIEF]W=6D+L2[%(D+R.<*,#)P!T% 'ME%>*_$[_@HS\
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M4@XP:\X^&W_!3_\ 9S^,?Q!3PIX5^.7PKU[Q'+)Y,.GV7B:TEGN7SC9$H?\
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M^"3GBCX"^/OV?],U'X>ZIJ5U>I*MMJ=S<>7<V/V26WNXWF=W24&1MQ#8)"G
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M^-7Q>^*7BC4;F:;4M/G_ -#LX&V[71Q?P227#OO=Y) >2 .A+?L5_P $$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<6^N>(M0N=5U9_#6F64EU<.9)94MO$4%M$68\L1'"@R22<9Y-?3G_!J(,?\
M!$KX:_\ 83UO_P!.=S5#X+?\$IO'GQ)_X-NK']EWQE!;>"_B)<>'KBV:*XN8
M[J"RO4U62^MA)) SJ8V*Q!BA8@,>"1BOC3_@G'\"_P#@J5^Q5\$+K]FOPG\,
M_ ?AWPO)?W/V/QQK5];7 \-QW+EIIX&ANCYH#,TB*8'<,QRI'"@&/_P9Z_\
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M(EBD=,JH*L22!S?@_6O^"L7[:WQL\&V^I^'? O[+_A+0KM9=9U2T@L[M=07
M$F^VEGNGN/EW%(P$0,06<$!@ >4_\'3G@;XU_M6_L]?LV_$S1_"_B;Q)\(QH
M46N>*='T196&GWUS';S"2X1 S*IA9XTF*,(CO!(+@-\X^#K_ /X)8_MKV?@_
MP_I%K\3/V1_'EC?VO_$]N;J>^M92DBEXWN6GF2-FY"W#I#Y;[6;*KL/[%?\
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MQGRH$=@9&Z#"@\LHZL 6M^T9X!C^.2?#-O&7AD?$.33SJJ^&_P"T8O[3-J"
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU\&Z3:>*[/1%MR#"EG'J]LL*H>Z! H4CJ #7T[\.?^#3OQK\ ?B!KVF_#/\
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M,;LY.,$ _'7X*>*O$>C_ /!E%XPDT.6X\X7EW8SM&3NCL9?$,:W(_P!UHY)
MPZ;6;/&:^UO^#47X8>!8O^",?A>\TO3='NM4\5:GJX\5NT"227=PMY+$D4^1
M\P%JL&$;(VMG'S$GZ&_X)W_\$I?#_P"Q;_P3A;]F_P 5ZO:_%#PU>C4H=3FN
M-,^P1:A;WTCN\1A\V0K@.1N#YR 1@XQ\(W'_  :F?$+X'ZYXCTO]G_\ :^^(
M7PO^'?BV1CJ&@&"X9_+8@;6DM[J%)B$&W>T:,0,$D$T >$_\&YMO:_#K_@XH
M_:<\)_#DJOPQA@\11)!:G-G';P:S"EH5QP0F]D0_W6;'!)KDO^#=/]F;P3^T
M!_P7?_:(U3QEX?TWQ(W@:;7-4TBWU"W2XM[>[?6%A$Y1@5+I&\@4D'!;<,$
MC]@O^"17_!&'X;_\$AOAMJ^G^%;S4/%/B[Q2T;:]XFU*-8[B]$>2D,4:Y$,*
MEF8)EB2Q+,V%"^>_\$M_^"%G_#MG]MSXN?&+_A9O_"8_\+2CO(_[)_L#[!_9
MOGWXO/\ 7?:)/,V[=GW%SUXZ4 ?=^D^!=#T+3C9V.CZ79V9N?MA@@M(XXC/N
M#^;M  W[@#NQG(!SD5>FTRWN;V&XDMX9+BU#"&5D!>(-C=M;J,X ..N*LT4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 QXUDQN56VG(R,X/K08E9U;:NY<X..
M1FGT4 ?SM_\ !TQX'TWXG?\ !<S]F/PWK$*W6D>(=*T/3+Z$])8)M>N8Y%]>
M58BOK3_@[T^$_A?1_P#@D%HK6?A_1['_ (13Q?IEOHWV:SCA&F1-%<1M%"%
M"1LH *+@':O&0,>T?\%+/^"%/_#PW_@H-\(_CK_PL[_A$_\ A5J::G]B_P!@
M?;?[1^R:C)>Y\_[1'Y>[?L^XV,9YSBO8/^"P?_!-3_AZY^Q\_P *?^$Q_P"$
M&W:U::Q_:?\ 9?\ :/\ J!(/+\KS8OO;_O;N,=#F@#\O_P!N'Q1X@TO_ (,U
M_A2-+N+I;>_L="LM5=&.?L0O'(5C_<\Q(%QT(P.AQ7W)_P &ZWP9^'$O_!$3
MX6V>GZ)X?U#2_%VE7<WB=9;:.9-4NWN9H[E;H,,2;=OEX?.$15Z 5[=\#/\
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M_9O_  C$&G0_\)1_87F_:?LD_FY^R^>NW?TQYIQUYZ4 ><?\$+?V;O ^F_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291128256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONCOLYTICS BIOTECH INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">A0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">804, 322 11th Avenue SW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Calgary<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AB<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">T2R 0C5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">no<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONCY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">74,423,960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">International Financial Reporting Standards<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001129928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">804, 322 11th Avenue SW<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Calgary<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">AB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">T2R 0C5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Kirk Look<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">670-7377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">info@oncolytics.ca<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291508496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Calgary, Canada<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012295692000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,912<span></span>
</td>
<td class="nump">$ 11,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssetsAvailableforsale', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables (note 5)</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepaid expenses (note 5)</a></td>
<td class="nump">3,246<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">38,173<span></span>
</td>
<td class="nump">35,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment (note 6)</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets (note 8)</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPrepayments', window );">Prepaid expenses (note 5)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">38,820<span></span>
</td>
<td class="nump">37,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities (note 7)</a></td>
<td class="nump">3,572<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities (note 5)</a></td>
<td class="nump">332<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities (note 8)</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative (notes 9, 17)</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liability (note 13)</a></td>
<td class="nump">6,730<span></span>
</td>
<td class="nump">6,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities (note 8)</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">157<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,257<span></span>
</td>
<td class="nump">10,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommitmentsAndContingencies1', window );">Commitments and contingencies (note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital (note 10) &#160;&#160;Authorized: unlimited &#160;&#160;Issued: December&#160;31, 2023 &#8211; 74,423,960 December&#160;31, 2022 &#8211; 61,327,914</a></td>
<td class="nump">430,906<span></span>
</td>
<td class="nump">404,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionalPaidinCapital', window );">Contributed surplus (note 11)</a></td>
<td class="nump">42,116<span></span>
</td>
<td class="nump">40,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Accumulated other comprehensive income</a></td>
<td class="nump">544<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(446,003)<span></span>
</td>
<td class="num">(418,251)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">27,563<span></span>
</td>
<td class="nump">26,502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total liabilities and shareholders' equity</a></td>
<td class="nump">$ 38,820<span></span>
</td>
<td class="nump">$ 37,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionalPaidinCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionalPaidinCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssetsAvailableforsale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssetsAvailableforsale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommitmentsAndContingencies1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments And Contingencies1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommitmentsAndContingencies1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270501088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNatureAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development (note 20)</a></td>
<td class="nump">$ 17,709<span></span>
</td>
<td class="nump">$ 15,432<span></span>
</td>
<td class="nump">$ 12,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative (note 20)</a></td>
<td class="nump">16,082<span></span>
</td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">13,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Loss before the following</a></td>
<td class="num">(33,791)<span></span>
</td>
<td class="num">(26,924)<span></span>
</td>
<td class="num">(26,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative (notes 9, 17)</a></td>
<td class="nump">5,285<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss', window );">Foreign exchange (loss) gain</a></td>
<td class="num">(475)<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
<td class="num">(136)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents', window );">Interest income, net</a></td>
<td class="nump">1,326<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income taxes</a></td>
<td class="num">(27,655)<span></span>
</td>
<td class="num">(24,751)<span></span>
</td>
<td class="num">(26,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax expense (note 15)</a></td>
<td class="num">(97)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="num">(27,752)<span></span>
</td>
<td class="num">(24,835)<span></span>
</td>
<td class="num">(26,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive (loss) income items that may be reclassified to net loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Translation adjustment</a></td>
<td class="num">(118)<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss</a></td>
<td class="num">$ (27,870)<span></span>
</td>
<td class="num">$ (24,561)<span></span>
</td>
<td class="num">$ (26,316)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic loss per common share (cad per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted loss per common share (cad per share)</a></td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.43)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of shares (basic) (shares)</a></td>
<td class="nump">67,624,036<span></span>
</td>
<td class="nump">58,029,745<span></span>
</td>
<td class="nump">53,513,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">Weighted average number of shares (diluted) (shares)</a></td>
<td class="nump">67,624,036<span></span>
</td>
<td class="nump">58,029,745<span></span>
</td>
<td class="nump">53,513,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNatureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNatureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 21<br> -IssueDate 2023-01-01<br> -Paragraph 52<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=21&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_52_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestIncomeOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestIncomeOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291410928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>At-the-market equity distribution agreement</div></th>
<th class="th"><div>Public offering</div></th>
<th class="th"><div>Share Capital</div></th>
<th class="th">
<div>Share Capital </div>
<div>At-the-market equity distribution agreement</div>
</th>
<th class="th">
<div>Share Capital </div>
<div>Public offering</div>
</th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Contributed Surplus</div></th>
<th class="th">
<div>Contributed Surplus </div>
<div>Public offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 24,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 356,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,618<span></span>
</td>
<td class="nump">$ 31,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="num">$ (367,112)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(26,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="num">(26,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 11)</a></td>
<td class="nump">238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(544)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="nump">34,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,168<span></span>
</td>
<td class="nump">$ 34,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 10)</a></td>
<td class="num">(1,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity', window );">Issued pursuant to warrant derivative exercised (note 10)</a></td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 11)</a></td>
<td class="nump">3,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">36,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">391,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="nump">34,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388<span></span>
</td>
<td class="num">(393,416)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(24,561)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="num">(24,835)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 11)</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity', window );">Issued pursuant to incentive share award plan (note 11)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity', window );">Expiry of equity warrant agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,618)<span></span>
</td>
<td class="nump">3,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="nump">13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 10)</a></td>
<td class="num">(764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 11)</a></td>
<td class="nump">2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">26,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">662<span></span>
</td>
<td class="num">(418,251)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Net loss and other comprehensive income (loss)</a></td>
<td class="num">(27,870)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="num">(27,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Issued pursuant to stock option plan (note 11)</a></td>
<td class="nump">781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issue of equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 18,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs (note 10)</a></td>
<td class="num">(2,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,805)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation expense (note 11)</a></td>
<td class="nump">1,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">$ 27,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 42,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
<td class="num">$ (446,003)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Expiration Of Warrant, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Incentive Share Awards, Equity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012295711936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the year</a></td>
<td class="num">$ (27,752)<span></span>
</td>
<td class="num">$ (24,835)<span></span>
</td>
<td class="num">$ (26,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation - property and equipment (notes 6, 20)</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdjustmentsForDepreciationRightOfUseAssets', window );">Depreciation - right-of-use assets (notes 8, 20)</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation expense (notes 11, 20, 21)</a></td>
<td class="nump">1,917<span></span>
</td>
<td class="nump">2,378<span></span>
</td>
<td class="nump">3,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Compensation warrant expenses (note 11)</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestRevenueExpense', window );">Interest expense (income), net</a></td>
<td class="nump">71<span></span>
</td>
<td class="num">(76)<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains', window );">Unrealized foreign exchange loss (gain)</a></td>
<td class="nump">282<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value of warrant derivative (notes 9, 17)</a></td>
<td class="num">(5,285)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Net change in non-cash working capital (note 18)</a></td>
<td class="nump">1,765<span></span>
</td>
<td class="nump">391<span></span>
</td>
<td class="num">(908)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash used in operating activities</a></td>
<td class="num">(28,448)<span></span>
</td>
<td class="num">(23,355)<span></span>
</td>
<td class="num">(22,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Acquisition of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,348)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Maturities of marketable securities</a></td>
<td class="nump">20,230<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Acquisition of property and equipment (note 6)</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash provided by investing activities</a></td>
<td class="nump">20,222<span></span>
</td>
<td class="num">(20,403)<span></span>
</td>
<td class="num">(286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfOptions', window );">Proceeds from exercise of stock options (note 11)</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants (note 9)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities (note 8)</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">31,994<span></span>
</td>
<td class="nump">12,205<span></span>
</td>
<td class="nump">33,015<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">23,768<span></span>
</td>
<td class="num">(31,553)<span></span>
</td>
<td class="nump">10,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">11,666<span></span>
</td>
<td class="nump">41,262<span></span>
</td>
<td class="nump">31,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Impact of foreign exchange on cash and cash equivalents</a></td>
<td class="num">(522)<span></span>
</td>
<td class="nump">1,957<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">34,912<span></span>
</td>
<td class="nump">11,666<span></span>
</td>
<td class="nump">41,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market equity distribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">10,261<span></span>
</td>
<td class="nump">12,574<span></span>
</td>
<td class="nump">32,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from share issuance</a></td>
<td class="nump">$ 21,359<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestRevenueExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestRevenueExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdjustmentsForDepreciationRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments For Depreciation, Right-of Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdjustmentsForDepreciationRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292146464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">Nature of Operations</a></td>
<td class="text">Nature of Operations<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Avenue S.W., Calgary, Alberta, Canada.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2023, we had an accumulated deficit of $446,003. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares. Failure to raise additional capital would have a material adverse impact on our business, results of operations, and financial condition. As at December&#160;31, 2023, we had cash and cash equivalents of $34,912. We believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months from the balance sheet date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292597392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract', window );"><strong>Corporate information and statement of IFRS compliance [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Presentation</a></td>
<td class="text">Basis of Presentation<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statement of compliance</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements for the year ended December&#160;31, 2023, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;7, 2024. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies, and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. </span></div>Our accounts are prepared on the historical cost basis, except for certain assets and liabilities, which are measured at fair value as explained in the notes to these financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012296654464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory', window );">Summary of Material Accounting Policies</a></td>
<td class="text">Summary of Material Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the material accounting policies summarized below.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents and marketable securities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include interest-bearing deposits with our bank totaling $31,534 as at December&#160;31, 2023 (December&#160;31, 2022 - $9,501). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deferred income taxes</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial instruments </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification and measurement</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial assets</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial liabilities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities, other liabilities, and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derecognition</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency translation</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Loss per share</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and equipment </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development costs</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-based compensation </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share award plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments became effective on January 1, 2023. Adopting the amendments did not have a</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material impact on our consolidated financial statements.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates, changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on our consolidated financial statements. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification of Liabilities as Current or Non-Current</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 Presentation of Financial Statements, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments are effective for annual periods beginning on or after January 1, 2024, and are to be applied retrospectively. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of material accounting policy information applied by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012296654464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Judgments, Estimates and Assumptions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract', window );"><strong>Significant Judgments, Estimates And Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Judgments, Estimates and Assumptions</a></td>
<td class="text">Significant Judgments, Estimates, and Assumptions<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of our consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the application of accounting policies and the reported amount and disclosures in our consolidated financial statements and accompanying notes. Management makes estimates based on our best knowledge of current events and actions that the Company may undertake in the future. We consider the potential impact of certain external factors outside of our control, including global political conflicts, supply chain disruptions, pandemics, inflation, rising interest rates, and liquidity, when making certain estimates and judgments relating to the preparation of these consolidated financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from these estimates, and such differences could be material. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates made by management affecting our consolidated financial statements include:</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of share-based compensation </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of share-based compensation and compensation warrants requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of share-based compensation are disclosed in note 11. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of warrant derivative </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative issued are disclosed in note 9.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency</span></div>We assess the relevant factors related to the primary economic environment in which our entities operate to determine the functional currency. Where the assessment of primary indicators are mixed, we assess the secondary indicators, including the relationship between the foreign operations and reporting entity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Judgments, Estimates And Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291344240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherAssetsExplanatory', window );">Other Assets and Liabilities</a></td>
<td class="text">Other Assets and Liabilities <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial was jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2023, we recorded nil (December&#160;31, 2022 - US$360 ($488)) in other receivables related to unbilled BRACELET-1 cost from Pfizer. As at December&#160;31, 2023, Pfizer had completed its funding obligations.  </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2023, we recorded $1,319 (December&#160;31, 2022 - $1,327) in current prepaid expenses and nil (December&#160;31, 2022 -  $998) in non-current prepaid expenses.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span>In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$5&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at December&#160;31, 2023, we recorded US$225 ($298) in other liabilities representing unapplied funding received from PanCAN.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory', window );">Other Assets and Liabilities</a></td>
<td class="text">Other Assets and Liabilities <div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial was jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2023, we recorded nil (December&#160;31, 2022 - US$360 ($488)) in other receivables related to unbilled BRACELET-1 cost from Pfizer. As at December&#160;31, 2023, Pfizer had completed its funding obligations.  </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">We paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2023, we recorded $1,319 (December&#160;31, 2022 - $1,327) in current prepaid expenses and nil (December&#160;31, 2022 -  $998) in non-current prepaid expenses.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span>In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$5&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at December&#160;31, 2023, we recorded US$225 ($298) in other liabilities representing unapplied funding received from PanCAN.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other assets. [Refer: Other assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other liabilities. [Refer: Other liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292205840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory', window );">Property and Equipment</a></td>
<td class="text">Property and Equipment<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS16_g73-79_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292169584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts payable and accrued liabilities<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,082</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,490</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292133040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfLeasesExplanatory', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of leases consists of office spaces with lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, we extended the office lease for our subsidiaries, for which we recorded an addition of $392 to the lease liability and right-of-use asset. Under the terms of the lease, we have the option to extend the lease term for one of our subsidiaries for an additional three years. We did not include the extension option in the lease term as we were not reasonably certain to exercise the option. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g47-50_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS16_g51-60_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292201984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory', window );">Warrant Derivative</a></td>
<td class="text">Warrant Derivative<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common share purchase warrants ("warrants") with a U.S. dollar exercise price, which differs from our functional currency, are treated as a derivative measured at fair value, and revalued each period end at fair value through profit and loss. The fair value of these warrants is presented as a liability on our consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the value of our warrant derivative were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,731,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding warrant derivative as at December&#160;31, 2023:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.90</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 16, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 16, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 7, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,731,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase one common share at an exercise price of US$2.81 up to 60 months from the date of issuance. The expiry of the warrants may be accelerated by the Company at any time prior to the expiry date if the volume weighted average price (if applicable, as converted to U.S. dollars at the Bank of Canada posted rate for the respective trading day) of the issued and outstanding common shares on the Toronto Stock Exchange or such other principal stock exchange on which the common shares are listed and posted for trading is greater than US$6.50 for any 20 consecutive trading days, at which time the Company may, within 10 business days, accelerate the expiry date by issuing a press release announcing the reduced warrant term whereupon the warrants will expire on or after the 75th calendar day after the date of such press release.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. The difference between the fair value of the warrants and their allocated proceeds was a discount of $1,822, which is amortized on a straight-line basis over the five-year expected life of the warrants and recorded under change in fair value of warrant derivative on our consolidated statement of loss and comprehensive loss.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative with an exercise price of US$2.81 was determined using the following assumptions: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 7,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 8,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$1.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.70</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292309104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text">Share Capital<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Authorized:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unlimited number of no par value common shares</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,166,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,401,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,043,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,235,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,327,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,978,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74,423,960</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$40,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. During the year ended December&#160;31, 2021, we sold 5,685,097 common shares for gross proceeds of $23,413 (US$18,503) at an average price of $4.12 (US$3.25). We received proceeds of $22,711 (US$17,948) after commissions of $702 (US$555). In total, we incurred share issue costs (including commissions) of $707.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold 2,719,770 (2021 - 2,715,932) common shares for gross proceeds of $5,744 (US$4,560) (2021 - $10,755 (US$8,655)) at an average price of $2.11 (US$1.68) (2021 - $3.96 </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(US$3.19)). We received proceeds of $5,572 (US$4,423) (2021 - $10,432 (US$8,395)) after commissions of $172 (US$137) (2021 - $323 (US$260)). In total, we incurred share issue costs (including commissions) of $209 (2021 - $549). </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the years ended December&#160;31, 2023 and 2022, no warrants were exercised. During the year ended December&#160;31, 2021, 201,722 warrants with a fair value of $456 were exercised for gross proceeds of $231 (US$182).</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2023, we sold 4,978,605 (2022 - 3,515,462) common shares for gross proceeds of $10,676 (US$7,904) (2022 - $7,594 (US$5,632)) at an average price of $2.14 (US$1.59) (2022 - $2.16 (US$1.60)). We received proceeds of $10,356 (US$7,667) (2022 - $7,366 (US$5,463)) after commissions of $320 (US$237) (2022 - $228 (US$169)). In total, we incurred share issue costs (including commissions) of $415 (2022 - $555).</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants (see note 11). In total, we incurred transaction costs of $3,130 (including a fair value of $638 (US$473) for the compensation warrants), of which $2,390 were allocated to share issue costs and $740 were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292054944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock options and share awards</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our amended and restated Stock Option Plan and Share Award Plan (collectively, the "Equity Incentive Plans") were approved by our shareholders at the annual general meeting of shareholders on May 9, 2023. Pursuant to our Equity Incentive Plans, we may grant stock options, restricted share awards, and performance share awards. The number of common shares reserved for issuance under our Equity Incentive Plans in aggregate shall not exceed 14% of the total number of issued and outstanding common shares from time to time. As at December&#160;31, 2023, we reserved 10,419,354 common shares for issuance relating to our Equity Incentive Plans. Our share-based compensation expense for the year ended December&#160;31, 2023, was $1,917 (2022 - $2,378; 2021 - $3,826). </span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our stock option activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,963,185</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,145,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(280,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(314,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(450,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,063,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,039,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420,482&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165,679&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.14 - $2.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.01 - $2.70</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.71 - $3.11</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.12 - $4.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.01 - $16.53</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option grants vest either immediately or annually over periods ranging from <span style="-sec-ix-hidden:f-703">one</span> to three years.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government of Canada benchmark bond yield rates in effect at the time of grant. The expected life of the options represents the</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">estimated length of time the options are expected to remain outstanding. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.99</span></td></tr></table></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our share award activity for the years ended December&#160;31 was as follows:</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,440</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSAs granted was $2.23in 2023.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, we granted restricted share awards to officers of the Company. Restricted share award grants vest over a three-year period. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation warrants </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, in consideration of the services rendered by the underwriter as part of a public offering (see note 10(e)), we issued 536,693 compensation warrants. Each compensation warrant is exercisable into one common share at an exercise price of US$2.25 up to 60 months from the date of issuance. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Black-Scholes valuation model to estimate the fair value of the services rendered. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. We used the following weighted average assumptions:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$2.28</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.88</span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The resulting fair value of $638 (US$473) was included as part of the public offering transaction costs, which were allocated    to share issue costs and operating expenses based on the relative fair values of the common share and warrant of each unit issued. No compensation warrants were exercised during the year ended December&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292198544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">Loss Per Common Share</a></td>
<td class="text">Loss Per Share<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2023, of 67,624,036 (2022 - 58,029,745; 2021 - 53,513,225). The effect of any potential exercise of our stock options, share awards, and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012293213424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">Contract Liability</a></td>
<td class="text">Contract Liability<div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. </span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292309104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to payments of approximately $12,686 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next three years. We are able to cancel most of these agreements with notice. We are also committed to office lease payments of approximately $1,098 over 5.3 years for one of our subsidiaries which have not yet commenced. </span></div><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnification of Officers and Directors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#8217; and officers&#8217; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012293213424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,655)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,751)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,255)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,361)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,693)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,039)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,841</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">441</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax balances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Barbados rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,088)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,382</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,215)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,770</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we have non-capital losses of $110,450 and $129,884 in Canada and Barbados, respectively (December&#160;31, 2022 - $98,475 and $145,405, respectively). These losses are expected to expire between 2024 and 2043, if not utilized. At December&#160;31, 2023, we have Canadian investment tax credits of $4,056 (December&#160;31, 2022 - $4,368) that are expected to expire between 2024 and 2043, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#8217; taxable income of $28,376 (December&#160;31, 2022 - $27,663).&#160;We also have unclaimed U.S. credits for research activities available to reduce future years' taxable income of $1,232 (December&#160;31, 2022 - $1,285) expiring between 2031 and 2043. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">382</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292247440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory', window );">Capital Disclosures</a></td>
<td class="text">Capital Disclosures<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity, cash and cash equivalents, and marketable securities in the definition of capital.  </span></div><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#8217;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2022, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  </span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewing our Base Shelf provides additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received from using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Base Shelf allowed us to enter into our ATM equity distribution agreements and 2023 public offering (see note 10). We use these equity arrangements to assist us in achieving our capital objectives. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 134<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_134&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292166160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Instruments</a></td>
<td class="text">Financial Instruments<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value of financial instruments</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments consist of cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, other liabilities, and warrant derivative.&#160;As at December&#160;31, 2023, and December&#160;31, 2022, the carrying amount of our cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at December&#160;31, 2023, the fair value of our warrant derivative was $200 (December&#160;31, 2022 - $79) (see note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial risk management</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at December&#160;31, 2023, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest rate risk </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign exchange risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the year ended December&#160;31, 2023, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities were denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss for the year ended December&#160;31, 2023, by approximately $140.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies as at December&#160;31, 2023, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and the Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss for the year ended December&#160;31, 2022, by approximately $170. The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss for the year ended December&#160;31, 2022, by approximately $22.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies as at December&#160;31, 2022, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity risk</span></div>Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk by managing our capital structure as outlined in note 16. Accounts payable and accrued liabilities are all due within the current operating period. See note 8 for a maturity analysis of our lease liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292133040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory', window );">Additional Cash Flow Disclosures</a></td>
<td class="text">Additional Cash Flow Disclosures<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">506</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfCashFlowStatementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Presentation of a statement of cash flows<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS07_g10-17_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfCashFlowStatementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292134272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceAbstract', window );"><strong>Disclosure Of Economic Dependence [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfEconomicDependenceTextBlock', window );">Economic Dependence</a></td>
<td class="text">Economic Dependence<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical-grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfEconomicDependenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Economic Dependence [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfEconomicDependenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292201984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Components of Expenses</a></td>
<td class="text">Components of Expenses<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,082</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, our research and development personnel-related expenses included employee compensation and benefits of $6,324 (2022 - $5,983; 2021 - $4,645).</span></div>For the year ended December&#160;31, 2023, our general and administrative office expenses included employee compensation and benefits of $3,332 (2022 - $2,870; 2021 - $2,542).<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292247440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation of Key Management Personnel</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel consists of the Board of Directors, Executive Officers, President, and Vice Presidents. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,496</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012290874080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash and cash equivalents and marketable securities</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and cash equivalents and marketable securities</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents include interest-bearing deposits with our bank totaling $31,534 as at December&#160;31, 2023 (December&#160;31, 2022 - $9,501). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory', window );">Deferred income taxes</a></td>
<td class="text">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory', window );">Financial assets</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#8217;s business model for managing the assets; and whether the financial asset&#8217;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). </span></div>Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory', window );">Financial liabilities</a></td>
<td class="text">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities, other liabilities, and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory', window );">Impairment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#8217;s original effective interest rate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory', window );">Derecognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. </span></div>A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory', window );">Fair value measurement</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: </span></div><div style="margin-top:10pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory', window );">Foreign currency translation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  </span></div>Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory', window );">Leases</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:</span></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the contract involves the use of an identified asset;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we have the right to direct the use of the identified asset. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  </span></div>We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory', window );">Loss per share</a></td>
<td class="text">iluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory', window );">Property and equipment</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory', window );">Research and development costs</a></td>
<td class="text">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue', window );">Revenue recognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. </span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.</span></div><div style="margin-bottom:8pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory', window );">Share-based compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock option plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of options that are expected to vest.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share award plan</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  </span></div>We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#8217;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations', window );">Adoption of New Accounting Standards and Accounting Standards and Interpretations Issued but Not Yet Effective</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Adoption of New Accounting Standards</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Financial Statements </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and IFRS Practice Statement 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Making Materiality Judgements,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments became effective on January 1, 2023. Adopting the amendments did not have a</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">material impact on our consolidated financial statements.  </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Policies, Changes in Accounting Estimates and Errors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates, changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our consolidated financial statements. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 12 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on our consolidated financial statements. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Standards and Interpretations Issued but Not Yet Effective</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IAS 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Classification of Liabilities as Current or Non-Current</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 Presentation of Financial Statements, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments are effective for annual periods beginning on or after January 1, 2024, and are to be applied retrospectively. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for foreign currency translation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 117<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_117&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 30<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_30_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292169584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of depreciation rates</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292205840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract', window );"><strong>Disclosure of detailed information about property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory', window );">Schedule of property and equipment</a></td>
<td class="text">Depreciation is recorded using the declining balance method at the following annual rates:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.608%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office equipment and furniture</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Straight-line over the term of the lease</span></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.471%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.762%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Computer Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Office Equipment and Furniture</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions, net of foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net book value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">85</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">128</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">282</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292252224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock', window );">Disclosure of accounts payables and accrued liabilities</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade payables</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,082</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,252&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,490</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,572</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,650&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detailed Disclosure Of Trade And Other Payables Explanatory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012290949168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory', window );">Right-of-use assets</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">         </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">296</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(322)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(299)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock', window );">Lease liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our lease liabilities activity for the years ended December&#160;31:    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">              </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.422%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(407)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense on lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">71</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory', window );">Total undiscounted lease liability</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total undiscounted lease liability as at December&#160;31, 2023 was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One to five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">More than five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease liability </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 97<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_97&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Quantitative Information About Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292166160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory', window );">Reconciliation of change in fair value of warrant derivative</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the value of our warrant derivative were as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of Warrant Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,035&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount on warrants issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,822)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of discount on warrants issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,431)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange impact</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,731,085</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our outstanding warrant derivative as at December&#160;31, 2023:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.542%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiry date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Warrants Outstanding</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.90</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 16, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 16, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.81</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 7, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 8, 2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,731,085&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the warrant derivative with an exercise price of US$2.81 was determined using the following assumptions: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 7,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">August 8,<br/>2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$1.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.39</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$2.26</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.6 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value per warrant</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">US$0.70</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291036848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of share capital</a></td>
<td class="text"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,166,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356,824&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)(b)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,401,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to warrant derivative exercised</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,043,789&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to incentive share award plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,235,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(764)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,327,914&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">404,040&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to stock option plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to "At the Market" (ATM) equity distribution agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,978,605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,676&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued pursuant to public offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,667,050&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,724&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,805)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">74,423,960</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">430,906</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$40,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. During the year ended December&#160;31, 2021, we sold 5,685,097 common shares for gross proceeds of $23,413 (US$18,503) at an average price of $4.12 (US$3.25). We received proceeds of $22,711 (US$17,948) after commissions of $702 (US$555). In total, we incurred share issue costs (including commissions) of $707.</span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold 2,719,770 (2021 - 2,715,932) common shares for gross proceeds of $5,744 (US$4,560) (2021 - $10,755 (US$8,655)) at an average price of $2.11 (US$1.68) (2021 - $3.96 </span></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(US$3.19)). We received proceeds of $5,572 (US$4,423) (2021 - $10,432 (US$8,395)) after commissions of $172 (US$137) (2021 - $323 (US$260)). In total, we incurred share issue costs (including commissions) of $209 (2021 - $549). </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the years ended December&#160;31, 2023 and 2022, no warrants were exercised. During the year ended December&#160;31, 2021, 201,722 warrants with a fair value of $456 were exercised for gross proceeds of $231 (US$182).</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2023, we sold 4,978,605 (2022 - 3,515,462) common shares for gross proceeds of $10,676 (US$7,904) (2022 - $7,594 (US$5,632)) at an average price of $2.14 (US$1.59) (2022 - $2.16 (US$1.60)). We received proceeds of $10,356 (US$7,667) (2022 - $7,366 (US$5,463)) after commissions of $320 (US$237) (2022 - $228 (US$169)). In total, we incurred share issue costs (including commissions) of $415 (2022 - $555).</span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants (see note 11). In total, we incurred transaction costs of $3,130 (including a fair value of $638 (US$473) for the compensation warrants), of which $2,390 were allocated to share issue costs and $740 were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291131024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract', window );"><strong>Disclosure of share-based payment arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory', window );">Schedule of stock options and weighted average exercise prices of share options</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Our stock option activity for the years ended December&#160;31 was as follows:</span><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.039%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,963,185</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,764,055&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,145,400</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.23</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,005,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,832,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(280,288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.83</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(110,612)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(314,573)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.17</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(304,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.80</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.63</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(450,391)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.74</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,333)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.94</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,063,333</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,963,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,334,420&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.53</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable, end of year</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,039,604</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.85</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,420,482&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.01</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,165,679&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.82</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory', window );">Schedule of stock options outstanding and exercisable by range of exercise price</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.14 - $2.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.01 - $2.70</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.71 - $3.11</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.12 - $4.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.01 - $16.53</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory', window );">Schedule of weighted average remaining contractual life and outstanding stock options by exercise price</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2023:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.456%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Exercise Prices</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number Exercisable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price<br/>$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.14 - $2.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015,400&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.75</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,082,629&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.61</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.01 - $2.70</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260,664&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,063,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2.71 - $3.11</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.12 - $4.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,665,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.30</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4.01 - $16.53</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.20</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,063,333&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,039,604&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.85</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory', window );">Disclosure weighted average assumptions and fair value of options</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$1.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.24</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.99</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Schedule of number of other equity instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Our share award activity for the years ended December&#160;31 was as follows:</span><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,618&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">403,200</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,760)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,560)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94,058)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of year</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">398,440</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (1) The weighted average fair value of the RSAs granted was $2.23in 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory', window );">Schedule of compensation warrants weighted average assumptions</a></td>
<td class="text">We used the following weighted average assumptions:<div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:80.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.029%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Underlying share price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$2.28</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">36.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nil</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average fair value of options</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US$0.88</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the range of exercise prices for outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofsharebasedpaymentarrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of share-based payment arrangement [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofsharebasedpaymentarrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292187952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Contract liability balances</a></td>
<td class="text"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liability balance at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which w</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e expect to record in revenue over the next five years, is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,730</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012295902752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,655)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,751)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,255)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Statutory Canadian corporate tax rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.00%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anticipated tax recovery</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,361)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,693)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,039)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Difference in tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,841</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,552</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,716</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">441</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revaluation of tax balances</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(338)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of Barbados rate change</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,088)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other permanent differences</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">325</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(368)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expiry of tax benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,382</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,614</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,661</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of warrant derivative</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,215)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision to offset deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,770</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current income taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory', window );">Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-capital losses carried forward</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,174</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scientific research and experimental development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,742</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,648&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,123</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">382</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share issue costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">833</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net capital losses carried forward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized deferred tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,260</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012295645600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock', window );">Schedule of capital components</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,912</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,666&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shareholders' equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfCapitalComponentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Capital Components [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfCapitalComponentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292092960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Disclosure of detailed information about financial instruments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock', window );">Schedule of balances in foreign currencies</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies as at December&#160;31, 2023, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,476)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,818&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant balances in foreign currencies as at December&#160;31, 2022, were as follows:</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.104%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.005%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.007%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Euro</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,635&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,093)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,657&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,035)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Foreign Currency Held [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012290898704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CashFlowOperatingCapital1TableTextBlock', window );">Net change in non-cash working capital</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Change In Non-Cash Working Capital</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Change in:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">506</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(78)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">332</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(352)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash impact of foreign exchange</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in non-cash working capital related to operating activities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,765</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(908)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock', window );">Other cash flow disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Cash Flow Disclosures</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash interest received</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,554</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashFlowOperatingCapital1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Capital1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashFlowOperatingCapital1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292245728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract', window );"><strong>Analysis of income and expense [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock', window );">Other expenses and adjustments</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,675</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing &amp; related process development expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intellectual property expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">397</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Translational science expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,324</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,305</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,709</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Public company-related expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,278</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,789</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation - right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">322</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,082</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,492&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,315&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AnalysisOfIncomeAndExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AnalysisOfIncomeAndExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherExpensesAndAdjustmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Expenses And Adjustments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherExpensesAndAdjustmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292383936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory', window );">Schedule of related party transactions</a></td>
<td class="text"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,870</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,308&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">319</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,496</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,685</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,622&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291047664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Operations (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">$ (446,003)<span></span>
</td>
<td class="num">$ (418,251)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CashAndCashEquivalentsAndCurrentInvestments', window );">Cash and cash equivalents and current investments</a></td>
<td class="nump">$ 34,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CashAndCashEquivalentsAndCurrentInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Current Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CashAndCashEquivalentsAndCurrentInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Notes And Other Explanatory Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270477568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>plan</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary Of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashEquivalents', window );">Cash equivalents | $</a></td>
<td class="nump">$ 31,534<span></span>
</td>
<td class="nump">$ 9,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfStockOptionPlans', window );">Number of plans | plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement', window );">Maximum option expiration term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Term Of Options Granted For Share-based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012290865232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Disclosure of detailed information about property, plant and equipment [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate', window );">Annual depreciation rate</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PropertyPlantandEquipmentAnnualDepreciationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant and Equipment, Annual Depreciation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PropertyPlantandEquipmentAnnualDepreciationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291273760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets and Liabilities (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaidExpenses', window );">Current prepaid expenses</a></td>
<td class="nump">$ 1,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentPrepayments', window );">Non-current prepaid expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember', window );">BRACELET-1 collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="nump">$ 360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_ClinicalTrialMember', window );">Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=oncyf_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=oncyf_ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=oncyf_ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012269906784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">$ 356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">977<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(614)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(695)<span></span>
</td>
<td class="num">(614)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember', window );">Medical Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">108<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">436<span></span>
</td>
<td class="nump">429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember', window );">Computer Equipment | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(351)<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember', window );">Office Equipment and Furniture | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(92)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">(120)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions, net of foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember', window );">Leasehold Improvements | Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract', window );"><strong>Reconciliation of changes in property, plant and equipment [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, beginning balance</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationPropertyPlantAndEquipment', window );">Depreciation expense</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property and equipment, ending balance</a></td>
<td class="num">$ (169)<span></span>
</td>
<td class="num">$ (148)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 75<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_75_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis=ifrs-full_AccumulatedDepreciationAndAmortisationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_MedicalEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=oncyf_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291061712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables</a></td>
<td class="nump">$ 1,082<span></span>
</td>
<td class="nump">$ 2,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccrualsClassifiedAsCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,490<span></span>
</td>
<td class="nump">1,398<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 3,572<span></span>
</td>
<td class="nump">$ 3,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccrualsClassifiedAsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accruals classified as current. [Refer: Accruals]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccrualsClassifiedAsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291392480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16', window );">Weighted average rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Additions</a></td>
<td class="nump">$ 392<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems', window );"><strong>Disclosure of quantitative information about right-of-use assets [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph C12<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_C12_a&amp;doctype=Appendix&amp;subtype=C<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Remaining Lease Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012269869328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Right-of-use Assets and Lease Liabilities (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_RightOfUseAssetsAbstract', window );"><strong>Right-Of-Use Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, beginning balance</a></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsToRightofuseAssets', window );">Additions</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation expense</a></td>
<td class="num">(322)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ForeignExchangeImpactRightofUseAssets', window );">Foreign exchange impact</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets, ending balance</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilitiesAbstract', window );"><strong>Lease Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, beginning balance</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities', window );">Additions</a></td>
<td class="nump">392<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashOutflowForLeases', window );">Payment of lease liabilities</a></td>
<td class="num">(407)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestExpenseOnLeaseLiabilities', window );">Interest expense on lease liabilities</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities, ending balance</a></td>
<td class="nump">$ 423<span></span>
</td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 655<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsToRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to right-of-use assets. [Refer: Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsToRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashOutflowForLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashOutflowForLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 44B<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44B&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestExpenseOnLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest expense on lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestExpenseOnLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ForeignExchangeImpactRightofUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Exchange Impact, Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ForeignExchangeImpactRightofUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesFromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) From Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesFromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RightOfUseAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RightOfUseAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292800640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Total Undiscounted Lease Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">$ 513<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Less than one year</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">One to five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember', window );">More than five years</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems', window );"><strong>Disclosure of maturity analysis of operating lease payments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossLeaseLiabilities', window );">Total undiscounted lease liability</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 58<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_58&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph B11D<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B11D_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291238688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstanding', window );">Balance at beginning of period (in shares)</a></td>
<td class="nump">64,035<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstanding', window );">Balance at end of period (in shares)</a></td>
<td class="nump">7,731,085<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward', window );"><strong>Fair Value of Warrant Derivative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance at beginning of period</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
<td class="nump">$ 34,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityUnamortizedDiscount', window );">Discount on warrants issued</a></td>
<td class="num">(1,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="nump">5,285<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">(6)<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Balance at end of period</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstandingRollForward', window );"><strong>Number of Warrants Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued pursuant to public offering (in shares)</a></td>
<td class="nump">7,667,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward', window );"><strong>Fair Value of Warrant Derivative</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityUnamortizedDiscount', window );">Discount on warrants issued</a></td>
<td class="num">(1,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityAmortizedDiscount', window );">Amortization of discount on warrants issued</a></td>
<td class="nump">146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives', window );">Change in fair value</a></td>
<td class="num">(5,431)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GainsLossesFromForeignExchangeImpact', window );">Foreign exchange impact</a></td>
<td class="num">$ (132)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ChangeInFairValueWarrantDerivativeRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Fair Value Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ChangeInFairValueWarrantDerivativeRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GainsLossesFromForeignExchangeImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains (Losses) From Foreign Exchange Impact</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GainsLossesFromForeignExchangeImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantLiabilityAmortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Amortized Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantLiabilityAmortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantLiabilityUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Unamortized Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantLiabilityUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270991120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Derivative - Warrant Derivative Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 07, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 16, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract', window );"><strong>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantExercisePrice', window );">Exercise price (usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsOutstanding', window );">Number of Warrants Outstanding</a></td>
<td class="nump">7,731,085<span></span>
</td>
<td class="nump">1,000,050<span></span>
</td>
<td class="nump">6,667,000<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
<td class="nump">64,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270133968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Derivative - Narrative (Details)<br> $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>CAD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>CAD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>USD ($) </div>
<div>d </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Aug. 16, 2019 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsAndSharesOutstanding', window );">Number of warrants and shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfUnitsGross', window );">Gross proceeds from units</a></td>
<td class="nump">$ 3,077<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">$ 20,185<span></span>
</td>
<td class="nump">$ 15,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantExercisePrice', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement', window );">Expiration period, granted</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice', window );">Class of warrant or right, threshold trading price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays', window );">Class of warrant or right, threshold consecutive trading days | d</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays', window );">Class of warrant or right, accelerated threshold trading days | d</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays', window );">Class of warrant or right, expiration days | d</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="nump">$ 34,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityUnamortizedDiscount', window );">Discount on warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantsTerm', window );">Warrants, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="nump">34,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 of fair value hierarchy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantExercisePrice', window );">Exercise price (usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WarrantLiabilityUnamortizedDiscount', window );">Discount on warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingMember', window );">Public offering | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1', window );">Number of common shares issuable per warrant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember', window );">Shares Under Warrant Derivative Agreement | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_CommonSharesPerUnit', window );">Common shares per unit (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_CommonSharesPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Shares Per Unit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_CommonSharesPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsAndSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants And Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsAndSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsFromIssueOfUnitsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issue Of Units, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsFromIssueOfUnitsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantLiabilityUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability, Unamortized Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantLiabilityUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WarrantsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WarrantsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012269249744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details) - Warrants<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>year </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>year </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems', window );"><strong>Disclosure of fair value measurement of liabilities [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Underlying share price (usd per share)</a></td>
<td class="nump">$ 1.35<span></span>
</td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.032<span></span>
</td>
<td class="nump">0.039<span></span>
</td>
<td class="nump">0.038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted', window );">Expected life | year</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Expected volatility</a></td>
<td class="nump">0.365<span></span>
</td>
<td class="nump">0.365<span></span>
</td>
<td class="nump">0.365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted', window );">Fair value per warrant (usd per share)</a></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">$ 0.79<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Dividend As Percentage, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments Life, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012269976480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period</a></td>
<td class="nump">$ 26,502<span></span>
</td>
<td class="nump">$ 36,099<span></span>
</td>
<td class="nump">$ 24,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
<td class="nump">34,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(2,805)<span></span>
</td>
<td class="num">(764)<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period</a></td>
<td class="nump">27,563<span></span>
</td>
<td class="nump">$ 26,502<span></span>
</td>
<td class="nump">$ 36,099<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember', window );">At-the-market equity distribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued, beginning (shares)</a></td>
<td class="nump">61,327,914<span></span>
</td>
<td class="nump">55,043,789<span></span>
</td>
<td class="nump">46,166,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Share capital issued ending (shares)</a></td>
<td class="nump">74,423,960<span></span>
</td>
<td class="nump">61,327,914<span></span>
</td>
<td class="nump">55,043,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at beginning of period</a></td>
<td class="nump">$ 404,040<span></span>
</td>
<td class="nump">$ 391,348<span></span>
</td>
<td class="nump">$ 356,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
<td class="nump">34,168<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue costs</a></td>
<td class="num">(2,805)<span></span>
</td>
<td class="num">(764)<span></span>
</td>
<td class="num">(1,256)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity balance at end of period</a></td>
<td class="nump">$ 430,906<span></span>
</td>
<td class="nump">$ 404,040<span></span>
</td>
<td class="nump">$ 391,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | At-the-market equity distribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="nump">4,978,605<span></span>
</td>
<td class="nump">6,235,232<span></span>
</td>
<td class="nump">8,401,029<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="nump">$ 34,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Warrant derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital | Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="nump">7,667,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="nump">$ 17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderStockOptionPlanMember', window );">Stock option plan | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="nump">450,391<span></span>
</td>
<td class="nump">8,333<span></span>
</td>
<td class="nump">123,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="nump">$ 1,271<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderIncentiveAwardPlanMember', window );">Incentive share award plan | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalNumberSharesAbstract', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,560<span></span>
</td>
<td class="nump">150,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareCapitalAmountAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">$ 544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareCapitalAmountAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareCapitalAmountAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareCapitalNumberSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Capital, Number, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareCapitalNumberSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesUnderAtthemarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingWarrantDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderStockOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderStockOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesUnderIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012266291312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Schedule of Share Capital Footnotes (Details)<br> $ / shares in Units, $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 17, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfUnitsGross', window );">Gross proceeds from units</a></td>
<td class="nump">$ 3,077<span></span>
</td>
<td class="nump">$ 2,250,000<span></span>
</td>
<td class="nump">$ 20,185<span></span>
</td>
<td class="nump">$ 15,001,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsfromWarrantExercises1', window );">Gross proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231<span></span>
</td>
<td class="nump">$ 182,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfWarrantsAndSharesOutstanding', window );">Number of warrants and shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquitySharesNumberOfCommonShares', window );">Number of common shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquitySharesNumberOfWarrants', window );">Number of warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WarrantLiability', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareWarrantsIssuedOperatingExpense', window );">Share issue operating expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember', window );">Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Contributed Surplus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees', window );">Expense from share-based payment transactions with parties other than employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">638<span></span>
</td>
<td class="nump">$ 473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingMember', window );">Public offering | Share Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,724<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember', window );">Compensation Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareWarrantsIssuedTransactionCosts', window );">Warrants issued, transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,667,050<span></span>
</td>
<td class="nump">7,667,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="nump">201,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClassofWarrantorRightWarrantsExercised', window );">Warrants exercised, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issued pursuant to public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2020 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,685,097<span></span>
</td>
<td class="nump">5,685,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfUnitsGross', window );">Gross proceeds from units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,413<span></span>
</td>
<td class="nump">$ 18,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,711<span></span>
</td>
<td class="nump">$ 17,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">702<span></span>
</td>
<td class="nump">$ 555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2021 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,719,770<span></span>
</td>
<td class="nump">2,719,770<span></span>
</td>
<td class="nump">2,715,932<span></span>
</td>
<td class="nump">2,715,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfUnitsGross', window );">Gross proceeds from units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,744<span></span>
</td>
<td class="nump">$ 4,560,000<span></span>
</td>
<td class="nump">$ 10,755<span></span>
</td>
<td class="nump">$ 8,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.11<span></span>
</td>
<td class="nump">$ 3.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,572<span></span>
</td>
<td class="nump">$ 4,423,000<span></span>
</td>
<td class="nump">10,432<span></span>
</td>
<td class="nump">$ 8,395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">$ 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember', window );">2022 United States ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementAmount', window );">Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharePurchaseAgreementTerm', window );">Agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IssueOfEquityShares', window );">Issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,978,605<span></span>
</td>
<td class="nump">4,978,605<span></span>
</td>
<td class="nump">3,515,462<span></span>
</td>
<td class="nump">3,515,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsFromIssueOfUnitsGross', window );">Gross proceeds from units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">$ 7,904,000<span></span>
</td>
<td class="nump">$ 7,594<span></span>
</td>
<td class="nump">$ 5,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharesIssuedPricePerShare1', window );">Purchase price (cad and usd per share) | (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Net proceeds from issue of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,356<span></span>
</td>
<td class="nump">7,667,000<span></span>
</td>
<td class="nump">7,366<span></span>
</td>
<td class="nump">$ 5,463,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ShareIssueRelatedCostCommissions', window );">Share issue related cost, commissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320<span></span>
</td>
<td class="nump">$ 237,000<span></span>
</td>
<td class="nump">228<span></span>
</td>
<td class="nump">$ 169,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareIssueRelatedCost', window );">Share issue related cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareIssueRelatedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost related to the issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareIssueRelatedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Number Of Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquitySharesNumberOfCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares, Number Of Common Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquitySharesNumberOfCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IssueOfEquitySharesNumberOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issue Of Equity, Shares, Number Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IssueOfEquitySharesNumberOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfWarrantsAndSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants And Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfWarrantsAndSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsFromIssueOfUnitsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issue Of Units, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsFromIssueOfUnitsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromWarrantExercises1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Warrant Exercises1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromWarrantExercises1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareIssueRelatedCostCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Issue Related Cost, Commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareIssueRelatedCostCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharePurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharePurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareWarrantsIssuedOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Warrants Issued, Operating Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareWarrantsIssuedOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ShareWarrantsIssuedTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Warrants Issued, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ShareWarrantsIssuedTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharesIssuedPricePerShare1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Price Per Share1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharesIssuedPricePerShare1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_IssuedCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_SharesPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SaleOfStockAxis=oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270085024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details)<br> $ / shares in Units, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 07, 2023</div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum', window );">Common shares reserved for issuance, maximum percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="nump">$ 3,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Purchase price (cad and usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement', window );">Expiration period, granted</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember', window );">Contributed Surplus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees', window );">Expense from share-based payment transactions with parties other than employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
<td class="nump">$ 473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember', window );">Restricted share units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,200<span></span>
</td>
<td class="nump">403,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember', window );">Reserve of share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares', window );">Common shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,419,354<span></span>
</td>
<td class="nump">10,419,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember', window );">Compensation Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="nump">536,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1', window );">Vesting period, if not immediately vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issue under options and contracts for the sale of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_SharePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_ReserveOfSharebasedPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270339424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_StockOptionsOutstandingAbstract', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, beginning of the year (shares) | shares</a></td>
<td class="nump">5,963,185<span></span>
</td>
<td class="nump">5,334,420<span></span>
</td>
<td class="nump">3,764,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Granted during the year (shares) | shares</a></td>
<td class="nump">2,145,400<span></span>
</td>
<td class="nump">1,005,000<span></span>
</td>
<td class="nump">1,832,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the year (shares) | shares</a></td>
<td class="num">(280,288)<span></span>
</td>
<td class="num">(62,962)<span></span>
</td>
<td class="num">(110,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement', window );">Expired during the year (shares) | shares</a></td>
<td class="num">(314,573)<span></span>
</td>
<td class="num">(304,940)<span></span>
</td>
<td class="num">(28,364)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Exercised during the year (shares) | shares</a></td>
<td class="num">(450,391)<span></span>
</td>
<td class="num">(8,333)<span></span>
</td>
<td class="num">(123,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Outstanding, end of the year (shares) | shares</a></td>
<td class="nump">7,063,333<span></span>
</td>
<td class="nump">5,963,185<span></span>
</td>
<td class="nump">5,334,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Options exercisable, end of the year (shares) | shares</a></td>
<td class="nump">5,039,604<span></span>
</td>
<td class="nump">4,420,482<span></span>
</td>
<td class="nump">3,165,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageExercisePriceOutstandingAbstract', window );"><strong>Weighted Average Exercise Price $</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the year (cad per share) | $ / shares</a></td>
<td class="nump">2.23<span></span>
</td>
<td class="nump">2.04<span></span>
</td>
<td class="nump">2.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the year (cad per share) | $ / shares</a></td>
<td class="nump">2.86<span></span>
</td>
<td class="nump">3.83<span></span>
</td>
<td class="nump">6.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019', window );">Expired during the year (cad per share) | $ / shares</a></td>
<td class="nump">4.17<span></span>
</td>
<td class="nump">10.80<span></span>
</td>
<td class="nump">37.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Exercised during the year (cad per share) | $ / shares</a></td>
<td class="nump">1.74<span></span>
</td>
<td class="nump">1.45<span></span>
</td>
<td class="nump">1.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Outstanding, beginning of the year (cad per share) | $ / shares</a></td>
<td class="nump">2.72<span></span>
</td>
<td class="nump">2.91<span></span>
</td>
<td class="nump">3.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Options exercisable, end of the year (cad per share) | $ / shares</a></td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options expired in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_v&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_StockOptionsOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_StockOptionsOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageExercisePriceOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageExercisePriceOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270176320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">7,063,333<span></span>
</td>
<td class="nump">5,963,185<span></span>
</td>
<td class="nump">5,334,420<span></span>
</td>
<td class="nump">3,764,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.72<span></span>
</td>
<td class="nump">$ 2.91<span></span>
</td>
<td class="nump">$ 3.53<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">5,039,604<span></span>
</td>
<td class="nump">4,420,482<span></span>
</td>
<td class="nump">3,165,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.85<span></span>
</td>
<td class="nump">$ 3.01<span></span>
</td>
<td class="nump">$ 3.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">2,015,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">1,082,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember', window );">$0.54 - $1.79 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">1,260,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">1,063,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember', window );">$1.80 - $3.01 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 2.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">978,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">364,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">2.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember', window );">$3.02 - $3.90 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">2,665,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">2,385,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 3.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">3.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember', window );">$3.91 - $7.41 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOutstandingShareOptions', window );">Number Outstanding (shares) | shares</a></td>
<td class="nump">143,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019', window );">Weighted Average Remaining Contractual Life (years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement', window );">Number Exercisable (shares) | shares</a></td>
<td class="nump">143,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019', window );">Weighted Average Exercise Price (cad per share)</a></td>
<td class="nump">$ 9.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember', window );">$7.42 - $52.63 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems', window );"><strong>Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price (cad per share)</a></td>
<td class="nump">$ 16.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOutstandingShareOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOutstandingShareOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercisable in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause vi<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_vi&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis=oncyf_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012290866608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($) </div>
<div>year</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract', window );"><strong>Disclosure of Share-based Payment Arrangements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted', window );">Expected life | year</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted', window );">Expected volatility</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="nump">110.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted', window );">Weighted average fair value of options (cad per share) | $</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfOptionLifeShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The option life of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfOptionLifeShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of an expected dividend used to calculate the fair value of share options granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Share-based Payment Arrangements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012266081072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details) - Restricted share units<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, beginning of the year (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,560<span></span>
</td>
<td class="nump">134,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted (in shares)</a></td>
<td class="nump">403,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited (in shares)</a></td>
<td class="num">(4,760)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Released (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(40,560)<span></span>
</td>
<td class="num">(94,058)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Outstanding, end of the year (in shares)</a></td>
<td class="nump">398,440<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">40,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value at measurement date, other equity instruments granted | $</a></td>
<td class="nump">$ 2.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=ifrs-full_RestrictedShareUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012295940896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Compensation Warrants Weighted Average Assumptions (Details) - Compensation Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>year </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted', window );">Underlying share price (usd per share)</a></td>
<td class="nump">$ 2.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted', window );">Risk-free interest rate</a></td>
<td class="nump">0.038<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted', window );">Expected life | year</a></td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted', window );">Expected volatility</a></td>
<td class="nump">0.365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted', window );">Expected dividend yield</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted', window );">Weighted average fair value of options (usd per share)</a></td>
<td class="nump">$ 0.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Dividend As Percentage, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Volatility, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Equity Instruments Life, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risk Free Interest Rate, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Share Price, Other Equity Instruments Granted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=oncyf_CompensationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292391264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted average number of common shares outstanding (shares)</a></td>
<td class="nump">67,624,036<span></span>
</td>
<td class="nump">58,029,745<span></span>
</td>
<td class="nump">53,513,225<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012295695216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContractLiabilityRecognitionPeriod', window );">Expected recognition period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContractLiabilityRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Liability, Recognition Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContractLiabilityRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012296015216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contract Liability - Schedule of Contract Revenues and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract', window );"><strong>Disclosure of revenue from contracts with customers [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, beginning of year</a></td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities', window );">Revenue recognized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Balance, end of year</a></td>
<td class="nump">$ 6,730<span></span>
</td>
<td class="nump">$ 6,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue from contracts with customers [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012296284800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ContingenciesAbstract', window );"><strong>Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PurchaseObligation1', window );">Commitment for payment</a></td>
<td class="nump">$ 12,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PurchaseObligationCommitmentTerm', window );">Commitment term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_LeaseNotYetCommencedPayments', window );">Lease not yet commenced, payments</a></td>
<td class="nump">$ 1,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_LeaseNotYetCommencedTerm', window );">Lease not yet commenced, term</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ContingenciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingencies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ContingenciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_LeaseNotYetCommencedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Not Yet Commenced, Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_LeaseNotYetCommencedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_LeaseNotYetCommencedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Not Yet Commenced, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_LeaseNotYetCommencedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PurchaseObligationCommitmentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Obligation, Commitment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PurchaseObligationCommitmentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012264809344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofincometaxAbstract', window );"><strong>Disclosure of income tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccountingProfit', window );">Loss before income taxes</a></td>
<td class="num">$ (27,655)<span></span>
</td>
<td class="num">$ (24,751)<span></span>
</td>
<td class="num">$ (26,255)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ApplicableTaxRate', window );">Statutory Canadian corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate', window );">Anticipated tax recovery</a></td>
<td class="num">$ (6,361)<span></span>
</td>
<td class="num">$ (5,693)<span></span>
</td>
<td class="num">$ (6,039)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectOfForeignTaxRates', window );">Difference in tax rates</a></td>
<td class="nump">2,841<span></span>
</td>
<td class="nump">3,552<span></span>
</td>
<td class="nump">2,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfStockBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">441<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfTaxPools', window );">Revaluation of tax balances</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(338)<span></span>
</td>
<td class="num">(552)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TaxEffectFromChangeInTaxRate', window );">Impact of Barbados rate change</a></td>
<td class="num">(9,088)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome', window );">Other permanent differences</a></td>
<td class="nump">325<span></span>
</td>
<td class="num">(368)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfExpirationOfTaxBenefits', window );">Expiry of tax benefits</a></td>
<td class="nump">3,382<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative', window );">Change in fair value of warrant derivative</a></td>
<td class="num">(1,215)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1', window );">Provision to offset deferred tax asset</a></td>
<td class="nump">9,770<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxExpenseIncome', window );">Current income taxes</a></td>
<td class="nump">$ 97<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccountingProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccountingProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The applicable income tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 80<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_80_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectFromChangeInTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectFromChangeInTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxEffectOfForeignTaxRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxEffectOfForeignTaxRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TaxExpenseIncomeAtApplicableTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TaxExpenseIncomeAtApplicableTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofincometaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of income tax [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofincometaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Change in Fair Value Of Warrant Derivative</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfExpirationOfTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Expiration Of Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfExpirationOfTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Stock Based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TaxEffectOfTaxPools">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Effect Of Tax Pools</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TaxEffectOfTaxPools</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270788800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA | Non-capital losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">$ 110,450<span></span>
</td>
<td class="nump">$ 98,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA | Non-refundable federal investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">4,056<span></span>
</td>
<td class="nump">4,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">CANADA | Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">28,376<span></span>
</td>
<td class="nump">27,663<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_BB', window );">BARBADOS | Non-capital losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised', window );">Unused tax losses</a></td>
<td class="nump">129,884<span></span>
</td>
<td class="nump">145,405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES | Unclaimed scientific research and experimental development expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised', window );">Unused tax credits</a></td>
<td class="nump">$ 1,232<span></span>
</td>
<td class="nump">$ 1,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxLossesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=ifrs-full_UnusedTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012291251248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 49,260<span></span>
</td>
<td class="nump">$ 38,627<span></span>
</td>
<td class="nump">$ 37,584<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember', window );">Non-capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">37,174<span></span>
</td>
<td class="nump">26,726<span></span>
</td>
<td class="nump">25,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember', window );">Scientific research and experimental development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">7,742<span></span>
</td>
<td class="nump">7,648<span></span>
</td>
<td class="nump">7,705<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember', window );">Investment tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">3,123<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">3,716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember', window );">Share issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">833<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="nump">648<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember', window );">Net capital losses carried forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems', window );"><strong>Disclosure of temporary difference, unused tax losses and unused tax credits [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised', window );">Unrecognized deferred tax asset</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph 81<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedNetOperatingLossCarryForwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_InvestmentTaxCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_ShareIssueCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis=oncyf_UnusedCapitalLossCarryForwardNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292813904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Disclosures (Details) - CAD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 12, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfChangesInEquityAbstract', window );"><strong>Statement of changes in equity [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,912,000<span></span>
</td>
<td class="nump">$ 11,666,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,262,000<span></span>
</td>
<td class="nump">$ 31,220,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Shareholders' equity</a></td>
<td class="nump">$ 27,563,000<span></span>
</td>
<td class="nump">$ 26,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,099,000<span></span>
</td>
<td class="nump">$ 24,752,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_EquityAuthorized', window );">Base Shelf securities authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfChangesInEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfChangesInEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_EquityAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_EquityAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012269470784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - CAD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency (cad per share)</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">Increase (decrease) in net loss due to change in currency value</a></td>
<td class="nump">140,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember', window );">Currency risk | Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount', window );">Impact of increase in value of currency (cad per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings', window );">Increase (decrease) in net loss due to change in currency value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of nature and extent of risks arising from financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Warrant derivative</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level2OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012269440352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)<br> $ in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CAD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,262<span></span>
</td>
<td class="nump">$ 31,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">$ (3,572)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">U.S. dollars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAvailableforsale', window );">Financial assets available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,093)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_Currency1LineItems', window );"><strong>Currency1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAvailableforsale', window );">Financial assets available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_BalanceHeldInForeignCurrencyNet', window );">Balances in foreign currencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAvailableforsale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables; (b) held-to-maturity investments; or (c) financial assets at fair value through profit or loss. [Refer: Derivative financial assets; Financial assets at fair value through profit or loss; Held-to-maturity investments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Note Expired 2023-01-01<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 8<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2017-en-b&amp;anchor=para_8_d&amp;doctype=Standard&amp;book=b<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAvailableforsale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_BalanceHeldInForeignCurrencyNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance Held In Foreign Currency, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_BalanceHeldInForeignCurrencyNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_Currency1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Currency1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_Currency1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012271157920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Other receivables</a></td>
<td class="nump">$ 506<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="num">$ (776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">777<span></span>
</td>
<td class="num">(1,247)<span></span>
</td>
<td class="num">(349)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(78)<span></span>
</td>
<td class="nump">1,662<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables', window );">Other liabilities</a></td>
<td class="nump">332<span></span>
</td>
<td class="num">(352)<span></span>
</td>
<td class="nump">228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet', window );">Non-cash impact of foreign exchange</a></td>
<td class="nump">228<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(194)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Change in non-cash working capital related to operating activities</a></td>
<td class="nump">$ 1,765<span></span>
</td>
<td class="nump">$ 391<span></span>
</td>
<td class="num">$ (908)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012292035904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_AdditionalCashFlowDisclosuresAbstract', window );"><strong>Additional Cash Flow Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ProceedsfromInterestReceived', window );">Cash interest received</a></td>
<td class="nump">$ 1,554<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
<td class="nump">$ 190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefund', window );">Cash taxes paid</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_AdditionalCashFlowDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Cash Flow Disclosures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_AdditionalCashFlowDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ProceedsfromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Interest Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ProceedsfromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012290922800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Economic Dependence (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>manufacturer</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member', window );">Toll manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskType1LineItems', window );"><strong>Concentration Risk Type1 [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ConcentrationRiskNumber', window );">Concentration, number</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1LineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Concentration Risk Type1 [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1LineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ConcentrationRiskType1Axis=oncyf_SupplierConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012269945488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Components of Expenses (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">$ 1,917<span></span>
</td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="nump">$ 3,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">17,709<span></span>
</td>
<td class="nump">15,432<span></span>
</td>
<td class="nump">12,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">16,082<span></span>
</td>
<td class="nump">11,492<span></span>
</td>
<td class="nump">13,315<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ClinicalTrialExpense', window );">Clinical trial expenses</a></td>
<td class="nump">3,675<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="nump">3,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ManufacturingExpense', window );">Manufacturing &amp; related process development expenses</a></td>
<td class="nump">5,789<span></span>
</td>
<td class="nump">2,148<span></span>
</td>
<td class="nump">1,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IntellectualPropertyExpense', window );">Intellectual property expenses</a></td>
<td class="nump">397<span></span>
</td>
<td class="nump">544<span></span>
</td>
<td class="nump">618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_TranslationalScienceExpense', window );">Translational science expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherEmployeeExpense', window );">Personnel-related expenses</a></td>
<td class="nump">6,324<span></span>
</td>
<td class="nump">6,023<span></span>
</td>
<td class="nump">4,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">1,305<span></span>
</td>
<td class="nump">1,371<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other expenses</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee compensation and benefits expense</a></td>
<td class="nump">6,324<span></span>
</td>
<td class="nump">5,983<span></span>
</td>
<td class="nump">4,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_ResearchAndDevelopmentExpenseAbstract', window );"><strong>Research and development expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation expense</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="nump">1,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_GeneralAndAdministrativeExpenseAbstract', window );"><strong>General and administrative expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_PublicCompanyExpense', window );">Public company-related expenses</a></td>
<td class="nump">11,278<span></span>
</td>
<td class="nump">6,790<span></span>
</td>
<td class="nump">8,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_OfficeExpenses', window );">Office expenses</a></td>
<td class="nump">3,789<span></span>
</td>
<td class="nump">3,303<span></span>
</td>
<td class="nump">2,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AmortisationExpense', window );">Depreciation - property and equipment</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">93<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationRightofuseAssets', window );">Depreciation - right-of-use assets</a></td>
<td class="nump">322<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EmployeeBenefitsExpense', window );">Employee compensation and benefits expense</a></td>
<td class="nump">$ 3,332<span></span>
</td>
<td class="nump">$ 2,870<span></span>
</td>
<td class="nump">$ 2,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EmployeeBenefitsExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EmployeeBenefitsExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherEmployeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of employee expenses that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 19<br> -IssueDate 2023-01-01<br> -Paragraph 5<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=19&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_5&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherEmployeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ClinicalTrialExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Trial Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ClinicalTrialExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_GeneralAndAdministrativeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General And Administrative Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_GeneralAndAdministrativeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IntellectualPropertyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intellectual Property Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IntellectualPropertyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Manufacturing Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_OfficeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Office Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_OfficeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_PublicCompanyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Company Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_PublicCompanyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_ResearchAndDevelopmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_ResearchAndDevelopmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_TranslationalScienceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Translational Science Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_TranslationalScienceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_IncomeStatementLocation1Axis=oncyf_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140012270336608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - CAD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_oncyf_DisclosureofrelatedpartyAbstract', window );"><strong>Disclosure of related party [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits', window );">Short-term employee compensation and benefits</a></td>
<td class="nump">$ 4,870<span></span>
</td>
<td class="nump">$ 4,308<span></span>
</td>
<td class="nump">$ 3,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits', window );">Termination benefits</a></td>
<td class="nump">319<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment', window );">Share-based compensation expense</a></td>
<td class="nump">1,496<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_KeyManagementPersonnelCompensation', window );">Compensation of key management personnel</a></td>
<td class="nump">$ 6,685<span></span>
</td>
<td class="nump">$ 5,923<span></span>
</td>
<td class="nump">$ 6,622<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_oncyf_DisclosureofrelatedpartyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of related party [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">oncyf_DisclosureofrelatedpartyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>oncyf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>102
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MKH\^*N?^M)/[?X8PWWT08$\PCYB6@F=DHG7E#]$6S0MT.CG/IYT\_Y,LP ;
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M(&V"V=\+H8^!/6#HU_E?4$L#!!0    ( $V!;%CJ=BL7C@4  # 7   8
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MF<.G8AW/V&6/MUC!\F?6N_K73]32_B.3)1+FM.,WAM9(-YL5F")]NDB8)ZF
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M"$5KRNB0Z$#/R'10;\[2]MXW-8Q63I#:46?=0!,9SJO"]+QB+C0V#TKSH;0
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M:.4\6UE]Q\IR1>^<C6V@"UMQ]:V!.4+:Q[7:Q76^^J'%EUS.:+V<TFJQ6O_
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M':C% :D$!! 39>+7:-FF,HBXH4Z<*%1DN8/3*JJIB\K0&D$W%60+LX3PU/A
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M>)0:NAKJMJ$FB3:TPJ2Z#E=Z6FE"X':,S")"OY9MY?TOFOLV/! T6D"C*%M
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MOG=;_G-C2LB$!N#^RKD^_* %XE<4G_T?4$L#!!0    ( $V!;%B)N8E-@0D
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MAF#MX1GLYCX<PZCD(0G&46OJJ IAZ4>4_5#K/$(34?,IDF[UE&=.QBKX7(%
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MFX7PZ>>$]"6ZGJ_P-RY&U_''K9+@<EJ ]XT#9^<O)&#\3>?J/U!+ P04
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MI?-7YG)/51R<G$R\^JY'3R$H04EWSP0X;B? \7\Z ;X?[74"O$Z UPGP/TR
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MXQ7H_U9K=SAX!]/3O?X'4$L#!!0    ( $V!;%@U"Y;$8 (  )$%   9
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M+CQA$V6GLP%DC?.F:I6)025U?(O[-@X]A<7X&86D54@"[V@HL+P67BS/K=F
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M='BKL,Y<WZY$)]E+L59&5)<S Y/T8E8,RU^XY<&)Y7[ WK:-66GVNBEE^=#
M#+[L' JV#KT(SEI\)8LI"WW. B\(S]@+=P&&UEYXRI[21=7J'E&V"_8@7,[>
M2RV[.ZG935.R7\U*=NSUIUZ9>_:F,;*3VK!_W<RUZ4">?Q]#Q^T='=^;"NJY
M7HM"7HU0,7:KT?6//_B)]].9R*)=9-$YZU].W3<L9S>]6;6=^H\LG[,/F%LK
M(TO6]/4<F "XIF5KT;$[4?62%6U=HZ(T6= .4\U^<7-OZK9O#+O13!B&9$H[
M.B348U'"_23A>>:Q"Q;&"<^"B+W1NL=NZ[[3O<!BTS(0O_C(VK4MW74E&N8'
M(??CG(69?VR!:@K94(4[MYC8B*X<5L8>S_*<Q='1K48W^+.2[*WH/DHS8N.;
MW]Y.F'0\*!6RK^:]DY!E)R44R;"QF(SG$Y;QR/.Y%\"K"'%EQ\S#CXX>2]FI
M.V$]E)]E5RB-B>-B EQ\G@8!2[)TX*<B*T!9&\U^_"$+_. G-O9Y$">3$\#Z
M+(ZY%X4\S7("-O=Y&!UUYRFP&0_#$$:^$=7(XW'BL?SH+M^%Z7PR+B<LX4$8
MXU_ _!">9><P29/H%"+ $Q@$*<_]"(A$7@1\CL;X%)$(A &$#)"G1\GV7>$A
MMHCG:<83+V:^QY,T.69[W<\K5:#F%B!,LV1C.6$I3Y*4>[''_!1<B<YA$O#,
MBT^A$K(TXA$J*4^H */0X[F7$)W9KPW[N6\DJL65*F<;,-7*8 D>P#,@@SB_
M$.9&F154I1%%T8(J?Y?-H*>0]=\ &5D0%7H!6.VUY=@0Q8&F</(=DGDG5$48
MU!9GC*B"7MH]!.V*;9?"R#U:3J @6/V:?;B] $D]SV/M'2 0+(B?U71:L34F
MMR52V+7]<F53N1 %]C(*2H;5-/*+T*7XM%-(EVL@85]^:*Q WAKLKBDRI9D6
M%58?0"$0G^QP:@N:B^A@HUB!!;9DI^Q5;WTF>_<2ZBKI#'U:VS83NJU*%O,D
M0YWGZ2,)1G/&EEVK-2!J"RE+&\0%\ASY(1L#"#_CL1=."%<"#GB@Y7* VJG1
M%$<Y30RG03R9LM\E6JY"HO++1S8#GOJ^LXGBBC+87"!*ZQ%2"3:XB:GG#,8Q
MV7L#V%I[YB(6J$K?$:WT$QJ/\:[J2X+EP.!DL)A.226(J@[)^ "@_VNJPC:@
MRAZPU4_^QVQU<I X.?U:M@9[MA)3<IZF'D2)CJAG=B3F>1A,OH[ ,4]Q9A.+
M(CIL)CM#%]#/-([M*P@J*'::VL%TR]=IDAV8"*=Y,E#>SR?G.!_S. T&-R">
M#]V(PF!P(\RM&T>KP1\,^&%ZZ$+@JC- ;']2D01>OK<?1SG,4I.!DKGIE_B>
M&!**Q#PX=8!<CWQVFTX9(YO'IY#SR!U6/<BDL3$^S+0A'[#MPVP*=--#VZ.?
M\$:?($YHESD&-;NV26/C[J!C^@;1W/95>TNV%E$[JML7WT44)X_V."VG X^R
M@% M#\[,](#[_T4ATG^-#B7Q7W-J?ETJP[VB[/NGL6WQGK&0QU"4*/E:11GZ
M+DHC3B\OFNPLX7><.['!,0N).JLHT: H<7Y@ >/)5FF\LXH"-_#Q,[B!WNZ!
M&V&2#&Y$27A244)T[%8[PL/509 Y#Y+\SU*4R-_#/9SFU)/N%27;IND[!25Q
MW2T8YZ3E5/EYW,^<Y/M$4-\E:)\7 @/="_'46IJ2C[=R;1R=TF-N$O>(Y\^H
MOHRMQN%+8"\'\WL[;1>.[ Z])X:4I:(UX+M/<=A._6PL(??2U*4/GW7>ER-Y
M+=#NT.-6>.F(7N"4?B@#5D-I<! ].+I26&D%3M6U+!5*K[IG6N)S7LPKMV((
MQ0W:][9@E=[ERPJ1EH]DN:@$F+)0!(,F:47ST!0*.%1*S$D9[ME82PE!A^+0
M6?1NBX)=3Z 7MMT0"&&IS9F#A-(@UNOJGD@J4%>5^Y@^D'.\[EH M8T:)OK*
M6"FF$]A^.:$>H;%NS$%6#%)%FR&9"B!3!$>^V_=!V784A>K9$K,IP3QAB3,(
M(5WWD/9B1R+.%WD4AZB#/"0$UK+1SM8N^#V*OG^RK@WF:N&N.UU=.Z[YH7=8
MX4^.P"1THA&EZ&V(L>3F43\FG!8X=$'=,/<>)Y(^J)_("T%[D4;')K=KBQO<
MDI]I/SJLZ)K5=J#DQY%$[PZ;)]3?)@WOY;9BIL?NVF8'5Z:U[);V8IBZFKXQ
M[O9T-[J[>[YQ5Z[[Z>[B&D?<4D&4*[G 4F]*5[V=NPQV/TR[MA>P\]:8MK:/
M*RE  IJ ]XL6>1U^T :[&_GK/P!02P,$%     @ 38%L6&IVSA,;"0  $!@
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M(1=%UF&V>W=7$YT4U)VIY_6M&Q29B4;(TD"/[#VZL*?'45T8II:YNGVSDD+
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MS_%1)/A(YG#J /N1:!=HZ[8G,=@(6'&DH;1Z7?)..JP&RE"41[XOPS!@21H
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M; B5VO,"S&\<@EY>^(##Q[&;_P)02P,$%     @ 38%L6.@NS3P?!P  LQ4
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M.BNR8'3P?F-5[U^)I;+TYOCEFAYYU$Z OJ^4LON-N^#PV[#X&U!+ P04
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M"D!W;;7;6-7X5K96EAJC7U;T)T+M#$A?*F5?-BY _V];_ -02P,$%     @
M38%L6'4D$ %?&   8$X  !D   !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
MS5Q9C]NXEOXK1-TE">!:T^E.9P,JU6E,+I).W50O& SF@99HFUVRZ(B27>Y?
M/V?C(EM652\#W)>D+(GDX>%9OK-(KS:NN?4+8UIUMZQJ__IHT;:K%Z>GOEB8
MI?8G;F5JN#-SS5*W\+.9G_I58W1)@Y;5Z<79V=>G2VWKHS>OZ-IU\^:5Z]K*
MUN:Z4;Y;+G6S?6LJMWE]='X4+GRV\T6+%T[?O%KIN;DQ[4^KZP9^G<992KLT
MM;>N5HV9O3ZZ/'_Q]OPY#J G?K9FX[._%6YEZMPM_GA?OCXZ0XI,98H6I]#P
MW]I<F:K"F8".+S+I45P3!^9_A]F_I\W#9J;:FRM7_6++=O'ZZ/F1*LU,=U7[
MV6W^R\B&GN%\A:L\_:LV\NS9D2HZW[JE# 8*EK;F__6=,.(A RYDP 71S0L1
ME=_I5K]YU;B-:O!IF W_H*W2:"#.UG@J-VT#=RV,:]_<\&DH-U,?=6L:JRMU
M612NJUM;S]6UJVQAC5>/PU]/7IVVL"Z./BUDC;>\QL6!-<XOU$=7MPNOWM6E
M*?L3G +!D>J+0/7;B]$9OS/%B7IZ/E$79Q=/1^9[&KGPE.9[>@\7/LW4C9W7
M=F8+7;>#C/B?RZEO&Q"F_QUB!"_SU? RJ&$O_$H7YO41J) WS=H<O?GGW\Z_
M/GLYLHFOXB:^&IO]S97V"Z7K4A7XA_G2V;6N3-UZN@C[NS6MGE9&>5-TC6UA
M-T-;^,L745>[C]JZJ+K2P/\@<<:WQU.C&^1R:5;.6WAB8]N%<AUJ7'VK6M?J
M"N__'<[\V=.OE(;E6@528)93TT1)4(]W+UVH8_7W;R?/SLZ?G(" #U$7B $+
M!RI<@](UC:F+K0+:ECL4:=AABP-)8>9@!N$AU2YTK;X]4Z7>,ALJXSU?=;51
M6]C<R<CY/HOG^VR4]=^9F0'22J38+8UJ]=WP"8Y/\PMNM0)K#!0:55D]M15N
M:&G:A2MQ7SJ)/3"EM]R)^@E4N!D<.D%KN$^ATHT!^UTXT*O?X!Y.B<-+.X.G
M@=-&34V[,::FRS-;Z[I ,^1;X"XX@!9DK6FV2 X(4&>8Q_@LR,[*D%G/5D0C
M;3WMPWLC@AEH)5,&LZY<@_J>:/ @'P,,/C0'[FEIM._P\<XC;;X#PP!6 ZBI
MMLK48"+Z4S6P'9E);[PR=T@[/-(ZI5<K&&.9 R@O*)9JL[#%0@U22P3D,TR9
MQVN#! &'@>JV,N6)^A%F-#"N:$$8AT[HT!:1@:H (9X;HBSN )@+EYLY+U3
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M]<"I&#\!C1 )X3RU"\=*>T1!,'?6MXR1&X,9 +'^R#N@G=4#Q:C$Q=Q*82H
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MW5"K#H(SV"+63%KI=4 304?*\,ZM6+,P$)KM&I5@L"-^@+T8++)3-HN\"C5
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MZ]26+KVGY0K6G=7*=Q;IJ.%[N,>*CJ8YV!2F;TR[[2AW#^8SGO\9Z;K6IJE
MM5MK'I&7')"7DN_J3^PRT+0-P@B@Y>!QOV'+@>YN@!V87J;VNN]>Z?XPZ'[1
M\.E0PQ?C"?C&.$HSQZ&AG,9V1<C[O$[A.Q@):O)D1*U(Q]R*";73-(.KJE)\
M".X=:'JY23:]S_0":<"GLI9Z@^PSY2F\?3,1J7@/(B-HR* 8GV 4S)>+*8A\
M0KM3F(Z3_\$S'GHO,\<)L\'%++B8LW-,3"Z.R:@UUJM_^EP[':2"&S$IN,L
MJ>!(%;3V*EGQB<H8G:D (LMR"BA,LY.1*"A8O$- 2JI&:7X2+"%N!IND9[PL
M6%T6E*:4L=2.INS\M(!?**I<L^!1-AV>%#2%-)E 6HQ@0M+H<YJ,W0_A2$.V
MA B+B8!C;TQ\4#A:M)M0'AV$=Z^O(</L4(&O^L+SLKTOW_?2;I1V='769)I<
MC(L(;%\2^X$WVU"&5L9340O=FOXBT/(&6E\;XY\'3##\ERS^!5!+ P04
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M3"F6&;A"Q;?,9@A.O[.E0'TV=0TYL&IN7(-=5&#!*V!^ %]D9C8:KK,$DV,
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M?; L2N?.[Z,.>;0IU;5>2FG([2HO]/%@:<SZ<#S6LZ5<">V6:UG FWFI5L+
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MZ4SR8\I<2&P%\-49? 1PV:Q$3G[/YI(,[6(P>BDQ.RAX5N6UYWH^>4M> VN
M*P[U:DYQ-T+0!LBKF#DA2V 8>E;.J^4C"B]9"(0)$5;X8U8> )HD6UJBG)7G
MKN>1)(H!B!QIA'"."= &L8>HI%:&H:Q?QQ("**,0'0<0#X<5SN$Q(![7!)=3
M*V=M>R&"W_.YXX<1H2">N$")YH$=='D4-ESJDJ(']F$+^_#%L'_T$5'M_,XZ
M\YOC_"*ZNFC;Q2'0XGDV] ?VDPT_V?##V!"U;(AZ0==I%A^106B 7Z?EFHM,
MD1N15[+35NS#>;]+Q+G4)@,LRX=&=^&\V'81::4L)?HZ+@D9I-)(!=L(>%?I
M1N.>4GT)/NK1+C)]_7:NI 3B@54(&+Y[1B(.#F N_0.8M.@ NP_8@8%-NT;
MAWH;X;Z[5O:FS(''.7:2$8#S@"0A7J&O<8..R12:S10;A+M,YBGYG.7M[^IA
M*GOGQE*%X97Y>$V2'L3$+6+B%Z^?Q7V3":561'ZO,*FL@"U%A=N+O?#HMV^[
M;MNXBXU0Z0]KNI]I;]^\BIG'WA&?.D$(1(2.+?3N&UF?<H<!Q1NQYK_3L_K
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M I)U0.)YMXD\RRMFV6RBU0JT\R8T-_%2?321X])=RJ/5M,LISLYNN&2RX$S
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M:+P W6^U=L>-?^#TBR[_!5!+ P04    " !-@6Q8Y]H/%HL#  ">!P  &0
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MV:L5KD_0S@'?2Z7LWG )AH6<_0-02P,$%     @ 38%L6#5M,@!Z @  #@8
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MH-H7C,GG@KX_*6[D)G\!4$L#!!0    ( $V!;%CT?YCJS@<  +X_   9
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M](\"A0G0WW/.U6YB>E'_ZXG_ %!+ P04    " !-@6Q8!JMVFR$#  #N#
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MAHGZ( &N-ZCK,\;D9J(#5)\XX5]02P,$%     @ 38%L6'A2"0/S P  +Q$
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M><^QS\'V<$?9 T\ !'K*TIR/C$2(XM(T>91 AGF/%I#+-VO*,BQDEVU,7C#
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M_2BSE4R2W SJPX#O'P%M6:OT^GM!!(%K6X/^ZV6<O+>S+?GK6V]R\M[.]_U
M6KY)2XN=9[EOO,X[62W^954MI;EWW*KKVG?,-B3G*(6UY*R>NN"PZ@I4=00M
M] F\HD*>Y[J9R%LC,&4@WZ\I%2\==:@W]]#P+U!+ P04    " !-@6Q8I%P.
MTR@*  "?>0  &0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6R]G>]OHS@>
MQO\5*[<ZS4BS38#\:J^-U 8;6[I=5=N=W1>G>T$3MT%+( >DG9'VCS_S(R%.
MJ OM,YT74R#VYVO@B3%^'/OR.4[^2E=29N3;.HS2J]XJRS87_7ZZ6,FUGY[%
M&QFI3Q[B9.UG:C=Y[*>;1/K+(M,Z[-N#P;B_]H.H-[LLCMTFL\MXFX5!)&\3
MDF[7:S_Y?B/#^/FJ9_5V!WX+'E=9?J _N]SXC_).9E\WMXG:Z^\IRV MHS2(
M(Y+(AZO>M74AAL,\0Y'BCT ^IP?;)#^5^SC^*]\1RZO>("^1#.4BRQ&^^O,D
MYS(,<Y(JQ_\J:&\?,\]XN+VCL^+DU<G<^ZF<Q^&?P3);7?6F/;*4#_XVS'Z+
MG[FL3FB4\Q9QF!;_D^<J[:!'%MLTB]=59E6"=1"5?_UOU84XR& /7\A@5QGL
MHPQ#^X4,3I7!:1MA6&48MHTPJC*,CB.\E&%<91BWS3"I,DS:9IA6&:;'&48O
M9#BO,IP7<BCO7W'S73_S9Y=)_$R2/+6BY1N%@HK<ZIX'42[VNRQ1GP8J7S;[
MTT\2/\J(*Y/@R<^%1WXFO^8'B^U/KLS\($P_DY](GZ0K/Y$I"2+R-0JR](LZ
MJ+9_7\7;U(^6)_N7_4R5,(_37U2E865I[!=*8]GDESC*5BFAT5(N=4!?G=K^
M_.S=^=W81N*=W)R1P>0+L0>V0^;7+OGTTV>R;"C:O OHZUT%.KPNY9\&M&M&
M7V\?%7K:HHRT"ZA;&9D9[<K%&7$LO8P-&*\]QC9@>'N,9<"(%M?+&N<8Z_S@
M*AETY^R_5TZ!=EXJ89 NPCC=)I+$#^3!#Q+RY(=;2=;2SX^JYT66?Q(&_GT0
M!EF@[LU_<@@),KE._]MP,C=EQ&%SQ/RI>)%N_(6\ZJG'7BJ3)]F;_?,?UGCP
MKR:U(V$N$D:1,(:$>4@81\($"*9)?;B7^M!$G_VZ7=_+)!?S<_DP28FJ_7<5
MCFI@I9G:#Z)'\DD]'<K#G\G?+U=%-\9X785>PD8%+&_Z/<VL@?HW&ESVGPXU
MC Q*3X..Q^.)"JL'9<B@'A+&D3 !@FGR'.WE.3+*TTOB-"6;)%Y(N4S)0Q*O
MR39OOC0IKT2-#^Z;,YA,])LV/TUDVR=R:D@TL*8C/14]366-!@/K2"7&$^RJ
M$B2,(V$"!--4,MZK9&Q4R>TV6:S42Y,22K!0[=Z%ORQJL6VZ)!M5NQ6555YK
MO=1**/5C#-*UYBIADT,)G=E'"G*1$6F;B P9T4/".!(F0#!-C9.]&B=&-=)O
M,ED$M1H[JM ([ZK"28,FID<UE(N,2$O8N3$B0T;TD#".A(G3JS\X.]]?"DU<
MT[VXIJ^(:Q/DK_=QE&LJB)=?R&/>;#M^WRZU9&:-!V1=O+ W*>?M65UCUJYZ
M0L+8VT_*0Y:#(V$"!-/D>+Z7X[GQDLU#7[7/ZK<'$B<DR;LHOY!LI<*MXG!)
MLL0OWB#>5A\:"]"U/CP_^4:.SXX?RLB M$5 A@SH(6$<"1,@F*93:U!WE0[>
MK]1%'*5RL2UZ3W>J7?K?4R72QOJUBGGXJF@?O4O,6Z1Q6Z2A+=(P\S7H*B4H
MC4-I D73U730\6Z]54W^8B%#J9[1<ME0!QK59#7T=ARKZ?4T;HLTM$4:9KX&
MG=6$I'$H3:!HNIKL6DWV6]4DZ_:>43KVR>V<C(ZE\WH:MT4:VB(-,Y]P9^D@
M:1Q*$RB:+IW:J;",O<,SD:9;5=%LMDFZS963Q6K[/@P62DX/Z@4A>FR4"]2-
M@-)<*(U":0Q*\RJ:UH'H.,Y4_R[QAF3.T!H?)1.HLNE"K'T$RVPD[+SHG2?V
MO5%W4', 2G.A- JEL8IV*(&),SYZ7GO0F!Q*$RB:KL[:1K#,/D+NZ,;;_,D:
MU4974-2=C3I%=HW/H3072J-0&K-.+9&?K:EM'PL5:F- :0)%TX5:.QF6V<JH
MJM%4O97*9-VH3:A- :6Y4!J%TM@K%WY$ODL_:>SZ@Y:#0VD"1=/E6EL=EMGK
MN"O'"7R-EC(A#</1KA\360R7:50RU.J TEPHC4)I#$KSH#0.I0D435=W[;58
M9=_Y1XX#LY!]_W,HS872*)3&H#0/2N-0FD#1=-'7CHYEMG1 @RG,43KK_-1'
M:1A. 8U)6\5DT)@>E,:A-(&BZ4/!:P/'-ALX15.#S/U-D/EAD^+,^;LJ#DIS
MH30*I3$HS8/2.)0F4#1=P;5I9%L?WIRPD3[('$ISH30*I3$HS8/2.)0F4#1=
M]+6W99N]K;<9%&9H9UDC:2Z41J$T!J5Y%>TU@\(^-02;# I4V70AUDZ9;7;*
MM/:#:KZ^J^O"'*NS/J$&&I1&H30&I7E0&H?2!(JFJ[VVX^SAQ[<UH.X=E.9"
M:11*8U":!Z5Q*$V@:+KH:Y?/-KM\;VQK0,T^*,V%TBB4QJ T#TKC]JD1.9Y.
MCALD/\+JLVNKSS8[3O^63S(DSE']O IDXB>+5>/X"3.QLU2AWA^41J$T!J5Y
M4!J'T@2*IFNZ]@/MR<<W.Z V(93F0FD42F-0F@>E<2A-H&BZZ&N;T'[M-UGO
M^L&?F=Y9W],&U^+D)W_0F!1*8U":!Z5Q*$V@:+IN:Z?/-CM]N[%&C:*$VG=0
MF@NE42B-06D>E,:A-(&BZ3/TU':@,_CPEH8#=1"A-!=*HU :@](\*(U#:0)%
MTT5?.XB.^6=G;^O@,$,[RQKJ$4)I%$IC%>V54??0F!Q*$RB:+M?:^W/,WE_'
M4?=F6F>=0DT_*(U":<PY]=^:1MU#@W(H3:!HNE /YOLS>X.W>B6Z<P=-HXW,
MQ,YBQ<[HAYW2#SNG'W92/^RL?MAI_7Z$ ^C4#J#S\0Z@ W4 H3072J-0&H/2
M/"B-0VD"1=-%7SN SH]P ,W0SK*&.H!0&H72F-,P ^)D8@^/&QY0:P]*$RB:
MKM?: W3,'N"[!B&9V9UE"W4#H30*I3$HS8/2.)0F4#1=W;4;Z'R\&^A W4 H
MS872*)3&H#0/2N-0FD#1=-'7;J!C=@/K&;47\7H=1_N%%U33Q+\/96$-[B;Z
M:3NIMCEF9]5/3SH,C@U":$ *I3$HS8/2.)0F4#1=RK5!Z)@-PM:M$Z5=DYEH
M#M-9O5 S$4JC4!J#TCPHC4-I D73UT"HS<3AQYN)0ZB9"*6Y4!J%TAB4YD%I
M'$H3*)HN^MI,'+XRAZ76/,E;)?G*"NW7^8"ZBL.&^2B/U_B 6H50&H/2/"B-
M0VD"1=-%6UN*0[.EV*5)\JJ'8X[56<)0PQ%*HU :@](\*(U#:0)%T]5>^Y+#
MCU^(; @U+J$T%TJC4!J#TCPHC4-I D7317^P(IG1(WIWNP3J458T8[L$:CQ"
M:0Q*\Z T#J4)%*T4;?]@4=:U3!Z+%7U34HQFRH,<'-VO&GQ=K)5[=/S&NIA;
M#<==ZX(V'6?6!2_7"J[#EDL7_^(GCT&4DE ^J"(,SB9*DTFY&G"YD\6;8JG8
M^SC+XG6QN9*^:B?E"=3G#W&<[7;R /LUF6?_!U!+ P04    " !-@6Q8HA+P
M8U8#  !\"@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6RM5MMNVS@0
M_96!MEBTP-:Z^=;4%I!$6W0?B@UBI'TH^L!((XL()6I)VHZ!_?@=2HK65F37
M#WV1>#ES.&>&0W*QD^I)YX@&G@M1ZJ63&U-=N:Y.<BR8'LD*2YK)I"J8H:Y:
MN[I2R-+:J!!NX'E3MV"\=*)%/7:GHH7<&,%+O%.@-T7!U/X&A=PM'=]Y&;CG
MZ]S8 3=:5&R-*S0/U9VBGMNQI+S 4G-9@L)LZ5S[5_'<XFO 5XX[?= &J^11
MRB?;^2M=.IYU" 4FQC(P^FWQ%H6P1.3&/RVGTRUI#0_;+^R?:NVDY9%IO)7B
M&T]-OG3F#J28L8TP]W+W&5L]$\N72*'K+^Q:K.= LM%&%JTQ>5#PLOFSYS8.
M!P;A*8.@-0@N-0A;@_!2@W%K,*XCTTBIXQ SPZ*%DCM0%DULME$'L[8F^;RT
M:5\91;.<[$STC2G%2@,Q*KYE-@?P'E;-'@"9P;6F#5'9%&EXT)@"+\'D"#>"
M)4^P2G(I4,/?-0+N%$]XN88O,D4!M">AI=?P-D;#N-#OB/YE<.$:4F#]<)/6
MVYO&V^"$MS$F(PC]/R#P@A#VR!2\ 1=TSA0.T=V>IUMA-0)O=C%=?)[N>K,F
MNODE="ZEJ<M5T.4JJ/G#4^JY3H34&X4V,QGC"K9,;! *9':4JM'8&<'9(Q?<
M<,K,=TL"W&"A?PS%NUEQ/+RB/7.N=,427#ITJ&A46W2BWW_SI]['H6C_2K+X
M%Y$=13KL(AV>8X\>RA25V-N]7&</*MK9"&\W.H4*53/X;BB>#>^LYK5'[C;R
M1^%DX6X/X_0:%(S"#\>@> @43#O0D:YQIVM\5M<]UT_O,X6T(TJ#%#<#BAD<
M$M(0^=[!^M[("X.>E!.POI@3L/FPG$DG9W)6SI_/%5T?="@)GB'\6Y?<D):&
MQ?</5A^/ICTE#6AR@.FE+3Z'./)_VOD_O<S_K11T]E+)[H?<GPX%+YSV=]5E
ML/BGL",ILT[*[#(I*=_R%,L4]AQ%.B1G]BJ,7D_)3Q'Q.<21__/.__E9_S_]
M?YK: M^UU^(%%3]_5:?>R)_W% V!9OTB&03U9+D'5[U]EWUA:LWI;A:8D17A
M*2:J>>LT'2.K^O9_E(;>$G4SI^<A*@N@^4Q*\]*Q#XKNP1G]!U!+ P04
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M1&(22HW ZM<C69(XUB25Q]\5=%#7J0/;UR_TH&B\:LP#%F3)XF\TDMOKP>4
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M8= JYUF<]TXK(^34:04)\R!A/B0L ()U9)W5LL[>P?%S!CDJ(&$>),R'A 5
ML,ZHL*WFSV'KM66Y.+RL.4MZY9=*?8'#<HCLJ-RJ3[BDZK3*Y%9MPW*+U1$H
MR6+V3/IW8',&IXZ*BM8^:TS<O?.(UU-H-'7WME;0O (H6E?'EJUA&W6\)T(M
MVZ%>M0L54:Z]BEXYC*"3Y8"D>: T'Y060-&Z CN-P,X[6,"K)* &!R3- Z7Y
MH+0 BM8='(VW9!M-BL57-?MINJE/UG2-4B8131(242Q)_(P>59'^L[:9?;+F
MYDQ=]$PP[SU]OSG2!VU! $7K:MDX0K;9$OJY_*L(?:0OOM!9KVJ@?D]%&[<W
M3,MU+&M_8SVNG-]3;J](8"S2[;O&HK'-'LU]V=(#*V'_=@CJSX#2/%":#TH+
MH&A=I1MSR)Z\A^T0U#T"I7F@-!^4%D#1NH.CL9ILLU-SA*O^ZO(*:>@L*UI[
MK;.MD3USQ_N>^M$E?= , RA:5['&=+)?<YU:AOJW8HH>6*Y!C2=0F@=*\T%I
M 12MJV_C/MGOP7ZR0?TG4)H'2O-!:0$4K?NN0N-!.68/ZL@3KYERJKH5K;W0
MCMW)9+;G$GE'EO-!LPN@:%U%&C?),;M)MS35_W'N50'4/@*E>: T'Y060-&Z
MBC;VD?,>[",'U#X"I7F@-!^4%D#1NH.CL8^<_]$^,K-/UMR<J5V80+WROC'0
M!\T_@*)UE6S,(\=L'MV6KPKUZ@1J&('2/%":#TH+H&A=11M+RQF_AX4;U 4#
MI7F@-!^4%D#1NH.C<<$<\SM2_VWA!C6W7LG4X/N_.=(';4$ 12NU'+;>44\(
MWQ3?)A!JVN:I+%_DKI_6WUCX7+RGO_=\:5\%Y?<.&DSY-8A;S#=4S?^8K!72
MNIBJP<C+;Q:4-Y)EQ9OP#TQ*EA276X(CPG4!]?F:,?ERHRNHO]^Q^!=02P,$
M%     @ 38%L6%?)YZR>!   6A0  !D   !X;"]W;W)K<VAE971S+W-H965T
M-3DN>&ULM9A;;]LV%,>_"J$50PLT$B^Z.;,-Q%&[[:%KT&#KLVS1MA!)]$@Z
M3H%]^)&2(EL2I=A9]A+K\C^'YW=('9YP>F#\06PIE> ISPHQL[92[JX=1ZRV
M-(^%S7:T4&_6C.>Q5+=\XX@=IW%2&N69@R'TG3Q."VL^+9_=\?F4[666%O2.
M ['/\YC_6-",'686LIX??$LW6ZD?.//I+M[0>RK_W-UQ=><T7I(TIX5(60$X
M7<^L&W0=H5 ;E(J_4GH0)]= HRP9>] WOR<S"^J(:$974KN(U<\CO:59ICVI
M./ZNG5K-F-KP]/K9^^<27L$L8T%O6?8]3>1V9H462.@ZWF?R&SO\1FL@3_M;
ML4R4?\&AUD(+K/9"LKPV5A'D:5']QD]U(DX,"!XPP+4!/M> U ;D7 .W-G#+
MS%0H91ZB6,;S*6<'P+5:>=,793)+:X6?%GK>[R57;U-E)^?WVYC3JX7*7 )N
M6:Z6DXC+";D"]VJ-)?N, K8&]Y*M'L#7G7XE0%PDX'N9465U\TBY6B'@TQ/E
MJU10<,?3%17@?41EG&;BP]21*E ]G+.J@UI40>&!H! &7U@AMP)\*A*:M!TX
MBK#!Q,^8"SSJ,:(K&Q#T$6"("1 :6H!WP*DO#2'>GN\0G^4P.M\A>LEA*P>D
MF6I2CD &1OACGR\IU[/)JGDT34SEPC6[T$7H6NSB%9U9JLH(RA^I-?_Y)^3#
M7TPI?$MGT1LY:Z7.;5+GCGF??]U+(=6J3XO-1["DF[0HU*5.I=Q2\(/&'+RO
MYND#^&=X"2RJ4;QR%%V1'^?>Q"<H]*;.XVGB##I"7!?#MB[JZTC@N] [^FOA
M>@VN-XK[*X\+_6DG>ZXQ+V/T>C%AY'HN[,1^V]<A"#W8U44&74BP=Z)K,?H-
MHS_*J':--4U?3>GWHKK"(<1AV*$TZ'P\\7$'TB!#"/H(FR&#!C(8A?STM$OY
M:Q&#?DQ$S61 .H@F'70G;G<B#3H<$M\U(X8-8O@"8K7MO!(R[ ?E>I!,4 ?2
MH L)Z:0B,J@0)LB;F!DG#>/D_/)#U>9[<>&9] (+H$]Z +=]G;% 109=IT"U
M0!$\MB-P'+5N,6@UK?$RHZ]$K@=JQ:@FUH=NA]D@U"1NV/U(#4*"?,\/!J87
MG31A:'1K?J&9 N^,@.@M]^HW]1:]E;=V/O$QG_@_[]>K. $[U0^5*T@OI='N
M;5&/&)SN:W:O3!A4Q/:Z9<*@<FT8#JRB8W^'1GN@X6W[4M1JF$D+%7=+A5'5
M_;@BHVHR],$<^S$TWI"-[-Z7PKJ& $._"]M7$3OLS6M?Y=L8#< >NS$TWHX-
M[N*7HGJ]\%P;!5W4O@I!.^RB]E4DL'TRP'KLRM!X6S:RG5]*Z_<Y[*!7_$TJ
MM[O=&563@<X%';LS--Z>_1]E*C LYP!WJ4VJ;C&+#*I6,6M3'QLV--ZQG;?%
M7\H=&LIS[_\J@XK8L,=M4H7=5MPY.73)*=^4AU<"K-B^D-7!1/.T.2"[*8^%
M.L\7^N"L/,PYNJE.W;[$7*T) 3*Z5BZA':B/CE<'6=6-9+OR:&?)I&1Y>;FE
M<4*Y%JCW:\;D\XT>H#E.G/\+4$L#!!0    ( $V!;%@$I2G.9 H  %AV   9
M    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;,V=;V_;.!+&OXK@*Q9=8->6
M2(FRNXF!QN+A%MC>%@WN]L7A7B@VDQBU+9\D)RVP'_XD63$UDD*;QI.%^Z*Q
M$_)':F8TXCSZ=_6<I%^S1Z5RY]MZM<FN!X]YOOTP&F7S1[6.LV&R59OB+_=)
MNH[SXFOZ,,JVJ8H75:?U:L1<5XS6\7(SF%Y5O_N<3J^27;Y:;M3GU,EVZW6<
M?K]1J^3Y>N -7G[Q9?GPF)>_&$VOMO&#NE7YO[:?T^+;Z$!9+-=JDRV3C9.J
M^^O!1^^##'G9H6KQ[Z5ZSAJ?G7)3[I+D:_GEU\7UP"UGI%9JGI>(N/CQI&9J
MM2I)Q3S^5T,'AS'+CLW/+_2_5QM?;,Q=G*E9LOICN<@?KP?C@;-0]_%NE7])
MGO^AZ@T*2MX\6675_\YSW=8=./-=EB?KNG,Q@_5RL_\9?ZL-T>C V2L=6-V!
MG=J!UQWXJ1W\NH-_:H>@[E!M^FB_[97AHCB/IU=I\NRD9>N"5GZHK%_U+NRU
MW)2!<INGQ5^71;]\>OL8I^KGF\+4"V>6K(OXR^+*@S\[MT50+G8KY23WSFV>
MS+\ZOV_+/V7.[[L\R^/-8KEY<(H?CORFTODRB^^*QG??G2_QYJ'J5?]>.9_3
MY5PY[R.5Q\M5]N/5*"^F7DY@-*^G>;.?)GMEFAYS/B6;_#%SY&:A%A0P*K;Y
ML.'L9<-OF)$8J?G0X=Y/#G,9=[+2#)GSSAG5'WNF.#L=R$X"1J<#O9. \G2@
M>PQ(C,H/T<2K$?AK(RRS^2K)=FGE_LUN?:?2*D*>JQVVB+'X2:5% BIR3)G%
MR@":%WY-BWRQBU?.:GE?]4P: 59-SDGJT/M/.:2SS-4Z^V]?&.WGY_?/K\RZ
M'[)M/%?7@R*M9BI]4H/I#W_SA/M+G\.1L @)DR 8<;)_<+)OHD__N7=K,PF\
MWT?0C\Z?KP?GS9X:5-3R^/4T#5W!BW]7HZ>FU;OM@HG@WCB@[:*>=IS[/G-I
M.]EMQT/ANX'F$3,$!S,$1C/\\1+2'^N0_G((Z5DCI'\K0_K]=Q6G_7G// AS
MJIY.Z*SWZ4\XB_A[;W8R@FR#%0F3(!CQDCAX2=AYJ7U,FL<+9UN$<Q6WO1[:
M#Q VXH<-0]8*VKY&$Z\5L=U&?!BTPE]V&_E#=]P?J^'!"N$INVSS.'W2+AMV
M=S&73X3KM[:^VZ[<#_UQRTI1MQWW1"#"2<L&QJTY,V+&!UN-WSIBQCW!T$Y?
MLVXC/G3;$=/7J&U5:=R>,ZTU.5AK8K36.W<8^,5B\9TW++W8M86QN^T!&0F+
MD# )@A$?>*Y>Q+L7ONZJ)PCR,Y0606D21:.N;M1KWINLOFIL,_<RUPM\M[5<
MFIG'M[8]DB91-&I[IFW/_HHEWY%1>+WF&[^L^8KB][5%GQEE[2PD3:)HU%FZ
M%/6,11#B.%Z/T#S\%H>Y]H'</ ]K'T#K1!2-^D!7BMY)I:+UNM/KUFR>.V:"
M3=JV-XYO;7LD3:)HU/:Z//4LZ],SXC_HB7_AM7T K3RA-(FB41_HXM,S5Y]D
M=5Q$_*?B8+'>K7MM;219+Z"0M A*DR@:]8DNA;WPTM?*H/*V=C62%D%I$D6C
MKM:5O&<NY0\9;WMRQML#)R3C>6VYPSRLM<F1-(FB49-K.<"ST /*C!=_>S7C
M0:4!*"V"TB2*1D]T:76 7;HZP*#J )0606D21:.NUNH ,ZL#]AFO!HJF+M!*
M=^8QK>T-5010-&IOK0@P<ZU>I+FQ6Z:[O7;;8UYD23V#TB(H3:)HU!.ZW&>7
M?NJ90<\]0VD1E"91-.IJK2JPMSD!S7I4!29<(=KK._/XUK:'J@HH&K6]5A78
M7W+6^\@H+Z>]_1<)E/FO2J!FE+6SH/(#BD:=I>4']N8GOUG?B6W6ED#-\[#V
M 51N0-&H#[3<P-[FU#OKGBOW7,$GD_;Y&O/XUK:'UO\H&K6]KO_9FY_*9WWG
M\EG[DB7S/*Q] !4$4#3J RT(L"."0'.%;)9 S23K!114$(#2)(I&+]+4@@"_
M=$& 0P4!*"V"TB2*1EVM!0&.%@1JX(1DO/:%23/SL-8FAVH"*!HUN=8$N(4F
M8)9 S23KW0"J#D!I$D6C/FE<EW[IZ@#'7IF.O30=>VWZ6Z@#7*L#W*P.G)'Q
M_)XU7MA.>%!- $J3*!JUN-8$N+E:+Q,=VR>\LCKI,3"RJ)Y!:1&4)E$TZ@E=
M\'-QZ6D.>AD#E!9!:1)%HZ[6N@(_25>P%D%Y5U>8A&.W<Q>.>7AKTT-E!12-
MFE[+"MQ25CA/ STRBE]KH-Y> S7<^6,&6;L*JCZ@:-156GW@9O4!H #5([16
M!^/V[@)5&Z TB:+1NP6UVN ;2]RS%= :2^X6$KXGVN*S>7A;TT-I$D6CIM?5
MOV^N_@'A7X_0NIFI[0*H&@"E212-ND"K ?X1-:"Y.#;KGV:2[=H)2HN@-(FB
M49]H-<"_=#7 AZH!4%H$I4D4C;JZ<:\Z6@VH@53_#-OZIWE8:Y-#Y0 4C9I<
MRP&^A1Q@UC_-).O= "H,0&D21:,^T<* ?^G"@ \5!J"T"$J3*!IUM18&?+,P
M<$;&"SM+/#[T.AD/*@A :1)%HR;7@H!O+M7+3.>5&2\<^KU7@9K[6P<_M-Z'
MTB2*1CVAZWU_<NEY#GH1 Y0606D21:-/W]&R0G"2K& M@ 9=68$)$82B?6^I
M>7Q;VT-I$D6CMM>Z0F"I*YSY["/S*%ZE@#JBO@BT;_\P$ZQ]!!4>4#3J(RT\
M!)8/*[#7?NH1Z,* MV\/,<_#V@=0H0%%HS[00D-@?@;!N=)GC24YBH\#WGY8
MU,P\OK7MH94_BD9MKRO_P%SY(^*_>V% $?]M%T"5 "A-HFC4!8TGY!U5 O2Z
MV*Q]FDFVRR8H+8+2)(I&?:*5@.#2E8  J@1 :1&4)E$TZFJM! 1H): &3DC"
M\SH'?*@2 *5)%(V:7"L!@8428-8^S23KW0"J"4!I$D6C/M&:0'#IFD  U02@
MM A*DR@:?=:KU@2$61.PSW@UL'G[>_MN4/.8MO:&TB2*1NVM=0!AKM#+-%>=
MZ@G84/!>^R)+ZAF4%D%I$D6CKM#EOF 7GN4$]/(%*"V"TB2*1EVM505QDJI@
MK7R*KJK@^=P7[4O=S<-;FQXJ*J!HU/1:5!"6HL)YPN>144R*I[FKM7.@<@.*
M1IVCY0;QYD\\%-TG'DZ&WH3\:^\M4*T!2I,H&G5(X]G[YN</G"M_UMCCB0I:
M^T-I$D6CIM>UOS#7_HA]H7M9P-%] :H,0&D21:,.T<J .*(,D*6R60PUHZQ7
M4E!I $J3*!IUBI8&Q*5+ P(J#4!I$90F433Z A0M#81H:: &-L50OWLCO'E8
M6Y-#:1)%HR;7ZD!HHPZ8U5 SRG8_@-(B*$VB:-0I6B<(+UTG"*$Z 90606D2
M1:.NUCI!:-8)SDAY/2\\$)U75,W,XUK;'"H0H&A[FX\:;]9<J_2A>J5I5NP0
MNTV^?\GFX;>'UZ9^K%X6.M+-]^]<_12G#\MB]UBI^Z*K.PR+\B;=O\9T_R5/
MMM5[.N^2/$_6U<='%2]46C8H_GZ?)/G+EW* P\MDI_\'4$L#!!0    ( $V!
M;%BZ%7]V3@,  #$*   9    >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;*U6
MWV_3,!#^5ZR $)/8\JN_-MI(;<,$#XAI$_" >'"32VO-B8/MMJO$'\_924-3
MLJX/O+2V\]WG^^YLWXVW0CZJ%8 F3SDOU,19:5W>N*Y*5I!3=25**/!+)F1.
M-4[ETE6E!)I:HYR[@><-W)RRPHG&=NU.1F.QUIP5<">)6N<YE;L9<+&=.+ZS
M7[AGRY4V"VXT+ND2'D!_+>\DSMR&)64Y%(J)@DC()L[4OXE'!F\!WQALU<&8
M&"4+(1[-Y%,Z<3SC$'!(M&&@^+>!.7!NB-"-7S6GTVQI# _'>_9;JQVU+*B"
MN>#?6:I7$V?DD!0RNN;Z7FP_0JVG;_@2P97])=L:ZSDD62LM\MH8/<A94?W3
MISH.!P;!\!F#H#8(SC4(:X/P7(->;="SD:FDV#C$5--H+,662(-&-C.PP;36
M*)\5)NT/6N)7AG8Z>EA1"9<SC%Q*YB+'TZ2H3<@EB9E*N%!K">2[#1]"IAN0
M>!K(5.$Y*0U0$5JDY)8R2;Y1O@8B,O*E_O(V!DT95Q=C5Z.O9D<WJ?V:57X%
MS_CE!^2S*/1*D0]%"FF;P$61C=)@KW06G&2,(;DBH?^.!%X0DODT)F]?7Y =
M4-GAW?Q\KN EKOA\+O\$5TMTV*0WM.3A<^1_<XAYJ9*]L,F^HSN\O9I,I:3%
M$LQ8D1_3A=(2[^+/KHQ56_6ZMS+OTXTJ:0(3!Q\@!7(#3O3FE3_PWG<%^'^2
MQ?^)K!7B7A/BWBGVZ)ZIQ\M, A!6:$!^3235T!7 BLBO3H)YD#>1=^7U_+&[
M.0Q--RSLM6%Q-\P;-K"6G'XCIW]2SH>G$I]D/""<94!^/W>H9Q5+_V#S\$C&
MBXCX%*+E_*!Q?G">\QO!\1GC3.^Z?*](1JW #8,C][M UX,C!8-_<^!?^5Z_
M6\:PD3$\3T;*-BP%?%]W#'C:)67XKY='.EY$Q*<0+?]'C?^CD_XWY8+6Y2(S
MY6&S+P]B7QX2FI(2L DQ[](%'K;771*KO8;M$!]GJPL4'-^8+M#U]9%6]Z"8
MYB"7MBE1)!'K0E?5IEEM^IZI+?='ZS/LAZKVY2]-U4Q]IG+),  <,J3$LX=7
M0%8-2C71HK0E>R$T-@!VN,*>#J0!X/=,"+V?F V:+C'Z U!+ P04    " !-
M@6Q8?V6FD)P#  "B"P  &0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6RM
M5M]OVS80_E<(K1@2((YD2?Z5V0)BN]OZT#9(L/5AV ,MG2VB$NF2E-T ^^-[
MI!3-EF7%!?)BD]1W'^^[(X\WW0OY5:4 FGS/,ZYF3JKU]LYU59Q"3M6MV +'
M+VLA<ZIQ*C>NVDJ@B37*,]?WO*&;4\:=:&K7'F0T%87.&(<'2521YU0^SR$3
M^YG3=UX6'MDFU6;!C:9;NH$GT']M'R3.W)HE83EPQ00G$M8SY[Y_MYP8O 7\
MS6"O#L;$*%D)\=5,/B0SQS,.00:Q-@P4_W:P@"PS1.C&MXK3J;<TAH?C%_;?
MK7;4LJ(*%B+[PA*=SIRQ0Q)8TR+3CV+_)U1Z!H8O%IFROV1?83V'Q(72(J^,
MT8.<\?*??J_B<&#@3\X8^)6!WS3HGS$(*H/@4H.P,@AM9$HI-@Y+JFDTE6)/
MI$$CFQG88%IKE,^X2?N3EOB5H9V.GE(JH3?'R"5D(7(\38K:A/3($QZQI,B
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MH;'CLL,4FVB0!H#?UT+HEXG9H&[+HQ]02P,$%     @ 38%L6-,S#FH+ P
MU@<  !D   !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULC55;;YLP%/XK%INF
M5EH"(<VE78*4M)NVATI5HZX/TQX<. 2KQF:V(8VT'[]C0UBZDJPOX-OY+L?V
M\6PKU9/.  QYSKG0<R\SIKCR?1UGD%/=EP4(G$FERJG!KMKXNE! $Q>4<S\,
M@K&?4R:\:.;&[E0TDZ7A3,"=(KK,<ZIV2^!R._<&WG[@GFTR8P?\:%;0#:S
M/!1W"GM^BY*P'(1F4A %Z=Q;#*Z6EW:]6_"=P58?M(EULI;RR7:^)7,OL(*
M0VPL L5?!=? N05"&;\:3*^EM(&'[3WZ%^<=O:RIAFO)'UEBLKDW]4@"*2VY
MN9?;K]#X&5F\6'+MOF3;K T\$I?:R+P)1@4Y$_6?/C=Y. @8'@L(FX#0Z:Z)
MG,H;:F@T4W)+E%V-:+;AK+IH%,>$W92543C+,,Y$JXPJZ"W15T*N98Y[K:E+
M5X^L\  D)0<BTY=3CU0I*HPFC\XS1BXJ4+B%9*%Q<PN[2).S&S"4<7V.4)WA
M,]^@ 2O#CQNQRUIL>$3L("2W4IA,D\\B@>0E@(_.6_OAWOXR/(EX W&?# <?
M21B$0[(#JLA[XA-MLZ)/X _;] X=_O 8/M,QE[I4+HL&5*X)%0F)I4A8G2<<
M=W2]M=N$@N[PS!OBDK0!U_YA80DSD.N?75FK-5QT:[#7^DH7-(:YA_=6@ZK
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M&]GMC&ENLN0\H7$0):F_V9?P_\3114 _G<>CP\390&(T"B-*GQ)=Z_[>.6Y
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MOU]6^/* =@YX7BAE3X8+,+QEZ5]02P,$%     @ 38%L6!8AC@ZU @  ,P<
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MY78Y+SCMT!QT- <G:;;W ?^[3,X%^[/?I0V]!F.PE7F?VRF/'6)Q1RQ^G7Z
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ME:7Q5"\+^A^@=@YTOE+*'@V7H/W#I+\ 4$L#!!0    ( $V!;%B=N7O\:P0
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MKPW4\X0Q^3+0WP?J[T&S[U!+ P04    " !-@6Q8=\<)/7P$   H'   &0
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M65&N!ZCS:\;DZX[^[J'^5F?Q#U!+ P04    " !-@6Q8VUA#97P#  #E"@
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M7LR;)$DO_B%FX@=1#Y6.H,)H/NX@[AS$5QVLLTP<N%:DIM_,%A!\/C!%9/(
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M-4#^OZ-4/%W4#^A/@]?_ 5!+ P04    " !-@6Q8"?J!+A #   9"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6RM5DUOVD 0_2LK-ZI2J8D_,9""
M)<"MVD,DE*3MH>IAL0=LQ=YU=Q<(_[[[85P#AN:0B[V[GO=FWHP]X]&6LF>>
M 0CT4A:$CZU,B.K.MGF208GY+:V R"=+RDHLY):M;%XQP*D&E87M.4YHES@G
M5C329W,6C>A:%#F!.4-\79:8[:90T.W8<JW]P4.^RH0ZL*-1A5?P".)[-6=R
M9S<L:5X"X3DEB,%R;$W<N[BO[+7!CQRVO+5&2LF"TF>U^9:.+4<%! 4D0C%@
M>=O #(I"$<DP_M2<5N-2 =OK/?L7K5UJ66 .,UK\S%.1C:V!A5)8XG4A'NCV
M*]1Z>HHOH0775[0UMJ%GH63-!2UKL(R@S(FYXY<Z#RV &YX!>#7 .P8$9P!^
M#?!?"PAJ0* S8Z3H/,18X&C$Z!8Q92W9U$(G4Z.E_)RHLC\*)I_F$B>B!RBP
M@!3-,1,[],0PX5A7A*/K& 3."_X!W:#9)$;75Q_0%<H)>LKHFF.2\I$M9 B*
MR$YJ=U/CSCOCSO70/24BX^@S22$])+!E[(T ;R]@ZEUDC"&Y1;[[$7F.YW<$
M-'L]W.N QZ^'NQ?4^$TY?,WGG^/+>5)0OF: Z%)^5J8XE2[.K\F""R:K\[LK
M[X8WZ.95S>..5SB!L26[ P>V 2MZ_\X-G4]=.7M+LOB-R [R&33Y#"ZQ1X\9
M9>)& "L1E%5!=P HH:5LFAR;OD-2M  "RUQTOLZ&/M3TJH5NHF#0=T;VIIVN
M#B/?&1P:Q:=&_M =-D8'\GJ-O-Y%>4]26$Z,DDLJ#$NO[;OEVH@XM3F2&5^R
M. @_;,(/_U,=S.!&M>WTL"KPHM;0)24\"<(-AN&1E@ZCT.T=R3DU\OJ.WZVH
MWRCJ7U0T:ZN07_ S[&2W)G* RE$I4 6,4T*@Z%+6/WE!PG!P%/3LU*@W]/PC
M95U,JKL=*+-;0Z,$MM+#E\LZK(DP[;<Y;>;[1(^UH_.IG/MF3/^C,3\-]YBM
M<CE)"EA*2N>V+Y/-S" V&T$K/9H65,A!IY>9_'<!I@SD\R6E8K]1#IJ_H>@O
M4$L#!!0    ( $V!;%A,1F3L.@,  *P3   -    >&PO<W1Y;&5S+GAM;-U8
MT4[;,!3]E<B,":2)M,T(S6@K;960)FT3$CSL#;F-DUIR[,QQ6<O7XQNG:5I\
M$>-A*TM%8]_C<^ZQ?4,,H\JL!;M9,&:"52%D-28+8\I/85C-%ZR@U9DJF;1(
MIG1!C>WJ/*Q*S6A: :D0X:#7B\."<DDF([DLK@I3!7.UE&9,XC84N-O7=$SZ
M\4<2.+FI2MF8W)V\_[54YO)=X.Y''XZ.>G>GE_OQDQHX):%7]/P%HF<]7-=B
MF'2\*UT//[9"CGB,T2X\-)NEUS*A@Y&'7G*'BA$3?];C;E9G.6QV:S+*E-QN
M6D1<P*K3@@7W5(S)E H^TQQ8&2VX6+OP  )S)90.C*T6FZX/D>K!P7W7@T)J
M= HNE:YSNPSN>]8,WP,V/3#(A6@-#H@+3$8E-89I>64[]> Z^ 0*FO;MNK0.
M<TW7_<$YV1+JFTTR4SIENDW3)YO09"18!G8TSQ=P-ZH, 31&%;:1<IHK26L/
M&T;3L+)S)L0-/&4_LQWM5=;9MQ[LFFR;UE#3=#*N _I=-:?=E8U>I1N4_%Z9
M+TL['5GWX;%@UYIE?%7W5UEK %/OX^JT+,7ZL^"Y+)B;_(L33D9TPPL62O,'
MFPU*96X#3)/@GFG#Y]W(;TW+6[8RFW):9;CGP1OT_'?7.6>2:2JZIFWM'_(J
MO]IQ=/&O+->_5?8->STVK\Y#-WG^%DS&AV\R2@[?8W/,.723P[=@\C"W.VP.
M&9V3S,XYIHT&<%X<DQ]P^A3;I,%LR87ALNDM>)HR^>0X8^4-G=D_17;T[?B4
M970IS&T+CLFV_9VE?%DD[:AK6(AFU+;]#:;7C]O#JLW%9<I6+)TV79W/ZF9@
M&S9K<P%A'[FJ+S^"<1SF1P##\F .,(YC87G^I_D,T?DX#/,V]")#E#-$.8[E
M0Z;U!\OCYR3V\L\T2:(HCK$5G4Z]#J;8NL4Q_/C5,&_ P/) IC];:WRW\0IY
MO@ZP/7VN0K"9XI6(S11?:T#\ZP:,)/'O-I8'&-@N8+4#^?UYH*;\G"B"7<6\
M84\PCB0)AD M^FLTCI'5B>'CWQ_L*8FB)/$C@/D=1!&&P-.((Y@#\( A452_
M!_?>1^'F/15N_S\W>0102P,$%     @ 38%L6)>*NQS     $P(   L   !?
M<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^O
MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M1*R)%NH(AF1H4A-=PY7L_G@\PEPQ(I;%I;;0_F$@ ;A:*];RAG"8+4;$NIC
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MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 38%L6)E<G",0!@
MG"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !-@6Q8,89IN6H&  "7'@  &               @($-"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 38%L6-*!SHPY @
MNP4  !@              ("!K0X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( $V!;%CJ=BL7C@4  # 7   8              " @1P1
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !-@6Q8[2+8
M93@%  #Z$P  &               @('@%@  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ 38%L6%"%TJW%"   I5(  !@
M ("!3AP  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( $V!
M;%C'$G-&*P<  "DB   8              " @4DE  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    " !-@6Q8)X6.N7 &  !C#0  &
M        @(&J+   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ 38%L6)&&'\H%!   2PD  !@              ("!4#,  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $V!;%@J7K6(NAD  %%1   8
M              " @8LW  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    " !-@6Q8B;F)38$)  #?&0  &0              @(%[40  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $V!;%AF,1^!S@,
M #L,   9              " @3-;  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ 38%L6+ S%PD] P  Q@<  !D              ("!
M.%\  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !-@6Q8
M-0N6Q& "  "1!0  &0              @(&L8@  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( $V!;%B?QE]"M@0  $ +   9
M      " @4-E  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ 38%L6#<"7G;W"   =18  !D              ("!,&H  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !-@6Q8=A9/GQ((  "=%P
M&0              @(%><P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( $V!;%AJ=LX3&PD  ! 8   9              " @:=[  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 38%L6"=4ZQ?I
M @  6P8  !D              ("!^80  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    " !-@6Q8V\#PXHP#  "N!P  &0
M@($9B   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( $V!
M;%A90;"VS00  ,\*   9              " @=R+  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ 38%L6)PUJ?SD!0  EPT  !D
M         ("!X)   'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    " !-@6Q8R^ EN%$(   H$P  &0              @('[E@  >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $V!;%CH+LT\'P<  +,5
M   9              " @8.?  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ 38%L6#X?:'0' P  U 8  !D              ("!V:8
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !-@6Q8]?;E
MLF@#  #9!P  &0              @($7J@  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( $V!;%B^.6.+P@,  $((   9
M  " @;:M  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M38%L6&6S(O<> P  YP8  !D              ("!K[$  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    " !-@6Q8=200 5\8  !@3@  &0
M            @($$M0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( $V!;%CRMK,&KP,  *,(   9              " @9K-  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 38%L6*@(4(VS P
ML@@  !D              ("!@-$  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    " !-@6Q8+F.M/W,"  " !0  &0              @(%J
MU0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( $V!;%C[
MT4A=7P,   <)   9              " @138  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ 38%L6,0MY5PU!   ZPD  !D
M     ("!JML  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $V!;%A*AML(@0(  &<%   9              "
M@:;V  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ 38%L
M6$*QNY/= @  K 8  !D              ("!7OD  'AL+W=O<FMS:&5E=',O
M<VAE970S.2YX;6Q02P$"% ,4    " !-@6Q8K4"Q RH#  !1!P  &0
M        @(%R_   >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0
M   ( $V!;%CGV@\6BP,  )X'   9              " @=/_  !X;"]W;W)K
M<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 38%L6"W.-TN, @  G 4
M !D              ("!E0,! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q0
M2P$"% ,4    " !-@6Q8-6TR 'H"   .!@  &0              @(%8!@$
M>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( $V!;%B4"@4E
MP (  '\'   9              " @0D) 0!X;"]W;W)K<VAE971S+W-H965T
M-#0N>&UL4$L! A0#%     @ 38%L6$/=IZS7 @  N@D  !D
M ("!  P! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !-
M@6Q8'[T?38D#  "=$P  &0              @($.#P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( $V!;%CT?YCJS@<  +X_   9
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M970U,2YX;6Q02P$"% ,4    " !-@6Q8=#V4A90$   K&0  &0
M    @($2* $ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (
M $V!;%@,RLN,]0(  ),*   9              " @=TL 0!X;"]W;W)K<VAE
M971S+W-H965T-3,N>&UL4$L! A0#%     @ 38%L6*1<#M,H"@  GWD  !D
M             ("!"3 ! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"
M% ,4    " !-@6Q8HA+P8U8#  !\"@  &0              @(%H.@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $V!;%A<??S)S08
M ',R   9              " @?4] 0!X;"]W;W)K<VAE971S+W-H965T-38N
M>&UL4$L! A0#%     @ 38%L6/G8W<R+$P  FT(! !D              ("!
M^40! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !-@6Q8
MPH2^54 &  #K,0  &0              @(&[6 $ >&PO=V]R:W-H965T<R]S
M:&5E=#4X+GAM;%!+ 0(4 Q0    ( $V!;%A7R>>LG@0  %H4   9
M      " @3)? 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%
M  @ 38%L6 2E*<YD"@  6'8  !D              ("!!V0! 'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " !-@6Q8NA5_=DX#   Q"@
M&0              @(&B;@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+
M 0(4 Q0    ( $V!;%A_9::0G ,  *(+   9              " @2=R 0!X
M;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ 38%L6-,S#FH+
M P  U@<  !D              ("!^G4! 'AL+W=O<FMS:&5E=',O<VAE970V
M,RYX;6Q02P$"% ,4    " !-@6Q8GK6,S(<"  "L!@  &0
M@($\>0$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    ( $V!
M;%C-Z"1M-@(  -<$   9              " @?I[ 0!X;"]W;W)K<VAE971S
M+W-H965T-C4N>&UL4$L! A0#%     @ 38%L6!8AC@ZU @  ,P<  !D
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M=#<P+GAM;%!+ 0(4 Q0    ( $V!;%A13#3>[P(  .<*   9
M  " @5.1 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @
M38%L6'\:V@OO P  M!0  !D              ("!>90! 'AL+W=O<FMS:&5E
M=',O<VAE970W,BYX;6Q02P$"% ,4    " !-@6Q8JX?54JT$  "W(P  &0
M            @(&?F $ >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4
M Q0    ( $V!;%C;6$-E? ,  .4*   9              " @8.= 0!X;"]W
M;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#%     @ 38%L6 ><!$.9 @
M>@<  !D              ("!-J$! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX
M;6Q02P$"% ,4    " !-@6Q83>_MCC@"  !$!0  &0              @($&
MI $ >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( $V!;%CN
M:?9PF 4  !D>   9              " @76F 0!X;"]W;W)K<VAE971S+W-H
M965T-S<N>&UL4$L! A0#%     @ 38%L6 GZ@2X0 P  &0D  !D
M     ("!1*P! 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"% ,4
M" !-@6Q83$9D[#H#  "L$P  #0              @ &+KP$ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( $V!;%B7BKL<P    !,"   +              "
M ?"R 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( $V!;%A4+"(CZ 4  $PS   /
M              "  =FS 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !-
M@6Q8>@0#75P"   A+@  &@              @ 'NN0$ >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !-@6Q8+B@*V!4"  #\+   $P
M            @ &"O $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5@!6
+ )$7  #(O@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>238</ContextCount>
  <ElementCount>300</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/NatureofOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/BasisofPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies</Role>
      <ShortName>Summary of Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Significant Judgments, Estimates and Assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions</Role>
      <ShortName>Significant Judgments, Estimates and Assumptions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Other Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities</Role>
      <ShortName>Other Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Warrant Derivative</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivative</Role>
      <ShortName>Warrant Derivative</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Contract Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiability</Role>
      <ShortName>Contract Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Capital Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</Role>
      <ShortName>Capital Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Additional Cash Flow Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</Role>
      <ShortName>Additional Cash Flow Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Economic Dependence</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependence</Role>
      <ShortName>Economic Dependence</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Components of Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpenses</Role>
      <ShortName>Components of Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Summary of Material Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Material Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Summary of Material Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables</Role>
      <ShortName>Summary of Material Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipment</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Warrant Derivative (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables</Role>
      <ShortName>Warrant Derivative (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/WarrantDerivative</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Share Capital (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalTables</Role>
      <ShortName>Share Capital (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareCapital</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ShareBasedCompensation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Contract Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityTables</Role>
      <ShortName>Contract Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ContractLiability</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Capital Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</Role>
      <ShortName>Capital Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosures</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/FinancialInstruments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Additional Cash Flow Disclosures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables</Role>
      <ShortName>Additional Cash Flow Disclosures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Components of Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables</Role>
      <ShortName>Components of Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ComponentsofExpenses</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails</Role>
      <ShortName>Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/NatureofOperations</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Summary of Material Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Material Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails</Role>
      <ShortName>Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Other Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails</Role>
      <ShortName>Other Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Right-of-use Assets and Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails</Role>
      <ShortName>Leases - Total Undiscounted Lease Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails</Role>
      <ShortName>Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Warrant Derivative - Warrant Derivative Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails</Role>
      <ShortName>Warrant Derivative - Warrant Derivative Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Warrant Derivative - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails</Role>
      <ShortName>Warrant Derivative - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails</Role>
      <ShortName>Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Share Capital - Schedule of Share Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails</Role>
      <ShortName>Share Capital - Schedule of Share Capital Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Share-Based Compensation - Schedule of Compensation Warrants Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Schedule of Compensation Warrants Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails</Role>
      <ShortName>Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/LossPerCommonShare</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Contract Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails</Role>
      <ShortName>Contract Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails</Role>
      <ShortName>Contract Liability - Schedule of Contract Revenues and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Capital Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails</Role>
      <ShortName>Capital Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails</Role>
      <ShortName>Financial Instruments - Schedule of Balances in Foreign Currencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails</Role>
      <ShortName>Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - Economic Dependence (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails</Role>
      <ShortName>Economic Dependence (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/EconomicDependence</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - Components of Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails</Role>
      <ShortName>Components of Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="oncyf-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" isDefinitelyFs="true" isIfrs="true" original="oncyf-20231231.htm">oncyf-20231231.htm</File>
    <File>oncyf-20231231.xsd</File>
    <File>oncyf-20231231_cal.xml</File>
    <File>oncyf-20231231_def.xml</File>
    <File>oncyf-20231231_lab.xml</File>
    <File>oncyf-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>oncyf-20231231_g1.jpg</File>
    <File>oncyf-20231231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="45">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="691">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "oncyf-20231231.htm": {
   "nsprefix": "oncyf",
   "nsuri": "http://www.oncolyticsbiotech.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "oncyf-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "oncyf-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "oncyf-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "oncyf-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "oncyf-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "oncyf-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 222,
   "keyCustom": 78,
   "axisStandard": 17,
   "axisCustom": 3,
   "memberStandard": 30,
   "memberCustom": 28,
   "hidden": {
    "total": 7,
    "http://xbrl.sec.gov/dei/2023": 6,
    "http://www.oncolyticsbiotech.com/20231231": 1
   },
   "contextCount": 238,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 479,
   "unitCount": 10,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 691,
    "http://xbrl.sec.gov/dei/2023": 45
   },
   "report": {
    "R1": {
     "role": "http://www.oncolyticsbiotech.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.oncolyticsbiotech.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorFirmId",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
     "longName": "0000003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentFinancialAssetsAvailableforsale",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ResearchAndDevelopmentExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLossFromOperatingActivities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "ifrs-full:Equity",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "ifrs-full:Equity",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.oncolyticsbiotech.com/role/NatureofOperations",
     "longName": "0000008 - Disclosure - Nature of Operations",
     "shortName": "Nature of Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.oncolyticsbiotech.com/role/BasisofPresentation",
     "longName": "0000009 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies",
     "longName": "0000010 - Disclosure - Summary of Material Accounting Policies",
     "shortName": "Summary of Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions",
     "longName": "0000011 - Disclosure - Significant Judgments, Estimates and Assumptions",
     "shortName": "Significant Judgments, Estimates and Assumptions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities",
     "longName": "0000012 - Disclosure - Other Assets and Liabilities",
     "shortName": "Other Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfOtherLiabilitiesExplanatory",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipment",
     "longName": "0000013 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities",
     "longName": "0000014 - Disclosure - Accounts Payable and Accrued Liabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.oncolyticsbiotech.com/role/Leases",
     "longName": "0000015 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfLeasesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivative",
     "longName": "0000016 - Disclosure - Warrant Derivative",
     "shortName": "Warrant Derivative",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapital",
     "longName": "0000017 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensation",
     "longName": "0000018 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.oncolyticsbiotech.com/role/LossPerCommonShare",
     "longName": "0000019 - Disclosure - Loss Per Common Share",
     "shortName": "Loss Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiability",
     "longName": "0000020 - Disclosure - Contract Liability",
     "shortName": "Contract Liability",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies",
     "longName": "0000021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxes",
     "longName": "0000022 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosures",
     "longName": "0000023 - Disclosure - Capital Disclosures",
     "shortName": "Capital Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstruments",
     "longName": "0000024 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures",
     "longName": "0000025 - Disclosure - Additional Cash Flow Disclosures",
     "shortName": "Additional Cash Flow Disclosures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependence",
     "longName": "0000027 - Disclosure - Economic Dependence",
     "shortName": "Economic Dependence",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DisclosureOfEconomicDependenceTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpenses",
     "longName": "0000028 - Disclosure - Components of Expenses",
     "shortName": "Components of Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions",
     "longName": "0000029 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Summary of Material Accounting Policies (Policies)",
     "shortName": "Summary of Material Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Summary of Material Accounting Policies (Tables)",
     "shortName": "Summary of Material Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
     "longName": "9954473 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "longName": "9954474 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTables",
     "longName": "9954475 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables",
     "longName": "9954476 - Disclosure - Warrant Derivative (Tables)",
     "shortName": "Warrant Derivative (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalTables",
     "longName": "9954477 - Disclosure - Share Capital (Tables)",
     "shortName": "Share Capital (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables",
     "longName": "9954478 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityTables",
     "longName": "9954479 - Disclosure - Contract Liability (Tables)",
     "shortName": "Contract Liability (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables",
     "longName": "9954480 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables",
     "longName": "9954481 - Disclosure - Capital Disclosures (Tables)",
     "shortName": "Capital Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables",
     "longName": "9954482 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables",
     "longName": "9954483 - Disclosure - Additional Cash Flow Disclosures (Tables)",
     "shortName": "Additional Cash Flow Disclosures (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:CashFlowOperatingCapital1TableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables",
     "longName": "9954484 - Disclosure - Components of Expenses (Tables)",
     "shortName": "Components of Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables",
     "longName": "9954485 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails",
     "longName": "9954486 - Disclosure - Nature of Operations (Details)",
     "shortName": "Nature of Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:RetainedEarnings",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:CashAndCashEquivalentsAndCurrentInvestments",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails",
     "longName": "9954487 - Disclosure - Summary of Material Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Material Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails",
     "longName": "9954488 - Disclosure - Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)",
     "shortName": "Summary of Material Accounting Policies - Schedule of Depreciation Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-52",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-52",
      "name": "oncyf:PropertyPlantandEquipmentAnnualDepreciationRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails",
     "longName": "9954489 - Disclosure - Other Assets and Liabilities (Details)",
     "shortName": "Other Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentPrepaidExpenses",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
     "longName": "9954490 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-62",
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "longName": "9954491 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
     "longName": "9954492 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
     "longName": "9954493 - Disclosure - Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "shortName": "Leases - Right-of-use Assets and Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:RightofuseAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ForeignExchangeImpactRightofUseAssets",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails",
     "longName": "9954494 - Disclosure - Leases - Total Undiscounted Lease Liability (Details)",
     "shortName": "Leases - Total Undiscounted Lease Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:GrossLeaseLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
     "longName": "9954495 - Disclosure - Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)",
     "shortName": "Warrant Derivative - Reconciliation of Change in Fair Value of Warrant Derivative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "oncyf:NumberOfWarrantsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-122",
      "name": "oncyf:WarrantLiabilityAmortizedDiscount",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails",
     "longName": "9954496 - Disclosure - Warrant Derivative - Warrant Derivative Outstanding (Details)",
     "shortName": "Warrant Derivative - Warrant Derivative Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-125",
      "name": "oncyf:WarrantExercisePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "oncyf:NumberOfWarrantsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
     "longName": "9954497 - Disclosure - Warrant Derivative - Narrative (Details)",
     "shortName": "Warrant Derivative - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-125",
      "name": "oncyf:NumberOfWarrantsAndSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-125",
      "name": "oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails",
     "longName": "9954498 - Disclosure - Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)",
     "shortName": "Warrant Derivative - Summary of Assumptions Used in the Black Scholes Option Pricing Model for Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-135",
      "name": "oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-135",
      "name": "oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
     "longName": "9954499 - Disclosure - Share Capital - Schedule of Share Capital (Details)",
     "shortName": "Share Capital - Schedule of Share Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:Equity",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:DisclosureOfCapitalComponentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
     "longName": "9954500 - Disclosure - Share Capital - Schedule of Share Capital Footnotes (Details)",
     "shortName": "Share Capital - Schedule of Share Capital Footnotes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-128",
      "name": "oncyf:ProceedsFromIssueOfUnitsGross",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "oncyf:ProceedsfromWarrantExercises1",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
     "longName": "9954501 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails",
     "longName": "9954502 - Disclosure - Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "shortName": "Share-Based Compensation - Schedule of Stock Options and Weighted Average Exercise Prices (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
     "longName": "9954503 - Disclosure - Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "shortName": "Share-Based Compensation - Schedule of Stock Options Outstanding and Exercisable by Range of Exercise Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:NumberOfOutstandingShareOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails",
     "longName": "9954504 - Disclosure - Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "shortName": "Share-Based Compensation - Disclosure Weighted Average Assumptions and Fair Value of Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
     "longName": "9954505 - Disclosure - Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)",
     "shortName": "Share-Based Compensation - Schedule of Number of Other Equity Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-188",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-190",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
     "longName": "9954506 - Disclosure - Share-Based Compensation - Schedule of Compensation Warrants Weighted Average Assumptions (Details)",
     "shortName": "Share-Based Compensation - Schedule of Compensation Warrants Weighted Average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-164",
      "name": "oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails",
     "longName": "9954507 - Disclosure - Loss Per Common Share (Details)",
     "shortName": "Loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:WeightedAverageShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R65": {
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails",
     "longName": "9954508 - Disclosure - Contract Liability - Narrative (Details)",
     "shortName": "Contract Liability - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ContractLiabilityRecognitionPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails",
     "longName": "9954509 - Disclosure - Contract Liability - Schedule of Contract Revenues and Liabilities (Details)",
     "shortName": "Contract Liability - Schedule of Contract Revenues and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "ifrs-full:ContractLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails",
     "longName": "9954510 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:PurchaseObligation1",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "oncyf:PurchaseObligation1",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "longName": "9954511 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AccountingProfit",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954512 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-195",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-195",
      "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails",
     "longName": "9954513 - Disclosure - Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
     "longName": "9954514 - Disclosure - Capital Disclosures (Details)",
     "shortName": "Capital Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-223",
      "name": "oncyf:EquityAuthorized",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
     "longName": "9954515 - Disclosure - Financial Instruments - Narrative (Details)",
     "shortName": "Financial Instruments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CurrentDerivativeFinancialLiabilities",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-226",
      "name": "oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
     "longName": "9954516 - Disclosure - Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "shortName": "Financial Instruments - Schedule of Balances in Foreign Currencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-227",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
     "longName": "9954517 - Disclosure - Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "shortName": "Additional Cash Flow Disclosures - Net Change In Non-Cash Working Capital (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:CashFlowOperatingCapital1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails",
     "longName": "9954518 - Disclosure - Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "shortName": "Additional Cash Flow Disclosures - Other Cash Flow Disclosures (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ProceedsfromInterestReceived",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "oncyf:ProceedsfromInterestReceived",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails",
     "longName": "9954519 - Disclosure - Economic Dependence (Details)",
     "shortName": "Economic Dependence (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-232",
      "name": "oncyf:ConcentrationRiskNumber",
      "unitRef": "manufacturer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-232",
      "name": "oncyf:ConcentrationRiskNumber",
      "unitRef": "manufacturer",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
     "longName": "9954520 - Disclosure - Components of Expenses (Details)",
     "shortName": "Components of Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-233",
      "name": "oncyf:ClinicalTrialExpense",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "oncyf:OtherExpensesAndAdjustmentsTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails",
     "longName": "9954521 - Disclosure - Related Party Transactions (Details)",
     "shortName": "Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
      "unitRef": "cad",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oncyf-20231231.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "oncyf_A2020SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "A2020SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 United States ATM",
        "label": "2020 Shares Under At-the-market Agreement, United States [Member]",
        "documentation": "2020 Shares Under At-the-market Agreement, United States"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_A2021SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "A2021SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 United States ATM",
        "label": "2021 Shares Under At-the-market Agreement, United States [Member]",
        "documentation": "2021 Shares Under At-the-market Agreement, United States"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_A2022SharesUnderAtTheMarketAgreementUnitedStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "A2022SharesUnderAtTheMarketAgreementUnitedStatesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 United States ATM",
        "label": "2022 Shares Under At-the-market Agreement, United States [Member]",
        "documentation": "2022 Shares Under At-the-market Agreement, United States"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AccountingProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccountingProfit",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss before income taxes",
        "label": "Accounting profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r28",
      "r29"
     ]
    },
    "ifrs-full_AccrualsClassifiedAsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccrualsClassifiedAsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accruals classified as current"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accruals classified as current. [Refer: Accruals]"
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "ifrs-full_AccumulatedDepreciationAndAmortisationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedDepreciationAndAmortisationMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Accumulated depreciation and amortisation [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r202",
      "r205",
      "r206",
      "r207"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated other comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "Accumulated other comprehensive income [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "oncyf_AdditionalCashFlowDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "AdditionalCashFlowDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Disclosures [Abstract]",
        "documentation": "Additional Cash Flow Disclosures"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdditionalPaidinCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionalPaidinCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributed surplus (note 11)",
        "label": "Additional paid-in capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions, net of foreign exchange impact",
        "label": "Additions other than through business combinations, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_AdditionsToRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdditionsToRightofuseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Additions to right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of additions to right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Address Type [Domain]",
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares (diluted) (shares)",
        "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Adjustments for decrease (increase) in other operating receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation - property and equipment (notes 6, 20)",
        "label": "Adjustments for depreciation and amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "oncyf_AdjustmentsForDepreciationRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "AdjustmentsForDepreciationRightOfUseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation - right-of-use assets (notes 8, 20)",
        "label": "Adjustments For Depreciation, Right-of Use Assets",
        "documentation": "Adjustments For Depreciation, Right-of Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in fair value of warrant derivative (notes 9, 17)",
        "label": "Adjustments for gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherOperatingPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInOtherOperatingPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Adjustments for increase (decrease) in other operating payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in other operating payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Adjustments for increase (decrease) in trade and other payables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense (notes 11, 20, 21)",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized foreign exchange loss (gain)",
        "label": "Adjustments for unrealised foreign exchange losses (gains)"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r166",
      "r211"
     ]
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedTimeBandsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregated time bands",
        "label": "Aggregated time bands [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r89",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108",
      "r114",
      "r133",
      "r159",
      "r175",
      "r178"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All levels of fair value hierarchy",
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r82"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AmortisationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation - property and equipment",
        "label": "Amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of amortisation expense. Amortisation is the systematic allocation of depreciable amounts of intangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_AnalysisOfIncomeAndExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AnalysisOfIncomeAndExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of income and expense [abstract]",
        "label": "Analysis of income and expense [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ApplicableTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ApplicableTaxRate",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory Canadian corporate tax rate",
        "label": "Applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The applicable income tax rate."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r83",
      "r144",
      "r146"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188"
     ]
    },
    "oncyf_AuditorInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "AuditorInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Information [Abstract]",
        "documentation": "Auditor Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188"
     ]
    },
    "country_BB": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "BB",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BARBADOS",
        "label": "BARBADOS"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_BalanceHeldInForeignCurrencyNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "BalanceHeldInForeignCurrencyNet",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balances in foreign currencies",
        "label": "Balance Held In Foreign Currency, Net",
        "documentation": "Balance Held In Foreign Currency, Net"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic loss per common share (cad per share)",
        "label": "Basic earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r108",
      "r124",
      "r168",
      "r169",
      "r215"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Contact",
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r187",
      "r188"
     ]
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CANADA",
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]",
        "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r36",
      "r55",
      "r56",
      "r58",
      "r59",
      "r60",
      "r61",
      "r62",
      "r130",
      "r136",
      "r137"
     ]
    },
    "ifrs-full_CarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CarryingAmountMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount",
        "label": "Carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r36",
      "r56",
      "r58",
      "r60",
      "r61",
      "r130",
      "r136",
      "r137"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r68",
      "r79"
     ]
    },
    "oncyf_CashAndCashEquivalentsAndCurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "CashAndCashEquivalentsAndCurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and current investments",
        "label": "Cash And Cash Equivalents And Current Investments",
        "documentation": "Cash And Cash Equivalents And Current Investments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "oncyf_CashFlowOperatingCapital1TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "CashFlowOperatingCapital1TableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net change in non-cash working capital",
        "label": "Cash Flow, Operating Capital1 [Table Text Block]",
        "documentation": "Cash Flow, Operating Capital1 [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by financing activities",
        "label": "Cash flows from (used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r69"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing Activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash provided by investing activities",
        "label": "Cash flows from (used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r69"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing Activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cash used in operating activities",
        "label": "Cash flows from (used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r166"
     ]
    },
    "ifrs-full_CashOutflowForLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashOutflowForLeases",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of lease liabilities (note 8)",
        "negatedTerseLabel": "Payment of lease liabilities",
        "label": "Cash outflow for leases"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for leases."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "oncyf_ChangeInFairValueWarrantDerivativeRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ChangeInFairValueWarrantDerivativeRollForward",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Warrant Derivative",
        "label": "Change In Fair Value Warrant Derivative [Roll Forward]",
        "documentation": "Change In Fair Value Warrant Derivative"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares issuable per warrant (in shares)",
        "label": "Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1",
        "documentation": "Class Of Warrant Or Right, Number Of Securities Called By Each Warrant Or Right1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ClassOfWarrantOrRightNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in shares)",
        "label": "Class Of Warrant Or Right, Number Of Warrants Exercised",
        "documentation": "Class Of Warrant Or Right, Number Of Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of liabilities [axis]",
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of property, plant and equipment [axis]",
        "label": "Classes of property, plant and equipment [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of other provisions [axis]",
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Classes of share capital [axis]",
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital",
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "oncyf_ClassofWarrantorRightWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ClassofWarrantorRightWarrantsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercised, fair value",
        "label": "Class of Warrant or Right, Warrants Exercised",
        "documentation": "Class of Warrant or Right, Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ClinicalTrialExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ClinicalTrialExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical trial expenses",
        "label": "Clinical Trial Expense",
        "documentation": "Clinical Trial Expense"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ClinicalTrialMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Trial",
        "label": "Clinical Trial [Member]",
        "documentation": "Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BRACELET-1 collaboration agreement",
        "label": "Collaboration Agreement [Member]",
        "documentation": "Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_CommitmentsAndContingencies1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "CommitmentsAndContingencies1",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (note 14)",
        "label": "Commitments And Contingencies1",
        "documentation": "Commitments And Contingencies1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_CommonSharesPerUnit": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "CommonSharesPerUnit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares per unit (in shares)",
        "label": "Common Shares Per Unit",
        "documentation": "Common Shares Per Unit"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_CompensationWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "CompensationWarrantsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Warrants",
        "label": "Compensation Warrants [Member]",
        "documentation": "Compensation Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "terseLabel": "Net loss and other comprehensive income (loss)",
        "label": "Comprehensive income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r23",
      "r73",
      "r75",
      "r78",
      "r167"
     ]
    },
    "ifrs-full_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer equipment",
        "verboseLabel": "Computer Equipment",
        "label": "Computer equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "oncyf_ConcentrationRisk1Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ConcentrationRisk1Table",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk1 [Table]",
        "label": "Concentration Risk1 [Table]",
        "documentation": "Concentration Risk1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ConcentrationRiskNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ConcentrationRiskNumber",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration, number",
        "label": "Concentration Risk, Number",
        "documentation": "Concentration Risk, Number"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ConcentrationRiskType1Axis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ConcentrationRiskType1Axis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type1 [Axis]",
        "label": "Concentration Risk Type1 [Axis]",
        "documentation": "Concentration Risk Type1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ConcentrationRiskType1Domain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ConcentrationRiskType1Domain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type1 [Domain]",
        "label": "Concentration Risk Type1 [Domain]",
        "documentation": "[Domain] for Concentration Risk Type1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ConcentrationRiskType1LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ConcentrationRiskType1LineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type1 [Line Items]",
        "label": "Concentration Risk Type1 [Line Items]",
        "documentation": "[Line Items] for Concentration Risk Type1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelEmailAddress": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelEmailAddress",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Email Address",
        "label": "Contact Personnel Email Address",
        "documentation": "Email address of contact personnel."
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contact Personnel Name",
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ContingenciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ContingenciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies [Abstract]",
        "label": "Contingencies [Abstract]",
        "documentation": "Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ContractLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, beginning of year",
        "periodEndLabel": "Balance, end of year",
        "label": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r87"
     ]
    },
    "oncyf_ContractLiabilityRecognitionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ContractLiabilityRecognitionPeriod",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected recognition period",
        "label": "Contract Liability, Recognition Period",
        "documentation": "Contract Liability, Recognition Period"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CorporateInformationAndStatementOfIFRSComplianceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CorporateInformationAndStatementOfIFRSComplianceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Information And Statement Of IFRS Compliance [Abstract]",
        "label": "Corporate information and statement of IFRS compliance [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_Currency1LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "Currency1LineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency1 [Line Items]",
        "label": "Currency1 [Line Items]",
        "documentation": "[Line Items] for Currency1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_Currency1Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "Currency1Table",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails",
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency1 [Table]",
        "label": "Currency1 [Table]",
        "documentation": "Currency1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrencyRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrencyRiskMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency risk",
        "label": "Currency risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r112",
      "r141"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r76",
      "r167"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant derivative (notes 9, 17)",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "verboseLabel": "Warrant derivative",
        "label": "Current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_CurrentFinancialAssetsAvailableforsale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentFinancialAssetsAvailableforsale",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Current financial assets available-for-sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets available-for-sale. [Refer: Financial assets available-for-sale; Current financial assets]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "label": "Current investments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current investments."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities (note 8)",
        "label": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r77",
      "r167"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepaidExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current prepaid expenses",
        "label": "Current prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses (note 5)",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_CurrentTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current income taxes",
        "label": "Current tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "ifrs-full_DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityScheduleofContractRevenuesandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Decrease through performance obligation being satisfied, contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in contract liabilities resulting from the performance obligation being satisfied. [Refer: Contract liabilities; Performance obligations [member]]"
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized deferred tax asset",
        "label": "Deductible temporary differences for which no deferred tax asset is recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationPropertyPlantAndEquipment",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r35",
      "r38"
     ]
    },
    "ifrs-full_DepreciationRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationRightofuseAssets",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation expense",
        "verboseLabel": "Depreciation - right-of-use assets",
        "label": "Depreciation, right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Description of accounting policy for deferred income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derecognition",
        "label": "Description of accounting policy for derecognition of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the derecognition of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "oncyf_DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents and marketable securities",
        "label": "Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities [Policy Text Block]",
        "documentation": "Description Of Accounting Policy For Determining Components Of Cash And Cash Equivalents And Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Description of accounting policy for earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measurement",
        "label": "Description of accounting policy for fair value measurement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets",
        "label": "Description of accounting policy for financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities",
        "label": "Description of accounting policy for financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation",
        "label": "Description of accounting policy for foreign currency translation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for foreign currency translation."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Description of accounting policy for impairment of financial assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for the impairment of financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Description of accounting policy for leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Description of accounting policy for property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognition",
        "label": "Description of accounting policy for recognition of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development costs",
        "label": "Description of accounting policy for research and development expense [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Description of accounting policy for share-based payment transactions [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]"
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption of New Accounting Standards and Accounting Standards and Interpretations Issued but Not Yet Effective",
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the known or reasonably estimable information relevant to assessing the possible impact that the application of a new IFRS, that has been issued but is not yet effective, will have."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Expected volatility, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfOptionLifeShareOptionsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Option life, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The option life of share options granted."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "label": "Risk free interest rate, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "oncyf_DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of accounts payables and accrued liabilities",
        "label": "Detailed Disclosure Of Trade And Other Payables Explanatory [Table Text Block]",
        "documentation": "Detailed Disclosure Of Trade And Other Payables Explanatory"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted loss per common share (cad per share)",
        "label": "Diluted earnings (loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51"
     ]
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SignificantJudgmentsEstimatesandAssumptions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Judgments, Estimates and Assumptions",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/BasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of Presentation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "oncyf_DisclosureOfCapitalComponentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureOfCapitalComponentsTableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of capital components",
        "label": "Disclosure Of Capital Components [Table Text Block]",
        "documentation": "Disclosure Of Capital Components [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfCashFlowStatementExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCashFlowStatementExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Cash Flow Disclosures",
        "label": "Disclosure of cash flow statement [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for a statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of share capital",
        "label": "Disclosure of classes of share capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [line items]",
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of classes of share capital [table]",
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Disclosure of commitments and contingent liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentTables",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of depreciation rates",
        "verboseLabel": "Schedule of property and equipment",
        "label": "Disclosure of detailed information about property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Common Share",
        "label": "Disclosure of earnings per share [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "oncyf_DisclosureOfEconomicDependenceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureOfEconomicDependenceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Economic Dependence [Abstract]",
        "label": "Disclosure Of Economic Dependence [Abstract]",
        "documentation": "Disclosure Of Economic Dependence [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureOfEconomicDependenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureOfEconomicDependenceTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependence"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Economic Dependence",
        "label": "Disclosure Of Economic Dependence [Text Block]",
        "documentation": "Disclosure Of Economic Dependence [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of Expenses",
        "label": "Disclosure of expenses by nature [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of change in fair value of warrant derivative",
        "label": "Disclosure of fair value measurement of liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of fair value measurement of liabilities [line items]",
        "label": "Disclosure of fair value measurement of liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of fair value measurement of liabilities [table]",
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [abstract]",
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_DisclosureOfFinancialLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant Derivative",
        "label": "Disclosure of financial liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/NatureofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Operations",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Disclosure of income tax [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureOfIndemnificationOfOfficersandDirectorsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Indemnification Of Officers and Directors [Abstract]",
        "label": "Disclosure Of Indemnification Of Officers and Directors [Abstract]",
        "documentation": "Disclosure Of Indemnification Of Officers and Directors [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureOfIndemnificationOfOfficersandDirectorsTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IndemnificationofOfficersandDirectors"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indemnification of Officers and Directors",
        "label": "Disclosure Of Indemnification Of Officers and Directors [Text Block]",
        "documentation": "Disclosure Of Indemnification Of Officers and Directors [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of compensation warrants weighted average assumptions",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, other equity instruments granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure weighted average assumptions and fair value of options",
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_DisclosureOfLeasesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfLeasesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Disclosure of leases [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for leases."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105"
     ]
    },
    "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Material Accounting Policies",
        "label": "Disclosure of material accounting policy information [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure of material accounting policy information applied by the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total undiscounted lease liability",
        "label": "Disclosure of maturity analysis of operating lease payments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [line items]",
        "label": "Disclosure of maturity analysis of operating lease payments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of maturity analysis of operating lease payments [table]",
        "label": "Disclosure of maturity analysis of operating lease payments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of nature and extent of risks arising from financial instruments [table]",
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135"
     ]
    },
    "oncyf_DisclosureOfNotesAndOtherExplanatoryInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "label": "Disclosure Of Notes And Other Explanatory Information [Abstract]",
        "documentation": "Disclosure Of Notes And Other Explanatory Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of number of other equity instruments",
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock options and weighted average exercise prices of share options",
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of weighted average remaining contractual life and outstanding stock options by exercise price",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]",
        "label": "Disclosure of number and weighted average remaining contractual life of outstanding share options [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the number and weighted average remaining contractual life of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosures"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Disclosures",
        "label": "Disclosure of objectives, policies and processes for managing capital [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of information that enables users of financial statements to evaluate the entity's objectives, policies and processes for managing capital."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ifrs-full_DisclosureOfOtherAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherAssetsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets and Liabilities",
        "label": "Disclosure of other assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other assets. [Refer: Other assets]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfOtherLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets and Liabilities",
        "label": "Disclosure of other liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of other liabilities. [Refer: Other liabilities]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]",
        "label": "Disclosure of detailed information about property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Disclosure of property, plant and equipment [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]",
        "label": "Disclosure of detailed information about property, plant and equipment [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]",
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "oncyf_DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Disclosure Of Quantitative Information About Lease Liabilities [Text Block]",
        "documentation": "Disclosure Of Quantitative Information About Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Disclosure of quantitative information about right-of-use assets [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of quantitative information about right-of-use assets. [Refer: Right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [line items]",
        "label": "Disclosure of quantitative information about right-of-use assets [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfQuantitativeInformationAboutRightofuseAssetsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of quantitative information about right-of-use assets [table]",
        "label": "Disclosure of quantitative information about right-of-use assets [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to right-of-use assets."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of stock options outstanding and exercisable by range of exercise price",
        "label": "Disclosure of range of exercise prices of outstanding share options [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the range of exercise prices for outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions",
        "label": "Disclosure of related party [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiability"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Liability",
        "label": "Disclosure of revenue from contracts with customers [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r91"
     ]
    },
    "oncyf_DisclosureOfShareBasedPaymentArrangementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureOfShareBasedPaymentArrangementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Share-based Payment Arrangements [Abstract]",
        "label": "Disclosure of Share-based Payment Arrangements [Abstract]",
        "documentation": "Disclosure Of Share-based Payment Arrangements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Disclosure of share-based payment arrangements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of unrecognized non-capital losses, non-refundable credits and deferred tax assets",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]",
        "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "label": "Disclosure of trade and other payables [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of related party transactions",
        "label": "Disclosure of transactions between related parties [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "oncyf_DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureofShareCapitalReservesAndOtherEquityInterestAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "label": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]",
        "documentation": "Disclosure of Share Capital, Reserves And Other Equity Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofincometaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureofincometaxAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of income tax [Abstract]",
        "label": "Disclosure of income tax [Abstract]",
        "documentation": "Disclosure of income tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofrelatedpartyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureofrelatedpartyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of related party [Abstract]",
        "label": "Disclosure of related party [Abstract]",
        "documentation": "Disclosure of related party [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofrevenuefromcontractswithcustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureofrevenuefromcontractswithcustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of revenue from contracts with customers [Abstract]",
        "label": "Disclosure of revenue from contracts with customers [Abstract]",
        "documentation": "Disclosure of revenue from contracts with customers [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_DisclosureofsharebasedpaymentarrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "DisclosureofsharebasedpaymentarrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of share-based payment arrangement [Abstract]",
        "label": "Disclosure of share-based payment arrangement [Abstract]",
        "documentation": "Disclosure of share-based payment arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Accounting Standard",
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r190"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Registration Statement",
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Shell Company Report",
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r187"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "EUR",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euro",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share [abstract]",
        "label": "Earnings per share [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of foreign exchange on cash and cash equivalents",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66"
     ]
    },
    "ifrs-full_EmployeeBenefitsExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EmployeeBenefitsExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation and benefits expense",
        "label": "Employee benefits expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r26",
      "r150"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Addresses, Address Type [Axis]",
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Equity balance at beginning of period",
        "periodEndLabel": "Equity balance at end of period",
        "terseLabel": "Shareholders' equity",
        "label": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r18",
      "r72",
      "r74",
      "r81",
      "r82",
      "r83"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders' equity",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities And Shareholders\u2019 Equity",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_EquityAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "EquityAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CapitalDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Shelf securities authorized",
        "label": "Equity Authorized",
        "documentation": "Equity Authorized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (cad per share)",
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "oncyf_ExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ExercisePriceRangeFiveMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$7.42 - $52.63",
        "label": "Exercise Price Range Five [Member]",
        "documentation": "Exercise Price Range Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3.91 - $7.41",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$0.54 - $1.79",
        "label": "Exercise Price Range One [Member]",
        "documentation": "Exercise Price Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$3.02 - $3.90",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$1.80 - $3.01",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ExpectedDividendAsPercentageOtherEquityInstrumentsGranted": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ExpectedDividendAsPercentageOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Expected Dividend As Percentage, Other Equity Instruments Granted",
        "documentation": "Expected Dividend As Percentage, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpectedDividendAsPercentageShareOptionsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Expected dividend as percentage, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "oncyf_ExpectedVolatilityOtherEquityInstrumentsGranted": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ExpectedVolatilityOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Expected Volatility, Other Equity Instruments Granted",
        "documentation": "Expected Volatility, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseByNatureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseByNatureAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenses",
        "label": "Expenses by nature [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation warrant expenses (note 11)",
        "label": "Expense from equity-settled share-based payment transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense from share-based payment transactions with parties other than employees",
        "label": "Expense from share-based payment transactions with parties other than employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with parties other than employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "oncyf_ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period, granted",
        "label": "Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement",
        "documentation": "Expiration Period Of Other Equity Instruments Granted In Share-Based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ContractLiabilityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability balances",
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ifrs-full_FinancialAssetsAvailableforsale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialAssetsAvailableforsale",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets available-for-sale",
        "label": "Financial assets available-for-sale"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-derivative financial assets that are designated as available for sale or are not classified as (a) loans and receivables; (b) held-to-maturity investments; or (c) financial assets at fair value through profit or loss. [Refer: Derivative financial assets; Financial assets at fair value through profit or loss; Held-to-maturity investments]"
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "oncyf_ForeignExchangeImpactRightofUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ForeignExchangeImpactRightofUseAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange impact",
        "label": "Foreign Exchange Impact, Right-of-Use Assets",
        "documentation": "Foreign Exchange Impact, Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_GainsLossesFromForeignExchangeImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "GainsLossesFromForeignExchangeImpact",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign exchange impact",
        "label": "Gains (Losses) From Foreign Exchange Impact",
        "documentation": "Gains (Losses) From Foreign Exchange Impact"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant derivative (notes 9, 17)",
        "verboseLabel": "Change in fair value",
        "label": "Gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r200"
     ]
    },
    "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign exchange (loss) gain",
        "label": "Foreign exchange gain (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r42"
     ]
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "General and administrative (note 20)",
        "terseLabel": "General and administrative expenses",
        "label": "General and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "oncyf_GeneralAndAdministrativeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "GeneralAndAdministrativeExpenseAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expense [Abstract]",
        "documentation": "General And Administrative Expense"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General And Administrative Expense [Member]",
        "documentation": "General And Administrative Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossCarryingAmountMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Gross carrying amount [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      }
     },
     "auth_ref": [
      "r33",
      "r55",
      "r59",
      "r62",
      "r130",
      "r137",
      "r138",
      "r173"
     ]
    },
    "ifrs-full_GrossLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total undiscounted lease liability",
        "label": "Gross lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of contractual undiscounted cash flows in relation to lease liabilities before deducting finance charges. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r100",
      "r176"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit or loss [abstract]",
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IncomeStatementLocation1Axis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IncomeStatementLocation1Axis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location1 [Axis]",
        "label": "Income Statement Location1 [Axis]",
        "documentation": "Income Statement Location1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IncomeStatementLocation1Domain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IncomeStatementLocation1Domain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location1 [Domain]",
        "label": "Income Statement Location1 [Domain]",
        "documentation": "[Domain] for Income Statement Location1 [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax expense (note 15)",
        "label": "Tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r24",
      "r27",
      "r28",
      "r29",
      "r49",
      "r80",
      "r143"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefund": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeTaxesPaidRefund",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash taxes paid",
        "label": "Income taxes paid (refund)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Increase (decrease) in cash and cash equivalents",
        "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 9.0
      },
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net change in non-cash working capital (note 18)",
        "negatedTotalLabel": "Change in non-cash working capital related to operating activities",
        "label": "Increase (decrease) in working capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued pursuant to stock option plan (note 11)",
        "label": "Increase (decrease) through exercise of options, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued pursuant to warrant derivative exercised (note 10)",
        "label": "Increase (decrease) through exercise of warrants, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of warrants."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "oncyf_IncreaseDecreaseThroughExpirationOfWarrantEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IncreaseDecreaseThroughExpirationOfWarrantEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry of equity warrant agreement",
        "label": "Increase (Decrease) Through Expiration Of Warrant, Equity",
        "documentation": "Increase (Decrease) Through Expiration Of Warrant, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresNetChangeInNonCashWorkingCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash impact of foreign exchange",
        "label": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net",
        "documentation": "Increase (Decrease) Through Foreign Exchange, Financial Assets (Liabilities), Net"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IncreaseDecreaseThroughIncentiveShareAwardsEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IncreaseDecreaseThroughIncentiveShareAwardsEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issued pursuant to incentive share award plan (note 11)",
        "label": "Increase (Decrease) Through Incentive Share Awards, Equity",
        "documentation": "Increase (Decrease) Through Incentive Share Awards, Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense (note 11)",
        "label": "Increase (decrease) through share-based payment transactions, equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Increase through new leases, liabilities arising from financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]"
       }
      }
     },
     "auth_ref": [
      "r165",
      "r166"
     ]
    },
    "oncyf_IntellectualPropertyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IntellectualPropertyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual property expenses",
        "label": "Intellectual Property Expense",
        "documentation": "Intellectual Property Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_InterestExpenseOnLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestExpenseOnLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense on lease liabilities",
        "label": "Interest expense on lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_InterestIncomeOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestIncomeOnCashAndCashEquivalents",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest income on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of interest income on cash and cash equivalents. [Refer: Interest income; Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_InterestRevenueExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRevenueExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense (income), net",
        "label": "Interest income (expense)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]"
       }
      }
     },
     "auth_ref": [
      "r144",
      "r148",
      "r200"
     ]
    },
    "oncyf_InvestmentTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "InvestmentTaxCreditsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment tax credits",
        "label": "Investment Tax Credits [Member]",
        "documentation": "Investment Tax Credits [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issue of equity",
        "verboseLabel": "Issued pursuant to public offering",
        "label": "Issue of equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "oncyf_IssueOfEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IssueOfEquityShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issued pursuant to public offering (in shares)",
        "terseLabel": "Issued (in shares)",
        "label": "Issue Of Equity, Shares",
        "documentation": "Issue Of Equity, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IssueOfEquitySharesNumberOfCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IssueOfEquitySharesNumberOfCommonShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of common shares (in shares)",
        "label": "Issue Of Equity, Shares, Number Of Common Shares",
        "documentation": "Issue Of Equity, Shares, Number Of Common Shares"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_IssueOfEquitySharesNumberOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "IssueOfEquitySharesNumberOfWarrants",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants (in shares)",
        "label": "Issue Of Equity, Shares, Number Of Warrants",
        "documentation": "Issue Of Equity, Shares, Number Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital (note 10) \u00a0\u00a0Authorized: unlimited \u00a0\u00a0Issued: December\u00a031, 2023 \u2013 74,423,960 December\u00a031, 2022 \u2013 61,327,914",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Issued capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Compensation of key management personnel",
        "label": "Key management personnel compensation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationSharebasedPayment",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Key management personnel compensation, share-based payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term employee compensation and benefits",
        "label": "Key management personnel compensation, short-term employee benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_KeyManagementPersonnelCompensationTerminationBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "KeyManagementPersonnelCompensationTerminationBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails": {
       "parentTag": "ifrs-full_KeyManagementPersonnelCompensation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination benefits",
        "label": "Key management personnel compensation, termination benefits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of compensation to key management personnel in the form of termination benefits. [Refer: Termination benefits expense; Key management personnel of entity or parent [member]]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "ifrs-full_LaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanFiveYearsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "More than five years",
        "label": "Later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than five years."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r114",
      "r175",
      "r177",
      "r179"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One to five years",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r179"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Lease liabilities, beginning balance",
        "periodEndLabel": "Lease liabilities, ending balance",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_LeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Liabilities [Abstract]",
        "label": "Lease liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_LeaseNotYetCommencedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "LeaseNotYetCommencedPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease not yet commenced, payments",
        "label": "Lease Not Yet Commenced, Payments",
        "documentation": "Lease Not Yet Commenced, Payments"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_LeaseNotYetCommencedTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "LeaseNotYetCommencedTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease not yet commenced, term",
        "label": "Lease Not Yet Commenced, Term",
        "documentation": "Lease Not Yet Commenced, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold Improvements",
        "label": "Leasehold improvements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "ifrs-full_Level2OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level2OfFairValueHierarchyMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Level 2 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 of fair value hierarchy",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Levels of fair value hierarchy [axis]",
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r82"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r81",
      "r82",
      "r83",
      "r144",
      "r147"
     ]
    },
    "ifrs-full_LiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ManufacturingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ManufacturingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing &amp; related process development expenses",
        "label": "Manufacturing Expense",
        "documentation": "Manufacturing Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity [axis]",
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r89",
      "r101",
      "r102",
      "r106",
      "r107",
      "r108",
      "r114",
      "r133",
      "r139",
      "r159",
      "r175"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum option expiration term",
        "label": "Maximum Term Of Options Granted For Share-based Payment Arrangement",
        "documentation": "Maximum Term Of Options Granted For Share-based Payment Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_MedicalEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "MedicalEquipmentMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medical equipment",
        "verboseLabel": "Medical Equipment",
        "label": "Medical Equipment [Member]",
        "documentation": "Medical Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses",
        "label": "Miscellaneous other operating expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r196"
     ]
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liability (note 13)",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities (note 8)",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "ifrs-full_NoncurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses (note 5)",
        "verboseLabel": "Non-current prepaid expenses",
        "label": "Non-current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesTotalUndiscountedLeaseLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than one year",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r101",
      "r102",
      "r114",
      "r175",
      "r179"
     ]
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Number of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r214"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Released (in shares)",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of the year (in shares)",
        "periodEndLabel": "Outstanding, end of the year (in shares)",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_NumberOfOutstandingShareOptions": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOutstandingShareOptions",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of the year (shares)",
        "periodEndLabel": "Outstanding, end of the year (shares)",
        "terseLabel": "Number Outstanding (shares)",
        "label": "Number of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r121",
      "r124"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, end of the year (shares)",
        "verboseLabel": "Number Exercisable (shares)",
        "label": "Number of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised during the year (shares)",
        "label": "Number of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired during the year (shares)",
        "label": "Number of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options expired in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited during the year (shares)",
        "label": "Number of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the year (shares)",
        "label": "Number of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITIONParenthetical",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share capital issued (shares)",
        "periodStartLabel": "Share capital issued, beginning (shares)",
        "periodEndLabel": "Share capital issued ending (shares)",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "oncyf_NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for issuance, maximum percentage",
        "label": "Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum",
        "documentation": "Number Of Shares Reserved For Issue Under Options And Contracts For Sale Of Shares, Percentage Of Common Shares, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfStockOptionPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "NumberOfStockOptionPlans",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plans",
        "label": "Number Of Stock Option Plans",
        "documentation": "Number Of Stock Option Plans"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfWarrantsAndSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "NumberOfWarrantsAndSharesOutstanding",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrants and shares outstanding (in shares)",
        "label": "Number Of Warrants And Shares Outstanding",
        "documentation": "Number Of Warrants And Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "NumberOfWarrantsOutstanding",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "terseLabel": "Number of Warrants Outstanding",
        "label": "Number Of Warrants Outstanding",
        "documentation": "Number Of Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_NumberOfWarrantsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "NumberOfWarrantsOutstandingRollForward",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants Outstanding",
        "label": "Number Of Warrants Outstanding [Roll Forward]",
        "documentation": "Number Of Warrants Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OfficeEquipmentAndFurnitureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OfficeEquipmentAndFurnitureMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office Equipment and Furniture",
        "label": "Office equipment and furniture [Member]",
        "documentation": "Office equipment and furniture"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment and furniture",
        "label": "Office equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "oncyf_OfficeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OfficeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office expenses",
        "label": "Office Expenses",
        "documentation": "Office Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Operating Lease, Remaining Lease Term",
        "documentation": "Operating Lease, Remaining Lease Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income items that may be reclassified to net loss",
        "label": "Other comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translation adjustment",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r17",
      "r25"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities (note 5)",
        "verboseLabel": "Other liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables (note 5)",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_OtherEmployeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherEmployeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Personnel-related expenses",
        "label": "Other employee expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of employee expenses that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, accelerated threshold trading days",
        "label": "Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days",
        "documentation": "Other Equity Instruments In Share-Based Payment Arrangement, Accelerated Threshold Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, expiration days",
        "label": "Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days",
        "documentation": "Other Equity Instruments In Share-Based Payment Arrangement, Expiration Days"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, threshold consecutive trading days",
        "label": "Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days",
        "documentation": "Other Equity Instruments In Share-Based Payment Arrangement, Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of warrant or right, threshold trading price (usd per share)",
        "label": "Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price",
        "documentation": "Other Equity Instruments In Share-Based Payment Arrangement, Threshold Trading Price"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected life",
        "label": "Other Equity Instruments Life, Other Equity Instruments Granted",
        "documentation": "Other Equity Instruments Life, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherExpensesAndAdjustmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OtherExpensesAndAdjustmentsLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Expenses And Adjustments [Line Items]",
        "label": "Other Expenses And Adjustments [Line Items]",
        "documentation": "[Line Items] for Other Expenses And Adjustments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherExpensesAndAdjustmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OtherExpensesAndAdjustmentsTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Expenses And Adjustments [Table]",
        "label": "Other Expenses And Adjustments [Table]",
        "documentation": "Other Expenses And Adjustments [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_OtherExpensesAndAdjustmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "OtherExpensesAndAdjustmentsTableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expenses and adjustments",
        "label": "Other Expenses And Adjustments [Table Text Block]",
        "documentation": "Other Expenses And Adjustments [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other provisions",
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/OtherAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other permanent differences",
        "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Presentation of leases for lessee [abstract]",
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options (note 11)",
        "label": "Proceeds from exercise of options"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of options."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of warrants (note 9)",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from issue of ordinary shares",
        "label": "Proceeds from issue of ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "oncyf_ProceedsFromIssueOfUnitsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ProceedsFromIssueOfUnitsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from units",
        "label": "Proceeds From Issue Of Units, Gross",
        "documentation": "Proceeds From Issue Of Units, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from share issuance",
        "label": "Proceeds from issuing shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "oncyf_ProceedsfromInterestReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ProceedsfromInterestReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresOtherCashFlowDisclosuresDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash interest received",
        "label": "Proceeds from Interest Received",
        "documentation": "Proceeds from Interest Received"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ProceedsfromWarrantExercises1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ProceedsfromWarrantExercises1",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross proceeds from warrant exercises",
        "label": "Proceeds from Warrant Exercises1",
        "documentation": "Proceeds from Warrant Exercises1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss for the year",
        "label": "Profit (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r22",
      "r64",
      "r73",
      "r75",
      "r144",
      "r145",
      "r167",
      "r172"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Profit (loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r150",
      "r151",
      "r180",
      "r181"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before the following",
        "label": "Profit (loss) from operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r160",
      "r200"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment (note 6)",
        "periodStartLabel": "Property and equipment, beginning balance",
        "periodEndLabel": "Property and equipment, ending balance",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r36"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipmentMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails",
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, plant and equipment [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r161",
      "r171"
     ]
    },
    "oncyf_PropertyPlantEquipmentRelatedTemporaryDifferencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "PropertyPlantEquipmentRelatedTemporaryDifferencesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant, Equipment Related Temporary Differences [Member]",
        "documentation": "Property, Plant, Equipment And Intellectual Property Related Temporary Differences [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PropertyPlantandEquipmentAnnualDepreciationRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "PropertyPlantandEquipmentAnnualDepreciationRate",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/SummaryofMaterialAccountingPoliciesScheduleofDepreciationRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual depreciation rate",
        "label": "Property, Plant and Equipment, Annual Depreciation Rate",
        "documentation": "Property, Plant and Equipment, Annual Depreciation Rate"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PublicCompanyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "PublicCompanyExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public company-related expenses",
        "label": "Public Company Expense",
        "documentation": "Public Company Expense"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PurchaseObligation1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "PurchaseObligation1",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment for payment",
        "label": "Purchase Obligation1",
        "documentation": "Purchase Obligation1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_PurchaseObligationCommitmentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "PurchaseObligationCommitmentTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment term",
        "label": "Purchase Obligation, Commitment Term",
        "documentation": "Purchase Obligation, Commitment Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of marketable securities",
        "label": "Purchase of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]"
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of property and equipment (note 6)",
        "label": "Purchase of property, plant and equipment, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [axis]",
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r108",
      "r124",
      "r168",
      "r169",
      "r215"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges",
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r108",
      "r124",
      "r168",
      "r169",
      "r215"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options [axis]",
        "label": "Ranges of exercise prices for outstanding share options [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesOfExercisePricesForOutstandingShareOptionsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ranges of exercise prices for outstanding share options",
        "label": "Ranges of exercise prices for outstanding share options [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated ranges of exercise prices for outstanding share options that are meaningful for assessing the number and timing of additional shares that may be issued and the cash that may be received upon exercise of those options. It also represents the standard value for the 'Ranges of exercise prices for outstanding share options' axis if no other member is used. [Refer: Ranges [member]]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReconciliationOfChangesInPropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of changes in property, plant and equipment [abstract]",
        "label": "Reconciliation of changes in property, plant and equipment [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development (note 20)",
        "verboseLabel": "Research and development expenses",
        "label": "Research and development expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "oncyf_ResearchAndDevelopmentExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ResearchAndDevelopmentExpenseAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research And Development Expense [Abstract]",
        "documentation": "Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research And Development Expense [Member]",
        "documentation": "Research And Development [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve of share-based payments",
        "label": "Reserve of share-based payments [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted share units",
        "label": "Restricted share units [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing restricted share units."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/NatureofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained earnings"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained earnings [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r152"
     ]
    },
    "oncyf_RightOfUseAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "RightOfUseAssetsAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-Of-Use Assets [Abstract]",
        "label": "Right-Of-Use Assets [Abstract]",
        "documentation": "Right-Of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/LeasesRightofuseAssetsandLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets (note 8)",
        "periodStartLabel": "Right-of-use assets, beginning balance",
        "periodEndLabel": "Right-of-use assets, ending balance",
        "label": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r98"
     ]
    },
    "oncyf_RiskFreeInterestRateOtherEquityInstrumentsGranted": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "RiskFreeInterestRateOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Risk Free Interest Rate, Other Equity Instruments Granted",
        "documentation": "Risk Free Interest Rate, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SaleOfStockAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Axis]",
        "label": "Sale Of Stock [Axis]",
        "documentation": "Sale Of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SaleOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SaleOfStockDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale Of Stock [Domain]",
        "label": "Sale Of Stock [Domain]",
        "documentation": "[Domain] for Sale Of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ScheduleOfForeignCurrencyHeldTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ScheduleOfForeignCurrencyHeldTableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of balances in foreign currencies",
        "label": "Schedule Of Foreign Currency Held [Table Text Block]",
        "documentation": "Schedule Of Foreign Currency Held [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ScheduleofCashFlowSupplementalDisclosures1TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ScheduleofCashFlowSupplementalDisclosures1TableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AdditionalCashFlowDisclosuresTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other cash flow disclosures",
        "label": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]",
        "documentation": "Schedule of Cash Flow, Supplemental Disclosures1 [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]",
        "documentation": "Schedule of Components of Income Tax Expense (Benefit)1 [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r183"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of increase in value of currency (cad per share)",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Amount",
        "documentation": "A reference variable for a specific type of market risk, defined in non-percentage terms. Positive value indicates an increase; negative value indicates a decrease."
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Increase (decrease) in net loss due to change in currency value",
        "label": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings",
        "documentation": "Sensitivity Analysis For Types Of Market Risk, Reasonably Possible Change In Risk Variable, Impact On Pre-Tax Earnings"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareCapitalAmountAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ShareCapitalAmountAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "label": "Share Capital, Amount [Abstract]",
        "documentation": "Share Capital, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareCapitalNumberSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ShareCapitalNumberSharesAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number",
        "label": "Share Capital, Number, Shares [Abstract]",
        "documentation": "Share Capital, Number, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareIssueCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ShareIssueCostsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue costs",
        "label": "Share Issue Costs [Member]",
        "documentation": "Share Issue Costs [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ShareIssueRelatedCost",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share issue costs (note 10)",
        "negatedLabel": "Share issue costs",
        "terseLabel": "Share issue related cost",
        "label": "Share issue related cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "oncyf_ShareIssueRelatedCostCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ShareIssueRelatedCostCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue related cost, commissions",
        "label": "Share Issue Related Cost, Commissions",
        "documentation": "Share Issue Related Cost, Commissions"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contributed Surplus",
        "label": "Share premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "oncyf_SharePurchaseAgreementAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharePurchaseAgreementAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement",
        "label": "Share Purchase Agreement, Amount",
        "documentation": "Share Purchase Agreement, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharePurchaseAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharePurchaseAgreementTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement term",
        "label": "Share Purchase Agreement, Term",
        "documentation": "Share Purchase Agreement, Term"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareWarrantsIssuedOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ShareWarrantsIssuedOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share issue operating expense",
        "label": "Share Warrants Issued, Operating Expense",
        "documentation": "Share Warrants Issued, Operating Expense"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_ShareWarrantsIssuedTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ShareWarrantsIssuedTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued, transaction costs",
        "label": "Share Warrants Issued, Transaction Costs",
        "documentation": "Share Warrants Issued, Transaction Costs"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting period, if not immediately vested",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period1"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangements",
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "oncyf_SharesIssuedPricePerShare1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharesIssuedPricePerShare1",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (cad and usd per share)",
        "label": "Shares Issued, Price Per Share1",
        "documentation": "Shares Issued, Price Per Share1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharesPublicOfferingMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering",
        "label": "Shares Public Offering [Member]",
        "documentation": "Shares Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesPublicOfferingWarrantDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharesPublicOfferingWarrantDerivativesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Under Warrant Derivative Agreement",
        "verboseLabel": "Warrant derivatives",
        "label": "Shares Public Offering, Warrant Derivatives [Member]",
        "documentation": "Shares Public Offering, Warrant Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares reserved for issuance (in shares)",
        "label": "Number of shares reserved for issue under options and contracts for sale of shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares reserved for issue under options and contracts for the sale of shares."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "oncyf_SharesUnderAtthemarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharesUnderAtthemarketAgreementMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market equity distribution agreement",
        "label": "Shares Under At-the-market Agreement [Member]",
        "documentation": "Shares Under At-the-market Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesUnderIncentiveAwardPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharesUnderIncentiveAwardPlanMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive share award plan",
        "label": "Shares Under Incentive Award Plan [Member]",
        "documentation": "Shares Under Incentive Award Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesUnderOverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharesUnderOverAllotmentOptionMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares Under Over-Allotment Option",
        "label": "Shares Under Over-Allotment Option [Member]",
        "documentation": "Shares Under Over-Allotment Option"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesUnderPublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharesUnderPublicOfferingMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering",
        "label": "Shares Under Public Offering [Member]",
        "documentation": "Shares Under Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SharesUnderStockOptionPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SharesUnderStockOptionPlanMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option plan",
        "label": "Shares Under Stock Option Plan [Member]",
        "documentation": "Shares Under Stock Option Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SignificantJudgmentsEstimatesAndAssumptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SignificantJudgmentsEstimatesAndAssumptionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "label": "Significant Judgments, Estimates And Assumptions [Abstract]",
        "documentation": "Significant Judgments, Estimates And Assumptions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_Statement1LineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "Statement1LineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement1 [Line Items]",
        "label": "Statement1 [Line Items]",
        "documentation": "[Line Items] for Statement1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_Statement1Table": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "Statement1Table",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement1 [Table]",
        "documentation": "Statement1 [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of cash flows [abstract]",
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [abstract]",
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [line items]",
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of changes in equity [table]",
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of financial position [abstract]",
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_StockOptionsOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "StockOptionsOutstandingAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options",
        "label": "Stock Options, Outstanding [Abstract]",
        "documentation": "Stock Options, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Abstract]",
        "label": "Summary Of Significant Accounting Policies [Abstract]",
        "documentation": "Summary Of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_SupplierConcentrationRisk1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "SupplierConcentrationRisk1Member",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/EconomicDependenceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Toll manufacturer",
        "label": "Supplier Concentration Risk1 [Member]",
        "documentation": "Supplier Concentration Risk1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectFromChangeInTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectFromChangeInTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of Barbados rate change",
        "label": "Tax effect from change in tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "oncyf_TaxEffectOfChangeinFairValueOfWarrantDerivative": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "TaxEffectOfChangeinFairValueOfWarrantDerivative",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of warrant derivative",
        "label": "Tax Effect Of Change in Fair Value Of Warrant Derivative",
        "documentation": "Tax Effect Of Change in Fair Value Of Warrant Derivative"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_TaxEffectOfExpirationOfTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "TaxEffectOfExpirationOfTaxBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiry of tax benefits",
        "label": "Tax Effect Of Expiration Of Tax Benefits",
        "documentation": "Tax Effect Of Expiration Of Tax Benefits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxEffectOfForeignTaxRates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxEffectOfForeignTaxRates",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Difference in tax rates",
        "label": "Tax effect of foreign tax rates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "oncyf_TaxEffectOfStockBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "TaxEffectOfStockBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share-based compensation expense",
        "label": "Tax Effect Of Stock Based Compensation",
        "documentation": "Tax Effect Of Stock Based Compensation"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_TaxEffectOfTaxPools": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "TaxEffectOfTaxPools",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revaluation of tax balances",
        "label": "Tax Effect Of Tax Pools",
        "documentation": "Tax Effect Of Tax Pools"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TaxExpenseIncomeAtApplicableTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anticipated tax recovery",
        "label": "Tax expense (income) at applicable tax rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]",
        "label": "Temporary difference, unused tax losses and unused tax credits [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary difference, unused tax losses and unused tax credits",
        "label": "Temporary difference, unused tax losses and unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r108",
      "r124",
      "r168",
      "r169",
      "r215"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFFINANCIALPOSITION",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities (note 7)",
        "totalLabel": "Accounts payable and accrued liabilities",
        "negatedTerseLabel": "Accounts payable and accrued liabilities",
        "label": "Trade and other current payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r153",
      "r199"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_TranslationalScienceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "TranslationalScienceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ComponentsofExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Translational science expenses",
        "label": "Translational Science Expense",
        "documentation": "Translational Science Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r113",
      "r132",
      "r134",
      "r135"
     ]
    },
    "ifrs-full_TypesOfRisksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfRisksMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks",
        "label": "Risks [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r113",
      "r132",
      "r134",
      "r135"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UNITED STATES",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "localname": "USD",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsScheduleofBalancesinForeignCurrenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. dollars",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unclaimed scientific research and experimental development expenditures",
        "verboseLabel": "Scientific research and experimental development",
        "label": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]",
        "documentation": "Unclaimed Scientific Research And Experimental Development Expenditures [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_UnusedCapitalLossCarryForwardNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "UnusedCapitalLossCarryForwardNetMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net capital losses carried forward",
        "label": "Unused Capital Loss Carry Forward, Net [Member]",
        "documentation": "Unused Capital Loss Carry Forward, Net [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_UnusedNetOperatingLossCarryForwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "UnusedNetOperatingLossCarryForwardsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesScheduleofUnrecognizedDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital losses carried forward",
        "label": "Unused Net Operating Loss Carry Forwards [Member]",
        "documentation": "Unused Net Operating Loss Carry Forwards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax credits",
        "label": "Unused tax credits for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_UnusedTaxCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxCreditsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-refundable federal investment tax credits",
        "label": "Unused tax credits [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax credits that have been received and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused tax losses",
        "label": "Unused tax losses for which no deferred tax asset recognised"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]"
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_UnusedTaxLossesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnusedTaxLossesMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-capital losses",
        "label": "Unused tax losses [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for tax losses that have been incurred and are carried forward for use against future taxable profit."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "oncyf_ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1",
     "crdr": "credit",
     "calculation": {
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "parentTag": "ifrs-full_CurrentTaxExpenseIncome",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Provision to offset deferred tax asset",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1",
        "documentation": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount1"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_WarrantExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "WarrantExercisePrice",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeWarrantDerivativeOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (usd per share)",
        "label": "Warrant Exercise Price",
        "documentation": "Warrant Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant liability",
        "label": "Warrant liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of warrant liabilities."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "oncyf_WarrantLiabilityAmortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "WarrantLiabilityAmortizedDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of discount on warrants issued",
        "label": "Warrant Liability, Amortized Discount",
        "documentation": "Warrant Liability, Amortized Discount"
       }
      }
     },
     "auth_ref": []
    },
    "oncyf_WarrantLiabilityUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "WarrantLiabilityUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Discount on warrants issued",
        "label": "Warrant Liability, Unamortized Discount",
        "documentation": "Warrant Liability, Unamortized Discount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WarrantsMember",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://www.oncolyticsbiotech.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/ShareCapitalScheduleofShareCapitalFootnotesDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeReconciliationofChangeinFairValueofWarrantDerivativeDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants",
        "verboseLabel": "Warrants",
        "label": "Warrants [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a class of antidilutive instrument representing warrants."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "oncyf_WarrantsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "WarrantsTerm",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, term",
        "label": "Warrants, Term",
        "documentation": "Warrants, Term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price (cad and usd per share)",
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, end of the year (cad per share)",
        "verboseLabel": "Weighted Average Exercise Price (cad per share)",
        "label": "Weighted average exercise price of share options exercisable in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercisable in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised during the year (cad per share)",
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired during the year (cad per share)",
        "label": "Weighted average exercise price of share options expired in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options expired in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited during the year (cad per share)",
        "label": "Weighted average exercise price of share options forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the year (cad per share)",
        "label": "Weighted average exercise price of share options granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails",
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning of the year (cad per share)",
        "periodEndLabel": "Outstanding, beginning of the year (cad per share)",
        "terseLabel": "Weighted Average Exercise Price (cad per share)",
        "label": "Weighted average exercise price of share options outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r121"
     ]
    },
    "oncyf_WeightedAverageExercisePriceOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "WeightedAverageExercisePriceOutstandingAbstract",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsandWeightedAverageExercisePricesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price $",
        "label": "Weighted Average Exercise Price, Outstanding [Abstract]",
        "documentation": "Weighted Average Exercise Price, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofNumberofOtherEquityInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value at measurement date, other equity instruments granted",
        "label": "Weighted average fair value at measurement date, other equity instruments granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationDisclosureWeightedAverageAssumptionsandFairValueofOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average fair value of options (cad per share)",
        "label": "Weighted average fair value at measurement date, share options granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "oncyf_WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value per warrant (usd per share)",
        "terseLabel": "Weighted average fair value of options (usd per share)",
        "label": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted",
        "documentation": "Weighted Average Fair Value Price At Measurement Date, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average rate",
        "label": "Weighted average lessee's incremental borrowing rate applied to lease liabilities recognised at date of initial application of IFRS 16"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average lessee's incremental borrowing rate applied to lease liabilities recognised in the statement of financial position at the date of initial application of IFRS 16. The incremental borrowing rate is the rate of interest that a lessee would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": {
     "xbrltype": "durationItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofStockOptionsOutstandingandExercisablebyRangeofExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life (years)",
        "label": "Weighted average remaining contractual life of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "oncyf_WeightedAverageSharePriceOtherEquityInstrumentsGranted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.oncolyticsbiotech.com/20231231",
     "localname": "WeightedAverageSharePriceOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/ShareBasedCompensationScheduleofCompensationWarrantsWeightedAverageAssumptionsDetails",
      "http://www.oncolyticsbiotech.com/role/WarrantDerivativeSummaryofAssumptionsUsedintheBlackScholesOptionPricingModelforWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying share price (usd per share)",
        "label": "Weighted Average Share Price, Other Equity Instruments Granted",
        "documentation": "Weighted Average Share Price, Other Equity Instruments Granted"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.oncolyticsbiotech.com/role/CONSOLIDATEDSTATEMENTSOFLOSSANDCOMPREHENSIVELOSS",
      "http://www.oncolyticsbiotech.com/role/LossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average number of shares (basic) (shares)",
        "verboseLabel": "Weighted average number of common shares outstanding (shares)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "134",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_134&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "75",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_75_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS16_g73-79_TI",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2023-01-01",
   "Paragraph": "52",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2023-en-r&anchor=para_52_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "76",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Presentation of a statement of cash flows",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS07_g10-17_TI",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "58",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_58&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "C12",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_C12_a&doctype=Appendix&subtype=C",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_v&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "vii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "3",
   "IssueDate": "2023-01-01",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI",
   "URIDate": "2023-03-23"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2023-03-23"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Expired 2023-01-01",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_d&doctype=Standard&book=b",
   "URIDate": "2023-03-23"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "80",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2023-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "44B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_44B&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2023-03-23"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B11D",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B11D_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "5",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_5&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001129928-24-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001129928-24-000018-xbrl.zip
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M^@^2PW#6/86M*V'+9?+&T5I6X3&N5>6VJSQSBZS^#7?:3OQ=NO\!4$L#!!0
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M+K]KN!HQLJEB8O1$4G@K^*B^P[>U#Y5YJ<U,HG8Z-M%K\C5T@=J?B<RM!P$
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M<RV3W&RJ?.<^:/4L;Z<.BENQ?P!02P,$%     @ 38%L6)=O.6<O!   IA$
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MI/YD\> @L;8"R<]GZLR?X7  &#K39L;=N._;Q/7#G:FS=*;NVC-=9+'Q483
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M/LC !2^,Y@CO1O]0[9'4*5A#LXB@XLHYV#0M#@!<HUG3';PVIAFPER'G/G#
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M/ 8@ YV)9$K6?Q:[VB_*)A/TDF #<.A)I@@/+4+X#!8'H@CQV:AP:1'6L'1
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MUR*FJ[T<^^4(.U$D"MJ"-K17#1N7,\4=%)& ?[O?Z,H'?C+UQSXJ"),#BT%
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MKSU0]\P-S!\8YA0TX2S!UB26LC#N3SZ_NSPE\ _:=@/^!P;_!^5+67:+0%O
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M*GHI(>T:1\1A-YY/7_@'GR)LDB'<*17%PA<83..O9G=TW6ZO\O??*#&KMJF
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M#1^H(79('CNTLA[8>\&>O37V+*L^V+-Y\C*#.S%+QAX;GO I2M\(-#^ KE8
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MSR*9S5.SN+28-E'U_ZYR+UU08V@O"3VK1IEGUWY"<NHDD1*3\J4QTC:$ /7
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M$^%0@KRY)UA_3^!3>^>$.\J_M$U[,-B%O,HD51#&\J(]R]YZ47ME48L[A4^
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MU_*U'FA&P\Y*#RJCNU,\(L9@8F?IYD<>?1[)EHP[7)I"4OKO--:;F0/QML9
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ME2#YKH:IASWUR!S9.\P0^*Z>J?>3TD<,W('9[>XP_+(![B[ [9O=O77[?7;
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M$11WZX;BWR2-%@><6H[9&?7-3K=?061"DYP1X91%/(\C,*X\DF:.U1X:L,T
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M$L2)"N%Q\$2F;>-75-@@U(H#$5AF8F$DV(VE6!0W3SS!R"--CQU,P-HU0<P
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M-!H+ 7M>F-(;(J'KCU_;B58)(- 'DQRCHV[IX.698&@;I1N"JUM/N^JMFW\
MR-[OK"MP,=L==C-W'G;5:SN=^XTCNG5PD-6VAIN_OO>R3KO?WVX>T8YCCCK6
M_>8NW;'LH/L(@\3L=G<TW,M0IH<>P/,00F%]*4Y9/CVN4%K__J\1Z)<=YHP<
MQ_"47] :)U_8(@?_^P[XO3,_-NC@@\44-Q2%&2V'HR$[CU1YMC#K&BVC]W!
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MT_/^C2(43%&1GG7S22Q;B\0K!.TV$7-M3+'!*FJ2 1N]@I5'[KL(Z9 >0LV
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MA6#-BNU..-<)5<Q&LBN@#<3%!ZX#3I>Z["_*8A!+S>G:]TAX.%O"8T;H[Y#
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MWENSPAV?8Q=]S]=)H#7ED1LM^7L<$-R! !?(P22&@?^9I4?R9W=DS/NPR";
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MC>?/,KJ9&RSN2(%3 D\<S8//N(TXH0E&!ZCW#O,L/$.MKZ+L-N4I9V$(Q.)
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M6<VJ7\ C2NK!]RUMYP.U7#8; Y5<@6J-!W,#/2PO#D)BB"&V\X:#8.ZY6?<
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MR[R==$YLLQN<.Z] /=VAAP8=D(J3E,H[D9'*A/ (WV0Z]>B1X.LI5]<,7AX
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MCL]0AR1A5'+T9RR;G1:<E[C\C<??U&E0UG"*YE/2)#4C=(:"]6I+ V0]50=
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M?GKIB+%D61'1[Y :B:V6M<R3[()[NJOE9N=@_P5Z!S</D2[MMEL=(H5IZ"Q
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MAJ<)!J4,N/G>CGIC_F@VE$SZGZK<2],!M;J*,Z"$15>[_=-H#%=?*9FTWMR
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M^/KBYBJ$B_'<+OO]TP[\V-)TGI3FME3 2I-*14XQ1*S@AF402:&Y-AID DQ
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M9Z#6$K542=9LW*WF<"^5)"@1\&!?P9T\^:$&]5-,,UPA>'E0AM,2! %O&AW
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M+^#W68+J*3(PM"*5KN (A1?>$R-W^)0[W8E3[KUX,N.>=M'[8:?*1*MPE#9
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M<YZR/QY, Y5)TE8R>_*4JSUW=*Q5#B-AQ5/I:8YK15<'/][LN?XXW1']\:K
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M=YDRP(E #?G&L>]N4("ZKH4R!W97T@5Y]S?3MC+AC%?%^.J>DL4T+5BCJ7
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M$<E //0@]#HI.T@578J+;Y%>I(<O 3F[H!IO$PRWU''@PM98C<_HBQHT,YX
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M6"8_TA;6;6G6K"H)+S,%)W9,PWO>N[?9[38ZA1MWYM_$LS(O44_T[\L4E"#
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M_V&+^WX''[=.L\3F0T 5<;@BA'EW2@K9^1Y,GA' !9]HF@T3\$MC\ -'T^M
M;&[H5Z X'U4R]5NG_@BM?B+O2S1W.<-21K3'W&E]MW,L3^YS+'<XQW*KY[B
M2)NJY4)!2K5V2)!=N6#%;231OA&%9HDSX"K18I:6E.")0E$Y%/-SBD4%'L6
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M\E#*JC8VL.%*,2D8+W"(DA:&Y;:XHBY.UPMW;GDOM585QX<DS-MM]CGP8N3
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MUPN]TGFYQ"ON!7G?!?E7UGPH.HPV-()B&!1"49)J[H2:?PT8 !T-Z+M.";A
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MP-J>G)Y7[]UBKV1F-J+,=!M3CV9562=QFY( $?EVU,1\Q"7OH(K'7_F>;>Q
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M@NF*R@GL*],%K8(Q9N@>F@YJ>+:8#.X@Y5 =NYABV*BFCLT+VCY'-[W#7AD
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M!P']='P9K8Y#:BZ[F):^ZX^R=EG:J\%+&UDZ;IHV(!2%$^:FB2[A9"ZK-$T
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MW07^^)W&O\V9P\%$+#FP$55QH_]=4YTW$#RNY.?(&"#BA9\->RI:8P!#_P-
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M%)45R#*O8$I[@]WR0&+W?0SJ3OCN2_A.\VRB-.Y:F4HQLT)E98B#'(+>F7+
MJS8J6_H6U1T?&,X7GSEJH,:2=#$S3U1*Q8^@QC(%(X2/ 8JBVZ^#W@^U5CH
M;*A5,,$](N6>W4C>N((41URQ.JQG1DG?8@"4[)R*>BFU$A\$2H?E-@STJ*B
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ML>MFO[45+WUYVMZSMFKU+];;4L&LH*/OD5/E48Q@.35M_Y;)RJE:?@,;'2R
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MR=Z)Z38K_G]]X;]MH+P>Y=Z%S7_5V,*SH0KG\,\DBZ/7_P]02P,$%     @
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ME@D\Q_=A *5MKS0N]IHQ8LS4=BS@$[R8B:  3$B 0,1GZ\-:S@E+Z[!9D*P
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M-QOTN[]T &D.:R][[Q!!]&R[WWW_Q9B!!?K.L0/:M-"_&^!=;_#:C[#[5T?
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MYAB9)/LD0'%^&X$%;R\+FHIPR:=:F.!F)% ;'H.*#N)]+C@J]'$,6@;,ER8
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M9#27)^71 U-HS,4[=..R1 CC!!J)"I 1K.Y\:!-P:%$TJD$(QHPHJ%[-9J7
M0@+DGQ=X-']EG'W%48^'&SC="C>,79^LRO*QN5NDY[++4IEUN5V/_/QNZK$8
M2V(+6 \ =^0+1F"$#?F+87"+^564Q342AL'X#D;S6KK40B//'UL,D+)B122N
MN0^C8<>8#B9"$2Z,5ZE+L3A!?^S+1@*G_%J4>6-3'AK&V3*5D1!)5608&\,:
M[C;8&7H;#&U=2M)Q7N"6C W@DVC)V58^5H-F7]%L1('QBF=?N P?"L6A5&H#
MN@/R2NGD3U!5I!,23HMPPKHH0E<)E7S;AO$$"UEP=(:HY#1@;$\%^OL#BE#
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MWC:QI&^I&H?%>&ENO'%VXGUN?"\(BG$1@1 9G.0CE>(O4C7"I2X5.H#&:FD
M\>@VX6,"XE3E/ECM@T,_C</X8GD83L-LPD4>;:F-PF>A[&?1:RM06VK#\O'9
M0!- ].B6Z!)KX4V SZ.;R,NK1#8!/*T1>R=5H+LX5:#7&K%/>=NM$?O4-]X:
ML0T!1&O$/L>M-\R(7>316B/VIU2\YXE1]5HCMO$@:HW89L.G-6(;#9ZE-F(?
MSZ)J &@V6F/W-@5M@5DY&ZVQ^]0WWAJ[#0%$:^P^QZT_NK'[XM"_"0GO2VW'
M/[%%^$P@6FJC_2DMPF>"SU);[$]H$3X3>!IGL$MYH!^ID^%9G@0_&"9.U6#V
M/1ZH="_/L48O_:'RO8M44<W@+2!J2?=^N-$X;\$CXL9R@FBS<5Z#NX+H6]&'
M%4Z&0SAM?-$2[D*QHG'>C>9CQ8N7])N-<\ \"E(L*7"6VBGS)-[?!5;!;BZU
M,^;)O+^+O/&E=J0\M_=WD8!8:G?)DWI_%WGKC7."--B2>I[XZ^9K<H3\+(B>
M)P5_<QG]$:] >7V_C$Z()X7+\["T]\OH!GA2N#P/'WO?.$O<T<$B'UN<G0R_
MI0F<*9]^BT#IV8L'J)!-<+FJ3@:@"@-EOGXA',ZT;8D+W/B<]F 3^*=>X.X-
MO=XWV=B_(_R99+^H01CXT4L#?@5<3?86W)M<T<@J<I6^-)@9@IW #<R0*Z,K
M?O4 <FVR[\*!_V6(WV8N?>XG4>3WI9GL(QH'CV,UOV^RKZ)Q%_]3R6J&>HIL
M?O?*[V</Z%[YOG&NC[L#,0IC%&_G:;@\'1[?-\Z/X=RWGZ93T.KWQMC2VO&J
M'JA)JH*0J66<I'DH[:#CP?%XXH<I2;)X\'N:9%EEE8I\JWED@6'$AFE'CU.]
M^+YQ?I97B$)/JK$]#AYM-<XO] KQB%E1Q4B'QXZ*%&0VR/"EP:;&>;-^AJ@_
M@P*E1DF$2 7*!ZF'MX6SEAZ]FX-+3?; M:"[$71-=IXU$G1+K-\V((BRU63O
MWVO!M^=S7SX3TC79Y?A:D.X9-.<FH-Z2.%U;-?NE(5Z3'<4MG!<'Y]9!W139
M]J0.Z@4V4]AJ'=3/CT+/Y:!>Y&RNUD']_'CTO [J16)3ZZ!>=O1N#BZU#NJE
M!5WKH&Z*4'D5Z:G;K8/Z^?'MY>?75I"N=5 _/](]MX/ZF5"O=5 O.RTL*>*U
M#NK7 >?60=T4V?:D#NH%)N%OMP[JYT>AYW)0+Q"/=EH']?/CT?,ZJ!>)3:V#
M>MG1NSFXU#JHEQ9TK]Q!/6_5>. N_"I4W@7FY>^\<C=T4['J!=01[KQR9W-3
M4>O%E!;NM"[E%XCQS4&O5^XX?F'0?.7NX69+HU=1D[CSRMW+347!UU:FN/O*
MW=--Q</G3@QY)FQLW=LOD#R6%!=?N7O\-8.^=:\W6"@N:\GC;NM>;R16O8 J
MR-W6O=Y(U'HQA9&[K7O]!6)\<]"K=:^_)&BV[O4&2Z-745&YV[K7&XF"KZW(
MLKO>^M<;B8C/[5]_+G1L'>POD#Z6%1E;#_OKA7WK8F^P7%S6HLWN>NMC;R1:
MO8!"SNYZZV1O)&Z]F.+.[GKK97^!*-\@_&K=["\*G$WVLS=7WUQ@I*.[WF0_
M<\-ULT7"H=MD-^M2Z#$+A<:K]S(V"!9-=K(U5T@L4DYWF^SK:KB06"@<FNP<
M6@HAL5!H--F=L@1"8J&P:)SC(4OS#Z=^?*'XHO'/+V$<CHOQRXR'=!MGFM=!
MP+]^P1!HL#7]Q0?6#ENJ<IVO2?X9#IR>C_SX)%;_5'ZZ/#RGP:;SO/NN7C9(
M!!<$1^$E?;P\C+_78+OY5B LX74O@V'\.?3[813FH<JJ5_^'GZ;^HR@V#:CZ
MZ_:6P51^?N@\DWSN/;H5?2^^T-U=7=]9[6X]C"\48*S1P8IL\$VE9R,_5>9X
M@_ 2MN4^^K48J]3/$X-"8S WP-C[%&;)9J^[_>'[V8%^D_Y*_UW[>_SP0,7)
M.(SKEA7(XJZRF]8M+?&NO'OGL7D0?71[_+Z<'B"ZOK,83O_HUNV]SP8(N[V8
MLSVZM?@ EN1"[F:65'KTYUA2XXPV=@^=^9$Z&9[E2?##]1H1E\F^%7WX\<EP
M"">-+T1F', ?EWX."M5C*U,+)+%'-]@>@(8ND=V"ANZC/X>&C;.DE@ -%\8-
M-QIL0IU/)Z@STHWW_4P-OOE3\E[B;5^PDW+AH'F(5DLOWO<G8>Y'5;7V.,L*
M-9 OEP<M7H>IUW1D;!!"--BZ?.V@:7" ]K.Z5!' YL@/TW_X4:'^!@OZ:3":
M]8OADQMU3S87$,8.'A@(:#NSR-,/-QJU\X#9Y"AO,IXD,5+3R1!#B;/.S?L(
MNR<F\)?I5MI8AC!T$YQ^I2M_,N@T+C#=4.@\B^&YT3C_1U.A\R3>*2-,I\I/
M9^0I,W;\ZB%"M<'!\243JM_C@4K)*7(RP7(#3"UZ9 3LWEVT=A?)O!OGEUH(
M[([C '=PJ?:N_'1P!_ ]&RXO*=YL-LZC=@=_)J'&7I[#MOSTA\KW+E*E[I >
MVR+'/9&C<7ZUQW=VMSAR3QQIL*NMU59N0YIGRO[9;+ 3L-56&HPWC?,WMMI*
M<Y"CR=[%5A+=[KAY#I?T9I.=GD^+-/?6K5\H1C3.T7HC8/;@^.LE07,^4E_*
M@N9['.9J<);#G3QNH'A]=7UKM?O^8?')*AP:YP9M.!Q*Q%.!Q$W$4WGTYXBG
M<6[(90+:,YGP[Y?+!_C\0'N<2;G=]\OE;D,X=)L#AW70%Q8C>=XWSJ75<#A4
MF9@+B9N96.G1GV-BC7,I+1/0GLED?[]<_IR& >VYU(7&^5D:#K1'ZC;UOG&N
MB^6!PT+5ML8Y#!J9F?5<W&KYW B]IE!)CSP#B\G[?[]\GH'GA4-5/W,A<;-^
M5GKTIXAG:_D\ PT"VC,YL+>6SXW0(* ]DR6TM7P^A\:(J45V#=I:/C="8^"P
M2.-FJW&>@8?'U#&."ZM0P_N7W3=HJW&N@8= S?[F5&4JO50UOUHBCM8X-X%S
MO[;GI?WPMR3/D_')D+Y<7"8,+8>9%-<J#<),?4O#0&5'27I2Y'B]@S"^(#!S
MRDN)@DN_H85.XN7I_KO58 ?%4T/E9Y'S/)G<#3,;!/[&>4!:H@2H-,X?LE10
M:8*VL]TX[\A+D*SG5\G2$/%VXUPMSP>55RA9MQOGM&F)$J#2.!?.4D&E$9*U
MP=Z?)9:LHU0M$7-ML"_IZ>'R&J5KTQU7KY4P7XT[Z9'@T@@)VW2GT%)*V*.D
M6)ZA0-NOQ@-U!["\0OFZTW3WU>LDRYU7XU-Z'+ T0;KNO!K'$,X%>V36>A_)
MWR R?C5>J"= @664KDUW83TE_!L$EE?C57H<L#1"NC;=,?3$$JP1,&FZ4^@I
M14HC -)@!\\#4S%SX&V8R8P_PZ3FY<EFWFFPJV4I@+'(>LW=!OL]E@(8ZXL$
M1H.]'<T%1A,$S&Z#?1Q+ KEGJC7;;;!K8DD@]TS%[+L-=BHT%W*/Y$K8;9PK
M(4OS#U3GA\__KI*+U)^,PD"/^0R2(L[3Z8?]O44XZL[5>)*D?CH]"+$?J(H#
M@%\!<#_WKS\GV'5B+QZ83_93-0AG$:#RB^6!?>-<$'>$_6^_M;#_6=@WSM71
MTOU3&?*[C?.JM'3_9+!OG!-GB>E>OE\6IM];;YS3J 7^4U%^;[UQ3JIE 3X'
M)[_'0>3#RH.S(.0S!]A9 >=EPR\/KQ$8>! _.L"YVLD$_\"/8UBI2)='-X35
M6DQYN9BR4)[2."?<'3'E^UF+*4_+4QKG]&LQI:$\I7$>R86"$;_[JO(3N!,_
M#^,+_-F^GZ;3HR3%@7M+1-*-<Q^^($ ME*(:Y^M[08!:8%)';[UQCKE7(\$6
MRA@;YV-[-6!<)-OL-LY;]FK N$BFVFV<WVN!8#R.+U66XWN7T!W=;9R?:9DA
MLU#6USB_SC)#9J'<K'%^E 5"YEN:P&7D4YS4G..P8)(ZIRKR<_C)[.I+Q.I>
MLE.C66!;*!]\R2Z.9H%MH4SR)3L\*,F49J;O)]DR:7LOV;GQE$!9*(-[R:Z*
MIP3*(ME7[V4['O"[?7\2YGY4==5^5?G2\+/>2_8K/"N4%LG@>B_9Q_"L4%HH
MQWMT?\-],1#'#_86<[8&6^R?T;>;G0R/_##]AQ\5ZF^P(/J I]6T1WJR5_?D
M\C#L!MO@C0?$0GERDZUJ+@ \#;,?,ZF_^T6*3'J*7]YRV;>^$;./]'J2<"1_
M??A^=K!((#:@S+K7:YQ!_G3W_UC<K,GF],LFHN>I>._U&F>KWW#_A]]/'P[7
MA6/2DD)\HW&.@&=AFXO4/38:9[4_D(@:=*6-,['UQ%HPJ.,\I9&UR"20F71+
M#L)B DNH=.;)[B/SDZ=2PXHX9#"-_;@8^@%F[J0&6F/E9_"!7(;[B%Y./Z'_
MQO7F84'C4@9TM#](QLHD^G]. H)R"0^<S*=JME/V,COK]38:YY58#G ]ER;0
M.-_%<H#K>5H<]38:Y^&X.[A^5[%*_0B@M3<8AW&8D5R\5"^;'3;.0;$L 'LN
MAM@X]\>R .SQ6>*[\/I#JK*D2 .5\9\CY0]H\X/P\M,O\!^"8]A?WP7S8:,;
MJ)W-337H[?B]G75_=WM=;0\"?_C^_Z*U9G^3Y=,(X EWMCI2X<4H_[#96]M^
M/\D_7H6#?/2AN[[^/U=*C^*&5OTHO(@_H(9/RF\V\>-/O_33=[ T_]N\8?Z7
M,YN8M[+^/DBB)/WPEW7Z/Q^'<#>K0W\<1M,/?ST'I,F\K^K*.TU Z_YK)_/C
M;#6#VQSR@UGX;P6'@7/1GU=\UFU8)PICI<_>[>%IOW\]/C\\\,[.]\X/SV8.
MU+3=GAWN?S\]/C\^///VOAYXA_^]_[>]K[\?>OLG7[X<GYT=GWR]^Q$^TB=A
MC#3[H;?6 SQXIE/]X6>C,+[(D[CC':SMKWF]]?>;N_? KMN^?#HP[MSIP$<G
MIU^\7X"NXR3^6HQAD< 3\C]50VHTM.+%/C+?@0H_'"1!0?G68("O$.4/X0'@
M,*M'Q!WL*G7WDOO]2.D3]I,4&,DJ'#3R)YGZH/_Q<1!FD\B??@ACVB[]Z./8
M3R^ 6?2I=?T'9!27*LVQR%MND2Z4OQ8>LKN[MO-^ ]E(#OPJ'^@7"X=9@^._
MJ_E\8VUK9[OVJ_6U;OU/YBS5X_<O8*4=^,%6_5=ZJ7=T2#XH7"7>_:\K&ROZ
MX8D_P'D-'WJ3:Z\+MS=+@]7[3"9W1\D_8&E</KLK]6U6D9'Y_;WQ\%1=B-!-
M8B.J5[QADH[]',32=?YA&%ZK >PTR@S&]D!^ST77?/" .XS4<!8C[W.##^1B
M]??XGW\!;/FXG">:85-THM/#WX_/SD_WSD&NL(3\<OCUW/OV_?3L^Q[\X_S$
M X%$WW9[;_IOO9-3[\T%_,^1=_ZW0\\15D90[>V?X]?=W8W-TDW5$M+N0Z^,
M.=+=5)FGOM0*FC10TZ!MGIPV:(MW(CC6,^<BTXOGRGMQ7/C1J9HD:2TSSM/"
M\.*-E4_7+2]NYHGJZ7'OZ]?O>Y^]T\-O)Z=S6/ &\M_N^S>#G^' ^ESZY9MD
M%=Q\>>MX=:(F+?"QA\N$>C(V4N$YX'>4I-XPS& WWE3YJ:? [AJ\4A%X?][V
MC5PEA^Q *3.W 7RR.H8E1OBSU8$_7<4+7E6Q9G;O[_-&#B7G1P2J?\)"=WVI
M?=_FRJ<#%9"[B?D0NH#*O+;CH0/V9N/M!JKL+255+AN:MBK0LJE YRF\+J0L
MA+EJ4,DFW6IMTEM/]&>1Y>%PVAQ5""S2KV?'I/,\NCKT,I0/00/TC:(>DH^4
MEQM2\3@.X0W39.S]7_@_7I[0_[Y2[:0UT%OI]"C2Z6RDHF@_&<,VIW>43]NM
M?&KLB>K)\NQOAY\_8SSNV][7?[;RZ=[R"6TM+QEZZA*VZ:7J7T68PD% 9H69
MER$%P7&)A.!+I*$/L]?RCJ)7C6",]?$_/N_#_ML@KE]_..!PXS##I YO&$;*
MBPNTA#_<(]YY2+D81_#CK_1;S0UW,.>DN[JQ\QYK2V\)?)IL!XYA D>@ &;=
M+2U#A'1W9VUW_4[!R(JO8.,&5X&<578/?,++DB@<>!I)ZHW_>Y/7<T?E>[<*
MH]ZL,'K<'=23SGU)1 =BX_PK?*/)9!>4PZ_[)Y__>7Z\?^;]=GQR?KC_-^_X
MZ_Y:2S3+0S1/J(H1[KTYO/:#G% ,Y:]%+<\'P3M1 >;U#;PP]L(\\X*1G\)>
MW]Z;J)^;%]Q1B'U+D\LP#N@J]B*00;G?\?;]V!_X+=&T1&.(YK^*-,P&84".
M%, 5P)DDQ:XD_$$*_^_"C\-_T]^SU+)4-'%?Z;0W&*0JR^1_/L-Z79.]MK[R
M:6=]L^-M]'I>MYN/O#W0]POEG?TQ&RIYX'OWX9\GZ7ER90(SV,IXWX\N_'2Z
ML+=0_M-)JOE%R:*'BPXP03A7$_@:%[!!(FS>*XQE<2?FF2NS>Y!A+)4=;.!M
M,$<K;^"A[_^6P&&C_R^<["<#FZBXN?+IO'?JK>^_;]6/EI/.Y:2"0\A$)V#Q
M!^'$CSQUK8("<_OAXV$8J.PEL]!>*0X-7X$^]DVE61+'*G(5?.R&^_<P_>%]
M3I(?=R:JY;N#V\7(UJ+$R/SWUHB1[8>*D?EO>; 8V7FH&+GAQ/<3([MSQ<A#
M-U K1["KXWWE2%-0_EQ%'[PW]R!^O(M4^:7S@_*RN3Z3,_+V'I>,U531MU$2
M5_QJV.1O:WM]=7MC>WOI[O9P=>R'T2WNQ1M9ZR$N(*AGK@24HS >)O]/ @I]
M- 7M(%L+9C"\56!:!<8H,"BA.QZ0NIH@B74\QDS/CP?OP! \\H,L'%N'.'[N
M.4J/! 8]P4Z/T?/G]1U)W[BW^Z7\NZ>^S3/0^](P#V'%E#Q1*E4#;U*D68$N
MJ3SQX FRL;GR "X0LQKV B<>U'BBW.FNO=_>N2]1]G;7NCM;BZF5ZJUM;[Q?
MR%*;FVO;V[L_4RPEUXWAW!JN(-\B\.:SC*9%.^N#WN=A'G&,TP]&7A#Y67:'
M"/CKN9[4Q]UZ9]-Q/XD6=3,IO^$E7]Q7<=T36JGK8.3'%_!![%V-0OC$\M';
M$PGN+JT?!RUORQE[G@O&R#9<)_7%S^[CI1-I-NWV^D3\1LO<7/D4SR3X>!,_
M]2ZQ-VU-ZE23H-1 &K@[3(3-,)<Q 'E/L=-_/B#G:B$@6#27:F[NY1S>#SK<
M_<GJ4'@=^\BJ7@ODA&67!390_NIG _]?,Z1WEB?!#^^+G_Y0N??Y\_Z\Y,49
M<^0%J]<7)?7:\[Z"=;-@L^09SP_H(@(23I@J+\P\7U++4 M)^K!=CN;57@_E
M[[G7PUDD-]S14Y_U[FECSPN3XW@ 7"I7=)5B(\/%)D6.S35))<Q(\AH=1Z[=
MIBK\YU]V>MWMCQDKU?QDP.,=,!8;L/S.B,;]3/\^B)),Z3\D&3Y(+HDD^E/Z
MU*?:6IUQJ%G44>HS%F!?1V)0O,&5"M,"(3%003CVH^S7E>.O1[..3]8LB/FP
M=G%B3UU.$H:+61TD^:HL".('.#NLM6Z8V_;*I^W-SF9OH[.[M:X9G-[J)W,)
M?)5P"W[N5<O5='G:4M.XP2> 83!2 '(PT7]X(<,YM?DM1/%7*HI6?\3)%>Q3
M^1F0[P"^R J5=O"2!FH8QIS^<EJ ];:Y_EYCC,-+@ &L>?^$?]PSB>SG4]+I
MQ,FCY*[=\>7W#AK_ 3?^=[SP,[EO&C5EG=([(*1G=>/GN=G__$OO_<8#>.C2
MT,J0$ZR9P1%%Q)KI8<&0+1;B)SI "#=1UVF)NN)$9W(#!8'PI+1@7BBKEZH;
M^-:2;'6H3*M[2&[X->;&MV1W5[+[1Q(5<>ZGE%^=VH#';DMNSRV:KD8*== J
M!;WIOO5&((.0; :>'T6&=ERBZBMY -9\.!UY@T+*+4 52D$M(+VKV_.HV#WS
MWF ; _C_60'Z5S9*, E4ZTSY"%2)BFR]\K-9TJ<?RQG>=B@0\J;'9^R#F0;?
M]_^$$^#S]"C\"'<AZV I%:OMM$D_R[W==6_@3[.U>Q.#5/N?:G4?P_"%H0F<
M'P!LI5%$<=^7+Q1OOR;/S6)?)2]PZ EI!,AC'.8Y$)2*@$S2)$;O3C3%FJET
MRCK\,3IQ4.6_5-Z!G_O>$<O<$K^P"[E"V-5O@0L5$5N_9ZOGWAM<?/MC;Z.W
M9A3@D)+!)Y@,_MC,@_=K>(+*WJZ5*J/N2?S.'>$5"2\PQ-]M(/&WU/^"+-$Y
MXI[,T<A/03#[00 DGN) <4)XM$7CVD]!QXY7:[Y(,,_  YF)P>D+[R)-KO*1
MKJ L4<^94FSEACJ7';TI/3C/G*W0UUW 27EN_A,HX.6A.3LQ=G6WUU_M:5W%
M55#6;JR!;*1GK9QOL"0I/QO=M9W-WD)2 D!*;/?J?_* I;H;-_>'?7A/@64+
MDGRN)\BG9\[KSVG].H7CMQ5)+ZZO0)/1XB'UU>D^X,]%4I?LRPWQ";,"><A&
MT'!FU5X5 9]?5:)[N'Z-P#=1IUDEX$%ES2^'.3R\_<QB&^B] "0[G*.\/3-N
M_5QL_MD<[O/U<C:&P8*>4(P.ZZU!+_?C(/0C+],-US-4FH':08_TL5+Y*H05
MOJ^=K7F_[^U]N\U#7_$ID"<!. :ZZL'2+C(.PP+B4:/2NG9A'%"=1%,\ +T<
MMQ[#_< WJ;H,,^) >M^XTR*FF#I%-OUTD'E8T!(.YJ4>;+SQW];: O>V@U^"
MI_]GFL:T_WVN_[:.2\MD)("AHXQ)3)X!/\\5,C4D>:!^Y':P-_^"F)S)Z*!\
MC@P_TAQ!#8>*G'>Q5%"$Q!)!/,9^1.IOFD0>YG$X7,@F]A3 UU+#:S;7-YTR
M@C,_[?NP[.K)=:2F%!]YTWU/S'5_S=ON;6'-P5N='%+*H.I'H'L[O&X8IN,2
M/Q\@>Z3,@@'MV"\&82[[6GLFOG9WT^$X&*9[N.,DW;-P.XK\BUM;SM_4<[Z!
MWIOEI\^AE]E@'V#>?2MIYJH0+HG7*B:R1O/OR,T"BH.H&'"*#Q],@H[#B&*1
MF"B6I*DRK3Y0?TM3#$,F2-N785)DT523=MV]-)^\=:O*HS ^R\?Y(9YOWYQZ
M'IF76E;B9-SY/2M?I ,?]5Y"><PC9)RPJ*))SR$/$@<FL(7RD-(-I["0'TVS
M,)-.,NB"N52K?1\U:=2U59SYDH43*/B*@OWF[:Z\-7*SVD$AS=PH70IZ_Z5/
MC19E"Z+=N_Q!@GZ;ZVO=]8/5+C")YT+DUQ@&QLQDP !&"D>QJ-&OBHSCI*)I
MS.?/95X79L+L9DLGGSIF 9;]VCI[,^\5M.BM]386,_1MT4MM/NG\N&>MO6&%
MRG@@%M_5M\F^L0?,:S*T?";^$"-"WR,_($,&N3W0[I&A8I.JY.E?S:8H "M@
M+<0U1,58*:]K]V"7\WY+X'\6X41O+(Z>H-BNM=(?HSOY?0^\</_HJR# .G N
M8>"IP2ATDW.](<;[LUG:DMXBC(737DP^*^ESK&V!'3 !FT"AFB9I<F0X>O\J
MP$((<0+R7*,[I+2W&77."^%_;_+I8]HM*&K)U?S6& T@8KY)/$IW^[G-B]?J
MWN?KWWE65OKB#3U)FBW5V-Q257-3IF!Y)L*;FEJUN3EUY?19_N_SE='<-W_%
M':=RNU?JIDE?SU*W\VS9M+<4U\BSF[VU;339)PF'?3^D"A/!+Y6UU/]G61$4
M.W_=_L3O9TE4Y+,_F4^Q[G]Q;81>V%_?[6WT-KJ!VMG<5(/>CM_;6?=WM]?5
M]B#PA^__[_:*_LTHM3K6A5KMI\K_L>H/0:)]\*,K?YJAU>WF:(;Q:N7$\\YW
MSX[FMYVQ@:WTYDX-^$GG[;,>ZNCD](O76U\]6NYCG._]]OD0)P'MGWP]/_QZ
M?M80W;=1BGCC$[*WU[?OZ]O<WESK=F]NK';G=F\;:UL[-R=D/UX6]5R,& X?
MS2O ^QNH0!KR?Z"@/SX%>_(;LQ=OE**6\Y?;!1TV/'95]35OGBKO'0\X@Q<5
MOX,0@U%)FG6\,Q6'2>I],1D6TH<2T[72[)=W?E58/97SB%H?S6>N+9;<#TNV
MYH"R)?!F@VZW1. ]L=!JR-P[&0XQ@0DS<#+L3TR$?'@]8:</'HPD54O2+P4O
M6I)>2M!A=W6'I#?J9+9\]'<U]8YC=F7 ZUK2?2GP;TEW.4'WOD2ZFS7^TK+.
M;6D7LYO1WRH.RI:47PH^]+9;6EY*V.V4:7EOS8/_\SU.599$F$H)FO20QC!0
MCEQ+L"\%Z!L[+<$N(^RP 8]#L.]O,H4G6/",66QH [O)<I<AG <__)8F.,2V
M)>R7@QPM82\I[#9+A+U51]CRQZV.Z\/Q)$JF2K5D_6)08V.W)>NEA-UVB:RW
M;Y#77_P_@92IT_DHB098E(3$?(HI)J")?_/3?.J=8\L![EK>4O>+P9#WW9:Z
MEQ%VF^LEZMY9JY'6[G^M$MXZM%\@*KS?:,EX*6&W42+CW=L\VCB0B0/-** _
M8Z0YOFC)^*6@0DO&2PJ[2A[8>@T=XW#A4.H\6QG\ A&@)=XEA5TYQZO;K2/>
M_Q>[;X0YE5R0[(4/(OWW09CAT+("NP/N]9,BUQ,+3\/L1TO@+P5)MC9; E]&
MV+TO9WQU>W4$?J"R( TGNIN4,Y>'BHA!\P8X'/ZKP!1N^V5+W"\%0;;>M\2]
ME+ KYY%T-^J)>^@749YU0%1C@ULLL4A3Y:?^A6)?]X&"]_ZK4''04O4+PHR6
MJI<3=EOE9)-N7:HG*-DY;!#,Z2_)(!QBH3[U]Y-6'J>XH\R1Y5/O;TYPZSO/
M&/Z6)H%2@Y;D7PS:M"2_I+ KIZ%TW\_UA7O["363SG0F6: &:'NW-/Q2\*"E
MX26%73GGI+M%2=W>_SY5L*=+-?@_+8F^%#!OM3542PF[[?4*B>[I DB:(T %
M%SB$5CEYVUC%G.8M[;X4^+>TNZ2PVZC0[F]K%;UX0$;M83X*@U8=?C$P;^EU
M26%720O9VJ^Q:;^E(4C9B>W^C:TDCY3XI<] ;PZ#UK9].0C1$O.2PJZ2)K)U
M4*ZH.+Q6XPE[H(=IPAV@)4'3:>:/8QHKBG9+VR\&/[;:9@1+";N=2H;(UF%9
ML?Y6I,'(YXC13 Z(GCMXC#,^.#%[;X@3?+AX2G[:4OF+P926RI<4=N\K5'Y4
M,9^Y$SOV:3=-W?^:>?L(EB&-5;8:>DO.+P8E6G)>4MA5,K^V?E\S?K!T@BLK
M[W><HHAN[+;OYHN!>4NORPF[W4I.U];?,#K\!1;QSORA IW:UE&TU/I2(-Y2
MZY+"KI*.M76,U&HI%'5D/T40>4=)"B^/O?\"@S@;A#)FF:8J?TO5)?8&.HZI
MVU?;.^0EH<=6V_!K*6'7V]KJZ=E^6_^%9 WD&0ZPR"GUB:*_)5'8%D*\+'BW
MU+JTT-LQU/IWI-;]:5^EF10UM"3Z<H#<DNAR0@\6*BO+V[?U\;&YE6=Z;G K
M;%\.+FRU/3.7%'B5#,N=F^FXI>;7@! M-2\K\"KYE[>UU].)7*.P'[84_(*0
MH*7@906>2;H\@POV\[;,]T6!=GN]I<NE!%[7)$RVNN^+!O)1UUOUCFX>LO:.
M!MOJSQVXR(XV>VO;.)%]DF34 /5#BH,%PDLE@]AQQV6 RACW=?L3OY\E49'/
M_XF# P'@H$KG(\'Z8\Z\[U5NR?DO[C8<_+IR%^:XHG\T2BVA7*C5?JK\'ZO^
M$ [XP8^N_&F&8^*=>QB'\6KEWN][99]^Z:?O*M VG+/NRQG /STPMFN!L;_W
M_?SXY.O>Z3^]KR?GA][IX>][IP?'7W_WCDY._X!_KGX^.?D[_GUVOG=^^.7P
MZ_F9=X^#WR1/'A7+]J+( SI6J8H#6#7$X98A5HS%A8_?3)(TQY&71TDZ]GKK
MJT>Z*Q+ 8IQY__F7G5YO_>.5ZM"_NA_U)TF15C\JLNHGSAQ-\Q5FO<O7)S'<
MPA1'8.LO::>X _N5]UN8Y"H8><=QL.9]CR.595Z"G1:OP@QS< ?8STD-.IY?
M/BJLLO(_5NA]*X,DBOPT6YES_K$"P.S[L3\(X1_R\-I2P!=SCOT07ZMEZEU@
MC)>"P!DD0<$_\O/<#T9JX/F9I\2N952HKM0!V1QG>9@#D]60'";IE9\.5J,D
M^8%A8;L;#=FK$%;BR:IXV_A0,J0_OZ7A)69@.G42G^%_+G@:ZZG"!MC>7I#C
M\]W=W?<=W*(/BP_48,T[*P UYK\>+N,2IT1Z/^+D*J9S%S'_.PVS'UD'_@SX
M"NG-^  AES?T:7Z5=S4*X0UC?^H%?@$(AUN&K_@^,NX5.%$IM>F&I;PDA:]'
MH;J4#<"NYR!S!Y\%_"VR/)W:Q>#2^W!)TK(LFGJ#<$A(G7.Y&!"3-RS0P+G;
M!M3U!)[+ +3XNO$D"N&?_:F7W7QS:X@N\V[5AY<[?U(&#WX6)[D'" ,7AXH8
MW2'L#B\UC(.H&*B.UR_LHU$X#K'T)4\ZG@*4PD-G&CG#U&-EA!+J_2PKI&KN
MH_OJU"0732(@([C3_I^8/W0I"\'IX4]I^(9(B)>&'VD^IX;8$"Z8(J" J7D(
MGAB(]P+0X2-S0MBE3"B4"\=G Z!%.F26%P-$G52&(,&ZL^L(P!*>=YC@1B=I
M,BB"G+>92?4NOQ&@Y#/"P_$*6#8!!('7Y:'/)\/6L_ .NQS_#AD'_HJP>(+$
M6L1,4<[FB 2IZS07&<YN]D+%L&YD<1/7&_M!FH">&"?C,/ NTN0*[Q(!]K%\
MR<ZK0"G+0M#XO#^3D.>^O4M02\&?7< JF/%%O;#I"NJ *O?FX/>->"D[CZ:,
M9XACK/MT".>PH6<>#H4 \"*N$JRU%"[&QYB18MC/&^NNX:C5K_HJ0D*;^1Q.
M"_QIYF.#X]4O !<0:S6W[)C/@5O V_UH]@N^65>J9H"G(+@TP3.6P7T3=5)V
M789_ @AYO("5[F$457<$#*_Z49 4T4!_!@O)Q]FH]'D 7'RM(<*1#<^&; 8G
MLMPHJ&Z7VLAU"^)O2%V7?AHF1<:"3$2;(\LZWCC)B(FP",-?HR@) V!A1)VI
MPAQ,^J4A') ]TP391T&8@MWS0,@F8Z7%-? FV!BV'ICS7L8W0A;/!\D%;[CA
MV+0KZJC=!ZH<%BD)7V+\S-(X&=0;*4XX$Z0C-_W&FO=W-2T-;\>ONX"&!VO4
M4M\[8BFNL1/H-;D2W_XQ\/N8Q.4X2?7Q0,#SL9*T<BHMD 'B3%;A<(Y\0LY^
MB9HI&-4X!;-#EUG6&4BA  !.74$OU> );()9$6JUFF>0^!8^ 8J/^%1NQR>M
MXAFAZVO 2P-S8;$.@PA3^ DLA6IT1\0Q;NKF)^E(^ )F ;S!WT%<Q7*Q%>P$
M92K-#%8Y,!1580 P3U48=^0#/!]H<RHCM0QW-9'1P"'=MOD&M@BJ&BX%:^"&
M$-<C/\ =# K4FJ*0-:7X5B5(4,4LSLR.-&"D(@3LOPH_S1$-:$]"OEC5&U^(
MQB%XK+7; .OYF3_C)6JV[8AZV/THD:=#L4Q\H[2?'>Z3X/;MF!CW^I)X+F6R
M.P5."#=RZZ'_0/. ,09QF[3-">P93(,(ZYJ'22K*,)P,%2A\'YQM$BD06F2E
M:9)RUFX(,VZ49+A%T>[[I+RSRD<:QQ YT 040D2A&2T7N*^HK62M3&F1L8_*
M-SY[584K&A1)/](6%^!&,1F@18;ONTEB#84OS.R)^*.[)_J [:H*=]$$116U
MP.VN S7!G0&V_:L(4];4_ E8+0'Z#KW(OYJ'0W/L\J:YFLZ^?_F"?J:3(^_T
M^.SOWM'>_OG)Z7)XDY@1,B<F]+!LS673K#R,Q\A@<59LYKU9V>>_:79LMO*V
MHRUSP%<P&2]&H 5<I(KD,+(O ^3%'K-WIV-ZC_/RN]WQ/Y/"4 7<U;! U0 %
M3JAU(F;O0+M@QL'" U9K'-\%/T!Z&% [6.%(^G#!( @B>'P09D%! LAJAP$<
MM(\*:D%2 U^U %4+O1D7BO9$DI"W5Q;V=W)6D;7+?IFJ9 5QN.:=XQI\(U,O
M"EGOY6N +Y#9J>N1#]8LZ@JB<V@/#]T3*B^BK1(_Y$?$>4E'W?Z8W:C(RB[[
M11:2],,/AB;F)7K?FG<\=%Y@U$W6#@'0I#QU2BMUG&6,\=:IK.]Z@*X(>:+P
MAR)]WE4Q_<$E9H1'^K#H0CL6-2@ .=-AT2'5'9,T#)1VC)0)NO2.@4)O"(^[
MF@+ZXF5&*!DF/@(S)=<L+#/%=5A3PTM;\WXCQ$7P&^#!8YEC;DQ,TS.^*,'G
M#_=DER;HX:<78;PJ8:,MC#5Q5'$50X@?-K9T7#&,T5?P8;6[,[DA2OC(.@I0
MTM;'Y^-%Y;OI;JZ]Q[O88U@B*(U[PCBS7"DP 6TS56!;3<3[PNY?P![EIVB0
M K8,P)B(D@D9*$!,%XQ#Z)#0"H"Q"=U'21462=1'#[%H.L+%V+VE2!T=JS0@
MW)_5]EJD6!Q2H%,:I LY.1%6D8\>2^LES9$!68?C;?AB_>T%A2'@J:)D\01)
MQC8HOXIL8ZX@11RS< __[6M#UWVO&"O(PS+X68I<#!C;N,1X6XQY1(PY09$"
M4 C)U!"X=$I( '*AK[3KG7@">J3"&&QX#I(4:!@AEB7C/DA" K3H!2%(:90^
M()S2XB)##0$%$F 11E)(+A+.P2.Q0C.#?F??3AP+[ YTY0P^>J/D"M&D@_)G
MY(,.H4,7@'AQHCUE'C8187._ )/%D?*RB6/&0K;#0:4;A1/19&1CN)ZX60(,
M0_8Q+P.5%'04X)JA$A<'ZC0@ML&(RD!%I(TAT?054X2Y&#3'R>3'<)_#0LL$
M84'18OUC8[W5Z\H6TUS!Z$:-1CX2A8HE)C.MDL2L@J=#'?LG_S@^6.WN LX#
M>#"(0X[?*.FC_$ZBD)*G<+TA&-OY#7CP&K-U-N9GZRQEXDU+RPNAY1GVZ6HN
M<'-9F)+;"HUW##5CD ]Y.<D0-FAA"1R:4(F<U*DU8=E)3,+)!]9/LJBB]^"R
M8"I+.-A(,@]$BHK('<<6*4J)#/"+QJ+!:V)UP:.*T>.@:,ZA0K4M D.-1?'4
M4?M9T:;/93>M]'A$C/N#T0L]J^)MT&H( !/^E+2G29%F(!!\TFXPW.>G.D\*
M-21R'("NCH\&_B3,*:CED3-&/^1X1=">0@.+$(H2.$E)@?_/GB-$8L4V_ 6P
M/F!2[!8(1TDR('.>M906,QX?,V*%&5S62A+_$/MKR>?%NB7&?PH))\U7.VI,
M)OCA6"D.?"7Q18)+"PYI@YW<82VP'Q'8W]!2]0-5L,9F 53.#Z D%/0PSLH,
M_ W29*OM/[J&8)5W';-F8 EK=>#%ZL %-:(D H0]%>BD+E)M!&N?EX"4,K]:
M #XJ6R5-#=WN!>=C:+NKS%#E@4ZMP\OQ*I"VA4F.29&33HAK?(])AE-9C$E_
M](X.]DQ*A1]06!043%^R1'AULR]:&)WX41*T>/$4>$$N0]"9,"]0QW]0E4]#
ME6,<@^J+6!U+,><W+R=:MN[HQX3/.?K_6/V5Q*0 M-&,%1^TBAAJ&(E$WDHZ
M"Y"N'XX!D!=^&&>Y5V0?01T:@J8M#II,4;B:Z(]HS8\B=:%3B\EJZRMR3&/^
M*:9?K%*>$&8/=S#HFJ? S"7]!H[MRWNM*]H-U'$LLG5'/Q'&' _1@XH:5!&3
MC>,0+EO6\9#3AWW*?K+*L:%X-ZR-,,4R@]41!<%A ="Z"C639#XM*P6!QJ)9
M-UX+_4=6U-RTP+S$/\2PR20611%P!F/J#RBU+U48RF)[.(SA3YSCP?%K2M3F
MC#DNDR"GO,K#'"UH#&I@.H8.'(Q-PO;,^OPP6N-A1GH\()[."QUPM]462QX5
M2PZL<4QYF2)$(O]*")=T1=_ZT'0=1]SR\:?EXY+@F/2I-D[X./)EFUC^-S\/
M1JM_^-=C=(]B.9G-X]$IN4/I5QSAE ^VMTBA!Q"(6J K)9&Q:TV0B!F_5#ZP
M@[EQMG*2CW&U614 K?R6HA\76^)<@1+'J?GBB#>JNR!1K-!3XJ<AI4\-4LKM
MBB+'"YZ/T.^9Z<HO#=+9/-46<H\1?&':(8\VUB10[ 5IIZ.=*TB+A3;%B I!
MTHM,9J6_);)'!!4N70(54E5?B5/#!JC'6)5"$>CQ&.L6IU*MADGJ:0NBQ^:#
M:3@V=?O)9!5_Z%873E _!E,6+1WKAZ+$T(K+2^<=^W&<%%*1/"GZ49B-Q'E%
ME0D)_R\;YS1/R\\DT@22%A4K>DU?!9@.ZE\"?9-A1E4V94^W3W,R\0N4O$,=
MZ"(G]X *3)W(JHU[:EDK[\^,3R_$V F^O67AC\S"W<)C48$(W GFA:A<M53_
M-%Y,-V'.AATPU\Q(354F]E)8$"T<BEZ4#6<TEL',55B*&I/!2\[M%,Y!:?[]
M(OI!J7%(S%P2Q YV^DS>L.;]H4QVO;M/R=UCO%$Q#=S#/&%=XXH[J*GXSZA_
M0W@9SDVY0+,MY#Q5K290.(WJ[Q5+)2YSJ^-_+<H^(<JZJ*;15#QJEQA>R0I)
M64C!2-?\?B8J(YA&915@L?_P+\AEZT;<?"P] *T?_K<,[U73[X"?_'ETI4P.
M,2XSY>SZ[KCJD+![3A=SM2J<. B<^?BE/DF+R,^$R,(L.Y3QJSON<'B1$(M<
MPVI&[S(5,\*8C1Z6FLQ?B2-W*%R(<A9K?KCGS!B+A-%;XJ0+8*@DDT)?*N>9
M<6(0MKLZO;C.Q?-2EWI0+0&PF4:BF1G%TDU&44/X'1>=RI$H+BJO,YM/I"01
M'L%J0G;I,%45P:ARU>BG)QN$E\&&5QVN:E74Z,=]5IP!4F8EV7BZ:XM;KZI[
M ]0MHK.N4/$%V),@'-(DZ&FYTXL-)(Q4I VD,97FMO+EL772"$ :8RF<@W\=
MR>@7]01C>6&_X%"/1C3&L[U!Y(?>5T#6J<)V3Q-*UO'VDS6/2A2-T2*%^3<7
MZ]M^0@.%27]* A3\%MH+Y6 9-V(8&Z_EG^Z4M19K'AEK%(C.9*JX$%H#*^?*
M$"XT[3C%C%P$B27W](5^RB;C)>F%'TOQ$C^ O!'G27?$T(T'B5$F+GP>1SW&
M4%*LY;I4VX[9L>EHO6[E09S$I!-P[$OT9<.*4"D?^-@CB=M?V0P_Z>HE5<E<
M,/IQMBJSQ;+'RB:[(5:, D-W:9$\(U/$2X5*'4E@R#QJE>U3$-+/0 1B&--/
MN6'#2/D1H(.:A%0OTE:$E+!DLZT(:2FT$B .L=^3N#D2M.LH&5X;9L M@=:0
MS8:9Y FU8OEQ;2RV?;0PED#\#S6UXEK2KYQ:RQ8FCYJ99[IJ(!5( PG? TZ9
M99@SH;57VR:"?!;P_(K3BY4S+5CP>=_7SM:\H1I(TTIR(.?^=;6$*>4'*7UG
ME$2#-JCTR&4*)D ^"*-"5^%C;TJ=]>@V<#-@P>XN%'*:"YL6$C^G.4JJ2;W>
M"(I@6D@C0S$]77^$D[GX9N7X?.6METU!;QR7; IW#?+F!.X@4@_UH6"D,JV4
M'I]3(B[HGVE!/LOY83='_?D3N_D,IS?K/Z]907V_D $#&^V @45T??NV=WKN
M'=\?KY^>@]4V1KPKMFRM-.-P]4 X/C_\XG77O..#PZ_GQ^?4@^_@^/20&O!U
MO+/#K\<GI]Z7O:][O].(!V_OZX&W=_"/X[/#T[/EA5W3]ODUR;T]T]+Q <R^
M*1=[1Z+8;3Y1]-: %HX.3VF\R?'9^?'^&2'_X7]_ ^HX//#.C[\<GN_]]OEP
M>:'5M'V^,C+H]9I/!MCF\O"?WO'7HY/3+WLX$>BE0Z6[T]NI@TL3;*QZ0.T]
M4FO8N[R];%[MK/7H&O[WZ2$H"/\X//@_]VQ*>4<0;>^LWP-$)9QL#-1^:Q#4
M=C;Q&O9UZQ-;L7<,]]0'.Q@CJ<M+^$W;YT_+N9\DGYWU]\O%X?8;1"O,X4Z5
MGY$S1WK^GPPY;67@?<\HMO@-4ZW5H*6:ET,U[VMM^>92S4'SJ,9IB[X\W?W'
MW!CA+DW\;^OA[]W8R[[C^;#8A:2IC/V<TP^H L/TF\-U3*=VV)5N;J4GF3VH
MH_S52,6>PHI\'H=2*L3L*S/H3]JSF_?;R%.I9UY]F>^<MNWBAZ<F/C),#HO6
ML#8&9Q.5^\/;$A7.$K.3DKCE/PT0I.1YBG/E<EINDXY]+MPN^3--YJEE-IZI
M4G3ZH&-T*N?8LUW(;AP4I1OJ8G;E5.7NC#9="G^E=-2H- F!^IV&8W-%U,(_
MRI+'.,[" Q*-L7M/W?9O3H4[#75H"MNB%3^0NA[<Q41<TA;U]YQL\SQ2XIL$
M;5D;Y-A\:(OG^CSA5&*$9H2D'3 GT4>>\<@#9PU;\"[TO#!.3+-3YYQ1E!W,
MVDYH/B0FY-I$ =I#^?UV>R*&*F_&DQ0< N3"C=3M$7XW=*"96W-:F.,5C8HQ
M=V"-I#"Q8Z:XP,;T*C312Z<ZW'R9("1R/=;$C-BT _TZ,C&JF*#HENFD*#KC
M<(QU C0PRD^CZ2J_F?=7J2; ;B8\N,6I'R&DY^EVS'TS?\CDP*UM>1 ;+YBM
M>=\JO]3DXC2HG'>U+I%2MP7*#7'[_YOM,HUU-)%=*=,HI5*,0,/*I K!5$ND
M*@)%@"3GO/%KSO0I*MI)=9D&D;![/R5:]LZI,:K0>YS0N"U._R*I=B-FP2XO
M4G],@EQG],H=ZNK5<ET/Z0RZGS#755 I)37H=+;E789T$LL-.8^79^%*IV&?
MA^ X)4)F4;=&XRXG $ 2KA:QI/H0$]00*NW,EO@R+<3%N _GP;DQ"N=Q+P-S
M/$_T\.52OUR;>W&%%8Z1#)ZT,Y%P6F>1N1W]::P.72?20N[4M@G>N34T@&PW
MU=Q(P9M%#$K2X-5QZJ9A4D4F!9BY/8?34UIVUZEG&7R"@1KC>' <\6OQ7&,2
M5D @RRB]43H>5AX%?GV5F>G,./D]@RO,6!6?6N69#HV'H-G8;LMC9'W3TLQ#
M7V/ES'P1OP^;2*S1$[(91$:&;Y#9$_>'WB-?)'(@G*/TU2'Q3-.]%"(.+%7-
M3GI@QNR9.\$%.V:^:.[_4" RB&2F(98##?W+A-N*NU.E9MJ7P2H^5]WS&9PN
ME#1P"0#1<1AWCDU,Z-0DU_$4J3M6P@SD<ZZK3O$IEZ&Y?(%:(UU92TL&03],
M[5GXEZ\Y56CKA>2R-\4 8='/%@7^TTQ+1KE=[MX\3X NA;C[=K>S(,-!_Q#(
M-$?A%LVC[$'B]EO6MU+U*)V;Z?4ZJSX9EI25*U/L:O5 )[TQQF8R.#5;^W1F
MYUV[NJ>>(J_[[.?)AX=QE2;X39<J9Y7F%4EG1 )R$>NAV "%ZS!@_1Q$5>0'
M/WC. "H+H50+D]K "<>B]NCL\1^*JVE!4N;<DO52\;QOTRV@I)_,#Q:T0+TG
M4-TF0EJ#0RL<!QH9"Q5YP+O$SK:P2A%2I%-L+DU#<FZ#";\'!><"E18A9)QU
M>N?F'"TL[PG+<G=Z,X^O9(12PT3'>4[$5_ZA2Z'P7JV.=JAN%8DSP!$W*!;B
M)%[5O5-1#VM!N3BRG.E;3EI\J5E"JAO7QA<68DE-"R<@<A2?-5,86Y M#&1D
MC>$H@?GV?F4@5*EI@4MU#D?5UG1;?[-08,GD:H<1ZJYV$R O:G7'S)!!AJWF
M2>,5=;KC%9/5#/@@^3F3M,)!;56<=0X:[8F& YH1J"4%G7<5I*$9(X.M*9;#
MSU9J_\E-?5U[@R.*.+&3AR4Z_9"H69E?\FK!Z;7;ZV:7+17-VV;M.I+CK"T-
MOK-<0K.^]Z\"-11NRY0JVFEEF5GO[!KFTVCY27'3/)P[R98!SY[UFB&?Z'$I
MXTN)89/S_IH&T&6*S:OZ<':-C_@^2Y,Q[+J0^LKQ0(9.#.A6Q[GV\)=\I325
MJC18W>XEX!:/H ]2ET>MI+B3WU/<HIS0$F #S?'[1D)?XESFIL#B1@Z%?;'0
M'ZZC-S:*-=,O-:DXS3FNED]U9,V8LJ6;<@)M^S/!,.I.KSWA-$F9A@9FI%F;
MEG/\:G2WL"\&N[]Q] V)+Q=E?<KQ%^I9)-WC)&KD1F[]S*3D%#D*MS7.M-NS
M^#?T).Y!75YU1Y+*;>";*3_%$W^Y!%F'I09[>@PB:*W(%XQ7I\!$($7VI#1
M8<E*8M-'+Y/(R&3(4=CRZ_5<-#W+8<XLSD+*6D'15>$E6Z7509BB,!MTUWE&
M=8W@+:V5DI]:5],3CB*OQK)\[5)4=IX#R70@:( 64;+)%:*,$,;*@0K"@9()
MJ[4A95=@%]Q\3S.)V@"WQ.,Q7LBOT-$7K;$9L<@.,I&N\.T8+(2;^CBVF/*
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M#'8&?,7[!T96IMYO>) W9__X[2UE5$\B2JFAI$C)74DQ]=&FV1Y)_=.!(I(
MC5>W'=]/TDDB\N/-T<'Q_MN.(R!0G8@P'1135$<XH ]$,;S7C <<XX_3D ;*
M2O(:7D)_BD^9W'FMN6,66X3521<C&F85#HA#LR A!1/? R_%5YC.-DX30K?L
MBL1E$&%S2-)91.>Y*'PX6:Z<$8T(=Z=3CF55-2LG$9?]\%9(J\95G8;,&0@3
MC'2PQ<;E);0NOZ:LZY7>0."X&H&!H+,,\"?<P\Q-6.4<UQ(DT3&O'; 93A6+
M\ZHB;&M1;$J<=HP[37SQPK2BG6H]\B<1730^;<U0M)<O4"=]A536.BCG$F+'
M/N.$Y(JTXWU\9-^/_0&8!+?AZS[B:\5^"W44VZVQH\-3G9EH!,8-?CMM_J'G
MD*0TX5E2D>EZ0(CR\J4$-^>L,GA;73,[&9I3OL.MV]H2<SS25)QB6IV+4<^;
M[@^I-Y(M %A ^ZG@ =T<0>XMY17<X8*$CXHR:";6:SM!:_UQQ7TC9HIMMZ^3
M8ZGLT6T6+394EB2Q#GA(J=$2*/LN7F+-!S?)Y.+H<OCU^]K9&F=V2,HKG=YR
M$G&\R77;<2@1:<]F;*J3VFB]*9+X:A51*5TN^_HX7I5IRQ0/4N*6!',&(#E[
M 1?8:D=EDW8'6F\EMF9+,P,T1-F4,$Y4'0<6,Z@_U4%=>)#L>AM@XM13QG^9
M3&^.AU8&E1#8:]!YR;JFH./8,(2J,XC*"JTIQ' <O;=&H[@)9DT\JND(.L<%
M9=W2S#.!3Z.C6]MML[YHUUK MA#5Y!PGUN?D[\Q)QBB'O70UEUMA:/M*2<$4
MO\.=UE)J:5!VC4D>O.L7(^,O4W5?$0N7 9_&D.G4.5A<%+LY8:D!:/&P?"2)
M_%)"!@D/-OC@ GP$3H[=(#*= )Z1;\^:@38?O 'GOY$LSMQSA5DYYNV4_DG/
MA0*1$=,P^U1V[V9.ULZ]U^:_2969GZY5F6:NX_:DE'"9*W$Z&J%4KI HP::F
M^,YNG,C%;+UNQVM>Z49D=J$-\_7#I#+YUX3Z7">BHG&XXH*Z,"D7[A1STC\*
M&:F$!,:6+5RH\E.D4ISV@H6,=!#VZV<SL4S$.?(MSVTFS1H(%KX$6ER4"+1L
MD)7R((CWN=>!$8I8\;";5&'F"U>N1.I"V31'+GN1=B;^3'^(/T9*]%8<;0;:
M&9FH4M0EFCM:KA1.2&*L@=9>'8PC<_V=/4_YK;PKXJBFAT-IZD9%*1ZHH:IV
M/]#CX2EH9117;,P@R7U:E["-$OS ]&!TG&U&-24^P>>T>5_]:?ERQ9^,"Z=A
MX&1F<=H@N>MH;(C&WVKC#IW4HD=O84H9^K)\@R5A[-*-O7[B<#A72-)<J=6-
M%O?EN2DF?VJB1T1Q+Q84'[2S@I6AV)PN5CFV(:$"=-7'[C^LK/"NV)R@U3@3
M<NZO*'TC-FUAP1Z/DJFRN5T!S5[".)"?54Z*0U02SE"N%A.*]+]27'_)?G9&
M%VN]:72<@X(.I;%YKKOAD'(E]DR'L<2=)A-8[.2'V;BF25E5,GU^.?* !)]9
M3N],'HNQRR"KL)1T8^*P4F5N*HIH]IRV/.?,<N)*Q9HAFAU6TSEQNU0+A;5(
MNO9.Y[U1OEO'*KED8CO:GZ$%1#:P0SDP:%K@$FK9R')-4=4RY-*><QY)M:N%
M!+81_U44 <)%)H%U0#$K-(EC_T)506HN>TA#PS*37)N54T1NFA;H6,DW(0Z>
M&(,&):'@^+;Z)O.D/^598L1N\KK^+!F:9EJH(_:EY,S#:'^=TN-J\U<HXH)D
MM=3W0W.-4H9EQDDY^!7-:*LH%WBUH'+H\8<V;7%^3F.%V/3TJYMN3=\6K*GE
M3BI75YH@Z+;1HQ^4%G+R/8)IG@#KIG@OZGTVJ V*!B@P?=P=1[\JD*H"I'J)
M-?=W/*_1#"&$>##=)N*S%S4[>I2\=.[@9'>V7VDX3_D NL&;_KYTXI\]J^OX
M=(=P@K61VV&-.G6A5C.?5S'!8<>C@SV.ZQ]^V>LX7F0@".P'.V<2&K/D),4[
M9+]%0"DC>B/5]^,G;F'$W"J.H12PB]..,_-5*6MY.1CJR#2@6M544B*=4GJ8
MSO1.59 6(1.YJ*1.D2QW]5*#4F<W4S:5Z\;(95%F*=@D>&OU!#L+A6C_5#.$
MJF3N*M%6Q8H(2N)!A9TG(#/_K=,74"@8Q[>IE-())ED.!^\XA16XED[$'4I"
M2S5X84O[Q=HI.'<S3Z[#@-&R)E$I!G**9D>=RW%BU'I1OH%4QUBT[M9$87W)
MZIHM"V$>/37' 6TE0P,T(LO5SO+3L\(H)V?V::_(JN4<EA"HW9LNIB,)5"->
MX0+Z0*^V8*GJ0G*ZO143T=%G1KDB NB9"+Q7"8YIH$IK*X*J*34T>%46+?,(
MN^K8+7O0"94U6I?K5_Q\U ;17=;276^CZ(\^:2.<A\<2M\QJ-'T3B$S,G.J(
M!LR8VI&Y&IEHJ.R6$=V!W07.Q/$278BK!>M]DOB"<[39*%DM)E[2AUNX9&8E
MR49(S&BU#_@]I<F71J!<C4R,W=$W9_@4MJ5S2GR<K*G;+2>7$3@G:D>)/$U3
M[1M&VZ)0':3^E4'HS 1-!>[M(("G@(,>.^D8P%<^];;.=,HA.2U::"P,&O5&
MEF36B]L2*X8+J_])VCO^J0MO2?\J3R#7K7-\M^L\C?U#A3<*=<=RB21I>BL)
M!^30[L2LLJ[DN\&.A+,'Z"=.68OTLDLY>>*=L?),15(NWA<>8(]1@!:Y%HE<
M-N^XT-XS10T@2!4@:*$'6-0 ![XWCP5I07%/4'!@?E+H' Z*L%#V_U)X%?9,
M&(,<-)P[(*GKXA4O='N\8!2J2V.Y<5Z7DQ5?K@&I-(^947M)(=;.J36O-/YA
MME%CRIH>7BZA]1T*GLL]*APM,IHV!3+W;;@D766O)SK:J//T0?>5!A%4)Y<"
M3\!PF+U^Z^SB?$L=BN)<,>JQ&9?J^-V!(Y191/X!=E8FY,RSZ2\2)333+ZD)
M33A*N!Y!.HXNI/?EHY/#;XKC2M4&ZN6D+G9&Z?8[.B7K2DG?"VJZ+\7GU20&
MTT')IG_HEB[&IJ-B!-TQRW53HI??-X:.CG(3V5K/+8$_9"=IJ0<-^_BED43=
M1@2N.HFX@@QL>)JN1G0]&N)N3$R;;FO>"><L2:-*,"0% VT'$B>01ZA;CY?2
MRK4<>',=\1HQZUKO\#9T(1@5BSD]V"6!:6ZO@#N ;QZTC%-P&E(>>,E/9AO4
MFA#$TL5F_ZC-A:#<6<U]8LG&KK0(<]59"CO,YI&M/9^<7_DTRZJ:Y5CZ@_-]
M,/.7LV/DKF5^K200E<8&54;ES'AL*\W$T>L\2&RQ >D'A@>6Q$TI7&!'Z;IO
MI $R3MLBJCLSW4/O@$"=&@RIM%K5J*C/WS1Y4T]#1^9.]TUR["G:;0W9_/U9
M J$+3K\QB<]ZA!(7"GNC,",?!8 /D^I59J= P,\,9R]-.7-8/\YH*M5GQ!CZ
M%^54<8/FC"H.M&"@R%135+Z[T+7-=H/[!T6C)E^0*Q^G]NHH]8=F(CCN4KY?
M;!L<*$GVDL%V:Y[)S[@REY\[>67.A&L#/\PF&@XS9;*1ZV6F38D'BR"AA'U=
M_%I^!P=*J(]'-O*&...++ MJ;N @$ .2M!] F@-@,>@G_L^_=+?6/VYT=<D7
MG6- B3A@,8P+CI!B)[R M:'_L;FYM;:.U;Z1UH.OG(N+E;DP?+BWO;:CG^W
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M1\#\&C2$X/YFIWA[I-MCR<,2QJ:T0O1(TTK)3K@1[P?\*)%TD,IO,*PLHH"
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MPCW?'CY$/XY>*'\+R#-*#L(7*:/^(IH7J3!K40BID67)''\B<=R%"EH.U51
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M)IX5X[HZ(UZXRZ+&?[Q3%0V<%\!5U8^B7.=Q4 ,15^;7[O]@*_%93MZN<V#
MBI>B,Y!LRMKKT [//2L"%9D8W*:J:G""10(,KJH4O'D?D7JI;$$7DZH3:$:
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MD]F]SDCWN3IZE32CZ>!8<U&YW1'G#3!(MQ\AA6WTK.B9.7E6EGI79HD>4I(
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M& PW)QCG.CGF'.S;?$$;9<=]XN3X[2Y-C9+A. .53X5A[)A(9\UR_&DM=-I
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M&S>.FP12IK6']' I&TE]KH/;7^LB!4^PN,X\%S_FC/KS0@6B'1E6J*>%]S$
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M.1^J-Z\H,WB,^0IC%U:,M*J&0EQKI;G1R66=#;SO-PB;T9^$N%NH'-Q67=[
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M&BV,&_[SL$98.VF-JB'IUF;5\FQ!]9W*IXX9S;ZL%]$ B?(4PJIS#"9+0_+
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M'@#T)!8Z8)#$)[.?EYA12FL,JAMTCU]X$>PLX&/G=7X>*>Q!8A/<SU&E.6X
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M'R)V3-33B!Y$_L3E/J/FWM+V,74!1JJ$_=6,:W@<*^['%^B0!?R(38<+$*&
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MR]/A 0W#ST7#@$FWNU[&M60#6KD/B9P> 6]2[4;+(,Z?2&%\LSH(?E1S=Q)
M L0:=Y<= LG.\?0,+=Z[<)N.YW4Q30X&$+E[BH/GR9-G3PZ?)O*9Y)=%%EFE
M=_J5I_P5EC&A X!#G3)E/O,UT[;A;M<[TG"ZAEBR\5R++NYYNG\T2 X/#I+1
MZ+O,Z./AHUL\=4\U J.X=TC?)J27.[CE7$#>!Q=X\%^+BSM=A<<NN'9AU>EO
M VBDGJ>U"X%DT0VT&/SQX$.R?_*(<X7SBZIT4?O1_N%N\OC)_MZ3PR=/A@DF
MS$7FY4)PR)R=+0QGGYNR#\1005SFQ_394\F2.6\*BW*0/'5+_K=T^LF9D0_
MY9XND1<Y&.T=..LYY09FM]SWCS9] 1\C_^;BPKEE#G4^&5)H@'I>JL186SHM
M>+C.MJ'TJVIBGE.QBO:&XEJH4.P"59,8(EVB\(NT_4AM'G<?Q0BCJ4 -)M6R
M]/G!-R__GW0V?W$LN5R.L2OATHWU? P%B;31H:NVR5G.J1?PONFS^E'X5Y11
M HV+O^5G#2?O4FIWX-\+,<O T,/%2=>@;1 P&/83EGF->5V\0BWQP81R1A 3
M57H8%- 7B_GSAP^OKJZ&33X>N@B.XX<)]9=P9,8"?I6J>L9DL;XX?"7O!\8.
M=[7*GR=G?)P,70PTC&16XPO]1[A$H5 YC^<0UIZ)6Q$(3Z3%<7U2X(LIUF[I
MZ3[;[XU+-M?3_7&#/-VG1Q@&[V2]NX3U=S?:$,?UCT:Y?FG5689KPTW?;TQF
MEGK93O>>J*\X*S"'\HCST);DX'A2$#G5N.\&,-[*&<4!N+73B1#HY].I>Z]I
M7DO-SUDY=S RECYS_A%K"Q<H3I*%3.=T$_$TR!@252.3N1,\C?I_&%>6SEE@
M!U_/HUK(59Y^@@CL8CE#^Y"S/R44-[P6(6PEFM^9MK]I=Q7R66ZNRA56('/&
M2,/5J#916IENT'"2L%6@3:7UB$N@2,S LB)W340=(J*Q1<)8),R3+1+F.PSK
M>[\[F8J!U3'R!9$=- #>T?IT'Z'"'[8P%7NXN F0:4VE:Z2*Y^GBHG*[TVW2
MK%JZI;Y'K@M\OP]OCY.=K''_V>4*HF#8IZO@8L99[BLXI&X3F =$9T!S@?(\
MEVAM\RR0KHB M4.'=_>L&->5N6ZR\_'-JUW9X5IM3WF+3M++BLN=[C-MU:E
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M2D@@ P7"*2->RC8X^ON['W]Y]1%;=('Z/3W.:M.MW-J<A1<00&]+43+M?N@
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M<0"B#PW5T-QM2WR2O!NDNI00>0Y&!#[I54RATZ(V3([+M:QS"1IB"U2D +M
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M^B0G>U9G250^]H4399@(2+PDAL#20UVW2+P@$?D3(AN9J301+HG2,1R-#/>
MWNMQE,,H0X!9D^VHCY6AWJE)8R016[1(Q)#!JH7D#@1_.F+'0(4J+1_*2K_2
ME32\FS7BH**H2]XXG%KF.[=E3.4:*)BN0U9N-H_P9H]5#)O5#TK+]-F6G*B*
M-%M%O^ESZJ[D 5N)N7QWZOP'!I=I;6;%<?:%=%"/.5 (S"R0VBXC[1D0?^16
MHIIL[9:1.$YH-XW@K'BVU]FI49LOXC//Z&;A>_6LSA:">UKRMMA4A%;(I&,)
MPNH;&WJ:BV0-L]@S1B[QM I.FP?F<9W)D DE@DB8)B-#JJ(7;S@&3J(BU<AF
M9V27H5W<;7?[&4#H$*0U^BX4DN9E"+P<HR]TQB [ JN+ /L2*U,]SKPU*YZ@
M]AFNYUP'8:SRK"2$HE3H,5*DLTNB\ ?-"&[??J=C'W3;=XSL>HS9QGV5)!2!
M'#O7(61F]',;.Y(WN,))IGE0/O%C+(1+'E:,0RVPB"1*"DGPGTNP*%1J&<=C
M*3>6(UWHQ"!Q#FR(;LA$T-]D7@U9)WK&'4(XI:V@O_9LHST)3&CG$CC-6+Q;
M=3:_Q.J#CPZ:C__MS.;OK8_>-<6>FO"R&5[>;\++/Z,A6[O;VP41F!!$L41$
M5.T?$O+3*&# ;GM@]P\&C":3*Q3Y]=O_]_;7TV_=/6OVX5B!_K8RZJ]6<?@T
M2>;QN[=O8P$\2+(B$.YO4=5%9TO\=IK,_+=(16 6@B*!\>RXA1]:.XR8A[B^
M8F0=V;32U9C?U3CCJRE'MF7@"9,$9:6YU.Z56F[XO^]EG2LX6N8N C) ?.8[
M^!MU)B!"PQF>*\M0_N)S +(N02@])?0RJN2.?'QVNJ^GRH?GI1+<]%^Z[</6
M$5C*)/(JH+'<>TY@U&<XB]JD1LPZ4#IAK%B[U*)$^[(-_$<)N$@Y#6:NATK+
M!!$Y0;*>.V-NA>I(_$%.E=*0E\HC2*4KE!FA%28* KEAAF['"!# *-%,]1<Y
M#$Q"N,6ES#+E"RZ9R,5:C,%9G9FAAAH3]\AIT'DWB(V[5?Q(>D:,31QKK".'
M<<GQSS3P*"$C,?),;Y2I.T]'/F'R2D0E3Y*B=D(O=,!&SCR,I _"6):/N8*"
MTEIA[V&?/9Q?P:6K \<\<RH'-$LL8 Z\#:S W>+.MZPOF#&SO'ICJ02!K4,9
M-+4,#"3S^Y)QI.(<Q1(DS+"D%),5@$BLA"[G&%&&"CMHC+W70,OE6Z0W>^S,
MV4CR"HN^E&$I=+Z:63<9E!782"K0Q1W?1N5T%J)=EFT/ID(1 A'KNJ$O359N
M3Q>A*]I :_1I[\G:4Z$K@NM7LPBC9>):04D5YT=?"P0^8>M217^!-80%5*7K
M*$SG+&94$=H=W?&,50XJ4O%0JZY=".BI$HVE3<+U EZ>:YJ=!M"M /0;P5_P
MU[(>5GU'3A>5C:?'>K_R!)LC>^"1Z7PB;S9+ ]W^ 3,I&3)09B.N^-+DUIP*
M^+YI/OELA\,!$WU$&3@_(?/O<2J7>3;JO%AZE!Q.<S;/=3:2O]V _44>4T,G
M!$F++)" B_7WV;$P/R/_&?6P"D2XAU?J&I2A]_1<<TK/=DJ@7<M[8D@BE=MP
M//RV=V6K#I&(-#,'O8*?9]ES_@_^3O^X%CJ2-H1"JJ0&[4^A4(X$YXGB^CAK
M-E8EW\*GX!E9RLNVA-E?("M@0C^_3AWG:''$<*V1]/*RB][#F 7IVA-Q6P#]
MH8G@SWR<,5H";!,XOHP(E'4S4J%DQ?1(+3=RJ\CGR2$83P51KD5B0(W&81C0
M$$Y@HJ^VK**220H\?R 4T#W."<@E2KU$10DQ+YT-$P40L!1MAK-UKF4LAGA$
M(/Q"OEDAWPZCK](:7$X/HW+>/'^W38LR!Q^;,Z1U'P:V1QGA5\0R'X#B7UR*
M+S>& 0 (+ ;#L["(,-4]%!2Q5?YF7!CY>1CFQ5C45, T0M^U^7KDCMG,E)!P
M%XK"L[8O3$TR12?(6:RR&P!0#W-\I1*/TH2Q*O^#88T)M<=$Y S,,?+B&1>C
MC]FQ<961GKY)1C:8S#C 2V1VQJ6V'4+BTTS#6]5KQ$BTU-E",G]>YA&1U2A3
MT[-&-AKN&!TMN98T\Q5[BCT79!!&[9#<8M_[3A5Z,FUT]>46/SQ&"%66A#+@
M8AH#C8CQ]WGH(?R0'XZ_.Z[(\WAI5>2-C24;PT@3-'+R#'Y_C.T9_TRS;D]J
M U:MW5@P12_)/I=>*+Y=V#-ZJIB/.E].S\@?KMX# T)E7@];G5QRP/3#6RSG
MLF7430+.J-5*KPXV1J-TBR6_6S%;B3T:^AZRDUB([RI;2$JIHO%I]N+,Z="2
M&?+Y4TD2)8=CX(W=FJ!;@T!;Q(F8+5,_E6%E\?,<MG3&2GQ?9K*7YT&I<BX]
MSEH(SXU_XA':H,E"5>KU$H2,F<C=V$O/MO>,OV1+!2:+UWG<%FKI[E!W7!/F
MH5C,*)W\.K.>,>V:$WNV$Z.&7*O:#C1WY&?P)]WUPO#Y4[(A60!1 @3.#;<D
M/E?#N5["AY S=TU&9?JT7= R RY"D9EU*[J6&(HZ04X8+225H\^P:T$;F2YB
MA-8,R(4>4Z6)RD;T(G</Z6(!U+$ 8[4Y]6<[=4P2IO12+6 ((00#?*29JJ,P
M],?F#'[*&=BZ$D9G<%-3NA7M53G?(%/XT\AHE<D.UN:$GNN$C-(R5N,$>U$4
MP-&?J:.*2?*L3T-EHZU<@3R8!V;NJH*O#([A$EF_N%YL?BGWIO3PIF=*A.I'
MKA "!,LSHQUGJ@O:LF0#55G'6 <&_@JC6DF/I]H>G42QD(E<'[CA%B8G8/IV
M)E:5]F\4.A>T'*<P8_+*,*0MI21C5B0G Y@YY3$?$()(F9J4!J*_+\UB"9>*
M_1$+<P3^0$*+:3PN+A8 LV5$>1:<[4(5509^+J7!H=-.);I-,E146[=#SC3$
MY0FJ\@>U/$Z&T0[&:X%^W/F4(5G0XT+]R50/.0/$*\:J:S5:0M0G<YS-@U (
MJQ*7,HU,_W:Q#RWY_G5YCY'NDU5Y\JP-\, &S2J7;GS0I!N_"&N_Y':YR*HJ
MSLN_<M&00G#A[N]T?^FZ,3X>.:2Y;@:#8<"AQK+K9)PMM'X"^)MS"\)75A5N
M?O;WN<)S;F.50(F= F 9NJR)I$*@0GMY;$J*Q&7JDRX*CH316="Y<3P?\0NJ
M$!UXX($>A]$<A:^@Q&W8C6^$B*G#TRA13B\_56!A=Q='Q5@B"\:[2ZFDE(5H
M:]^ES!"5Z<!*82#QKI#1%D(!?RB, NQ:H2-'#M?YR9P&W)!Y"!N\4)81P;-8
MOZJH"X?QU<Y>AU2J'0E"V_ B S'&A(-A)B%5P\A$)XG-ZBO;C+(;^:J8_*X6
M2B4+TGU%81YJW$,_EZW':3((FI--)IOPC>.G0@=$X1KH%/#KB'#\<GXRVS#T
MV%04LU'DC+FU "? +JBZ$A/]RS=G$HY3:3G"' G)4QW>4JHTI1AGJ1;"]-8I
M$'M\![J^N<!;P<(&>6<J=3SBF=^(I7@G,PU*EG9CG0C@PZ-QRSK%.E&L?R,5
M,8R^8X<E1A8;3XGEX SDP:.G@JIE\;>R^;RRK;G[BRP6 S7<SBO$O%H@!SH%
M?(_9?CGK/N^&1,4$,HMTP=47RA#7])K!<RA(#+H$G.>.U0'<Z%U8PL^:K:H1
M3.3#K[0Z+(2E:(X>G$+$E)X0XG[(UL34)-@EBA:@<(_5)((,2HUN Z?;3SS$
M_E!5XKY:Q*T8454\(AG)RAT=58SEU6[!PMYR%7H8[>'\L"O!6TUM>]F<W_(B
MU*@2_,,+]+.NA55/'N'B$'0<=;E:R0<-C>V/-$;<HWLZUWONW]YXH_91M]?M
M=<;BL-\7;O?0Z1ZVG:.#MCAPQ\YD\+^=H^[1FXJZ3%9(E-;+>$ONQW\_;'5I
M&[X:[86H]5V4DNMDA1K]\CXFLP??AB?S-;!.P/[%X#_/J]>Q)=^^1>@OEXQ[
MK3O=3H%;+?;"6X++85XL86$]UP,;^KWU55]2ZX,4P#L?G&CDN&&\"U)AW+)V
M9$?WKQ\^J([N"'FAGE(".ZM%R] ?RT;'DF >&4<Y ?7MEGM=\<UFD16;E>VY
M96231X8%<UJ^],]SLX\.ZW6S3RIWLR^D^]FV+GQ'^C]._TP]<I54Y$95ZGK_
MRTRB\ZGV$V7K5.#%QI"+X([O_C7YOX;^"+4Q6_: -],<\6?R%S$6$9*SZA)6
M=.*)ZQ!_X7N@C@0>_)K@'_%LU(U6I8,H<N'245<JF@PY]LBK9XY=4 %5[RQ9
M9274@;/+CT=E[ H83;76F/L(1,#P[3%) .XJR7Y4?#(;]<6E?#?'"39SNS]?
MG9Y9_6&N8>#OY]].+[]^^>?IB75Y-?SXT3K^>G9V>GYU^? -VNIK=PY"\Q%$
M59$]6Y.(>YV*$/$ 5/N+TV_#J\_GGZSA^8GU\?/Y\/SX\_"+]>WTGY]/_T4?
M7GS[>GEQ>EQ"R\]RH]O=;KVD^[!E[5DGL'5:B_O&3D[;^N(!EW25.^C8F:-[
M";]6E=G?5%TK?F\T: 2YC$T&92'Z%YGP;EM7$0:-/AM-41YV"!O*9&<9%0L6
MF@1;<)8%7T[ >$ZYYQ@U-@1;8Q%34R7K],?4&WF)U1FT.AJE+WZ$M7DW:5:>
MQDY;EG6,X*\8#$- HS0@2CO5<$85]S.>@VHQU'BUCSR?K8RC':Z.HSU Q/0U
M3ZU5\&V#PG"_99U\_@9R[NNW2]NZ/#W__/6;=38\'WXZ14V.1.'IV<67K_\^
M/5TE"NNEAW0[1[VZB=ZJ&=8G5"<2RFC!I0BP<TTFZ^H@K:]RB!0)=?R)9?Z-
M3'X(G)FJ\_,=%1H4L>R.B^$/=#^G"L-5;4?,VV'F75#NQAFJ0$R[!^0TZ^<*
M QG_/_:R: 7;N#&(?I]#PU@@RS6*JG(9N[C-P>@=>W/$O!R/T[D$05^S7 5(
M6JY=R1!LEK='489Y+-ZIO[Q'8$W?6;SS MI+^M%[.984/,@T":058VK,(.D*
M\=<9/VVUF:<F$?S/56^67[?@J[<EG_=;G7:_]*MVJ_/ SWN'#QMIY:1ZK?W]
M_8I-:M!O]0>#BDVJTVGM=WMW#O66R(%) J@.J?=O;WIO"H0I2:TSQX"][[F6
MXA223[WKSG]8'<6\32E=)$T>Z>59.M'^N2,[BET@9T%>\DTQEH)T2]Q5.Z)6
MW,;URIU]]1MWH>+O.D7MF+W_S8:MV# M';YFTJ'9K/+-4GJ-2G&5M&5=PAZ*
MW*;=QZV<\7=$N0K</3GW\5B(R>2]W"^R4Q^R6:A^+0G7</YF,QH44Y:#K3D\
MQQH&;B1NE_.]-C,M'.;?8?3=MGZ_'/X4Q7D?L^SOG4F)X8ZGOM=KE>A)F#C$
MV.\[O=V=?@$J](YKNI+0UKV_+T>HFR &=:'78'@UVLF-W:VSN*5N.P$!$X\\
M_8KL\C*=><"X0VR<&,T<CKR'UPM;1]H+Z7:1Z10V4]A7X55*X+E/?CB"SW[E
MF*1^#^>MH2^5^DC<".LKF4_4<V5I=L<A3.E+XK:X;*S;[AQ@\(\!B2]4+_D_
M0L[ HBJ T$@38?#B3L^V8M@!W(GLM?_$N.2%M!,EC/S4$Q,4)JH 1TT-K$+8
MG45"G:?A?V!+JOZZA*F,HYOPD93\EPV3FQ*^R'?2 %M?$*3NQ(MB]%_LC7TG
MIG8;\M\*UE>#KJJ\U=^<[\[$JQ_/!)7YH+^I*BRZ&"WK4A("@5]$*DO6YY/5
M^8A%[%154X]MS?S$F_MY)%)U,(P%Q 5 "E"5":=EF7>2/ 4&<H</EX1+:DS7
M0F)=3&!M$=-^Y^BHL]=MMP]E4^>I!*+UK2CTA:P[*B'J3[)G&KM]M,I$P7Q]
M*3^HA2,T='ZN".SEW7!DPSIK?6@-6UF3@M\5-"HEV9QYXZEW[3"-X^/9PQ\B
M3!#('L^_0R*11)A8*9NK<N8A#/K)7XS#,R "S YJ-0+W>2[";TZ08FK4@#U<
M3].9)_1_-9.1)P*S<Z= TDR<MG7V80A2\/BD=5(_UKK3V=WI+B/7;V9KOR($
MFA>J?*,GW-D"93WXSCZ%,FNG!V]RLU:$>+G.>6,Z,$N=7*J<&S-5>C"C2UW4
M>F$6M8+@/44Q!8^A/HP_DH65V">8).@U*[>&CJ?;"<O:;&Q!PQ"&G%3'R/^L
M?Y#X5\V"&5!)!B-0E/,$SDZL2Q&%0:@TWW:;-=].WP3.6*G/PB3/11J%#'!+
M0EY7++.:_DO,2D!6>V'+AI"F^D!J [ZIZ'/)1M'[F8TDZT0Z7=O*S@'5KN.I
MX^DA=(^(B[P=869Z6SM!> NCZ0*/,^P+0:"PS%UV93 G8I!?4JD_*.4A"X"I
M73Q0N\A'P?B4FD!B_+740/0@^(]?/UQ>' ];QFJFH4_=%U%L\.C_ A- 1*:6
M@VG0G8/WL74YGH8A-3M3FA;NM?4KZGD?6I?CE2K5IU3X\RD?#/8IRQ11?#9K
MJA&BW:**<;)5GQ!NE-Q($FV[3U&AMHT=GX<WE$-O=6VR/9_%M5B;U9\Y"1#9
M+1#69"(P.7MZ0DH2A8<+.<6;=-S49D/+O W+?A!*OJN /ZPVVSJ$9>U-0FK,
M68@(V-9)U)($;/!.:IH4X@8CNW0%"&+*F->>%MF7*,^+93Z] K2@8D<E+#)D
MS%S#$SF;2(0$F$E]5,RJ<YR(=K!1LCO5G%,)'7F28%(*2T)6%^:1D?\(TR@@
M[.),)[ADK<.V?DUA;\D!@._->D+@)$[//GRU?N-?M\Q=2L+P.V-KD;@NIU&8
M%A:J(E/<MS&S@1UQG!(I/2S\VRP/5?TVQB"-+D]"F7S8XLB-/D=Z/"L)0I5)
MN6Q(=\KG8.#1T+LNLWW13D44J^:[^CC/W,MM4IWV<JJ30J@QDF!YJ-]2T!(Z
M1T='Q6'ZMG&I/ZH&0?EY7(IYPC]0(YPY"U+M6LU%7TL@P=Y3(5NGLSF/Q498
MG _\ %C-K^C"@]% &+=.@^L6_'EV@4+YRGHVJ;QM2E[><+++[GZSCVN)8=BY
MB:#4>>!\0)[P",5U-"A KI,;FX:*HBF( T\9;)^#-VTCT,-.;F=.P.78\"XN
M,7M+SJ_P*A424UJ6C5:N49A&]8=R^E2H)F-/O3T*0+&13*TUM5==/=+&1WJM
M_/NH2K5\<W;4/1Y>G'X:[I:,3;(G]^,=NO,79Y]WI3N!+5%X'NU/,C*]4+5/
MO,HZ%>P F]A5VLX*>U/7#%*='UFF_ ,ZCE$(FL_Q5,QH:'.+Z/$, 5ZJ(/'C
MY-JVW9SSM\-E<?:64C>;N@.N.SAZO?A=379OD]W;9/<VV;TUVK@FN[?)[JUS
M=F]M-,.K*8P16\=@3(#I(\CR/SLA5SQI&3EXCLMAXT5:8T_917<F[2/IH*O=
MSFTNG;R8=9E9[.QM5Y1JS<(XH?0Q#JURA!:H6=8AEN2JJ6318]6MQO2_.FC2
M!^%-B(8F9YX:K@'TI"/:<O9883;9^Q_QXD\PXE@X^&8=TZ??.7[XG\5,^=<I
M@*VS0LU,0XHARY=<1;#]OHI]JWBV!-"CQ(/;LGX]7N!JB&G5@_,NB,A6;OTZ
M%&W 1T_22#:+8W1$]+!XUQ*IFQ-UQXX+UKZ3K6@>B1L,1\")DBM>9BSH4\U\
M*C(!6&_I*G0)VE_?^1%>SD";^ =2'",OQ#%BF29">3_"2,5E+A%VT?H2IEYL
M^B^R*+O:U/P>R CZGI,FTQ#Q.RG,L=^VY@*D)RY,W,*G#&!HP%'"6S@=$4$M
MN3DEG,=G%)SF"=*SGP/JDH4!FQ/.WT5/D"@$GR8"*UHIX9-&6OJ-6JE.D="A
M?HIW "GY">_DE! H<"HTG.Q/3UKLBCC6F1,M?'BNL#EP.(&<WMG)B@@8XI\C
M+)0F!YE&*U-$'11,N*(94,4X]9V(\'4KDKE9&PE5Z@]Z]0F9P^!:^([U:PB4
M[<QD.N;'XPOZ[UF3FKEUJ9D21:LZ][*VV9F;RK^4=YDU!;,;Z40'R(TP/N4<
M6)VC/4)D1O!L;"NJ/0PJRS /['GNC+QX',KJI<B+93/3D0")*^[0-5=$ZF7F
M8KO+-4,R*G451K#@$(%*Z?Y(!/%?PYA!M*AVR1M_QU%]-Q+!LIYIRW>)N]YN
MF]#EL4H5Q=%I:[GJ"+-(@#2NN09$[E,LDR2P$XB'KH:$M939 A1(_!N,Z3!T
M-;8^T6&M!'OZ2AUC(B<X28.Q 6^187.3=DH30:#ST@Y2"%@]"7TO+#8TF0EL
M*2QQRQ&O49X[;3CUF&%3@=>HUT,; (0C(E2/#+!J5CS#+#^&\C6S,!7EB"A$
M;%PEZB?P[B $@@^C/9CQQ$O +,@00>A=\10AMT&?FB'&)/QPG&1$*@-[DJP]
MRO\T1=1R4NBR$B5IR=J#6Y:@XF6HK?DM>^Z$SX9=W5$0@ZV*.X>47/+$<IBZ
MJ9O#V<+ZU+*^@/T3V-:W<]OZ<'G>N)>>*9U$V[]?-1^MW3YNM)"9Z-(:1=1-
M@)2$Y!:;E:-K@HQA[2M96:ILB###_<$=!KQK3D^4O4%(.A)[U<F@;I1B"[;
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MN^WV$7MGM(]MO<XFV,_HXEC5HY$0S3H_KD#SUBTJ3[#B[ 2Q'N DJ(TL]KQ
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M(Y'M]*_NHF-K!W;>ARL <_<)1]%ZLXHJWI1<]LJ<H@DDZ 7PYXQ/;1P&,/=
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MRC14R# 2<$8KLW1\$JE"L8T[5.<:G$_>5%#;-07"E.S0&?^9PKFX<ITP0[E
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MCLH?LJP=_*4S:-LP68E0Y2^T7HSP3Z ((6Q5^5@[+"! 30(%*O 2ZG9>G$L
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MJLE"-;-0C_+;T62A_H3<'97AI4*K*V ?<IEEI5<R#2BPE^6]K2BZM/.")A\
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M:[05N_[>]IZ_N[%>PCR,LO4D)$';L;[09OSROD]E9[?1W*O5@;S./BSB7EX
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M>?HF[NA!=!.!6M&OZH1<4Y)0QXW-=/#Z38*H3]3?E_50FQSL]^K$^<7G8X^
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M!E=XCC I>AWJW&%*#5HDX2*X@A]<4:Y$,?10/JI,K]35:JF>E^$@%K2ZNRF
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MVTJ0["RV5IJKN1/B')F(U.-T.D%/4JKKAMC,L3 \Z3R52\)NWVAY'^@WJH:
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ME!ZE+$)<15K)Q]REN9?;OER^6F963A]!%D-Q.<VYG(G"%99LY8P+;I)X0A
M[L]4W4CJM"HJR!1,5-:@2F45.I0 S1 AQL]7$,%N0/'^!LM3[+-?8&VXDVFF
MHDWB6UUXAN1HM[Q1/,<2N3P*,970I*+:V7940,:L1HG?*29\7>D"82N0_=R.
MA$4\![*U45*6J<P'A Z%O%J&]T?O8PF!E/);=&OD*>?>NQ2DUCJ%A$P(#@4J
MLAXIMBR<78IU426VK3-/WFD!@RGZ32MS=\I/Z %&<6$[*9-#W)L84"II>:[R
MM-BZ2,-)D.291*I#3@[K4UY9P[1R6FB@TO(L;!PM!_(Y5&I4?#%OB 9YPNW#
MI#'\75JC?F95&F91VNAU..$OXUB;([[$8N%XEP+3RSN^$<F+3,+2@:(QH>N1
ML,-=5D[PO@++E#(AUBKIZMS$ICJS3&U:Z-XJ"/2@;,YNG*'$X>\7+YBH6R/.
M,%8(@2O!$%OV7%WKDEWQ0YE@V:H)OR-:I0FXYV2NB39I(TI$KYVTETMR!0TS
M'H7:#J8\TUBTDHIEE^HC1KXXNM+\!!%S77*IWCJ/H-#Q<8XUKU*<4N\M>7>=
M(B2&W*/=8E&A,/;S&(!P9R8Z#1<Q\#+3(\7/5\D)OY4@4> X/30O-%6HN9+8
MTKTFWCSBP#7L&%4GR64SCQJCB2HB3'MH!Z!*F5_:F[20)TG0\@L( +(QA2TI
M5@]2BS?6'ZUFX 7.4-3CYUK2)$#Q7;G-(< O:U=50P&%]6!N8&H:5^MJ1<XM
MI[+XA4!67/ "5!&U5T=M7&%#D&]DJ"7!'#-0;WXK:;:5EWO5M"'U:LK51VI\
MZ?D;2LX?&F>0..@.A!B(C]X5]55#&#]$?NK./KB\2NI/[<TQX]@_E=,1L4/5
MJT8QTLSMDV[MX(..+PY*1WYP'U":CEWFGLZ9/JVRZBSOR?;><V1X>WT9&7XR
MCV2Y 43XA<#8F9,:&!2G;MBN-19.V.:R\*YU#0G3C\$$B?&+ECF@)LPN[E^E
MG6]%"7*ZD.GXJ83+M56P;K,#D0 8S,@+  D\2. Q=VW3LE(BI?"YMGO!D6 C
MGNG2G3E6VH."ERP#E<)?E8Z2EHI C8Z.E;9454J.AY+JGQ(SJ'9ZV;RH>T7&
M>/T75;RPV@U7E05/_7#-12F4TN"OB73)2->*A_6[8E*T^#_R#UN^R_*W,5@S
M%BT2["@Y42E!W&.4%VRN; "8@?*XZ9-*RTNPV1&&@_I&R)^;WR.U=M0S^/(H
MY4B:"E3KEXC#*)W!:".#<HI%DM,DG0:,CV#:FFN84=I[_8YVCT%1"6-:8WO=
ML0))7R2&P)CW7&L:>%<8#1Z/N%I=M=G2:3$$U9M7YV4A4>I)]J=OVE QZGZT
MRHQ'S4Y/">..> K(&FZP1T7HJR;(OH57A0QF&(-"H]K 3I.;$,B \#AL-R)_
MS6[&8DFO<<';#34*:RJ?JKT\-XG>89*E#_O <M.IJF>3@MA<J;$.5X<H(GI2
MG[821:L+O,!8SD/JRS6*,T&I#/7^(N 64FZ?[TEJ0J?B&4NM"R%Q7ZO@1[U)
M!W#XV'U[B,I+FK]SZI*J"'LO&(;C/EALQ=S-LAGZ-L@VG%M?H&7A!W_@Q1&$
M C30,K >,)>KN87>V%2-+3WIY*V"0='P3AVZ+><?=RPI*'1JJ_2RE@S.^&L:
MG:S(&;7:$=X?.$H7'H$"0LNMO1^Q,AI976YUAXOXI1*VBJ$#5V6<'Q6J6AXE
MG3&0V+@LBRTN!EWN%X$KSW1T4UP*%BSGO.C,DI)8G/_@7;5=QRIPE"O.U>63
M5M&1!8+QQL+)#R+ZX5#C3U#<W4EI\Q^08X5 4IQV$*(,,(D9/4)G5^4D5L)?
M*5Q/2>C1H/>A2#=9"8:&53I:)25S>H5@8.H\BK(;]]#-1$M*)5:H_!X)=-YK
M8^ZYA)+MTKM1N<<E0<H5C!>2SNTFU,C&8W*:J6 JSX,A>[<DPZQJVPB?!1B+
MJ?9)WT;EW0-(Q(@0@LYXF90?%Q4LE_AC2#2?[%.QAES>#WE/@P=DZ,Q-&9I[
MQ4QP.I^!BQ-0'U'^T H*%ZSLHYK3NQA1R=[EW[#@)I41M7LAY5V/.XORN^,=
MQ6FJO+=ZY6B%Z#S+LAX3+&,M"G7*Y88\IC;/-"U*@+4,"O&-J8EW$=]BGL3'
M> ;;E>_F#LAI(0SNFIY53ZO$*XF$:US70GQ5(N%%+D,Q9C$M[G"?+!X7#S5+
M>0(L6XE5<A&E4NW*LNO\ZB-^&V)'1>P+R=44"%>UM\:5NZC%4Z)#C&/WI-1;
MB)KFUUZ7A.M*(IQDF.M40CAB;D,C[,^UX-E04$0'0QAS>*Z\$$/-I C@#;V)
MH[[*[K/AM"GY2M!M%K Z<GD#^2TIXD'Q>+F-D5TK+0$7<,0B<)(*JYO\H'HC
MH,WS:)_H-*JWTA>B#'@!N\HYV N*#Z*9&Z4IPO(19AF:J>6M..&&E)9((&%,
MI$*"2SSXAI3H4%A /M^F+LN#M,L?5UFK4^\F+,X!]78I[>C-\S&][SB/TK14
M7 D;5PV?NB_IF QY!%/'7ZTJ+M OZ[1Y7+7\'[BCRP"R'4!N+@/(C]@^:H\V
MB'H/[/>!XO &.;(#3#S"-A&6;E9TUJHK!=?C3>@<^PJU4NP^C/ X_5-P(]C;
MEA>!.7E?B7$YIS;OKAA_ [5O@V)<@/7:!:-K93O'FTLXYQ0MG-QAI2H@-A,0
M[F$<L%[A"U/&WXA:9%M'9?S=SY5.7 <WU&Q5.'6YU5SBG7H+)#.G.NCV.E;=
M5_/[+;I.'Z,>:)IH!<X4A(GYD6;A!.24#MJ.+4=)N6\+,>,+;C []U>_%47H
M@N4+DV'0>QO5>ZKCM63:$W2KG5IM_'HJ1DC\#WNI9.7)B3-LO1"-*%I64IZG
M\G^MKMNLT-L3\>VWH4; A97%W#]G?*H!X:\URC@E2W.H 3BL\6,X:$3D"RTL
MC],&>&/LKFVN'DY1;CMS%6B)!S>(/^7C<XL[]!=$$@<F:*%Y%B]MP?W-WJH)
M% R3\I6]"4*^N'8@6_7>AC]\@TKY!(UQ3$G*=7R;_Y@$WCW;A3T2RK,^YEUY
MTS^!.A \V+;C/L1UGSC-SP[FK/2M4.$@1O<M$HV$'ZDJ4'P"[$83/J2(J; I
M<SO"%?UP:*9%IJMPQ$G3F):7A)EFY0Z'+3@I3([P=<@)'JH5QH)=&RL116MW
M3',QC'-AW[='@B4!*%&3TIQ =M-;*>T_F;)"X_ZLJ+W;NU+:1DF%CUT=HEA\
MGX]$<<A#.AQX*_CF>(HK4$$0E>)#_00B S*!?!5_S7UC4-,HO&RU/'RI$"1(
M^O9ZTY%DL]T;#(""T2AT"!IDL9*(MEEL,=N)"T^+_22S(LJ,P!FFE;:45D0*
MR1TN0J1JN).'4@5MJ BFD%/P%(CK$^]J<9;Y@G-.6W$Q"Z2 &B%"!$2@</KE
MB+!WA%9%S8,WH\\$7TJ^LER7F\3*<"NUUKR5\U!'3<[E&?9X7HC)-T\8JKUB
MA.*<+\RNL6&G7S1FIQT>C,!-*K<SB8J2TR#5F8KT*"V2>$ E/2?8DV@R5'U\
M"LH6SH2@9S(N)1FIK.Z\#I]K>W!G-$)GG*OVM/IFZ'LEC4!@.Z5ORASPV,N9
MY7%TDLO+\[P*9H0<:+_X+AW'58+2-H$L%<#"O5''H7(("P65A==?PBSI\.0.
MH;^!^XA7)2\#$Y6<0WH[66UN:-+*_54YFF9Y9)GE#@W6,X[':^4;:0L=+)Z&
M@:9@=OHE[*^P.D:+Y6:]%LO+QZ3+@+$X%:UO6N?H;54.[5P^&VZ]:B(T[DN4
MA@+DU'LO"OMN)[H<$+[01VDWWFA<8,1Y'EQ(]+38,,:B%&T_G[&3BX!QDC'I
M>?57@N8I>/=GM?5?[X>_?E/EBH]/N;D?%D]U"ANW$48;%RY"=HO@Q=HF[H.)
M!(2O<\YZ07IM."5UP:O,3\/;Q7VBLIGG-%]9+%FJQ ?(R)V)%:WB#4,),<AE
M_94/>E=Q2>74[.V@CH"ZJBJG+OQJ[[J+VL[^,^?@[0,OSJ8*.U"=*>9)6-@U
M"KN]Z@UER><D[ FQ6C=R-,7'B#I,S.PM7*W3<J%C&H!K?VG5MI;"YD6IPLIG
M">A3R4X64O$-V&$I^Q^QDB,)K;>-XRHQ.*#SN^<4W!9Y!TI'X=%LT$@1,U84
M.HV ! <@(^#FVTJ+\21@3&59]KMXU+:UC-H^PM/8-F'(?:##J*_ZH=:?R\Q3
M6,Y0Q$W(7E4NN'WB!KU9_1?&'E&WO86CZY+]4 P(CW6XHB=K);YH*3E^20G9
M8NI.B:%AZRVE"HI3):>FY,;W]73R;25B!=Z5T5")G.?*G-AVX4W8T#P>@X&?
M41Q9 :_P- 5I#O\'3J[0>(I6R;BO1=]&X4UZ+]!&*-F+TL7 *^%@\]%<F7%:
MJEII$[4P _:KE&V9]B($)?-6V^^H,E8JDAMD+TD2-]#(10JAI7%/Y=P3)"A+
M8FO&Q7<@BG!FN?MG>>P<VC#,W>)84"_!4Q@!23!>.!EJ/2HM!0-M\=18^LD<
M*V_1"!7KV92&J=(QK<@$5X/FC^0-:'?S^*YBMF B>OMTIO5?#\8O',],7.;!
M+('KE+-;<TB\ZC*4(!M+C CCV%>QOE7%1GXJ\%7Q0^,SGW>AVJIY5;DYE*\[
MF=NZJN2JN\XOWA#[=0U/)3X5$;BIYG9!IYR#@,1M>)S.3[0TV&,=Z2B9RX([
M=J&+,J1BX"9(L$9+>8T<_5UHIC3S0V5W2FH397HHWY:\]7*FN<XDF(780\;)
M^JE,<36,L23YP^IAO6+Y68N7U!Y6MWWDGDQVHII3+X^;J'>9@DCB"Y05QP5O
M9%"RW[X)#1!ZTJ4+G*1\A#@1Y^W:1Z <BZ9"YFDY2&LQA>UY7KX8^Y+;0?1Q
M@,B9'&C&5&D4060!@PD8DN)U-8TX-I&%([1A$_1D3X)I6N'#U,W9^1K.IYTW
M(+T^_/7<+=;*):C<O4@I^W>07%5;^Z*_8(* !RM*4=6XI\3E&/K4NCNKE1%:
M-^/H;G%5HJ\C),.0,J;83:4K44H*UGU);*=$0=UQU535T6T6WF6<;\6Y.UT[
M I-"13Y2&"RL""=6J5BFN1MGRI&6O08S6!.%F_1T[#."L4:W$O#NMZH7B9_G
M[D8:*"0HHI2K#J/)H;-N[7*V1N$*MA\HKFOJSQ!'M81M+TXME&WF8!BHKITF
M[%$BXPH!$)I8-+Z)AS=A&1,0)%QJQJM!S\OW$-E/A+'2Q.M%26\Z2C-"P,N!
MERX:;+E+%Z]:W1O@1//TZ,]![_MT0LB-2JSB$=D(:F<$4PC?U'^EJL*G\E8'
MM[X6-*+E1FQ#.=HBX3]C(:@#X<8Y"Z5(9A%Z173F%?9_H3 AT;G^R+*+;;>N
MDPA/TY#D" .$Y,67H-^(-D8].\G3BM&8$/0EC/ZNTC6SVEM:X5O.WD["$I48
M#UWOB%16<'H,3=2@,H&F%'+:@6DYI*N-KF$W:"3IXR)Q4-"KQR8G?I'!*2V)
MRP8)T<#Z"=O7J4Z7X)3]XEB1)!M(\OXTH[QI72=+ 0])GLB/1URN="3I)Z-J
M_G1]@52(T8,85:<-YDXR_(@[6C+EQC@4MLZ2 .A'!V L^I&:,(Y!X!L2?F2*
M_E_D>S,;$DG8([]5-^G5;6\HQUI#2!$88"-'[6PNN+7EI ?+Q7<U8E-P#%1?
M3%K0&ZSW&/4 12KEY]3P3A4=L\<FB(:$H!7S+71UP[3\6DH !,4 QEYRBRS+
MU>8EW!%J=]:.]A9WF2B9@9MRX#RI5P*[8DK/]S9VWX#X^/#74V[HE)H:8JLG
M!;$ZHQ^ &DJ0#OS7*.KWAR%,P.<\"J5/J@XI5.R-26E@'I!A4$C4FN<[]LM<
M)T8A=6G:/3!%V3B)2Y:!.=.RB-N$F!-(F5R6 B<>I=?5L6/@\=0,P#&W/5Q_
M1G$YFLAX.KK$D<VD8XM ?EO;6V4L07E;J!MW+3RV3UB!7(K-[%?R@? MY1C%
MR'DLG!A<,B<Z<F"?C#Q"+H[ M'.TU_*=9,3"OK5Y>)^CP4S5?;$0HUH(&/]_
MP+STYTQ-[46?=+?[;#.;76*5J")?E#5Z;PHO9!4]KZ67K]/*\S,UP&#\9L*;
M':0.@G\3T!)%] 7&=@>5L@+J?2Y^H^#\G?(_FB*ZYU3C/)V1:X+"M/:*"\'*
M>0$RR?(N!93,E3W4UK(07DP#@"0<X/3Z?FF3&7,Q2E%WQ?3&LR8YJ'M,8+7G
M'*R3=QG@WOBI MRUDJ"<%JCK32AF4ZI<@1Z,&A H)USX(1<9M;EQG[FPE4YK
M$&VD8F2BM.V 7!"EK] N8NW1=:XK!B@M_8O]GC.KCU/IH-P D"UJTOTHCULM
M5B<K2?JF@_FI+BAZ9=$02"51G/NI,&O2-IMMZ:N&E?;+W'71:%IS4VQO.E;6
MD]0I3L?:NUN^OB=!NWD :Z^7<EB>V''QI>.U/Y_\L^.=?_OZM7WVN]<]]XY/
M+KSN\47G^*!SX%V<>/LGQ^<7W8MO%_!;^./KZ5$'_WG</OK]''Y^<NBUCXZ\
MB_:_Z)?=@\Y9^Z(+__+:IZ='W?WVYZ,.#L,'<'($WY][OW4OOGAGG?/3SOX%
M?DD3V?_'M^YY%Y_UO9/?CN%W7[JG/KSIP#OHGI^>\'?X0IC%5_C7^9<VC-%P
MAS[_<O+MZ(#F\NWH D?NGN%P-,/VP3^[YR?PJ_:Y>NV=$X<??84-\8ZZOWZY
MP+>;(4_;9Q?=_6]'[3-OOWNV_^WK^47[>!^F5"F<+(Z),'2@2,UGF: -_>5#
M=+F^U]IH;31[X>[F9MAO[0:MW?5@;V<]W.GW@L'6_VUM;6]^J*Y4%,E&<8H)
M:A7CJ[5A.,@^;FS#)S2G:(QJU\>UYNZK%30>-EXF0%+V=G=;]AJ;N LFY(LW
M'2PIO-WM*^1)-9%-__D?S>WU3\<@94S]YWWS A>EL-W=,@JK+SG]6AMRVFGL
M;. VZ'X65 [3^8&9UO6BI)I,YBZ"7I1FMYNM.5Q1U6_7F"5^J1T-'^@FK* *
M87'',*C*EGS7)/Q;6 ;Z:>F1^50)4;7M=A$D=LCUR#IG:M5.%?K3X,/GG7UV
MW\,_M',<5?+?N,T7VP_HOZ;/950JV?HQD_B>&3;5[,JO>+%1DKG91A)H(X6F
M33'/)![#/1XJK"*9)SJ6;V]O&VG8:US%-[7'+I7SM"NQ[W,R5JE?3_<:X0(7
M#(@'#>_W>,IAH/%-)/8-UA#2P+UX,B-K1Y^8?3;:TVJ]V6F\  <^8*\:$!W[
MP%/QTMV&O P]4:K>8R]_^9R)P-)0C<,M,1#=)G?8IIFA:1ZO8O_GW$H%PP4=
M_92G6(O7ALLQ4Z'PLS!+HO &YK/RX;QST#[[WQ]6O14FG7Z08$E3HQ>L^NX;
M\)ANL&N$+D8'FOMS:DU2MP/TK@+<*F70)?I]W/"E/C @E83Y@;S*4A)ZB50B
M]6$?BEWM"@<.^^*+-3\* Y4Q=LN95A+&Y.!D@M&9O(MN!F2K7DE[B!\0M\/'
M=,MN9DOVL]:<^\ZD50&/?B-&S?@4X1MTKC.C;ZVO'>*)\5]4 \693&[CQRE8
M/O!/)LKII,^%K534AJ[=$&.6]# WG;6?%4;)_7?FS'=<-K6ZTTT[M6*+DP1N
M2Q9*Q-+'XV<O-[G ]05F+[+Q.#O":I(P\(G.NF#WKKI7N)FA K)'<6-8&/FJ
M#*YJC9!W*J^<TY!186G 9B17H89\5K%D"PN$6O!BSBHQ6 *CH2RJVVL"\"(^
MKR@]X(9X$J_!< =5_?7#872#7:U\E=2E&FE2["XPW3!5RI:.:>OQ5><Z6(.^
MH7*%Q;/&\+K$%4S!8:QAC^^^#.[L$1B>KX;9C/#'-1"+G#ZWM+0&+3 NI$=T
MIRH(2;K/\^9AAM4CK39 G-#FI"8C#38%19PX!2]#R:CBC9BF*A/.@ ^!6@RD
MGG[T3N#MPQGPEM3[',59"(-UQ[V&[^VN;_K>1JOE-9O/HK]O-[86R1TJAC[P
MXJQMT--80(*[*-XHK+CAM*+L^C7S5+WV38@=#L]_\T&:#T&_G/E>>WB)3F1?
ME"7OHG7FK>]OP1=(^+1$IJZ_1\EW[RB.OS?X;_[?"Y#ZDVNLC5W97-]8];9W
MUKTU;V=C9Z?A'0:]-!JA1*3OA'_O;JRM[V[M>IVO[>[11R*A_R_6IWW)A]T
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M!K:J/)(3FL5NHYH/*6G!ZX+)=L@:P.!'WP.B:(K0++MFX?@*?XQH8G WR,6
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M:05-0 M"RI%U#\(?49K-*4Q>$NBS$&@>/T*=(5!K"M26,#T*JZMJM8G)UO!
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M2XJ="-.(;1W$L-0V$'Z%#3.Q< HU".8-O1Z5FL5ZBP=!+QJRPH#=J&=I%HY
M$N\7]ZG0[UL4 <N.&<:X,_B_2*W] /LE4U&<441!I"13(FA>K!IL!(M ?;MP
MF"A\K(\0T[HO\^3UQ4.L%<MMM8 S8HEA$E\2> ^8D=.)(1\"XHO2($4S#=0L
M+)L%JS-,%?*FIAE8,^@PM =U%QQ4G5YV710QD9L#9.\ ;("0Q?"$$$FI9FB(
M$ICO51"-<!,BH">^$ IB=!C,"*M52$F.P(>!,BXA132F\(9[8MN7 ]&4P@ M
M#RD#QQDQYBH3IPUZQ'6E$S" 197E:T>W]&8Z'(=)<*GH%E]!MQQF5W[1-88G
M'R)5B)H=BM,,S2&L9,8I(0EP7311*YI67.@Y#H?LBIHWSZM@"NM!U2<<#'!#
M;OBF<NDUG#7IY?#?QD+*[O/2TCVET5?-'K5.=1:SYJAET4\D?O0BBT+#EA1D
M_63H$[V:6:)'0&*5A(Z,A%9@O[)'6LT6+HN$XKZ1105#'?"+B3Q5);'K+=6S
MS@DS DF#/8Z&L[GN"5556^F?. V3TO>1>4$Z?)7<P_ES_7(T&H7]"!9.^+@"
M9*M\<SDA/*!::HK@:3AG] <"*^AAZLV%ETXG9 OCSQN.H\X2'%<A,HVA)3,,
M+H/ZS&'[I:H"+D'D7I^G,BI>"B5$%&3TV+S60S'C>/YPYEB\O9CQ6RM^P 7+
M5J&1WH$3JF&&7^*W9X:N'7[P^NN=RPG*5"#G^('MP:SP0-$)4V +=/?QGTJD
M$J2!=A@CMC-0OP(-S5TFANOL*8^TJRNQT$Q9^*RA\)EQ^"- & 72%0.465'<
M!Y,=-*:(*%L<A-_#F6/&6W=$U#^E1).3$56C$49_!.QDH-5$;SJ!#T4 1R.*
M%@G*RYGCT$Z5IYPW<)H*\B,]?M=<Q$]5MDGVDS(E&_U$^)&S=W]V^"*#N&"T
M 31!T+.1;].U!Z4:5DPK\Y4_&&8 &BD<,VJ5I+$*WS8,CG7L.4=7QIPIF$":
MAQQ0V5++E3H-F" W$9<=DAX["X/% @?S+> [@%O>98[&[D^6H_&&W"''L7>*
MEP3MD*_J^KE\^H)UI9K+%D'!PG@+&?,65"VOKEP!),?!=7!C(C-###2BG8'@
M.0D-:K4>&$;?0XY]%W[ONAT.P$*+V-2UW SC?D&J*0N.IW(;\FRTE2BA4/(#
MF\B4?NB6 76-48E3[L>33+EL!U,TQ7PR\RS/!*G8+ \D@$ 85M(@Q!&#C+RK
MI!?&B&F&Y"A5[1.4 3DD=52O%Z]K[YH46-B7*?H%;J($O2_DTZ#9CJ@F&/5.
M]FX()QZANA<F"06ETUZ \[R<)E<@7&8P@RGLH/XZZ+%@O('IH, &S7R$&>()
MG^)ME(0Z0)(2DA"[OD=X28@XX*,>Z/(1[JT)0")V43HEJWPPA2^R+.A]1UV
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MBWI5XV<7>DA;Y_M??G;:N@A^Q.-X-/,Z/S+$6@5;\[QW'8Z"=W' ^^VC]WK
MH;<?#'O3(:D6WE$T_HX51._BU \ZA^_WU _"032.WM^A'[4_O]]#/PHNP^'[
M.N_3L\[[/6\L9\"2H_=VS3=_QB/?CV\PRAQ<H<9O%'DLU/0&J,BO#.($,7I
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MIQ33;4V(]8I:FU3>SP14C1-X362(OY@9,Q1RH[0L^+YE;0AL4,(G'/$(@AB
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MLJMWI;UNO1 QZZLE]%8P6$ISN_46C_VI=NZ"KBL979",8;,]Z!RR6E^+10[
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MW,)_OEU>W]YHDR_:Q1_GU[]?WL![:)?_^_>KVW_6Z&6*6?N=[6KA@Q?!/:P
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MHD)<:GO4]JCM4=NCMJ=NV[-=X<)N;)=1;6R7-QJF?^)-<V&S??N19B9H3"#
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MC]H>M3VUMDZJ,TYZ-3%.WD*@7<V74A$$M3UJ>VJ(N=GO^))AOS'6FYU!7>)
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M1<9 !P%J-T>C?,CS\-SP6I2$J$[!N\<0[$@6.A3^UUOY*FK%CV^9'U>R5G;
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MLUUX.2^">U@T?_C"< W+AH58GN,8/D9+?ID,=3Y6$VO&#,Z.,*# RM,#@T]
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MJ%-3Y""NT>YAD;X'3$ZSK5!0Z!5P7WTONG\@*OX^^?3U\A8U<HC6 RWG^?0
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MQL]_3JTA /DK8*JR>V1B%)CSO4^@$8\,+ GF@EQG;^43#(GN9#P% @0 /\'
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M,K5%75U=[AN^Q\@G\8.XT%B 2ZY&*K;!X#F*]<X.^(Z=[Z.3PXN5I=ZUGF:
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M"QINO.MV_3[>@L'<U@<'4/@1ED9QI[CT?0]*SP4E2)60[8Q##TTH?SNX+7R
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MB>[YTPI-5KWE+5P*E/BRO)J9[XCP^.\0%@H<908KP#!@%094A67%*#P\XOO
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MN![.YX'S6J]:I'3"=K<U="JQ-3@7TWK#69#TU[ @_ )Q/%@3UG?0+\#GJ&R
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MJFM7W9K30!QX/3>B_])K4<=AW(3KP<6B>$^OM#FJ2%I@;5P%W 1R4?#$UY[
M<#ZNJ&@[UOIL&5U]14;_VK(YQ[8FDX,+HSJ;HM6)O+E,>45*RFN-66G'Y^!=
MEWH'J%PH-$;JB@NWUB84WHA[&O\;"^,=?)U>Y0I33M""]65CKQ<?[;KE$ZEZ
MH:FF:<>*H[@=M ^W#_4/M]NX+^SXM%9NQ4:7146%&\I;^=M,4]2*MK4]KSY
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M^AKZGX]Y?R,7THV__/!_4$L#!!0    ( $V!;%B]2,*AFQ0  .._   6
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MD.+5EU.,1&!BC?.,&4JR\1A91.:(CQR'!'+@#K^T><B<KV^0^D0WE@PVL6H
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MX$LCJ21*U]A,,&*U&&* E_G_$\7J(>>;*6-/D475=A#_>]8O^^Z\;KM]..T
M#=)BL&=I[Z3MYDV_>'NYHI=2,+QD*H$(DI162\1'-$)9@XF!:AW%<'MG3Z5^
M] Y(-61M5:Z5FFH]3..BO_5A_OVJOS7C-EB<!.CF2%L2;DI=D4Z$@A5&&J;$
M[57<!UMLK?[4<6WUUT?+5J6P-1UU=.P[*&>EI'>7V?X.W0867"+"^XBZ,TOB
M=.;$ 9)H7%(Q#M=;^C%JQ[63/YP.VE!N-=M[+55>X7C9<0/!/9]"ND/A(M/%
MQ\58',S^.&[B\=_:-F$,=P3=IR9"OZQ$@K3?I+?M_'_._+3)Y\CL16+,0JS]
M98]^0WF04I(L9.G#H<OL"9Q8&U&Y2C F#5?&_3QCL KVU9\"^]\!QK:0=_4>
M/L'L[&KW%[+*0!DE65*&0XA&P[+2J%8&)7AF+,GA$'\_C:L@4C]K%%\-DA6$
MM#6C_ONL \0U,HQO<*RO,@^7F8B+I,2)$-P$&C7AI5F>="X@N'$TG$@)_^OH
MU7!KHT^G?Q6HF3^%\MNR;+>&PJ>D93,,*XS%4 D4I1@O\4B"%4"RXHGGZ)#B
MX=9.UF9C%4S:/X?Z&T;4=5,YNM)P9A^6O]$[* =OSCY>]HC,3)KDM"$\ADPD
M5^5L 1>)L@S <6N\&R[L>8S:59#F_AQ(JRJXK0+J@2SKTC0-&*I@H;,K)U&E
M4HX/&/'K8*2@7L0A_;;5J-[V'D&D0@N.%LH*7LJ]')"@G"5!"Y^RDI+;X18^
MG[!'\-SKYUM!W?U=B>H(;[N[3O=NRO$@*'5E$ZST)P,G2$B"DF2=3<IYH=UP
MAVBLD^OSW"OISX>Q3<6Y7;!=)!C<H(Y2"MPJ=%^L1V^&HI7S@%;.X:2@I4XG
MB>&RI%:C>5P+\<\'MDW%.3S8#+6E+UP@U$ YEQ3G@Z/)$P/": $,U?&S:K9'
MP;9I4MBK+]#%IF1,')XN39&6VE"C#,D\HO.',00)P0>2J ;)N+-*#.>U?Y/4
M<?D16T#<M].U-A/=EI(,OQ+UA^\ZOVB\2(4/45FB.2V[**4<4J!"D#PR9J2A
M(0U:>O@-6L?E-3PCHM82WI8@58XE08X7.Q-H3[C3-BA***?HO.!+XIAC)&<C
MC$D^"S5H"=']9([+(Q@<2.N+K+(+<'@VS\CXZ[9;]$;N)UQ'+X+-Q%J+[HBQ
M0)R3J"<MI$!U1 J']2YO4_C$[?=G6(>J#YV-)35,6=%>C.T9*L6+ YG]+.$G
MW1E</U=LOYQN,>W7*C!ZROVKEAJMS5BUHJ-OGGLMJ%-"E35.5LX;B<(3ZZTC
M+@>7K966AN$2LU<_G+SV.'QH%]\>G9V>3AOH^DFT3C+#/ Y$+EV>A")>@4;O
MKV0LYQC8@-6T3Z%\7(Y[->P][3CWC<19]TBM[LQ/;Q1V7) ZD>!+\^)$E =/
MI$#9NZ@4@9@3\]Q[O.%PFX@/$SHNOWV+@*HEK&$,YE7Y,/3H'7YJ>KQQ;KMK
M'V]B+E>_>U5CN293]>ISE^+^6I1]T:S3<,F%U.AEF]*C6BB.+E@Y282RA/^8
MCVFX=9L'B*Q@(&_=<6^^5_1G+),+OWOOYS"APC &7!,EV:+[(4X$D(QXC#0$
M<P&L'*X?RPH$C\L<UL#7/9:PLMPJ&L!"6LX0YX?Y(@'H@B",7'UD4BE/%!A%
MI \18Q K2(J HR +G<-%BP_3.2[SMST 59!2I=*0:]0<S=OXKU]+QFSI=8S\
M+IL7RVAE9!$(9%[.?<BZI&A0X@):9JVE<';50]<??=C82CTK F ;PUT? _CR
M7=M.^TGV*: 'YXF(^'"9BY_GN"(J<E4.VT)V]=.E?GG[D95F;%/,:XWH-HQ"
M6?>ZS+^[-%1.26J=RR1K!NC#:TU"8)QH*IU@03/.A]O1^!:E(ZMGV*YAV%12
MM0\ZN"*LORB&F,5FNJQ<^Q7FGP%F%^MNS>SCLM 68\8[@\.-HS8'35(HB^<Z
M8;Q(,6C47*9L0Y3"#!>"U^/KB74-WR4RGPD%]<T;TM(L,]46BOE7F '2V4^T
M$-;)% AZZ>40>$%1-\=,F&4T4F:UE^[IUNZ!IXVL/&&;QJ_&>-='P5*W-M>S
MT"^VB;\FHT\2==8'#-JT9!Y]<0SD; GD='0:-/C$DWDZ)%9Y]!-+!;YG?%27
M1"6P%%J60SZ=MI_]+,(^9,"!* IM40%X.S=M[Z2H/C9)$$TPH%"K^<6!1)($
MB4Z?#@)B-!ZL6M5O7IN(L54 5$?0,.(9:"\VI45EJ9]>[E#O-WV<MOU9!_U;
MF%\Z@F_;1?;CS0*'C39I:SRX[NYM]:&HME;]:*6)B-0F33V)O"BI:!',@3O"
M' LIQYS$[7D_FA*AS<OYOC[G\O?"8[SJ@GW]&%'AA%)HX8DJZ=J2<C3]O/3"
MSEJ$Y (H'X;;B5N7C9'UC:P*S\=[W&Q'VEMLMG2;X,4)IDVZL$>EUY\V)G)%
M(G@T1:$T:_.1$]"L'&G/90SC >4MXD?6LOF9H;B)9+<&P+MC<F-G_6I+G485
MK%P<IIM*VY]46E%;17C&UY%&;P?,Z5N+A9$MX \*QFU(>4!(WE3B5]3J<C:%
MU(IH6BIJ3'#$>>6(<>@N8QA/]>TX^!DQ>3\/(\M$?6905I!SI2C[-FT?CKOV
M[./QK>855[U[EYUWKF5R8D@P06]"\G+0B<^Y3":@Q$KMB<H& K(38[*/AD+5
MR'GB-L5WB;3GD=TPP?A[P)N5CE'=_/QZOZA-XNS'[EDUA'X2 ]6BX_^&\]_\
MS'^$HG7>0=>WLQE,;VQKN\PC,\81(;0IG1@\\0Q?90E&*R.8&K#3P>/T;FYN
M'W_&T7';S>?0G;Q"'+7G %?+X^B74N,U>@A@RPE_.$Y!@24N2^:MIRH/V/)F
M T;&E0]6&:5W+>]0(J_H%#Y.\@>D%K7X<IOO@EAAC0L,,I)(2VM\$8DMY3(I
MYV@<\\'%X=(&UF)A7(EF(T#FIF(>%)-W>CM.DA0N8^!$(-NRK1P]L<);PBTO
MC:.L#@.>"KH& ^,JLQP!'C<3\8K>XL7GY4=YU"\__!]02P,$%     @ 38%L
M6&^L\>X/6P  '08$ !8   !O;F-Y9BTR,#(S,3(S,5]D968N>&UL[+W;=EM'
MDB9\WT_AO^9VLISG0ZWNGD7K4*TUMJF6Y*KIN<&*S(P4\1L$-  H6_/T$PF0
M$DF Y ;V 22H"],B16%'QO?MS(C(./SK__CS?/+#9YPOQK/IO_U%_)7_Y0><
MIED>3S_^VU]^^_":^;_\CW__EW_YU_^/L?_UT[N??W@Y2Q?G.%W^\&*.L,3\
MPQ_CY=D/RS/\X9^S^>_CS_##VPDLRVQ^SMB_K_[9B]FG+_/QQ[/E#Y)+??5K
M5W\[_QM72A0E#"M2.*954@P4:.9SD-$9*#[%__[Q;UI",3EI!L%;IDV,]!N%
M_H%+,DGM3"QI]:&3\?3WO]4O$1;X RUONEA]^V]_.5LN/_WMQQ__^../O_X9
MYY._SN8??Y2<JQ^O?OLOE[_^Y\;O_Z%6ORU""#^N_O;KKR[&VWZ1/E;\^+]^
M^?E].L-S8./I8@G3].T!]/B\_/H/KTMC?ES_)?WJ8ORWQ>K?_SQ+L%P!]. 2
M?KCS-^IW[.K76/T1$Y(I\=<_%_DO__XO/_RPUAS,TWPVP7=8?KC\XV_OWFQ*
M.IXN?\SC\Q\O?^='F$Q(XM4G++]\PG_[RV)\_FF"5S\[FV.Y4_JK)5>A3!7G
MO]5/^[&U3&<DR#Q=1&3T4YQ6BG<HX[9/;R_SU\]B&0M<3)8=2KSYV9W*.SN'
M<9<*WOCH#J1=?1 [Q_.(\RY%O?&YU^2\$O*VA/4C9[3/3KXLQVD1Q[,EIK._
MIMGYCRLY7\P^-Y&//N%+(2FD$G+](O^W];^\)@%!/9Z.Z^[Q,WU[^<_K0UK(
M@G\N<9IQO6U</6@R2S=^:5(WK=G7?SF!B)/53T<9QZ.K<^3-M)X5<"D?OEGB
M^6($*DAOE&0A.* =WCL6BP16D X Z8J6/&PBM;A"?H'IKQ]GGW^DY_Q8E5/_
ML-+2&JL'GKY67F>K^@!Q@B,M+-KD!$O(Z?02/C O#&>0Z']%V82@NU[1ZLDW
M5_.-#"?SJW5=OAL[;?%E/COO <OEK&-5KC&C!?SEA]D\XYPL'/JKU<O[MS29
M+3#_VU^6\PO\]L/9=$GL?C7!^FQZZ_!C_4,;3KR:+L?++R<YSW&QP,7E'S[0
MOSSY<[P8R> -%VAI.;(P'1R9/][0FI(K0A>'.996S+C_^1WRXY[C]D&^[ 'M
MK!<5;V-,"_"OB?)R=48T$F9TZ^S?"_>-1W<(]9U6RDV@N\1EUK52>T>:@S 6
MG621!T%"9<=\04]6=PK&!.>B@*> \ V[[D  [Z++CH']Z6)!A]EB\8*.!DC+
M7U8VWBBG2&YGCLSJE*H36NB LXX%3""%U#K'U K<K8_M$N!MIO!-=%O",.M2
MAYN@\BX,M;JV$2814P'/HE2>:1XT"PD%@V)XS"6J9-L=P=>?-BR$O9IF.RNO
M)Q#?X<?Q8CE?K>[]$I8KVVTD2DXJ9:)I <ZT%(9%3>L$QWET$&U,IA-4MS[^
MB&!NK]Z.=^0KP4ZFTPN8O,-/L_ERY-!$R(J,Q9B)A\(0!4T"%M$8X(D;5V0G
M<%]_ZA&AO+<R-\&578#[%N?C67XUS2^)<:.B$J1"E@0X$-4S\ QL<$PII9&C
M$L%W@^Z-QQX1O/NK<Q-?U0;?%Q?S.<GS>KQ(,/DOA/F53, #3\XD9KDGF319
M&0$!&?=66.65+G)+>&X'B.]Z\A&@W(E2-X'6G9A8<R!'HJ[S<G,Q1B :#8Q<
M@<PTILA !CHY)/=%11]\;N<7W?7D(P"Z$Z5N FVZ /K]&4XF+V;GGV#ZY5(J
M)6,P,ABF4PY, VTQP6I=S40R_<$YF;O9MC>??41@MU3L)MRV?3SS]7B"OUZL
MW+@@%'K!-5%/2)* Q/#"(W.\*$R9MIB6<8[;3SP":%LI<1-0UQ[0*RM_NOP5
MSG&D.2AMO&;%5X)AU P\1_H6 WJGI%"N U!O/O5H@&VAS$UP?7MPWTS3;$X;
MQS<?[L7L8KJ<?WDQRS@RQ2O4,C)?@S%:2<."H*/$Q>P$ES8+TP76]PIQ--!W
MI^I-)H3.[J$N_U<7+49.)%&DS"QY3POF2%8$$$?19>4"-^3)M[MNO?/11X-Z
M6[5NB9"T"HW=D.H%_?%T_F'VQW0$]9"QT;)H-3GV7B;FG2/O'I)5 %QIWLX@
MN^/!QP;TGBK= G.K2-@-F5:;S>G\[7SV>3Q--3(K@<NLB'^.7() UD0H]*>"
M"LCW+\9SVQW6MYY^;("W4>X6U%N%R&XR<7VZC+((7AOMF+92,4U[#WD$0-8&
M3U"$C()#AWD$ET\]-I3W4>86=%L%R&X(]':V6,+D?X\_K:P';T"' )*1=T=K
M#%!82)8S'R*/DKP^;3M\HV\\^]B0WE^Q6_!N%2>[O!-]B_/%;#K%R<IC""EQ
MSK-GI@AR\M%D%F1-BG9('$2OK%/M@J%;GGH$&+=6YA9T6P7'JJ%P,D=8T8Q+
M(Z/WB06M"UG_8&HJA&7*&6EU\@4*;X?JM:<= YK[*F\+BJUB7C4!?_+V;#:]
M"M<0D6)R$%F&1,>"<(E%+VIP75JC/9;(V[G,MY]X!&BV4N(61%L%O6YO%*](
M)Y/+LV$DC;$J><%BR(F. T7&/13+,"IC32Z0I.]T][W^]"- NC/E;D&]533L
M/::+.6TJ9,)]&"\G.(KH2ZPI:43%FG%::CRF!*9R5E+4' ;7+O1Q^XE'@&XK
M)6Y!M%54Z\,<:JW:^R_G<389@<N6F^!8C@'II$<Z(YS/+-E0,*DL?6EG-MUX
MW!%@N;_ZMJ1]M(I87;'JU9_I#*8?<66Y)><@HP46H_2T+"3+S7K-(B9 8ZVQ
MT,Y@VO;4(X"UM3*WH-M!H.K%[/R\!L5GZ??W9T"GP>G%LA9&5@J.>(R@8R:?
MFWORN8&\[Q#)!T.@<\)R)7+N(H!QGPQ'@'S'BM["@PY"5__$R>1_3F=_3-\C
MD(6 ^<UB<5$O0;FTTMK(ZG4G[3]:L1I$9<+YD'36I?AV55+W/OYHT.]"O5N
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M8NRB_5X(<6G:7LD3+'C.0QTFPTL-#>LZW+R0@XS1"E.R]L.-?[LIVR%\SI:
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M7B,R(&]V@:2_]*=\4R@!(!3XPH*7=*#Z3&<I&=TLU+YD#F+*9;@135L$/,B
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M=;G>1=N]I,<U;M' D0N?BF4!ZCARF[&64 GFBK=*92MD&&Z7.)KF/>WLD%[
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MK/WZ:5,Y@0(F%%I$)&%7309UW)5\!+JJI2W,3X<A55]X/0*PB%&!G=V;=H^
MDO&V&[<Q>UY+[4= +Y/A@P@]\N(1L*#^"-#,]*;>7/FC_>M!>2(P(BB@JD%D
M3NK!9VJ29O2ZDNQJW#8B\2LMF?%8&LFW.T3@R^[^V &6(?_-JL7E=&E'#+"8
M)^(UK,S%TC.VHQI_RE$O[]I[ZL&*^L?=W;*^P;!+G':!Z&Q;73 ,:T*]#7IR
MOV(/-@S5;Z%W(HKC!"74&3535?V4J^SR2%>YK-!=:/[^]QR.2=68E6%W4X%
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M?12&\C8EIMN9AG=R))HIZ[3GS%)J-/V6>F?S-WHZRY5]PNF::Y #@]:T?8F
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M_DX#U>^PN>&S,4F^/Q<JB!R<S>*)"SW97/,3&"?/\Q?#<5/6Q16GH"G\U>]
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M?]PC($Y&;.9.LD3= >NJQ!:/=SE*C!F/=FSB".TEEI(4NO^^#NIT_?+ZLY2
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MY.\PT)84?GGHJJ?:U3;CPRVZA@7OB!)GDAGPE>Y=3\1EZJI :A]?;SP"8DU
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M^8'V4[156V]'R4KW_-PA@'6H'^Q?>?#S -I9VVDZ^FB65NYJ0Y-4%E]N XK
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M.Q>^C-.1.O2 ^K>V9RR9*]8&T',W^J=AU*]_N^J0:=>(]@D #HW_HZ%WY#O
M9^=_O-IH')1+BP=>1X&>4.UA9E-OQU]?A(6=XC&5T%)><G2WS95HSP0]JXQ%
M LEEB_:*UY96Q'7EI[2/AOPGM[3QOJX?X_4_IKMR7KU[VH;J<YYOEB_=\6/,
M3$D/E?,5FMO3>:]Y#PCDO_[<[Q$G])>7)DZK.,6^VRA+SQMF<W2.]3*9%(&I
MCI1=4%QM%E?>2M7JFHSFX$Q0T<T^ZXQRNO7Q%N#=3Z&OQ?4U7/\ ES7P_=>E
M]WD.?.H8N7:=_-?4H^ZHOSF=!1.N0%(T7%H\RK9L//89&\T!CW[5NNWK2HF3
M1IX/DA7N^YEU+)8WF#UDF^9QY+,4O\DON)+S;D]N@;A%,J>G/_W@$>X(5Y%?
M9C]V,6*8BZNL>.UW:CQQ=7N,JPQ8M:7^\;LU%,N\MF^4.W_$Z,!,&B ^C7C:
M;,2;[>.&6CRO29"4AT>^KZI1)T-F][]M^"HMH2>+D;NP1KN$ :VS/0PC.T[5
M,*;IP41Q=>F1!E2T[$K3S_F.%@0JU'R=H]P8]!(ADAUW(EC$6AH:%N5I- Q6
MF8 MZJ?R0$-NI$ZZ_FYNBCVCM7R@G:,DU@\+?CORQD;;VHS47T%-HMP!&G0[
M*D@;E<K1+^K<QEJ$34)W_I,PBVB61[5P=-$-9?+TQ@@3$W12Z5ZH<)EP:\IS
M:PT*)119W.YH>:>SVO<:V^%L;V,*L'K(>!N#9EDVO[I(Z[I(W$JL?H7+IV0V
MK=OOO9(C*RHR^J 7:?+> $M[3"(#),44?0^( B()9O+35>O&O0R.<P:VEMH]
M7'S8W+I?NL^9GW3EOMWQ9037YZ+,XF0X(8(W#MM*Z(IXKPJ#73T_G*$JW*^R
MR*]TZWV-<I"-I :5:WF;W8I16YG;PF]$4<FYR[]#*<V;%S*Q&,(./XXH+VB0
M"HP,+*=0.WT$/XM5:?X0$;]9--T\P26/T+]2T]7B=YL%5P(MZ>G;Z+"BZC48
MQO/XMICS4B'?-H0Y7+2VZX,-=2PEHBM_S?7)58:)_G./[^ L;"QFO<>4#$.T
M((;X+YIP+W52;-B- L:31X0>**E3RT>38Y*A:,7^_F$(\\@JG_!PR2%MQ0)D
M4&$&#F5M;V5J&JO<:/MJ3T<ADC3LNH_8^$&4/H"F9J'&:G]^K8" !Y*^QWJ@
MF?^U<F" G<M:C. NP[IPG"RJ"SU20-R3S0A=S9%*QWLXI)C$J?S J>-C^]HO
M'4'TJM)4L_"Z43#QJG$\%2GYSK51O+I2'77^=L[1N\U/E8<,=N1YYEL;SH_L
M*@DZ5BG.84^Q_J#)LYL_A\BQ\R(,9<J3'_W$>X5VS&Y[@&@9K7?? \$JIK>_
MA:$?G$#Y"/1%"DEYL'7ITN+N@L-BQZQ((G>2$C7'8_@$U?96'P, CU7Q6?KJ
M==L58UU\L,TJJ;T3BLN,%%N]=WW:?L>*0!]!>4M*H*E9]-&;(;SF7DF+@XK1
M==$/?P5T)KQ=A;L<K!?@\+'V7FX;V+_[()3B6%?FX<\)W%3DJV,W^X<U&6O>
M_TYI(T>_F\?^<I6AO/U]S@6D=Z!>**"/!W8%L53/(OJ@EDK%]?[^)?5,*L\_
MVGHF?_F2H "AG F:8*9N)L>P=M*%V=?^W3-EF1(6;D9,6: O+[CL9ZZ2BB+5
MSS*:+Y*RQ1[H?+(*];'(8&[1 K4 D6UK.>0>I6E9<WJ3JVC%MMR[9V3HJ[:#
MU__WCNR5KO6KS_MFVO> =H81X%K>_VL Z*4HB[H'A/ROERK2LZ8]CE<VL7C@
M_'9LH+/VC83JF]9-<M[-]C*P?]VQSK<CJ9-W$R%'<D+R^\RZ^%25W]I3*[*=
M7RJV/& -P^Y7+AE@)3L?KJ!4:T]-0$+/U):ND@32#B#&'OLF9N$R5'4QS>2_
M5PT@6:I3/"ZL:?L'6<LR@V][++V^4!J'-#V;OUWQ#_VLBY4O"] 129/@S;F.
M6(X/KYLTZJ7^>4PN4;DFK2BVC7 #/BUH'ONP6\V6K- YK#3W+H7X^U,SY+H8
M<*))8%[>@CP)4U\*JU!3;Y*F1Z:W2YJ1J;CP=!RE.&_:!!9\<1=],( )?;(?
MEW.^DT-UF^!E5-Y_#I+II4ID@&U(?<:W*!]9O4S,JP"&K] FK'91">QI+!DI
M$G5E!6S[?7W_.8%?$<-@27GATSD:72LC@@T4RC2+P*D4+W!>:?1U6@Q-*&CW
MM<N.$'#U6Y"6 @*%[-:VDM/B6XA*IPIT9$ &NY/7#5O!1#*,V-^+H&JP)&5M
MW<(IB'VM:OZQ) W^?IK8Z.8BY2J6HU.4"5B;8557+Y'=,A=KI6_)H6!AE-?C
ME^#O/ZU*VJ.WH%#D@J2J,6)#U-N]V-^*T*;B&$[29A:TMTPHX&!C<#LC/5@M
MW,\1Q>BFN[D40><0U?X-;1"*LKY-UJ0^ GO..*5'WD:_+A802B<C$UL'M:"
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MD/YW:&(;%6QG8B2+$0T[MZLXNZQ'ZW[SI!=RO;$)AW8<I_PZ[AX\^W>EE]
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M6GK[]DN1CUW/MF G+^+0"DTH0G42AQEJ;W+[!4?!]M(5.=IZT+I3M= &_PO
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M[UZO4:>E!Q/-4@5XW JO_;4GU?9NN,Y/I>W7-D%O)X.._P.PP<'22XZ.-J(
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M^I1LQ0&)@ 6.]2I4@$,,8JYXV^"?BCX5"V?Q%HE]I*W9*1-,%*EP 2A*DA7
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M@X.#D&NSN_@)KR0:3I$/AWQ')XPU#6;K26LRL+02R0PQ2^3%M;?YZK)EU;@
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M/4?P]1QD5]3W7@)M-:/_ %<L4R"6&:-MT<Z'D,C#@J1W%!YE3FINTCS,^&%
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M//(Q7!^-OB)X37X<7'ASPK9:]LU34H=4O[O6)O-GW0Q-&B [W+L=[%I"5SD
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MA?H2WVK*1@^<VY@['[P)!XXKB/";+?:II\4T]O;PS7$2237"EH8E+@%G Y*
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M=L:!4 4!5X&!T ':E\(>$3XG\26.FK<6]I]NF6 3W#;8XL]V/I6IX[\)^%?
MGB2UT?5O$&J>&=0OKN"SMX]>TE;=P9(UD::>*&:6:UMXU;YY9HU5.YZD>UE/
M#V99IS_V=1E5<-6HZO[MWMT3.?&9A@L'.,<1)1<MK_YG.Q7*S*,\^E=!X.^&
MTWB^[+;H[6TA&^>XE;;'"@ZL2> !70:/^S9J4VO:K:VFJ>']870=332;S['?
M*K+<O%YT<8681EB\9#+MR"&7GD4[Q%X0UH6<<6O6&H^&_"\;956CQ]O8?W7^
MZYX/()5>V364LIQ%"=L="5)*U^:+3UU5D[7NM5]YS8C.J4J?^PM59R^%)JWJ
MWT1H:3JL^MPW6@?#W;IFEP)MUCQ1= QG8>H0]44\X"_O'_V1FN?OOBIH?PFT
M^;1?!:L]U.OEWNLS ?:;OU"_\\X_]E>O<DUA_$KXHRW^B1:-I,2Z;HMKGR[:
M'@$]V8]68]V/)KSBV4F92/O9J\7FG-2^JX5<E+MUEYR?7TV1Y.5\,\F)_M',
MY>UQ'1_9@NT%T\WN^NYV=M/-JLQFF=I'8Y))SFM3PW\/M8^(GB"/3-#T^;4+
MR09VIA5B7.-SNQ"HO/5B!6;HGRVHSUQFM'P_\:_$?P6UN34O#.J2:7>3P^1(
MZQ1R!USG!5U9<@\@XR*\+$>U]G+V%N?I>]K^=M?N/L>A]6^%OV1;C]F3X*ZG
MJ'BS5='TJPU;8VJZG))E7"C,=M:)@/.PW,?E'S,1T !KY;^,WQ4_X61XFCEM
MX)+'1--C^R:59,P9K: '.7(X,LC9=R.K' X50.2\;?&?Q-\7_$HO_%&O:KKU
M\J[$EO;AI?*7^Z@^Z@]E %4IF/E_AUKPLER&>%J3QF,J>TKSWDE9)=HK6RV7
MR];W+$U)4U3>RZ+^M66X@LTG7K7VM^Q?=QW_ .R-8V=V/.M=%\97,CIGI');
MV\@7Z%@3^=?#ME>>4X[\5]2_L,>+?[;^'GC3PRS!9(9[37(,G[RC=:RC_P B
MPG\#3XLH.IEE2V\>67W23_(UP,^6O&7K^*:_4^U/V<-6;PQXEUSQ%J7EK$UH
MVHZA(7Q]FMHHS(47\!S]:^*_V4/VP$T+]J/7_$'BUH)-%^*4LMIKS3H'2%)Y
M-T;L"#^[C)"L.FPGT%>A>//CC<>&?V(?&5]--)%J'B:8^&[1 W+>:Y,Q'LL$
M;@^[#UKXEB;SQSVZCUKQ.$<#]8P5>=>]JDG%=-%I=/H[W=UU#,<.H8AKR7^?
MZH_3']IGX<0_LM?LX^-M7MY(VTWPUI,FE^'HVN&D-K-/((<\G&(T8$,>3YH-
M?FCX5EW0* <JHP#GL*^A?@5_P4N\4?![PN^@Z]HMGXTTW['_ &=#)=3;+J*W
MR,1,65TD5=H W+D  9(  YSX^?&SP'\9M-L[CPO\.8_!FM1.3=W,-Q'Y5TFT
M_*8HT5=V[!W8! &.<\>OD^%Q&"JRHSIN2E)OGO%Z=.:[4K[[)[_,B=1U&G)]
M%IM]W2WS^0_XK7M]J?@'X>^&W2Y,>EV,=Y9BU<QRQ"1VEED4 ##ALAF)!^[[
M5U6M_M4?&CP/X3M;>Q\=1M92VD5TL-W8V]W+#&?NAI)(V<C! ^8GG [5WOA7
MX,C4_$5W>W!FLFL])M--@\U-IF>2,.[/R>%$6 !C.:\M^)]Q#?Q^'+W3+A6O
MK56T\J[*[,5!SYB8P 5QM4C 7;U/3]1HX7#UXPI58*22ZI/IYG\Q8C&8R&/K
M8BE4E%SE)Z2:OK;I;;I<Z-/VLO''@;3[/5]:TKP#J=XMR!=1R:;]BDG4'YN8
MV&TD8&X(<9!QVKT3XL_M1^(_%\5AXJ^%.IIH>C:E;1K>Z3_9]K-=:5=J&,JM
M(T9:52%RK#AL\8(*CYG\0Z]JFM)IMYXBA35=/@C_ +.17(5L'(5NF6()ZD'(
M&/0UZ1\%M&U/X:>!M2U.WL;#5]+M^+F"YDV268; WQMU5BO&#P>.X%5+A7+J
M=2-2&'AIO[J:=_)Z>FQZRXFS2*]A6JRE%K>\KKS33Z=G=/RW/'?VO_C5KGQ2
MO=-AU^W:XUS2]UM+>P:?!;QR0OM;#F(##'!!&T#C@\D5S:W"_P!F6=C=6JVS
M+&/+5TQ\IY&,^I/7O7=>-Y6\=:TU])IL&GVMF1';P21K%YD0^9&F* ;W8=7(
M!..E>C^//AO;_$?X?0S6K:3'/:1IY<\-O*-X;J(Q)AC]2,<>]>E3P\:--4Z4
M;1Z)))+TMH>#BG7Q2=24W+NWN_F)^R?J=K#:G3+AK>W2,M)&\LH3>3@#:A&6
M(R>G7.<<5Z)\9/#ND^$]&N=6DO%C-K&PF$3IN9"0#$@X^9L9( .!^-?/%IKT
MOP^\3:?+/')_:.F3*&M^/.X^1C'N&.G()&.:N?&SX@V7C?Q?I;:+9S/;+;&W
M$=W<DO)-(C&69MN ,$#"CY?E]ZIX63>^AMAL.W0=*6_37>_]:GG6ER:;X^\8
MM=BU:33].G:Y^S]?+ ^ZI?L1D$]>#7WI^R[KDGAR\L;6]O\ 2[C4TO,B.UN5
MG!C.,L74E2,D 8/(!KYC^$OP+U'P]X0EOI_L=S;M:23H4CXBD(Y!;&"..G.<
M \=^@_9YN-2TR_\ ,2WGMY;F G3WVC[V&",/4%U(_.O/Q$>:+3Z'EX6,J&)4
M?.WDM3Q+X[^'H]$^*GB:SMQBWL]5NXHP%VX59G X[<=JX[3K0O<9(KL/$L4U
M_=3373M-<3.TDKL<L[DY8GW))K/M-*ROIS7QO,?U9&#229#'#L2KME;+(GO2
M7BB"$+Z56ANV5OEXHZE#]5M/+'M7N_\ P2)+#_@HM\/?[O\ Q,O_ $V7=>"W
MUQ]JKZ#_ ."1MMM_X*&_#]NR_P!H_P#IMNZ#FQO\"?H_R/GZY<QC.<52^T2:
MC=QVUJOF7%PZQ1IG!=V.%'XDBG^([GRX-P[USCW>P,P^8X)QZTS=GV)\39/"
M/B3X=>)OA/I/BM]0OO!NBP2:+9-IODVAU731-+J+QW1E*R&Y$UX!A!OV0C/R
MC./\3M$O=(\ SS>&_#/@FX^&L.@Z?=:;K5Q;6IN)+ORX&E<3Y\Z6\-P9D>W?
M<NS(,84 US/BS]B*X\)_%G0O#JZ]%J&CZ]IMS=P:K':86*XMK-KF>T>/=\LB
M$(.O*2HXX.*S?!_[+LVK^%/#?B:ZU6/2_#.H:1)K6M:I-:EHM%C6[FM4B4 Y
MGGE:+$<8VEF;'"JS!:'%3Y%9\U^NW_#:Z???N>Q?&^VN/'GQQN-0\0:9X=D\
M,ZAX'O+O1;U+"SBCO+B/P_&0RO& SM%.H"!L[&7:N",5YOX[T[PO'\*F\=6=
MOX=AO?B-9V&AV>F_(L>AWT3!=5N?+',*D0Q%' &!?/MY7CR&#39/$_B:'3=*
MM;J^N;ZY6WLH$AS<7+,V(UVKGYR2. 3R>IZUU6N?LP>,=(UC2]/;15N[O7;A
M[*S^P7MO>QS3QX,D)DA=D1XP065V&T<GCF@OV,8V7-:WY+^M3W+]H+X=_P#"
M#_">_P!8&CZ"VL^#/%-B;6ZMO#VGV-C_ &<Z3H[01K+)+=V)E6';-=*2S,".
M68"[^T);3:W\2OC5J7B+3-%2W?2YM0\-7<-G:1M=Q/J=H%N8FB&97:-F =LL
M5+<XS7A7A+]E:^M/$MY#X@B6UM1X;U76]/N]-O+>\MKR2S@9]BS1,\; . KJ
M#N&1TR#3M3^"EU):> X?#D,U]J7BCP[+KMVLTL4,-F(KFYBD<R.52.%(X S,
M[8&3SR!013@HM7E^'S[^3/8/V@_#5KI?@OXAF70?"UA\.['1TE\#ZO:06Z75
MY=EX!!Y<Z'SKB21#,9TD)"8;(0JM9/Q?U31->\5_&KPS;Z'X/L='\):9:WV@
M/I^GP03QW(N+))'6=?GE\Q9IMR%F7IA5VBOGWXA>$M5\"^)AI>M6L5M>201W
M41BGBN(;B&0926.6-F21&'1E8C@CJ"*;X=TU-X.U<@\#'2@UA0O9W_K3_+\3
MUK]G31_[5M/%IT_3=*UCQI:Z5&_ANQOX8KA)I3<1BX:.&7]W+.D!8HC _P 1
M"DJ*Z]-<'PP\2^-/)TWPAIOB:^^%4ESXCL%TRRGM8-66Y0"-8V5HXW: Q/+!
M'\GF$Y7*X7P_4[!7A^8 J.>1TKFIU2*?Y8UX.1QTHW+J4.:5V_Z_R_4CTR&2
M:[FFD6-7N)&D8)&(T!)).%4 *.> !@#@<5Z[^SW^T9XJ_9B\8+K'AF\55F 2
M^T^XR]GJ<0_Y9RIW[X889>Q['S*P=63++C%:",)8NOM3\C7V<91Y9;'ZN_LX
M_M&>$?VLO#;WGA=S8:]9Q^9J?AVXD!NK/U>(_P#+:'/1EY'0@'BNA_X2B\C^
M)L?A_P#X1G7&TU]*;43X@'E?V:DPE\L69^;S/.(^?IC&/<C\?]#\8:M\/?%-
MEK6AZA>:3J^FR"6VO+60QS0,.X(]>X/!'!R*_0K]D#_@IOH/QX-KX<^(TEAX
M7\:2;8K?6 !#IFLMT E[6\Q]?N,>A7[M95(RE;E=M?O\OG]YY%3"1H.<^3VD
M6FE=M.+>TE9J]NB=UW3/I,A859G9(XT!9W=@JH!R22> !ZGI5RT+02+)&Q1E
MPRLIZ>A!%97Q(^&UCXT\+:QX7\3::M[I.M6K6=]:2,RK<PMC(#(0<' (*D=*
MTO#&@0V=OI^DV,<=K:VZ165M&"=D,:A41><G 4 <\\5/O\]K+EM\[^EMOG\C
MS+4/8*2D_:7=U9<O+96?->][W37+9))W=[(US7H=*TZ^U74[S[-9Z7:RWUW<
ML&?[/!"AD=\+DG:JDX SQQ7S#^U7\"?!O[7/PAUKXP>$%\3?\5'HDVD>(SI5
MH]EJ]W:0SQL]W#'E7+A8O+E",#+!(<'<N#[%\"/VE]$_:$?Q1-X;TWQ)IL7A
M2_%C)/JMNL/VQB71BJ?>0AD8%''*D$$@D#M-/U*31Y[=[,0V8L^(([>)88HA
MDDA44!0"220!SDUQ)QQD+TY7I--.UT[WZ/R]#W*U*KD=9T<52E'%PE"2NXN*
MBX\UI1L[N5XOXM%=-7/RE^-'@_4/'?@+PSKOAS3;I_"?AW0!;VUU?748U*^M
MDE<FY^SM(\PMT+A5+$X4 \+C'FO@?6['2O$D%QJ4+3VJI(ORPI.89&1ECE\I
MR$EV.5?8Q ;;@D9K]#/^"AGP"O--^'NK^.OAKX7T0-<Z8=,\3+;P/]OT^S.<
MR0(#L,.TLK87=&"2.,[?SC6R4JK)R&'!'>C X>I"A+#U4E%74;-WY?-]_2WR
M/H,5FE'%UXX^A)RG*TI\T8V]HW>24=4X^JL^UC<\1ZQ9ZYXFNKJQMUM;60KL
M01+%DA5#/L7Y4WL"^U>%W8' K-NY=U=-<ZUHL_P]L=/MM+\O6(2AGNS$BG*M
M*6(D!W/Y@>,;& ">3QG<:C\4?#ZZT#PVFH320L=MM)+"(Y0T*7*/) =Y41L6
M5&)",2O&<=NFG6A3483]V[Y5=ZNVW5WNE?77N34PM6JYU:7OJ*4Y.*:44VD[
MJR22E)1=ERW:46U:_#3VPGE/%+]DVP_=Z5=107_G2:BXAMCMKK//L9L$?S],
M"M2TMF0>M8]I>?Z0H;H376Z8BR6PH")G@LK>U3VD>Y\^M6)=/#O^-6H[3;%]
MVDR[,A6#S!AJC^S^2W%6/-VOBK$-J;D4_,:([>/<*[OPM\6]&\-ZOH7B*Z\(
MVNI^-/"MA_9FDZLUSM18%9VB6:(H2WELY*E&3.%W9VBN6M=-\L<\4Z73PPYK
MDQ6%HXF*A6C=)W^9WX''XG!S=3"S<)-.+:ZI[H[']G#XVV_AG4=0\.^*HQJW
MA/Q0K6VJ6LAX<.<[U/\ "ZM\RL.0P!KUSX:?"RZ\#:9XN^'/C'4;+_A6=G:_
MVYX=\6W\HBM[,2EBD8/);S-C[HT!*/$S8VL37AFC?L_ZSXJ\/KJEF=+5;CSC
M96L]]'%>:EY* #Q P[_NF^SQ$[I-@!)QZ$#)XKVS]GS6M"_:3^"UU\+?&NG+
MKGV67^U/#Z/,D;)>I%(B*&D1T^=9&4;E8!BK<$ UZ5'.:L,'7P6'Y9\UM&](
MS5K2\G:ZZ)]=$?*8[A/!5LWP>;XZ4Z*IM\TH*\I4W=.-FGS1YM=$VFGRKF/G
MWX\>"M6\$^*OL.I77]I*8(Y[*[2Z^U075LXW120R9(:-E((Q^AJO\(O$K>#K
M^Z:ZTRRUO2M4M_LFH:==_P"KNHA(DJ\_PLLD<;J<$97D$$BO<_'M[IW[5/P=
MFU#3=#_X1GQ)\- NC7^BE]\D-HA812DX7)SO5_E #@\ $"O"+';;*5QM(ZBL
M<9EU:A?"8Z"4DK2735=/+JFCT,FS[!X^$<QRFHW3NW"6TM'I=;J2MJNC.P^(
M7Q$C\:6FDZ?9Z9!HNBZ#$\=E9QR>:P,C!G=WPNYCA1PJ@!5 '%<W?:)=76B3
M7D=K=26<+!);A8F:*-CT#-C /3@GO6YJGP1\6VW@Q=<_LO;9RVQODC-S$+M[
M90"TX@W>88P""6"\ @].:R]&^(*R:58HMCNO]/T^[TN&Y^V2+$8+ERTFZ '8
MTGS, YYQMR#M7'F0E&%)4\&E)1:35]EU[ZKMNSZ*7[^M.MF,Y1<HRDGR\SE*
MSM>[6DGHY:VWL]CB7TQOM'W<X-;VE*JQA<8KH/"7P]D\6FX;SS:PVYA1Y%M9
M;I]TT@BC CC!;&X\MT49)[ \OK$C>'KRXAF9?,MY&B8J<J2I(.#W'%=4:T)3
M=*+]Z-KKM?;[['#+"U84XUY1?+)M)]&U:Z7I=7]4+XAB5+*3'WB*\^:,K>;?
M]K%=-?ZPUU#(V[J.*YD[FO5;K\U;G))W.XT2'%HO.[ I-1N%M8\"-3GVJWX8
MME:U#?WA4UYI'VB3[M%S2SL8<4"S/P.:D33V@G$B_*JG<"O!!]?K[UK6NC?9
MG.X?A5J\M/\ 0_\ :[5-Q<IL^)?VA/%7C[3;ZPU+4K:1=3V?VA-!IUM;W6I[
M2&7[1-'&LDWS!6.]CE@"<D9KFHM+41_=7YNO'6J&GV#17;#[V6+9/:MV.%E3
MYJ+Z!3@HZ)&?-;&$_P J:D"],*N?05H21"1?>NB^$'P9U+XP>,(["S62.TB9
M6OKH+E;.(L!N.<#)S@ D9/H,FJCS-J*W"K4C3BYS=DMVSBR%B'RGYLUTIC\-
M^,O!&O6?C32XH6\06"Z4_B:P00ZZD D5_(\\?O)(6 ,;*"&\N1UW8(%>S?#X
M7UK_ &UX-U_P#X&M([&Y@;3[V1XKB:ZL(KF);OS9(PTJW#0LY1CM_>LJ@%?F
M'F7Q3^&B^$/B/K7]I!_LNEWDEMI]B[JS*BMP)"N5.WH2I(9E)!(QGU>'LYQN
M78E8["SG1E'9[-VEM;JKQO9JVB?33PLXC0QD/J:4:C=MG=1NDU*ZVT?1_@U?
MSGQGX3U;P7!=>)]5\1-'INL6^H6"QVKS0Z-8V$8MKB*Z5(MSS7?[F*-0XB9C
M$HE1PI8]=X:\3:K=?LYZY#XOL]6\/ZE#J&W3?"2VWV6Q\+-=3/-Y+29)O9#;
MQK/Y@PJ&Z' 8XK-_X3G5+"YNI+>ZDC6\C,$\/WH;B(\&.1#\KH1QM((K)\5>
M-)M:TVSLUM--TO3[$N\-GI]L+>$2/M\R4@9+2/M7<[$DX Z "OU?/O%V.;9!
M4R^OA^6O*RYHM<ENK2>L?=;C97O=/FC[T9_+X#@583,*>)A.\(N]MG?HM.E]
M^K2MWOASV(F3IN)JO'H'D3;MOZ5IZ9.)'J[=?NH\XW5^*GZ'8JV3>2.:P_%4
M9F!;\:U)IV89JC=.;B0+_#2Z@]CG]/MFDF!'7-;ZVG[H9^]BK&G:.K/Q5^>S
M6!=Q[4"43%&GD<UZY^Q%K;:7\=H]/:3RUU_2K_2QG^)W@9XQ]?,C3'OBO+;B
MZ4;MOWJM>&KV\T36;/4;&>2VO[&=+FWF3[T4B,&5A]"!7-C,.L1AYT']I-?>
MK#IRY9*2Z:GO?[4DDFH? ;P4MLH^P6VKWZ3!?X)BB %O<JKD?C7ST(Q;RU]8
M)K>C_$KP/J6N26+3>$M<*1:_I=F<7'AK5",I<P@Y_<R,"R'D9+1GL#\PZAIN
MEZCXCFM=)UJVNE60JOVJ,VLAQZ@Y /XU\CP[F5'!T/[.Q3Y)TV][V:;OOMUZ
M[K5'JYA'ZQ5]O3:?,E=:7NDEMOTOIW,QE^TY.,8KH? FGBZNF9US;V:^9(?7
M^ZOXG^51/X.O[964V[3<@ P$2@D]/NYZUWL_@K_A"O#4.FL!]J;]]>,/^>A'
M"Y]%''US7V5*M3JQYZ4E)=T[_D>56C.D^6::?FCVOPW\4]:M/"NE^)++3YO%
M6EZI90Z3JNFC,D[7$:-;XC*MN23;M*\<@U\^7%U=7OQ'\NWT7['J$,TN%EEW
M7,B# 5)1@)YB8()49.><FNN_9R^/:_!;Q9<:7J$*-I>N7=O)]H>0H+":,D"3
M_=925)!!'!SQBK7QY^'$?@WQJ_C/3+GQ-J%O?WR&WU*]D656/WFBW @[D &3
MM.2!SS7UV4XI.SZ['\^\597++L>ZC5Z<FY+T>_W/^M34U.72/!4U]I)F5EOX
MUDAG\CY1N',7S#@@]QT/0T>'=<UOP?I\5K>:5#-8S/YL/VE'_P!*BX#(''X=
M>5."*]N^#=]H_P 4/"EJVKVMIJ5YY3PW/FVZM'"KDL'CP.2>G.""#Z5P7Q8\
M"VOA#QU!9SSBVMU"LT'V@+($/3:>1EAT)'..]?62J2<%!QUZ_EH5BL-4I48N
M"YHO6]NZV2U_K[CSCQ0+/4M0W6=K=?9;XCS([N7SF'9V) !  V\>U>PZ9IMC
M)H5C>:=<26]O;A89UGN%5 H'RE!D_>..3G\#65X13P5X/\2WMX^K3:@TUL5B
MMI[<]\C:2I +,3C/ SC) INOW?AO6?"MNU@K+=1S&;RH4V\,23"6Y7@8!/(4
MYZUZ'[N+A0DK:=5_6I[F#IX?#J%";2YE>S2U_P F<W^TUX"N/%?PSU+5-%O+
M!I]*5#=6,4;2O# I50YE/#98@Y5N#GC ./"?ACX=NKGQ-87L_G3;2$DC$98E
M2=I('?@]!C/2OH;;X,U2]DN==.MLL)YM%GDN);F->0G90I8#.2!D  5UFF6&
MFZM/I^I>#]#T_1])CD,QAFC*W4N"H!())4YYPF1UY/)'C5XU(5W3E>W=_EYG
MS^,P5;ZZZ?/H[=V[7Z>273U,_3M5L/!?PI73M-DCTYKHRQ^9<VWF7!)V#<JY
M.S<%PORGH3N%3?L\>%-0LM7L;A8]4FL]/F\U8;>R2&RB7*L;F[NMN<1_,0A)
M8C)'%1S?#J^^*?Q)L=/CDNK%/E6/,/,I+$%(^>8\8&\X[X!S@4?V_-4A\"_V
M3X3T&\N;>W:T(U1(6VQWX4C8S8_AW>8 .AQGGBOG,PQ4:=[!E>4SS3,51A[L
M8Z77EJW;_/1Z'@/QC\0:3KOQ-\17FC?\@BZU.YELN-NZ%I&*G';(YQVS7-64
MXF?[N*KSP.[YV\5/8@HP7;Q7RO4_H2,>5**'7L/F*W%8\]NT9:MZ]NE"!<5F
MW-LUVIVB@J1G(3(P7)^G8U]._P#!).R\K]OOP"W_ &$?_3;=5\Z6.G;#\RU]
M,?\ !*-53]O?P%_W$/\ TW75#1RXQ?[//_"_R/E#6XVNH !TK!_L]FE./XE(
MYKLH;+[1!R,5"-%5GXVDT&UCW[P%^V-IUC\4?&%_J&CZA>^&_$$9NM/MMZ"Y
MTO41IQLEN%.=NUD:1)%!^9"AZH*K^'?VHO['^'_@?PC=P:AJ7@W1]+N]+\0Z
M,TBK!J:W-U)*TT7]V:-3$8W;E)(ACY2<^*16+0KQ5L0MY5"\R(X>GV_I*WZE
MGX7_ ! C^#7QNT7Q-:V\NI6NA:B+B.&<B&6YA!92"5R$D*$\C(5N1D"O1_A1
M\4/ _P $?'NAZIX3M?%FJ0VKW<=^VJ?9H7%O<6[6_EPQ+YD9E179O-DX<A5*
M!<UXCKC%;CY15[PQ.Q<>E#'*G&3U]#Z&F_:#T5?$%C:W6H>+-5\.1Z1JVFSR
M/I>G6$MN]_ (3+!;6^V,E0J;M\A+[1C9@ \/-\?_  [X9E\!W*W?C32;_P ,
MZ->>'KF73[>SF1[>6>>6.4QS%DG5A/LEMI%56"\/TKDYW3RCFN"\9L+NZX/?
M@4B98>%K+^M_\SH_C%XXT'XF?$FTOO#>D#2K2#3X;6Y<64-@=3N$+%[HVT!,
M,!<,HV1DCY,]6-7-,L/LD(;OCTKEO!&DYN?,(^E=S&N8&'H*9K2@HJR,;5=9
M6W1HV/S5@N[7$V5.><CVIGB+S&U$KGWQ5FPL)'M5*T=0)$W".K,"LV-O;K56
M:Y^SR+&V/K6AI<J3,0GIS3ZC(=23S#[]ZSOLRL3N&?8UL7UN2A9>6JBT>Q/F
MZTO0#Z9_8Y_X*;^(/@5!:^%_&,-UXP\#1XCA5I,ZEHZ],V\C?>0?\\G./[I7
MI7Z)?#[QKX?^+_@J+Q)X/UBV\0:'+P9H?EEM7_YYS1GYHW'HP'Y5^*]K8><_
MI7HOP8^-?B;]G?Q/'K?A+6+C2=04 2!#NAND_P"><T9^613Z$<=L'FCS/-Q6
M6QJ>_3T?X,_6_4KR6Z5M[YW-O;@#>W]XX^\WN<FN+^,&A>,O$_P[FL? /B:Q
M\(^(I+N)VO[F'>6M0KB2*-MK>7(6,;!RIX1ACFO"_@[^WAKGQ_\ CQX&FG\8
M_#7P3X)DLE@\0Z'<E8;R[U+=('"M+_RRD4Q&,HP*,#DX!#?4UQH%U::I':2Q
M&&:0@*'/RD'OGH1WR*\^\<1"I2:<4G:^U_-?YDRHU<HQ&&QBE3J3:4^5KG2U
M:Y9QDK-Z7MKHUJ3:7?W&DSV\BW2W%U##&D\ZQ"-+J0(HD?9T"NVX[<8YZ"OC
M7]N[_@G"NH6VH>/?A3IFXJ&N=9\+P+\T1ZM/9KW3J6B'(Y*\?+7U-\+_ (J^
M%_C)HUYJ'A/6HM<L=.N_L5Q,D$D2B0IO4KO WHRG(=<@X/0C%=1!-)8W"30R
M-'+&=RNIP0:ZL/4A."E2=UWO?\3AQ%/&8#%RIXB#IU$_>BURM7ULXV5M'=:;
M;'XY^--/\/:9I]K_ &1=6]Q*9%7S([IY7N(_*4L\L;(H@<2EU" G@<],G!U3
M6;S4+&WLYKR[FM;0'R())F:.#/7:I.%_ 5^D/[87_!.K1?VD)KKQ-X-2Q\.^
M/GS+<VAQ#I^OMZGM#.?[P^5C][GYA^='C'P1J_PZ\5ZAH_B#3KS1]6TYS'<V
MEW&8Y(3[@]0>H(R".02**%+DCRRDY;ZNU]7\MMEY'T"S&GC)<\(J&B3BKV5D
ME?5MZVNW>UV[)+19_@WP+JWQ&\9Z?H&@V%QJ>LZM.MM9VL(^>=VZ 9X ')))
M  !)( S6?XV\)ZEX,\1ZGH>L6TMCJFDW,EG=VTA&Z"6-BK*<<<$=1P>U?I=_
MP3:_9$/[/?@%?'OB"U\OQQXJML:=#*OSZ+8/SN(/W9IAR>ZI@=V%?,?_  5Y
M^&7_  A?[7$^MV\?EV/CK3+?6$(''G@>3./KOC#'_?K9'#3QRJ5W1CM;?S/E
M:VT"\%BM[]ENOL7F>6+CR6\G?_=WXV[O;.:Z71@WDBO;(?C]X=N?A5):G4M=
ME9_#G]AQ>%C;[=.MI_*2,W&X?(P\Q6GW',F]L #!)\AL+%A%M [5QX/$5:JD
MZL'"SLK]5W/H,9A*%'V?L*JJ<T4W9-<LGO'7=KJUIV)K15W_ #=ZN7#+Y.T#
M\:-&\(ZEX@MKR6SBC>.Q7=*7D5,G:[!%S]YBL<C!1SA&]*IZ<K7X]1CBNCFC
M)M)ZK?R.;DG%*4D[/9]^FG<A6("?KWK<TQ41!FLJ^LVM!FDTZ[?S%5B:IJZ(
MV.@G=5&0*@>TNI;66X6WN&M8F"/,L;&-&/0%L8!/H:DCA8Q9-;^E^(4BTVWB
M\N^%Q;6-UIR!+]ULY([B0.[R6X&UYAC:KD\ +P=H-<]:52*7LX\VJOK:RZOY
M=NIU86G2FVJTN56;6E[M+1;JUWI?I>]F)X8^-^K>"?#\>G6T.E226Z7$=C>W
M%HLE[IJ3C$RP2=5#]2"#@DD8-97@C6;CPSK-M?6LAAEM7#*0<8Q6Q$Z6<VCS
M)KEE9:':6EW'K>B/I(GN=:N'W^1(EP0=JJ#&,;D*%"PW%L5C_#GPO-XRU6XM
M_MVGZ79Z?:M>WVH7\OE6ME"A4%W;!/WF50 ,DL!7+1K4TZLI4^1)ZMV7-IN=
MF*PLI0H0A555SCI%<S<&Y-<C36[>MHW7O>9]-ZQXAT?0?#>J_%K1?$,/@C6O
M%BVFEZUJYTK^T8[9T+&5?+V/L-THCRY0@O 1P9 :\<_;&^&NG^&_BE=ZMH7D
M_P#",^)%74=+EA4+#+#*H8,@Z*#DG;_#G':NV^"EC::+=W/@KQ%>6>J^#?B!
MI@\J]M&9H9HI"1'<1[@&5DD7.& (9,5H? VT\50>%V^$?_"1^'M'\0?#?6[F
M?58M4TY+J34M$+0NOV9G5@81F9FC +,)TQP,K]!54<3ET\THN56K344XIW3I
M[1E%=.712\K/<_/L'4JY7Q#0X<Q"I8?"UG5:G*/(XUF^:4*DDFY<UGR)JZES
M+;;RZY^,?A.T\02>,ET/5I/'4FGO9%)'WV*2M;1VWG(QD^2,(F1$L8)+L"Y7
M 'EG@7289-8L;6XN%M8)YXXI9VZ0H6 +GZ#)_"O0QX2TWQ]\3=>AL9H/#_AZ
MUDO+][F[5F33K&(LY9E&6)"8 4<DD#WK.\7?#:QT31M+UK0]4DUK0=9>>*VN
M9+)[.420L!(K1L3_ 'E96!(8,.A! ^;PL,'A:CH4O=G/WK=?Z6I^DXZOFF88
M>&,Q/-.G14::E;2*W4;K_A]O(=XAM8=#N;5K&66SN)H&^U6\>H)=_9CO90OG
MQ!4<.@1R /EW[3G%>8^-[>43_(/EKN=.T^1EZ>U1WWA@7C[67.:]"C%P@HR;
MDUU=KOUM9'DXJ4:U252$%!-MJ*O9*^RYFY66RNV^[9PGAK1&O(_WGIWJVW@?
M;<;OX<Y! ZUVMGX9%EP%^6KEU8#[(VU?FQ6ES'V?0YBV06,*H#BGQ:DK2;5;
MYA67XEN)-,CDD;/H*Q/#.JR7^JJG]XC%5T)YK.QZ# _FKDBJ>J&0L OW?:MJ
MVTWR;9=U5M1M0D?M4Q=BN5F-9D1S-NQFM:*+[5#_ (5BF%C><=S73:5;K%;
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MEP .^*=?DL22>W2I;*UV#=BJE]+M+9H#4QY(W^T_*OWCS73:!9;;9=W>LJ"
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M7AL;!PJ0:YHO=75_R=S\F?AY\-M6\=W#6FAZ5>ZM=QQ^:\=M$9"BYQN/8#)
MY[T2V4VE7LUK<6\EO=6[F*6*5"CQ,#@JRGD$'L:W_@SXZL="\+:WH7B"PU2?
M3=:,,DIT^<0W$4L0D4*P;Y7C(D;*MP&"MSC!3XK>+W^(OC_4M<^RBR6^==D
M<R&)$18T!8\LVU1ECU.36$:E=XB4)1]Q)6=]WUT/M)4<,L+"I";=1M\T>71)
M6L^:^M]=+*UO,C\(^#Y->M=3>/6'TN-8Q%*J-CSU8.W[P;U_=#9AC\V"Z#:<
M\9&C6ZV:Y(Y;MZ4ZS*R+M/5:T(-.WX.X"MHQ:DVWH^G;_,YY2BXJ*6JW??\
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MD&Y3T:S: CCO7T1^S/K6O_%/QUH.@^&?!NE:IXZM[9+.TUR:1D6RM8MX26Y
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M#06%JEO&\K8#.50 %B !D]@!TK8T))K#5+>XCAD9H9%?A#V-?FSXO_X*)?M
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M,G!/ &:US\.+7PYJ\L5U?+KUU:_,([=3]FBP1@@D[B<\<X'L:ZZ?]C.#X">
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M987%XGZU"%6;^)*STZ[-?YF>9X/"T\OKVBK\LM?^W=+&=IUK<602;6I+>3'
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M7U>FU&]TM79>MOQ,922@G5E?IH3?'#Q?XD\5:L;N[TR^T[*C][';[@WJ7(R
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M*J$:[+W0\'.MY5KVDTL02A*7V'-*!DV[FDF+UET#6"^V@7J)@U+&W=]-TKQ
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M1[?!5^NMSPW%LI4*DU]RMAYHS^_<,&?8-W.X3[9)31[1AR3?YN&HR]+#!2;
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MO9*@:\[1,1(9(Y]?56G*+ER\G6@ Z63/M+6G64R:_CS==^SE$8@W %JWI];
M[QK.9#]M:<LW6@!$W/G9+RF\]>$$>OBVB&!6BV%?HO0*#C[[>7E:ZX/WIXA1
M?QBJ,>G8#A_[+B:F24(W9Y.WM38=\_[6-ON%81VZ(V!HX4MVN-QJT4N.%5OH
M6RL)_H#^3P_D.=C-Z84:[WS3LYMX.>VM0_GFB'B;^I6[MLGWEA;3:3LAY"BZ
M(P7XOMVVO+=Y'B7>L^)N?)D[KY3=Z'RH)\#I40*I2=F;W^N\OQN,ZKX&U&UC
M#%I1<E-/7AW%@5S7\L,Z9"PZ.?&C*(ZLCR?^:+XIQ_&DP:]\>O1?=$:P/8>1
M/PGOTD<DO8V)6CBN"/J#1O9DL5.*1MJ=N[K%:I31W+22WDO9^Z',9= (J6%O
M 10&O7F1@;RQW?9.9&3E;:U$#$^^C&2LW+-#?F+^W-+EG\WAXP%TMT77M'N2
M=BFSB! _!J0'/ 1.JA)(E+PK&G3S;M;BE47B.6_15*)H;TNA EH.156$."HX
MZP'I&C!"F5M['SU2<*N322'YM"W$)D+(".XBYE_QH@"W#=@H^1\ 0T"\OV]<
M#A5_B8J.]?=?Q$\&V'BCP+>1K9V<+7BHY1D823R*#S@>N0!GDXK!\!?LD7NF
M:=I,-U#-##?,M[>%AC<2H*#H/E1#W[LQK;..),-5Q%:OAZ2A&Z44MM(I>FEG
MM:YP^'N$C@<KI8/'8F524'/WY_%*\G*^MWUV;E;:[2.#GU./Q&L-CHUK/I.B
M:9:BST^%^9%ACSB24_Q2.V68C )<XXQ73^%-/O+#P]",G<Y).YOF)KH?VC_"
MECX%T];?P^R[3$JS7('^LQ@[1Z?SKQ2_\>^(M$@A9EFCM=Q_TG'[JXVG!"/]
MUL=,*3T/I7RM&6,QT/:8=.V[WTWU?8_3JN/HUZ%.-*481>D5)V;V775N[7=Z
MJ^K/HKX:6MUK6H1PF=9I%P?)7AD&>,D_='O7IFK:K!9:1J&EZK8Z3=6NK6RV
MFI*L>&OHEC:)8Y7!!8*CLHQC@GZUX+^S?\1_^$AT[6III?)FMV)Y?:VS')S]
M!6OH_P 2;6Z^(L=O;R-KC6[B9[1(WF#HA!;?M_A/0G(Z]>E?99%E>)K2C&5Y
MZ+3LVME]]N[9^=YC&G3E7KXJ2IQC?FV6VNK^2>NBM?H?3&H+9>/_ -G+7/#>
MDVO^AZCH4^EVUE;N(UVF%HA "/NKCY<CH*\A_8N^'OAGP/\ #]O#NK>"M/63
MXAEQJ&G:E;/&FI+:M^YM9TD4E4"AGVOA2>>*])^"/CQ=7$):.>U:-)(SO6-K
ME6)?#N%C2/>FX  IC$:AL\D^AZ'XRTBZMIK?>^JRV=PNCZI=3BW@D<^1_I%U
M(/E5LD*'2 9+28 PIKZS*LPA@H3A5I7OUZI[6TW_ *U/QOB[A:>:5X3PU=Q2
MZ)Z-;W6BL]%JW?IRWV_*C_@JKX5\#_L\_MN:LW@B\L=)FU:"UU&7PWI5EY%K
MX;9HE#)O#%3YFWS!&H&T/D]0*\.7XP:YXR#R6[ZE=06YR8[0%8T/N1W]J_4*
M]_8(^$'[0/[2_B+XB:[X!L-<T>XLV6XU*7Q),MI>ZY%(D'V5[6-P4$4*%W;&
M"0HQUSH6NLR>+?V(=>TRQ\'VW@'4I;.^6RT72;-;65%@GD^SH%7:V98XXPPW
M D2'GD5Y-:M3G+S/J,JIXJC#V$%S*-E=N_Y;M=?\SSW_ ()[>'/&7@SQ;\!_
MBEIFC6;W=YX>U[0]7\R$3/);1PW$UC(5)SOR@B++SMC0<AC7PK\ =7G^/7[2
M'ASPU?:=YNH^)];0W=F;?R?F>3?*"F/D0?-D8PJ_2OTM_P""<7[1NH7OQH^%
MO@/6[.ZN/$B^%+V_UB[N_P#1;BP<0,\,/DD[F_=,BLY49VIU.['=_$OXFQZ#
MI*W6DZ;;S:Q=2Q0K/!$BSY9@K;F #8*DC.X')'4 BO2I82ECJU#"8=ZR=M;)
M7T_"WS\CYS&YAB<JI8[,,RBN6G%2O!-RY$YM?.][=$K7:.'^(/P'3PS\<9/C
M;XKM/"MKX;\4:'-X%\?Z-9PSB'3&=#9,]G*L:N[@+#!^[4,V[*$@DCL;#Q3X
M7\4? [P_/H-[:G3[&%8+*?2[B=[.);=GB2)/M&98G50B.2?,5D/;BN*^/?BB
M?XC_  F-]KUBWV74K,G5]8?4Y&/A?3,&X$MO%'(5DG@E2+"A=S;7!!W'$/A;
MX?Z#\!?V1?#VBZ1?V.K:);:6E[;ZDOF176IW<\K2RRM <JD11PP^8MG /?$X
MBMBLGQ4HW7/%VNM4WU_7^M"LOR_*N)LJI5)QE[*JDU&7NM+[.SU:T:[K965S
MRO\ :"\ :G?VKZG)9[;2,HDCV\K3K'\G!+'+8.,;FQDGGK7AGP4M8=?UC7+M
MHFN5AB*$R("$!.!@]OJ*]#^(WQQU.6[E.GVZZ?,67#V\K^9(!R6,F\C!/.SH
MN!BH[72+K7_A!?\ BO1]!_M#6-++SZC$C&,ZM;#YGRJX.]>3E>HYQD5R5,VP
M=''>UG)2]KUV7-+?T_'7JT?H/#F4X["9;&E73A&F^6,7J^5+W7=-W[)Z=%RJ
MS/)?%?AE/"-W'K5BWV>%9<.!D[C_ '0?RYJWX \<:OXZBO+"QTNUU#[8I2ZC
M=%D\Q%YR5)&W /7IGIS7)_%SXM:/KEC;_P!@Z?K5A;W9\Z1-3F$BKT;;&R@$
M\\98#I72?!G2+O5O"M\VD:YH>DR:@ZPSQW%U&D[*K"16B5D^3:Z@Y+C=R,8-
M&89=EN/S&*J2Y(M6<O/IM?R7EO?0Z,XS;%8?*:N(P]!5JD;-1VTZN[:V5WI>
M]K):GI_P=_:*\0?LU^(9?#LDVH6WAR^C\N]TN2/:LD;<[""""&Z!O2O9_P!O
M/XL^(/VGO".AZE8W'V3PY8PC^SK2TC,,%JH7:$*9/*XV\D]#7S,FD3>+_$NG
M6T=BLT>C+Y4C.#OU"5B6EF<[B.6P!@XP!Q7V!^S/X<^U>&;CPWKFGR7FGR1F
M6!8CM>)PO8X/!XSQ_#7C5LOA1Q#AA)\T';7OU_7Y[V)R3,I2I4\9CJ"A7BI)
M]TWHVF^MDO1-J[/S[^&GP5U'Q!\:+%)#YETWF-ND(()X!YZ=Z]4^(G[+=Q;V
M=S<75I&^5 V(O(']X^E?2GB/]F.>Y\0V]U926NE36<N(7"G#9/(8?[0[]1Q6
MWXK\(Z/?>'IT>]NM-U2Q 1X)Y\-N_O$'JIP.>]?18/.E2Y:,=UNOGO\ IY'@
MU<8J&*O4O*_4_-*Z^%U]X%\9QS":>UCCX@=><,2.-IZYZ8_QKVKX3_';PK!\
M:/#MQ\2O#5Y>> _M/EZ];::Y$^H1B)D1@NX$'?L9D#9P&"D9K8^)=Q8>+]2.
MGWMO'=6EO,KR>4XB#$$'&>,9P<\\CTSFN%^-VJZ)XRM;<V,95S*4MY8[?R!;
MQ*B*L3#))Y#]<G@'<<UU9E0G&A.O3J*,9--P:WMV_6WSLB7*AB<VP]&>'G)V
MDE4B[<B:MJ[^KC?9J\;RV]*^/WPDM?"&K2?$+X4W#:E\%]9O-MI=6\CRS>'6
M8 FPOXW_ 'D$HR0"^5< ;6:O8O@%\7;*#P7:[KYMVS:=KXXKR3]F/Q;=?LN?
M KQIXRDEF_<V<JW.FR6ZW%GK<7EEA:W,+_))$[E%(;D!LJ0<&NI^ G@KPC\?
M? #>(_A%;FSU1(OM>K>!9+A[B:Q*C,KZ:[?/<6XY/DM^_B''[Q1NKP,'@X5X
M3JT59WL[=>NGEK_PYIXC8Z>">&P-67,HIM2=[M.R2GT;5OB3UW:CU].\9>.K
MSQ(YM[1I)EF!_>NQ)0 $DG\/UP*\L\=^'XM"62YN;M^FW>W.#V( [YXQ_/K7
M/7?[1ZZ#KWEP(TS#,5Q$APP&1D#T((!^HYK>\-KK'Q@A7[/IVH75O'\[DP85
M>1A0!P2?;^M?;Y-A,JI954JXFSJZZ/?RY5Y]UY]C\]6.C*GYFM\%?&M]J$<U
MC=,TD,H$2QO\P93P>O4&OF[XQ:K>^"_C/K-G8V\PBT^_>W@E6,KO56QT(Y%?
M7?@_X57:ZFL]Q +%;%A*RNNUL*<GCMQ3M#MK#QOXNU!M1A%U#YS2.[Q*6#$]
M,^M?,X/%*E)U+V:VL3/!NM14D^74\)\!_#_6OCIIB/;VMS<16H GFD&8XO0;
MCP/I7NOP/_9WL=%ECN]5D9;&Q=1(P&Y93V1.[,3Z5ZII-EH.D^'/[.TVS:&%
M3O(X523W(& 37$_%OQ'KFB:1)?:?"U_9Z1;/*L$"?OA(%X8)_%Z\54\7'$5G
M.K-N^][W?WFE'+ZM*/,M9?+3SW.G\)>'?#MG\0_$VHZ?#%<:K=3!-TV)A:84
M9" ],# XJ]/>2WEZT32-)(I^\6.W-?%/P;_:5O;#1+BZDN9H[J\OYI&E_C4D
M@5[%X%^.T'B&Z$-]J7V8.,*[GEI.V3],_CBH66SQF)5.-DY:+6R1U1Q$8VIJ
M6G=[M]7\SUS7M:M]+=O,<R3(."%R$_/->9_&>RUKQ-JND^+%U)KRST>.6.^M
ML88!\!9@!UQR".V0?6I/%'BZX@,GV>9+^WDPQ88W'W]#UZ5QVG?&F#1]<6'<
M)H+H^5<1$?>4@@Y'YBM<5D^+P'N55H]FG=/^O,SJ8Q>T4*FW1]5Z?KY%[5_V
MF[KP]8B"#4)!M&,*WMQ52T\=S:U8[IKZ2\N+A20D3@KDJ3C/0]NOZ5YI\8_
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ML5*MTTN]M$GTN]]=NYC1Q7--SE'7IH=[X,\ /XLL[=FM0IN'(0;L1QKU+OZ
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MDTM#QWX@?LR?$;_A;G@FZ\.Z%,;MI]UZ\5P+O3;A%E1Y40\!5>(M@#D&-R
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M:OG*F(@EGC;)."%Z]*=H/Q3M-#\%6?A'X[Z=?ZYX5T\[]!O%D1=>\,R'!/\
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MRM6@M?*S^]6.C_:N\,:S\1](MK&)F6XCDC:"9VRZJQ"G  P!SV.>*^+?C?\
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MW1I([E7EUG>A%S L('[O:H3;DY=EQ@ YKX=^+/A2SU#3895MO,$HV,&4KC_
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MT7\]Z9B$]J<L)23Z3RJ'6G&I+@?RU6?)%P"U+8>@+J6SLI32DS0UAR@<NYE
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M7"$J9N::D+G.UJ06]\QW'";A3Y#_C84N9HU"FU13K&IJ4830#[M+E&?Q3R\
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MQYVN'S""Y%RSJ4";;\>9F_=[\:&WXYDJ ^TL4.[8*X"^5M"&R@]>3TJX#=S
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MLO"+?<!;(0[!(*QH7YR7L*C(GIV6EG/$""J"48/FN>T[S6>]MQ>B_23$WV@
MT$7(+HJ0$_-@E5<3>W6+]5G3<A\*$A]]S FN2:?%%H:[\KC?C-WKK #> U/V
MY,O4ULHT9U2>4)GQ^OZP"/Z^M?*#%UKSSMU[OGH$>B&?&N^.'CMNB%+EG9DL
MD+]W9N:JT'_Q-$W'[#2P<O'5MP/$+@WI%A&!!<6[B>SZMICX2KT0KN^K$]#2
MUI^OT>L2I./TG/3PDGW8^E(7(V%-[23AC&G/\R_9TO PK1)>?WC/INN7VNH-
M[X&N]5+$!.<BNU.^S+AP*Q,NIKVOT$I(M]BE-^4B34&,TR(1-O* M$S4H%5
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M95;W9>**QO@D-/@:MIL:Q*A-:)<8K@"6'+99XU/P-;'. T&@[Z>E"Q=V/F>
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MH >%I8D$WX?0<S/PG%'59^2UOLLD&<RG]B2CB%G*H+:#WV:4**WN]B"&A55
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M5[U(M#T,^B'19T(L3/#X5WB)Y.'J^65BE+?\]WW!/]V[;:P[7E]-O^K,=L=
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MDP'N6CD?#<52Y.-G;YU/L#V-0ZOL1ONW'96TZA Q2Y@>%RE+DD0"QN>B1=:
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MC4(LG[G;KT#NG%)M&&\YWFI+%K4%VK_>]7'ULPW"'A*\.\M:A'=>+CNK\]U
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MXHWQ@A'G@WC[]#Q=^\'&];WNIDL[<O5^GKQ<L?O,C>*,])T)CI?;*@E7#&N
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M&4!$G(]-\7H4IV/IQ/E/@/;%/ZJ2?%$Z;3Q]PJ86"OW574]?7GO?-Z"^2..
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MD((C^14PY_&%4X^.?SQ&.;:[_:/MQQT.R4++\2Q;_RIJV0ZS''H(3>3'5'2
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MNE/<%&<^BO2PJX%>_[.A5(;@AF2BK2TJBWBL*VT$L?OIBW7G&'%&(X3X^<9
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M;77 !/]Q_ F 7W6OO)X]7K=/4F9?9-'K14#7H%$ML^W@]C8TY#D=Q;5JW!,
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M]2$^ZF/NYWR+I+3!- /UHJZ;!@DT]C)G%GKFTO.H=%LR+4-#@^RJ#&L6<
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MB7J67ZZWSY]D9UZF.M7*P6IH.LM1(BY9G2#O0* TF6N<SB@)SN9J$V-#5PI
MYV\QI^LJP,D5@_=4RPMH@:T-:'Q =HM9(2U*=W,=[B?JP.Y6J4'BLM>=63;A
MR^9.^?RH:0[KJ$A[.D9O(,0_'/M5Z>\;D%(KL"6F*K\YVT$"W/.O*MOKS!0
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M_FZ64(C><UD%2HEP,'QI*21\AS>J YX6LV,N['X"^(('D)D+!*AJ/]IA%39
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M/=Q!WKZRR)NR>3HVN>Y#7[8R+&A[AN*]Z6*CSU/.*5J^[<^*T\Y\:VOPB-]
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M^QJ&_A*P_(X-QX;WADC2"Z'B=U%,/)0'6EHA7KY.CQ05\7L"8)#VUA @<2:
M^KR^X"2__!H<M&:!++D<VF4J:<5G)S0R#UTM.GD"H)Y>&E)X"#_CG\.T5L=^
M O!K9N"S(F[BI,6J=T95N=E'O!<9@K/"Y>9T0KLD15V5O.O:F><8-$,67U7W
MDT")YCZ""/&3_+(*@'&BT36BXLXS:I8W"7R7CCUI6ZD!8\.^5L7QBSLWK=K-
M:B+:H4YDN#-Q!+(C_;HM*1^)"]E%>$>M#9F]^#_,QRD6Y4&(^\(BB+9B$]K/
MU5F=-D(4:JGX#1,*+LM?-2YY[U1%DIE'ZR)I>V6E'$K%O7WN(K;O\L-WFE5:
M^!.T>U!=?QQM$#QX$V9E7+KR&0<UV=8BRM6(,4/0]%:7^P]LKX(_9;TWO2SZ
M1%\Q.9?(5CRU*%1MH)3#*:(K7;H4R\7G\)&^J#$=X*YYDQUGM:C8C-E$E5EA
MFR'W^Q(/)R%RM=ZZ[P3[:.7ZEN'L0^=1E8,NS5V2_9FF4CYSQ SV[*%@EWV#
M"26EOKB-\U%Q6/=O&=Y0!(I)L@2A/Q=3T",+(N5](D]C4N72@NDETFM+V@*B
M#[.8#WM<,@*_4NC$(;/>KCPCAO'I(YSV=?!=;!SU&<\L);WX1CHDR<NJ]M=G
M(.!0SX2-8;@2,PC6R0-C;EF 5A2-[&[$)66"J?02EJ;U'+%T"F,^>>!,'1G.
M'*((^C<,ARA^CP K4JU/E:,[+S 3GL,RV1* %LX=03/) ;+$@,8AD)0;R_/=
MJ:!G-[I$&S?$E!W='V1="M",RS(QJL)C/E;'@05EM;CX>@R$"C!O-<D6FCBV
MSNFK](KNA,GW=-=;>N[+P !E+P(F_N<)SK"J0:X,L=]O*FZGI)UT [[*?,G*
MW-@E9G"=VL$_\'8K,*OZG(Z5I *)L0%AN["X<Y=G/JI0?"T$)HWM,N;4HH/F
M:$K,/'^*[2^W.IN4O%FPDE2%0R.+^E7??(@W?B; <-->:1!YW?YJ,%HXFEV:
ME-B]MX-II@VG1JIRCW26PK/0QDM:E%,[HEPL4JS[IUB_=D(\J\ATMOO)AV]9
MMF# K4EW)RF?Q,+7Q27#DHZH4W.%=XYI+[86O>,D18JH-D<_WN/,)B7CZOX2
M#5SCP.L[XU])H$ $ZO&\:9UB%(I\<]<O-&P*EWDC1DJ\":9?6.UG=Q/5>/<A
M\G<_D ?W/<H,O@_J)_X3&A;X]A,@CI\;;*?CMG?;U@B;-EQ!?J?*^Z%POJ6+
M_?_CZBV#XG"";]$E.$&"NP0-'MPA0/#@OKC#+HL&=PCN#HN%X!YD<7<)D. L
M[N[N]_>_]]9[KU[5?)SJ_C"GN\_IZIGQ,EL,H4*G[9(8/\<?O< =-&48+3QA
M:)T>:]ILY7-M0@5R<.18C5/ED%T'3%V*SJN?4\$*D)]44DMEXT<E%A>3) \K
M$31P:OFJUN-#Q.GO0_S3'OTSN5DI>.\D]L_E<G>6$"]':HS/=;K*;:%^G2%F
ME0N?F3N9J;;+!TFRXYKIR>+5NN9^S:U/.W#2Q\CO^?;GU)<.(^,XY[["MK0N
MWI./"$[G4]FVF63"[H!WERW[&Y?EA'S9\,NF0V</$V2V]O>;"]<OH+,3'H.-
M4W64A7A2M,)@^1N''^YG)CJ^'/<Y&R=,M]ZS5=\S/T[=Q$8CM]OLT O<R9GU
MD%)>G)B('E!CP^+Q[GLLIDZH'D]%">)%?K<,WEE_U)9SD0<X&\WWH\'.4$!
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MX1G%--<R!6#*TR3("Z&V5%=LY(7PKB'?%S.S\X7-9<C09?+L\K)\" HS1IO
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MP09YV8A 7/Z=2CN"P:5R'S_)=,H!A)E_%LEJBD^3,"7R,S4_.S+\">(H@$'
M33#,+,1%QR\;"?<$B*M<*U>$:&SIH;/\?;/N%/)0%6E]A:S6HF:"$G2J&7.R
M6=D[$"NWX_LB6/;AV%$1_5!ELIY@>*$]QV[D:7HZRBG$/BM\1\-6[P= SKLQ
M'%I&LJ,*RJ2PJ5+G8DA/U";?\6[6I(L*3=\K6X#@ 3E O4O;UZ6;ZQA-I S>
MZLW#N6(YM>H(83<5Q.PPH7(-XU!>L2^9NJY^\#3!)C[=IM9EEAG-<BI;;WM$
MAW5R5B+/QHD EN66#,'->HY?W H:B%78?WQF.Y:UP7H803J]ECJ!,FQM(%SQ
MO;)=*:U9C5S#5.[E]\R,MDNM^;&OH$0%=OG\<8!8>?98[:-.H=I#M/89Q)U/
MO(E1<8=0I+G\#O<L(: >^&')=^8HF@T[Q15_U++"/F$V@J%/RT/]1#RC=-.E
M#E,=+Y:A>4#:U0]6JW[V (KM#Q<Z@O[B,%BM@\K"QMS*;ZN!9@= YYY.T;\B
MR_F\/B;P'$Q24)*/M<WU #].<H@F3:) (A3#_J=RD%K'7SX=/%U&GN>P?&+R
M<;F."+JY-!*#/]O.<ZG'8F&&#E9\7Z4CP6;KRZDJ2I"ZZ]UD^MJBTP'(PA\M
MUYY*']G+B[@;F&VG&>FOK]?\WUL^RWQO-=@C_*/_E4!7LG \6U/WT(*GL(Z4
MT!UY2?_10W 7QHYR2Y 9;:12TO=*84+MRWQQ%V9IU ?\QQ2I2_H0XU" .,\
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M&==N:<%>',=7VG7CR_(0GQ,/SGJ_T(%TZ#/;F&H5OZQ#V#&)L2*@$]O^U-G
M9,;D@B4U,\*$6*7U))"D6F7_>T5MTF;W>6&0&7,H\R).L)1IV5N[K=2]:ZK
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M=%_F<\3C55*(%'-^["F#.GXYWMRH) *!Y7;B\*D"0-LD4O=\7UVZ:,U.@S[
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M@D"*%(S00Q&RFD5^3,GZ'\<TP9&^*)6(K[*$_3L^&9ZZX6])*6HUE$70C<U
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M2C;:IG&)>&$""K>++$)UQ<9IXDO7IN>S66E157&H@]9^(QZG !O:._?HG%+
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MB:,(D:>;+.2VU&O(+L2BIS2N/?M_?E<OC^4WO=MS*HK4 HDP[S\9P^VFC41
MD[C3DVG\3UK>?P9,';V3<'>$EC_+RN*HR:GYIQKHB-M#C D;:I]LI-/;<S*7
MYOG$X_E5L"3=B$:&EW2^+VE,(<(S&1X07E@:=[\Y U'6=A [>.&6UP, ?KAF
MN^5<\/*.'UCL)Q>?LJV"O5:CEA)JL@QF# Z!-I[!C/5"#CA[]H:'1% T%]91
MQK$_[B+<=YQ:!^.BB$+9*4Q)7JT^Z!M/L;BHK%IT!;Y21V1KX^([L%I_+RED
M*R$95S:-C?,F^VVZ%R)9* LO0RG*U$6%B2,/@2#]/AWE'MBAI+]T2J0!IH*_
MW.""N]!T$6)ZC<5(UM@N,TRW/,K1],>91]C$O;>.WI@?*",N3S%"'N8"-L3<
MK/^NX$QR4Y4*^3<E,V0>ODC2!0,J66G?5> :>!7PF2XBQ1?A_3Y9*!;_PCRJ
M'2KGA!X 2IO#6BC(0.)_BOMRI%-5Y1P/;(%8-;MJ^F4PP:03#8M]EBR:^(!'
MW[C90<,Z7/' R"*XL(WX3$N(*]+!D\E]<Q7YUP68N5Z?5B)PQP_44M7LDMGD
M?F]_R[O$:G7% R36.?Z7'54<8<Y[YLQ]Z_YS0+NU\U*\@:_G0YX:*][I1<R"
MF(%@43UNQ6U3%L4SS*SJ1T&1]?XE3S9N-]_?I<%?;#<E3$6C42VIPA$X[X+\
MMCGY7-5"=?!F1\%DT>A180.TQF&QN^5387LQ9#LW"NTCJH0E$#HCN0;?Q?)T
M*/A,U)]0ETX'>#Z:;H@#/#*#K8#$*J#G Y&Q(=B9NZVE.Y=;2])6/;96JPM>
M)45R*'E/JZEU;:0MA)R+VIVG\'3:%D7WV^BV8E!NO<._BA.*]76?N:G>W^]F
M\SS'A.@\>!'EQZ;^A8VO>09!%U7D%(-[Q_96YAI"&^D>;)N_5L3,>IEVB_XO
M #) S;]\U7#&Q;IUI/*./FH&4(XF+=,5,MKE#[U,L&7'-7H+3*].*GF%RG-W
M=JP8XJ&"!D;FNBO+'!/%4Y;+<N0/FJKBY2@TODITJI-+OY/2KUU;XXQ6?>0L
M$.!TJDQ,2&53]*OQ0JR9 K%MVVR<\$UL69S%5 -N D7:JSS;1Q5B[BW#)JI,
M,!JGH3(@O)AL]<U2_LU9VW8ZU,_SEJL6?)IV"UR73=.\OMTK0BMO+8&GVH"K
MSZ4V6?/ XI+0&BY;,%85JZ;-YTH'2N8ANV$WM72>'F\R0"B)C+R.N\/QLS"N
MJM%5$_VJY_1(M@'K6]""<5)C(=)PU=M\(M.B\46OB'09@K1:YI<ULP/(.Y2I
MX^CUP\F<5U?P;U?^R_B%IS9P)&,1_P"! @?KB@YZGPL_)2SLY=%U&YL9E99;
M*9[=P>"&1BI!]\BMBVNMG>NJ_:\\&_\ "O/VM/B#I:IY<4>M3SQ*!@;)3YJX
M]L/7$Q,=M:'J1E>-S874F(VYXK5T>YZ9-<Q;S_GQ6WI$F[;CU%!FSOO#0W8[
M"NKL[9BBFN5\,#]ROK79:4I,6&H+CJ6;.,Y^[6M:#Y!FJEO#M(Q6A"/EX%3L
M/<CN NVJK(IDS5J>+<#59VV-TX%#T))8X0/FQS5+4I@K59:[V 5EZM*6E%-#
MN36DXED K>LK=6B_VJY6TRLZUU&F2_(.]&PXDEQ:X/ J."U^?FKK'<:GBL=S
M"D]BK%5853&*=N /-6KFV$0^[S5'&Z7FE?L!,%4TL5KENF!4]G;;F%:,5DJJ
M6;H!G\NM.4K >K_LH_M'R?"E[KPKK^G2>)OA_P"),Q:GI#(96CW#F>%>H8 9
M*C&<9!#*#47[2W[)\_PSU#2]:\&FX\6^ ?%4J?V5J=J/-%MN8#RIVZ*5R0&(
M ."" P('C?@[QA_PL/QFFA^$;1-3UO3KAS>372E+2SB\KB9)58-&REB"Q!QG
MCD '[1_8.^-%C\!)M<TOX@>-OM5GK"02V:S FRMY1N$BQH$W9?(8N>7()(!Z
M^A3P,N3VC5WO;R_S/SW&<42J8R=# ^['9ST:OWL]/)/Y['A_A/X26@NK?3=.
ML]%UG6+>57U&VFA,F]-ZE%7=G<#D B-T."22 >/6O#GA>S\!>.YK&;P7I.BO
M]M,<EO;Q?OWM"=T4JR.<+DY! ##Y0"03BN;^-$7P_P#B-\?M6N/!\K:/(LZK
M;"WC:$74A0%G1& 41[N3@  G<03Q73:'X0NO#MM"NN7K:K<I9F**XTV4ZA&5
MWF1@7P6\V-@&8#!/RXX!%>S' TW&.MFUM;_@V/G8QKU)\E2O*3;[MKRWTU_I
M$VMZ%X1\?:IJFIV5I8>++2>U1GTMK%!>6[*@9A$Z!&9T)PQC)]2IX%>1^/?V
M5K/QQ=QW?PX+2?:4,C:)>WT37,# ',:-D$L"""D@##CDDXKV'PIX2M?%MQ8W
M>G:FJ:I'&Y%SYF]+=N=QB  V;@ <$C'(."#5;QS\-;C1-1BU);^YUK6AM>YN
MY'@2.["%CDQ@Y$@4*#R0^,G!-<V+R^$'R^7H_F=U/&YCETE.$N:.[3O:W71M
MM->6WEL?(,&GOIEU+#/%)!/ YCDCD4J\; X((X((/4&IYGP/05]#?M-^#Y?C
M%X5TCQ9I=G->^(X4CM-2\A0SWZ!"4E"J22RXP> Q!SR #7S7J-RRP<=>G_ZZ
M\&I3<'9GZ-E>9TL905:G\UV_KH+/J.U]JT02--+\QSNK%-TSR,,<J:VM(8R*
M"PZXJ5L>AJR5K12<XJ R;'X%;!C4H!UK+UL"U4L.*FY31'-JODH5Z&IO _AF
M;XE>.-*T.-9F;4;@1MY2[I F"6('J%!QGC.,UR=SJ#/<?>R,^M?3O_!,3P3;
M^)?B9XLUJXVAO#OA]YK<MU21Y$&\=\A58?CBF<N*K>SI2FNB,[XC_"_5M+\:
M#PO'+>-]EM%ELK6*V=QIP R+=#&<L1@ESR,GGK4WPS^)GB/3]#ATW3XKB>%Y
MOM4[I;":1WX7(+$*&&" 2"%ZD9Q7J7C&PU#XCW6K7>H:@_AL274D^GVSW#6J
M11A"6GF7AY"V[/! ^;@<Y#?V?? ]D;C_ $A5MK?38/FV*9F*1$%G"K@XE<EP
M20"&YZ$5ZF50CSRJS6D5^+T/DZ*4I.4U=?YG Z]\*M4\:^.]/99O)GU17>.>
M4&+840DDON!8@9W$< =L&O5=&_93FU;P!9W&H+I.ES06B- T<C3B>3@&0!>6
MWDYX)'/;BO2].@;Q)#+!*;>\L))6DBE:$>9$I!#JC$%N0<$9(YP#@"N:G^TZ
M'*T>C^=>21N;;9=REE3YP$V<;E &,@YQV)'%>K+,:]11HT=&K??M_P  TJ5.
M=Q4=X_G_ ,,?/GCCX)-;ZS(UK?S7T7,DZ"T>!4?@94OT!(((..:NZ?X5E\7V
MUK%YMMI\]LB>8?/VJ.N PZ AA@ XR3G/.:Z_4_B->6?BU+7QAITECI=P6+S1
M@3.&&<[3@CGD?X&N%U#7%LM:%QIRL\%S<B  P$LD.24.>H)[@Y['VKZ"/MZM
M+V6+6_\ 5SGQ%2I4E["<6G:\7T;*/Q,TW4-$U81/<QO/<X,4ENVQ[C><$-SQ
MM(ZC![@YKT']G#QI-X6UNUM]<M5U2VMH!/! 9R$CA8.5*ODX;()R1@@$$9YK
MAO%WB&0_$'1[JX:&^^TNIEEE0;LL0 JG [9.,>QXZ:7@_5]2NO&=P?L=C%9P
M11F_7[.1Y"$L@;(&X@#YB><=@<8KS,VPL5A.6"UCO_7JS:CS2PBYOB6Y] >-
M]>\%WNGM:+%#<:+K@$-S9O:QA'97!+J#@N5P&P>,@#&"*^-_C=ITUMXK'VIH
MY+O8\4[Q0"&.0I*ZHZ(. K1^60!P!P.E=3\8/%,-EXK70;_48;(:1>,%N Y\
MM(^ P;:<@C"X  .,=N*N?M)3+J7@GPS-.T<E_#))%%(DGF"2W**V0W1EW8(/
MN<U\2=.4S<<2EWNOU/$IH.FT41P%TYX-7&AXYIUM;[F]:FY]7RE.>SW1=.E9
M=Q:N&XKK#99CJA<685^5H4@Y;F-!&4'-+<7&T;<5?N+':.!5"YM\GWIDZE2:
M0#ZU);,LK#/-5+Z-E:EL9,,/:K0K&J81MZ<56G=8SC%7#_J@!5*YB ;-,'L0
MR3X-4KQUED*]<U8N>%JJ#EJ2(&V^DC?NQ6U8V6R,#%06 W8;K6FKK$OO4HJ*
M'6D7E#FM2QF\JL:6X^0GI5G3+K<^#3W,I'7:.3, :Z[0H<H-W:N5\,_OE6NQ
MTM,1C%(PDC1;:$XJ;PMJ']E^*-/N,_ZFX1C],C/Z55*D+4/*2Y[]12,9'QS_
M ,%8O!W_  B'[:^M7"+MAU^QM-24@8!8IY;'W^:,YKP/2Y=CCWQ7V)_P6>\.
M_;M4^&/BR->-1TR:PE8?WD*R*"?H[5\;:6?FIIV.S#MNDOZV.Y\,7+!E%=A;
MW&U!7#^&GY6NNMFR@I\QT="[+J1 P#3+6X9Y<DU3EE\N4^E/LWW2?6J,9'3Z
M.WGR#^==19VWF)7+^&$Z5UVF0L.O1J35RHBQVQ4[:MVJ%33A&N?0U-;_ "TM
MB@FVCJ*HS!7J_/'N%4IUV=*KH*6X0Q9INH/Y45-6Y*+TJMJ=P9(.G-*.P-6*
MJ7>'K<TA5<"N94%A[UO:$VV(4I"6YKR6WR\"JYLLM5R-ODJ:"W\T4^AH6&\=
MV?@WX=WB:E?W&G:<+A0\D,8=I&<$!=O')VG)]!CBO"]&\;&\@O9VDMK(1I)<
MV,33EHY%/9CG.\+G()P><#/![K]H^)5^%,MKL8O-=PR(^3A&4GKQU^;C\:\Q
M^!M]X<OM-U31]<M[R+55&VQN8KD1)&H^8AU93N( ( Z$L <$ TZ<>:21\KF4
M4L0UZ&=INM:MH7B-];M9X9+I5969XPT<J,I VJ<@@C<<CD8SQ7HWA'XM7&@W
M&G:E;67VI;>4/):W&?(EQG<"P(8YR>>.W8<YUOI>BZ?K$'V"5FACMB7AG5T&
MYBI,9/( .3R<C/?'->F^%/ASI_Q1T5+6WNKJ:.8>9));Q[Y.'"@';SD$D<9[
M$U]5_9DY)PI[-?I^K,ZE!O2Q=\=?M.ZU\<_!EAX771]+TO2[.1I%C@A!FD8@
M DRL2Q) &<G\A7JGP^T+3-*T(6<-M;^9):A1+-*%CR0,A%4#+ DDG.,]1TKE
M_%_P A^'5C%#I]S)&\=P(6N@H._HQ4'G<2I(/'?)P*]+C^!O_".V,I74+?>?
MET^T3!(C"Y+E6(P"=PR<9(XX.:Z,+AI8>"4HMRD_RL$>2%+5/WI6TT>GZ?F:
M?A3QE;>'=.LK.2#[0MI$(8GND+K'DY!(P%)QP,@C'XFMW1?"VI:U':W5]%<+
M9W_$$C*5AVGGY1@#(' [CI3/@E\/;KQ(NDK?6*-=6UPUQ,DJ%YI(5?!0#H"1
MCKCK@<&NL^&7[-7B_P"&GQ;^)WBCQ7\2+SQEX<\8E9M!\/B)UAT*/S=Z*5QL
M0QJ!&!&3N.2<#BO%SZM*E6C2A3YE)ZNZ]U?\%GT%/*\'5HUZN(KJG*,5*,6F
MW-W2<8VV>M[OM\T[0_!MC9W@M;:\>XNXV):8JJ* ,_(A')/())]\9KKM$@;Q
M1KLFGZQ')=331JJS,3Y@"# 7..N/4_K3T\%'1RNHS6-Q8V\@9XD9=AW8QD>V
M>?;..M=UX)^%LWB7P7=:U/<S6]S:[FC!;;P!R<^I X/%>;6II*\=CYVO1Y5=
M=#XH_;,DU;_A,]&M;J.&'1+2VD&F11ON(8N/.=^^XL%ZY& H!ZUY/G$8KU3]
MMRZOKCXR00W'_'O;:;"+4  ?(22Q^I8'K7D)E*1G-<_*?38'_=X>@V\O?)Z&
MH5N6GQSFLV[ED:X555F9V"@ 9.3T '>MZZ\!^(/"MO!<:KHNJZ;;W6##)=6K
MQ))WX+ 9/M4\R3LSKU8@M_-1<\TDUG*L+21PR-&GWG5"5'U.,"KUJ!Y6<\UZ
M+:>&O%6I?%;P#XATCXA6NA^ ])\/M-JW@C ^VZCY?F":X$/+7$<IXWD +@D$
MXQ7GYACI8:*E&#E=I67F>OD^6TL;6E2JUHTDHRE>5VFXIM15D]7:R/(C>&W7
M)-4[G4FD8G/RX-4->U#=<N%.U=Q('H"<@?E4-@6NEP*] \6^I0U69I7/XFK?
MAA?,8COFB^TAPU6_#NEM'(#M92IYXJDQ6.HM+7-M]*J7EAYAZ9%78IO*7 KH
MM-\!_;;S1[*YUGP[IVK^(D,NE:7>7XBO=04;@"B8/#%2%R1G'%8UL13HKFJR
M45MKH=V'P=;$2<*$')I-V2;=DKMZ=$MWT.J_9E=AX,\<::#LWC3[U3VRD[1$
M?^1@?PKT7]F[XHMX-\&^)/&%Z=D'AUV2SC)XN)P3%;Q#WW#)QU&XGI7F_P %
M-UE:>.;=OW%P=#9&1AAD*W4&[Z%1GZ4[QSJ?V#X'>$]/MT\JTO[B?4I #_K'
M"JH)]<;W(_WJ_.LXP,<7Q!3P\U[LE&3\^52=OG:QZF%LLNK3ZKW5_P!O.-_P
MN>7^))9]3OKBYN)6FNKIVFFE;DR.Q+,Q]R237M7[%W[6,WPCT@>%-7OWL=,:
MY>XLKXH9%L6E*B9& R=C!0P(!VN,]"2/%KR996(]:CL;53)NK] QN$AB:,J%
M2]I=M&O-,\*,N6:DDM.ZNON/J/XT?LQZ/\7_ !)KGB?P+XBCNVNY6N3;7%S%
M/'*2 2$D0[E'H'4X'4CK7!>#_A/-X]\ >&/#ZOY9U2ZFU*\:4'R;>&*7#!AT
M?<$ &#U< 9R2/*X;954E/E;&"5X/XFO?/A_\7X?AWX>\%7&L)YWARXTEM.O9
M8/+66SQ=G+G<0254)DC.!VQ6^0X;$4*DHSJ<ZM[ONI->6FC\M$_-]/C./)0_
MLZ,9:1<HI[OH][^>[,GXI^$_[$\/>+H5-M97;K;^6L>1+M'F,I;'RHN#TZDX
MXQFO(?#5SIJ2R7-P+J&_NK);OSH@I4W*Y78.>(V!SDY.0!C%;W[0GQ&76_%_
MBJ/2/%NDWK3E$D@MW\U-3A=P8W0@$!XP,,"00.03DUS'AK2TTI=&U#4]DMO>
M8(A.1@*2I!'&0,9X(R.E?HV5T_=O+K_DC\DP_*WS4ULVNGRL=W\*/V@O'7PZ
M\8:/JS:U_;6ES!7;2[PM);2H3AAC!*GT*'(/8C(/O7QR\:>-;/7DO/!>L:K'
M::_#)>Z7% 86A*A PC82 @%<L2,'(4X[9^7_  WX$FU+XFF'2Y8[^&.83(EN
MQBBG(RP1-P!# 9P",D@#GO:^(%U<>'Y]3L8M1U*PT34)HY#87Y#FY=7^4JA^
MX,\-M(P0<CK7/C.',$ZZJ1A'FZIQ5G?NNZ[^JZGL3QF/P]&=/GE*+:?Q.\7Y
M:[=ULM'Z^;^/_&'BK]I;XE:6NM/H\USIT3I'/9V"VA+$@L)=H"L<KP54#DX'
M<YZO<:1X@ETF_@D@N8'"E2,@@]"/4'J#WKT[P%HWV/QTMUI;WQD"-YEO;!/G
M/!!;<"&7/&!@GJ.A%6/BAX0C\57-O>*UPMY;1@RH$5O+4$9+;06+ 'D8]P:]
M*.5_5H*E2BHQ6R222^2V//Q^38NK'ZQ5;E)O7[EN]]#TS]E.WC\0V<NFSW=G
MI4]J2L0>8).5))#%&&&X&"1G ZXS6_\ $+3+73H)]822:PFTY6>6[DCS'$I
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M@([TMF+T,U[;SD..:S;O1&W[B,XS6I'(86JRY:>,86J%9&-91>5P!S6M:/\
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M*"?,]_ZV0L#@ZN98J/U>&BLEILD][WT\W^!\D^-O#S^$O%.JZ;,,2:=>S6S
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MX]*[2)]D8Q7 >$;G"(/I7<P/F!<TC2.J+D%WF0+CBM2W52HKG5O ).M;>F7
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M2/9'>QJ#;/*< "7J5!/1\''(;CD=$*C3NCY7'Y7*$O:T%=;V[?YGI6FZ#/\
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M@ <D;C I& ,X RV<#'.3P">*\/\ B1X9;XN?%#4O">AZMX>U2+PS$?/T:/4
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ME'EBZ<E4E3C**E&>K@F[-KXDN:.Z/?(KZ;XA2PMJ3,L@=VDB:(A+9U)5B0<
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M'H<5[U\=O@[X9\,S":_TJZ6XR/,E2"1T=APH+J,$'K@9&/K7$^-/!?A7Q?\
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M'B^U\0:AIGB2'6K:[AU"Z@TXVR6^J7$,'D1O)(Z-+&#%A66-@& !P",UP/Q
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M*QI&=2*\DX S@9))%?1'_!5;QQ:^&O$7@_P^UQMDL[ 22JK;4&,*#M]\<9Z
M5\CZY\5/L^DS>5$ES P6,JLNPNK.%(!YP0"2"> 0,UV1P-;$9BL%2E\4^57=
MMW;?_)7?1-GFUL\EA\F>955:T')VC?1;:>FM[KS:6IW=YX8T_P )WR;=7U6&
MXN<QP*=5(DR 6(4E3D@ DY!P*H/XO\0:>WDV_C:ZB+MA(M0@$JX]-Z%3SZ[3
M7,^&/%.K>--,\6ZUJ?AW58O[ OA;$-)&BZ6CH"JN&.7)V*"5QS*HQDYK(NO$
M]IJ-Q";@*5!&$SP,>GO77Q!D.)RFK&C4J<]U>Z:WU^R]5IU:U[]%Y'"O&O\
M;%&>(A2Y4G:SCV2^U:S^337XGO7A#XQ^+-!MUD_L32O$,:+\S6%V'E(''W)
MK$GK@ ^U7;;]J;1_&\\UO)$]C?V[;)K:>,H\1[AE8 BO(_#UM<Z?"FL6=KJ$
M&F("IN=I$6[., ]"02,@9J]X]\!1_%:RMM4O8G@U6-!'%JNGOLEVCD+*A&&
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M*9;L6AD*G\=KK7U9J]G@$^N:\'_X*]>'CX@_9O\ AGXF5<OI5]+ITK>BR19
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MCV,82;FK7YDFFE?KJDN5V3N[OOWUOKWB:PN&U30X;$7,:@?:89,7,L8!&6#
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MIK>Y2X\QR268@'.223]T<G %>PZE)-X+U5H;F:2WO9(5D@_=E6EADX#J&&X
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MYT48=;B*'.V2W.X9 485E8$C..5UGQ_X@U;1+'6M//VF\T226">W=7:*2&1
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MCL7LYKZS36ZM^*_R+H\DU[:E%):IKK?3K]QW6K_#O_A%/"]Y#NCNS%:NWVG
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M-#^T]KK3LMSX?OIH. \>U)E(/H 23^%<O\$_CUJ7BU;>UUA7DL[@;6DN9"<
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MYIGG7$<<L[EG&&))8DDDG.023FO>/@O^TA#X<\:Z#KEG\1O#-MX L]!AMO\
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M;FX8%M[8)Z#DA0#@9Y/UK$UC7[&+P=9>+-%DUS^S9+ZXL6M]4LA;W8DM\%I
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M6DEA[[MNS]V_Q6WZ\EO/M(]6^*_[0MUK/@V]6X@:YO+C']F1P(7!E4AE$RY
MVD @G) .#@XP:WASQYJ'B"ZL=;>TU3PY/?/YFGV;1R6T\80C+HV1Y@+8*N ,
M@C '-<3X <2V"3.8;CS3OM')!R.^3TY!(Q]0:]$\%QCP-X1LM8U2^^U7\!-G
MI44K$K&P)9I%5B<+&&! SC<R]ABO$_M'*Z>2?4%1_?7^+UU=GJUI%)K9FO\
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M=)R3\CX:^)GA+_A$/C-XITG[2]O'I&KW$#)C^$2,5 ^H(K7T+QM)%$D$A\J
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MN(TWZ1-.B'RTD1UD**3D?*#DXZ=,4MEXPOY"\F6^3A@?Z5+IWQ*\N>617=A
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M>ONNW+*UI1=T[7:OK))I'AOQM\%6^B73?9+%1M!#.5"*!W(.>_\ ^NL/X3^
M]/UZ[BCUB6:TT^>]M[,3Q2AI@)0[%U!!!"A!D8)^;H "1[Y\:_A=)XU\:)IE
MNBM ,27+LW.2<J@], 9.,=13[3X%P^%&L&T^!,VTZW,H=B5=E! 5EQCA6;)!
M# G@GDUZW!>0X55H5LT=XN^FCZ-:_/:UFM&M;%<6<2Y[/))X?(6HUUR6DVT[
MJ<6[/6RLFGS)IJZDTKGSCKW@*V\.ZG:7,ET]S87I,EK(8'AE$>[ :56 (Z@
MX )XZ"F6/PTDU74)),LKNQ9,]".N/6O4OB/X1USQ+XJT^ZUR\O-1738#:P,Z
M&9H+=7+%=O5BH8D9R3QTP*Z[2[K2]2\;_P#"$Z'HEKJ_B;3Y6O8;J$O%#_9L
MD2F)Y'88,SY)$8P3D\8!KZS'>'_UNO4Q.7:05[)NRMTLVMM-4]?,^*_XC16R
M'"X7+^(GS5Y)<SBDVG=<W,E):V=TUH]-.[O@1\+KS2OA+XFN5NIK?S(UM'B4
MD+*)#DY'0@!,X]<5SNK_  59K(-9P>1$N#*J?Q]@Q_/D?E7T]\+=$A7X8M'Y
M4,L=U>LT9BE259-@*$$J<#:^\$9)RN*C^*GP:U&X^'$S:-KFE^%;@W=L;C4=
M0C1H(K43(9Q^\PN73* D@ L.]?EWU'DK<M177EJC]9CQ=>G*3^T]+IK9):Z7
MW3U[;:6/F_3/A3!X9TRSNM6NX]/T^[O!8/=NZ;;>5D+1[PS X<[5& 2"P) &
M2*NA?#V'Q'X=_M*.9KR.5#Y%R8S$)""5/!P1M((]<@$<'->H?MA>'/#'P4BB
MU_Q'-X=32TGBN8+#4W-J+F91Y<0A?E68 L7#C:!MR5SDV_\ A"O$VH_":PO?
M$^B6>EZTRL-MNZ,?)R1$S% %#&/;D D 8Y)S7WV8X;(\/E%.K@_]X]UMVM9V
M?1[Z[M;JSL^GXQDN<<4X[B2M3S*RP,G-15]&KQVDM=NC6CNDXW:?R_\ &R'Q
M)+HTD$UY&]H\ZSS/!&!<7<BQF-6EDQN?"DC!.#U()YKPB6.Z=6_L^&0R0_,'
M!VG(YX(Y!'8CH:^Q-;\*V.J^(QH^I7MS%=7%E/+:6MJT44M[*B$K"CRD(KN>
M 6.,\8KA?$7[+UUIFM7MOX?TK6-:T_[1Y-M<10>8TK&%7DBW1Y21XW;8?+R&
M*DKD#CY/+99GGN(G4Q4I5))75[NZ6F^W376[LV?LN"Q>1\,9>L-A(4\/"3>W
M+%7;_P Y))O36U^ASMI^V=XHU'P?=:3=:C'HFJ:O;16MSK8TV+[9<K&ZDB::
M-1(R[5.[)(. 37G'B_QE'X>\3:7J>BZW>-J=BUP'U1+@-YDFX8DC8'< 0Q&#
MP,XQUJS\5_A=JWP]U@Z;JMCJ&@WS1><D%W#)!*48=2& ."..GM7C_C2"72]2
M1&D2Z$Q#.H4;]N1@^YQZU[^(I_5LMEE\:<8IN]TK75UZIO>_RUT//R_(:/\
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MX(V.B,FI>($:25SO@L-Y^<8X+GJ![#KWJCH/@&U\(V<UY<1K*UC'OV'G+Y
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M94I3J.*AKHW9WY;I]MOB6J[,^A/@K\3(_#7AZYO/$FH:5:6MLV1<M,8HTBX
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M"NMWOB+Q+K4=_8:Y%8^%+P0O&8)UFB$UUG8BOMY4;B00<#@U\^_#;Q=\-?\
M@LC^UWX=URZ\:>)/"NJ65S;ZG=_#_4K!KL2BR56*V-XK"..!RF^4%0^XYYR
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M5PG1SYXZO5S)^YNES*UY=4E?9)JSLET[GTTF@R>*[K3X;7>;N2/RMB@-\W0
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M<T(SU7*Y)R]W5)V34NBEH4/A#\1]4U"\\BUTNXU"\E9F*V\86.-B<CH" /0
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MG)[VV\?VNC^(+769K"\,^%C:.;3;E?*D(WJ Y& #P#M.&7VYKE/$G[7?PO\
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M9V&/F)&<  >AQU&/K7EX+!3QM>-"#LG_ %?_ (!-:6JG.S?]:'JVN?%VUO\
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M_P 8O#L>M>!]-\8)X2L],U:S75=;TCQ&K?;=,1HSY#JVUHE<3CRCYA3)+$,
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MTRL>2Q&3@#H1DGU?$'"ZPN:2KY9>5"^FJT[];V71V6EKKJ_6X#KXBMPW3GQ
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MK13PVJ_K\3LHY?4PW-+%[]$GOYW['K&F:'X8^ /C7Q_XB\&Q^($UGXE7XO\
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M&^O0?%'[.-SX[\=+NNELK&TLX_MDIPS%\<*H[''7->)_\%>+;2?@E^S%\/\
MPMIK32SZ]JTER[.^6V1(6R>WWI!VKJIUGR^R<K77W!1O*JM?=O\ D?('@J[4
M7T'V=F=RP"JN278G@?B:^D_#<5K#:PMJ"6LES$5+9.1&V,8SW(]:^>/@U:MI
MLK:CYGF)&A$6X '>W0_@,UU^I^*SI>DS[I7\QQW/4D]:\*I>_+'<^NO[MI;'
MO>O_ !&AT>U^SK,LK@?,.A'&< ]#Q^-96A?$:"20LL3[R0,@]:\:\#>,KC5H
MYVD9VC1MFTD8[8)/?)[<_A6SI7VCQ-X@B6U?@@)M#<EB>W4<5Z=?)8T<%]8J
M2?,[:=-?UL<LJB:5O^'/HKX=B\U?4XY(E;>SC8,\Y->MZMX0\.LNW5(%U21E
M_?1 XC1CUP>I)]J\]^%FA1?#7PZJS2>=J<R_,3_RQ![#WQU_*MI?&UO:W<:[
MMY3);!ZMZU\Y*LTW[-^IWU*<5"]1>B\_Z^\[G1+#3/"]K_Q*O#^GV<9&-T$
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M &UO <=NTVF>%_B L923P_J=X($N)@./(F8 21L<?[8&<@XR?C[X[^-/VCM
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MM;/5_:24GNK^Z>*_V#/!/CCQ$NA>'?&%YI7Q O-'_MQ-'^QR2V=O$8A,J27
MP%=HSE<@CL2#BOGGQ-H'B3X'2M'K5FUQ;+@K=VP,BGCC<,9!QZ_A7TS^R[\0
M_&GC_1SX=U+Q%H^AV6G:5/;2ZU>::#?P6@ "Q)."&:,_=)(R.!D@'&'XV\-2
M>&]3M;76&C$%U#&7:-P_V<$# 8 G:2"#@C!!R*\["Y1GN P/]H55S4%;=W=M
M=>C2TM;OINSGS#-N%<PSEY,IN.)MK9?:3U6D4K---)W:2;YFCC?!7_!071-
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M(SL*G.5;N&#*<G.02!@\=%X2^,[>$_AU:"UMX[IDG5Y2S$N$!5E*@$#<C(&
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M>DZ[I-K-)%%?QI?W$(<JMR\!W .N<,%5W*@@X(R.:U/'?A^'PIXC^QW<@F;
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MTFW1C@YC<@_AR:Z/P+:Z'X1UE+D1LRC[J.0=AQP?SKD#XA0G<J2!$ R<'O\
MK3#KFZ0;5W $$@\C!]_:NJ5"O3_BIKU,)<BW1ZU/XOBFC-LSMNNGW/*/XR>
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MRY5,3]:A]I)[V3:_SNK^:U.#\7^"K_0TBOIDN)K%9&@6;.%W*-Q3;U  (.2
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M(+!4 F'=SV%>N>-/AO;>&?&>HZ&UGK$4FFRF,V<MW$Y12 Q^:,$'=G.>I!Y
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MLY8+EXWT_8WFQF$@YC.78G;C)!/4FOT9_9<_X**_"SP-^RYX:\0?M'>(-/\
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M3[_6O=E3A&-FU?\ KL?*RITX1LWK_78@M/VE8==O(H;VPMA82Y^X"< <$$$
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MVR,'$L(C=0VW!P0ZY!< XX/@G[3,%_9?%"]O=?D;4-2U>7[3,ZVS6N<\ A6
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MU4$R*6?YMI&-I(SSGZV_9G^"EOX<@6]CO6UBXA9HVO5^2%&4D.$!^9B#D$G
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MP)2($J22KR%!QDG.!SQ7BP4^3VC6G?IW_(^C]FI5O8P?O/TOV_,^)?\ @O\
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M3WL[O5K3?6I6PTL<\,W&$M9:_9BE>4VNLFEU^%67Q;<O^U?^T]X6_9S\'?\
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M \$@>^>?I^/2O+5UY8KL*S(I<Y;)_+COQ70^$_$46KWLD4D4<LB$($+''?D
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MI)&X)Y+;"R[B1G)P>V,5K>%OVS;?X??$9=4T^+4+J.YD6YN$D=(8)I@"IDV
M, S#!SG.>>]?$RLY_'RI[VL[?)?UV/US X?%I0:P_M81U47*4.;1^ZY7NDVT
MTUU6J:9TEYHNG_!+QR=)O/ %G%##;1WMI'N\F6)I8@S0N3Q(%8X)! XR #7'
M^-/BCHOC-;JQ\2?#?1A:38$,MM-_I$6!RI9F!<$YY!!QQVS7T[I_Q/MOVF_#
MD,F@^(+'2;^X8M-HVJ20RAV(R6@WABN3U !!/("GKX9\9_AOXN\*^8'\.W&L
MV<#_ +YA'$]O ?\ ?C4J.P^< CN!UK?%96X_OH>_'H[*WS:_5)^1\QE/U3$U
M?89C35.O%6<>>2=UU2:MKY.5^YY-JGP<^'\5XNN>#[ZZT+4?LK)-IZQ[VYP2
MJK(26R0,!9"<G@<9&=X=^#>FR>-KS3](\7//;Z?Y4EW>7&Z2=Y7B$TL;*H 1
MER< D[@,YSP=#Q-HEWXATL6LWAN\T1[X-%+'+)PXY& ZG"DCD,,$<&O1_@AJ
MEM\,]+C_ +0BM;:W:)?+%[<.UQ<2IE!(I4,7&-P+$9SP#P:^XR'.,I>2U<)F
M$92K*Z@KW459).-TU'K>R;;=WK:WYGQ5P?G]#B3#YADDHK"RLZEU[TG=W4K-
M2GT:NXJ*2BM.:_M?A+P]+I?AVWL[Y[J\A7:JH7>2:X;'&0"._4  8ZUK>*KJ
M;X4_#G4;S0]#\5>*[N;4WOWT9-2>>\>6X<%U0R*QCA3 "QH"%W# QDCA=)U'
MPCXF\-7D-Q?ZAJ;:K:3V%W9P22VH\F52K[9V82(0#P4&1CK73/\ %.T\/^'M
M.@M%CLK*QM8+&TV3EB5 $2(TSMO=]H!)8Y/7DFO$P\)UGRTEK;1K5J_X?UL?
M08RM##RC4Q"?+S7<97C&272ZDI7=VM%I>ZE?0[ZU\GP/X_U#7]2\47]GI%GI
M MVT27RFL;!T<S27S.!O$@3*,"V  2!TQ^$?_!1S_@H%)^W'\=;J^T-I-,^'
MVCEK3PWI2D0QF+>6>\>)2%\^X<F1C@D H,DJ2?T._P""BW[:6N?LU_#[5+[P
MWXHL[R?7I(&T_2FTFVD;0[:T3;?$N2WG^?(\8;S  HWKD$C!X;_9<^#7B_6]
M1F^(?A/X1VOP_P#C$ME;^ =*T#P\FF^)4FGB$QF%P@#K(BODJI9!C<2 0ATC
M+F7LW>.KW_IZ?U9$T:<L%...:51\J2Y5;9*Z2Y8WDKM-N][2:G)-2?Y)Q>*+
M:3PS:V\=J(KZ*8N\P_C7'3U]/RKM]?AOM#\*:;J$BLWF 2$+V!['W*G\ZU?^
M"BG['5A^P5^U+J7@C2?$5]XDT-K&WU6PN+RW$5S'#,6 BD( 5W0HP+* "-O
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MI5_J"A+NYU)A CP)<AC*ETH#;UC4@QC'W2#U)#O!/QSTJZ\1EKJ^U;3+*>W
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MOI+^*]-M]<2W99K;$DH _A! .3WP<&N!T#XR2>#?C=XKTZZ5DNIM3DN=ASN
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M.]"=RG! )!!%>M']F6S^+%I?^)M#N]/TJ:"$WL^D'$\4X !:>S?CS(Q@DQL
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MD^'=K9?8--\%V-M:SL+%%NM;N)%$^[S0GF/"@=51 Q7(8XS73?\ !.+X<_M
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M[4O#=]X1TOQ'>O;KI3^)$S90*7)N-BD%3)MQMR.,G%<KX;T.YTF^%W(,N_+
M>O?';GTKI/C9\/Y_B=\*]'M[6[A@<7LDS+(/G?" #OG )-?)_5U43HQ;C?JM
M_D1@<1+#U8XJ$(U.1II27-%V>TEU3ZHX_P 8>/\ 1+_XK7KZ:+.XMV2%6:Q!
MALYY1$BS%%;D(SAB,=L=JS_%EJWB.]1L.K<84>@&!GUXK*T/]F3Q!I.H;E"2
MX.%VOP:^B?A[\!+;0_#UO<ZL9KO49%'[E!A(_8MU) ZXKZ'$9EB'AHX>;NE;
M7J[=V>/4=>M4;E&UW>RV^1P_PX\'7,\,2F!F(QD@=!]:]D\3?"*\;P#I5FMM
M',MU<>;+O;'EC&!_.MSPGX7M?"\!U"X6,1@#R;=#PY[$GOS3O%'Q1\K7M+L9
M)5EN)GWR 8 10"0![#O7!1C9>TET-.754HI:[]DBUX;^ WAOP-%&K0?;+O +
M%\!4/ICK716VG6NG_P"IMX8D]!4<'BBTN; %ID\]N2K'))_H*=::G#"PWOG<
M.F>A]_QKF_>O5LJ4HO1+1'1?#Z&.VU6YU"3>L.F6LD['/  ')_(&OR%O?A'H
M>M>+]5U6\BN+ZYUB_GO)I9'P2TDA<\=ADU^J/Q,\6_\ ")_LX_$'6!*(]FG2
M6T9SCYG&P 'URXK\U].U2V5O+D:-<<#<0<\?X5<I5.5)'7E_LW*<II.UEM]Y
M;T7X,>&8IX;A;6/* ?+NXX_7FO8/"FCVNFV"S6\%O#:Q(1)( %V C'/]*\OT
MEUDG"Q2[5(XP!BO6/A-J,B[K.\3SH)AL;(Z@\<CO6<:C32DSTIRA*+]FM;/\
MB?P%K!@7Q;8J-MW]@CN[(;=PD,4H+C&1G,;L?7CBO(/VP=#UKP;_ &1]H1?L
M99I"57:Y5P"F_C& I !Z>^37J7C)/^$,\;VB1_Z/+"X:TD;[LF/O1'D9RIZ9
MY!(JS\;;SS/ %A<Z7\-%\3ZRL9M+6>=Y3H]P[*2QE5B"7C^4!&(4\$$GD_89
M#+V4'271Z>C_ ,F?C?B!A?:5HXQ:<R2>^CC\GNMO1GB'P+\&Q>-UO=/N&MMM
MO;F27DM/'N&!@="N.<@$COQU].\$ZA=:9\.M,6,ZJD5JKV\;M,53 )VG&,;,
MYQDGKP .*\S_ &8/A)XC\9^(9[BX9-+OX8&%T@.(Y224RO48'3@G&".QKV+2
M+O5?ASI,/@_4/#MKJ@#2FPBN)GB,K,,L@8 EB.J_7'M7WU.2DHR>^Y\Q1K*7
M+5DNCL^GDBOK.D:E<>&RMW:)]LBF6Y6:W02LA/)W$D$C'?OZ8J[HGC'1TL-0
M\Z=3<3@WGE)9E ),X//"J2<X ! "XSDXJ[\ =4TGQ/X1@M]1\3:;X5^()N)_
M)M+M)(6CV ,H:0 HNY2 N<YVG."37HGQ#U;Q5\*/%G@/PMX-\!^%?%VB^)M.
MCN-6\2O;#4;:[O/.D273L1*QCPHCP05*[RW(!QX^=9]2RZ@L543DKI62UU_#
M_,^QX(X8Q'$N/AAL+5C&?*Y7E))-)7??6WELKZGB/C9+'Q MOJ,=S)IMU:7$
M2QWMME)H,_Q#D8(]00<>W%?4_P //BGIWP-\#:3=ZM;W%_<ZG"+Q+\:6E]/+
M;NSQ%E;.R,KM#_,-[$@< 8//ZG^REX;^)7Q@U/0_#%E??V7:7A2X:;Y[>!>0
M^YLD%8R"-Y.3@ 8S71^"?A'8ZYXDL?"\^K>9H]Q&T$,EO)OCMI,[FB)R I9@
M0!DX/7DBM,54HUU&2TC9-Z:VW^9\SF&&C+$\U!<MFT_-IJ]G?7U_0J^(/$$G
MQSF_M"ZM&DM8RT-A)=(L4\L![R*I*J2 ,]SCGTK%\/:@OP9N(+C0=;L+S54\
MQ?L4,0DMH03\K,Q4!6QNP4(;@8(!Y^AO#7P"T?P7X1OOM>ZZN(>$9R3C@@ #
M[HR,9P,^]>+>._!4/B>XU'3]"M+6SO$4B- 7>>\9@%)RH(4 $9. H+ D\\<C
MJ1<I4U\*_(QS"C5HMQD[M)6[Z;+^OS.8^%46N?&#XF/XNU;P['XFLYI6M62=
MCL?:N L6YMQ:-<$8!.,@@Y-;/[1?P8T']I.PM_")CU6WETBY6SM)UD,AL+P0
MF6*3=CYE )5@0#@D8[U>TS]C_2]'?X=ZEXZU+5+'4/AAJ,FHP"SU1([&\+2B
M0+(.I96 !*CE>,X-'QW_ &A-.^'6M:MXPFDDME@AN-1TJU,@B;4+N1/)1T3&
MXHI?)<C [DD@5X4L54E*M]8@HTXZ1=[\RMVZ,].CE.'IPP#RJO*IBZNM2#AR
MNG/FT2E=\RM:3>B6W<^+K#]L-/A]X,_LO$-]KEH1%T\RUM)%X(D8$>8P(.43
M@'@D8.>)^(?[07B/XIV5M)K&H37T%NI2*-XDB@BR<DK"@"Y[9;<3QD\5RNE_
M"%;S4S/YR3VN\2RD$[XF<Y(<'& 2?O#(/KFG>--:CTG54M88('6$;(XQ'@1_
M[6,\Y[9K\5Q^(56MRT_5G^D/"V!P6"P].,8J52R?,UJO3M_5[GK7PJ^$VAZ]
M\.KK5M6GN[NXF;R+*VTR(B422-&D4AF(*;0Y(:,C<0,KUR*\7@>W^'.O7CZE
M>;ET^=HF?[-]GFD=3A@R,,J01CD>XZYKF_A7XJC54TO3+II+G4&_?6^"ZW;
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MA^R7=W]PTUKJ4-P)'+'(PQR<GVYKT?X)?LOW"WKMK$K_ &"%>$@Y:5AVSC
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MHT/[L>YZ ?6O0+'P]/I?B!_"NCVR:GXGU*WDC9'D CM%(VF65SE55<]3DDX
M!) /Q-:--PO/;KV.K!WA[WX'KW[(?Q9^#/[26F-XBT&71=%\3O;*)UN@IF1%
M_P">;MC<BDXQP5. 0.!7KFJZ9X1M[%;R^U)];ALR51VD,L2MW_V<YX]>U?&O
MP1_X)E_#/X O-)K&O>(/$NKWQ,EY''>"QT[S"3NV#!D(Y()RN1U Z5]!?#>Q
MT708UTG1;/P?9Z:HV[+J[^W2R#W\R0_H :^=Q5?!Q_=4K22ZVD_PNHO\CIC@
M:TKU^:<8[ZM+Y)ZR_ ?XK\2Q^(M6T^;PK=:7IFFVMXDNJ1FV/G7$2,&>-RPX
M4J#P!SZU\??%C7_$&O\ C'4[Z\M;K2H]1GEN8(+B!_-:)G+!FX&,@Y/IWK]$
MOA[X!%MK=G-8V'AF2R1PTJV]M'&ZXZ$$$_E7IGB3PM;ZK'YC6]G*RJ0#) KD
M ^AKJRG(ZM>C*KT3T3C;[K.W]6.#%<04,-45)1O=;\UVO6ZO_2/Q/U_3;W7[
MM;?Y&*G*YY!_#.:T+?XC:IX!TB[L=%TRSU74'D2PANUMG>]TB\E)'H5*E-I7
M.1CDD$&OTR\=?L1^#?'-Y)='0[:"[&6$MA^X;/?*K\IS]!7B'CO_ ()Y+907
MTVCW6J6=W)M>)+R %796&W+ E2!S@$@@GW-?7<*9IA,KQ+EF%+F35E>*=G=7
M=WTTV7GYI_+\987$YWA(T,NK^S:=Y>\U=)/1)75VW>[VLO)KY2^)EK>:3X8U
M*TBO-2O-6AE4S&Z+>8[J-DJ@%F 7N-IP3WR:=^SAI4D\7]HWDMOI^DVTA-_=
M7<H5[6-(BYD5/O. =J_*/O.H.!G'O5]^Q5XRU:_C$,+7L$LA+&5U1PQ.2S<G
M//)-6-<_8$\2)K$.FI!8C[58RF>^;S1%:Q28C8(Z@CSLX(0@\ G /->UP[FV
M7U\TJ2Q]X4JG-+I)*Z>CV:2TM:]FDMMN'B+"9EEN20I91.,Z\.5;\K=FM4G=
M2D]6U*R=V]SR74?BA=-8PW5K937$'B.WCNM+CC1!Y4  ^8A<G<^X,0Q^4$ <
M@FG)X8UCQ,)YH["ZDNKW'[F$EECP, >Y ZGUZ5]!? ']BZQ\+:-9KX@T:%/%
M>@PPVD][<6ODP:AP72965B7QO.[@8?<"#@&O:-*^'.C>'V:6ZFEOI(TWB*"+
M9'GT&.>?_P!=>7Q=+"2QDZ& ?[I-6\]%:SN[QMLWJ]W=L]3A&OCJN64JF:+]
MZ]6E=ZW=[Z*S\EHME9(^5OV=OV0]:?7%\2:]8!++19!,(YE :>3(VY'4JI(8
MD]< =,U['X]U=+6R2'[--<.A+/M.7;)R2!W/?;U)XKNOCM\2==^"WP@U'4O"
M'A6'QEXJG@#:9X7CN!"EX'948%N6) 8DG &%(&.M<7XV\!:[X3TRT7Q!9V]A
MJ]U9Q37$-K*9H+:5E!=$<@%@CD@$CG&>]?#XK .351ZI:6_X;N?7T<5.:<$^
M6][6:OIOIY7WM;7K8^+;GXBWGQ ^)NLZ)8^%/$0TF:UAU&XEMH#(]HSDB15*
MMRK#YV(P4Y..:V-1\6^9I<2QS2,H;!(!&<'!&/K7I7C'X<S01QW&GR364]O,
M;B:6(;?MA92L@900!O!.<8 /.#7EOBFP;3;H$ASDG*[3VYX'M7T/$>-R[%JD
ML#2<'%6?_!TUT2]YM-K='C\'Y7FF!5;^TZRJ<S7+Y>G\NK?NI67V63?#;Q=#
M8?%:=;VX6&WNXE>+>P )P 3CKP?3\Z[CQK\9]"\.I)&+R&61'*8A.XN 0<XP
M#D9(]Z\5\57%K-9_OU5AVR,$$^AZC/M7 _V':)J1FB:6W>)U8;YF;!!X('4X
M_&HRW'48J,<1%^[9=+6^=O\ )GT<ISC>=*W6U[[_ "N?35I\2=4\1:' HT:Z
MMK>\B^U0W<F 9+4OY9E5/O,I;"@C@MQ6Y^T+?/;_  >N[V"XUR;4)A;P0V-C
M=;9757 ,L,1!4S)O#' )( &"< \=\([W4_%LVGI?ZIJCV]G;&VTQK&3R+:V8
M,92\D6PAO,/#AGP<#;@DU]$^&M>CTK3XH7\EI[=%&\ *'8 9..V2,XS7WF88
MO+\MQN&QF!G[11M)Q3:OJK:V:5VM5JTU9=&?EU&MFN>X#&8+-*7L7)N,6[.R
M:L]+IMI/W7HI*S?5'SO^RYH7C&_^-MWXM\3+#XGF\/R6NBV>923]G*2%IC\H
MC!&0/GRP)R2AS7T=^T5XEU+XN?"RZ\"^$YO"ME\4_$VD-J?A^P\301W,5ND<
ML<<\Q7#J9(UD.T@$!N3D UY5\#_AKH/P;\5>*E\/WFJSIXJUB36+Z*[OC<)]
MID)+&($#:#G!&3P!SQ7T&^L^'/AQ/IWB[4-+TN[\66EG)::/<RQ*T]E"Y!D(
M;J$) XS@XR>.OS_&7&<<VQ4*B@H622M=V6[71;MVT734]/@?@E</8.5*%657
MFDY>\DDWHDVKMZI+F]YZ7ZF7^V-8?$KX=>"/A/H/P_FCFFC\1:'%XF2VBB@@
MT_3H=[WLK?=+),PC#  D!5P.37E?_!4SPMK'QX_94U6U\):5<ZWXFTB]BO=,
MAM9-MP =T,VP9&_,,C@QYPP[$@59\:_&O5/$VI7P_M5+N]N+J)$6([I(U<,7
M9QC&%V'&,DYZ #)P-#^.%C<^(K%;R;_1'D,)"R&,NS!E #?=!)P!D$9YKCHY
M-F%:M1BX<JJ_#Z635^U[^3O>RV/6P_$>78*A5K*:E+#.\[*S;N[KSM9[:6W>
M[.#^"?[5?B3X8_M ?!#X$Z6BZ'HWA'PY%9>([+4)Q+>WLITH3\':0%ADVA2K
M#<Q<8VK7V4OQ$2,\R8S7R#<:_;^'/B##J&K:?H=WXCL[7RXM4A9+FYM[9AM1
M#*JA4#A.%B)4X8D DYO7/QOU#Q%J,=AI%M<:CJ$I'EQ1 D ' #,>R@G'N2 .
M36&;91C,%F']G6YIZ;:WOU7EU]-3T,KX@R_-\NAFM+]W!W3YFE:5W>[[W=GV
M>EV>Z_%R_NM<EM=0T6^AT_5K+=MN)74*ZE'7: QVEU+EER".H/!KYL^/WA3P
MOJ&@6.C_ !:OM6UWX:^)-5T_2M)L],D=[_3]9!DC>=G15$=NT893M+%A*5"@
M 8[CPQ=*UB9M8+3WMRHYN$(,1R<J%[8'8#USGK4?B#3)]/B^V:?-]DG)#QE2
M0 PZ$]>AZ?IUKZFG1QD\#]0G-63MM?;I?71/:RTZ'/1R3"4\<LZI)\UM+.VZ
M6J[-K1]UOW/2OCPUKX4\*PV5NL<45E L$$:-D1QHH10!G. % &?3K7QKXL^*
M-_I^K2);W-Q"P8C"2%<>X.17KGBOXYV^I)X>L[BRN=2UJ]BNXM3-M;2W"6D2
M$")W*@!2'W$Q\D@Y' R?G'XP6[76MW#6<_FQ12%?,7^+!(R/;^70U\_GG#6)
MP,(5,2E::Z:V]=+>:UU1Q\/\787,*U6AAV^:F[.^GW*]_)Z736IZM\&_BOJB
M>)K&\GNKZ6ZL)%,<OF?(5) ,4B9VR1D<'(!QSGC%7OVY?@M8PZSH_C#P8]A9
MV-Y>"+5;7S3$FEW SN+#[P1@K'Y01\IQZ5YC\&KN2+7+!9I7$4C#S&[!<@$_
ME7O$$4.GZA)=:A)'<Z3K4MW:7\4BF6&0EY$. K*0XPI&""<9!R,'YG!YD\#C
M(REK"ZNNZ\KW7X/T/JJE.IC*%5X=VFHNS]5U2LW\FGYGS7\0_AI8FQE;3=9>
M\OM/53>I>*+;?.'*S&V"G#PQC82YYPP. #7,Z?X7C\0^'[G3;MY/)N&#'"@M
M"0,!U;!((/(([@5[]XU^#'B"[^#^IM'XEAN]":Z%_/'8HTH=U1$\R9F^>)55
M%)C  !&2">:\,^$WCO3O&WBJ#2M,:_N)'026E^U@\5KJ"ABI:)FP2N00"0 >
MQ-?HF><F/QWUOAJG)1IQ5VM+6N^:[7NJRO=R[;'YSP_BJ^$R_P"I\8UX2J59
M.R=M;V7)9?$[NR48VWW-_P"&_@F;P_I=W:Z,UY8W&J'%Q.&>+S0"1@QYQM;@
MD9Z=#TQZ]\'?#NJ>'M?MYI%WM%(=VY3MD[$$>A&01W!Q78?#3X8M>74<EW$F
MX*/E4=^F:]J\-_"3:J2)!F/H2P'6OD,9F6(QU3GQ#OVT6GEHD?=9?D>#RZG[
M/#KE6E]79O:^K?\ PVAYG;?!^.QU.[M;9)H85=9;/?S^Y<;E4GN0"!GOBN/^
M*7P!U[4]6T^U\.Z9<PI$DL[WUL)8Y+*Y"DHRE2 ZN7PP&2IPP'!(^L;OP%]@
MN=/D9&#2VP!##^$,P&/PK=3PMY$2;#C:@<GTYP:]7A[.JV4XI8NBKR2>CV=U
M;7O;6QXO%O#N'SS+W@:\G&+MJK75FGH^EVE?R^]?&_PKT"^^!OP[T*UU"*&]
MMM50W6KWT]L(VCO&E;<2REB1M/'F$^FX=!S?[0OB33?/^U:5/''YN501?=QT
M!/8_AZFOJ;Q-X9\._"K0[/3[Z\TW0+#7]4&DZ8MX'=;^ZG+.(E&#]XEB2W S
MUKPWXC?LA0ZEK\[8N-/:-V0PPN3$&!(X4\ ?0@5Z>,XPAC,=/$8B"4F]UVZ7
M5WK9+6Y/#'",\FRZEAZ=^2SLWLW?WN5V5US/Y>1\\Z7+) 6OG=?M4:;U8.8F
M)P1C<IW*W'4>OI6B-&;7'%I':2*)YY;@N6)P)""JLN2"R<_. "<].M=?XE^%
MDGPCF19]'N-5?6L6FG/J3_9;4/,_DK+&V1ND24( I)!$JG%>Q> ?@A-<V]K)
M<Z1?:1(8%Q#?1"*Y=AP6*J2H#8SPQ'/&*]7B*GCJ&1PQD)KV51[77,K_ #\K
M-*^[O9Z+Y/ YIE.8<35,-[.7MJ*UE9\KMMTWL[W=MO=;5FXO@'96OPX^%>MZ
MMJEG#<VV@V<MVZ3C,<H1=R@CT:14'XU\!:?XZM_B)\9/$?B35-0:2^U^],L6
MH(P50V>A7IM)R5/8'':OV4^$?[->B^*O@V8/$5J;G1[V\9K^!9#']KCB(*0,
M5(.TR89@",A #P37Y\_M<?L._#>__:)U+1_AT;SPGYDA(@;,UC X W(%QO5,
MGCEB.>,8K\URO&8?!_O<1\4^G]WOZ7/U*4'FJ>%H.W+9W>U]K>NKZ>=QOA?6
MI-=^%_B[PKJ7B:\\!ZKXDTI;'3_$]ENQ:*)%9P&7YE\Q%,99<D G'6LZ_P#B
M1)X-\%^"/"^G>);SQC=>#[![.XUJX\S%XS2%MBM)\[*BG:&."?3'6K:?L3_'
M+P)IJPV6GV/BS1@PV"VO(IMB_P"[(R2#V&VK>E_#KXP:)-Y<GPKORR<@.J(N
M,_7 S]:]2AC,#'%QQU&M:4=M;?@S"5/-J.#>5\D>3G4VURN5XII>\O>2L_AV
M;UMH;7@JVUSX@2;;736C:X<F29?]4BDY)!X /4>W4"O0H/A+JVE01^=;K!"[
M?>+#&/SSBO/]%^.'C+P!XH&A^(]&C\'7CQ^;&EZF04[LC9*,/H3COS7HFB?%
M#2P&U+6-=DU1XQ^[@B&%D;KCZ"O2S#,JV/M*<DTMK;?\$X(Y?B&^:OI8U-4\
M/P>"_"LTK+YK7L>QPYPH4')(]LX JK\,IXS$UQ);H\98",-DC'<X]*YWQA\0
M)_B?JL$;#RK0 !8TX 7L*] \"Z-;PZ3YLQ\N&W'0$ GG  SW->;[R]R-_D5+
M$*RIP^?4ZZP\6J8Q;QPPPJPP<*%P/Z5#>M]NM)8E>2(S8+2(V>>@)^E8^L30
MZ):Q74ML_DW"!PRN'(^HZGUXIMEXPMS"P5\<'*G@_0UT5L+BZ&M2,DOO7WZH
MTK2IQC\*^X\U_:'M=:T/3;2,Q//IIX:YBR4#$\!O0_7K5[1/'$BPP1MO9=BX
MQGC %=]8ZQ!JDDD#A)()059&PRX/&".A!K$\1?#JV\/Q+<:>/]'7 :)CN,7T
M/4CT[BMJ-;F5I[GDU/>^#2W0T_#/CV&*X5[C?Y: [@,YP1U[]/I77K=V>N20
M1V<C;Y9%3*=3G'/3G->,G6HX;M6 0*Q*D>F#T/;FNY^#EPM_X_TF&*1U19/,
MVG!5=H)X].17T& Q4*4/8U%IZ?F>;]::O&1X_P#\%.-7&K_M#Z=I[2930-(B
MBP#P&D8N01ZXV_I7G'PTT]K9O,G6..%E.<^A'8=ZB_:;O;WXH_M8^-M0:5VL
MX-1-LI'39"!&,'_@)JWI\L<%JK;N% 10>< < 5\YBYKVDIQ[Z'U.6TTJ$8OM
MJ7?#?@K0M$U:2^N(OME]. C$ @%025!&>V>O6O0M*DT6'8TED@9B,$'ICV.1
MS7!R:1Y-HMUOY;&%&0>:NZ)?.3^^&0#CD]/2N9XJM:[DS2I1PK7P)_G]Y[YI
M5LLOA=+JWB6:W4$L01\AQD CWZ<5YAXC\52&02 _/N)V@X" 5T?PG\<C0;IK
M.\9FL+P>6P!^X3T(^AK ^+7PKOO#>NRR1[GAE8M'VZC('XCD>U3+]['GEZ/_
M #_0RHQC3C*G#:3NOU7RT?H;OPUUB/6YH);F3(D.W;N)4 8)!'(]SWQQQFNL
MO-+AN[5+6-85*8,+?Q $9 )Y."<#'3(YQTKQ;P_JMQHB/Y<SQ29 88SCGIU]
M./IQ72PV^HZQI@D)NG^0 9SC;DG)Z  GGI@U]QAN(,!A\*J48.2[67XWT_,A
MXB,%:URVET^G7DI9OWD1*J5(P2#C(Y(P<5LVM_'XFT:6.Y"7$1!5T(S@8YR/
M2N.CLKVTU$6EY')&'/R'&1QUP>E>J?#W]G;4-4MK+4KB;3]'LM1E\BR^W7J6
MLFHR$X"1*Q!<D\ #J>!DU\'6E!MRV7Y>1EAZ<JD_=/GW5?$-W^RQK37=U;R:
MEX#U"4)):^88_(E;!5XI.JM@$ $[3T/O]<? OQU\/?BU\+[$^#?%%CI\ELR-
M=:4=.D6_MS][9)$J[!N)R7&0PYR<DUY3\;OA]IWQL\)ZG\/[V:31-'TNZ$FJ
M3>26O)2G/D0P\,S$]22J#@ENU<M\/K?PO^SGI\TGA'0=1:XMH6LS>:IJP^W2
M0'!,;'Y80,C(!!*]CR<^/B:N#OI)<^S2O^G7U/TK(L'FF/@H04N2&JE[MO2T
MD[KT3_(^L8O#?AW2;*ZU*SLKS6KJ4YO+F_8L=O?"YP, =\8'Y5YO\===O/#/
MPXU[5M!CD@-[8FSM3$SR(CORI55 &0B2 X '(JE\(/VQ=0\8^9:ZC>>$[&*8
M8,#NMQ\N, %FSG ZD<&O:_V6-376OB5J\.LV^B:EX=O[;R(Y[&:.2SMBI!7<
M@)\MCR"<#)ZYK@IT8U\1&E2=DW9Z=?S]6SNQ5/$Y93J8G%+GY$G;GOS+3W5H
MHW71+M:W;\N]8O=6)8M*U_(Q(DVPE/*;'0EN,^HZ^U<?I'@ZYUZ_N+Z:.3[%
M;R W31Y,D2@Y8@#.>XZ?2OVP^+'[+VDA[Y8-,TM-%U3:\SO:I<&1P!C<"  "
M?XAR!WKRG0_V&]&TJTN+K2_"=C/=749CF6*=O)D).5.W<0H'? ]^.E>G'"QR
M[$*51:7UTNFNNC[KT]>IX]3BO"XS!SE1GRRDK+WN5IVTO);6>^_FK.Q\(:!K
MM]XJN;+P[9Z3:Z;H-E93ZG>ZIHMEL_M2U4D0DEL$G&#@$,<'()%<IXON;ZVM
M]%L@EU<VXC"7.T%GW*,!^Y.1P2>>/6ON3XB_L%6D<UH+*QUOP^B1R13PPOYB
M<D,NTYVLF025ZG(X!'/%Z7^P=XHU+Q/)#*EL+:!=\=^Y*H5]-O+ ^V./6OKN
M).(L%CY4*F#H\D:=]%9;Z.Z2M=)>Z]+7M;H?F/!O"^)RRCB:F.Q4:TZC5I.[
MV5TU)N]FW[RLVVKW;U/-_ >@V_@3PC97%]+8)=ZI+:V.CVB2+*UY--EF$QQB
M$1Y&XN<Y( [9FM/$FH-?QZ3:V$U[<Z>&MKFZ;!$LF,%R(P%XSD!1QP#R#7H4
MO[&>N^(=;:SM9-#AU#0[Z'6#IK2+]NOX%;R6DE@<G-O(%PDA4 D<Y)R/7O!G
MP.A\#:7!<:!I\/@N#5X1<W?FV1:^B9R7:%5&57:6.>3SGDU[G%4LEEE].KED
MVZKMS:+1VM[RO9/=KEO&][W25OG>#,3Q56S:M1SJRHI/DU;O%O1P:5Y+;6?O
M6M;=W^<=>_9G\2>/=&6WM-$U**.)0!<7,R(FT<\[B.3Z=*[+X9_L9K\%'DU[
M59K>X>XA$(\@?(A(#.A/'S$<9 QC/7FOH/1O#$%Z8--43:K+>;O.GORTK[ ,
MYVKA5)/0<\=?2J'B+4?%7BKXP^$/AUX3\,Z+KOA76EN3XEUVYO26T$1 ,IC5
M2<S.6(4'C@@@#D?D\LIE*E[&FWKU[O\ X)^S4<TG@?A=DE=_X5N[OTT6[/GG
MXPW6FQZ'>/>:+<7TE[+#&ZQR!9(59MI7D@ X(.21_"..37S383ZGXE^']EXF
MNO#NM:)%%,]G#</ 5M[O#E5+$L2LKKM.W!! SG)./K#XU^ ]0\,ZO=:1J$?F
M2VDACG5E!$Z@DD-D<ALYSU->'_%;PCJ%S!-,TLPL[A8Q]EQF-&0$!QWW;3C/
MIWYKU,EQ&7X/+*V#Q-&]63=I?<K7=W%VYMDTT[2.'&Y+G.,SW#9EAL5;#JUX
MO5/=K1-*4;\OQ-.+7-%W/(9_'-X^M.LCR+\I3:3T)&*]H_9J^(5B_P /KH7]
MU'%=618N)&R%V\X/&0.G7/7M7B5_H_V"]/F1MACPV,DG^M8GB;Q;&4:S4R<$
M_*I,9XX()&#^!KS<'.-!N$H/E=KV\M?38^]S*C&JU[%KF7Y?\.?0_B3XU:;=
M>(X+/24N-2OKJ5(+>"V0R%Y&;"H.0"<\#U]AT]#\->.->CUVVBU*QCTS[-%+
MIH<P12W6%D)EMC-@ND:R#+1[L;^V*^-?AQXD'PS\46&JV>H)'/P5@>(S+,00
M0C\C !Y)Z@#C/2OJOX9^.;CQ2(KZ275I;^6Y>YO+K5+X217Y8%AMC*J$*EMH
M*<$* 1G)/Z3AZ>3ULHJ3E)1JQV35V^STOHWI?1Q=NCN?EG$&;<14,]P^$P]#
MFPLE[TT[6[J[MJDKVU4DW9\T6C7^+OC_ %SP5J.EV?A>);RZTJ&?5['5=4"W
MAT"^".&V22 F!Y(Y$"/G:",$9*UWW[%FF7GP?^&_AJ2>31Y+K74NM1\4-);W
M,E[=SS$FV%M*Q6-5C?<9 5!(VD+DC.?\5+/2?C#\&];\-Z_*BZ3K-J;:^%O=
M^5(4.#A67D$X'\CD5)\ M#E%CI.BZ)+(^EZ);1VRW$\XF,,2C"AG;JP P,\\
M>U<V-XSH?V.\MA249-Q<Y)^]-QN_>LEL[*S;T[N[?@Y7P'5GQ!_;5?$N<(1J
M1A3DO<HJ:2]R\I)-WD[J*M+56NDO1O#&I:Q^T!^U#X1UCPGK'A>;PC\/]0U'
M3_&-O):A]2EO8XML4 EVDK$A<,1D9/// JAXQ\4^/O"G[<GB!=0U9]1^'-IX
M0L[2PNGDB'VS4VN9))CL0C8T:$1G@ A4Y)S6=X_^//A_X7QZEH/@-=+LY]2F
M-UJVJPQJAN[I@ SY4?.P &7.2<$\  UY+XV\=7=KIT6HKJ"7D5M;1?:YHPWE
M/*[NN%+ -P%R20 <X&<9/S."P^+QM"I5H0O&&LG\NG?Y?EJ?55L1@,'CZ5+&
MS4'5]V$6M7=K63^R]=.:VGFK+G_VL_AIJ_C?]N;X6^.K'0[_ %#PSI,L.H:_
M<V5R%*36/G/"SIN'S!64*5!+XV$CBNL_84_;.\1_M):E\1]8UJ_L9-,CU.T.
MD65NY?\ LJ-[;<\!;:I8@A2Q.?G+@8'%1^ ?&=OXY\+ZC;VMQ;?\) LL$T!F
MO%@1%#%64[@0=P(  PV>AXKS[3/B?I_P[N[JUT^UTW3Q<2F61[--D=VV,&7<
M0';.W 9QN.,GU/IYIP]B\)EM/,IM.,[)=U?77UUMUT=[6,\KXOR_,LWK9!3@
MU5HK=VLTGJUZ:7>VL;-IW/L.;XL+"NTS*".V>E>>ZQK6IVGB:>71]9NM-L+V
M59+FUL+@1W4K+G & S%2S;P% .00>#BO%M)\6ZY\1X!=:7;:E_9:D"ZU)8R4
M^]M(C&,D*<AFZ \=37?^'-5TO3M/GL UQ;M=6LEJ]S9.8KN,.1B1'R<-@8(S
M\P9AD9S77D=/,<)%XBUN9:1:^);]=%K:SU[K0K,\HRO.E]5<_P"')7E%ZP>W
M37:]XW5UOK9F3\$/#'AG4/VOK.'QJNK:S\9_"&A2W">(HA(;'[),\J0C,A D
MN88YL!I$ R649Q@4OVK=5N/#?A[3[%M8O/$=]IT4J7&JWA"SWA:5V ^4G 0,
M$&23A>>, :7C/Q7>^'-8AOM+OIH[6TM[>TE^TSM*\Z1HL7FRO@Y8@;F89P<]
M:\Y^/7Q#T_Q8GBQ=-T[4+32=.NR+&]FM9%CO,@!HU=C@DR%BKX ?D <9JJG"
M>.Q5&>/=GRJ[2[O5JR5K]5T>MNIY^/XRP>4X^CE$KVG91NE;2ZB^:3NHZM-7
MLG:ZV9X>_P 6IA=[$N+Z%LX=DG*G:#P,Y&"*^C?AE;:;\;OV?9?"MYJ]]X;F
MCO)+D73VTMQ!=+,D<3&6*)E9I%"X7.5.]LC/-?$,^B37GB6.19I1'*_R[N#U
MZ'WKZ?\ @=XOC\%^ Y)I;C;/]JM[>,2\QE'E",6.>@)4#KC.<5^=YE"RC"'5
MZGZ/EN;5J>,I2I2Y)QDFGH[>=FFGI?HS7^-=W?6O[6%_>:?J>H:+X,_L.TM_
MM&/.U/4(K951G6%B4>8@'_6'.T*02:\%^+_@Z73/&<6LVMQ'J<6HF0E7D(N-
MP8@12I]T2>6\<A48&UAC.,GZ_P#B?X#$]CJ%K;7%O:0AF2);R%Y(XBX =XY(
MV#H"A8$ 'C) X!'CW[7OA;1_#,6A^(-6\6:I>&WMX-/L&MHQ?6SLH"I:0K&=
MX9S@ N.>K-QD?HV$S++L7D4,MIT6\6VDK;:/39/=-Z>6KV3_ ##.<+Q!E7%4
MLRQ.)2RZ,&[.UW>.MW=*Z:6K=KRTCJY+S.^^'W@_QEX8LKAT\06>I6EF5VM;
M1S0ZBQPK1DQD&,8YW')!&>><Z6G^$=2UW0=/T^Q:YMK*P4I':"5WC&3RX#$@
M,>^!R.#FK_P)T^3XIV$MY86-_9I#*5O+>\@\KRG!*YSDJ3D<[21V-?1/P]^$
MEO'!&6VS3N<DH"!GIC&.!WKR\=C,VPU-9?CKQ:U<96;2E9I6U:[I=&TTMF>M
ME>69!CZCSC+U&7,[*<;I-QNFTU92_E<M;I-7>J.=^"7A'4;7S-)F\QX]0B6%
M5QCRY ,HP'LW4=P6'>O4]-^%#:CH\TD-LTC30&&\L3;!XXU49=P3G&2N0,9'
MKQ7>?#[X>3:C<6MO);H[1L#'/MQ( .Q;N![\UVNFZ4^AZC.P1V1]ZD X+@Y!
MR><^]>?12A[R/:Q%:\'1W7;='Q#XN_9Q\0>*?$[?:$N=%TNZU:VMYFB5L:C8
MB0L-Z,X59%+^6<C:0%(!.17IVK>++?PY?WVC^(K6SM4LE>/3F:W$)N80Y$9P
MH*$A<9VXP>PY%?1WC_X8Z?XTT@PW%NEU;RLI\LD9WHP921Q@ J"#TXYKSOXG
M>#-+\9:MJGA&35-!EUW1;&UU"\L+EC$+>&X<1P.)WQ&7=B  K9)( Y.*^OSS
MCS$8O#4<'B:<>2#\[Z+1IM[VO=6[?+\JX;\,</EV9U\QP4IRE-7EU23DN:Z4
M=(\SBDVWJ[;VO\4?%G7(W\3M;V,J/%'+O.Y?D=<]QU ]<8S["N<U#Q%MLKJU
M=$,.HJT;+$S+Y' PQ13M= 4Z$Y )P17NGC?]BLZ=J<L5C+J$MXLQB>-#YI+9
MP54'D@'@UAZ)\'FNO%C>$8_"EU-JUH&N=1E^T)_:IRWV8HR,ZH;>.0H^5 8C
M)YQ@^WPU&MF4*LLODHNG%WYK6U3Z7UULM=%?5KKOQ]G>6Y;1H8;-*<JD:TDE
MR7NFFM;I76EWI[SM9)INWA+>%Y/BIXR2ZM;3[/'',K1Q<MA0 -H9B3C/.,X!
M/'K7MG[3WCJV^%WP6OVMH;;3[S5%CTN"Z"#SBJ('8(QSC,T@R1V4BO2O@O\
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MF* #DL><G)/3*L]=9- O;?3M:MY--MI9C;S!I%-MID61\B8#L&#&-6)(  8
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M?1GP5\*_%.L?##X=7\/A33HY;ZZA$-ZLM@!<6TDS[8IXIV(.T#(SG"D'));
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M#@LQ).<5R/B_6[/Q+I6K7-G!-97^MW-O<WDC7+R_/$LBH(DP/+7YW)&2>@&
M,5QNN^/W_P"$3TK1X]$NO$7B%M4FAO&6+)BM/*"JCLS@!V8ADVY+$ '&"1Z3
MX=QV>5I2J-*>KMV2V>BM;;?9/R/FLVSG+^"<#24(R]ES*.B6KE9R33D[/1V:
M^)J[2O8\%^*NOM?7,DCW<:?,04==F#GG#9.<>E-_9S^*O_"N_C)I>I32IJ5H
MZRV]RL4I69(9HFB<HW0.%<D'L0,XKROXW^)_LWC2_LUN'NK&.8K%." 0HR!N
M"D@$$$$$]1QD5H? 5[6ZU!MCI/*'4A&ZYSU_.OR[-L+/"PG"HMKK_@G[I@<X
MAB<&I_9E';JKK9]4]=>S/K+]HRTO/@K^S_=:C\+]4NKFXUSQ#:7.K7US;FV_
ML^TCB"QQK&'D,B@9W'.2"P P0!Y1^T1\-+7XA_#^ZE@EO$U31K-IKC4&L_+L
MM4ER)E$/EIF$")9#F0DDHP!R<5]7_#G2?"OC/]G#6/#^M6>EZD]]#(MQ8:C>
MFU2["H2@CF4%HV#<YX'&"><5\]^,OV6_%<7P*U.?7O$__",>&[P16XT^)_MD
M6JK$"MJ\]Q&Q,@3/ )P",D8KZCP_XDRZAE-;#9E1<ZE1/D:[RYD[V3MTVN[[
M(_%O$+ \39AFV$QV!QGLH4YIU>9*]11Y'&UK*6BM:T8I*[E>Y\S?!./1[R]O
MK76YM>ET]K<QG^S(06O<9 9C( RH0>@ )!P178:SX.TWP[HLD/A6:[G_ +1C
M%K/=7-D;>Z$0(  96P<@8)P"0,D$DFN;^$=M)XE\46FEV&FZQ-]G$J1:A;*D
MXG:)R'98U)<1$<JSJ 1TR.3]-_#CX12ZBL?VZ)(6D8>8LF0YSR"1V!'4#H:Z
M\33SO*::IXCFIPJ?"KO9.[:B]5OK=)ZGM8'&<+<45I8C"N%:K1TFTDW=JR4I
M)6E\-U9M:*VQY[\'O@[<3R*55X8)-N5&>>, D=,@U]??LOZ!K7AE[G3;'>S7
M$+'RR@<94$%@",$[2W;MGM57P)\+8=-EC^SIC;@#CKCM7NGPE\%R/XIM;B.%
MHI$)&4&WD@@ ?7.,5Y="///G>[[:?D>QC,9'#T7".R777;O?5^KU9\R?&+]G
M^^U/688;6PC-E<7 DU+S(T)$8(=)(F)&)D9 02,$,RY&<BI\)?!NJ?!/X5PG
M3[BXU9FO;LZZQB2X(.]0A5%PR[ I!P2<8)S7V%X[\'QW3,P"_P"AMY,N2,_@
M/0=,^N:\WU[P]IGPG\):GKUS;WEIH\U]#;F6QTU[R6:XN) BD(@!.6.68]/K
M7U%7C3'X3*7E5-1]FNZ;NKMR3N[==--.A^1XSPYR[->(8Y_%S>(FTDHNRYK*
M,>51CS7_ .WKNY\P?M%_$'PWK.FM>6+HQC("!$QD8 .3@'(/(X'./<5\[#Q'
M.[->2W+!=I"^8OF?+SPP[A@3P.<#J.M?87QS_93LO&&L:C<_:-+O+:QO9;&X
MNM*G!'VF-MLD+A3@2H3\RD9'<UY$/@JOP6BO=<ET)-6L[<AH'U:,W&F1N#M8
M,@&&DV.Q3!R"O3&36W!TXX[%T\'A_<J/5-O2Z3>]TVW;IJ?2<79M0R/(:V.Q
ME-U*<4E**5W:32V::5KWUT[GSAXR\>76N:-+)%IEM92WEPEQ,A4N<B/850MG
M*'&[# \X /&:Z/\ 9;^%K3_$/3-0:V_T99!YBN/N* ,@CT(->]?$C]BS5-'T
M2/6)]%^RIA;=Y/MT5RLDBDJ77:20KXW!2 5!P>:]O_9!_9"A&O\ AM;T,$U6
MY6-TVC[O))_('\J^2XTJXJEF4L/5FIRYN5-;-7MTT3>[MUT>MS[_ ,/<VRC"
M<.4LTP=-THU(J3C+XD^6[3;]Y\NJBWTV]VQ\;?'W]L'7?AS^T=;:#;:C=>&=
M'LM-22XALV\MY9[H^>9VSU(B:%1CD 9!R37HOPB^)-BNAZM:ZYJM_/H7B;2+
MK2O[:T^8F^T];A"AE4]2ZY/.03D\YKOOVW1J/Q8^,.OZ/:6&CW&CZ5*NGH-0
M53:1VZ *J L"6;"CIDCMCBOFRY^$W@7PAJ+V>EZ[X@T2[R3,NFS--8;LX(59
M@V /4$#TK>GB<+3H_5ZBMI:ZM=VTOW.+.. <UQM6.:X:K%RG:?*V_=YO>23?
MNNVBU:^X[S0;C0O@U\&]#^'W@C4M;US3=&O[C4&U*_A,0+RA0(HT)8A0%R23
MR22!7L9^(/Q"^'_[-VE:]X'L=%CU#66U$ZYKMR"DME+"81;6T1V/\[QM(RJ0
M Y!!/ !^=]7\":YX7T2&_P!(\527T;@;?.BAVY ]5.,'_)JK\/?VV?B-\%];
MDCM_%[Z,T@"2K# ZB3'0G!8<=CCCUK.&94G@7E^"K.,;WZ[_ )ZG/1RO.\)G
M/]LYM1IUVVW*+E!1DVK*R7NJVZ7*U=+1GVM\0_A+JD_ASPKK&K1Z78Z_JVEI
M-K"VT7V9)Y@S!9Q"0#&TD85F7 P3T&<5GS>'8/!?AE[Y0IFD5H@[G"D'J<>@
M''XUY7\-?VH])\8:C-?>)-8U+5=6C(:2.>7)E<\C)R<@^HXQ770^(]2_:&\7
MZ9HMJT=M%=R%5#';%;QJ"S.W^RJJ2?I713IJG33YMEO^K/B<='V6,G6J047*
M3?*M$KOX4NRV71+[B;X<7'GW$MWY49ASB/*]3GJ!7I$'CB:-%CQ'$",= ./H
M*YWX1^(_A;\1?$%_X<\&>+[C7M6TBP;42/LR+:ZA&BAI!"ZL2)$7YC'( 2.1
MT.+>M7"VVDI?1VL,B2%E,:N3( #QQZD>N/RK3!TJF/4I87WE'?6WZF^*R_&X
M&M[',*4J<VDTI*SL]GK\UZIK=,LZG="^BD3'F"489D;#8'?\*\$_:A\&:]!X
M(W:+OU2R1F>Y2/\ UT2GH=O5@.^,D=<8KT\?$"!!AA);LPR%88/(S]/RK%_X
M3:*YU3Y77/< _J/<4<V(H3Y*B:[IGFUJT;[6??U/G_PKXWNK7PS81+)(HC@5
M,#VXHKVK4OAAX9U.\>X:*2U>8EG6W<(CL3DMCU/?%%;?6(/4P]FOYOS/H[QI
MXU6PL)523_29<L<=4!S^1KC%UFXGN;:-)6,;L&9<X!(((!&0.3W/ZG@\)XK\
M;,;XY=MSY!;U/6I1JZ)86UW#=-'-#DLBDY=2,$ =R.H_'OBM,EC3AC*4Z[]V
M^M_S^^QTU,5%22Z(O^/'N--OUDA#B.1B'A"_ZGOD#J #P1CGJ!5>WL[RYA*%
M,_*"6!XP?YUN^'/$MCXXM7CNC'S\K*Y*9'4EN3M(P!U[9'2L#2[F32-9-FKM
M-$)"$DR2'YX.<#(].*^DXKRJA2Y<73M>3LUWTO?_ #]4*I!2DI1/;/V:+VVU
MW2+KPSJ"_NYOFB+'[C8P"/8]#[5R_B'PWX3\<?:K%8IK>ZTVXDM3-%'L8.K$
M'AL C(XQG->G? GX;?V=(FK72^4 /,+-P-N,U3\7W5CJNLW(M%CG9IC(KR(,
MYSP0,< =CU/4U\G3K4U3_>K3IW\R:F!G5K_NG9V3?9/I?Y'C]O\ LZ*EP#'K
MNI&/JJJ@0@@]<@$ ^]=5X<^ ^@V))OI-5O"Y!;=,=KG/<<"N@U;PMI]KHU_K
M&N:TN@Z5IJ*]W?7%W)% FX[54*IR68\  $D]!7(ZA-IMYX>TO5M$UX:]X;\0
M0_:K"]AE>2"X4$JV P#HRD$$$ @\$5/U[".7+)/[U^03R?%^R]KSJU[7Y6E?
M>W-:U[:VWMJ;OQF_:5T?]GWX>O9Z?+INER,GEV\'FJUS.QX&%7)))[G-8VAZ
MA:_ 7X82ZIJ2-<>,M?VRW+ROF1RR\;L'Y8HU8[4SR6R<GIXM^TIX&%]HUKKE
MO8VVHW&@NMW;O-@N-KAC$QZE& P<\C.:R=>^*4WC?1_[?:>2]M=?D:>U>7Y6
M4 X,;#H&C/R$#@%>.,5XV>1]IR1I_#_6AZ&64Y4H.4DKWU_2_KK]Q+X__:KU
M;Q!K=Q9V\#MY8.]8%&(E' !/7..E:/PG^(MCJ7AN?9:ZE?>)Y=0MH;.VCA+B
M)2Q:4SG<H6%E !ER=IXP<@5YU\*[BST34]075ID,CR,6+8  .2N"1C&"2"<X
M/N!7J]KX%T'Q1I:^7/Y8E5D2>%@?E8 -E@<9(QGC' ]*^RX3P.58.<*^-I\Z
M:\FD_1^5[KL^CU7B<7QS7-,$\/E^(]E.^]VM%TTU6MK-;=;JZ?21_''Q5\.O
M%<R6-[=6\UI,5DAF8&:!AC,;!25R.G!Q^.:^J_V8O^"A>G>-KZV\/Z_)81ZP
MQ*.L=W'YF\#./*W;LD<X KX7T_\ 9NU"[\0&UT7Q'<:(8V2\:ZBBCG$X0@-'
M(LG #@\D$'C.:]Z^!W[$O@31/BX_Q,7PG9R^,1'YQU!=[2.ZH/G1&)19&V@;
M@,^_7/S6.I_5,QJ2P?NINZ2U5GTL^BZ=4CTZ."IU<OC1S*7M)Q5N:UI7[MWZ
M]=6F[NQ]N>+_ (Z>%?A[KD=OJUQ)I=Q<1AXY982L$F>,!_NG\Q@<G%<'J?\
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MM?$6D,MO? '("3C:5F"\$,P+'D$U]??#&#5O"ND0MX3\5VWB[3& Q:WB+#=
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M';..U>U?&']N#6OCI9W'A3X6^!;?P3X)D=5GNY1_I^J1J>%DVC:D9(!*#.<
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M()[D=CWKF]%UU- O/.CE>2*0 LH!;8<$'(S@ C\N?:O2(DL?$WAMKA985N$
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MK$ P1DN2SB+<2,*F0#DD5]N_LYZ:_P .?"T[:IX/>X\0ZG+)/>ZE#>I);7;
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M]<XQZUTDOCGPWX=\%:2EWJ?A6+1(-.NX?$.FW=F9M7O;UD80&W=02%'R %2
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M?0RPVL[6$<@Y:\8 AV"\X SC_@)YK\[XTQF$J9E[;+U:-TUNM=+W3\[Z+O\
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M*/#^EVMIMQT9@96&/HXKS7X1?#BZU:Y22%/)A!&2WR@>_K^5=E^TU=V_C?\
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M'J:^!VM[FY&[RY""=N6X&>O4XYJBY?:[*&PA 8X. 3T!]":*F+?V$H^BL=^
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M;T#*S ]^:X7P+\&?B1=^,[[Q)/%)XP\1:U^_U&1HEFFN, #YEP
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M[(<6C)XN\?Z5)J$,CVJ:?87!^SK,Q\N0RN,-)@L020%'4Y !KI_VX/V,-/\
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M #K%W(BA*@N3@NX &0IS\5_M(?M7WD=K90^)-'O[745D=4@V*!&JXY()&.P
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MI>(H(4A8T5H23RQ4X/0G'-=?X6TWXC3>(UGTG3TT31[J!;:RM4L(K:RLT!W
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M<M&<#80QZ$=">A4^A[5YU_P4S\?7GQ5_8=TN\T_1M3TO2+'Q@/M<E[:FUEO
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M QMB4X.!GUI_Q)^&=E^SCH\\OB#Q/8Z!H^LZ@M@MW-EBDI#-Y>Y00H 5BS,
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M.1Z#@U[1^TE^U9X7_9*^'&JWWP]L9+?QMXYN))XFDM"THF<X>X*Y)D92<)&
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M'U%8N*<E)G92FU%QCZ$_P \)^(_''A#4O[6UR\M='U,$36T<HCCG16$@C$0
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M3O"2!N2O<#/%9?C"_P!)UBT\/6=CJ%QJ3^&M)M],35+A3%=7[1 CSB<EASP
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MP <BM:]&5*?LZFZ/D8XR4:C=-**=]%MKOO>_SO\ <:/['GACPF_[/<F@^'M
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MEMNAD$D4BDJRDJPR58$$9!&*^P?B9/IOPE\'>%? .GQW]E&R-9:3+;64DUO
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MV]]2DWHM%\2=M%9_9W2[_!_[0?[/.G^%/&6I)IL&=+69HK.,X=T120%)488
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M^=RC?M;GY+];);-.UFK_ %@O_!6;XK>)[F[6ZT/X>PZ5?)]FN8T\.PH#$!@
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M"M<\)0ZYJUC:Z?>BZ2?3IXEFNI;<NR1*[$Q@O(C(-Q&QU5B  ,_(?[>_P#\
M^%E^%VG^"9;ZUUKX*I92>*-'N[[[=<:=#<L9K=+J91Y<EPERY4[3@(YP H K
MPH4Y4*JP^(3C*.Z:UVOK_5STJN.IXRA+%Y>U+G>G*URKWMUJW:+NNJLDK[7\
M%\6V4?A\,&A:7S5*A2Y"(W0DC(SBJ_QF_;&OOA_'X.99(].M[MS'JWV(&3^T
M+4-&LRNI"@,59AN^8G;CKS3?V@]5FMX+1K5&NYYR6(3^\QR?S)KGOA_^SQ+^
MT3^T[X;\)WTL<L%ILMX!.H'FK-(I+E"075-S' .3@ XYKTLOSFO0IRH1G:#3
MNOD_Z^2/-XHX8PU=+'>RO5@U9]M4[_*WXM]3V;XO_#C2_&WPV&MZ/-9ZQH4E
MLTMM>P8>"YA.0%;L&.,,IP0<@BL/]F;X:^*OB%\)[C31X7\3W&DJ&M;*ZBTJ
MYOHKO"DI$K1JQ##&P$X4?+DC!KU+XC_\$]?%W[+/PK:V\"Z3XSM8_B%9RPS>
M'+RW$DL=S'>PQJKK$SQH\D;-,N""44@Y(K[FTSP)\2/AOXOM/AKHNA:?_P *
M1T7PB(KNZTE%EUC49#9D7*A]ZO#=?:-YB*D!B5'0DCP<16BE[75J3[.^OKJ?
M48&I.2]FW3A5A&=[R2C:&CC&2NI-OX4G:5M[*Y\<?L(_!2W_ &)?VC6FUBVU
MZX^*VJ:5+8:1ID-D_P#8NAWMS )([;4+B,DR.RF/)1?*C);+%AD?1W[2O[5O
M[3'PB/@'1;[1O#VG1:SI<=UJWBF"U^TV O#-(LEH8MLFZ,+Y>4R"59F!)Z>M
M?LN>#]<^'?PB\-V.L:M?^*]4MXQ,;N[4O=SP,YEA@G^9B9(HV6)AN;#(PR>M
M1^+M'T"Y^%_Q$^&OB+Q!XD\9:;J,QC\2VUU?21:AI8O42:WB1\;!A8MXV$C)
M8%5!Q79CLMK/#PE3DUS*ZUMTO:VC;MKI9JUSCRO-L)0S*6+Q]"->-)I3BXN:
MY>;E<EHXQ46U9334W)1O=W6+\=?@MX1^.VI?#GQU9FVL[C1+*[ELM;\/:Y%%
M#X?OEB \B.VV,+C%P\A ^4QF,%L@D'#_ &1].TO1[#QAI\G@N^\*7.M:]*^H
MRWEVMR_B"411J-2!7Y%\PY)1 %!W8 R0,NVDT/X9?##2?!?A&UO+?0]'DDN/
M-O#']HN97"KN(C4* JHH& 20,DD\UJ>"X]6:.RNS:7@ANY!';R^6=DK@_=4]
M"<]A[^AI864HP4ZWQ?+LCY?,,3AY5IX?!N]%-J+]Y-QYFTVG)J]G:R26B=E*
M[</Q1\1R> D;1Y([B./[/Y*1^1";:6;S_,^UF7'G"3R_W7EYV8YZUX7\3_'5
MYIUN8_,D&_))!X&?3MBOH'XV^)=.NI)([M]/OK9)A97+VUY%,+2XQDQ.RD^7
M(.NUL9KR?Q)\%K'58?/6\O'0C(5E P.V#R#7?"$/BINZ;OO<\?$4\1S*-6-G
M%)622=NETDKWO>[U?<\T\+?#G_A+=;\.:;<>+-'TOQ+XT62;0-(GD?[1J*(2
M"X905C!*L%W'DCM7H4G[+^J^';&6\DF@NY5&9#R6!'4'/7!KI?AW:0>#'T:X
METW1+S5/#D<D&E:I<60:\TR-R2P1\XY+-@D$C)Q72:I\39=0M_L.GPJTLBE6
MFF(5!GJ>>37/3^L7E&I+W;Z)7V\_,[,5A\+*%'ZI&:ER_O.:UN:[UCVCRVWU
MO<\D\(?#&Z\4>*;>&+AS,H(/H.2<>@')KO-9^"NJ?$OXKW4EK<1QPV")'&1(
M45%48!8]22<X YQ3O%/Q!TGX%>%Y%LYH]2\3:@A#S9^6!3R0*O? +Q%,G@*/
M4+NX>74-3E>>3;G 7.%!/8 "M/;2I)\OQ;>G_!.?E;<8K;\_/R7Y_GT<_P !
M-4TNU+/J^EQ3X 4K"\K;1TR6(Q@UYA\1OAEXLCF/V?Q7;OL^[$]MM3W[G'Y5
MZAKWBS4+NUW *(5'^L+;3Z5PWB7Q9;O"4DDC,B<9#Y.[N#7'&IB)N\I7-EAE
M%:67I_F>27MEXBT^X:*\\/:+?3+QYQB4[Q^E%=;=ZTLDVY9\#'<T5K[:2TO^
M9',_YCU&Y\9MJ$[*QSDE<>OOZ51TN*X7Q:9))"(?)+ 9) P<8Z$#)/)//3WK
MFIS)9)<SAF$D<A&#W6H](\81J%FW.\\+-A&;"N#U!]C73P_6IX3&PJU/AU3^
M:W.NIB)0K:G9>(O#']HZ4[2?NY3.%0%B3Q@Y'3C Y^OOS1A\/W%D\:^0KJY&
M>IXY_2M3PQJ?_"2744EQMC^78%3'[M>"0#U()&><U]&_"#X'6]Q81ZMJOS0;
M0\41&"X[$^@/7'>NCB;-(8G%IT-8Q5K[7UNWZ:V^7F95L1%2YWM^9Q/[.WPN
MU.YC::XA:"R8L5+GG@<D#TKR?P[XZO?$7Q$\0>$]8T5[W1=-OI8K/5FQ''(
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MJ@<GHI)>8 @DDHPX(-;_ /P4B^ 7@7P+\$=7\07E]:P*\D8LK64)ON)A(K$
M$C(5 [%ARH!.>F53O%/[CT,PS"&(KT:26_+)VV;NM&O+^MCXU\8> +7QW\.+
M6R+K')&-H?&.<< ^E?,7BWX9ZAX)UJ2TGC;@G:P'!'8U])_#"\\7^.=.O!IG
MP^\::G8B0&.2UT:YD610!@[MAZC!X[4SQZFF>*(7BNK&\M+RR!65) %E@8=0
MR'# CN&%847)+8^IQL:4G\2OZGS58^%F0!R54Y_+WJA\4=/:#X>W<-FJR76H
MRPZ?&",^8TS[<#W(W'V'->AZ]I<-]IDMWI+MJ$=LV9HP"KH@^\VWJ<>M=/\
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M@ 9R01GFOU#+<PI_4G7YM8I)KJ_E_77L?$XK,W2Q:P?(_>N^96LO7^OS./\
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MN" 0:ZS2?V<O"CA9/ED<'(#3#\NM6OB-\*-%^(L;,QDL[[#/)<VC^6X/8L>
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M/73M0DEO)7DBD^9]KDDJNXR.KA2JGY2O()YKVJ>99=/+JF)YDIQVCHGZ_/\
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MG!() R017TGXJ\,Z1XA^"5CXLT^_VRZM%C:D?W' P2<< 9)SGID>M?/OC?\
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M&.?5?V;O$^GZ9X^7P?I=QYD'@F:,:_=ICRHK@99X6?H64\%03\X ).*^:/\
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MK:Q?^"_$&G^%]<MM!\4:C9>7I&H7*C9;2B1&<9/"LT8=5+< L"2!R/&?AO\
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M26[7<*#:M\J;L@=-P'0^O4'VKEQ&!GSNK2UONO,X*>+@U9+OZZ_UT/8/BO\
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M]Y6&J?!?]DG7+C4DF2/4;I!"MO;2FZEB7N%7/R@XY)//KBO (O 0UZ\B\/\
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M&&)"H N:XGX'_M=Z3%H,>AZQHLUQHEQ,@GTZ<;;K2Y6.6:,$*)%!.X@;7')
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MM%O_ !#>23:QKTT>V?1[?!RL(QS.W"JPY4 E<$@CXOL?^$H\/Z3+)97:7US
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M2_X)_?"#Q1^S!KOB>TO/%NAS^$-5O8%T@M*+.>2^F)!0[MJAY0H"Q*6)()&
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MJ=L_3/4=NHXZ<[\6OA];>(-32YBMU\I!N<+U&>X'I6=.,8RYD9UJ=6G.T_\
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MT598EA+%<R1MMR01G  /4G(SV'->_P /Y++$4GB*DG:[5EY&:IQG%IZ'YO\
MCSX)?8]3%Q9?:--G9N&C.WGJ,CIFMSX?_%+XA?"F=-ODZQ:QX&UV*.1Z9P1T
M^E>S?$GP1<:IJ1LU1?W6&+C&TGL,^N.3[U8^&W[,'B3QGI%[J2R:/I.CZ<PC
MFU#5;U;6U#D A S=3@@GC !&2*X\TI86E-TYM-+=OI\SCHRJJLJ=%.4NB6K?
MEW.X^$?_  4=\.^%/#US</X U*X\430JABEF"6;LN>I4$XQV&,\ D#FOIO\
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M$5@U;2F=P-CRCRFR>N2,CBMG29]6$8:QN?#-PPZ-+?$'\MM=6!Q5:@[T7O\
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M"XL?#TEVB:C9P8W#SE0M]G4)M(CC);))9\@BOD/_ (*._P#!6WX:>++ ^"?
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M8RM.5.K[OLUJG[J2[K3=QM>VJ;LT>N>!_P!J>V^-GAZS\%>)H4U;[0Z6^GW
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M>/)X[?6FN;/S'@Y1(W;< N<[2,>O.?6O>Y?BA%XDTYH]4TRWN(V_B@;:2/4
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M";X.MH]K,;>Z^T8?S8P5P0>X!SR#7*^.O%]G<: ]C?63QSP9V2<A@XR 0<8
M /3D5#X._:*DGA\FSN[:5<_+#<K^\0>F,C(^AK<UWQAI?BBW7^UM*RV/]9;O
MR/P;!Q[9-.G)TY*<&XR1R5J-=/WM5W1\[W=[+I-[+&D;7"2$M\Y+$D]2#ZGO
M6EH7PCU+QYF2QTN9\'+;%R >N2>E>P:=X>\*B96M6C=F;[EPA7'XX(_6O8O
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M"2<D\]ZJZOX7QX@>V:-E123NQQ@>]<.48)8&DZ47=MMM^9YF:M5;58*R>O\
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M8O\ 9M/F@BMI81YCQ>7$JLH';)W9]ZY7X8>)=/\ AD1#&VJ2S*</]IN7./\
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M2B\7-25&FJ4=$K15VEHE?5O5W=NIY;\??&6I1:?_ &4MLEW=BWD@\Z3 D.<
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MGE:C05*2NDTEY)M+]3\W-)^ E_KA&I:U--<3-SAY68*/3))))ZDGDGDU[_\
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MJJ=WLU:UO4XZ$:%*K>I[R2OH]]B;X@_$J_\ %NJ/!#,MS<L/*\T\+$H_A4=
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M*O?8_P"R?B;8ZS-$%CO@4GR./, X./<>G/7%:GBSXBQ7\TT*Q0ID@;QP#M
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MCQK7@^T#+=[GXP6&['M7"XRY5S:L]_%4Z<I2M*W;S7Z'WYIWQ#^P'$ENT(3
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M2KRJ8:'+%]//KZ>AG[-1]]:(YWX1-<V;*GS%<C+<_J*ZSQSX*.ML)[&94NE
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ME;L<7XUTK_A((MT;K'*X.[:WRGWQD$'L3W&0<YKSW4O!$D-WYDK/@-G!/R<
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MS_+%=<*BO?J<M;+:\7IJNZU.HT'PQ9>']/>Y\L23MC;N Y;USUP/3IQ7BO\
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MS:;]^."O*$2"ZL :DRI7\V%WVZ6PN^1;LQ@F841"$.4HQRE2I:DJH=6;^&'
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M%8,!#MJ1*5;,YW6LAS[H=.2("N]DVTH9D^=AEWW)X!#A'LU@H:)YY%_X ]C
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MG(9C:MFD<IUHG#V-PBB&"1*82Z*7KP'4V[IGYD12"M\HAWHYN8B^O7 >3KJ
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M7K'UTM4->@_DKKK"OV@1M&\@Z@P!( CP=Y%^=T\T,_H>(/L]ZC7S9Z>[^^K
M8C;(J3>N*M^@U_'&Y\\,>!\'\/6R"_L)GU4LYJI<B68T!?Q>.?<R.CB4A]M/
M5A5%]K, I^ K<FUB.$$#92&9S\$W?8C.V0_49^3/>(_654QS\4/%(_PR*4<8
M0,P5DD.GZW^53'6 80-M%XF&X-4'4#/4-S^8BC:6_U+4> =I9*"GA+PSYD.T
M3T9T1^H[F?HA21G^Y:4(WJCZK7XC^0K7$K6(/GWWY'HKWN[X\$:;<3-S0S>,
MRSD<2?>J>)=C=N?@AI]F+2Y%\5IE8;W7@+O%)S,T?QT*61'O SD(6E?@):N(
M5[WZ63C'E8"XP7<*CZ-=;RC='Y)^K'&% *[#O[>#MC4GISN](?BAP2OX<FZ'
M72A<8'(9$=K8BK=DT@+BH9-)N(V;/8]#GS!< RCQ\B+#UP"M-PJF_M)'*+[V
MK6^^=C< !*XP/7/$\$3X:L;6^\%J;C@1"]2Z^@$3-YKOY<;S4M.K\W6[Q2J5
M,?!YQW@<)>52XQ\,H1,D</8K =S_'M]0U,X9;0@RKVVB@0PO:U+8&(-7;V=!
MXKB'NOL_FU?C7%<ZG4?)&<&X*ZMM2.GB'J][*;RM"NM/?*.[ G#LQ=5"1E++
MJ&%BMTQ'%RA_:_N_"1A+Z"G-56:TTR(Y5$\-OI$"P1O37_;*0\9-U4_'X5NE
M&2&\>=BVD&=_;O\O_A?_B__%_Z^Q"I7##K42:"971T[4[]M42_[@8/33%RV_
M+20\FU23@S?$5)=U(G]6*C?%GX((^OD;$9.B%TV&KN(-WL*9&073.Z()6_7D
MA5[?M]9Z6,X?5FF96=:0/<OX]K_X_SAXBD^+[7(5#%96[M(K*,>\_D/=,<F]
MHCXCM7S@ORQDVRR)@245CLWM,&#10-W\7S'S21\S-;W?\%]P5F>40Q^AI;E7
MJ(/LW</)-<LF7A6.+]Y92]EY)4R!YME6 H7PQ"75"_\R@O#%)1ZJ=]]"G<9C
M_;+WPE/;.[]$,R]%6*Z1K!1< YYQ4,1S?)-X7%>+?YFQ%0C$_?:T.6 +$444
M]-)9??@X/O&:B)?6D^?NWG=C[J[+'1_@C&/G@'N>P93\FB'UXC>&CQ7?:_.G
M(^IZ2.LZO^!8Y/UURIL-0^W(<5'/(]V4A5YPI.ROTH/,6*G&-_KZ]L[@B1=I
M9$:U*HZ79?CHEGDH?\5H<>=>W%Y=G94.PW.GOFA!"<K*P _S*4?#$2243;PZ
M-3&G"K$=D^R4%=\;<Z)!.@D"AU1Y5"HEI*^59?[H+,2Y+TO+G([HKV-.LB^D
MX-8DS\K?YDKIO%'B>-#")['TN:H1:)-E,+WM8B**D)RIBZKO9HQEY7ZB4D!9
M2\09%KN8E-!7SS)6F=!8(BQ;CW4[&[#+Q;^>Q&=I@!@I>4QD7>^)]WPQ?0&B
MB:'6B(C+ML.*K3Q-S55V!88]:M!S:/Z[XOL$2"0^]_5H*\5JQPBT9^>TCI8?
MQFODW@,.U$@*R3E@\Y<JHQL"[#=2[ONV/$YUFIPX[&31QZV<_F/A9<O2"?&3
MBZZM$*K[Q?XGYL\Q26'<L14(H_4$^P;\"M5S/&"&1G6HD\PHBJQM_'!(MR(S
ML3;W-]W66UH"2*:-ZPC.)NM46-@5@N_,&[YHFYO=^?XH.DB;JMWZTZ::SS%2
M8J2D\AI L8UR''L%8; =K=;>%\A]AZQX#BH\B+JOJ%E6(@5PXK6%,&]>=.(]
M'CZ-%*VQLLU2JH[__G;7D^7M=SITOJGS%.OJ1\VD[4$O<YQ8TY-SV/N#8KBC
M]<K=FN8']1'*M]STW.\:9VG@;7,IM*B4B0 Z^PF73CC7#Z,3>\>1--W6WD/T
MY7-OP4L:9?2KU"N^,G_G!=(S[71>++!V**1PBQ)'R/T^H^=:^MX#P,B;=TLW
M)[H-Z_47M]1PB.PU&@A><,7<.FQXWP?@CDQ4/@:-7RJ?2:RUXY[;,S0[$NX=
MOX54!WW3%C.Q99QQ 'QVV#4/N[6M=A<8;K<%J5)L;S(7G,8;9XH2DG.FKP'I
MGYOM*BHP%"[!)2)L3]?[')/6?6;'+<7(7I,_<DWYWD(:1<I*EF)'(*\<*Q%H
MG+_!5[7H]TY[-;2*&[=?/DS-LF*[*[X1JUB=M(5C'5E.X<49H:@/94I&FY_A
MK'29J[ DX>#+A&C$CB'#3&K3MC]EAU#@ID:[9;/P&%1D.11!:BBEOZ5PH5^^
M#GS65$&K'Q=(<COB+@?!:"+KIIFHI$&3BZ<'%-MG5=O0&1J#8&96_E'S09RD
MF,P=6L/,I%SR]MTQN,@U@/CR=@ANMN.4?XG-F&'H([:"JXRRU.;"'Q2V&B5S
M"2!E&WP>C7^+[8IH2)^0X?#R]<\NVK&6NO>N=B,E2@BPJ6KDS*A;-B3 6-AH
MV>P!6?=-E(<&6%W*XE5&4!XR^5ZU5[T.;DII,Z823\P5B&DE;]_B_IY6E9E-
MF(3<IZ@NBO:$?*B*P]>MUE);\,>:(A8Y7\Q0?U"091/6W9NT=.T/= YUT#VZ
M!KSRU9>']II=.N+R_OS&/5W4+!/Z'3"?NM^3#.R@^$;;_(,HK4FB^!(^:WDH
M[@^!@K"O7EX#AO3,(_1Z3D@YT)C,6<7\(5 0&[ ,ASR2/@S!4G*>[F**CR,J
MK E\5=:]E WO+0&1[MR<<\X&]1Y[Q9A]7*F]I9W.1[\:!I=T(&Y/MSK(-4U?
M1TAJ)&%NR""C5E7J]#>&JLB9-*32!3Z;W'\-&"XS/ 730J4+_MC9>RC6 G=-
M%!8G"E-E<OE*3\RP\LA8L6=YIDV!N[!MO=5]T5(1$8V?&O)T@/_%_TMHS!EU
M?ZF+>1ONJ[=2-^^(YOX!%2AQ!]-[NJK3^%X#*K<_=-;LU 4^5U%V,'H^Z#"L
M>L$F0K_2+' -\ O#DV!X$'OJH8O4>\YCE+;,=R_VS$RL5E X :M=Y/+C'>[.
M)MKS6-P7T[0-C^&"^W#)-KT^&EQ.P@!["3"HXK^/ +1K)61Q70/D=FQYEX!T
M\-9>5(5,8/&IM%R7]ZB@G2K):VKT(X.CR <WEX["[QVO1[M%!H'O5UELF*GP
M[WGX>DAT[QB5#V"<%S+P-_WR3/KR&<TXSLGUO 1RQ=.]S4^/6UM!XB0'OVJ^
M ON5$TU747HYP8DC(P<;9SM1&+?N+M[33YEX,0Q5?-8GZ&5R<CS[>5\8@7Y(
M@*-5L H>*^TM0XL54=U\=C$(SK3:KZ+'[^$*"51R5WGNJQ:58Z '&87LE-6!
M7)^.A83A/$>H!_!61[ M@I'!!L9OJ\-2'PY6KZXFVOHA7N+E+$K_)?E<<#RM
M"GC'M1=.ZX:^!C@J$S3 .2&!*Q<L3^9?_>MJ<MEE0/VZ!MQ(6.O;9AG<L.0V
M@HG ::QPWD?Y62D!8=%"O^&]T8EDPO5ISJ!"\8;Y#\;F[1B%K@&;:G;,SO+@
M"M*SM%1!8F?PX24]_=;-,F(/+OY.$D X8)M3PW;:2TQ)6MD5VK6@E0%\D(.4
MP%KAZ?I/?3&B:^,R+Z'@&HMM1KT0(_@B\>0ATM?B=(M<:4CX&N"M*P 7E<AI
MM6"+N084A/D$W#R>IWD$)L'&8QN<X(](K+,0+/K=T1="0J/N-> .^BH.]!39
ML%*2G >"MYI9.3L9;NJ @(.-DYUPC"MP]]_R"?@SHEORWS4@U_C.&(Q$P8#@
M:Y;*!OZA[=,0@[8-FX#LD#S9C3D''TEMX51CY-!QRMZ]@GW<^V+!J*4=2,#7
M'/E_,&;<I=:GLX=>_,5:5S!+SD.1#1G>:X!_Z<$JZ27Y4I'-ICNE)^LU8+%V
M![L.%*)>WOEXC_S$H'=#K\ZW$!H]K][>Z(? UZZ?_$(I1(Y2,\);QR$/W9^S
M2W.W *E?14W/C#0-]',30'\(VNMI+VX6OKEU6U5[ZFEW%,EFW[Q,]Y_,4KRY
MY= :Y)YZKM=0?=9#E^@C5_UW+SOZO5 [P[NY;8DB@O[DU"F.UX!LHXL@HYMJ
MF8.-LXL*,3<+VGWE?>I2S1!_VCY'F1^->W@D^)"PN,@.<GPZ\!'-V.%3Z;@L
M.?</*?-=J=/+4ZL*HG)7V6M'7Z5)WY'[K*(\S?A'-I[G16368Q27C=TUX#Y(
M>V72:AQDN!*NG!PO9E#5D77E(3'@6C.A4>DB')CTIK'R1]W67(SMN87)"?UV
M?(UO<]"Y#BQ7R^))AM5_0SMB0Q;X4A**XF4W_ETD %YMG7VS68$P>*M(,],U
M8 ITDUWV\K#O_@1B:<95. ^6&A_^$HA.(/SZBPQ6+A+;^X@FRD@6K=?C[Y=S
M^_LH404@%T=\&>9!4N8.#&*<6=U;MVYF@9?%3*H(['^*6.1TOAN]]*)+_2^5
M.M/M*AD^FP]VP,J#L/3:VK%B87N*Z*;4U?C!W3*BRE^MG*Q+4>+[=F^ ?@;2
MZP@KD;'Z'^6O_=1?(HU2HE,JK/B'O@ZQCP_]C86A\D^GE)\$Y<+7(E?#I"[Y
MY11+JV0\ E?+?I-41[SSD/G$23H(3W[N'W:'V'O<9Y'D*O!BVAUR9\N[HBO@
MC[^"UD .-56:W2- ;,\0*3'1@"UUD!,U5;C*C&%#7"U?,6N"()_A.YJ?6I@_
M:4H JY+G]6?^4/"R,)=D9+!(/Q/ZAQ$JN=#H?-BO559G\$ULU["7./IVA$6Y
M9%/&5JTU3*!F1#!MRPU"HY0/C.&(F#*>,Q!5-NT2Y?6?71??ZGX<M3/IG1;Z
MY,=#M<+3T/._6T[5"ZJ-IE%:#I]A7\+N"[FF8-]78\Z"3O(SJ\LF!=(DTFGU
MJYKS3.TF)9XP^Q,]DE8"';I(C:>"6Q\J-/TQMB4OV(G^&9>1Q'S"_%;'A:/5
M.)$L0(F)YQ:;['JDA]-ZR.1P@OY8HZJ(7W5VYF:];Z,F7YKC:>A</G2)5)9L
M61D4I29%%K@.8?1T.24/1BT#QP221#7LB6.F7W\&T"I_1O-XD?[W3S4""6D,
M554UM5Y5O(8>C*7)J=KDO76>88E*3G6]%*MA*5;?-;9ASQK'1+@;8B[?_7O:
MH,'RUB+DPK-X,I!'VR^ *V;0!;!D'D('23C!^1F_$N$[1C":V PX._IFM3/\
MH9AD00L^ZKD&Q']AXODFWJOI@[&9!-(60>72GR80QPA4_BWS#37S^MDG.Q_F
MRMQ-)43]?B,D1P1.:S>C7/9#7OJG^V&5_=/=@V<29+IV)!3B7*)W=REUXHJ*
M[7O\.PD*N:7W^&3^T87;,RC9EY57?)/=\/\>\[*3M>D: %B$MR@)5LU;Z4L9
MMET#9A@=/O>,KB51_J%5.#%]YWYG"EW*7I]D$KW2P!#/]APJ]5DKH-;G.W\O
M*>#'AR*4 )4LM_3/ _WJ!&$]I1B#'0;&+UK%*<@\V5,?>4YKCHVX#RZ,=X);
M0&ZQ;__MKPL;V<">U4=JEI$HFS=;QBSL<Z;T<D%O"U%SVA ![HOG/HOCKZ=7
M#!1(VM_?<@N_O21?+U78L^YC]WM(DUE%['=N@9]L-_%904*2ZEK5+U[G7,^0
MK:>FU7[\+O1)KU@MN8W3M?R_-51,)?VKKS4LU*JMP_[ZBO3NTAI-M_[S,-0[
MP,5BICUC(XI4T];F"U3,)CLKWN1QG66#Z5OJO/.,*>K&?O:5QU/"*:9$K;G(
M$Z=U7[AF$66^=9E(VU;ST[HT5J^7N,##IWI43JR5%LFFFR3*W*.Q.GP)'097
MV6,# K&O]&D76N*+ZBS6WELY=[]GW>?.NYV%0?[8=?=9Y%;':J_GQ72-!*<W
MV4VM 98R&X1-K5)N2V0W_"MYM;6?#J&5RSD7U]_+/$S>\V?-6\BN)04^)]8<
M=<A8AX 3+0\TL98UN44).@26T<K\::=_\\JO?G/9$^^1R4HKM1*EDQ28;$K.
M+Y16)Y1["FUHQ@NO_1EE[3+;"=:JXQ.7\@*PICP,U9F8&5B[\:!E 4QSE8WD
MCTO6[#N[1'E:A[US+^>_<;BH2DI+&8V)/#<?=3"K&+,DZYAA0G[L_T#_VH8Q
M#IT"D.4R=\_*-'^V^S B%,D_%N\B@,B#6W6O&Y2&_YH-9'JFK425XJ1P=U.Y
M,/X:0)-@],_LW_)HVJ(^XH5(C J3+--J']-M49I1<2[LU*B%Y.K7,X.X[I!C
MZ>>[*09S$.EOAI:MS.^55F^S^,FV@FYIN^UY[[RKI=7;]KZSUU9F657_VU"X
MT#TN:S7 <9GKOI"B1(^$ PJ)^[2P8Y*6O2>GAH5%1?\_U)Q54%S/$^\7AV#!
M77Y!@[L$C^ 27!8+$MS=+4BPQ=W='19W=R=9?'%W6&RY^;_?YUMU'^:I3]54
MG^F>^7[F].E)-UR<WZ9QWVPG+%@L/$B3, #^PCL O"QR)%AS[9]LFF]^<NH3
MPIT2IM^87BT-.JYE^]2\>O\+Y]<:&?P4#G*S/'-C!\HL5).-2_*=G9IG9J%D
M2"(1':"@8B '>VO&>/1YI_[BQ[18<!,S>=;0Y)5]<'8@H7V/./X>>Q2-BD?,
M1W5B#O(&6#'Q+;9).Y!?YLS/M:L-NQM WCRZ?]!2;BC*/8WSUT3*@PPLWI4Y
M^%.M8?]GX8 #,SI5:-[RE07CUXO2A8Z@B1H?!,J*1A[6B.*);41GI-1#%3(Q
MHY+7/PVPZ*WJW[%4<6<A] (.J,:F5!/[EUL,J<(U,@[T>0W:8NP6U%* .FT2
M OV?RP#X7*BXG[WGS)Z)*VQNX!V49^'A37),6K/;2\V8AW(D G@J[(6]WBAC
MQ@AH6=?<,\TV5G"4JP7(V&LNM".&V'./E?[G^;YGX=;[2(6808O$V9Q C0,#
M(/-?UX (@4]1==R=J=*8;<;(YM\)66\(^M.17/K0BB4W<"X/8OG2T]U^7F'?
M9R"M#WAQNTE+>$TJ(H;-4 2>!<H@QFKVW#T1,)!Q>OD=_Y,),=BL&K!B;/"J
M[8NO>3U8BP"S;*+5G#)Y*QB7DO*]2*)6*6SORJ>_9+VXLV79M@9/EZEE04MF
MS:OO\_>MYW]:IS'6NNH-@(MX.%&F5&YTE.G<8^X#CMS8PI'$.[!BHDX7.HFT
M&RYV@Z)K84LU52JPBZ-R-:=4D4.W@P-13YEC0,;.4@>BSG>';P#>'!U%OH=?
M1F-4 C'/BB_J+8]NV"3]48(I/XFOE4\<3:F4E^B13GGO^,N+_?_DL/;4DVC!
ML1;N3OS@0+EBZ]$-W7-2 72Z5B&Z^<Z'O@WR10XMDL:,-X#<8F33J/W%=/[!
MF="?Z5[NF'#27MH#TF'K77_R92:;2B<W 9"%_92+\S)/A0)]D,2263E;D6G6
MP7(N7RI$^-A<Z*,#"JQV+*?8[ME$OR8K53 '>:4@M#Z=-N=C.!-51*76&Z!E
M,W0P0<:K&%;0+WO3*5=*O!K;QJ+D.9A#Q&M#;&.*%L%9T!$H;_]AV4-G>' K
M",?1T6<+X'>CQ0!2B=*/'8$3**GMTW G0!W _7 @5CSR =([*2%*EZP%3:;-
M2V'S.&/#L5H9N(?8],+]*,S'!7&,L>E>=G/(Q8K-6KS47D)O;:''\@V <(+T
M2C/DS1O0Y?@/7#X/^?Y;75_>ABNBLQ5(LY(W5.%C9R'F)DVC72\S,8/(NZUH
M,X+<_K9UA6WL[I8&:U21_I2:N7&457HAPVT>PN!/EW*B/[-LY%]QO!PW\#H^
MCOEM[H)J3_UI+?4*0ARJC@0IVKT\G,#7_.78D]IT#\[TN=*HW=3=E\2I'TI7
MFW&Q6,#3Y/-C>'Q[^K[S8_O8&\=_9I@BER])^KI(#(+WJE^D*@SE* -?2Y4Z
M!*X^Q:$SXT6>'0/&#IVMN^OIFXUR'RGOA$PP##3> &,!6[F6JD8T@F'\[/C8
MTM"9X1RNQG#EI,&Z8IC?031E"QK]-9K00_7ZOX48$2>?I^MHO%IN<]7YR.KD
M0#B.0#8VBD835'C"6C_%05Y^;\TYY!_]E!#Y&-X?0.C/<DR@F+NJIR#C$#WF
M5HK00T<72@ORA1-9.T!"AKNI6UN!1Z)HCBGG'R93>?0Z0=%GWP=W#Y!B>8>T
ME^E\=-,4PIWD_NH^2=R()Q5T^RWTV("(Q,,<]B\-JM=8X$"_5#6$$*1@@88#
MX>K\9Z"!;I52F2?NX'+EQW=82H1K.2'!+-WU.+4WPGL)IJ:=$D1PBR950PG3
M9PO8S_W-R4REJV]Y8VI&2C\!L9W!WEK)J6=^ET][]P)M]]I46E"(SO@S9;5:
M-=KB00HP*O9V[X%WH:R&4^&U0!2SVN(4SC:[5HM,4:S^2*EUEQK39""GL7K\
M9#Y\GF,P+A! IU&4,[F?_"X>5K REK&HX:B<&%W(ZA.2D5 VREP0"?C_?I1T
M1N';_]1474P,TGD:&73 A=D&# [HSU7YO &*#$=HX+_Z$ZWL-7Y\%/FF#RGH
M+!TR M/T]2"S4JE#4P-/)P.\C(!@-@G (#QY?^/C/RX9AT]VX]'K^QI>3IYV
M:2U,M='!85]T5$BD:0CG'PL7!W:%LP.V?APKS.,')(CG%G137=&\4/(^\UGF
MF$!@(8,9 TQ2IGG3V_#08- ,T0&<X1_:I<'Q="H#S& T4('JV LKE#*)*%F;
ME!*GX/ A+0FO\Q^=(E#K-\! [^+C4.WTR!$1T:,@% 3[A+/*UL[9EZW[!FA=
M>=KEAO_ Z_EBZ 5U@ E70I.O:4Y!8=3H"^W;-<T442%G<?DR)_J)4,5NB>MK
M^.\W0/S%CQ<***3G!G/B1(CSM?6UM* 'N5/N#8!&Z#__:2V:K6?;Z+#B;V^X
MK->X'U:LMT_DS05A0)_5/PKE)"STRB54SBH5M7H2:T+VPYFW22@EWC(%\SX&
M](F=<@;J*VGKMCO>)08DZ;Z2:+@HIQRUK:OZR?76[DL,25RJ.H#@W!;P.=C"
M%;XJ[0#;)]#?19"B-"&"H0<4-SJ'_\H;?%\;ZVM7?KX;E>V\U_<BN'-;HY=E
M+N7+M[F1^IBS3W-XDJX @[4[W:JE'HP'J).O#*E@>5IXW(,BFJA$\R;\2N#,
M+2"_2=:93N!SP ONY2=>ZUQB422;QF <,%+="]'OVKWK-X"*P;<)_<X5F66O
M'/4W (A ,RS&!G>]!4QZ3D<&UYS@X''8*GWH@:&!90Z/I"5&AL%'R#W"O$]2
M5T8OQ!/W!I>)/#-7/@-@Q:ZJ!)NJ7,4"O-SASH/!S4NGD=.)?#J_5)TKP[J3
M65U+WO?^T:LR)T:!)^3#_IJJMP U[K%__AA$!6"9_*^B5&R2<^Z9%G15J9DZ
MS?H&L'M5634B? /TS;X!T%T?AN.W:"+:6T_-PC"_!UR4\A^(L_R+F'(2TQC<
MK>HKB=Z5IU-K":*O3-?\CQ0,?-&1!ZD$IGOW";>R#\PPAOZD9E=S3MV)6\M7
MCBN)%RJR*Y,W0 S-=F[@[=*IO8.]O<H.V+)6^)^)TN%9T2;RQ,)I2XS(J/3O
MK3HOT^SHKK_Q2K^9F;IIC=5!VJ.#ZDL5R )W.QQ3%<;E^+AA]*1NL;C!^K][
M!?@BG,5EWU>K;>%F567^K/H*=LI_X,_\S_3;?Y::#Q];94=F4&[9J+/^N!HQ
MMP] M%,E7!9=;).A&\9B1"0GD2E6(<J4, M'Q<_R^X_F^A,-OJ_A56Y4@YL#
M.6Q"G4GX60OL0OL2!6T#5O(OTK,[7NOW5,WSA=^8*"G0/X?2<]OOM^VIJ7DW
M+I6&%LL+E!+1?(V7/7*_%)Q ICL,>816?[&O:$.BD4_?4?N(-MZ=].ZK6B/M
MC'5H39VWQO, Y7=3M1[W"B:^> T,!O'@(@^\D1MRE]'Z=[7.OH-'>HS.XX+T
MTOCL LH4B(7!3N0F1;HI\G.\*45?S1[+!9E%U=/;IJ2W=99*G)5ISXGS+;'^
MCI6GHRU'SLGNE!/P0/\F*'*<:G;(^K:NT&7$9RO<E@JRZGW+<OL@O<"9#JX6
MBK66:/1_<+>6;TPIDG_0CB(P+2\0UONR0)C*$0^>_/C;MZ9/0RN<K4"!3WXG
MH] Q@>"YFU6FK&S<MB0[UNOK3&R_%25OLY)C SWVM+_Z2\5"R]#4%[9^'1J'
M!Y7K2MZ]17ANSU94SW6,0YC$/:[$$X6JS N>#URU]G($WG?P!OABS7J+17/Y
MWV$/W:-*1,"N5<0;@++GMN3'"Q#D<<:[P_1,W.BU-V3M?I0INIW4]P;0^7Q&
M&^<U-HWR<\*GC+<Y.H?V*OV&^]['TQ8:(T\=M*<#'@'GHS1X]@E/N6ZP70DD
M;^="9H;QK?6&8M.H-]8_Z]=),?_!Q7%$1;\;._I^ N<-.ZLU7=B=;\[T4Y;4
M5=?@FJ T!C" K.N-<3^C V+;JDP[M/YI4][3.C>:NI+J>]-'RLEVG$2O\NPO
MS\*T+!T&G*1=@]8 G!.2-$<5(18NJ1'&&AV('N/FJ0'-T+*[[>[GA&ZZ[/JX
M\88.GF%T^F $-#1D)VW.*GY6B@F1&'6ENC3@R+7!&:Z/?UXPDOA:"1HR5HIH
MEFMUC T4-:1V_8\AT$:U28"S>Y_!!&2/@)QB2$DPBV5\S:5D>3%[? ]2H.Q:
MRLEJ6= [UF-_J77=W@E>QN71V4,3B0I%</3B#)3JHV)1B!$J&F^PS!%/\%RQ
MT6\I,&V(KW]8]SVMHQK[#*2,/*3KN"*)/FAM;VY9.*TN_D(PY-*U[..2A:\\
M6QN=A164]=X['/,-@&_@:<ZF_;G9AC#*]!BW#$7W R7JU^] (:I1JC[A\I4G
MLW90[;Z+D]SVR0^&:E!8LZP;!JG8TM1TC@P$L!LS,Q$VC+B#[ K0++ZB3BV5
M<S>;/;?CRVQ] \SMPL><^#,18FH)K5IEUM[+4@FA@IL"R +Z\80-O >>.39.
MPTD&.)'MHE'B9V@IS?"Y>*3HNJ:TH3B)IM5293'2P]!!O3HYNP/\IIJ1B%XU
M*:8Z)*9#%K?NP?:$KFI8%N6(4@\XDM2-RG[O')U+JF2"C;BQUB,^61JP:QR'
MJTA=J-OYHV1ME3\&%-JLH'"$,YP G2(R.05.KJVFQ0::):Y00H>F[LLKA!)D
MYJN!.FLGIDZ.B@V$9*AXK?8L@/50X6$$@$8JG/:*'?J'?S&#*GOR;%^'/5..
M/I6-BTS73!\A%F-:VI,?F+3GX;#R$DG^ZTF_7Z#SDO^N.@O'<)MA(4_"AMZX
MO<AV-<V-?BMH@2FRG)Y<O!D+3/QI<:RT?X*B\_OI#1W3OC26(!$I()2,";$]
M&SB8T7PV5*COJ:W1U-D8-T9>O:C&,$+C9$ A+';=BM1VI.'V;\+,<C=VK1')
ML.LI8AEMKV(%<U'FM<H$W*LLQT]8JO@_5"^>T@ELB!L%T_,\[?(3I.#)/E4Z
M<@1G(^.F._L2:@!H84^NI%6.G8""G?B34+\A_U[(ZDNO$UUC'E;1I;+L#.U#
M=9>,X956UK6,?[MMW;$J*.&C2J)EH'&:O]*TCKLSE[?3D%[GHJC&/1YDS2I#
M7BI)X&'"<7Y0!N%K/!?R0?1VO?3FY=Y'?H<;WDZC4I@;\3(4M@KYJX)ZY5&\
M1HJT5HMD,RQ%?TOEU=M7X?XI-\2U YV]&1-S!ER0W:A_M$+"3B&@_/7Y78(S
MSVI]3DE3E:A@K=43Z \TI._"L_Z,U0%S=<B&C#ZA_MR8GJ$Q09(NQ_KK%6<,
M&[Z"Y^T_1EP#0NHB4N7FXGT0*W0LJ&Y"#C^IM:08I8N>+_= 5<EKHDSSK"XA
MD*,&%<Q$+^K<=_81G QD)&QD#4([3#DH%B<"D)^U-O]K7$^BU]@2&I6IA6&_
M4$Z9%NV\Q24:)XOL5CFL<,:=X,7>*>X[KT5*S8VR#@%UYV<Z&7<$J0&0\J>=
MV0_)EW("4ZZ.O#G '/G(\W)BA1"QIAH=X^VB#P*BB.[UI&2E-M8]/&W5%2^3
M9&<F,:8$C."2HY1 !9Q</XO[W 8N9!)&L=T$'$GZQ*Q '.M3O;.P^NV#)FJJ
M)8<$R?'VZ'99!;_!A/SXB+@:3PE&[J-8 7YLA4&22B\_QMP?)0-!=AY8*V%&
M["K_!7WKB[,HD45J*[-[D8+: 0<V;<'++ZP!Q;RD9-55I3P[^1316?_2?-AK
MF'FY]UA,8N;I95),1>URK1XDE@$4_ESQ1U=O_'JT%_LP$C%)4VR,]*[L='EX
M _M)^?>.&"/V6I&@[,)8 JJV;RRB:1@9\M//=G:&%U4OKV[2IG5IRYUWE^L?
M6V(]P]_IUHU,4O&@HI^RO*3"F=NZ(F5=Q224NEM"XTURO^,#DYCV'54]C%T!
M9?1/[P06[C T&L''CM=_K+0]C"P70\]/N$RUEQFEPR8HRW]ME:E)<P=N;1',
MU_11)U*">#PM-(!'B:;65Y^)-[9"<C.Q6^,ZS1/_4-MXN?:\MWF2P"A6LN4Y
M<;/MJUG^+&>LFI0/R$$8.XJS7' +P+>Y5[4\^6%_A&\"A1O=!@BBL9C&..<Y
M(M!'9VU;PL$4Y0$PYYC2:%^F4L5&])J<#:%)*2.ES*G6M*RX]WGL0;.!@+N*
ME:<"_8U'B*\X[7Q>&[7ZD$"<F8>A,@63J[PL!9">(./P3K93V?X,^+UNCL/,
M9&X I6CJN5>&(;H"53L8("3&4A-B6G,4KV13 '/?$!LL'IHN]FDA<XK3Q!?M
M@4J.*%N[;MY]9<EP\2\[, U I/A-G[+S?4GTLW-==Z6#\PH%Z'/D(6*9V"(*
M=3/WHBN%R.AN;G\%F\D(Q.B9[W%^ G0WGK;V.3ZF%]]9EE)KJ.?^_M\.;4.<
M [Y7DI@06J3LM"_RW[&?'^:11A-%FHT$SI"<0-9^4T(H/XE>M=>WVH2UR1C+
M2@56##E[3>.65FOV5"9/OOK_I.]F 7XT[YF]8[TA5G1B/P_W<-I%BBZ01A0>
MV\6710OVJGJUD0;IM3>F0"'"M78SZ>SPTF*O1'UAX=7WHSJ+N-!AJ1UAR@<>
M'<]Q=C4:GG\$8E,N:ON?DX508(F4.>N^68O7*%ULWI4FX]Q=D2Y=PHQ2^W4-
M)FOU!*%<)D4!\X (Z59(!^U!Y(<W0.T1LG7M4=:Q=,OR/'^T]WW$X5 -IVB(
MB\6GNH%'Z^+(Q&')=RZCTQC55"(#3_RIO_:ZXSBJBU=!#+>MIX46/ 0Q10*D
M]?0T:3L]E!F9ZE><OVMK##=.GCEEP1&!=M5(*BQ<NS]--(PI*9&ITXL67XC\
M7JNQ[^ZS305*/46;,Q7:!?H="S](RPB;%,8AT%-+H?%Y@R#BM4_PSLFH\$2E
MWWKS,U#4\)+0[_?+/)(SB+<HR5'O/]DQ#VZ9 C1(OBAT=4DQQD,5*HOV,2LK
M0WUD*81Q][PBOU ?_)0ZR-*6V>[BU:]/^-;8"/_;>CW5(5>^EG0=%^=XT=29
M-@P09FKKG?I:7B;'%::$O['/_5]SY#'D"N_KKX.'^#B*H-E@EUA)U-R[5I>3
M-P!RV."AH'O]&N3(\0C;P;G^^*>-60PE7O992!@RXA>SG:RM:"W#-K<\:U[,
M*!#6"<GHJ=[TA4(2\%$5:1@C19!^1ZB/[&C*QL#2HQ+*O),K,W=6ZHKI@+S2
M,#D?O<,3JDI>2=V;@*O,JV8#0>TJ:1F"+]N$J3:[#K9DR$)GF+&&-)B9 -&"
M*M6LG$=1V1XOBFF<HA_M7(B&[F-JC=;RI[) =OQ3@[+2&.X_:;G.Y=9#UC2\
M_9,M'$3=[[6Z^7B(>4B)K4B4Z!,\4>KD*.THD<:0R&J"JN_8.16!2[/Y[4$1
MR>3W)[;S^.CH?9I).'MATIY]E$LE5^OW/:60U8'M+I-E&PL9CYC"9S[;TE\R
MMAA(.&CC@(L0F=)]ZKG;EVGI Z7Z)4[3FQ>F2NM[3V,[\V[WQ0_VS^'I#9(J
MWXV"%NB"RDL,++O)P$%NG.B&.JN!7SWJ=8KB=.BH"=\KE"%=O"]"2DS4EMAF
MSORZ^",!%VN3+R5ZPLV)#TKZR.3X/1\B#=@A!<0'JA Q1D']!&66.,[YU*ML
MGOSS6H&8GAE?Y?ZEB5(!-Z@K 4&\M.Q\5M[N7T+\PS0N+3%N-ZUG_O (#LY2
M^L<6P1(1B^_^DL=47^2BS_Z30T..[RN##YF7\G:5AOLZ%:Z_'K2W+2)8.;K$
MZ5DA)#X7IR)EQ1M\%7S*#6?/7R08J)H;5M[7A6JU:HNR!$OWET9G(0I16;6O
MKVTP]L1>&V%[9HPM<^,WS=B;Q,M-+V&R8D]Z4P(\QQ!C>RZ_0'PV#$MY'4SZ
M7YNQ!0:&R)5+6;QXY%L$;HQ4R.BZ][]W323V'5!&UE.!P_^+16_.13N!3"UU
MT'# ?1"\S4V<)RFY?X2LT%+>DE:C-1D(RF:,BQ@1'RGQ]=L,RX(G=N/AQ0:Z
MP=RB9Y]Y<[#)!7\W<V(;.H";FQ=NO=;XZO2E1%,SN0C%->LHD!@^TWQVF1*H
M44^T^<)S3H-K]$?&PJEPQ+S\([W\$S?0I\X'PSU.!Z<H?MI)U[V;^K(K]&G,
M"P=4MMKV87E5%FQU7G,I;IKV![%"69 2ZXX^\G3ORO?Z\/V1P#W)CM7D@\OP
ME6145DS,W+0C^A9"UI/FA,<54ZB;T'G-[:J?4HE63-Y\\H<;0N<:8IE><TI*
M+F3*+9/"9+?/]PER+T]96!O8\W9WO$[O8#L#\Y_"@V?.U"*R'F2X+_ 24*68
MT.C*1ZM!,"7VL^"! L]"*&<FV'J"+$-!9W,NXQL2V;$DW:.V+/QCMZ#'@ESA
MB:I"V2!M&"J8K.44*SHT6=I9:FQ&/D1WWNUH6R%&;7E=@#;:+RV=*VJVWEX3
MI!XK=O@==#N:RG:;823B7XSI$.7/,A>>SA0CJFEE@X/OY89-*I]?/_ 1HL#H
M'3_K[+G?#D+SU83%5%N50#>'J$F[\>K7:DU'#>53(%)DE-=H1&%N/7C6WDG$
M.0:QN<@,* 5*F%V]QERU_V$'XJI5X/[#GW)82._#4\QMHC5$D=VKCGVP7;E@
MN6YM6!EI_!<HB1K+K,6'NNG1VW"3-\=35+0IB>Z!$X;Z\"*@$LDGK*@7XLEH
MI8!'3@]&-]??XHFK*J*IMK$R:C&*9,!I\!7I;.>.(X48 $C=QB^0Z-8H+2+[
M$@<-:2^)\NH3!UH*IA8F&A+F3^/)>O>_]QI[C)O%IM%EV"Y3,U^NO=]D<W?Y
M8MR*QUK'TZ^LJ^\2AA8W0)<WXFVM=O@&('298.V;@!O4LAL=3H]SKKJ+R.FZ
M<2+ I@>'>9QL&6<6K X.A:MQ8?8@%,A0.YP&S\JTK7U^5Y-&:S<@U-%#XGWU
MBUP%9-UR&?PT6X=2%+8NS^6^Q4'_)S]</[%W9CZ3<(.CNR7'Q@@FXWHB[9'A
MVK/I0<^^3LK*$LB]DO5DFB%6_*UMBBT5=;G>!K[Q!N";T5D(L,4-]\ZC\/WF
M0+R%?E.0("Y>[ 2$.(S,H%AO^>4.D;,>Y G*EEXS=J(]"PXJ%# 6VKQ&N;U#
M8G-2L'X#=&(Y/X=M!P:$1Y?MAFBX 8$@DC'[TGYOCE0'7BAGR^GSM\F0+)3O
M B,Y1;OQL:C67<4J=!B.YU0O/ '>;P!Z/TUSZ#J3VLC?.R7Q'3'1CB2'79O/
MPL2:C[JZ?E)3OA9EONCD87D+@J&^XI XP!A12Z58=I/D+E(H<HM3 I=8S*>!
M[:%%3OZNZM!]V#1#ZP+_(QY;%DXF98HQ]Y\#43S-L^*_?OOXVW_\,GJ\C5[B
M[\V)KJF#MM\ ) ;'\P*9T#< L57="'E2<V>7'#V([J(%TUSGMI?2;;\IOP=6
MN=UF#$Z%$E6EDMAK(0GD4 F=2M$G^$DA+8,<Y@HQ',^^%5G+7+T!&/TTO_FN
ME/K*PMJH=K[@5&]3J9]6X;LGS$$IZK.PBZY%HJ^T^7(AK-#O:3)>>3"E"53+
MT1[/R<A2Y)TLZDZ:+T>:9U"7B?\&J]N,9EY._?"^^9X4^*^M>(>5WO-?3N7D
M.V41+=QI)HKNT+$@D-TRMBOQWG< RW:M.BF@KK)9PU.(,H[YX8::84YG*JO?
M[$U%4\FHMO]7'9@1>:WS!K %86!/N#E V46')1-G%N@1><^E;>17[AM@ :Z.
M&Q_ +0X*$441\(J/%75^RE[F?\HNE(U<Q#Y$[MYNQE)C+]V_Y@Y"V#+;<9L+
M<D<SUAJOQ#/+W@ CW?FF3F\ _0-IN'2YG%BLEVJ6/_W*Z&Q!1C2]?CDR-31;
MXR>AZC? _[NAVUX:Q=?UCI/G07WA=.=\88W>](9>U0>'V^XON89VCF?J/X>-
MMN:ERZ\(^@08I&4S@6#U1X=:D2O.%R*?>[?+,H=F7^!E8H.;@D]8J\,8X3+!
MD%KX"'V7GABEN%*:-AP%8V*>)R!!/+R@6^0*[87$Z-YI3K^Z)[(YQACTA';H
MP1/RF%<K<:7R0OGCTD-^K=TAM)O>>EK\XD5^?AUXY27T4IF@V_U.9 FT ?+
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M!! 4-P<<\G&.]$=QJVM2W5Q:Z%)&-1 @D^T72(]NJC!)"[MQ.>@.!SDU<M?
MT<U\D<.OZY=//&9?M/VDR[,' *'!12>0< =.1FJMYX*U5+Z2WM=6UR-85#!8
M+I%4J2>0NWJ3G//7TH27]7)52/2WXE6[\5:M<V45J=&6V6V('G7$HEBN&7@
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MVBC\LD_.JG=B08P 21CGVK+T[3YM'L)+Z/1O#[1>:5=+5S )3CEI1M(5@.>
M0?;-=%IGA.XU^&::3Q-J$=RLA,S6,R*@[@<K]T#[O'3G)JO9:3YS2W5KXB>R
MMY7V;K@0R07X'!.#W]U([9%2NPE4LK?YF7-J.K:G-';,/"]Q9S8%M'#OD;:<
MX*ON(;CJ"H 'KQ5J)/$&@1SQPMX8TLQ1B:4&*1H8(P"!L52N?<DY''!&*FTS
M0+7S(X8M72U^V.PC.GQ10RV\A'(9LDDL >2!Z8R:M:UX=D\)K#*^L7-\TF^-
MCJ5PJXC888!\  9P1D$$XZ4:; ZBORF3I>J:]9:9/<V)T>]B)#W$]X\RNQ/3
M:J@X7G !P0.#TJ2"#6;K3)KC[)HD=M-E[AE+B2-ACA..5..<D'DXK6?Q7?)I
MPL[/2;B*Z&(WNY54V@ XWAE/SD]AQ@]2!UAO/#D$".S>*+HF,?-8QW,7E$CJ
MI0<DYZ\YS1\@]H9FO6^L7LEM_:6G^$YY;@^7;Q7)>2W<'&"=RD[^W3&.]3PW
M^M6CCRM$T^QO+.)EE5I?+LRI/,BD L5 '0@'/&<5H:7X&&LRW2G6;^Z@C8+'
M(TZN\? (*%0 H!Z=>GL:=>>"=0TZ:..'7=2E,B,7>[*2&51U0G;P.<Y&"#WH
MTV)]I';_ #.<O_!-[)/#JEQIWA]X408E>XGCF (X.TC9N!/ _(C-7M0;Q%I5
MO;KY.GVD-N=]J89)',G8B7C !![<\\5/JFF7EO;6L^I:M<?8,?);648$:1@#
M!<9+2-WQG'M5S5/!DVEZ>+H:YK]_#)@""6=?**MTR-H) [#.:.URO:[791T[
MQ1.M\UXWA_5GOW012P6T89"_=U=BHVGU.".A!-1ZM9ZGXIEG,WAVS,DD:[[>
MZU'8T"<X<M&IR2><9!&!S5W4+?4_"[HT>O6TDYBR%U"U!$<>1A%$90DYZ9))
MQS58:C</*6U+Q-I.B7L^$=1$BF=.P59')4]L\Y[4<O5?J'-;WE^I1M]'U"SL
M_MD.GZ(]H2I!A9A)>,. )6() !X&,\]:O2:UXBUS44M'T[2[*2+;,D/VQII
MPR5\PA0%4_GZ9J1+6:/36"^);=+8YQ8W$4;/P3@*VX,,GG&#ST.*DTSQA+I;
MRW365KJ)N6VW+:=>1-Y<B@#Y@Y4#(P2"<@^M%NH.;?9D<2>+/M<\:VWA^2XE
M :X1Y941%.0 A49.1GDX.:J&/7EL;JS5=-FTRW_=2)$KI<0=\ALE6&1CH"!U
M.:UX]-U/QO?23+>7^@VY !CA:+S]H&5!8;@,DD\'D<9K-ET"ZMF9QJU_9VUN
MY663[2$CF;_;)!+,?0'/.,9HBNF@1FO+H6KGQBNHQ6ZQZ-XB5[5UD&^Q*JX
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M#;0-':://?2,QENV= ]HH ^\3R#V X ]:CNG\/WJ?Z/9WFFP$[I[V"WDM1(
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ML/P=D5-7IX6F_P#MU/\ .XWQ+?>)/$,<IUOXE_$76!."'2;6G"$$]-J@ #V
MK B\$Z/?@1W5SKU[TXN=6N'!QZC<!^E;D7AV7?\ O&RHI+G[':S $885Q3QE
M>>DJDI?-GM4<KP='^%1C'TBE^ARM[\,_#MI<9CT"QD]#*AE/YL36EX=T/3;%
MP$T?3857NMJ@_7%;UUJ,*VH94W5034?MN8UCV[NX%8<SDM3T(Q4=C9L]>ATU
ML0F./_=4"NAT7Q.;]A'(W)Z$'[U<&?"KM)NWM6WHZ?V6T>3N"U5'$.E)<LM
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MWRD5#/ L,+E>.#_*K('ZTRY7?$^?3^E5S,S=(_IW_P"",'_*-CX8_P#8//\
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M.2.WIZT:;!S+:W]?>-E\-M!''NU:_@=BH,:2H/LX.>G!*Y^N#4;Z9"EPD?\
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MJP9I*]=J 3[93WG)*Z4K8267[]C??9WYQ*"AP>*7H)9)(13X\CJVJ_3)VFR
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MY- DCP=P:1%"QYHA5<);T.L9B_LT/L8M!+_L?P&!]B9HMZR+BW2C9S,'QMH
M(MSS1EVG_SD><%[TG@5 /[Y\DY!CK0.IP?-"=@6S5XSE$H7]@/L&8R5-HZKC
M\;^(L$T+5DY?+&0,V]S'ZV, J4"[IJ"H^ +J@Z@O+1JH*0&F J!VUKBI(!J(
MAC'OVJ<5"WSSFYZN6W<M#EG^Y7?_TG53;*/8Y@K_PQ[QD\N+:-<1%!6'O\%
M1S!QN>\%T "OGA!''4X=+:X3&:N!OF>Y3@&]?CZ=/ D%!J.@?R()SJ*-..!A
MYPU"!0X)X9E6<$_4("LCP U60BT&VO[#HO8A>'\+^9@$<M,C@1BS_S)W+'9
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M6=RK)0+;VJ]4O9!:""S=ZP8VND'M"DB@Y""J_\$K2KP/)^36$"L!Y\5,(%6
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M1(JZ=9>&/G8N6KTE(AYPIJ.MD#OXA%&O&,MVA"LO($M] D;3'$%;R/"E,(T
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M56I'K@XW"CRHO559/X0!3Z:0[,H6>4D5MDK#U@.<TK=4F=[SD?_<*)U,'@3
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M#T!&'=H=<* K=B"SRUOL9<+(0>KX5K'V]GNR(1OWKFFDQ86W3Y@DI6)Z&^"
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MA=Q:7!5PSX3C&WFU_V_X<K\\-OSG>?*2\Y7\&%C05JP?4U" \30"F65;WII
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M#4U-H1L&0S+W,^)?&R1SE?Y'Y@[W<R@D6IA_>8DUQ1 @E0O<A6_OT>[3_9O
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MFS+VF6X!E.2F"J;JRSYI,;"^9/]MX$W"E[X?@VXV=YSSKAY.0#[O9_*?!DN
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MV%;EC@*FL,,V?ZEK236O-DBCG9[ 8YF5?M5R01 &)Y9C>MO7#C,@7 [@Q>3
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MIW\ R;@R#@(@P:QMLRY%9I)P]Q\#3G>''__VW[_?+<%76=7E>O77']#/T0]
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M6Q@'\H$MFI:8V88M<>>V,"XXVFJU4.CXQ80;.X!\6L5XR!F^=8P+4W.WDO$
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MEP)07[4C4IO'B<?@^( QQT0<)[[F'X[C ]O).3E>"P739KW3O\BYS'@>:0N
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M!\?JV'*\R(Y;]ZBD9W/J-87(H^J<W$7W//]SAV!L0=.A:*ZU3/W=SUG&="C
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M#'6P(=_U[+,L"1L&S'9?3P"#UY;V0,!C,P](-V(?GUMYYBT\(.#Q[AVZP3M
ML#=_[>72G*S6_?C<E_2^;.BR;>6SH!K* O$4QF8J!,X3!(N8Q5 B%DL6\UQ2
MQXZ%=H0#;^O#,=J\8\-\[%Q<WG$"/K=9",YSTRRQM8X+3(Z8FP:8""R?>("3
MY.%C ';LS.WW.X%TPM=WN]\GN?C7!Y.?K%<U1D@7-_B@OV+U(E=IG#%20$(2
M;29P)"!EVF"(LY3D*%-%$4G[#.!S9 (KDXZLV1"F;,0I!?<L,)=UPW3BNFF"
M7M(;U9GVH",*/DPFMDL>Z!3B^R5K>L'@F%8Y)-U [N/9VV=,4!P2X3"+</!J
MOZJ&AI9+*?9UW*>*"GF]$C?-K:P^T$>CW?9+OIZTT\0QIS*B!622<(A%DD'*
M(P5EG&&5THQR9C6A9RJ&9K6,^E)),X^Q8ZO-+]"_K1ZT_>_<SVNRAV*C'N>%
MVM&DZGD#AY.N6_;:E.V60;#A$.RQ.+*3[ 3@NR7KS_D0?'/OO1_&=$GT4\$T
MF!,_FM"L*>Y3P?(T8WVR=;T'!+1DJO77LATXT-=[)H6*.(MCB!*9F>9)"A88
M<9@0FJ81)7$:.8X@/TDG\#NDVR_W6Z+.(P%.8F/K+H^6V$V5/Q4VS$B 2S*%
M'PEPDOK<(P$N07!B),#%RZ>(FG4&J]88_Y#EE]M&BNNOLJ)?Y$&)[L:5[@_+
M]QMIQ%S0-$,$%B(7IOHUAS3+"%12("55BG-*_$-K([D+K"'V1PO4K0^UR2HQ
M]N6WGF5 .YZ!W!27W[=<[V)/_5UC G1C'Z-/%&_&AS,FU+?J_%RO1Q*ND<KT
M.,X:.!S+\S-&%R>"^W((<BHB(57\1WE'^WK&5=M/\X$NWY5*W[%WMKK/X+MR
M)=\V\JY>T"A"<4IR&$G3'I,@!2F-"$R3+*,949(0JX/1N1B>-=QP2>%4&Q$
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MHQ":5*&&<?B*:C0*RNO*,V[)\ S;VR<UM]^:7]V7IW;/*HC*LI# _0!041%
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MCJ9_R]AS@%Q7CB.(&:8"PR0,:@Y[18ZHKK#GUINL'>P58;I]8*]]+.HNKSW
M5^:P7U?&^I*K!_V9?V\KCG[62VWF6_BR)RS&6%%1 %,Q#A O-:#*!>0K:?4>
MYU1QK[TWG)7$V_3C>O7-NLZK97UU-*]9<H--PUJ7#,+:ZR9Q(@0#KQP[-N)Q
MW_>&L\RRMNN4FOW4<O<W.- V&@1VT'7F1*#'64\3@!]Z/3H"7GWWJ$-(3'GA
M.@(4+VYFQUAQE.F_+IV\DR# M='*92]6"I?63',=;DNC0*XYHI06DJ" ]N$]
MU!*?!J=38;.:?G1&11]X/KI_1$C"U/OD: R:'!R/RDAY)Y?A2CQ7^+SDH?.%
M7ZSRFG.&SPO4,V_XPD/AONB;.IMN^]XZOGSA:O3>+=5;:Y'/-"]SS@H,"@8+
M@)A&@-&* R/R2N905Z;P2@Z]1B2U@FO(9@W=S!'.+.7,D?9W3B\BU.^ACB%W
MH!:+$3G(6^V3*<IEO;CH9'YKGUA=Y[7WLU&6QX)OK(W33J9=K>MBC/9?FW??
M]5K.-UK-#);8B#('DE5U"R$,!.0("%(0R9' A@34E/D13;Q-=_0RO2-XTVD:
M%W3D^F'H98>,CDS@1G;TG7_3TK3?I*9.ZB;;X[5G(P%&0=;)Z%C%&2GC8!9J
MH 0)WV>G^"TVI;D2)-X+JR7LV4A_S?6*UDOI\D*$ZS DM[,*<98CQ('(W=QI
MS0C@"!O N>N$KS6J2J^R_RLTTOMF!YK9EQW54 ?D##:>3M@PB8-=KT3"!OI8
MPX2.5%JAPH<[4)?%ZG>;SCP[K;-TF?D3%^G*1V-S:=_PS=?WB]5?&Y=L]J?5
M5A^6YW(X65D9*4D!8$E=!R2K>K@4!)0<ZI)B0JE 8=W'_ @'::'PQF2."3?3
MX=M<:96)Y["4S6&07M=3*8$*5%X.(^,8:+):?WIR?47FR[\ESV\-DSS]E%@_
M=J:>&AL$TIDILF'/AP=@;I6RWZZ-"^B\73WP^7+&":LD% P4!N?6>E$(4&(H
M4*PJ*H,44WZ-3<^NGMAN:>G5L<#L2T/2\QP_#T9_D&60B&%[/4RZH+#*12FB
MXBFGJTT62+DH2#>"<OE#L0?U)[VURVCUCJ^7=FON>NFQ0E0F1P3DRMB#66@%
MF& 0:"@T)TI6&M&P2I;SA%)OJT[1V%MMYG(>/,KJ D"^Q^QPL<.VVHY>IEN"
M2<KAKDN5_,B\0'[B(_(Z"*='8L_G8]SX-BBPJ_%X_G/95$+^CU8N)<\U9Y\)
MDQN(* =0&PX0DSE@LK(_E9)#4\(<E62VU/=NDWSV]>T]"'M]QUGS'3\A[_U]
MWU'+5LOLKUVP:NXFM@1%]WR ](D C(5+U-[?A>_VU&^R#OULQ\#8N(0$"T;&
M)RYT,!2GP$A"@,P]<06?E2:,,@0(=AQS"'DP.@+A@JBNH^'%,7AU'TXNN**Y
M+("2J@ (8@DXPPQ4A"EL<HDJO[*T4,*IXZ -$RZHWS-;,JK-J2>XWK&(T2&+
MN#0: :V88$20Z.F#$7[L3!V," +I3# B[/E8E=.M@KA,:1=CS[FF@E,"M$0N
M9SK'@+O)"R6198XXK@0.[/X>1#^Q NJ4[=A=I9SINZCC>V:U?F@;=XC5T[9W
MPX5=:L2^#%]-E0SB,(4U';HQ8X5C,$H_/SB(JZD'!<= =F8B<-0R48ZG=G?2
M6MU^TVM^K_=S[CZNYU+?;G_3W''AR+D$G[OM5[UNYF=^6%KJM<V^^<79@"YE
M0K(RIQ "74%A33#[]KBQ_BKC&AI:(J,I#RF0'9&WD!T<54#[_C#DT;ZMG0?K
M+D-4_8NZYWK0).$QWPSAG$/)$:@$*]RH, .$,00@S H.*<50>$747_6]Q&16
MM9QFO&&U.XO3ZMM5/7-[\Z.\):^XQ.M@'QB_V,'><IG5NZ/F,ZL9S6ZW68?5
M.COS)JNY;4<F9QU^LY;AUWHO07&1UWD_D?&3B=]3:+QE?"S[XC(C4IPR?C,^
M4"_B/ D(Q#IG'^V7^2O?6,NHO8?FBPZ5VD.<F[GE=?-A^4UOML=9%5 86AA&
M 6&*VI.0&7>W+( RE82HH%Q1&1!$'XFM:4+LM]*^DTW=YLV=?@]\_4_K<+CR
MP(V63^NH9)9A;\/76TL/;M0YMV.KGO*]8\PZ;WO.;C*YYRWC&_NGEKM$&3&C
MX)3<@QO&Y<0>W2B0GGIXXRP;U2G V;@[\K?W:UWK;:M.'F9$H)(H:8#"SDVH
M6 68Z_2&J"Z%K!0DU"M9H(]0ZF2!':W,/NPYI*(7&Q_C?!R)PW1033/;:Z(]
MU9OL\WC"!]71CP)"9)5\'!BAE>^]$O;5M5]>8,JJ]5XQ7M2D]W\^^HYO5U#6
MJL)F_,[M-SY?./O$K-8;OM S6)BJ$CD$98E=\")'@"FA0*641IJ(*N>![<+]
M""?65[^-88AY0NA]DS<Z,($W>6T=Y\&LXC4'&=^Q "P/P#$QZBU>D-CI;_'\
MV)GZ%B\(I#.W>&'/QRJ5=]_=54E]@-R9/^;W2VM02>N#OJDG?EF[RE5,N !Z
M2W^I=K_HM-K=+>(Z<O$<<4)A#B@2E36/H&M61BC06G&M%#4H1V'J9VP64R<C
MM,3W+:V?,\'M)V2XNAK]Y?@JMM>$/$P%=CBMI[8>>,V:H77.G\SD[IWL].-2
M'7[7;3W^9>MZ (F1>@"E!S2Y<AV=\8G5<"K@3Q5V,DHQ_NN?2[G@\P>M_I!S
M>XHX5C[IC;:K?'6WH]\?]7I>>PZ+M_J;7JSJN]*Z89*JNP;O$K^A*IC]/P2(
M]78!@J4&C%<5( 9"BHH<<A70]&XDKA(K\#V7V6;/9K9N^6QR"CJ<9NK :OV'
M':\A7N58KPL)4?$B5R"'QETN%Q!PY5HP8\F4)+#,2Q9RN?P*+RRR,W/8BWJ-
M=^,3&WD%O,..V\/>Z$"^8S&S/&9=)K,.EUF7S:@^^6.]B) XS2N\D+B@SF0O
M)C ,-#* /3&CL:A-&& :&:#C:-38BT?GBG;&6;7SHY_V0\IUI2NIJ0$\EP2@
MDI> LE*!4JJJ8%SAO"IWMXV^/N,U@A'WB&&G49=X8Q)L/!L4>2)6,E+J'&&@
M.+/'?(YRP# 20$%-RM(42DOM=\R/B-B0\_L(,9"M=Z/>+0>MRS8J?KYN\%B8
MA)VQ7:HW05C$I*]ZB)@^6_4:$U,GIWH <B87U>>I&$?N]R>G@.]V[9$V=T_;
MS=::MO/E_:?58O%^M?Z+K]6,(6%*RBC O,0 48S=+#X"-)&D9 74%:K\_30_
MHHG=L(:)3J.N3=;A(\1P],30QT ?'YDPW=""<G<>E.R+8R)KN0@RKCTQ"K&=
MQ\<JSC2^CME8AFZ8M#UVK.=B$YJI8>(=6Z&!SXY1D'0G_EN[3!"]^;A:S.MF
M3TOU<;V2VI5&68J_\26_MPRT\UNZ07("#6&:*1?D0JZSB@'40&[M4<@8,27$
M,+ ;Q$B<I;ZX:*<-';@-M[I&>@7>!MKTP ;:<D>E2ZL]BS?98\MD':=ZW+%9
M=\U^:!G=#QE+=2LQ,GR35C4-X?<5ZYU&@/EZ)=08!&(,U2:5^?9I^W6U=J7M
M,\(+1*64@&-HW?JJTH!*1@ 51LF"Z0HK[&^2OEP^L2[\V65&_?%5+TPGVR3C
M>_(AIM4),CZ&YA!Y V]0FQ*%VW%D"S$0A\@89PKZRQIH_5T2I<?..WEL0HON
M$LO'MMO%3\5::9TF574)A!O=LM9?]7)C=58SNZ6-TTM("VG* D"#M/5II0%,
M8@0$+6!942DD"BP9]Z:=.O>VTZBKJ1,ZXJ2=5A1J?/DCZVM>)<$K3#MUH5K5
M4,DCJ-KQ9"G:?@5+G]S^\>=H8@LG&*I3&R9\B1@KY:A.G'?KQ)?+)W<+T@GC
MN>D=>6&@@A4#1I6TN9M@J,I!*2!4FG.%3$#^0R#UU%JH)IJI;NQ][3WT) Y/
M'],G(4IANN?COIW$QWT[B3TS-UF+W]'=Q:?$^(685PEQC+.^QL8ST$:+Q*/'
MA M==4(++U+@8P,P=I$QHGA-X-#ZKR]*:S]IUPW6^;!M!IUEY->Y<=[O(;18
M5V+<-<T+NK$E6A##.>) EZ0"J$ 0,(X(4,;D5")-9>4U]F$ZEA.? ]VIF7^]
M[ 6QWO&]SY=U>W1A.:^W[ZIS^;#9KN0_]^TBQ/-^4D_VZ"J@A\02DWP18H*,
MK_UZAT0?E\T]B'MM(:_9Q2V[;[FN'MN]Y2DBDRDQGS1DF4205XQEIGPQUX.<
M22F/<7+5--H(J\NX6G^KX[!'31^LJM:;[='1I&0IF3V+2EDH@*2J &6< "E@
M+DLC#=<F_FB*XBGUV5-KDY:I(2=$'. Q1T!R&(?H^$8[M_=&-W4RM..O.:OK
M\(EN0J#SEL=)-/@@R"95T7&<OJ(.'@3M=24[;.F8Z,ROFF_T[ZOM?^GMF]6#
M=3)DW<+E8<9-02C)"\#R4@)$7/=04QB "Z2)U9B&AK1FNT0FL:ZKR6;+U39[
MUEL7QFPHWP0W8+@(DT]T90SAPS14([<EF5F:V9N#W*&]%R[*'1(5&4/^N/!'
M' Z!08X^\7JB&1<?GS!LT2?"<7RB]]/1+;3<G;E6]4BGW1C*0P[3#%,*:25*
MP,H* :1<"T^"2U!!R$I3(I63P#KGZP03*Z<=\68\V=YS=R&!7=+<3U9UZ8QY
M=G[T!M+7!AL/GN H< \RHS:G\I(R??>IZVQ,W5[*"Y0S_:/\G@O3$+)NS""?
M9^_^_#2S>S]GSA(AJ!+6,'$%EQ()P#'7FA02$Z%]M$!WT<0[_=W3>N6WA8\D
MO;Y-8_D/VXJ.]:RY!;3GYY-U\><NE>ZJ1-Y[\)P(5\:J[3[>S%;;_>LP8.UH
MN4GVRSD!=GOB[-\B1RE+[6(K3:7#YI]N.ANLYU^@'&&>EPP0J'/7-5*[>?,*
M&%QJGFM3&1Q@I%\FE'A_'!'.'.5ZDA_,OMSZ#P_I!<O'5!\'@K M-HWT@1.7
M1T A>NQR%!KATY=[1.P?P7QI@6GG,/>(<3*,N>_S\06GZDENYV*A/^N'Q]6:
MKY_?SHW13@G66;#_^#J77W]?O=7V=VOK,?#O=;'6A\TG+5?W2S=R?I931&$!
M$2BT8 !155F%!ADH&-18ZAQR$CJS9 2V$JN_/Y?KAI0;#J9:/C)K5#;%A^%U
MF".\".\P[<3P!D9J]]QEVQU[F3KP5^?^_^4XS):K,]!G\TVVWO,Y;A'H>+A-
M4"PZ K.3%Y6.!_"YXM,15Q_02,[5N=>N5AT<M@2V"ZWJ*++@EL1'_ESWPK3.
MU\9U=EXM-Q^6-6N_K%9J<[?^0Z^_S2W'EBL]_^:FXZG?5]O_?.*+N7FV8K3<
MNB=O-VTI-RV*DN4( D5S[-K-:4")-3^MQM9((04)*8/;S;V"(,F-V@<G56/'
M[.:NM*T)=I$="(-#.Z_TTGW/@Q__50;ZOXT\;22JE@BT(C4W?Z 6*GMLI,JV
M';%&[F;WBKA.T?/N-<2;OC/>*[[$L_WS7I.?Z'.OG6_]4:]K3O=#]H2&FB/A
MBE8$ @A39']B!F!48 HUTQA[U;_UDTH=,-S-5M\/?QHPJ/ B7-XZ?000 K5N
ME/PQ:K5'M/2*[Q(#4ZNF'B#.*(^^)Z*'0&S^7-K/?WP2B[F\<T:U)=.641%>
MD5Q1"$P)2X"H$$! A$!90 ()%B1'H9,@+E-+??]7D\Q6+<W@D0A78/()=8XH
M?-CF;@AG->6L!6%'.ZI+81\:P5,BQD%EP*B("^B,.BBB7TB?:1%75IEZ9$2_
M0&?F1G@\%#T\PCJ 3]LF<:LNWVB_CH)33(6QFHN5$*"B4(!Q+-U$^()(494F
M5X'3(LY3FL#!=50/\WZ#9T-<0(@:*DU9"H"0ZV.0(PXXT1I4+*]R:5A.*AG:
M;&\$C*+Z[.U1>C<V2K[FVPB2AUYHO?QB)"D6[I$K_1","_2GGGIQ'88S8RYZ
M'HC5=[4^_;#9/.E/NBXJ?K/:;&?$&&/W+74)]LSN98Z **SMQHJ\*DJ.%.0P
M:K#A67)>7^K! PN;%/JYHYU)2W4?SLN#PWGG0:-(L8I0Z\CFQ+B!0@5@!E&
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MT@M<?%5-O+1A2N1=._@ZR4"I\T(DW_$OR$Z\E\\+?;I++WPNIF"O:^B\DP[
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M$2208F%J(H*+Q-KCSY>E9*%*(@987]V1&*XPE7*"5-TZZB_'4+9<9:IEJ?Y
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MOQ[S_+PJ6_;#\#('$Y]L5Z$X/::N/S*L'VUWG<Q?VQ'$3R#3OD^'T@3PDC.
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MSU.?6,WV0G"J9/L_/MZ5J9_F]DJQ8F4)A-;4H"R]"I'$ *ZY! ()+;4PW/D
M0R](7>4BLWKV<7GEM]#",3+\(LUU4$/<^PF@2K'*SER*\3R-6U.;BNOPZTBC
MXCORY:.!.(]RSR@8GZ1;1==7O_D=HF  0FX,A2^6HO)?#6TW#\NYG2O1]OW\
M8-W?G:ITIM+;9IS[:OW2&K*NH.:DM$ II^\)8P3(&E5 <E,S(V )<42SF&0^
MIDL4?K#%*\[\CW:\-0VK]MR%3&\?]6V$G!:38)R<*/Q+PQMS:$P"<]JQD1'N
MR)-C,$A7SH[T]2<\/0:#<'Q^#%]NQ#[-[Y?/9K,]:KHZ$Y9""&4)9.7#,\0H
M(!6WP$""*HDQL4+'58R'$8XZ(^*+R)NFPX_KU?-<._] ^LD7'0L'O89':-1\
M#M+0@,/X0,4I^LN-F:/ &J<;<X_DM^C"?(Z=VW=?[@$IJ.MRW_/)]S>:WA9O
M5IOM+IMK*"42E00@J*!3*;H&LC046$V9MI6Q)4&1%S5>TYCB1D8Q]T0+Y:E&
M9[Y/0 DQ!@>+&K?_6RD;>D5#,#W1?R)N=$9_B-@#4O=QXJ=DZB\)%I*2/WEV
MZMS[)>;/)-DO?C35@/EMZ<^CS^)/WXEC?U6$0J0X5S6@F E A*B 4-0K%Z(J
M4FM#363;]K-T,BN87U9+L.O-M&C(QMHBY]$)-3T&RQRG:5IROJ=-)VV6AE2]
M0F4W(LY3G]AFZ(7@U$3H_WB*1=#=K=DEF+_=/_C.'/_/:.\(^8$U,XHJ 4T%
M@2:U L0R QB!;C_72AOI? Y-(^IKKM++O)$[>F(W\$EW9 OWSZY(>],:$E&!
M].LPAM@3HX(3F=WL[K_M:=\5>^K%CORXB,28'*,BDV9^#$,HTA()EO>*57)]
MG0DME&"ACJV5\,>26V=V33K?-]WK/BR])^8'P[L_?,+@62Q\JF"&-<%<4 @P
MKYTI0QD'7!'I=2(2')4<5['=-(,(9U:)^^ZR;?.^NV(9VLT\&L%0<V=\7.*T
MX2M(_.&@?/#%1W2;OY@7+D9MT1DE=_ZNG6'L3-W(,PJD,[T]XYY/52KWB\5/
MOFIW<U"=\^]SLW9+??W6F?]$E$III0!2)0*D%A:(BAA0$\@UE4*;V/Z\ 51S
M6U@+YR(U++RJ6_NZ8R-6N80@&:I91L8G3JU<AR:+GQ4A<W:5$L++Q/HD IY3
M91+S<'IF:+W^YH/ #][:.>C;<3A2J[6*-NW?E_K]PZ-CIVF-LM0_KIV[^&J5
M/^>;&=2&(DD-L)1!0+0A0"HJ@3'.N('$2LEH[*S//*QFUED[@H5H*-[Y.< '
MS5$.)]*) ^8;>V"^9[_YYQ<O@#,2CA8L?A=.B.B*YVPO/CSC=?O7&9LCN^V;
M3$JNY05Y@G1<)@$F3^#E?1'G4GZ9*8[1^>*S63]LO(&\6NJY9\*==4T&09YO
MP/73OO4"0IP+45K K:^CJ[ !O-0(0(T9ES5$6@X8LIC,UW37W9R5M_5<MH[C
MGL]]/0IH6"T>N_9VXH79T3IEI+^]T$-B\G<2=R),^#H&=M88#-ZDC3;2N;UA
MWXW!$/>WX1B^?*K";BM7/IJ-63\;_6ZU;M*[38N*#X\-)RU;S5VUC?O])[$P
M'7.;F22<(%S6P/HY;@1+ YBQ[@L@"*G=?ZQ!D4G:0?SDMO:/"MG6'8]^PF63
M^6FF&7XWWWT@NJIMV*L(U;J3 1RG;7]Y77!Y J\IGIK&*:N6RYTN;OEL/K5Q
MG+ZL,*:V'06T[%IV&)<3:]=1(#W5JN,LFY(1_]$LS5HLW/+W^F&^G/OKO;[I
M1-=4;G^=G6AC:P(UJ,N2 L*1!0(A#)!2=46YJA@)JIB.HII9,W9<-'M2'/&1
MU'4R%,J0W'@&@.(TVPX;QT%QS,*N86-B144H2C'Y\@QHI67-KZ,V5LH\4N0K
MB?/0U29,GT<*>)Q$CWTX17.V"34_TZ<U;E=MW01J0HZ($T%$19QUB9R):60%
M9*4PH-P/V3$6VCI"7?:1RIXN;U+">]K%GKC;_^%1W@#(0M3B6$#$YL>GPB!&
MZ8V%19JF2\<D4M&%B'E%N_4N,:%*"Q'E6(\%/9&<LM?_];39-G7!WN)<JK5Q
M?OM;T_[Y?NDG"ABG0IM28N?-^_DZFUDME:YK@IW+7/OY89H"B;0 BE34>=+,
M:!S9.B>)C]QI?=7<M=KXZ)BGU]J(2JV?FGX.R4VSTC /3O?G1C+R L +.ZT_
MW#%4?*<[EGPM5S,1J 5XU30AZ" ?U14>A$S^:P))W$U]<6 (A&>N$@Q:+L5@
M\[<5VK328K'ZP\>]WAIKUNOFBGDS0^PU%VV*"<UJHQ45PGF[4/OI)YP (:T
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M6EODMI5W<LJ'H 1P'^ML &,@,(5@M7<2M5!&RV<E]-PJ1YG^Y5=?#Z=7;_+
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MAM##,_<%N2EZ1S=_[\6[3DN?"F5MZ**O4'OU_>MP^8S[LJSN%5?<8<A.,U_
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M+Z]'D]_O)M'EH),,)0,ASQ!60H3H1 2;-"J1L=@66V9LH_3("_:;+_/ES5Y
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MWZ:3V>S!5Q;U/\@YUU( .AZJQ>;@E+!0K)2)O 0K8F[O+#T1EUT?QNW%J'V
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MB0206*:,A$T&G+[8WOSDJV?7P._U%[V7J#S[ZL"WVV$J6KC*N"HEJ!)K^[
M2J0$J#F"5[ZD0KI(=Q[L=('%))AL*5'2H>&.T\FT#'P@'1QXP))$,8GY-E,/
M+[V8Y!C<]5),<HRHF_!F/]+?7+W=\#;@*J=MF>2;JF,^K<G<Y*P[F;7V0H!E
MM2Y'%Z),L@+<,_+"E)5A=ZS(@"#NNNN+2F(\ 4'/(#N(.)L ZD&2MMGLR+(S
M2$1M&BT;Y8EMUD+"&*STPD8W'D8[;'AJ> Z#EF>@[%MTD_LIFV2^=W?A>A;?
M%MH 6<I;.H*E*T<)54?#$AVVTJ$0P3GA68HN2,8Z6CHOKS(U;GH7Z&( [C:"
MDC_(]EZ^_2LOWUQ?+V[72O]+E=1] 0XBT]Q;D(&<+*4U@\!D AM0,;H'I//I
M*+P<7F_J]+<QD-,CQQO!T-.S\,S_>^CR@[5;=V2@BEL/:M?DJRL.@OM@4@HR
M%3Q#][RT[M3=E,;71KU(H FKZJ%$];%SM;[RM;665"V"M%F#8FC!:?J1M%7.
M%)EQ-T%WC&+RW6U.K<]&-_#[$5B[V-L>).84CS(+<%YD4"IF<*4FUBLCB6\L
MI1%'IA[8Z-266$]PZ :S$V33!-#6:9_I*1$<D4MT!;P3I*Y=(DU-IB3XVJG,
M8HBIC#?X><\&FP36*0#8GX1[AC2:@-2+K1V2TT9QH2$:3\>N\)J;@ DB,B3G
M)&+<?;1MM0?+@!;;=+?F.>)J GC/^T&@2$Q:'0&KCE?6:/!UG'640BO#:K'I
MB)-7+Z8'RU&2[]"#Y1@Q-(&DG4X@/%L7M%=D(&AR73SCX#D*0,,C$\9INYN1
M\1_<@^4H8;_6@^48SC>!G-_R7_EZ]4AU_]<L+VE/GS>3 J)/J(A#H$T@\\ (
M#RB,@EQXB5X71O\;3R$=W.O4$P%'OPA[%%T34'QS??TR2?<]M26JPE2&%#C2
M8;6\/@(7("?(<*:*)EMV-#QVV/#DZJY'C#P?!-*SP)I X9HB>8 B%%(GSY"L
M"\*%*L:!9]I JNE3DGQQ%L8;;/3:;J?&7^\0V:\%^Y)7$PC\<7'S93&O >_[
M\M;U60W$G5C[BP1;ZN#70A9+;31HC.12I,AMB:/A;O\>IQZL.KXO>KZHFH#<
M9N_W-FR42=>-V_74].(9H(H1-#+G>?)%A/'":8]W-K4RZT/:SR!T,NN; ,Z^
M *#G/+I82ZB]<*3/70:O@@+)(VE?GK@<L4%'@^'8TR7>*?YZ#/NG?Q/':]+5
M'VX7\<_U62K%&I<Y.<Q<UD?74)-"2@$7,V,N,>&[/WL__?34TYE'NIO.9VM+
MF/AI<8.S^96VTEI4#IRO\3T7$WBG/# A'/DOF4?>M;WALX]/F1%]EIA>$O@)
M/)M>Y,<D9@CG1)TZ!%H@*3B=6,T!KV.V-%HDIA76M=U8[ZDQPP/E%/&>G@1S
M#*^;,$A.[,G&,%@3>89<7*I]_P*$8.E6=N2*RLQ*U(V6=?QV5$?IWFN^)W2^
M1A#UY(IQMYSOS3QMSN_CNKX<C"0S+]<,N%PG M*U(1+2W>&Y8I9)CEWS3KNL
M-[7]/(;<#]94GBV$R6'U;KF(.:=U*X]M([4_YK/;U7H.VI43&;7A=:BN)E*X
MHS_1;4,.13V04L80NYI;!Q>ZJ(2_/H#4']LG1]#F &S\SW5U^KN\7/^.7QE1
MP[=UY*D6](-[!3XG!]QC$);,$Y,[6^LOKG)1:2]]8*<GAD\.G!\7-S>+^=8(
MS<N*_RLO/3+F WA!VU;)%4#!#9CB.7-&LIBZ=I#8\_F+>ACN RKGLGAZC-1$
MGX?[]NWR_>S3Y]O[6_A#CG4V*/'J1[R^SNF'KS]C_/ST[_*K(KU0EF7P18I:
M+<S !<XA11V2]I$ET;5VZ_S=7-2[2"\('%> DP-V;[L69XO64@70"77U;@(=
M.7+YI"F(WGL3.YM1)_?%:26@V0>HSF;RY##Y^=]?9LNUB-ZMNX6]+4\:'JQN
MEW?K0J>_53IS^G6CPW_87PY%*IWIQ.NY<#5Q+3%)SH:TP"5Y&R[ZQ$WHB*]>
M-W91@8@^@#F=6"=']'Y"#U/XD<"X^KRX3A^76%WGS4$NA:%3E=\EL-IX.4)P
MKE;U(6;-4Q1>=D1S;YOJA&3W'2%Y&G%>-HI_7,Q79-'4J/F6 S_AU]45ETGE
M9#2@,61PYSH82'$$J8DOZT)5T_7V'V![G9#M_Q^R>Q/Q16+\38SY.B_7O>IW
M3OF: <PZ*12W4.O$0#E+5U4)"42,VG"="]EC V+\E>UUBU.S_W"0]RGCBP3Y
M-^MM<Z@S=X)C "ZPMI2($K#4M\^ 15N3@U1^0$P_W4TW"']/;RTC2[")-^NG
MHVR\<L5@)C\64\U7KGWNI',0T*9H##D$=KS&5\>/%N+?QX--'])I9,CV[K"2
M*Z&SB:IF"#I&QR+65TKF A2>C8O.53I&0]CN[KJ![/MXV>E)1I-?NUT&*SG.
M3*[UD)%Y.CA99W")S IE>+"*65UBUWNUKW%6_'MZ].E;!HT-MUK1]VZN7(PN
M:HE@DUD?#0X8Z@_''5<\2S)'CP/1^KO=T/(]/="<S-7+ZPO^X>[F!I=?%^4-
M7>0WZ^YQJS_(CIS-R=3\X1KCGQ\B.3UYM>DL5\-7M4GA(N7KLEC>,ZK7IN+]
M;FG@CN0#\J^%=N:$=)N=S,!,B:"X4>!$5I"#,1+I7&76-89Q@>W,2_:QY((@
M/:O-8)4$GRH?,N>.V6BS&*^H\#^JG?DQN.NEG?DQHF["+7ZQW8MSEGE'O#(^
M"U#,U/X:VH(SS+D4D'RQ$2MAS^G+U$KDY@2$=._+=(RXF@#>\QXQCA>4(AG0
MRA()#@/M7CO(-C.OM9%9CUCS?S%]F8Z2?(>^3,>(H0DD[78'BB)Y7PL<(O>@
MBK004' Z;T:J:.@+WHT&H];[,ATE[%?[,AW!^4;"=B?ZA$&8))5&,B36;*M*
M7.D I3AR[\C-$W&\CDT#5C*U$F;NX^H<0=33QPASS>O,Z0V=$OR4UQ;S.E7D
M8*[4%0IT"GD"RZ,%)3UI :?R^C+1(6>A;=<DM]-V,+5B' ,;BY$%-3D8W\]6
M?_ZRS/G>*WN/MZ^0QY,.FM,%8DJ=YVYDS<\C&J/#[!-Z7437R./1BU^4/NP#
M@L.*9W+T[2?EMUEYA<C:R$I[RVI3#_K!K ?/E:Z#?+0(THOLNA:^G[B%"ZVZ
M.AV)8XAJ<CS^_.\O.=*N_[&X)EG6QZ/#Q.5@2D0I:U=34O!)&$!;"C&VJ)IP
MSR07'7%XY-(76LIU.OZ&%$TSN/MI]M<LY7EZ4ZO58I7HIU>.5Q39<H\,;.)T
MO'B@XV5U!BD-*P:3D+EKFZ"3-W&A15WG8W%8<4V.RAW[]X&U:QOXS>TC#O_T
MJEF2K8X6/4*PC)Q!%P1= ZF +DR):+G0O&MGAAZW=:&58[VY-*.)M,=(TE#/
MY8]?KC[$SSG=7>^\9YWS\MW]Z_T^8I](50OOT>3 H ]T>9=89X^E.CDEDSLC
MZRPRK1EWKNO5UM)[]-X9-)O8F1!6>Q$1>- *E#(*@M >DN%,")V5+.,EO';;
M\P6_.Q^#K\.1RIY$VL1#3>?IN=Z;(CE9,39G28X=F=H>I0=C34;2_H%%,QI8
M+W%T=E^H.7U<]C$B; *<G89B<@Q2\@"1W#^H,[W "R[!U&IBIJ+4.%[3W>]I
M7/91:#EM7/81HIO<.WHTEG?=CG*;]'>-]R-YH[>HO'.0M0B@HDG@5.9@/$=K
MT0K/34?[Y;6UIL90[\)]:0#R^9QN"3>_SFO08/97?O,O7*9'!(6"0F:1(7-#
MKI45'%SUM'+BT6J.T7-W/'1>6F[J5Y71T-,+OYNX"%]HP)\<(O?KL2%8ZN,[
M@V#H!U,Y^(()91G/)CMC,L9(3WB#66 ]B*<)F#UIT&^E%:I.=,O)RFT[%J8M
M8"$^D>*-ST)X_]G3,(Z2]N%I&,>PO@G@[!O'8'147&8+HM270"'KJ-WH@7G#
MF(U)E]V2I?_@:1A'2;S3-(QCV#^]D;0S#\ %8X5E]0VO-C>3O #&@& TCRJ(
M9+MW^#IE&L9(#_D]WT?GL[(E'&S;_6<IE<V>P"OK4!<D?]31H0#AE%(EH\N=
M.Z0V/0'C*#&],@'C&)Y-+_)O]OJ;V]O/^0:7?^;;-Y^6>>T0?)OMHU@ASO@B
MB3VJQ-HECM1E#+98450VKS_*'+%@(] X1: O>4,]<;<1P'0<XR&M+(X\1]"U
M+[3R+ -*#'3 )*KDG)6=FY'U/C*E=Z]G*/@,P.M)2PU>IFU+"<O:Q2@T9"X1
M%",K*LBHP0:F!,_<Z]"U)>/+JTQCB8R#D1/XV(0?\ZIU]MM#4H:7P0@D8H26
ME6$L !))D)G@18C,BAHO]M)]WRTE$@X6CQE(C&U<?5L2-DW%-X?OX8W;I9)M
M5@@ILVI%(IUG3 58$&B*0\=XUYK^U]::VGT>2L;/=5M?#&]"PSWTHG\T5>-*
M6/(O@BQ@N%[;?S5TQ0589;527"KFQDM$V;?#2<WQ7C'P3%>=+9"38?5EW;/[
MPRTN;WO034^ZQ6V((;_"VR*M K9NTV,P06"U2$I%*01R84/7NHT]GY_4R!X"
M%/TPLETUHWGR)BD)M4<PJ"1K?#,[,"@02W0,E6U?S0QEDD^@9HX1R)EJYN=Y
MZMD >G-36[L]L(=[$TPI#D+A1)#4=9HB6Y>"%!:Q8(CZ!-/GZ2K-OV;V;?2<
MP>0F]-"V>2F*Y&/P&:)-GG8;/3B% 1(3SJ/3)DH^FN8YIJ?L\+KF' F_\(IY
M%+LG-U]>:GCK2->JS P$23]4KK5E/@@@-4Q')TL3^7B3<8]O1SR"X=,K=$YG
M?B-M2]:<65/Q/E_71J _+E:W5U;E.@C5 6>E,H4N6ZP_+%-"HW Q\_%:=NW=
M8BM&3Z]H.E\8Y[:![?<"$[62/Y@ W&DDLU]PP(06>.!87"$#4(SGH1^AA7J/
M)(YS@1W#[EX-X^FJW7Y9+&[G]/\ZJ^'K"<N,7?]VF,X6"N&8<J5PE!"]H+O/
M1++<,_W)H749O;76='U]NI!".&,L3\5'*-QR\E7JX(K(/$2G>+122V[&,[6^
M^T*X8_!U<B'<,2*=_EUE-QDGEQ*TSB"24'2'" _>.[(3(I/.8+!%=\XV.2']
M;/J"M*.D=SC][ A6MH2#[;-X4:$DEFM[^5HTZKR$X"LA6)*7EED13D!"@^EG
MQXCIE?2S8W@VN<C?D*38DRRICY_SWY]F2=4YXKE&&FX?<EV\-MZ+S"$Q&4$5
MG\#5+EQ6\U"DS)FEKK@X;0>-@.<4D2]&YG\3&./'T^@$JBA*ID,8>9U.(6H-
M5(2 02CC:I95U]RUTW;05A;;>1@;F/]-8$P<3Z/6.F%*'I*+Y.B*HBI[R>^5
MS.G 8BBJ:^7A:3MH*PON/(P-S/\F'E1>;'DN42KNZA.U<*21C='@9'#@='(A
M^6)UVBG9:'4VP?35B*>8WSV+J FP/>^-'EU SB2"3JPV<0D1D*,CBD@9BVB5
MS>.A['+F$1PE^0[S"(X10Q-(VNF*GVWT-B@',GE/_"!#$DURI.PQFF*"=7Z\
M<'KK\PB.$O9K\PB.X7P3R.G<+X5EQETL!CQBG2R8<JW>Y&"+,U(FPX4?3S7U
MVB!I^G+(\R[$0438!#B[M-*@\ZJ=).M2I*1!Y<+IL!4+J)Q2:%W@8CQ<?D\-
MDHY"RTD-DHX1W>0>Z($ZH*@8#TK0QH6JZ:N2@\\E@65&%Y],"J)K:\<SZZDF
M;HITE$"[5ED=P]W)45*;9^3Y:BV77=. )T&*/@.+I8ZOI_/DHK;@B8JB=)82
MNV9POKS*U![@L"CIB;M-W&TOM%E1(1:Z]0M8$9#0SC3XH Q$HDB0G1H<7D3/
MH^EK[,Z,,IPOGB9@]J0-BRE>Z" $Z11R492V!8+P)/A: A\U8R6/EZUW 3V/
MCI+VX9Y'Q["^">#L:[J3BT@J) L%Z2 I[@L@UIBNPY)LE"G)\2I<6N]Y=)3$
M._4\.H;]36!H.V,LW\SN;NY?!!A70H:X>817QC((23@2;RE)*6XTCC<J\_G^
MIK:?>D30F<QO D!'% 0YEPO+24#DHDYFJL5>$1E@MB&0*1BR&&^4;\\-"T::
M-C.8,360&"?W]C9'[&X9/Y/'\_ .NLG8OLK!ZXQ* %^?WI))44<?@%L9O6'9
MZ-V.\H>C B^L,_6=-Y1LGX<'^F!THY#YF)<W5^2_<N&R )^P3I@-Q!D5,W'+
M:1FL+B4>U99G[RI37W 3PN5H)D\.EGVU\H%[5Q0K!&^;00EFP&N4X*5DWG);
MQV)V1,FI30>F?##I Q[GLG5R7+Q;+F+.:?4+<7!+3$V^6?UMN5BMKK3(-H8Z
M,[6&UA33 M Z!*Z<R(QG*7A7A!Q<J/DX4!]8Z8_5DZ/F<6^$]82T=]LF#/PJ
M8BPF9 M1U$X)T3H(B!I2D<$$Y]6S O)77C#VK=*\J=O;U7,^DYOPOO9@_^TR
MS>:XO->:E@DA7$F@G*;;%&4$-$5"<%I%E;"P,IXW_^IV6YJ/.   AQ)<&XIK
MM]KYQ\7-S6RU(N&MKHS2G-L20)"72B1E \@9!TW'*QL9F,KL&/5U8*U.&+(7
MBZ$!&-Z$*MM?,"\M.E="!,V5J1S"F@^-D(O@46(TGHT7SSZ]>X&[6+CU*:#)
MU=2:/V_+]F'Z[?)]'4Y[WYCJ_KGZYW_G99RMZL!966O/2@0IR1)0C'YX6ZIA
M$*-A5I/YV+7^Y;B5.V'*7RRF!A=&&T!;W%.QV-#VG";C>8YU2#S&6D06B!P7
M108Z4S($R;GIW"VUVXK=0I'L>T!6O]R?'%'W!F-EZI:4>TI6_$K8$&4@WS8[
MNN,5UQP"]PHLRP%),7N[^V;W:D!A[T+=\'/IL>S^>#TY;';UZ9MYVO@7;^]N
M5[<X)Y?CTY5"RZ1$A*BD!U6?'T,V"J0W6AJ7"K*N75*[K-<-1)<>X>Z=\Y-C
M:4]0]I[(ZGDLYEO/E5AB41:ZGXT2H%3(@-XPX$E:KX0A#Z3K*TG');LAZCL,
MBI_-_Y9!=7]RK@HK/J*-4!@Q2DG)@<X%ARP(+LY9-*%K[+/#<MW =.E1\[[Y
MWD0,X6D+1U2&$& ]I)!9S8C0Y#$$!.$,CPQ+46:\T.?Q_3/YY0;:^Y!((TTU
MMX?AOBCQZQ7YH$%9DT#EFJ$E+(+/AH.P,G!3&)F!XT6D=G?7#5C?0P#]++DT
MH:SNU>VO\]7M\FY=?O&D:=K#;_]6":TS&82-K"0#SCNB, 0/(7$+O%:M!EXP
MF_$*#X[=?3=D7FY8?B2Y3FZOK3EV;R%L'E$_TI]7&*LL:TAX=25](=Q$5DO\
M+2A="<K6@$:/W*.7K!S5"?_P<MV0=;D1^&'XWH0*_/G?M5@LUT?09V5ICZA;
M_7-V^_D=+FM+@/51^O@9YS_??+E>?,WD[Q1C.2],02@V$-E:UQ2/2#SVM15O
MJK[U:'JQ%Y*Z0?IR'P"F1$"+&O3ME[PD\<X_;=EQ)067IA KM3:%#&5#SKPK
M%DSR3C/)O7%'/9<?7JY;QNFEOPKTS??>@#1HR^T?ZH%Z7)7[>^5 G9IZ=IOM
MUS\]0&OM(^GIN9WV%I4_O-25X;[#L3%&I'K_&J_I)LXY@E/*@LQ6!$G0-;+K
M>\S1B_=;TU-3LFOL^L?%/,W6JOAP9XI-,4K,7#..!8I'1_1[!9YA!G3!<$[L
M""Z-=B6?34X;K;:'P-[A0J#A9=^$%?J^[G]=36R,]\QJ7SM"Z4V7LJ!5!,&3
M,AQSU&4\V#YLJZ7ZH1$@\0R2I\FG'6@]M#%#QEUR"%K4E#P='"#F0)+G10D4
MSF8<%UV--#PZ4<#[@7(*MYO R@^+V]O%S=NRIN*^$8L06A0EP:R)8$&#5^CI
M3Z5$M!Y+DJ-!9L\&FT#.21)_!IYSV=\$ACXNOCRE(!2>/$H.J=011$84<-I*
MB"*IVH['R1%USN[NIJYT[!$]9S&^#>AT[3KG/;%%!H2D!5$6Z!X/41;(P=#_
M4?'"\WBM2WMM,SE2RM$4-M0@TFT"MUWZF5DTGMQJ0]J;<U#)<G"".W"&B^R+
M]3[^OPZ4@Z/EI Z4QXBN"3R^S^2'SV+MLU_)6Y>BWL]SX$H+<L@A9EO[&#->
MTQ\$^, M4RX9D?-X#L"+^YP:?;W#XKFCT(^,6L%;G;FVY[3>D\0T#U)X) Q$
MLEU52>!D8N1C*65%[4HUXASA5[<[]4T]"OIZE-CD[UF'6GXZA6BB F>)62K6
M&7_<)K"EZ)BU2SEV#8.?V5!UP-S?H0#3*W>;4%4O]' L7*-3ND"PO#8^"YDH
M*@HR$U:DD'7PXUV+9S14'2F_? KWH0?)-8' )\W[- 9A,4NPZPI[(];'$X$+
MYE6.R3A51L/=!?1:/4K:AWNM'L/Z)H"SK]FG3\QK1 ^\9$'ZU]"1BJ3>DS/&
MF9*1E_&\RM9[K1XE\4Z]5H]A?Q,8VM/N$W6Q1B@)L51#STD//N<$*1OIZ4PE
MG\=308WW6CT/06<ROPD G6,%_/:0016-1QU(@\NLR<-50H!#GT'S*(U%5;P<
M[TVI%Y)::G,VA74V/BXF=SKOD^PWE6M;CSK]LEBN;XKU ,RW7];D;WBQ3HU9
MT7_?CMS<##/)RUB1\BD_K:#\._Y[=G-W<Y6M%DXR#[IF42M#6L+5>6&*!8.V
M2&[23CK(JW710^YWZOM^ ACNK;AN!A--7!IG<>/*1Y9X$ Z2,G423 K5R H@
M'$>>DK52J'$-E%-)F=J6F>YT3(&%)J!_3''!MV*"C*Q@3?\.V5LZURC 8PD@
MK?)21Y=5&"]EXB02+CE:U1?4AY?]Y#;0-[H>!XD?\3)\?<[I?^$RK7_\(Z]J
MY0/==[-%XN1-VQ)9L)"#377ZA $GZ(;C"6TVII2@CYJ0U].^+MFT[\.FF4S&
MC93?'UU,R[GTFFD-S*P'0G%#3I0NM7&%Y1J#HU5&T]Z#%$F/U!9B*L4]J,2;
M,$O^F6L_NIS>T%$A/^.^M=BZ%_7;<I#87^>'1" 8]U=><_1)D5M20@95L$Y8
ME *41B:]DL:+\4**@Y+:4K/HJ4Y+.UB:W!PBBV^V7(M_<]]U(_^%<JJK5$NE
M0N2 P9.S$U1M$YD5:17I:OLCK7/7)F:];JRE[M93&$332;F)NZ.?>GF/C#'E
MR'\W6M:T30E.,SK<S ;%A&=9C]<9:[R."2/U +D$E[<?;%QH"?R'^#FGN^N\
M*!]N%_'/;>@+Y^G0;;KJOU[^O'V,45S?(Z<FJL1W3!;'2*4SQQ70B8H$YY2A
M"!Z4U5SHW0#V])7X6]?_$<<?]8Q]H"S;%*UF 9(0Y/=PI^G:(HU!!IIFWB-=
M8*$C9:\L=5GU[\=(?"?8TB/'F[ 6[GWI1\2L>;BE\8HSQ64BAUG*6&I/_0*A
MA'KSR(#&*1MQO%#W*YN=$H2] N/%B$<?4CH9=E_6UO2'6[(+>@;?8UHZN9Y7
MWC#,.5L@DZ..>L "+BH%A=&1)@<TZ0D:'1Y-QC0/CF,"=EC)-J5!'Y/ZRV)9
M\NQU8E$KF[1U$%T=6!D\!^>B@>)==EYI4>3XVO4$0J9Y3IP*R$-(]W@H^PV4
MY_E3G;3T<6!$KX,JKU(<9;$HW=HQ)8JM),/*B0),\&P-V90X8K[\R61,\Z(X
M%9K[EVS[6-[.]WF%9A:<M463F\!2[46>UD'  BD7Z:4R$G>'>XV.YDZ$3/-F
M.!V>^Y=NBXA^R1<H.:=BC(6 E:-1&<#L)=C,>13&2.7'ZU#6A\?6^_M<"Q[;
M,5(ZTV/[>9Z&5Z8U1_V5 U>4\S&[!"Q)<E(C$^#KCZRE2H[E6L_<@CI]G90I
M_;9QHEU3R'SRY^&#+^5[-(3,3KBX&?ZMR28B[GJ9D/Q59B-*U#'O!"%>#*\>
MN?24_M:8X=8A)=)$\.!P<L;C,_>(W YI&=%+%W2T$$T.H+(E'HA(AKN,&HO7
M&N-XNG8@(J<,]PX*S"-3>,9!24-AX^[LZ)['%+GBV20'F9?:U(?^%%+.0(98
M1J*%ES)>R[H!")S29&GUL R#C@N[5SH&,]=LX,4@,EY FA!!,1' *<$A26&E
M$DK[$;N3#4+BE(95J\=D*(1<V$'I%"==,T&E:%'J CHG#DKG CXI 442&YRM
M[>/&*Y\?@, IX^.M'I)AT'%Q1Z13Z'7-!J>R*H'5 M&J*6+4@#)&$*58QE11
M:<0JG$%(G#+LWNXQ&08A%W90CG/3I*R=^F2 (-&"\KRZ:8I#B,ASS%HHR1L\
M*OT[\P.]!+1Z6(9#23,O"D=KCM=CSINR)!*(T)$,3\-(=Y12+UDM($IRV[C3
M6LD11S /0^249MC8KQ MX.2[*F5XI%OHYR.FA:_K&16+\H3'8U4VG+BMZ0H=
M^N#C1'4/R*+F669RSB5A7WD/WGH+FJ&-0@@?=DN\IJ][V%].M7FC?/.LYN1]
MOL'9G$1SW[#FKLX)+?G%9_E-JS52"2ZX$(!'TE(JDZ_F"DKRU7P=]9*82^/5
MO@U'YV75;!R#UL/][R9$2Q-NRF:FT=NGBJE&^5X@<]W9U]70!+=UXIJJV5*L
M=O85 FP6,B8T.<3Q8EJG4-!2Z[LI$?C"2+P!X7"1H+]OH"^TRHH,5AL-L384
M!QBC &>8TC98+<V(@S%.HF%JX ^/K[,A?8*P)T]6>D+;FN"W\_O)<E$ZR[PV
MM>\>J0$1)" Q#@*/R=NHO3.OF^VO+G-IP#I%RHLA6-X@=C[^:[$EA*?B+-T9
MD-?LB5H1#28 *EDGWELTZ$_&SL,R4[?:;  [I[&\1>P0#/(#*1*#2AF,UFF3
M5.]CS% TL]+6YHB6G8Z>;PM-W;^R!?R<R/8&$?3+XFYY/]?*6X/2*^ RT\4?
MI $,28$0(60?H@F[O<F. -"W=:9N&MD ?DYD>HOPF?UU?Q 4LRY:[B!HIT!Q
M2Y3H5(#NYF(U2X%)?3I\'M:9N@MC"_ YC>GM.(-K/P.EC#(8VC5S@;8N#(1(
M;H<+.B=KE&)EQ'F;]]N:VCIJ.U9QM.#:P=S#"-$@E//)@V%(/BY3"KS3EHYD
M%EPKEHT;;R[4XYTUX=,=+^ 7(@ G<+L)K/RPN+U=W#R=%B^R%\9[A.+62M;4
MS$JB*7"FLRA1.<5&@\R>#3:!G),D_@P\Y[*_"0Q]7'QY2H&U/F+@Q Y=.P>R
MC(")19"6.6LQ2I7'>]7:W=W4-UZ/Z#F+\4U 9Y#K_[>'%I8JZ#H4)(#EM:.J
M*I+,19/!*NF4#E:%W9E)E_:\^MM18\=&&K/1E"'7$,2:.'*[7;GW$[C)\].8
MT0L.AAM9.[PI<)&4E4LFNNRR-V:\;-#N^Y[:/F@)<7OZ\@XB_B:@_6KO0L.M
M"RR!RXDL*\T9A)P5B$P:1B=5_(C5,GWT*[DTQ[PO$/<IZ":0>RYCMS760@;$
M#$4:#DHX0RYLJJ'6Z%WP0ADSGMG=!T7?I4W3UQD8'3*-#&$:JJB!%1Z]YQYR
MK Y4(5 '4AJ 7"E;LK'1CQ<HF[+T9:0!9JT?J$F U<1E=%X?)L&J!E$U@0H]
MJ%@T8"@,'$O1F2)T]N,;6</UWAII %ISIV4\D%S<O7-D71!+FB>1(>EB23WH
M6!,J%&3N8TC!QBC':_TY9?W82,/1FCM)+0"KQS,V;LG9-\GNL/'-:G5W\S A
MYA><+?^!UW=Y4;:\[+_,[.RMC%%:UB^_)BHG2YAY,4%#8;'6'P<)7M+)XRZS
MX(/AVK9<3I97<3E;<_5M>3];_?G+,M-Y)@LNKV[?XVW>TSCJRDM)ATXID$AW
MI?*.[DJE-(3B950NYX)QO)>,$RBXK!*P8Q"VY\EA: DW8A(]H7-#3KTQ]U%G
M<TJ)90?*QGI%:@&N> ?6Y%!*"%Z7\:R<[ON^K/:[/:*V/VDVX=(^H:V.)HQ$
MQC\6UR3*Z]GMUWTTU@'.)@@+F94 RA0##D6$HI,(S@EAU7CY>L?O_[+Z]O:(
MW/ZEVP2"[\GZ:?;7+)'1]6;UCIR!*M-/>X]H9CRP7 ID5Q*=4Y4@&)5!VFQJ
MKJQ,.%X8YLC-7U:[D?.P.Z1<FP#NCI_QX%F\N?U[QLKGRLV?7C"*DC/6F"@A
M*Z9 )1/K2.0$S'@OR;..S(^7BG@.)5-V:!L;TJ-)_.+;Y&QB48L7IH8/V0FG
MV\KC-KLY@1L3!2"BB$'K.L;'JU(STFSM'%AG"/J8=6):[XXJ;2H <<9X\$U&
M7I(,M78&-*]/6G0T(22ZDY3PJ3BNI,KCJ>6SR;FLT,0QV#N<#3F\[)LP0#[2
MWWR%LDTG"!ZDCIG17</6I:VHP?&B(#C#4:2H4QXOQM9UURTE.XX J.<Y\$-(
MMPG<'B1IF_!O2D:CC0+MB&TJ&PLHC 8C BM%F$(&W&B0[;#AJ=$Z#%J>@;)O
MT36!Q_>9;J!9]577Y/TQGSW0HC@FGRR#K)VMTUT*N)0BB!"L*3%%IT?L7?3B
M/J=&7^^P>%Z,V(^,FL#;.3?+M[?YHDN(3'GP+@I0P3% BPF,T[D(QY,.X\T)
M[H6DEC+#I[CQQ\=%$\?A(>=]KW?<.27QJD3E R>'@15DH+P*X#-1;PS/@<><
MBA^O7W5/1$VMV"> Y,LU$2/BHZ%);??D/Z9Y+R?N XV*JQ31DNHQM990R%"3
MM@K8**PSB>[<,/Z,V*Z[O^0[H&_ #R+Q"U#Y'8=E7:$I*+CDM=,;W;$R*T >
M.'CZ-6*P/KCQ@7X622W5!4V-_O&PT>1D^KW4/XS^>;O\!SE$KW)!H1)":O*Y
M/#.@%#KPM;54"$DH$E+*J!LY(4>2UE+!3YLG94BL7,Z)Z6X>1BF5-TQ#":D&
MQE2IEVB ;$OPB8?HY'C^])CNPTB%/FV>DF'PT>ILJ)<S%@X;F)BX\*58,++V
M$Q=TFSI4'- X7U16"3V.=C;ZH:FERIVICL8$Z+CXS);'O_TG5IG<KEZN.!DR
MT^6TG8R;^=(#M\[,A.DSO"N+3P(30LG<D5,1'+@4%!1#[H1VR6,<KY*^Y^R0
M01,04HD!<RA0+*Y'6I,WQIB Y)*2R28IPGCWQW]. L(Q>#TC >$8Z381?NKR
M7)F$EHGK0*34//K !2"6]<1IS]'Q+(08#;+?4P+"46@Y*0'A&-%-WHI]WPVY
MI<.SG#G3"+9H3IPR#H*R"7P.-C@3B;#XJA7QVBI3XZ9W@2X&X&X36JL?CR%(
M+R.3&81)GMQ88\$'HMU+&:VJ]6]EFL&,_\%I ^?=T^/C8G*EN>-"K"G<M)4X
MZ*BRD+BG0PXVUTIDJP1X]!&"X]8C5F=5=E2HI^U@:F4[ 506(\MM<FSN*XL_
M3%Y1TIK:S\1:M1X=PR!XY.!M\4''.JRO:]'%T8M?LO+L Y'#2FMR,.XG9=W]
MYR"16JD061WGKA-97)9G<+YXJ%VL-,/DG>_:B.3$+7P?3^&G W,,R4T.S^<E
M[8>)XXX'8X0%9R492C[7 =8Y02JF6&&CCKS[:+RCEOX^WIM/A^.0DFH&AOM*
MU5^Q3#!X)BTA+-8TWT3^(W+.@/Q'XWD@PR5UGY5VXB:^CT?>\Z$YK/0F!^E+
MCW5K^_G(%[NB!./%U>[(CI/#Z8G/++ Z*3JJPA4OTISF")VSK>_C2;8W[V@T
M"3?_)OO;8E7/](^+FYO%)DGCG'?5E[_6[]MHQUWW]K[Y,RYKE\^ZYGJU;X75
M2>N87"VLMF07ULA2X(6!]3HXRSB/9KS"B)=VV7NNR_KK]3BJR&RB0UABG:Q3
M$O@H%/BDB]%UQJ8:;]3+WBU.'13J!3>O)I><((X+Z-UZWU+WMQF&M57\>WUD
MN)W]=9:&>OVK_6JJ(ZGHN3?)HBSS7WE^ERLXXW8KJW_-;C_'N]7MXH8NF0=(
M!NM5CJZ M+4AL:F0C,4"#Y8N.U&PY*ZCK4_:P+EO?3M\?I_CXM-\;5^\6V?^
M73DDYZB.[ RF=@G2BNYMSPVHP)(/)6%"T9' UU=KHS_(4/+??0GLE??-VTS/
MZ'V<E+7Y3^\W;*]MD>__UBR?E;)V]J(#Z[6S>#"AVN.IE!R9 [;N3<IJ4T<?
M(Q#HM1!>"[8[ *D-M??-&M@5!3'YR@H;@E(!4I)D7Q0OR?,V#$JQ4G"R!N2(
MU2E[-GAYZO$8G#RWV,Z544-%LS_EN"1W.7_\O%S<??I,"KXLEC<XC_EMN)Y]
M6@OQAUSG'M ?5V56\U>?$Z\#]UZ8 )%@0^Q,#I"% DR(( PG#OCQ?(=>2&JC
M[?-XD!X?!TVD"NTC0KEL4*$'&6KYNS,6'/,(3&M6K*JNWGC5LJ="<_"^SM-J
MVV-DU&N-T7!6Z,W-['8=F<1U,/66SEJ>Q[/MS%<_V[<E>1P=O=B*3Y9Y0)UR
M,3#I!/ LZLM:)"\E10V<(2_&BJSBZPP\L,!Y+NZ[NV7\3 KWFWKE5S%$+= R
M8$Y+\J9L)!O""G!1Q*18#,*GCCO>\_DIK;3S)?3423V7>Y,_4CTGX-O)J4\J
M5SF*(J44I#,#@DHY #IRM$M*JHY?%MU3\%Y;:TI;9WA@G,'7R5'R6S7)?E_<
M_J]\6\D@+CT\J:VNG"+F".-!&5[K YR!P(@<DXS0+-E0=IN5OHB00^M,:6[T
MC8[>^-DD,M;X5I%<36(,R$+6MPJ!04@I@>4FE*H/G>YZZ[VTQI3#&<9 Q-%\
M;#[&^2O]IYO\$?^=5^^6B[]F*_HP^7>/?GV.D=G]Z_W:FB=2U7MX<K9>D-R]
M!SPRJ:R3*0-Z7\/B2H*S24&Q(7HF@PCJE->79PN=[P"_B7%QMSY2Q,(RNZU9
M&;E(YP%5+9173 ,*.@%29E9'/S".XPT]VMU=*X'&\R3^W,4]2PI-!%+>?/ER
M/8NU2(<.7LT-OTHZ,\>2!D/[!24U!V]D@F2L$IAC,+L&[)! VMU>*_&]WI%T
MEAR:@!)MO&8JSE=YH\G?W#XG*AH6Z8+79*;5\7,I<T F/&3I4R)"B4_C]2#J
ML.%68G9]PZUO634#P!JPO'U;?EDL\^S3?$O*ZLH6:ZUT&5146$=O( 1O#4A7
ML@W<167'RQ![>9]MC$\;!FX]2&9R[^T1'1]N%_'/9XUAKK(WJ!DYH]S2>5&N
M%EU[Z4EU:Q:+3H%^W]&"?'6Q-B:3]866(3@\?1N_9U31']\M%M>K*\V%LMXS
M2-H3\*-#\,&2T9C(@0T2F7+\>*3<?WZ:5//1L'$2%]NZI'XAKOWXN:;7_WJO
M#:^R% 5S[78F#-%0$[\PU7 GL<;&R*Q1XTWG.K333O"REP*O :33!-;6%10/
M)-76PC4G<!YGU[-M8L#MOW*>[WJQ;^9IUSZ\T@&59R4"REAJZ:4'5S" L)@M
MSZP4-]X4\/[HZH1C=WDXGDCR+1EH1,5LB9O)TO3K'_(\$X6KJ\R9L#[;VA;'
MU)HX!%=S8HLA[X8CV1.\:S."UU?KA"]_*?@:A,<M86:C\6?SA\JTMV7;5.FG
MO)S]M:X8N)**96L- \EBS6%1')P+%HCD;)(QAJ$_'D!=ENX61F47"Z?>V3\Y
MMBH5&P%=7R_^5=/R?MIN@\A^LUKE6]*RZP2^^T2^-S=5(_.KK()#ZR(DY7RM
M(S) YFR$R')BWF;'6%<U=?(FNN'M8N+V8XID>L_S42+>W7*Y;L6U<[,G+2P7
MY#;IS"R=).; 9RS H[7%1RM2'"\8^\(FNT'P @/^?0CE=/6VN,7K<=^O>ZD;
M//2]P=ZH!ZT5?*DX_^;+8HG+KS_-Z&I<UNR&/^9WJ[6*JE77N5;N/_SF1Q([
M65W;"7TIQ5R'@ FY;B7I'6#4"I(7143G%6=334T\E:93->!J>7OU@5"P[BCP
MM[SXM,0OGV<1K]=M6AVS0K"JR'&=>T(>CO?KB"(C_AF41APJSBFX"FM&T2IK
M'OV/?'V[JO^VANR:$0<W,'55] 1XN]>"_0EF0@-O343^M$O"3XL;G,VOM,F8
M>8Y04NWH1_X.^(@&DI->*^&2.Q@OZ8RNES8P#;IZ%.RB;RY/")5UD&7Y]>K'
M-U=2"QZ$<4 ^C !EK04L/(%.$5.1*M*_',#%*L?__FGQU__8?G$#C>V_?$/&
MM_4FA$$_0EN<Q<$&9/[##U>69U*%40*YK0B*JPC!TPD02D0=R(W(\5"5W7$R
M_^&':5)DAI/YD1QL0.9_?+@R@NF<! )R\A"4-Q)\20BDZKQ4++JD^Y/Y'Q^F
MR5,93N9'<K")UY:3C*CUQ:@Q6%>0\%Q8(DY) VC(I [H@\M!UF96XSW[G4I&
M6YUV1S5HQP;!Y>)].YM F.)#%@68%Z0;>$[@E"P0Z697Q3OMQ'C/B6<0,K43
M-Q+<^H'Y";)O N@[E&W)X*DP[[4 S2/Y,)XA!%,D)*2+C3F;@C:C07CO%B\2
MG*> Y!D\SY=86\![RANKM0I1:N!:UA9SWD!P1!$JB=I$#$Y,@+SC]>* MD #
MT#M=9I._6OXQC]<XN\GI0YP1NV=E%M^3!&E'GXEM];UB.:M&/YGZ^:]\O?A2
M_V7]C$$4D_WUP$D9N<ETX$).U0-0]*="QKQW105!KIPM7>OB>]K2U$WWQ\;E
M=/)L0H&>[1+\]FT0+4-6R)T%)E2= :L8(.,"G%$),2-Q8[P)C_W1-?6!:,)I
MFP@F31R1'>)^62S_^7D6/_^^V,V*V+:37-7>VY9X[2V'F&K%O9 .G&8*$ WG
M5B:IXV2F;Q<"IC:,I\+;:W9R[\)O"^%;YG6BLK:6ST(;R!)SO>HRN<>U09K)
M+B;,&<UX(;E3*)C: F\/XT.)_Y*Z2'SK#_O'?+DA]__DM,N(OKI*'+G:8!D\
MYU ]0M<)XYF42D8(3'!0AB&@E0@L%V9*%%FIKBVQ!^XZT9.U9A-C"GT!;YP%
M5>K+D.0*' ]22!^"E>-%?X?(46JIP\4QZ!K -#Y>XDT8#6<$UJ,17I<,)CI%
M_*[UJ9(Y2$('G92.5A_*\&C@:>,[RDX["G=]/N8= 8++Q?LV+&0L*HU!@R[.
M@(J1C"55FV\I+I.*K,0QFWK\1S[F'0.W7A_SCI%] W'M2L/O^?;MEUQ3NN>?
M*GD_XG+YE;R"?^$R/40Z/1:>K0.9,Y%5H@&?:S.G7&IA&[IBNK9QZ+SH1<+O
M%!@LAI=) U#K)^2>R'(3,E@PA9'U9AVYO=D%8"Z@=3+JB%V;A8[YA-+HT]XY
M,!U?GCV.!SL5QK_._\JK31/>75[ZD%"84L!)NFZ4B1Z"T)&01P:6L<IXJSHB
M\^55IGZ>F 9L/7%]<B7X;KF@<W'[]=TUTF'X_^]FZU/Q/E]O*AR?L?:!R!R9
M++% 5BX2YVI'<*TY,!VY=]$48D)':)VXA:FG84^#NS'D-3DHUW,:?UVM[O*/
MB]4#TUA)NA0EP>M<.TDG#BX9"TQYP3S3WOFN1?U[%YAZAO4T@#J?UY/#9<.3
M'_'+K);,[IBF9+;>Y_<XIIQ.&E+.Y(%E5S,I48$5PEAKR#=CX2B'X;45IYXE
M/:6WT*LTF@B_]/A:IGC**:"K3[.6F)O(5E"6@8R*<XS1/9L@VG)P_;A$E9;?
M,_L(2$X$DS:.2$YW\796&]3NL41>?M7]=?7H75?+@%%H!_7=@TC/ECA/YG,L
MTOI2?/9AO,R5/BB:.F@T%2+W#,(;&1[-/_MO;\EO$CIO(MF+7^MY$%FW7??6
M=N.A7/V^_=3JUWEU?6Z_/KR@9J<P,;)7E4PUXZEH\#[2F;:%);32H(^C*8W7
M]]M#PR!<U:A6_4?]]%]XO1ZTX[,3VMI21QH$8D:PM5J(;+=DDR,C3J<TWHB)
M_7N<6AWVC*8];8/.%\VD8<5G#9"^Q;I65SP+48(ADXB32:24(<>P7@@^D2:.
M9+:C&R_'^OG^IC9!AP?7>2)I!%@;EEQ)=$R7^@B*K!Z)S#8IX<5&=+SVBD W
M&I@V>YHZFCTX@$Y@_>0!GBT#[FX_+Y8U+?"*5@A99X3U1&2EA06O/>$^,\9M
MXL7O7G,OAG)VOSUU6'D@ /3 R.:MZ5]F<YS'&5[_.B=.W:VU8R\][3I]N%\;
M^WA:!NERMV\;W[HK9L%(47"('@F,/#I Z>CB*28RIZ,P^E![MN'"6(=VW6\@
M\'>L+\?KY^7;]9E]/UO]N7JSG*UF\T^U0?V^K6S"3.@-5R4[D'52A@I*@1.V
MUNQIPTJT[MD,Y9&X=SI-4YOV@R#W<(AO)  T$=[[K:9-K(BU][V?_VN6ES6]
MXNNV705MF D#"K$.HS(2G/*!F,H$9]:$(L8;X'1XKRT!=2P$/8-QC^)L IYO
MKJ]?)NG^&9PX9;1/]36S/F:E!"&J!%&HI+G+4>%XP>4.&YX:J'UBY/E Q9X%
MU@0*UQ2) Q0)D61@R,D_MZ7.[$/ G!AHIZU7-J LXU76O+;;J?'7.T3V:\&^
MY-4$ C_2WUS=7R/UE/KH4S1T.62EB0*NR=<OS #77HIB;)1R/*6WN[NI(W9-
M7,5GB:PYT&T/#DHFM4X.HC*ICHV4X*W4D(HPT3"9O3S47W,XV+6AVLZ3^4$(
MG2" )D"T"6['KY6(+0W1A&B+]%#3@D"QZJ1Q.E=8H@])*:G#>"!ZOK^60'2*
MU%]X7SA9!!,W>[_?_?H\12M=9%H#X[6JUBD#0<LZE$C(J)FTK!SR1[OV=W^\
MYM2O!Q->9F>Q?\J&T-L]5U-SN_]97MWW1PXJ8 P)T".2DY--?;V-0%J:%>V0
M,2L.0.BA1?1VC6V/Z.V_/6H2?6 /T[6'/UV:BYY9VP(\_OCPTU5"[JPO="ZL
MKYI01/ &'027DE12:=S-(#X/#K3F-.+O3W*[4#B6C2V(_N<_WE\1A8+N4[I&
M3:%;U?-,^/<.>$HQ9<-UEH>>JH\6/:TYC6<TG.B/9>/DS\X?\#IO9YRO=:"(
M3AHN&##OZ#*4=9"US8PV[Y(O$4O.79O ['QZZD?G">V&\UG=$DZVYZ3HY'4,
M"#857_-D#3'"%##91F&$4B&>@)0I#8(>Q/22P$_@V?0BKU53JW=WX7H6W]84
M9CH;S^:@/A04ZQ*\28EL)U>'*L4 /@<+R2ONG7-2^JYEN,>LVPA03A'O\PJU
M(7C=1LSC&FO:_=ORVPS#['IV2[?M^FR9(#C/M'\RD!@H&PIXQE+UO=$$KH0K
MAWR/GB,?+^QRZIK))J*WO8BP"3 ^(N#^/(D2I<T!BH^U$)21P9:R!J3=\\B2
MMB.^'3S;WM3AMWXD__Q-ZBPQ-(&DK8*^WW\((7D7-1VK0HZ#E@A.U9&Y&,AW
ML$HY-QZ,GNYM:@R=*>QGX#F#\TT@YVR5_MM#N5H64CA#9-=VL&0,D$9W+DK@
M5I.[6I2-?KS\\O[HFKJNO(E+=R*8-'%$MD4@WZS?!_H>*9,K0;LOCKC*;.W)
M[+($3[H#8I1>T+'77(^7:-)IRU.KXJDP]5*53X\";J!1U8<\7]'&_ZH5"'.\
M_KJ:U9K?[0OFWW'Y9[ZM/'Z?<;68DX;X^FZQ6M5JX4T=Q*_S^E__@<M9U1YO
M;NH8RBM7DN<L$@M\+'2[(>F0&(C7' TS4<I@NHZO&6![%Y_;<AZ>VQ#[]+&B
M/AGPZ\T7C+=OY^^6M6_ZS[B<D_A65RI896NGQ5P$B<=D#H[N4-"BZH:@C0R=
M0TS#;_?BG\F;.Q<]P.+X<^(WYV2>/VV:CTU7Y?5M>L />(VUF\1L3LS,LT_S
M1V]8/5> ';7H\-5AI_-@_,JQ8C**H!TD@B.=FB !,Q-@33&<RXQ,L4D<LR$J
MQS;'_3Z;@F^=GR@*(P\<@B7/7N4ZZ#(;#;5/KI!,\&"[&BY/O]R2#=T;!IYJ
MSC-8V5)^&K<JH;,.C(@.5-0<4$8&9+WP5*1+.1P*\ ^6GS;0D] Y4GLIQ^P8
M%K:02;(OIR+:6)^L%(A %[4*I7;F%,0-M"6X%)@3A\98?4<Y9D=)LTN.V3&L
M;0$>-3DJBQ1SD(4.0NVS5<AD\SDEVKA766<=?#R4\/R=Y)@=);E].6;'L+$%
MT=?D*!^<8(:35VN$ "5B@. D@M>\,,DS:4K?I^C;S#$[2_3'LG'RX,##K?C-
MI93!$9$^@$"60#'2@"%Y#RPK)RW9299W[7/\_.O3"+PW"Z 7IK41P]_?)0RE
M="9X#LPG#RK5-!EB5.UVR&Q&+.C'\XQ::N#6C^2[-FL[1@R-]-1Z<+8VDQ+?
M_$6.?CUG9;%<89V_G'.TG.[!C*0,Z;@%0!81-&.!>YET$>,U'7YELTUHJ;X@
MUJ=@FE!='Y>8:L3T[>WGO-P^5;W#KY6FU173#NF&9J"5MJ!4P%HX75^F4D3)
MZ$XV(Q8;']CI-$'H@3#6FTCZC@*?:A=M8YC_E:_3KSMAS*^_Y]LK&SCW9.V
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M=3H NS;*W?Z'^J,>D__OO_U?4$L! A0#%     @ 38%L6)WM*HRH!P  4B<
M !T              ( !     &5X,3(Q8V5O8V5R=&EF:6-A=&EO;C(P,C,N
M:'1M4$L! A0#%     @ 38%L6,5U.(2O!P  R28  !T              ( !
MXP<  &5X,3(R8V9O8V5R=&EF:6-A=&EO;C(P,C,N:'1M4$L! A0#%     @
M38%L6!L<L3!#!   '!,  !T              ( !S0\  &5X,3,Q8V5O8V5R
M=&EF:6-A=&EO;C(P,C,N:'1M4$L! A0#%     @ 38%L6)=O.6<O!   IA$
M !T              ( !2Q0  &5X,3,R8V9O8V5R=&EF:6-A=&EO;C(P,C,N
M:'1M4$L! A0#%     @ 38%L6%RWG;JWC   F&T% !$              ( !
MM1@  &5X,34Q+3(P,C-M9&$N:'1M4$L! A0#%     @ 38%L6%Z!P6U6!
MN!$  !8              ( !FZ4  &5X,34R97DR,#(S8V]N<V5N="YH=&U0
M2P$"% ,4    " !-@6Q8S .@CXP;  "K_   '@              @ $EJ@
M97@Q-C$M8V]R<'1R861I;F=P;VQI8WER978N:'1M4$L! A0#%     @ 38%L
M6"?205Q<!   : P  !X              ( ![<4  &5X,C%E>&1E<V-R:7!T
M:6]N;V9S96-U<FET+FAT;5!+ 0(4 Q0    ( $V!;%A,VR[\?X0  /O' P >
M              "  87*  !E>#0Q,F5M<&QO>6UE;G1A9W)E96UE;G1A;2YH
M=&U02P$"% ,4    " !-@6Q8T3:W_P06  !ZC   '@              @ %
M3P$ 97@T,3,M86UY;&5V:6YA;65N9&UE;G0Q>&4N:'1M4$L! A0#%     @
M38%L6"#W2"RD @  2@T  !@              ( !@&4! &5X.#!S=6)S:61I
M87)I97,R,#(S+FAT;5!+ 0(4 Q0    ( $V!;%B%:UB9R!8   R0   >
M          "  5IH 0!E>#DW,6]N8V]L>71I8W-C;&%W8F%C:W!O;"YH=&U0
M2P$"% ,4    " !-@6Q8EU]41M>R @ FJ!H $@              @ %>?P$
M;VYC>68M,C R,S$R,S$N:'1M4$L! A0#%     @ 38%L6(L@)%'0&   \B(!
M !(              ( !93($ &]N8WEF+3(P,C,Q,C,Q+GAS9%!+ 0(4 Q0
M   ( $V!;%B]2,*AFQ0  .._   6              "  65+! !O;F-Y9BTR
M,#(S,3(S,5]C86PN>&UL4$L! A0#%     @ 38%L6&^L\>X/6P  '08$ !8
M             ( !-& $ &]N8WEF+3(P,C,Q,C,Q7V1E9BYX;6Q02P$"% ,4
M    " !-@6Q8LK1M=J=! @"&0@( %0              @ %WNP0 ;VYC>68M
M,C R,S$R,S%?9S$N:G!G4$L! A0#%     @ 38%L6$GF102\U 8 .P<' !4
M             ( !4?T& &]N8WEF+3(P,C,Q,C,Q7V<R+FIP9U!+ 0(4 Q0
M   ( $V!;%C4U]V(0N(   OR"  6              "  4#2#0!O;F-Y9BTR
M,#(S,3(S,5]L86(N>&UL4$L! A0#%     @ 38%L6 K\I"_?DP  T+(& !8
M             ( !MK0. &]N8WEF+3(P,C,Q,C,Q7W!R92YX;6Q02P4&
/ !0 % "'!0  R4@/

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>oncyf-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:oncyf="http://www.oncolyticsbiotech.com/20231231"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="oncyf-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">oncyf:ClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis">ifrs-full:AccumulatedDepreciationAndAmortisationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:MedicalEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">oncyf:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2019-08-16</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <startDate>2023-09-07</startDate>
            <endDate>2023-09-07</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-07</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-07</startDate>
            <endDate>2023-09-07</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingWarrantDerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesUnderAtthemarketAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:SharesUnderStockOptionPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:SharesPublicOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2020SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-05</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2021SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-17</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-17</startDate>
            <endDate>2022-06-17</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:SaleOfStockAxis">oncyf:A2022SharesUnderAtTheMarketAgreementUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">oncyf:CompensationWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:ReserveOfSharebasedPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangesOfExercisePricesForOutstandingShareOptionsAxis">oncyf:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">ifrs-full:RestrictedShareUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BB</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxLossesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">ifrs-full:UnusedTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedNetOperatingLossCarryForwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnclaimedScientificResearchAndExperimentalDevelopmentExpendituresMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:InvestmentTaxCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:PropertyPlantEquipmentRelatedTemporaryDifferencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:ShareIssueCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis">oncyf:UnusedCapitalLossCarryForwardNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
        </entity>
        <period>
            <instant>2022-06-12</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level2OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:ConcentrationRiskType1Axis">oncyf:SupplierConcentrationRisk1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001129928</identifier>
            <segment>
                <xbrldi:explicitMember dimension="oncyf:IncomeStatementLocation1Axis">oncyf:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="cadPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:CAD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="plan">
        <measure>oncyf:plan</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="year">
        <measure>oncyf:year</measure>
    </unit>
    <unit id="manufacturer">
        <measure>oncyf:manufacturer</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-37">0001129928</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-38">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-39">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-40">false</dei:AmendmentFlag>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-41">A0</dei:EntityIncorporationStateCountryCode>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-42">false</dei:EntityEmergingGrowthCompany>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-186" id="f-703">P1Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c-1" id="f-2">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-3">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-5">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-6">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c-1" id="f-7">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-8">001-38512</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-9">ONCOLYTICS BIOTECH INC.</dei:EntityRegistrantName>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">804, 322 11th Avenue SW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Calgary</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">AB</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="c-1" id="f-13">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">T2R 0C5</dei:EntityAddressPostalZipCode>
    <dei:ContactPersonnelName contextRef="c-2" id="f-15">Kirk Look</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1 contextRef="c-2" id="f-16">804, 322 11th Avenue SW</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-2" id="f-17">Calgary</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-2" id="f-18">AB</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressCountry contextRef="c-2" id="f-19">CA</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-2" id="f-20">T2R 0C5</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-2" id="f-21">403</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-2" id="f-22">670-7377</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c-2" id="f-23">info@oncolytics.ca</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle contextRef="c-1" id="f-24">no</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-25">ONCY</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-27" unitRef="shares">74423960</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-28">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-29">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-32">Accelerated Filer</dei:EntityFilerCategory>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-33">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-34">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:DocumentAccountingStandard contextRef="c-1" id="f-35">International Financial Reporting Standards</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c-1" id="f-36">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c-1" id="f-43">1263</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-44">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-45">Calgary, Canada</dei:AuditorLocation>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-46" unitRef="cad">34912000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-47" unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentFinancialAssetsAvailableforsale contextRef="c-3" decimals="-3" id="f-48" unitRef="cad">0</ifrs-full:CurrentFinancialAssetsAvailableforsale>
    <ifrs-full:CurrentFinancialAssetsAvailableforsale contextRef="c-4" decimals="-3" id="f-49" unitRef="cad">20472000</ifrs-full:CurrentFinancialAssetsAvailableforsale>
    <ifrs-full:OtherCurrentReceivables contextRef="c-3" decimals="-3" id="f-50" unitRef="cad">15000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables contextRef="c-4" decimals="-3" id="f-51" unitRef="cad">521000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments contextRef="c-3" decimals="-3" id="f-52" unitRef="cad">3246000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments contextRef="c-4" decimals="-3" id="f-53" unitRef="cad">3025000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentAssets contextRef="c-3" decimals="-3" id="f-54" unitRef="cad">38173000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets contextRef="c-4" decimals="-3" id="f-55" unitRef="cad">35684000</ifrs-full:CurrentAssets>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-56" unitRef="cad">282000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-57" unitRef="cad">356000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-58" unitRef="cad">365000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-59" unitRef="cad">296000</ifrs-full:RightofuseAssets>
    <ifrs-full:NoncurrentPrepayments contextRef="c-3" decimals="-3" id="f-60" unitRef="cad">0</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:NoncurrentPrepayments contextRef="c-4" decimals="-3" id="f-61" unitRef="cad">998000</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:Assets contextRef="c-3" decimals="-3" id="f-62" unitRef="cad">38820000</ifrs-full:Assets>
    <ifrs-full:Assets contextRef="c-4" decimals="-3" id="f-63" unitRef="cad">37334000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-3" decimals="-3" id="f-64" unitRef="cad">3572000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-4" decimals="-3" id="f-65" unitRef="cad">3650000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-3" decimals="-3" id="f-66" unitRef="cad">332000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-4" decimals="-3" id="f-67" unitRef="cad">0</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-68" unitRef="cad">133000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-69" unitRef="cad">216000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-3" decimals="-3" id="f-70" unitRef="cad">200000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-4" decimals="-3" id="f-71" unitRef="cad">79000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-3" decimals="-3" id="f-72" unitRef="cad">4237000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities contextRef="c-4" decimals="-3" id="f-73" unitRef="cad">3945000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-3" decimals="-3" id="f-74" unitRef="cad">6730000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities contextRef="c-4" decimals="-3" id="f-75" unitRef="cad">6730000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-3" decimals="-3" id="f-76" unitRef="cad">290000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities contextRef="c-4" decimals="-3" id="f-77" unitRef="cad">157000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:Liabilities contextRef="c-3" decimals="-3" id="f-78" unitRef="cad">11257000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities contextRef="c-4" decimals="-3" id="f-79" unitRef="cad">10832000</ifrs-full:Liabilities>
    <oncyf:CommitmentsAndContingencies1 contextRef="c-3" id="f-80" unitRef="cad" xsi:nil="true"/>
    <oncyf:CommitmentsAndContingencies1 contextRef="c-4" id="f-81" unitRef="cad" xsi:nil="true"/>
    <ifrs-full:NumberOfSharesIssued contextRef="c-5" decimals="INF" id="f-82" unitRef="shares">74423960</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:NumberOfSharesIssued contextRef="c-6" decimals="INF" id="f-83" unitRef="shares">61327914</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:IssuedCapital contextRef="c-3" decimals="-3" id="f-84" unitRef="cad">430906000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital contextRef="c-4" decimals="-3" id="f-85" unitRef="cad">404040000</ifrs-full:IssuedCapital>
    <ifrs-full:AdditionalPaidinCapital contextRef="c-3" decimals="-3" id="f-86" unitRef="cad">42116000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AdditionalPaidinCapital contextRef="c-4" decimals="-3" id="f-87" unitRef="cad">40051000</ifrs-full:AdditionalPaidinCapital>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-3" decimals="-3" id="f-88" unitRef="cad">544000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome contextRef="c-4" decimals="-3" id="f-89" unitRef="cad">662000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:RetainedEarnings contextRef="c-3" decimals="-3" id="f-90" unitRef="cad">-446003000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings contextRef="c-4" decimals="-3" id="f-91" unitRef="cad">-418251000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-92" unitRef="cad">27563000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-93" unitRef="cad">26502000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities contextRef="c-3" decimals="-3" id="f-94" unitRef="cad">38820000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities contextRef="c-4" decimals="-3" id="f-95" unitRef="cad">37334000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-96" unitRef="cad">17709000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-97" unitRef="cad">15432000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-98" unitRef="cad">12920000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-99" unitRef="cad">16082000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-100" unitRef="cad">11492000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-101" unitRef="cad">13315000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-1" decimals="-3" id="f-102" unitRef="cad">-33791000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-7" decimals="-3" id="f-103" unitRef="cad">-26924000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities contextRef="c-8" decimals="-3" id="f-104" unitRef="cad">-26235000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-1" decimals="-3" id="f-105" unitRef="cad">5285000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-7" decimals="-3" id="f-106" unitRef="cad">-20000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-8" decimals="-3" id="f-107" unitRef="cad">17000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-1" decimals="-3" id="f-108" unitRef="cad">-475000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-7" decimals="-3" id="f-109" unitRef="cad">1665000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss contextRef="c-8" decimals="-3" id="f-110" unitRef="cad">-136000</ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-111" unitRef="cad">1326000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-112" unitRef="cad">528000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:InterestIncomeOnCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-113" unitRef="cad">99000</ifrs-full:InterestIncomeOnCashAndCashEquivalents>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-1" decimals="-3" id="f-114" unitRef="cad">-27655000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-7" decimals="-3" id="f-115" unitRef="cad">-24751000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax contextRef="c-8" decimals="-3" id="f-116" unitRef="cad">-26255000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-1" decimals="-3" id="f-117" unitRef="cad">97000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-7" decimals="-3" id="f-118" unitRef="cad">84000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations contextRef="c-8" decimals="-3" id="f-119" unitRef="cad">49000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-120" unitRef="cad">-27752000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-3" id="f-121" unitRef="cad">-24835000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-8" decimals="-3" id="f-122" unitRef="cad">-26304000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-1" decimals="-3" id="f-123" unitRef="cad">-118000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-7" decimals="-3" id="f-124" unitRef="cad">274000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation contextRef="c-8" decimals="-3" id="f-125" unitRef="cad">-12000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-126" unitRef="cad">-27870000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-7" decimals="-3" id="f-127" unitRef="cad">-24561000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-8" decimals="-3" id="f-128" unitRef="cad">-26316000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-129"
      unitRef="cadPerShare">-0.41</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-1"
      decimals="2"
      id="f-130"
      unitRef="cadPerShare">-0.41</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-7"
      decimals="2"
      id="f-131"
      unitRef="cadPerShare">-0.43</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-7"
      decimals="2"
      id="f-132"
      unitRef="cadPerShare">-0.43</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="c-8"
      decimals="2"
      id="f-133"
      unitRef="cadPerShare">-0.49</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="c-8"
      decimals="2"
      id="f-134"
      unitRef="cadPerShare">-0.49</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-135" unitRef="shares">67624036</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="0" id="f-136" unitRef="shares">67624036</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-7" decimals="0" id="f-137" unitRef="shares">58029745</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-7" decimals="0" id="f-138" unitRef="shares">58029745</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-8" decimals="0" id="f-139" unitRef="shares">53513225</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-8" decimals="0" id="f-140" unitRef="shares">53513225</ifrs-full:WeightedAverageShares>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-141" unitRef="cad">356824000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-10" decimals="-3" id="f-142" unitRef="cad">3618000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-11" decimals="-3" id="f-143" unitRef="cad">31022000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-12" decimals="-3" id="f-144" unitRef="cad">400000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-13" decimals="-3" id="f-145" unitRef="cad">-367112000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-14" decimals="-3" id="f-146" unitRef="cad">24752000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome contextRef="c-15" decimals="-3" id="f-147" unitRef="cad">-12000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-16" decimals="-3" id="f-148" unitRef="cad">-26304000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-8" decimals="-3" id="f-149" unitRef="cad">-26316000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-17" decimals="-3" id="f-150" unitRef="cad">381000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-18" decimals="-3" id="f-151" unitRef="cad">-143000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-8" decimals="-3" id="f-152" unitRef="cad">238000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-17" decimals="-3" id="f-153" unitRef="cad">544000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-18" decimals="-3" id="f-154" unitRef="cad">-544000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-8" decimals="-3" id="f-155" unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <ifrs-full:IssueOfEquity contextRef="c-17" decimals="-3" id="f-156" unitRef="cad">34168000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-8" decimals="-3" id="f-157" unitRef="cad">34168000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-17" decimals="-3" id="f-158" unitRef="cad">1256000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-8" decimals="-3" id="f-159" unitRef="cad">1256000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-17" decimals="-3" id="f-160" unitRef="cad">687000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity contextRef="c-8" decimals="-3" id="f-161" unitRef="cad">687000</ifrs-full:IncreaseDecreaseThroughExerciseOfWarrantsEquity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-18" decimals="-3" id="f-162" unitRef="cad">3826000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-8" decimals="-3" id="f-163" unitRef="cad">3826000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-19" decimals="-3" id="f-164" unitRef="cad">391348000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-20" decimals="-3" id="f-165" unitRef="cad">3618000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-21" decimals="-3" id="f-166" unitRef="cad">34161000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-22" decimals="-3" id="f-167" unitRef="cad">388000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-23" decimals="-3" id="f-168" unitRef="cad">-393416000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-24" decimals="-3" id="f-169" unitRef="cad">36099000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome contextRef="c-25" decimals="-3" id="f-170" unitRef="cad">274000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-26" decimals="-3" id="f-171" unitRef="cad">-24835000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-7" decimals="-3" id="f-172" unitRef="cad">-24561000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-27" decimals="-3" id="f-173" unitRef="cad">20000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-28" decimals="-3" id="f-174" unitRef="cad">-8000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-7" decimals="-3" id="f-175" unitRef="cad">12000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-27" decimals="-3" id="f-176" unitRef="cad">98000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-28" decimals="-3" id="f-177" unitRef="cad">-98000</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity contextRef="c-7" decimals="-3" id="f-178" unitRef="cad">0</oncyf:IncreaseDecreaseThroughIncentiveShareAwardsEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity contextRef="c-29" decimals="-3" id="f-179" unitRef="cad">-3618000</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity contextRef="c-28" decimals="-3" id="f-180" unitRef="cad">3618000</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity contextRef="c-7" decimals="-3" id="f-181" unitRef="cad">0</oncyf:IncreaseDecreaseThroughExpirationOfWarrantEquity>
    <ifrs-full:IssueOfEquity contextRef="c-27" decimals="-3" id="f-182" unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-7" decimals="-3" id="f-183" unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-27" decimals="-3" id="f-184" unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-7" decimals="-3" id="f-185" unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-28" decimals="-3" id="f-186" unitRef="cad">2378000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-7" decimals="-3" id="f-187" unitRef="cad">2378000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-188" unitRef="cad">404040000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-30" decimals="-3" id="f-189" unitRef="cad">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-31" decimals="-3" id="f-190" unitRef="cad">40051000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-32" decimals="-3" id="f-191" unitRef="cad">662000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-33" decimals="-3" id="f-192" unitRef="cad">-418251000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-193" unitRef="cad">26502000</ifrs-full:Equity>
    <ifrs-full:ComprehensiveIncome contextRef="c-34" decimals="-3" id="f-194" unitRef="cad">-118000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-35" decimals="-3" id="f-195" unitRef="cad">-27752000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome contextRef="c-1" decimals="-3" id="f-196" unitRef="cad">-27870000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-36" decimals="-3" id="f-197" unitRef="cad">1271000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-37" decimals="-3" id="f-198" unitRef="cad">-490000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions contextRef="c-1" decimals="-3" id="f-199" unitRef="cad">781000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IssueOfEquity contextRef="c-38" decimals="-3" id="f-200" unitRef="cad">10676000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-39" decimals="-3" id="f-201" unitRef="cad">10676000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-40" decimals="-3" id="f-202" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-41" decimals="-3" id="f-203" unitRef="cad">638000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity contextRef="c-42" decimals="-3" id="f-204" unitRef="cad">18362000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-36" decimals="-3" id="f-205" unitRef="cad">2805000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-1" decimals="-3" id="f-206" unitRef="cad">2805000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-37" decimals="-3" id="f-207" unitRef="cad">1917000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions contextRef="c-1" decimals="-3" id="f-208" unitRef="cad">1917000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-209" unitRef="cad">430906000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-43" decimals="-3" id="f-210" unitRef="cad">0</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-44" decimals="-3" id="f-211" unitRef="cad">42116000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-45" decimals="-3" id="f-212" unitRef="cad">544000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-46" decimals="-3" id="f-213" unitRef="cad">-446003000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-214" unitRef="cad">27563000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss contextRef="c-1" decimals="-3" id="f-215" unitRef="cad">-27752000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-7" decimals="-3" id="f-216" unitRef="cad">-24835000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss contextRef="c-8" decimals="-3" id="f-217" unitRef="cad">-26304000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-1" decimals="-3" id="f-218" unitRef="cad">81000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-7" decimals="-3" id="f-219" unitRef="cad">93000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense contextRef="c-8" decimals="-3" id="f-220" unitRef="cad">130000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets contextRef="c-1" decimals="-3" id="f-221" unitRef="cad">322000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets contextRef="c-7" decimals="-3" id="f-222" unitRef="cad">299000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <oncyf:AdjustmentsForDepreciationRightOfUseAssets contextRef="c-8" decimals="-3" id="f-223" unitRef="cad">322000</oncyf:AdjustmentsForDepreciationRightOfUseAssets>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-1" decimals="-3" id="f-224" unitRef="cad">1917000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-7" decimals="-3" id="f-225" unitRef="cad">2378000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments contextRef="c-8" decimals="-3" id="f-226" unitRef="cad">3826000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-1" decimals="-3" id="f-227" unitRef="cad">151000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-7" decimals="-3" id="f-228" unitRef="cad">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets contextRef="c-8" decimals="-3" id="f-229" unitRef="cad">0</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:InterestRevenueExpense contextRef="c-1" decimals="-3" id="f-230" unitRef="cad">-71000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense contextRef="c-7" decimals="-3" id="f-231" unitRef="cad">76000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:InterestRevenueExpense contextRef="c-8" decimals="-3" id="f-232" unitRef="cad">-92000</ifrs-full:InterestRevenueExpense>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-1" decimals="-3" id="f-233" unitRef="cad">282000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-7" decimals="-3" id="f-234" unitRef="cad">-1625000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains contextRef="c-8" decimals="-3" id="f-235" unitRef="cad">426000</ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="c-1" decimals="-3" id="f-236" unitRef="cad">5285000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="c-7" decimals="-3" id="f-237" unitRef="cad">-20000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives contextRef="c-8" decimals="-3" id="f-238" unitRef="cad">17000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-1" decimals="-3" id="f-239" unitRef="cad">-1765000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-7" decimals="-3" id="f-240" unitRef="cad">-391000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-8" decimals="-3" id="f-241" unitRef="cad">908000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-1" decimals="-3" id="f-242" unitRef="cad">-28448000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-7" decimals="-3" id="f-243" unitRef="cad">-23355000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations contextRef="c-8" decimals="-3" id="f-244" unitRef="cad">-22433000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-245" unitRef="cad">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-246" unitRef="cad">20348000</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-247" unitRef="cad">0</ifrs-full:PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-248" unitRef="cad">20230000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-249" unitRef="cad">0</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-250" unitRef="cad">0</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-1" decimals="-3" id="f-251" unitRef="cad">8000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-7" decimals="-3" id="f-252" unitRef="cad">55000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities contextRef="c-8" decimals="-3" id="f-253" unitRef="cad">286000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-254" unitRef="cad">20222000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-255" unitRef="cad">-20403000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities contextRef="c-8" decimals="-3" id="f-256" unitRef="cad">-286000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-1" decimals="-3" id="f-257" unitRef="cad">781000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-7" decimals="-3" id="f-258" unitRef="cad">12000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfOptions contextRef="c-8" decimals="-3" id="f-259" unitRef="cad">238000</ifrs-full:ProceedsFromExerciseOfOptions>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-1" decimals="-3" id="f-260" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-7" decimals="-3" id="f-261" unitRef="cad">0</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants contextRef="c-8" decimals="-3" id="f-262" unitRef="cad">231000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-39" decimals="-3" id="f-263" unitRef="cad">10261000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-47" decimals="-3" id="f-264" unitRef="cad">12574000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-48" decimals="-3" id="f-265" unitRef="cad">32912000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-49" decimals="-3" id="f-266" unitRef="cad">21359000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-50" decimals="-3" id="f-267" unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares contextRef="c-51" decimals="-3" id="f-268" unitRef="cad">0</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:CashOutflowForLeases contextRef="c-1" decimals="-3" id="f-269" unitRef="cad">407000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-7" decimals="-3" id="f-270" unitRef="cad">381000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-8" decimals="-3" id="f-271" unitRef="cad">366000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-272" unitRef="cad">31994000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-273" unitRef="cad">12205000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities contextRef="c-8" decimals="-3" id="f-274" unitRef="cad">33015000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-275" unitRef="cad">23768000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-276" unitRef="cad">-31553000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-277" unitRef="cad">10296000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-278" unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-24" decimals="-3" id="f-279" unitRef="cad">41262000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-14" decimals="-3" id="f-280" unitRef="cad">31220000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-1" decimals="-3" id="f-281" unitRef="cad">-522000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-7" decimals="-3" id="f-282" unitRef="cad">1957000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents contextRef="c-8" decimals="-3" id="f-283" unitRef="cad">-254000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-284" unitRef="cad">34912000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-285" unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-24" decimals="-3" id="f-286" unitRef="cad">41262000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory contextRef="c-1" id="f-287">Nature of Operations&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Oncolytics Biotech Inc. was incorporated on April 2, 1998, under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. On April 8, 1998, we changed our name to Oncolytics Biotech Inc. We are a limited company incorporated and domiciled in Canada. Our shares are publicly traded on the Nasdaq Capital Market and the Toronto Stock Exchange. Our principal place of business is located at 804, 322 11&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Avenue S.W., Calgary, Alberta, Canada.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a clinical-stage biopharmaceutical company developing pelareorep, a safe and well-tolerated intravenously delivered&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. Our primary focus is to advance our programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma to registration-enabled clinical studies. In addition, we are exploring opportunities for registrational programs in other gastrointestinal cancers through our GOBLET platform study. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not been profitable since our inception and expect to continue to incur substantial losses as we continue our research and development efforts. As at December&#160;31, 2023, we had an accumulated deficit of $446,003. We do not expect to generate significant revenues until and unless pelareorep becomes commercially viable. To date, we have funded our operations mainly through issuing additional capital via public offerings, equity distribution arrangements, and the exercise of warrants and stock options. There can be no assurance that we will be able to raise additional funds through the sale of our common shares. Failure to raise additional capital would have a material adverse impact on our business, results of operations, and financial condition. As at December&#160;31, 2023, we had cash and cash equivalents of $34,912. We believe we have sufficient existing cash resources to fund our presently planned operations for at least the next twelve months from the balance sheet date.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <ifrs-full:RetainedEarnings contextRef="c-3" decimals="-3" id="f-288" unitRef="cad">-446003000</ifrs-full:RetainedEarnings>
    <oncyf:CashAndCashEquivalentsAndCurrentInvestments contextRef="c-3" decimals="-3" id="f-289" unitRef="cad">34912000</oncyf:CashAndCashEquivalentsAndCurrentInvestments>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory contextRef="c-1" id="f-290">Basis of Presentation&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Statement of compliance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB"). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements for the year ended December&#160;31, 2023, were authorized for issue in accordance with a resolution of the Board of Directors (the "Board") on March&#160;7, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements include our financial statements and the financial statements of our subsidiaries, Oncolytics Biotech (Barbados) Inc. and Oncolytics Biotech (U.S.) Inc., and are presented in Canadian dollars, our functional currency. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsidiaries are entities over which we have control which is achieved when we are exposed, or have the rights, to variable returns from our involvement with the investee and have the ability to affect those returns through our power to govern. The accounting policies of our subsidiaries are consistent with our accounting policies, and all intercompany transactions, balances, income, and expenses are eliminated on consolidation. &lt;/span&gt;&lt;/div&gt;Our accounts are prepared on the historical cost basis, except for certain assets and liabilities, which are measured at fair value as explained in the notes to these financial statements.</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory contextRef="c-1" id="f-291">Summary of Material Accounting Policies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the framework of the material accounting policies summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include interest-bearing deposits with our bank totaling $31,534 as at December&#160;31, 2023 (December&#160;31, 2022 - $9,501). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification and measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities, other liabilities, and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derecognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Loss per share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is calculated by dividing the loss attributable to common shareholders by the weighted average number of common shares outstanding during the year. Diluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and equipment &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.608%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and development costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share-based compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Presentation of Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and IFRS Practice Statement 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Making Materiality Judgements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments became effective on January 1, 2023. Adopting the amendments did not have a&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;material impact on our consolidated financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates, changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 12 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards and Interpretations Issued but Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 Presentation of Financial Statements, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments are effective for annual periods beginning on or after January 1, 2024, and are to be applied retrospectively. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory>
    <oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock contextRef="c-1" id="f-292">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and cash equivalents and marketable securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents include interest-bearing deposits with our bank totaling $31,534 as at December&#160;31, 2023 (December&#160;31, 2022 - $9,501). Marketable securities include foreign currency term deposits with a maturity of greater than 90 days and less than one year.&lt;/span&gt;&lt;/div&gt;</oncyf:DescriptionOfAccountingPolicyForDeterminingComponentsOfCashAndCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <ifrs-full:CashEquivalents contextRef="c-3" decimals="-3" id="f-293" unitRef="cad">31534000</ifrs-full:CashEquivalents>
    <ifrs-full:CashEquivalents contextRef="c-4" decimals="-3" id="f-294" unitRef="cad">9501000</ifrs-full:CashEquivalents>
    <ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory contextRef="c-1" id="f-295">We follow the liability method of accounting for income taxes. Under the liability method, deferred income taxes are recognized for the difference between the financial statement carrying values and the respective income tax basis of assets and liabilities (temporary differences). Deferred income tax assets and liabilities are measured using substantively enacted income tax rates and laws expected to apply in the years in which temporary differences are expected to be recovered or settled. The effect on deferred income tax assets and liabilities of a change in tax rates is charged or credited to income, except when it is related to items charged or credited to either other comprehensive income or directly to equity.</ifrs-full:DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory contextRef="c-1" id="f-296">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are initially measured at fair value. In the case of a financial asset not at fair value through profit or loss, the financial asset is initially measured at fair value plus or minus transaction costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets are subsequently measured at amortised cost, fair value through profit or loss (FVPL), or fair value through other comprehensive income (FVOCI). The classification is based on two criteria: the Company&#x2019;s business model for managing the assets; and whether the financial asset&#x2019;s contractual cash flows represent 'solely payments of principal and interest' on the principal amount outstanding (the 'SPPI criterion'). &lt;/span&gt;&lt;/div&gt;Our financial assets include cash and cash equivalents, marketable securities, and other receivables. The classification and measurement of these financial assets are at amortized cost, as these assets are held within our business model with the objective to hold the financial assets in order to collect contractual cash flows that meet the SPPI criterion.</ifrs-full:DescriptionOfAccountingPolicyForFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory contextRef="c-1" id="f-297">Financial liabilities are initially measured at fair value and are subsequently measured at amortised cost or FVPL. Our financial liabilities include accounts payable and accrued liabilities, other liabilities, and warrant derivative. The classification and measurement of accounts payable and accrued liabilities are at amortized cost. The classification and measurement of the warrant derivative is at FVPL.</ifrs-full:DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory contextRef="c-1" id="f-298">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting for impairment losses for financial assets uses a forward-looking expected credit loss (ECL) approach. We are required to record a loss allowance for ECLs on all financial assets not held at FVPL. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Company expects to receive. The shortfall is then discounted at an approximation to the asset&#x2019;s original effective interest rate.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-299">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial asset is derecognized when the contractual rights to the cash flows from the financial asset expire, or we transfer the financial asset and substantially all the risks and rewards of ownership of the financial asset to another entity. &lt;/span&gt;&lt;/div&gt;A financial liability is derecognized when our obligations specified in the contract are discharged or canceled, or expired.</ifrs-full:DescriptionOfAccountingPolicyForDerecognitionOfFinancialInstrumentsExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory contextRef="c-1" id="f-300">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received to sell an asset, or paid to transfer a liability in an orderly transaction between market participants, at the measurement date. In determining the fair value measurement of our financial instruments, we prioritize the related inputs used in measuring fair value into the following hierarchy: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than quoted prices included within Level 1 that are either directly or indirectly observable;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which little or no market activity exists, therefore requiring an entity to develop its own assumptions about the assumptions that market participants would use in pricing.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory contextRef="c-1" id="f-301">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The financial statements for each of our subsidiaries are prepared using their functional currency. Our functional and presentation currency is the Canadian dollar. Foreign currency transactions are translated into the functional currency using exchange rates prevailing at the dates of the transactions. Exchange differences resulting from the settlement of such transactions and from the translation at exchange rates ruling at the statement of financial position date of monetary assets and liabilities denominated in currencies other than the functional currency are recognized directly in the consolidated statement of loss and comprehensive loss.  &lt;/span&gt;&lt;/div&gt;Exceptions to this are where the monetary items form part of the net investment in a foreign operation, and the foreign operation's functional currency is the local currency. These exchange differences are initially recognized in equity. The statement of financial position of foreign operations is translated into Canadian dollars using the exchange rate at the statement of financial position date and the income statements are translated into Canadian dollars using the average exchange rate for the period. Where this average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, the exchange rate on the transaction date is used. Exchange differences on translation into Canadian dollars are recognized as a separate component of equity. On disposal of a foreign operation, any cumulative exchange differences held in equity are transferred to the consolidated statement of loss and comprehensive loss.</ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory contextRef="c-1" id="f-302">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of a contract, we assess whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, we assess whether:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the contract involves the use of an identified asset;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to obtain substantially all of the economic benefits from the use of the identified asset throughout the period of use; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;we have the right to direct the use of the identified asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A right-of-use asset and corresponding lease liability are recognized on the lease commencement date. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term. In addition, the right-of-use asset is reduced by impairment losses and adjusted for certain remeasurements of the lease liabilities, if any. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, our incremental rate of borrowing is used. The lease liability is subsequently measured at amortized cost using the effective interest method. The lease liability is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in our estimate of the amount expected to be payable under a residual value guarantee, if we change our &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;assessment of whether we will exercise a purchase, extension or termination option, or if the underlying lease contract is amended.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have elected not to separate fixed non-lease components from lease components and instead account for each lease component and associated fixed non-lease components as a single lease component.  &lt;/span&gt;&lt;/div&gt;We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less. We recognize the lease payments associated with these leases as an expense on a straight-line basis over the lease term.</ifrs-full:DescriptionOfAccountingPolicyForLeasesExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory contextRef="c-1" id="f-303">iluted loss per share is computed in a manner consistent with basic loss per share except that the weighted average common shares outstanding are adjusted to include the effects of all dilutive potential common shares, which comprise stock options, share awards, and warrants.</ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-304">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is provided on bases and at rates designed to amortize the cost of the assets over their estimated useful lives. Depreciation is recorded using the declining balance method at the following annual rates:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.608%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-305">Depreciation is recorded using the declining balance method at the following annual rates:&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.608%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Straight-line over the term of the lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment and Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="c-52"
      decimals="INF"
      id="f-306"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="c-53"
      decimals="INF"
      id="f-307"
      unitRef="number">0.20</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <oncyf:PropertyPlantandEquipmentAnnualDepreciationRate
      contextRef="c-54"
      decimals="INF"
      id="f-308"
      unitRef="number">0.30</oncyf:PropertyPlantandEquipmentAnnualDepreciationRate>
    <ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory contextRef="c-1" id="f-309">Research and development costs are expensed as incurred, net of recoveries. We record accruals for the estimated costs of our research and development activities performed by third parties. Advance payments for goods or services that will be used or rendered for future research and development activities are capitalized as prepaid expenses and recognized as an expense as the related goods are delivered or the related services are performed. Development costs that meet specific criteria related to technical, market, and financial feasibility will be capitalized. To date, all development costs have been expensed.</ifrs-full:DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory>
    <ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue contextRef="c-1" id="f-310">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue relates to a long-term contract associated with a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai"). The pricing for the contract was based on the specific negotiations with Adlai and included non-refundable upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. We account for a contract with a customer when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance, and the collectability of consideration is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Licensing Agreement, we have granted a regional license to our intellectual property. The granting of this license is accounted for as one performance obligation. We have determined that we provide Adlai with a right to access our intellectual property and, therefore, recognize revenue related to the upfront license fee over time. Revenue is recognized based on the extent of progress toward completion of the performance obligation using the input method. Under the input method, the extent of progress toward completion is measured based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligation. We use this method because Adlai receives and consumes the benefit of our intellectual property as we undertake activities that impact the intellectual property. Management must use judgment in making assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contract also provides for development and regulatory milestone payments, royalties, and sales-based milestone payments. These amounts are contingent on the occurrence of a future event and, therefore, give rise to variable consideration. We estimate variable consideration at the most likely amount to which we expect to be entitled. We include estimated amounts in the transaction price when it becomes highly probable that the amount will not be subject to significant reversal when the uncertainty associated with the variable consideration is resolved. Our estimates of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of our anticipated performance and all information (historical, current, and forecasted) that is reasonably available to us. Based on this information and related analysis, any quarterly adjustments to revenue are recognized as necessary in the period they become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The upfront license fee is not considered a significant financing component because it is used to meet working capital demands that can be higher in the early stages of a contract and to protect us from the other party failing to adequately complete some or all of its obligations under the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from sales-based royalties and the achievement of annual sales volumes will be recognized when the subsequent sale occurs, as the license of the intellectual property is the predominant item to which the royalty relates. We consider payments associated with the achievement of annual sales volumes to be, in substance, royalty payments, and we will recognize such sales-based payments upon achievement of such sales volumes, provided that collection is reasonably assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contract liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Our contract liability includes upfront license fees and billings in excess of the revenue recognized. Contract liabilities are recognized as revenue as or when we perform under the contract. We classify our contract liability as current or non-current based on the timing of when we expect to recognize revenue.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfAccountingPolicyForRecognitionOfRevenue>
    <ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory contextRef="c-1" id="f-311">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock option plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have one stock option plan (the "Stock Option Plan") available to directors, officers, employees, and consultants with grants under the Stock Option Plan approved from time to time by our Board of Directors (the "Board"). Under the Stock Option Plan, no option shall be granted with an exercise price at a discount to the closing price of our stock on the Toronto Stock Exchange on the last trading date prior to the date of the grant. Vesting is provided at the discretion of the Board, and the expiration of options is to be no greater than ten years from the date of grant. Exercised stock options are settled with common shares issued from treasury. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the fair value-based method of accounting for stock option awards granted under the Stock Option Plan. We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the fair value of the stock options granted using the Black-Scholes valuation model over the vesting periods of the respective options. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of options that are expected to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options awarded to non-employees are accounted for at the fair value of the goods received or the services rendered. The fair value is measured at the date the Company obtains the goods or the date the counterparty renders the service. If the fair value of the goods or services cannot be reliably measured, the fair value of the options granted will be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share award plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share award plan (the "Share Award Plan") is available to directors, officers, employees, and consultants. Under our Share Award Plan, performance and restricted share awards may be approved from time to time by the Board. Performance share awards  ("PSAs") can be awarded to certain officers and employees to which common shares shall be issued based upon achieving the applicable performance criteria. Restricted share awards ("RSAs") can be awarded to certain officers, employees, non-employee directors, and consultants to which common shares shall be issued in accordance with the Share Award Plan.  &lt;/span&gt;&lt;/div&gt;We recognize compensation expense and a corresponding adjustment to contributed surplus equal to the market value of our common shares at the grant date based on the number of PSAs/RSAs expected to vest, recognized over the vesting period. Compensation expense is adjusted for subsequent changes in management&#x2019;s estimate of the number of PSAs/RSAs that are expected to vest. The effect of these changes is recognized in the period of the change.</ifrs-full:DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory>
    <oncyf:NumberOfStockOptionPlans contextRef="c-3" decimals="INF" id="f-312" unitRef="plan">1</oncyf:NumberOfStockOptionPlans>
    <oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement contextRef="c-1" id="f-313">P10Y</oncyf:MaximumTermOfOptionsGrantedForSharebasedPaymentArrangement>
    <ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations contextRef="c-1" id="f-314">&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Adoption of New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Presentation of Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and IFRS Practice Statement 2 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Making Materiality Judgements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in which it provides guidance and examples to help entities apply materiality judgements to accounting policy disclosures. The amendments became effective on January 1, 2023. Adopting the amendments did not have a&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;material impact on our consolidated financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 8 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Policies, Changes in Accounting Estimates and Errors&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, the IASB issued amendments to IAS 8, in which it introduced a new definition of 'accounting estimates'. The amendments clarify the distinction between changes in accounting estimates, changes in accounting policies, and the correction of errors. Also, the amendments clarify how entities use measurement techniques and inputs to develop accounting estimates. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 12 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the IASB issued amendments to IAS 12, which narrowed the scope of the initial recognition exception under IAS 12, so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences. The amendments became effective on January 1, 2023. Adopting the amendments did not have a material impact on our consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounting Standards and Interpretations Issued but Not Yet Effective&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;IAS 1 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Classification of Liabilities as Current or Non-Current&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, the IASB issued amendments to clarify how conditions with which an entity must comply within 12 months after the reporting period affect the classification of a liability. This is in addition to the amendment from January 2020 where the IASB issued amendments to IAS 1 Presentation of Financial Statements, to provide a more general approach to the presentation of liabilities as current or non-current based on contractual arrangements in place at the reporting date. These amendments specify that the rights and conditions existing at the end of the reporting period are relevant in determining whether the Company has a right to defer settlement of a liability by at least 12 months, provided that management's expectations are not a relevant consideration as to whether the Company will exercise its rights to defer settlement of a liability and clarify when a liability is considered settled. The amendments are effective for annual periods beginning on or after January 1, 2024, and are to be applied retrospectively. The adoption of this standard is not expected to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory contextRef="c-1" id="f-315">Significant Judgments, Estimates, and Assumptions&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of our consolidated financial statements requires us to make judgments, estimates, and assumptions that affect the application of accounting policies and the reported amount and disclosures in our consolidated financial statements and accompanying notes. Management makes estimates based on our best knowledge of current events and actions that the Company may undertake in the future. We consider the potential impact of certain external factors outside of our control, including global political conflicts, supply chain disruptions, pandemics, inflation, rising interest rates, and liquidity, when making certain estimates and judgments relating to the preparation of these consolidated financial statements. Estimates and underlying assumptions are reviewed on an ongoing basis. Actual results could differ from these estimates, and such differences could be material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant estimates made by management affecting our consolidated financial statements include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a Licensing Agreement which provides, among other payments, upfront license fees in exchange for a regional license to our intellectual property. Management uses its judgment in applying the input method when determining the extent of progress toward completion of the performance obligation. Revenue recognition requires assumptions and estimates regarding total estimated costs, the complexity of the work to be performed, and the length of time to complete the performance obligation, among other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Clinical trial and manufacturing expenses&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial and manufacturing expenses represent significant components of our research and development expenses, and we outsource a significant portion of these activities to third-party contract research/manufacturing organizations. The financial terms of these agreements are subject to negotiation, vary from contract to contract, and may result in uneven payment flows to these organizations. Payments under the contracts depend on factors such as achieving certain milestones. As part of preparing the consolidated financial statements, we estimate the expense to recognize based on services that the contract research/manufacturing organizations have performed. When making these estimates, we use operational and contractual information from third-party service providers, operational data from internal personnel, and considerable judgment. We base our estimates on the best information available at the time. However, additional information may become available to us which may allow us to make a more accurate estimate in future periods. In this event, we may be required to record adjustments to research and development expenses in future periods when the actual level of activity becomes more certain. Such increases or decreases in cost are generally considered to be changes in estimates and will be reflected in research and development expenses in the period identified.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of share-based compensation &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of share-based compensation and compensation warrants requires determining the most appropriate valuation model, which is dependent on the terms and conditions of the grant. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value of share-based compensation are disclosed in note 11. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of warrant derivative &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating the fair value of the warrant derivative at initial measurement, at each exercise date and at each reporting period requires determining the most appropriate valuation model. This estimate also requires determining the most appropriate inputs to the valuation model, including the expected life, volatility, and dividend yield, and making assumptions about them. The assumptions and inputs used for estimating fair value for warrant derivative issued are disclosed in note 9.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Uncertainties exist with respect to the interpretation of complex tax regulations and the amount and timing of future taxable income. Currently, we are accumulating tax loss carry-forward balances in various tax jurisdictions creating a deferred tax asset. Deferred tax assets are recognized for all unused tax losses to the extent that it is probable that taxable profit will be available against which the losses can be utilized. Management's judgment is required to determine the amount of deferred tax assets that can be recognized based on the likely timing and the level of future taxable profits together with future tax planning strategies.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, we have determined that none of our deferred tax assets should be recognized. Our deferred tax assets are mainly comprised of our net operating losses from prior years, prior year research and development expenses, and non-refundable investment tax credits. These tax pools relate to entities that have a history of losses, have varying expiry dates, and may not be used to offset taxable income within our other subsidiaries. There are also no taxable temporary differences or any tax planning opportunities available that could partly support the recognition of these losses as deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Functional currency&lt;/span&gt;&lt;/div&gt;We assess the relevant factors related to the primary economic environment in which our entities operate to determine the functional currency. Where the assessment of primary indicators are mixed, we assess the secondary indicators, including the relationship between the foreign operations and reporting entity.</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <ifrs-full:DisclosureOfOtherLiabilitiesExplanatory contextRef="c-1" id="f-317">Other Assets and Liabilities &lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial was jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2023, we recorded nil (December&#160;31, 2022 - US$360 ($488)) in other receivables related to unbilled BRACELET-1 cost from Pfizer. As at December&#160;31, 2023, Pfizer had completed its funding obligations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;We paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2023, we recorded $1,319 (December&#160;31, 2022 - $1,327) in current prepaid expenses and nil (December&#160;31, 2022 -  $998) in non-current prepaid expenses.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$5&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at December&#160;31, 2023, we recorded US$225 ($298) in other liabilities representing unapplied funding received from PanCAN.</ifrs-full:DisclosureOfOtherLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfOtherAssetsExplanatory contextRef="c-1" id="f-316">Other Assets and Liabilities &lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;In 2019, we entered into a co-development agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc ("Pfizer"), known as BRACELET-1. This phase 2 clinical trial was jointly funded by Oncolytics and Pfizer. As at December&#160;31, 2023, we recorded nil (December&#160;31, 2022 - US$360 ($488)) in other receivables related to unbilled BRACELET-1 cost from Pfizer. As at December&#160;31, 2023, Pfizer had completed its funding obligations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;We paid deposits to our manufacturer related to the production of pelareorep required for our clinical trial program. We classify the related prepaid expenses as current or non-current based on the timing of when we expect to receive services. As at December&#160;31, 2023, we recorded $1,319 (December&#160;31, 2022 - $1,327) in current prepaid expenses and nil (December&#160;31, 2022 -  $998) in non-current prepaid expenses.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;In 2023, we were selected by the Pancreatic Cancer Action Network (PanCAN) as the recipient of its Therapeutic Accelerator Award to conduct a clinical trial with pelareorep in combination with modified FOLFIRINOX chemotherapy with or without an immune checkpoint inhibitor in pancreatic cancer patients. Under the terms of the award agreement, we are entitled to receive up to US$5&#160;million in funding for eligible research expenses, and we must comply with the conditions set out with the award agreement, including providing periodic performance progress reports. As at December&#160;31, 2023, we recorded US$225 ($298) in other liabilities representing unapplied funding received from PanCAN.</ifrs-full:DisclosureOfOtherAssetsExplanatory>
    <ifrs-full:OtherReceivables contextRef="c-55" decimals="-3" id="f-318" unitRef="cad">0</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c-56" decimals="-3" id="f-319" unitRef="usd">360000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables contextRef="c-56" decimals="-3" id="f-320" unitRef="cad">488000</ifrs-full:OtherReceivables>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-3" decimals="-3" id="f-321" unitRef="cad">1319000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:CurrentPrepaidExpenses contextRef="c-4" decimals="-3" id="f-322" unitRef="cad">1327000</ifrs-full:CurrentPrepaidExpenses>
    <ifrs-full:NoncurrentPrepayments contextRef="c-3" decimals="-3" id="f-323" unitRef="cad">0</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:NoncurrentPrepayments contextRef="c-4" decimals="-3" id="f-324" unitRef="cad">998000</ifrs-full:NoncurrentPrepayments>
    <ifrs-full:OtherReceivables contextRef="c-57" decimals="-3" id="f-325" unitRef="cad">5000000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-57" decimals="-3" id="f-326" unitRef="usd">225000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities contextRef="c-57" decimals="-3" id="f-327" unitRef="cad">298000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory contextRef="c-1" id="f-328">Property and Equipment&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.471%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.371%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.762%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Computer Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Office Equipment and Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions, net of foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net book value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;85&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;128&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;282&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-58" decimals="-3" id="f-329" unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-59" decimals="-3" id="f-330" unitRef="cad">406000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-60" decimals="-3" id="f-331" unitRef="cad">217000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-61" decimals="-3" id="f-332" unitRef="cad">228000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-62" decimals="-3" id="f-333" unitRef="cad">913000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-63" decimals="-3" id="f-334" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-64" decimals="-3" id="f-335" unitRef="cad">23000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-65" decimals="-3" id="f-336" unitRef="cad">31000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-66" decimals="-3" id="f-337" unitRef="cad">3000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-67" decimals="-3" id="f-338" unitRef="cad">57000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-68" decimals="-3" id="f-339" unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-69" decimals="-3" id="f-340" unitRef="cad">429000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-70" decimals="-3" id="f-341" unitRef="cad">248000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-71" decimals="-3" id="f-342" unitRef="cad">231000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-72" decimals="-3" id="f-343" unitRef="cad">970000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-73" decimals="-3" id="f-344" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-74" decimals="-3" id="f-345" unitRef="cad">7000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-75" decimals="-3" id="f-346" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-76" decimals="-3" id="f-347" unitRef="cad">0</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment contextRef="c-77" decimals="-3" id="f-348" unitRef="cad">7000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-78" decimals="-3" id="f-349" unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-79" decimals="-3" id="f-350" unitRef="cad">436000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-80" decimals="-3" id="f-351" unitRef="cad">248000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-81" decimals="-3" id="f-352" unitRef="cad">231000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-82" decimals="-3" id="f-353" unitRef="cad">977000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-83" decimals="-3" id="f-354" unitRef="cad">-51000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-84" decimals="-3" id="f-355" unitRef="cad">-285000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-85" decimals="-3" id="f-356" unitRef="cad">-58000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-86" decimals="-3" id="f-357" unitRef="cad">-127000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-87" decimals="-3" id="f-358" unitRef="cad">-521000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-88" decimals="-3" id="f-359" unitRef="cad">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-89" decimals="-3" id="f-360" unitRef="cad">36000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-90" decimals="-3" id="f-361" unitRef="cad">34000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-91" decimals="-3" id="f-362" unitRef="cad">21000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-92" decimals="-3" id="f-363" unitRef="cad">93000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-93" decimals="-3" id="f-364" unitRef="cad">-53000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-94" decimals="-3" id="f-365" unitRef="cad">-321000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-95" decimals="-3" id="f-366" unitRef="cad">-92000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-96" decimals="-3" id="f-367" unitRef="cad">-148000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-97" decimals="-3" id="f-368" unitRef="cad">-614000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-98" decimals="-3" id="f-369" unitRef="cad">2000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-99" decimals="-3" id="f-370" unitRef="cad">30000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-100" decimals="-3" id="f-371" unitRef="cad">28000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-101" decimals="-3" id="f-372" unitRef="cad">21000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:DepreciationPropertyPlantAndEquipment contextRef="c-102" decimals="-3" id="f-373" unitRef="cad">81000</ifrs-full:DepreciationPropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-103" decimals="-3" id="f-374" unitRef="cad">-55000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-104" decimals="-3" id="f-375" unitRef="cad">-351000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-105" decimals="-3" id="f-376" unitRef="cad">-120000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-106" decimals="-3" id="f-377" unitRef="cad">-169000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-107" decimals="-3" id="f-378" unitRef="cad">-695000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-108" decimals="-3" id="f-379" unitRef="cad">9000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-109" decimals="-3" id="f-380" unitRef="cad">108000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-110" decimals="-3" id="f-381" unitRef="cad">156000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-111" decimals="-3" id="f-382" unitRef="cad">83000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-383" unitRef="cad">356000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-112" decimals="-3" id="f-384" unitRef="cad">7000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-113" decimals="-3" id="f-385" unitRef="cad">85000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-114" decimals="-3" id="f-386" unitRef="cad">128000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-115" decimals="-3" id="f-387" unitRef="cad">62000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-388" unitRef="cad">282000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory contextRef="c-1" id="f-389">Accounts payable and accrued liabilities&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,490&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock contextRef="c-1" id="f-390">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.250%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade payables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,490&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,572&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DetailedDisclosureOfTradeAndOtherPayablesExplanatoryTableTextBlock>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-3" decimals="-3" id="f-391" unitRef="cad">1082000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers contextRef="c-4" decimals="-3" id="f-392" unitRef="cad">2252000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c-3" decimals="-3" id="f-393" unitRef="cad">2490000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:AccrualsClassifiedAsCurrent contextRef="c-4" decimals="-3" id="f-394" unitRef="cad">1398000</ifrs-full:AccrualsClassifiedAsCurrent>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-3" decimals="-3" id="f-395" unitRef="cad">3572000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-4" decimals="-3" id="f-396" unitRef="cad">3650000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:DisclosureOfLeasesExplanatory contextRef="c-1" id="f-397">Leases&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our portfolio of leases consists of office spaces with lease terms generally between 3 to 6 years. We currently do not have leases with residual value guarantees. We have variable lease payments related to office space lease operating costs that are not material. Lease liabilities have been measured by discounting future lease payments using our incremental borrowing rate as rates implicit in the leases were not readily determinable. The weighted-average rate applied was 15%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, we extended the office lease for our subsidiaries, for which we recorded an addition of $392 to the lease liability and right-of-use asset. Under the terms of the lease, we have the option to extend the lease term for one of our subsidiaries for an additional three years. We did not include the extension option in the lease term as we were not reasonably certain to exercise the option. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our lease liabilities activity for the years ended December&#160;31:    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liability as at December&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liability &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfLeasesExplanatory>
    <oncyf:OperatingLeaseRemainingLeaseTerm contextRef="c-116" id="f-398">P3Y</oncyf:OperatingLeaseRemainingLeaseTerm>
    <oncyf:OperatingLeaseRemainingLeaseTerm contextRef="c-117" id="f-399">P6Y</oncyf:OperatingLeaseRemainingLeaseTerm>
    <ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16 contextRef="c-3" decimals="2" id="f-400" unitRef="number">0.15</ifrs-full:WeightedAverageLesseesIncrementalBorrowingRateAppliedToLeaseLiabilitiesRecognisedAtDateOfInitialApplicationOfIFRS16>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-401" unitRef="cad">392000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-1" decimals="-3" id="f-402" unitRef="cad">392000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory contextRef="c-1" id="f-403">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our right-of-use assets activity for the years ended December&#160;31:      &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;         &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;296&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(322)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(299)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;365&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfQuantitativeInformationAboutRightofuseAssetsExplanatory>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-404" unitRef="cad">296000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-24" decimals="-3" id="f-405" unitRef="cad">584000</ifrs-full:RightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-1" decimals="-3" id="f-406" unitRef="cad">392000</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:AdditionsToRightofuseAssets contextRef="c-7" decimals="-3" id="f-407" unitRef="cad">0</ifrs-full:AdditionsToRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-1" decimals="-3" id="f-408" unitRef="cad">322000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-7" decimals="-3" id="f-409" unitRef="cad">299000</ifrs-full:DepreciationRightofuseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets contextRef="c-1" decimals="-3" id="f-410" unitRef="cad">-1000</oncyf:ForeignExchangeImpactRightofUseAssets>
    <oncyf:ForeignExchangeImpactRightofUseAssets contextRef="c-7" decimals="-3" id="f-411" unitRef="cad">11000</oncyf:ForeignExchangeImpactRightofUseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-3" decimals="-3" id="f-412" unitRef="cad">365000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets contextRef="c-4" decimals="-3" id="f-413" unitRef="cad">296000</ifrs-full:RightofuseAssets>
    <oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock contextRef="c-1" id="f-414">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our lease liabilities activity for the years ended December&#160;31:    &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;              &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.422%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(407)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(381)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;71&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DisclosureOfQuantitativeInformationAboutLeaseLiabilitiesTextBlock>
    <ifrs-full:LeaseLiabilities contextRef="c-4" decimals="-3" id="f-415" unitRef="cad">373000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-24" decimals="-3" id="f-416" unitRef="cad">655000</ifrs-full:LeaseLiabilities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-1" decimals="-3" id="f-417" unitRef="cad">392000</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities contextRef="c-7" decimals="-3" id="f-418" unitRef="cad">0</ifrs-full:IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities>
    <ifrs-full:CashOutflowForLeases contextRef="c-1" decimals="-3" id="f-419" unitRef="cad">407000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:CashOutflowForLeases contextRef="c-7" decimals="-3" id="f-420" unitRef="cad">381000</ifrs-full:CashOutflowForLeases>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-1" decimals="-3" id="f-421" unitRef="cad">71000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <ifrs-full:InterestExpenseOnLeaseLiabilities contextRef="c-7" decimals="-3" id="f-422" unitRef="cad">80000</ifrs-full:InterestExpenseOnLeaseLiabilities>
    <oncyf:GainsLossesFromForeignExchangeImpact contextRef="c-1" decimals="-3" id="f-423" unitRef="cad">-6000</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:GainsLossesFromForeignExchangeImpact contextRef="c-7" decimals="-3" id="f-424" unitRef="cad">19000</oncyf:GainsLossesFromForeignExchangeImpact>
    <ifrs-full:LeaseLiabilities contextRef="c-3" decimals="-3" id="f-425" unitRef="cad">423000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities contextRef="c-4" decimals="-3" id="f-426" unitRef="cad">373000</ifrs-full:LeaseLiabilities>
    <ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory contextRef="c-1" id="f-427">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our total undiscounted lease liability as at December&#160;31, 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less than one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;One to five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;More than five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease liability &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-118" decimals="-3" id="f-428" unitRef="cad">202000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-119" decimals="-3" id="f-429" unitRef="cad">311000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-120" decimals="-3" id="f-430" unitRef="cad">0</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:GrossLeaseLiabilities contextRef="c-3" decimals="-3" id="f-431" unitRef="cad">513000</ifrs-full:GrossLeaseLiabilities>
    <ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory contextRef="c-1" id="f-432">Warrant Derivative&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our common share purchase warrants ("warrants") with a U.S. dollar exercise price, which differs from our functional currency, are treated as a derivative measured at fair value, and revalued each period end at fair value through profit and loss. The fair value of these warrants is presented as a liability on our consolidated statement of financial position. As these warrants are exercised, the fair value at the date of exercise and the associated non-cash liability will be included in our share capital along with the proceeds from the exercise. If these warrants expire, the non-cash warrant liability is reversed through the consolidated statement of loss and comprehensive loss. There is no cash flow impact as a result of the accounting treatment for changes in the fair value of the warrant derivative or when warrants expire unexercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the value of our warrant derivative were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of Warrant Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,731,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding warrant derivative as at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$0.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 16, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,667,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,731,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. Each warrant entitles the holder to purchase one common share at an exercise price of US$2.81 up to 60 months from the date of issuance. The expiry of the warrants may be accelerated by the Company at any time prior to the expiry date if the volume weighted average price (if applicable, as converted to U.S. dollars at the Bank of Canada posted rate for the respective trading day) of the issued and outstanding common shares on the Toronto Stock Exchange or such other principal stock exchange on which the common shares are listed and posted for trading is greater than US$6.50 for any 20 consecutive trading days, at which time the Company may, within 10 business days, accelerate the expiry date by issuing a press release announcing the reduced warrant term whereupon the warrants will expire on or after the 75th calendar day after the date of such press release.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. The difference between the fair value of the warrants and their allocated proceeds was a discount of $1,822, which is amortized on a straight-line basis over the five-year expected life of the warrants and recorded under change in fair value of warrant derivative on our consolidated statement of loss and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the warrant derivative with an exercise price of US$2.81 was determined using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 7,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;August 8,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$1.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$0.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$0.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialLiabilitiesExplanatory>
    <ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory contextRef="c-1" id="f-433">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the value of our warrant derivative were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of Warrant Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,822)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of discount on warrants issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,431)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign exchange impact&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,731,085&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our outstanding warrant derivative as at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.542%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issuance date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Warrants Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$0.90&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 16, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 16, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,667,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.81&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,731,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the warrant derivative with an exercise price of US$2.81 was determined using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.169%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.423%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 7,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;August 8,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$1.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$2.26&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.6 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value per warrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$0.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;US$0.70&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFairValueMeasurementOfLiabilitiesExplanatory>
    <oncyf:NumberOfWarrantsOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-434"
      unitRef="shares">64035</oncyf:NumberOfWarrantsOutstanding>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-24" decimals="-3" id="f-435" unitRef="cad">56000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-121" decimals="-3" id="f-436" unitRef="cad">20000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <oncyf:GainsLossesFromForeignExchangeImpact contextRef="c-121" decimals="-3" id="f-437" unitRef="cad">3000</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:NumberOfWarrantsOutstanding contextRef="c-4" decimals="INF" id="f-438" unitRef="shares">64035</oncyf:NumberOfWarrantsOutstanding>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-4" decimals="-3" id="f-439" unitRef="cad">79000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <oncyf:IssueOfEquityShares
      contextRef="c-122"
      decimals="INF"
      id="f-440"
      unitRef="shares">7667050</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-122" decimals="-3" id="f-441" unitRef="cad">7360000</ifrs-full:IssueOfEquity>
    <oncyf:WarrantLiabilityUnamortizedDiscount contextRef="c-122" decimals="-3" id="f-442" unitRef="cad">1822000</oncyf:WarrantLiabilityUnamortizedDiscount>
    <oncyf:WarrantLiabilityAmortizedDiscount contextRef="c-122" decimals="-3" id="f-443" unitRef="cad">146000</oncyf:WarrantLiabilityAmortizedDiscount>
    <ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives contextRef="c-122" decimals="-3" id="f-444" unitRef="cad">-5431000</ifrs-full:GainsLossesOnChangeInFairValueOfDerivatives>
    <oncyf:GainsLossesFromForeignExchangeImpact contextRef="c-122" decimals="-3" id="f-445" unitRef="cad">-132000</oncyf:GainsLossesFromForeignExchangeImpact>
    <oncyf:NumberOfWarrantsOutstanding contextRef="c-3" decimals="INF" id="f-446" unitRef="shares">7731085</oncyf:NumberOfWarrantsOutstanding>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-3" decimals="-3" id="f-447" unitRef="cad">200000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <oncyf:WarrantExercisePrice
      contextRef="c-123"
      decimals="2"
      id="f-448"
      unitRef="usdPerShare">0.90</oncyf:WarrantExercisePrice>
    <oncyf:NumberOfWarrantsOutstanding
      contextRef="c-123"
      decimals="INF"
      id="f-449"
      unitRef="shares">64035</oncyf:NumberOfWarrantsOutstanding>
    <oncyf:WarrantExercisePrice
      contextRef="c-124"
      decimals="2"
      id="f-450"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:NumberOfWarrantsOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-451"
      unitRef="shares">6667000</oncyf:NumberOfWarrantsOutstanding>
    <oncyf:WarrantExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-452"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:NumberOfWarrantsOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-453"
      unitRef="shares">1000050</oncyf:NumberOfWarrantsOutstanding>
    <oncyf:NumberOfWarrantsOutstanding contextRef="c-3" decimals="INF" id="f-454" unitRef="shares">7731085</oncyf:NumberOfWarrantsOutstanding>
    <oncyf:NumberOfWarrantsAndSharesOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-455"
      unitRef="shares">6667000</oncyf:NumberOfWarrantsAndSharesOutstanding>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-126" decimals="-3" id="f-456" unitRef="cad">20185000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-126" decimals="-3" id="f-457" unitRef="usd">15001000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-127"
      decimals="2"
      id="f-458"
      unitRef="usdPerShare">2.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:NumberOfWarrantsAndSharesOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-459"
      unitRef="shares">1000050</oncyf:NumberOfWarrantsAndSharesOutstanding>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-128" decimals="-3" id="f-460" unitRef="cad">3077000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-128" decimals="-3" id="f-461" unitRef="usd">2250000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-129"
      decimals="2"
      id="f-462"
      unitRef="usdPerShare">2.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:CommonSharesPerUnit
      contextRef="c-130"
      decimals="INF"
      id="f-463"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:CommonSharesPerUnit
      contextRef="c-131"
      decimals="INF"
      id="f-464"
      unitRef="shares">1</oncyf:CommonSharesPerUnit>
    <oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1
      contextRef="c-132"
      decimals="INF"
      id="f-465"
      unitRef="shares">1</oncyf:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight1>
    <oncyf:WarrantExercisePrice
      contextRef="c-133"
      decimals="2"
      id="f-466"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement contextRef="c-128" id="f-467">P60M</oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice
      contextRef="c-125"
      decimals="2"
      id="f-468"
      unitRef="usdPerShare">6.50</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice
      contextRef="c-124"
      decimals="2"
      id="f-469"
      unitRef="usdPerShare">6.50</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdTradingPrice>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays contextRef="c-126" decimals="INF" id="f-470" unitRef="d">20</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays contextRef="c-128" decimals="INF" id="f-471" unitRef="d">20</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementThresholdConsecutiveTradingDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays contextRef="c-126" decimals="INF" id="f-472" unitRef="d">10</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays contextRef="c-128" decimals="INF" id="f-473" unitRef="d">10</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementAcceleratedThresholdTradingDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays contextRef="c-128" decimals="INF" id="f-474" unitRef="d">75</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays>
    <oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays contextRef="c-126" decimals="INF" id="f-475" unitRef="d">75</oncyf:OtherEquityInstrumentsInShareBasedPaymentArrangementExpirationDays>
    <ifrs-full:IssueOfEquity contextRef="c-134" decimals="-3" id="f-476" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:WarrantLiability contextRef="c-3" decimals="-3" id="f-477" unitRef="cad">7360000</ifrs-full:WarrantLiability>
    <oncyf:WarrantLiabilityUnamortizedDiscount contextRef="c-1" decimals="-3" id="f-478" unitRef="cad">1822000</oncyf:WarrantLiabilityUnamortizedDiscount>
    <oncyf:WarrantsTerm contextRef="c-1" id="f-479">P5Y</oncyf:WarrantsTerm>
    <oncyf:WarrantExercisePrice
      contextRef="c-133"
      decimals="2"
      id="f-480"
      unitRef="usdPerShare">2.81</oncyf:WarrantExercisePrice>
    <oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="c-135"
      decimals="2"
      id="f-481"
      unitRef="usdPerShare">1.35</oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="c-136"
      decimals="2"
      id="f-482"
      unitRef="usdPerShare">2.39</oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="c-137"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">2.26</oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted contextRef="c-135" decimals="3" id="f-484" unitRef="number">0.032</oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted contextRef="c-136" decimals="3" id="f-485" unitRef="number">0.039</oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted contextRef="c-137" decimals="3" id="f-486" unitRef="number">0.038</oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted contextRef="c-135" decimals="1" id="f-487" unitRef="year">4.6</oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted>
    <oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted contextRef="c-136" decimals="1" id="f-488" unitRef="year">5.0</oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted>
    <oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted contextRef="c-137" decimals="1" id="f-489" unitRef="year">5.0</oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted>
    <oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted contextRef="c-135" decimals="3" id="f-490" unitRef="number">0.365</oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted contextRef="c-136" decimals="3" id="f-491" unitRef="number">0.365</oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted contextRef="c-137" decimals="3" id="f-492" unitRef="number">0.365</oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="c-135"
      decimals="INF"
      id="f-493"
      unitRef="number">0</oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="c-136"
      decimals="INF"
      id="f-494"
      unitRef="number">0</oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="c-137"
      decimals="INF"
      id="f-495"
      unitRef="number">0</oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c-135"
      decimals="2"
      id="f-496"
      unitRef="usdPerShare">0.18</oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c-136"
      decimals="2"
      id="f-497"
      unitRef="usdPerShare">0.79</oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c-137"
      decimals="2"
      id="f-498"
      unitRef="usdPerShare">0.70</oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory contextRef="c-1" id="f-499">Share Capital&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Authorized:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unlimited number of no par value common shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,166,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,401,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,043,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,235,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,327,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,978,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74,423,960&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;430,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$40,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. During the year ended December&#160;31, 2021, we sold 5,685,097 common shares for gross proceeds of $23,413 (US$18,503) at an average price of $4.12 (US$3.25). We received proceeds of $22,711 (US$17,948) after commissions of $702 (US$555). In total, we incurred share issue costs (including commissions) of $707.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold 2,719,770 (2021 - 2,715,932) common shares for gross proceeds of $5,744 (US$4,560) (2021 - $10,755 (US$8,655)) at an average price of $2.11 (US$1.68) (2021 - $3.96 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(US$3.19)). We received proceeds of $5,572 (US$4,423) (2021 - $10,432 (US$8,395)) after commissions of $172 (US$137) (2021 - $323 (US$260)). In total, we incurred share issue costs (including commissions) of $209 (2021 - $549). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the years ended December&#160;31, 2023 and 2022, no warrants were exercised. During the year ended December&#160;31, 2021, 201,722 warrants with a fair value of $456 were exercised for gross proceeds of $231 (US$182).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2023, we sold 4,978,605 (2022 - 3,515,462) common shares for gross proceeds of $10,676 (US$7,904) (2022 - $7,594 (US$5,632)) at an average price of $2.14 (US$1.59) (2022 - $2.16 (US$1.60)). We received proceeds of $10,356 (US$7,667) (2022 - $7,366 (US$5,463)) after commissions of $320 (US$237) (2022 - $228 (US$169)). In total, we incurred share issue costs (including commissions) of $415 (2022 - $555).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants (see note 11). In total, we incurred transaction costs of $3,130 (including a fair value of $638 (US$473) for the compensation warrants), of which $2,390 were allocated to share issue costs and $740 were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory contextRef="c-1" id="f-500">&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,166,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,401,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to warrant derivative exercised&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(c)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,256)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,043,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to incentive share award plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,235,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(764)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,327,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;404,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to stock option plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to "At the Market" (ATM) equity distribution agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(d)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,978,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued pursuant to public offering&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(e)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,667,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,805)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;74,423,960&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;430,906&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On June 15, 2020, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up US$40,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on March 4, 2021. During the year ended December&#160;31, 2021, we sold 5,685,097 common shares for gross proceeds of $23,413 (US$18,503) at an average price of $4.12 (US$3.25). We received proceeds of $22,711 (US$17,948) after commissions of $702 (US$555). In total, we incurred share issue costs (including commissions) of $707.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On March 5, 2021, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allowed us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$80,000 over a 16-month period through the facilities of the Nasdaq Capital Market in the United States. This sales agreement was terminated on June 16, 2022. During the year ended December&#160;31, 2022, we sold 2,719,770 (2021 - 2,715,932) common shares for gross proceeds of $5,744 (US$4,560) (2021 - $10,755 (US$8,655)) at an average price of $2.11 (US$1.68) (2021 - $3.96 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(US$3.19)). We received proceeds of $5,572 (US$4,423) (2021 - $10,432 (US$8,395)) after commissions of $172 (US$137) (2021 - $323 (US$260)). In total, we incurred share issue costs (including commissions) of $209 (2021 - $549). &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 16, 2019, pursuant to an underwritten public offering, we issued units consisting of common shares and warrants. During the years ended December&#160;31, 2023 and 2022, no warrants were exercised. During the year ended December&#160;31, 2021, 201,722 warrants with a fair value of $456 were exercised for gross proceeds of $231 (US$182).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(d)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;On June 17, 2022, we entered into an ATM equity distribution agreement with Canaccord Genuity Inc. The ATM allows us to issue common shares, at prevailing market prices, with an aggregate offering value of up to US$65,000 over a 25-month period through the facilities of the Nasdaq Capital Market in the United States. During the year ended December&#160;31, 2023, we sold 4,978,605 (2022 - 3,515,462) common shares for gross proceeds of $10,676 (US$7,904) (2022 - $7,594 (US$5,632)) at an average price of $2.14 (US$1.59) (2022 - $2.16 (US$1.60)). We received proceeds of $10,356 (US$7,667) (2022 - $7,366 (US$5,463)) after commissions of $320 (US$237) (2022 - $228 (US$169)). In total, we incurred share issue costs (including commissions) of $415 (2022 - $555).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(e)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;On August 8, 2023, pursuant to an underwritten public offering, we issued 6,667,000 units for gross proceeds of $20,185 (US$15,001) at a price of US$2.25 per unit. On September 7, 2023, pursuant to the over-allotment option exercised by the underwriter, we issued an additional 1,000,050 units for gross proceeds of $3,077 (US$2,250) at a price of US$2.25 per unit. Each unit consisted of one common share and one warrant, which were immediately separable and issued separately in this offering. These warrants were classified as a financial liability (see note 9). Proceeds were allocated amongst common shares and warrants by applying a relative fair value approach, which resulted in $17,724 recorded in share capital and an initial warrant derivative liability of $7,360. In consideration of the services rendered by the underwriter, we issued 536,693 compensation warrants (see note 11). In total, we incurred transaction costs of $3,130 (including a fair value of $638 (US$473) for the compensation warrants), of which $2,390 were allocated to share issue costs and $740 were allocated to operating expenses, based on the relative fair values of the common share and warrant of each unit.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <ifrs-full:NumberOfSharesIssued contextRef="c-9" decimals="INF" id="f-501" unitRef="shares">46166980</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-9" decimals="-3" id="f-502" unitRef="cad">356824000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="c-138"
      decimals="INF"
      id="f-503"
      unitRef="shares">123159</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-138" decimals="-3" id="f-504" unitRef="cad">381000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-139"
      decimals="INF"
      id="f-505"
      unitRef="shares">150899</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-139" decimals="-3" id="f-506" unitRef="cad">544000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-140"
      decimals="INF"
      id="f-507"
      unitRef="shares">8401029</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-140" decimals="-3" id="f-508" unitRef="cad">34168000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-141"
      decimals="INF"
      id="f-509"
      unitRef="shares">201722</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-141" decimals="-3" id="f-510" unitRef="cad">687000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-17" decimals="-3" id="f-511" unitRef="cad">1256000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued
      contextRef="c-19"
      decimals="INF"
      id="f-512"
      unitRef="shares">55043789</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-19" decimals="-3" id="f-513" unitRef="cad">391348000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="c-142"
      decimals="INF"
      id="f-514"
      unitRef="shares">8333</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-142" decimals="-3" id="f-515" unitRef="cad">20000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-143"
      decimals="INF"
      id="f-516"
      unitRef="shares">40560</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-143" decimals="-3" id="f-517" unitRef="cad">98000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-144"
      decimals="INF"
      id="f-518"
      unitRef="shares">6235232</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-144" decimals="-3" id="f-519" unitRef="cad">13338000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-27" decimals="-3" id="f-520" unitRef="cad">764000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued contextRef="c-6" decimals="INF" id="f-521" unitRef="shares">61327914</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-6" decimals="-3" id="f-522" unitRef="cad">404040000</ifrs-full:Equity>
    <oncyf:IssueOfEquityShares
      contextRef="c-145"
      decimals="INF"
      id="f-523"
      unitRef="shares">450391</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-145" decimals="-3" id="f-524" unitRef="cad">1271000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-38"
      decimals="INF"
      id="f-525"
      unitRef="shares">4978605</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-38" decimals="-3" id="f-526" unitRef="cad">10676000</ifrs-full:IssueOfEquity>
    <oncyf:IssueOfEquityShares
      contextRef="c-146"
      decimals="INF"
      id="f-527"
      unitRef="shares">7667050</oncyf:IssueOfEquityShares>
    <ifrs-full:IssueOfEquity contextRef="c-146" decimals="-3" id="f-528" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-36" decimals="-3" id="f-529" unitRef="cad">2805000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:NumberOfSharesIssued contextRef="c-5" decimals="INF" id="f-530" unitRef="shares">74423960</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:Equity contextRef="c-5" decimals="-3" id="f-531" unitRef="cad">430906000</ifrs-full:Equity>
    <oncyf:SharePurchaseAgreementAmount contextRef="c-147" decimals="INF" id="f-532" unitRef="usd">40000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm contextRef="c-148" id="f-533">P25M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="c-149"
      decimals="INF"
      id="f-534"
      unitRef="shares">5685097</oncyf:IssueOfEquityShares>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-149" decimals="-3" id="f-535" unitRef="cad">23413000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-149" decimals="-3" id="f-536" unitRef="usd">18503000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-150"
      decimals="2"
      id="f-537"
      unitRef="cadPerShare">4.12</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-150"
      decimals="2"
      id="f-538"
      unitRef="usdPerShare">3.25</oncyf:SharesIssuedPricePerShare1>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-149" decimals="-3" id="f-539" unitRef="cad">22711000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-149" decimals="-3" id="f-540" unitRef="usd">17948000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-149" decimals="-3" id="f-541" unitRef="cad">702000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-149" decimals="-3" id="f-542" unitRef="usd">555000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-149" decimals="-3" id="f-543" unitRef="cad">707000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:SharePurchaseAgreementAmount contextRef="c-151" decimals="INF" id="f-544" unitRef="usd">80000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm contextRef="c-152" id="f-545">P16M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="c-153"
      decimals="INF"
      id="f-546"
      unitRef="shares">2719770</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="c-154"
      decimals="INF"
      id="f-547"
      unitRef="shares">2715932</oncyf:IssueOfEquityShares>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-153" decimals="-3" id="f-548" unitRef="cad">5744000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-153" decimals="-3" id="f-549" unitRef="usd">4560000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-154" decimals="-3" id="f-550" unitRef="cad">10755000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-154" decimals="-3" id="f-551" unitRef="usd">8655000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-155"
      decimals="2"
      id="f-552"
      unitRef="cadPerShare">2.11</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-155"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">1.68</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-156"
      decimals="2"
      id="f-554"
      unitRef="cadPerShare">3.96</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-156"
      decimals="2"
      id="f-555"
      unitRef="usdPerShare">3.19</oncyf:SharesIssuedPricePerShare1>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-153" decimals="-3" id="f-556" unitRef="cad">5572000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-153" decimals="-3" id="f-557" unitRef="usd">4423000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-154" decimals="-3" id="f-558" unitRef="cad">10432000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-154" decimals="-3" id="f-559" unitRef="usd">8395000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-153" decimals="-3" id="f-560" unitRef="cad">172000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-153" decimals="-3" id="f-561" unitRef="usd">137000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-154" decimals="-3" id="f-562" unitRef="cad">323000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-154" decimals="-3" id="f-563" unitRef="usd">260000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-153" decimals="-3" id="f-564" unitRef="cad">209000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-154" decimals="-3" id="f-565" unitRef="cad">549000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="c-122"
      decimals="INF"
      id="f-566"
      unitRef="shares">0</oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="c-121"
      decimals="INF"
      id="f-567"
      unitRef="shares">0</oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised
      contextRef="c-157"
      decimals="INF"
      id="f-568"
      unitRef="shares">201722</oncyf:ClassOfWarrantOrRightNumberOfWarrantsExercised>
    <oncyf:ClassofWarrantorRightWarrantsExercised contextRef="c-157" decimals="-3" id="f-569" unitRef="cad">456000</oncyf:ClassofWarrantorRightWarrantsExercised>
    <oncyf:ProceedsfromWarrantExercises1 contextRef="c-8" decimals="-3" id="f-570" unitRef="cad">231000</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:ProceedsfromWarrantExercises1 contextRef="c-8" decimals="-3" id="f-571" unitRef="usd">182000</oncyf:ProceedsfromWarrantExercises1>
    <oncyf:SharePurchaseAgreementAmount contextRef="c-158" decimals="INF" id="f-572" unitRef="usd">65000000</oncyf:SharePurchaseAgreementAmount>
    <oncyf:SharePurchaseAgreementTerm contextRef="c-159" id="f-573">P25M</oncyf:SharePurchaseAgreementTerm>
    <oncyf:IssueOfEquityShares
      contextRef="c-160"
      decimals="INF"
      id="f-574"
      unitRef="shares">4978605</oncyf:IssueOfEquityShares>
    <oncyf:IssueOfEquityShares
      contextRef="c-161"
      decimals="INF"
      id="f-575"
      unitRef="shares">3515462</oncyf:IssueOfEquityShares>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-160" decimals="-3" id="f-576" unitRef="cad">10676000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-160" decimals="-3" id="f-577" unitRef="usd">7904000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-161" decimals="-3" id="f-578" unitRef="cad">7594000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-161" decimals="-3" id="f-579" unitRef="usd">5632000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-162"
      decimals="2"
      id="f-580"
      unitRef="cadPerShare">2.14</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-162"
      decimals="2"
      id="f-581"
      unitRef="usdPerShare">1.59</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-163"
      decimals="2"
      id="f-582"
      unitRef="cadPerShare">2.16</oncyf:SharesIssuedPricePerShare1>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-163"
      decimals="2"
      id="f-583"
      unitRef="usdPerShare">1.60</oncyf:SharesIssuedPricePerShare1>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-160" decimals="-3" id="f-584" unitRef="cad">10356000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-160" decimals="-3" id="f-585" unitRef="usd">7667000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-161" decimals="-3" id="f-586" unitRef="cad">7366000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares contextRef="c-161" decimals="-3" id="f-587" unitRef="usd">5463000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-160" decimals="-3" id="f-588" unitRef="cad">320000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-160" decimals="-3" id="f-589" unitRef="usd">237000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-161" decimals="-3" id="f-590" unitRef="cad">228000</oncyf:ShareIssueRelatedCostCommissions>
    <oncyf:ShareIssueRelatedCostCommissions contextRef="c-161" decimals="-3" id="f-591" unitRef="usd">169000</oncyf:ShareIssueRelatedCostCommissions>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-160" decimals="-3" id="f-592" unitRef="cad">415000</ifrs-full:ShareIssueRelatedCost>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-161" decimals="-3" id="f-593" unitRef="cad">555000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:NumberOfWarrantsAndSharesOutstanding
      contextRef="c-124"
      decimals="INF"
      id="f-594"
      unitRef="shares">6667000</oncyf:NumberOfWarrantsAndSharesOutstanding>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-126" decimals="-3" id="f-595" unitRef="cad">20185000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-126" decimals="-3" id="f-596" unitRef="usd">15001000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-124"
      decimals="2"
      id="f-597"
      unitRef="usdPerShare">2.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:NumberOfWarrantsAndSharesOutstanding
      contextRef="c-125"
      decimals="INF"
      id="f-598"
      unitRef="shares">1000050</oncyf:NumberOfWarrantsAndSharesOutstanding>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-128" decimals="-3" id="f-599" unitRef="cad">3077000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:ProceedsFromIssueOfUnitsGross contextRef="c-128" decimals="-3" id="f-600" unitRef="usd">2250000</oncyf:ProceedsFromIssueOfUnitsGross>
    <oncyf:SharesIssuedPricePerShare1
      contextRef="c-125"
      decimals="2"
      id="f-601"
      unitRef="usdPerShare">2.25</oncyf:SharesIssuedPricePerShare1>
    <oncyf:IssueOfEquitySharesNumberOfCommonShares
      contextRef="c-125"
      decimals="INF"
      id="f-602"
      unitRef="shares">1</oncyf:IssueOfEquitySharesNumberOfCommonShares>
    <oncyf:IssueOfEquitySharesNumberOfWarrants
      contextRef="c-125"
      decimals="INF"
      id="f-603"
      unitRef="shares">1</oncyf:IssueOfEquitySharesNumberOfWarrants>
    <ifrs-full:IssueOfEquity contextRef="c-134" decimals="-3" id="f-604" unitRef="cad">17724000</ifrs-full:IssueOfEquity>
    <ifrs-full:WarrantLiability contextRef="c-3" decimals="-3" id="f-605" unitRef="cad">7360000</ifrs-full:WarrantLiability>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-164"
      decimals="INF"
      id="f-606"
      unitRef="shares">536693</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <oncyf:ShareWarrantsIssuedTransactionCosts contextRef="c-164" decimals="-3" id="f-607" unitRef="cad">3130000</oncyf:ShareWarrantsIssuedTransactionCosts>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c-37" decimals="-3" id="f-608" unitRef="cad">638000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c-37" decimals="-3" id="f-609" unitRef="usd">473000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ShareIssueRelatedCost contextRef="c-164" decimals="-3" id="f-610" unitRef="cad">2390000</ifrs-full:ShareIssueRelatedCost>
    <oncyf:ShareWarrantsIssuedOperatingExpense contextRef="c-1" decimals="-3" id="f-611" unitRef="cad">740000</oncyf:ShareWarrantsIssuedOperatingExpense>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory contextRef="c-1" id="f-612">Share-Based Compensation&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock options and share awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Our amended and restated Stock Option Plan and Share Award Plan (collectively, the "Equity Incentive Plans") were approved by our shareholders at the annual general meeting of shareholders on May 9, 2023. Pursuant to our Equity Incentive Plans, we may grant stock options, restricted share awards, and performance share awards. The number of common shares reserved for issuance under our Equity Incentive Plans in aggregate shall not exceed 14% of the total number of issued and outstanding common shares from time to time. As at December&#160;31, 2023, we reserved 10,419,354 common shares for issuance relating to our Equity Incentive Plans. Our share-based compensation expense for the year ended December&#160;31, 2023, was $1,917 (2022 - $2,378; 2021 - $3,826). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Our stock option activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,963,185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,145,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(280,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(314,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(450,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,063,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,039,604&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,165,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.14 - $2.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.01 - $2.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,063,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.71 - $3.11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.12 - $4.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,665,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,385,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.01 - $16.53&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,063,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,039,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Option grants vest either immediately or annually over periods ranging from &lt;span style="-sec-ix-hidden:f-703"&gt;one&lt;/span&gt; to three years.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate fair value. We use historical data to estimate the expected dividend yield&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and expected volatility of our stock in determining the fair value of the stock options. The risk-free interest rate is based on the&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government of Canada benchmark bond yield rates in effect at the time of grant. The expected life of the options represents the&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;estimated length of time the options are expected to remain outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(c)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Our share award activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;403,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (1) The weighted average fair value of the RSAs granted was $2.23in 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, we granted restricted share awards to officers of the Company. Restricted share award grants vest over a three-year period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Compensation warrants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, in consideration of the services rendered by the underwriter as part of a public offering (see note 10(e)), we issued 536,693 compensation warrants. Each compensation warrant is exercisable into one common share at an exercise price of US$2.25 up to 60 months from the date of issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use the Black-Scholes valuation model to estimate the fair value of the services rendered. The expected volatility is based on the Company's common share historical volatility less an estimated market participant risk adjustment. The risk-free interest rate is based on the Government of Canada benchmark bond yield rates with an approximate equivalent remaining term in &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effect at the time of valuation, and the expected life represents the estimated length of time the warrants are expected to remain outstanding. We used the following weighted average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$2.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The resulting fair value of $638 (US$473) was included as part of the public offering transaction costs, which were allocated    to share issue costs and operating expenses based on the relative fair values of the common share and warrant of each unit issued. No compensation warrants were exercised during the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum contextRef="c-3" decimals="INF" id="f-613" unitRef="number">0.14</oncyf:NumberOfSharesReservedForIssueUnderOptionsAndContractsForSaleOfSharesPercentageOfCommonSharesMaximum>
    <ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares
      contextRef="c-165"
      decimals="INF"
      id="f-614"
      unitRef="shares">10419354</ifrs-full:SharesReservedForIssueUnderOptionsAndContractsForSaleOfShares>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-1" decimals="-3" id="f-615" unitRef="cad">1917000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-7" decimals="-3" id="f-616" unitRef="cad">2378000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-8" decimals="-3" id="f-617" unitRef="cad">3826000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory contextRef="c-1" id="f-618">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Our stock option activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.923%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.039%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,963,185&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,764,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.08&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,145,400&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,005,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,832,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(280,288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(110,612)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(314,573)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.17&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(304,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,364)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.63&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(450,391)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1.74&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,333)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(123,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.94&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,063,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,963,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,334,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.53&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,039,604&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,420,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,165,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-4" decimals="INF" id="f-619" unitRef="shares">5963185</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-4"
      decimals="2"
      id="f-620"
      unitRef="cadPerShare">2.91</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-24"
      decimals="INF"
      id="f-621"
      unitRef="shares">5334420</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-24"
      decimals="2"
      id="f-622"
      unitRef="cadPerShare">3.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-14"
      decimals="INF"
      id="f-623"
      unitRef="shares">3764055</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-14"
      decimals="2"
      id="f-624"
      unitRef="cadPerShare">4.08</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-1" decimals="INF" id="f-625" unitRef="shares">2145400</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-626"
      unitRef="cadPerShare">2.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-7" decimals="INF" id="f-627" unitRef="shares">1005000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-7"
      decimals="2"
      id="f-628"
      unitRef="cadPerShare">2.04</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement contextRef="c-8" decimals="INF" id="f-629" unitRef="shares">1832500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-8"
      decimals="2"
      id="f-630"
      unitRef="cadPerShare">2.99</ifrs-full:WeightedAverageExercisePriceOfShareOptionsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c-1" decimals="INF" id="f-631" unitRef="shares">280288</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-632"
      unitRef="cadPerShare">2.86</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c-7" decimals="INF" id="f-633" unitRef="shares">62962</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-7"
      decimals="2"
      id="f-634"
      unitRef="cadPerShare">3.83</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement contextRef="c-8" decimals="INF" id="f-635" unitRef="shares">110612</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019
      contextRef="c-8"
      decimals="2"
      id="f-636"
      unitRef="cadPerShare">6.21</ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c-1" decimals="INF" id="f-637" unitRef="shares">314573</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-638"
      unitRef="cadPerShare">4.17</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c-7" decimals="INF" id="f-639" unitRef="shares">304940</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c-7"
      decimals="2"
      id="f-640"
      unitRef="cadPerShare">10.80</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement contextRef="c-8" decimals="INF" id="f-641" unitRef="shares">28364</ifrs-full:NumberOfShareOptionsExpiredInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019
      contextRef="c-8"
      decimals="2"
      id="f-642"
      unitRef="cadPerShare">37.63</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExpiredInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c-1" decimals="INF" id="f-643" unitRef="shares">450391</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-644"
      unitRef="cadPerShare">1.74</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c-7" decimals="INF" id="f-645" unitRef="shares">8333</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-7"
      decimals="2"
      id="f-646"
      unitRef="cadPerShare">1.45</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement contextRef="c-8" decimals="INF" id="f-647" unitRef="shares">123159</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="c-8"
      decimals="2"
      id="f-648"
      unitRef="cadPerShare">1.94</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-3" decimals="INF" id="f-649" unitRef="shares">7063333</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-650"
      unitRef="cadPerShare">2.72</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-4" decimals="INF" id="f-651" unitRef="shares">5963185</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-4"
      decimals="2"
      id="f-652"
      unitRef="cadPerShare">2.91</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-24"
      decimals="INF"
      id="f-653"
      unitRef="shares">5334420</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-24"
      decimals="2"
      id="f-654"
      unitRef="cadPerShare">3.53</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-3" decimals="INF" id="f-655" unitRef="shares">5039604</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-656"
      unitRef="cadPerShare">2.85</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-4" decimals="INF" id="f-657" unitRef="shares">4420482</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-4"
      decimals="2"
      id="f-658"
      unitRef="cadPerShare">3.01</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-24"
      decimals="INF"
      id="f-659"
      unitRef="shares">3165679</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-24"
      decimals="2"
      id="f-660"
      unitRef="cadPerShare">3.82</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory contextRef="c-1" id="f-662">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.14 - $2.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.01 - $2.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,063,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.71 - $3.11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.12 - $4.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,665,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,385,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.01 - $16.53&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,063,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,039,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory>
    <ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory contextRef="c-1" id="f-661">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information about the stock options outstanding and exercisable at December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.208%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.456%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of Exercise Prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;br/&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.14 - $2.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,082,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.61&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.01 - $2.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,063,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$2.71 - $3.11&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.12 - $4.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,665,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,385,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.30&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4.01 - $16.53&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,063,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,039,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-166"
      decimals="2"
      id="f-663"
      unitRef="cadPerShare">1.14</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-167"
      decimals="2"
      id="f-664"
      unitRef="cadPerShare">2.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-168"
      decimals="INF"
      id="f-665"
      unitRef="shares">2015400</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-169" id="f-666">P3Y8M12D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-168"
      decimals="2"
      id="f-667"
      unitRef="cadPerShare">1.75</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-168"
      decimals="INF"
      id="f-668"
      unitRef="shares">1082629</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-168"
      decimals="2"
      id="f-669"
      unitRef="cadPerShare">1.61</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-170"
      decimals="2"
      id="f-670"
      unitRef="cadPerShare">2.01</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-171"
      decimals="2"
      id="f-671"
      unitRef="cadPerShare">2.70</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-172"
      decimals="INF"
      id="f-672"
      unitRef="shares">1260664</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-173" id="f-673">P2Y4M24D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-172"
      decimals="2"
      id="f-674"
      unitRef="cadPerShare">2.25</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-172"
      decimals="INF"
      id="f-675"
      unitRef="shares">1063990</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-172"
      decimals="2"
      id="f-676"
      unitRef="cadPerShare">2.23</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-174"
      decimals="2"
      id="f-677"
      unitRef="cadPerShare">2.71</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-175"
      decimals="2"
      id="f-678"
      unitRef="cadPerShare">3.11</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-176"
      decimals="INF"
      id="f-679"
      unitRef="shares">978033</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-177" id="f-680">P4Y1M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-176"
      decimals="2"
      id="f-681"
      unitRef="cadPerShare">2.78</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-176"
      decimals="INF"
      id="f-682"
      unitRef="shares">364165</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-176"
      decimals="2"
      id="f-683"
      unitRef="cadPerShare">2.80</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-178"
      decimals="2"
      id="f-684"
      unitRef="cadPerShare">3.12</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-179"
      decimals="2"
      id="f-685"
      unitRef="cadPerShare">4.00</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-180"
      decimals="INF"
      id="f-686"
      unitRef="shares">2665769</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-181" id="f-687">P1Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-180"
      decimals="2"
      id="f-688"
      unitRef="cadPerShare">3.32</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-180"
      decimals="INF"
      id="f-689"
      unitRef="shares">2385353</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-180"
      decimals="2"
      id="f-690"
      unitRef="cadPerShare">3.30</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-182"
      decimals="2"
      id="f-691"
      unitRef="cadPerShare">4.01</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="c-183"
      decimals="2"
      id="f-692"
      unitRef="cadPerShare">16.53</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:NumberOfOutstandingShareOptions
      contextRef="c-184"
      decimals="INF"
      id="f-693"
      unitRef="shares">143467</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-185" id="f-694">P0Y6M</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-184"
      decimals="2"
      id="f-695"
      unitRef="cadPerShare">9.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement
      contextRef="c-184"
      decimals="INF"
      id="f-696"
      unitRef="shares">143467</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-184"
      decimals="2"
      id="f-697"
      unitRef="cadPerShare">9.20</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOutstandingShareOptions contextRef="c-3" decimals="INF" id="f-698" unitRef="shares">7063333</ifrs-full:NumberOfOutstandingShareOptions>
    <ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019 contextRef="c-1" id="f-699">P2Y7M6D</ifrs-full:WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-700"
      unitRef="cadPerShare">2.72</ifrs-full:WeightedAverageExercisePriceOfShareOptionsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement contextRef="c-3" decimals="INF" id="f-701" unitRef="shares">5039604</ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019
      contextRef="c-3"
      decimals="2"
      id="f-702"
      unitRef="cadPerShare">2.85</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisableInSharebasedPaymentArrangement2019>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-187" id="f-704">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory contextRef="c-1" id="f-705">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock options granted during the years ended December&#160;31 were determined using the following weighted average assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$1.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.99&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-1" decimals="4" id="f-706" unitRef="number">0.041</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-7" decimals="4" id="f-707" unitRef="number">0.034</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted contextRef="c-8" decimals="4" id="f-708" unitRef="number">0.007</ifrs-full:DescriptionOfRiskFreeInterestRateShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-1" decimals="1" id="f-709" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-7" decimals="1" id="f-710" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfOptionLifeShareOptionsGranted contextRef="c-8" decimals="1" id="f-711" unitRef="year">3.0</ifrs-full:DescriptionOfOptionLifeShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-1" decimals="4" id="f-712" unitRef="number">0.720</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-7" decimals="4" id="f-713" unitRef="number">0.960</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted contextRef="c-8" decimals="4" id="f-714" unitRef="number">1.105</ifrs-full:DescriptionOfExpectedVolatilityShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-1" decimals="INF" id="f-715" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-7" decimals="INF" id="f-716" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted contextRef="c-8" decimals="INF" id="f-717" unitRef="number">0</ifrs-full:ExpectedDividendAsPercentageShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-3" decimals="2" id="f-718" unitRef="cad">1.12</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-4" decimals="2" id="f-719" unitRef="cad">1.24</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted contextRef="c-24" decimals="2" id="f-720" unitRef="cad">1.99</ifrs-full:WeightedAverageFairValueAtMeasurementDateShareOptionsGranted>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory contextRef="c-1" id="f-721">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt"&gt;Our share award activity for the years ended December&#160;31 was as follows:&lt;/span&gt;&lt;div style="margin-top:10pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;403,200&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,760)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,560)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;398,440&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; (1) The weighted average fair value of the RSAs granted was $2.23in 2023.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-188"
      decimals="INF"
      id="f-722"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-189"
      decimals="INF"
      id="f-723"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-190"
      decimals="INF"
      id="f-724"
      unitRef="shares">134618</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-191"
      decimals="INF"
      id="f-725"
      unitRef="shares">403200</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-192"
      decimals="INF"
      id="f-726"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-193"
      decimals="INF"
      id="f-727"
      unitRef="shares">0</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-191"
      decimals="INF"
      id="f-728"
      unitRef="shares">4760</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-192"
      decimals="INF"
      id="f-729"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="c-193"
      decimals="INF"
      id="f-730"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-191"
      decimals="INF"
      id="f-731"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-192"
      decimals="INF"
      id="f-732"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="c-193"
      decimals="INF"
      id="f-733"
      unitRef="shares">94058</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-194"
      decimals="INF"
      id="f-734"
      unitRef="shares">398440</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-188"
      decimals="INF"
      id="f-735"
      unitRef="shares">0</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="c-189"
      decimals="INF"
      id="f-736"
      unitRef="shares">40560</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted contextRef="c-194" decimals="2" id="f-737" unitRef="cad">2.23</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1 contextRef="c-191" id="f-738">P3Y</oncyf:SharebasedCompensationArrangementbySharebasedPaymentAwardAwardVestingPeriod1>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="c-164"
      decimals="INF"
      id="f-739"
      unitRef="shares">536693</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <oncyf:IssueOfEquitySharesNumberOfCommonShares contextRef="c-3" decimals="INF" id="f-740" unitRef="shares">1</oncyf:IssueOfEquitySharesNumberOfCommonShares>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="c-1"
      decimals="2"
      id="f-741"
      unitRef="usdPerShare">2.25</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement contextRef="c-1" id="f-742">P60M</oncyf:ExpirationPeriodOfOtherEquityInstrumentsGrantedInShareBasedPaymentArrangement>
    <ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory contextRef="c-1" id="f-743">We used the following weighted average assumptions:&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.029%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Underlying share price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$2.28&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.8%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;36.5%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nil&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average fair value of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US$0.88&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedOtherEquityInstrumentsGrantedDuringPeriodExplanatory>
    <oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted
      contextRef="c-164"
      decimals="INF"
      id="f-744"
      unitRef="usdPerShare">2.28</oncyf:WeightedAverageSharePriceOtherEquityInstrumentsGranted>
    <oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted contextRef="c-164" decimals="3" id="f-745" unitRef="number">0.038</oncyf:RiskFreeInterestRateOtherEquityInstrumentsGranted>
    <oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted contextRef="c-164" decimals="1" id="f-746" unitRef="year">5.0</oncyf:OtherEquityInstrumentsLifeOtherEquityInstrumentsGranted>
    <oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted contextRef="c-164" decimals="3" id="f-747" unitRef="number">0.365</oncyf:ExpectedVolatilityOtherEquityInstrumentsGranted>
    <oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted
      contextRef="c-164"
      decimals="INF"
      id="f-748"
      unitRef="number">0</oncyf:ExpectedDividendAsPercentageOtherEquityInstrumentsGranted>
    <oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="c-164"
      decimals="INF"
      id="f-749"
      unitRef="usdPerShare">0.88</oncyf:WeightedAverageFairValuePriceAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c-37" decimals="-3" id="f-750" unitRef="cad">638000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees contextRef="c-37" decimals="-3" id="f-751" unitRef="usd">473000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithPartiesOtherThanEmployees>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory contextRef="c-1" id="f-752">Loss Per Share&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding for the year ended December&#160;31, 2023, of 67,624,036 (2022 - 58,029,745; 2021 - 53,513,225). The effect of any potential exercise of our stock options, share awards, and warrants outstanding during the year has been excluded from the calculation of diluted loss per common share, as it would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares contextRef="c-1" decimals="0" id="f-753" unitRef="shares">67624036</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-1" decimals="0" id="f-754" unitRef="shares">67624036</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-7" decimals="0" id="f-755" unitRef="shares">58029745</ifrs-full:WeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-7" decimals="0" id="f-756" unitRef="shares">58029745</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares contextRef="c-8" decimals="0" id="f-757" unitRef="shares">53513225</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:WeightedAverageShares contextRef="c-8" decimals="0" id="f-758" unitRef="shares">53513225</ifrs-full:WeightedAverageShares>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory contextRef="c-1" id="f-759">Contract Liability&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We entered into a regional licensing agreement (the "Licensing Agreement") with Adlai Nortye Biopharma Co., Ltd. ("Adlai") in November 2017. Under the terms of the Licensing Agreement, Adlai will have exclusive development and commercialization rights to pelareorep in China, Hong Kong, Macau, Singapore, South Korea, and Taiwan. We are entitled to receive upfront license fees, development and regulatory milestone payments, royalties, and sales-based milestone payments. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory contextRef="c-1" id="f-760">&lt;div&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contract liability balance at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31&lt;/span&gt;&lt;span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which w&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e expect to record in revenue over the next five years, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,730&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <oncyf:ContractLiabilityRecognitionPeriod contextRef="c-1" id="f-761">P5Y</oncyf:ContractLiabilityRecognitionPeriod>
    <ifrs-full:ContractLiabilities contextRef="c-4" decimals="-3" id="f-762" unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-24" decimals="-3" id="f-763" unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-1" decimals="-3" id="f-764" unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities contextRef="c-7" decimals="-3" id="f-765" unitRef="usd">0</ifrs-full:DecreaseThroughPerformanceObligationBeingSatisfiedContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-3" decimals="-3" id="f-766" unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities contextRef="c-4" decimals="-3" id="f-767" unitRef="usd">6730000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory contextRef="c-1" id="f-768">Commitments and Contingencies &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are committed to payments of approximately $12,686 for activities mainly related to our clinical trial and manufacturing programs, which are expected to occur over the next three years. We are able to cancel most of these agreements with notice. We are also committed to office lease payments of approximately $1,098 over 5.3 years for one of our subsidiaries which have not yet commenced. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Indemnification of Officers and Directors&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our corporate by-laws require that, except to the extent expressly prohibited by law, we will indemnify our officers and directors against all costs, charges, and expenses, including an amount paid to settle an action or satisfy a judgment reasonably incurred in respect of any civil, criminal, or administrative action or proceeding as it relates to their services to the Company.&#160;The by-laws provide no limit to the amount of the indemnification.&#160;We have purchased directors&#x2019; and officers&#x2019; insurance coverage to cover claims made against the directors and officers during the applicable policy periods.&#160;The amounts and types of coverage have varied from period to period as dictated by market conditions.&#160;We believe that we have adequate insurance coverage; however, there is no guarantee that all indemnification payments will be covered under our existing insurance policies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There is no pending litigation or proceeding involving any of our officers or directors as to which indemnification is being sought, nor are we aware of any threatened litigation that may result in claims for indemnification.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory>
    <oncyf:PurchaseObligation1 contextRef="c-3" decimals="-3" id="f-769" unitRef="cad">12686000</oncyf:PurchaseObligation1>
    <oncyf:PurchaseObligationCommitmentTerm contextRef="c-1" id="f-770">P3Y</oncyf:PurchaseObligationCommitmentTerm>
    <oncyf:LeaseNotYetCommencedPayments contextRef="c-1" decimals="-3" id="f-771" unitRef="cad">1098000</oncyf:LeaseNotYetCommencedPayments>
    <oncyf:LeaseNotYetCommencedTerm contextRef="c-1" id="f-772">P5Y3M18D</oncyf:LeaseNotYetCommencedTerm>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory contextRef="c-1" id="f-773">Income Taxes&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27,655)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,751)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,255)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,361)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,693)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,039)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,841&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,716&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;441&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of tax balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Barbados rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,088)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;325&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiry of tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to offset deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2023, we have non-capital losses of $110,450 and $129,884 in Canada and Barbados, respectively (December&#160;31, 2022 - $98,475 and $145,405, respectively). These losses are expected to expire between 2024 and 2043, if not utilized. At December&#160;31, 2023, we have Canadian investment tax credits of $4,056 (December&#160;31, 2022 - $4,368) that are expected to expire between 2024 and 2043, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years&#x2019; taxable income of $28,376 (December&#160;31, 2022 - $27,663).&#160;We also have unclaimed U.S. credits for research activities available to reduce future years' taxable income of $1,232 (December&#160;31, 2022 - $1,285) expiring between 2031 and 2043. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;382&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock contextRef="c-1" id="f-774">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27,655)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,751)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,255)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Statutory Canadian corporate tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.00%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anticipated tax recovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,361)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,693)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,039)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Difference in tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,841&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,552&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,716&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;441&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revaluation of tax balances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(552)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of Barbados rate change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,088)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;325&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(368)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expiry of tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,382&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,614&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,661&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of warrant derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,215)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision to offset deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,770&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofComponentsofIncomeTaxExpenseBenefit1TableTextBlock>
    <ifrs-full:AccountingProfit contextRef="c-1" decimals="-3" id="f-775" unitRef="cad">-27655000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit contextRef="c-7" decimals="-3" id="f-776" unitRef="cad">-24751000</ifrs-full:AccountingProfit>
    <ifrs-full:AccountingProfit contextRef="c-8" decimals="-3" id="f-777" unitRef="cad">-26255000</ifrs-full:AccountingProfit>
    <ifrs-full:ApplicableTaxRate contextRef="c-1" decimals="INF" id="f-778" unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-7" decimals="INF" id="f-779" unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:ApplicableTaxRate contextRef="c-8" decimals="INF" id="f-780" unitRef="number">0.2300</ifrs-full:ApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-1" decimals="-3" id="f-781" unitRef="cad">-6361000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-7" decimals="-3" id="f-782" unitRef="cad">-5693000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxExpenseIncomeAtApplicableTaxRate contextRef="c-8" decimals="-3" id="f-783" unitRef="cad">-6039000</ifrs-full:TaxExpenseIncomeAtApplicableTaxRate>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-1" decimals="-3" id="f-784" unitRef="cad">2841000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-7" decimals="-3" id="f-785" unitRef="cad">3552000</ifrs-full:TaxEffectOfForeignTaxRates>
    <ifrs-full:TaxEffectOfForeignTaxRates contextRef="c-8" decimals="-3" id="f-786" unitRef="cad">2716000</ifrs-full:TaxEffectOfForeignTaxRates>
    <oncyf:TaxEffectOfStockBasedCompensation contextRef="c-1" decimals="-3" id="f-787" unitRef="cad">-441000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation contextRef="c-7" decimals="-3" id="f-788" unitRef="cad">-547000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfStockBasedCompensation contextRef="c-8" decimals="-3" id="f-789" unitRef="cad">-880000</oncyf:TaxEffectOfStockBasedCompensation>
    <oncyf:TaxEffectOfTaxPools contextRef="c-1" decimals="-3" id="f-790" unitRef="cad">2000</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools contextRef="c-7" decimals="-3" id="f-791" unitRef="cad">-338000</oncyf:TaxEffectOfTaxPools>
    <oncyf:TaxEffectOfTaxPools contextRef="c-8" decimals="-3" id="f-792" unitRef="cad">-552000</oncyf:TaxEffectOfTaxPools>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-1" decimals="-3" id="f-793" unitRef="cad">-9088000</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-7" decimals="-3" id="f-794" unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:TaxEffectFromChangeInTaxRate contextRef="c-8" decimals="-3" id="f-795" unitRef="cad">0</ifrs-full:TaxEffectFromChangeInTaxRate>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-1" decimals="-3" id="f-796" unitRef="cad">325000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-7" decimals="-3" id="f-797" unitRef="cad">-368000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome contextRef="c-8" decimals="-3" id="f-798" unitRef="cad">45000</ifrs-full:OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits contextRef="c-1" decimals="-3" id="f-799" unitRef="cad">3382000</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits contextRef="c-7" decimals="-3" id="f-800" unitRef="cad">1614000</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfExpirationOfTaxBenefits contextRef="c-8" decimals="-3" id="f-801" unitRef="cad">1661000</oncyf:TaxEffectOfExpirationOfTaxBenefits>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="c-1" decimals="-3" id="f-802" unitRef="cad">-1215000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="c-7" decimals="-3" id="f-803" unitRef="cad">5000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative contextRef="c-8" decimals="-3" id="f-804" unitRef="cad">-4000</oncyf:TaxEffectOfChangeinFairValueOfWarrantDerivative>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="c-1" decimals="-3" id="f-805" unitRef="cad">-9770000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="c-7" decimals="-3" id="f-806" unitRef="cad">-765000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1 contextRef="c-8" decimals="-3" id="f-807" unitRef="cad">-1342000</oncyf:ValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount1>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-1" decimals="-3" id="f-808" unitRef="cad">97000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-7" decimals="-3" id="f-809" unitRef="cad">84000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:CurrentTaxExpenseIncome contextRef="c-8" decimals="-3" id="f-810" unitRef="cad">49000</ifrs-full:CurrentTaxExpenseIncome>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-195" decimals="-3" id="f-811" unitRef="cad">110450000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-196" decimals="-3" id="f-812" unitRef="cad">129884000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-197" decimals="-3" id="f-813" unitRef="cad">98475000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised contextRef="c-198" decimals="-3" id="f-814" unitRef="cad">145405000</ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-199" decimals="-3" id="f-815" unitRef="cad">4056000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-200" decimals="-3" id="f-816" unitRef="cad">4368000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-201" decimals="-3" id="f-817" unitRef="cad">28376000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-202" decimals="-3" id="f-818" unitRef="cad">27663000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-203" decimals="-3" id="f-819" unitRef="cad">1232000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised contextRef="c-204" decimals="-3" id="f-820" unitRef="cad">1285000</ifrs-full:UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised>
    <ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory contextRef="c-1" id="f-821">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37,174&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Scientific research and experimental development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,742&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,123&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;382&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share issue costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;833&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net capital losses carried forward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;49,260&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-205" decimals="-3" id="f-822" unitRef="cad">37174000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-206" decimals="-3" id="f-823" unitRef="cad">26726000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-207" decimals="-3" id="f-824" unitRef="cad">25158000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-208" decimals="-3" id="f-825" unitRef="cad">7742000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-209" decimals="-3" id="f-826" unitRef="cad">7648000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-210" decimals="-3" id="f-827" unitRef="cad">7705000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-211" decimals="-3" id="f-828" unitRef="cad">3123000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-212" decimals="-3" id="f-829" unitRef="cad">3363000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-213" decimals="-3" id="f-830" unitRef="cad">3716000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-214" decimals="-3" id="f-831" unitRef="cad">382000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-215" decimals="-3" id="f-832" unitRef="cad">366000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-216" decimals="-3" id="f-833" unitRef="cad">351000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-217" decimals="-3" id="f-834" unitRef="cad">833000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-218" decimals="-3" id="f-835" unitRef="cad">518000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-219" decimals="-3" id="f-836" unitRef="cad">648000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-220" decimals="-3" id="f-837" unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-221" decimals="-3" id="f-838" unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-222" decimals="-3" id="f-839" unitRef="cad">6000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-3" decimals="-3" id="f-840" unitRef="cad">49260000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-4" decimals="-3" id="f-841" unitRef="cad">38627000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised contextRef="c-24" decimals="-3" id="f-842" unitRef="cad">37584000</ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised>
    <ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory contextRef="c-1" id="f-843">Capital Disclosures&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our objective when managing capital is to maintain a strong statement of financial position. We achieve our objective by obtaining adequate cash resources to support planned activities which include the clinical trial program, product manufacturing, administrative costs, and intellectual property expansion and protection.&#160;We include shareholders' equity, cash and cash equivalents, and marketable securities in the definition of capital.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,912&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have no debt other than accounts payable and accrued liabilities and lease liabilities. We also have commitments and potential contingent obligations relating to the completion of our research and development of pelareorep.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In managing our capital, we estimate our future cash requirements by preparing a budget and a multi-year plan annually for review and approval by our Board. The budget establishes the approved activities for the upcoming year and estimates the associated costs. The multi-year plan estimates future activity along with the potential cash requirements and is based on our assessment of our current clinical trial progress along with the expected results from the coming year&#x2019;s activity.&#160;Budget to actual variances are prepared and reviewed by management and are presented quarterly to the Board.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Historically, funding for our plan is primarily managed through the issuance of additional common shares and common share purchase warrants that upon exercise are converted to common shares.&#160;Management regularly monitors the capital markets attempting to balance the timing of issuing additional equity with our progress through our clinical trial program, general market conditions, and the availability of capital.&#160;There are no assurances that funds will be made available to us when required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2022, we renewed our short form base shelf prospectus (the "Base Shelf") that qualifies for distribution of up to $150,000 of common shares, subscription receipts, warrants, or units (the "Securities") in either Canada, the U.S. or both. Under a Base Shelf, we may sell Securities to or through underwriters, dealers, placement agents, or other intermediaries. We may also sell Securities directly to purchasers or through agents, subject to obtaining any applicable exemption from registration requirements. The distribution of Securities may be performed from time to time in one or more transactions at a fixed price or prices, which may be subject to change, at market prices prevailing at the time of sale, or at prices related to such prevailing market prices to be negotiated with purchasers and as set forth in an accompanying Prospectus Supplement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Renewing our Base Shelf provides additional flexibility when managing our cash resources as, under certain circumstances, it shortens the time required to close a financing and is expected to increase the number of potential investors that may be prepared to invest in the Company. Funds received from using our Base Shelf would be used in line with our Board approved budget and multi-year plan. Our renewed Base Shelf will be effective until July 16, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Base Shelf allowed us to enter into our ATM equity distribution agreements and 2023 public offering (see note 10). We use these equity arrangements to assist us in achieving our capital objectives. These arrangements provide us with the opportunity to raise capital and better manage our cash resources. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are not subject to externally imposed capital requirements, and there have been no changes in how we define or manage our capital in 2023.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfObjectivesPoliciesAndProcessesForManagingCapitalExplanatory>
    <oncyf:DisclosureOfCapitalComponentsTableTextBlock contextRef="c-1" id="f-844">&lt;div style="margin-bottom:10pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;34,912&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shareholders' equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;27,563&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:DisclosureOfCapitalComponentsTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c-3" decimals="-3" id="f-845" unitRef="cad">34912000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-4" decimals="-3" id="f-846" unitRef="cad">11666000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentFinancialAssetsAvailableforsale contextRef="c-3" decimals="-3" id="f-847" unitRef="cad">0</ifrs-full:CurrentFinancialAssetsAvailableforsale>
    <ifrs-full:CurrentFinancialAssetsAvailableforsale contextRef="c-4" decimals="-3" id="f-848" unitRef="cad">20472000</ifrs-full:CurrentFinancialAssetsAvailableforsale>
    <ifrs-full:Equity contextRef="c-3" decimals="-3" id="f-849" unitRef="cad">27563000</ifrs-full:Equity>
    <ifrs-full:Equity contextRef="c-4" decimals="-3" id="f-850" unitRef="cad">26502000</ifrs-full:Equity>
    <oncyf:EquityAuthorized contextRef="c-223" decimals="INF" id="f-851" unitRef="cad">150000000</oncyf:EquityAuthorized>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory contextRef="c-1" id="f-852">Financial Instruments&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments consist of cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, other liabilities, and warrant derivative.&#160;As at December&#160;31, 2023, and December&#160;31, 2022, the carrying amount of our cash and cash equivalents, marketable securities,&#160;other receivables, accounts payable and accrued liabilities, and other liabilities approximated their fair value due to their short-term maturity. The warrant derivative is a recurring Level 2 fair &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;value measurement as these warrants have not been listed on an exchange and, therefore, do not trade on an active market. As at December&#160;31, 2023, the fair value of our warrant derivative was $200 (December&#160;31, 2022 - $79) (see note 9). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial risk management&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credit risk is the risk of a financial loss if a counterparty to a financial instrument fails to meet its contractual obligations.&#160;As at December&#160;31, 2023, we were exposed to credit risk on our cash and cash equivalents in the event of non-performance by counterparties, but we do not anticipate such non-performance. Our maximum exposure to credit risk at the end of the period is the carrying value of our cash and cash equivalents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our exposure to credit risk connected to our cash and cash equivalents by maintaining our primary operating and investment bank accounts with Schedule I banks in Canada.&#160;For our foreign-domiciled bank accounts, we use referrals or recommendations from our Canadian banks to open foreign bank accounts. Our foreign-domiciled bank accounts are used solely for the purpose of settling accounts payable and accrued liabilities or payroll.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest rate risk &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.&#160;We hold our cash and cash equivalents in bank accounts or high-interest investment accounts with variable interest rates. We mitigate interest rate risk through our investment policy that only allows the investment of excess cash resources in investment-grade vehicles while matching maturities with our operational requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in market interest rates do not significantly impact our results of operations due to the short-term maturity of the investments held.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign exchange risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange risk arises from changes in foreign exchange rates that may affect the fair value or future cash flows of our financial assets or liabilities. For the year ended December&#160;31, 2023, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar as a portion of our financial assets and liabilities were denominated in such currency. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss for the year ended December&#160;31, 2023, by approximately $140.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances in foreign currencies as at December&#160;31, 2023, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.006%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2022, we were primarily exposed to the risk of changes in the Canadian dollar relative to the U.S. dollar and the Euro as a portion of our financial assets and liabilities are denominated in such currencies. The impact of a $0.01 increase in the value of the U.S. dollar against the Canadian dollar would have decreased our net comprehensive loss for the year ended December&#160;31, 2022, by approximately $170. The impact of a $0.01 increase in the value of the Euro against the Canadian dollar would have increased our net comprehensive loss for the year ended December&#160;31, 2022, by approximately $22.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances in foreign currencies as at December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We mitigate our foreign exchange risk by maintaining sufficient foreign currencies by purchasing foreign currencies or receiving foreign currencies from financing activities to settle our foreign accounts payable and accrued liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity risk&lt;/span&gt;&lt;/div&gt;Liquidity risk is the risk that we will encounter difficulty in meeting obligations associated with financial liabilities.&#160;We manage liquidity risk by managing our capital structure as outlined in note 16. Accounts payable and accrued liabilities are all due within the current operating period. See note 8 for a maturity analysis of our lease liabilities.</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-224" decimals="-3" id="f-853" unitRef="cad">200000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities contextRef="c-225" decimals="-3" id="f-854" unitRef="cad">79000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="c-226" decimals="2" id="f-855" unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="c-226" decimals="-3" id="f-856" unitRef="cad">-140000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock contextRef="c-1" id="f-857">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances in foreign currencies as at December&#160;31, 2023, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:81.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.006%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,476)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,818&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant balances in foreign currencies as at December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.005%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.007%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,093)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,035)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleOfForeignCurrencyHeldTableTextBlock>
    <ifrs-full:CashAndCashEquivalents contextRef="c-227" decimals="-3" id="f-858" unitRef="usd">24294000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-227" decimals="-3" id="f-859" unitRef="usd">1476000</ifrs-full:TradeAndOtherCurrentPayables>
    <oncyf:BalanceHeldInForeignCurrencyNet contextRef="c-227" decimals="-3" id="f-860" unitRef="usd">22818000</oncyf:BalanceHeldInForeignCurrencyNet>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="c-228" decimals="2" id="f-861" unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="c-228" decimals="-3" id="f-862" unitRef="cad">-170000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount contextRef="c-229" decimals="2" id="f-863" unitRef="cad">0.01</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableAmount>
    <oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings contextRef="c-229" decimals="-3" id="f-864" unitRef="cad">22000</oncyf:SensitivityAnalysisForTypesOfMarketRiskReasonablyPossibleChangeInRiskVariableImpactOnPreTaxEarnings>
    <ifrs-full:CashAndCashEquivalents contextRef="c-230" decimals="-3" id="f-865" unitRef="usd">6635000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents contextRef="c-231" decimals="-3" id="f-866" unitRef="cad">0</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:FinancialAssetsAvailableforsale contextRef="c-230" decimals="-3" id="f-867" unitRef="usd">15115000</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:FinancialAssetsAvailableforsale contextRef="c-231" decimals="-3" id="f-868" unitRef="cad">0</ifrs-full:FinancialAssetsAvailableforsale>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-230" decimals="-3" id="f-869" unitRef="usd">1093000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables contextRef="c-231" decimals="-3" id="f-870" unitRef="cad">1035000</ifrs-full:TradeAndOtherCurrentPayables>
    <oncyf:BalanceHeldInForeignCurrencyNet contextRef="c-230" decimals="-3" id="f-871" unitRef="usd">20657000</oncyf:BalanceHeldInForeignCurrencyNet>
    <oncyf:BalanceHeldInForeignCurrencyNet contextRef="c-231" decimals="-3" id="f-872" unitRef="cad">-1035000</oncyf:BalanceHeldInForeignCurrencyNet>
    <ifrs-full:DisclosureOfCashFlowStatementExplanatory contextRef="c-1" id="f-873">Additional Cash Flow Disclosures&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;506&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,765&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfCashFlowStatementExplanatory>
    <oncyf:CashFlowOperatingCapital1TableTextBlock contextRef="c-1" id="f-874">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Change In Non-Cash Working Capital&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Change in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;506&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;777&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(78)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;332&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash impact of foreign exchange&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in non-cash working capital related to operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,765&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:CashFlowOperatingCapital1TableTextBlock>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c-1" decimals="-3" id="f-875" unitRef="cad">506000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c-7" decimals="-3" id="f-876" unitRef="cad">345000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables contextRef="c-8" decimals="-3" id="f-877" unitRef="cad">-776000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c-1" decimals="-3" id="f-878" unitRef="cad">777000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c-7" decimals="-3" id="f-879" unitRef="cad">-1247000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses contextRef="c-8" decimals="-3" id="f-880" unitRef="cad">-349000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-1" decimals="-3" id="f-881" unitRef="cad">-78000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-7" decimals="-3" id="f-882" unitRef="cad">1662000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables contextRef="c-8" decimals="-3" id="f-883" unitRef="cad">183000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-1" decimals="-3" id="f-884" unitRef="cad">332000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-7" decimals="-3" id="f-885" unitRef="cad">-352000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables contextRef="c-8" decimals="-3" id="f-886" unitRef="cad">228000</ifrs-full:AdjustmentsForIncreaseDecreaseInOtherOperatingPayables>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet contextRef="c-1" decimals="-3" id="f-887" unitRef="cad">228000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet contextRef="c-7" decimals="-3" id="f-888" unitRef="cad">-17000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet contextRef="c-8" decimals="-3" id="f-889" unitRef="cad">-194000</oncyf:IncreaseDecreaseThroughForeignExchangeFinancialAssetsLiabilitiesNet>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-1" decimals="-3" id="f-890" unitRef="cad">-1765000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-7" decimals="-3" id="f-891" unitRef="cad">-391000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital contextRef="c-8" decimals="-3" id="f-892" unitRef="cad">908000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock contextRef="c-1" id="f-893">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Cash Flow Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash interest received&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,554&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash taxes paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:ScheduleofCashFlowSupplementalDisclosures1TableTextBlock>
    <oncyf:ProceedsfromInterestReceived contextRef="c-1" decimals="-3" id="f-894" unitRef="cad">1554000</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived contextRef="c-7" decimals="-3" id="f-895" unitRef="cad">452000</oncyf:ProceedsfromInterestReceived>
    <oncyf:ProceedsfromInterestReceived contextRef="c-8" decimals="-3" id="f-896" unitRef="cad">190000</oncyf:ProceedsfromInterestReceived>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c-1" decimals="-3" id="f-897" unitRef="cad">120000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c-7" decimals="-3" id="f-898" unitRef="cad">46000</ifrs-full:IncomeTaxesPaidRefund>
    <ifrs-full:IncomeTaxesPaidRefund contextRef="c-8" decimals="-3" id="f-899" unitRef="cad">35000</ifrs-full:IncomeTaxesPaidRefund>
    <oncyf:DisclosureOfEconomicDependenceTextBlock contextRef="c-1" id="f-900">Economic Dependence&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are economically dependent on our toll manufacturers. We primarily use one toll manufacturer in the U.S. to produce the clinical-grade pelareorep active ingredient and a second toll manufacturer to formulate finished product required for our clinical trial program.&#160;Any significant disruption of the services provided by our primary toll manufacturers has the potential to delay the progress of our clinical trial program.&#160;We have used another toll manufacturer in the U.K. that has also produced clinical-grade pelareorep at a smaller scale.&#160;We have attempted to mitigate this risk by identifying an alternative toll manufacturer, establishing stability profiles for long-term storage of pelareorep, and producing sufficient pelareorep in advance of patient enrollment in a particular clinical trial.&lt;/span&gt;&lt;/div&gt;</oncyf:DisclosureOfEconomicDependenceTextBlock>
    <oncyf:ConcentrationRiskNumber
      contextRef="c-232"
      decimals="INF"
      id="f-901"
      unitRef="manufacturer">1</oncyf:ConcentrationRiskNumber>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory contextRef="c-1" id="f-902">Components of Expenses&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing &amp;amp; related process development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translational science expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,324&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public company-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, our research and development personnel-related expenses included employee compensation and benefits of $6,324 (2022 - $5,983; 2021 - $4,645).&lt;/span&gt;&lt;/div&gt;For the year ended December&#160;31, 2023, our general and administrative office expenses included employee compensation and benefits of $3,332 (2022 - $2,870; 2021 - $2,542).</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <oncyf:OtherExpensesAndAdjustmentsTableTextBlock contextRef="c-1" id="f-903">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,675&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing &amp;amp; related process development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intellectual property expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;397&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Translational science expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Personnel-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,324&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,305&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,709&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Public company-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,278&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Office expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,789&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;81&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation - right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;322&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,082&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</oncyf:OtherExpensesAndAdjustmentsTableTextBlock>
    <oncyf:ClinicalTrialExpense contextRef="c-233" decimals="-3" id="f-904" unitRef="cad">3675000</oncyf:ClinicalTrialExpense>
    <oncyf:ClinicalTrialExpense contextRef="c-234" decimals="-3" id="f-905" unitRef="cad">4970000</oncyf:ClinicalTrialExpense>
    <oncyf:ClinicalTrialExpense contextRef="c-235" decimals="-3" id="f-906" unitRef="cad">3205000</oncyf:ClinicalTrialExpense>
    <oncyf:ManufacturingExpense contextRef="c-233" decimals="-3" id="f-907" unitRef="cad">5789000</oncyf:ManufacturingExpense>
    <oncyf:ManufacturingExpense contextRef="c-234" decimals="-3" id="f-908" unitRef="cad">2148000</oncyf:ManufacturingExpense>
    <oncyf:ManufacturingExpense contextRef="c-235" decimals="-3" id="f-909" unitRef="cad">1547000</oncyf:ManufacturingExpense>
    <oncyf:IntellectualPropertyExpense contextRef="c-233" decimals="-3" id="f-910" unitRef="cad">397000</oncyf:IntellectualPropertyExpense>
    <oncyf:IntellectualPropertyExpense contextRef="c-234" decimals="-3" id="f-911" unitRef="cad">544000</oncyf:IntellectualPropertyExpense>
    <oncyf:IntellectualPropertyExpense contextRef="c-235" decimals="-3" id="f-912" unitRef="cad">618000</oncyf:IntellectualPropertyExpense>
    <oncyf:TranslationalScienceExpense contextRef="c-233" decimals="-3" id="f-913" unitRef="cad">0</oncyf:TranslationalScienceExpense>
    <oncyf:TranslationalScienceExpense contextRef="c-234" decimals="-3" id="f-914" unitRef="cad">264000</oncyf:TranslationalScienceExpense>
    <oncyf:TranslationalScienceExpense contextRef="c-235" decimals="-3" id="f-915" unitRef="cad">673000</oncyf:TranslationalScienceExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-233" decimals="-3" id="f-916" unitRef="cad">6324000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-234" decimals="-3" id="f-917" unitRef="cad">6023000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:OtherEmployeeExpense contextRef="c-235" decimals="-3" id="f-918" unitRef="cad">4754000</ifrs-full:OtherEmployeeExpense>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-233" decimals="-3" id="f-919" unitRef="cad">1305000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-234" decimals="-3" id="f-920" unitRef="cad">1371000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-235" decimals="-3" id="f-921" unitRef="cad">2087000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-233" decimals="-3" id="f-922" unitRef="cad">219000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-234" decimals="-3" id="f-923" unitRef="cad">112000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense contextRef="c-235" decimals="-3" id="f-924" unitRef="cad">36000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-925" unitRef="cad">17709000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-926" unitRef="cad">15432000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-3" id="f-927" unitRef="cad">12920000</ifrs-full:ResearchAndDevelopmentExpense>
    <oncyf:PublicCompanyExpense contextRef="c-236" decimals="-3" id="f-928" unitRef="cad">11278000</oncyf:PublicCompanyExpense>
    <oncyf:PublicCompanyExpense contextRef="c-237" decimals="-3" id="f-929" unitRef="cad">6790000</oncyf:PublicCompanyExpense>
    <oncyf:PublicCompanyExpense contextRef="c-238" decimals="-3" id="f-930" unitRef="cad">8161000</oncyf:PublicCompanyExpense>
    <oncyf:OfficeExpenses contextRef="c-236" decimals="-3" id="f-931" unitRef="cad">3789000</oncyf:OfficeExpenses>
    <oncyf:OfficeExpenses contextRef="c-237" decimals="-3" id="f-932" unitRef="cad">3303000</oncyf:OfficeExpenses>
    <oncyf:OfficeExpenses contextRef="c-238" decimals="-3" id="f-933" unitRef="cad">2963000</oncyf:OfficeExpenses>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-236" decimals="-3" id="f-934" unitRef="cad">612000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-237" decimals="-3" id="f-935" unitRef="cad">1007000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees contextRef="c-238" decimals="-3" id="f-936" unitRef="cad">1739000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:AmortisationExpense contextRef="c-236" decimals="-3" id="f-937" unitRef="cad">81000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-237" decimals="-3" id="f-938" unitRef="cad">93000</ifrs-full:AmortisationExpense>
    <ifrs-full:AmortisationExpense contextRef="c-238" decimals="-3" id="f-939" unitRef="cad">130000</ifrs-full:AmortisationExpense>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-236" decimals="-3" id="f-940" unitRef="cad">322000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-237" decimals="-3" id="f-941" unitRef="cad">299000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:DepreciationRightofuseAssets contextRef="c-238" decimals="-3" id="f-942" unitRef="cad">322000</ifrs-full:DepreciationRightofuseAssets>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-943" unitRef="cad">16082000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-944" unitRef="cad">11492000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense contextRef="c-8" decimals="-3" id="f-945" unitRef="cad">13315000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-233" decimals="-3" id="f-946" unitRef="cad">6324000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-234" decimals="-3" id="f-947" unitRef="cad">5983000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-235" decimals="-3" id="f-948" unitRef="cad">4645000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-236" decimals="-3" id="f-949" unitRef="cad">3332000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-237" decimals="-3" id="f-950" unitRef="cad">2870000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:EmployeeBenefitsExpense contextRef="c-238" decimals="-3" id="f-951" unitRef="cad">2542000</ifrs-full:EmployeeBenefitsExpense>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory contextRef="c-1" id="f-952">Related Party Transactions&lt;div style="margin-bottom:10pt;margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Compensation of Key Management Personnel&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Key management personnel are those persons having authority and responsibility for planning, directing, and controlling our activities as a whole. We have determined that key management personnel consists of the Board of Directors, Executive Officers, President, and Vice Presidents. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,496&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory contextRef="c-1" id="f-953">&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,870&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Termination benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;319&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,496&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-1" decimals="-3" id="f-954" unitRef="cad">4870000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-7" decimals="-3" id="f-955" unitRef="cad">4308000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits contextRef="c-8" decimals="-3" id="f-956" unitRef="cad">3919000</ifrs-full:KeyManagementPersonnelCompensationShorttermEmployeeBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-1" decimals="-3" id="f-957" unitRef="cad">319000</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-7" decimals="-3" id="f-958" unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits contextRef="c-8" decimals="-3" id="f-959" unitRef="cad">0</ifrs-full:KeyManagementPersonnelCompensationTerminationBenefits>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-1" decimals="-3" id="f-960" unitRef="cad">1496000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-7" decimals="-3" id="f-961" unitRef="cad">1615000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment contextRef="c-8" decimals="-3" id="f-962" unitRef="cad">2703000</ifrs-full:KeyManagementPersonnelCompensationSharebasedPayment>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-1" decimals="-3" id="f-963" unitRef="cad">6685000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-7" decimals="-3" id="f-964" unitRef="cad">5923000</ifrs-full:KeyManagementPersonnelCompensation>
    <ifrs-full:KeyManagementPersonnelCompensation contextRef="c-8" decimals="-3" id="f-965" unitRef="cad">6622000</ifrs-full:KeyManagementPersonnelCompensation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
